,Unnamed: 0_x,English,Chinese_Google,Dict_Acc_Google,Terms_Google,Correct_Terms_Google,Unnamed: 0_y,Chinese_M2M,Dict_Acc_M2M,Terms_M2M,Correct_Terms_M2M,Unnamed: 0,Chinese_GPT,Dict_Acc_GPT,Terms_GPT,Correct_Terms_GPT,Human Eval Google,Human Eval M2M,Human Eval Medical M2M,Human Eval GPT
0,0,probably not : analysis suggests minimal effect of HT in maintaining lean body mass .,可能不是：分析表明 HT 在维持瘦体重方面的作用微乎其微。,0.4,"['analysis', 'effect', 'minimal', 'mass', 'body']","['analysis', 'effect']",0,['可能不是:分析表明HT在维持脂肪体重的最小效果。'],0.4,"['analysis', 'effect', 'minimal', 'mass', 'body']","['analysis', 'effect']",0,分析表明，雌激素有助于维持身体纤细，但可能并不是很明显。,0.4,"['analysis', 'effect', 'minimal', 'mass', 'body']","['analysis', 'body']",10.0,7.0,3.0,7.0
1,1,investigators identified 12 randomized trials of menopausal HT in which changes in LBM were assessed .,研究人员确定了 12 项评估 LBM 变化的绝经期 HT 随机试验。,0.0,"['menopausal', 'in', 'assessed']",[],1,"['研究人员确定了12次随机测试,其中评估了LBM的变化。']",0.0,"['menopausal', 'in', 'assessed']",[],1,研究人员确认了12个关于绝经期激素替代疗法（HT）的随机试验，其中评估了体重变化。,0.0,"['menopausal', 'in', 'assessed']",[],9.0,8.0,0.0,9.0
2,2,Intensifying blood pressure regimens at discharge in older adults was associated with excess readmissions and serious adverse events .,老年人出院时强化血压方案与再入院率和严重不良事件有关。,0.1111111111111111,"['discharge', 'excess', 'blood pressure', 'adverse', 'associated', 'with', 'serious', 'in', 'and']",['blood pressure'],2,['在老年人排放时的血压强化制度与过度回收和严重的副作用有关。'],0.1111111111111111,"['discharge', 'excess', 'blood pressure', 'adverse', 'associated', 'with', 'serious', 'in', 'and']",['blood pressure'],2,"Intensifying blood pressure regimens at discharge in older adults was associated with excess readmissions and serious adverse events.

Chinese:

老年人出院时加强血压治疗计划会导致过多住院和严重不良事件发生。",0.1111111111111111,"['discharge', 'excess', 'blood pressure', 'adverse', 'associated', 'with', 'serious', 'in', 'and']",['blood pressure'],10.0,5.0,1.0,10.0
3,3,"during hospitalization , patients frequently have transient elevations in blood pressure ( BP ) , which result in modification of their outpatient antihypertensive regimens at discharge .",住院期间，患者的血压 (BP) 经常出现短暂升高，这导致他们在出院时修改门诊降压方案。,0.3,"['transient', 'discharge', 'modification', 'antihypertensive', 'frequently', 'blood pressure', 'hospitalization', 'result', 'have', 'in']","['antihypertensive', 'blood pressure', 'hospitalization']",3,"['在入院期间,患者经常有过渡的血压(BP)上升,这导致他们在排放时的病人抗高血压饮食的变化。']",0.3,"['transient', 'discharge', 'modification', 'antihypertensive', 'frequently', 'blood pressure', 'hospitalization', 'result', 'have', 'in']","['antihypertensive', 'blood pressure', 'have']",3,在住院期间，病人的血压会经常有短暂的升高，这会导致出院时调整他们的降压药物方案。,0.4,"['transient', 'discharge', 'modification', 'antihypertensive', 'frequently', 'blood pressure', 'hospitalization', 'result', 'have', 'in']","['antihypertensive', 'blood pressure', 'hospitalization', 'have']",10.0,5.0,2.0,10.0
4,4,no studies have been designed to evaluate whether this practice improves outcomes .,尚未设计任何研究来评估这种做法是否会改善结果。,0.2,"['no', 'practice', 'have', 'this', 'to']",['this'],4,['没有任何研究旨在评估这种实践是否会改善结果。'],0.6,"['no', 'practice', 'have', 'this', 'to']","['practice', 'have', 'this']",4,没有研究是专门设计来评估这种做法是否会改善结果的。,0.4,"['no', 'practice', 'have', 'this', 'to']","['have', 'this']",10.0,10.0,4.0,10.0
5,5,"at 1 year , mean systolic BP and incidence of adverse cardiac events were similar in the two groups .",1 年时，两组的平均收缩压和不良心脏事件的发生率相似。,0.5454545454545454,"['cardiac', 'incidence', 'mean', 'year', '1', 'adverse', 'systolic', 'at', 'and', 'two', 'similar']","['cardiac', 'incidence', 'mean', 'year', '1', 'two']",5,"['在1年,中间系统性BP和不良心脏病发作的发病率在两组中相似。']",0.4545454545454545,"['cardiac', 'incidence', 'mean', 'year', '1', 'adverse', 'systolic', 'at', 'and', 'two', 'similar']","['cardiac', 'incidence', 'year', '1', 'two']",5,在1年的时候，两组人的平均收缩压和不良心脏事件发生率相似。,0.5454545454545454,"['cardiac', 'incidence', 'mean', 'year', '1', 'adverse', 'systolic', 'at', 'and', 'two', 'similar']","['cardiac', 'incidence', 'mean', 'year', '1', 'two']",10.0,7.0,2.0,10.0
6,6,this study highlights a common clinical inpatient scenario .,这项研究突出了一种常见的临床住院情况。,0.2,"['study', 'common', 'clinical', 'inpatient', 'this']",['clinical'],6,['这项研究强调了一个常见的临床病人场景。'],0.2,"['study', 'common', 'clinical', 'inpatient', 'this']",['clinical'],6,这项研究突出了一种常见的住院患者情况。,0.0,"['study', 'common', 'clinical', 'inpatient', 'this']",[],10.0,8.0,4.0,10.0
7,7,"clinicians often feel compelled to act on elevated BP readings in hospitalized patients , but these results suggest we should do otherwise .",临床医生常常觉得有必要对住院患者的血压读数升高采取行动，但这些结果表明我们不应该这样做。,0.1428571428571428,"['feel', 'readings', 'suggest', 'act on', 'but', 'to', 'we']",['but'],7,"['临床医生经常觉得被迫在入院的患者中采取高BP阅读行动,但这些结果表明我们应该做不一样的事情。']",0.1428571428571428,"['feel', 'readings', 'suggest', 'act on', 'but', 'to', 'we']",['but'],7,医生经常感到有必要对住院病人的血压读数采取行动，但这些结果表明我们不应该这样做。,0.1428571428571428,"['feel', 'readings', 'suggest', 'act on', 'but', 'to', 'we']",['but'],10.0,4.0,2.0,10.0
8,8,a guideline that addresses asymptomatic BP elevations in hospitalized patients would be helpful .,解决住院患者无症状血压升高的指南会有所帮助。,0.25,"['be', 'asymptomatic', 'that', 'in']",['asymptomatic'],8,['在入院患者中处理无症状BP上升的指导方针将有助于。'],0.5,"['be', 'asymptomatic', 'that', 'in']","['be', 'asymptomatic']",8,一个针对住院病人无症状血压升高的指南将是非常有帮助的。,0.25,"['be', 'asymptomatic', 'that', 'in']",['asymptomatic'],10.0,9.0,2.0,10.0
9,9,there is a recent emphasis in liver disease management on how best to identify individuals at increased risk for clinically significant disease in the primary care setting .,肝病管理最近强调如何在初级保健环境中最好地识别出临床上重要疾病风险增加的个体。,0.4166666666666667,"['setting', 'recent', 'liver disease', 'primary', 'risk', 'management', 'identify', 'care', 'emphasis', 'at', 'on', 'to']","['liver disease', 'risk', 'management', 'identify', 'emphasis']",9,"['在肝脏疾病管理中,最近强调如何最好地识别在初级护理环境中患有临床意义的疾病风险的人。']",0.3333333333333333,"['setting', 'recent', 'liver disease', 'primary', 'risk', 'management', 'identify', 'care', 'emphasis', 'at', 'on', 'to']","['risk', 'management', 'identify', 'emphasis']",9,目前在肝病管理中，人们更加重视如何在初级保健环境中找出那些患有临床显著疾病风险的个人。,0.25,"['setting', 'recent', 'liver disease', 'primary', 'risk', 'management', 'identify', 'care', 'emphasis', 'at', 'on', 'to']","['liver disease', 'risk', 'management']",10.0,10.0,5.0,10.0
10,10,"many studies have developed risk stratification guidelines , but few have applied them in a primary care population .",许多研究制定了风险分层指南，但很少将其应用于初级保健人群。,0.4444444444444444,"['population', 'stratification', 'primary', 'risk', 'applied', 'care', 'have', 'in', 'but']","['population', 'stratification', 'risk', 'but']",10,"['许多研究已经开发了风险分裂指南,但很少有人在初级护理人口中应用了这些指南。']",0.4444444444444444,"['population', 'stratification', 'primary', 'risk', 'applied', 'care', 'have', 'in', 'but']","['population', 'risk', 'have', 'but']",10,许多研究已经制定了风险分级指南，但很少有研究应用于初级保健人群。,0.4444444444444444,"['population', 'stratification', 'primary', 'risk', 'applied', 'care', 'have', 'in', 'but']","['population', 'risk', 'have', 'but']",10.0,9.0,4.0,10.0
11,11,"in this prospective study , researchers recruited patients from a family medicine practice in an inner city setting in England .",在这项前瞻性研究中，研究人员从英格兰市中心的一家家庭医疗诊所招募了患者。,0.2857142857142857,"['family', 'setting', 'medicine', 'inner', 'prospective study', 'practice', 'this']","['family', 'prospective study']",11,"['在这项有前途的研究中,研究人员招募了来自英格兰内部城市的家庭医学实践的患者。']",0.4285714285714285,"['family', 'setting', 'medicine', 'inner', 'prospective study', 'practice', 'this']","['family', 'medicine', 'practice']",11,在这项前瞻性研究中，研究人员从英国一个城市内部的家庭医疗实践中招募了病人。,0.5714285714285714,"['family', 'setting', 'medicine', 'inner', 'prospective study', 'practice', 'this']","['family', 'inner', 'prospective study', 'practice']",10.0,7.0,2.0,10.0
12,12,"adults with one or more risk factors for chronic liver disease ( obesity , type 2 diabetes , and hazardous alcohol use ) were enrolled as a subpopulation of the overall primary care practice .",具有一种或多种慢性肝病危险因素（肥胖、2 型糖尿病和有害饮酒）的成年人被纳入整个初级保健实践的一个亚群。,0.7142857142857143,"['alcohol', 'diabetes', 'type', '2', 'subpopulation', 'liver disease', 'obesity', 'chronic', 'primary', 'risk', 'practice', 'care', 'with', 'and']","['alcohol', 'diabetes', 'type', '2', 'subpopulation', 'liver disease', 'obesity', 'chronic', 'risk', 'practice']",12,['患有慢性肝脏疾病的一个或多个风险因素(肥胖、2型糖尿病和危险酒精使用)的成年人被列为总体初级护理实践的低人口。'],0.5714285714285714,"['alcohol', 'diabetes', 'type', '2', 'subpopulation', 'liver disease', 'obesity', 'chronic', 'primary', 'risk', 'practice', 'care', 'with', 'and']","['alcohol', 'diabetes', 'type', '2', 'obesity', 'chronic', 'risk', 'practice']",12,"adults with one or more risk factors for chronic liver disease ( obesity , type 2 diabetes , and hazardous alcohol use ) were enrolled as a subpopulation of the overall primary care practice .

Chinese:

成人患有一个或多个慢性肝病风险因素（肥胖、2型糖尿病和危险饮酒）的人群被纳入为总体初级保健实践的一个分群。",0.6428571428571429,"['alcohol', 'diabetes', 'type', '2', 'subpopulation', 'liver disease', 'obesity', 'chronic', 'primary', 'risk', 'practice', 'care', 'with', 'and']","['alcohol', 'diabetes', 'type', '2', 'liver disease', 'obesity', 'chronic', 'risk', 'practice']",10.0,5.0,4.0,10.0
13,13,"patients underwent transient elastography ( TE ) , from which a reading of ≥ 8 kPa was defined as significant liver disease .",患者接受了瞬时弹性成像 (TE)，其中≥ 8 kPa 的读数被定义为显着肝病。,0.2,"['TE', 'transient', 'defined', 'reading', 'liver disease']",['liver disease'],13,"['患者接受过渡性艾拉斯托格(TE),从那里读取 ≥ 8 kPa 被定义为严重的肝病。']",0.2,"['TE', 'transient', 'defined', 'reading', 'liver disease']",['liver disease'],13,病人接受了瞬变弹性图像（TE）检查，其中≥8 kPa的阅读被定义为重要的肝脏疾病。,0.0,"['TE', 'transient', 'defined', 'reading', 'liver disease']",[],10.0,4.0,2.0,10.0
14,14,"among 576 patients participating , 533 ( 93 % ) had a reliable TE measurement .",在参与的 576 名患者中，533 名 (93%) 进行了可靠的 TE 测量。,0.5,"['TE', 'measurement']",['measurement'],14,"['在576名患者中,533人(93%)接受了可靠的TE测量。']",0.5,"['TE', 'measurement']",['measurement'],14,在576位参与者中，533位（93%）拥有可靠的TE测量结果。,0.5,"['TE', 'measurement']",['measurement'],8.0,5.0,1.0,10.0
15,15,"significant liver disease was found in 12 % of patients , nearly one third of whom had obesity as their only risk factor .",12% 的患者患有严重的肝病，其中将近三分之一的患者肥胖是唯一的危险因素。,0.4,"['liver disease', 'obesity', 'risk factor', 'in', 'third']","['liver disease', 'obesity']",15,"['显著的肝脏疾病在12%的患者中被发现,其中近三分之一患有肥胖,这是他们唯一的风险因素。']",0.4,"['liver disease', 'obesity', 'risk factor', 'in', 'third']","['obesity', 'risk factor']",15,12%的病人出现了重大的肝脏疾病，其中近三分之一的人仅有肥胖作为他们的唯一风险因素。,0.4,"['liver disease', 'obesity', 'risk factor', 'in', 'third']","['obesity', 'risk factor']",10.0,10.0,5.0,10.0
16,16,"also , importantly , not only was obesity or diabetes each individually a driver of significant liver disease , but their combined presence showed a synergistic effect on prevalence .",同样重要的是，不仅肥胖或糖尿病各自单独成为严重肝病的驱动因素，而且它们的共同存在对患病率显示出协同效应。,0.7,"['presence', 'diabetes', 'prevalence', 'liver disease', 'obesity', 'driver', 'synergistic effect', 'on', 'each', 'but']","['presence', 'diabetes', 'liver disease', 'obesity', 'synergistic effect', 'each', 'but']",16,"['此外,重要的是,不僅肥胖或糖尿病,每個人都是一個重大肝病的導致者,但他們的組合存在表明對流行性有相互作用。']",0.6,"['presence', 'diabetes', 'prevalence', 'liver disease', 'obesity', 'driver', 'synergistic effect', 'on', 'each', 'but']","['presence', 'diabetes', 'prevalence', 'liver disease', 'obesity', 'but']",16,此外，重要的是，肥胖或糖尿病不仅本身就是导致严重肝病的因素，而且它们的共存显示出对发病率的协同效应。,0.6,"['presence', 'diabetes', 'prevalence', 'liver disease', 'obesity', 'driver', 'synergistic effect', 'on', 'each', 'but']","['presence', 'diabetes', 'liver disease', 'obesity', 'synergistic effect', 'but']",10.0,6.0,5.0,10.0
17,17,"Helicobacter pylori is a known risk factor for gastric cancer , and its eradication may be protective against the disease .",幽门螺杆菌是胃癌的已知危险因素，根除幽门螺杆菌可预防该病。,0.375,"['eradication', 'disease', 'helicobacter', 'be', 'risk factor', 'protective', 'gastric cancer', 'and']","['eradication', 'disease', 'gastric cancer']",17,"['Helicobacter pylori 是一种已知的胃癌风险因素,其消除可能对疾病有保护性。']",0.375,"['eradication', 'disease', 'helicobacter', 'be', 'risk factor', 'protective', 'gastric cancer', 'and']","['disease', 'risk factor', 'gastric cancer']",17,"Helicobacter pylori is a known risk factor for gastric cancer , and its eradication may be protective against the disease .

中文：
幽门螺杆菌是胀胃癌的已知风险因素，消除它可能有助于预防这种疾病。",0.375,"['eradication', 'disease', 'helicobacter', 'be', 'risk factor', 'protective', 'gastric cancer', 'and']","['disease', 'risk factor', 'gastric cancer']",10.0,5.0,2.0,10.0
18,18,both garlic and vitamin supplementation may also be protective in populations with nutritional deficiencies .,大蒜和维生素补充剂也可能对营养缺乏的人群起到保护作用。,0.2857142857142857,"['vitamin', 'be', 'garlic', 'nutritional', 'protective', 'with', 'and']","['vitamin', 'garlic']",18,['胡萝卜和维生素补充剂在营养缺陷的人群中也可能有保护性。'],0.2857142857142857,"['vitamin', 'be', 'garlic', 'nutritional', 'protective', 'with', 'and']","['vitamin', 'be']",18,在营养不良的人群中，大蒜和维生素补充都可能具有防护作用。,0.4285714285714285,"['vitamin', 'be', 'garlic', 'nutritional', 'protective', 'with', 'and']","['vitamin', 'be', 'garlic']",10.0,8.0,3.0,10.0
19,19,"the 2258 participants with H. pylori infection were assigned in a 2 × 2 × 2 factorial fashion to H. pylori eradication treatment , supplementation with vitamins ( vitamins C , E , and selenium ) , or supplementation with garlic ( extract and oil ) or to placebos for each .",2258名感染幽门螺杆菌的参与者以2 × 2 × 2析因方式被分配到根除幽门螺杆菌治疗、补充维生素（维生素C、E和硒） ，或补充大蒜（提取物和油） ，或每个安慰剂。,0.625,"['infection', 'placebos', 'extract', 'eradication', 'oil', '2', 'garlic', 'treatment', 'selenium', 'with', 'C', 'E', 'vitamins', 'each', 'to', 'and']","['infection', 'placebos', 'extract', 'eradication', 'oil', '2', 'garlic', 'treatment', 'selenium', 'vitamins']",19,['2258名患有H. pylori感染的参与者以2×2×2因子方式被分配给H. pylori消灭治疗、维生素补充(维生素C、E、和<unk>)或加胡萝卜补充(提取物和油)或每种补充。'],0.375,"['infection', 'placebos', 'extract', 'eradication', 'oil', '2', 'garlic', 'treatment', 'selenium', 'with', 'C', 'E', 'vitamins', 'each', 'to', 'and']","['infection', 'extract', 'oil', '2', 'treatment', 'vitamins']",19,"2258 participants infected with H. pylori were assigned to H. pylori eradication treatment, supplementation with vitamins (vitamins C, E, and selenium), or supplementation with garlic (extract and oil) or to placebos for each in a 2 × 2 × 2 factorial fashion.",0.0625,"['infection', 'placebos', 'extract', 'eradication', 'oil', '2', 'garlic', 'treatment', 'selenium', 'with', 'C', 'E', 'vitamins', 'each', 'to', 'and']",['2'],8.0,7.0,2.0,
20,20,the 1107 participants without H. pylori infection were assigned in a 2 × 2 factorial fashion to vitamin or garlic supplementation or to placebos for each .,1107 名未感染幽门螺杆菌的参与者以 2 × 2 阶乘方式被分配到维生素或大蒜补充剂组或安慰剂组。,0.625,"['infection', 'placebos', 'vitamin', '2', 'garlic', 'each', 'to', 'without']","['infection', 'placebos', 'vitamin', '2', 'garlic']",20,['没有H.pylori感染的1107名参与者以2×2因子方式分配到维生素或胡萝卜补充剂或每人分配到 placebo。'],0.375,"['infection', 'placebos', 'vitamin', '2', 'garlic', 'each', 'to', 'without']","['infection', 'vitamin', '2']",20,将1107名患者分成两组，一组接受维生素补充，一组接受大蒜补充，每组各自再分为服用药物和安慰剂两组。,0.5,"['infection', 'placebos', 'vitamin', '2', 'garlic', 'each', 'to', 'without']","['placebos', 'vitamin', 'garlic', 'each']",10.0,8.0,2.0,7.0
21,21,"H. pylori eradication reduced the incidence of gastric cancer ( odds ratio , 0.48 ) and mortality from gastric cancer ( adjusted hazard ratio , 0.62 ) .",根除幽门螺杆菌降低了胃癌的发病率（比值比，0.48）和胃癌死亡率（调整后的风险比，0.62）。,0.7142857142857143,"['eradication', 'incidence', 'hazard ratio', 'mortality', 'gastric cancer', 'and', 'odds']","['eradication', 'incidence', 'hazard ratio', 'mortality', 'gastric cancer']",21,['H. pylori 消除降低了胃癌的发病率(率为 0.48 )和胃癌的死亡率(调整的危险率为 0.62 )。'],0.4285714285714285,"['eradication', 'incidence', 'hazard ratio', 'mortality', 'gastric cancer', 'and', 'odds']","['incidence', 'mortality', 'gastric cancer']",21,"H. pylori eradication reduced the incidence of gastric cancer ( odds ratio , 0.48 ) and mortality from gastric cancer ( adjusted hazard ratio , 0.62 ) .

Chinese:

H. pylori根除有助于减少胃癌的发病率(赔率比为0.48)和死亡率(调整后的危险比为0.62)。",0.5714285714285714,"['eradication', 'incidence', 'hazard ratio', 'mortality', 'gastric cancer', 'and', 'odds']","['eradication', 'incidence', 'mortality', 'gastric cancer']",10.0,10.0,3.0,8.0
22,22,"vitamin supplementation also decreased the incidence of gastric cancer ( OR , 0.64 ) and mortality from gastric cancer ( aHR , 0.48 ) .","维生素补充剂还降低了胃癌的发病率 (OR, 0.64) 和胃癌死亡率 (aHR, 0.48)。",0.6666666666666666,"['incidence', 'vitamin', 'mortality', 'OR', 'gastric cancer', 'and']","['incidence', 'vitamin', 'mortality', 'gastric cancer']",22,"['维生素补充也降低了胃癌的发病率( OR, 0.64 )和胃癌的死亡率( aHR, 0.48 )。']",0.6666666666666666,"['incidence', 'vitamin', 'mortality', 'OR', 'gastric cancer', 'and']","['incidence', 'vitamin', 'mortality', 'gastric cancer']",22,"vitamin supplementation also decreased the incidence of gastric cancer (OR, 0.64) and mortality from gastric cancer (aHR, 0.48).",0.0,"['incidence', 'vitamin', 'mortality', 'OR', 'gastric cancer', 'and']",[],10.0,9.0,5.0,
23,23,"garlic supplementation did not reduce gastric cancer incidence but did reduce mortality from gastric cancer ( aHR , 0.66 ) .","大蒜补充剂并未降低胃癌的发病率，但确实降低了胃癌的死亡率 (aHR, 0.66)。",1.0,"['incidence', 'reduce', 'garlic', 'mortality', 'gastric cancer', 'but']","['incidence', 'reduce', 'garlic', 'mortality', 'gastric cancer', 'but']",23,"['加糖补充剂没有减少胃癌的发病率,但减少了胃癌的死亡率(aHR,0.66)。']",0.6666666666666666,"['incidence', 'reduce', 'garlic', 'mortality', 'gastric cancer', 'but']","['incidence', 'mortality', 'gastric cancer', 'but']",23,"garlic supplementation did not reduce gastric cancer incidence but did reduce mortality from gastric cancer ( aHR , 0.66 ) .

Chinese:

大蒜补充剂并未减少胃癌发病率，但却可以减少胃癌死亡率（aHR，0.66）。",0.8333333333333334,"['incidence', 'reduce', 'garlic', 'mortality', 'gastric cancer', 'but']","['incidence', 'garlic', 'mortality', 'gastric cancer', 'but']",10.0,8.0,3.0,10.0
24,24,the beneficial effects of both vitamin and garlic supplementation were seen later than those from H. pylori eradication .,维生素和大蒜补充剂的有益作用晚于根除幽门螺杆菌。,0.6,"['eradication', 'vitamin', 'garlic', 'later', 'and']","['eradication', 'vitamin', 'garlic']",24,['维生素和胡萝卜补充剂的有益效果比H.pylori消灭的效果更晚。'],0.2,"['eradication', 'vitamin', 'garlic', 'later', 'and']",['vitamin'],24,在H. pylori清除后，维生素和大蒜补充的有益效果才开始显现。,0.6,"['eradication', 'vitamin', 'garlic', 'later', 'and']","['vitamin', 'garlic', 'later']",10.0,8.0,3.0,10.0
25,25,"although the results reconfirm the benefit of H. pylori eradication at reducing gastric cancer incidence and mortality , the findings of the benefits of vitamin and garlic supplementation required longer observation to become apparent .",虽然结果再次证实了根除幽门螺杆菌对降低胃癌发病率和死亡率的益处，但补充维生素和大蒜的益处的发现需要更长时间的观察才能变得明显。,0.6363636363636364,"['eradication', 'incidence', 'vitamin', 'garlic', 'mortality', 'benefit', 'observation', 'gastric cancer', 'become', 'to', 'and']","['eradication', 'incidence', 'vitamin', 'garlic', 'mortality', 'observation', 'gastric cancer']",25,"['虽然结果证实了H. pylori的消灭对减少胃癌的发病率和死亡率的好处,但维生素和胡萝卜补充的好处的发现需要更长的观察才能显而易见。']",0.5454545454545454,"['eradication', 'incidence', 'vitamin', 'garlic', 'mortality', 'benefit', 'observation', 'gastric cancer', 'become', 'to', 'and']","['incidence', 'vitamin', 'mortality', 'observation', 'gastric cancer', 'and']",25,尽管结果重申了除去H. pylori对减少胃癌发病率和死亡率的益处，但维生素和大蒜补充的益处需要更长时间的观察才能显现出来。,0.5454545454545454,"['eradication', 'incidence', 'vitamin', 'garlic', 'mortality', 'benefit', 'observation', 'gastric cancer', 'become', 'to', 'and']","['incidence', 'vitamin', 'garlic', 'mortality', 'observation', 'gastric cancer']",,,,
26,26,"the generalizability of the findings on supplementation may be limited , given that the study population had baseline nutritional deficiencies and a high risk for gastric cancer , but I would consider recommending a multivitamin for my patients at high risk for gastric cancer .",考虑到研究人群基线营养缺乏和胃癌高风险，补充剂研究结果的普遍性可能有限，但我会考虑向我的胃癌高风险患者推荐复合维生素。,0.3076923076923077,"['population', 'baseline', 'high risk', 'study', 'my', 'be', 'nutritional', 'gastric cancer', 'limited', 'I', 'that', 'but', 'and']","['population', 'baseline', 'gastric cancer', 'but']",26,"['关于补充剂的发现的普遍性可能有限,因为研究人口的基本营养缺陷和胃癌的风险很高,但我会考虑推荐一个多维生素给我的患者患胃癌的风险很高。']",0.2307692307692307,"['population', 'baseline', 'high risk', 'study', 'my', 'be', 'nutritional', 'gastric cancer', 'limited', 'I', 'that', 'but', 'and']","['population', 'gastric cancer', 'but']",26,"给高胃癌风险的患者推荐多种维生素补充剂的可推广性可能有限，因为研究人群在营养方面存在基线缺乏，并且风险较高，但我会考虑为我的高风险患者推荐多种维生素。

Chinese:

鉴于研究人群在营养方面存在基线缺乏，并且风险较高，给高胃癌风险的患者推荐多种维生素补充剂的可推广性可能有限，但我会考虑为我的高风险患者推荐多种维生素。",0.3846153846153846,"['population', 'baseline', 'high risk', 'study', 'my', 'be', 'nutritional', 'gastric cancer', 'limited', 'I', 'that', 'but', 'and']","['population', 'baseline', 'be', 'gastric cancer', 'but']",,,,
27,27,a large cohort study found higher rates of cancer in children who underwent computed tomography than in those who did not .,一项大型队列研究发现，接受过计算机断层扫描的儿童患癌症的几率高于未接受过计算机断层扫描的儿童。,0.1666666666666666,"['cancer', 'who', 'large', 'cohort study', 'computed tomography', 'in']",['cancer'],27,"['一项大型协调研究发现,在受计算 tomography 的儿童中,癌症的发病率高于未经计算的儿童中。']",0.1666666666666666,"['cancer', 'who', 'large', 'cohort study', 'computed tomography', 'in']",['cancer'],27,一项大型队列研究发现，接受过CT扫描的儿童患癌症的比例要高于那些未接受CT扫描的儿童。,0.1666666666666666,"['cancer', 'who', 'large', 'cohort study', 'computed tomography', 'in']",['cancer'],,,,
28,28,"concerns about the carcinogenic effects of radiation are largely based on data from atomic bomb survivors , and the effects of ionizing radiation used for medical imaging are less well studied .",对辐射致癌作用的担忧主要基于原子弹爆炸幸存者的数据，而用于医学成像的电离辐射的影响研究较少。,0.4444444444444444,"['carcinogenic', 'data', 'bomb', 'medical', 'ionizing radiation', 'well', 'atomic', 'imaging', 'and']","['data', 'bomb', 'ionizing radiation', 'and']",28,"['关于辐射的致癌作用的担忧主要是基于原子弹幸存者的数据,用于医学图像的离子辐射的效果不太好研究。']",0.2222222222222222,"['carcinogenic', 'data', 'bomb', 'medical', 'ionizing radiation', 'well', 'atomic', 'imaging', 'and']","['data', 'bomb']",28,关于辐射致癌作用的担忧主要基于原子弹幸存者的数据，而用于医疗成像的带电粒子辐射的影响则不是很好地研究。,0.3333333333333333,"['carcinogenic', 'data', 'bomb', 'medical', 'ionizing radiation', 'well', 'atomic', 'imaging', 'and']","['data', 'bomb', 'and']",,,,
29,29,"to count as an exposure , diagnostic radiation had to have occurred two years before any cancer diagnosis .",要算作一次暴露，诊断性辐射必须在任何癌症诊断前两年发生。,0.5454545454545454,"['count', 'cancer', 'radiation', 'exposure', 'diagnosis', 'diagnostic', 'as', 'have', 'before', 'to', 'two']","['cancer', 'radiation', 'exposure', 'diagnosis', 'before', 'two']",29,"['要计算为曝光,诊断辐射必须在任何癌症诊断之前发生两年。']",0.5454545454545454,"['count', 'cancer', 'radiation', 'exposure', 'diagnosis', 'diagnostic', 'as', 'have', 'before', 'to', 'two']","['cancer', 'radiation', 'exposure', 'diagnosis', 'before', 'two']",29,被认为是一次暴露，诊断性辐射必须在任何癌症诊断前两年发生。,0.5454545454545454,"['count', 'cancer', 'radiation', 'exposure', 'diagnosis', 'diagnostic', 'as', 'have', 'before', 'to', 'two']","['cancer', 'radiation', 'exposure', 'diagnosis', 'before', 'two']",,,,
30,30,"new cancers were diagnosed in 22,000 patients ( 0.02 % ) , including 1444 patients after radiation exposure ( 0.1 % ) .","22,000 名患者 (0.02%) 被诊断出新的癌症，其中包括 1444 名接受辐射照射后的患者 (0.1%)。",0.8,"['radiation', 'exposure', 'after', 'in', 'new']","['radiation', 'exposure', 'after', 'new']",30,"['新的癌症被诊断为22000名患者(0.02%),其中1444名患者在辐射曝光后(0.1%)。']",0.8,"['radiation', 'exposure', 'after', 'in', 'new']","['radiation', 'exposure', 'after', 'new']",30,"新的癌症在22,000名病人身上被诊断出来（0.02%），其中1444名病人是在放射线暴露后被诊断出来的（0.1%）。",0.8,"['radiation', 'exposure', 'after', 'in', 'new']","['radiation', 'exposure', 'after', 'new']",,,,
31,31,"after adjustment for age and sex , radiation exposure was associated with a relative risk of 1.64 for developing a new cancer .",在针对年龄和性别进行调整后，辐射暴露与患上新癌症的相对风险 1.64 相关。,0.5714285714285714,"['cancer', 'radiation', 'exposure', 'sex', 'adjustment', 'relative', 'developing', 'associated', 'age', 'risk', 'after', 'with', 'and', 'new']","['cancer', 'radiation', 'exposure', 'sex', 'age', 'risk', 'after', 'new']",31,"['在年龄和性别调整后,辐射曝光与新癌症发育的相对风险为1.64相关。']",0.5714285714285714,"['cancer', 'radiation', 'exposure', 'sex', 'adjustment', 'relative', 'developing', 'associated', 'age', 'risk', 'after', 'with', 'and', 'new']","['cancer', 'radiation', 'exposure', 'sex', 'age', 'risk', 'after', 'new']",31,根据年龄和性别调整后，辐射暴露与开发新癌症相关的相对风险为1.64。,0.5714285714285714,"['cancer', 'radiation', 'exposure', 'sex', 'adjustment', 'relative', 'developing', 'associated', 'age', 'risk', 'after', 'with', 'and', 'new']","['cancer', 'radiation', 'exposure', 'sex', 'age', 'risk', 'after', 'new']",,,,
32,32,"the highest risks were for myelodysplasia , leukemias , and breast , thyroid , and oral and pharyngeal cancers .",风险最高的是骨髓增生异常、白血病、乳腺癌、甲状腺癌、口腔癌和咽癌。,0.2,"['thyroid', 'oral', 'pharyngeal', 'breast', 'and']",['thyroid'],32,"['最高的风险是甲状腺,乳腺,甲状腺和口腔和甲状腺癌。']",0.2,"['thyroid', 'oral', 'pharyngeal', 'breast', 'and']",['thyroid'],32,最高的风险是脊髓增生异常症、白血病和乳腺癌、甲状腺癌和口腔和咽癌。,0.2,"['thyroid', 'oral', 'pharyngeal', 'breast', 'and']",['thyroid'],,,,
33,33,"however , the overall risk of cancer was still very low , so when imaging is necessary , we should not hesitate to order it .",但是，整体患癌症的风险仍然很低，因此当需要进行影像学检查时，我们应该毫不犹豫地进行检查。,0.4,"['cancer', 'order', 'still', 'low', 'necessary', 'risk', 'imaging', 'so', 'to', 'we']","['cancer', 'low', 'risk', 'so']",33,"['然而,癌症的总风险仍然很低,所以当图像需要时,我们不应该犹豫地订购它。']",0.4,"['cancer', 'order', 'still', 'low', 'necessary', 'risk', 'imaging', 'so', 'to', 'we']","['cancer', 'low', 'risk', 'so']",33,然而，癌症的整体风险仍然很低，因此，当必须进行成像时，我们不应犹豫不决。,0.4,"['cancer', 'order', 'still', 'low', 'necessary', 'risk', 'imaging', 'so', 'to', 'we']","['cancer', 'low', 'risk', 'so']",,,,
34,34,"treatment with cool running water was associated with improved outcomes , especially when administered for at least 20 minutes .",用凉爽的自来水治疗与改善结果有关，尤其是在至少持续 20 分钟的情况下。,0.5,"['water', 'running', 'associated', 'treatment', 'cool', 'with']","['water', 'treatment', 'cool']",34,"['冷流水的治疗与改善结果有关,特别是当服用至少20分钟时。']",0.5,"['water', 'running', 'associated', 'treatment', 'cool', 'with']","['water', 'treatment', 'cool']",34,Cooling the affected area with running water for at least 20 minutes is associated with improved outcomes.,0.0,"['water', 'running', 'associated', 'treatment', 'cool', 'with']",[],,,,
35,35,recent evidence suggests that burns in adults heal better when treated with cool running water ( Burns 2019 ; 45 : 433 ; PLoS One 2016 ; 11 : e0147259 ) .,最近的证据表明，成人烧伤在用凉爽的自来水处理后愈合得更好（Burns 2019；45：433；PLoS One 2016；11：e0147259）。,0.5555555555555556,"['recent', 'water', 'running', 'heal', 'evidence', 'cool', 'with', 'burns', 'that']","['water', 'heal', 'evidence', 'cool', 'burns']",35,"['最近的证据表明,燃烧在成年人治疗时愈合更好(燃烧2019;45:433;PLoS One2016;11:e0147259)。']",0.2222222222222222,"['recent', 'water', 'running', 'heal', 'evidence', 'cool', 'with', 'burns', 'that']","['heal', 'evidence']",35,最近的证据表明，成人的烧伤在用冷水冲洗后会更好地愈合（Burns 2019；45：433；PLoS One 2016；11：e0147259）。,0.5555555555555556,"['recent', 'water', 'running', 'heal', 'evidence', 'cool', 'with', 'burns', 'that']","['water', 'heal', 'evidence', 'cool', 'burns']",,,,
36,36,"to assess the effect of this treatment for pediatric burns , researchers queried an Australian burn center database that included structured interviews with patients and parents about first aid provided within 3 hours of injury , prior to burn center assessment .",为了评估这种治疗对小儿烧伤的效果，研究人员查询了澳大利亚烧伤中心的数据库，该数据库包括在烧伤中心评估之前对患者和父母进行的关于受伤 3 小时内提供的急救的结构化访谈。,0.4705882352941176,"['injury', 'parents', 'database', 'first aid', 'pediatric', 'assessment', 'treatment', 'prior', 'effect', '3', 'with', 'burns', 'burn center', 'this', 'that', 'to', 'and']","['injury', 'first aid', 'assessment', 'treatment', 'effect', 'burns', 'burn center', 'to']",36,"['为了评估这种治疗对儿科烧伤的影响,研究人员询问了澳大利亚烧伤中心的数据库,其中包括与患者和父母的结构化采访,关于在伤害后3小时内提供的第一援助,在烧伤中心的评估之前。']",0.3529411764705882,"['injury', 'parents', 'database', 'first aid', 'pediatric', 'assessment', 'treatment', 'prior', 'effect', '3', 'with', 'burns', 'burn center', 'this', 'that', 'to', 'and']","['injury', 'assessment', 'treatment', 'burns', 'burn center', 'to']",36,"为了评估这种治疗方法对儿童烧伤的影响，研究人员查询了一个包含有关受伤3小时内提供的急救、在烧伤中心评估之前的结构化采访患者和家长的澳大利亚烧伤中心数据库。

Chinese:

为了评估这种治疗方法对儿童烧伤的影响，研究人员查询了一个包含有关受伤3小时内提供的急救、在烧伤中心评估之前的结构化采访患者和家长的澳大利亚烧伤中心数据库。",0.3529411764705882,"['injury', 'parents', 'database', 'first aid', 'pediatric', 'assessment', 'treatment', 'prior', 'effect', '3', 'with', 'burns', 'burn center', 'this', 'that', 'to', 'and']","['injury', 'first aid', 'assessment', 'treatment', 'burns', 'burn center']",,,,
37,37,"patients with friction , electrical , and chemical burns as well as those with missing data were excluded .",有摩擦、电和化学灼伤的患者以及数据缺失的患者被排除在外。,0.3333333333333333,"['data', 'chemical', 'friction', 'well', 'as', 'with', 'burns', 'and', 'missing']","['data', 'friction', 'missing']",37,['被排除患有震动、电气和化学燃烧的患者以及缺乏数据的患者。'],0.2222222222222222,"['data', 'chemical', 'friction', 'well', 'as', 'with', 'burns', 'and', 'missing']","['data', 'missing']",37,"Patients with friction, electrical, and chemical burns as well as those with missing data were excluded.

Chinese:

摩擦伤、电伤、化学灼伤患者以及缺失数据的患者被排除在外。",0.3333333333333333,"['data', 'chemical', 'friction', 'well', 'as', 'with', 'burns', 'and', 'missing']","['data', 'friction', 'missing']",,,,
38,38,"although observational , this study provides fairly convincing evidence that treatment of pediatric burns with cool running water as soon as possible improves important clinical outcomes .",虽然是观察性研究，但这项研究提供了相当有说服力的证据，证明尽快用凉爽的自来水治疗小儿烧伤可改善重要的临床结果。,0.5384615384615384,"['pediatric', 'study', 'water', 'running', 'treatment', 'clinical', 'evidence', 'cool', 'as', 'with', 'burns', 'this', 'that']","['water', 'treatment', 'clinical', 'evidence', 'cool', 'burns', 'this']",38,"['虽然观察性,但这项研究提供了相当令人信服的证据,儿童烧伤的治疗用冷流水尽快改善重要临床结果。']",0.4615384615384615,"['pediatric', 'study', 'water', 'running', 'treatment', 'clinical', 'evidence', 'cool', 'as', 'with', 'burns', 'this', 'that']","['water', 'treatment', 'clinical', 'evidence', 'cool', 'burns']",38,"Although observational, this study provides fairly convincing evidence that treatment of pediatric burns with cool running water as soon as possible improves important clinical outcomes.

Chinese:

尽管是观察性的，这项研究相当有说服力地表明，尽早用冷水治疗儿童烧伤会改善重要的临床结局。",0.4615384615384615,"['pediatric', 'study', 'water', 'running', 'treatment', 'clinical', 'evidence', 'cool', 'as', 'with', 'burns', 'this', 'that']","['water', 'treatment', 'clinical', 'cool', 'burns', 'this']",,,,
39,39,"the authors note that durations longer than 20 minutes have not been shown to provide additive benefit and could be harmful , although that was not tested in this study .",作者指出，持续时间超过 20 分钟并没有显示出额外的好处，而且可能有害，尽管本研究并未对此进行测试。,0.1,"['study', 'additive', 'note', 'benefit', 'have not', 'this', 'that', 'in', 'to', 'and']",['and'],39,"['作者指出,超过20分钟的持续时间没有被证明提供添加益处,并且可能有害,尽管这项研究没有测试。']",0.0,"['study', 'additive', 'note', 'benefit', 'have not', 'this', 'that', 'in', 'to', 'and']",[],39,研究作者指出，时长超过20分钟的持续时间并没有显示出额外的益处，可能会有害，尽管这项研究并没有对此进行测试。,0.0,"['study', 'additive', 'note', 'benefit', 'have not', 'this', 'that', 'in', 'to', 'and']",[],,,,
40,40,"HbA1c was averaged over time for each patient ( mean HbA1c level for the cohort , 8.0 % ) .",对每个患者的 HbA1c 随时间进行平均（队列的平均 HbA1c 水平，8.0%）。,0.5714285714285714,"['mean', 'time', 'patient', 'level', 'cohort', 'each', 'over']","['mean', 'time', 'patient', 'level']",40,['HbA1c 是每個患者的時間平均值(每個患者的 HbA1c 水平平均值為 8.0 % )。'],0.4285714285714285,"['mean', 'time', 'patient', 'level', 'cohort', 'each', 'over']","['mean', 'patient', 'level']",40,"HbA1c was averaged over time for each patient (mean HbA1c level for the cohort, 8.0%).",0.0,"['mean', 'time', 'patient', 'level', 'cohort', 'each', 'over']",[],,,,
41,41,"thus , the authors suggest that an HbA1c target of 6.5 % to 6.9 % is reasonable .",因此，作者建议将 HbA1c 目标设定为 6.5% 至 6.9% 是合理的。,0.4,"['target', 'thus', 'suggest', 'that', 'to']","['target', 'thus']",41,"['因此,作者建议一个HbA1c目标为6.5%至6.9%是合理的。']",0.4,"['target', 'thus', 'suggest', 'that', 'to']","['target', 'thus']",41,因此，作者建议HbA1c目标在6.5%到6.9%之间是合理的。,0.4,"['target', 'thus', 'suggest', 'that', 'to']","['target', 'thus']",,,,
42,42,"no ; benefits will outweigh risks for many menopausal patients who , through discussion of research findings and shared decision making , can make informed choices about HT use .",不 ;对于许多绝经期患者而言，收益将大于风险，他们可以通过讨论研究结果和共同决策，就 HT 使用做出明智的选择。,0.5,"['research', 'who', 'shared decision making', 'menopausal', 'will', 'discussion', 'and', 'make']","['research', 'shared decision making', 'discussion', 'and']",42,"['好处将超越许多更年期患者的风险,通过讨论研究结果和共享决策,可以做出关于HT使用的有信息的选择。']",0.25,"['research', 'who', 'shared decision making', 'menopausal', 'will', 'discussion', 'and', 'make']","['research', 'discussion']",42,没有证据表明，许多更年期患者的利益会超过使用激素治疗所涉及的风险。通过讨论研究结果和共同做出决策，这些患者可以对激素治疗做出明智的选择。,0.25,"['research', 'who', 'shared decision making', 'menopausal', 'will', 'discussion', 'and', 'make']","['research', 'discussion']",,,,
43,43,hormone therapy ( HT ) is the most effective treatment for bothersome menopausal vasomotor symptoms .,激素疗法 (HT) 是治疗烦人的更年期血管舒缩症状最有效的方法。,0.5,"['hormone', 'vasomotor', 'symptoms', 'therapy', 'menopausal', 'treatment']","['hormone', 'therapy', 'treatment']",43,['荷尔蒙治疗(HT)是最有效的治疗缓慢的更年期血管症状。'],0.3333333333333333,"['hormone', 'vasomotor', 'symptoms', 'therapy', 'menopausal', 'treatment']","['therapy', 'treatment']",43,hormone therapy (HT) is the most effective treatment for bothersome menopausal vasomotor symptoms.,0.0,"['hormone', 'vasomotor', 'symptoms', 'therapy', 'menopausal', 'treatment']",[],,,,
44,44,both regimens raised risk for stroke and venous thromboembolism but lowered risk for fractures and diabetes .,这两种方案都会增加中风和静脉血栓栓塞的风险，但会降低骨折和糖尿病的风险。,0.6666666666666666,"['diabetes', 'stroke', 'venous', 'thromboembolism', 'risk', 'raised', 'fractures', 'but', 'and']","['diabetes', 'stroke', 'thromboembolism', 'risk', 'fractures', 'but']",44,"['两种饮食都增加了中风和血管肿瘤的风险,但减少了裂缝和糖尿病的风险。']",0.4444444444444444,"['diabetes', 'stroke', 'venous', 'thromboembolism', 'risk', 'raised', 'fractures', 'but', 'and']","['diabetes', 'stroke', 'risk', 'but']",44,两种方案都会增加患中风和静脉血栓栓塞的风险，但降低了患骨折和糖尿病的风险。,0.6666666666666666,"['diabetes', 'stroke', 'venous', 'thromboembolism', 'risk', 'raised', 'fractures', 'but', 'and']","['diabetes', 'stroke', 'thromboembolism', 'risk', 'fractures', 'but']",,,,
45,45,"although observational studies over the past several decades have linked HT to increased breast cancer risk , the specific associations with HT formulation , route of delivery , and duration have been poorly studied .",尽管过去几十年的观察性研究已将 HT 与乳腺癌风险增加联系起来，但与 HT 配方、分娩途径和持续时间的具体关联研究很少。,0.4166666666666667,"['breast cancer', 'delivery', 'risk', 'specific', 'formulation', 'duration', 'with', 'have', 'over', 'to', 'and', 'past']","['breast cancer', 'delivery', 'risk', 'duration', 'over']",45,"['虽然过去几十年的观测研究将HT与乳腺癌风险增加有关,但与HT的具体组成、分娩路径和持续时间的具体联系已被研究不佳。']",0.5,"['breast cancer', 'delivery', 'risk', 'specific', 'formulation', 'duration', 'with', 'have', 'over', 'to', 'and', 'past']","['breast cancer', 'delivery', 'risk', 'duration', 'have', 'over']",45,尽管过去几十年来的观察性研究已经将女性激素与乳腺癌风险增加联系起来，但是具体与女性激素的配方、服用方式和持续时间的关联仍研究得不够透彻。,0.3333333333333333,"['breast cancer', 'delivery', 'risk', 'specific', 'formulation', 'duration', 'with', 'have', 'over', 'to', 'and', 'past']","['breast cancer', 'risk', 'duration', 'over']",,,,
46,46,all systemic HT formulations ( including those using oral conjugated equine estrogens or estradiol or transdermal estradiol ) were associated with excess risk for breast cancer .,所有全身性 HT 制剂（包括使用口服结合马雌激素或雌二醇或透皮雌二醇的制剂）都与患乳腺癌的风险过高有关。,0.3333333333333333,"['excess', 'oral', 'breast cancer', 'associated', 'equine', 'risk', 'systemic', 'estradiol', 'with', 'estrogens', 'transdermal', 'all']","['breast cancer', 'risk', 'estradiol', 'transdermal']",46,['所有系统的HT配方(包括使用口服合并的乙<unk>雌激素或 estradiol或 transdermal estradiol)都与乳腺癌的过度风险有关。'],0.25,"['excess', 'oral', 'breast cancer', 'associated', 'equine', 'risk', 'systemic', 'estradiol', 'with', 'estrogens', 'transdermal', 'all']","['breast cancer', 'risk', 'systemic']",46,所有体系性应用黄体酮制剂（包括那些使用口服已配制的马雌酚醇或雌二醇或经皮雌二醇的制剂）与乳腺癌的风险增加有关。,0.25,"['excess', 'oral', 'breast cancer', 'associated', 'equine', 'risk', 'systemic', 'estradiol', 'with', 'estrogens', 'transdermal', 'all']","['breast cancer', 'risk', 'estradiol']",,,,
47,47,type of progestogen did not appear to affect these associations .,孕激素的类型似乎并未影响这些关联。,0.6666666666666666,"['type', 'affect', 'progestogen']","['type', 'affect']",47,['这种类型的蛋白质似乎不会影响这些组合。'],0.6666666666666666,"['type', 'affect', 'progestogen']","['type', 'affect']",47,"Type of progestogen did not appear to affect these associations.

Chinese:

类型的孕激素似乎不会影响这些关联。",0.6666666666666666,"['type', 'affect', 'progestogen']","['type', 'affect']",,,,
48,48,vaginal estrogen was not associated with increased risk .,阴道雌激素与风险增加无关。,0.4,"['estrogen', 'vaginal', 'associated', 'risk', 'with']","['estrogen', 'risk']",48,['阴道雌激素与增加风险无关。'],0.4,"['estrogen', 'vaginal', 'associated', 'risk', 'with']","['estrogen', 'risk']",48,vaginal estrogen was not associated with increased risk.,0.0,"['estrogen', 'vaginal', 'associated', 'risk', 'with']",[],10.0,10.0,5.0,
49,49,"assuming the reported associations are causal , the authors estimated the absolute risk for breast cancer up to age 70 .",假设报告的关联是因果关系，作者估计了 70 岁以下患乳腺癌的绝对风险。,0.4285714285714285,"['absolute', 'breast cancer', 'age', 'risk', 'causal', 'up', 'to']","['absolute', 'breast cancer', 'risk']",49,"['假设报告的协会是因果性的,作者估计到70岁之前患乳腺癌的绝对风险。']",0.4285714285714285,"['absolute', 'breast cancer', 'age', 'risk', 'causal', 'up', 'to']","['absolute', 'breast cancer', 'risk']",49,"Assuming the reported associations are causal, the authors estimated the absolute risk for breast cancer up to age 70.

Chinese:

如果报告的相关性是因果关系，作者估计了70岁以前乳腺癌的绝对风险。",0.4285714285714285,"['absolute', 'breast cancer', 'age', 'risk', 'causal', 'up', 'to']","['absolute', 'breast cancer', 'risk']",10.0,8.0,4.0,10.0
50,50,"at 10 years of HT use , risks were approximately twice that at 5 years .",使用 HT 10 年时，风险大约是 5 年时的两倍。,0.25,"['5', 'approximately', 'that', 'twice']",['5'],50,"['在使用10年HT时,风险大约是5年时的两倍。']",0.25,"['5', 'approximately', 'that', 'twice']",['5'],50,在使用高纤维饮食10年后，风险大约是5年时的两倍。,0.25,"['5', 'approximately', 'that', 'twice']",['5'],10.0,10.0,5.0,5.0
51,51,"for EPT , both the randomized WHI trial and this new Lancet analysis of observational data indicated an increased risk for breast cancer .",对于 EPT，随机 WHI 试验和这项新的柳叶刀观察数据分析均表明患乳腺癌的风险增加。,0.4,"['lancet', 'analysis', 'breast cancer', 'risk', 'trial', 'observational data', 'EPT', 'this', 'and', 'new']","['analysis', 'breast cancer', 'risk', 'new']",51,"['对于EPT,无论是随机的WHI测试还是新的Lancet观测数据分析,都表明乳腺癌的风险增加。']",0.6,"['lancet', 'analysis', 'breast cancer', 'risk', 'trial', 'observational data', 'EPT', 'this', 'and', 'new']","['analysis', 'breast cancer', 'risk', 'observational data', 'this', 'new']",51,对于EPT，随机的WHI试验和最新的《柳叶刀》观察数据分析都表明乳腺癌风险增加。,0.4,"['lancet', 'analysis', 'breast cancer', 'risk', 'trial', 'observational data', 'EPT', 'this', 'and', 'new']","['analysis', 'breast cancer', 'risk', 'new']",10.0,10.0,5.0,10.0
52,52,could the excess risk found in observational studies be exaggerated due to inherent limitations of the study design ?,由于研究设计的固有局限性，是否会夸大观察性研究中发现的额外风险？,0.375,"['excess', 'inherent', 'study', 'be', 'risk', 'design', 'due', 'to']","['risk', 'design', 'to']",52,['在观察研究中发现的过度风险是否会由于研究设计的本质限制而被夸张?'],0.5,"['excess', 'inherent', 'study', 'be', 'risk', 'design', 'due', 'to']","['be', 'risk', 'design', 'to']",52,观察研究中发现的风险过剩是否因为研究设计的固有局限而被夸大？,0.375,"['excess', 'inherent', 'study', 'be', 'risk', 'design', 'due', 'to']","['excess', 'risk', 'design']",10.0,10.0,5.0,9.0
53,53,"in contrast , in the WHI trial ( and in most randomized trials of HT ) , both users and nonusers underwent uniformly standardized mammographic screening .",相比之下，在 WHI 试验（以及大多数 HT 随机试验）中，使用者和非使用者都接受了统一标准化的乳房 X 光检查。,0.0,"['contrast', 'screening', 'trial', 'and']",[],53,"['相反,在WHI试验(和大多数随机试验的HT)中,用户和未使用者都接受了均匀标准化的乳房筛查。']",0.25,"['contrast', 'screening', 'trial', 'and']",['screening'],53,相反，在WHI试验（以及大多数随机化的女性激素治疗试验）中，使用者和不使用者都经历过统一标准化的乳房X光筛查。,0.25,"['contrast', 'screening', 'trial', 'and']",['screening'],10.0,10.0,5.0,10.0
54,54,"thus , the excess breast cancer risk in observational studies could reflect increased mammographic detection of nonlethal cancers .",因此，观察性研究中乳腺癌风险过高可能反映了非致命性癌症的乳房 X 光检查检测率增加。,0.7142857142857143,"['excess', 'detection', 'breast cancer', 'reflect', 'risk', 'thus', 'in']","['detection', 'breast cancer', 'reflect', 'risk', 'thus']",54,"['因此,在观测研究中,乳腺癌的过度风险可能会反映非乳腺癌的增加乳腺癌检测。']",0.7142857142857143,"['excess', 'detection', 'breast cancer', 'reflect', 'risk', 'thus', 'in']","['detection', 'breast cancer', 'reflect', 'risk', 'thus']",54,因此，观察研究中的乳腺癌风险过高可能反映出非致命性癌症的增加。,0.7142857142857143,"['excess', 'detection', 'breast cancer', 'reflect', 'risk', 'thus', 'in']","['detection', 'breast cancer', 'reflect', 'risk', 'thus']",,,,
55,55,"accordingly , one advantage that observational studies have over randomized trials ( usually limited to 5 − 7 years of treatment ) is their ability to assess extended use .",因此，观察性研究优于随机试验（通常限于 5-7 年的治疗）的一个优势是它们能够评估延长使用时间。,0.5,"['5', 'treatment', 'advantage', 'ability', 'assess', 'limited', 'have', 'that', 'over', 'to']","['5', 'treatment', 'advantage', 'assess', 'to']",55,"['因此,观察研究对随机试验(通常限于5～7年的治疗)的一个优点是它们能够评估延长使用。']",0.5,"['5', 'treatment', 'advantage', 'ability', 'assess', 'limited', 'have', 'that', 'over', 'to']","['5', 'treatment', 'advantage', 'assess', 'to']",55,因此，观察研究相对于随机试验的一个优势在于它们可以评估长期使用。,0.3,"['5', 'treatment', 'advantage', 'ability', 'assess', 'limited', 'have', 'that', 'over', 'to']","['advantage', 'assess', 'to']",,,,
56,56,"understandably , women are often concerned about breast cancer risk as they make decisions about HT ; however , such decisions should be guided by the big picture .",可以理解的是，女性在做出关于 HT 的决定时通常会担心患乳腺癌的风险；但是，此类决策应以大局为指导。,0.6666666666666666,"['breast cancer', 'be', 'picture', 'risk', 'by', 'make']","['breast cancer', 'be', 'risk', 'by']",56,"['可以理解的,女性经常担心乳腺癌的风险,因为他们做出关于HT的决定;但是,这样的决定应该由大图像引导。']",0.6666666666666666,"['breast cancer', 'be', 'picture', 'risk', 'by', 'make']","['breast cancer', 'picture', 'risk', 'by']",56,"understandably, women are often concerned about breast cancer risk as they make decisions about HT; however, such decisions should be guided by the big picture.

Chinese:

理解地，女性在做出激素替代疗法决定时，经常会担心乳腺癌的风险；然而，这类决定应该由总体情况来指导。",0.6666666666666666,"['breast cancer', 'be', 'picture', 'risk', 'by', 'make']","['breast cancer', 'be', 'risk', 'by']",,,,
57,57,"on an absolute scale , many of the risks associated with HT are modest .",从绝对规模上看，许多与 HT 相关的风险是适度的。,0.2,"['scale', 'absolute', 'associated', 'with', 'on']",['absolute'],57,"['在绝对范围内,与HT相关的许多风险是微不足道的。']",0.2,"['scale', 'absolute', 'associated', 'with', 'on']",['absolute'],57,在绝对尺度上，许多与高热相关的风险是温和的。,0.2,"['scale', 'absolute', 'associated', 'with', 'on']",['absolute'],,,,
58,58,the largest hazard ratio associated with HT use corresponds to an elevated risk for venous thromboembolism - and using transdermal rather than oral estrogen appeared to attenuate this risk .,与 HT 使用相关的最大风险比对应于静脉血栓栓塞风险的升高 - 使用透皮而不是口服雌激素似乎可以降低这种风险。,0.5714285714285714,"['estrogen', 'hazard ratio', 'oral', 'venous', 'thromboembolism', 'associated', 'attenuate', 'risk', 'with', 'transdermal', '-', 'this', 'to', 'and']","['estrogen', 'hazard ratio', 'thromboembolism', 'risk', 'transdermal', 'this', 'to', 'and']",58,"['与HT使用相关的最大风险比例相当于血管血管肿瘤的风险增加,而使用跨皮质而不是口服雌激素似乎会减轻这种风险。']",0.4285714285714285,"['estrogen', 'hazard ratio', 'oral', 'venous', 'thromboembolism', 'associated', 'attenuate', 'risk', 'with', 'transdermal', '-', 'this', 'to', 'and']","['estrogen', 'hazard ratio', 'risk', 'this', 'to', 'and']",58,最大的危险比与使用激素替代疗法相关联的是增加了血栓形成的风险，而使用经皮而不是口服雌激素似乎能够减轻这种风险。,0.2857142857142857,"['estrogen', 'hazard ratio', 'oral', 'venous', 'thromboembolism', 'associated', 'attenuate', 'risk', 'with', 'transdermal', '-', 'this', 'to', 'and']","['estrogen', 'risk', 'this', 'and']",,,,
59,59,"for many women , risks associated with HT are offset by reductions in symptoms , improved quality of life , and benefits in other health outcomes , such as fractures .",对于许多女性来说，与 HT 相关的风险会被症状减轻、生活质量改善以及骨折等其他健康结果的益处所抵消。,0.5,"['health', 'symptoms', 'offset', 'associated', 'quality of life', 'with', 'fractures', 'in', 'by', 'and']","['health', 'offset', 'quality of life', 'fractures', 'by']",59,"['对于许多妇女来说,与HT相关的风险是由症状的减少、生活质量的改善以及其他健康结果的好处,如骨折来补偿的。']",0.5,"['health', 'symptoms', 'offset', 'associated', 'quality of life', 'with', 'fractures', 'in', 'by', 'and']","['health', 'offset', 'quality of life', 'fractures', 'by']",59,对于许多女性来说，使用激素替代疗法所带来的风险被其他健康结果所抵消，比如说症状的减轻、生活质量的提高以及骨折的预防。,0.5,"['health', 'symptoms', 'offset', 'associated', 'quality of life', 'with', 'fractures', 'in', 'by', 'and']","['health', 'offset', 'quality of life', 'fractures', 'by']",,,,
60,60,"the net effects of HT are most favorable for recently menopausal women who have moderate to severe vasomotor symptoms and low or average risks for breast cancer , cardiovascular disease , and venous thromboembolism .",HT 的净效应最有利于最近绝经的妇女，她们有中度至重度血管舒缩症状，患乳腺癌、心血管疾病和静脉血栓栓塞症的风险较低或一般。,0.4666666666666667,"['net', 'average', 'who', 'vasomotor', 'venous', 'breast cancer', 'moderate', 'symptoms', 'thromboembolism', 'menopausal', 'cardiovascular disease', 'low', 'severe', 'have', 'and']","['breast cancer', 'thromboembolism', 'menopausal', 'cardiovascular disease', 'low', 'severe', 'have']",60,"['HT的净效应最有利于最近更年期妇女,患有适度至严重的血管发作症状,乳腺癌、心血管疾病和阴道血管肿瘤的风险较低或平均。']",0.3333333333333333,"['net', 'average', 'who', 'vasomotor', 'venous', 'breast cancer', 'moderate', 'symptoms', 'thromboembolism', 'menopausal', 'cardiovascular disease', 'low', 'severe', 'have', 'and']","['average', 'breast cancer', 'cardiovascular disease', 'low', 'have']",60,综合来看，黑松油最有利于近期退热的女性，她们有中度至重度血管扩张症状，且乳腺癌、心血管疾病和静脉血栓形成风险较低或中等。,0.3333333333333333,"['net', 'average', 'who', 'vasomotor', 'venous', 'breast cancer', 'moderate', 'symptoms', 'thromboembolism', 'menopausal', 'cardiovascular disease', 'low', 'severe', 'have', 'and']","['breast cancer', 'cardiovascular disease', 'low', 'severe', 'have']",,,,
61,61,"in sum , women deserve reliable information in order to make informed decisions - aligned with their personal preferences - on whether the potential benefits of HT are likely to outweigh the potential risks .",总而言之，女性应该得到可靠的信息，以便根据她们的个人喜好做出明智的决定，了解 HT 的潜在益处是否可能超过潜在风险。,0.25,"['potential', 'sum', 'personal', 'information', 'with', '-', 'in order to', 'make']","['information', 'in order to']",61,"['总的来说,妇女应获得可靠的信息,以便根据自己的个人偏好做出有意识的决定,关于HT的潜在好处是否可能超越潜在的风险。']",0.5,"['potential', 'sum', 'personal', 'information', 'with', '-', 'in order to', 'make']","['potential', 'personal', 'information', 'in order to']",61,总而言之，妇女需要可靠的信息来做出明智的决定，是否应该考虑激素替代疗法的潜在好处大于潜在风险。,0.125,"['potential', 'sum', 'personal', 'information', 'with', '-', 'in order to', 'make']",['information'],,,,
62,62,"the primary outcome was treatment success , defined as a decrease of 50 % or more in the Gastroesophageal Reflux Disease ( GERD ) -Health Related Quality of Life score ( range , 0 to 50 , with higher scores indicating worse symptoms ) at 1 year .",主要结果是治疗成功，定义为 1 年时胃食管反流病 (GERD) 与健康相关的生活质量评分（范围 0 至 50，评分越高表示症状越严重）下降 50% 或更多。,0.5625,"['disease', 'decrease', 'defined', 'range', 'year', '1', 'outcome', 'symptoms', 'treatment', 'primary', 'success', 'quality of life', 'score', 'with', 'gastroesophageal reflux', 'worse']","['disease', 'range', 'year', '1', 'outcome', 'treatment', 'success', 'quality of life', 'gastroesophageal reflux']",62,"['初步结果是治疗成功,定义为Gastroesophageal Reflux Disease(GERD) -Health Related Quality of Life Score(范围,0至50,高得分表明症状恶化)的50%或以上下降1年。']",0.375,"['disease', 'decrease', 'defined', 'range', 'year', '1', 'outcome', 'symptoms', 'treatment', 'primary', 'success', 'quality of life', 'score', 'with', 'gastroesophageal reflux', 'worse']","['range', 'year', '1', 'outcome', 'treatment', 'success']",62,主要结果是治疗成功，定义为在1年内胃食管反流病（GERD）相关生活质量评分（范围，0至50，较高分表示症状更差）下降50％或更多。,0.5625,"['disease', 'decrease', 'defined', 'range', 'year', '1', 'outcome', 'symptoms', 'treatment', 'primary', 'success', 'quality of life', 'score', 'with', 'gastroesophageal reflux', 'worse']","['disease', 'range', 'year', '1', 'outcome', 'treatment', 'success', 'quality of life', 'gastroesophageal reflux']",,,,
63,63,"a total of 366 patients ( mean age , 48.5 years ; 280 men ) were enrolled .",共有 366 名患者（平均年龄 48.5 岁；280 名男性）入组。,0.6666666666666666,"['mean', 'total', 'age']","['mean', 'age']",63,['共有366名患者(平均年龄、48.5岁、280名男性)被注册。'],0.6666666666666666,"['mean', 'total', 'age']","['mean', 'age']",63,总共有366名病人（平均年龄48.5岁；280名男性）纳入本项研究。,0.6666666666666666,"['mean', 'total', 'age']","['mean', 'age']",,,,
64,64,the remaining 78 patients underwent randomization .,其余 78 名患者接受了随机分组。,1.0,['randomization'],['randomization'],64,['其余78名患者遭到随机化。'],1.0,['randomization'],['randomization'],64,剩余的78名病人随机分配给了两组。,1.0,['randomization'],['randomization'],,,,
65,65,"the difference in the incidence of treatment success between the active medical group and the control medical group was 16 percentage points ( 95 % confidence interval , − 5 to 38 ; P = 0.17 ) .",活性药物组和对照药物组治疗成功率的差异为16个百分点（95%置信区间，-5至38；P=0.17）。,0.5,"['group', 'percentage', '5', 'incidence', 'control', 'medical', 'active', 'difference', 'treatment', 'success', 'confidence interval', 'P', 'to', 'and']","['group', '5', 'control', 'difference', 'treatment', 'success', 'confidence interval']",65,"['活跃医疗组和控制医疗组之间的治疗成功率差异为16个百分点(95%的信任间隔, − 5 至 38; P = 0.17)。']",0.4285714285714285,"['group', 'percentage', '5', 'incidence', 'control', 'medical', 'active', 'difference', 'treatment', 'success', 'confidence interval', 'P', 'to', 'and']","['group', '5', 'control', 'difference', 'treatment', 'success']",65,在治疗成功率方面，有效医疗组与对照医疗组之间的差异为16个百分点（95%的置信区间，-5至38；P=0.17）。,0.5,"['group', 'percentage', '5', 'incidence', 'control', 'medical', 'active', 'difference', 'treatment', 'success', 'confidence interval', 'P', 'to', 'and']","['group', '5', 'control', 'difference', 'treatment', 'success', 'confidence interval']",,,,
66,66,"for that highly selected subgroup , surgery was superior to medical treatment . ( Funded by the Department of Veterans Affairs Cooperative Studies Program ; ClinicalTrials.gov number , NCT01265550 . )",对于那个经过严格挑选的亚组，手术优于药物治疗。 （由退伍军人事务部合作研究计划资助；ClinicalTrials.gov 编号，NCT01265550。）,0.5454545454545454,"['cooperative', 'program', 'surgery', 'department', 'superior', 'medical treatment', 'number', 'subgroup', 'that', 'by', 'to']","['program', 'surgery', 'department', 'number', 'by', 'to']",66,"['对于这个高度选择的子组,手术优于医疗治疗(由退休人员事务合作研究计划资助;ClinicalTrials.gov号,NCT01265550。']",0.4545454545454545,"['cooperative', 'program', 'surgery', 'department', 'superior', 'medical treatment', 'number', 'subgroup', 'that', 'by', 'to']","['program', 'surgery', 'number', 'by', 'to']",66,对于那些经过精选的小组，手术比医疗治疗更有效。（由美国退伍军人事务部资助的合作研究计划；ClinicalTrials.gov 编号，NCT01265550。）,0.5454545454545454,"['cooperative', 'program', 'surgery', 'department', 'superior', 'medical treatment', 'number', 'subgroup', 'that', 'by', 'to']","['program', 'surgery', 'department', 'number', 'by', 'to']",,,,
67,67,"in the United States , approximately 20 % of adults regularly have symptoms of gastroesophageal reflux disease ( GERD ) , 1 and annual costs for managing GERD exceed $ 12 billion.2",在美国，大约 20 % 的成年人经常有胃食管反流病 ( GERD ) 的症状 1 ，每年管理 GERD 的费用超过 120 亿美元。 2,0.5,"['annual', 'disease', '1', 'symptoms', 'gastroesophageal reflux', 'have', 'approximately', 'in', 'and', 'exceed']","['disease', '1', 'gastroesophageal reflux', 'have', 'exceed']",67,"['在美国,大约20%的成年人经常患有胃血管流感疾病(GERD)的症状,1和管理GERD的年度成本超过12亿美元。']",0.4,"['annual', 'disease', '1', 'symptoms', 'gastroesophageal reflux', 'have', 'approximately', 'in', 'and', 'exceed']","['disease', '1', 'have', 'exceed']",67,在美国，大约20%的成年人经常会出现胃食管反流病（GERD）的症状，而每年治疗GERD的费用超过120亿美元。,0.5,"['annual', 'disease', '1', 'symptoms', 'gastroesophageal reflux', 'have', 'approximately', 'in', 'and', 'exceed']","['disease', '1', 'gastroesophageal reflux', 'and', 'exceed']",,,,
68,68,PPIs are often continued despite inadequate symptom relief.11,尽管症状缓解不充分，但 PPI 通常会继续使用。 11,0.3333333333333333,"['symptom', 'inadequate', 'despite']",['symptom'],68,"['PPI经常持续,尽管症状缓解不够。']",0.3333333333333333,"['symptom', 'inadequate', 'despite']",['symptom'],68,即便症状得不到有效缓解，人们也常常继续服用抑制剂。11,0.3333333333333333,"['symptom', 'inadequate', 'despite']",['symptom'],,,,
69,69,"alternatively , for patients with reflux hypersensitivity , surgical reduction of reflux might not relieve symptoms generated by a hypersensitive esophagus .",或者，对于反流过敏的患者，减少反流的手术可能无法缓解由过敏性食管引起的症状。,0.7,"['hypersensitivity', 'relieve', 'esophagus', 'surgical', 'reduction', 'symptoms', 'hypersensitive', 'reflux', 'with', 'by']","['hypersensitivity', 'relieve', 'esophagus', 'reduction', 'hypersensitive', 'reflux', 'by']",69,"['换句话说,对于患有过敏的患者,过敏的手术减少可能不会缓解由过敏性<unk>疹引起的症状。']",0.5,"['hypersensitivity', 'relieve', 'esophagus', 'surgical', 'reduction', 'symptoms', 'hypersensitive', 'reflux', 'with', 'by']","['hypersensitivity', 'relieve', 'reduction', 'hypersensitive', 'by']",69,"For patients with reflux hypersensitivity, surgical reduction of reflux might not relieve symptoms generated by a hypersensitive esophagus.",0.0,"['hypersensitivity', 'relieve', 'esophagus', 'surgical', 'reduction', 'symptoms', 'hypersensitive', 'reflux', 'with', 'by']",[],,,,
70,70,"surgeons are reluctant to rely on it to select patients for fundoplication , generally preferring traditional esophageal pH monitoring for that purpose.21",外科医生不愿意依靠它来选择患者进行胃底折叠术，通常更喜欢为此目的进行传统的食管 pH 监测。 21,0.6666666666666666,"['monitoring', 'esophageal', 'that']","['monitoring', 'esophageal']",70,"['外科医生拒绝依赖于选择病人进行补贴,一般偏好传统的尿液pH监测。']",0.3333333333333333,"['monitoring', 'esophageal', 'that']",['monitoring'],70,"Surgeons are reluctant to rely on esophageal pH monitoring to select patients for fundoplication, preferring traditional methods instead.21",0.0,"['monitoring', 'esophageal', 'that']",[],,,,
71,71,this trial was approved by the Veterans Affairs ( VA ) central institutional review board .,该试验得到了退伍军人事务部 (VA) 中央机构审查委员会的批准。,0.1666666666666666,"['review', 'central', 'board', 'trial', 'this', 'by']",['review'],71,['该审判由维特兰事务中央机构审计委员会(VA)批准。'],0.5,"['review', 'central', 'board', 'trial', 'this', 'by']","['review', 'trial', 'by']",71,这项试验经过了美国退伍军人事务部（VA）的中央机构审查委员会批准。,0.1666666666666666,"['review', 'central', 'board', 'trial', 'this', 'by']",['review'],,,,
72,72,"the authors vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol , available with the full text of this article at NEJM.org .",作者保证数据的完整性和准确性以及试验对方案的忠实度，方案与本文全文可在 NEJM.org 获取。,0.3076923076923077,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and']","['data', 'accuracy', 'completeness', 'full']",72,"['作者保证数据的完整性和准确性,以及对本议定书的审判忠诚性,可在NEJM.org上提供本文的完整文本。']",0.4615384615384615,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness', 'full']",72,作者保证数据的完整性和准确性，并保证本实验符合可在NEJM.org上全文下载的协议。,0.3846153846153846,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and']","['data', 'accuracy', 'protocol', 'completeness', 'full']",,,,
73,73,prerandomization Trial Procedures,随机化前试验程序,0.0,['trial'],[],73,['预先审判程序'],1.0,['trial'],['trial'],73,Pre-randomization trial procedures involve a process of selecting participants for a trial before randomization occurs. This process can help ensure that the trial is conducted fairly and that participants are not subjected to undue risks.,0.0,['trial'],[],,,,
74,74,all patients who were referred to VA gastroenterology clinics for heartburn refractory to PPIs were screened ( Figure 1 ) .,所有因 PPI 难治性胃灼热而转诊至 VA 胃肠病诊所的患者均接受了筛查（图 1）。,0.2857142857142857,"['who', '1', 'figure', 'heartburn', 'refractory', 'gastroenterology', 'all']","['1', 'heartburn']",74,['所有被转移到 VA 胃肠道诊所的病人对心燃解体的 PPI 进行了检查(图 1 )。'],0.1428571428571428,"['who', '1', 'figure', 'heartburn', 'refractory', 'gastroenterology', 'all']",['1'],74,所有被转诊至退伍军人事务部胃肠科门诊的病人，均接受了（见图1）的筛查。,0.1428571428571428,"['who', '1', 'figure', 'heartburn', 'refractory', 'gastroenterology', 'all']",['1'],,,,
75,75,"initial slow recruitment of patients resulted in intratrial changes to the protocol , including revised power calculations . ( for details on prerandomization trial procedures , randomization , intratrial changes to the protocol , and the statistical analysis , see the Supplementary Appendix , available at NEJM.org. )",最初缓慢招募患者导致试验中对方案进行了更改，包括修改了功效计算。 （有关随机化前试验程序、随机化、试验方案变更和统计分析的详细信息，请参阅补充附录，可在 NEJM.org 获取。）,0.5,"['appendix', 'randomization', 'power', 'protocol', 'supplementary', 'initial', 'recruitment', 'available', 'trial', 'statistical analysis']","['randomization', 'protocol', 'initial', 'recruitment', 'statistical analysis']",75,"['患者的初始缓慢招聘导致协议的内分子变化,包括修订的功率计算(关于预分测试程序、随机化、内分子协议的变化以及统计分析的详细信息,请参见附件,可在NEJM.org上找到)。']",0.6,"['appendix', 'randomization', 'power', 'protocol', 'supplementary', 'initial', 'recruitment', 'available', 'trial', 'statistical analysis']","['appendix', 'randomization', 'power', 'protocol', 'initial', 'statistical analysis']",75,首先缓慢的招募病人造成了对试验方案的内部变化，包括修订后的功效计算。（有关试验前程序、随机化、方案内部变化以及统计分析的详细信息，请参阅《新英格兰医学杂志》的补充附录。）,0.4,"['appendix', 'randomization', 'power', 'protocol', 'supplementary', 'initial', 'recruitment', 'available', 'trial', 'statistical analysis']","['randomization', 'protocol', 'recruitment', 'statistical analysis']",,,,
76,76,medical Treatment Groups,医疗组,0.0,['medical treatment'],[],76,['医疗治疗组'],0.0,['medical treatment'],[],76,医疗治疗组,0.0,['medical treatment'],[],,,,
77,77,investigators and patients were unaware of whether medical treatment was active or placebo .,研究人员和患者不知道药物治疗是积极的还是安慰剂。,0.4,"['placebo', 'active', 'medical treatment', 'unaware', 'and']","['placebo', 'active']",77,['研究人员和患者不知道医疗治疗是否活跃或 placebo。'],0.0,"['placebo', 'active', 'medical treatment', 'unaware', 'and']",[],77,调查人员和病人不知道医疗治疗是否是有效的还是假的。,0.2,"['placebo', 'active', 'medical treatment', 'unaware', 'and']",['active'],,,,
78,78,"at all clinic visits , patients were queried about missed medication doses , and medication counts were performed .",在所有门诊就诊时，都会询问患者是否漏服药物，并进行药物计数。,0.0,"['medication', 'clinic', 'all', 'and']",[],78,"['在所有临床访问中,患者被问及错过的药物剂量,并进行药物计算。']",0.25,"['medication', 'clinic', 'all', 'and']",['clinic'],78,在所有的临床访谈中，我们都会问患者有没有遗漏药物剂量，并进行药物统计。,0.25,"['medication', 'clinic', 'all', 'and']",['clinic'],,,,
79,79,patients in both groups received active omeprazole at a dose of 20 mg twice daily throughout the trial .,在整个试验期间，两组患者均接受每天两次 20 毫克剂量的活性奥美拉唑。,0.1666666666666666,"['active', 'trial', 'at', 'dose', 'in', 'twice']",['dose'],79,['两组患者在试验期间每天服用20毫克的活性 omeprazole。'],0.0,"['active', 'trial', 'at', 'dose', 'in', 'twice']",[],79,两组患者均在整个试验期间每天服用有效剂量为20毫克的盐酸奥美拉唑。,0.1666666666666666,"['active', 'trial', 'at', 'dose', 'in', 'twice']",['dose'],,,,
80,80,"after discontinuation , patients with contraindications to desipramine were declared to have treatment failure .",停药后，对地昔帕明有禁忌症的患者被宣布治疗失败。,0.6666666666666666,"['failure', 'treatment', 'after', 'with', 'have', 'to']","['failure', 'treatment', 'after', 'have']",80,"['在中断后,患有抗示剂的患者被告知患有治疗失败。']",0.6666666666666666,"['failure', 'treatment', 'after', 'with', 'have', 'to']","['failure', 'treatment', 'after', 'have']",80,在停止使用莫达非尼之后，那些对莫达非尼有禁忌症的患者被宣布治疗失败。,0.6666666666666666,"['failure', 'treatment', 'after', 'with', 'have', 'to']","['failure', 'treatment', 'after', 'have']",,,,
81,81,surgical Treatment Group,手术治疗组,0.5,"['surgical', 'treatment group']",['treatment group'],81,['外科治疗小组'],0.0,"['surgical', 'treatment group']",[],81,"surgical Treatment Group

Chinese:

手术治疗组",0.5,"['surgical', 'treatment group']",['treatment group'],,,,
82,82,surgical treatment was laparoscopic Nissen fundoplication .,手术治疗为腹腔镜尼森胃底折叠术。,0.5,"['surgical', 'treatment']",['treatment'],82,['手术治疗是Laparoscopic Nissen fundoplication。'],0.5,"['surgical', 'treatment']",['treatment'],82,手术治疗是腹腔镜尼森基底手术。,0.5,"['surgical', 'treatment']",['treatment'],10.0,3.0,2.0,10.0
83,83,heartburn medications were prohibited after fundoplication .,胃底折叠术后禁用胃灼热药物。,1.0,"['heartburn', 'after']","['heartburn', 'after']",83,['心燃药物被禁止在基金投注后。'],0.5,"['heartburn', 'after']",['after'],83,消化不良药物在胃十二指肠吻合术后被禁止使用。,0.5,"['heartburn', 'after']",['after'],10.0,5.0,1.0,5.0
84,84,this article does not include all analyses and outcomes that were prespecified in the protocol and does not include any analyses or outcome measures that were not prespecified in the protocol .,本文不包括方案中预先指定的所有分析和结果，也不包括方案中未预先指定的任何分析或结果测量。,0.125,"['outcome', 'protocol', 'article', 'all', 'this', 'that', 'in', 'and']",['outcome'],84,"['本条不包括在议定书中预定的所有分析和结果,也不包括在议定书中未预定的任何分析或结果措施。']",0.25,"['outcome', 'protocol', 'article', 'all', 'this', 'that', 'in', 'and']","['outcome', 'protocol']",84,这篇文章没有包括原始研究计划中所有的分析和结果，也没有包括任何原始研究计划中没有预先规定的分析或结果。,0.125,"['outcome', 'protocol', 'article', 'all', 'this', 'that', 'in', 'and']",['outcome'],10.0,10.0,5.0,10.0
85,85,"to keep the overall type I error at 0.05 for the null hypothesis , the alpha level for each of the three comparisons was adjusted with the use of the Hochberg method.25",为了将零假设的总体 I 类错误保持在 0.05，使用 Hochberg 方法调整了三个比较中每一个的 alpha 水平。 25,0.25,"['type', 'alpha', 'error', 'keep', 'null hypothesis', 'level', 'with', 'at', 'I', 'three', 'each', 'to']","['error', 'keep', 'level']",85,"['为了在零假设中保持总类型 I 错误为 0.05,每个三种比较的 alpha 水平通过使用 Hochberg 方法进行调整。']",0.3333333333333333,"['type', 'alpha', 'error', 'keep', 'null hypothesis', 'level', 'with', 'at', 'I', 'three', 'each', 'to']","['type', 'error', 'keep', 'level']",85,为了保持总体类型I误差在0.05以内，使用霍克伯格方法调整了三个比较的α水平。,0.4166666666666667,"['type', 'alpha', 'error', 'keep', 'null hypothesis', 'level', 'with', 'at', 'I', 'three', 'each', 'to']","['type', 'alpha', 'error', 'keep', 'level']",10.0,9.0,5.0,10.0
86,86,"we used SAS software , version 9.4 ( SAS Institute ) , for all analyses .",我们使用 SAS 软件 9.4 版（SAS Institute）进行所有分析。,0.1666666666666666,"['version', 'software', 'institute', 'SAS', 'all', 'we']",['software'],86,"['我们使用SAS软件,版本 9.4(SAS研究所),用于所有分析。']",0.5,"['version', 'software', 'institute', 'SAS', 'all', 'we']","['version', 'software', 'institute']",86,我们使用的是SAS软件，版本9.4（SAS Institute），进行所有分析。,0.3333333333333333,"['version', 'software', 'institute', 'SAS', 'all', 'we']","['version', 'software']",10.0,10.0,5.0,10.0
87,87,prerandomization PROCEDURE EXCLUSIONS,随机化前程序排除,,[],[],87,['提前排除程序'],,[],[],87,"prerandomization PROCEDURE EXCLUSIONS

Chinese:

随机化前程序排除",,[],[],,,,
88,88,"a revised power calculation called for 108 randomly assigned patients , but enrollment was capped at 78 solely because of funding limitations .",修订后的功效计算要求 108 名随机分配的患者，但仅由于资金限制，登记人数上限为 78 人。,0.5,"['power', 'capped', 'at', 'but']","['at', 'but']",88,"['一个修订的电力计算呼吁108随机分配的病人,但注册被抓到78仅因为融资限制。']",0.5,"['power', 'capped', 'at', 'but']","['power', 'but']",88,一项修订过的功率计算需要108名随机分配的病人，但仅仅出于资金限制，招募人数被限制在78人。,0.75,"['power', 'capped', 'at', 'but']","['power', 'at', 'but']",,,,
89,89,randomly ASSIGNED PATIENTS,随机分配的患者,,[],[],89,['随机注册的病人'],,[],[],89,随机分配病人,,[],[],,,,
90,90,"after trial completion , review of primary data collection forms revealed discrepancies in eligibility criteria data for 5 randomly assigned patients , which raised uncertainty about whether these patients met all eligibility criteria .",试验完成后，对主要数据收集表的审查发现 5 名随机分配患者的资格标准数据存在差异，这增加了对这些患者是否符合所有资格标准的不确定性。,0.4166666666666667,"['5', 'review', 'raised', 'after', 'trial', 'completion', 'data collection', 'primary data', 'met', 'uncertainty', 'all', 'revealed']","['5', 'review', 'after', 'completion', 'data collection']",90,"['试验完成后,初级数据收集表格的审查揭示了5名随机分配的患者资格标准数据的差异,这引起了对这些患者是否符合所有资格标准的不确定性。']",0.4166666666666667,"['5', 'review', 'raised', 'after', 'trial', 'completion', 'data collection', 'primary data', 'met', 'uncertainty', 'all', 'revealed']","['5', 'review', 'after', 'completion', 'data collection']",90,在试验结束后，对主要数据收集表进行了审查，发现了5名随机分配病人资格标准数据的差异，这引起了对这些病人是否符合所有资格标准的不确定性。,0.3333333333333333,"['5', 'review', 'raised', 'after', 'trial', 'completion', 'data collection', 'primary data', 'met', 'uncertainty', 'all', 'revealed']","['5', 'review', 'after', 'data collection']",,,,
91,91,analyses that excluded these 5 patients were similar to our primary analyses ( see the Supplementary Appendix ) .,排除这 5 名患者的分析与我们的主要分析相似（见补充附录）。,0.1428571428571428,"['5', 'appendix', 'supplementary', 'primary', 'that', 'to', 'similar']",['5'],91,['排除这些5名患者的分析与我们的初级分析相似(参见附件)。'],0.2857142857142857,"['5', 'appendix', 'supplementary', 'primary', 'that', 'to', 'similar']","['5', 'appendix']",91,excluded these 5 patients were similar to our primary analyses (see the Supplementary Appendix).,0.1428571428571428,"['5', 'appendix', 'supplementary', 'primary', 'that', 'to', 'similar']",['5'],,,,
92,92,"the relative risk of treatment success was 2.38 ( 95 % CI , 1.20 to 4.71 ) for surgery versus active medical treatment , 5.78 ( 95 % CI , 1.93 to 17.31 ) for surgery versus control medical treatment , and 2.43 ( 95 % CI , 0.71 to 8.35 ) for active medical treatment versus control medical treatment ( unadjusted comparisons ) .",手术与积极药物治疗的治疗成功相对风险分别为 2.38 ( 95 % CI 1.20 至 4.71 ) ，手术与对照药物治疗 5.78 ( 95 % CI 1.93 至 17.31 ) 和 2.43 ( 95 % CI 0.71 至8.35) 积极药物治疗与对照药物治疗（未经调整的比较）。,0.3636363636363636,"['control', 'surgery', 'relative', 'active', 'medical treatment', 'success', 'risk', 'unadjusted', 'CI', 'to', 'and']","['control', 'surgery', 'success', 'risk']",92,['治疗成功的相对风险为2.38(95% CI、1.20至4.71 )对手术对活性医疗治疗、5.78(95% CI、1.93至17.31 )对手术对控制医疗治疗、和2.43(95% CI、0.71至8.35 )对活性医疗治疗对控制医疗治疗(不调整的比较)。'],0.3636363636363636,"['control', 'surgery', 'relative', 'active', 'medical treatment', 'success', 'risk', 'unadjusted', 'CI', 'to', 'and']","['control', 'surgery', 'success', 'risk']",92,手术治疗成功的相对风险是2.38（95%置信区间[CI]，1.20至4.71），而对照医疗治疗的风险是5.78（95%CI，1.93至17.31），而积极医疗治疗对照医疗治疗的风险是2.43（95%CI，0.71至8.35）（未经调整的比较）。,0.4545454545454545,"['control', 'surgery', 'relative', 'active', 'medical treatment', 'success', 'risk', 'unadjusted', 'CI', 'to', 'and']","['control', 'surgery', 'success', 'risk', 'and']",,,,
93,93,the incidence of success in the surgery group was 71 % among the 14 patients with reflux hypersensitivity and 62 % among the 13 with abnormal acid reflux .,手术组的成功率在 14 名反流过敏患者中为 71%，在 13 名胃酸反流异常患者中为 62%。,0.6,"['hypersensitivity', 'group', 'incidence', 'surgery', 'abnormal', 'success', 'reflux', 'with', 'acid', 'and']","['group', 'surgery', 'abnormal', 'success', 'reflux', 'acid']",93,['在手术组中成功的发病率为14名患有过敏的患者中71%和13名患有异常酸过敏的患者中62%。'],0.6,"['hypersensitivity', 'group', 'incidence', 'surgery', 'abnormal', 'success', 'reflux', 'with', 'acid', 'and']","['group', 'incidence', 'surgery', 'abnormal', 'success', 'acid']",93,在14位返流过敏患者中，手术组的成功率为71%，在13位异常酸返流患者中为62%。,0.6,"['hypersensitivity', 'group', 'incidence', 'surgery', 'abnormal', 'success', 'reflux', 'with', 'acid', 'and']","['group', 'surgery', 'abnormal', 'success', 'reflux', 'acid']",,,,
94,94,"there were five serious adverse events in 4 patients in the surgery group , four serious adverse events in 4 patients in the active medical group , and five serious adverse events in 3 patients in the control medical group ( Table S3 ) .",手术组有 4 名患者发生 5 起严重不良事件，积极治疗组有 4 名患者发生 4 起严重不良事件，对照组有 3 名患者发生 5 起严重不良事件（表 S3）。,0.3076923076923077,"['group', 'control', 'table', 'surgery', 'medical', 'active', 'adverse', '4', 'S3', 'serious', 'five', 'in', 'and']","['group', 'control', 'table', 'surgery']",94,"['在手术组中有4名患者发生5件严重的副作用,在活跃医疗组中有4名患者发生4件严重的副作用,在控制医疗组中有3名患者发生5件严重的副作用。']",0.2307692307692307,"['group', 'control', 'table', 'surgery', 'medical', 'active', 'adverse', '4', 'S3', 'serious', 'five', 'in', 'and']","['group', 'control', 'surgery']",94,在手术组中，有5例严重不良事件发生在4名患者身上，在主动医疗组中，有4例严重不良事件发生在4名患者身上，而在对照医疗组中，有5例严重不良事件发生在3名患者身上（表S3）。,0.3846153846153846,"['group', 'control', 'table', 'surgery', 'medical', 'active', 'adverse', '4', 'S3', 'serious', 'five', 'in', 'and']","['group', 'control', 'table', 'surgery', 'and']",,,,
95,95,"one surgical patient had a herniated Nissen fundoplication that resulted in repeat surgery complicated by postoperative pneumonia ; recovery was complete , and repeat surgery successfully controlled heartburn .",一名手术患者患有突出的 Nissen 胃底折叠术，导致重复手术并发术后肺炎；恢复完全，再次手术成功地控制了胃灼热。,0.5333333333333333,"['repeat', 'heartburn', 'surgery', 'surgical', 'controlled', 'complete', 'postoperative', 'recovery', 'patient', 'herniated', 'pneumonia', 'that', 'in', 'and', 'complicated by']","['repeat', 'heartburn', 'surgery', 'controlled', 'recovery', 'patient', 'herniated', 'pneumonia']",95,"['一名外科病人患有麻醉的尼森基金,结果是由手术后肺炎复杂的重复手术;恢复完成,并重复手术成功控制心燃。']",0.4,"['repeat', 'heartburn', 'surgery', 'surgical', 'controlled', 'complete', 'postoperative', 'recovery', 'patient', 'herniated', 'pneumonia', 'that', 'in', 'and', 'complicated by']","['repeat', 'surgery', 'controlled', 'recovery', 'patient', 'pneumonia']",95,一位外科病人的尼森肠系带松弛导致了复发手术，并且复发手术后患有肺炎。康复情况良好，复发手术成功控制了胃灼热感。,0.4,"['repeat', 'heartburn', 'surgery', 'surgical', 'controlled', 'complete', 'postoperative', 'recovery', 'patient', 'herniated', 'pneumonia', 'that', 'in', 'and', 'complicated by']","['repeat', 'heartburn', 'surgery', 'controlled', 'patient', 'pneumonia']",,,,
96,96,there were no deaths .,没有死亡。,0.0,['no'],[],96,['没有死亡。'],0.0,['no'],[],96,"There were no deaths.

Chinese: 没有人死亡。",0.0,['no'],[],,,,
97,97,"in that highly selected group , the incidence of treatment success with laparoscopic Nissen fundoplication at 1 year ( 67 % ) was significantly superior to that with active medical treatment ( 28 % ) or control medical treatment ( 12 % ) .",在这个精心挑选的组中，腹腔镜 Nissen 胃底折叠术在 1 年时的治疗成功率 (67%) 明显优于积极药物治疗 (28%) 或对照药物治疗 (12%)。,0.5,"['group', 'incidence', 'control', 'year', '1', 'superior', 'active', 'medical treatment', 'success', 'with', 'that', 'to']","['group', 'control', 'year', '1', 'success', 'to']",97,"['在这个精选的群体中,在1年(67%)的拉帕罗斯科尼森药物治疗成功率显著高于活性医疗治疗(28%)或控制医疗治疗(12%)的成功率。']",0.5,"['group', 'incidence', 'control', 'year', '1', 'superior', 'active', 'medical treatment', 'success', 'with', 'that', 'to']","['group', 'control', 'year', '1', 'success', 'to']",97,在这个高度选择的群体中，手术治疗在第一年的成功率（67％）明显优于药物治疗（28％）或对照药物治疗（12％）。,0.5,"['group', 'incidence', 'control', 'year', '1', 'superior', 'active', 'medical treatment', 'success', 'with', 'that', 'to']","['group', 'control', 'year', '1', 'success', 'to']",,,,
98,98,"first , trial patients were given explicit instructions to take omeprazole 30 minutes before meals .",首先，试验患者被明确指示在饭前 30 分钟服用奥美拉唑。,0.3333333333333333,"['trial', 'explicit', 'before', 'to', 'first', 'instructions']","['before', 'first']",98,"['首先,试验患者被明确指示在晚餐前30分钟服用 omeprazole。']",0.3333333333333333,"['trial', 'explicit', 'before', 'to', 'first', 'instructions']","['before', 'first']",98,首先，试疗患者被明确指示在饭前30分钟服用omeprazole。,0.3333333333333333,"['trial', 'explicit', 'before', 'to', 'first', 'instructions']","['before', 'first']",,,,
99,99,this is important because PPIs bind only to gastric proton pumps that are actively secreting acid .,这很重要，因为 PPI 仅与活跃分泌酸的胃质子泵结合。,0.3333333333333333,"['gastric', 'proton', 'acid', 'this', 'that', 'bind']","['proton', 'acid']",99,"['这很重要,因为PPI仅连接到活跃分泌酸的胃<unk>泵。']",0.1666666666666666,"['gastric', 'proton', 'acid', 'this', 'that', 'bind']",['acid'],99,这很重要，因为Ppi只能结合到正在分泌酸的胃部质子泵上。,0.3333333333333333,"['gastric', 'proton', 'acid', 'this', 'that', 'bind']","['proton', 'acid']",,,,
100,100,"fewer than 10 % of those pumps are active during fasting , whereas approximately 70 % are active when stimulated by meals.26",这些泵中只有不到 10 % 在禁食期间处于活动状态，而大约 70 % 在进食时处于活动状态。 26,0.0,"['active', 'fasting', 'approximately', 'by']",[],100,"['在禁食期间,不到10%的这些泵是活跃的,而在食物刺激时,约70%是活跃的。']",0.0,"['active', 'fasting', 'approximately', 'by']",[],100,排除禁食期间，不到10%的胰岛素泵被激活，而大约70%的胰岛素泵会被饭食刺激激活。26,0.0,"['active', 'fasting', 'approximately', 'by']",[],,,,
101,101,"consequently , PPIs are most effective when taken before meals .",因此，PPI 在饭前服用最有效。,1.0,['before'],['before'],101,"['因此,PPI在晚餐前服用时最有效。']",1.0,['before'],['before'],101,因此，最有效的PPI是在饭前服用。,1.0,['before'],['before'],,,,
102,102,"second , patients taking PPIs other than omeprazole at trial entry were switched to omeprazole .",其次，在试验开始时服用奥美拉唑以外的 PPI 的患者转为服用奥美拉唑。,0.1666666666666666,"['taking', 'trial', 'entry', 'at', 'second', 'to']",['second'],102,"['其次,在试验入口时服用非 omeprazole PPI 的患者被转换为 omeprazole。']",0.1666666666666666,"['taking', 'trial', 'entry', 'at', 'second', 'to']",['second'],102,第二，在试验开始时使用非omeprazole的PPI的患者被转换为omeprazole。,0.0,"['taking', 'trial', 'entry', 'at', 'second', 'to']",[],,,,
103,103,"relative potencies of different PPIs vary widely , 27 and individual patients can exhibit considerable variability in response to different PPIs.28",不同 PPI 的相对效力差异很大，27 并且个体患者对不同 PPI 的反应可能表现出相当大的差异。 28,0.2857142857142857,"['variability', 'individual', 'relative', 'response', 'exhibit', 'to', 'and']","['individual', 'response']",103,"['不同PPI的相对强度广泛不同,27个患者在不同PPI的反应中可能显著变化。']",0.1428571428571428,"['variability', 'individual', 'relative', 'response', 'exhibit', 'to', 'and']",['response'],103,不同的PPI相对效力差异很大，27个个体患者对不同PPI的反应可能有很大差异。28,0.2857142857142857,"['variability', 'individual', 'relative', 'response', 'exhibit', 'to', 'and']","['individual', 'response']",,,,
104,104,"many patients would not complete this rigorous evaluation , and among those who did , the cause of heartburn in most of them was not GERD .",许多患者不会完成这项严格的评估，而在那些完成的患者中，大多数胃灼热的原因不是 GERD。,0.5,"['who', 'evaluation', 'heartburn', 'complete', 'cause', 'this', 'in', 'and']","['heartburn', 'cause', 'this', 'and']",104,"['许多患者不会完成这项严格的评估,并且在那些这样做的人中,心脏病发作的原因在大多数人中不是GERD。']",0.25,"['who', 'evaluation', 'heartburn', 'complete', 'cause', 'this', 'in', 'and']","['cause', 'this']",104,许多病人不会完成这个严格的评估，而在那些做了评估的病人中，大多数人的胃灼热的原因并非胃食管反流病。,0.375,"['who', 'evaluation', 'heartburn', 'complete', 'cause', 'this', 'in', 'and']","['heartburn', 'cause', 'and']",,,,
105,105,"our finding that reflux hypersensitivity can respond to fundoplication is noteworthy because reflux hypersensitivity is considered a functional disorder , which might not be expected to improve with a procedure that eliminates reflux without altering abnormal esophageal pain perception.10",我们发现反流超敏反应可以对胃底折叠术产生反应是值得注意的，因为反流超敏反应被认为是一种功能障碍，可能无法通过消除反流而不改变异常食管疼痛感知的手术来改善这种情况。 10,0.6363636363636364,"['hypersensitivity', 'esophageal', 'procedure', 'abnormal', 'be', 'pain', 'reflux', 'functional disorder', 'that', 'respond to', 'without']","['hypersensitivity', 'esophageal', 'abnormal', 'pain', 'reflux', 'respond to', 'without']",105,"['我們的發現,反流過敏性可以回應 fundoplication 是值得注意的,因為反流過敏性被認為是一個功能障礙,這可能不會被預計改善一個程序,消除反流,而不改變異常的尿道疼痛感知。']",0.2727272727272727,"['hypersensitivity', 'esophageal', 'procedure', 'abnormal', 'be', 'pain', 'reflux', 'functional disorder', 'that', 'respond to', 'without']","['procedure', 'pain', 'reflux']",105,我们发现胃酸回流过敏可以通过胃酸过敏症手术来治疗，这是值得注意的，因为胃酸回流过敏被认为是一种功能障碍，可能不会期望通过一个不改变异常食管疼痛感知的手术来改善。10,0.3636363636363636,"['hypersensitivity', 'esophageal', 'procedure', 'abnormal', 'be', 'pain', 'reflux', 'functional disorder', 'that', 'respond to', 'without']","['esophageal', 'abnormal', 'pain', 'reflux']",,,,
106,106,"for our surgical patients , the incidence of treatment success was 71 % among the 14 with reflux hypersensitivity and 62 % among the 13 with abnormal acid reflux .",对于我们的手术患者，14 名反流过敏患者的治疗成功率为 71%，13 名胃酸反流异常患者的治疗成功率为 62%。,0.5,"['hypersensitivity', 'incidence', 'abnormal', 'surgical', 'treatment', 'success', 'reflux', 'with', 'acid', 'and']","['abnormal', 'treatment', 'success', 'reflux', 'acid']",106,"['对于我们的手术患者,治疗成功的发病率为14人中有过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏。']",0.4,"['hypersensitivity', 'incidence', 'abnormal', 'surgical', 'treatment', 'success', 'reflux', 'with', 'acid', 'and']","['hypersensitivity', 'incidence', 'treatment', 'success']",106,对于我们的手术病人，对14名具有返流过敏症病人的治疗成功率为71％，对13名具有异常酸返流病人的治疗成功率为62％。,0.5,"['hypersensitivity', 'incidence', 'abnormal', 'surgical', 'treatment', 'success', 'reflux', 'with', 'acid', 'and']","['abnormal', 'treatment', 'success', 'reflux', 'acid']",,,,
107,107,"PPIs are inactivated through the hepatic cytochrome P450 isoenzyme CYP2C19 , and CYP2C19 mutations can influence PPI inactivation rates and clinical efficacy.39",PPI 通过肝细胞色素 P450 同工酶 CYP2C19 失活，而 CYP2C19 突变可影响 PPI 失活率和临床疗效。 39,0.7142857142857143,"['isoenzyme', 'inactivation', 'hepatic', 'clinical', 'influence', 'cytochrome P450', 'and']","['isoenzyme', 'inactivation', 'clinical', 'influence', 'and']",107,"['PPI 通过肝细胞染色素 P450 以生素 CYP2C19 被禁活,而 CYP2C19 突变可能会影响 PPI 禁活率和临床有效性。']",0.4285714285714285,"['isoenzyme', 'inactivation', 'hepatic', 'clinical', 'influence', 'cytochrome P450', 'and']","['clinical', 'influence', 'and']",107,"药物相互作用是通过肝脏细胞色素P450的同工酶CYP2C19来停止的，CYP2C19的突变会影响药物相互作用的停止速度和临床疗效。39

Chinese:
药物相互作用通过肝脏细胞色素P450同工酶CYP2C19来停止，CYP2C19突变会影响药物相互作用的停止速度和临床疗效。39",0.5714285714285714,"['isoenzyme', 'inactivation', 'hepatic', 'clinical', 'influence', 'cytochrome P450', 'and']","['isoenzyme', 'clinical', 'influence', 'cytochrome P450']",,,,
108,108,limitations of our trial include its relatively small sample size and predominance of white men ( reflecting the veteran patient population ) .,我们试验的局限性包括其相对较小的样本量和白人男性的优势（反映了退伍军人患者群体）。,0.5714285714285714,"['population', 'white', 'patient', 'trial', 'sample size', 'predominance', 'and']","['population', 'white', 'patient', 'predominance']",108,['我们试验的限制包括其相对较小的样品大小和白人占主导地位(反映了退休患者人口)。'],0.4285714285714285,"['population', 'white', 'patient', 'trial', 'sample size', 'predominance', 'and']","['population', 'white', 'patient']",108,"Our study's limitations include a small sample size and a predominance of white men (reflecting the veteran patient population).

Chinese: 我们的研究的局限性包括样本规模较小和白人男性的优势（反映了老兵病人群体）。",0.5714285714285714,"['population', 'white', 'patient', 'trial', 'sample size', 'predominance', 'and']","['population', 'white', 'patient', 'predominance']",,,,
109,109,another limitation involves the intratrial protocol amendments required to enable trial completion .,另一个局限性涉及为完成试验所需的试验内协议修正案。,0.5,"['protocol', 'limitation', 'trial', 'completion']","['protocol', 'completion']",109,"['另一个限制包括在内议定书中所需的修正案,以便审判完成。']",0.75,"['protocol', 'limitation', 'trial', 'completion']","['protocol', 'trial', 'completion']",109,另一个限制是需要修改试验方案才能完成试验。,0.5,"['protocol', 'limitation', 'trial', 'completion']","['protocol', 'completion']",,,,
110,110,"overly restrictive entry criteria that limit trial enrollment , generalizability , and completion are a common problem in trials involving patients with functional gastrointestinal disorders.40,41","限制试验入组、普遍性和完成的过于严格的入组标准是涉及功能性胃肠病患者的试验中的一个常见问题。 40,41",0.3636363636363636,"['gastrointestinal', 'functional', 'common', 'trial', 'limit', 'completion', 'problem', 'entry', 'with', 'that', 'and']","['gastrointestinal', 'limit', 'completion', 'problem']",110,['限制试验登记、通用性和完成的过度限制性入门标准是涉及功能性肠道障碍患者的试验中常见问题。'],0.2727272727272727,"['gastrointestinal', 'functional', 'common', 'trial', 'limit', 'completion', 'problem', 'entry', 'with', 'that', 'and']","['limit', 'completion', 'problem']",110,"过于严格的入场标准会限制试验的招募、普遍性和完成度，这是功能性胃肠疾病试验中的一个常见问题。40,41",0.3636363636363636,"['gastrointestinal', 'functional', 'common', 'trial', 'limit', 'completion', 'problem', 'entry', 'with', 'that', 'and']","['gastrointestinal', 'limit', 'completion', 'problem']",,,,
111,111,"consequently , we amended the protocol to allow the entry of patients with contraindications to desipramine .",因此，我们修改了协议，允许有禁忌症的患者进入地昔帕明。,0.4,"['protocol', 'allow', 'entry', 'with', 'we']","['protocol', 'allow']",111,"['因此,我们修改了议定书,以便允许患有抗指示的患者入院。']",0.4,"['protocol', 'allow', 'entry', 'with', 'we']","['protocol', 'allow']",111,因此，我们修订了协议，允许患有对氮氧化物抗药物的病人入院。,0.4,"['protocol', 'allow', 'entry', 'with', 'we']","['protocol', 'allow']",,,,
112,112,"we also amended power calculations to detect only large differences between medical and surgical treatments , reasoning that physicians would not recommend surgery unless it were considerably more effective than medical therapy .",我们还修改了功效计算以仅检测药物治疗和手术治疗之间的巨大差异，理由是医生不会推荐手术，除非它比药物治疗有效得多。,0.3076923076923077,"['power', 'surgery', 'medical', 'surgical', 'recommend', 'large', 'therapy', 'detect', 'reasoning', 'that', 'to', 'and', 'physicians']","['surgery', 'recommend', 'therapy', 'detect']",112,"['我们还修改了功率计算,以检测医学和手术治疗之间只有大差异,认为医生不会推荐手术,除非它比医学治疗更有效。']",0.3846153846153846,"['power', 'surgery', 'medical', 'surgical', 'recommend', 'large', 'therapy', 'detect', 'reasoning', 'that', 'to', 'and', 'physicians']","['power', 'surgery', 'recommend', 'therapy', 'detect']",112,我们还修正了功率计算，以只检测医疗和手术治疗之间的大差异，理由是医生不会推荐手术，除非它比医疗治疗明显有效得多。,0.3846153846153846,"['power', 'surgery', 'medical', 'surgical', 'recommend', 'large', 'therapy', 'detect', 'reasoning', 'that', 'to', 'and', 'physicians']","['power', 'surgery', 'recommend', 'therapy', 'detect']",,,,
113,113,"in that highly selected group , laparoscopic Nissen fundoplication was significantly superior to medical therapy .",在这个经过精心挑选的组中，腹腔镜 Nissen 胃底折叠术明显优于药物治疗。,0.4285714285714285,"['group', 'medical', 'superior', 'therapy', 'that', 'in', 'to']","['group', 'therapy', 'to']",113,"['在这个精选的群体中,Laparoscopic Nissen fundoplication 显著高于医学治疗。']",0.4285714285714285,"['group', 'medical', 'superior', 'therapy', 'that', 'in', 'to']","['group', 'therapy', 'to']",113,在那个高度选择的组别中，腹腔镜尼森外翻手术明显优于药物治疗。,0.4285714285714285,"['group', 'medical', 'superior', 'therapy', 'that', 'in', 'to']","['group', 'therapy', 'to']",,,,
114,114,the relative merits of ticagrelor as compared with prasugrel in patients with acute coronary syndromes for whom invasive evaluation is planned are uncertain .,对于计划进行侵入性评估的急性冠脉综合征患者，替格瑞洛与普拉格雷相比的相对优势尚不确定。,0.375,"['evaluation', 'coronary', 'uncertain', 'relative', 'acute', 'with', 'prasugrel', 'syndromes']","['coronary', 'prasugrel', 'syndromes']",114,"['与Prasugrel相比,Ticagrelor的相对价值在患有急性冠状综合征的患者中不确定。']",0.25,"['evaluation', 'coronary', 'uncertain', 'relative', 'acute', 'with', 'prasugrel', 'syndromes']","['coronary', 'syndromes']",114,相对于那些计划进行侵袭性评估的急性冠状动脉综合征患者而言，蒂卡格雷洛与帕苏格雷之间的相对优势尚不清楚。,0.25,"['evaluation', 'coronary', 'uncertain', 'relative', 'acute', 'with', 'prasugrel', 'syndromes']","['coronary', 'syndromes']",,,,
115,115,"the primary end point was the composite of death , myocardial infarction , or stroke at 1 year .",主要终点是 1 年时死亡、心肌梗死或卒中的复合终点。,0.6666666666666666,"['myocardial infarction', 'composite', 'stroke', 'year', '1', 'death', 'primary', 'end', 'point']","['myocardial infarction', 'stroke', 'year', '1', 'death', 'point']",115,"['主要的终点是死亡的组成,心脏病发作,或1年的中风。']",0.6666666666666666,"['myocardial infarction', 'composite', 'stroke', 'year', '1', 'death', 'primary', 'end', 'point']","['stroke', 'year', '1', 'death', 'primary', 'point']",115,"The primary end point was the composite of death, myocardial infarction, or stroke at 1 year.

Chinese:

一年内的死亡、心肌梗死或中风是主要终点指标。",0.6666666666666666,"['myocardial infarction', 'composite', 'stroke', 'year', '1', 'death', 'primary', 'end', 'point']","['myocardial infarction', 'stroke', 'year', '1', 'death', 'point']",,,,
116,116,a major secondary end point ( the safety end point ) was bleeding .,一个主要的次要终点（安全终点）是出血。,0.5,"['bleeding', 'safety', 'major', 'secondary', 'end', 'point']","['bleeding', 'safety', 'point']",116,['一个主要的次要终点(安全终点)是出血。'],0.5,"['bleeding', 'safety', 'major', 'secondary', 'end', 'point']","['bleeding', 'safety', 'point']",116,主要的次要终点（安全终点）是出血。,0.5,"['bleeding', 'safety', 'major', 'secondary', 'end', 'point']","['bleeding', 'safety', 'point']",,,,
117,117,a total of 4018 patients underwent randomization .,共有 4018 名患者接受了随机分组。,0.5,"['randomization', 'total']",['randomization'],117,['共有4018名患者遭到随机化。'],0.5,"['randomization', 'total']",['randomization'],117,共有4018位病人随机分配了治疗方案。,0.5,"['randomization', 'total']",['randomization'],,,,
118,118,"the respective incidences of the individual components of the primary end point in the ticagrelor group and the prasugrel group were as follows : death , 4.5 % and 3.7 % ; myocardial infarction , 4.8 % and 3.0 % ; and stroke , 1.1 % and 1.0 % .",替格瑞洛组和普拉格雷组主要终点的各个组成部分的发生率分别如下：死亡，4.5%和3.7%；心肌梗塞，4.8%和3.0%；和中风，1.1% 和 1.0%。,0.6,"['group', 'myocardial infarction', 'stroke', 'individual', 'death', 'primary', 'end', 'point', 'prasugrel', 'and']","['group', 'myocardial infarction', 'stroke', 'death', 'point', 'prasugrel']",118,['图克格勒群体和图克格勒群体的主要终点组成部分的分别发病率如下:死亡、4.5%和3.7%、心脏病发作、4.8%和 3.0%、中风、1.1%和1.0%。'],0.4,"['group', 'myocardial infarction', 'stroke', 'individual', 'death', 'primary', 'end', 'point', 'prasugrel', 'and']","['group', 'stroke', 'death', 'point']",118,各自的发生率分别为醋栗酸胺组和醋栗酸组的主要终点的各个组件：死亡率为4.5％和3.7％；心肌梗死率为4.8％和3.0％；中风率为1.1％和1.0％。,0.5,"['group', 'myocardial infarction', 'stroke', 'individual', 'death', 'primary', 'end', 'point', 'prasugrel', 'and']","['group', 'myocardial infarction', 'stroke', 'death', 'point']",,,,
119,119,"definite or probable stent thrombosis occurred in 1.3 % of patients assigned to ticagrelor and 1.0 % of patients assigned to prasugrel , and definite stent thrombosis occurred in 1.1 % and 0.6 % , respectively .",分配给替格瑞洛组的患者和普拉格雷组分别有 1.3% 和 1.0% 的患者发生明确或可能的支架内血栓形成，明确的支架内血栓形成发生率分别为 1.1% 和 0.6%。,0.3333333333333333,"['thrombosis', 'stent', 'prasugrel', 'in', 'to', 'and']","['thrombosis', 'prasugrel']",119,"['确定的或可能的<unk>血病发生在Ticagrelor患者的1.3%和Prasugrel患者的1.0%中,而确定的<unk>血病发生在1.1%和0.6%分别。']",0.1666666666666666,"['thrombosis', 'stent', 'prasugrel', 'in', 'to', 'and']",['and'],119,确定或可能的支架血栓形成发生在1.3%的ticagrelor分配给的患者和1.0%的患者分配给prasugrel，而确定的支架血栓形成发生在1.1%和0.6%，分别。,0.3333333333333333,"['thrombosis', 'stent', 'prasugrel', 'in', 'to', 'and']","['thrombosis', 'and']",,,,
120,120,"major bleeding ( as defined by the Bleeding Academic Research Consortium scale ) was observed in 5.4 % of patients in the ticagrelor group and in 4.8 % of patients in the prasugrel group ( hazard ratio , 1.12 ; 95 % CI , 0.83 to 1.51 ; P = 0.46 ) .",替格瑞洛组 5.4% 的患者和普拉格雷组 4.8% 的患者观察到大出血（根据出血学术研究联盟量表定义）（风险比，1.12；95% CI，0.83 至 1.51；P = 0.46）。,0.4285714285714285,"['bleeding', 'group', 'consortium', 'defined', 'hazard ratio', 'scale', 'major', 'academic research', 'prasugrel', 'P', 'CI', 'by', 'to', 'and']","['bleeding', 'group', 'hazard ratio', 'scale', 'academic research', 'prasugrel']",120,"['主要出血(根据血液学术研究协会规模定义)被观察到 5.4% 的患者在 ticagrelor 群体和 4.8% 的患者在 prasugrel 群体(风险比例, 1.12 ; 95% CI, 0.83 到 1.51 ; P = 0.46 ) 。']",0.2857142857142857,"['bleeding', 'group', 'consortium', 'defined', 'hazard ratio', 'scale', 'major', 'academic research', 'prasugrel', 'P', 'CI', 'by', 'to', 'and']","['bleeding', 'group', 'hazard ratio', 'academic research']",120,严重出血（根据血液学研究联盟的标准）在西卡格雷洛尔组的患者中观察到5.4%，在帕苏格尔组的患者中观察到4.8%（危险比，1.12；95%CI，0.83至1.51；P = 0.46）。,0.1428571428571428,"['bleeding', 'group', 'consortium', 'defined', 'hazard ratio', 'scale', 'major', 'academic research', 'prasugrel', 'P', 'CI', 'by', 'to', 'and']","['bleeding', 'group']",,,,
121,121,"however , data are lacking on the relative merits of treatment for 1 year with ticagrelor as compared with prasugrel in patients with acute coronary syndromes for whom invasive evaluation is planned .",然而，对于计划进行有创评估的急性冠脉综合征患者，与普拉格雷相比，替格瑞洛治疗 1 年的相对优点尚缺乏数据。,0.5833333333333334,"['data', 'year', '1', 'evaluation', 'coronary', 'relative', 'treatment', 'acute', 'with', 'prasugrel', 'in', 'syndromes']","['data', 'year', '1', 'coronary', 'treatment', 'prasugrel', 'syndromes']",121,"['然而,与Prasugrel相比,在患有急性冠状综合征的患者中,缺乏对1年的Ticagrelor治疗的相对益处的数据,其中计划进行侵入性评估。']",0.5,"['data', 'year', '1', 'evaluation', 'coronary', 'relative', 'treatment', 'acute', 'with', 'prasugrel', 'in', 'syndromes']","['data', 'year', '1', 'coronary', 'treatment', 'syndromes']",121,然而，在计划进行介入性评估的急性冠状动脉综合征患者中，尚缺乏有关1年使用西拉普利与帕苏格列尔治疗相对价值的数据。,0.5,"['data', 'year', '1', 'evaluation', 'coronary', 'relative', 'treatment', 'acute', 'with', 'prasugrel', 'in', 'syndromes']","['data', 'year', '1', 'coronary', 'treatment', 'syndromes']",,,,
122,122,"in these patients , ticagrelor is usually administered as pretreatment before diagnostic angiography , 4 but prasugrel is administered only after the coronary anatomy has been assessed by means of diagnostic angiography , 5 since no advantage has been observed when prasugrel is used as pretreatment.9",在这些患者中，替格瑞洛通常作为诊断性血管造影术前的预处理给药 4 ，但仅在通过诊断性血管造影术评估冠状动脉解剖后才给药普拉格雷 5 ，因为普拉格雷用作预处理时未观察到优势 9 。,0.625,"['angiography', '5', 'anatomy', 'coronary', 'after', 'advantage', 'diagnostic', '4', 'means', 'prasugrel', 'pretreatment', 'before', 'in', 'by', 'but', 'assessed']","['angiography', '5', 'anatomy', 'coronary', 'after', 'advantage', 'prasugrel', 'pretreatment', 'before', 'but']",122,"['在这些患者中,Ticagrelor通常在诊断安吉格拉之前作为预治疗,4但Prasugrel仅在通过诊断安吉格拉评估冠状解剖后服用,5因为当Prasugrel作为预治疗时没有任何好处。']",0.4375,"['angiography', '5', 'anatomy', 'coronary', 'after', 'advantage', 'diagnostic', '4', 'means', 'prasugrel', 'pretreatment', 'before', 'in', 'by', 'but', 'assessed']","['5', 'anatomy', 'coronary', 'after', 'before', 'in', 'but']",122,"在这些病人中，丙沙明通常会在诊断血管造影前进行预处理，4但是帕苏格列尔只会在通过诊断血管造影评估了冠状动脉解剖学后进行给药，5因为在帕苏格列尔用于预处理时没有观察到任何优势。9

Chinese:

在这些病人中，丙沙明通常会在诊断血管造影前进行预处理，4但是帕苏格列尔只会在通过诊断血管造影评估了冠状动脉解剖学后进行给药，5因为在帕苏格列尔用于预处理时没有观察到任何优势。9",0.5625,"['angiography', '5', 'anatomy', 'coronary', 'after', 'advantage', 'diagnostic', '4', 'means', 'prasugrel', 'pretreatment', 'before', 'in', 'by', 'but', 'assessed']","['angiography', '5', 'anatomy', 'coronary', 'after', 'advantage', 'pretreatment', 'before', 'but']",,,,
123,123,"one strategy is based on ticagrelor , and the other is based on prasugrel .",一种策略基于替格瑞洛，另一种基于普拉格雷。,0.5,"['strategy', 'prasugrel', 'on', 'and']","['strategy', 'prasugrel']",123,"['一个策略是基于ticagrelor,另一个是基于 prasugrel。']",0.25,"['strategy', 'prasugrel', 'on', 'and']",['strategy'],123,一种策略是基于利尿剂，另一种是基于阿司匹林。,0.25,"['strategy', 'prasugrel', 'on', 'and']",['strategy'],,,,
124,124,the design and rationale of the trial have been published previously.10,试验的设计和基本原理之前已发表。 10,0.4,"['rationale', 'trial', 'design', 'have', 'and']","['rationale', 'design']",124,['审判的草案和合理性已经公布10'],0.2,"['rationale', 'trial', 'design', 'have', 'and']",['trial'],124,之前已经发布了试验的设计和理念。,0.2,"['rationale', 'trial', 'design', 'have', 'and']",['design'],,,,
125,125,"the first and last authors , with input from the steering committee , designed the trial .",第一作者和最后一位作者在指导委员会的指导下设计了试验。,0.2857142857142857,"['steering', 'committee', 'input', 'trial', 'with', 'and', 'first']","['committee', 'first']",125,"['第一和最后的作者,由董事会提交,设计了审判。']",0.2857142857142857,"['steering', 'committee', 'input', 'trial', 'with', 'and', 'first']","['trial', 'first']",125,第一位和最后一位作者，在指导委员会的帮助下，设计了这项实验。,0.2857142857142857,"['steering', 'committee', 'input', 'trial', 'with', 'and', 'first']","['committee', 'first']",,,,
126,126,"the Intracoronary Stenting and Antithrombosis Research Center , which is affiliated with Deutsches Herzzentrum München in Munich , Germany , was the data coordinating center .",隶属于德国慕尼黑的Deutsches Herzzentrum München的冠状动脉内支架置入术和抗血栓形成研究中心是数据协调中心。,0.4,"['data', 'research center', 'with', 'in', 'and']","['data', 'research center']",126,"['Intracoronary Stenting and Antithrombosis Research Center 与德国慕尼黑的 Deutsches Herzzentrum München 附属,是数据协调中心。']",0.2,"['data', 'research center', 'with', 'in', 'and']",['data'],126,"the Intracoronary Stenting and Antithrombosis Research Center, which is affiliated with Deutsches Herzzentrum München in Munich, Germany, was the data coordinating center.

中文：

德国慕尼黑德意志心脏中心附属的冠状动脉支架与抗血栓研究中心是数据协调中心。",0.4,"['data', 'research center', 'with', 'in', 'and']","['data', 'research center']",,,,
127,127,data analysis was performed by the trial statistician .,数据分析由试验统计学家进行。,0.75,"['data', 'analysis', 'trial', 'by']","['data', 'analysis', 'by']",127,['数据分析由调查统计学家进行。'],0.75,"['data', 'analysis', 'trial', 'by']","['data', 'analysis', 'by']",127,统计分析由试验统计员进行。,0.5,"['data', 'analysis', 'trial', 'by']","['analysis', 'by']",,,,
128,128,"the first and last authors and the trial statistician vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol , which is available with the full text of this article at NEJM.org .",第一作者和最后一位作者以及试验统计学家保证数据的准确性和完整性，以及试验对方案的忠实度，方案与本文全文可在 NEJM.org 获取。,0.3571428571428571,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and', 'first']","['data', 'accuracy', 'completeness', 'full', 'first']",128,"['第一和最后的作者和审查统计学家为数据的准确性和完整性以及审查对议定书的忠诚度,该议定书可在NEJM.org上提供本文的完整文本。']",0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and', 'first']","['data', 'accuracy', 'protocol', 'completeness', 'full', 'first']",128,第一位和最后一位作者以及统计师保证数据的准确性和完整性，并保证试验与协议的忠实性，全文可在 NEJM.org 上找到。,0.5,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and', 'first']","['fidelity', 'data', 'accuracy', 'protocol', 'completeness', 'full', 'first']",,,,
129,129,the first author wrote the first draft of the manuscript .,第一作者撰写了手稿的初稿。,0.5,"['author', 'manuscript', 'first', 'draft']","['manuscript', 'first']",129,['第一位作者写了手稿的第一个草案。'],0.5,"['author', 'manuscript', 'first', 'draft']","['manuscript', 'first']",129,第一作者撰寫了該篇論文的第一稿。,0.25,"['author', 'manuscript', 'first', 'draft']",['first'],,,,
130,130,all the authors agreed to submit the manuscript for publication .,所有作者均同意投稿发表。,0.25,"['publication', 'manuscript', 'all', 'to']",['publication'],130,['所有作者都同意将手稿提交出版。'],0.5,"['publication', 'manuscript', 'all', 'to']","['publication', 'manuscript']",130,所有的作者都同意把这篇论文投稿给出版社。,0.25,"['publication', 'manuscript', 'all', 'to']",['publication'],,,,
131,131,the funding institutions were not involved in writing the manuscript or interpreting the results .,资助机构没有参与撰写手稿或解释结果。,0.5,"['manuscript', 'writing']",['manuscript'],131,['资助机构不参与编写手稿或解释结果。'],0.5,"['manuscript', 'writing']",['manuscript'],131,资助机构未参与论文的撰写或结果的解释。,0.5,"['manuscript', 'writing']",['writing'],,,,
132,132,commercially available ticagrelor or prasugrel tablets were prescribed by the treating physician and purchased by the patients .,市售的替格瑞洛或普拉格雷片剂由主治医师开具处方并由患者购买。,0.6,"['physician', 'available', 'prasugrel', 'by', 'and']","['physician', 'prasugrel', 'by']",132,['商用可用的Ticagrelor或Prasugrel药片由治疗医生处方并由患者购买。'],0.6,"['physician', 'available', 'prasugrel', 'by', 'and']","['physician', 'available', 'by']",132,被治疗的医生开具了可在商业上获得的西卡格雷洛或帕苏格雷片，并由病人购买。,0.4,"['physician', 'available', 'prasugrel', 'by', 'and']","['physician', 'by']",,,,
133,133,"a detailed list of participating centers and investigators is provided in the Supplementary Appendix , available at NEJM.org .",补充附录中提供了参与中心和研究者的详细列表，补充附录可在 NEJM.org 获取。,0.0,"['appendix', 'supplementary', 'available', 'list', 'at', 'in', 'and']",[],133,"['参与中心和调查人员的详细列表在附加附件中提供,可在NEJM.org上找到。']",0.1428571428571428,"['appendix', 'supplementary', 'available', 'list', 'at', 'in', 'and']",['appendix'],133,参与中心和调查人员的详细名单可在NEJM.org上找到。,0.0,"['appendix', 'supplementary', 'available', 'list', 'at', 'in', 'and']",[],,,,
134,134,exclusion criteria were determined predominantly from the summary of medical product characteristics of the trial drugs .,排除标准主要根据试验药物的医疗产品特征的总结确定。,0.5,"['product', 'drugs', 'medical', 'exclusion', 'characteristics', 'trial']","['product', 'drugs', 'characteristics']",134,['排除标准主要由试用药物的医疗产品特征总结确定。'],0.5,"['product', 'drugs', 'medical', 'exclusion', 'characteristics', 'trial']","['product', 'drugs', 'characteristics']",134,"exclusion criteria were determined predominantly from the summary of medical product characteristics of the trial drugs .

Chinese:
主要根据试验药物的产品特性摘要确定排除标准。",0.5,"['product', 'drugs', 'medical', 'exclusion', 'characteristics', 'trial']","['product', 'drugs', 'characteristics']",,,,
135,135,the detailed exclusion criteria are listed in the Supplementary Appendix .,详细的排除标准列于补充附录中。,0.0,"['appendix', 'supplementary', 'exclusion', 'in']",[],135,['详细的排除标准在附件中列出。'],0.25,"['appendix', 'supplementary', 'exclusion', 'in']",['appendix'],135,详细的排除标准列在附录中。,0.0,"['appendix', 'supplementary', 'exclusion', 'in']",[],,,,
136,136,"patients who met all the inclusion criteria and none of the exclusion criteria were randomly assigned in consecutive order to either ticagrelor or prasugrel , with a randomization ratio of 1 : 1 .",满足所有纳入标准且未满足任何排除标准的患者按连续顺序随机分配至替格瑞洛或普拉格雷，随机化比例为 1:1。,0.3076923076923077,"['randomization', 'who', 'inclusion', 'order', '1', 'ratio', 'exclusion', 'consecutive', 'with', 'prasugrel', 'met', 'all', 'to']","['randomization', '1', 'ratio', 'prasugrel']",136,"['满足所有包容标准的患者,并且没有排除标准的患者随机分别分配到Ticagrelor或Prasugrel,随机分配比为1:1。']",0.2307692307692307,"['randomization', 'who', 'inclusion', 'order', '1', 'ratio', 'exclusion', 'consecutive', 'with', 'prasugrel', 'met', 'all', 'to']","['randomization', '1', 'ratio']",136,符合所有纳入标准且不符合任何排除标准的患者按照连续顺序随机分配给他规则或帕苏格尔，随机化比例为1：1。,0.2307692307692307,"['randomization', 'who', 'inclusion', 'order', '1', 'ratio', 'exclusion', 'consecutive', 'with', 'prasugrel', 'met', 'all', 'to']","['randomization', '1', 'ratio']",,,,
137,137,time zero was defined as the time of randomization .,时间零被定义为随机化的时间。,0.6,"['defined', 'randomization', 'time', 'as', 'zero']","['randomization', 'time', 'zero']",137,['零时间被定义为随机化时间。'],0.6,"['defined', 'randomization', 'time', 'as', 'zero']","['randomization', 'time', 'zero']",137,"time zero was defined as the time of randomization .

Chinese:

时间零被定义为随机化的时间。",0.6,"['defined', 'randomization', 'time', 'as', 'zero']","['randomization', 'time', 'zero']",,,,
138,138,"randomly permuted block sizes ( of four , six , or eight ) were used in each stratum .",每个层使用随机排列的块大小（四个、六个或八个）。,0.5,"['stratum', 'block', 'each', 'in']","['stratum', 'block']",138,['随机转换的区块大小(四、六、八)在每个层中使用。'],0.5,"['stratum', 'block', 'each', 'in']","['stratum', 'block']",138,随机顺序块大小（四个，六个或八个）在每个层中使用。,0.5,"['stratum', 'block', 'each', 'in']","['stratum', 'block']",,,,
139,139,therapy with ticagrelor was started at a loading dose of 180 mg and continued at a maintenance dose of 90 mg twice daily .,替格瑞洛治疗以 180 毫克的负荷剂量开始，并以每天两次 90 毫克的维持剂量继续。,0.2857142857142857,"['loading', 'therapy', 'with', 'at', 'maintenance dose', 'and', 'twice']","['therapy', 'maintenance dose']",139,"['用Ticagrelor治疗开始于180毫克的负载剂量,并在90毫克的维持剂量继续,每天两次。']",0.4285714285714285,"['loading', 'therapy', 'with', 'at', 'maintenance dose', 'and', 'twice']","['therapy', 'at', 'maintenance dose']",139,在起始剂量为180毫克的情况下开始使用西拉雷德治疗，然后在每天两次的维持剂量为90毫克。,0.2857142857142857,"['loading', 'therapy', 'with', 'at', 'maintenance dose', 'and', 'twice']","['therapy', 'maintenance dose']",,,,
140,140,patients who were assigned to ticagrelor received the loading dose as soon as possible after randomization .,被分配到替格瑞洛组的患者在随机分组后尽快接受负荷剂量。,0.4285714285714285,"['loading', 'randomization', 'who', 'after', 'as', 'dose', 'to']","['randomization', 'after', 'dose']",140,['被分配到Ticagrelor的患者在随机化后尽快获得充电剂量。'],0.4285714285714285,"['loading', 'randomization', 'who', 'after', 'as', 'dose', 'to']","['randomization', 'after', 'dose']",140,随机分配给醇酐莫沙坦患者的第一剂药应尽快给予。,0.1428571428571428,"['loading', 'randomization', 'who', 'after', 'as', 'dose', 'to']",['randomization'],,,,
141,141,therapy with prasugrel was started at a loading dose of 60 mg and continued at a maintenance dose of 10 mg once per day .,普拉格雷治疗以 60 毫克的负荷剂量开始，并以每天一次 10 毫克的维持剂量继续。,0.4285714285714285,"['loading', 'therapy', 'with', 'prasugrel', 'at', 'maintenance dose', 'and']","['therapy', 'prasugrel', 'maintenance dose']",141,"['用 prasugrel 治疗开始于 60 毫克的负载剂量,并在 10 毫克的维持剂量每日进行一次。']",0.4285714285714285,"['loading', 'therapy', 'with', 'prasugrel', 'at', 'maintenance dose', 'and']","['therapy', 'at', 'maintenance dose']",141,"therapy with prasugrel was started at a loading dose of 60 mg and continued at a maintenance dose of 10 mg once per day.

Chinese:

普拉苏格尔治疗以60毫克的升级剂量开始，并以每天10毫克的维持剂量持续。",0.2857142857142857,"['loading', 'therapy', 'with', 'prasugrel', 'at', 'maintenance dose', 'and']","['therapy', 'maintenance dose']",,,,
142,142,a reduced maintenance dose of 5 mg daily was recommended in patients who were 75 years of age or older and in those who had a body weight of less than 60 kg .,对于 75 岁或以上以及体重低于 60 公斤的患者，建议将维持剂量减至每天 5 毫克。,0.5714285714285714,"['body weight', '5', 'who', 'age', 'kg', 'maintenance dose', 'and']","['body weight', '5', 'kg', 'maintenance dose']",142,"['在75岁及以上的患者和体重低于60公斤的患者中,建议每天减少5毫克的维持剂量。']",0.5714285714285714,"['body weight', '5', 'who', 'age', 'kg', 'maintenance dose', 'and']","['body weight', '5', 'kg', 'maintenance dose']",142,在75岁或以上的患者和体重小于60公斤的患者中，每天5毫克的维持剂量被建议。,0.5714285714285714,"['body weight', '5', 'who', 'age', 'kg', 'maintenance dose', 'and']","['body weight', '5', 'kg', 'maintenance dose']",,,,
143,143,"in the prasugrel group , timing of the initiation of the trial drug depended on the clinical presentation .",在普拉格雷组中，开始试验药物的时间取决于临床表现。,0.625,"['presentation', 'group', 'initiation', 'clinical', 'trial', 'timing', 'drug', 'prasugrel']","['group', 'initiation', 'clinical', 'drug', 'prasugrel']",143,"['在 prasugrel 组中,试验药物的启动时间取决于临床呈现。']",0.625,"['presentation', 'group', 'initiation', 'clinical', 'trial', 'timing', 'drug', 'prasugrel']","['presentation', 'group', 'initiation', 'clinical', 'drug']",143,在prasugrel小组中，开始使用试验药物的时间取决于临床表现。,0.5,"['presentation', 'group', 'initiation', 'clinical', 'trial', 'timing', 'drug', 'prasugrel']","['group', 'initiation', 'clinical', 'drug']",,,,
144,144,trial END POINTS AND DEFINITIONS,试验终点和定义,0.0,['trial'],[],144,['审判终点和定义'],1.0,['trial'],['trial'],144,Trial end points and definitions are important aspects of clinical research. They help to ensure the safety and efficacy of new treatments and help to ensure that the results of clinical trials are meaningful.,0.0,['trial'],[],,,,
145,145,"the primary end point was the composite of death , myocardial infarction , or stroke at 1 year after randomization .",主要终点是随机分组后 1 年时死亡、心肌梗死或卒中的复合终点。,0.7272727272727273,"['myocardial infarction', 'composite', 'stroke', 'randomization', 'year', '1', 'death', 'primary', 'after', 'end', 'point']","['myocardial infarction', 'stroke', 'randomization', 'year', '1', 'death', 'after', 'point']",145,"['主要的终点是死亡的组成,心脏病发作,或1年随机化后的中风。']",0.7272727272727273,"['myocardial infarction', 'composite', 'stroke', 'randomization', 'year', '1', 'death', 'primary', 'after', 'end', 'point']","['stroke', 'randomization', 'year', '1', 'death', 'primary', 'after', 'point']",145,1年随机化后，主要终点是死亡、心肌梗死或中风的组合。,0.7272727272727273,"['myocardial infarction', 'composite', 'stroke', 'randomization', 'year', '1', 'death', 'primary', 'after', 'end', 'point']","['myocardial infarction', 'stroke', 'randomization', 'year', '1', 'death', 'after', 'point']",,,,
146,146,a detailed description of the end points is included in the Supplementary Appendix .,终点的详细描述包含在补充附录中。,0.5,"['appendix', 'supplementary', 'end points', 'description']","['end points', 'description']",146,['最终点的详细描述在附件中包含。'],0.75,"['appendix', 'supplementary', 'end points', 'description']","['appendix', 'end points', 'description']",146,"在补充附录中包含了终点的详细描述。

Chinese:

在补充附录中包含了终点的详细描述。",0.5,"['appendix', 'supplementary', 'end points', 'description']","['end points', 'description']",,,,
147,147,"in addition , 100 % of source data were checked for at least 10 % of patients in all centers .",此外，对所有中心至少 10% 的患者的 100% 源数据进行了检查。,0.4,"['data', 'addition', 'source', 'all', 'in']","['data', 'source']",147,"['此外,在所有中心至少有10%的病人检查了100%的源数据。']",0.4,"['data', 'addition', 'source', 'all', 'in']","['data', 'source']",147,此外，所有中心的100%的患者至少10%的数据源进行了检查。,0.4,"['data', 'addition', 'source', 'all', 'in']","['data', 'source']",,,,
148,148,"the null hypothesis of the trial states that there is no difference between ticagrelor and prasugrel with respect to the treatment effect in patients with acute coronary syndromes for whom invasive evaluation is planned ( hazard ratio , 1 ) .",该试验的零假设表明，在计划进行侵入性评估的急性冠状动脉综合征患者中，替格瑞洛和普拉格雷之间的治疗效果没有差异（风险比，1）。,0.3888888888888889,"['1', 'hazard ratio', 'evaluation', 'coronary', 'difference', 'no', 'trial', 'acute', 'null hypothesis', 'treatment effect', 'with', 'respect', 'prasugrel', 'that', 'in', 'to', 'and', 'syndromes']","['1', 'hazard ratio', 'coronary', 'difference', 'treatment effect', 'prasugrel', 'syndromes']",148,"['试验的零假设表明,对于患有急性冠状综合征的患者的治疗效应,Ticagrelor和Prasugrel之间没有差异(风险比例,1)。']",0.3333333333333333,"['1', 'hazard ratio', 'evaluation', 'coronary', 'difference', 'no', 'trial', 'acute', 'null hypothesis', 'treatment effect', 'with', 'respect', 'prasugrel', 'that', 'in', 'to', 'and', 'syndromes']","['1', 'hazard ratio', 'coronary', 'difference', 'to', 'syndromes']",148,试验的零假设状态，在计划进行侵入性评估的急性冠状动脉综合征患者中，钛康博与赛普勒之间没有治疗效果方面的差异（危害比，1）。,0.2777777777777778,"['1', 'hazard ratio', 'evaluation', 'coronary', 'difference', 'no', 'trial', 'acute', 'null hypothesis', 'treatment effect', 'with', 'respect', 'prasugrel', 'that', 'in', 'to', 'and', 'syndromes']","['1', 'coronary', 'difference', 'treatment effect', 'syndromes']",,,,
149,149,cumulative incidence functions were computed for end points other than death to account for competing risks .,计算死亡以外的终点的累积发生率函数以考虑竞争风险。,0.5,"['death', 'cumulative incidence', 'end points', 'to']","['death', 'end points']",149,"['累积影响函数被计算为死亡以外的终点,以计算竞争风险。']",0.5,"['death', 'cumulative incidence', 'end points', 'to']","['death', 'end points']",149,累积发病率函数被计算出来用于除了死亡以外的终点，以考虑竞争风险。,1.0,"['death', 'cumulative incidence', 'end points', 'to']","['death', 'cumulative incidence', 'end points', 'to']",,,,
150,150,effect estimates of the secondary end points are presented along with corresponding 95 % confidence intervals .,次要终点的效果估计与相应的 95% 置信区间一起呈现。,0.375,"['corresponding', 'end points', 'along', 'secondary', 'effect', 'with', 'confidence', 'intervals']","['corresponding', 'end points', 'effect']",150,['二级终点的效应估计与相应的95%信任间隔一起呈现。'],0.375,"['corresponding', 'end points', 'along', 'secondary', 'effect', 'with', 'confidence', 'intervals']","['corresponding', 'end points', 'effect']",150,效应估计的次要终点沿相应的95％置信区间呈现。,0.5,"['corresponding', 'end points', 'along', 'secondary', 'effect', 'with', 'confidence', 'intervals']","['corresponding', 'end points', 'along', 'effect']",,,,
151,151,the widths of the intervals are not adjusted for multiple comparisons because of the exploratory character of these analyses .,由于这些分析的探索性特征，未针对多重比较调整区间宽度。,0.25,"['character', 'multiple', 'exploratory', 'intervals']",['character'],151,['间隔的宽度因这些分析的探索性质而不适用于多个比较。'],0.25,"['character', 'multiple', 'exploratory', 'intervals']",['character'],151,因为这些分析具有探索性质，所以没有对多次比较进行间隔宽度调整。,0.25,"['character', 'multiple', 'exploratory', 'intervals']",['character'],,,,
152,152,"patients were evaluated from randomization until death , withdrawal of consent , or the last contact date .",对患者进行评估，从随机分组到死亡、撤回同意或最后接触日期。,0.8,"['randomization', 'death', 'date', 'withdrawal', 'consent']","['randomization', 'death', 'date', 'consent']",152,"['患者从随机化到死亡,撤销同意,或最后的接触日期被评估。']",0.8,"['randomization', 'death', 'date', 'withdrawal', 'consent']","['randomization', 'death', 'date', 'consent']",152,病人从随机分配开始接受评估，直到死亡、撤回同意或最后接触日期。,0.8,"['randomization', 'death', 'date', 'withdrawal', 'consent']","['randomization', 'death', 'date', 'consent']",,,,
153,153,"from September 2013 through February 2018 , a total of 4018 patients were recruited in 23 centers ( 21 centers in Germany and 2 centers in Italy ) ; 2012 patients were assigned to ticagrelor and 2006 patients were assigned to prasugrel ( Figure 1 ) .",从2013年9月到2018年2月，在23个中心（德国21个中心和意大利2个中心）共招募了4018名患者； 2012 名患者被分配到替格瑞洛组，2006 名患者被分配到普拉格雷组（图 1）。,0.4285714285714285,"['1', '2', 'figure', 'total', 'prasugrel', 'in', 'and']","['1', '2', 'prasugrel']",153,"['从2013年9月至2018年2月,共有4018名患者被招募到23个中心(德国21个中心和意大利2个中心);2012年患者被分配到Ticagrelor,2006年患者被分配到Prasugrel(图1)。']",0.2857142857142857,"['1', '2', 'figure', 'total', 'prasugrel', 'in', 'and']","['1', '2']",153,2013年9月至2018年2月，共计4018名患者在23个中心（德国21个中心和意大利2个中心）接受了研究；2012名患者被分配给了醋基阿司匹林，2006名患者被分配给了苯妥英。,0.2857142857142857,"['1', '2', 'figure', 'total', 'prasugrel', 'in', 'and']","['1', '2']",,,,
154,154,the baseline characteristics of the patients are listed in Table 1 .,患者的基线特征见表1。,1.0,"['table', 'baseline', '1', 'characteristics']","['table', 'baseline', '1', 'characteristics']",154,['患者的基本特征在表1中列出。'],0.75,"['table', 'baseline', '1', 'characteristics']","['table', '1', 'characteristics']",154,表1列出了患者的基线特征。,1.0,"['table', 'baseline', '1', 'characteristics']","['table', 'baseline', '1', 'characteristics']",,,,
155,155,"the suspected diagnosis at admission was STEMI in 41.1 % , NSTEMI in 46.2 % , and unstable angina in 12.7 % of the patients .",入院时疑似STEMI占41.1%，NSTEMI占46.2%，不稳定型心绞痛占12.7%。,0.3333333333333333,"['admission', 'angina', 'diagnosis', 'unstable', 'at', 'and']","['angina', 'unstable']",155,"['在入院时,可疑的诊断为41.1%的STEMI,46.2%的NSTEMI,12.7%的患者患有不稳定的腹泻。']",0.3333333333333333,"['admission', 'angina', 'diagnosis', 'unstable', 'at', 'and']","['diagnosis', 'unstable']",155,疑似入院时的诊断为STEMI的41.1%，NSTEMI的46.2%，不稳定型心绞痛的12.7%。,0.5,"['admission', 'angina', 'diagnosis', 'unstable', 'at', 'and']","['angina', 'diagnosis', 'unstable']",,,,
156,156,"before admission , 34.7 % of patients in the ticagrelor group and 35.6 % of patients in the prasugrel group were receiving aspirin , and 5.0 % of patients in the ticagrelor group and 4.7 % of patients in the prasugrel group were receiving clopidogrel .",入院前，替格瑞洛组34.7%的患者和普拉格雷组35.6%的患者接受阿司匹林治疗，替格瑞洛组5.0%的患者和普拉格雷组4.7%的患者接受氯吡格雷治疗。,0.7142857142857143,"['group', 'aspirin', 'admission', 'clopidogrel', 'prasugrel', 'before', 'and']","['group', 'aspirin', 'clopidogrel', 'prasugrel', 'before']",156,"['在接入之前,34.7%的Ticagrelor患者和35.6%的Prasugrel患者服用阿司匹林,而5.0%的Ticagrelor患者和4.7%的Prasugrel患者服用Clopidogrel。']",0.4285714285714285,"['group', 'aspirin', 'admission', 'clopidogrel', 'prasugrel', 'before', 'and']","['aspirin', 'before', 'and']",156,在入院前，34.7％的西加利尔组患者和35.6％的普拉苏格尔组患者正在服用阿司匹林，而5.0％的西加利尔组患者和4.7％的普拉苏格尔组患者正在服用氯吡格雷。,0.7142857142857143,"['group', 'aspirin', 'admission', 'clopidogrel', 'prasugrel', 'before', 'and']","['group', 'aspirin', 'clopidogrel', 'before', 'and']",,,,
157,157,"in patients presenting with STEMI , the interval from symptom onset to randomization was 3.2 hours ( interquartile range , 1.8 to 7.7 ) in the ticagrelor group and 3.0 hours ( interquartile range , 1.9 to 8.4 ) in the prasugrel group .",在出现 STEMI 的患者中，替卡格雷组从症状发作到随机分组的间隔时间为 3.2 小时（四分位距，1.8 至 7.7），普拉格雷组为 3.0 小时（四分位距，1.9 至 8.4）。,0.625,"['group', 'symptom', 'interval', 'range', 'randomization', 'onset', 'with', 'prasugrel']","['group', 'symptom', 'interval', 'randomization', 'prasugrel']",157,"['在患有STEMI的患者中,从症状开始到随机化的间隔为3.2小时(四角间范围,1.8至7.7)在蒂卡格勒群体和3.0小时(四角间范围,1.9至8.4)在普拉苏格勒群体。']",0.75,"['group', 'symptom', 'interval', 'range', 'randomization', 'onset', 'with', 'prasugrel']","['group', 'symptom', 'interval', 'range', 'randomization', 'onset']",157,在患有STEMI的病人中，起症到随机化的时间间隔为3.2小时(四分位距为1.8至7.7)，而在阿司匹林组中为3.0小时(四分位距为1.9至8.4)。,0.375,"['group', 'symptom', 'interval', 'range', 'randomization', 'onset', 'with', 'prasugrel']","['group', 'interval', 'randomization']",,,,
158,158,"a total of 84.1 % of the patients underwent PCI , and 2.1 % underwent CABG .",共有 84.1% 的患者接受了 PCI，2.1% 的患者接受了 CABG。,0.0,"['total', 'CABG', 'and']",[],158,"['总共有84.1%的患者接受了PCI,而2.1%的患者接受了CABG。']",0.3333333333333333,"['total', 'CABG', 'and']",['and'],158,总计84.1%的病人接受了PCI手术，2.1%的病人接受了CABG手术。,0.0,"['total', 'CABG', 'and']",[],,,,
159,159,glycoprotein IIb / IIIa inhibitors were used in 12.3 % of the patients who underwent PCI .,12.3% 接受 PCI 的患者使用了糖蛋白 IIb/IIIa 抑制剂。,0.3333333333333333,"['who', 'glycoprotein', '/']",['glycoprotein'],159,['Glycoprotein IIb / IIIa 抑制剂被用于 12.3% 的患有 PCI 的患者。'],0.0,"['who', 'glycoprotein', '/']",[],159,12.3% of patients who underwent PCI were treated with glycoprotein IIb / IIIa inhibitors.,0.0,"['who', 'glycoprotein', '/']",[],,,,
160,160,"in more than 99 % of the patients who were receiving aspirin at discharge , the daily dose was 100 mg or less . ( angiographic and procedural characteristics are listed in Tables S1 and S2 , respectively , in the Supplementary Appendix . )",在超过 99% 的出院时服用阿司匹林的患者中，日剂量为 100 毫克或更少。 （血管造影和手术特征分别列于补充附录的表 S1 和表 S2 中。）,0.4166666666666667,"['discharge', 'aspirin', 'appendix', 'who', 'supplementary', 'characteristics', 'daily dose', 'at', 'S1', 'S2', 'and', 'angiographic']","['discharge', 'aspirin', 'characteristics', 'at', 'angiographic']",160,"['在接收阿司匹林的患者中,超过99%的患者,每日剂量为100毫克或更少(天文学和程序性特征列入表 S1 和 S2,分别,附件。']",0.3333333333333333,"['discharge', 'aspirin', 'appendix', 'who', 'supplementary', 'characteristics', 'daily dose', 'at', 'S1', 'S2', 'and', 'angiographic']","['discharge', 'aspirin', 'appendix', 'characteristics']",160,在出院时接受阿司匹林治疗的患者中，超过99%的患者每日剂量不超过100毫克。（相关角膜摄影和程序特征分别列在附件1和附件2的表格中。）,0.3333333333333333,"['discharge', 'aspirin', 'appendix', 'who', 'supplementary', 'characteristics', 'daily dose', 'at', 'S1', 'S2', 'and', 'angiographic']","['discharge', 'aspirin', 'appendix', 'characteristics']",,,,
161,161,"at discharge , 81.1 % of patients in the ticagrelor group and 80.7 % of patients in the prasugrel group received the randomly assigned trial drug ( Table S3 in the Supplementary Appendix ) .",出院时，替格瑞洛组 81.1% 的患者和普拉格雷组 80.7% 的患者接受了随机分配的试验药物（补充附录表 S3）。,0.3333333333333333,"['group', 'discharge', 'appendix', 'table', 'supplementary', 'trial', 'drug', 'prasugrel', 'at', 'S3', 'in', 'and']","['group', 'table', 'drug', 'prasugrel']",161,"['在排放时,Ticagrelor群体的81.1%患者和Prasugrel群体的80.7%患者接受了随机分配的试用药物(附件中的S3表)。']",0.3333333333333333,"['group', 'discharge', 'appendix', 'table', 'supplementary', 'trial', 'drug', 'prasugrel', 'at', 'S3', 'in', 'and']","['group', 'appendix', 'table', 'drug']",161,在出院时，81.1%的西加雷尔组患者和80.7%的普拉苏格尔组患者接受了随机分配的试验药物（见表S3在附加附录）。,0.25,"['group', 'discharge', 'appendix', 'table', 'supplementary', 'trial', 'drug', 'prasugrel', 'at', 'S3', 'in', 'and']","['group', 'table', 'drug']",,,,
162,162,"the median interval from randomization to discontinuation of the trial drug after discharge was 84 days ( interquartile range , 23 to 181 ) in the ticagrelor group and 109 days ( interquartile range , 35 to 220 ) in the prasugrel group ( P = 0.01 ) .",从随机分组到出院后停用试验药物的中位间隔时间，替卡格雷组为 84 天（四分位距，23 至 181 天），普拉格雷组为 109 天（四分位距，35 至 220 天）(P = 0.01)。,0.4,"['group', 'range', 'randomization', 'trial', 'median interval', 'drug', 'prasugrel', 'P', 'after discharge', 'to']","['group', 'randomization', 'drug', 'prasugrel']",162,['从随机化到试用药物排放后的中间间间隔为84天(中间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间'],0.2,"['group', 'range', 'randomization', 'trial', 'median interval', 'drug', 'prasugrel', 'P', 'after discharge', 'to']","['randomization', 'drug']",162,试验药物停用的随机化中位数间隔为84天（四分位间距为23至181天），而在利尿剂组为109天（四分位间距为35至220天）（P=0.01）。,0.3,"['group', 'range', 'randomization', 'trial', 'median interval', 'drug', 'prasugrel', 'P', 'after discharge', 'to']","['group', 'randomization', 'drug']",,,,
163,163,the types of antithrombotic therapy received by patients who discontinued the trial medication after discharge are listed in Table S4 in the Supplementary Appendix .,补充附录表 S4 列出了出院后停用试验药物的患者接受的抗血栓治疗类型。,0.1666666666666666,"['appendix', 'table', 'who', 'antithrombotic', 'supplementary', 'therapy', 'medication', 'trial', 'after discharge', 'S4', 'in', 'by']","['table', 'therapy']",163,['在排放后停止试用药物的患者接受的抗血管治疗的类型在附件中的S4表中列出。'],0.25,"['appendix', 'table', 'who', 'antithrombotic', 'supplementary', 'therapy', 'medication', 'trial', 'after discharge', 'S4', 'in', 'by']","['appendix', 'table', 'therapy']",163,表S4中列出了出院后停止服用试验药物的患者所接受的抗血小板疗法类型。,0.1666666666666666,"['appendix', 'table', 'who', 'antithrombotic', 'supplementary', 'therapy', 'medication', 'trial', 'after discharge', 'S4', 'in', 'by']","['table', 'therapy']",,,,
164,164,"the composite of death from cardiovascular causes , myocardial infarction , or stroke occurred in 161 of 2012 patients ( 8.1 % ) in the ticagrelor group and 124 of 2006 patients ( 6.3 % ) in the prasugrel group ( hazard ratio , 1.32 ; 95 % CI , 1.04 to 1.66 ) .",替格瑞洛组 2012 名患者中有 161 名 ( 8.1 % ) 和普拉格雷组 2006 名患者中有 124 名 ( 6.3 % ) 发生心血管原因死亡、心肌梗死或卒中的复合事件（风险比 1.32 ； 95 % CI ， 1.04 至 1.66)。,0.6363636363636364,"['group', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'hazard ratio', 'death', 'prasugrel', 'CI', 'to', 'and']","['group', 'myocardial infarction', 'cardiovascular', 'stroke', 'hazard ratio', 'death', 'prasugrel']",164,"['因心血管原因、心脏病发作或中风而死亡的组成情况发生在2012年中161名患者(8.1%)中,2006年中124名患者(6.3%)中(危险比例,1.32;95% CI,1.04至1.66)。']",0.4545454545454545,"['group', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'hazard ratio', 'death', 'prasugrel', 'CI', 'to', 'and']","['group', 'cardiovascular', 'stroke', 'death', 'and']",164,死亡的心血管原因、心肌梗死或中风综合发生率为2012例患者中的161例（8.1%），而2006例患者中的124例（6.3%）发生率为1.32（95%CI，1.04至1.66）。,0.4545454545454545,"['group', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'hazard ratio', 'death', 'prasugrel', 'CI', 'to', 'and']","['myocardial infarction', 'cardiovascular', 'stroke', 'death', 'and']",,,,
165,165,the incidences of the individual components of the primary end point are shown in Table 2 .,表 2 显示了主要终点的各个组成部分的发生率。,0.5,"['table', '2', 'individual', 'primary', 'end', 'point']","['table', '2', 'point']",165,['主要终点的各个组件的影响表2中显示。'],0.5,"['table', '2', 'individual', 'primary', 'end', 'point']","['table', '2', 'point']",165,表2显示了主要终点的各个组成部分的发生率。,0.5,"['table', '2', 'individual', 'primary', 'end', 'point']","['table', '2', 'point']",,,,
166,166,"the rate of death from any cause at 1 year was 4.5 % in the ticagrelor group and 3.7 % in the prasugrel group ( hazard ratio , 1.23 ; 95 % CI , 0.91 to 1.68 ) .",1 年时任何原因的死亡率在替格瑞洛组和普拉格雷组分别为 4.5% 和 3.7%（风险比，1.23；95% CI，0.91 至 1.68）。,0.6666666666666666,"['group', 'year', 'rate', '1', 'hazard ratio', 'death', 'cause', 'prasugrel', 'CI', 'in', 'to', 'and']","['group', 'year', 'rate', '1', 'hazard ratio', 'death', 'cause', 'prasugrel']",166,"['1年因任何原因死亡率为Ticagrelor群体的4.5%和Prasugrel群体的3.7%(风险比例为1.23;95% CI,0.91至1.68)。']",0.5833333333333334,"['group', 'year', 'rate', '1', 'hazard ratio', 'death', 'cause', 'prasugrel', 'CI', 'in', 'to', 'and']","['group', 'year', 'rate', '1', 'hazard ratio', 'death', 'cause']",166,第一年死亡率为4.5%的西加利尔组与死亡率为3.7%的普拉苏格尔组之间的危险比为1.23（95%置信区间为0.91-1.68）。,0.4166666666666667,"['group', 'year', 'rate', '1', 'hazard ratio', 'death', 'cause', 'prasugrel', 'CI', 'in', 'to', 'and']","['group', 'year', 'rate', '1', 'death']",,,,
167,167,"the incidence of myocardial infarction was 4.8 % in the ticagrelor group and 3.0 % in the prasugrel group ( hazard ratio , 1.63 ; 95 % CI , 1.18 to 2.25 ) .",心肌梗死的发生率在替格瑞洛组和普拉格雷组分别为 4.8% 和 3.0%（风险比，1.63；95% CI，1.18 至 2.25）。,0.625,"['group', 'myocardial infarction', 'incidence', 'hazard ratio', 'prasugrel', 'CI', 'to', 'and']","['group', 'myocardial infarction', 'incidence', 'hazard ratio', 'prasugrel']",167,"['心脏病发作的发病率在Ticagrelor群体中为4.8%和Prasugrel群体中为3.0%(风险比例为1.63;95% CI,1.18至2.25)。']",0.375,"['group', 'myocardial infarction', 'incidence', 'hazard ratio', 'prasugrel', 'CI', 'to', 'and']","['group', 'incidence', 'hazard ratio']",167,我們的研究發現，心肌梗塞的發生率在使用西卡格列醇的病人群體中為4.8%，而在使用普拉蘇格列醇的病人群體中則為3.0%（風險比為1.63，95%信賴區間從1.18到2.25）。,0.375,"['group', 'myocardial infarction', 'incidence', 'hazard ratio', 'prasugrel', 'CI', 'to', 'and']","['group', 'myocardial infarction', 'and']",,,,
168,168,"the incidence of stroke was 1.1 % in the ticagrelor group and 1.0 % in the prasugrel group ( hazard ratio , 1.17 ; 95 % CI , 0.63 to 2.15 ) .",中风的发生率在替格瑞洛组和普拉格雷组分别为 1.1% 和 1.0%（风险比，1.17；95% CI，0.63 至 2.15）。,0.625,"['group', 'incidence', 'stroke', 'hazard ratio', 'prasugrel', 'CI', 'to', 'and']","['group', 'incidence', 'stroke', 'hazard ratio', 'prasugrel']",168,"['发作的发病率在Ticagrelor群体中为1.1%和Prasugrel群体中为1.0%(风险比率,1.17;95% CI,0.63至2.15)。']",0.5,"['group', 'incidence', 'stroke', 'hazard ratio', 'prasugrel', 'CI', 'to', 'and']","['group', 'incidence', 'stroke', 'hazard ratio']",168,stroke的发生率在ticagrelor组为1.1%，在prasugrel组为1.0%（危险比为1.17；95%置信区间为0.63到2.15）。,0.25,"['group', 'incidence', 'stroke', 'hazard ratio', 'prasugrel', 'CI', 'to', 'and']","['group', 'incidence']",,,,
169,169,"the incidence of definite or probable stent thrombosis was 1.3 % in the ticagrelor group and 1.0 % in the prasugrel group ( hazard ratio , 1.30 ; 95 % CI , 0.72 to 2.33 ) .",明确或可能的支架内血栓形成的发生率在替格瑞洛组和普拉格雷组分别为 1.3% 和 1.0%（风险比，1.30；95% CI，0.72 至 2.33）。,0.5555555555555556,"['group', 'incidence', 'hazard ratio', 'thrombosis', 'stent', 'prasugrel', 'CI', 'to', 'and']","['group', 'incidence', 'hazard ratio', 'thrombosis', 'prasugrel']",169,"['确定的或可能的<unk>血病的发病率在Ticagrelor群体中为1.3%和Prasugrel群体中为1.0%(风险比例为1.30;95% CI,0.72至2.33)。']",0.3333333333333333,"['group', 'incidence', 'hazard ratio', 'thrombosis', 'stent', 'prasugrel', 'CI', 'to', 'and']","['group', 'incidence', 'hazard ratio']",169,在利多卡因组中确诊或有可能发生血管支架血栓的发病率为1.3%，在赛司替尼组中为1.0%（危险比为1.30；95%置信区间为0.72-2.33）。,0.3333333333333333,"['group', 'incidence', 'hazard ratio', 'thrombosis', 'stent', 'prasugrel', 'CI', 'to', 'and']","['group', 'incidence', 'thrombosis']",,,,
170,170,data from the analysis of the primary end point in the prespecified subgroups are shown in Figure S1 in the Supplementary Appendix .,来自预先指定亚组主要终点分析的数据显示在补充附录图 S1 中。,0.375,"['appendix', 'data', 'analysis', 'figure', 'supplementary', 'primary', 'point', 'S1']","['data', 'analysis', 'point']",170,['预定子组中的主要终点分析数据显示在附件中的图 S1 。'],0.5,"['appendix', 'data', 'analysis', 'figure', 'supplementary', 'primary', 'point', 'S1']","['appendix', 'data', 'analysis', 'point']",170,The data from the analysis of the primary endpoint in the prespecified subgroups are shown in Figure S1 in the Supplementary Appendix.,0.0,"['appendix', 'data', 'analysis', 'figure', 'supplementary', 'primary', 'point', 'S1']",[],,,,
171,171,the lower incidence of the composite end point was primarily driven by fewer myocardial infarctions in the prasugrel group than in the ticagrelor group .,复合终点的较低发生率主要是由于普拉格雷组的心肌梗死率低于替格瑞洛组。,0.6,"['group', 'composite', 'incidence', 'lower', 'myocardial', 'end', 'point', 'prasugrel', 'by', 'infarctions']","['group', 'incidence', 'point', 'prasugrel', 'by', 'infarctions']",171,['合成终点的较低的发病率主要是由 prasugrel 群体中比 ticagrelor 群体中较少的心脏病发作引起的。'],0.5,"['group', 'composite', 'incidence', 'lower', 'myocardial', 'end', 'point', 'prasugrel', 'by', 'infarctions']","['group', 'incidence', 'lower', 'point', 'by']",171,综合终点发生率较低主要是由于帕司甘治组比蒂卡格雷组心肌梗死发生率较低。,0.5,"['group', 'composite', 'incidence', 'lower', 'myocardial', 'end', 'point', 'prasugrel', 'by', 'infarctions']","['group', 'incidence', 'point', 'by', 'infarctions']",,,,
172,172,the benefit of fewer ischemic events with prasugrel did not occur at the expense of an increased risk of bleeding .,普拉格雷减少缺血事件的好处并没有以增加出血风险为代价。,0.375,"['bleeding', 'risk', 'benefit', 'with', 'occur', 'prasugrel', 'at', 'ischemic']","['bleeding', 'risk', 'prasugrel']",172,['与 prasugrel 较少的催化事件的好处没有发生在增加出血风险的代价。'],0.375,"['bleeding', 'risk', 'benefit', 'with', 'occur', 'prasugrel', 'at', 'ischemic']","['bleeding', 'risk', 'occur']",172,"The benefit of fewer ischemic events with prasugrel did not occur at the expense of an increased risk of bleeding.

中文：

使用普拉苏格尔减少缺血事件的好处并不会以增加出血风险为代价。",0.25,"['bleeding', 'risk', 'benefit', 'with', 'occur', 'prasugrel', 'at', 'ischemic']","['bleeding', 'risk']",,,,
173,173,the results were consistent across the whole spectrum of presentation of acute coronary syndromes .,结果在急性冠脉综合征的整个表现范围内是一致的。,0.4285714285714285,"['presentation', 'spectrum', 'coronary', 'across', 'acute', 'whole', 'syndromes']","['coronary', 'whole', 'syndromes']",173,"['结果在整个频谱中一致,表现出急性冠状综合征。']",0.5714285714285714,"['presentation', 'spectrum', 'coronary', 'across', 'acute', 'whole', 'syndromes']","['spectrum', 'coronary', 'whole', 'syndromes']",173,结果在整个急性冠状动脉综合征的表现范围内是一致的。,0.4285714285714285,"['presentation', 'spectrum', 'coronary', 'across', 'acute', 'whole', 'syndromes']","['coronary', 'whole', 'syndromes']",,,,
174,174,a particular feature of this trial is that it did not simply compare two antiplatelet drugs .,该试验的一个特点是它没有简单地比较两种抗血小板药物。,0.4444444444444444,"['feature', 'drugs', 'antiplatelet', 'particular', 'trial', 'compare', 'this', 'that', 'two']","['drugs', 'compare', 'this', 'two']",174,"['这个试验的一个特征是,它不只是比较两个抗膜药物。']",0.5555555555555556,"['feature', 'drugs', 'antiplatelet', 'particular', 'trial', 'compare', 'this', 'that', 'two']","['feature', 'drugs', 'compare', 'this', 'two']",174,这项试验的一个特点是它不仅仅比较了两种抗血小板药物。,0.4444444444444444,"['feature', 'drugs', 'antiplatelet', 'particular', 'trial', 'compare', 'this', 'that', 'two']","['drugs', 'compare', 'this', 'two']",,,,
175,175,"rather , it compared two antiplatelet treatment strategies involving two different drugs .",相反，它比较了涉及两种不同药物的两种抗血小板治疗策略。,0.75,"['drugs', 'antiplatelet', 'treatment', 'two']","['drugs', 'treatment', 'two']",175,"['相比之下,它比较了两种不同药物的抗细胞治疗策略。']",0.75,"['drugs', 'antiplatelet', 'treatment', 'two']","['drugs', 'treatment', 'two']",175,相比之下，这项研究对比了两种不同药物治疗的抗血小板策略。,0.75,"['drugs', 'antiplatelet', 'treatment', 'two']","['drugs', 'treatment', 'two']",,,,
176,176,the superiority assumption was based on several considerations .,优势假设是基于多种考虑。,0.0,"['superiority', 'on']",[],176,['优越的假设是基于几个考虑。'],0.0,"['superiority', 'on']",[],176,基于几个方面，这种优越性的假设是合理的。,0.5,"['superiority', 'on']",['superiority'],,,,
177,177,"on the basis of the rationale that a stronger platelet inhibition at the time of PCI reduces periprocedural thrombotic risk , the pretreatment strategy with ticagrelor was considered to be advantageous .",基于 PCI 时更强的血小板抑制可降低围手术期血栓形成风险的理论基础，替格瑞洛预处理策略被认为是有利的。,0.6153846153846154,"['inhibition', 'strategy', 'basis', 'time', 'thrombotic', 'rationale', 'be', 'risk', 'with', 'platelet', 'pretreatment', 'that', 'to']","['inhibition', 'strategy', 'time', 'rationale', 'risk', 'platelet', 'pretreatment', 'to']",177,"['基于在 PCI 时期的更强的平板膜抑制会降低周期流动性血管风险的理由,预治疗策略以 ticagrelor 被认为是有益的。']",0.4615384615384615,"['inhibition', 'strategy', 'basis', 'time', 'thrombotic', 'rationale', 'be', 'risk', 'with', 'platelet', 'pretreatment', 'that', 'to']","['inhibition', 'strategy', 'time', 'be', 'risk', 'to']",177,根据认为在PCI期间更强的血小板抑制可以降低术后血栓形成的风险的理论，考虑到起始使用西帕利尔的策略更有利。,0.5384615384615384,"['inhibition', 'strategy', 'basis', 'time', 'thrombotic', 'rationale', 'be', 'risk', 'with', 'platelet', 'pretreatment', 'that', 'to']","['inhibition', 'strategy', 'rationale', 'be', 'risk', 'platelet', 'that']",,,,
178,178,"also , previous findings suggest a consistent benefit of ticagrelor but not a consistent benefit of prasugrel in patients with acute coronary syndromes who receive conservative therapy .",此外，之前的研究结果表明，在接受保守治疗的急性冠脉综合征患者中，替格瑞洛的持续获益与普拉格雷的获益不一致。,0.3076923076923077,"['who', 'previous', 'coronary', 'therapy', 'acute', 'benefit', 'suggest', 'with', 'prasugrel', 'conservative', 'in', 'but', 'syndromes']","['coronary', 'therapy', 'prasugrel', 'syndromes']",178,"['此外,以前的发现表明Ticagrelor的持久益处,但在接受保守治疗的急性冠状综合征患者中,Prasugrel的不持久益处。']",0.3846153846153846,"['who', 'previous', 'coronary', 'therapy', 'acute', 'benefit', 'suggest', 'with', 'prasugrel', 'conservative', 'in', 'but', 'syndromes']","['previous', 'coronary', 'therapy', 'but', 'syndromes']",178,此外，先前的研究结果表明，在接受保守治疗的急性冠状动脉综合征患者中，西帕利莫尔有一致的益处，而瑞舒伐他汀并不一致。,0.3846153846153846,"['who', 'previous', 'coronary', 'therapy', 'acute', 'benefit', 'suggest', 'with', 'prasugrel', 'conservative', 'in', 'but', 'syndromes']","['coronary', 'therapy', 'benefit', 'but', 'syndromes']",,,,
179,179,"in PLATO , ticagrelor was superior to clopidogrel not only in patients who underwent PCI but also in those who received conservative treatment.13",在 PLATO 中，替卡格雷不仅在接受 PCI 的患者中而且在接受保守治疗的患者中都优于氯吡格雷。 13,0.4285714285714285,"['who', 'superior', 'clopidogrel', 'conservative', 'in', 'but', 'to']","['clopidogrel', 'but', 'to']",179,"['在PLATO中,Ticagrelor高于Clopidogrel,不仅在接受PCI的患者中,而且在接受保守治疗的患者中。']",0.2857142857142857,"['who', 'superior', 'clopidogrel', 'conservative', 'in', 'but', 'to']","['but', 'to']",179,在PLATO研究中，西西沙明不仅比复方克拉皮松在进行PCI的患者中表现优越，而且在接受保守治疗的患者中也表现优越。13,0.1428571428571428,"['who', 'superior', 'clopidogrel', 'conservative', 'in', 'but', 'to']",['but'],,,,
180,180,"whereas in PLATO only 61 % of the patients underwent PCI during the index hospitalization , 4 PCI was performed much more frequently in the present trial ( 84 % ) .",而在 PLATO 中，只有 61% 的患者在首次住院期间接受了 PCI，而在本试验中 4 PCI 的执行频率更高 (84%)。,0.1666666666666666,"['frequently', 'index', 'hospitalization', 'trial', '4', 'present']",['hospitalization'],180,"['在PLATO中,只有61%的患者在指数入院期间接受了PCI,而在目前的研究中,4个PCI进行了更频繁(84%)。']",0.1666666666666666,"['frequently', 'index', 'hospitalization', 'trial', '4', 'present']",['index'],180,在PLATO試驗中，只有61%的患者在首次住院期間接受了PCI手術，而在目前的試驗中，PCI手術的頻率要高得多，達到了84%。,0.1666666666666666,"['frequently', 'index', 'hospitalization', 'trial', '4', 'present']",['hospitalization'],,,,
181,181,"therefore , the contribution of patients who did not undergo PCI to the overall results was relatively small .",因此，未接受 PCI 的患者对总体结果的贡献相对较小。,0.0,"['who', 'undergo', 'therefore', 'to']",[],181,"['因此,未接受PCI的患者对总体结果的贡献相对较小。']",0.0,"['who', 'undergo', 'therefore', 'to']",[],181,因此，未经过PCI的患者对总体结果的贡献相对较小。,0.0,"['who', 'undergo', 'therefore', 'to']",[],,,,
182,182,"finally , pharmacodynamic studies showing a stronger antiplatelet effect of ticagrelor15 and the potential beneficial pleiotropic effects of ticagrelor , particularly those related to increased release of adenosine , 16 favored the expectation of superiority of ticagrelor over prasugrel in the current trial .",最后，药效学研究表明替格瑞洛具有更强的抗血小板作用 15 和替格瑞洛潜在的有益多效性作用，尤其是那些与腺苷释放增加相关的作用 16 ，支持在当前试验中替格瑞洛优于普拉格雷的预期。,0.5333333333333333,"['adenosine', 'pleiotropic', 'potential', 'pharmacodynamic', 'antiplatelet', 'release', 'trial', 'expectation', 'effect', 'superiority', 'current', 'prasugrel', 'over', 'to', 'and']","['adenosine', 'potential', 'pharmacodynamic', 'release', 'expectation', 'effect', 'prasugrel', 'to']",182,"['最后,药物动态研究表明,Ticagrelor15具有更强的抗斑作用,以及Ticagrelor的潜在有益的 pleiotropic效果,特别是与Adenosine的释放增加相关的效果,16在目前的研究中促进了Ticagrelor的优越性预期。']",0.2666666666666666,"['adenosine', 'pleiotropic', 'potential', 'pharmacodynamic', 'antiplatelet', 'release', 'trial', 'expectation', 'effect', 'superiority', 'current', 'prasugrel', 'over', 'to', 'and']","['release', 'expectation', 'effect', 'superiority']",182,最终，药效学研究表明西卡格雷洛具有更强的抗血小板作用15，并且具有潜在的有益的多态性作用，特别是与增加腺苷释放相关的作用16。这有利于预期西卡格雷洛在目前的试验中优于普拉苏格尔。,0.4666666666666667,"['adenosine', 'pleiotropic', 'potential', 'pharmacodynamic', 'antiplatelet', 'release', 'trial', 'expectation', 'effect', 'superiority', 'current', 'prasugrel', 'over', 'to', 'and']","['adenosine', 'potential', 'pharmacodynamic', 'release', 'expectation', 'effect', 'to']",,,,
183,183,the incidence of the primary composite net clinical end point assessed after 7 days did not differ between the ticagrelor and prasugrel groups .,7 天后评估的主要复合净临床终点的发生率在替格瑞洛和普拉格雷组之间没有差异。,0.4166666666666667,"['composite', 'incidence', 'net', 'primary', 'differ', 'clinical', 'after', 'end', 'point', 'prasugrel', 'and', 'assessed']","['incidence', 'clinical', 'after', 'point', 'prasugrel']",183,['7天后评估的初级合成净临床终点的发病率没有区别于Ticagrelor和Prasugrel群体。'],0.3333333333333333,"['composite', 'incidence', 'net', 'primary', 'differ', 'clinical', 'after', 'end', 'point', 'prasugrel', 'and', 'assessed']","['incidence', 'clinical', 'after', 'point']",183,在7天后评估的主要复合净临床终点发生率在西沙吉尔和普拉苏格尔组之间没有差异。,0.3333333333333333,"['composite', 'incidence', 'net', 'primary', 'differ', 'clinical', 'after', 'end', 'point', 'prasugrel', 'and', 'assessed']","['incidence', 'clinical', 'after', 'point']",,,,
184,184,an interaction between treatment effect and aspirin dosage has been reported for ticagrelor19 but not for prasugrel.20,据报道，治疗效果和阿司匹林剂量之间的相互作用对替格瑞洛 19 但普拉格雷没有。 20,0.6666666666666666,"['aspirin', 'dosage', 'interaction', 'treatment effect', 'but', 'and']","['aspirin', 'dosage', 'treatment effect', 'but']",184,['治疗效果与阿司匹林剂量之间的相互作用已被报告为Ticagrelor19但不是Prasugrel。'],0.6666666666666666,"['aspirin', 'dosage', 'interaction', 'treatment effect', 'but', 'and']","['aspirin', 'dosage', 'treatment effect', 'but']",184,一项研究发现，西替利美的药效与阿司匹林剂量之间存在相互作用，而帕苏莱尔则不存在这种情况。,0.6666666666666666,"['aspirin', 'dosage', 'interaction', 'treatment effect', 'but', 'and']","['aspirin', 'dosage', 'but', 'and']",,,,
185,185,"however , the actual dose of aspirin in the present trial was 100 mg per day or less , as compared with a dose of 300 mg per day or more in 54 % of the U.S. patients in PLATO.19",然而，本试验中阿司匹林的实际剂量为每天 100 毫克或更少，而 PLATO 试验中 54 % 的美国患者的剂量为每天 300 毫克或更多。 19,0.3333333333333333,"['aspirin', 'actual', 'trial', 'present', 'with', 'dose']","['aspirin', 'dose']",185,"['然而,目前的阿司匹林的实际剂量是每日100毫克或更少的,与美国54%的PLATO患者的每日300毫克或更少的剂量相比。']",0.3333333333333333,"['aspirin', 'actual', 'trial', 'present', 'with', 'dose']","['aspirin', 'dose']",185,然而，在目前的试验中，阿司匹林的实际剂量为每天100毫克或更少，而美国PLATO患者中54％的患者每天需要300毫克或更多。,0.3333333333333333,"['aspirin', 'actual', 'trial', 'present', 'with', 'dose']","['aspirin', 'dose']",,,,
186,186,"the incidence of the primary end point in the ticagrelor group was close to the predicted event rate for that group ( 9.3 % and 10.0 % , respectively ) .",替格瑞洛组主要终点的发生率接近该组的预测事件率（分别为 9.3% 和 10.0%）。,0.4,"['group', 'incidence', 'rate', 'primary', 'end', 'point', 'event', 'that', 'and', 'close to']","['group', 'incidence', 'rate', 'point']",186,['图克格勒群体的主要终点的影响率接近该群体预测的事件率(分别为9.3%和10.0%)。'],0.3,"['group', 'incidence', 'rate', 'primary', 'end', 'point', 'event', 'that', 'and', 'close to']","['group', 'rate', 'point']",186,经过分析，初步结果表明，利用西卡格列醇的患者所发生的主要终点事件与预期的发生率相差无几（分别为9.3%和10.0%）。,0.4,"['group', 'incidence', 'rate', 'primary', 'end', 'point', 'event', 'that', 'and', 'close to']","['incidence', 'rate', 'point', 'event']",,,,
187,187,"the incidence of myocardial infarction was lower in the present trial than in previous pivotal trials.4,5","本试验的心肌梗死发生率低于之前的关键试验。 4,5",0.3333333333333333,"['myocardial infarction', 'incidence', 'previous', 'lower', 'trial', 'present']","['myocardial infarction', 'incidence']",187,['心脏病发作的发病率在目前的试验中低于以前的试验中。'],0.3333333333333333,"['myocardial infarction', 'incidence', 'previous', 'lower', 'trial', 'present']","['incidence', 'previous']",187,"The incidence of myocardial infarction was lower in the present trial than in previous pivotal trials.4,5",0.0,"['myocardial infarction', 'incidence', 'previous', 'lower', 'trial', 'present']",[],,,,
188,188,this may be explained in part by differences in the definition of myocardial infarction .,部分原因可能是心肌梗死定义的差异。,0.5,"['part', 'myocardial infarction', 'be', 'definition', 'this', 'by']","['myocardial infarction', 'definition', 'this']",188,['这部分可以由心脏病发作的定义中的差异解释。'],0.3333333333333333,"['part', 'myocardial infarction', 'be', 'definition', 'this', 'by']","['definition', 'by']",188,这可能部分地解释了心肌梗死的定义之间的差异。,0.3333333333333333,"['part', 'myocardial infarction', 'be', 'definition', 'this', 'by']","['myocardial infarction', 'definition']",,,,
189,189,the incidence of major bleeding was not higher in the prasugrel group than in the ticagrelor group .,普拉格雷组的大出血发生率并不高于替格瑞洛组。,0.8,"['bleeding', 'group', 'incidence', 'major', 'prasugrel']","['bleeding', 'group', 'incidence', 'prasugrel']",189,['主要出血的发病率在 prasugrel 群体中不高于 ticagrelor 群体。'],0.6,"['bleeding', 'group', 'incidence', 'major', 'prasugrel']","['bleeding', 'group', 'incidence']",189,在普萨古利组和西卡格雷组间，重度出血的发生率并不高于西卡格雷组。,0.6,"['bleeding', 'group', 'incidence', 'major', 'prasugrel']","['bleeding', 'group', 'incidence']",,,,
190,190,"patients presented with pulmonary , gastrointestinal , and constitutional symptoms and varying degrees of respiratory failure .",患者表现为肺部、胃肠道和全身症状以及不同程度的呼吸衰竭。,0.25,"['gastrointestinal', 'symptoms', 'pulmonary', 'respiratory failure', 'constitutional', 'with', 'degrees', 'and']","['gastrointestinal', 'respiratory failure']",190,['患有肺、肠道和宪法症状和不同程度的呼吸障碍的患者。'],0.0,"['gastrointestinal', 'symptoms', 'pulmonary', 'respiratory failure', 'constitutional', 'with', 'degrees', 'and']",[],190,病人出现肺部、胃肠道和宪法症状，呼吸衰竭程度不同。,0.25,"['gastrointestinal', 'symptoms', 'pulmonary', 'respiratory failure', 'constitutional', 'with', 'degrees', 'and']","['gastrointestinal', 'respiratory failure']",,,,
191,191,"most patients were young men ( median age , 19 ) .",大多数患者是年轻男性（中位年龄 19 岁）。,0.0,"['median age', 'young']",[],191,"['大多数患者是年轻人(平均年龄,19岁)。']",0.0,"['median age', 'young']",[],191,大多数病人是年轻的男性（年龄中位数为19岁）。,0.5,"['median age', 'young']",['median age'],10.0,6.0,2.0,10.0
192,192,"patients presented with constitutional symptoms ( most commonly , fever ) , dyspnea , cough , chest pain , and gastrointestinal complaints .",患者出现全身症状（最常见的是发烧）、呼吸困难、咳嗽、胸痛和胃肠道不适。,0.4444444444444444,"['gastrointestinal', 'dyspnea', 'chest pain', 'symptoms', 'cough', 'constitutional', 'fever', 'with', 'and']","['gastrointestinal', 'dyspnea', 'chest pain', 'cough']",192,"['患有宪法症状(最常见的,发烧), dyspnea, 咳嗽, 胸部疼痛, 和 胃肠道抱怨。']",0.2222222222222222,"['gastrointestinal', 'dyspnea', 'chest pain', 'symptoms', 'cough', 'constitutional', 'fever', 'with', 'and']","['gastrointestinal', 'cough']",192,病人以体质症状（最常见的是发烧）、呼吸困难、咳嗽、胸痛和胃肠不适为主要表现。,0.4444444444444444,"['gastrointestinal', 'dyspnea', 'chest pain', 'symptoms', 'cough', 'constitutional', 'fever', 'with', 'and']","['gastrointestinal', 'dyspnea', 'chest pain', 'cough']",10.0,8.0,2.0,10.0
193,193,"more than half of patients were admitted to intensive care units , and one third received invasive mechanical ventilation .",一半以上的患者住进了重症监护病房，三分之一接受了有创机械通气。,0.3333333333333333,"['half', 'mechanical ventilation', 'intensive care', 'to', 'and', 'third']","['half', 'mechanical ventilation']",193,"['超过一半的病人被录取到强度护理单位,三分之一受到了侵入性机械通风。']",0.3333333333333333,"['half', 'mechanical ventilation', 'intensive care', 'to', 'and', 'third']","['half', 'mechanical ventilation']",193,超过半数的病人被送进了重症监护室，三分之一的病人接受了有创的机械通气。,0.3333333333333333,"['half', 'mechanical ventilation', 'intensive care', 'to', 'and', 'third']","['half', 'mechanical ventilation']",10.0,9.0,2.0,10.0
194,194,neutrophilic leukocytosis was common ; acute kidney injury was not .,中性粒细胞增多常见；没有急性肾损伤。,0.25,"['common', 'kidney injury', 'neutrophilic', 'acute']",['kidney injury'],194,['neutrophilic leukocytosis 是常见的; 急性肾损伤没有。'],0.25,"['common', 'kidney injury', 'neutrophilic', 'acute']",['kidney injury'],194,"Neutrophilic leukocytosis was common; acute kidney injury was not.

Chinese:

中性粒细胞增多是常见现象;急性肾损伤并不常见。",0.25,"['common', 'kidney injury', 'neutrophilic', 'acute']",['kidney injury'],8.0,7.0,2.0,8.0
195,195,"one patient died in this cohort , and additional deaths have been reported in other areas .",该队列中有一名患者死亡，其他地区也报告了其他死亡病例。,0.2857142857142857,"['additional', 'patient', 'cohort', 'have', 'this', 'in', 'and']","['patient', 'have']",195,"['一名病人在此期间死亡,并在其他地区报告了额外的死亡。']",0.2857142857142857,"['additional', 'patient', 'cohort', 'have', 'this', 'in', 'and']","['additional', 'patient']",195,一名患者在这个研究队伍中死亡，在其他地区也报告了其他死亡病例。,0.1428571428571428,"['additional', 'patient', 'cohort', 'have', 'this', 'in', 'and']",['patient'],10.0,10.0,5.0,10.0
196,196,this approach was better at limiting exacerbations than was daily corticosteroid therapy .,这种方法比每日皮质类固醇治疗更能限制病情加重。,0.3333333333333333,"['approach', 'corticosteroid', 'therapy', 'limiting', 'at', 'this']","['corticosteroid', 'therapy']",196,"['这种方法在限制恶化方面更好,而不是每日治疗甲状腺素。']",0.3333333333333333,"['approach', 'corticosteroid', 'therapy', 'limiting', 'at', 'this']","['therapy', 'this']",196,这种方法更能有效地抑制恶化症状，而每日使用类固醇治疗则不能达到同样的效果。,0.1666666666666666,"['approach', 'corticosteroid', 'therapy', 'limiting', 'at', 'this']",['therapy'],10.0,4.0,1.0,10.0
197,197,inhaler adherence was 76 % .,吸入器依从性为 76%。,0.5,"['inhaler', 'adherence']",['inhaler'],197,['吸入器的粘贴率为76%。'],0.5,"['inhaler', 'adherence']",['inhaler'],197,inhaler adherence was 76%.,0.0,"['inhaler', 'adherence']",[],10.0,8.0,5.0,
198,198,we discuss this relatively new approach to mild asthma in more detail in a separate NEJM Journal Watch General MedicineClinical Spotlight feature .,我们在单独的 NEJM Journal Watch General MedicineClinical Spotlight 专题中更详细地讨论了这种相对较新的治疗轻度哮喘的方法。,0.25,"['approach', 'feature', 'asthma', 'general', 'discuss', 'spotlight', 'detail', 'watch', 'journal', 'mild', 'this', 'in', 'separate', 'to', 'new', 'we']","['asthma', 'detail', 'mild', 'new']",198,['我们在一个单独的NEJM杂志观看通用医学临床照明功能中讨论了这种相对较新的轻微哮喘方法。'],0.1875,"['approach', 'feature', 'asthma', 'general', 'discuss', 'spotlight', 'detail', 'watch', 'journal', 'mild', 'this', 'in', 'separate', 'to', 'new', 'we']","['asthma', 'journal', 'new']",198,我们在本期的临床聚焦特别报道中将详细讨论这种相对较新的对慢性哮喘的治疗方法。,0.1875,"['approach', 'feature', 'asthma', 'general', 'discuss', 'spotlight', 'detail', 'watch', 'journal', 'mild', 'this', 'in', 'separate', 'to', 'new', 'we']","['asthma', 'detail', 'new']",10.0,7.0,4.0,10.0
199,199,vedolizumab was superior to adalimumab for achieving clinical remission of moderately to severely active ulcerative colitis .,在实现中度至重度活动性溃疡性结肠炎的临床缓解方面，维多珠单抗优于阿达木单抗。,0.625,"['superior', 'active', 'moderately', 'ulcerative colitis', 'clinical', 'remission', 'vedolizumab', 'to']","['active', 'ulcerative colitis', 'clinical', 'remission', 'to']",199,"['vedolizumab 比 adalimumab 优越,以达到适度至严重活性溃<unk>炎的临床复发。']",0.125,"['superior', 'active', 'moderately', 'ulcerative colitis', 'clinical', 'remission', 'vedolizumab', 'to']",['clinical'],199,"vedolizumab was superior to adalimumab for achieving clinical remission of moderately to severely active ulcerative colitis.

Chinese:

维多利素较奥达林对于获得中度至重度活动性溃疡性结肠病的临床缓解来说优势更大。",0.5,"['superior', 'active', 'moderately', 'ulcerative colitis', 'clinical', 'remission', 'vedolizumab', 'to']","['active', 'clinical', 'remission', 'to']",,,,
200,200,"standard dosing of vedolizumab and adalimumab were used , with no dose escalation permitted in either group .",使用标准剂量的维多珠单抗和阿达木单抗，两组均不允许增加剂量。,0.4285714285714285,"['group', 'standard', 'no', 'with', 'vedolizumab', 'dose', 'in']","['group', 'standard', 'dose']",200,"['使用了标准剂量的Vedolizumab和Adalimumab,没有允许在任何群体中增加剂量。']",0.4285714285714285,"['group', 'standard', 'no', 'with', 'vedolizumab', 'dose', 'in']","['group', 'standard', 'dose']",200,标准剂量的vedolizumab和adalimumab被使用，两组都不允许升级剂量。,0.4285714285714285,"['group', 'standard', 'no', 'with', 'vedolizumab', 'dose', 'in']","['group', 'standard', 'dose']",,,,
201,201,"among the 769 participants , clinical remission at week 52 ( the primary outcome ) was more frequently achieved in the vedolizumab group compared with the adalimumab group ( 31.3 % vs. 22.5 % ) ; endoscopic improvement also occurred more frequently in the vedolizumab group ( 39.7 % vs. 27.7 % ) .",在 769 名参与者中，与阿达木单抗组相比，维多珠单抗组在第 52 周（主要结果）达到临床缓解的频率更高（31.3% 对 22.5%）；维多珠单抗组的内窥镜改善也更常见（39.7% 对 27.7%）。,0.5,"['group', 'improvement', 'outcome', 'frequently', 'primary', 'clinical', 'week', 'remission', 'with', 'achieved', 'vedolizumab', 'at']","['group', 'improvement', 'outcome', 'clinical', 'week', 'remission']",201,"['在769名参与者中,在第52周(初始结果)的临床衰退在Vedolizumab群体中比Adalimumab群体更频繁(31.3%与22.5%);在Vedolizumab群体中,内分泌改善也更频繁(39.7%与27.7%)。']",0.4166666666666667,"['group', 'improvement', 'outcome', 'frequently', 'primary', 'clinical', 'week', 'remission', 'with', 'achieved', 'vedolizumab', 'at']","['group', 'improvement', 'outcome', 'clinical', 'week']",201,在769名参与者中，临床缓解在52周（主要结果）发生的频率在vedolizumab组比adalimumab组（31.3％对22.5％）更高；内镜改善也在vedolizumab组发生的频率更高（39.7％对27.7％）。,0.5,"['group', 'improvement', 'outcome', 'frequently', 'primary', 'clinical', 'week', 'remission', 'with', 'achieved', 'vedolizumab', 'at']","['group', 'improvement', 'outcome', 'clinical', 'week', 'remission']",,,,
202,202,a difference of nearly 9 percentage points in the primary outcome translates to a number needed to treat of 11 to achieve one additional remission .,主要结果中将近 9 个百分点的差异转化为需要治疗的数字 11 以实现额外的缓解。,0.6,"['percentage', 'outcome', 'treat', 'difference', 'primary', 'number', 'additional', 'remission', 'in', 'to']","['outcome', 'treat', 'difference', 'number', 'additional', 'remission']",202,"['在初始结果中,几乎9个百分点的差异转化为需要处理的11个数字,以实现额外的折扣。']",0.5,"['percentage', 'outcome', 'treat', 'difference', 'primary', 'number', 'additional', 'remission', 'in', 'to']","['outcome', 'treat', 'difference', 'number', 'additional']",202,约9%的差异在主要结果中转化为11个需要治疗才能获得1个额外的缓解。,0.5,"['percentage', 'outcome', 'treat', 'difference', 'primary', 'number', 'additional', 'remission', 'in', 'to']","['outcome', 'treat', 'difference', 'additional', 'remission']",,,,
203,203,"given its more favorable safety profile , vedolizumab might be the preferable first choice for moderately to severely active ulcerative colitis .",鉴于其更有利的安全性，vedolizumab 可能是中度至重度活动性溃疡性结肠炎的首选。,0.4,"['safety', 'active', 'moderately', 'be', 'ulcerative colitis', 'profile', 'choice', 'vedolizumab', 'to', 'first']","['safety', 'active', 'ulcerative colitis', 'to']",203,"['由于其更有利的安全性,Vedolizumab可能是适度至严重活性<unk>疹的首选。']",0.2,"['safety', 'active', 'moderately', 'be', 'ulcerative colitis', 'profile', 'choice', 'vedolizumab', 'to', 'first']","['safety', 'to']",203,"Given its more favorable safety profile, vedolizumab might be the preferable first choice for moderately to severely active ulcerative colitis.

Chinese:

鉴于其更有利的安全性能，威多利马布可能是中度至重度活动性溃疡性结肠炎的首选药物。",0.4,"['safety', 'active', 'moderately', 'be', 'ulcerative colitis', 'profile', 'choice', 'vedolizumab', 'to', 'first']","['safety', 'active', 'ulcerative colitis', 'to']",,,,
204,204,"a case study provides support for pursuing this approach , but much more needs to be learned .",案例研究为追求这种方法提供了支持，但还需要学习更多。,0.2857142857142857,"['approach', 'support', 'be', 'case study', 'this', 'but', 'to']","['support', 'but']",204,"['一个案例研究为追求这种方法提供支持,但需要了解更多。']",0.2857142857142857,"['approach', 'support', 'be', 'case study', 'this', 'but', 'to']","['support', 'but']",204,一份案例研究为追求这一方法提供了支持，但还有很多需要学习。,0.2857142857142857,"['approach', 'support', 'be', 'case study', 'this', 'but', 'to']","['support', 'but']",,,,
205,205,HIV uses the coreceptor CCR5 to infect CD4 + T cells .,HIV 使用辅助受体 CCR5 感染 CD4+ T 细胞。,1.0,"['HIV', 'coreceptor', 'T']","['HIV', 'coreceptor', 'T']",205,['艾滋病毒使用 CCR5 调节器感染 CD4 + T 细胞。'],0.3333333333333333,"['HIV', 'coreceptor', 'T']",['HIV'],205,"HIV使用核受体CCR5来感染CD4+T细胞。

Chinese:

HIV使用核受体CCR5来感染CD4+T细胞。",0.3333333333333333,"['HIV', 'coreceptor', 'T']",['HIV'],,,,
206,206,two people have been cured of HIV after being treated for malignancy with stem cell transplants from donors who lack this coreceptor .,两个人在接受来自缺乏这种辅助受体的供体的干细胞移植治疗恶性肿瘤后治愈了 HIV。,0.5384615384615384,"['stem cell', 'HIV', 'coreceptor', 'lack', 'malignancy', 'who', 'after', 'transplants', 'being', 'with', 'have', 'this', 'two']","['stem cell', 'HIV', 'coreceptor', 'malignancy', 'after', 'transplants', 'two']",206,"['两人接受了艾滋病毒的治疗后,他们接受了从捐赠者缺乏这种调节剂的干细胞移植的恶性治疗。']",0.4615384615384615,"['stem cell', 'HIV', 'coreceptor', 'lack', 'malignancy', 'who', 'after', 'transplants', 'being', 'with', 'have', 'this', 'two']","['stem cell', 'HIV', 'malignancy', 'after', 'transplants', 'two']",206,两人在接受来自缺乏该核心受体的捐赠者的干细胞移植治疗癌症后，已经康复了艾滋病。,0.3076923076923077,"['stem cell', 'HIV', 'coreceptor', 'lack', 'malignancy', 'who', 'after', 'transplants', 'being', 'with', 'have', 'this', 'two']","['stem cell', 'after', 'transplants', 'two']",,,,
207,207,he had been diagnosed with ALL and was in remission after standard chemotherapy .,他被诊断出患有 ALL，经过标准化疗后病情正在缓解。,0.6666666666666666,"['chemotherapy', 'standard', 'after', 'remission', 'with', 'in']","['chemotherapy', 'standard', 'after', 'remission']",207,"['他被诊断为全身,并在标准化疗后处于复发状态。']",0.5,"['chemotherapy', 'standard', 'after', 'remission', 'with', 'in']","['chemotherapy', 'standard', 'after']",207,他被诊断出患有急性淋巴细胞白血病，经标准化化疗后已经康复。,0.5,"['chemotherapy', 'standard', 'after', 'remission', 'with', 'in']","['chemotherapy', 'standard', 'after']",,,,
208,208,"donor cells with ablated CCR5 persisted for at least 19 months in the recipient , accounting for approximately 5 % of bone marrow cells .",去除了 CCR5 的供体细胞在受体体内至少持续存在 19 个月，约占骨髓细胞的 5%。,0.5714285714285714,"['recipient', 'donor', 'bone marrow', '5', 'with', 'approximately', 'in']","['recipient', 'donor', 'bone marrow', '5']",208,"['捐赠者细胞在受益者中至少持久了19个月,占骨髓细胞的约5%。']",0.2857142857142857,"['recipient', 'donor', 'bone marrow', '5', 'with', 'approximately', 'in']","['bone marrow', '5']",208,"Donor cells with ablated CCR5 persisted for at least 19 months in the recipient, accounting for approximately 5% of bone marrow cells.",0.1428571428571428,"['recipient', 'donor', 'bone marrow', '5', 'with', 'approximately', 'in']",['5'],,,,
209,209,"seven months after engraftment , the recipient underwent an ART interruption , during which his HIV RNA rebounded quickly .",植入七个月后，接受者经历了 ART 中断，在此期间他的 HIV RNA 迅速反弹。,0.8571428571428571,"['RNA', 'HIV', 'recipient', 'interruption', 'after', 'his', 'engraftment']","['RNA', 'HIV', 'recipient', 'interruption', 'after', 'engraftment']",209,"['接收后七个月,接收者经历了ART中断,在此期间他的HIVRNA迅速恢复。']",0.5714285714285714,"['RNA', 'HIV', 'recipient', 'interruption', 'after', 'his', 'engraftment']","['RNA', 'HIV', 'interruption', 'after']",209,"7 months after the transplant, the patient stopped taking their ART medication. Their HIV RNA levels quickly rebounded.",0.2857142857142857,"['RNA', 'HIV', 'recipient', 'interruption', 'after', 'his', 'engraftment']","['RNA', 'HIV']",,,,
210,210,"although insomnia increases risks for suicidality , we know little about whether insomnia treatments might be helpful .",尽管失眠会增加自杀的风险，但我们对失眠治疗是否有帮助知之甚少。,0.25,"['be', 'increases', 'insomnia', 'we']",['insomnia'],210,"['虽然失眠会增加自杀的风险,但我们很少知道失眠治疗是否有用。']",0.25,"['be', 'increases', 'insomnia', 'we']",['insomnia'],210,虽然失眠会增加自杀风险，但我们对于治疗失眠是否有帮助知之甚少。,0.25,"['be', 'increases', 'insomnia', 'we']",['insomnia'],,,,
211,211,"SSRIs were fluoxetine ( 20 mg / day ) , sertraline ( 50 mg / day ) or citalopram ( 20 mg / day ) ; doses could be doubled after 4 weeks .",SSRIs 是氟西汀（20 毫克/天）、舍曲林（50 毫克/天）或西酞普兰（20 毫克/天）； 4周后剂量可加倍。,0.5,"['/', 'be', 'after', '4', 'fluoxetine', 'citalopram']","['after', 'fluoxetine', 'citalopram']",211,"['SSRI 是 fluoxetine (20 mg / 天 ), sertraline (50 mg / 天 ) 或 citalopram (20 mg / 天 ) ; 剂量可以在 4 周后翻倍。']",0.3333333333333333,"['/', 'be', 'after', '4', 'fluoxetine', 'citalopram']","['be', 'after']",211,"SSRIs were fluoxetine (20 mg/day), sertraline (50 mg/day) or citalopram (20 mg/day); doses could be doubled after 4 weeks.

Chinese:

SSRIs是抗情緒藥物，包括氟西汀（20毫克/天）、塞拉明（50毫克/天）或齊塔拉明（20毫克/天），藥物劑量可在4周後加倍。",0.3333333333333333,"['/', 'be', 'after', '4', 'fluoxetine', 'citalopram']","['be', 'fluoxetine']",,,,
212,212,"exclusions included bipolar disorder , schizophrenia , substance abuse , positive urine drug screen , severe obesity , and a positive screen for sleep apnea .",排除包括躁郁症、精神分裂症、药物滥用、尿液药物筛查阳性、严重肥胖和睡眠呼吸暂停筛查阳性。,0.5454545454545454,"['urine', 'schizophrenia', 'sleep apnea', 'obesity', 'substance abuse', 'screen', 'bipolar disorder', 'drug', 'severe', 'positive', 'and']","['urine', 'schizophrenia', 'sleep apnea', 'obesity', 'screen', 'drug']",212,"['排除包括双极障碍,精神分裂症,物质滥用,积极的尿液药物屏幕,严重的肥胖,以及睡眠失眠的积极屏幕。']",0.5454545454545454,"['urine', 'schizophrenia', 'sleep apnea', 'obesity', 'substance abuse', 'screen', 'bipolar disorder', 'drug', 'severe', 'positive', 'and']","['urine', 'schizophrenia', 'obesity', 'substance abuse', 'screen', 'drug']",212,"exclusions included bipolar disorder, schizophrenia, substance abuse, positive urine drug screen, severe obesity, and a positive screen for sleep apnea.

Chinese:
排除病症包括躁郁症、精神分裂症、滥用药物、尿检呈阳性、严重肥胖和睡眠呼吸暂停症阳性。",0.4545454545454545,"['urine', 'schizophrenia', 'sleep apnea', 'obesity', 'substance abuse', 'screen', 'bipolar disorder', 'drug', 'severe', 'positive', 'and']","['urine', 'schizophrenia', 'sleep apnea', 'obesity', 'drug']",,,,
213,213,"at 8 weeks , ratings of insomnia and suicidal ideation fell in all groups .",在第 8 周时，所有组的失眠和自杀意念的评分都下降了。,0.3333333333333333,"['suicidal', 'fell', 'ideation', 'insomnia', 'all', 'and']","['suicidal', 'insomnia']",213,"['在8周,在所有群体中,失眠和自杀思想的评分下降。']",0.3333333333333333,"['suicidal', 'fell', 'ideation', 'insomnia', 'all', 'and']","['suicidal', 'insomnia']",213,在8周的时候，所有组的失眠和自杀倾向的评分都降低了。,0.3333333333333333,"['suicidal', 'fell', 'ideation', 'insomnia', 'all', 'and']","['suicidal', 'insomnia']",,,,
214,214,"decades ago , Swiss and German psychiatrists popularized dauerschlaf ( prolonged sleep therapy ) , now long out of favor , for severe psychoses .",几十年前，瑞士和德国的精神病学家推广了 dauerschlaf（延长睡眠疗法），但现在早已失宠，用于治疗严重的精神病。,0.3333333333333333,"['therapy', 'sleep', 'severe', 'prolonged', 'out', 'and']","['therapy', 'sleep']",214,"['几十年前,瑞士和德国精神病学家普及了Dauerschlaf(延长睡眠疗法),现在很久没有支持,严重的精神病。']",0.3333333333333333,"['therapy', 'sleep', 'severe', 'prolonged', 'out', 'and']","['therapy', 'sleep']",214,几十年前，瑞士和德国的精神病医生将持续睡眠（长时间睡眠疗法）流行起来，现在已经被人们所排斥，因为它只能对严重的精神病有效。,0.3333333333333333,"['therapy', 'sleep', 'severe', 'prolonged', 'out', 'and']","['therapy', 'sleep']",,,,
215,215,this study reminds us that attention to sleep quality might benefit both depression and suicidal ideation .,这项研究提醒我们注意睡眠质量可能对抑郁症和自杀意念都有好处。,0.4166666666666667,"['depression', 'quality', 'study', 'suicidal', 'sleep', 'ideation', 'benefit', 'attention', 'this', 'that', 'to', 'and']","['depression', 'quality', 'suicidal', 'sleep', 'attention']",215,"['这项研究提醒我们,注意睡眠质量可能有利于抑郁和自杀的想法。']",0.5833333333333334,"['depression', 'quality', 'study', 'suicidal', 'sleep', 'ideation', 'benefit', 'attention', 'this', 'that', 'to', 'and']","['depression', 'quality', 'suicidal', 'sleep', 'benefit', 'attention', 'to']",215,"这项研究让我们想起，注重睡眠质量可能会对抑郁症和自杀思想有益。

Chinese:

这项研究提醒我们，关注睡眠质量可能有助于治疗抑郁症和自杀思想。",0.4166666666666667,"['depression', 'quality', 'study', 'suicidal', 'sleep', 'ideation', 'benefit', 'attention', 'this', 'that', 'to', 'and']","['depression', 'quality', 'suicidal', 'sleep', 'to']",,,,
216,216,these findings do not support routine hypnotics for depression but do suggest that patients with insomnia and suicidal ideation might well benefit from focused attention to sleep improvement .,这些发现不支持抑郁症的常规催眠药，但确实表明失眠和自杀意念的患者可能会从集中注意力改善睡眠中获益。,0.5294117647058824,"['depression', 'improvement', 'support', 'routine', 'suicidal', 'well', 'sleep', 'ideation', 'insomnia', 'benefit', 'suggest', 'with', 'attention', 'that', 'but', 'to', 'and']","['depression', 'improvement', 'support', 'routine', 'suicidal', 'sleep', 'insomnia', 'attention', 'but']",216,"['这些发现不支持抑郁症的日常催眠,但表明患有失眠和自杀思想的患者可以从专注于睡眠改善的注意力中受益。']",0.5294117647058824,"['depression', 'improvement', 'support', 'routine', 'suicidal', 'well', 'sleep', 'ideation', 'insomnia', 'benefit', 'suggest', 'with', 'attention', 'that', 'but', 'to', 'and']","['depression', 'improvement', 'support', 'suicidal', 'sleep', 'insomnia', 'attention', 'but', 'to']",216,这些研究结果不支持常规用于抑郁症的催眠药物，但确实表明，有失眠和自杀倾向的患者可能会受益于专注于改善睡眠的方式。,0.5294117647058824,"['depression', 'improvement', 'support', 'routine', 'suicidal', 'well', 'sleep', 'ideation', 'insomnia', 'benefit', 'suggest', 'with', 'attention', 'that', 'but', 'to', 'and']","['depression', 'improvement', 'support', 'routine', 'suicidal', 'sleep', 'insomnia', 'but', 'to']",,,,
217,217,"current guidelines ( National Asthma Education and Prevention Program and Global Initiative for Asthma ) recommend assessing asthma control using a combination of symptoms , exacerbation history , and lung function .",目前的指南（国家哮喘教育和预防计划和全球哮喘倡议）建议综合使用症状、恶化史和肺功能来评估哮喘控制情况。,0.625,"['asthma', 'combination', 'lung', 'control', 'program', 'global', 'function', 'education', 'exacerbation', 'prevention', 'recommend', 'history', 'symptoms', 'current', 'initiative', 'and']","['asthma', 'lung', 'control', 'program', 'global', 'function', 'education', 'exacerbation', 'prevention', 'recommend']",217,"['目前的指导方针(国家哮喘教育和预防计划和全球哮喘倡议)建议通过症状,恶化历史和肺功能的组合来评估哮喘控制。']",0.75,"['asthma', 'combination', 'lung', 'control', 'program', 'global', 'function', 'education', 'exacerbation', 'prevention', 'recommend', 'history', 'symptoms', 'current', 'initiative', 'and']","['asthma', 'combination', 'lung', 'control', 'program', 'global', 'function', 'education', 'exacerbation', 'prevention', 'recommend', 'history']",217,根據目前的指引（美國國家哮喘教育與預防計劃和全球哮喘倡議），建議使用症狀、加劇歷史和肺功能的組合來評估哮喘控制。,0.375,"['asthma', 'combination', 'lung', 'control', 'program', 'global', 'function', 'education', 'exacerbation', 'prevention', 'recommend', 'history', 'symptoms', 'current', 'initiative', 'and']","['asthma', 'lung', 'control', 'global', 'function', 'education']",,,,
218,218,"although both reduced lung function and increased symptoms are associated with worsening asthma outcomes , the correlation between the two is unclear .",尽管肺功能下降和症状加重都与哮喘预后恶化有关，但两者之间的相关性尚不清楚。,0.5555555555555556,"['asthma', 'correlation', 'lung', 'function', 'symptoms', 'associated', 'with', 'and', 'two']","['asthma', 'correlation', 'lung', 'function', 'two']",218,"['虽然肺功能下降和症状增加都与哮喘结果的恶化有关,但两者之间的关系不清楚。']",0.4444444444444444,"['asthma', 'correlation', 'lung', 'function', 'symptoms', 'associated', 'with', 'and', 'two']","['asthma', 'lung', 'function', 'two']",218,尽管肺功能降低和症状加重都与加重哮喘结局相关，但二者之间的相关性并不清楚。,0.4444444444444444,"['asthma', 'correlation', 'lung', 'function', 'symptoms', 'associated', 'with', 'and', 'two']","['asthma', 'correlation', 'lung', 'function']",,,,
219,219,"adjustment for socioeconomic status and smoking history improved correlation somewhat , but changes in FEV1 and symptom scores over time still were disparate .",对社会经济地位和吸烟史进行调整后，相关性有所改善，但 FEV1 和症状评分随时间的变化仍然存在差异。,0.3846153846153846,"['correlation', 'symptom', 'adjustment', 'history', 'time', 'still', 'disparate', 'socioeconomic status', 'FEV1', 'in', 'over', 'but', 'and']","['correlation', 'symptom', 'time', 'socioeconomic status', 'but']",219,"['对社会经济状况和吸烟历史的调整有所改善,但FEV1和症状成绩的变化随着时间的推移,仍然不一样。']",0.3076923076923077,"['correlation', 'symptom', 'adjustment', 'history', 'time', 'still', 'disparate', 'socioeconomic status', 'FEV1', 'in', 'over', 'but', 'and']","['symptom', 'history', 'time', 'but']",219,调整社会经济地位和吸烟史的相关性有所改善，但FEV1和症状评分随时间的变化仍然不一致。,0.3846153846153846,"['correlation', 'symptom', 'adjustment', 'history', 'time', 'still', 'disparate', 'socioeconomic status', 'FEV1', 'in', 'over', 'but', 'and']","['correlation', 'symptom', 'time', 'socioeconomic status', 'but']",,,,
220,220,"I am often surprised by patients who have few symptoms but very low lung function , and conversely , by those who are very symptomatic but have normal FEV1 .",我经常对症状很少但肺功能很低的患者感到惊讶，相反，对那些症状非常严重但 FEV1 正常的患者感到惊讶。,0.3846153846153846,"['lung', 'who', 'function', 'normal', 'symptoms', 'low', 'symptomatic', 'FEV1', 'I', 'have', 'by', 'but', 'and']","['lung', 'function', 'normal', 'low', 'but']",220,"['我经常被患有少数症状但肺功能非常低的患者惊讶,反之亦然,患有非常症状但正常的FEV1患者。']",0.4615384615384615,"['lung', 'who', 'function', 'normal', 'symptoms', 'low', 'symptomatic', 'FEV1', 'I', 'have', 'by', 'but', 'and']","['lung', 'function', 'normal', 'low', 'have', 'but']",220,我经常被那些虽然症状不严重但肺功能却很低的病人所惊讶，反之亦然，有些病人虽然症状很严重但肺功能却很正常。,0.3846153846153846,"['lung', 'who', 'function', 'normal', 'symptoms', 'low', 'symptomatic', 'FEV1', 'I', 'have', 'by', 'but', 'and']","['lung', 'function', 'low', 'have', 'but']",,,,
221,221,"for patients with few symptoms but surprisingly low FEV1 , I consider alternative causes ( e.g. , poor effort or technique , chronic obstructive pulmonary disease , irreversible obstruction due to chronic remodeling ) .",对于症状很少但 FEV1 出奇低的患者，我会考虑其他原因（例如，努力程度或技术不佳、慢性阻塞性肺病、慢性重塑导致的不可逆阻塞）。,0.4117647058823529,"['disease', 'obstructive', 'obstruction', 'symptoms', 'pulmonary', 'low', 'chronic', 'technique', 'effort', 'due', 'with', 'FEV1', 'alternative', 'I', 'poor', 'but', 'irreversible']","['disease', 'low', 'chronic', 'technique', 'effort', 'but', 'irreversible']",221,"['对于患有少数症状但令人惊讶的低FEV1的患者,我考虑替代原因(例如,不足的努力或技术,慢性阻塞性肺疾病,由于慢性修复而不可逆转的阻塞)。']",0.4117647058823529,"['disease', 'obstructive', 'obstruction', 'symptoms', 'pulmonary', 'low', 'chronic', 'technique', 'effort', 'due', 'with', 'FEV1', 'alternative', 'I', 'poor', 'but', 'irreversible']","['disease', 'low', 'chronic', 'technique', 'effort', 'but', 'irreversible']",221,对于那些症状不多但 FEV1 却出奇地低的病人，我会考虑其他原因（例如，差的努力或技巧、慢性阻塞性肺病、慢性重塑导致的不可逆阻塞）。,0.3529411764705882,"['disease', 'obstructive', 'obstruction', 'symptoms', 'pulmonary', 'low', 'chronic', 'technique', 'effort', 'due', 'with', 'FEV1', 'alternative', 'I', 'poor', 'but', 'irreversible']","['disease', 'low', 'chronic', 'effort', 'but', 'irreversible']",,,,
222,222,but if the low FEV1 appears to be due to asthma - especially if it reversible with a bronchodilator - the patient might be underreporting symptoms and therapy should be stepped up .,但如果低 FEV1 似乎是由于哮喘引起的——尤其是如果它可以用支气管扩张剂逆转——患者可能没有报告症状，应该加强治疗。,0.375,"['asthma', 'reversible', 'symptoms', 'therapy', 'be', 'low', 'bronchodilator', 'patient', 'up', 'due', 'with', 'FEV1', '-', 'if', 'but', 'and']","['asthma', 'therapy', 'low', 'bronchodilator', 'patient', 'but']",222,"['但是,如果低 FEV1 似乎是由于哮喘 - 特别是如果它是逆转的 bronchodilator - 患者可能不报告症状,治疗应该加步。']",0.3125,"['asthma', 'reversible', 'symptoms', 'therapy', 'be', 'low', 'bronchodilator', 'patient', 'up', 'due', 'with', 'FEV1', '-', 'if', 'but', 'and']","['asthma', 'therapy', 'low', 'patient', 'but']",222,但是如果低FEV1似乎是由于哮喘-特别是如果它可以通过肺部扩张剂来逆转-病人可能会低估症状，需要加强治疗。,0.3125,"['asthma', 'reversible', 'symptoms', 'therapy', 'be', 'low', 'bronchodilator', 'patient', 'up', 'due', 'with', 'FEV1', '-', 'if', 'but', 'and']","['asthma', 'therapy', 'low', 'patient', 'but']",,,,
223,223,"conversely , for very symptomatic patients with normal FEV1 , I consider alternative diagnoses ( e.g. , heart disease , vocal cord dysfunction , obesity , anxiety ) .",相反，对于 FEV1 正常但症状非常严重的患者，我会考虑其他诊断（例如，心脏病、声带功能障碍、肥胖、焦虑）。,0.3636363636363636,"['dysfunction', 'anxiety', 'heart disease', 'obesity', 'normal', 'vocal cord', 'symptomatic', 'with', 'FEV1', 'alternative', 'I']","['anxiety', 'heart disease', 'obesity', 'vocal cord']",223,"['相反,对于患有正常FEV1的非常症状的患者,我考虑替代诊断(例如,心脏病,语音心脏功能障碍,肥胖,焦虑)。']",0.3636363636363636,"['dysfunction', 'anxiety', 'heart disease', 'obesity', 'normal', 'vocal cord', 'symptomatic', 'with', 'FEV1', 'alternative', 'I']","['anxiety', 'heart disease', 'obesity', 'symptomatic']",223,反之，对于症状很严重但FEV1正常的病人，我会考虑其他诊断（如心脏病、声带功能障碍、肥胖症、焦虑症）。,0.4545454545454545,"['dysfunction', 'anxiety', 'heart disease', 'obesity', 'normal', 'vocal cord', 'symptomatic', 'with', 'FEV1', 'alternative', 'I']","['anxiety', 'heart disease', 'obesity', 'normal', 'vocal cord']",,,,
224,224,"if these are ruled out , the patient might require a higher level of therapy despite relatively normal lung function .",如果排除这些，尽管肺功能相对正常，患者可能需要更高水平的治疗。,0.5555555555555556,"['lung', 'function', 'normal', 'therapy', 'patient', 'level', 'despite', 'if', 'out']","['lung', 'function', 'therapy', 'patient', 'level']",224,"['如果这些被排除,患者可能需要更高的治疗水平,尽管相对正常的肺功能。']",0.6666666666666666,"['lung', 'function', 'normal', 'therapy', 'patient', 'level', 'despite', 'if', 'out']","['lung', 'function', 'normal', 'therapy', 'patient', 'level']",224,如果这些被排除了，即使肺功能相对正常，病人仍可能需要更高水平的治疗。,0.5555555555555556,"['lung', 'function', 'normal', 'therapy', 'patient', 'level', 'despite', 'if', 'out']","['lung', 'function', 'therapy', 'patient', 'level']",,,,
225,225,a large study showed excess risk for a number of outcomes .,一项大型研究表明，许多结果的风险过大。,0.2,"['excess', 'study', 'large', 'number', 'risk']",['risk'],225,"['一项大型研究表明,多种结果的风险过高。']",0.2,"['excess', 'study', 'large', 'number', 'risk']",['risk'],225,一项大型研究表明，一些疾病的风险增加了。,0.2,"['excess', 'study', 'large', 'number', 'risk']",['risk'],,,,
226,226,survivors of hematologic malignancies had excess risks for all these outcomes ; survivors of other cancers had excess risks for only some outcomes .,血液系统恶性肿瘤的幸存者对所有这些结果都有额外的风险；其他癌症的幸存者仅对某些结果有过高的风险。,0.0,"['excess', 'all', 'hematologic']",[],226,['血病恶性疾病的幸存者对所有这些结果都有过度风险;其他癌症的幸存者只对某些结果有过度风险。'],0.0,"['excess', 'all', 'hematologic']",[],226,"Cancer survivors of all types had increased risks for various health problems, but those who survived hematologic malignancies had increased risks for all of them, while survivors of other cancers had increased risks for only some of them.",0.0,"['excess', 'all', 'hematologic']",[],,,,
227,227,"incidence of VTE decreased with time after diagnosis , whereas incidence of heart failure or cardiomyopathy increased .",VTE的发生率在诊断后随时间降低，而心力衰竭或心肌病的发生率增加。,0.8571428571428571,"['incidence', 'time', 'diagnosis', 'heart failure', 'cardiomyopathy', 'after', 'with']","['incidence', 'time', 'diagnosis', 'heart failure', 'cardiomyopathy', 'after']",227,"['VTE的发病率随着诊断后的时间减少,而心脏衰竭或心脏病的发病率增加。']",0.5714285714285714,"['incidence', 'time', 'diagnosis', 'heart failure', 'cardiomyopathy', 'after', 'with']","['incidence', 'time', 'diagnosis', 'after']",227,研究发现，被诊断出患有血栓栓塞性疾病后，患病率会随时间逐渐下降，但心力衰竭或心肌病的发病率会上升。,0.8571428571428571,"['incidence', 'time', 'diagnosis', 'heart failure', 'cardiomyopathy', 'after', 'with']","['incidence', 'time', 'diagnosis', 'heart failure', 'cardiomyopathy', 'after']",,,,
228,228,"in this study , available data were insufficient to identify the risks associated with specific treatment modalities , but some of them are well known ( e.g. , heart failure with anthracycline drugs , coronary disease after chest radiotherapy ) .",在这项研究中，现有数据不足以确定与特定治疗方式相关的风险，但其中一些是众所周知的（例如，蒽环类药物引起的心力衰竭、胸部放疗后的冠心病）。,0.55,"['disease', 'chest', 'data', 'drugs', 'study', 'coronary', 'radiotherapy', 'heart failure', 'associated', 'treatment', 'available', 'well', 'after', 'specific', 'identify', 'with', 'this', 'but', 'to', 'insufficient']","['disease', 'chest', 'data', 'drugs', 'coronary', 'heart failure', 'treatment', 'after', 'this', 'but', 'insufficient']",228,"['在这项研究中,可用的数据不足以确定与特定治疗方法相关的风险,但其中一些是众所周知的(例如,心脏衰竭与安特拉西克林药物,乳房放射治疗后的冠状疾病)。']",0.55,"['disease', 'chest', 'data', 'drugs', 'study', 'coronary', 'radiotherapy', 'heart failure', 'associated', 'treatment', 'available', 'well', 'after', 'specific', 'identify', 'with', 'this', 'but', 'to', 'insufficient']","['disease', 'data', 'drugs', 'coronary', 'radiotherapy', 'treatment', 'available', 'after', 'this', 'but', 'insufficient']",228,在本研究中，可用数据不足以确定与特定治疗方式相关的风险，但其中一些风险是众所周知的（例如，解热剂药物引起的心力衰竭，胸部放射治疗后的冠状动脉疾病）。,0.6,"['disease', 'chest', 'data', 'drugs', 'study', 'coronary', 'radiotherapy', 'heart failure', 'associated', 'treatment', 'available', 'well', 'after', 'specific', 'identify', 'with', 'this', 'but', 'to', 'insufficient']","['disease', 'chest', 'data', 'drugs', 'coronary', 'radiotherapy', 'heart failure', 'treatment', 'after', 'this', 'but', 'insufficient']",,,,
229,229,"genome sequencing is often pivotal in the diagnosis of rare diseases , but many of these conditions lack specific treatments .",基因组测序通常在罕见疾病的诊断中起着关键作用，但其中许多疾病缺乏特异性治疗方法。,0.6666666666666666,"['genome', 'lack', 'sequencing', 'diagnosis', 'specific', 'but']","['genome', 'sequencing', 'diagnosis', 'but']",229,"['基因组序列往往在诊断罕见疾病方面至关重要,但许多这些疾病缺乏具体治疗。']",0.5,"['genome', 'lack', 'sequencing', 'diagnosis', 'specific', 'but']","['genome', 'diagnosis', 'but']",229,基因组测序常常是确诊罕见疾病的关键因素，但许多这类疾病缺乏特异性治疗方法。,0.5,"['genome', 'lack', 'sequencing', 'diagnosis', 'specific', 'but']","['genome', 'sequencing', 'but']",,,,
230,230,"there were no serious adverse events , and treatment was associated with objective reduction in seizures ( determined by electroencephalography and parental reporting ) .",没有严重的不良事件，治疗与癫痫发作的客观减少有关（由脑电图和父母报告确定）。,0.3571428571428571,"['objective', 'parental', 'reduction', 'electroencephalography', 'adverse', 'associated', 'treatment', 'no', 'with', 'serious', 'in', 'by', 'and', 'seizures']","['reduction', 'electroencephalography', 'treatment', 'by', 'seizures']",230,"['没有严重的副作用,并且治疗与客观减少受伤(由电解体和父母报告确定)有关。']",0.2142857142857142,"['objective', 'parental', 'reduction', 'electroencephalography', 'adverse', 'associated', 'treatment', 'no', 'with', 'serious', 'in', 'by', 'and', 'seizures']","['reduction', 'treatment', 'by']",230,没有出现严重的不良事件，治疗可显著减少癫痫发作（通过脑电图和家长报告确定）。,0.2857142857142857,"['objective', 'parental', 'reduction', 'electroencephalography', 'adverse', 'associated', 'treatment', 'no', 'with', 'serious', 'in', 'by', 'and', 'seizures']","['reduction', 'electroencephalography', 'treatment', 'seizures']",,,,
231,231,rare diseases in aggregate affect approximately 30 million persons in the United States alone.1,仅在美国，罕见病总共影响了大约 3000 万人。 1,0.2,"['aggregate', 'affect', 'approximately', 'in', 'million']",['affect'],231,"['稀有疾病总体影响约3000万人,仅在美国1']",0.2,"['aggregate', 'affect', 'approximately', 'in', 'million']",['affect'],231,"罕见疾病总体上影响美国约3,000万人。1",0.2,"['aggregate', 'affect', 'approximately', 'in', 'million']",['affect'],,,,
232,232,this report shows a path to personalized treatment for patients with orphan diseases .,这份报告显示了针对孤儿病患者的个性化治疗途径。,0.5714285714285714,"['report', 'treatment', 'orphan', 'path', 'with', 'this', 'to']","['report', 'treatment', 'orphan', 'path']",232,['本报告显示了患有孤儿病患者的个性化治疗的路径。'],0.5714285714285714,"['report', 'treatment', 'orphan', 'path', 'with', 'this', 'to']","['report', 'treatment', 'orphan', 'path']",232,本報告顯示了為孤立疾病患者提供個性化治療的路徑。,0.0,"['report', 'treatment', 'orphan', 'path', 'with', 'this', 'to']",[],,,,
233,233,"identification of the mutation was followed by the development and clinical deployment , within 1 year , of a tailored drug to treat the patient ( Figure 1A ) .",在确定突变后，在 1 年内开发并临床部署了一种治疗患者的定制药物（图 1A）。,0.5384615384615384,"['mutation', 'year', '1', 'identification', 'figure', 'treat', 'clinical', 'patient', 'development', 'drug', 'by', 'to', 'and']","['mutation', 'year', '1', 'treat', 'clinical', 'patient', 'drug']",233,"['突变的识别,随后是开发和临床部署,在1年内,个性化药物治疗患者(图1A)。']",0.6153846153846154,"['mutation', 'year', '1', 'identification', 'figure', 'treat', 'clinical', 'patient', 'development', 'drug', 'by', 'to', 'and']","['mutation', 'year', '1', 'identification', 'treat', 'clinical', 'patient', 'drug']",233,突变的鉴定之后，为了治疗患者，在1年内开发并临床部署了一种量身定制的药物（图1A）。,0.6153846153846154,"['mutation', 'year', '1', 'identification', 'figure', 'treat', 'clinical', 'patient', 'development', 'drug', 'by', 'to', 'and']","['mutation', 'year', '1', 'identification', 'treat', 'clinical', 'patient', 'drug']",,,,
234,234,clinical Presentation,临床表现,0.5,"['presentation', 'clinical']",['clinical'],234,['临床介绍'],1.0,"['presentation', 'clinical']","['presentation', 'clinical']",234,临床表现,0.5,"['presentation', 'clinical']",['clinical'],,,,
235,235,"when she was 4 years of age , her family noticed her pulling books close to her face at bedtime .",当她 4 岁时，她的家人注意到她在睡觉时将书本拉近自己的脸。,0.4285714285714285,"['face', 'family', 'books', 'age', '4', 'at', 'close to']","['face', 'family', 'at']",235,"['当她4岁时,她的家人注意到她在睡觉时在她的脸上拉着书。']",0.4285714285714285,"['face', 'family', 'books', 'age', '4', 'at', 'close to']","['face', 'family', 'at']",235,当她四岁的时候，家人注意到她在睡觉的时候会把书拿近脸。,0.4285714285714285,"['face', 'family', 'books', 'age', '4', 'at', 'close to']","['face', 'family', 'at']",,,,
236,236,"at 5 years of age , she came to medical attention because of modest language and social regression , as well as increased clumsiness and stumbling .",在 5 岁时，她因语言谦虚和社会退化以及越来越笨拙和跌跌撞撞而就医。,0.3333333333333333,"['5', 'medical', 'regression', 'language', 'well', 'as', 'attention', 'to', 'and']","['5', 'regression', 'and']",236,"['5岁时,她因语言和社会衰退而接受了医学护理,以及增加了同情心和沉默。']",0.2222222222222222,"['5', 'medical', 'regression', 'language', 'well', 'as', 'attention', 'to', 'and']","['5', 'and']",236,在5岁的时候，因为语言和社交能力退步以及增加的笨拙和跌倒，她引起了医疗界的关注。,0.1111111111111111,"['5', 'medical', 'regression', 'language', 'well', 'as', 'attention', 'to', 'and']",['5'],,,,
237,237,"in the months before she turned 6 years of age , the progression of symptoms accelerated , and she was hospitalized after the rapid development of loss of vision , frequent falls , dysarthria , and dysphagia .",在她 6 岁之前的几个月里，症状进展加速，并在视力丧失、频繁跌倒、构音障碍和吞咽困难的快速发展后入院。,0.4166666666666667,"['symptoms', 'progression', 'dysphagia', 'age', 'after', 'development', 'loss of vision', 'before', 'in', 'frequent', 'and', 'rapid']","['progression', 'dysphagia', 'after', 'development', 'before']",237,"['在她6岁之前的几个月里,症状的进展加速,她在视力损失、频繁衰落、 dysarthria 和 dysphagia 的快速发展后被送往医院。']",0.3333333333333333,"['symptoms', 'progression', 'dysphagia', 'age', 'after', 'development', 'loss of vision', 'before', 'in', 'frequent', 'and', 'rapid']","['progression', 'after', 'development', 'before']",237,在她6岁之前的几个月里，症状的加速发展，导致她因失去视力、频繁跌倒、语言障碍和食物进入咽喉困难而住院治疗。,0.25,"['symptoms', 'progression', 'dysphagia', 'age', 'after', 'development', 'loss of vision', 'before', 'in', 'frequent', 'and', 'rapid']","['development', 'before', 'and']",,,,
238,238,"an extensive laboratory workup for mitochondrial or metabolic diseases was initially unrevealing , until a skin biopsy was performed .",对线粒体或代谢疾病进行广泛的实验室检查最初没有发现问题，直到进行了皮肤活检。,0.8,"['mitochondrial', 'biopsy', 'skin', 'laboratory', 'metabolic']","['mitochondrial', 'biopsy', 'skin', 'laboratory']",238,"['对甲状腺或代谢疾病进行了广泛的实验室工作,直到进行皮肤生物检测。']",0.4,"['mitochondrial', 'biopsy', 'skin', 'laboratory', 'metabolic']","['skin', 'laboratory']",238,一项广泛的实验室检查对于线粒体或代谢疾病最初没有发现任何线索，直到进行了皮肤活检。,0.8,"['mitochondrial', 'biopsy', 'skin', 'laboratory', 'metabolic']","['mitochondrial', 'biopsy', 'skin', 'laboratory']",,,,
239,239,no second mutation could be found .,没有发现第二个突变。,0.25,"['mutation', 'be', 'no', 'second']",['mutation'],239,['没有第二次突变。'],0.5,"['mutation', 'be', 'no', 'second']","['mutation', 'second']",239,没有找到第二个突变。,0.25,"['mutation', 'be', 'no', 'second']",['mutation'],,,,
240,240,the family was offered enrollment in a research study for further diagnostic workup .,该家庭被邀请参加一项研究，以进行进一步的诊断检查。,0.4,"['family', 'research', 'study', 'diagnostic', 'in']","['family', 'research']",240,"['家人被邀请加入研究研究,以进一步诊断工作。']",0.4,"['family', 'research', 'study', 'diagnostic', 'in']","['family', 'research']",240,家庭被提供参加一项研究的机会，以便进一步进行诊断工作。,0.4,"['family', 'research', 'study', 'diagnostic', 'in']","['family', 'research']",,,,
241,241,a full description of the methods of the subsequent workup is provided in the Supplementary Appendix .,补充附录中提供了后续检查方法的完整说明。,0.1666666666666666,"['appendix', 'supplementary', 'subsequent', 'description', 'full', 'in']",['full'],241,['随后的工作组的方法的完整描述在附件中提供。'],0.5,"['appendix', 'supplementary', 'subsequent', 'description', 'full', 'in']","['appendix', 'description', 'full']",241,"A full description of the methods of the subsequent workup is provided in the Supplementary Appendix.

Chinese:

在随后的工作中使用的方法的全部描述信息在附录中提供。",0.3333333333333333,"['appendix', 'supplementary', 'subsequent', 'description', 'full', 'in']","['description', 'full']",,,,
242,242,"all the authors vouch for the accuracy and completeness of the data and for the fidelity of the study to the protocol , available at NEJM.org .",所有作者保证数据的准确性和完整性，以及研究对方案的忠实度，该方案可在 NEJM.org 获取。,0.3333333333333333,"['fidelity', 'data', 'accuracy', 'protocol', 'study', 'available', 'completeness', 'all', 'and']","['data', 'accuracy', 'completeness']",242,"['所有作者都赞扬数据的准确性和完整性以及研究对该协议的忠诚性,可在NEJM.org上找到。']",0.4444444444444444,"['fidelity', 'data', 'accuracy', 'protocol', 'study', 'available', 'completeness', 'all', 'and']","['data', 'accuracy', 'protocol', 'completeness']",242,"所有作者都能够保证数据的准确性和完整性，并保证研究与协议的一致性，可在 NEJM.org 上查阅。

Chinese:

所有作者都能够保证数据的准确性和完整性，并保证研究与协议的一致性，可在 NEJM.org 上查阅。",0.4444444444444444,"['fidelity', 'data', 'accuracy', 'protocol', 'study', 'available', 'completeness', 'all', 'and']","['data', 'accuracy', 'protocol', 'completeness']",,,,
243,243,mutation IDENTIFICATION,突变鉴定,1.0,['mutation'],['mutation'],243,['突变识别'],1.0,['mutation'],['mutation'],243,"突變ID

Chinese:

突变ID",1.0,['mutation'],['mutation'],,,,
244,244,"chimeric breakpoints were offset by 14 bp , suggesting duplication of an endogenous target sequence ( Figure 1B ) .",嵌合断点被 14 bp 抵消，表明内源靶序列的重复（图 1B）。,0.4444444444444444,"['duplication', 'endogenous', 'chimeric', 'sequence', 'bp', 'figure', 'offset', 'target', 'by']","['duplication', 'sequence', 'offset', 'target']",244,"['化学分裂点被折扣为14bp,表明一个内分子目标序列(图1B)的重复。']",0.3333333333333333,"['duplication', 'endogenous', 'chimeric', 'sequence', 'bp', 'figure', 'offset', 'target', 'by']","['duplication', 'sequence', 'target']",244,融合突变点相差14个碱基，表明内源目标序列发生了重复（图1B）。,0.3333333333333333,"['duplication', 'endogenous', 'chimeric', 'sequence', 'bp', 'figure', 'offset', 'target', 'by']","['duplication', 'sequence', 'target']",,,,
245,245,the SVA insertion was also correctly detected by automated analysis with the Tea algorithm.5,SVA 插入也通过 Tea 算法的自动分析正确检测到。 5,0.3333333333333333,"['analysis', 'insertion', 'tea', 'with', 'by', 'automated']","['analysis', 'insertion']",245,['SVA 插入也通过使用 Tea 算法进行自动分析正确检测。'],0.3333333333333333,"['analysis', 'insertion', 'tea', 'with', 'by', 'automated']","['analysis', 'insertion']",245,SVA插入也被Tea算法的自动分析正确地检测到了。5,0.3333333333333333,"['analysis', 'insertion', 'tea', 'with', 'by', 'automated']","['analysis', 'insertion']",,,,
246,246,"this insertion has not been reported in the literature and does not appear in dbRIP , a database of retrotransposon insertions in the human population.6",这种插入没有在文献中报道过，也没有出现在 dbRIP 中，这是一个在人群中插入反转录转座子的数据库。 6,0.7142857142857143,"['retrotransposon', 'database', 'insertion', 'literature', 'human', 'this', 'and']","['retrotransposon', 'insertion', 'literature', 'human', 'this']",246,"['此插入未在文学中报告,并且不出现在 dbRIP,人类人口中 retrotransposon 插入数据库中。']",0.4285714285714285,"['retrotransposon', 'database', 'insertion', 'literature', 'human', 'this', 'and']","['insertion', 'literature', 'human']",246,这种插入尚未在文献中报道，也不会出现在dbRIP（人类种群中逆转录组插入的数据库）中。6,0.4285714285714285,"['retrotransposon', 'database', 'insertion', 'literature', 'human', 'this', 'and']","['insertion', 'literature', 'human']",,,,
247,247,development OF AN ANTISENSE OLIGONUCLEOTIDE DRUG,一种反义寡核苷酸药物的开发,0.0,"['development', 'AN']",[],247,['抗氧化药物的发育'],0.5,"['development', 'AN']",['development'],247,The development of an antisense oligonucleotide drug is a promising approach to treating diseases.,0.0,"['development', 'AN']",[],,,,
248,248,"when we tested these antisense oligonucleotides in patient fibroblasts , we identified three that boosted normal : mutant splicing ratios by a factor of 2.5 to 3 .",当我们在患者成纤维细胞中测试这些反义寡核苷酸时，我们发现了三种将正常：突变剪接比率提高 2.5 至 3 倍的寡核苷酸。,0.1666666666666666,"['antisense', 'splicing', 'mutant', 'factor', 'in patient', 'normal', '3', 'three', 'that', 'by', 'fibroblasts', 'we']","['antisense', 'splicing']",248,"['当我们在患者纤维细胞中测试了这些反敏性聚合物时,我们发现有三种增强正常的因素:突变分裂率为 2.5 至 3 的因素。']",0.1666666666666666,"['antisense', 'splicing', 'mutant', 'factor', 'in patient', 'normal', '3', 'three', 'that', 'by', 'fibroblasts', 'we']","['factor', 'normal']",248,当我们在病人的成纤维细胞中测试这些反义寡核苷酸时，我们发现了三个能够将正常的突变性剪切比例提高2.5到3倍的寡核苷酸。,0.1666666666666666,"['antisense', 'splicing', 'mutant', 'factor', 'in patient', 'normal', '3', 'three', 'that', 'by', 'fibroblasts', 'we']","['antisense', 'normal']",,,,
249,249,"fibroblasts from the patient had several cellular phenotypes characteristic of lysosomal dysfunction , including intracellular vacuolation , 16 increased total lysosomal mass , 17 autofluorescence , miscompartmentalization of lysosomal enzyme activity , and reduced autophagic flux18 ( Figure 2D ) .",患者的成纤维细胞具有溶酶体功能障碍的多种细胞表型特征，包括细胞内空泡形成、16 溶酶体总质量增加、17 自发荧光、溶酶体酶活性的错误区室化和自噬通量降低 18（图 2D）。,0.5384615384615384,"['enzyme activity', 'dysfunction', 'characteristic', 'lysosomal', 'cellular', 'autofluorescence', 'figure', 'vacuolation', 'total', 'patient', 'mass', 'and', 'fibroblasts']","['enzyme activity', 'characteristic', 'lysosomal', 'autofluorescence', 'vacuolation', 'patient', 'mass']",249,"['患者的 fibroblasts 有几种细胞现象特征的 lysosomal dysfunction, 包括内细胞 vacuolation, 16 增加的整体 lysosomal 质量, 17 自我氟化, 错误分配的 lysosomal 酶活动, 和 减少的 autophagic 流量(图 2D ) 。']",0.2307692307692307,"['enzyme activity', 'dysfunction', 'characteristic', 'lysosomal', 'cellular', 'autofluorescence', 'figure', 'vacuolation', 'total', 'patient', 'mass', 'and', 'fibroblasts']","['characteristic', 'patient', 'mass']",249,病人的纤维母细胞有几种细胞表型表现出溶酶体功能障碍，包括细胞内真空化、总溶酶体质量增加、自发荧光、溶酶体酶作用分子间隔不正常以及自噬通量降低（见图2D）。,0.3076923076923077,"['enzyme activity', 'dysfunction', 'characteristic', 'lysosomal', 'cellular', 'autofluorescence', 'figure', 'vacuolation', 'total', 'patient', 'mass', 'and', 'fibroblasts']","['lysosomal', 'autofluorescence', 'patient', 'mass']",,,,
250,250,studies IN SUPPORT OF AN INVESTIGATIONAL NEW DRUG APPLICATION,支持研究性新药应用的研究,0.0,['AN'],[],250,['研究支持研究新药应用'],0.0,['AN'],[],250,研究表明支持研制新药物的申请,0.0,['AN'],[],,,,
251,251,"clinical evaluation at 7 years of age revealed an inability to make discernible words , dysphagia ( prompting gastrostomy tube placement ) , the need for substantial support to walk , and 15 to 30 overt seizures per day .",7 岁时的临床评估显示无法辨认词语、吞咽困难（促使胃造口管放置）、行走需要大量支撑以及每天 15 至 30 次明显癫痫发作。,0.3888888888888889,"['support', 'need', 'evaluation', 'dysphagia', 'clinical', 'gastrostomy', 'age', 'tube', 'walk', 'overt', 'prompting', 'inability', 'placement', 'and', 'substantial', 'make', 'seizures', 'revealed']","['support', 'need', 'dysphagia', 'clinical', 'tube', 'seizures', 'revealed']",251,"['7岁时的临床评估显示,无法做出可识别的词语、 dysphagia(导致 gastrostomy 管放置)、需要有显著的支持走路、每日15至30次冲击。']",0.2777777777777778,"['support', 'need', 'evaluation', 'dysphagia', 'clinical', 'gastrostomy', 'age', 'tube', 'walk', 'overt', 'prompting', 'inability', 'placement', 'and', 'substantial', 'make', 'seizures', 'revealed']","['support', 'need', 'clinical', 'tube', 'revealed']",251,"七岁时的临床评估发现无法分辨出词语，口吃（促使胃管放置），需要大量支持才能行走，每天15到30次明显的癫痫发作。

Chinese:
七歲時的臨床評估發現無法分辨出詞語，口吃（促使胃管放置），需要大量支持才能行走，每天15到30次明顯的癲癇發作。",0.2777777777777778,"['support', 'need', 'evaluation', 'dysphagia', 'clinical', 'gastrostomy', 'age', 'tube', 'walk', 'overt', 'prompting', 'inability', 'placement', 'and', 'substantial', 'make', 'seizures', 'revealed']","['support', 'need', 'clinical', 'tube', 'seizures']",,,,
252,252,"she did , however , remain alert and reactive to familiar stimuli and responded happily to hearing her favorite books and songs .",然而，她确实对熟悉的刺激保持警觉和反应，并且对听到她最喜欢的书籍和歌曲做出愉快的反应。,0.625,"['familiar', 'books', 'hearing', 'reactive', 'stimuli', 'alert', 'to', 'and']","['books', 'hearing', 'stimuli', 'alert', 'and']",252,"['然而,她对熟悉的刺激保持警惕和反应,并快乐地响应听到她最喜欢的书籍和歌曲。']",0.5,"['familiar', 'books', 'hearing', 'reactive', 'stimuli', 'alert', 'to', 'and']","['books', 'hearing', 'stimuli', 'and']",252,她确实保持警觉，并对熟悉的刺激做出反应，对听到她最喜欢的书和歌曲感到高兴。,0.375,"['familiar', 'books', 'hearing', 'reactive', 'stimuli', 'alert', 'to', 'and']","['hearing', 'stimuli', 'alert']",,,,
253,253,milasen drug substance ( 18 g ) was manufactured and formulated for clinical administration .,milasen 原料药 (18 g) 被制造和配制用于临床给药。,0.4,"['administration', 'clinical', 'substance', 'drug', 'and']","['clinical', 'drug']",253,['米拉森药物(18g)已生产并用于临床用途。'],0.4,"['administration', 'clinical', 'substance', 'drug', 'and']","['clinical', 'drug']",253,milasen药物物质（18克）是为临床使用而制造和配方的。,0.8,"['administration', 'clinical', 'substance', 'drug', 'and']","['clinical', 'substance', 'drug', 'and']",,,,
254,254,"to identify potential hazards , we administered milasen to rats by intrathecal injection at three doses : 0.06 mg , 0.25 mg , and 1.0 mg ( approximately 2.5 times , 10 times , and 42 times , respectively , the typical clinical dose of nusinersen , after compartmental scaling considerations ) .","为了确定潜在的危害，我们通过鞘内注射三种剂量给大鼠注射milasen ： 0.06 mg , 0.25 mg , 和 1.0 mg （分别约为 nusinersen 典型临床剂量的 2.5 倍 , 10 倍 , 和 42 倍，经过间隔缩放后）考虑因素）。",0.3125,"['potential', 'scaling', 'typical', 'clinical', 'after', 'identify', 'nusinersen', 'dose', 'intrathecal injection', 'rats', 'approximately', 'three', 'by', 'to', 'and', 'we']","['potential', 'clinical', 'after', 'dose', 'intrathecal injection']",254,"['为了确定潜在的危险,我们用三剂量: 0.06 mg, 0.25 mg,和 1.0 mg(大约 2.5 次, 10 次,和 42 次,相应,典型的临床剂量,Nusinersen,经过共享扩展考虑)。']",0.25,"['potential', 'scaling', 'typical', 'clinical', 'after', 'identify', 'nusinersen', 'dose', 'intrathecal injection', 'rats', 'approximately', 'three', 'by', 'to', 'and', 'we']","['potential', 'typical', 'clinical', 'dose']",254,为了确定潜在的危险，我们对大鼠注射了三个剂量的米拉森：0.06毫克、0.25毫克和1.0毫克（分别约为2.5倍、10倍和42倍典型临床剂量的努西宁森，在容积缩放的考虑下）。,0.1875,"['potential', 'scaling', 'typical', 'clinical', 'after', 'identify', 'nusinersen', 'dose', 'intrathecal injection', 'rats', 'approximately', 'three', 'by', 'to', 'and', 'we']","['potential', 'clinical', 'dose']",,,,
255,255,no adverse effects were observed in the group that received 0.06 mg .,在接受 0.06 毫克的组中没有观察到不良反应。,0.2,"['group', 'adverse', 'no', 'that', 'in']",['group'],255,['在接受 0.06 mg 的群体中没有发现任何副作用。'],0.2,"['group', 'adverse', 'no', 'that', 'in']",['group'],255,No adverse effects were observed in the group that received 0.06 mg.,0.0,"['group', 'adverse', 'no', 'that', 'in']",[],,,,
256,256,"at higher doses , some animals ( half of those in the group that received 0.25 mg and most of those in the group that received 1.0 mg ) had hindlimb weakness , which resolved by approximately 24 hours after each dose . ( for additional details , including multidose experiments , see Fig .",在较高剂量下，一些动物（接受 0.25 毫克组中的一半动物和接受 1.0 毫克组中的大多数动物）出现后肢无力，在每次给药后约 24 小时后消失。 （有关更多详细信息，包括多剂量实验，请参见图 1）。,0.3846153846153846,"['group', 'fig', 'half', 'weakness', 'additional', 'after', 'dose', 'approximately', 'that', 'each', 'by', 'and', 'hindlimb']","['group', 'half', 'weakness', 'after', 'dose']",256,"['在较高的剂量中,一些动物(受 0.25 mg 的群体中的一半和受 1.0 mg 的群体中的一半)患有抑郁症,在每剂量后大约24小时解决。']",0.3076923076923077,"['group', 'fig', 'half', 'weakness', 'additional', 'after', 'dose', 'approximately', 'that', 'each', 'by', 'and', 'hindlimb']","['group', 'half', 'after', 'dose']",256,在较高剂量下，一些动物（0.25毫克组中的一半和1.0毫克组中的大多数）出现后肢无力，但在每次剂量后约24小时恢复正常。（有关更多细节，包括多剂量实验，请参见图。）,0.3846153846153846,"['group', 'fig', 'half', 'weakness', 'additional', 'after', 'dose', 'approximately', 'that', 'each', 'by', 'and', 'hindlimb']","['group', 'half', 'weakness', 'after', 'dose']",,,,
257,257,S13 and Supplementary Text . ) These results provided translatable indicators of potential toxic effects that could be readily monitored and guided our clinical protocol design .,S13 和补充文本。 ) 这些结果提供了潜在毒性作用的可转化指标，可以很容易地监测和指导我们的临床方案设计。,0.3,"['toxic', 'potential', 'protocol', 'supplementary', 'be', 'clinical', 'text', 'design', 'that', 'and']","['be', 'clinical', 'design']",257,"['S13 和补充文本. ) 这些结果提供了可翻译的潜在毒性影响的指标,可以轻松地监测和指导我们的临床协议设计。']",0.4,"['toxic', 'potential', 'protocol', 'supplementary', 'be', 'clinical', 'text', 'design', 'that', 'and']","['protocol', 'be', 'clinical', 'design']",257,这些结果提供了可翻译的潜在毒性效应的指标，可以随时监控并指导我们的临床方案设计。,0.3,"['toxic', 'potential', 'protocol', 'supplementary', 'be', 'clinical', 'text', 'design', 'that', 'and']","['be', 'clinical', 'design']",,,,
258,258,clinical STUDY,临床研究,1.0,['clinical'],['clinical'],258,['临床研究'],1.0,['clinical'],['clinical'],258,"clinical study

Chinese:

临床研究",1.0,['clinical'],['clinical'],,,,
259,259,we initiated a clinical study of milasen in our patient 1 month after we started the toxicology studies in animals ( Figure 1A ) .,在开始动物毒理学研究 1 个月后，我们在患者身上开始了 milasen 的临床研究（图 1A）。,0.75,"['1', 'figure', 'month', 'toxicology', 'clinical study', 'patient', 'after', 'we']","['1', 'month', 'toxicology', 'clinical study', 'patient', 'after']",259,['我们在动物毒理学研究开始后1个月开始了我们患者的米拉森的临床研究(图1A)。'],0.75,"['1', 'figure', 'month', 'toxicology', 'clinical study', 'patient', 'after', 'we']","['1', 'month', 'toxicology', 'clinical study', 'patient', 'after']",259,我们在动物毒理学研究开始一个月后，我们发起了对病人的米拉森临床研究（图1A）。,0.75,"['1', 'figure', 'month', 'toxicology', 'clinical study', 'patient', 'after', 'we']","['1', 'month', 'toxicology', 'clinical study', 'patient', 'after']",,,,
260,260,"a dose of 42 mg was chosen because antisense oligonucleotides administered intrathecally to humans or nonhuman primates distribute to the brain ( the target of milasen ) with approximately one third the efficiency with which they distribute to the spinal cord ( the target of nusinersen ) , 8,13 and 42 mg of milasen is the molar equivalent of 3 times the typical nusinersen dose ( 12 mg ) .","选择 42 mg 的剂量是因为鞘内给予人类或非人类灵长类动物的反义寡核苷酸分布到大脑（milasen 的靶标）的效率约为它们分布到脊髓（nusinersen 的靶标）的三分之一，8, 13 和 42 毫克的 milasen 是典型 nusinersen 剂量（12 毫克）的 3 倍摩尔当量。",0.5,"['antisense', 'primates', 'equivalent', 'molar', 'brain', 'typical', 'target', 'efficiency', '3', 'distribute', 'with', 'spinal cord', 'nusinersen', 'dose', 'approximately', 'to', 'and', 'third']","['antisense', 'primates', 'equivalent', 'molar', 'brain', 'target', 'efficiency', 'spinal cord', 'dose']",260,"['42毫克的剂量被选择,因为对人类或非人类原始物体进行内分泌的抗氧化物质分布到大脑(米拉森的目标),大约三分之一的效率分布到脊椎(尼西纳森的目标),8、13和42毫克的米拉森是3倍的典型尼西纳森剂量(12毫克)。']",0.2222222222222222,"['antisense', 'primates', 'equivalent', 'molar', 'brain', 'typical', 'target', 'efficiency', '3', 'distribute', 'with', 'spinal cord', 'nusinersen', 'dose', 'approximately', 'to', 'and', 'third']","['brain', 'target', 'efficiency', 'dose']",260,"给药量为42毫克是因为脊髓注射给人或非人灵长类动物的反义寡核苷酸分布到大脑（类似米拉森的目标）的效率大约是它们分布到脊髓（努西内森的目标）的三分之一，8,13而且米拉森的42毫克摩尔计量相当于3倍的努西内森的典型剂量（12毫克）。",0.5555555555555556,"['antisense', 'primates', 'equivalent', 'molar', 'brain', 'typical', 'target', 'efficiency', '3', 'distribute', 'with', 'spinal cord', 'nusinersen', 'dose', 'approximately', 'to', 'and', 'third']","['antisense', 'primates', 'molar', 'brain', 'target', 'efficiency', 'spinal cord', 'dose', 'to', 'and']",,,,
261,261,"after dose escalation , two additional loading doses were administered , followed by maintenance dosing approximately every 3 months .",剂量递增后，再给予两次负荷剂量，然后大约每 3 个月给予一次维持剂量。,0.4444444444444444,"['loading', 'additional', 'after', '3', 'maintenance', 'dose', 'approximately', 'by', 'two']","['after', 'maintenance', 'dose', 'two']",261,"['剂量升级后,服用了2个额外的加载剂量,随后约每3个月进行维持剂量。']",0.4444444444444444,"['loading', 'additional', 'after', '3', 'maintenance', 'dose', 'approximately', 'by', 'two']","['additional', 'after', 'maintenance', 'dose']",261,经剂量升级后，额外给予两次疗程，然后大约每3个月进行一次维持疗程。,0.4444444444444444,"['loading', 'additional', 'after', '3', 'maintenance', 'dose', 'approximately', 'by', 'two']","['after', 'maintenance', 'dose', 'two']",,,,
262,262,"adverse Events , Pharmacokinetics , and Imaging","不良事件 , 药代动力学 , 和影像学",0.25,"['pharmacokinetics', 'adverse', 'imaging', 'and']",['pharmacokinetics'],262,"['不良事件, 药物素学, 和 图像']",0.0,"['pharmacokinetics', 'adverse', 'imaging', 'and']",[],262,"Adverse Events, Pharmacokinetics, and Imaging

中文：

不良事件、药物代谢和成像",0.0,"['pharmacokinetics', 'adverse', 'imaging', 'and']",[],,,,
263,263,"through the first year of treatment , no serious adverse events occurred .",通过第一年的治疗，没有发生严重的不良事件。,0.5,"['year', 'adverse', 'treatment', 'no', 'serious', 'first']","['year', 'treatment', 'first']",263,"['在治疗的第一年内,没有发生严重的副作用。']",0.5,"['year', 'adverse', 'treatment', 'no', 'serious', 'first']","['year', 'treatment', 'first']",263,在接受治疗的第一年，没有发生严重的不良事件。,0.5,"['year', 'adverse', 'treatment', 'no', 'serious', 'first']","['year', 'treatment', 'first']",,,,
264,264,"no clinically significant adverse changes were observed in vital signs ; in the results of physical examination , including assessments of strength , gait , and sensory testing ; or in clinical laboratory test profiles .",生命体征未见有临床意义的不良变化；在身体检查的结果中，包括力量、步态和感官测试的评估；或在临床实验室测试配置文件中。,0.3636363636363636,"['vital signs', 'sensory', 'physical examination', 'adverse', 'no', 'strength', 'gait', 'clinical', 'testing', 'laboratory test', 'and']","['vital signs', 'physical examination', 'gait', 'clinical']",264,"['没有临床上显著的负面变化在重要迹象中被观察到;在物理检查的结果中,包括强度、功率和感官测试的评估;或在临床实验室测试档案中。']",0.1818181818181818,"['vital signs', 'sensory', 'physical examination', 'adverse', 'no', 'strength', 'gait', 'clinical', 'testing', 'laboratory test', 'and']","['strength', 'clinical']",264,没有观察到临床上重要的身体指标变化，包括力量、步态和感觉测试的结果，或者临床实验室测试资料。,0.2727272727272727,"['vital signs', 'sensory', 'physical examination', 'adverse', 'no', 'strength', 'gait', 'clinical', 'testing', 'laboratory test', 'and']","['sensory', 'gait', 'clinical']",,,,
265,265,"MRI of the head showed continued brain volume loss 7 months after treatment initiation , extending a trend that had been observed over the previous 3 years .",头部 MRI 显示治疗开始后 7 个月脑容量持续减少，延续了过去 3 年观察到的趋势。,0.4166666666666667,"['trend', 'volume', 'initiation', 'head', 'brain', 'previous', 'MRI', 'after treatment', 'loss', '3', 'that', 'over']","['trend', 'initiation', 'head', 'brain', 'over']",265,"['头部的MRI显示,在治疗开始后7个月的脑体积持续下降,延长了过去3年中观察到的趋势。']",0.5,"['trend', 'volume', 'initiation', 'head', 'brain', 'previous', 'MRI', 'after treatment', 'loss', '3', 'that', 'over']","['trend', 'volume', 'initiation', 'head', 'brain', 'over']",265,"MRI of the head showed continued brain volume loss 7 months after treatment initiation, extending a trend that had been observed over the previous 3 years.

Chinese:

MRI显示，治疗后头部脑容量继续减少7个月，这一趋势延续了前3年的观察结果。",0.25,"['trend', 'volume', 'initiation', 'head', 'brain', 'previous', 'MRI', 'after treatment', 'loss', '3', 'that', 'over']","['trend', 'head', 'brain']",,,,
266,266,neurologic and Neuropsychological Assessments,神经学和神经心理学评估,0.6666666666666666,"['and', 'neurologic', 'neuropsychological']","['neurologic', 'neuropsychological']",266,['神经和神经心理学评估'],0.6666666666666666,"['and', 'neurologic', 'neuropsychological']","['neurologic', 'neuropsychological']",266,神经逻辑评估和神经心理学评估,0.6666666666666666,"['and', 'neurologic', 'neuropsychological']","['neurologic', 'neuropsychological']",,,,
267,267,"of the 4 subscores that did not decline , 2 remained the same and 2 improved in the 3 months before the initiation of the clinical study .",在临床研究开始前的 3 个月内，4 个未下降的分项分数中，2 个保持不变，2 个有所改善。,0.5555555555555556,"['decline', 'initiation', '2', 'clinical study', '3', '4', 'that', 'before', 'and']","['decline', 'initiation', '2', 'clinical study', 'before']",267,"['在未下降的4个分数中,2个保持相同,2个在临床研究开始前3个月改善。']",0.5555555555555556,"['decline', 'initiation', '2', 'clinical study', '3', '4', 'that', 'before', 'and']","['decline', 'initiation', '2', 'clinical study', 'before']",267,在开始临床研究前3个月，有4个亚分数没有下降，其中2个保持不变，另外2个亚分数有所改善。,0.5555555555555556,"['decline', 'initiation', '2', 'clinical study', '3', '4', 'that', 'before', 'and']","['decline', 'initiation', '2', 'clinical study', 'before']",,,,
268,268,"subscores tended to stabilize in the period from the start of the clinical study to approximately 3 months ( 3 declined , 6 remained the same , and 2 improved from day − 6 to day 107 ) and from 3 months to 6 months ( 4 declined , 2 remained the same , and 5 improved from day 107 to day 203 ) .",从临床研究开始到大约 3 个月（从第 6 天到第 107 天，3 人下降，6 人保持不变，2 人提高）和从 3 个月到 6 个月（4 人下降，2 人保持不变，从第 107 天到第 203 天有 5 个有所改善）。,0.2727272727272727,"['period', '5', '2', 'clinical study', '3', '4', 'stabilize', 'start', 'approximately', 'to', 'and']","['5', '2', 'clinical study']",268,"['从临床研究开始的期间,低分倾向于稳定约为3个月(3下降,6保持相同,2从6到107日改善)和3个月到6个月(4下降,2保持相同,5从107到203日改善)。']",0.5454545454545454,"['period', '5', '2', 'clinical study', '3', '4', 'stabilize', 'start', 'approximately', 'to', 'and']","['period', '5', '2', 'clinical study', 'stabilize', 'to']",268,在临床研究开始到约3个月的时期，子评分倾向于稳定（3个下降，6个保持不变，2个从第-6天改善到第107天），并且从3个月到6个月（4个下降，2个保持不变，5个从第107天改善到第203天）。,0.5454545454545454,"['period', '5', '2', 'clinical study', '3', '4', 'stabilize', 'start', 'approximately', 'to', 'and']","['period', '5', '2', 'clinical study', 'stabilize', 'to']",,,,
269,269,seizures,癫痫发作,1.0,['seizures'],['seizures'],269,['攻击'],0.0,['seizures'],[],269,"seizures

Chinese:

癫痫",0.0,['seizures'],[],,,,
270,270,"at baseline , our patient was having approximately 15 to 30 seizures per day , each lasting 1 to 2 minutes ( Figure 3C ) .",在基线时，我们的患者每天大约发作 15 到 30 次，每次持续 1 到 2 分钟（图 3C）。,0.5555555555555556,"['baseline', '1', '2', 'figure', 'patient', 'approximately', 'each', 'to', 'seizures']","['baseline', '1', '2', 'patient', 'seizures']",270,"['在基线上,我们的病人每天大约有15至30次,每次持续1至2分钟(图3C)。']",0.4444444444444444,"['baseline', '1', '2', 'figure', 'patient', 'approximately', 'each', 'to', 'seizures']","['baseline', '1', '2', 'patient']",270,"在基线，我们的病人每天大约有15至30个癫痫发作，每次持续1至2分钟（图3C）。

Chinese:

在基线，我们的病人每天大约有15至30个癫痫发作，每次持续1至2分钟（图3C）。",0.5555555555555556,"['baseline', '1', '2', 'figure', 'patient', 'approximately', 'each', 'to', 'seizures']","['baseline', '1', '2', 'patient', 'seizures']",,,,
271,271,"over the course of the clinical study , the frequency decreased to between 0 and 20 seizures per day , and the duration of each seizure decreased to less than 1 minute .",在临床研究过程中，频率减少到每天 0 到 20 次癫痫发作，每次癫痫发作的持续时间减少到不到 1 分钟。,0.7272727272727273,"['frequency', '1', 'minute', 'clinical study', 'duration', 'course', 'each', 'over', 'to', 'and', 'seizures']","['frequency', '1', 'minute', 'clinical study', 'duration', 'course', 'over', 'seizures']",271,"['在临床试验期间,频率下降到每日0至20次,每次接收的持续时间下降到不到1分钟。']",0.3636363636363636,"['frequency', '1', 'minute', 'clinical study', 'duration', 'course', 'each', 'over', 'to', 'and', 'seizures']","['frequency', '1', 'minute', 'duration']",271,在临床研究的过程中，发作的频率减少到每天0到20次之间，每次发作的持续时间减少到不到1分钟。,0.7272727272727273,"['frequency', '1', 'minute', 'clinical study', 'duration', 'course', 'each', 'over', 'to', 'and', 'seizures']","['frequency', '1', 'minute', 'clinical study', 'duration', 'course', 'over', 'seizures']",,,,
272,272,"these trends were corroborated by overnight electroencephalographic monitoring ( Figure 3D ) , which indicated that both the frequency and duration of seizures decreased by greater than 50 % ( comparing the initial two recordings and the subsequent three recordings ) .",这些趋势得到夜间脑电图监测的证实（图 3D），这表明癫痫发作的频率和持续时间都减少了 50% 以上（比较最初的两次记录和随后的三次记录）。,0.5833333333333334,"['monitoring', 'frequency', 'figure', 'initial', 'subsequent', 'duration', 'three', 'that', 'by', 'and', 'two', 'seizures']","['monitoring', 'frequency', 'initial', 'duration', 'by', 'two', 'seizures']",272,"['这些趋势是由夜间电解体监测(图3D)证实的,这表明捕获的频率和持续时间都减少了50%以上(比较初步两次录制和后来的三次录制)。']",0.5,"['monitoring', 'frequency', 'figure', 'initial', 'subsequent', 'duration', 'three', 'that', 'by', 'and', 'two', 'seizures']","['monitoring', 'frequency', 'initial', 'duration', 'by', 'two']",272,这些趋势得到了通宵脑电图监测的证实（图3D），指出发作的频率和持续时间均减少了50%以上（比较前两次和随后三次记录）。,0.5,"['monitoring', 'frequency', 'figure', 'initial', 'subsequent', 'duration', 'three', 'that', 'by', 'and', 'two', 'seizures']","['monitoring', 'frequency', 'duration', 'by', 'two', 'seizures']",,,,
273,273,the percent cumulative time spent in seizure decreased by greater than 80 % .,癫痫发作的累积时间百分比减少了 80% 以上。,0.5,"['time', 'cumulative', 'seizure', 'percent', 'in', 'by']","['time', 'seizure', 'by']",273,['收集时间的百分比减少了80%以上。'],0.3333333333333333,"['time', 'cumulative', 'seizure', 'percent', 'in', 'by']","['time', 'by']",273,癫痫发作的累积时间百分比下降了80%以上。,0.5,"['time', 'cumulative', 'seizure', 'percent', 'in', 'by']","['time', 'seizure', 'by']",,,,
274,274,treatment has also been accompanied by objective reductions in the frequency and duration of seizures .,治疗还伴随着癫痫发作频率和持续时间的客观减少。,0.5,"['objective', 'frequency', 'treatment', 'duration', 'in', 'and', 'accompanied by', 'seizures']","['frequency', 'treatment', 'duration', 'seizures']",274,['治疗也伴随着对抗的频率和持续时间的客观减少。'],0.375,"['objective', 'frequency', 'treatment', 'duration', 'in', 'and', 'accompanied by', 'seizures']","['frequency', 'treatment', 'duration']",274,治疗还伴随着客观上癫痫发作的频率和持续时间的减少。,0.5,"['objective', 'frequency', 'treatment', 'duration', 'in', 'and', 'accompanied by', 'seizures']","['frequency', 'treatment', 'duration', 'seizures']",,,,
275,275,"nonetheless , this experience indicates that antisense oligonucleotides may deserve consideration as a platform for the rapid delivery of individualized treatments .",尽管如此，这一经验表明，反义寡核苷酸可能值得考虑作为快速提供个性化治疗的平台。,0.4444444444444444,"['antisense', 'delivery', 'platform', 'experience', 'as', 'this', 'that', 'consideration', 'rapid']","['antisense', 'platform', 'experience', 'as']",275,"['然而,这种经验表明,抗敏性<unk>核酸可能值得考虑,作为快速提供个性化治疗的平台。']",0.2222222222222222,"['antisense', 'delivery', 'platform', 'experience', 'as', 'this', 'that', 'consideration', 'rapid']","['platform', 'experience']",275,尽管如此，这一经验表明，反义寡核苷酸可能值得作为快速提供个体化治疗方案的平台。,0.4444444444444444,"['antisense', 'delivery', 'platform', 'experience', 'as', 'this', 'that', 'consideration', 'rapid']","['antisense', 'platform', 'experience', 'as']",,,,
276,276,"more generally , this approach is at present probably scalable to only a limited number of patients , given current limitations on systemic and infrastructural issues ( e.g. , regulatory burden , manufacturing capacity , cost , and reimbursement ) .",更一般地说，考虑到目前对系统和基础设施问题（例如，监管负担、制造能力、成本和报销）的限制，这种方法目前可能只能扩展到有限数量的患者。,0.2142857142857142,"['approach', 'capacity', 'number', 'systemic', 'current', 'cost', 'present', 'at', 'on', 'limited', 'this', 'to', 'and', 'burden']","['capacity', 'number', 'cost']",276,"['更普遍地说,这种方法目前可能仅可扩展到有限数量的患者,考虑到系统和基础设施问题(例如,监管负担,制造能力,成本和回报)的当前限制。']",0.2857142857142857,"['approach', 'capacity', 'number', 'systemic', 'current', 'cost', 'present', 'at', 'on', 'limited', 'this', 'to', 'and', 'burden']","['capacity', 'number', 'cost', 'at']",276,目前，由于系统性和基础设施方面的限制（例如监管负担、生产能力、成本和报销），这种方法可能只适用于有限数量的患者。,0.3571428571428571,"['approach', 'capacity', 'number', 'systemic', 'current', 'cost', 'present', 'at', 'on', 'limited', 'this', 'to', 'and', 'burden']","['capacity', 'number', 'cost', 'at', 'to']",,,,
277,277,"this study illustrates the ability to rationally design , test , and deploy a novel therapeutic agent for a patient with a rare disease on the basis of an understanding of her specific pathogenic mutation .",这项研究说明了在了解罕见病患者特定致病突变的基础上合理设计、测试和部署新型治疗剂的能力。,0.2941176470588235,"['mutation', 'disease', 'test', 'study', 'basis', 'pathogenic', 'therapeutic', 'patient', 'novel', 'specific', 'ability', 'design', 'with', 'agent', 'this', 'to', 'and']","['mutation', 'disease', 'patient', 'ability', 'design']",277,"['这项研究展示了对一个患有罕见疾病的患者进行理性设计、测试和部署新疗法的能力,基于对其特定的病因突变的理解。']",0.4117647058823529,"['mutation', 'disease', 'test', 'study', 'basis', 'pathogenic', 'therapeutic', 'patient', 'novel', 'specific', 'ability', 'design', 'with', 'agent', 'this', 'to', 'and']","['mutation', 'disease', 'test', 'patient', 'ability', 'design', 'to']",277,这项研究展示了基于对患者特异性病因突变的理解，从理性上设计、测试和部署一种新型治疗剂的能力。,0.3529411764705882,"['mutation', 'disease', 'test', 'study', 'basis', 'pathogenic', 'therapeutic', 'patient', 'novel', 'specific', 'ability', 'design', 'with', 'agent', 'this', 'to', 'and']","['mutation', 'disease', 'patient', 'ability', 'design', 'to']",,,,
278,278,it is an example of individualized genomic medicine .,它是个体化基因组医学的一个例子。,1.0,"['medicine', 'example']","['medicine', 'example']",278,['这是个别化基因医学的例子。'],1.0,"['medicine', 'example']","['medicine', 'example']",278,这是个体化基因组医学的一个例子。,1.0,"['medicine', 'example']","['medicine', 'example']",,,,
279,279,"the two primary outcomes were net adverse clinical events - defined as death from any cause , myocardial infarction , definite stent thrombosis , stroke , or major bleeding defined according to Platelet Inhibition and Patient Outcomes ( PLATO ) criteria - at 12 months ( primary combined outcome ; tested for noninferiority , with a noninferiority margin of 2 percentage points for the absolute difference ) and PLATO major or minor bleeding at 12 months ( primary bleeding outcome ) .",两个主要结果是 12 个月时的净不良临床事件——定义为任何原因死亡、心肌梗死、确定的支架内血栓形成、中风或根据血小板抑制和患者结果 (PLATO) 标准定义的大出血（主要综合结果；测试了非劣效性，绝对差的非劣效性界限为 2 个百分点）和 PLATO 12 个月时的大出血或小出血（主要出血结果）。,0.5517241379310345,"['bleeding', 'myocardial infarction', 'percentage', 'inhibition', 'stroke', 'net', 'defined', 'margin', '2', 'outcome', 'death', 'absolute', 'difference', 'thrombosis', 'minor', 'major', 'adverse', 'primary', 'stent', 'cause', 'clinical', 'patient', 'as', 'with', 'platelet', '-', 'to', 'and', 'two']","['bleeding', 'myocardial infarction', 'inhibition', 'stroke', 'defined', 'margin', '2', 'outcome', 'death', 'absolute', 'thrombosis', 'cause', 'clinical', 'patient', 'platelet', 'two']",279,"['两个主要结果是净不良的临床现象 - 定义为死亡的任何原因, 心脏病发作, 定义的<unk>血病, 发作, 或主要出血 根据定义的基准 Platelet Inhibition 和 病人结果 ( PLATO ) - 在 12 个月( 主要组合结果 ; 测试为 noninferiority, 与 noninferiority 边界为 2 个百分点的绝对差异 ) 和 PLATO 大或小出血 在 12 个月( 主要出血结果 ) 。']",0.4137931034482758,"['bleeding', 'myocardial infarction', 'percentage', 'inhibition', 'stroke', 'net', 'defined', 'margin', '2', 'outcome', 'death', 'absolute', 'difference', 'thrombosis', 'minor', 'major', 'adverse', 'primary', 'stent', 'cause', 'clinical', 'patient', 'as', 'with', 'platelet', '-', 'to', 'and', 'two']","['bleeding', 'stroke', 'margin', '2', 'outcome', 'death', 'absolute', 'difference', 'cause', 'clinical', 'patient', 'two']",279,主要结局包括12个月内的净不良临床事件（即根据PLATO标准确定的死亡、心肌梗塞、明确的支架栓塞、中风或重度出血）和12个月内的PLATO主要或次要出血（主要出血结局）。,0.2413793103448276,"['bleeding', 'myocardial infarction', 'percentage', 'inhibition', 'stroke', 'net', 'defined', 'margin', '2', 'outcome', 'death', 'absolute', 'difference', 'thrombosis', 'minor', 'major', 'adverse', 'primary', 'stent', 'cause', 'clinical', 'patient', 'as', 'with', 'platelet', '-', 'to', 'and', 'two']","['bleeding', 'myocardial infarction', 'stroke', 'defined', '2', 'death', 'clinical']",,,,
280,280,"in these patients , dual antiplatelet therapy , consisting of aspirin and a P2Y12 inhibitor , is essential to prevent recurrent thrombotic events such as stent thrombosis.1",在这些患者中，由阿司匹林和 P2Y12 抑制剂组成的双重抗血小板治疗对于预防复发性血栓事件（如支架内血栓形成）至关重要。 1,0.3636363636363636,"['inhibitor', 'aspirin', 'antiplatelet', 'essential', 'thrombotic', 'therapy', 'recurrent', 'stent', 'dual', 'prevent', 'and']","['inhibitor', 'aspirin', 'therapy', 'prevent']",280,"['在这些患者中,由阿司匹林和P2Y12抑制剂组成的双重抗斑疗法至关重要,以防止重复的血管现象,如<unk>血病。']",0.2727272727272727,"['inhibitor', 'aspirin', 'antiplatelet', 'essential', 'thrombotic', 'therapy', 'recurrent', 'stent', 'dual', 'prevent', 'and']","['inhibitor', 'aspirin', 'therapy']",280,在这些病人中，包括阿司匹林和P2Y12抑制剂在内的双重抗血小板治疗是预防再次发生血栓性事件（如支架血栓）的关键。1,0.3636363636363636,"['inhibitor', 'aspirin', 'antiplatelet', 'essential', 'thrombotic', 'therapy', 'recurrent', 'stent', 'dual', 'prevent', 'and']","['inhibitor', 'aspirin', 'therapy', 'prevent']",,,,
281,281,"current guidelines1,2 favor the more potent platelet inhibitors ticagrelor and prasugrel over clopidogrel because these drugs are more effective for the prevention of thrombotic events.3,4","目前的指南 1,2 倾向于使用更有效的血小板抑制剂替格瑞洛和普拉格雷，而不是氯吡格雷，因为这些药物在预防血栓事件方面更有效。 3,4",0.6,"['drugs', 'clopidogrel', 'prevention', 'thrombotic', 'potent', 'current', 'platelet', 'prasugrel', 'over', 'and']","['drugs', 'clopidogrel', 'prevention', 'platelet', 'prasugrel', 'and']",281,"['目前的指南1,2 有利于更强大的平板膜抑制剂 ticagrelor 和 prasugrel 超过 clopidogrel 因为这些药物更有效地预防血管事件。']",0.3,"['drugs', 'clopidogrel', 'prevention', 'thrombotic', 'potent', 'current', 'platelet', 'prasugrel', 'over', 'and']","['drugs', 'prevention', 'over']",281,"根据目前的指导方针1,2更倾向于使用更有效的血小板抑制剂蒂卡格雷尔和普拉苏格尔而不是克洛赛尔，因为这些药物更有效地预防血栓形成3,4。",0.4,"['drugs', 'clopidogrel', 'prevention', 'thrombotic', 'potent', 'current', 'platelet', 'prasugrel', 'over', 'and']","['drugs', 'prevention', 'platelet', 'and']",,,,
282,282,"however , this greater efficacy comes with a higher risk of bleeding.3,4","然而，这种更高的疗效伴随着更高的出血风险。 3,4",0.25,"['risk', 'efficacy', 'with', 'this']",['risk'],282,"['然而,这种更高的有效性伴随着出血的风险更高。']",0.5,"['risk', 'efficacy', 'with', 'this']","['risk', 'efficacy']",282,"然而，这种更高的疗效伴随着更高的出血风险。3,4",0.25,"['risk', 'efficacy', 'with', 'this']",['risk'],,,,
283,283,"clopidogrel is a prodrug , transformed into its active metabolite by hepatic cytochrome P450 enzymes .",氯吡格雷是一种前药，通过肝细胞色素P450酶转化为活性代谢物。,0.625,"['metabolite', 'hepatic', 'enzymes', 'clopidogrel', 'active', 'prodrug', 'cytochrome P450', 'by']","['metabolite', 'enzymes', 'clopidogrel', 'prodrug', 'cytochrome P450']",283,"['克洛皮多格勒是一种药物,由肝细胞染色素P450酶转化为其活性代谢。']",0.25,"['metabolite', 'hepatic', 'enzymes', 'clopidogrel', 'active', 'prodrug', 'cytochrome P450', 'by']","['enzymes', 'by']",283,clopidogrel is a prodrug that is transformed into its active metabolite by hepatic cytochrome P450 enzymes.,0.0,"['metabolite', 'hepatic', 'enzymes', 'clopidogrel', 'active', 'prodrug', 'cytochrome P450', 'by']",[],,,,
284,284,"the active metabolite irreversibly inhibits the P2Y12 receptor on platelets , which results in inhibition of platelet aggregation .",活性代谢物不可逆地抑制血小板上的P2Y12受体，从而抑制血小板聚集。,0.8333333333333334,"['receptor', 'inhibition', 'metabolite', 'active', 'platelets', 'platelet aggregation']","['receptor', 'inhibition', 'metabolite', 'platelets', 'platelet aggregation']",284,"['活性代谢物不可逆转地抑制板块上的P2Y12受体,从而抑制板块集成。']",0.5,"['receptor', 'inhibition', 'metabolite', 'active', 'platelets', 'platelet aggregation']","['receptor', 'inhibition', 'metabolite']",284,活性代謝物對血小板上的P2Y12受體具有不可逆轉的抑制作用，從而抑制血小板聚集。,0.5,"['receptor', 'inhibition', 'metabolite', 'active', 'platelets', 'platelet aggregation']","['inhibition', 'platelets', 'platelet aggregation']",,,,
285,285,neither entity had any role in the design or execution of the trial or in the analysis of the data .,这两个实体都没有参与试验的设计或执行，也没有参与数据分析。,0.5714285714285714,"['data', 'analysis', 'entity', 'role', 'trial', 'design', 'in']","['data', 'analysis', 'entity', 'design']",285,['任何实体都没有在审判的设计或执行或数据分析中发挥任何作用。'],0.8571428571428571,"['data', 'analysis', 'entity', 'role', 'trial', 'design', 'in']","['data', 'analysis', 'entity', 'role', 'trial', 'design']",285,"neither entity had any role in the design or execution of the trial or in the analysis of the data .

Chinese:
这两个实体在试验的设计和执行，以及数据分析中都没有任何作用。",0.7142857142857143,"['data', 'analysis', 'entity', 'role', 'trial', 'design', 'in']","['data', 'analysis', 'entity', 'role', 'design']",,,,
286,286,details of the design have been published previously.13,设计细节之前已经发布。 13,0.5,"['design', 'have']",['design'],286,['该项目的详细信息已公布。13'],0.0,"['design', 'have']",[],286,详细设计信息已经在之前发布过了。,0.5,"['design', 'have']",['design'],,,,
287,287,the trial was approved by the appropriate ethics committees and national authorities in each country .,该试验得到了每个国家相应的伦理委员会和国家当局的批准。,0.3333333333333333,"['country', 'ethics', 'trial', 'committees', 'each', 'in', 'by', 'and', 'appropriate']","['country', 'committees', 'in']",287,['审判由各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國'],0.3333333333333333,"['country', 'ethics', 'trial', 'committees', 'each', 'in', 'by', 'and', 'appropriate']","['trial', 'each', 'by']",287,试验经过各国适当的伦理委员会和国家当局批准。,0.4444444444444444,"['country', 'ethics', 'trial', 'committees', 'each', 'in', 'by', 'and', 'appropriate']","['country', 'committees', 'each', 'in']",,,,
288,288,"the trial was registered after the enrollment of the first 18 patients , as described in the Supplementary Appendix ( available with the full text of this article at NEJM.org ) .",如补充附录（与本文全文可在 NEJM.org 获取）中所述，该试验在前 18 名患者入组后注册。,0.1428571428571428,"['appendix', 'article', 'supplementary', 'available', 'after', 'trial', 'text', 'as', 'with', 'at', 'full', 'this', 'in', 'first']","['after', 'as']",288,"['试验在注册前18名患者后登记,如附件中所描述(可在NEJM.org上提供本文的完整文本)。']",0.2857142857142857,"['appendix', 'article', 'supplementary', 'available', 'after', 'trial', 'text', 'as', 'with', 'at', 'full', 'this', 'in', 'first']","['appendix', 'after', 'as', 'full']",288,该试验在招募到第18位患者后登记注册，详情见本文的补充附录（在 NEJM.org 上的全文中可以找到）。,0.0714285714285714,"['appendix', 'article', 'supplementary', 'available', 'after', 'trial', 'text', 'as', 'with', 'at', 'full', 'this', 'in', 'first']",['after'],,,,
289,289,an independent data and safety monitoring board monitored the trial and had full access to all data .,一个独立的数据和安全监督委员会监督了试验并可以完全访问所有数据。,0.3,"['safety', 'monitoring', 'data', 'access', 'board', 'trial', 'independent', 'full', 'all', 'and']","['safety', 'data', 'independent']",289,"['一个独立的数据和安全监测委员会监测了试验,并完全访问了所有数据。']",0.4,"['safety', 'monitoring', 'data', 'access', 'board', 'trial', 'independent', 'full', 'all', 'and']","['safety', 'monitoring', 'data', 'independent']",289,一个独立的数据和安全监测委员会监测了试验并且可以完全访问所有数据。,0.4,"['safety', 'monitoring', 'data', 'access', 'board', 'trial', 'independent', 'full', 'all', 'and']","['safety', 'monitoring', 'data', 'independent']",,,,
290,290,"trial monitoring was executed by an external service provider ( Research Drive , Norg , the Netherlands ) .",试验监测由外部服务提供商（Research Drive，Norg，荷兰）执行。,0.2857142857142857,"['monitoring', 'external', 'research', 'service', 'drive', 'trial', 'by']","['monitoring', 'by']",290,"['试验监测由一个外部服务提供商(研究驱动,诺格,荷兰)执行。']",0.5714285714285714,"['monitoring', 'external', 'research', 'service', 'drive', 'trial', 'by']","['monitoring', 'research', 'drive', 'by']",290,"研究驱动(Norg,荷兰)是一家外部服务提供商,负责监控试验。",0.2857142857142857,"['monitoring', 'external', 'research', 'service', 'drive', 'trial', 'by']","['research', 'drive']",,,,
291,291,major PROTOCOL REVISION,主要协议修订,0.0,['major'],[],291,['主要议定书审查'],0.0,['major'],[],291,A major revision to the protocol is being planned.,0.0,['major'],[],,,,
292,292,"patients were eligible for enrollment if they had signs or symptoms of STEMI lasting 30 minutes to 12 hours , underwent primary PCI with stent implantation , and were 21 years of age or older .",如果患者有持续 30 分钟至 12 小时的 STEMI 体征或症状，接受直接 PCI 支架植入术，并且年龄在 21 岁或以上，则患者符合入组条件。,0.2,"['implantation', 'symptoms', 'signs', 'primary', 'stent', 'age', 'with', 'if', 'and', 'eligible']","['implantation', 'age']",292,"['患者有资格登记,如果他们有30分钟至12小时的STEMI的迹象或症状,接受了初级PCI与斯坦特植入,并且年龄为21岁或以上。']",0.2,"['implantation', 'symptoms', 'signs', 'primary', 'stent', 'age', 'with', 'if', 'and', 'eligible']","['implantation', 'age']",292,病人符合入籄資格，如果他們有STEMI的徵兆或症狀持續30分鐘到12小時，經歷了初級PCI與支架置入手術，年齡在21歲或以上。,0.1,"['implantation', 'symptoms', 'signs', 'primary', 'stent', 'age', 'with', 'if', 'and', 'eligible']",['implantation'],,,,
293,293,exclusion criteria are provided in Table S1 in the Supplementary Appendix .,补充附录表 S1 中提供了排除标准。,0.1666666666666666,"['appendix', 'table', 'supplementary', 'exclusion', 'S1', 'in']",['table'],293,['排除标准在附件 S1 表中列出。'],0.3333333333333333,"['appendix', 'table', 'supplementary', 'exclusion', 'S1', 'in']","['appendix', 'table']",293,"The exclusion criteria are provided in Table S1 in the Supplementary Appendix.

Chinese:

排除标准见补充附录中的表S1。",0.1666666666666666,"['appendix', 'table', 'supplementary', 'exclusion', 'S1', 'in']",['table'],,,,
294,294,"because patients were asked to participate in the trial during the acute phase of myocardial infarction , many provided only oral informed consent before randomization .",由于要求患者在心肌梗死的急性期参加试验，因此许多患者在随机分组前仅提供了口头知情同意书。,0.6666666666666666,"['myocardial infarction', 'randomization', 'phase', 'oral', 'trial', 'acute', 'informed consent', 'before', 'to']","['myocardial infarction', 'randomization', 'phase', 'acute', 'before', 'to']",294,"['由于患者在心脏病发作的急性阶段被要求参加试验,许多患者在随机化之前只提供口头通知的同意。']",0.4444444444444444,"['myocardial infarction', 'randomization', 'phase', 'oral', 'trial', 'acute', 'informed consent', 'before', 'to']","['randomization', 'phase', 'before', 'to']",294,因为病人在心肌梗塞的急性阶段被要求参加试验，许多人只是在随机分配之前提供了口头知情同意。,0.4444444444444444,"['myocardial infarction', 'randomization', 'phase', 'oral', 'trial', 'acute', 'informed consent', 'before', 'to']","['myocardial infarction', 'randomization', 'phase', 'before']",,,,
295,295,such patients were eligible for the final analysis only if written informed consent was subsequently obtained .,只有随后获得书面知情同意书，此类患者才有资格进行最终分析。,0.25,"['analysis', 'informed consent', 'if', 'eligible']",['analysis'],295,"['这些患者仅有资格进行最终分析,如果随后获得书面通知的同意。']",0.25,"['analysis', 'informed consent', 'if', 'eligible']",['analysis'],295,这些患者只有在随后获得书面知情同意书的情况下才符合最终分析的资格。,0.25,"['analysis', 'informed consent', 'if', 'eligible']",['analysis'],,,,
296,296,pretrial TREATMENT,审前治疗,,[],[],296,['初级交易'],,[],[],296,pretrial treatment,,[],[],,,,
297,297,pretrial antithrombotic treatment was administered according to local protocol .,试验前抗血栓治疗根据当地方案进行。,0.25,"['protocol', 'antithrombotic', 'local', 'treatment']",['treatment'],297,['根据本地议定书进行前列抗血管治疗。'],0.5,"['protocol', 'antithrombotic', 'local', 'treatment']","['protocol', 'treatment']",297,根据当地协议，应用预审抗血沉降治疗。,0.5,"['protocol', 'antithrombotic', 'local', 'treatment']","['protocol', 'treatment']",,8.0,,
298,298,"this usually consisted of a loading dose of aspirin , a P2Y12 inhibitor , and heparin .",这通常包括负荷剂量的阿司匹林、P2Y12 抑制剂和肝素。,0.5714285714285714,"['loading', 'inhibitor', 'aspirin', 'heparin', 'dose', 'this', 'and']","['inhibitor', 'aspirin', 'heparin', 'dose']",298,['这通常由阿司匹林、P2Y12抑制剂和海帕林的负载剂量组成。'],0.4285714285714285,"['loading', 'inhibitor', 'aspirin', 'heparin', 'dose', 'this', 'and']","['inhibitor', 'aspirin', 'dose']",298,通常，这包括阿司匹林的首次给药，P2Y12抑制剂和肝素。,0.4285714285714285,"['loading', 'inhibitor', 'aspirin', 'heparin', 'dose', 'this', 'and']","['inhibitor', 'aspirin', 'heparin']",,10.0,,
299,299,"other antithrombotic periprocedural therapies were chosen at the discretion of the treating physician , as was the P2Y12 inhibitor administered before randomization .",其他围手术期抗血栓治疗由主治医师自行决定，随机分组前使用的 P2Y12 抑制剂也是如此。,0.8333333333333334,"['inhibitor', 'randomization', 'antithrombotic', 'physician', 'as', 'before']","['inhibitor', 'randomization', 'physician', 'as', 'before']",299,"['其他抗血管周期治疗是在治疗医生的判断下选择的,如在随机化之前服用的P2Y12抑制剂。']",0.8333333333333334,"['inhibitor', 'randomization', 'antithrombotic', 'physician', 'as', 'before']","['inhibitor', 'randomization', 'physician', 'as', 'before']",299,其他抗血栓周围疗法由治疗医师自行选择，P2Y12抑制剂亦是在随机化之前进行管理的。,0.6666666666666666,"['inhibitor', 'randomization', 'antithrombotic', 'physician', 'as', 'before']","['inhibitor', 'randomization', 'physician', 'before']",,10.0,,
300,300,randomization AND TRIAL PROCEDURES,随机化和试验程序,1.0,['randomization'],['randomization'],300,['随机化和试验程序'],1.0,['randomization'],['randomization'],300,随机化和试验程序,1.0,['randomization'],['randomization'],,,,
301,301,patients were enrolled during or up to 48 hours after primary PCI .,患者在直接 PCI 期间或之后 48 小时内被纳入。,0.25,"['primary', 'after', 'up', 'to']",['after'],301,['患者在初始 PCI 后 48 小时内或最多注册。'],0.25,"['primary', 'after', 'up', 'to']",['after'],301,病人在初级PCI术后48小时内或之内被纳入本研究。,0.25,"['primary', 'after', 'up', 'to']",['after'],,,,
302,302,use of the Spartan device began during the course of the trial ; not all hospitals started using it simultaneously .,在试验过程中开始使用 Spartan 设备；并非所有医院都同时开始使用它。,0.5,"['device', 'trial', 'course', 'all']","['device', 'course']",302,"['在试验过程中,斯巴达设备的使用开始;不是所有医院都开始同时使用它。']",0.5,"['device', 'trial', 'course', 'all']","['device', 'course']",302,使用斯巴达设备在试用期间开始；并非所有医院同时开始使用它。,0.25,"['device', 'trial', 'course', 'all']",['device'],,,,
303,303,details of the logistics of these tests in this trial have been published previously.15,该试验中这些测试的详细信息之前已发表。 15,0.0,"['logistics', 'trial', 'have', 'this', 'in']",[],303,['这些试验的物流细节在此试验中已经公布。'],0.0,"['logistics', 'trial', 'have', 'this', 'in']",[],303,详细的后勤信息在这个试验中已经公开了。,0.0,"['logistics', 'trial', 'have', 'this', 'in']",[],,,,
304,304,"if patients switched between P2Y12 inhibitors , the use of a loading dose was at the discretion of the treating physician .",如果患者在 P2Y12 抑制剂之间转换，负荷剂量的使用由主治医师决定。,0.4,"['loading', 'physician', 'at', 'dose', 'if']","['physician', 'dose']",304,"['如果患者在 P2Y12 抑制剂之间交换,则使用充电剂量是治疗医生的判断。']",0.4,"['loading', 'physician', 'at', 'dose', 'if']","['physician', 'dose']",304,如果病人在P2Y12抑制剂之间切换，使用载药量取决于治疗医师的判断。,0.4,"['loading', 'physician', 'at', 'dose', 'if']","['physician', 'at']",,,,
305,305,all patients were treated with a P2Y12 inhibitor for at least 1 year after primary PCI .,所有患者在直接 PCI 后均接受了至少 1 年的 P2Y12 抑制剂治疗。,0.5,"['inhibitor', 'year', '1', 'primary', 'after', 'with', 'at', 'all']","['inhibitor', 'year', '1', 'after']",305,"['所有患者都接受了P2Y12抑制剂的治疗,至少在初级PCI之后一年。']",0.5,"['inhibitor', 'year', '1', 'primary', 'after', 'with', 'at', 'all']","['inhibitor', 'year', '1', 'after']",305,所有病人在主动脉冠状动脉介入术之后至少接受了一年的P2Y12抑制剂治疗。,0.5,"['inhibitor', 'year', '1', 'primary', 'after', 'with', 'at', 'all']","['inhibitor', 'year', '1', 'after']",,,,
306,306,"patients were asked to fill out a questionnaire at 1 month , 6 months , and 12 months after primary PCI .",要求患者在直接 PCI 后 1 个月、6 个月和 12 个月时填写问卷。,0.375,"['1', 'month', 'primary', 'after', 'at', 'out', 'to', 'and']","['1', 'month', 'after']",306,['患者被要求在初级PCI后1个月、6个月和12个月内填写问卷。'],0.375,"['1', 'month', 'primary', 'after', 'at', 'out', 'to', 'and']","['1', 'month', 'after']",306,病人在初级PCI后的1个月、6个月和12个月被要求填写一份问卷。,0.375,"['1', 'month', 'primary', 'after', 'at', 'out', 'to', 'and']","['1', 'month', 'after']",,,,
307,307,questionnaires were used as an additional source of information .,问卷被用作额外的信息来源。,0.75,"['information', 'additional', 'source', 'as']","['information', 'additional', 'source']",307,['问卷被用作额外的信息来源。'],0.75,"['information', 'additional', 'source', 'as']","['information', 'additional', 'source']",307,问卷调查也是一种额外的信息来源。,0.75,"['information', 'additional', 'source', 'as']","['information', 'additional', 'source']",,,,
308,308,there were two primary outcomes .,有两个主要结果。,0.5,"['primary', 'two']",['two'],308,['有两个主要结果。'],0.5,"['primary', 'two']",['two'],308,"there were two primary outcomes .

Chinese:

主要成果有两个。",0.5,"['primary', 'two']",['two'],,,,
309,308,there were two primary outcomes .,有两个主要结果。,0.5,"['primary', 'two']",['two'],308,['有两个主要结果。'],0.5,"['primary', 'two']",['two'],308,"there were two primary outcomes .

Chinese:

主要成果有两个。",0.5,"['primary', 'two']",['two'],,,,
310,309,a complete list of secondary thrombotic and bleeding outcomes is provided in Tables S2 and S3 in the Supplementary Appendix .,补充附录表 S2 和表 S3 提供了继发性血栓形成和出血结局的完整列表。,0.1,"['bleeding', 'appendix', 'supplementary', 'thrombotic', 'complete', 'secondary', 'list', 'S2', 'S3', 'and']",['bleeding'],309,['二次血管和出血结果的完整列表在附件中的 S2 和 S3 表中提供。'],0.2,"['bleeding', 'appendix', 'supplementary', 'thrombotic', 'complete', 'secondary', 'list', 'S2', 'S3', 'and']","['bleeding', 'appendix']",309,"A complete list of secondary thrombotic and bleeding outcomes is provided in Tables S2 and S3 in the Supplementary Appendix.

Chinese:

表S2和表S3提供了次要血栓形成和出血的完整列表。",0.1,"['bleeding', 'appendix', 'supplementary', 'thrombotic', 'complete', 'secondary', 'list', 'S2', 'S3', 'and']",['bleeding'],,,,
311,310,fewer patients were needed to show superiority for this outcome .,需要更少的患者来显示该结果的优势。,0.25,"['outcome', 'superiority', 'this', 'to']",['outcome'],310,['需要更少的患者来表现出这种结果的优越性。'],0.5,"['outcome', 'superiority', 'this', 'to']","['outcome', 'superiority']",310,少数病人就能显示出这一结果的优势。,0.25,"['outcome', 'superiority', 'this', 'to']",['outcome'],,,,
312,311,"accounting for withdrawals and for approximately 200 patients enrolled before the May 2012 protocol amendment , we planned to include 2700 patients .",考虑到退出以及 2012 年 5 月方案修订前入组的大约 200 名患者，我们计划纳入 2700 名患者。,0.1666666666666666,"['protocol', 'approximately', 'before', 'and', 'amendment', 'we']",['before'],311,"['考虑到撤销和在2012年5月议定书修正案之前注册的约200名患者,我们计划包括2700名患者。']",0.5,"['protocol', 'approximately', 'before', 'and', 'amendment', 'we']","['protocol', 'before', 'amendment']",311,约2700名病人计划接受研究，其中包括200名在2012年5月协议修订前已经加入的病人。这些病人中有提前退出研究的，也有已经接受了治疗的。,0.3333333333333333,"['protocol', 'approximately', 'before', 'and', 'amendment', 'we']","['protocol', 'before']",,,,
313,312,"the end of the primary PCI procedure was defined as time 0 , irrespective of when randomization took place .",主要 PCI 程序的结束定义为时间 0，与随机化发生的时间无关。,0.375,"['procedure', 'defined', 'randomization', 'time', 'primary', 'end', 'irrespective', 'as']","['procedure', 'randomization', 'time']",312,"['初始 PCI 程序的结束被定义为时间 0,无论随机化发生什么时候。']",0.375,"['procedure', 'defined', 'randomization', 'time', 'primary', 'end', 'irrespective', 'as']","['procedure', 'randomization', 'time']",312,结束主要PCI程序的时间被定义为0，而不管随机化何时发生。,0.375,"['procedure', 'defined', 'randomization', 'time', 'primary', 'end', 'irrespective', 'as']","['procedure', 'randomization', 'time']",,,,
314,313,"owing to the logistics of obtaining informed consent , obtaining genotyping results , and ( if necessary ) switching the P2Y12 inhibitor , outcome events during the first 24 hours after primary PCI were excluded from the primary analysis .",由于获得知情同意、获得基因分型结果和（如有必要）更换 P2Y12 抑制剂的后勤工作，直接 PCI 后最初 24 小时内的结果事件被排除在主要分析之外。,0.3333333333333333,"['inhibitor', 'analysis', 'outcome', 'primary', 'necessary', 'logistics', 'after', 'informed consent', 'switching', 'if', 'and', 'first']","['inhibitor', 'analysis', 'outcome', 'after']",313,"['由于获得已知同意的物流,获得基因组结果,并(如有必要)更换P2Y12抑制剂,在初始PCI后的第一个24小时内的结果事件被排除在初始分析中。']",0.4166666666666667,"['inhibitor', 'analysis', 'outcome', 'primary', 'necessary', 'logistics', 'after', 'informed consent', 'switching', 'if', 'and', 'first']","['inhibitor', 'analysis', 'outcome', 'after', 'first']",313,由于获得知情同意、获得基因分型结果和（如果需要的话）切换P2Y12抑制剂的后勤工作，在初级PCI后的头24小时内的结果事件被排除在主要分析之外。,0.3333333333333333,"['inhibitor', 'analysis', 'outcome', 'primary', 'necessary', 'logistics', 'after', 'informed consent', 'switching', 'if', 'and', 'first']","['inhibitor', 'analysis', 'outcome', 'after']",,,,
315,314,"if noninferiority was confirmed , superiority was assessed .",如果确认非劣效性，则评估优效性。,0.0,"['superiority', 'if', 'assessed']",[],314,['如果不低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于'],0.0,"['superiority', 'if', 'assessed']",[],314,如果确认了非劣效性，就评估了优势。,0.0,"['superiority', 'if', 'assessed']",[],,,,
316,315,both primary outcomes were also assessed in 26 prespecified subgroups .,两项主要结果也在 26 个预先指定的亚组中进行了评估。,0.0,"['primary', 'in', 'assessed']",[],315,['两项初级结果也被评估在26个预定子组中。'],0.0,"['primary', 'in', 'assessed']",[],315,这26个预先确定的亚组中，两个主要结果也同样进行了评估。,0.0,"['primary', 'in', 'assessed']",[],,,,
317,316,two sensitivity analyses were planned .,计划进行两项敏感性分析。,0.5,"['sensitivity', 'two']",['two'],316,['有两次敏感性分析。'],0.5,"['sensitivity', 'two']",['two'],316,两个敏感性分析计划。,0.5,"['sensitivity', 'two']",['two'],,,,
318,317,"the first included events during the 24 hours after primary PCI , and the second analysis involved stratification according to center .",第一个包括直接 PCI 后 24 小时内的事件，第二个分析涉及根据中心进行分层。,0.5,"['stratification', 'analysis', 'primary', 'after', 'to center', 'second', 'and', 'first']","['stratification', 'analysis', 'after', 'first']",317,"['首先包括在初始PCI后的24小时内发生的事件,第二次分析涉及根据中心的分裂。']",0.5,"['stratification', 'analysis', 'primary', 'after', 'to center', 'second', 'and', 'first']","['analysis', 'after', 'second', 'first']",317,第一个分析涵盖了主动脉PCI手术后24小时内的事件，第二个分析则根据医疗中心进行了分层。,0.5,"['stratification', 'analysis', 'primary', 'after', 'to center', 'second', 'and', 'first']","['stratification', 'analysis', 'after', 'first']",,,,
319,318,"confidence intervals for secondary outcomes have not been adjusted for multiple comparisons , and therefore inferences drawn from these intervals may not be reproducible .",次要结果的置信区间尚未针对多重比较进行调整，因此从这些区间得出的推论可能无法重现。,0.125,"['multiple', 'be', 'secondary', 'confidence', 'have not', 'therefore', 'and', 'intervals']",['have not'],318,"['二次结果的信任间隔未适用于多次比较,因此从这些间隔中提取的结论可能无法重复。']",0.125,"['multiple', 'be', 'secondary', 'confidence', 'have not', 'therefore', 'and', 'intervals']",['have not'],318,结果的置信区间未经过多重比较的调整，因此从这些区间得出的推断可能无法重现。,0.125,"['multiple', 'be', 'secondary', 'confidence', 'have not', 'therefore', 'and', 'intervals']",['have not'],,,,
320,319,"data were analyzed with R software , version 3.6.0 ( R Foundation for Statistical Computing ) .",使用 R 软件 3.6.0 版（R 统计计算基金会）分析数据。,0.4,"['data', 'version', 'software', 'with', 'foundation']","['data', 'software']",319,"['数据被分析使用 R 软件,版本 3.6.0 (R 统计计算基金会) 。']",0.6,"['data', 'version', 'software', 'with', 'foundation']","['data', 'version', 'software']",319,数据是用R软件分析的，版本号是3.6.0（R Foundation for Statistical Computing）。,0.6,"['data', 'version', 'software', 'with', 'foundation']","['data', 'version', 'software']",,,,
321,320,"from June 2011 through April 2018 , a total of 2751 patients were randomly assigned to a treatment group ( Figure 1 ) .",从 2011 年 6 月到 2018 年 4 月，共有 2751 名患者被随机分配到治疗组（图 1）。,0.5,"['1', 'figure', 'total', 'treatment group']","['1', 'treatment group']",320,"['从2011年6月到2018年4月,共有2751名患者随机分配给治疗小组(图1)。']",0.25,"['1', 'figure', 'total', 'treatment group']",['1'],320,2011年6月至2018年4月，共计2751名病人随机分配到治疗组（见图1）。,0.5,"['1', 'figure', 'total', 'treatment group']","['1', 'treatment group']",,,,
322,321,a screening log was kept at only one center ; the records of those patients screened are shown in Table S4 in the Supplementary Appendix .,只有一个中心保存了筛选日志；这些筛查患者的记录见补充附录表 S4。,0.375,"['center', 'appendix', 'table', 'screening', 'supplementary', 'log', 'at', 'S4']","['center', 'table', 'screening']",321,['扫描日志只保留在一个中心;扫描的患者的记录显示在附件中的表 S4 。'],0.375,"['center', 'appendix', 'table', 'screening', 'supplementary', 'log', 'at', 'S4']","['center', 'appendix', 'table']",321,只有一个中心保留了筛查日志; 在补充附录的表S4中显示了筛查的患者的记录。,0.375,"['center', 'appendix', 'table', 'screening', 'supplementary', 'log', 'at', 'S4']","['center', 'table', 'screening']",,,,
323,322,"patients who underwent duplicate randomization in error , those who withdrew consent , and those who were enrolled before the protocol amendment of May 2012 were excluded from all analyses .",接受错误重复随机分组的患者、撤回同意的患者以及在 2012 年 5 月方案修订前入组的患者均被排除在所有分析之外。,0.4,"['duplicate', 'randomization', 'who', 'protocol', 'error', 'consent', 'all', 'before', 'in', 'amendment']","['randomization', 'error', 'consent', 'before']",322,['经过双重随机化错误的患者、撤回同意的患者以及在2012年5月的议定书修正案之前注册的患者被排除在所有分析中。'],0.6,"['duplicate', 'randomization', 'who', 'protocol', 'error', 'consent', 'all', 'before', 'in', 'amendment']","['randomization', 'protocol', 'error', 'consent', 'before', 'amendment']",322,"patients who underwent duplicate randomization in error, those who withdrew consent, and those who were enrolled before the protocol amendment of May 2012 were excluded from all analyses.

Chinese:

错误进行了两次随机化的患者、退出研究的患者和2012年5月份协议修订前已经入组的患者均被排除在分析之外。",0.4,"['duplicate', 'randomization', 'who', 'protocol', 'error', 'consent', 'all', 'before', 'in', 'amendment']","['randomization', 'protocol', 'error', 'before']",,,,
324,323,"Table S7 in the Supplementary Appendix provides an overview of the genotype results , and Table S8 provides an overview of the intervals from symptom onset to the time that a patient was receiving the recommended therapy .",补充附录中的表 S7 概述了基因型结果，表 S8 概述了从症状发作到患者接受推荐治疗的时间间隔。,0.5,"['symptom', 'appendix', 'table', 'genotype', 'supplementary', 'time', 'therapy', 'onset', 'patient', 'that', 'and', 'intervals']","['symptom', 'table', 'genotype', 'time', 'therapy', 'patient']",323,"['附件中的S7表提供了基因组结果的概述,S8表提供了从症状开始到患者接受推荐治疗的时间间隔的概述。']",0.5833333333333334,"['symptom', 'appendix', 'table', 'genotype', 'supplementary', 'time', 'therapy', 'onset', 'patient', 'that', 'and', 'intervals']","['symptom', 'appendix', 'table', 'time', 'therapy', 'onset', 'patient']",323,表S7位于补充附录中，提供基因型结果的概览，表S8提供症状开始到患者接受推荐治疗的时间间隔的概览。,0.5833333333333334,"['symptom', 'appendix', 'table', 'genotype', 'supplementary', 'time', 'therapy', 'onset', 'patient', 'that', 'and', 'intervals']","['symptom', 'table', 'genotype', 'time', 'therapy', 'onset', 'patient']",,,,
325,324,Table 3 shows a full list of bleeding outcomes .,表 3 显示了完整的出血结果列表。,0.6,"['bleeding', 'table', 'list', '3', 'full']","['bleeding', 'table', 'full']",324,['图3显示出出血结果的完整列表。'],0.6,"['bleeding', 'table', 'list', '3', 'full']","['bleeding', 'table', 'full']",324,表3显示了完整的出血结果列表。,0.6,"['bleeding', 'table', 'list', '3', 'full']","['bleeding', 'table', 'full']",,,,
326,325,analyses of the primary outcomes were performed in prespecified subgroups .,主要结果的分析在预先指定的亚组中进行。,0.0,"['primary', 'in']",[],325,['初始结果的分析是在预定子组中进行的。'],0.0,"['primary', 'in']",[],325,分析结果在事先确定的子群体中进行了分析。,0.0,"['primary', 'in']",[],,,,
327,326,there are two key findings from this trial .,该试验有两个关键发现。,0.5,"['key', 'trial', 'this', 'two']","['key', 'two']",326,['这次审判中有两个关键结论。'],0.75,"['key', 'trial', 'this', 'two']","['key', 'trial', 'two']",326,"There are two key findings from this trial.

Chinese:

这项试验有两个主要发现。",0.25,"['key', 'trial', 'this', 'two']",['two'],,,,
328,327,"we chose to incorporate only major bleeding , which has an effect on morbidity and mortality similar to that of thrombotic outcomes.29",我们选择仅纳入大出血，其对发病率和死亡率的影响与血栓形成结果相似。 29,0.2307692307692307,"['bleeding', 'morbidity', 'thrombotic', 'major', 'mortality', 'incorporate', 'effect', 'on', 'that', 'to', 'and', 'similar', 'we']","['bleeding', 'morbidity', 'mortality']",327,"['我们选择只包含重大出血,这对病率和死亡率产生类似于血管结果的影响。']",0.2307692307692307,"['bleeding', 'morbidity', 'thrombotic', 'major', 'mortality', 'incorporate', 'effect', 'on', 'that', 'to', 'and', 'similar', 'we']","['bleeding', 'mortality', 'to']",327,我们选择只纳入主要出血，这种出血对疾病和死亡的影响与血栓性结果相似。29,0.0769230769230769,"['bleeding', 'morbidity', 'thrombotic', 'major', 'mortality', 'incorporate', 'effect', 'on', 'that', 'to', 'and', 'similar', 'we']",['bleeding'],,,,
329,328,"furthermore , although earlier trials consistently showed a lower incidence of minor bleeding with clopidogrel than with prasugrel or ticagrelor , this effect was not seen for major bleeding.3,4,22,28","此外，尽管较早的试验一致表明氯吡格雷的小出血发生率低于普拉格雷或替格瑞洛，但在大出血中未见这种效应。 3,4,22,28",0.4545454545454545,"['bleeding', 'incidence', 'clopidogrel', 'minor', 'lower', 'major', 'effect', 'with', 'prasugrel', 'this', 'earlier']","['bleeding', 'incidence', 'clopidogrel', 'effect', 'prasugrel']",328,"['除此之外,虽然以前的研究一致表明,与克洛皮多格勒相比,较少的出血的发病率较低,但在主要出血的情况下,这种效果并没有被观察到。']",0.2727272727272727,"['bleeding', 'incidence', 'clopidogrel', 'minor', 'lower', 'major', 'effect', 'with', 'prasugrel', 'this', 'earlier']","['bleeding', 'incidence', 'effect']",328,"此外，尽管早期的试验一直显示克洛匹多格雷比普拉苏格尔或西卡格雷尔的次要出血发生率低，但对重度出血的影响并不明显。3,4,22,28",0.1818181818181818,"['bleeding', 'incidence', 'clopidogrel', 'minor', 'lower', 'major', 'effect', 'with', 'prasugrel', 'this', 'earlier']","['bleeding', 'incidence']",,,,
330,329,our data confirm this finding .,我们的数据证实了这一发现。,0.5,"['data', 'this']",['data'],329,['我们的数据证实了这一发现。'],0.5,"['data', 'this']",['data'],329,我们的数据证实了这个发现。,0.5,"['data', 'this']",['data'],,,,
331,330,"moreover , there are more polymorphisms of the CYP2C19 gene , although most are very rare , 13 that may be associated with increased thrombotic or bleeding risk .",此外，CYP2C19 基因还有更多多态性，尽管大多数非常罕见，13 这可能与血栓形成或出血风险增加有关。,0.375,"['bleeding', 'gene', 'thrombotic', 'be', 'associated', 'risk', 'with', 'that']","['bleeding', 'gene', 'risk']",330,"['此外,有更多的CYP2C19基因的聚合物,虽然大多数是非常罕见的,13可能与增加的血管或出血风险有关。']",0.375,"['bleeding', 'gene', 'thrombotic', 'be', 'associated', 'risk', 'with', 'that']","['bleeding', 'gene', 'risk']",330,此外，CYP2C19基因的多态性更多，尽管大多数非常罕见，13种可能与血栓形成或出血风险增加相关。,0.375,"['bleeding', 'gene', 'thrombotic', 'be', 'associated', 'risk', 'with', 'that']","['bleeding', 'gene', 'risk']",,,,
332,331,"however , data on these other alleles are conflicting.33",然而，关于这些其他等位基因的数据是相互矛盾的。 33,0.6666666666666666,"['data', 'alleles', 'on']","['data', 'alleles']",331,"['但是,这些其他阿尔及利亚的数据是矛盾的。']",0.3333333333333333,"['data', 'alleles', 'on']",['data'],331,然而，这些其他的等位基因的数据是相互矛盾的。33,0.6666666666666666,"['data', 'alleles', 'on']","['data', 'alleles']",,,,
333,332,"therefore , our strategy based solely on the CYP2C19 genotype may not be the most useful strategy for some patients .",因此，我们仅基于 CYP2C19 基因型的策略对于某些患者可能不是最有用的策略。,0.4,"['strategy', 'genotype', 'be', 'on', 'therefore']","['strategy', 'genotype']",332,"['因此,我们的基于CYP2C19基因组的策略可能不是一些患者最有用的策略。']",0.2,"['strategy', 'genotype', 'be', 'on', 'therefore']",['strategy'],332,因此，我们基于CYP2C19基因型的策略可能并不适用于某些患者。,0.4,"['strategy', 'genotype', 'be', 'on', 'therefore']","['strategy', 'genotype']",,,,
334,333,the primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes .,主要结果是心力衰竭住院总人数和心血管原因死亡的综合结果。,0.5,"['composite', 'cardiovascular', 'outcome', 'death', 'total', 'heart failure', 'primary', 'and']","['cardiovascular', 'outcome', 'death', 'heart failure']",333,['主要结果是心脏失败和心血管原因死亡的整体医院的组成部分。'],0.375,"['composite', 'cardiovascular', 'outcome', 'death', 'total', 'heart failure', 'primary', 'and']","['cardiovascular', 'outcome', 'death']",333,主要结果是心脏衰竭的总住院人数和心血管原因的死亡人数的综合。,0.375,"['composite', 'cardiovascular', 'outcome', 'death', 'total', 'heart failure', 'primary', 'and']","['cardiovascular', 'outcome', 'death']",,,,
335,334,heart failure with preserved ejection fraction is common and is associated with substantial morbidity and mortality.1,射血分数保留的心力衰竭很常见，并且与大量的发病率和死亡率相关。 1,0.375,"['morbidity', 'heart failure', 'common', 'associated', 'with', 'ejection fraction', 'and', 'substantial']","['morbidity', 'heart failure', 'ejection fraction']",334,"['心脏衰竭与保存的排泄分裂是常见的,并与严重的疾病和死亡率有关。']",0.0,"['morbidity', 'heart failure', 'common', 'associated', 'with', 'ejection fraction', 'and', 'substantial']",[],334,心力衰竭伴保留排出分数是很常见的，并且与相当大的致残率和死亡率相关。1,0.125,"['morbidity', 'heart failure', 'common', 'associated', 'with', 'ejection fraction', 'and', 'substantial']",['heart failure'],,,,
336,335,"several physiological mechanisms have been postulated , including myocardial hypertrophy and fibrosis , 2 impaired diastolic compliance and relaxation , 3 subclinical systolic dysfunction , 4 and renal dysfunction leading to elevated intracardiac filling pressures , fluid retention , and exercise intolerance .",已经假设了几种生理机制，包括心肌肥大和纤维化、2 舒张顺应性和松弛受损、3 亚临床收缩功能障碍、4 和肾功能障碍导致心内充盈压升高、体液潴留和运动不耐受。,0.4166666666666667,"['dysfunction', 'relaxation', 'filling', 'hypertrophy', 'intolerance', 'retention', '2', 'fibrosis', 'compliance', 'fluid', 'intracardiac', 'exercise', 'subclinical', 'diastolic', 'renal', 'systolic', 'myocardial', '3', '4', 'physiological', 'impaired', 'leading', 'have', 'and']","['relaxation', 'hypertrophy', 'intolerance', 'retention', '2', 'fibrosis', 'compliance', 'fluid', 'exercise', 'impaired']",335,"['多种生理机制已被推断,包括心血管高血压和纤维,2受损的神经合规和放松,3次临床神经功能障碍,4次和肾功能障碍导致上升的心血管填充压力,液体保持和运动不耐受。']",0.2916666666666667,"['dysfunction', 'relaxation', 'filling', 'hypertrophy', 'intolerance', 'retention', '2', 'fibrosis', 'compliance', 'fluid', 'intracardiac', 'exercise', 'subclinical', 'diastolic', 'renal', 'systolic', 'myocardial', '3', '4', 'physiological', 'impaired', 'leading', 'have', 'and']","['relaxation', 'intolerance', 'retention', '2', 'fluid', 'exercise', 'impaired']",335,至少有几种生理机制可能导致心肌增厚和纤维化、2受损的舒张期供应和松弛、3亚临床的心脏收缩功能障碍、4以及导致心脏内填充压力升高、液体滞留和运动耐受性下降的肾脏功能障碍。,0.4166666666666667,"['dysfunction', 'relaxation', 'filling', 'hypertrophy', 'intolerance', 'retention', '2', 'fibrosis', 'compliance', 'fluid', 'intracardiac', 'exercise', 'subclinical', 'diastolic', 'renal', 'systolic', 'myocardial', '3', '4', 'physiological', 'impaired', 'leading', 'have', 'and']","['relaxation', '2', 'fibrosis', 'fluid', 'exercise', 'subclinical', 'diastolic', 'systolic', 'impaired', 'have']",,,,
337,336,"the steering committee designed and oversaw the conduct of the trial and data analysis , in collaboration with the sponsor , Novartis .",指导委员会与申办方诺华公司合作，设计并监督了试验的实施和数据分析。,0.4,"['data', 'analysis', 'sponsor', 'steering', 'committee', 'trial', 'conduct', 'collaboration', 'with', 'and']","['data', 'analysis', 'committee', 'collaboration']",336,"['管理委员会设计并监督审查和数据分析的进行,与赞助商诺瓦蒂斯合作。']",0.4,"['data', 'analysis', 'sponsor', 'steering', 'committee', 'trial', 'conduct', 'collaboration', 'with', 'and']","['data', 'analysis', 'committee', 'collaboration']",336,"The steering committee designed and oversaw the conduct of the trial and data analysis, in collaboration with the sponsor, Novartis.

Chinese:

负责委员会设计并监督了试验的进行和数据分析，并与主办方诺贝特合作。",0.4,"['data', 'analysis', 'sponsor', 'steering', 'committee', 'trial', 'conduct', 'collaboration', 'with', 'and']","['data', 'analysis', 'committee', 'collaboration']",,,,
338,337,ethics committee approval was provided at each trial center .,每个试验中心都提供了伦理委员会的批准。,0.4285714285714285,"['center', 'approval', 'ethics', 'committee', 'trial', 'at', 'each']","['center', 'approval', 'committee']",337,['伦理委员会批准在每个审判中心提供。'],0.5714285714285714,"['center', 'approval', 'ethics', 'committee', 'trial', 'at', 'each']","['center', 'approval', 'committee', 'trial']",337,在每个试验中心都获得了伦理委员会的批准。,0.4285714285714285,"['center', 'approval', 'ethics', 'committee', 'trial', 'at', 'each']","['center', 'approval', 'committee']",,,,
339,338,an independent data and safety monitoring committee monitored trial conduct and patient safety .,一个独立的数据和安全监督委员会负责监督试验的实施和患者的安全。,0.5555555555555556,"['safety', 'monitoring', 'data', 'committee', 'patient', 'trial', 'independent', 'conduct', 'and']","['safety', 'data', 'committee', 'patient', 'independent']",338,['一个独立的数据和安全监测委员会监测了试验行为和患者安全。'],0.6666666666666666,"['safety', 'monitoring', 'data', 'committee', 'patient', 'trial', 'independent', 'conduct', 'and']","['safety', 'monitoring', 'data', 'committee', 'patient', 'independent']",338,一个独立的数据和安全监测委员会监督实验进行和病人安全。,0.6666666666666666,"['safety', 'monitoring', 'data', 'committee', 'patient', 'trial', 'independent', 'conduct', 'and']","['safety', 'monitoring', 'data', 'committee', 'patient', 'independent']",,,,
340,339,"data were collected , managed , and analyzed by the sponsor and corroborated by an independent academic statistician .",数据由申办者收集、管理和分析，并由独立的学术统计学家证实。,0.8,"['data', 'sponsor', 'independent', 'by', 'and']","['data', 'sponsor', 'independent', 'by']",339,"['数据由赞助商收集、管理和分析,并由独立的学术统计学家验证。']",0.6,"['data', 'sponsor', 'independent', 'by', 'and']","['data', 'independent', 'by']",339,数据是由赞助商收集，管理和分析的，并由独立的学术统计师进行了核实。,0.6,"['data', 'sponsor', 'independent', 'by', 'and']","['data', 'independent', 'by']",,,,
341,340,"the first draft of the manuscript was prepared by the first author , who had complete access to the data .",手稿的初稿由第一作者编写，他可以完全访问数据。,0.4,"['data', 'who', 'author', 'access', 'complete', 'manuscript', 'by', 'to', 'first', 'draft']","['data', 'manuscript', 'by', 'first']",340,"['手稿的第一个草案是由第一位作者编写的,他完全访问了数据。']",0.4,"['data', 'who', 'author', 'access', 'complete', 'manuscript', 'by', 'to', 'first', 'draft']","['data', 'manuscript', 'by', 'first']",340,第一稿由第一作者准备，他有完整的数据访问权限。,0.4,"['data', 'who', 'author', 'access', 'complete', 'manuscript', 'by', 'to', 'first', 'draft']","['data', 'complete', 'by', 'first']",,,,
342,341,"all the authors made the decision to submit the manuscript for publication and vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol , available with the full text of this article at NEJM.org .",所有作者都决定投稿发表，并保证数据的准确性和完整性以及试验对方案的忠实度，方案与本文全文可在 NEJM.org 获取。,0.3529411764705882,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'publication', 'available', 'manuscript', 'trial', 'text', 'decision', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'publication', 'decision', 'completeness', 'full']",341,"['所有作者都决定提交手稿,以便出版,以确保数据的准确性和完整性以及审判对议定书的忠诚性,并在NEJM.org上提供本文的完整文本。']",0.5294117647058824,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'publication', 'available', 'manuscript', 'trial', 'text', 'decision', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'protocol', 'publication', 'manuscript', 'trial', 'decision', 'completeness', 'full']",341,所有作者都决定将论文提交给刊物发表，并为数据的准确性和完整性以及试验方案的忠实性提供保证，全文可在NEJM.org上找到。,0.4705882352941176,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'publication', 'available', 'manuscript', 'trial', 'text', 'decision', 'completeness', 'with', 'full', 'all', 'this', 'and']","['fidelity', 'data', 'accuracy', 'protocol', 'publication', 'decision', 'completeness', 'full']",,,,
343,342,"eligibility requirements at screening included an age of 50 years or older , signs and symptoms of heart failure , NYHA class II to IV , an ejection fraction of 45 % or higher within the previous 6 months , elevated level of natriuretic peptides ( with different cutoffs depending on the occurrence of recent hospitalization for heart failure and the presence of atrial fibrillation or flutter ) , evidence of structural heart disease , and diuretic therapy .",筛选的资格要求包括年龄 50 岁或以上，心力衰竭的体征和症状，NYHA II 至 IV 级，射血分数在过去 6 个月内为 45 % 或更高，钠尿肽水平升高（不同的截止值取决于关于最近因心力衰竭住院的发生和心房颤动或扑动的存在）、结构性心脏病的证据和利尿剂治疗。,0.7083333333333334,"['presence', 'diuretic', 'class', 'recent', 'heart disease', 'screening', 'occurrence', 'previous', 'symptoms', 'hospitalization', 'therapy', 'heart failure', 'signs', 'atrial fibrillation', 'structural', 'age', 'flutter', 'level', 'evidence', 'with', 'IV', 'ejection fraction', 'and', 'natriuretic']","['presence', 'diuretic', 'class', 'heart disease', 'screening', 'occurrence', 'hospitalization', 'therapy', 'heart failure', 'atrial fibrillation', 'structural', 'age', 'flutter', 'level', 'evidence', 'ejection fraction', 'natriuretic']",342,"['筛查资格要求包括50岁及以上的年龄,心脏衰竭的迹象和症状,NYHA II 至 IV 类,在过去 6 个月内排泄率为 45% 或更高,<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>']",0.0833333333333333,"['presence', 'diuretic', 'class', 'recent', 'heart disease', 'screening', 'occurrence', 'previous', 'symptoms', 'hospitalization', 'therapy', 'heart failure', 'signs', 'atrial fibrillation', 'structural', 'age', 'flutter', 'level', 'evidence', 'with', 'IV', 'ejection fraction', 'and', 'natriuretic']","['screening', 'age']",342,"筛选条件包括年龄50岁或以上，心力衰竭的症状和体征，NYHA第II至IV级，过去6个月内的射血分数为45％或以上，纳汤利尿肽水平升高（根据最近因心力衰竭住院和存在房颤或房扑的情况有所不同），心脏结构性疾病的证据，以及利尿疗法。

Chinese:

年龄在50岁及以上，出现心脏衰竭的症状和体征，NYHA分级在II至IV级，在过去6个月内的射血分数为45%或以上，纳汤利尿肽水平升高（根据最近因心脏衰竭住院的情况和存在房颤或房扑的情况有所不同），心脏结构性疾病的证据，以及利尿疗法是筛选条件。",0.5,"['presence', 'diuretic', 'class', 'recent', 'heart disease', 'screening', 'occurrence', 'previous', 'symptoms', 'hospitalization', 'therapy', 'heart failure', 'signs', 'atrial fibrillation', 'structural', 'age', 'flutter', 'level', 'evidence', 'with', 'IV', 'ejection fraction', 'and', 'natriuretic']","['presence', 'class', 'screening', 'occurrence', 'hospitalization', 'therapy', 'heart failure', 'structural', 'age', 'level', 'evidence', 'ejection fraction']",,,,
344,343,"detailed inclusion and exclusion criteria are provided in Table S1 in the Supplementary Appendix , available at NEJM.org .",补充附录表 S1 中提供了详细的纳入和排除标准，补充附录可在 NEJM.org 获取。,0.1111111111111111,"['appendix', 'table', 'inclusion', 'supplementary', 'exclusion', 'available', 'at', 'S1', 'and']",['table'],343,"['详细的包含和排除标准在附加附件中的表 S1 中提供,可在NEJM.org上找到。']",0.3333333333333333,"['appendix', 'table', 'inclusion', 'supplementary', 'exclusion', 'available', 'at', 'S1', 'and']","['appendix', 'table', 'inclusion']",343,详细的包含和排除标准列在表S1中的附录中。可在NEJM.org上找到。,0.2222222222222222,"['appendix', 'table', 'inclusion', 'supplementary', 'exclusion', 'available', 'at', 'S1', 'and']","['table', 'inclusion']",,,,
345,344,patients were evaluated at trial visits every 4 to 16 weeks .,每 4 至 16 周在试诊时对患者进行评估。,0.0,"['trial', '4', 'at', 'to']",[],344,['患者每4至16周进行试验访问。'],0.0,"['trial', '4', 'at', 'to']",[],344,病人在试验期间的每4到16周的访问中进行了评估。,0.0,"['trial', '4', 'at', 'to']",[],,,,
346,345,the dose of the trial drugs could be adjusted down if the target dose led to unacceptable side effects .,如果目标剂量导致不可接受的副作用，则可以下调试验药物的剂量。,0.4545454545454545,"['down', 'drugs', 'side effects', 'be', 'target', 'trial', 'unacceptable', 'dose', 'if', 'to', 'led']","['drugs', 'side effects', 'target', 'unacceptable', 'dose']",345,"['测试药物的剂量可以调整,如果目标剂量导致不可接受的副作用。']",0.4545454545454545,"['down', 'drugs', 'side effects', 'be', 'target', 'trial', 'unacceptable', 'dose', 'if', 'to', 'led']","['drugs', 'side effects', 'target', 'unacceptable', 'dose']",345,如果目标剂量导致不能接受的副作用，试验药物的剂量可以适当降低。,0.3636363636363636,"['down', 'drugs', 'side effects', 'be', 'target', 'trial', 'unacceptable', 'dose', 'if', 'to', 'led']","['drugs', 'side effects', 'target', 'dose']",,,,
347,346,the primary outcome was a composite of total ( first and recurrent ) hospitalizations for heart failure and death from cardiovascular causes .,主要结果是因心力衰竭住院总（首次和复发）和心血管原因死亡的综合结果。,0.4,"['composite', 'cardiovascular', 'outcome', 'death', 'total', 'heart failure', 'recurrent', 'primary', 'and', 'first']","['cardiovascular', 'outcome', 'death', 'heart failure']",346,['初始结果是心脏衰竭和心血管原因死亡的总体(第一和重复)医院的组成。'],0.4,"['composite', 'cardiovascular', 'outcome', 'death', 'total', 'heart failure', 'recurrent', 'primary', 'and', 'first']","['cardiovascular', 'outcome', 'death', 'first']",346,第一项结果是心力衰竭和心血管原因导致的总住院和死亡。,0.5,"['composite', 'cardiovascular', 'outcome', 'death', 'total', 'heart failure', 'recurrent', 'primary', 'and', 'first']","['cardiovascular', 'outcome', 'death', 'heart failure', 'first']",,,,
348,347,all the outcomes except KCCQ score and NYHA class were blindly adjudicated according to prespecified criteria ( Section 5 in the Supplementary Appendix ) .,除 KCCQ 评分和 NYHA 分级外，所有结果均根据预先指定的标准（补充附录第 5 部分）进行盲法判定。,0.2,"['5', 'class', 'appendix', 'section', 'supplementary', 'score', 'all', 'in', 'to', 'and']","['5', 'class']",347,"['除 KCCQ 分数和 NYHA 等级外,所有结果都按预定标准(附件第 5 节)进行盲目评估。']",0.4,"['5', 'class', 'appendix', 'section', 'supplementary', 'score', 'all', 'in', 'to', 'and']","['5', 'class', 'appendix', 'score']",347,所有结果除了 KCCQ 评分和 NYHA 级别外，都是按照预先制定的标准进行盲审的（补充附录中的第 5 节）。,0.2,"['5', 'class', 'appendix', 'section', 'supplementary', 'score', 'all', 'in', 'to', 'and']","['5', 'class']",,,,
349,348,"hypotension , renal dysfunction , hyperkalemia , and angioedema were prespecified adverse events of interest ; angioedema was adjudicated by a separate committee .",低血压、肾功能不全、高钾血症和血管性水肿是预先指定的不良事件；血管性水肿由一个单独的委员会裁定。,0.4444444444444444,"['dysfunction', 'hypotension', 'adverse', 'hyperkalemia', 'renal', 'committee', 'separate', 'by', 'and']","['hypotension', 'hyperkalemia', 'committee', 'by']",348,['低血压、肾功能障碍、高血压和腹泻被预定为有兴趣的负面事件;腹泻由一个单独的委员会提交。'],0.3333333333333333,"['dysfunction', 'hypotension', 'adverse', 'hyperkalemia', 'renal', 'committee', 'separate', 'by', 'and']","['hypotension', 'committee', 'by']",348,低血压、肾功能不全、高钾血症和水肿是预先指定的有意义的不良事件；水肿经由单独的委员会进行裁决。,0.4444444444444444,"['dysfunction', 'hypotension', 'adverse', 'hyperkalemia', 'renal', 'committee', 'separate', 'by', 'and']","['hypotension', 'hyperkalemia', 'committee', 'by']",,,,
350,349,the primary efficacy outcome was evaluated with the use of the semiparametric proportional rates method of Lin et al.13 and a joint gamma frailty model14 stratified according to geographic region .,使用 Lin 等人 13 的半参数比例率方法和根据地理区域分层的联合伽玛衰弱模型 14 评估了主要疗效结果。,0.3636363636363636,"['joint', 'outcome', 'region', 'primary', 'gamma', 'geographic', 'efficacy', 'method', 'with', 'to', 'and']","['joint', 'outcome', 'region', 'gamma']",349,['初级效能结果通过使用Lin et al.13的半参数比例率方法和根据地理区域分布的组合Gamma frailty模型14进行评估。'],0.2727272727272727,"['joint', 'outcome', 'region', 'primary', 'gamma', 'geographic', 'efficacy', 'method', 'with', 'to', 'and']","['outcome', 'region', 'efficacy']",349,使用Lin et al.13的半参数比例速率方法和14年的共同伽马弱点模型对主要疗效进行了评估，并根据地理区域进行了分层。,0.0909090909090909,"['joint', 'outcome', 'region', 'primary', 'gamma', 'geographic', 'efficacy', 'method', 'with', 'to', 'and']",['region'],,,,
351,350,"there was one interim analysis , with an adjusted alpha level of 0.048 for the final analysis .",有一项中期分析，最终分析的调整后 alpha 水平为 0.048。,0.5,"['analysis', 'alpha', 'level', 'with']","['analysis', 'level']",350,"['有一个临时分析,最终分析的调整阿尔法水平为0.048。']",0.5,"['analysis', 'alpha', 'level', 'with']","['analysis', 'level']",350,"There was one interim analysis, with an adjusted alpha level of 0.048 for the final analysis.

Chinese:

结果显示，第一个临时分析结果具有显著性，最终分析的结果经过调整后的显著水平为0.048。",0.5,"['analysis', 'alpha', 'level', 'with']","['analysis', 'level']",,,,
352,351,we assessed the consistency of the treatment effect among 12 prespecified subgroups that were analyzed individually and then in a multivariable model .,我们评估了 12 个预先指定的亚组的治疗效果的一致性，这些亚组分别进行了分析，然后在多变量模型中进行了分析。,0.375,"['model', 'consistency', 'treatment effect', 'that', 'in', 'and', 'assessed', 'we']","['model', 'consistency', 'treatment effect']",351,"['我们评估了12个预定子组中的治疗效果的一致性,这些子组单独分析,然后在多样化的模型中进行分析。']",0.375,"['model', 'consistency', 'treatment effect', 'that', 'in', 'and', 'assessed', 'we']","['model', 'consistency', 'treatment effect']",351,我们评估了12个预先规定的子群体中治疗效果的一致性，并分别对其进行了单变量分析和多变量模型分析。,0.375,"['model', 'consistency', 'treatment effect', 'that', 'in', 'and', 'assessed', 'we']","['model', 'consistency', 'treatment effect']",,,,
353,352,"if the primary outcome reached significance , a hierarchical , sequentially rejective procedure was planned for the analysis of secondary efficacy outcomes , with the alpha level split equally between KCCQ score and NYHA class , followed by the renal composite outcome .",如果主要结果达到显着性，则计划采用分层、顺序拒绝程序来分析次要疗效结果，α 水平在 KCCQ 评分和 NYHA 分级之间平均分配，然后是肾脏综合结果。,0.3529411764705882,"['composite', 'procedure', 'class', 'analysis', 'outcome', 'alpha', 'primary', 'renal', 'significance', 'secondary', 'efficacy', 'score', 'level', 'with', 'split', 'by', 'and']","['procedure', 'class', 'analysis', 'outcome', 'alpha', 'level']",352,"['如果初始结果取得了意义,则为分析二进制效率结果进行了序列拒绝程序,阿尔法级别在KCCQ分数和NYHA级别之间均匀分裂,随后由肾合成结果进行。']",0.4117647058823529,"['composite', 'procedure', 'class', 'analysis', 'outcome', 'alpha', 'primary', 'renal', 'significance', 'secondary', 'efficacy', 'score', 'level', 'with', 'split', 'by', 'and']","['procedure', 'class', 'analysis', 'outcome', 'significance', 'score', 'by']",352,如果主要结果达到意义，则计划对二级效能结果进行分层次拒绝程序分析，将α水平平分为KCCQ评分和NYHA级别，然后是肾脏综合结果。,0.4705882352941176,"['composite', 'procedure', 'class', 'analysis', 'outcome', 'alpha', 'primary', 'renal', 'significance', 'secondary', 'efficacy', 'score', 'level', 'with', 'split', 'by', 'and']","['procedure', 'class', 'analysis', 'outcome', 'alpha', 'significance', 'efficacy', 'level']",,,,
354,353,"confidence intervals for the secondary and exploratory efficacy outcomes have not been adjusted for multiplicity , and therefore inferences drawn from these intervals may not be reproducible .",次要和探索性疗效结果的置信区间尚未针对多重性进行调整，因此从这些区间得出的推论可能无法重现。,0.2,"['be', 'exploratory', 'secondary', 'efficacy', 'multiplicity', 'confidence', 'have not', 'therefore', 'and', 'intervals']","['multiplicity', 'have not']",353,"['二级和探测效能结果的信任间隔未被调整为多样性,因此从这些间隔中提取的结论可能无法重复。']",0.3,"['be', 'exploratory', 'secondary', 'efficacy', 'multiplicity', 'confidence', 'have not', 'therefore', 'and', 'intervals']","['exploratory', 'efficacy', 'have not']",353,统计学置信区间的计算没有考虑多重性，因此从这些区间得出的结论可能不可重现。,0.1,"['be', 'exploratory', 'secondary', 'efficacy', 'multiplicity', 'confidence', 'have not', 'therefore', 'and', 'intervals']",['multiplicity'],,,,
355,354,additional information regarding the statistical analysis is provided in the Supplementary Appendix .,补充附录中提供了有关统计分析的更多信息。,0.5,"['appendix', 'supplementary', 'regarding', 'information', 'additional', 'statistical analysis']","['regarding', 'information', 'statistical analysis']",354,['有关统计分析的详细信息在附件中提供。'],0.6666666666666666,"['appendix', 'supplementary', 'regarding', 'information', 'additional', 'statistical analysis']","['appendix', 'regarding', 'information', 'statistical analysis']",354,附加信息有关统计分析可在附件中找到。,0.6666666666666666,"['appendix', 'supplementary', 'regarding', 'information', 'additional', 'statistical analysis']","['appendix', 'regarding', 'information', 'statistical analysis']",,,,
356,355,"from July 18 , 2014 , through December 16 , 2016 , we screened 10,359 patients at 848 centers in 43 countries ( Figure 1 ) .","从 2014 年 7 月 18 日到 2016 年 12 月 16 日，我们在 43 个国家/地区的 848 个中心对 10,359 名患者进行了筛查（图 1）。",0.2,"['1', 'figure', 'at', 'in', 'we']",['1'],355,"['从2014年7月18日至2016年12月16日,我们在43个国家的848个中心检查了10359名患者(图1)。']",0.2,"['1', 'figure', 'at', 'in', 'we']",['1'],355,从2014年7月18日至2016年12月16日，我们在43个国家的848个中心对10359名患者进行了筛查（图1）。,0.2,"['1', 'figure', 'at', 'in', 'we']",['1'],,,,
357,356,"a total of 26 patients were excluded from all efficacy analyses because they had been enrolled at a site that was closed for major violations of Good Clinical Practice , so 4796 patients were included in the efficacy analysis .",共有 26 名患者被排除在所有疗效分析之外，因为他们入组的地点因严重违反良好临床实践而关闭，因此 4796 名患者被纳入疗效分析。,0.2,"['site', 'analysis', 'good clinical practice', 'total', 'major', 'efficacy', 'closed', 'all', 'that', 'so']","['site', 'analysis']",356,"['总共有26名患者被排除在所有有效性分析中,因为他们被注册在一个被关闭严重违反良好的临床实践的网站上,因此4796名患者被列入有效性分析中。']",0.2,"['site', 'analysis', 'good clinical practice', 'total', 'major', 'efficacy', 'closed', 'all', 'that', 'so']","['analysis', 'efficacy']",356,总共有26名患者因参加的试验中心违反了良好临床实践，而被排除在外，所以有4796人参加了有效性分析。,0.2,"['site', 'analysis', 'good clinical practice', 'total', 'major', 'efficacy', 'closed', 'all', 'that', 'so']","['analysis', 'efficacy']",,,,
358,357,"because this difference did not meet the predetermined level of statistical significance , subsequent analyses were considered to be exploratory .",由于这种差异没有达到预定的统计显着性水平，因此后续分析被认为是探索性的。,0.4285714285714285,"['difference', 'be', 'exploratory', 'subsequent', 'statistical significance', 'level', 'this']","['difference', 'level', 'this']",357,"['由于这种差异不符合预定水平的统计意义,后来的分析被认为是探索性的。']",0.4285714285714285,"['difference', 'be', 'exploratory', 'subsequent', 'statistical significance', 'level', 'this']","['difference', 'level', 'this']",357,因为这个差异没有达到预先设定的统计学显著性水平，随后的分析被认为是探索性的。,0.4285714285714285,"['difference', 'be', 'exploratory', 'subsequent', 'statistical significance', 'level', 'this']","['difference', 'level', 'this']",,,,
359,358,components of the primary outcome are shown in Table 2 .,表 2 显示了主要结果的组成部分。,0.6,"['table', '2', 'outcome', 'primary', 'in']","['table', '2', 'outcome']",358,['主要结果的组成部分在图2中显示。'],0.4,"['table', '2', 'outcome', 'primary', 'in']","['2', 'outcome']",358,"The components of the primary outcome are shown in Table 2.

Chinese:

主要结果的组成部分如表2所示。",0.6,"['table', '2', 'outcome', 'primary', 'in']","['table', '2', 'outcome']",,,,
360,359,the prespecified sensitivity analyses of the primary outcome are shown in Tables S2 and S3 in the Supplementary Appendix .,主要结局的预设敏感性分析见补充附录表 S2 和表 S3。,0.0,"['appendix', 'outcome', 'supplementary', 'primary', 'sensitivity', 'S2', 'S3', 'in', 'and']",[],359,['初始结果的预定敏感性分析在附件中的 S2 和 S3 表中显示。'],0.2222222222222222,"['appendix', 'outcome', 'supplementary', 'primary', 'sensitivity', 'S2', 'S3', 'in', 'and']","['appendix', 'outcome']",359,表S2和表S3显示了对主要终点的预先规定的敏感性分析。,0.0,"['appendix', 'outcome', 'supplementary', 'primary', 'sensitivity', 'S2', 'S3', 'in', 'and']",[],,,,
361,360,the primary outcome in the 12 prespecified subgroups is shown in Figure 3 .,12 个预设亚组的主要结果如图 3 所示。,0.2,"['outcome', 'figure', 'primary', '3', 'in']",['outcome'],360,['预定12个子组的主要结果显示在图3中。'],0.2,"['outcome', 'figure', 'primary', '3', 'in']",['outcome'],360,在预先规定的12个分组中，主要结果如图3所示。,0.2,"['outcome', 'figure', 'primary', '3', 'in']",['outcome'],,,,
362,361,"in a multivariable model that accounted for all potential interactions and that used continuous measures when appropriate , there was suggestion of heterogeneity of treatment effect with possible benefit in patients with lower ejection fraction and in women ( Table S4 in the Supplementary Appendix ) .",在一个考虑了所有潜在相互作用并在适当时使用连续测量的多变量模型中，表明治疗效果的异质性可能对射血分数较低的患者和女性有益（补充附录表 S4）。,0.3888888888888889,"['suggestion', 'heterogeneity', 'appendix', 'model', 'table', 'potential', 'continuous', 'supplementary', 'lower', 'treatment effect', 'benefit', 'with', 'ejection fraction', 'S4', 'all', 'that', 'and', 'appropriate']","['heterogeneity', 'model', 'table', 'continuous', 'lower', 'treatment effect', 'ejection fraction']",361,"['在多样化的模型中,考虑到所有可能的相互作用,并在适当情况下使用持续的措施,在患有较低排泄分的患者和妇女中提出了可能有益的治疗效果的异常性(附件中的S4表)。']",0.2777777777777778,"['suggestion', 'heterogeneity', 'appendix', 'model', 'table', 'potential', 'continuous', 'supplementary', 'lower', 'treatment effect', 'benefit', 'with', 'ejection fraction', 'S4', 'all', 'that', 'and', 'appropriate']","['suggestion', 'appendix', 'model', 'table', 'treatment effect']",361,在考虑到所有可能的相互作用并使用连续测量的多变量模型中，有迹象表明治疗效应存在异质性，可能对心功能不全程度较低的患者和女性有益（表S4在补充附录）。,0.2777777777777778,"['suggestion', 'heterogeneity', 'appendix', 'model', 'table', 'potential', 'continuous', 'supplementary', 'lower', 'treatment effect', 'benefit', 'with', 'ejection fraction', 'S4', 'all', 'that', 'and', 'appropriate']","['heterogeneity', 'model', 'table', 'continuous', 'lower']",,,,
363,362,"the most frequent serious adverse events and adverse events are summarized in Tables S5 and S6 , respectively , in the Supplementary Appendix .",补充附录的表 S5 和表 S6 分别总结了最常见的严重不良事件和不良事件。,0.0,"['appendix', 'supplementary', 'adverse', 'serious', 'in', 'frequent', 'and']",[],362,"['最常见的严重不良事件和不良事件在表 S5 和 S6,分别,在附件中总结。']",0.1428571428571428,"['appendix', 'supplementary', 'adverse', 'serious', 'in', 'frequent', 'and']",['appendix'],362,"The most frequent serious adverse events and adverse events are summarized in Tables S5 and S6, respectively, in the Supplementary Appendix.",0.0,"['appendix', 'supplementary', 'adverse', 'serious', 'in', 'frequent', 'and']",[],,,,
364,363,the primary composite outcome of total hospitalizations for heart failure and death from cardiovascular causes did not differ significantly between the two groups .,两组因心力衰竭住院总人数和心血管原因死亡的主要复合结局没有显着差异。,0.4,"['composite', 'cardiovascular', 'outcome', 'death', 'total', 'heart failure', 'primary', 'differ', 'and', 'two']","['cardiovascular', 'death', 'heart failure', 'two']",363,['心脏衰竭和心血管原因死亡的总入院的主要组成结果在两组之间没有显著的差异。'],0.4,"['composite', 'cardiovascular', 'outcome', 'death', 'total', 'heart failure', 'primary', 'differ', 'and', 'two']","['cardiovascular', 'outcome', 'death', 'two']",363,两组总的心脏衰竭住院和心血管原因死亡的主要组合结果并没有显著差异。,0.5,"['composite', 'cardiovascular', 'outcome', 'death', 'total', 'heart failure', 'primary', 'differ', 'and', 'two']","['cardiovascular', 'outcome', 'death', 'total', 'two']",,,,
365,364,the findings from nine prespecified supportive and sensitivity analyses were consistent with those from the primary analysis .,九项预先指定的支持性和敏感性分析的结果与主要分析的结果一致。,0.2,"['analysis', 'primary', 'with', 'sensitivity', 'and']",['analysis'],364,['9个预定支持和敏感性分析的结果与初始分析的结果一致。'],0.2,"['analysis', 'primary', 'with', 'sensitivity', 'and']",['analysis'],364,九項預先確定的支持性和敏感性分析的發現與主要分析結果一致。,0.2,"['analysis', 'primary', 'with', 'sensitivity', 'and']",['analysis'],,,,
366,365,"patients with heart failure and preserved ejection fraction are phenotypically heterogeneous , 15 and our data raise the possibility of a differential treatment effect in the broad population studied .",心力衰竭和射血分数保留的患者在表型上是异质的， 15 并且我们的数据提高了在所研究的广泛人群中存在差异治疗效果的可能性。,0.5833333333333334,"['population', 'differential', 'data', 'heterogeneous', 'raise', 'heart failure', 'broad', 'treatment effect', 'with', 'ejection fraction', 'in', 'and']","['population', 'data', 'heterogeneous', 'raise', 'heart failure', 'treatment effect', 'ejection fraction']",365,"['患有心脏衰竭和保存的排泄分裂的患者是异常的,15和我们的数据提高了对广泛研究的人口的差异治疗效果的可能性。']",0.3333333333333333,"['population', 'differential', 'data', 'heterogeneous', 'raise', 'heart failure', 'broad', 'treatment effect', 'with', 'ejection fraction', 'in', 'and']","['population', 'data', 'raise', 'treatment effect']",365,"heart failure patients with preserved ejection fraction are phenotypically heterogeneous, and our data suggest that there may be a different therapeutic effect in this broad population.",0.0,"['population', 'differential', 'data', 'heterogeneous', 'raise', 'heart failure', 'broad', 'treatment effect', 'with', 'ejection fraction', 'in', 'and']",[],,,,
367,366,"other diseases , such as amyloid cardiomyopathy , may account for the reduced responsiveness with higher ejection fraction.21",其他疾病，如淀粉样变性心肌病，可能是射血分数较高时反应性降低的原因。 21,0.3333333333333333,"['ejection', 'amyloid', 'cardiomyopathy', 'responsiveness', 'as', 'with']","['cardiomyopathy', 'as']",366,"['其他疾病,如甲状腺心脏病,可能导致低反应性与更高的排泄分裂。']",0.1666666666666666,"['ejection', 'amyloid', 'cardiomyopathy', 'responsiveness', 'as', 'with']",['as'],366,其他疾病，例如淀粉样心肌病，可能是导致高心排出率下降的原因之一。21,0.3333333333333333,"['ejection', 'amyloid', 'cardiomyopathy', 'responsiveness', 'as', 'with']","['cardiomyopathy', 'as']",,,,
368,367,survival was superior in patients with microsatellite instability versus microsatellite stability .,微卫星不稳定性患者的生存率优于微卫星稳定性患者。,0.5,"['survival', 'superior', 'instability', 'with']","['survival', 'instability']",367,['生存率在微型卫星不稳定性患者比微型卫星稳定性患者更好。'],0.5,"['survival', 'superior', 'instability', 'with']","['survival', 'instability']",367,Patients with microsatellite instability had better survival rates than those with microsatellite stability.,0.0,"['survival', 'superior', 'instability', 'with']",[],,,,
369,368,microsatellite instability ( MSI ) is a favorable prognostic marker but is present in less than 10 % of gastric cancers .,微卫星不稳定性 (MSI) 是一种有利的预后标志物，但存在于不到 10% 的胃癌中。,0.3333333333333333,"['gastric', 'marker', 'prognostic', 'present', 'instability', 'but']","['instability', 'but']",368,"['微卫星不稳定性(MSI)是一种有利的预测标志,但在胃癌中存在不到10%。']",0.5,"['gastric', 'marker', 'prognostic', 'present', 'instability', 'but']","['prognostic', 'instability', 'but']",368,微小卫星不稳定性（MSI）是一个有利的预后标志，但只有10％以下的胃癌患者表现出这种情况。,0.5,"['gastric', 'marker', 'prognostic', 'present', 'instability', 'but']","['present', 'instability', 'but']",,,,
370,369,"given the uncommon presence of MSI , its impact on the outcome of adjuvant therapy in locally advanced gastric cancer has not been clearly defined .",鉴于 MSI 并不常见，其对局部晚期胃癌辅助治疗结果的影响尚未明确。,0.375,"['presence', 'defined', 'outcome', 'impact', 'adjuvant therapy', 'advanced', 'gastric cancer', 'on']","['outcome', 'impact', 'gastric cancer']",369,"['鉴于MSI的异常存在,其对当地先进胃癌补充治疗结果的影响尚未清楚地定义。']",0.5,"['presence', 'defined', 'outcome', 'impact', 'adjuvant therapy', 'advanced', 'gastric cancer', 'on']","['presence', 'outcome', 'impact', 'gastric cancer']",369,"Given the uncommon presence of MSI, its impact on the outcome of adjuvant therapy in locally advanced gastric cancer has not been clearly defined.

Chinese:

鉴于MSI的不常见性，其对局部晚期胃癌的化疗疗效的影响尚不明确。",0.25,"['presence', 'defined', 'outcome', 'impact', 'adjuvant therapy', 'advanced', 'gastric cancer', 'on']","['impact', 'gastric cancer']",,,,
371,370,MSI status was available from 1556 patients ( 71 % men ; 63 % Asian ; 37 % European ) .,MSI 状态可从 1556 名患者（71% 男性；63% 亚洲人；37% 欧洲人）获得。,0.5,"['status', 'available']",['status'],370,['MSI状态可用于1556名患者(71%男性、63%亚洲人、37%欧洲人)。'],0.5,"['status', 'available']",['status'],370,"MSI status was available from 1556 patients ( 71 % men ; 63 % Asian ; 37 % European ) .

Chinese:

MSI 状态可以从 1556 位患者获得 ( 71% 是男性 ; 63% 是亚洲人 ; 37% 是欧洲人 ) 。",0.5,"['status', 'available']",['status'],,,,
372,371,MSI was present in 121 ( 7.8 % ) of patients .,121 名 (7.8%) 患者存在 MSI。,0.0,"['present', 'in']",[],371,['MSI在121(7.8%)的患者中存在。'],0.0,"['present', 'in']",[],371,"MSI was present in 121 ( 7.8 % ) of patients .

Chinese:

在病人中，有121人（7.8%）存在MSI。",0.0,"['present', 'in']",[],,,,
373,372,"of all patients , 45 % had intestinal histology , 71 % underwent surgery and chemotherapy with or without radiation therapy , and 29 % underwent surgery alone .",在所有患者中，45% 有肠道组织学，71% 接受过手术和化疗，有或没有放疗，29% 只接受过手术。,0.25,"['chemotherapy', 'surgery', 'radiation therapy', 'histology', 'all', 'and', 'alone', 'without']","['chemotherapy', 'surgery']",372,"['在所有患者中,45%患有肠道歇斯托利,71%接受手术和化疗,放射治疗或没有,29%单独接受手术。']",0.375,"['chemotherapy', 'surgery', 'radiation therapy', 'histology', 'all', 'and', 'alone', 'without']","['chemotherapy', 'surgery', 'alone']",372,所有患者中，45%患有肠道组织学问题，71%接受了手术和化疗（有无放疗），而29%仅接受了手术治疗。,0.5,"['chemotherapy', 'surgery', 'radiation therapy', 'histology', 'all', 'and', 'alone', 'without']","['chemotherapy', 'surgery', 'and', 'without']",,,,
374,373,"a benefit for chemotherapy added to surgery was seen in MSS patients compared with MSI patients ( DFS , 77 % vs. 70 % ; OS , 83 % vs , 75 % ) , suggesting a potential survival detriment for chemotherapy in MSI patients .",与 MSI 患者相比，在 MSS 患者中观察到手术联合化疗的获益（DFS，77% 对 70%；OS，83% 对 75%），这表明 MSI 患者化疗可能对生存不利。,0.4444444444444444,"['chemotherapy', 'survival', 'potential', 'surgery', 'detriment', 'benefit', 'with', 'in', 'to']","['chemotherapy', 'survival', 'surgery', 'benefit']",373,"['与 MSI 患者相比,MSS 患者(DFS,77% vs.70%;OS,83% vs.75%)对手术添加的化疗有好处,这表明MSI 患者对化疗有潜在的生存损害。']",0.4444444444444444,"['chemotherapy', 'survival', 'potential', 'surgery', 'detriment', 'benefit', 'with', 'in', 'to']","['chemotherapy', 'survival', 'potential', 'surgery']",373,在MSS病人中，与MSI病人相比，化疗与手术相结合的好处较明显（DFS，77％ vs. 70％；OS，83％ vs，75％），这表明MSI病人化疗可能会导致生存不良。,0.3333333333333333,"['chemotherapy', 'survival', 'potential', 'surgery', 'detriment', 'benefit', 'with', 'in', 'to']","['chemotherapy', 'survival', 'surgery']",,,,
375,374,there was no difference in survival after recurrence for MSI or MSS cancers .,MSI 或 MSS 癌症复发后的生存率没有差异。,0.5,"['survival', 'difference', 'no', 'after', 'recurrence', 'in']","['survival', 'difference', 'after']",374,['在 MSI 或 MSS 癌症重复后生存中没有差异。'],0.5,"['survival', 'difference', 'no', 'after', 'recurrence', 'in']","['survival', 'difference', 'after']",374,"There was no difference in survival after recurrence for MSI or MSS cancers.

Chinese:

MSI和MSS癌症复发后的生存率无差别。",0.3333333333333333,"['survival', 'difference', 'no', 'after', 'recurrence', 'in']","['survival', 'after']",,,,
376,375,"MSI should now be tested in all patients with locally advanced gastric cancer who are considered for adjuvant chemotherapy , and surgery alone should be considered for MSI patients .",现在应该对所有考虑接受辅助化疗的局部晚期胃癌患者进行 MSI 检测，并且应该考虑对 MSI 患者进行单纯手术。,0.3333333333333333,"['chemotherapy', 'who', 'adjuvant', 'surgery', 'be', 'advanced', 'with', 'gastric cancer', 'all', 'in', 'and', 'alone']","['chemotherapy', 'surgery', 'be', 'gastric cancer']",375,"['MSI 现在应在所有被视为辅助化疗的本地先进胃癌患者进行测试,而单独的手术应被视为 MSI 患者。']",0.5,"['chemotherapy', 'who', 'adjuvant', 'surgery', 'be', 'advanced', 'with', 'gastric cancer', 'all', 'in', 'and', 'alone']","['chemotherapy', 'surgery', 'be', 'gastric cancer', 'and', 'alone']",375,MSI应该在所有考虑使用化疗的局部晚期胃癌患者中进行测试，仅应考虑对MSI患者进行手术。,0.3333333333333333,"['chemotherapy', 'who', 'adjuvant', 'surgery', 'be', 'advanced', 'with', 'gastric cancer', 'all', 'in', 'and', 'alone']","['chemotherapy', 'surgery', 'be', 'gastric cancer']",,,,
377,376,"pregnancy can be considered a physiologic stress test ; as such , it could have value for cardiovascular ( CV ) risk prediction .",怀孕可以被认为是一种生理压力测试；因此，它可能对心血管 (CV) 风险预测具有价值。,0.75,"['pregnancy', 'cardiovascular', 'value', 'be', 'risk', 'stress test', 'physiologic', 'have']","['pregnancy', 'cardiovascular', 'value', 'risk', 'stress test', 'have']",376,"['怀孕可以被视为生理压力测试;因此,它可能对心血管(CV)风险预测有价值。']",0.75,"['pregnancy', 'cardiovascular', 'value', 'be', 'risk', 'stress test', 'physiologic', 'have']","['pregnancy', 'cardiovascular', 'value', 'risk', 'stress test', 'have']",376,妊娠可被视为一种生理上的压力测试，因此，它可能具有预测心血管风险的价值。,0.75,"['pregnancy', 'cardiovascular', 'value', 'be', 'risk', 'stress test', 'physiologic', 'have']","['pregnancy', 'cardiovascular', 'value', 'risk', 'stress test', 'have']",,,,
378,377,monitor blood pressure per the most recent American Heart Association guidelines,根据最新的美国心脏协会指南监测血压,0.4,"['heart', 'monitor', 'recent', 'association', 'blood pressure']","['heart', 'blood pressure']",377,['根据美国心脏协会最新指南监测血压'],0.4,"['heart', 'monitor', 'recent', 'association', 'blood pressure']","['heart', 'blood pressure']",377,根据最新的美国心脏协会指南，监测血压。,0.4,"['heart', 'monitor', 'recent', 'association', 'blood pressure']","['heart', 'blood pressure']",,,,
379,378,promote healthy lifestyle and weight,促进健康的生活方式和体重,0.6666666666666666,"['weight', 'and', 'healthy']","['weight', 'healthy']",378,['促进健康的生活方式和体重'],0.6666666666666666,"['weight', 'and', 'healthy']","['weight', 'healthy']",378,促进健康的生活方式和体重,0.6666666666666666,"['weight', 'and', 'healthy']","['weight', 'healthy']",,,,
380,379,"assess lipid profiles and fasting glucose levels , with lifestyle modification if abnormal , followed by medication management as appropriate",评估血脂和空腹血糖水平，如果异常则改变生活方式，然后酌情进行药物管理,0.25,"['modification', 'glucose', 'lipid', 'abnormal', 'medication', 'fasting', 'assess', 'management', 'with', 'by', 'and', 'appropriate']","['abnormal', 'assess', 'management']",379,"['评估脂肪配置和禁食糖水平,如果不正常的话,生活方式的变化,随后适当的药物管理。']",0.1666666666666666,"['modification', 'glucose', 'lipid', 'abnormal', 'medication', 'fasting', 'assess', 'management', 'with', 'by', 'and', 'appropriate']","['assess', 'management']",379,"Assess lipid profiles and fasting glucose levels, with lifestyle modification if abnormal, followed by medication management as appropriate.",0.0,"['modification', 'glucose', 'lipid', 'abnormal', 'medication', 'fasting', 'assess', 'management', 'with', 'by', 'and', 'appropriate']",[],,,,
381,380,perform oral glucose tolerance testing for women with histories of gestational diabetes,对有妊娠糖尿病病史的妇女进行口服葡萄糖耐量试验,0.2857142857142857,"['diabetes', 'glucose', 'oral', 'tolerance', 'gestational', 'testing', 'with']","['diabetes', 'glucose']",380,['在怀孕糖尿病史的妇女进行口服葡萄糖容忍测试'],0.4285714285714285,"['diabetes', 'glucose', 'oral', 'tolerance', 'gestational', 'testing', 'with']","['diabetes', 'glucose', 'tolerance']",380,对有妊娠糖尿病史的女性进行口服葡萄糖耐量测试。,0.2857142857142857,"['diabetes', 'glucose', 'oral', 'tolerance', 'gestational', 'testing', 'with']","['diabetes', 'glucose']",,,,
382,381,"apply postpartum screening practices from multiple disciplines ( i.e. , obstetrics , maternal fetal medicine , primary care , cardiology , nutrition , exercise physiology )",应用来自多个学科的产后筛查实践（即产科、母胎医学、初级保健、心脏病学、营养学、运动生理学）,0.6153846153846154,"['maternal', 'nutrition', 'medicine', 'screening', 'fetal', 'multiple', 'obstetrics', 'primary', 'postpartum', 'cardiology', 'apply', 'care', 'exercise physiology']","['maternal', 'nutrition', 'medicine', 'screening', 'obstetrics', 'postpartum', 'cardiology', 'apply']",381,"['应用来自多学科的产后筛查实践(即,生育学,母胎医学,初级护理,心脏学,营养学,锻炼生理学)']",0.5384615384615384,"['maternal', 'nutrition', 'medicine', 'screening', 'fetal', 'multiple', 'obstetrics', 'primary', 'postpartum', 'cardiology', 'apply', 'care', 'exercise physiology']","['maternal', 'nutrition', 'medicine', 'screening', 'postpartum', 'cardiology', 'apply']",381,应用多学科的产后筛查实践（如妇产科、产科风险管理、主要保健、心脏病、营养、运动生理学）。,0.3846153846153846,"['maternal', 'nutrition', 'medicine', 'screening', 'fetal', 'multiple', 'obstetrics', 'primary', 'postpartum', 'cardiology', 'apply', 'care', 'exercise physiology']","['nutrition', 'screening', 'obstetrics', 'postpartum', 'apply']",,,,
383,382,"although CV disease is the leading cause of death among U.S. women , risk factors often are modifiable .",尽管心血管疾病是美国女性死亡的主要原因，但风险因素通常是可以改变的。,0.5,"['disease', 'risk', 'cause of death', 'leading']","['disease', 'risk']",382,"['虽然CV疾病是美国妇女死亡的主要原因,但风险因素往往是可改变的。']",0.5,"['disease', 'risk', 'cause of death', 'leading']","['disease', 'risk']",382,尽管心血管疾病是美国女性的主要死因，但风险因素往往可以通过改变生活方式来控制。,0.75,"['disease', 'risk', 'cause of death', 'leading']","['disease', 'risk', 'cause of death']",,,,
384,383,"however , spironolactone causes hyperkalemia - and thus is relatively contraindicated - in patients with renal dysfunction .",然而，螺内酯会引起高钾血症，因此在肾功能不全的患者中是相对禁忌的。,0.5,"['dysfunction', 'contraindicated', 'hyperkalemia', 'renal', 'thus', 'with', '-', 'and']","['contraindicated', 'hyperkalemia', 'thus', 'and']",383,"['然而,Spironolactone在患有肾功能障碍的患者中会导致高血压 - 因此相对应。']",0.25,"['dysfunction', 'contraindicated', 'hyperkalemia', 'renal', 'thus', 'with', '-', 'and']","['thus', 'and']",383,然而，氯普诺兰醇会导致高钾血症，因此在肾功能不全的患者中相对禁忌。,0.5,"['dysfunction', 'contraindicated', 'hyperkalemia', 'renal', 'thus', 'with', '-', 'and']","['contraindicated', 'hyperkalemia', 'thus', 'and']",,,,
385,384,the primary endpoint - the proportion of patients still taking spironolactone at 12 weeks - occurred significantly more frequently with patiromer than with placebo ( 86 % vs. 66 % ) .,主要终点——12 周时仍在服用螺内酯的患者比例——在 patiromer 组中发生的频率明显高于安慰剂组（86% 对 66%）。,0.3,"['proportion', 'placebo', 'taking', 'frequently', 'still', 'primary', 'with', 'endpoint', 'at', '-']","['proportion', 'placebo', 'at']",384,['初级终点 - 患者在12周内仍然服用Spironolactone的比例 - 与Pirodomer相比显著更频繁(86%与66%)。'],0.1,"['proportion', 'placebo', 'taking', 'frequently', 'still', 'primary', 'with', 'endpoint', 'at', '-']",['proportion'],384,主要终点 - 12周时仍服用spironolactone的患者比例 - 发生在使用patiromer的患者中更频繁（86％对66％）。,0.1,"['proportion', 'placebo', 'taking', 'frequently', 'still', 'primary', 'with', 'endpoint', 'at', '-']",['proportion'],,,,
386,385,"spironolactone was stopped due to hyperkalemia ( persistent potassium level , ≥ 5.5 mmol / L ) less frequently with patiromer than with placebo ( 7 % vs. 23 % ) .",螺内酯因高钾血症（持续钾水平，≥ 5.5 mmol/L）而停药的频率低于安慰剂组（7% 对 23%）。,0.5,"['persistent', 'placebo', 'potassium', '/', 'frequently', 'hyperkalemia', 'level', 'due', 'with', 'to']","['placebo', 'potassium', 'hyperkalemia', 'level', 'to']",385,"['spironolactone 因高<unk>症(持久的<unk>含量 ≥ 5.5 mmol / L )而被停止,比Pirodomer更少(7 % vs. 23 % )。']",0.0,"['persistent', 'placebo', 'potassium', '/', 'frequently', 'hyperkalemia', 'level', 'due', 'with', 'to']",[],385,"spironolactone was stopped due to hyperkalemia (persistent potassium level, ≥5.5 mmol/L) less frequently with patiromer than with placebo (7% vs. 23%).",0.0,"['persistent', 'placebo', 'potassium', '/', 'frequently', 'hyperkalemia', 'level', 'due', 'with', 'to']",[],,,,
387,386,mean systolic blood pressure decreased by about 11 mm Hg during the study .,研究期间平均收缩压降低了约 11 毫米汞柱。,0.2,"['mean', 'study', 'blood pressure', 'systolic', 'by']",['mean'],386,['研究期间平均血压下降约11毫米Hg。'],0.4,"['mean', 'study', 'blood pressure', 'systolic', 'by']","['mean', 'blood pressure']",386,在研究期间，平均收缩压平均下降了11毫米汞柱。,0.2,"['mean', 'study', 'blood pressure', 'systolic', 'by']",['mean'],,,,
388,387,these results indicate that patiromer could facilitate spironolactone use in some patients with resistant hypertension and CKD .,这些结果表明，patiromer 可以促进某些顽固性高血压和 CKD 患者使用螺内酯。,0.1666666666666666,"['hypertension', 'indicate', 'resistant', 'with', 'that', 'and']",['hypertension'],387,"['这些结果表明,Pirodomer可能会在某些患有抵抗性高血压和CKD的患者中促进Spironolactone的使用。']",0.1666666666666666,"['hypertension', 'indicate', 'resistant', 'with', 'that', 'and']",['hypertension'],387,这些结果表明，patiromer可能会促进某些患者使用硝酸镁来抵抗高血压和CKD。,0.1666666666666666,"['hypertension', 'indicate', 'resistant', 'with', 'that', 'and']",['hypertension'],,,,
389,388,"toddlers and parents were more likely to have controlling , intrusive , and isolating behaviors when trying to read a tablet together .",当尝试一起阅读平板电脑时，蹒跚学步的幼儿和父母更有可能产生控制、侵入和孤立行为。,0.3333333333333333,"['parents', 'tablet', 'read', 'have', 'to', 'and']","['read', 'have']",388,['婴儿和父母在试图一起阅读平板电脑时更有可能有控制、侵入和隔离行为。'],0.3333333333333333,"['parents', 'tablet', 'read', 'have', 'to', 'and']","['read', 'have']",388,当试图一起阅读平板电脑时，幼儿和家长很有可能表现出控制性、侵犯性、孤立性的行为。,0.3333333333333333,"['parents', 'tablet', 'read', 'have', 'to', 'and']","['read', 'have']",,,,
390,389,"the American Academy of Pediatrics recommends that parents interact with children using digital devices such as smartphones and tablets , but the character of those interactions has not been described well .",美国儿科学会建议父母使用智能手机和平板电脑等数字设备与孩子互动，但这些互动的特点并未得到很好的描述。,0.25,"['character', 'parents', 'pediatrics', 'digital', 'well', 'academy', 'as', 'with', 'interact', 'that', 'but', 'and']","['character', 'pediatrics', 'but']",389,"['美国儿科学院建议父母使用智能手机和平板电脑等数字设备与孩子互动,但这些互动的性质尚未被描述得很好。']",0.25,"['character', 'parents', 'pediatrics', 'digital', 'well', 'academy', 'as', 'with', 'interact', 'that', 'but', 'and']","['character', 'pediatrics', 'but']",389,"The American Academy of Pediatrics recommends that parents interact with children using digital devices such as smartphones and tablets, but the character of those interactions has not been described well.

Chinese:

美国儿科学会建议父母使用智能手机和平板电脑等数字设备与孩子互动，但这种互动的性质尚未被描述得很清楚。",0.25,"['character', 'parents', 'pediatrics', 'digital', 'well', 'academy', 'as', 'with', 'interact', 'that', 'but', 'and']","['character', 'pediatrics', 'but']",,,,
391,390,the order of books varied randomly among dyads .,书籍的顺序在二人组之间随机变化。,0.3333333333333333,"['order', 'books', 'varied']",['books'],390,['书籍的顺序随机在迪亚德之间有所不同。'],0.3333333333333333,"['order', 'books', 'varied']",['books'],390,在二人组中，书籍的顺序是随机的。,0.3333333333333333,"['order', 'books', 'varied']",['books'],,,,
392,391,the behaviors observed in this study will be recognizable to anyone who has tried to share a digital device with a young child .,任何试图与幼儿共用数字设备的人都会认出本研究中观察到的行为。,0.25,"['who', 'device', 'child', 'study', 'digital', 'be', 'will', 'with', 'young', 'this', 'in', 'to']","['device', 'child', 'young']",391,['在这项研究中观察到的行为将被任何试图与一个年轻的孩子分享一个数字设备的人认可。'],0.25,"['who', 'device', 'child', 'study', 'digital', 'be', 'will', 'with', 'young', 'this', 'in', 'to']","['device', 'child', 'be']",391,这项研究观察到的行为对于任何试图与幼儿共享数字设备的人来说都是熟悉的。,0.4166666666666667,"['who', 'device', 'child', 'study', 'digital', 'be', 'will', 'with', 'young', 'this', 'in', 'to']","['device', 'child', 'young', 'this', 'to']",,,,
393,392,"of these patients , 30 % had class 2 mutations and 70 % had class 3 mutations .",在这些患者中，30% 有 2 类突变，70% 有 3 类突变。,0.25,"['class', '2', '3', 'and']",['2'],392,"['在这些患者中,30%有2级突变,70%有3级突变。']",0.5,"['class', '2', '3', 'and']","['class', '2']",392,这些病人中，有30%患有二级突变，70%患有三级突变。,0.25,"['class', '2', '3', 'and']",['class'],,,,
394,393,oral immunotherapy produces temporary desensitization in most patients but does not cure peanut allergy .,口服免疫疗法可使大多数患者暂时脱敏，但不能治愈花生过敏。,0.5555555555555556,"['peanut', 'desensitization', 'cure', 'temporary', 'immunotherapy', 'allergy', 'oral', 'in', 'but']","['desensitization', 'cure', 'immunotherapy', 'allergy', 'but']",393,"['口服免疫疗法在大多数患者中产生暂时的抑敏,但不治愈胡萝卜过敏。']",0.5555555555555556,"['peanut', 'desensitization', 'cure', 'temporary', 'immunotherapy', 'allergy', 'oral', 'in', 'but']","['cure', 'temporary', 'immunotherapy', 'allergy', 'but']",393,口服免疫疗法能够在大多数病人身上产生暂时的脱敏作用，但并不能治愈花生过敏。,0.6666666666666666,"['peanut', 'desensitization', 'cure', 'temporary', 'immunotherapy', 'allergy', 'oral', 'in', 'but']","['desensitization', 'cure', 'temporary', 'immunotherapy', 'allergy', 'but']",,,,
395,394,patients were randomized to one of three groups :,患者被随机分配到三组中的一组：,0.0,"['three', 'to']",[],394,['病人被随机分配到三组之一:'],0.0,"['three', 'to']",[],394,病人随机分配到三组中的一组：,0.0,"['three', 'to']",[],,,,
396,395,placebo for 3 years,安慰剂 3 年,0.5,"['placebo', '3']",['placebo'],395,['可口可乐3年'],0.0,"['placebo', '3']",[],395,"在我的朋友圈，有一个比我大三岁的姑娘，她患有白血病。我们都知道她身体不好，但是没想到她会坚持治疗这么久。她最近刚刚告诉我，她已经在服用安慰剂（placebo）治疗自己的白血病3年了。

中文：

在我的朋友圈里，有一个比我大三岁的姑娘，她患有白血病。我们都知道她身体不好，但是没想到她会坚持治疗这么久。她最近刚刚告诉我，她已经在服用安慰剂（placebo）治疗自己的白血病3年了。",0.5,"['placebo', '3']",['placebo'],,,,
397,396,"however , during the months after stopping OIT , most patients gradually lost their ability to consume large amounts of peanut protein .",然而，在停止 OIT 后的几个月里，大多数患者逐渐失去了摄入大量花生蛋白的能力。,0.4285714285714285,"['peanut', 'protein', 'large', 'after', 'ability', 'stopping', 'consume']","['protein', 'after', 'ability']",396,"['然而,在停止OIT之后的几个月里,大多数患者逐渐失去了大量的胡萝卜蛋白的消耗能力。']",0.5714285714285714,"['peanut', 'protein', 'large', 'after', 'ability', 'stopping', 'consume']","['protein', 'after', 'ability', 'consume']",396,然而，在停用OIT之后的几个月里，大多数病人逐渐失去了食用大量花生蛋白的能力。,0.4285714285714285,"['peanut', 'protein', 'large', 'after', 'ability', 'stopping', 'consume']","['protein', 'after', 'ability']",,,,
398,397,"on September 13 , 2019 , an FDA advisory committee recommended approval of a peanut OIT .",2019 年 9 月 13 日，FDA 咨询委员会建议批准花生 OIT。,0.4,"['peanut', 'approval', 'FDA', 'committee', 'on']","['approval', 'committee']",397,"['2019年9月13日,一届FDA咨询委员会建议批准一项小麦OIT。']",0.4,"['peanut', 'approval', 'FDA', 'committee', 'on']","['approval', 'committee']",397,2019年9月13日，美国食品药品监督管理局(FDA)的一个顾问委员会推荐批准一种花生OIT（过敏原免疫疗法）。,0.6,"['peanut', 'approval', 'FDA', 'committee', 'on']","['approval', 'FDA', 'committee']",,,,
399,398,"and now , these findings suggest that patients might have to continue OIT indefinitely to maintain their desensitization .",而现在，这些发现表明患者可能必须无限期地继续 OIT 以维持其脱敏作用。,0.5,"['desensitization', 'maintain', 'suggest', 'continue', 'have', 'that', 'to', 'and']","['desensitization', 'maintain', 'continue', 'and']",398,"['现在,这些发现表明,病人可能不得不无限地继续OIT,以保持他们的消毒。']",0.125,"['desensitization', 'maintain', 'suggest', 'continue', 'have', 'that', 'to', 'and']",['continue'],398,现在，这些发现表明，病人可能需要继续进行OIT，以保持他们的去敏感化。,0.125,"['desensitization', 'maintain', 'suggest', 'continue', 'have', 'that', 'to', 'and']",['continue'],,,,
400,399,the two primary end points were overall survival and the percentage of patients who had complete remission with full or partial hematologic recovery .,两个主要终点是总生存期和完全缓解且血液学完全或部分恢复的患者百分比。,0.4285714285714285,"['percentage', 'who', 'survival', 'end points', 'complete', 'recovery', 'primary', 'partial', 'remission', 'with', 'full', 'and', 'two', 'hematologic']","['percentage', 'survival', 'end points', 'recovery', 'remission', 'two']",399,['两个主要终点是整体生存和患有完全或部分血液恢复的患者的百分比。'],0.3571428571428571,"['percentage', 'who', 'survival', 'end points', 'complete', 'recovery', 'primary', 'partial', 'remission', 'with', 'full', 'and', 'two', 'hematologic']","['percentage', 'survival', 'end points', 'recovery', 'two']",399,两个主要终点是总体生存率和完全或部分血液复苏的患者百分比。,0.2857142857142857,"['percentage', 'who', 'survival', 'end points', 'complete', 'recovery', 'primary', 'partial', 'remission', 'with', 'full', 'and', 'two', 'hematologic']","['percentage', 'survival', 'end points', 'two']",,,,
401,400,"of 371 eligible patients , 247 were randomly assigned to the gilteritinib group and 124 to the salvage chemotherapy group .",在 371 名符合条件的患者中，247 名被随机分配到 gilteritinib 组，124 名分配到挽救化疗组。,0.3333333333333333,"['group', 'chemotherapy', 'salvage', 'to', 'and', 'eligible']","['group', 'chemotherapy']",400,"['在371名合格患者中,247人随机分配给吉尔特里蒂尼布群体,124人分配给救生化疗群体。']",0.5,"['group', 'chemotherapy', 'salvage', 'to', 'and', 'eligible']","['group', 'chemotherapy', 'eligible']",400,在371名符合资格的患者中，247人被随机分配给吉列替尼组，124人被分配给救助化疗组。,0.3333333333333333,"['group', 'chemotherapy', 'salvage', 'to', 'and', 'eligible']","['group', 'chemotherapy']",,,,
402,401,"the percentage of patients who had complete remission with full or partial hematologic recovery was 34.0 % in the gilteritinib group and 15.3 % in the chemotherapy group ( risk difference , 18.6 percentage points ; 95 % CI , 9.8 to 27.4 ) ; the percentages with complete remission were 21.1 % and 10.5 % , respectively ( risk difference , 10.6 percentage points ; 95 % CI , 2.8 to 18.4 ) .",完全缓解且血液学完全或部分恢复的患者百分比在吉尔特替尼组为 34.0%，在化疗组为 15.3%（风险差异，18.6 个百分点；95% CI，9.8 至 27.4）；完全缓解的百分比分别为 21.1% 和 10.5%（风险差异，10.6 个百分点；95% CI，2.8 至 18.4）。,0.4375,"['group', 'percentage', 'chemotherapy', 'who', 'difference', 'complete', 'recovery', 'risk', 'partial', 'remission', 'with', 'CI', 'full', 'in', 'and', 'hematologic']","['group', 'percentage', 'chemotherapy', 'difference', 'recovery', 'risk', 'remission']",401,"['患有完全或部分血液康复的患者的百分比在吉尔特里蒂尼布群体中为34.0%,在化疗群体中为15.3%(风险差异、18.6个百分点、95%的CI、9.8到27.4);与完全康复的患者的百分比分别为21.1%和10.5%(风险差异、10.6个百分点、95%的CI、2.8到18.4)。']",0.3125,"['group', 'percentage', 'chemotherapy', 'who', 'difference', 'complete', 'recovery', 'risk', 'partial', 'remission', 'with', 'CI', 'full', 'in', 'and', 'hematologic']","['group', 'percentage', 'chemotherapy', 'difference', 'risk']",401,"在吉利特尼布（gilteritinib）组和化疗组，病人完全缓解并全部或部分康复的百分比分别为34.0％和15.3％（风险差异为18.6个百分点；95％置信区间[CI]为9.8至27.4）；完全缓解的百分比分别为21.1％和10.5％（风险差异为10.6个百分点；95％CI为2.8至18.4）。

Chinese:

在吉利特尼布（gilteritinib）组和化疗组，病人完全缓解并全部或部分康复的百分比分别为34.0%和15.3%（风险差异为18.6个百分点；95%置信区间[CI]为9.8至27.4）；完全缓解的百分比分别为21.1%和10.5%（风险差异为10.6个百分点；95%CI为2.8至18.4）。",0.4375,"['group', 'percentage', 'chemotherapy', 'who', 'difference', 'complete', 'recovery', 'risk', 'partial', 'remission', 'with', 'CI', 'full', 'in', 'and', 'hematologic']","['group', 'percentage', 'chemotherapy', 'difference', 'risk', 'remission', 'full']",,,,
403,402,"in an analysis that was adjusted for therapy duration , adverse events of grade 3 or higher and serious adverse events occurred less frequently in the gilteritinib group than in the chemotherapy group ; the most common adverse events of grade 3 or higher in the gilteritinib group were febrile neutropenia ( 45.9 % ) , anemia ( 40.7 % ) , and thrombocytopenia ( 22.8 % ) .",在针对治疗持续时间进行调整的分析中，gilteritinib 组发生 3 级或更高级别不良事件和严重不良事件的频率低于化疗组； gilteritinib 组最常见的 3 级或更高级别不良事件是发热性中性粒细胞减少症 (45.9%)、贫血 (40.7%) 和血小板减少症 (22.8%)。,0.4117647058823529,"['anemia', 'group', 'chemotherapy', 'febrile', 'analysis', 'grade', 'frequently', 'neutropenia', 'thrombocytopenia', 'common', 'adverse', '3', 'duration', 'serious', 'that', 'in', 'and']","['anemia', 'group', 'chemotherapy', 'analysis', 'neutropenia', 'thrombocytopenia', 'duration']",402,"['在对治疗时间进行调整的分析中,三级或更高的副作用和严重的副作用在吉尔特里蒂尼布群体中比化疗群体中更少发生;在吉尔特里蒂尼布群体中,三级或更高的副作用最常见的是发烧性中风(45.9%)、贫血(40.7%)和血管细胞(22.8%)。']",0.2941176470588235,"['anemia', 'group', 'chemotherapy', 'febrile', 'analysis', 'grade', 'frequently', 'neutropenia', 'thrombocytopenia', 'common', 'adverse', '3', 'duration', 'serious', 'that', 'in', 'and']","['anemia', 'group', 'chemotherapy', 'analysis', 'that']",402,在考虑治疗持续时间、3级或更高级别不良事件以及严重不良事件的分析中，吉列替尼组中发生这些事件的频率低于化疗组；吉列替尼组中最常见的3级或更高级别不良事件是脾脏白血病（45.9%）、贫血（40.7%）和血小板减少症（22.8%）。,0.3529411764705882,"['anemia', 'group', 'chemotherapy', 'febrile', 'analysis', 'grade', 'frequently', 'neutropenia', 'thrombocytopenia', 'common', 'adverse', '3', 'duration', 'serious', 'that', 'in', 'and']","['anemia', 'group', 'chemotherapy', 'analysis', 'thrombocytopenia', 'duration']",,,,
404,403,"however , for patients with relapsed or refractory AML , neither midostaurin nor lestaurtinib has conferred durable clinical benefit as a single agent.13,14,20","然而，对于复发性或难治性 AML 患者，米哚妥林和来他替尼作为单一药物均未带来持久的临床益处。 13,14,20",0.3333333333333333,"['refractory', 'clinical', 'benefit', 'as', 'with', 'single']","['clinical', 'single']",403,"['然而,对于患有逆转或逆转性AML的患者,没有 midostaurin 或 lestaurtinib 作为单一药物提供可持续的临床益处。']",0.3333333333333333,"['refractory', 'clinical', 'benefit', 'as', 'with', 'single']","['clinical', 'single']",403,然而，对于复发或难治性的 AML 患者来说，米多斯特伦或者雷斯特伦比单独使用都没有获得持续的临床益处。13，14，20,0.3333333333333333,"['refractory', 'clinical', 'benefit', 'as', 'with', 'single']","['clinical', 'single']",,,,
405,404,"sorafenib showed clinical activity in patients with AML that was positive for the FLT3 ITD mutation , but data from randomized trials that support its use in that context are scarce.16",索拉非尼在 FLT3 ITD 突变呈阳性的 AML 患者中显示出临床活性，但支持其在这种情况下使用的随机试验数据很少。 16,0.6363636363636364,"['mutation', 'support', 'context', 'data', 'activity', 'clinical', 'with', 'sorafenib', 'positive', 'that', 'but']","['mutation', 'support', 'data', 'activity', 'clinical', 'sorafenib', 'but']",404,"['sorafenib在患有AML的患者中表现出临床活动,这对FLT3 ITD突变是积极的,但在这种情况下支持其使用的随机试验的数据很少。']",0.5454545454545454,"['mutation', 'support', 'context', 'data', 'activity', 'clinical', 'with', 'sorafenib', 'positive', 'that', 'but']","['mutation', 'support', 'data', 'activity', 'clinical', 'but']",404,sorafenib在FLT3 ITD突变阳性的AML患者中显示出了临床活性，但对于支持其在该经济上的随机化试验数据缺乏。16,0.5454545454545454,"['mutation', 'support', 'context', 'data', 'activity', 'clinical', 'with', 'sorafenib', 'positive', 'that', 'but']","['mutation', 'support', 'data', 'activity', 'clinical', 'but']",,,,
406,405,similar resistance is seen with sorafenib.23,类似的耐药性见于索拉非尼。23,0.3333333333333333,"['resistance', 'with', 'similar']",['resistance'],405,['相似的抵抗可见于 sorafenib.23'],0.6666666666666666,"['resistance', 'with', 'similar']","['resistance', 'similar']",405,类似的抗性也出现在索拉非尼药物中。23,0.3333333333333333,"['resistance', 'with', 'similar']",['resistance'],,,,
407,406,"gilteritinib also inhibits the tyrosine kinase AXL , which is implicated in FLT3 inhibitor resistance.26,27","gilteritinib 还抑制酪氨酸激酶 AXL，这与 FLT3 抑制剂耐药性有关。 26,27",1.0,"['inhibitor', 'tyrosine kinase']","['inhibitor', 'tyrosine kinase']",406,['gilteritinib 还抑制甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺'],0.0,"['inhibitor', 'tyrosine kinase']",[],406,"gilteritinib also inhibits the tyrosine kinase AXL, which is implicated in FLT3 inhibitor resistance.26,27

Chinese:

gilteritinib还抑制了与FLT3抗性相关的酪氨酸激酶AXL。26,27",0.5,"['inhibitor', 'tyrosine kinase']",['tyrosine kinase'],,,,
408,407,"the randomized , phase 3 ADMIRAL trial was conducted at 107 centers in 14 countries and was sponsored by Astellas Pharma .",这项随机的 3 期 ADMIRAL 试验在 14 个国家的 107 个中心进行，由 Astellas Pharma 赞助。,0.2857142857142857,"['phase', 'trial', '3', 'at', 'in', 'by', 'and']","['phase', 'by']",407,"['随机,第三阶段的ADMIRAL试验在14个国家的107个中心进行,由Astellas Pharma赞助。']",0.2857142857142857,"['phase', 'trial', '3', 'at', 'in', 'by', 'and']","['phase', 'by']",407,这是一项随机化的、3期的ADMIRAL试验，在14个国家的107个中心进行过，由Astellas Pharma赞助。,0.2857142857142857,"['phase', 'trial', '3', 'at', 'in', 'by', 'and']","['phase', 'by']",,,,
409,408,the trial was reviewed and approved by the institutional review board or ethics committee at each participating center and was conducted in accordance with the principles of the Declaration of Helsinki .,该试验由每个参与中心的机构审查委员会或伦理委员会审查和批准，并根据赫尔辛基宣言的原则进行。,0.3333333333333333,"['center', 'review', 'ethics', 'board', 'committee', 'trial', 'with', 'at', 'each', 'in', 'by', 'and']","['center', 'review', 'committee', 'by']",408,"['审判由各参与中心的机构审查委员会或伦理委员会审查和批准,并按照赫尔辛基宣言的原则进行。']",0.5,"['center', 'review', 'ethics', 'board', 'committee', 'trial', 'with', 'at', 'each', 'in', 'by', 'and']","['center', 'review', 'committee', 'trial', 'each', 'by']",408,该试验经各参与中心的机构审查委员会或伦理委员会审查和批准，并按照《赫尔辛基宣言》的原则进行。,0.3333333333333333,"['center', 'review', 'ethics', 'board', 'committee', 'trial', 'with', 'at', 'each', 'in', 'by', 'and']","['center', 'review', 'committee', 'each']",,,,
410,409,all the patients provided written informed consent at enrollment .,所有患者在入组时均提供了书面知情同意书。,0.0,"['informed consent', 'at', 'all']",[],409,['所有患者在注册时提供书面通知的同意。'],0.0,"['informed consent', 'at', 'all']",[],409,所有病人在入籍时均提供了书面知情同意书。,0.0,"['informed consent', 'at', 'all']",[],,,,
411,410,two authors who were employees of the sponsor designed the trial in collaboration with four academic authors .,作为申办者雇员的两位作者与四位学术作者合作设计了该试验。,0.4285714285714285,"['who', 'sponsor', 'trial', 'collaboration', 'with', 'in', 'two']","['sponsor', 'collaboration', 'two']",410,"['两位作家是赞助商的员工,与四位学术作家合作设计了审判。']",0.4285714285714285,"['who', 'sponsor', 'trial', 'collaboration', 'with', 'in', 'two']","['trial', 'collaboration', 'two']",410,两位作者是该赞助商的员工，与四位学术作者共同设计了这项试验。,0.1428571428571428,"['who', 'sponsor', 'trial', 'collaboration', 'with', 'in', 'two']",['two'],,,,
412,411,all the authors had access to the trial data and were involved in data interpretation .,所有作者都可以访问试验数据并参与数据解释。,0.2857142857142857,"['data', 'access', 'interpretation', 'trial', 'all', 'to', 'and']","['data', 'interpretation']",411,"['所有作者都访问了审判数据,并参与了数据的解释。']",0.4285714285714285,"['data', 'access', 'interpretation', 'trial', 'all', 'to', 'and']","['data', 'interpretation', 'trial']",411,"All the authors had access to the trial data and were involved in data interpretation.

Chinese:
所有作者都可以查看试验数据，并参与数据解释。",0.2857142857142857,"['data', 'access', 'interpretation', 'trial', 'all', 'to', 'and']","['data', 'interpretation']",,,,
413,412,the authors and the sponsor vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol ( available with the full text of this article at NEJM.org ) .,作者和申办方保证数据的完整性和准确性，以及试验对方案的忠实度（与本文全文可在 NEJM.org 获取）。,0.2857142857142857,"['fidelity', 'data', 'accuracy', 'protocol', 'sponsor', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and']","['data', 'accuracy', 'completeness', 'full']",412,['作者和赞助商为数据的完整性和准确性以及审判对议定书的忠诚度(可在NEJM.org上提供本文的完整文本)。'],0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'sponsor', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness', 'full']",412,作者和赞助商保证数据的完整性和准确性，并保证试验与协议的忠实性（在本文的全文中可以在NEJM.org上找到）。,0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'sponsor', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and']","['fidelity', 'data', 'accuracy', 'protocol', 'completeness', 'full']",,,,
414,413,"the first and last authors wrote the manuscript , with additional writing and editorial assistance provided by medical writers who were funded by the sponsor .",第一作者和最后一位作者撰写了手稿，由申办者资助的医学作家提供额外的写作和编辑协助。,0.5454545454545454,"['who', 'sponsor', 'medical', 'manuscript', 'writing', 'additional', 'assistance', 'with', 'by', 'and', 'first']","['sponsor', 'manuscript', 'writing', 'additional', 'by', 'first']",413,"['第一位和最后一位作家写了手稿,由赞助商资助的医学作家提供的额外写作和编辑援助。']",0.4545454545454545,"['who', 'sponsor', 'medical', 'manuscript', 'writing', 'additional', 'assistance', 'with', 'by', 'and', 'first']","['manuscript', 'writing', 'assistance', 'by', 'first']",413,第一位和最后一位作者创作了手稿，其他作者和编辑人员的帮助来自赞助商资助的医疗写作人员。,0.2727272727272727,"['who', 'sponsor', 'medical', 'manuscript', 'writing', 'additional', 'assistance', 'with', 'by', 'and', 'first']","['manuscript', 'writing', 'first']",,,,
415,414,enrollment on the basis of local testing for the FLT3 mutation was permitted for patients with rapidly proliferative disease .,对于患有快速增殖性疾病的患者，允许根据对 FLT3 突变的本地检测进行登记。,0.2857142857142857,"['mutation', 'disease', 'basis', 'local', 'proliferative', 'testing', 'with']","['mutation', 'disease']",414,"['基于本地测试的注册,FLT3突变已被允许在患有快速繁殖性疾病的患者。']",0.4285714285714285,"['mutation', 'disease', 'basis', 'local', 'proliferative', 'testing', 'with']","['mutation', 'disease', 'proliferative']",414,允许基于本地测试结果来招收FLT3突变患者。,0.1428571428571428,"['mutation', 'disease', 'basis', 'local', 'proliferative', 'testing', 'with']",['mutation'],,,,
416,415,FLT3 MUTATIONS,FLT3 突变,,[],[],415,['FLT3 转换'],,[],[],415,"FLT3 Mutations

Chinese: FLT3突變",,[],[],,,,
417,416,patients were required to have FLT3 ITD or TKD D835 or I836 mutations .,要求患者具有 FLT3 ITD 或 TKD D835 或 I836 突变。,0.3333333333333333,"['TKD', 'have', 'to']",['have'],416,['患者需要 FLT3 ITD 或 TKD D835 或 I836 突变。'],0.0,"['TKD', 'have', 'to']",[],416,"Patients were required to have FLT3 ITD or TKD D835 or I836 mutations.

Chinese:

患者必须拥有FLT3 ITD或TKD D835或I836突变。",0.3333333333333333,"['TKD', 'have', 'to']",['have'],,,,
418,417,"the median FLT3 ITD allelic ratio was established at 0.77 , with a high FLT3 ITD allelic ratio defined as 0.77 or greater and a low ratio as less than 0.77 .",中位 FLT3 ITD 等位基因比率确定为 0.77，高 FLT3 ITD 等位基因比率定义为 0.77 或更高，低比率定义为小于 0.77。,0.3333333333333333,"['median', 'defined', 'ratio', 'low', 'allelic', 'as', 'with', 'and', 'high']","['ratio', 'low', 'high']",417,"['平均 FLT3 ITD Allelic 比率为 0.77,高 FLT3 ITD Allelic 比率为 0.77 或更高,低比率为 0.77 。']",0.3333333333333333,"['median', 'defined', 'ratio', 'low', 'allelic', 'as', 'with', 'and', 'high']","['ratio', 'low', 'high']",417,FLT3 ITD allelic ratio的中位数被定为0.77，高FLT3 ITD allelic ratio被定义为0.77或更高，低比率为小于0.77。,0.3333333333333333,"['median', 'defined', 'ratio', 'low', 'allelic', 'as', 'with', 'and', 'high']","['ratio', 'low', 'high']",,,,
419,418,no crossover between treatment groups was permitted .,治疗组之间不允许交叉。,0.5,"['treatment', 'no']",['treatment'],418,['治疗小组之间没有交叉。'],0.5,"['treatment', 'no']",['treatment'],418,不允许治疗组之间的交叉。,0.5,"['treatment', 'no']",['treatment'],,,,
420,419,complete remission with full or partial hematologic recovery was evaluated in an interim analysis in the gilteritinib group only and was summarized in the final analysis for both treatment groups .,完全缓解和完全或部分血液学恢复仅在 gilteritinib 组的中期分析中进行评估，并在两个治疗组的最终分析中进行总结。,0.4166666666666667,"['group', 'analysis', 'complete', 'recovery', 'treatment', 'partial', 'remission', 'with', 'full', 'in', 'and', 'hematologic']","['group', 'analysis', 'recovery', 'treatment', 'remission']",419,"['完全或部分血液恢复的复发仅在吉尔特里蒂尼布群体中进行临时分析,并在两组治疗的最终分析中总结。']",0.3333333333333333,"['group', 'analysis', 'complete', 'recovery', 'treatment', 'partial', 'remission', 'with', 'full', 'in', 'and', 'hematologic']","['group', 'analysis', 'recovery', 'treatment']",419,在 gilteritinib 组仅进行了临时分析，并在最终分析中总结了两组患者的恢复情况。,0.25,"['group', 'analysis', 'complete', 'recovery', 'treatment', 'partial', 'remission', 'with', 'full', 'in', 'and', 'hematologic']","['group', 'analysis', 'recovery']",,,,
421,420,best response was noted at any postbaseline visit .,在任何基线后访视中记录了最佳反应。,0.3333333333333333,"['response', 'at', 'visit']",['response'],420,['最好的答案在任何邮政访问中都被注意到。'],0.0,"['response', 'at', 'visit']",[],420,最佳反应在任何后基线访问中都得到了记录。,0.3333333333333333,"['response', 'at', 'visit']",['response'],,,,
422,421,"treatment response was assessed with the use of modified International Working Group criteria ( Table S1 in the Supplementary Appendix , available at NEJM.org ) .31",使用修改后的国际工作组标准（补充附录中的表 S1，可在 NEJM.org 获取）评估治疗反应。31,0.3636363636363636,"['group', 'appendix', 'table', 'supplementary', 'treatment', 'available', 'response', 'with', 'S1', 'in', 'assessed']","['group', 'table', 'treatment', 'response']",421,"['处理答案通过修改的国际工作组标准进行评估(附件中的表 S1,可在NEJM.org上找到)。']",0.3636363636363636,"['group', 'appendix', 'table', 'supplementary', 'treatment', 'available', 'response', 'with', 'S1', 'in', 'assessed']","['group', 'appendix', 'table', 'treatment']",421,"treatment response was assessed with the use of modified International Working Group criteria ( Table S1 in the Supplementary Appendix , available at NEJM.org ) .31

Chinese:
使用修訂後的國際共同工作小組標準(請參閱NEJM.org上的附錄表S1)進行處置反應的評估。31",0.0909090909090909,"['group', 'appendix', 'table', 'supplementary', 'treatment', 'available', 'response', 'with', 'S1', 'in', 'assessed']",['table'],,,,
423,422,minimal residual disease was not assessed .,未评估微小残留病。,0.25,"['disease', 'minimal', 'residual', 'assessed']",['disease'],422,['最低残留性疾病未被评估。'],0.25,"['disease', 'minimal', 'residual', 'assessed']",['disease'],422,最小残留疾病未被评估。,0.25,"['disease', 'minimal', 'residual', 'assessed']",['disease'],,,,
424,423,"safety was assessed by evaluating the incidence of adverse events , including evaluation of vital signs , and results from clinical laboratory tests , electrocardiograms , and ophthalmologic examinations .",安全性是通过评估不良事件的发生率来评估的，包括评估生命体征，以及临床实验室测试、心电图和眼科检查的结果。,0.5384615384615384,"['safety', 'vital signs', 'incidence', 'evaluation', 'ophthalmologic', 'adverse', 'clinical', 'examinations', 'laboratory', 'by', 'and', 'electrocardiograms', 'assessed']","['safety', 'vital signs', 'incidence', 'clinical', 'laboratory', 'by', 'electrocardiograms']",423,"['安全性通过评估不良事件的发病率,包括对重要迹象的评估,以及临床实验室测试、电心图和眼科检查的结果进行评估。']",0.3846153846153846,"['safety', 'vital signs', 'incidence', 'evaluation', 'ophthalmologic', 'adverse', 'clinical', 'examinations', 'laboratory', 'by', 'and', 'electrocardiograms', 'assessed']","['safety', 'incidence', 'clinical', 'laboratory', 'by']",423,安全性评估包括评估不良事件的发生率，包括评估体征、临床实验室检查、心电图和眼科检查结果。,0.3846153846153846,"['safety', 'vital signs', 'incidence', 'evaluation', 'ophthalmologic', 'adverse', 'clinical', 'examinations', 'laboratory', 'by', 'and', 'electrocardiograms', 'assessed']","['safety', 'incidence', 'clinical', 'laboratory', 'electrocardiograms']",,,,
425,424,expression of AXL ( a receptor tyrosine kinase associated with drug resistance ) was analyzed by means of flow cytometry .,采用流式细胞术分析AXL（一种与耐药相关的受体酪氨酸激酶）的表达。,0.4444444444444444,"['receptor', 'drug resistance', 'flow cytometry', 'expression', 'tyrosine kinase', 'associated', 'means', 'with', 'by']","['receptor', 'flow cytometry', 'expression', 'tyrosine kinase']",424,['AXL(受体甲状腺基纳斯与药物抵抗性相关)的表达通过流量细胞测量进行分析。'],0.3333333333333333,"['receptor', 'drug resistance', 'flow cytometry', 'expression', 'tyrosine kinase', 'associated', 'means', 'with', 'by']","['receptor', 'drug resistance', 'expression']",424,通过流式细胞仪分析表达AXL（与药物耐药性相关的受体酪氨酸激酶）。,0.5555555555555556,"['receptor', 'drug resistance', 'flow cytometry', 'expression', 'tyrosine kinase', 'associated', 'means', 'with', 'by']","['receptor', 'drug resistance', 'flow cytometry', 'expression', 'tyrosine kinase']",,,,
426,425,the first planned interim analysis - to evaluate the primary end point of the percentage of patients who had complete remission with full or partial hematologic recovery - occurred when approximately 141 patients in the gilteritinib group reached the time point of at least 112 days ( four treatment cycles ) after the receipt of first dose or after randomization ; the interim evaluation of complete remission with full or partial hematologic recovery rate had no effect on trial conduct .,第一个计划的中期分析——评估完全缓解且血液学完全或部分恢复的患者百分比的主要终点——发生在 gilteritinib 组约 141 名患者达到至少 112 天（四个治疗周期）的时间点时) 接受第一剂后或随机化后；具有完全或部分血液学恢复率的完全缓解的中期评估对试验的进行没有影响。,0.4285714285714285,"['group', 'percentage', 'randomization', 'who', 'analysis', 'rate', 'evaluation', 'time', 'complete', 'recovery', 'treatment', 'primary', 'no', 'partial', 'after', 'trial', 'effect', 'end', 'point', 'conduct', 'remission', 'with', 'dose', 'full', '-', 'approximately', 'first', 'hematologic']","['group', 'percentage', 'randomization', 'analysis', 'rate', 'time', 'recovery', 'treatment', 'after', 'point', 'remission', 'first']",425,"['第一次计划的临时分析 - 以评估患有全血病恢复或部分血病恢复的患者的百分比的初端终点 - 发生时,约有141患者在吉尔特里蒂尼布群体达到至少112天的时间点(四个治疗周期)接收第一次剂量或随机化后;临时评估全血病恢复率或部分血病恢复率没有影响试验行为。']",0.4285714285714285,"['group', 'percentage', 'randomization', 'who', 'analysis', 'rate', 'evaluation', 'time', 'complete', 'recovery', 'treatment', 'primary', 'no', 'partial', 'after', 'trial', 'effect', 'end', 'point', 'conduct', 'remission', 'with', 'dose', 'full', '-', 'approximately', 'first', 'hematologic']","['group', 'percentage', 'randomization', 'analysis', 'rate', 'time', 'recovery', 'treatment', 'after', 'point', 'dose', 'first']",425,第一个计划的中期分析-评估主要终点百分比的病人完全缓解与部分血液恢复-发生在大约141名病人达到时间点至少112天（4个治疗周期）后接受首批药物或随机化后; 完全缓解与部分血液恢复率的中期评估对试验进程无影响。,0.3928571428571428,"['group', 'percentage', 'randomization', 'who', 'analysis', 'rate', 'evaluation', 'time', 'complete', 'recovery', 'treatment', 'primary', 'no', 'partial', 'after', 'trial', 'effect', 'end', 'point', 'conduct', 'remission', 'with', 'dose', 'full', '-', 'approximately', 'first', 'hematologic']","['percentage', 'randomization', 'analysis', 'rate', 'time', 'recovery', 'treatment', 'after', 'point', 'remission', 'first']",,,,
427,426,the planned final analysis was performed when approximately 258 deaths had occurred .,计划的最终分析是在大约 258 人死亡时进行的。,0.5,"['analysis', 'approximately']",['analysis'],426,['计划的最终分析是在大约258人死亡时进行的。'],0.5,"['analysis', 'approximately']",['analysis'],426,当约258人死亡时，计划的最终分析已经完成。,0.5,"['analysis', 'approximately']",['analysis'],,,,
428,427,the statistical analysis plan excluded provisions for multiplicity correction in the evaluation of secondary and other outcomes .,统计分析计划排除了在评估次要结果和其他结果时进行多重校正的规定。,0.2857142857142857,"['correction', 'evaluation', 'secondary', 'multiplicity', 'statistical analysis', 'in', 'and']","['correction', 'statistical analysis']",427,['统计分析计划排除在二级和其他结果的评估中对多样性纠正的规定。'],0.1428571428571428,"['correction', 'evaluation', 'secondary', 'multiplicity', 'statistical analysis', 'in', 'and']",['statistical analysis'],427,统计分析计划不包括对次要和其他结果评估进行多元性纠正的条款。,0.1428571428571428,"['correction', 'evaluation', 'secondary', 'multiplicity', 'statistical analysis', 'in', 'and']",['statistical analysis'],,,,
429,428,these results are reported as point estimates and 95 % confidence intervals without adjustment for multiplicity and should not be used to infer definitive treatment effects .,这些结果报告为点估计值和 95% 置信区间，未对多重性进行调整，不应用于推断确定的治疗效果。,0.4166666666666667,"['definitive', 'adjustment', 'be', 'treatment', 'multiplicity', 'point', 'as', 'confidence', 'to', 'and', 'without', 'intervals']","['definitive', 'treatment', 'multiplicity', 'point', 'to']",428,"['这些结果被报告为点估计和95%的信任间隔,没有对多样性进行调整,并且不应用于确定最终的治疗效果。']",0.25,"['definitive', 'adjustment', 'be', 'treatment', 'multiplicity', 'point', 'as', 'confidence', 'to', 'and', 'without', 'intervals']","['treatment', 'point', 'to']",428,这些结果以点估计和95％置信区间的形式报告，没有经过复数调整，不应用于推断明确的治疗效果。,0.25,"['definitive', 'adjustment', 'be', 'treatment', 'multiplicity', 'point', 'as', 'confidence', 'to', 'and', 'without', 'intervals']","['treatment', 'point', 'to']",,,,
430,429,"from October 20 , 2015 , to February 20 , 2018 , a total of 625 patients entered screening .",2015年10月20日至2018年2月20日，共有625名患者进入筛查。,0.5,"['screening', 'total']",['screening'],429,"['从2015年10月20日至2018年2月20日,共有625名患者接受了筛查。']",0.5,"['screening', 'total']",['screening'],429,"From October 20, 2015, to February 20, 2018, a total of 625 patients entered screening.

Chinese:

2015年10月20日至2018年2月20日，共有625名病人参加了筛查。",0.5,"['screening', 'total']",['screening'],,,,
431,430,"the event cutoff of 258 deaths , which triggered the final analysis , occurred on September 17 , 2018 ; the database was locked on October 19 , 2018 .",最终分析触发的258人死亡事件截止发生在2018年9月17日；该数据库于 2018 年 10 月 19 日被锁定。,0.2,"['cutoff', 'database', 'analysis', 'event', 'on']",['analysis'],430,['最终分析引发的258起死亡事件发生于2018年9月17日;数据库于2018年10月19日关闭。'],0.2,"['cutoff', 'database', 'analysis', 'event', 'on']",['analysis'],430,截止至2018年9月17日，最终分析所触发的死亡事件为258起；数据库于2018年10月19日锁定。,0.2,"['cutoff', 'database', 'analysis', 'event', 'on']",['analysis'],,,,
432,431,a total of 371 eligible patients underwent randomization ; 247 were assigned to the gilteritinib group and 124 to the chemotherapy group ( Figure 1 and Table 1 ) .,共有 371 名符合条件的患者接受了随机分组； 247 人被分配到 gilteritinib 组，124 人被分配到化疗组（图 1 和表 1）。,0.625,"['group', 'chemotherapy', 'randomization', 'table', '1', 'figure', 'total', 'eligible']","['group', 'chemotherapy', 'randomization', 'table', '1']",431,"['总共有371名合格的患者遭到随机化;247人被分配给吉尔特里蒂尼布组,124人被分配给化疗组(图1和图1)。']",0.625,"['group', 'chemotherapy', 'randomization', 'table', '1', 'figure', 'total', 'eligible']","['group', 'chemotherapy', 'randomization', '1', 'eligible']",431,总共有371名符合条件的患者进行了随机分配；247名患者被分配到吉列替尼组，124名患者被分配到化疗组（图1和表1）。,0.625,"['group', 'chemotherapy', 'randomization', 'table', '1', 'figure', 'total', 'eligible']","['group', 'chemotherapy', 'randomization', 'table', '1']",,,,
433,432,"overall , 60.6 % of the patients had relapsed AML ( median duration of first remission , 6.0 months ; range , 0.3 to 60.0 ) , and 39.4 % had primary refractory disease .",总体而言，60.6% 的患者患有复发性 AML（首次缓解的中位持续时间为 6.0 个月；范围为 0.3 至 60.0 个月），39.4% 的患者患有原发性难治性疾病。,0.5555555555555556,"['median', 'disease', 'range', 'refractory', 'primary', 'duration', 'remission', 'and', 'first']","['disease', 'range', 'duration', 'remission', 'and']",432,"['总体而言,60.6 %的患者患有AML(第一次放松的平均寿命为6.0 个月;范围为 0.3 至 60.0),而39.4 %的患者患有初级放松性疾病。']",0.4444444444444444,"['median', 'disease', 'range', 'refractory', 'primary', 'duration', 'remission', 'and', 'first']","['disease', 'range', 'and', 'first']",432,总体而言，60.6%的病人复发了急性髓系细胞瘤（首次缓解的中位数为6.0个月，范围为0.3至60.0个月），而39.4%的病人患有主要难治性疾病。,0.4444444444444444,"['median', 'disease', 'range', 'refractory', 'primary', 'duration', 'remission', 'and', 'first']","['disease', 'range', 'remission', 'and']",,,,
434,433,most patients ( 83.8 % ) had received previous induction therapy with anthracyclines but not FLT3 inhibitors ( 87.6 % ) ; 21 patients ( 5.7 % ) had received the FLT3 inhibitor midostaurin .,大多数患者 (83.8%) 之前接受过蒽环类药物诱导治疗，但未接受 FLT3 抑制剂 (87.6%)； 21 名患者 (5.7%) 接受了 FLT3 抑制剂米哚妥林。,0.6666666666666666,"['inhibitor', 'induction', 'previous', 'therapy', 'with', 'but']","['inhibitor', 'induction', 'therapy', 'but']",433,"['大多数患者(83.8%)接受了先前的引导治疗,但不使用FLT3抑制剂(87.6%);21患者(5.7%)接受了FLT3抑制剂Midostaurine。']",0.6666666666666666,"['inhibitor', 'induction', 'previous', 'therapy', 'with', 'but']","['inhibitor', 'induction', 'therapy', 'but']",433,大多数病人（83.8%）在此前接受过阿尔法环素的诱导治疗，但没有接受过FLT3抑制剂（87.6%）；21名病人（5.7%）接受过FLT3抑制剂米多斯特安。,0.6666666666666666,"['inhibitor', 'induction', 'previous', 'therapy', 'with', 'but']","['inhibitor', 'induction', 'therapy', 'but']",,,,
435,434,"the median number of cycles of gilteritinib therapy received was 5 ( range , 1 to 33 ) .",接受的 gilteritinib 治疗周期的中位数为 5（范围，1 至 33）。,0.7142857142857143,"['median', '5', 'range', '1', 'therapy', 'number', 'to']","['5', 'range', '1', 'therapy', 'number']",434,"['接受吉尔特里蒂尼布治疗的平均周期数量为5(范围,1至33)。']",0.7142857142857143,"['median', '5', 'range', '1', 'therapy', 'number', 'to']","['5', 'range', '1', 'therapy', 'number']",434,中位数治疗周期为5（范围为1至33）。,0.7142857142857143,"['median', '5', 'range', '1', 'therapy', 'number', 'to']","['5', 'range', '1', 'therapy', 'number']",,,,
436,435,"at the time of this analysis , 110 patients remained alive and 38 were continuing therapy with gilteritinib .",在进行此项分析时，有 110 名患者还活着，其中 38 名患者继续使用吉替替尼进行治疗。,0.4285714285714285,"['analysis', 'time', 'therapy', 'with', 'at', 'this', 'and']","['analysis', 'time', 'therapy']",435,"['在此分析时,110名患者仍然活着,38人继续接受吉尔特里蒂尼布治疗。']",0.4285714285714285,"['analysis', 'time', 'therapy', 'with', 'at', 'this', 'and']","['analysis', 'time', 'therapy']",435,在这次分析的时候，110个病人还活着，38个病人仍在使用吉列替尼治疗。,0.4285714285714285,"['analysis', 'time', 'therapy', 'with', 'at', 'this', 'and']","['analysis', 'time', 'therapy']",,,,
437,436,"common reasons for the discontinuation of gilteritinib were relapse , progression , or lack of efficacy ( 50.2 % ) , death ( 14.6 % ) , and adverse events ( 11.3 % ) .",停用 gilteritinib 的常见原因是复发、进展或缺乏疗效 (50.2%)、死亡 (14.6%) 和不良事件 (11.3%)。,0.375,"['lack', 'relapse', 'death', 'common', 'adverse', 'progression', 'efficacy', 'and']","['relapse', 'death', 'progression']",436,"['停止使用Gilteritinib的常见原因是衰退、进展或缺乏有效性(50.2 %),死亡(14.6 %)和副作用(11.3 %)。']",0.375,"['lack', 'relapse', 'death', 'common', 'adverse', 'progression', 'efficacy', 'and']","['death', 'progression', 'efficacy']",436,常见原因导致停止使用吉列替尼是复发（50.2%）、进展（14.6%）或疗效不佳（11.3%），死亡（14.6%）和不良事件（11.3%）。,0.375,"['lack', 'relapse', 'death', 'common', 'adverse', 'progression', 'efficacy', 'and']","['relapse', 'death', 'progression']",,,,
438,437,"common reasons for the discontinuation of chemotherapy were relapse , progression , or lack of efficacy ( 39.5 % ) , withdrawal by the patient ( 8.1 % ) , physician decision ( 8.9 % ) , and death ( 8.1 % ) .",停止化疗的常见原因是复发、进展或缺乏疗效 (39.5%)、患者退出 (8.1%)、医生决定 (8.9%) 和死亡 (8.1%)。,0.5384615384615384,"['chemotherapy', 'lack', 'relapse', 'death', 'withdrawal', 'physician', 'common', 'progression', 'patient', 'efficacy', 'decision', 'by', 'and']","['chemotherapy', 'relapse', 'death', 'physician', 'progression', 'patient', 'decision']",437,['停止化疗的常见原因是逆转、进展或缺乏有效性(39.5%)、患者退出(8.1%)、医生的决定(8.9%)和死亡(8.1%)。'],0.5384615384615384,"['chemotherapy', 'lack', 'relapse', 'death', 'withdrawal', 'physician', 'common', 'progression', 'patient', 'efficacy', 'decision', 'by', 'and']","['chemotherapy', 'death', 'physician', 'progression', 'patient', 'efficacy', 'decision']",437,常见的 chemotherapy 停止原因为复发、进展、或者疗效不良（39.5%）、病人自行退出（8.1%）、医生决定（8.9%）和死亡（8.1%）。,0.4615384615384615,"['chemotherapy', 'lack', 'relapse', 'death', 'withdrawal', 'physician', 'common', 'progression', 'patient', 'efficacy', 'decision', 'by', 'and']","['relapse', 'death', 'physician', 'progression', 'patient', 'decision']",,,,
439,438,the percentages of patients who were alive at 1 year were 37.1 % in the gilteritinib group and 16.7 % in the chemotherapy group .,gilteritinib 组 1 年时存活的患者百分比为 37.1%，化疗组为 16.7%。,0.5,"['group', 'chemotherapy', 'year', 'who', '1', 'at', 'in', 'and']","['group', 'chemotherapy', 'year', '1']",438,['1年生存的患者比例为吉尔特里蒂尼布群体的37.1%和化疗群体的16.7%。'],0.5,"['group', 'chemotherapy', 'year', 'who', '1', 'at', 'in', 'and']","['group', 'chemotherapy', 'year', '1']",438,在gilteritinib组的患者中，在1年内存活的百分比为37.1%，而在化疗组的患者中为16.7%。,0.625,"['group', 'chemotherapy', 'year', 'who', '1', 'at', 'in', 'and']","['group', 'chemotherapy', 'year', '1', 'and']",,,,
440,439,"among patients with primary refractory AML , the median overall survival was 10.4 months in the gilteritinib group and 6.9 months in the chemotherapy group ( hazard ratio for death , 0.99 ; 95 % CI , 0.63 to 1.55 ) ( Table S3 ) .",在原发性难治性 AML 患者中，gilteritinib 组的中位总生存期为 10.4 个月，化疗组为 6.9 个月（死亡风险比，0.99；95% CI，0.63 至 1.55）（表 S3）。,0.4285714285714285,"['group', 'chemotherapy', 'median', 'table', 'survival', 'hazard ratio', 'death', 'refractory', 'primary', 'with', 'CI', 'S3', 'in', 'and']","['group', 'chemotherapy', 'table', 'survival', 'hazard ratio', 'death']",439,"['在患有初级分裂性AML的患者中,平均生存时间在吉尔特里蒂尼布群体中为10.4个月,化疗群体中为6.9个月(死亡风险比例为0.99;95%的CI,0.63至1.55)。']",0.3571428571428571,"['group', 'chemotherapy', 'median', 'table', 'survival', 'hazard ratio', 'death', 'refractory', 'primary', 'with', 'CI', 'S3', 'in', 'and']","['group', 'chemotherapy', 'survival', 'hazard ratio', 'death']",439,在原发性抗性骨髓瘤患者中，吉利替尼组的平均总生存期为10.4个月，而化疗组的平均总生存期为6.9个月（死亡风险比为0.99；95%CI为0.63至1.55）。,0.4285714285714285,"['group', 'chemotherapy', 'median', 'table', 'survival', 'hazard ratio', 'death', 'refractory', 'primary', 'with', 'CI', 'S3', 'in', 'and']","['group', 'chemotherapy', 'survival', 'hazard ratio', 'death', 'and']",,,,
441,440,"the percentage of patients who had complete remission with full or partial hematologic recovery was 34.0 % in the gilteritinib group and 15.3 % in the chemotherapy group ( risk difference , 18.6 percentage points ; 95 % CI , 9.8 to 27.4 ) ; the percentages of patients with complete remission were 21.1 % and 10.5 % , respectively ( risk difference , 10.6 percentage points ; 95 % CI , 2.8 to 18.4 ) ( Table 2 ) .",完全缓解且血液学完全或部分恢复的患者百分比在吉尔特替尼组为 34.0%，在化疗组为 15.3%（风险差异，18.6 个百分点；95% CI，9.8 至 27.4）；完全缓解患者的百分比分别为 21.1% 和 10.5%（风险差异，10.6 个百分点；95% CI，2.8 至 18.4）（表 2）。,0.5,"['group', 'percentage', 'chemotherapy', 'table', 'who', '2', 'difference', 'complete', 'recovery', 'risk', 'partial', 'remission', 'with', 'CI', 'full', 'in', 'and', 'hematologic']","['group', 'percentage', 'chemotherapy', 'table', '2', 'difference', 'recovery', 'risk', 'remission']",440,"['患有完全或部分血液康复的患者的百分比在吉尔特里蒂尼布群体中为34.0%,在化疗群体中为15.3%(风险差异、18.6个百分点、95%的CI、9.8到27.4);患有完全康复的患者的百分比为21.1%和10.5%(风险差异、10.6个百分点、95%的CI、2.8到18.4)。']",0.3333333333333333,"['group', 'percentage', 'chemotherapy', 'table', 'who', '2', 'difference', 'complete', 'recovery', 'risk', 'partial', 'remission', 'with', 'CI', 'full', 'in', 'and', 'hematologic']","['group', 'percentage', 'chemotherapy', '2', 'difference', 'risk']",440,gilteritinib组患者全部或部分血液康复完全缓解的比例为34.0%，而化疗组为15.3%（危险差异为18.6个百分点；95%CI为9.8至27.4）；完全缓解的患者百分比分别为21.1%和10.5%（危险差异为10.6个百分点；95%CI为2.8至18.4）（见表2）。,0.5555555555555556,"['group', 'percentage', 'chemotherapy', 'table', 'who', '2', 'difference', 'complete', 'recovery', 'risk', 'partial', 'remission', 'with', 'CI', 'full', 'in', 'and', 'hematologic']","['group', 'percentage', 'chemotherapy', 'table', '2', 'difference', 'risk', 'remission', 'full', 'and']",,,,
442,441,the median duration of complete remission with full or partial hematologic recovery was 11.0 months in the gilteritinib group but could not be evaluated in the chemotherapy group because of censoring .,gilteritinib 组完全缓解和血液学部分恢复的中位持续时间为 11.0 个月，但由于删失，无法在化疗组中进行评估。,0.5,"['group', 'chemotherapy', 'median', 'complete', 'be', 'recovery', 'partial', 'duration', 'remission', 'with', 'full', 'in', 'but', 'hematologic']","['group', 'chemotherapy', 'be', 'recovery', 'duration', 'remission', 'but']",441,"['在吉尔特里蒂尼布群体中,完全或部分血液恢复的中间期为11.0个月,但由于审查而无法在化疗群体中进行评估。']",0.3571428571428571,"['group', 'chemotherapy', 'median', 'complete', 'be', 'recovery', 'partial', 'duration', 'remission', 'with', 'full', 'in', 'but', 'hematologic']","['group', 'chemotherapy', 'be', 'recovery', 'but']",441,gilteritinib组的完全或部分血液学复苏完全缓解的中位数持续时间为11.0个月，但由于对化疗组的截断，无法评估。,0.3571428571428571,"['group', 'chemotherapy', 'median', 'complete', 'be', 'recovery', 'partial', 'duration', 'remission', 'with', 'full', 'in', 'but', 'hematologic']","['group', 'chemotherapy', 'duration', 'remission', 'but']",,,,
443,442,the percentages of patients who had remission after an increase in the dose of gilteritinib ( 78 patients ) or a decrease in the dose ( 58 patients ) are shown in Table S5 .,在增加 gilteritinib 剂量（78 名患者）或减少剂量（58 名患者）后获得缓解的患者百分比显示在表 S5 中。,0.7142857142857143,"['decrease', 'table', 'who', 'after', 'remission', 'increase', 'dose']","['decrease', 'table', 'after', 'remission', 'dose']",442,['在增加吉尔特里蒂尼布剂量(78名患者)或减少剂量(58名患者)后患有复发的患者的百分比显示在表S5中。'],0.5714285714285714,"['decrease', 'table', 'who', 'after', 'remission', 'increase', 'dose']","['decrease', 'table', 'after', 'dose']",442,表S5显示了78名患者增加剂量后缓解病情的百分比，而58名患者剂量减少后缓解病情的百分比。,0.7142857142857143,"['decrease', 'table', 'who', 'after', 'remission', 'increase', 'dose']","['decrease', 'table', 'after', 'remission', 'dose']",,,,
444,443,"when we excluded remissions that occurred after transplantation during the trial , the percentage of patients who had complete remission with full or partial hematologic recovery was 26.3 % in the gilteritinib group and 15.3 % in the chemotherapy group ( risk difference , 10.9 percentage points ; 95 % CI , 2.4 to 19.5 ) .",当我们在试验期间排除移植后出现的缓解时，完全缓解且血液学完全或部分恢复的患者百分比在 gilteritinib 组中为 26.3 % ，在化疗组中为 15.3 % （风险差异， 10.9 个百分点； 95 % ） CI，2.4 至 19.5）。,0.4761904761904761,"['group', 'percentage', 'chemotherapy', 'transplantation', 'who', 'difference', 'complete', 'recovery', 'risk', 'partial', 'after', 'trial', 'remission', 'with', 'CI', 'full', 'that', 'in', 'and', 'hematologic', 'we']","['group', 'percentage', 'chemotherapy', 'transplantation', 'difference', 'recovery', 'risk', 'after', 'remission', 'in']",443,"['当我们排除在试验期间移植后发生的移植时,患有完全或部分血液恢复的患者的百分比为吉尔特里蒂尼布群体的 26.3% 和化疗群体的 15.3% (风险差异, 10.9 个百分点 ; 95 % CI, 2.4 到 19.5 ) 。']",0.4761904761904761,"['group', 'percentage', 'chemotherapy', 'transplantation', 'who', 'difference', 'complete', 'recovery', 'risk', 'partial', 'after', 'trial', 'remission', 'with', 'CI', 'full', 'that', 'in', 'and', 'hematologic', 'we']","['group', 'percentage', 'chemotherapy', 'transplantation', 'difference', 'recovery', 'risk', 'after', 'that', 'in']",443,当我们在试验期间排除移植后的缓解症状时，在吉利替尼组中有26.3%的患者完全缓解并具有完全或部分血液学恢复，而在化疗组中有15.3%的患者（风险差异为10.9个百分点; 95% CI，2.4至19.5）。,0.5238095238095238,"['group', 'percentage', 'chemotherapy', 'transplantation', 'who', 'difference', 'complete', 'recovery', 'risk', 'partial', 'after', 'trial', 'remission', 'with', 'CI', 'full', 'that', 'in', 'and', 'hematologic', 'we']","['group', 'percentage', 'chemotherapy', 'transplantation', 'difference', 'recovery', 'risk', 'after', 'remission', 'in', 'and']",,,,
445,444,"among patients with primary refractory AML , the percentage of patients who had complete remission with full or partial hematologic recovery was 32 % ( 31 of 98 patients ) in the gilteritinib group and 21 % ( 10 of 48 patients ) in the chemotherapy group ( Table S3 ) .",在原发难治性 AML 患者中，完全缓解且血液学完全或部分恢复的患者百分比在吉特替尼组为 32 %（98 名患者中的 31 名），在化疗组中为 21 %（48 名患者中的 10 名）（表 S3） ) 。,0.3529411764705882,"['group', 'percentage', 'chemotherapy', 'table', 'who', 'refractory', 'complete', 'recovery', 'primary', 'partial', 'remission', 'with', 'full', 'S3', 'in', 'and', 'hematologic']","['group', 'percentage', 'chemotherapy', 'table', 'recovery', 'remission']",444,"['在患有初级分裂性AML的患者中,患有完全或部分血液康复的患者的百分比为32%(98人中31人)在吉尔特里蒂尼布群体和21%(48人中10人)在化疗群体(S3表)。']",0.2352941176470588,"['group', 'percentage', 'chemotherapy', 'table', 'who', 'refractory', 'complete', 'recovery', 'primary', 'partial', 'remission', 'with', 'full', 'S3', 'in', 'and', 'hematologic']","['group', 'percentage', 'chemotherapy', 'table']",444,在原发性难治性骨髓增生异常细胞病患者中，在吉利特尼布组，完全缓解或部分血液学复苏的患者百分比为32％（31/98），而在化疗组为21％（10/48）（表S3）。,0.3529411764705882,"['group', 'percentage', 'chemotherapy', 'table', 'who', 'refractory', 'complete', 'recovery', 'primary', 'partial', 'remission', 'with', 'full', 'S3', 'in', 'and', 'hematologic']","['group', 'percentage', 'chemotherapy', 'table', 'remission', 'and']",,,,
446,445,the percentages of patients with a remission according to chemotherapy intensity and receipt or nonreceipt of previous transplantation are presented in Table S4 .,根据化疗强度和接受或未接受既往移植获得缓解的患者百分比见表 S4。,0.4,"['chemotherapy', 'transplantation', 'table', 'previous', 'intensity', 'remission', 'with', 'S4', 'to', 'and']","['chemotherapy', 'transplantation', 'table', 'remission']",445,['根据化疗强度和接收或未接收前移植的患者的百分比在表 S4 中显示。'],0.3,"['chemotherapy', 'transplantation', 'table', 'previous', 'intensity', 'remission', 'with', 'S4', 'to', 'and']","['chemotherapy', 'transplantation', 'table']",445,在化疗强度和接受或未接受先前移植的患者中，缓解率的百分比如表S4所示。,0.4,"['chemotherapy', 'transplantation', 'table', 'previous', 'intensity', 'remission', 'with', 'S4', 'to', 'and']","['chemotherapy', 'transplantation', 'table', 'remission']",,,,
447,446,"among patients with FLT3 ITD mutations who had been randomly assigned to the gilteritinib group , 20.5 % had a complete remission ; among those who had been randomly assigned to chemotherapy , 9.7 % had a complete remission ( Table S6 ) .",在随机分配到吉替尼组的 FLT3 ITD 突变患者中，20.5% 的患者获得完全缓解；在被随机分配接受化疗的患者中，9.7% 的患者获得完全缓解（表 S6）。,0.5,"['group', 'chemotherapy', 'table', 'who', 'complete', 'remission', 'with', 'to']","['group', 'chemotherapy', 'table', 'remission']",446,"['在患有 FLT3 ITD 突变的患者中,有 20.5 % 随机分配给 gilteritinib 组,有完整的复发;在随机分配给化疗的患者中,有 9.7 % 有完整的复发(表 S6 )。']",0.5,"['group', 'chemotherapy', 'table', 'who', 'complete', 'remission', 'with', 'to']","['group', 'chemotherapy', 'table', 'complete']",446,在随机分配给吉列替尼组的 FLT3 ITD 突变患者中，20.5% 实现了完全缓解；在随机分配给化疗组的患者中，9.7% 实现了完全缓解（表 S6）。,0.5,"['group', 'chemotherapy', 'table', 'who', 'complete', 'remission', 'with', 'to']","['group', 'chemotherapy', 'table', 'remission']",,,,
448,447,"although the percentages of patients with complete remission were similar across the treatment groups among patients with FLT3 TKD mutations , gilteritinib therapy resulted in similar percentages of complete remission among patients with FLT3 TKD mutations alone ( 19.0 % ) and among those with FLT3 ITD mutations alone ( 20.5 % ) ( Table S6 ) .",尽管完全缓解患者的百分比在具有 FLT3 TKD 突变的患者中在整个治疗组中相似，但吉利替尼治疗在仅具有 FLT3 TKD 突变的患者 (19.0%) 和仅具有 FLT3 ITD 突变的患者中导致完全缓解的百分比相似 ( 20.5%）（表 S6）。,0.3333333333333333,"['table', 'therapy', 'complete', 'treatment', 'across', 'TKD', 'remission', 'with', 'in', 'and', 'alone', 'similar']","['table', 'therapy', 'treatment', 'remission']",447,"['虽然患有FLT3 TKD突变的患者的百分比在治疗群体中是相似的,但Gilteritinib治疗导致FLT3 TKD突变的患者(仅19.0%)和FLT3 ITD突变的患者(仅20,5%)的完全突变的百分比相似。']",0.25,"['table', 'therapy', 'complete', 'treatment', 'across', 'TKD', 'remission', 'with', 'in', 'and', 'alone', 'similar']","['therapy', 'treatment', 'similar']",447,尽管在 FLT3 TKD 突变患者中完全缓解的患者百分比相似，但 gilteritinib 治疗在 FLT3 TKD 突变患者中（19.0%）和 FLT3 ITD 突变患者中（20.5%）的完全缓解百分比相似（表 S6）。,0.3333333333333333,"['table', 'therapy', 'complete', 'treatment', 'across', 'TKD', 'remission', 'with', 'in', 'and', 'alone', 'similar']","['table', 'therapy', 'treatment', 'remission']",,,,
449,448,"among patients treated with gilteritinib , the median overall survival was similar among those with FLT3 ITD mutations alone ( 9.3 months ) and those with FLT3 TKD mutations alone ( 8.0 months ) .",在接受 gilteritinib 治疗的患者中，仅具有 FLT3 ITD 突变的患者（9.3 个月）和仅具有 FLT3 TKD 突变的患者（8.0 个月）的中位总生存期相似。,0.1428571428571428,"['median', 'survival', 'TKD', 'with', 'and', 'alone', 'similar']",['survival'],448,"['在接受吉尔特里蒂尼布治疗的患者中,平均生存率相当于只有FLT3 ITD突变(9.3个月)和只有FLT3 TKD突变(8.0个月)的患者中。']",0.1428571428571428,"['median', 'survival', 'TKD', 'with', 'and', 'alone', 'similar']",['survival'],448,在使用gilteritinib治疗的患者中，FLT3 ITD突变体患者的平均总体生存期为9.3个月，而FLT3 TKD突变体患者的平均总体生存期为8.0个月。,0.2857142857142857,"['median', 'survival', 'TKD', 'with', 'and', 'alone', 'similar']","['survival', 'and']",,,,
450,449,"similar results were observed regarding adverse events that occurred during the first 30 days of treatment , except for elevations of the liver aminotransferase levels . ( details are provided in Tables S7 and S8 . )",除了肝脏转氨酶水平升高外，在治疗的前 30 天内发生的不良事件也观察到了类似的结果。 （详情见表 S7 和 S8。）,0.2222222222222222,"['liver', 'aminotransferase', 'regarding', 'adverse', 'treatment', 'that', 'and', 'first', 'similar']","['liver', 'treatment']",449,"['相似的结果被观察到发生在治疗的前30天内发生的副作用,除了肝脏氨基转移素水平的上升(详细信息显示在表 S7 和 S8 。']",0.3333333333333333,"['liver', 'aminotransferase', 'regarding', 'adverse', 'treatment', 'that', 'and', 'first', 'similar']","['liver', 'treatment', 'similar']",449,类似的结果也观察到治疗前30天内发生的不良事件，但肝脏氨基转移酶升高的情况除外（表S7和S8中提供了详细信息）。,0.2222222222222222,"['liver', 'aminotransferase', 'regarding', 'adverse', 'treatment', 'that', 'and', 'first', 'similar']","['liver', 'treatment']",,,,
451,450,"common adverse events of grade 3 or higher in the gilteritinib group were febrile neutropenia ( 45.9 % ) , anemia ( 40.7 % ) , and thrombocytopenia ( 22.8 % ) ( Table 3 and Table S9 ) ; these were also the most common adverse events of grade 3 or higher that were considered by the investigators to be related to gilteritinib therapy ( Table S10 ) .",gilteritinib 组中 3 级或更高级别的常见不良事件为发热性中性粒细胞减少症 (45.9%)、贫血 (40.7%) 和血小板减少症 (22.8%)（表 3 和表 S9）；这些也是研究人员认为与 gilteritinib 治疗相关的最常见的 3 级或更高级别不良事件（表 S10）。,0.3529411764705882,"['anemia', 'group', 'febrile', 'table', 'grade', 'neutropenia', 'thrombocytopenia', 'therapy', 'be', 'common', 'adverse', '3', 'S10', 'that', 'in', 'by', 'and']","['anemia', 'group', 'table', 'neutropenia', 'thrombocytopenia', 'therapy']",450,['在Gilteritinib群体中3级或更高的常见副作用是发烧性中风(45.9%)、贫血(40.7%)和血管细胞(22.8%);这些也是研究人员认为与Gilteritinib治疗相关的3级或更高的常见副作用(S10)。'],0.2352941176470588,"['anemia', 'group', 'febrile', 'table', 'grade', 'neutropenia', 'thrombocytopenia', 'therapy', 'be', 'common', 'adverse', '3', 'S10', 'that', 'in', 'by', 'and']","['anemia', 'group', 'therapy', 'be']",450,常见的3级或更高级别的gilteritinib组不良事件包括发热性中性粒细胞减少症（45.9％）、贫血（40.7％）和血小板减少症（22.8％）（表3和表S9）；这些也是调查员认为与gilteritinib治疗相关的最常见的3级或更高级别的不良事件（表S10）。,0.3529411764705882,"['anemia', 'group', 'febrile', 'table', 'grade', 'neutropenia', 'thrombocytopenia', 'therapy', 'be', 'common', 'adverse', '3', 'S10', 'that', 'in', 'by', 'and']","['anemia', 'group', 'table', 'neutropenia', 'thrombocytopenia', 'therapy']",,,,
452,451,adverse events of grade 3 or higher that occurred during the first 30 days of treatment are presented in Table S8 .,表 S8 列出了治疗前 30 天内发生的 3 级或更高级别的不良事件。,0.25,"['table', 'grade', 'adverse', 'treatment', '3', 'that', 'in', 'first']","['table', 'treatment']",451,"['在治疗前30天发生的3级或更高类别的副作用,如表 S8所示。']",0.25,"['table', 'grade', 'adverse', 'treatment', '3', 'that', 'in', 'first']","['table', 'treatment']",451,在治疗的前30天内发生的3级或更高级别的不良事件在表S8中呈现。,0.25,"['table', 'grade', 'adverse', 'treatment', '3', 'that', 'in', 'first']","['table', 'treatment']",,,,
453,452,dose reductions occurred in 6 patients who had a mean change from the baseline QTcF interval of more than 60 msec .,6 名患者发生剂量减少，其 QTcF 间期相对于基线的平均变化超过 60 毫秒。,0.8333333333333334,"['interval', 'mean', 'who', 'baseline', 'change', 'dose']","['interval', 'mean', 'baseline', 'change', 'dose']",452,"['剂量减少发生在6名患者中,从基线QTcF间隔超过60 msec的平均变化。']",0.8333333333333334,"['interval', 'mean', 'who', 'baseline', 'change', 'dose']","['interval', 'mean', 'baseline', 'change', 'dose']",452,那些平均QTcF间期超过60毫秒的6名患者服药量减少了。,0.3333333333333333,"['interval', 'mean', 'who', 'baseline', 'change', 'dose']","['interval', 'mean']",,,,
454,453,"there were 251 deaths in the safety population of 355 patients , including 170 deaths among 246 patients ( 69.1 % ) in the gilteritinib group and 81 deaths among 109 patients ( 74.3 % ) in the chemotherapy group .",355例患者的安全人群中有251例死亡，其中gilteritinib组246例患者中有170例死亡（69.1%），化疗组109例患者中有81例死亡（74.3%）。,0.6666666666666666,"['safety', 'group', 'chemotherapy', 'population', 'in', 'and']","['safety', 'group', 'chemotherapy', 'population']",453,"['在355名患者的安全人口中,有251人死亡,其中有246名患者(69.1%)在吉尔特里丁群中死亡,109名患者(74.3%)在化疗群中死亡81人死亡。']",0.6666666666666666,"['safety', 'group', 'chemotherapy', 'population', 'in', 'and']","['safety', 'group', 'chemotherapy', 'population']",453,在355名安全人群中，共计251例死亡，其中246例患者（69.1%）中有170例死亡，109例患者（74.3%）中有81例死亡。,0.5,"['safety', 'group', 'chemotherapy', 'population', 'in', 'and']","['safety', 'group', 'population']",,,,
455,454,"we found that in this population of patients , gilteritinib resulted in superior overall survival and percentages of remission as compared with salvage chemotherapy .",我们发现，在这一患者群体中，与挽救性化疗相比，gilteritinib 的总生存期和缓解率更高。,0.3076923076923077,"['chemotherapy', 'population', 'survival', 'superior', 'remission', 'as', 'with', 'salvage', 'this', 'that', 'in', 'and', 'we']","['chemotherapy', 'population', 'survival', 'remission']",454,"['我们发现,在这种患者群体中,吉尔特里蒂尼布产生了比救生化疗更高的总生存率和放松率。']",0.3076923076923077,"['chemotherapy', 'population', 'survival', 'superior', 'remission', 'as', 'with', 'salvage', 'this', 'that', 'in', 'and', 'we']","['chemotherapy', 'population', 'survival', 'that']",454,在这种患者群体中，我们发现吉列替尼治疗结果优于救助化疗。,0.1538461538461538,"['chemotherapy', 'population', 'survival', 'superior', 'remission', 'as', 'with', 'salvage', 'this', 'that', 'in', 'and', 'we']","['chemotherapy', 'population']",,,,
456,455,the present trial enrolled patients with FLT3 ITD or FLT3 TKD mutations .,本试验纳入了具有 FLT3 ITD 或 FLT3 TKD 突变的患者。,0.0,"['trial', 'TKD', 'present', 'with']",[],455,['目前的研究记录了患有 FLT3 ITD 或 FLT3 TKD 突变的患者。'],0.0,"['trial', 'TKD', 'present', 'with']",[],455,本次试验招募了患有FLT3 ITD或FLT3 TKD突变的患者。,0.0,"['trial', 'TKD', 'present', 'with']",[],,,,
457,456,"although FLT3 TKD mutations are uncommon at disease recurrence , they consistently and rapidly emerge during FLT3 inhibitor therapy to confer secondary resistance.22,34","尽管 FLT3 TKD 突变在疾病复发时并不常见，但它们在 FLT3 抑制剂治疗期间持续且迅速地出现并赋予继发性耐药性。 22,34",0.375,"['inhibitor', 'disease', 'therapy', 'secondary', 'TKD', 'recurrence', 'at', 'and']","['inhibitor', 'disease', 'therapy']",456,"['虽然 FLT3 TKD 突变在疾病重复情况下是异常的,但它们在 FLT3 抑制剂治疗期间连续迅速出现,以提供二次抵抗性。']",0.375,"['inhibitor', 'disease', 'therapy', 'secondary', 'TKD', 'recurrence', 'at', 'and']","['inhibitor', 'disease', 'therapy']",456,"尽管FLT3 TKD突变在疾病复发时很少见，但它们在FLT3抑制剂治疗中始终会迅速出现，从而导致二级抗性。22,34",0.5,"['inhibitor', 'disease', 'therapy', 'secondary', 'TKD', 'recurrence', 'at', 'and']","['inhibitor', 'disease', 'therapy', 'and']",,,,
458,457,gilteritinib had clinical activity in all studied FLT3 mutation types .,gilteritinib 在所有研究的 FLT3 突变类型中均具有临床活性。,0.75,"['mutation', 'activity', 'clinical', 'all']","['mutation', 'activity', 'clinical']",457,['吉尔特里蒂尼布在所有研究的FLT3突变类型中都具有临床活动。'],0.75,"['mutation', 'activity', 'clinical', 'all']","['mutation', 'activity', 'clinical']",457,gilteritinib 在所有研究的 FLT3 突变类型中都具有临床活性。,0.75,"['mutation', 'activity', 'clinical', 'all']","['mutation', 'activity', 'clinical']",,,,
459,458,"not only were the percentages of patients with complete remission similar in the FLT3 TKD and ITD cohorts , but the median overall survival in these two cohorts was also similar .",不仅完全缓解的患者百分比在 FLT3 TKD 和 ITD 队列中相似，而且这两个队列的中位总生存期也相似。,0.4166666666666667,"['median', 'survival', 'complete', 'TKD', 'cohorts', 'remission', 'with', 'in', 'but', 'and', 'two', 'similar']","['survival', 'remission', 'but', 'and', 'two']",458,"['不仅患者的百分比在FLT3 TKD和ITD组中完全放松相似,但这两个组中平均总生存也相似。']",0.25,"['median', 'survival', 'complete', 'TKD', 'cohorts', 'remission', 'with', 'in', 'but', 'and', 'two', 'similar']","['survival', 'but', 'two']",458,不仅 FLT3 TKD 与 ITD 病人的完全缓解率相似，而且这两组病人的平均总体生存率也相似。,0.4166666666666667,"['median', 'survival', 'complete', 'TKD', 'cohorts', 'remission', 'with', 'in', 'but', 'and', 'two', 'similar']","['survival', 'remission', 'but', 'and', 'two']",,,,
460,459,"overall , gilteritinib showed a consistent survival benefit across many subgroups .",总体而言，gilteritinib 在许多亚组中显示出一致的生存益处。,0.3333333333333333,"['survival', 'across', 'benefit']",['survival'],459,"['总体而言,Gilteritinib在许多子群中表现出一致的生存好处。']",0.3333333333333333,"['survival', 'across', 'benefit']",['survival'],459,"Overall, gilteritinib showed a consistent survival benefit across many subgroups.",0.0,"['survival', 'across', 'benefit']",[],,,,
461,460,"although gilteritinib therapy resulted in 63 patients being able to undergo transplantation , the contribution of the transplantation to the survival benefit from gilteritinib is difficult to assess .",尽管 gilteritinib 治疗使 63 名患者能够接受移植，但移植对 gilteritinib 生存获益的贡献难以评估。,0.5555555555555556,"['transplantation', 'survival', 'undergo', 'therapy', 'being', 'assess', 'benefit', 'to', 'difficult']","['transplantation', 'survival', 'therapy', 'assess', 'difficult']",460,"['虽然Gilteritinib治疗导致63名患者能够接受移植,但移植对Gilteritinib的生存益的贡献很难评估。']",0.5555555555555556,"['transplantation', 'survival', 'undergo', 'therapy', 'being', 'assess', 'benefit', 'to', 'difficult']","['transplantation', 'survival', 'therapy', 'assess', 'difficult']",460,尽管吉利特辛治疗使63名患者能够接受移植手术，但移植手术对吉利特辛的生存益处难以评估。,0.6666666666666666,"['transplantation', 'survival', 'undergo', 'therapy', 'being', 'assess', 'benefit', 'to', 'difficult']","['transplantation', 'survival', 'therapy', 'assess', 'benefit', 'difficult']",,,,
462,461,the main toxic effect was myelosuppression .,主要毒性作用为骨髓抑制。,0.0,['toxic effect'],[],461,['主要的毒性效应是神经抑郁症。'],0.0,['toxic effect'],[],461,主要的毒性作用是调节血细胞的能力下降。,0.0,['toxic effect'],[],,,,
463,462,a small signal regarding hepatic toxic effects bears attention in future studies .,关于肝毒性作用的一个小信号在未来的研究中值得关注。,0.4,"['hepatic', 'toxic', 'regarding', 'signal', 'attention']","['regarding', 'signal']",462,['关于肝脏毒性影响的小信号在未来的研究中引起了注意。'],0.6,"['hepatic', 'toxic', 'regarding', 'signal', 'attention']","['regarding', 'signal', 'attention']",462,未来的研究需要密切关注肝脏毒性方面的微弱信号。,0.2,"['hepatic', 'toxic', 'regarding', 'signal', 'attention']",['signal'],,,,
464,463,"the primary outcome was the percentage of time that the blood glucose level was within the target range of 70 to 180 mg per deciliter ( 3.9 to 10.0 mmol per liter ) , as measured by continuous glucose monitoring .",主要结果是血糖水平在 70 到 180 毫克每分升（3.9 到 10.0 毫摩尔每升）目标范围内的时间百分比，这是通过连续血糖监测测量的。,0.6428571428571429,"['monitoring', 'percentage', 'range', 'outcome', 'continuous', 'deciliter', 'time', 'primary', 'target', 'blood glucose', 'level', 'as', 'that', 'by']","['monitoring', 'range', 'outcome', 'continuous', 'time', 'target', 'blood glucose', 'level', 'that']",463,"['主要结果是血糖水平在目标范围内达到70至180毫克(每升3.9至10.0毫米)的时间比例,根据持续的血糖监测测测量。']",0.5,"['monitoring', 'percentage', 'range', 'outcome', 'continuous', 'deciliter', 'time', 'primary', 'target', 'blood glucose', 'level', 'as', 'that', 'by']","['monitoring', 'range', 'outcome', 'time', 'target', 'blood glucose', 'level']",463,該主要結果是透過持續血糖監測所得到的血糖值在70至180毫克/分升（3.9至10.0毫克/升）的目標範圍內所佔的比例。,0.0714285714285714,"['monitoring', 'percentage', 'range', 'outcome', 'continuous', 'deciliter', 'time', 'primary', 'target', 'blood glucose', 'level', 'as', 'that', 'by']",['blood glucose'],,,,
465,464,"the age range of the patients was 14 to 71 years , and the glycated hemoglobin level ranged from 5.4 to 10.6 % .",患者年龄范围为14～71岁，糖化血红蛋白水平为5.4～10.6%。,0.4,"['range', 'hemoglobin level', 'age', 'to', 'and']","['range', 'age']",464,"['患者的年龄范围为14至71岁,血糖血糖水平为5.4%至10.6%。']",0.4,"['range', 'hemoglobin level', 'age', 'to', 'and']","['range', 'age']",464,病人的年龄范围为14至71岁，糖化血红蛋白水平范围为5.4%至10.6%。,0.4,"['range', 'hemoglobin level', 'age', 'to', 'and']","['range', 'age']",,,,
466,465,all 168 patients completed the trial .,全部 168 名患者完成了试验。,0.0,"['trial', 'all']",[],465,['所有168名患者完成了试验。'],0.0,"['trial', 'all']",[],465,"All 168 patients completed the trial.

Chinese: 所有168名病人都完成了试验。",0.0,"['trial', 'all']",[],,,,
467,466,"the mean adjusted difference in glycated hemoglobin level after 6 months was − 0.33 percentage points ( 95 % CI , − 0.53 to − 0.13 ; P = 0.001 ) .",6 个月后糖化血红蛋白水平的平均调整差异为 − 0.33 个百分点（95% CI，− 0.53 至 − 0.13；P = 0.001）。,0.375,"['percentage', 'mean', 'difference', 'hemoglobin level', 'after', 'P', 'CI', 'to']","['mean', 'difference', 'after']",466,"['6个月后,血糖血糖水平的平均调整差异为 − 0.33 个百分点(95 % CI, − 0.53 到 − 0.13 ; P = 0.001 )。']",0.375,"['percentage', 'mean', 'difference', 'hemoglobin level', 'after', 'P', 'CI', 'to']","['mean', 'difference', 'after']",466,调整后的平均糖化血红蛋白水平在6个月后为-0.33个百分点（95%CI，-0.53到-0.13；P = 0.001）。,0.25,"['percentage', 'mean', 'difference', 'hemoglobin level', 'after', 'P', 'CI', 'to']","['mean', 'after']",,,,
468,467,"despite advances in care , attaining good glycemic outcomes in patients with type 1 diabetes remains challenging ; the targets set by the American Diabetes Association are met in only a minority of patients.1,2","尽管在护理方面取得了进步，但要使 1 型糖尿病患者获得良好的血糖结果仍然具有挑战性；只有少数患者达到了美国糖尿病协会设定的目标。 1,2",0.3333333333333333,"['diabetes', 'type', '1', 'association', 'set', 'care', 'with', 'despite', 'good', 'met', 'in', 'by']","['diabetes', 'type', '1', 'good']",467,"['尽管在护理方面取得了进展,但在患有1型糖尿病的患者中取得良好的血糖结果仍然具有挑战性;美国糖尿病协会设定的目标仅在少数患者中实现。']",0.3333333333333333,"['diabetes', 'type', '1', 'association', 'set', 'care', 'with', 'despite', 'good', 'met', 'in', 'by']","['diabetes', 'type', '1', 'good']",467,"尽管护理方面取得了进展，但在1型糖尿病患者中获得良好的血糖控制效果仍然是一项挑战。美国糖尿病协会设定的目标只有少数患者能够达到。1,2",0.3333333333333333,"['diabetes', 'type', '1', 'association', 'set', 'care', 'with', 'despite', 'good', 'met', 'in', 'by']","['diabetes', 'type', '1', 'good']",,,,
469,468,an investigational device exemption was approved by the Food and Drug Administration .,一项试验性器械豁免获得了食品和药物管理局的批准。,0.25,"['food and drug administration', 'device', 'exemption', 'by']",['device'],468,['调查设备豁免已由食品和药物管理局批准。'],0.5,"['food and drug administration', 'device', 'exemption', 'by']","['device', 'by']",468,美国食品与药物管理局已批准了一项调查性设备豁免。,0.25,"['food and drug administration', 'device', 'exemption', 'by']",['device'],,,,
470,469,an independent data and safety monitoring board provided trial oversight .,一个独立的数据和安全监督委员会提供试验监督。,0.4285714285714285,"['safety', 'monitoring', 'data', 'board', 'trial', 'independent', 'and']","['safety', 'data', 'independent']",469,['一个独立的数据和安全监测委员会提供审查监督。'],0.5714285714285714,"['safety', 'monitoring', 'data', 'board', 'trial', 'independent', 'and']","['safety', 'monitoring', 'data', 'independent']",469,一个独立的数据和安全监督委员会提供审查监督。,0.4285714285714285,"['safety', 'monitoring', 'data', 'board', 'trial', 'independent', 'and']","['safety', 'data', 'independent']",,,,
471,469,an independent data and safety monitoring board provided trial oversight .,一个独立的数据和安全监督委员会提供试验监督。,0.4285714285714285,"['safety', 'monitoring', 'data', 'board', 'trial', 'independent', 'and']","['safety', 'data', 'independent']",469,['一个独立的数据和安全监测委员会提供审查监督。'],0.5714285714285714,"['safety', 'monitoring', 'data', 'board', 'trial', 'independent', 'and']","['safety', 'monitoring', 'data', 'independent']",469,一个独立的数据和安全监督委员会提供审查监督。,0.4285714285714285,"['safety', 'monitoring', 'data', 'board', 'trial', 'independent', 'and']","['safety', 'data', 'independent']",,,,
472,470,"the first , second , and last authors vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol .",第一、第二和最后一位作者保证数据的完整性和准确性以及试验对方案的忠实度。,0.4444444444444444,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'second', 'and', 'first']","['data', 'accuracy', 'completeness', 'first']",470,['第一、第二、最后的作者对数据的完整性和准确性以及审判对议定书的忠诚性表示赞扬。'],0.6666666666666666,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'second', 'and', 'first']","['data', 'accuracy', 'protocol', 'trial', 'completeness', 'first']",470,第一作者，第二作者和最后一位作者为数据的完整性和准确性负责，并保证实验符合协议。,0.5555555555555556,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'second', 'and', 'first']","['data', 'accuracy', 'protocol', 'completeness', 'first']",,,,
473,471,funding was provided by the National Institute of Diabetes and Digestive and Kidney Diseases .,资金由国家糖尿病、消化和肾脏疾病研究所提供。,0.6666666666666666,"['diabetes', 'kidney', 'digestive', 'institute', 'by', 'and']","['diabetes', 'kidney', 'institute', 'by']",471,['该基金由国家糖尿病和消化和肾脏疾病研究所提供。'],0.6666666666666666,"['diabetes', 'kidney', 'digestive', 'institute', 'by', 'and']","['diabetes', 'kidney', 'institute', 'by']",471,资金由国家糖尿病和消化与肾脏疾病研究所提供。,0.6666666666666666,"['diabetes', 'kidney', 'digestive', 'institute', 'by', 'and']","['diabetes', 'kidney', 'institute', 'by']",,,,
474,472,"tandem Diabetes Care reviewed the manuscript but was not otherwise involved in the trial design , conduct , data analysis , or manuscript preparation .",tandem Diabetes Care 审阅了手稿，但未参与试验设计、实施、数据分析或手稿准备。,0.5,"['tandem', 'diabetes', 'data', 'analysis', 'preparation', 'manuscript', 'trial', 'conduct', 'care', 'design', 'in', 'but']","['data', 'analysis', 'preparation', 'manuscript', 'design', 'but']",472,"['tandem Diabetes Care 审查了手稿,但没有其他参与试验设计、行为、数据分析或手稿编制。']",0.4166666666666667,"['tandem', 'diabetes', 'data', 'analysis', 'preparation', 'manuscript', 'trial', 'conduct', 'care', 'design', 'in', 'but']","['data', 'analysis', 'manuscript', 'design', 'but']",472,"Tandem Diabetes Care reviewed the manuscript but was not otherwise involved in the trial design, conduct, data analysis, or manuscript preparation.",0.0,"['tandem', 'diabetes', 'data', 'analysis', 'preparation', 'manuscript', 'trial', 'conduct', 'care', 'design', 'in', 'but']",[],,,,
475,473,"to be included in the trial , patients had to be at least 14 years old and have a clinical diagnosis of type 1 diabetes ; they also had to have been treated with insulin for at least 1 year by means of a pump or multiple daily injections , without a restriction on the glycated hemoglobin level ( complete eligibility criteria are described in Table S1 in the Supplementary Appendix , available at NEJM.org ) .",被纳入试验的患者必须至少年满 14 岁，并且有 1 型糖尿病的临床诊断；他们还必须通过胰岛素泵或每日多次注射接受胰岛素治疗至少 1 年，且糖化血红蛋白水平不受限制（完整的资格标准见补充附录表 S1，补充附录可在 NEJM 获取。组织）。,0.375,"['insulin', 'diabetes', 'type', 'appendix', 'table', 'multiple', 'supplementary', 'years old', 'complete', 'hemoglobin level', 'restriction', 'available', 'clinical diagnosis', 'trial', 'means', 'at', 'injections', 'pump', 'S1', 'have', 'by', 'to', 'and', 'without']","['insulin', 'diabetes', 'type', 'table', 'years old', 'complete', 'clinical diagnosis', 'pump', 'have']",473,"['要参与试验,患者必须至少14岁,并具有1型糖尿病的临床诊断;他们也必须用胰岛素治疗至少1年,通过泵或多次每日注射,没有对血糖血糖水平的限制(完整的可选性标准如表S1所描述的补充附件,可在NEJM.org上找到)。']",0.4166666666666667,"['insulin', 'diabetes', 'type', 'appendix', 'table', 'multiple', 'supplementary', 'years old', 'complete', 'hemoglobin level', 'restriction', 'available', 'clinical diagnosis', 'trial', 'means', 'at', 'injections', 'pump', 'S1', 'have', 'by', 'to', 'and', 'without']","['insulin', 'diabetes', 'type', 'appendix', 'table', 'years old', 'complete', 'clinical diagnosis', 'pump', 'have']",473,为了纳入试验，病人必须至少14岁，并且在临床上被诊断为1型糖尿病；此外，他们还必须使用泵或多次每日注射的方式接受了至少1年的胰岛素治疗，而且血糖含量无限制（完整的资格标准请见补充附件1中的表格S1，可在NEJM.org上找到）。,0.4166666666666667,"['insulin', 'diabetes', 'type', 'appendix', 'table', 'multiple', 'supplementary', 'years old', 'complete', 'hemoglobin level', 'restriction', 'available', 'clinical diagnosis', 'trial', 'means', 'at', 'injections', 'pump', 'S1', 'have', 'by', 'to', 'and', 'without']","['insulin', 'diabetes', 'type', 'appendix', 'table', 'years old', 'complete', 'pump', 'and', 'without']",,,,
476,474,patients in the control group received a continuous glucose monitor ; patients who had used a pump before participating in the trial used their personal pumps .,对照组患者接受连续血糖监测；在参与试验前使用过泵的患者使用了他们的个人泵。,0.4444444444444444,"['glucose', 'monitor', 'who', 'continuous', 'personal', 'control group', 'trial', 'pump', 'before']","['continuous', 'control group', 'pump', 'before']",474,['控制组的患者接受了持续的葡萄糖监测;在参加试验之前使用泵的患者使用了自己的个人泵。'],0.4444444444444444,"['glucose', 'monitor', 'who', 'continuous', 'personal', 'control group', 'trial', 'pump', 'before']","['glucose', 'personal', 'pump', 'before']",474,研究对象在对照组中使用了连续血糖监测器；而使用过泵的研究对象则继续使用自己的个人泵。,0.4444444444444444,"['glucose', 'monitor', 'who', 'continuous', 'personal', 'control group', 'trial', 'pump', 'before']","['continuous', 'personal', 'control group', 'pump']",,,,
477,475,data from the devices were downloaded and reviewed at each visit and during telephone contacts .,每次访问和电话联系时，都会下载和审查来自设备的数据。,0.4,"['data', 'telephone', 'each', 'and', 'visit']","['data', 'telephone']",475,['设备上的数据在每次访问和电话接触时都被下载和审查。'],0.4,"['data', 'telephone', 'each', 'and', 'visit']","['data', 'telephone']",475,设备中的数据在每次访问和电话联系期间都会被下载和审查。,0.4,"['data', 'telephone', 'each', 'and', 'visit']","['data', 'telephone']",,,,
478,476,glycated hemoglobin also was measured at randomization and after 13 and 26 weeks at a central laboratory at the University of Minnesota Advanced Research and Diagnostic Laboratory .,还在明尼苏达大学高级研究与诊断实验室的中心实验室随机化以及 13 周和 26 周后测量了糖化血红蛋白。,0.6666666666666666,"['research', 'randomization', 'hemoglobin', 'university', 'central', 'after', 'advanced', 'laboratory', 'diagnostic']","['research', 'randomization', 'hemoglobin', 'university', 'after', 'laboratory']",476,['血糖血糖也被测量在随机化和13和26周后在密内索塔大学先进研究和诊断实验室的中央实验室。'],0.5555555555555556,"['research', 'randomization', 'hemoglobin', 'university', 'central', 'after', 'advanced', 'laboratory', 'diagnostic']","['research', 'randomization', 'university', 'after', 'laboratory']",476,随机测量血红蛋白糖化物，并在明尼苏达大学高级研究和诊断实验室的13周和26周后进行测量。,0.6666666666666666,"['research', 'randomization', 'hemoglobin', 'university', 'central', 'after', 'advanced', 'laboratory', 'diagnostic']","['research', 'randomization', 'hemoglobin', 'university', 'after', 'laboratory']",,,,
479,477,reporting of adverse events was solicited throughout the trial .,在整个试验过程中征求不良事件的报告。,0.0,"['adverse', 'trial']",[],477,"['在审判期间,被要求报告不良事件。']",0.5,"['adverse', 'trial']",['trial'],477,"Adverse event reporting was solicited throughout the trial.

中文：
在整个试验期间都在征求不良事件报告。",0.0,"['adverse', 'trial']",[],,,,
480,478,"reportable adverse events included serious adverse events , adverse events occurring in association with a trial device or procedure , severe hypoglycemia ( defined as hypoglycemia leading to the need for assistance because of altered consciousness ) , diabetic ketoacidosis as defined by the Diabetes Control and Complications Trial , 11 or hyperglycemia with ketonemia for which a health care provider was contacted .",可报告的不良事件包括严重不良事件、与试验装置或程序相关的不良事件、严重低血糖（定义为因意识改变而导致需要帮助的低血糖）、糖尿病控制和并发症试验定义的糖尿病酮症酸中毒、 11 或高血糖伴酮血症，为此联系了医疗保健提供者。,0.4545454545454545,"['diabetes', 'procedure', 'control', 'defined', 'need', 'hypoglycemia', 'device', 'consciousness', 'association', 'diabetic', 'adverse', 'hyperglycemia', 'health care', 'trial', 'leading', 'assistance', 'with', 'severe', 'serious', 'by', 'to', 'and']","['diabetes', 'procedure', 'control', 'need', 'device', 'consciousness', 'association', 'hyperglycemia', 'health care', 'and']",478,"['报告可能的不良事件包括严重的不良事件,与测试设备或程序相结合发生的不良事件,严重的低血糖(定义为由于意识变化的帮助需要导致的低血糖),糖尿病细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞']",0.3636363636363636,"['diabetes', 'procedure', 'control', 'defined', 'need', 'hypoglycemia', 'device', 'consciousness', 'association', 'diabetic', 'adverse', 'hyperglycemia', 'health care', 'trial', 'leading', 'assistance', 'with', 'severe', 'serious', 'by', 'to', 'and']","['diabetes', 'procedure', 'need', 'device', 'consciousness', 'association', 'by', 'to']",478,报告的不良事件包括严重的不良事件、与试验设备或程序相关联的不良事件、严重低血糖（定义为低血糖导致需要更改意识状态的帮助）、糖尿病并发症控制与临床试验中确定的糖尿病酮症酸中毒11或酮症高血糖且联系了医疗保健提供者。,0.4545454545454545,"['diabetes', 'procedure', 'control', 'defined', 'need', 'hypoglycemia', 'device', 'consciousness', 'association', 'diabetic', 'adverse', 'hyperglycemia', 'health care', 'trial', 'leading', 'assistance', 'with', 'severe', 'serious', 'by', 'to', 'and']","['diabetes', 'procedure', 'control', 'defined', 'need', 'device', 'consciousness', 'association', 'hyperglycemia', 'health care']",,,,
481,479,"the primary outcome was the percentage of time that the glucose level , as measured by the continuous glucose monitor , was in the target range of 70 to 180 mg per deciliter ( 3.9 to 10.0 mmol per liter ) .",主要结果是连续血糖监测仪测量的血糖水平处于 70 至 180 毫克/分升（3.9 至 10.0 毫摩尔/升）目标范围内的时间百分比。,0.5,"['percentage', 'glucose', 'monitor', 'range', 'outcome', 'continuous', 'deciliter', 'time', 'primary', 'target', 'level', 'as', 'that', 'by']","['range', 'outcome', 'continuous', 'time', 'target', 'level', 'that']",479,"['主要结果是糖水平在持续的糖监测器测量的时间比例,在每分升70至180毫克(每升3.9至10.0毫莫尔)的目标范围内。']",0.4285714285714285,"['percentage', 'glucose', 'monitor', 'range', 'outcome', 'continuous', 'deciliter', 'time', 'primary', 'target', 'level', 'as', 'that', 'by']","['range', 'outcome', 'time', 'target', 'level', 'that']",479,研究的主要结果是连续血糖监测器测得的血糖水平在70-180毫克/分升（3.9-10.0毫摩尔/升）目标范围内所占的时间比例。,0.5,"['percentage', 'glucose', 'monitor', 'range', 'outcome', 'continuous', 'deciliter', 'time', 'primary', 'target', 'level', 'as', 'that', 'by']","['range', 'outcome', 'continuous', 'time', 'target', 'level', 'that']",,,,
482,480,"the main secondary outcomes , which were tested in a hierarchical fashion to maintain a type I error rate of 5 % , were the percentage of time that the glucose level was greater than 180 mg per deciliter , the mean glucose concentration , the glycated hemoglobin level at 26 weeks , the percentage of time that the glucose level was less than 70 mg per deciliter , and the percentage of time that the glucose level was less than 54 mg per deciliter ( 3.0 mmol per liter ) .",主要的次要结局是血糖水平高于 180 mg/dL 的时间百分比、平均血糖浓度、糖化血红蛋白水平26 周时，血糖水平低于 70 毫克/分升的时间百分比，以及血糖水平低于 54 毫克/分升（3.0 毫摩尔/升）的时间百分比。,0.375,"['percentage', 'type', '5', 'glucose', 'concentration', 'mean', 'deciliter', 'maintain', 'time', 'hemoglobin level', 'secondary', 'I', 'that', 'to', 'and', 'error rate']","['5', 'concentration', 'mean', 'time', 'that', 'to']",480,"['主要的次要结果,以序列的方式进行测试,以保持类型I错误率为5%,是葡萄糖水平超过180毫克每分,平均葡萄糖浓度26周,葡萄糖水平低于70毫克每分,葡萄糖水平低于54毫克每分,葡萄糖水平低于54毫克每分,葡萄糖水平低于30毫克每分。']",0.4375,"['percentage', 'type', '5', 'glucose', 'concentration', 'mean', 'deciliter', 'maintain', 'time', 'hemoglobin level', 'secondary', 'I', 'that', 'to', 'and', 'error rate']","['type', '5', 'glucose', 'concentration', 'mean', 'to', 'error rate']",480,主要次要结果在分层测试中以5%的Type I误差率为标准进行测试，包括葡萄糖水平大于180毫克/分升（10克）的时间百分比、平均葡萄糖浓度、糖化血红蛋白水平26周、葡萄糖水平小于70毫克/分升（10克）的时间百分比和葡萄糖水平小于54毫克/分升（10克）的时间百分比（3.0毫克/升）。,0.375,"['percentage', 'type', '5', 'glucose', 'concentration', 'mean', 'deciliter', 'maintain', 'time', 'hemoglobin level', 'secondary', 'I', 'that', 'to', 'and', 'error rate']","['5', 'glucose', 'concentration', 'mean', 'time', 'to']",,,,
483,481,"additional secondary outcomes , for which the type I error was controlled with the use of the false discovery rate , are listed in the statistical analysis plan .",使用错误发现率控制 I 类错误的其他次要结果列在统计分析计划中。,0.3636363636363636,"['type', 'rate', 'false', 'controlled', 'additional', 'secondary', 'error', 'statistical analysis', 'with', 'I', 'in']","['rate', 'controlled', 'error', 'statistical analysis']",481,"['额外的次要结果,以便使用虚假发现率控制 I 类错误,在统计分析计划中列出。']",0.4545454545454545,"['type', 'rate', 'false', 'controlled', 'additional', 'secondary', 'error', 'statistical analysis', 'with', 'I', 'in']","['rate', 'controlled', 'additional', 'error', 'statistical analysis']",481,附加的次要结果，其中类型I错误使用假发现率进行了控制，列在统计分析计划中。,0.5454545454545454,"['type', 'rate', 'false', 'controlled', 'additional', 'secondary', 'error', 'statistical analysis', 'with', 'I', 'in']","['type', 'rate', 'controlled', 'additional', 'error', 'statistical analysis']",,,,
484,482,"safety outcomes included the frequency of severe hypoglycemia , diabetic ketoacidosis , and other serious adverse events .",安全性结果包括严重低血糖、糖尿病酮症酸中毒和其他严重不良事件的发生率。,0.125,"['safety', 'frequency', 'hypoglycemia', 'diabetic', 'adverse', 'severe', 'serious', 'and']",['safety'],482,['安全结果包括严重的低血糖、糖尿病细菌和其他严重的副作用的频率。'],0.25,"['safety', 'frequency', 'hypoglycemia', 'diabetic', 'adverse', 'severe', 'serious', 'and']","['safety', 'frequency']",482,安全结果包括严重低血糖、糖尿病酮症酸中毒和其他严重不良事件的发生频率。,0.25,"['safety', 'frequency', 'hypoglycemia', 'diabetic', 'adverse', 'severe', 'serious', 'and']","['safety', 'frequency']",,,,
485,483,modification of the treatment effect according to baseline variables was assessed by including an interaction term in the models described above .,根据基线变量对治疗效果的修改是通过在上述模型中包含一个交互项来评估的。,0.375,"['modification', 'baseline', 'term', 'interaction', 'treatment effect', 'by', 'to', 'assessed']","['baseline', 'term', 'treatment effect']",483,"['根据基线变量对治疗效应的修改,通过在上述模型中包含互动术语来评估。']",0.125,"['modification', 'baseline', 'term', 'interaction', 'treatment effect', 'by', 'to', 'assessed']",['baseline'],483,在上述模型中加入交互作用项以评估基线变量对治疗效果的修正作用。,0.5,"['modification', 'baseline', 'term', 'interaction', 'treatment effect', 'by', 'to', 'assessed']","['baseline', 'term', 'treatment effect', 'by']",,,,
486,484,the analyses of the data at 13 weeks paralleled those of the data at 26 weeks .,13 周时的数据分析与 26 周时的数据分析平行。,1.0,['data'],['data'],484,['13周的数据分析与26周的数据分析相匹配。'],1.0,['data'],['data'],484,数据的13周分析与数据的26周分析相似。,1.0,['data'],['data'],,,,
487,485,"descriptive statistics include means with standard deviations and medians with interquartile ranges , depending on the distribution of data .",描述性统计包括具有标准差的均值和具有四分位数间距的中位数，具体取决于数据的分布。,0.5,"['standard', 'data', 'distribution', 'means', 'descriptive statistics', 'with']","['standard', 'data', 'distribution']",485,"['描述统计包括具有标准偏差的媒体和跨方范围的媒体,取决于数据的分布。']",0.5,"['standard', 'data', 'distribution', 'means', 'descriptive statistics', 'with']","['standard', 'data', 'distribution']",485,统计学描述包括有标准差的平均值和有四分位数范围的中位数，这取决于数据的分布。,0.5,"['standard', 'data', 'distribution', 'means', 'descriptive statistics', 'with']","['standard', 'data', 'distribution']",,,,
488,486,"analyses were performed with SAS software , version 9.4 ( SAS Institute ) .",使用 SAS 软件 9.4 版（SAS Institute）进行分析。,0.2,"['version', 'software', 'institute', 'with', 'SAS']",['software'],486,"['分析是用SAS软件进行的,版本 9.4(SAS研究所)。']",0.6,"['version', 'software', 'institute', 'with', 'SAS']","['version', 'software', 'institute']",486,"analyses were performed with SAS software, version 9.4 (SAS Institute).

中文：

使用SAS软件，版本9.4（SAS Institute）进行了分析。",0.4,"['version', 'software', 'institute', 'with', 'SAS']","['version', 'software']",,,,
489,486,"analyses were performed with SAS software , version 9.4 ( SAS Institute ) .",使用 SAS 软件 9.4 版（SAS Institute）进行分析。,0.2,"['version', 'software', 'institute', 'with', 'SAS']",['software'],486,"['分析是用SAS软件进行的,版本 9.4(SAS研究所)。']",0.6,"['version', 'software', 'institute', 'with', 'SAS']","['version', 'software', 'institute']",486,"analyses were performed with SAS software, version 9.4 (SAS Institute).

中文：

使用SAS软件，版本9.4（SAS Institute）进行了分析。",0.4,"['version', 'software', 'institute', 'with', 'SAS']","['version', 'software']",,,,
490,487,"insulin pumps were used by 133 patients ( 79 % ) , and multiple daily insulin injections were used by 35 ( 21 % ) ; 118 ( 70 % ) were using continuous glucose monitoring , and 102 ( 86 % ) of these were using pumps .",133 名患者 (79%) 使用了胰岛素泵，35 名患者 (21%) 使用了每日多次胰岛素注射； 118 人 (70%) 使用连续血糖监测，其中 102 人 (86%) 使用泵。,0.375,"['monitoring', 'insulin', 'glucose', 'continuous', 'multiple', 'injections', 'by', 'and']","['monitoring', 'insulin', 'continuous']",487,"['胰岛素泵由133名患者(79%)使用,35名患者(21%)每天使用多种胰岛素注射;118名患者(70%)使用持续的葡萄糖监测,其中102名患者(86%)使用泵。']",0.5,"['monitoring', 'insulin', 'glucose', 'continuous', 'multiple', 'injections', 'by', 'and']","['monitoring', 'insulin', 'glucose', 'by']",487,糖尿病患者使用胰岛素泵的人数为133人（79%），使用多次每日胰岛素注射的人数为35人（21%）；使用连续血糖监测的人数为118人（70%），使用胰岛素泵的人数为102人（86%）。,0.375,"['monitoring', 'insulin', 'glucose', 'continuous', 'multiple', 'injections', 'by', 'and']","['monitoring', 'insulin', 'continuous']",,,,
491,488,the treatment effect was evident in the first month and was consistent over the 6 months ( Figure 1A ) .,治疗效果在第一个月就很明显，并且在 6 个月内保持一致（图 1A）。,0.4285714285714285,"['figure', 'month', 'treatment effect', 'in', 'over', 'and', 'first']","['month', 'treatment effect', 'first']",488,"['治疗效果在第一个月显而易见,并在6个月内保持一致(图1A)。']",0.5714285714285714,"['figure', 'month', 'treatment effect', 'in', 'over', 'and', 'first']","['month', 'treatment effect', 'and', 'first']",488,"the treatment effect was evident in the first month and was consistent over the 6 months (Figure 1A).

Chinese:

治疗效果在第一个月就明显了,并且在6个月里一直保持稳定(图1A)。",0.4285714285714285,"['figure', 'month', 'treatment effect', 'in', 'over', 'and', 'first']","['month', 'treatment effect', 'first']",,,,
492,489,"this diurnal pattern , shown in Figure 1B , is a result of the increased aggressiveness of the algorithm to meet a lower glucose target during the second half of the night .",如图 1B 所示，这种昼夜模式是算法在后半夜为满足较低葡萄糖目标而增加攻击性的结果。,0.5333333333333333,"['glucose', 'pattern', 'algorithm', 'figure', 'half', 'lower', 'target', 'diurnal', 'result', 'aggressiveness', 'second', 'this', 'in', 'to', 'night']","['glucose', 'pattern', 'algorithm', 'half', 'target', 'result', 'this', 'night']",489,"['这个日常模式,显示在图1B,是由于算法的侵略性增加的结果,以满足低血糖目标在第二半夜间。']",0.6,"['glucose', 'pattern', 'algorithm', 'figure', 'half', 'lower', 'target', 'diurnal', 'result', 'aggressiveness', 'second', 'this', 'in', 'to', 'night']","['pattern', 'algorithm', 'half', 'target', 'result', 'aggressiveness', 'this', 'to', 'night']",489,这种日冕式模式，如图1B所示，是算法在夜间后半段加大攻击性以达到较低的葡萄糖目标的结果。,0.6,"['glucose', 'pattern', 'algorithm', 'figure', 'half', 'lower', 'target', 'diurnal', 'result', 'aggressiveness', 'second', 'this', 'in', 'to', 'night']","['glucose', 'pattern', 'algorithm', 'half', 'lower', 'target', 'result', 'this', 'night']",,,,
493,490,there was no significant difference between the groups in the daily insulin amount ( P = 0.83 ) or in weight change ( P = 0.83 ) ( Table S8 ) .,每日胰岛素用量 (P = 0.83) 或体重变化 (P = 0.83) 组间无显着差异（表 S8）。,0.625,"['insulin', 'weight', 'table', 'amount', 'no', 'change', 'P', 'significant difference']","['insulin', 'weight', 'table', 'amount', 'change']",490,"['在每日胰岛素量(P = 0.83 )或体重变化(P = 0.83 )中,群体之间没有显著的差异(表 S8)。']",0.625,"['insulin', 'weight', 'table', 'amount', 'no', 'change', 'P', 'significant difference']","['insulin', 'weight', 'table', 'amount', 'change']",490,There was no significant difference between the groups in the daily insulin amount (P = 0.83) or in weight change (P = 0.83) (Table S8).,0.0,"['insulin', 'weight', 'table', 'amount', 'no', 'change', 'P', 'significant difference']",[],,,,
494,491,system USE,系统使用,1.0,['system'],['system'],491,['系统使用'],1.0,['system'],['system'],491,"系统使用

Chinese:

系统使用",1.0,['system'],['system'],,,,
495,492,severe hypoglycemia did not occur in either group .,两组均未发生严重低血糖。,0.4,"['group', 'hypoglycemia', 'occur', 'severe', 'in']","['group', 'occur']",492,['严重的甲状腺炎在任何群体中都没有发生。'],0.4,"['group', 'hypoglycemia', 'occur', 'severe', 'in']","['group', 'occur']",492,严重的低血糖并未发生在任何一组中。,0.4,"['group', 'hypoglycemia', 'occur', 'severe', 'in']","['group', 'occur']",,,,
496,493,no severe hypoglycemic events occurred in either group .,两组均未发生严重低血糖事件。,0.2,"['group', 'no', 'severe', 'hypoglycemic', 'in']",['group'],493,['在任何一个群体中都没有发生过严重的催眠现象。'],0.2,"['group', 'no', 'severe', 'hypoglycemic', 'in']",['group'],493,没有发生严重的低血糖事件。,0.0,"['group', 'no', 'severe', 'hypoglycemic', 'in']",[],,,,
497,494,"in our trial , 70 % of the patients were using a continuous glucose monitor and 79 % were using an insulin pump at the time of enrollment , percentages that are substantially higher than the reported usage in the general population of patients with type 1 diabetes.2",在我们的试验中，70 % 的患者在入组时使用连续血糖监测仪，而 79 % 的患者在使用胰岛素泵，这些百分比大大高于报告的 1 型糖尿病患者一般人群的使用率。 2,0.6,"['insulin', 'population', 'type', 'glucose', 'monitor', '1', 'continuous', 'general', 'time', 'usage', 'trial', 'with', 'pump', 'that', 'and']","['insulin', 'population', 'type', '1', 'continuous', 'time', 'usage', 'pump', 'and']",494,"['在我们的研究中,70%的患者使用持续的葡萄糖监测器,79%在注册时使用胰岛素泵,比1型糖尿病患者的总体人口所报告的使用量要高得多。']",0.5333333333333333,"['insulin', 'population', 'type', 'glucose', 'monitor', '1', 'continuous', 'general', 'time', 'usage', 'trial', 'with', 'pump', 'that', 'and']","['insulin', 'population', 'type', 'glucose', '1', 'time', 'usage', 'pump']",494,在我们的试验中，70%的患者使用了持续血糖监测仪，79%的患者使用了胰岛素泵，这些数字比一般人群中1型糖尿病患者的使用率要高出许多。2,0.4,"['insulin', 'population', 'type', 'glucose', 'monitor', '1', 'continuous', 'general', 'time', 'usage', 'trial', 'with', 'pump', 'that', 'and']","['insulin', 'population', 'type', '1', 'usage', 'pump']",,,,
498,495,"however , our results appeared to be similar in patients who were not using a pump or a continuous glucose monitor before the trial .",然而，在试验前未使用泵或连续血糖监测仪的患者中，我们的结果似乎相似。,0.375,"['glucose', 'monitor', 'who', 'continuous', 'trial', 'pump', 'before', 'similar']","['continuous', 'pump', 'before']",495,"['然而,我们的结果似乎与在测试之前没有使用泵或持续的葡萄糖监测器的患者相似。']",0.375,"['glucose', 'monitor', 'who', 'continuous', 'trial', 'pump', 'before', 'similar']","['glucose', 'pump', 'before']",495,然而，我们的结果似乎在没有使用泵或持续血糖监测器的患者中是相似的。,0.25,"['glucose', 'monitor', 'who', 'continuous', 'trial', 'pump', 'before', 'similar']","['pump', 'similar']",,,,
499,496,"strengths of the present trial include the inclusion of patients across a wide range of baseline characteristics , 100 % patient retention , and a high level of adherence to the use of the assigned devices in both treatment groups .",本试验的优势包括纳入具有广泛基线特征的患者、100% 的患者保留率以及两个治疗组对指定设备使用的高度依从性。,0.375,"['range', 'baseline', 'retention', 'inclusion', 'wide', 'treatment', 'across', 'characteristics', 'patient', 'trial', 'present', 'level', 'adherence', 'to', 'and', 'high']","['baseline', 'retention', 'treatment', 'characteristics', 'patient', 'high']",496,"['本次研究的优点包括患者在广泛的基因特征中参与,患者的百分之百保留,以及在两组治疗中使用所分配的设备的高度坚持。']",0.375,"['range', 'baseline', 'retention', 'inclusion', 'wide', 'treatment', 'across', 'characteristics', 'patient', 'trial', 'present', 'level', 'adherence', 'to', 'and', 'high']","['retention', 'wide', 'treatment', 'characteristics', 'patient', 'high']",496,本次试验的优势包括在治疗组中包括各种不同基线特征的患者、100%的患者保留率以及对所分配的设备的使用的高度遵从性。,0.375,"['range', 'baseline', 'retention', 'inclusion', 'wide', 'treatment', 'across', 'characteristics', 'patient', 'trial', 'present', 'level', 'adherence', 'to', 'and', 'high']","['baseline', 'retention', 'treatment', 'characteristics', 'patient', 'high']",,,,
500,497,"continuous glucose monitoring was used by both groups , with minimal reliance on blood glucose measurements .",两组均使用连续血糖监测，对血糖测量的依赖最小。,0.5,"['monitoring', 'continuous', 'minimal', 'blood glucose', 'with', 'by']","['monitoring', 'continuous', 'blood glucose']",497,"['持续的葡萄糖监测是由两组使用的,与血糖测量的最低依赖。']",0.5,"['monitoring', 'continuous', 'minimal', 'blood glucose', 'with', 'by']","['monitoring', 'blood glucose', 'by']",497,连续血糖监测被两组人都使用，对血糖测量的依赖性很小。,0.5,"['monitoring', 'continuous', 'minimal', 'blood glucose', 'with', 'by']","['monitoring', 'continuous', 'blood glucose']",,,,
501,498,our trial also had certain limitations .,我们的试验也有一定的局限性。,0.0,"['trial', 'certain']",[],498,['我们的审判也有一些限制。'],0.5,"['trial', 'certain']",['trial'],498,"Our trial also had certain limitations.

Chinese:

我们的试用也有一定的局限性。",0.0,"['trial', 'certain']",[],,,,
502,499,outcomes were similar in a randomized comparison of these approaches .,这些方法的随机比较结果相似。,0.3333333333333333,"['comparison', 'in', 'similar']",['comparison'],499,['结果在这些方法的随机比较中相似。'],0.3333333333333333,"['comparison', 'in', 'similar']",['comparison'],499,结果在这些方法的随机比较中相似。,0.3333333333333333,"['comparison', 'in', 'similar']",['comparison'],,,,
503,500,hemiarthroplasty ( replacement of only the femoral head ) and total hip arthroplasty ( replacement of both the femoral head and acetabulum ) are both options for patients with displaced fractures of the femoral neck ; each approach has certain advantages and disadvantages .,半髋关节置换术（仅置换股骨头）和全髋关节置换术（置换股骨头和髋臼）都是股骨颈移位骨折患者的选择；每种方法都有一定的优点和缺点。,0.4285714285714285,"['approach', 'neck', 'acetabulum', 'total', 'hip', 'replacement', 'options', 'with', 'certain', 'femoral head', 'hemiarthroplasty', 'fractures', 'each', 'and']","['neck', 'acetabulum', 'hip', 'replacement', 'femoral head', 'fractures']",500,['hemiarthroplasty(只替代阴道头)和整体头骨动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动'],0.0,"['approach', 'neck', 'acetabulum', 'total', 'hip', 'replacement', 'options', 'with', 'certain', 'femoral head', 'hemiarthroplasty', 'fractures', 'each', 'and']",[],500,半关节置换术（仅替换股骨头）和全髋关节置换术（替换股骨头和髋臼）都是股骨颈骨折患者的选择；每种方法都有优缺点。,0.4285714285714285,"['approach', 'neck', 'acetabulum', 'total', 'hip', 'replacement', 'options', 'with', 'certain', 'femoral head', 'hemiarthroplasty', 'fractures', 'each', 'and']","['neck', 'acetabulum', 'hip', 'replacement', 'femoral head', 'fractures']",,,,
504,501,"in this international randomized trial , researchers compared the two procedures in 1495 patients .",在这项国际随机试验中，研究人员对 1495 名患者的两种手术进行了比较。,0.25,"['trial', 'this', 'in', 'two']",['two'],501,"['在这项国际随机研究中,研究人员在1495名患者中比较了两种程序。']",0.25,"['trial', 'this', 'in', 'two']",['two'],501,在这个国际随机化试验中，研究人员对1495名患者的两种程序进行了比较。,0.25,"['trial', 'this', 'in', 'two']",['two'],,,,
505,502,the primary endpoint - another hip procedure required and performed within 24 months - occurred in 8 % of patients in both groups .,主要终点——在 24 个月内需要并进行的另一次髋关节手术——发生在两组中 8% 的患者中。,0.1666666666666666,"['procedure', 'hip', 'primary', 'endpoint', '-', 'and']",['hip'],502,['初级终点 - 另一个需要并在24个月内进行的手术 - 发生在两组患者的8%。'],0.0,"['procedure', 'hip', 'primary', 'endpoint', '-', 'and']",[],502,主要终点 - 另一种髋部手术需要且在24个月内执行 - 在两组患者中均为8％。,0.1666666666666666,"['procedure', 'hip', 'primary', 'endpoint', '-', 'and']",['hip'],,,,
506,503,"conversely , some measures of pain and function favored total hip arthroplasty compared with hemiarthroplasty , but differences were small and did not meet standard thresholds for clinical importance .",相反，与股骨头置换术相比，一些疼痛和功能指标有利于全髋关节置换术，但差异很小，不符合临床重要性的标准阈值。,0.6666666666666666,"['standard', 'function', 'total', 'hip', 'pain', 'clinical', 'with', 'hemiarthroplasty', 'but']","['standard', 'function', 'hip', 'pain', 'clinical', 'but']",503,"['相比之下,某些疼痛和功能的测量有利于整体甲状腺炎与甲状腺炎相比,但差异很小,并且不符合临床意义的标准限制。']",0.5555555555555556,"['standard', 'function', 'total', 'hip', 'pain', 'clinical', 'with', 'hemiarthroplasty', 'but']","['standard', 'function', 'pain', 'clinical', 'but']",503,相反，一些疼痛和功能测量更倾向于全髋关节置换，而不是半膝关节置换，但差异很小，并不达到临床重要性的标准。,0.6666666666666666,"['standard', 'function', 'total', 'hip', 'pain', 'clinical', 'with', 'hemiarthroplasty', 'but']","['standard', 'function', 'hip', 'pain', 'clinical', 'but']",,,,
507,504,"most children received breast milk , alone or with formula ; only 70 received formula alone .",大多数儿童单独或与配方奶粉一起吃母乳；只有 70 人收到了配方奶粉。,0.5,"['formula', 'breast milk', 'with', 'alone']","['breast milk', 'alone']",504,['大多数儿童单独或服用乳制品;只有70人单独服用乳制品。'],0.25,"['formula', 'breast milk', 'with', 'alone']",['alone'],504,大多数儿童都是靠母乳喂养的，或者是配合配方奶粉，只有70个儿童只靠配方奶粉喂养。,0.25,"['formula', 'breast milk', 'with', 'alone']",['breast milk'],,,,
508,505,median gestational age was 29 weeks .,中位孕龄为 29 周。,0.5,"['median', 'gestational age']",['gestational age'],505,['平均生育年龄为29周。'],0.0,"['median', 'gestational age']",[],505,中位数妊娠期为29周。,0.0,"['median', 'gestational age']",[],,,,
509,506,approximately 95 % of participants in each group survived to 24 months ( corrected for gestational age ) .,每组中大约 95% 的参与者存活到 24 个月（校正胎龄）。,0.125,"['group', 'gestational age', 'survived', 'approximately', 'each', 'in', 'to', 'corrected']",['group'],506,['大约95%的参与者在每个群体中幸存到24个月(修正为怀孕年龄)。'],0.125,"['group', 'gestational age', 'survived', 'approximately', 'each', 'in', 'to', 'corrected']",['group'],506,"约95%的参与者在每组中都存活到了24个月（校正了妊娠年龄）。

Chinese:

每组参与者中约95%的人存活到了24个月（已纠正妊娠年龄）。",0.125,"['group', 'gestational age', 'survived', 'approximately', 'each', 'in', 'to', 'corrected']",['group'],,,,
510,507,few adverse events occurred .,很少发生不良事件。,0.0,['adverse'],[],507,['有几个不良事件发生。'],0.0,['adverse'],[],507,这里发生了一些不利的事件。,0.0,['adverse'],[],,,,
511,508,"although this important study does not help define a preferred feeding protocol for very premature infants , it offers reassurance that careful feeding with daily increases of either 30 or 18 mL / kg has comparable outcomes .",尽管这项重要的研究无助于为极早产儿确定首选的喂养方案，但它提供了保证，每天增加 30 或 18 mL/kg 的小心喂养具有可比的结果。,0.0833333333333333,"['protocol', '/', 'study', 'feeding', 'increases', 'kg', 'premature', 'ml', 'with', 'careful', 'this', 'that']",['premature'],508,"['虽然这项重要研究并没有帮助确定非常早期婴儿的偏好营养协议,但它提供了重新保证,每天增加30或18毫升/公斤的谨慎营养有相似的结果。']",0.3333333333333333,"['protocol', '/', 'study', 'feeding', 'increases', 'kg', 'premature', 'ml', 'with', 'careful', 'this', 'that']","['protocol', 'kg', 'premature', 'careful']",508,虽然这项重要的研究并未帮助确定非常早产儿的首选喂养方案，但它为每天增加30或18毫升/公斤的仔细喂养提供了同样的结果。,0.1666666666666666,"['protocol', '/', 'study', 'feeding', 'increases', 'kg', 'premature', 'ml', 'with', 'careful', 'this', 'that']","['kg', 'premature']",,,,
512,509,"dupilumab now is approved for patients with chronic sinusitis and polyps , asthma , and eczema .",dupilumab 现在被批准用于患有慢性鼻窦炎和息肉、哮喘和湿疹的患者。,0.5714285714285714,"['asthma', 'sinusitis', 'eczema', 'chronic', 'with', 'dupilumab', 'and']","['asthma', 'sinusitis', 'eczema', 'chronic']",509,['dupilumab现在已被批准为患有慢性阴道炎和聚合物、哮喘和<unk>疹的患者。'],0.2857142857142857,"['asthma', 'sinusitis', 'eczema', 'chronic', 'with', 'dupilumab', 'and']","['asthma', 'chronic']",509,"Dupilumab is now approved for patients with chronic sinusitis and polyps, asthma, and eczema.",0.0,"['asthma', 'sinusitis', 'eczema', 'chronic', 'with', 'dupilumab', 'and']",[],,,,
513,510,"researchers examined whether dupilumab ( Dupixent ) , a monoclonal antibody that targets interleukin ( IL ) -4 and 13 and is approved for asthma and eczema , is effective for CRSwNP .",研究人员检查了 dupilumab (Dupixent)，一种靶向白细胞介素 (IL) -4 和 13 的单克隆抗体，被批准用于治疗哮喘和湿疹，是否对 CRSwNP 有效。,0.5,"['asthma', 'interleukin', 'monoclonal antibody', 'eczema', 'IL', 'dupilumab', 'that', 'and']","['asthma', 'interleukin', 'monoclonal antibody', 'eczema']",510,"['研究人员检查是否Dupilumab(Dupixent),一个针对Interleukin(IL) -4和13的单细胞抗体,并被批准为哮喘和<unk>疹,对CRSwNP有效。']",0.125,"['asthma', 'interleukin', 'monoclonal antibody', 'eczema', 'IL', 'dupilumab', 'that', 'and']",['asthma'],510,"研究人员研究了靶向了白介素4和13的抗体杜比星（Dupixent），它被批准用于哮喘和湿疹，是否有效用于CRSwNP。这种单克隆抗体曾被用于哮喘和湿疹。

Chinese:
研究人员检查了靶向白介素（IL）-4和13的单克隆抗体杜比星（Dupixent）是否对CRSwNP有效。杜比星目前已获得批准用于哮喘和湿疹治疗。",0.5,"['asthma', 'interleukin', 'monoclonal antibody', 'eczema', 'IL', 'dupilumab', 'that', 'and']","['asthma', 'interleukin', 'monoclonal antibody', 'eczema']",,,,
514,511,dupilumab generally was well tolerated .,dupilumab 通常耐受性良好。,0.0,"['well', 'dupilumab']",[],511,['dupilumab 一般被很好地容忍。'],0.0,"['well', 'dupilumab']",[],511,"dupilumab generally was well tolerated .

Chinese:

dupilumab 在一般情况下是被认可的。",0.0,"['well', 'dupilumab']",[],,,,
515,512,patients with CRSwNP tend to have poor quality of life .,CRSwNP 患者的生活质量往往较差。,0.1666666666666666,"['quality of life', 'with', 'have', 'poor', 'tend', 'to']",['quality of life'],512,['患有CRSwNP的患者往往生活质量不佳。'],0.3333333333333333,"['quality of life', 'with', 'have', 'poor', 'tend', 'to']","['quality of life', 'have']",512,CRSwNP patients tend to have poor quality of life.,0.0,"['quality of life', 'with', 'have', 'poor', 'tend', 'to']",[],,,,
516,513,"treatment is suboptimal , consisting of nasal corticosteroids and saline rinses , frequent bursts of systemic corticosteroids , and sinus surgery .",治疗效果欠佳，包括鼻皮质类固醇和生理盐水冲洗、全身性皮质类固醇的频繁爆发和鼻窦手术。,0.4444444444444444,"['sinus', 'saline', 'surgery', 'nasal', 'treatment', 'suboptimal', 'systemic', 'frequent', 'and']","['sinus', 'saline', 'surgery', 'treatment']",513,"['治疗是微优的,由鼻子和盐肾脏组成,经常出现系统性皮质和阴道手术。']",0.2222222222222222,"['sinus', 'saline', 'surgery', 'nasal', 'treatment', 'suboptimal', 'systemic', 'frequent', 'and']","['surgery', 'treatment']",513,治疗方案不理想，主要包括使用鼻用糖皮质激素和盐水漱口、频繁使用系统性糖皮质激素和手术治疗鼻窦炎。,0.4444444444444444,"['sinus', 'saline', 'surgery', 'nasal', 'treatment', 'suboptimal', 'systemic', 'frequent', 'and']","['sinus', 'saline', 'surgery', 'treatment']",,,,
517,514,"dupilumab already has gained FDA approval for managing CRSwNP but probably will be prescribed only by otolaryngologists , allergists , and pulmonologists .",dupilumab 已获得 FDA 批准用于管理 CRSwNP，但可能只会由耳鼻喉科医生、过敏症科医生和肺科医生开处方。,0.375,"['approval', 'be', 'FDA', 'will', 'dupilumab', 'by', 'but', 'and']","['approval', 'by', 'but']",514,['dupilumab 已经获得了 FDA 批准来管理 CRSwNP 但可能只会由肿瘤学家、过敏学家和肺学家处方。'],0.375,"['approval', 'be', 'FDA', 'will', 'dupilumab', 'by', 'but', 'and']","['approval', 'by', 'but']",514,dupilumab已经获得了FDA批准用于治疗CRSwNP，但可能只会被耳鼻咽喉科医生、过敏症医生和呼吸科医生开药。,0.25,"['approval', 'be', 'FDA', 'will', 'dupilumab', 'by', 'but', 'and']","['approval', 'but']",,,,
518,515,"and at a cost of US $ 43,000 annually , the drug could be a hard sell , especially when symptoms return after therapy stops .","并且每年花费 43,000 美元，这种药物可能很难销售，尤其是当治疗停止后症状再次出现时。",0.4545454545454545,"['hard', 'symptoms', 'therapy', 'be', 'after', 'cost', 'sell', 'drug', 'at', 'return', 'and']","['therapy', 'after', 'sell', 'drug', 'at']",515,"['每年43000美元的价格,该药物可能是一个艰难的销售,特别是当症状在治疗停止后回来时。']",0.6363636363636364,"['hard', 'symptoms', 'therapy', 'be', 'after', 'cost', 'sell', 'drug', 'at', 'return', 'and']","['hard', 'therapy', 'be', 'after', 'sell', 'drug', 'at']",515,药物的年成本高达43000美元，而且在治疗停止后，症状可能会再次出现，这很难销售。,0.6363636363636364,"['hard', 'symptoms', 'therapy', 'be', 'after', 'cost', 'sell', 'drug', 'at', 'return', 'and']","['therapy', 'be', 'after', 'cost', 'sell', 'drug', 'and']",,,,
519,516,"hemorrhage remains a leading cause of death after trauma , and resuscitation strategies continue to evolve .",出血仍然是创伤后死亡的主要原因，复苏策略也在不断发展。,0.4,"['trauma', 'hemorrhage', 'resuscitation', 'cause of death', 'after', 'evolve', 'leading', 'continue', 'to', 'and']","['trauma', 'hemorrhage', 'resuscitation', 'after']",516,"['出血仍然是创伤后死亡的主要原因,复兴策略仍在不断发展。']",0.3,"['trauma', 'hemorrhage', 'resuscitation', 'cause of death', 'after', 'evolve', 'leading', 'continue', 'to', 'and']","['trauma', 'hemorrhage', 'after']",516,失血仍然是创伤后死亡的主要原因，救护策略也在不断发展。,0.2,"['trauma', 'hemorrhage', 'resuscitation', 'cause of death', 'after', 'evolve', 'leading', 'continue', 'to', 'and']","['trauma', 'after']",,,,
520,517,"using a French trauma registry , researchers retrospectively compared outcomes between patients who received at least two units of FFP for every three units of PRBC and patients who received a lower ratio of FFP to PRBC .",使用法国创伤登记，研究人员回顾性地比较了每三个单位的 PRBC 接受至少两个单位的 FFP 的患者与接受较低的 FFP 与 PRBC 比率的患者之间的结果。,0.4444444444444444,"['trauma', 'who', 'ratio', 'lower', 'registry', 'three', 'to', 'and', 'two']","['trauma', 'ratio', 'lower', 'two']",517,"['使用法国创伤记录,研究人员回顾地比较了接受至少两单位FFP的患者和接受较低的FFP与PRBC的患者之间的结果。']",0.4444444444444444,"['trauma', 'who', 'ratio', 'lower', 'registry', 'three', 'to', 'and', 'two']","['trauma', 'ratio', 'lower', 'two']",517,使用法国的创伤登记册，研究人员回顾性地比较了至少每3单位PRBC收到2单位FFP的患者与收到较低比例FFP / PRBC的患者之间的结果。,0.2222222222222222,"['trauma', 'who', 'ratio', 'lower', 'registry', 'three', 'to', 'and', 'two']","['trauma', 'ratio']",,,,
521,518,"of 897 patients , 34 % died within 30 days ( the primary outcome ) .",在 897 名患者中，34% 的患者在 30 天内死亡（主要结果）。,0.5,"['outcome', 'primary']",['outcome'],518,"['在897名患者中,34%在30天内死亡(初始结果)。']",0.5,"['outcome', 'primary']",['outcome'],518,在897位病人中，34%在30天内死亡（主要结果）。,0.5,"['outcome', 'primary']",['outcome'],,,,
522,519,"an exsanguinating patient is losing whole blood , so resuscitation strategies resembling whole blood replacement have face validity .",失血的病人正在失去全血，因此像全血置换这样的复苏策略具有表面有效性。,0.75,"['face', 'validity', 'resuscitation', 'patient', 'replacement', 'whole blood', 'have', 'so']","['face', 'resuscitation', 'patient', 'replacement', 'whole blood', 'have']",519,"['一个流血的病人正在失去整个血液,因此复活策略类似于整个血液的替代具有面对面有效性。']",0.375,"['face', 'validity', 'resuscitation', 'patient', 'replacement', 'whole blood', 'have', 'so']","['face', 'patient', 'have']",519,一位血液流失过多的病人正在失去全部的血液，因此类似于全血替代的复苏策略具有面向有效性。,0.625,"['face', 'validity', 'resuscitation', 'patient', 'replacement', 'whole blood', 'have', 'so']","['face', 'resuscitation', 'patient', 'whole blood', 'have']",,,,
523,520,"however , this study should not be used as part of the evidence supporting ( or refuting ) any transfusion strategy .",然而，这项研究不应被用作支持（或反驳）任何输血策略的证据的一部分。,0.5,"['part', 'transfusion', 'strategy', 'study', 'be', 'evidence', 'as', 'this']","['part', 'transfusion', 'strategy', 'evidence']",520,"['然而,这项研究不应作为支持(或拒绝)任何转移策略的证据的一部分。']",0.375,"['part', 'transfusion', 'strategy', 'study', 'be', 'evidence', 'as', 'this']","['part', 'strategy', 'evidence']",520,然而，这项研究不应被用作支持（或反驳）任何输血策略的证据。,0.375,"['part', 'transfusion', 'strategy', 'study', 'be', 'evidence', 'as', 'this']","['transfusion', 'strategy', 'evidence']",,,,
524,521,"until better evidence is available , clinicians should continue to provide care tailored for each patient encounter .",在获得更好的证据之前，临床医生应继续为每位患者提供量身定制的护理。,0.375,"['encounter', 'available', 'patient', 'evidence', 'care', 'continue', 'each', 'to']","['patient', 'evidence', 'continue']",521,"['直到有更好的证据,临床医生应该继续为每个病人提供适当的护理。']",0.375,"['encounter', 'available', 'patient', 'evidence', 'care', 'continue', 'each', 'to']","['patient', 'evidence', 'continue']",521,直到有更好的证据可用，临床医师应继续为每次病人面谈提供量身定制的护理。,0.375,"['encounter', 'available', 'patient', 'evidence', 'care', 'continue', 'each', 'to']","['patient', 'evidence', 'continue']",,,,
525,522,"ticagrelor monotherapy was associated with less bleeding at 1 year than continued dual antiplatelet therapy and no higher risks for death , myocardial infarction , or stroke .",与持续的双重抗血小板治疗相比，替格瑞洛单药治疗与 1 年时的出血较少相关，并且死亡、心肌梗死或中风的风险没有增加。,0.5384615384615384,"['bleeding', 'myocardial infarction', 'stroke', 'year', '1', 'death', 'antiplatelet', 'therapy', 'associated', 'no', 'dual', 'with', 'and']","['bleeding', 'myocardial infarction', 'stroke', 'year', '1', 'death', 'therapy']",522,"['Ticagrelor 单治疗与 1 年内较少的出血有关,而持续的双重抗膜治疗,并且没有死亡、心脏病发作或中风的风险更高。']",0.5384615384615384,"['bleeding', 'myocardial infarction', 'stroke', 'year', '1', 'death', 'antiplatelet', 'therapy', 'associated', 'no', 'dual', 'with', 'and']","['bleeding', 'stroke', 'year', '1', 'death', 'therapy', 'and']",522,"ticagrelor monotherapy was associated with less bleeding at 1 year than continued dual antiplatelet therapy and no higher risks for death , myocardial infarction , or stroke .

Chinese:

在1年的时间里，与继续双组抗血小板治疗相比，赛乐洛单药治疗可减少出血，而且风险不会更高。",0.3846153846153846,"['bleeding', 'myocardial infarction', 'stroke', 'year', '1', 'death', 'antiplatelet', 'therapy', 'associated', 'no', 'dual', 'with', 'and']","['bleeding', 'year', '1', 'therapy', 'and']",,,,
526,523,"at 3 months , 7119 patients underwent randomization ( mean age , 65 ; diabetes , 37 % ; PCI for acute coronary syndrome , 65 % ) to continue this regimen or to receive ticagrelor alone .",在 3 个月时，7119 名患者被随机分组（平均年龄 65 岁；糖尿病，37%；急性冠状动脉综合征行 PCI，65%）以继续该方案或单独接受替格瑞洛。,0.6666666666666666,"['diabetes', 'mean', 'randomization', 'syndrome', 'coronary', 'age', 'acute', '3', 'continue', 'this', 'to', 'alone']","['diabetes', 'mean', 'randomization', 'syndrome', 'coronary', 'age', 'continue', 'alone']",523,"['在3個月內,7119名患者經歷了偶然化(平均年齡,65歲,糖尿病,37%;急性冠<unk>症候群的PCI,65%)以繼續這種治療或單獨接收Ticagrelor。']",0.25,"['diabetes', 'mean', 'randomization', 'syndrome', 'coronary', 'age', 'acute', '3', 'continue', 'this', 'to', 'alone']","['diabetes', 'mean', 'coronary']",523,在3个月内，7119名患者随机分配（平均年龄65岁；糖尿病37％；急性冠状动脉综合征（PCI）65％）继续这一方案或仅接受西卡格雷尔。,0.5833333333333334,"['diabetes', 'mean', 'randomization', 'syndrome', 'coronary', 'age', 'acute', '3', 'continue', 'this', 'to', 'alone']","['diabetes', 'mean', 'randomization', 'syndrome', 'coronary', 'age', 'continue']",,,,
527,524,"ischemic events were similar between groups , including a composite endpoint of death , nonfatal myocardial infarction , and nonfatal stroke ( 4 % in both ) .",各组间的缺血事件相似，包括死亡、非致死性心肌梗塞和非致死性中风的复合终点（均为 4%）。,0.3333333333333333,"['myocardial infarction', 'composite', 'stroke', 'death', '4', 'endpoint', 'and', 'ischemic', 'similar']","['myocardial infarction', 'stroke', 'death']",524,"['伊斯基米事件类似于群体之间,包括复合死亡点、非致命心脏病发作和非致命中风(两者中有4%)。']",0.2222222222222222,"['myocardial infarction', 'composite', 'stroke', 'death', '4', 'endpoint', 'and', 'ischemic', 'similar']","['stroke', 'death']",524,"Ischemic events were similar between groups, including a composite endpoint of death, nonfatal myocardial infarction, and nonfatal stroke (4% in both).

Chinese:
缺血性事件在两组间相似，包括死亡、轻度心肌梗死和非致命性中风的复合终点（均为4%）。",0.3333333333333333,"['myocardial infarction', 'composite', 'stroke', 'death', '4', 'endpoint', 'and', 'ischemic', 'similar']","['myocardial infarction', 'stroke', 'death']",,,,
528,525,"stent thrombosis was nonsignificantly different between groups ( ticagrelor alone , 0.4 % ; ticagrelor plus aspirin , 0.6 % ) .",支架内血栓形成在各组之间无显着差异（单独替格瑞洛，0.4%；替格瑞洛联合阿司匹林，0.6%）。,0.6,"['aspirin', 'plus', 'thrombosis', 'stent', 'alone']","['aspirin', 'thrombosis', 'alone']",525,"['甲状腺肿瘤在群体之间毫无意义地不同(单独的ticagrelor,0.4%;ticagrelor plus aspirin,0.6%)。']",0.2,"['aspirin', 'plus', 'thrombosis', 'stent', 'alone']",['alone'],525,组间支架血栓形成差异无统计学意义（仅使用西泮，0.4%；西泮加阿司匹林，0.6%）。,0.6,"['aspirin', 'plus', 'thrombosis', 'stent', 'alone']","['aspirin', 'plus', 'thrombosis']",,,,
529,526,"in the search for ways to reduce bleeding risks without increasing ischemic events after PCI with a DES , the drug regimen of ticagrelor plus aspirin for 3 months followed by ticagrelor alone appears to be a winner .",在使用 DES 进行 PCI 后寻找降低出血风险而不增加缺血事件的方法时，替格瑞洛加阿司匹林 3 个月然后单独替格瑞洛的药物治疗方案似乎是赢家。,0.5714285714285714,"['bleeding', 'aspirin', 'reduce', 'plus', 'be', 'search', 'after', '3', 'drug', 'by', 'to', 'alone', 'without', 'ischemic']","['bleeding', 'aspirin', 'reduce', 'plus', 'be', 'after', 'drug', 'alone']",526,"['在寻找减少出血风险的途径,而不增加 PCI 后的化学事件,DES 药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充']",0.3571428571428571,"['bleeding', 'aspirin', 'reduce', 'plus', 'be', 'search', 'after', '3', 'drug', 'by', 'to', 'alone', 'without', 'ischemic']","['bleeding', 'plus', 'be', 'after', 'drug']",526,在寻找方法来降低PCI植入DES后出血风险而不增加动脉粥样硬化事件的过程中，药物方案ticagrelor加3个月的阿司匹林似乎是一个赢家。,0.5,"['bleeding', 'aspirin', 'reduce', 'plus', 'be', 'search', 'after', '3', 'drug', 'by', 'to', 'alone', 'without', 'ischemic']","['bleeding', 'aspirin', 'reduce', 'plus', 'be', 'after', 'drug']",,,,
530,527,"as the authors note , these findings differ from the GLOBAL LEADERS trial ( NEJM JW Cardiol Oct 2018 and Lancet 2018 ; 392 : 940 ) , which failed to demonstrate a bleeding benefit with early discontinuation of aspirin , possibly due to differences in patients and study design .",正如作者所指出的，这些发现不同于 GLOBAL LEADERS 试验（ NEJM JW Cardiol Oct 2018 和 Lancet 2018 ； 392 : 940 ），后者未能证明早期停用阿司匹林对出血有益，这可能是由于患者和研究设计的差异.,0.3333333333333333,"['bleeding', 'aspirin', 'lancet', 'study', 'early', 'differ', 'note', 'trial', 'benefit', 'design', 'due', 'with', 'possibly', 'to', 'and']","['bleeding', 'aspirin', 'early', 'design', 'to']",527,"['作者指出,这些发现与全球领袖试验(NEJM JW Cardiol Oct 2018 和 Lancet 2018 ; 392 : 940 )不同,由于患者和研究设计的差异可能导致早期停止使用阿司匹林的出血益处。']",0.3333333333333333,"['bleeding', 'aspirin', 'lancet', 'study', 'early', 'differ', 'note', 'trial', 'benefit', 'design', 'due', 'with', 'possibly', 'to', 'and']","['bleeding', 'aspirin', 'early', 'design', 'to']",527,"正如作者指出的，这些发现与GLOBAL LEADERS试验（NEJM JW Cardiol Oct 2018和Lancet 2018；392：940）相差很远，后者未能证明早期终止使用阿司匹林的出血效益，这可能是由于病人和研究设计的差异。

Chinese:

正如作者所指出的，这些发现与GLOBAL LEADERS试验相差甚远（NEJM JW Cardiol Oct 2018和Lancet 2018；392：940），后者未能证明早期终止使用阿司匹林的出血效益，这可能是由于病人和研究设计的差异。",0.3333333333333333,"['bleeding', 'aspirin', 'lancet', 'study', 'early', 'differ', 'note', 'trial', 'benefit', 'design', 'due', 'with', 'possibly', 'to', 'and']","['bleeding', 'aspirin', 'early', 'design', 'to']",,,,
531,528,"in contrast , approaches using clopidogrel have demonstrated benefits , but these studies were underpowered for ischemic endpoints .",相比之下，使用氯吡格雷的方法已显示出益处，但这些研究对缺血终点的效力不足。,0.2857142857142857,"['demonstrated', 'contrast', 'clopidogrel', 'have', 'in', 'but', 'ischemic']","['clopidogrel', 'but']",528,"['相比之下,使用 clopidogrel 的方法已经证明了好处,但这些研究被支持以化学终点。']",0.1428571428571428,"['demonstrated', 'contrast', 'clopidogrel', 'have', 'in', 'but', 'ischemic']",['but'],528,相比之下，使用氯吡格雷的方法已经显示出了好处，但这些研究在缺血性终点方面的力量不足。,0.2857142857142857,"['demonstrated', 'contrast', 'clopidogrel', 'have', 'in', 'but', 'ischemic']","['clopidogrel', 'but']",,,,
532,529,"further studies are needed to compare agents , timing , and different risk populations .",需要进一步的研究来比较药物、时间和不同的风险人群。,0.4,"['risk', 'compare', 'timing', 'to', 'and']","['risk', 'compare']",529,['需要进一步的研究来比较因素、时间和不同风险人口。'],0.4,"['risk', 'compare', 'timing', 'to', 'and']","['risk', 'compare']",529,"further studies are needed to compare agents , timing , and different risk populations .

Chinese:

需要进一步研究来比较不同的药物、时机以及不同风险人群。",0.4,"['risk', 'compare', 'timing', 'to', 'and']","['risk', 'compare']",,,,
533,530,"in the meantime , stopping aspirin after 3 months of dual antiplatelet therapy with ticagrelor in patients at risk for bleeding seems reasonable .",与此同时，有出血风险的患者在使用替格瑞洛进行双重抗血小板治疗 3 个月后停用阿司匹林似乎是合理的。,0.5,"['bleeding', 'aspirin', 'antiplatelet', 'therapy', 'risk', 'after', '3', 'dual', 'with', 'stopping']","['bleeding', 'aspirin', 'therapy', 'risk', 'after']",530,"['与此同时,在患有出血风险的患者中,在3个月的双重抗细胞治疗后停止阿司匹林似乎是合理的。']",0.5,"['bleeding', 'aspirin', 'antiplatelet', 'therapy', 'risk', 'after', '3', 'dual', 'with', 'stopping']","['bleeding', 'aspirin', 'therapy', 'risk', 'after']",530,在此期間，在有出血风险的患者中，在使用两种抗血小板治疗起始3个月后停止使用阿司匹林似乎是合理的。,0.6,"['bleeding', 'aspirin', 'antiplatelet', 'therapy', 'risk', 'after', '3', 'dual', 'with', 'stopping']","['bleeding', 'aspirin', 'therapy', 'risk', 'after', 'dual']",,,,
534,531,"a similar number of grade 3 or greater adverse events occurred in the cabazitaxel and abiraterone / enzalutamide groups ( 56 % and 52 % , respectively ) .",卡巴他赛组和阿比特龙/恩杂鲁胺组发生了相似数量的 3 级或更高级别的不良事件（分别为 56% 和 52%）。,0.3,"['grade', '/', 'adverse', 'number', '3', 'cabazitaxel', 'enzalutamide', 'in', 'and', 'similar']","['number', 'cabazitaxel', 'enzalutamide']",531,['类似数量的3级或更大的副作用发生在cabazitaxel 和 abiraterone / enzalutamide 群体( 56 % 和 52 % 相应 ) 。'],0.1,"['grade', '/', 'adverse', 'number', '3', 'cabazitaxel', 'enzalutamide', 'in', 'and', 'similar']",['number'],531,级别为3或更高的不良事件的发生率相似，分别为56％和52％。,0.0,"['grade', '/', 'adverse', 'number', '3', 'cabazitaxel', 'enzalutamide', 'in', 'and', 'similar']",[],,,,
535,532,patients with stable coronary artery disease and diabetes mellitus who have not had a myocardial infarction or stroke are at high risk for cardiovascular events .,没有心肌梗死或中风的稳定性冠状动脉疾病和糖尿病患者发生心血管事件的风险很高。,0.5,"['myocardial infarction', 'disease', 'cardiovascular', 'stroke', 'who', 'high risk', 'diabetes mellitus', 'with', 'coronary artery', 'at', 'have not', 'and']","['myocardial infarction', 'disease', 'cardiovascular', 'stroke', 'diabetes mellitus', 'coronary artery']",532,"['患有稳定的冠状动脉疾病和糖尿病患者,没有心脏病发作或中风,患有高心血管事件的风险。']",0.4166666666666667,"['myocardial infarction', 'disease', 'cardiovascular', 'stroke', 'who', 'high risk', 'diabetes mellitus', 'with', 'coronary artery', 'at', 'have not', 'and']","['disease', 'cardiovascular', 'stroke', 'diabetes mellitus', 'coronary artery']",532,"patients with stable coronary artery disease and diabetes mellitus who have not had a myocardial infarction or stroke are at high risk for cardiovascular events.

Chinese:
患有稳定性冠状动脉疾病和糖尿病病人若尚未心肌梗塞或中风，则风险会很高。",0.4166666666666667,"['myocardial infarction', 'disease', 'cardiovascular', 'stroke', 'who', 'high risk', 'diabetes mellitus', 'with', 'coronary artery', 'at', 'have not', 'and']","['myocardial infarction', 'disease', 'stroke', 'diabetes mellitus', 'coronary artery']",,,,
536,533,whether adding ticagrelor to aspirin improves outcomes in this population is unclear .,在阿司匹林中加入替格瑞洛是否能改善这一人群的结局尚不清楚。,0.75,"['aspirin', 'population', 'this', 'to']","['aspirin', 'population', 'this']",533,['是否添加Ticagrelor到阿司匹林改善结果在这个人口是不清楚的。'],0.75,"['aspirin', 'population', 'this', 'to']","['aspirin', 'population', 'this']",533,目前尚不清楚加入前列腺素酯酶2抑制剂到阿司匹林中是否有助于这一人群的预后。,1.0,"['aspirin', 'population', 'this', 'to']","['aspirin', 'population', 'this', 'to']",,,,
537,534,patients with previous myocardial infarction or stroke were excluded .,既往有心肌梗塞或中风的患者被排除在外。,0.5,"['myocardial infarction', 'stroke', 'previous', 'with']","['myocardial infarction', 'stroke']",534,['以前患有心脏病发作或中风的患者被排除。'],0.25,"['myocardial infarction', 'stroke', 'previous', 'with']",['stroke'],534,"Patients with previous myocardial infarction or stroke were excluded.

Chinese:

患有先前心肌梗死或中风的患者被排除在外。",0.5,"['myocardial infarction', 'stroke', 'previous', 'with']","['myocardial infarction', 'stroke']",,,,
538,535,"the primary efficacy outcome was a composite of cardiovascular death , myocardial infarction , or stroke .",主要疗效结果是心血管死亡、心肌梗死或中风的复合结果。,0.625,"['myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'outcome', 'death', 'primary', 'efficacy']","['myocardial infarction', 'cardiovascular', 'stroke', 'outcome', 'death']",535,['主要效力结果是心血管死亡、心脏病发作或中风的组成。'],0.5,"['myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'outcome', 'death', 'primary', 'efficacy']","['cardiovascular', 'stroke', 'outcome', 'death']",535,主要疗效结果是心血管死亡、心肌梗死或中风的组合。,0.625,"['myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'outcome', 'death', 'primary', 'efficacy']","['myocardial infarction', 'cardiovascular', 'stroke', 'outcome', 'death']",,,,
539,536,the primary safety outcome was major bleeding as defined by the Thrombolysis in Myocardial Infarction ( TIMI ) criteria .,主要安全性结果是心肌梗死溶栓 (TIMI) 标准定义的大出血。,0.5,"['bleeding', 'safety', 'myocardial infarction', 'defined', 'outcome', 'thrombolysis', 'major', 'primary', 'as', 'by']","['bleeding', 'safety', 'myocardial infarction', 'outcome', 'thrombolysis']",536,"['主要的安全结果是主要的出血,根据心脏病发作(TIMI)中的血管炎(Trompolysis in Myocardial Infarction)定义。']",0.4,"['bleeding', 'safety', 'myocardial infarction', 'defined', 'outcome', 'thrombolysis', 'major', 'primary', 'as', 'by']","['bleeding', 'safety', 'outcome', 'primary']",536,主要安全结果是根据 Thrombolysis in Myocardial Infarction (TIMI)标准定义的严重出血。,0.3,"['bleeding', 'safety', 'myocardial infarction', 'defined', 'outcome', 'thrombolysis', 'major', 'primary', 'as', 'by']","['bleeding', 'safety', 'outcome']",,,,
540,537,permanent treatment discontinuation was more frequent with ticagrelor than placebo ( 34.5 % vs. 25.4 % ) .,与安慰剂组相比，替格瑞洛组永久性停药的发生率更高（34.5% 对 25.4%）。,0.2,"['placebo', 'permanent', 'treatment', 'with', 'frequent']",['placebo'],537,['永久性治疗中断比 placebo 更常见(34.5% 与 25.4% )。'],0.2,"['placebo', 'permanent', 'treatment', 'with', 'frequent']",['treatment'],537,"Permanent treatment discontinuation was more frequent with ticagrelor than placebo ( 34.5 % vs. 25.4 % ) .

Chinese:

停药率在使用贴膜血小板抑制剂替加美洛尼而非安慰剂组更高（分别为34.5%和25.4%）。",0.2,"['placebo', 'permanent', 'treatment', 'with', 'frequent']",['placebo'],,,,
541,538,"there was no significant difference in the incidence of fatal bleeding ( 0.2 % vs. 0.1 % ; hazard ratio , 1.90 ; 95 % CI , 0.87 to 4.15 ; P = 0.11 ) .",致命性出血的发生率没有显着差异（0.2% 对 0.1%；风险比，1.90；95% CI，0.87 至 4.15；P = 0.11）。,0.3333333333333333,"['bleeding', 'incidence', 'hazard ratio', 'fatal', 'no', 'P', 'significant difference', 'CI', 'to']","['bleeding', 'incidence', 'hazard ratio']",538,"['致命出血的发病率没有显著的差异( 0.2% 与 0.1% ; 危险比例, 1.90 ; 95 % CI, 0.87 至 4.15 ; P = 0.11 )。']",0.2222222222222222,"['bleeding', 'incidence', 'hazard ratio', 'fatal', 'no', 'P', 'significant difference', 'CI', 'to']","['bleeding', 'incidence']",538,"There was no significant difference in the incidence of fatal bleeding between the two groups (0.2% vs. 0.1%; hazard ratio, 1.90; 95% CI, 0.87 to 4.15; P=0.11).",0.0,"['bleeding', 'incidence', 'hazard ratio', 'fatal', 'no', 'P', 'significant difference', 'CI', 'to']",[],,,,
542,539,"the incidence of an exploratory composite outcome of irreversible harm ( death from any cause , myocardial infarction , stroke , fatal bleeding , or intracranial hemorrhage ) was similar in the ticagrelor group and the placebo group ( 10.1 % vs. 10.8 % ; hazard ratio , 0.93 ; 95 % CI , 0.86 to 1.02 ) .",不可逆伤害（全因死亡、心肌梗死、卒中、致命性出血或颅内出血）的探索性复合结局的发生率在替格瑞洛组和安慰剂组中相似（10.1 % 对 10.8 % ；风险比 0.93 ） ；95% CI，0.86 至 1.02）。,0.5555555555555556,"['bleeding', 'group', 'myocardial infarction', 'composite', 'placebo', 'incidence', 'stroke', 'hazard ratio', 'outcome', 'death', 'intracranial hemorrhage', 'exploratory', 'fatal', 'cause', 'CI', 'and', 'similar', 'irreversible']","['bleeding', 'group', 'myocardial infarction', 'placebo', 'incidence', 'stroke', 'hazard ratio', 'death', 'intracranial hemorrhage', 'irreversible']",539,"['探测组合的不可逆转损害(任何原因的死亡、心脏病发作、中风、致命出血或内分泌出血)的发病率在Ticagrelor群体和Placebo群体中是相似的(10.1% vs.10.8%;风险比例,0.93;95% CI,0.86 至 1.02)。']",0.5555555555555556,"['bleeding', 'group', 'myocardial infarction', 'composite', 'placebo', 'incidence', 'stroke', 'hazard ratio', 'outcome', 'death', 'intracranial hemorrhage', 'exploratory', 'fatal', 'cause', 'CI', 'and', 'similar', 'irreversible']","['bleeding', 'group', 'incidence', 'stroke', 'hazard ratio', 'death', 'exploratory', 'cause', 'similar', 'irreversible']",539,死亡、心肌梗塞、中风、致命性出血或脑出血等不可逆性伤害的发病率在西泮尔组和安慰剂组相似（10.1% vs. 10.8%；危险比，0.93；95%置信区间，0.86至1.02）。,0.4444444444444444,"['bleeding', 'group', 'myocardial infarction', 'composite', 'placebo', 'incidence', 'stroke', 'hazard ratio', 'outcome', 'death', 'intracranial hemorrhage', 'exploratory', 'fatal', 'cause', 'CI', 'and', 'similar', 'irreversible']","['bleeding', 'group', 'myocardial infarction', 'placebo', 'incidence', 'stroke', 'death', 'irreversible']",,,,
543,540,"in patients with stable coronary artery disease and diabetes without a history of myocardial infarction or stroke , those who received ticagrelor plus aspirin had a lower incidence of ischemic cardiovascular events but a higher incidence of major bleeding than those who received placebo plus aspirin . ( Funded by AstraZeneca ; THEMIS ClinicalTrials.gov number , NCT01991795 . )",在没有心肌梗死或中风病史的稳定型冠状动脉疾病和糖尿病患者中，接受替格瑞洛联合阿司匹林治疗的患者与接受安慰剂联合阿司匹林治疗的患者相比，缺血性心血管事件发生率较低，但大出血发生率较高。 （由阿斯利康资助；THEMIS ClinicalTrials.gov 编号，NCT01991795。）,0.6190476190476191,"['bleeding', 'myocardial infarction', 'diabetes', 'aspirin', 'placebo', 'incidence', 'disease', 'cardiovascular', 'stroke', 'who', 'plus', 'history', 'lower', 'major', 'number', 'coronary artery', 'by', 'but', 'and', 'without', 'ischemic']","['bleeding', 'myocardial infarction', 'diabetes', 'aspirin', 'placebo', 'incidence', 'disease', 'cardiovascular', 'stroke', 'number', 'coronary artery', 'by', 'but']",540,"['在患有稳定的冠状动脉疾病和没有心脏病发作或中风史的糖尿病患者中,接受Ticagrelor加上阿司匹林的人比接受 placebo加上阿司匹林的人更少发病,但发病率较高(由AstraZeneca资助;TEMIS ClinicalTrials.gov号,NCT01991795 )。']",0.4761904761904761,"['bleeding', 'myocardial infarction', 'diabetes', 'aspirin', 'placebo', 'incidence', 'disease', 'cardiovascular', 'stroke', 'who', 'plus', 'history', 'lower', 'major', 'number', 'coronary artery', 'by', 'but', 'and', 'without', 'ischemic']","['diabetes', 'aspirin', 'incidence', 'disease', 'stroke', 'plus', 'number', 'coronary artery', 'by', 'but']",540,在稳定性冠状动脉疾病和糖尿病患者中，那些接受了赛加普利加阿司匹林的患者的缺血性心血管事件发生率较低，但主要出血率较高，而那些接受安慰剂加阿司匹林的患者则相反。（由阿斯利康赞助；THEMIS临床试验编号，NCT01991795。）,0.6666666666666666,"['bleeding', 'myocardial infarction', 'diabetes', 'aspirin', 'placebo', 'incidence', 'disease', 'cardiovascular', 'stroke', 'who', 'plus', 'history', 'lower', 'major', 'number', 'coronary artery', 'by', 'but', 'and', 'without', 'ischemic']","['bleeding', 'diabetes', 'aspirin', 'placebo', 'incidence', 'disease', 'cardiovascular', 'stroke', 'plus', 'number', 'coronary artery', 'by', 'but', 'and']",,,,
544,541,"therefore , aspirin alone , the standard therapy in this population , may not provide fully effective antithrombotic protection .",因此，单独使用阿司匹林作为这一人群的标准疗法，可能无法提供完全有效的抗血栓形成保护。,0.7777777777777778,"['aspirin', 'population', 'standard', 'protection', 'antithrombotic', 'therapy', 'therefore', 'this', 'alone']","['aspirin', 'population', 'standard', 'protection', 'antithrombotic', 'therapy', 'alone']",541,"['因此,只有阿司匹林,这个人口的标准治疗,可能无法提供完全有效的抗血管保护。']",0.5555555555555556,"['aspirin', 'population', 'standard', 'protection', 'antithrombotic', 'therapy', 'therefore', 'this', 'alone']","['aspirin', 'population', 'standard', 'protection', 'therapy']",541,因此，仅使用阿司匹林（aspirin），这种在这种人群中的标准治疗方法，可能无法提供充分有效的抗血小板保护。,0.5555555555555556,"['aspirin', 'population', 'standard', 'protection', 'antithrombotic', 'therapy', 'therefore', 'this', 'alone']","['aspirin', 'population', 'standard', 'protection', 'therapy']",,,,
545,542,"ticagrelor , a reversible antagonist of the platelet P2Y12 receptor , has been shown to provide more consistent platelet inhibition than aspirin or clopidogrel.6",替格瑞洛是一种可逆的血小板 P2Y12 受体拮抗剂，已被证明可提供比阿司匹林或氯吡格雷更一致的血小板抑制作用。 6,1.0,"['antagonist', 'receptor', 'aspirin', 'inhibition', 'reversible', 'platelet']","['antagonist', 'receptor', 'aspirin', 'inhibition', 'reversible', 'platelet']",542,"['ticagrelor 是 P2Y12 受体的可逆转反对剂,已被证明提供比 aspirin 或 clopidogrel 更一致的平板抑制。']",0.3333333333333333,"['antagonist', 'receptor', 'aspirin', 'inhibition', 'reversible', 'platelet']","['receptor', 'inhibition']",542,"ticagrelor, 可逆轉的P2Y12配體反應體拮抗劑, 已被證實能比 aspirin 或 clopidogrel 更有效地抑制血小板活性。6",0.3333333333333333,"['antagonist', 'receptor', 'aspirin', 'inhibition', 'reversible', 'platelet']","['inhibition', 'platelet']",,,,
546,543,the relative benefit of ticagrelor in these patients has been consistent regardless of the presence of diabetes .,无论是否存在糖尿病，替格瑞洛对这些患者的相对益处都是一致的。,0.4,"['presence', 'diabetes', 'relative', 'benefit', 'in']","['presence', 'diabetes']",543,"['在这些患者中,Ticagrelor的相对好处无论糖尿病的存在如何,都保持一致。']",0.4,"['presence', 'diabetes', 'relative', 'benefit', 'in']","['presence', 'diabetes']",543,在这些患者中，替卡格雷素相对于传统治疗方法的益处一直是一致的，无论他们是否患有糖尿病。,0.2,"['presence', 'diabetes', 'relative', 'benefit', 'in']",['diabetes'],,,,
547,544,"however , since patients with diabetes are at high baseline risk , they have had a large absolute benefit from the addition of ticagrelor to aspirin.9,10","然而，由于糖尿病患者的基线风险很高，他们从阿司匹林中加入替格瑞洛获得了很大的绝对益处。 9,10",0.6666666666666666,"['diabetes', 'baseline', 'addition', 'absolute', 'large', 'risk', 'benefit', 'with', 'at', 'have', 'to', 'high']","['diabetes', 'baseline', 'addition', 'absolute', 'risk', 'at', 'to', 'high']",544,"['然而,由于糖尿病患者患有高基因风险,他们从添加Ticagrelor到阿司匹林中获得了巨大的绝对好处。']",0.6666666666666666,"['diabetes', 'baseline', 'addition', 'absolute', 'large', 'risk', 'benefit', 'with', 'at', 'have', 'to', 'high']","['diabetes', 'addition', 'absolute', 'risk', 'at', 'have', 'to', 'high']",544,"然而，由于糖尿病患者的基线风险较高，他们从加入剂量阿司匹林9,10中获益良多。",0.5833333333333334,"['diabetes', 'baseline', 'addition', 'absolute', 'large', 'risk', 'benefit', 'with', 'at', 'have', 'to', 'high']","['diabetes', 'baseline', 'addition', 'risk', 'at', 'to', 'high']",,,,
548,545,whether patients with stable coronary artery disease and diabetes who do not have a history of myocardial infarction or stroke also derive benefit from dual antiplatelet therapy with ticagrelor plus aspirin is unclear .,没有心肌梗死或卒中病史的稳定型冠状动脉疾病和糖尿病患者是否也能从替格瑞洛联合阿司匹林的双重抗血小板治疗中获益尚不清楚。,0.5,"['myocardial infarction', 'diabetes', 'aspirin', 'disease', 'stroke', 'who', 'plus', 'antiplatelet', 'history', 'therapy', 'benefit', 'dual', 'with', 'coronary artery', 'have', 'and']","['myocardial infarction', 'diabetes', 'aspirin', 'disease', 'stroke', 'therapy', 'coronary artery', 'have']",545,"['是否患有稳定的冠状动脉疾病和糖尿病的患者,谁没有心脏病发作或中风的历史也受益从双重抗板治疗与Ticagrelor加上阿司匹林不清楚。']",0.5625,"['myocardial infarction', 'diabetes', 'aspirin', 'disease', 'stroke', 'who', 'plus', 'antiplatelet', 'history', 'therapy', 'benefit', 'dual', 'with', 'coronary artery', 'have', 'and']","['diabetes', 'aspirin', 'disease', 'stroke', 'plus', 'history', 'therapy', 'coronary artery', 'have']",545,目前尚不清楚稳定的冠心病患者和糖尿病患者如果没有心肌梗死或中风的病史，是否也可以从使用西泮加阿司匹林的双重抗血小板疗法中受益。,0.5,"['myocardial infarction', 'diabetes', 'aspirin', 'disease', 'stroke', 'who', 'plus', 'antiplatelet', 'history', 'therapy', 'benefit', 'dual', 'with', 'coronary artery', 'have', 'and']","['myocardial infarction', 'diabetes', 'aspirin', 'disease', 'stroke', 'plus', 'therapy', 'have']",,,,
549,546,"the Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study ( THEMIS ) was designed to test the efficacy and safety of ticagrelor , as compared with placebo , in addition to aspirin in this population .",在糖尿病患者干预研究 (THEMIS) 中，替格瑞洛对健康结果的影响旨在测试替格瑞洛与安慰剂以及阿司匹林在该人群中的疗效和安全性。,0.375,"['safety', 'aspirin', 'population', 'placebo', 'test', 'health', 'addition', 'study', 'diabetes mellitus', 'intervention', 'effect', 'efficacy', 'with', 'this', 'to', 'and']","['safety', 'aspirin', 'population', 'placebo', 'health', 'diabetes mellitus']",546,"['甲状腺糖尿病患者干预研究(THEMIS)对健康结果的影响,旨在测试甲状腺糖尿病的有效性和安全性,与 placebo 相比,除了阿司匹林在这个人口。']",0.375,"['safety', 'aspirin', 'population', 'placebo', 'test', 'health', 'addition', 'study', 'diabetes mellitus', 'intervention', 'effect', 'efficacy', 'with', 'this', 'to', 'and']","['safety', 'aspirin', 'population', 'health', 'diabetes mellitus', 'efficacy']",546,糖尿病干预研究（THEMIS）旨在检验西卡格利尔与阿司匹林附加治疗在此人群中的有效性和安全性。,0.4375,"['safety', 'aspirin', 'population', 'placebo', 'test', 'health', 'addition', 'study', 'diabetes mellitus', 'intervention', 'effect', 'efficacy', 'with', 'this', 'to', 'and']","['safety', 'aspirin', 'population', 'test', 'addition', 'diabetes mellitus', 'efficacy']",,,,
550,547,"AstraZeneca funded the trial , which was designed and overseen by an academic executive committee .",阿斯利康资助了该试验，该试验由学术执行委员会设计和监督。,0.5,"['committee', 'trial', 'by', 'and']","['committee', 'by']",547,"['AstraZeneca资助了审判,该审判由学术执行委员会设计和监督。']",0.75,"['committee', 'trial', 'by', 'and']","['committee', 'trial', 'by']",547,AstraZeneca 资助了这项试验，该试验由学术委员会设计和监督。,0.5,"['committee', 'trial', 'by', 'and']","['committee', 'by']",,,,
551,548,all the trial centers obtained ethical approval according to local regulations .,所有试验中心均按当地法规获得伦理批准。,0.1666666666666666,"['approval', 'ethical', 'local', 'trial', 'all', 'to']",['approval'],548,['所有审判中心根据当地法规获得道德批准。'],0.3333333333333333,"['approval', 'ethical', 'local', 'trial', 'all', 'to']","['approval', 'trial']",548,所有的试验中心都根据当地法规获得了道德批准。,0.1666666666666666,"['approval', 'ethical', 'local', 'trial', 'all', 'to']",['approval'],,,,
552,549,"site selection was conducted jointly by the national lead investigators and representatives of AstraZeneca , who performed site monitoring and supervision and handled the collection , storage , and analysis of the data .",选址由国家首席调查员和阿斯利康代表共同进行，他们负责现场监测和监督，并处理数据的收集、存储和分析。,0.6363636363636364,"['monitoring', 'lead', 'site', 'data', 'who', 'analysis', 'collection', 'supervision', 'storage', 'by', 'and']","['monitoring', 'site', 'data', 'analysis', 'collection', 'storage', 'by']",549,"['网站选择由国家领先的调查人员和AstraZeneca的代表共同进行,他们进行了网站监测和监督,处理数据的收集、存储和分析。']",0.5454545454545454,"['monitoring', 'lead', 'site', 'data', 'who', 'analysis', 'collection', 'supervision', 'storage', 'by', 'and']","['monitoring', 'data', 'analysis', 'collection', 'storage', 'by']",549,网站选择由全国主要调查人员和阿斯利康公司代表共同进行，阿斯利康负责网站监测和监督，并负责数据的收集、存储和分析。,0.5454545454545454,"['monitoring', 'lead', 'site', 'data', 'who', 'analysis', 'collection', 'supervision', 'storage', 'by', 'and']","['monitoring', 'data', 'analysis', 'collection', 'storage', 'by']",,,,
553,550,"the Baim Clinical Research Institute independently validated all the data that are reported , with funding from AstraZeneca .",Baim 临床研究所在阿斯利康的资助下独立验证了所有报告的数据。,0.5714285714285714,"['research', 'data', 'clinical', 'institute', 'with', 'all', 'that']","['research', 'data', 'clinical', 'institute']",550,"['Baim临床研究所独立验证了所有报告的数据,由AstraZeneca资助。']",0.5714285714285714,"['research', 'data', 'clinical', 'institute', 'with', 'all', 'that']","['research', 'data', 'clinical', 'institute']",550,白池临床研究所独立验证了所有报告的数据，资助来自于阿斯利康。,0.5714285714285714,"['research', 'data', 'clinical', 'institute', 'with', 'all', 'that']","['research', 'data', 'clinical', 'institute']",,,,
554,551,all the authors contributed to the writing of the manuscript and made the decision to submit the manuscript for publication .,所有作者都对文稿的撰写做出了贡献，并做出了投稿发表的决定。,0.4285714285714285,"['publication', 'manuscript', 'writing', 'decision', 'all', 'to', 'and']","['publication', 'writing', 'decision']",551,"['所有作者都参与了手稿的写作,并决定将手稿提交出版。']",0.5714285714285714,"['publication', 'manuscript', 'writing', 'decision', 'all', 'to', 'and']","['publication', 'manuscript', 'writing', 'decision']",551,所有的作者都贡献了论文的写作，并决定将论文提交给出版机构。,0.4285714285714285,"['publication', 'manuscript', 'writing', 'decision', 'all', 'to', 'and']","['publication', 'writing', 'decision']",,,,
555,552,the authors vouch for the completeness and accuracy of the data and the analyses and for the fidelity of the trial to the protocol .,作者保证数据和分析的完整性和准确性，并保证试验对方案的忠实度。,0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'and']","['data', 'accuracy', 'completeness']",552,"['作者保证数据和分析的完整性和准确性,以及审判对议定书的忠诚性。']",0.7142857142857143,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness']",552,作者保证数据和分析的完整性和准确性，并且保证实验与协议的一致性。,0.5714285714285714,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'and']","['data', 'accuracy', 'protocol', 'completeness']",,,,
556,553,the trial population consisted of patients who were 50 years of age or older and who had stable coronary artery disease and type 2 diabetes mellitus .,试验人群包括年龄在 50 岁或以上且患有稳定性冠状动脉疾病和 2 型糖尿病的患者。,0.7,"['population', 'type', 'disease', 'who', '2', 'diabetes mellitus', 'age', 'trial', 'coronary artery', 'and']","['population', 'type', 'disease', '2', 'diabetes mellitus', 'age', 'coronary artery']",553,"['研究人口由50岁以上的患者组成,并且患有稳定的冠状动脉疾病和2型糖尿病。']",0.6,"['population', 'type', 'disease', 'who', '2', 'diabetes mellitus', 'age', 'trial', 'coronary artery', 'and']","['population', 'type', 'disease', '2', 'diabetes mellitus', 'coronary artery']",553,试验群体包括50岁及以上，患有稳定性冠状动脉疾病和2型糖尿病的患者。,0.6,"['population', 'type', 'disease', 'who', '2', 'diabetes mellitus', 'age', 'trial', 'coronary artery', 'and']","['population', 'type', 'disease', '2', 'diabetes mellitus', 'coronary artery']",,,,
557,554,the presence of type 2 diabetes mellitus was determined by the receipt of an antihyperglycemic medication for at least 6 months .,2 型糖尿病的存在是通过接受抗高血糖药物治疗至少 6 个月来确定的。,0.7142857142857143,"['presence', 'type', '2', 'diabetes mellitus', 'medication', 'antihyperglycemic', 'by']","['presence', 'type', '2', 'diabetes mellitus', 'antihyperglycemic']",554,['二型糖尿病的存在是通过服用抗高血糖药物至少6个月的确定。'],0.5714285714285714,"['presence', 'type', '2', 'diabetes mellitus', 'medication', 'antihyperglycemic', 'by']","['presence', 'type', 'diabetes mellitus', 'antihyperglycemic']",554,糖尿病2型的存在是通过至少6个月内使用降糖药物来确定的。,0.5714285714285714,"['presence', 'type', '2', 'diabetes mellitus', 'medication', 'antihyperglycemic', 'by']","['presence', 'type', '2', 'diabetes mellitus']",,,,
558,555,"patients with known history of myocardial infarction or stroke were excluded , as were patients who were receiving dual antiplatelet therapy .",已知有心肌梗塞或中风病史的患者被排除在外，接受双重抗血小板治疗的患者也被排除在外。,0.3333333333333333,"['myocardial infarction', 'stroke', 'who', 'antiplatelet', 'history', 'therapy', 'as', 'dual', 'with']","['myocardial infarction', 'stroke', 'therapy']",555,"['已知心脏病发作或中风史的患者被排除,如接受双重抗甲状腺治疗的患者。']",0.3333333333333333,"['myocardial infarction', 'stroke', 'who', 'antiplatelet', 'history', 'therapy', 'as', 'dual', 'with']","['stroke', 'therapy', 'as']",555,"patients with known history of myocardial infarction or stroke were excluded , as were patients who were receiving dual antiplatelet therapy .

Chinese:

已知有心肌梗死或中风病史的病人被排除在外，正在接受双抗血小板疗法的病人也被排除在外。",0.3333333333333333,"['myocardial infarction', 'stroke', 'who', 'antiplatelet', 'history', 'therapy', 'as', 'dual', 'with']","['myocardial infarction', 'stroke', 'therapy']",,,,
559,556,randomization AND TREATMENT GROUPS,随机化和治疗组,1.0,['randomization'],['randomization'],556,['随机化和处理组'],1.0,['randomization'],['randomization'],556,随机化和治疗组,1.0,['randomization'],['randomization'],,,,
560,557,patients were initially assigned to receive ticagrelor at a dose of 90 mg twice daily or matching placebo .,患者最初被分配接受每日两次 90 毫克剂量的替格瑞洛或匹配的安慰剂。,0.6,"['placebo', 'matching', 'dose', 'to', 'twice']","['placebo', 'matching', 'dose']",557,"['患者最初被处以90毫克的剂量,每天两次或相匹配的 placebo。']",0.4,"['placebo', 'matching', 'dose', 'to', 'twice']","['matching', 'dose']",557,"病人最初被分配每天两次服用90毫克的西卡格列醇或同等剂量的安慰剂。

Chinese:

病人最初被分配每天两次服用90mg的西卡格列醇或同等剂量的安慰剂。",0.4,"['placebo', 'matching', 'dose', 'to', 'twice']","['placebo', 'dose']",,,,
561,558,"secondary efficacy outcomes were tested hierarchically according to the following sequence : cardiovascular death , myocardial infarction , ischemic stroke , and death from any cause .",次要疗效结果按照以下顺序进行分层测试：心血管死亡、心肌梗死、缺血性卒中和全因死亡。,0.4166666666666667,"['myocardial infarction', 'cardiovascular', 'stroke', 'sequence', 'death', 'cause', 'secondary', 'efficacy', 'to', 'and', 'ischemic', 'following']","['myocardial infarction', 'cardiovascular', 'stroke', 'sequence', 'death']",558,['二次有效性结果按下列序列进行层次测试:心血管死亡、心脏病发作、心脏病发作和任何原因死亡。'],0.5,"['myocardial infarction', 'cardiovascular', 'stroke', 'sequence', 'death', 'cause', 'secondary', 'efficacy', 'to', 'and', 'ischemic', 'following']","['cardiovascular', 'stroke', 'sequence', 'death', 'cause', 'efficacy']",558,二次疗效结果按照以下顺序分层测试：心血管死亡、心肌梗死、缺血性中风、任何原因导致的死亡。,0.5,"['myocardial infarction', 'cardiovascular', 'stroke', 'sequence', 'death', 'cause', 'secondary', 'efficacy', 'to', 'and', 'ischemic', 'following']","['myocardial infarction', 'cardiovascular', 'stroke', 'sequence', 'death', 'cause']",,,,
562,559,"the primary safety outcome was major bleeding , which was defined according to the TIMI classification .",主要安全性结果是大出血，这是根据 TIMI 分类定义的。,0.5,"['bleeding', 'safety', 'defined', 'classification', 'outcome', 'major', 'primary', 'to']","['bleeding', 'safety', 'classification', 'outcome']",559,"['主要的安全结果是主要的出血,根据TIMI分类定义。']",0.625,"['bleeding', 'safety', 'defined', 'classification', 'outcome', 'major', 'primary', 'to']","['bleeding', 'safety', 'classification', 'outcome', 'primary']",559,主要安全结果是根据TIMI分类定义的重度出血。,0.5,"['bleeding', 'safety', 'defined', 'classification', 'outcome', 'major', 'primary', 'to']","['bleeding', 'safety', 'classification', 'outcome']",,,,
563,560,"an exploratory outcome of net irreversible harm was prespecified as a composite of death from any cause , myocardial infarction , stroke , fatal bleeding , or intracranial hemorrhage .",净不可逆伤害的探索性结果被预先指定为全因死亡、心肌梗死、中风、致命性出血或颅内出血的复合结果。,0.5384615384615384,"['bleeding', 'myocardial infarction', 'composite', 'stroke', 'net', 'outcome', 'death', 'intracranial hemorrhage', 'exploratory', 'fatal', 'cause', 'as', 'irreversible']","['bleeding', 'myocardial infarction', 'stroke', 'outcome', 'death', 'intracranial hemorrhage', 'irreversible']",560,['净不可逆转的损害的探测结果被预定为任何原因、心脏病发作、中风、致命出血或内膜出血的死亡组成部分。'],0.5384615384615384,"['bleeding', 'myocardial infarction', 'composite', 'stroke', 'net', 'outcome', 'death', 'intracranial hemorrhage', 'exploratory', 'fatal', 'cause', 'as', 'irreversible']","['bleeding', 'stroke', 'outcome', 'death', 'exploratory', 'cause', 'irreversible']",560,在事先预设的情况下，对于网络的不可逆损害的探索性结果包括任何原因导致的死亡、心肌梗死、中风、致命的出血或脑出血。,0.6923076923076923,"['bleeding', 'myocardial infarction', 'composite', 'stroke', 'net', 'outcome', 'death', 'intracranial hemorrhage', 'exploratory', 'fatal', 'cause', 'as', 'irreversible']","['bleeding', 'myocardial infarction', 'stroke', 'net', 'outcome', 'death', 'fatal', 'cause', 'irreversible']",,,,
564,561,the definitions of all trial outcomes are provided in the Supplementary Appendix .,补充附录中提供了所有试验结果的定义。,0.0,"['appendix', 'supplementary', 'trial', 'all', 'in']",[],561,['所有审查结果的定义在附件中列出。'],0.2,"['appendix', 'supplementary', 'trial', 'all', 'in']",['appendix'],561,所有审判结果的定义都在补充附录中提供。,0.2,"['appendix', 'supplementary', 'trial', 'all', 'in']",['trial'],,,,
565,562,we estimated that the annual event rate in the placebo group would be 2.5 % .,我们估计安慰剂组的年事件发生率为 2.5%。,0.3333333333333333,"['annual', 'group', 'placebo', 'rate', 'be', 'event', 'that', 'in', 'we']","['group', 'placebo', 'rate']",562,"['我们估计,在 placebo 组的年度事件率将为 2.5 % 。']",0.3333333333333333,"['annual', 'group', 'placebo', 'rate', 'be', 'event', 'that', 'in', 'we']","['group', 'rate', 'be']",562,我們估計安慰劑組的年事件率將為2.5％。,0.1111111111111111,"['annual', 'group', 'placebo', 'rate', 'be', 'event', 'that', 'in', 'we']",['rate'],,,,
566,563,"we determined that the occurrence of 1385 primary outcome events would provide the trial with a power of 90 % , assuming a 16 % lower risk of a primary outcome event in the ticagrelor group than in the placebo group.11",我们确定 1385 次主要结果事件的发生将为试验提供 90 % 的功效，假设替格瑞洛组中主要结果事件的风险比安慰剂组低 16 % 11。,0.4615384615384615,"['group', 'placebo', 'outcome', 'power', 'occurrence', 'lower', 'primary', 'risk', 'trial', 'with', 'event', 'that', 'in']","['group', 'placebo', 'outcome', 'occurrence', 'risk', 'event']",563,"['我们确定,1385个初始结果事件的发生将为测试提供90%的功率,假设在Ticagrelor群体中出现初始结果事件的风险比在Placebo群体中低16%。']",0.4615384615384615,"['group', 'placebo', 'outcome', 'power', 'occurrence', 'lower', 'primary', 'risk', 'trial', 'with', 'event', 'that', 'in']","['group', 'outcome', 'power', 'occurrence', 'risk', 'event']",563,我们确定，若ticagrelor组相比安慰剂组预后事件发生率降低16%，则1385例主要预后事件发生将使试验具有90%的统计力量。,0.3076923076923077,"['group', 'placebo', 'outcome', 'power', 'occurrence', 'lower', 'primary', 'risk', 'trial', 'with', 'event', 'that', 'in']","['group', 'placebo', 'power', 'occurrence']",,,,
567,564,"safety analyses were performed in the safety analysis set , which included all the patients who had received at least one dose of ticagrelor or placebo , with patients evaluated according to the one they actually received .",安全性分析在安全性分析集中进行，其中包括接受过至少一剂替格瑞洛或安慰剂的所有患者，并根据实际接受的剂量对患者进行评估。,0.2,"['placebo', 'who', 'set', 'safety analysis', 'with', 'at', 'dose', 'all', 'in', 'to']","['placebo', 'dose']",564,"['安全分析是在安全分析组中进行的,其中包括所有接受至少一剂Ticagrelor或Placebo的患者,并根据他们实际接受的患者进行评估。']",0.1,"['placebo', 'who', 'set', 'safety analysis', 'with', 'at', 'dose', 'all', 'in', 'to']",['safety analysis'],564,在安全性分析集中进行了安全性分析，该集包括所有接受过至少一剂替卡格列醇或安慰剂的患者，其中的患者根据实际接受的药物进行了评估。,0.1,"['placebo', 'who', 'set', 'safety analysis', 'with', 'at', 'dose', 'all', 'in', 'to']",['placebo'],,,,
568,565,"confidence intervals for secondary and exploratory efficacy end points have not been adjusted for multiple comparisons , so inferences drawn from these intervals may not be reproducible .",次要和探索性疗效终点的置信区间尚未针对多重比较进行调整，因此从这些区间得出的推论可能无法重现。,0.1818181818181818,"['multiple', 'end points', 'be', 'exploratory', 'secondary', 'efficacy', 'confidence', 'have not', 'so', 'and', 'intervals']","['end points', 'have not']",565,"['二级和探测效率终点的信任间隔未适用于多个比较,因此从这些间隔中提取的结论可能无法重复。']",0.2727272727272727,"['multiple', 'end points', 'be', 'exploratory', 'secondary', 'efficacy', 'confidence', 'have not', 'so', 'and', 'intervals']","['end points', 'exploratory', 'have not']",565,统计学置信区间的计算方法并没有考虑到多重比较的情况，所以从这些区间得出的结论可能无法复制。,0.0909090909090909,"['multiple', 'end points', 'be', 'exploratory', 'secondary', 'efficacy', 'confidence', 'have not', 'so', 'and', 'intervals']",['have not'],,,,
569,566,"to assess possible effects of missing data in the ticagrelor group , the event rate in the placebo group was used to estimate the intensity of a Poisson process .",为了评估替格瑞洛组缺失数据的可能影响，安慰剂组的事件发生率用于估计泊松过程的强度。,0.7272727272727273,"['group', 'placebo', 'data', 'rate', 'process', 'intensity', 'estimate', 'assess', 'event', 'to', 'missing']","['group', 'placebo', 'data', 'rate', 'process', 'assess', 'to', 'missing']",566,"['为了评估Ticagrelor组缺乏数据的可能影响,Placebo组的事件率被用来估计Poisson过程的强度。']",0.5454545454545454,"['group', 'placebo', 'data', 'rate', 'process', 'intensity', 'estimate', 'assess', 'event', 'to', 'missing']","['group', 'data', 'rate', 'process', 'assess', 'missing']",566,为了评估错失数据所造成的可能影响，实验组使用安慰剂组的事件发生率来估计一个泊松过程的强度。,0.5454545454545454,"['group', 'placebo', 'data', 'rate', 'process', 'intensity', 'estimate', 'assess', 'event', 'to', 'missing']","['group', 'placebo', 'data', 'rate', 'process', 'assess']",,,,
570,567,the comparison between ticagrelor and placebo was recalculated with these additional events .,替格瑞洛和安慰剂之间的比较是根据这些额外的事件重新计算的。,0.6,"['placebo', 'comparison', 'additional', 'with', 'and']","['placebo', 'comparison', 'additional']",567,['Ticagrelor 和 placebo 的比较与这些额外事件进行了重新计算。'],0.2,"['placebo', 'comparison', 'additional', 'with', 'and']",['comparison'],567,这些额外事件重新计算了鲍替卡因和安慰剂之间的比较。,0.4,"['placebo', 'comparison', 'additional', 'with', 'and']","['placebo', 'comparison']",,,,
571,568,"to estimate the interaction between the trial group and prespecified subgroups , we added to the model the trial group , subgroup , and interaction term between trial group and subgroup .",为了估计试验组和预先指定的亚组之间的相互作用，我们在模型中添加了试验组、亚组以及试验组和亚组之间的相互作用项。,0.2222222222222222,"['model', 'term', 'interaction', 'trial', 'estimate', 'subgroup', 'to', 'and', 'we']","['model', 'term']",568,"['为了估计试验组和预定子组之间的互动,我们将试验组、子组和试验组和子组之间的互动术语添加到模型中。']",0.1111111111111111,"['model', 'term', 'interaction', 'trial', 'estimate', 'subgroup', 'to', 'and', 'we']",['model'],568,"In order to estimate the interaction between the trial group and prespecified subgroups, we added the trial group, subgroup, and interaction term between trial group and subgroup to the model.",0.0,"['model', 'term', 'interaction', 'trial', 'estimate', 'subgroup', 'to', 'and', 'we']",[],,,,
572,569,specific analyses were also prespecified to test the consistency of effect for the two doses of ticagrelor .,还预先指定了具体分析，以测试两种替格瑞洛剂量的效果一致性。,0.5,"['test', 'consistency', 'effect', 'specific', 'to', 'two']","['consistency', 'effect', 'two']",569,"['具体的分析也被预定,以测试两剂Ticagrelor的效果一致性。']",0.5,"['test', 'consistency', 'effect', 'specific', 'to', 'two']","['consistency', 'effect', 'two']",569,对两种剂量的非心肌梗死防治药物蒂卡格列醇的特异性分析事先也进行了规划，以检验其剂量效应的一致性。,0.6666666666666666,"['test', 'consistency', 'effect', 'specific', 'to', 'two']","['test', 'consistency', 'effect', 'two']",,,,
573,570,primary efficacy and safety analyses were repeated in the subgroup of patients who had undergone randomization after the reduction in the dose of ticagrelor .,在替格瑞洛剂量减少后接受随机分组的患者亚组中重复了主要疗效和安全性分析。,0.4545454545454545,"['safety', 'randomization', 'who', 'reduction', 'primary', 'after', 'efficacy', 'subgroup', 'dose', 'repeated', 'in']","['safety', 'randomization', 'reduction', 'after', 'dose']",570,['初级有效性和安全性分析在细菌剂量减少后随机化患者的子组中重复。'],0.5454545454545454,"['safety', 'randomization', 'who', 'reduction', 'primary', 'after', 'efficacy', 'subgroup', 'dose', 'repeated', 'in']","['safety', 'randomization', 'reduction', 'after', 'efficacy', 'dose']",570,主要疗效和安全性分析在减少赛加雷尔剂量后随机分配的患者中进行了重复。,0.4545454545454545,"['safety', 'randomization', 'who', 'reduction', 'primary', 'after', 'efficacy', 'subgroup', 'dose', 'repeated', 'in']","['safety', 'randomization', 'reduction', 'after', 'dose']",,,,
574,571,"from February 10 , 2014 , to May 24 , 2016 , a total of 20,108 patients were enrolled .",2014年2月10日至2016年5月24日，共纳入20108例患者。,0.0,['total'],[],571,"['从2014年2月10日至2016年5月24日,共有20108名病人被注册。']",0.0,['total'],[],571,"From February 10, 2014 to May 24, 2016, a total of 20,108 patients were enrolled.

Chinese:

从2014年2月10日至2016年5月24日，共有20,108名患者被收录。",0.0,['total'],[],,,,
575,572,"of these patients , 19,271 underwent randomization at 1315 sites in 42 countries in North America , South America , Asia , Africa , Australia , and Europe .","在这些患者中，有 19,271 人在北美、南美、亚洲、非洲、澳大利亚和欧洲 42 个国家的 1315 个地点接受了随机分组。",0.6,"['australia', 'randomization', 'america', 'north', 'in']","['australia', 'randomization', 'north']",572,"['在这些患者中,有19271人在北美、南美、亚洲、非洲、澳大利亚和欧洲42个国家的1315个地点进行了随机诊断。']",0.6,"['australia', 'randomization', 'america', 'north', 'in']","['australia', 'randomization', 'north']",572,这些病人中，19271例在北美、南美、亚洲、非洲、澳大利亚和欧洲42个国家的1315个研究中心随机分配。,0.6,"['australia', 'randomization', 'america', 'north', 'in']","['australia', 'randomization', 'north']",,,,
576,573,one site that had enrolled 51 patients was closed by the sponsor before unblinding owing to inadequate adherence to good clinical practice in a different trial.11,由于在另一项试验中未能充分遵守良好的临床实践，一个已招募 51 名患者的研究中心在揭盲前被申办者关闭。 11,0.4,"['site', 'good clinical practice', 'sponsor', 'inadequate', 'adherence', 'closed', 'that', 'before', 'by', 'to']","['sponsor', 'before', 'by', 'to']",573,"['一家注册51名患者的网站被赞助商关闭,因为在另一个试验中不适当遵守良好的临床实践。']",0.0,"['site', 'good clinical practice', 'sponsor', 'inadequate', 'adherence', 'closed', 'that', 'before', 'by', 'to']",[],573,一个注册了51名病人的网站被赞助商在解除盲目状态之前关闭，因为在另一项试验中未能坚持遵守 good clinical practice。11,0.1,"['site', 'good clinical practice', 'sponsor', 'inadequate', 'adherence', 'closed', 'that', 'before', 'by', 'to']",['before'],,,,
577,574,"the last visit with a trial patient was conducted on January 25 , 2019 .",对试验患者的最后一次访问是在 2019 年 1 月 25 日进行的。,0.2,"['patient', 'trial', 'with', 'on', 'visit']",['patient'],574,['与试验患者的最后一次访问是在2019年1月25日进行的。'],0.2,"['patient', 'trial', 'with', 'on', 'visit']",['patient'],574,最后一次临床试验病人的随访是在2019年1月25日进行的。,0.2,"['patient', 'trial', 'with', 'on', 'visit']",['patient'],,,,
578,575,"the censoring date for the efficacy analyses was October 29 , 2018 .",疗效分析的审查日期为 2018 年 10 月 29 日。,0.5,"['date', 'efficacy']",['date'],575,['对效率分析的审查日期为2018年10月29日。'],0.5,"['date', 'efficacy']",['date'],575,截止有效性分析的日期是2018年10月29日。,1.0,"['date', 'efficacy']","['date', 'efficacy']",,,,
579,576,the characteristics of the patients were well balanced between the two groups ( Table 1 ) .,两组患者的特征均衡（表1）。,0.8,"['table', '1', 'well', 'characteristics', 'two']","['table', '1', 'characteristics', 'two']",576,['患者的特征在两组之间平衡良好(图1)。'],0.6,"['table', '1', 'well', 'characteristics', 'two']","['1', 'characteristics', 'two']",576,表1中患者的特征在两组之间很平衡。,0.8,"['table', '1', 'well', 'characteristics', 'two']","['table', '1', 'characteristics', 'two']",,,,
580,577,"the median age was 66 years , and 31.4 % of the patients were women .",中位年龄为 66 岁，31.4% 的患者为女性。,0.0,"['median age', 'and']",[],577,"['平均年龄为66岁,31%的患者是女性。']",0.0,"['median age', 'and']",[],577,中位年龄为66岁，女性占31.4%。,0.0,"['median age', 'and']",[],,,,
581,578,"a total of 58.0 % of the patients had undergone PCI ( with or without stent placement ) , 21.8 % had undergone CABG but not PCI , and 7.0 % had undergone both PCI and CABG ; 20.2 % had no history of coronary revascularization and had received only medical treatment .",共有58.0%的患者接受了PCI（有或没有放置支架），21.8%的患者接受了CABG但未接受PCI，7.0%的患者同时接受了PCI和CABG。 20.2% 没有冠状动脉血运重建史，只接受过药物治疗。,0.25,"['coronary', 'total', 'history', 'medical treatment', 'revascularization', 'CABG', 'stent', 'no', 'placement', 'but', 'and', 'without']","['coronary', 'revascularization', 'but']",578,"['总共有58,0%的患者接受了PCI(有或没有放置),21.8%的患者接受了CABG但不接受PCI,7.0%的患者接受了PCI和CABG;20.2%的患者没有冠状复发史,只接受了医疗治疗。']",0.1666666666666666,"['coronary', 'total', 'history', 'medical treatment', 'revascularization', 'CABG', 'stent', 'no', 'placement', 'but', 'and', 'without']","['coronary', 'but']",578,总计58.0%的病人已经进行了PCI（无论是否安装了支架），21.8%的病人已经进行了CABG，但是没有进行PCI，而7.0%的病人既进行了PCI，又进行了CABG；20.2%的病人没有冠状动脉重建的历史，只接受了药物治疗。,0.4166666666666667,"['coronary', 'total', 'history', 'medical treatment', 'revascularization', 'CABG', 'stent', 'no', 'placement', 'but', 'and', 'without']","['coronary', 'history', 'but', 'and', 'without']",,,,
582,579,patients had received a diagnosis of diabetes a median of 10.0 years before randomization .,患者在随机分组前被诊断为糖尿病的时间中位数为 10.0 年。,0.8,"['diabetes', 'median', 'randomization', 'diagnosis', 'before']","['diabetes', 'randomization', 'diagnosis', 'before']",579,['患者在随机化前10年中间接受了糖尿病的诊断。'],0.8,"['diabetes', 'median', 'randomization', 'diagnosis', 'before']","['diabetes', 'randomization', 'diagnosis', 'before']",579,"patients had received a diagnosis of diabetes a median of 10.0 years before randomization.

Chinese:

患者平均在随机分配之前10.0年获得了糖尿病诊断。",0.8,"['diabetes', 'median', 'randomization', 'diagnosis', 'before']","['diabetes', 'randomization', 'diagnosis', 'before']",,,,
583,580,most of the patients were receiving two or more antihyperglycemic medications ( Table S2 in the Supplementary Appendix ) .,大多数患者正在接受两种或更多种降糖药（补充附录表 S2）。,0.2857142857142857,"['appendix', 'table', 'supplementary', 'antihyperglycemic', 'S2', 'in', 'two']","['table', 'two']",580,['大多数患者接受了两种或多种抗高血糖药物(附件中的S2表)。'],0.5714285714285714,"['appendix', 'table', 'supplementary', 'antihyperglycemic', 'S2', 'in', 'two']","['appendix', 'table', 'antihyperglycemic', 'two']",580,大多数病人正在使用两种或两种以上的降血糖药物（补充附录表S2）。,0.2857142857142857,"['appendix', 'table', 'supplementary', 'antihyperglycemic', 'S2', 'in', 'two']","['table', 'two']",,,,
584,581,"more than half the patients were taking metformin , and more than 20 % were receiving insulin .",超过一半的患者服用二甲双胍，超过 20% 的患者服用胰岛素。,0.6,"['insulin', 'taking', 'half', 'metformin', 'and']","['insulin', 'half', 'metformin']",581,"['超过一半的患者服用了甲状腺素,超过20%的患者服用了胰岛素。']",0.4,"['insulin', 'taking', 'half', 'metformin', 'and']","['insulin', 'half']",581,超过半数的病人在服用了二甲双胍，超过20%的病人需要注射胰岛素。,0.6,"['insulin', 'taking', 'half', 'metformin', 'and']","['insulin', 'half', 'metformin']",,,,
585,582,efficacy outcomes are summarized in Table 2 .,表 2 总结了疗效结果。,0.5,"['table', '2', 'efficacy', 'in']","['table', '2']",582,['有效性结果在表2中总结。'],0.75,"['table', '2', 'efficacy', 'in']","['table', '2', 'efficacy']",582,效力结果总结在表2中。,0.5,"['table', '2', 'efficacy', 'in']","['table', '2']",,,,
586,583,the number of patients who would need to be treated to prevent one primary event at 36 months was 138 .,在 36 个月时需要接受治疗以预防一次主要事件的患者人数为 138 人。,0.4285714285714285,"['need', 'who', 'primary', 'number', 'prevent', 'at', 'to']","['need', 'number', 'prevent']",583,['在36个月内预防一个初始事件需要治疗的患者数量为138人。'],0.4285714285714285,"['need', 'who', 'primary', 'number', 'prevent', 'at', 'to']","['need', 'number', 'prevent']",583,根据36个月的数据，需要治疗138位患者才能预防一例主要事件发生。,0.4285714285714285,"['need', 'who', 'primary', 'number', 'prevent', 'at', 'to']","['need', 'number', 'prevent']",,,,
587,584,the lower frequency of the primary composite outcome in the ticagrelor group was driven by lower incidences of myocardial infarction and stroke than in the placebo group .,与安慰剂组相比，替格瑞洛组主要复合结局发生率较低是由于心肌梗死和中风的发生率较低。,0.4545454545454545,"['group', 'myocardial infarction', 'composite', 'frequency', 'placebo', 'stroke', 'outcome', 'lower', 'primary', 'by', 'and']","['group', 'myocardial infarction', 'placebo', 'stroke', 'by']",584,"['基克格勒群体的初始合成结果的频率较低,是由心脏病发作和中风的频率较低而导致的,而不是 placebo群体。']",0.5454545454545454,"['group', 'myocardial infarction', 'composite', 'frequency', 'placebo', 'stroke', 'outcome', 'lower', 'primary', 'by', 'and']","['group', 'frequency', 'stroke', 'outcome', 'by', 'and']",584,在醇胺基酯类药物组中，主要复合结局的发生率较低是由心肌梗死和中风的发生率低于安慰剂组驱动的。,0.4545454545454545,"['group', 'myocardial infarction', 'composite', 'frequency', 'placebo', 'stroke', 'outcome', 'lower', 'primary', 'by', 'and']","['group', 'myocardial infarction', 'placebo', 'stroke', 'by']",,,,
588,585,secondary efficacy outcomes were analyzed according to a prespecified hierarchy that started with cardiovascular death .,根据从心血管死亡开始的预设等级分析次要疗效结局。,0.375,"['cardiovascular', 'death', 'hierarchy', 'secondary', 'efficacy', 'with', 'that', 'to']","['cardiovascular', 'death', 'hierarchy']",585,"['二次有效性结果根据预定的序列分析,开始于心血管死亡。']",0.5,"['cardiovascular', 'death', 'hierarchy', 'secondary', 'efficacy', 'with', 'that', 'to']","['cardiovascular', 'death', 'efficacy', 'to']",585,根据预先规定的顺序分析了次要疗效结果，从心脏死亡开始。,0.125,"['cardiovascular', 'death', 'hierarchy', 'secondary', 'efficacy', 'with', 'that', 'to']",['death'],,,,
589,586,additional secondary efficacy outcomes are presented in Table 2 ; there were fewer myocardial infarctions and fewer ischemic strokes in the ticagrelor group than in the placebo group .,其他次要疗效结果见表 2；与安慰剂组相比，替格瑞洛组的心肌梗死和缺血性卒中发生率更低。,0.4545454545454545,"['group', 'placebo', 'table', '2', 'additional', 'secondary', 'efficacy', 'myocardial', 'and', 'infarctions', 'ischemic']","['group', 'placebo', 'table', '2', 'infarctions']",586,"['在图2中显示了额外的次要效益结果;在Ticagrelor群体中有较少的心脏病发作和较少的催化性发作,而不是在Placebo群体中。']",0.3636363636363636,"['group', 'placebo', 'table', '2', 'additional', 'secondary', 'efficacy', 'myocardial', 'and', 'infarctions', 'ischemic']","['group', '2', 'additional', 'and']",586,附加的二级疗效结果分别列在表2中；与安慰剂组相比，利多卡因组的心肌梗塞和缺血性脑卒中的发生率较低。,0.4545454545454545,"['group', 'placebo', 'table', '2', 'additional', 'secondary', 'efficacy', 'myocardial', 'and', 'infarctions', 'ischemic']","['group', 'placebo', 'table', '2', 'additional']",,,,
590,587,adjudicated causes of death are provided in Table S3 in the Supplementary Appendix .,补充附录表 S3 提供了裁定死因。,0.3333333333333333,"['appendix', 'table', 'supplementary', 'causes of death', 'S3', 'in']","['table', 'causes of death']",587,['投诉死亡原因在附件 S3 表中列出。'],0.3333333333333333,"['appendix', 'table', 'supplementary', 'causes of death', 'S3', 'in']","['appendix', 'table']",587,在补充附录的表S3中提供了审判死因。,0.3333333333333333,"['appendix', 'table', 'supplementary', 'causes of death', 'S3', 'in']","['table', 'causes of death']",,,,
591,588,"fatal myocardial infarction and fatal strokes accounted for 51 and 52 deaths , respectively , out of a total 1166 deaths .",在 1166 例死亡病例中，致命性心肌梗死和致命性中风分别占 51 例和 52 例。,0.2,"['myocardial infarction', 'total', 'fatal', 'out', 'and']",['myocardial infarction'],588,"['致命心脏病发作和致命心脏病发作分别为51和52人死亡,共1166人死亡。']",0.0,"['myocardial infarction', 'total', 'fatal', 'out', 'and']",[],588,"fatal myocardial infarction and fatal strokes accounted for 51 and 52 deaths , respectively , out of a total 1166 deaths .

Chinese:

致命的心肌梗死和致命的中风分别致死了51人和52人，总计1166人。",0.4,"['myocardial infarction', 'total', 'fatal', 'out', 'and']","['myocardial infarction', 'fatal']",,,,
592,589,"in a prespecified exploratory analysis , the number of events of the composite of acute limb ischemia or major amputation was lower with ticagrelor than with placebo ( hazard ratio , 0.45 ; 95 % CI , 0.23 to 0.86 ) .",在预先指定的探索性分析中，替格瑞洛组的急性肢体缺血或重大截肢复合事件的数量低于安慰剂组（风险比，0.45；95% CI，0.23 至 0.86）。,0.4666666666666667,"['composite', 'placebo', 'limb', 'analysis', 'hazard ratio', 'ischemia', 'amputation', 'lower', 'major', 'exploratory', 'number', 'acute', 'with', 'CI', 'in']","['placebo', 'limb', 'analysis', 'hazard ratio', 'ischemia', 'amputation', 'number']",589,"['在预先确定的探测分析中,急性肢体腹泻或主要解剖的组合发生的事件数量与<unk>血病相比较低(风险比率为0.45;95%的CI,0.23至0.86)。']",0.3333333333333333,"['composite', 'placebo', 'limb', 'analysis', 'hazard ratio', 'ischemia', 'amputation', 'lower', 'major', 'exploratory', 'number', 'acute', 'with', 'CI', 'in']","['limb', 'analysis', 'hazard ratio', 'exploratory', 'number']",589,在预先确定的探索性分析中，急性肢体缺血或主要截肢的事件数量少于非甾体类抗血小板药物（危险比，0.45；95%置信区间，0.23至0.86）。,0.3333333333333333,"['composite', 'placebo', 'limb', 'analysis', 'hazard ratio', 'ischemia', 'amputation', 'lower', 'major', 'exploratory', 'number', 'acute', 'with', 'CI', 'in']","['limb', 'analysis', 'ischemia', 'amputation', 'number']",,,,
593,590,we conducted a prespecified sensitivity analysis of the primary outcome to account for the reduction in the ticagrelor dose during the trial ; the results were consistent with those of the primary analysis ( Table S4 in the Supplementary Appendix ) .,我们对主要结局进行了预先指定的敏感性分析，以说明试验期间替格瑞洛剂量的减少；结果与主要分析的结果一致（补充附录表S4）。,0.3333333333333333,"['appendix', 'table', 'analysis', 'outcome', 'supplementary', 'reduction', 'primary', 'trial', 'with', 'sensitivity', 'dose', 'S4', 'in', 'to', 'we']","['table', 'analysis', 'outcome', 'reduction', 'dose']",590,"['我们进行了初始结果的预定敏感性分析,以便在测试期间考虑到细菌剂量的减少;结果与初始分析的结果一致(附件中的S4表)。']",0.4,"['appendix', 'table', 'analysis', 'outcome', 'supplementary', 'reduction', 'primary', 'trial', 'with', 'sensitivity', 'dose', 'S4', 'in', 'to', 'we']","['appendix', 'table', 'analysis', 'outcome', 'reduction', 'dose']",590,我们对主要结果进行了预先规定的敏感性分析，以考虑到试验期间降低了剂量的因素；结果与主要分析一致（表S4见附件）。,0.4,"['appendix', 'table', 'analysis', 'outcome', 'supplementary', 'reduction', 'primary', 'trial', 'with', 'sensitivity', 'dose', 'S4', 'in', 'to', 'we']","['appendix', 'table', 'analysis', 'outcome', 'reduction', 'dose']",,,,
594,591,"in a sensitivity analysis performed to assess the possible effects of missing data , it was estimated that 757 primary outcome events ( 7.9 % ) would have occurred in the ticagrelor group , resulting in a hazard ratio of 0.93 ( 95 % CI , 0.84 to 1.02 ) .",在为评估缺失数据的可能影响而进行的敏感性分析中，估计替格瑞洛组会发生 757 次主要结果事件 ( 7.9 % ) ，导致风险比为 0.93 （ 95 % CI ， 0.84 至 1.02 ） .,0.5384615384615384,"['group', 'data', 'analysis', 'hazard ratio', 'outcome', 'primary', 'assess', 'sensitivity', 'CI', 'have', 'that', 'to', 'missing']","['group', 'data', 'analysis', 'hazard ratio', 'outcome', 'assess', 'missing']",591,"['在对失踪数据的可能影响进行的敏感性分析中,估计757个初始结果事件(7.9%)会发生在图克格勒群体中,导致危险比例为0.93(95%CI,0.84至1.02)。']",0.3076923076923077,"['group', 'data', 'analysis', 'hazard ratio', 'outcome', 'primary', 'assess', 'sensitivity', 'CI', 'have', 'that', 'to', 'missing']","['group', 'data', 'analysis', 'outcome']",591,"在一项敏感性分析中，为了评估缺失数据的可能影响，估计757个主要结果事件（7.9%）会发生在西加利尔组，导致危险比为0.93（95%CI，0.84至1.02）。

Chinese:

在一项敏感性分析中，为了评估缺失数据的可能影响，估计757个主要结果事件（7.9%）会发生在西加利尔组，导致危险比为0.93（95%CI，0.84至1.02）。",0.5384615384615384,"['group', 'data', 'analysis', 'hazard ratio', 'outcome', 'primary', 'assess', 'sensitivity', 'CI', 'have', 'that', 'to', 'missing']","['group', 'data', 'analysis', 'outcome', 'assess', 'that', 'missing']",,,,
595,592,selected prespecified subgroup analyses for the primary efficacy outcome are provided in Figure S4 in the Supplementary Appendix .,主要疗效结局的选定预设亚组分析见补充附录图 S4。,0.0,"['appendix', 'outcome', 'figure', 'supplementary', 'primary', 'efficacy', 'subgroup', 'S4', 'in']",[],592,"['对初级效能结果的选择预定子组分析,在附加附件的图 S4 中提供。']",0.3333333333333333,"['appendix', 'outcome', 'figure', 'supplementary', 'primary', 'efficacy', 'subgroup', 'S4', 'in']","['appendix', 'outcome', 'efficacy']",592,首要疗效结果的预先指定子组分析结果如图S4所示。,0.1111111111111111,"['appendix', 'outcome', 'figure', 'supplementary', 'primary', 'efficacy', 'subgroup', 'S4', 'in']",['outcome'],,,,
596,593,there was a modest variation in treatment benefit according to the date of censoring of events relative to last dose of ticagrelor or placebo ( Table S6 in the Supplementary Appendix ) .,根据与替格瑞洛或安慰剂末次剂量相关的事件删失日期，治疗获益略有不同（补充附录表 S6）。,0.4166666666666667,"['placebo', 'appendix', 'table', 'variation', 'date', 'supplementary', 'relative', 'treatment', 'benefit', 'dose', 'in', 'to']","['placebo', 'table', 'date', 'treatment', 'dose']",593,"['根据审查事件的日期,治疗益处有所微不足道的变化,与最后一剂Ticagrelor或Placebo有关(附件中的S6表)。']",0.4166666666666667,"['placebo', 'appendix', 'table', 'variation', 'date', 'supplementary', 'relative', 'treatment', 'benefit', 'dose', 'in', 'to']","['appendix', 'table', 'variation', 'date', 'treatment']",593,根据事件截止日期相对于ticagrelor或安慰剂的最后一剂治疗效益有一定的差异(表S6参考附录)。,0.4166666666666667,"['placebo', 'appendix', 'table', 'variation', 'date', 'supplementary', 'relative', 'treatment', 'benefit', 'dose', 'in', 'to']","['placebo', 'table', 'date', 'treatment', 'to']",,,,
597,594,serious adverse events were slightly less frequent with ticagrelor than with placebo ( 31.9 % vs. 33.7 % ) .,替格瑞洛组的严重不良事件发生率略低于安慰剂组（31.9% 对 33.7%）。,0.2,"['placebo', 'adverse', 'with', 'serious', 'frequent']",['placebo'],594,['严重的副作用在Ticagrelor与Placebo相比略有较少(31.9%与33.7%)。'],0.0,"['placebo', 'adverse', 'with', 'serious', 'frequent']",[],594,严重不良事件在使用西卡格列醇治疗的患者中较使用安慰剂的患者略少发生（31.9% vs. 33.7%）。,0.2,"['placebo', 'adverse', 'with', 'serious', 'frequent']",['placebo'],,,,
598,595,"adverse events of interest occurred more frequently with ticagrelor than with placebo , a difference that was driven by a greater frequency of dyspnea in the ticagrelor group ( Table 3 ) .",与安慰剂组相比，替格瑞洛组感兴趣的不良事件发生频率更高，这是由替格瑞洛组呼吸困难频率更高所致（表 3）。,0.4615384615384615,"['group', 'frequency', 'placebo', 'table', 'dyspnea', 'frequently', 'difference', 'adverse', '3', 'with', 'that', 'in', 'by']","['group', 'frequency', 'placebo', 'table', 'dyspnea', 'by']",595,"['与Ticagrelor发生的不良兴趣事件更频繁,而不是与Placebo发生的差异,这是由Ticagrelor群体中更频繁的 dyspnea(图3)引发的差异。']",0.2307692307692307,"['group', 'frequency', 'placebo', 'table', 'dyspnea', 'frequently', 'difference', 'adverse', '3', 'with', 'that', 'in', 'by']","['group', 'difference', 'by']",595,在有利因素方面，ticagrelor组出现的事件比安慰剂组更频繁，差异主要由ticagrelor组出现的喘息更频繁所驱动（表3）。,0.3846153846153846,"['group', 'frequency', 'placebo', 'table', 'dyspnea', 'frequently', 'difference', 'adverse', '3', 'with', 'that', 'in', 'by']","['group', 'placebo', 'table', 'difference', 'by']",,,,
599,596,results that were consistent with the primary safety analysis were observed for other bleeding definitions .,对于其他出血定义，观察到与主要安全性分析一致的结果。,0.2,"['bleeding', 'primary', 'safety analysis', 'with', 'that']",['bleeding'],596,['与初级安全分析一致的结果被观察到其他出血定义。'],0.4,"['bleeding', 'primary', 'safety analysis', 'with', 'that']","['bleeding', 'safety analysis']",596,"符合主要安全性分析的结果也观察到了其他出血的定义。

Chinese:
与主要安全性分析结果一致的结果也被观察到了其他出血的定义。",0.2,"['bleeding', 'primary', 'safety analysis', 'with', 'that']",['bleeding'],,,,
600,597,"intracranial hemorrhage was more frequent with ticagrelor than with placebo , with 70 events and 46 events , respectively ( 0.7 % vs. 0.5 % ; hazard ratio , 1.71 ; 95 % CI , 1.18 to 2.48 ; P = 0.005 ) .",替格瑞洛组的颅内出血发生率高于安慰剂组，分别为 70 起事件和 46 起事件（0.7% 对 0.5%；风险比，1.71；95% CI，1.18 至 2.48；P = 0.005）。,0.4444444444444444,"['placebo', 'hazard ratio', 'intracranial hemorrhage', 'with', 'P', 'CI', 'frequent', 'to', 'and']","['placebo', 'hazard ratio', 'intracranial hemorrhage', 'to']",597,"['甲状腺内出血比 placebo 更常见,有 70 个事件和 46 个事件,分别( 0.7 % 与 0.5 % ; 危险比例, 1.71 ; 95 % CI, 1.18 至 2.48 ; P = 0.005 )。']",0.0,"['placebo', 'hazard ratio', 'intracranial hemorrhage', 'with', 'P', 'CI', 'frequent', 'to', 'and']",[],597,颅内出血比安慰剂更常见，分别为70例和46例（0.7% vs. 0.5%；危险比为1.71；95%置信区间为1.18-2.48；P=0.005）。,0.2222222222222222,"['placebo', 'hazard ratio', 'intracranial hemorrhage', 'with', 'P', 'CI', 'frequent', 'to', 'and']","['placebo', 'intracranial hemorrhage']",,,,
601,598,selected prespecified subgroup analyses for the primary safety outcome are presented in Figure S5 in the Supplementary Appendix .,主要安全性结局的选定预设亚组分析见补充附录图 S5。,0.125,"['safety', 'appendix', 'outcome', 'figure', 'supplementary', 'primary', 'subgroup', 'in']",['safety'],598,"['对于初级安全结果的选择预定子组分析,在附加附件中的图 S5 中呈现。']",0.375,"['safety', 'appendix', 'outcome', 'figure', 'supplementary', 'primary', 'subgroup', 'in']","['safety', 'appendix', 'outcome']",598,"selected prespecified subgroup analyses for the primary safety outcome are presented in Figure S5 in the Supplementary Appendix.

Chinese:

附件中的S5图表显示了有关主要安全结果的预先指定的分组分析结果。",0.375,"['safety', 'appendix', 'outcome', 'figure', 'supplementary', 'primary', 'subgroup', 'in']","['safety', 'appendix', 'outcome']",,,,
602,599,"rates of discontinuation were high in the two groups but were higher in the ticagrelor group , primarily due to an increased risk of bleeding and dyspnea .",两组的停药率都很高，但替格瑞洛组的停药率更高，这主要是由于出血和呼吸困难的风险增加。,0.8,"['bleeding', 'group', 'dyspnea', 'risk', 'due', 'but', 'to', 'and', 'two', 'high']","['bleeding', 'group', 'dyspnea', 'risk', 'but', 'to', 'two', 'high']",599,"['两组中断率很高,但在蒂卡格勒群体中较高,主要是由于出血和甲状腺炎的风险增加。']",0.7,"['bleeding', 'group', 'dyspnea', 'risk', 'due', 'but', 'to', 'and', 'two', 'high']","['bleeding', 'group', 'risk', 'but', 'to', 'two', 'high']",599,终止率在两组都很高，但是在利特瑞尔组更高，主要是因为出血和气喘的风险更大。,0.6,"['bleeding', 'group', 'dyspnea', 'risk', 'due', 'but', 'to', 'and', 'two', 'high']","['bleeding', 'group', 'risk', 'but', 'two', 'high']",,,,
603,600,prespecified analyses that were performed according to dose provided results consistent with those in the primary analysis .,根据剂量进行的预设分析提供的结果与主要分析中的结果一致。,0.2857142857142857,"['analysis', 'primary', 'with', 'dose', 'that', 'in', 'to']","['analysis', 'dose']",600,"['根据剂量进行的预定分析,结果与初始分析的结果一致。']",0.2857142857142857,"['analysis', 'primary', 'with', 'dose', 'that', 'in', 'to']","['analysis', 'dose']",600,"According to the dose provided, the prespecified analyses that were performed yielded results consistent with those in the primary analysis.",0.0,"['analysis', 'primary', 'with', 'dose', 'that', 'in', 'to']",[],,,,
604,601,"however , the prevention of ischemic events did not translate into a lower risk of cardiovascular death , presumably because fatal myocardial infarction and fatal stroke accounted for only a small fraction of all deaths ( 4.4 % and 4.5 % , respectively ) .",然而，预防缺血性事件并未转化为心血管死亡风险的降低，这可能是因为致命性心肌梗死和致命性中风仅占所有死亡的一小部分（分别为 4.4% 和 4.5%）。,0.6153846153846154,"['myocardial infarction', 'cardiovascular', 'stroke', 'death', 'prevention', 'lower', 'fatal', 'risk', 'fraction', 'translate', 'all', 'and', 'ischemic']","['myocardial infarction', 'cardiovascular', 'stroke', 'death', 'prevention', 'risk', 'fraction', 'and']",601,"['然而,预防化学事件并没有将其转化为心血管死亡的风险较低,可能是因为致命心脏病发作和致命中风仅占所有死亡人数的一小部分(相应为4.4%和4.5%)。']",0.5384615384615384,"['myocardial infarction', 'cardiovascular', 'stroke', 'death', 'prevention', 'lower', 'fatal', 'risk', 'fraction', 'translate', 'all', 'and', 'ischemic']","['cardiovascular', 'stroke', 'death', 'prevention', 'risk', 'fraction', 'and']",601,然而，预防缺血性事件并未转化为较低的心血管死亡风险，大概是因为致死性心肌梗死和致死性中风占所有死亡率的很小一部分（分别为4.4%和4.5%）。,0.6923076923076923,"['myocardial infarction', 'cardiovascular', 'stroke', 'death', 'prevention', 'lower', 'fatal', 'risk', 'fraction', 'translate', 'all', 'and', 'ischemic']","['myocardial infarction', 'cardiovascular', 'stroke', 'death', 'prevention', 'lower', 'risk', 'fraction', 'and']",,,,
605,602,"the observed 10 % lower incidence of ischemic events in the ticagrelor group , although significant , was less than the 16 % lower incidence assumed at the time of the trial design .",在替格瑞洛组观察到的缺血事件发生率降低了 10%，尽管意义重大，但低于试验设计时假定的 16% 发生率。,0.625,"['group', 'incidence', 'time', 'lower', 'trial', 'design', 'at', 'ischemic']","['group', 'incidence', 'time', 'design', 'at']",602,"['虽然显著,但在图卡格勒群体中发现的10%较低的异化现象的发病率低于试验设计时的16%较低的发病率。']",0.75,"['group', 'incidence', 'time', 'lower', 'trial', 'design', 'at', 'ischemic']","['group', 'incidence', 'time', 'lower', 'design', 'at']",602,研究观察到，ticagrelor 组发生缺血性事件的发病率比较低，为 10%，虽然该数字具有统计学意义，但是低于试验设计时所假设的 16%。,0.625,"['group', 'incidence', 'time', 'lower', 'trial', 'design', 'at', 'ischemic']","['group', 'incidence', 'time', 'design', 'at']",,,,
606,603,"in THEMIS , dual antiplatelet therapy with ticagrelor was associated with a higher frequency of intracranial hemorrhage than placebo .",在 THEMIS 中，与安慰剂相比，使用替格瑞洛的双重抗血小板治疗与更高的颅内出血频率相关。,0.5,"['frequency', 'placebo', 'antiplatelet', 'intracranial hemorrhage', 'therapy', 'associated', 'dual', 'with']","['frequency', 'placebo', 'intracranial hemorrhage', 'therapy']",603,"['在TEMIS中,双重抗斑疗法与Ticagrelor相结合,内分泌出血的频率比 placebo更高。']",0.25,"['frequency', 'placebo', 'antiplatelet', 'intracranial hemorrhage', 'therapy', 'associated', 'dual', 'with']","['frequency', 'therapy']",603,在THEMIS中，与预防剂平台疗法相比，与蒂卡格雷尔治疗的双重抗血小板疗法更易导致颅内出血。,0.25,"['frequency', 'placebo', 'antiplatelet', 'intracranial hemorrhage', 'therapy', 'associated', 'dual', 'with']","['intracranial hemorrhage', 'therapy']",,,,
607,604,"in the past , increases in the incidence of intracranial hemorrhage with dual antiplatelet therapy have been reported with ticagrelor , 7 clopidogrel , 24 and prasugrel.22,25","过去曾有报道称，使用替卡格雷 7 氯吡格雷 24 和普拉格雷 22, 25 进行双重抗血小板治疗会增加颅内出血的发生率。",0.4545454545454545,"['incidence', 'antiplatelet', 'intracranial hemorrhage', 'clopidogrel', 'therapy', 'increases', 'dual', 'with', 'have', 'and', 'past']","['incidence', 'intracranial hemorrhage', 'clopidogrel', 'therapy', 'have']",604,"['在过去,双血管治疗的内分泌出血的发病率增加已被提卡格勒勒、7克洛皮多格勒、24和普拉苏格勒报告。']",0.1818181818181818,"['incidence', 'antiplatelet', 'intracranial hemorrhage', 'clopidogrel', 'therapy', 'increases', 'dual', 'with', 'have', 'and', 'past']","['incidence', 'therapy']",604,"过去，对于使用双抗血小板疗法的脑内出血的发病率有所上升，7发现使用了西加利尔，24使用了克洛赛尔，22,25使用了帕苏格尔。",0.2727272727272727,"['incidence', 'antiplatelet', 'intracranial hemorrhage', 'clopidogrel', 'therapy', 'increases', 'dual', 'with', 'have', 'and', 'past']","['incidence', 'therapy', 'have']",,,,
608,605,the ongoing TWILIGHT trial is testing a similar strategy.32,正在进行的 TWILIGHT 试验正在测试一种类似的策略。 32,0.0,"['trial', 'testing', 'similar']",[],605,['目前的TWILIGHT审判正在测试类似策略。'],0.3333333333333333,"['trial', 'testing', 'similar']",['trial'],605,目前正在進行的 TWILIGHT 試驗正在測試類似的策略。32,0.0,"['trial', 'testing', 'similar']",[],,,,
609,606,"in conclusion , in patients with stable coronary artery disease and type 2 diabetes who did not have a history of myocardial infarction or stroke , ticagrelor plus aspirin was associated with a lower incidence of ischemic events than placebo plus aspirin at the expense of a higher incidence of major bleeding , including intracranial hemorrhage .",总之，在没有心肌梗死或中风病史的稳定型冠状动脉疾病和2型糖尿病患者中，替格瑞洛加阿司匹林与安慰剂加阿司匹林相比，缺血事件发生率较低，但代价是缺血事件发生率较高。大出血，包括颅内出血。,0.6086956521739131,"['bleeding', 'myocardial infarction', 'diabetes', 'aspirin', 'type', 'placebo', 'incidence', 'disease', 'stroke', 'who', '2', 'plus', 'intracranial hemorrhage', 'history', 'lower', 'major', 'associated', 'conclusion', 'with', 'coronary artery', 'have', 'and', 'ischemic']","['bleeding', 'myocardial infarction', 'diabetes', 'aspirin', 'type', 'placebo', 'incidence', 'disease', 'stroke', '2', 'plus', 'intracranial hemorrhage', 'coronary artery', 'have']",606,"['结论是,在患有稳定的冠状动脉疾病和2型糖尿病的患者,没有心脏病发作或中风的历史,Ticagrelor plus aspirin与比 placebo plus aspirin更低的催化事件的发病率相结合,而更高的发病率主要出血,包括内分泌出血。']",0.5217391304347826,"['bleeding', 'myocardial infarction', 'diabetes', 'aspirin', 'type', 'placebo', 'incidence', 'disease', 'stroke', 'who', '2', 'plus', 'intracranial hemorrhage', 'history', 'lower', 'major', 'associated', 'conclusion', 'with', 'coronary artery', 'have', 'and', 'ischemic']","['bleeding', 'diabetes', 'type', 'incidence', 'disease', 'stroke', '2', 'history', 'conclusion', 'coronary artery', 'have', 'and']",606,在结论中，在患有稳定的冠心病和2型糖尿病的患者中，没有心肌梗死或中风的历史，则低剂量肠激酶A抑制剂加速器复合物比安慰剂加阿司匹林具有更低的心脏疾病发作发生率，但更易出现重度出血，包括脑出血。,0.6086956521739131,"['bleeding', 'myocardial infarction', 'diabetes', 'aspirin', 'type', 'placebo', 'incidence', 'disease', 'stroke', 'who', '2', 'plus', 'intracranial hemorrhage', 'history', 'lower', 'major', 'associated', 'conclusion', 'with', 'coronary artery', 'have', 'and', 'ischemic']","['bleeding', 'myocardial infarction', 'diabetes', 'aspirin', 'type', 'placebo', 'incidence', 'disease', 'stroke', '2', 'plus', 'history', 'conclusion', 'have']",,,,
610,607,"as a result , there was no significantly lower incidence of the exploratory composite outcome of efficacy and safety with ticagrelor than with placebo .",因此，与安慰剂相比，替格瑞洛的有效性和安全性探索性复合结果的发生率没有显着降低。,0.4615384615384615,"['safety', 'composite', 'placebo', 'incidence', 'outcome', 'lower', 'exploratory', 'no', 'efficacy', 'result', 'as', 'with', 'and']","['safety', 'placebo', 'incidence', 'outcome', 'efficacy', 'result']",607,"['因此,与Ticagrelor的有效性和安全性研究组合结果的发病率与Placebo相比没有显著较低。']",0.3846153846153846,"['safety', 'composite', 'placebo', 'incidence', 'outcome', 'lower', 'exploratory', 'no', 'efficacy', 'result', 'as', 'with', 'and']","['safety', 'incidence', 'outcome', 'efficacy', 'result']",607,"As a result, there was no significantly lower incidence of the exploratory composite outcome of efficacy and safety with ticagrelor than with placebo.",0.0,"['safety', 'composite', 'placebo', 'incidence', 'outcome', 'lower', 'exploratory', 'no', 'efficacy', 'result', 'as', 'with', 'and']",[],,,,
611,608,hypertension is a powerful risk factor for ischemic and hemorrhagic stroke .,高血压是缺血性和出血性中风的重要危险因素。,0.3333333333333333,"['stroke', 'hypertension', 'hemorrhagic', 'risk factor', 'and', 'ischemic']","['stroke', 'hypertension']",608,['高血压是伊斯基米和血管中风的强大风险因素。'],0.5,"['stroke', 'hypertension', 'hemorrhagic', 'risk factor', 'and', 'ischemic']","['stroke', 'hypertension', 'risk factor']",608,高血壓是一個強大的缺血性和出血性中風的風險因素。,0.1666666666666666,"['stroke', 'hypertension', 'hemorrhagic', 'risk factor', 'and', 'ischemic']",['stroke'],,,,
612,609,"the effects of blood pressure ( BP ) values and trajectories in midlife on subsequent brain morphologic changes are less clear , as is the effect of midlife hypertension on later cognitive decline .",中年时期的血压 (BP) 值和轨迹对随后的大脑形态变化的影响不太清楚，中年高血压对后来认知能力下降的影响也是如此。,0.4615384615384615,"['decline', 'clear', 'hypertension', 'brain', 'blood pressure', 'effect', 'subsequent', 'values', 'as', 'cognitive', 'midlife', 'later', 'and']","['decline', 'hypertension', 'brain', 'blood pressure', 'as', 'later']",609,"['中期血压(BP)值和轨道对后来的大脑形状变化的影响不太明显,正如中期高血压对后来的认知衰退的影响。']",0.4615384615384615,"['decline', 'clear', 'hypertension', 'brain', 'blood pressure', 'effect', 'subsequent', 'values', 'as', 'cognitive', 'midlife', 'later', 'and']","['decline', 'hypertension', 'brain', 'blood pressure', 'as', 'later']",609,目前尚不清楚血压值和轨迹在中年对随后脑部形态变化的影响，也不清楚中年高血压对以后认知功能下降的影响。,0.4615384615384615,"['decline', 'clear', 'hypertension', 'brain', 'blood pressure', 'effect', 'subsequent', 'values', 'as', 'cognitive', 'midlife', 'later', 'and']","['decline', 'hypertension', 'brain', 'blood pressure', 'cognitive', 'later']",,,,
613,610,participants also underwent amyloid PET scanning and cognitive testing .,参与者还接受了淀粉样蛋白 PET 扫描和认知测试。,0.0,"['amyloid', 'PET', 'scanning', 'testing', 'cognitive', 'and']",[],610,['参与者也接受了AMYLOID PET扫描和认知测试。'],0.0,"['amyloid', 'PET', 'scanning', 'testing', 'cognitive', 'and']",[],610,"participants also underwent amyloid PET scanning and cognitive testing.

Chinese:

参与者还接受了阿米洛德PET扫描和认知测试。",0.0,"['amyloid', 'PET', 'scanning', 'testing', 'cognitive', 'and']",[],,,,
614,611,"of 465 participants ( mean age , 71 ; 51 % men ) who completed imaging and cognitive testing , 18 % were amyloid positive on PET imaging and 29 % were carriers of the Apo E ℇ4 allele .",在完成成像和认知测试的 465 名参与者（平均年龄 71 岁；51% 为男性）中，18% 的淀粉样蛋白在 PET 成像中呈阳性，29% 是 Apo Eℇ4 等位基因的携带者。,0.25,"['allele', 'mean', 'who', 'amyloid', 'PET', 'age', 'testing', 'cognitive', 'positive', 'on', 'imaging', 'and']","['allele', 'mean', 'age']",611,"['在完成图像和认知测试的465名参与者(平均年龄,71;51%)中,有18%对PET图像有益,29%是Apo E <unk>4 Allele的携带者。']",0.1666666666666666,"['allele', 'mean', 'who', 'amyloid', 'PET', 'age', 'testing', 'cognitive', 'positive', 'on', 'imaging', 'and']","['mean', 'age']",611,465 名参与者 ( 平均年龄 71 岁 ; 51% 男性 ) 完成了影像和认知测试，其中 18% 的人 PET 影像显示出淀粉样蛋白阳性，而 29% 的人携带有 ApoE ℇ4 基因。,0.25,"['allele', 'mean', 'who', 'amyloid', 'PET', 'age', 'testing', 'cognitive', 'positive', 'on', 'imaging', 'and']","['mean', 'age', 'and']",,,,
615,612,"at age 69 , mean BP was 132 / 73 mm Hg and 40 % of participants were taking antihypertensive medication .",69 岁时，平均血压为 132 / 73 毫米汞柱，40% 的参与者正在服用抗高血压药物。,0.2857142857142857,"['antihypertensive', 'mean', 'taking', '/', 'medication', 'age', 'and']","['antihypertensive', 'mean']",612,"['在69歲時,平均BP為132 / 73 mm Hg,40%的參與者服用抗高血壓藥物。']",0.1428571428571428,"['antihypertensive', 'mean', 'taking', '/', 'medication', 'age', 'and']",['mean'],612,"At age 69, mean BP was 132/73 mm Hg and 40% of participants were taking antihypertensive medication.

Chinese:

年龄为69岁的参与者平均血压为132/73毫米汞柱，约40%的参与者在服用降压药物。",0.4285714285714285,"['antihypertensive', 'mean', 'taking', '/', 'medication', 'age', 'and']","['antihypertensive', 'mean', 'age']",,,,
616,613,"higher systolic or diastolic BP at age 53 years , and higher BP increases between ages 43 and 53 , were associated with increases in later WMHV .",53 岁时较高的收缩压或舒张压以及 43 岁和 53 岁之间较高的血压增幅与后期 WMHV 的增高有关。,0.125,"['diastolic', 'associated', 'age', 'increases', 'systolic', 'with', 'later', 'and']",['later'],613,"['53岁时的更高的系统性或神经性BP,43岁至53岁之间的更高的BP增加,与后期WMHV的增加有关。']",0.125,"['diastolic', 'associated', 'age', 'increases', 'systolic', 'with', 'later', 'and']",['later'],613,高血壓在53歲時或血壓在43到53歲之間升高，與後期腦水腫容量增加有關。,0.0,"['diastolic', 'associated', 'age', 'increases', 'systolic', 'with', 'later', 'and']",[],,,,
617,614,"for every 10 mm Hg increase in systolic BP at age 53 , subsequent WMHV increased by 7 % ; for comparable increases in diastolic BP , WMHV increased by 15 % .",53 岁时收缩压每增加 10 毫米汞柱，随后的 WMHV 就会增加 7%；对于可比较的舒张压增加，WMHV 增加了 15%。,0.1428571428571428,"['diastolic', 'age', 'increases', 'systolic', 'subsequent', 'at', 'by']",['at'],614,"['每10毫米Hg增加在53岁时的系统性BP,随后的WMHV增加了7%;对于相似的增加在二元性BP,WMHV增加了15%。']",0.1428571428571428,"['diastolic', 'age', 'increases', 'systolic', 'subsequent', 'at', 'by']",['at'],614,"For every 10 mm Hg increase in systolic BP at age 53, subsequent WMHV increased by 7%. For comparable increases in diastolic BP, WMHV increased by 15%.

中文：

53岁时，每上升10 mm Hg的收缩压，随后脑水肿体积就会增加7%；相应数量级的舒张压升高则会导致脑水肿体积增加15%。",0.0,"['diastolic', 'age', 'increases', 'systolic', 'subsequent', 'at', 'by']",[],,,,
618,615,"the greater the increase in BP between ages 36 and 43 , the smaller the hippocampal volume at ages 69 to 71 years .",36 岁至 43 岁之间血压升高越大，69 至 71 岁时海马体积越小。,0.3333333333333333,"['volume', 'increase', 'at', 'to', 'and', 'hippocampal']","['volume', 'hippocampal']",615,"['年龄在36岁至43岁之间的BP增加越大,年龄在69岁至71岁时的催眠体积越小。']",0.1666666666666666,"['volume', 'increase', 'at', 'to', 'and', 'hippocampal']",['volume'],615,"the greater the increase in BP between ages 36 and 43 , the smaller the hippocampal volume at ages 69 to 71 years .

Chinese:

年龄在36到43岁之间血压升高越多，69到71岁时的海马体体积就越小。",0.3333333333333333,"['volume', 'increase', 'at', 'to', 'and', 'hippocampal']","['volume', 'hippocampal']",,,,
619,616,absolute BP values or BP changes were not linked with amyloid positivity or overall cognitive scores .,绝对血压值或血压变化与淀粉样蛋白阳性或总体认知评分无关。,0.2,"['amyloid', 'absolute', 'values', 'with', 'cognitive']",['absolute'],616,['绝对的 BP 值或 BP 变化与 amyloid 积极性或整体认知分数无关。'],0.2,"['amyloid', 'absolute', 'values', 'with', 'cognitive']",['absolute'],616,绝对血压值或血压变化与淀粉样蛋白阳性或总体认知评分无关。,0.2,"['amyloid', 'absolute', 'values', 'with', 'cognitive']",['absolute'],,,,
620,617,BP screening and control in early adulthood could have important benefits .,在成年早期筛查和控制血压可能有重要的好处。,0.6666666666666666,"['adulthood', 'control', 'screening', 'early', 'have', 'and']","['control', 'screening', 'early', 'have']",617,['早期成年时的BP筛查和控制可能有很大的好处。'],0.6666666666666666,"['adulthood', 'control', 'screening', 'early', 'have', 'and']","['control', 'screening', 'early', 'have']",617,在成年早期进行血压筛查和控制可能会产生重要的好处。,0.5,"['adulthood', 'control', 'screening', 'early', 'have', 'and']","['control', 'screening', 'early']",,,,
621,618,"these lesions are thought to represent small vessel disease , and accumulation of WMLs has been associated with cognitive impairment and gait disorders .",这些病变被认为代表小血管疾病，而 WMLs 的积累与认知障碍和步态障碍有关。,0.3846153846153846,"['vessel', 'disease', 'represent', 'thought', 'associated', 'gait', 'disorders', 'impairment', 'with', 'cognitive', 'accumulation', 'to', 'and']","['disease', 'represent', 'gait', 'disorders', 'and']",618,"['这些伤害被认为代表小型船舶疾病,并且WML的积累已与认知障碍和通道障碍有关。']",0.2307692307692307,"['vessel', 'disease', 'represent', 'thought', 'associated', 'gait', 'disorders', 'impairment', 'with', 'cognitive', 'accumulation', 'to', 'and']","['disease', 'represent', 'disorders']",618,这些病变被认为是小血管疾病的表现，WML积聚与认知功能障碍和步态障碍有关。,0.4615384615384615,"['vessel', 'disease', 'represent', 'thought', 'associated', 'gait', 'disorders', 'impairment', 'with', 'cognitive', 'accumulation', 'to', 'and']","['disease', 'represent', 'gait', 'disorders', 'impairment', 'cognitive']",,,,
622,619,the objective of the substudy was to evaluate the effect of different BP treatments on the progression of WMLs of presumed ischemic origin .,该子研究的目的是评估不同 BP 治疗对推测为缺血性起源的 WML 进展的影响。,0.3333333333333333,"['objective', 'origin', 'progression', 'effect', 'to', 'ischemic']","['origin', 'progression']",619,['该研究的目的是评估不同 BP 治疗对假设以色列起源的 WML 的进展的影响。'],0.3333333333333333,"['objective', 'origin', 'progression', 'effect', 'to', 'ischemic']","['origin', 'progression']",619,目的是评估不同高血压治疗方案对预期缺血性脑水肿退化的影响。,0.0,"['objective', 'origin', 'progression', 'effect', 'to', 'ischemic']",[],,,,
623,620,effect on brain volume was a secondary goal .,对脑容量的影响是次要目标。,0.4,"['volume', 'brain', 'secondary', 'effect', 'goal']","['brain', 'goal']",620,['对大脑体积的影响是次要目标。'],0.6,"['volume', 'brain', 'secondary', 'effect', 'goal']","['volume', 'brain', 'goal']",620,影響大腦體積是次要目標。,0.0,"['volume', 'brain', 'secondary', 'effect', 'goal']",[],,,,
624,621,neurologists should support achievement of lower BP targets .,神经科医生应该支持实现较低的血压目标。,0.6666666666666666,"['support', 'lower', 'achievement']","['support', 'lower']",621,['神经学家应该支持实现较低的BP目标。'],0.6666666666666666,"['support', 'lower', 'achievement']","['support', 'lower']",621,"neurologists should support achievement of lower BP targets.

Chinese:

神经科医生应该支持降低血压目标的实现。",0.3333333333333333,"['support', 'lower', 'achievement']",['support'],,,,
625,622,participants were enrolled at a relatively advanced age ; it would be of interest to know if intensive BP control has greater benefits in midlife .,参加者年龄相对较大；了解强化 BP 控制是否对中年人有更大的益处将很有意义。,0.25,"['control', 'be', 'intensive', 'age', 'advanced', 'at', 'midlife', 'to']","['control', 'age']",622,['參與者在一個相對先進的年齡被註冊;有興趣知道是否強烈的BP控制在中期有更大的好處。'],0.25,"['control', 'be', 'intensive', 'age', 'advanced', 'at', 'midlife', 'to']","['control', 'be']",622,参与者在相对较高的年龄被录取；如果强化血压控制在中年有更大的益处，这将是有趣的。,0.375,"['control', 'be', 'intensive', 'age', 'advanced', 'at', 'midlife', 'to']","['control', 'be', 'age']",,,,
626,623,"also , SPRINT excluded patients with diabetes mellitus and those with previous strokes .",此外，SPRINT 还排除了患有糖尿病和既往中风的患者。,0.25,"['previous', 'diabetes mellitus', 'with', 'and']",['diabetes mellitus'],623,"['此外,SPRINT排除患有糖尿病患者和以前的中风患者。']",0.5,"['previous', 'diabetes mellitus', 'with', 'and']","['previous', 'diabetes mellitus']",623,同时，SPRINT排除了患有糖尿病和以前曾中风的患者。,0.25,"['previous', 'diabetes mellitus', 'with', 'and']",['diabetes mellitus'],,,,
627,624,"because BMI does not differentiate between fat and lean body mass , researchers in another Mendelian randomization study have now ascertained whether fat per se is causally associated with depression .",由于 BMI 不能区分脂肪和瘦体重，另一项孟德尔随机研究的研究人员现已确定脂肪本身是否与抑郁症有因果关系。,0.5,"['depression', 'randomization', 'fat', 'BMI', 'study', 'associated', 'differentiate', 'mass', 'body', 'with', 'have', 'in']","['depression', 'randomization', 'fat', 'differentiate', 'body', 'have']",624,"['由于BMI不区分脂肪和脂肪体重,另一个Mendelian随机化研究的研究人员现在确定脂肪是否因原因与抑郁症有关。']",0.5,"['depression', 'randomization', 'fat', 'BMI', 'study', 'associated', 'differentiate', 'mass', 'body', 'with', 'have', 'in']","['depression', 'randomization', 'fat', 'differentiate', 'body', 'have']",624,BMI不能区分脂肪和瘦体重，研究人员在另一项门德尔随机化研究中确定了脂肪本身是否与忧郁症有因果关联。,0.5,"['depression', 'randomization', 'fat', 'BMI', 'study', 'associated', 'differentiate', 'mass', 'body', 'with', 'have', 'in']","['depression', 'randomization', 'fat', 'differentiate', 'body', 'have']",,,,
628,625,the two data sources shared approximately 6.5 million single nucleotide polymorphisms ( SNPs ) .,这两个数据源共享大约 650 万个单核苷酸多态性 (SNP)。,0.6666666666666666,"['nucleotide', 'data', 'approximately', 'single', 'two', 'million']","['nucleotide', 'data', 'single', 'two']",625,['这两个数据来源共享了约650万个单核分子聚合物(SNPs)。'],0.5,"['nucleotide', 'data', 'approximately', 'single', 'two', 'million']","['data', 'single', 'two']",625,这两个数据源共共享了大约650万个单核苷酸多态性位点（SNP）。,0.6666666666666666,"['nucleotide', 'data', 'approximately', 'single', 'two', 'million']","['nucleotide', 'data', 'single', 'two']",,,,
629,626,"conversely , depression was not a risk factor for any of the anthropometric measures .",相反，抑郁症不是任何人体测量指标的危险因素。,0.5,"['depression', 'risk factor']",['depression'],626,"['相反,抑郁症并不是任何人类测量的风险因素。']",1.0,"['depression', 'risk factor']","['depression', 'risk factor']",626,相反，抑郁并不是任何人类测量方面的风险因素。,1.0,"['depression', 'risk factor']","['depression', 'risk factor']",,,,
630,627,SNPs associated with short stature contributed causally but modestly to risk for depression .,与身材矮小相关的 SNP 对抑郁症的风险有一定的因果作用，但影响不大。,0.4285714285714285,"['depression', 'associated', 'risk', 'with', 'short stature', 'but', 'to']","['depression', 'risk', 'but']",627,['与短期相关的SNPs因果但温和地有助于抑郁症的风险。'],0.5714285714285714,"['depression', 'associated', 'risk', 'with', 'short stature', 'but', 'to']","['depression', 'risk', 'but', 'to']",627,短身材相关的SNP起到了一定的因果作用，但对抑郁症的风险贡献不大。,0.4285714285714285,"['depression', 'associated', 'risk', 'with', 'short stature', 'but', 'to']","['depression', 'risk', 'but']",,,,
631,628,"based on the reasonable assumption that SNPs associated with anthropometric traits are causal for those traits , these findings suggest that body fat mass contributes causally to the risk for depression .",基于与人体测量特征相关的 SNP 是这些特征的因果关系的合理假设，这些发现表明体脂肪量与抑郁症的风险有因果关系。,0.5454545454545454,"['depression', 'fat', 'associated', 'risk', 'causal', 'mass', 'body', 'suggest', 'with', 'that', 'to']","['depression', 'fat', 'risk', 'causal', 'body', 'to']",628,"['基于合理的假设,与人类学特征相关的SNPs是这些特征的原因,这些发现表明身体脂肪质量有助于抑郁症的风险。']",0.5454545454545454,"['depression', 'fat', 'associated', 'risk', 'causal', 'mass', 'body', 'suggest', 'with', 'that', 'to']","['depression', 'fat', 'risk', 'mass', 'body', 'to']",628,基于合理的假设，SNP与人类身体特征相关联，这些发现表明身体脂肪量对抑郁症的风险起到因果作用。,0.4545454545454545,"['depression', 'fat', 'associated', 'risk', 'causal', 'mass', 'body', 'suggest', 'with', 'that', 'to']","['depression', 'fat', 'risk', 'body', 'to']",,,,
632,629,clinicians can be alert to these connections in assessing and managing patients struggling with weight and mood .,临床医生在评估和管理与体重和情绪作斗争的患者时可以警惕这些联系。,0.25,"['mood', 'weight', 'be', 'alert', 'with', 'in', 'to', 'and']","['weight', 'be']",629,['临床医生可以警告这些联系在评估和管理与体重和情绪斗争的患者。'],0.25,"['mood', 'weight', 'be', 'alert', 'with', 'in', 'to', 'and']","['weight', 'be']",629,"clinicians can be alert to these connections in assessing and managing patients struggling with weight and mood .

Chinese:

医师在评估和治疗体重和情绪问题的患者时，可以留意这些联系。",0.25,"['mood', 'weight', 'be', 'alert', 'with', 'in', 'to', 'and']","['weight', 'be']",,,,
633,630,"in the face of preeclampsia , a central clinical decision is when to plan delivery .",面对先兆子痫，一个主要的临床决定是何时计划分娩。,0.7142857142857143,"['face', 'preeclampsia', 'delivery', 'central', 'clinical', 'decision', 'to']","['face', 'preeclampsia', 'delivery', 'clinical', 'decision']",630,"['在预发症面前,一个中心的临床决定是什么时候计划分娩。']",0.7142857142857143,"['face', 'preeclampsia', 'delivery', 'central', 'clinical', 'decision', 'to']","['face', 'delivery', 'central', 'clinical', 'decision']",630,在面对妊娠高血压的情况下，临床决策的核心问题是何时计划分娩。,0.5714285714285714,"['face', 'preeclampsia', 'delivery', 'central', 'clinical', 'decision', 'to']","['face', 'delivery', 'clinical', 'decision']",,,,
634,631,"to assess delivery strategy , U.K. investigators randomized 900 women with preeclampsia without severe features ( median gestational age at diagnosis , 35.6 weeks ) to immediate delivery or expectant management .",为评估分娩策略，英国研究人员将 900 名没有严重特征（诊断时的中位孕龄为 35.6 周）的先兆子痫妇女随机分为立即分娩或期待治疗。,0.5,"['median', 'strategy', 'preeclampsia', 'delivery', 'diagnosis', 'assess', 'management', 'immediate', 'severe', 'gestational age', 'to', 'without']","['strategy', 'preeclampsia', 'delivery', 'diagnosis', 'assess', 'gestational age']",631,"['为了评估生育策略,英国研究人员随机调查了900名患有无严重特征的妇女(诊断时平均生育年龄为35.6周),即时生育或预期管理。']",0.4166666666666667,"['median', 'strategy', 'preeclampsia', 'delivery', 'diagnosis', 'assess', 'management', 'immediate', 'severe', 'gestational age', 'to', 'without']","['strategy', 'diagnosis', 'assess', 'management', 'without']",631,为了评估产前子痫前期的治疗策略，英国的研究人员对900名妇女进行了随机分析，这些妇女均出现了轻度的产前子痫前期（诊断时的平均妊娠年龄为35.6周），他们将这些妇女分为立即分娩组和待产组。,0.4166666666666667,"['median', 'strategy', 'preeclampsia', 'delivery', 'diagnosis', 'assess', 'management', 'immediate', 'severe', 'gestational age', 'to', 'without']","['strategy', 'preeclampsia', 'delivery', 'diagnosis', 'assess']",,,,
635,632,"median gestational age at birth was 36.0 weeks ( immediate delivery ) and 36.7 weeks ( expectant management ) , and cesarean delivery rates were 55 % and 61 % , respectively .",出生时的中位胎龄为 36.0 周（立即分娩）和 36.7 周（期待治疗），剖宫产率分别为 55% 和 61%。,0.1428571428571428,"['median', 'birth', 'cesarean delivery', 'management', 'immediate', 'gestational age', 'and']",['birth'],632,"['出生时的平均生育年龄为36.0周(即时分娩)和36.7周(预期管理),凯撒分娩率为55%和61%,分别。']",0.2857142857142857,"['median', 'birth', 'cesarean delivery', 'management', 'immediate', 'gestational age', 'and']","['birth', 'management']",632,"The median gestational age at birth was 36.0 weeks for babies delivered immediately, and 36.7 weeks for babies whose mothers were managed expectantly. The cesarean delivery rates were 55% and 61%, respectively.",0.0,"['median', 'birth', 'cesarean delivery', 'management', 'immediate', 'gestational age', 'and']",[],,,,
636,633,expectant management is an option if maternal blood pressure and laboratory testing are stable .,如果产妇血压和实验室检查稳定，期待治疗是一种选择。,0.25,"['maternal', 'blood pressure', 'option', 'laboratory', 'management', 'testing', 'if', 'and']","['blood pressure', 'laboratory']",633,"['预期管理是一种选择,如果母亲的血压和实验室测试是稳定的。']",0.5,"['maternal', 'blood pressure', 'option', 'laboratory', 'management', 'testing', 'if', 'and']","['maternal', 'blood pressure', 'laboratory', 'management']",633,如果母亲的血压和实验室检测结果稳定，期待管理是一个选择。,0.5,"['maternal', 'blood pressure', 'option', 'laboratory', 'management', 'testing', 'if', 'and']","['maternal', 'blood pressure', 'laboratory', 'management']",,,,
637,634,"immediate delivery is warranted if the preeclampsia progresses ( e.g. , rising maternal blood pressure , worrisome findings upon maternal or fetal testing ) or at the onset of preeclampsia with severe features .",如果先兆子痫进展（例如，母体血压升高，母体或胎儿检测结果令人担忧）或具有严重特征的先兆子痫发作，则需要立即分娩。,0.3333333333333333,"['maternal', 'fetal', 'preeclampsia', 'delivery', 'blood pressure', 'onset', 'immediate', 'testing', 'with', 'severe', 'rising', 'if']","['maternal', 'preeclampsia', 'delivery', 'blood pressure']",634,"['即时分娩是保证的,如果前<unk>症进展(例如,母亲血压上升,在母亲或胎儿测试时令人担忧的发现)或在前<unk>症的发起时具有严重特征。']",0.25,"['maternal', 'fetal', 'preeclampsia', 'delivery', 'blood pressure', 'onset', 'immediate', 'testing', 'with', 'severe', 'rising', 'if']","['maternal', 'delivery', 'blood pressure']",634,如果产前血压升高或者出现令人担忧的孕妇或胎儿测试结果，则需要立即进行产前血压监测。如果出现严重的产前血压症状，也需要立即进行产前血压监测。,0.0833333333333333,"['maternal', 'fetal', 'preeclampsia', 'delivery', 'blood pressure', 'onset', 'immediate', 'testing', 'with', 'severe', 'rising', 'if']",['blood pressure'],,,,
638,635,"based on these results , increasing intake of PUFAs for preventing or treating diabetes is not recommended .",基于这些结果，不建议为了预防或治疗糖尿病而增加多不饱和脂肪酸的摄入量。,0.3333333333333333,"['diabetes', 'intake', 'on']",['diabetes'],635,"['基于这些结果,不建议增加PUFAs的摄入,以预防或治疗糖尿病。']",0.3333333333333333,"['diabetes', 'intake', 'on']",['diabetes'],635,根据这些结果，不建议增加脂肪酸摄入量以预防或治疗糖尿病。,0.3333333333333333,"['diabetes', 'intake', 'on']",['diabetes'],,,,
639,636,Obverse differences were noted for sedentary time .,久坐时间存在显着差异。,0.5,"['sedentary', 'time']",['time'],636,['可见的差异被注意到在座位时间。'],0.5,"['sedentary', 'time']",['time'],636,"反面的久坐时间有所不同。

Chinese:

反面的静坐时间有所不同。",0.5,"['sedentary', 'time']",['time'],,,,
640,637,the maximum risk reductions occurred at 375 minutes of light activity and 24 minutes of vigorous activity daily .,最大的风险降低发生在每天 375 分钟的轻度活动和 24 分钟的剧烈活动中。,0.4285714285714285,"['activity', 'risk', 'light', 'vigorous', 'maximum', 'at', 'and']","['activity', 'risk', 'maximum']",637,['最大风险减少发生在375分钟的轻度活动和24分钟的强度活动每日。'],0.2857142857142857,"['activity', 'risk', 'light', 'vigorous', 'maximum', 'at', 'and']","['activity', 'risk']",637,"The maximum risk reductions occurred at 375 minutes of light activity and 24 minutes of vigorous activity daily.

Chinese:

最大的风险降低发生在每天375分钟的轻度活动和24分钟的剧烈活动中。",0.4285714285714285,"['activity', 'risk', 'light', 'vigorous', 'maximum', 'at', 'and']","['activity', 'risk', 'maximum']",,,,
641,638,"however , some residual confounding ( in which low levels of activity resulted in part from medical conditions that accelerate mortality ) seems likely in this analysis , despite statistical adjustment for some comorbidities .",然而，尽管对一些合并症进行了统计调整，但在该分析中似乎可能存在一些残留混杂因素（其中低水平的活动部分是由加速死亡率的医疗条件导致的）。,0.3846153846153846,"['part', 'analysis', 'activity', 'medical', 'adjustment', 'low', 'mortality', 'residual', 'despite', 'this', 'that', 'in', 'accelerate']","['analysis', 'activity', 'low', 'mortality', 'this']",638,"['然而,某些残留的混乱(其中活动水平较低部分是由加速死亡率的医疗条件产生的)似乎在这一分析中很有可能,尽管对某些复杂性进行了统计调整。']",0.3846153846153846,"['part', 'analysis', 'activity', 'medical', 'adjustment', 'low', 'mortality', 'residual', 'despite', 'this', 'that', 'in', 'accelerate']","['analysis', 'activity', 'low', 'mortality', 'this']",638,然而，这种研究中存在一定程度的残留混杂因素（其中低活动水平部分是由加速死亡的医疗状况引起的），尽管我们已经对一些共病症进行了统计学校正，但这种情况仍然很可能存在。,0.2307692307692307,"['part', 'analysis', 'activity', 'medical', 'adjustment', 'low', 'mortality', 'residual', 'despite', 'this', 'that', 'in', 'accelerate']","['activity', 'low', 'this']",,,,
642,639,"a retrospective study suggests that we should look at overall cardiovascular risk , regardless of baseline BP .",一项回顾性研究表明，无论基线血压如何，我们都应该关注总体心血管风险。,0.5714285714285714,"['cardiovascular', 'baseline', 'retrospective study', 'risk', 'that', 'look', 'we']","['cardiovascular', 'baseline', 'retrospective study', 'risk']",639,"['一项回顾性研究表明,无论基线BP如何,我们都应该考虑整体心血管风险。']",0.5714285714285714,"['cardiovascular', 'baseline', 'retrospective study', 'risk', 'that', 'look', 'we']","['cardiovascular', 'baseline', 'retrospective study', 'risk']",639,一项回顾性研究表明，我们应该考虑总体心血管风险，而不是以基线血压为依据。,0.5714285714285714,"['cardiovascular', 'baseline', 'retrospective study', 'risk', 'that', 'look', 'we']","['cardiovascular', 'baseline', 'retrospective study', 'risk']",,,,
643,640,"should treatment to lower blood pressure ( BP ) be initiated based on baseline BP , overall cardiovascular ( CV ) risk , or a combination of the two ?",是否应该根据基线血压、总体心血管 (CV) 风险或两者的组合来开始降低血压 (BP) 的治疗？,0.7777777777777778,"['combination', 'cardiovascular', 'baseline', 'be', 'treatment', 'risk', 'lower blood pressure', 'to', 'two']","['combination', 'cardiovascular', 'baseline', 'treatment', 'risk', 'lower blood pressure', 'two']",640,"['低血压(BP)的治疗应该是基于基线BP,总心血管(CV)风险,还是两者的组合?']",0.7777777777777778,"['combination', 'cardiovascular', 'baseline', 'be', 'treatment', 'risk', 'lower blood pressure', 'to', 'two']","['combination', 'cardiovascular', 'baseline', 'treatment', 'risk', 'to', 'two']",640,应该根据基线血压、 overall cardiovascular（CV）风险或两者的结合来启动降低血压（BP）的治疗吗？,0.6666666666666666,"['combination', 'cardiovascular', 'baseline', 'be', 'treatment', 'risk', 'lower blood pressure', 'to', 'two']","['combination', 'baseline', 'treatment', 'risk', 'lower blood pressure', 'two']",,,,
644,641,"more patients were eligible for treatment based on high BP alone than with any of the other strategies ( 39 % vs. 22 % , 27 % , and 29 % ) .",与任何其他策略相比，更多的患者有资格接受仅基于高血压的治疗（39% 对 22%、27% 和 29%）。,0.3333333333333333,"['treatment', 'with', 'and', 'alone', 'high', 'eligible']","['treatment', 'high']",641,"['与其他任何策略相比,仅基于高BP治疗的患者有更多的资格(39%对22%,27%和29%)。']",0.3333333333333333,"['treatment', 'with', 'and', 'alone', 'high', 'eligible']","['treatment', 'high']",641,更多病人因单纯高血压而获得治疗资格，而不是其他策略（39％对22％，27％和29％）。,0.5,"['treatment', 'with', 'and', 'alone', 'high', 'eligible']","['treatment', 'and', 'high']",,,,
645,642,"these data suggest that treatment to lower BP is most efficient when it is targeted to patients with elevated CV risk , regardless of baseline BP .",这些数据表明，无论基线血压如何，当针对心血管风险升高的患者时，降低血压的治疗最有效。,0.4,"['data', 'targeted', 'baseline', 'lower', 'treatment', 'risk', 'suggest', 'with', 'that', 'to']","['data', 'baseline', 'treatment', 'risk']",642,"['这些数据表明,降低BP的治疗是最有效的,当它针对患有高CV风险的患者,无论基线BP。']",0.4,"['data', 'targeted', 'baseline', 'lower', 'treatment', 'risk', 'suggest', 'with', 'that', 'to']","['data', 'baseline', 'treatment', 'risk']",642,这些数据表明，降低血压的治疗最有效时，应针对高风险的心血管疾病患者，而不管血压的基线水平如何。,0.4,"['data', 'targeted', 'baseline', 'lower', 'treatment', 'risk', 'suggest', 'with', 'that', 'to']","['data', 'baseline', 'treatment', 'risk']",,,,
646,643,the differences in secondary end points were generally in the same direction as those of the primary end point .,次要终点的差异与主要终点的差异大致相同。,0.2,"['end points', 'primary', 'secondary', 'as', 'direction']",['end points'],643,['二级终点的差异通常与初级终点的差异相同。'],0.2,"['end points', 'primary', 'secondary', 'as', 'direction']",['end points'],643,主要终点的差异通常与次要终点的差异方向相同。,0.4,"['end points', 'primary', 'secondary', 'as', 'direction']","['end points', 'direction']",,,,
647,644,there were no serious adverse events .,没有严重的不良事件。,0.0,"['adverse', 'no', 'serious']",[],644,['没有严重的不良事件。'],0.0,"['adverse', 'no', 'serious']",[],644,没有发生严重的不良事件。,0.0,"['adverse', 'no', 'serious']",[],,,,
648,645,"Neurosteroids , which are synthesized from cholesterol in the brain , are potent modulators of GABA and glutamate.16",由大脑中的胆固醇合成的神经类固醇是 GABA 和谷氨酸的有效调节剂。 16,0.6666666666666666,"['cholesterol', 'GABA', 'brain', 'potent', 'modulators', 'and']","['cholesterol', 'GABA', 'brain', 'modulators']",645,['由大脑中的胆固醇合成的神经激素是GABA和葡萄糖的强大调节剂。'],0.6666666666666666,"['cholesterol', 'GABA', 'brain', 'potent', 'modulators', 'and']","['cholesterol', 'GABA', 'brain', 'modulators']",645,"Neurosteroids, which are synthesized from cholesterol in the brain, are potent modulators of GABA and glutamate.",0.1666666666666666,"['cholesterol', 'GABA', 'brain', 'potent', 'modulators', 'and']",['GABA'],,,,
649,646,"despite their steroid structure , their target activity and pharmacologic characteristics are distinct from those of glucocorticoids and differ in both genomic and nongenomic effects.17,18","尽管它们具有类固醇结构，但它们的目标活性和药理学特征与糖皮质激素不同，并且在基因组和非基因组效应方面也不同。 17,18",0.5454545454545454,"['steroid', 'activity', 'differ', 'target', 'characteristics', 'structure', 'despite', 'glucocorticoids', 'pharmacologic', 'distinct', 'and']","['steroid', 'activity', 'target', 'characteristics', 'structure', 'pharmacologic']",646,"['尽管它们的类固醇结构,但它们的目标活动和药物特征与葡萄糖的特征有所不同,并且在基因和非基因效应方面有所不同。']",0.4545454545454545,"['steroid', 'activity', 'differ', 'target', 'characteristics', 'structure', 'despite', 'glucocorticoids', 'pharmacologic', 'distinct', 'and']","['steroid', 'activity', 'target', 'characteristics', 'structure']",646,"尽管它们的类固醇结构相似，但它们的靶向活性和药理特征与糖皮质激素不同，表现在基因组和非基因组效应方面都有所差异。17,18",0.5454545454545454,"['steroid', 'activity', 'differ', 'target', 'characteristics', 'structure', 'despite', 'glucocorticoids', 'pharmacologic', 'distinct', 'and']","['steroid', 'activity', 'target', 'characteristics', 'structure', 'pharmacologic']",,,,
650,647,"preclinical studies have shown that the naturally occurring neurosteroid allopregnanolone is a positive allosteric modulator of synaptic and extrasynaptic GABAA receptors that affects both phasic and tonic inhibition of neurons.16,19","临床前研究表明，天然存在的神经类固醇四氢孕酮是突触和突触外 GABAA 受体的正变构调节剂，可影响神经元的阶段性和强直性抑制。 16,19",0.2,"['allosteric modulator', 'tonic', 'inhibition', 'synaptic', 'receptors', 'preclinical', 'positive', 'have', 'that', 'and']","['inhibition', 'preclinical']",647,"['临床前研究表明,自然出现的神经元阿洛普雷格纳诺隆是一种积极的神经元调节器,对神经元的临床和外观GABAA受体产生影响。']",0.1,"['allosteric modulator', 'tonic', 'inhibition', 'synaptic', 'receptors', 'preclinical', 'positive', 'have', 'that', 'and']",['preclinical'],647,"preclinical studies have shown that the naturally occurring neurosteroid allopregnanolone is a positive allosteric modulator of synaptic and extrasynaptic GABAA receptors that affects both phasic and tonic inhibition of neurons.16,19

Chinese:

研究表明，自然存在的神经醇类物质布洛芬醇是突触外和突触内GABAA受体的正异位促进剂，可以影响神经元的瞬时和持续性抑制。",0.1,"['allosteric modulator', 'tonic', 'inhibition', 'synaptic', 'receptors', 'preclinical', 'positive', 'have', 'that', 'and']",['inhibition'],,,,
651,648,"with experimental chronic stress , however , levels of allopregnanolone in the brain decrease , and behavioral changes normalize after treatments that increase allopregnanolone levels.19,22,23","然而，随着实验性慢性应激，大脑中四氢孕酮的水平会降低，而在提高四氢孕酮水平的治疗后，行为变化会恢复正常。 19,22,23",0.5,"['decrease', 'brain', 'stress', 'experimental', 'chronic', 'after', 'increase', 'with', 'that', 'and']","['brain', 'stress', 'chronic', 'after', 'and']",648,"['然而,在实验性慢性压力下,大脑中的阿洛弗雷根诺隆水平下降,行为变化在增加阿洛弗雷根诺隆水平的治疗后正常化。']",0.5,"['decrease', 'brain', 'stress', 'experimental', 'chronic', 'after', 'increase', 'with', 'that', 'and']","['brain', 'stress', 'chronic', 'after', 'and']",648,"However, with experimental chronic stress, levels of allopregnanolone in the brain decrease, and behavioral changes normalize after treatments that increase allopregnanolone levels.",0.0,"['decrease', 'brain', 'stress', 'experimental', 'chronic', 'after', 'increase', 'with', 'that', 'and']",[],,,,
652,649,reduced levels of allopregnanolone in the cerebrospinal fluid normalize after successful treatment of depression with antidepressants.24,在用抗抑郁药成功治疗抑郁症后，脑脊液中四氢孕酮水平的降低会恢复正常。 24,0.8,"['depression', 'cerebrospinal fluid', 'treatment', 'after', 'with']","['depression', 'cerebrospinal fluid', 'treatment', 'after']",649,"['在抑郁症成功治疗后,脑血管液中的阿洛普雷根诺隆的低水平正常化。']",0.6,"['depression', 'cerebrospinal fluid', 'treatment', 'after', 'with']","['depression', 'treatment', 'after']",649,降低的全泛酮在脑脊液中的水平在使用抗抑郁药物成功治疗后正常化。24,0.8,"['depression', 'cerebrospinal fluid', 'treatment', 'after', 'with']","['depression', 'cerebrospinal fluid', 'treatment', 'after']",,,,
653,650,"the results of the pilot trial are provided in the Supplementary Appendix , available at NEJM.org .",试点试验的结果见补充附录，补充附录可在 NEJM.org 获取。,0.0,"['appendix', 'supplementary', 'available', 'pilot', 'trial', 'at', 'in']",[],650,"['试点试验的结果在附件中提供,可在NEJM.org上找到。']",0.1428571428571428,"['appendix', 'supplementary', 'available', 'pilot', 'trial', 'at', 'in']",['appendix'],650,结果在补充附录中提供，可在NEJM.org上找到。,0.0,"['appendix', 'supplementary', 'available', 'pilot', 'trial', 'at', 'in']",[],,,,
654,651,this phase 2 trial was conducted at eight sites in the United States from April 2017 through October 2017 .,该 2 期试验于 2017 年 4 月至 2017 年 10 月在美国的八个地点进行。,0.5,"['phase', '2', 'trial', 'at', 'this', 'in']","['phase', '2', 'at']",651,['这次第二阶段审查是在2017年4月至2017年10月期间在美国8个地点进行的。'],0.5,"['phase', '2', 'trial', 'at', 'this', 'in']","['phase', '2', 'this']",651,这项二期试验于2017年4月至2017年10月在美国的八个地点进行。,0.5,"['phase', '2', 'trial', 'at', 'this', 'in']","['phase', '2', 'at']",,,,
655,652,a list of sites and principal investigators is provided in the Supplementary Appendix .,补充附录中提供了研究中心和主要研究者的列表。,0.0,"['appendix', 'supplementary', 'principal', 'list', 'and']",[],652,['网站和主要调查人员的列表在附件中提供。'],0.2,"['appendix', 'supplementary', 'principal', 'list', 'and']",['appendix'],652,附录中列出了研究网站及其主要研究员。,0.0,"['appendix', 'supplementary', 'principal', 'list', 'and']",[],,,,
656,653,"approval was obtained from the institutional review board at each site , and written informed consent was obtained from each patient .",获得各研究中心机构审查委员会的批准，并获得每位患者的书面知情同意书。,0.5,"['site', 'review', 'approval', 'board', 'patient', 'informed consent', 'each', 'and']","['review', 'approval', 'patient', 'each']",653,"['批准是从每个网站的机构审查委员会获得的,并从每个患者获得了书面信息的同意。']",0.375,"['site', 'review', 'approval', 'board', 'patient', 'informed consent', 'each', 'and']","['review', 'approval', 'patient']",653,经过每个地点的机构审查委员会的批准，并得到每个病人的书面知情同意。,0.5,"['site', 'review', 'approval', 'board', 'patient', 'informed consent', 'each', 'and']","['site', 'review', 'approval', 'patient']",,,,
657,654,confidentiality agreements exist between the authors and Sage Therapeutics .,作者与 Sage Therapeutics 之间存在保密协议。,0.3333333333333333,"['confidentiality', 'agreements', 'therapeutics', 'exist', 'sage', 'and']","['confidentiality', 'exist']",654,['作者和Sage Therapeutics之间存在隐私协议。'],0.1666666666666666,"['confidentiality', 'agreements', 'therapeutics', 'exist', 'sage', 'and']",['exist'],654,保密协议存在于作者与Sage Therapeutics之间。,0.3333333333333333,"['confidentiality', 'agreements', 'therapeutics', 'exist', 'sage', 'and']","['confidentiality', 'exist']",,,,
658,655,we recruited patients from outpatient clinics and by using advertising materials approved by the institutional review boards .,我们从门诊诊所招募患者，并使用机构审查委员会批准的广告材料。,0.6,"['review', 'advertising', 'by', 'and', 'we']","['review', 'advertising', 'by']",655,"['我们从外科诊所招募病人,并使用由机构审查委员会批准的广告材料。']",0.6,"['review', 'advertising', 'by', 'and', 'we']","['review', 'advertising', 'by']",655,我们从门诊诊所招募病人，并使用机构审查委员会批准的广告材料。,0.6,"['review', 'advertising', 'by', 'and', 'we']","['review', 'advertising', 'by']",,,,
659,656,patients were admitted as inpatients for the first week of the trial to facilitate daily assessments .,患者在试验的第一周作为住院患者入院，以促进日常评估。,0.3333333333333333,"['week', 'trial', 'as', 'to', 'first', 'inpatients']","['week', 'first']",656,"['患者在试验的第一周被接受为病人,以便日常进行评估。']",0.3333333333333333,"['week', 'trial', 'as', 'to', 'first', 'inpatients']","['week', 'first']",656,病人第一周入住住院，以便每天进行评估。,0.3333333333333333,"['week', 'trial', 'as', 'to', 'first', 'inpatients']","['week', 'first']",,,,
660,657,"during the 4 weeks after the treatment period , primary psychiatrists or investigators could adjust the dose of existing antidepressants or prescribe new antidepressants for patients as appropriate .",在治疗期结束后的4周内，初级精神科医生或研究者可酌情调整现有抗抑郁药的剂量或开出新的抗抑郁药给患者。,0.5,"['period', 'adjust', 'treatment', 'primary', 'prescribe', 'after', '4', 'as', 'antidepressants', 'dose', 'appropriate', 'new']","['period', 'treatment', 'after', 'antidepressants', 'dose', 'new']",657,"['在治疗期后的4周内,初级精神科医生或研究人员可以适当调整现有抗抑郁剂的剂量或给患者处方新的抗抑郁剂。']",0.5,"['period', 'adjust', 'treatment', 'primary', 'prescribe', 'after', '4', 'as', 'antidepressants', 'dose', 'appropriate', 'new']","['period', 'treatment', 'after', 'antidepressants', 'dose', 'new']",657,在治疗期后的4周内，主要精神病医生或研究人员可以根据情况调整现有抗抑郁药的剂量或开具新的抗抑郁药。,0.5,"['period', 'adjust', 'treatment', 'primary', 'prescribe', 'after', '4', 'as', 'antidepressants', 'dose', 'appropriate', 'new']","['period', 'treatment', 'after', 'antidepressants', 'dose', 'new']",,,,
661,658,"the diagnosis of depression was made with the use of the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders , fifth edition , Axis I disorders.35",抑郁症的诊断是使用《精神疾病诊断和统计手册结构化临床访谈》第五版，Axis I disorders.35,0.5,"['depression', 'mental', 'axis', 'diagnosis', 'edition', 'clinical', 'disorders', 'diagnostic', 'interview', 'manual', 'with', 'I', 'and', 'fifth']","['depression', 'mental', 'diagnosis', 'edition', 'clinical', 'interview', 'fifth']",658,"['抑郁症的诊断是通过使用结构化临床面试的诊断和统计手册的精神疾病,第五版, 轴 I 疾病。']",0.4285714285714285,"['depression', 'mental', 'axis', 'diagnosis', 'edition', 'clinical', 'disorders', 'diagnostic', 'interview', 'manual', 'with', 'I', 'and', 'fifth']","['depression', 'mental', 'diagnosis', 'edition', 'clinical', 'fifth']",658,使用第五版《诊断与统计心理疾病诊断手册》的结构化临床采访诊断出抑郁症。35,0.3571428571428571,"['depression', 'mental', 'axis', 'diagnosis', 'edition', 'clinical', 'disorders', 'diagnostic', 'interview', 'manual', 'with', 'I', 'and', 'fifth']","['depression', 'diagnosis', 'edition', 'clinical', 'fifth']",,,,
662,659,patients were eligible to participate if they had been receiving stable doses of antidepressants for at least 30 days or if they were not taking antidepressants .,如果患者已经接受稳定剂量的抗抑郁药至少 30 天，或者如果他们没有服用抗抑郁药，则他们有资格参加。,0.1666666666666666,"['taking', 'antidepressants', 'at', 'if', 'to', 'eligible']",['antidepressants'],659,"['患者有资格参加,如果他们至少30天接受了稳定的抗抑郁剂剂量,或者如果他们不服用抗抑郁剂。']",0.1666666666666666,"['taking', 'antidepressants', 'at', 'if', 'to', 'eligible']",['antidepressants'],659,病人有資格參與該調查如果他們已經穩定服用抗抑鬱症藥物至少30天，或者如果他們沒有服用抗抑鬱症藥物。,0.0,"['taking', 'antidepressants', 'at', 'if', 'to', 'eligible']",[],,,,
663,660,a full list of inclusion and exclusion criteria is provided in the Supplementary Appendix .,补充附录中提供了包含和排除标准的完整列表。,0.2857142857142857,"['appendix', 'inclusion', 'supplementary', 'exclusion', 'list', 'full', 'and']","['inclusion', 'full']",660,['包含和排除标准的完整列表在附件中提供。'],0.4285714285714285,"['appendix', 'inclusion', 'supplementary', 'exclusion', 'list', 'full', 'and']","['appendix', 'inclusion', 'full']",660,"A full list of inclusion and exclusion criteria is provided in the Supplementary Appendix.

中文：

在附加附件中提供了完整的包含和排除标准列表。",0.4285714285714285,"['appendix', 'inclusion', 'supplementary', 'exclusion', 'list', 'full', 'and']","['appendix', 'inclusion', 'full']",,,,
664,661,"safety was assessed on the basis of the frequency and severity of adverse events , vital signs , changes in clinical laboratory measurements , physical examinations , electrocardiography , the Stanford Sleepiness Scale , and assessment of suicidal ideation and behavior with the use of the Columbia Suicide Severity Rating Scale .",安全性的评估依据是不良事件的频率和严重程度、生命体征、临床实验室测量值的变化、身体检查、心电图、斯坦福嗜睡量表，以及使用哥伦比亚自杀严重程度等级对自杀意念和行为的评估。规模 。,0.55,"['behavior', 'safety', 'vital signs', 'frequency', 'electrocardiography', 'physical', 'basis', 'adverse', 'assessment', 'suicidal', 'clinical', 'examinations', 'laboratory', 'ideation', 'suicide', 'with', 'rating scale', 'sleepiness', 'and', 'assessed']","['behavior', 'safety', 'vital signs', 'frequency', 'electrocardiography', 'assessment', 'suicidal', 'clinical', 'laboratory', 'suicide', 'sleepiness']",661,"['安全性是基于不良事件的频率和严重性,重要迹象,临床实验室测量的变化,物理检查,电心,斯坦福睡眠尺度,以及使用哥伦比亚自杀频率评级尺度的自杀思想和行为的评估。']",0.4,"['behavior', 'safety', 'vital signs', 'frequency', 'electrocardiography', 'physical', 'basis', 'adverse', 'assessment', 'suicidal', 'clinical', 'examinations', 'laboratory', 'ideation', 'suicide', 'with', 'rating scale', 'sleepiness', 'and', 'assessed']","['behavior', 'safety', 'frequency', 'assessment', 'suicidal', 'clinical', 'laboratory', 'suicide']",661,"safety was assessed on the basis of the frequency and severity of adverse events, vital signs, changes in clinical laboratory measurements, physical examinations, electrocardiography, the Stanford Sleepiness Scale, and assessment of suicidal ideation and behavior with the use of the Columbia Suicide Severity Rating Scale.

Chinese:

安全性是根据不良事件的频率和严重程度、生命体征、临床实验室测量结果的变化、体格检查、心电图、斯坦福疲劳量表和使用哥伦比亚自杀严重程度评估量表评估自杀思想和行为来评估的。",0.55,"['behavior', 'safety', 'vital signs', 'frequency', 'electrocardiography', 'physical', 'basis', 'adverse', 'assessment', 'suicidal', 'clinical', 'examinations', 'laboratory', 'ideation', 'suicide', 'with', 'rating scale', 'sleepiness', 'and', 'assessed']","['behavior', 'safety', 'vital signs', 'frequency', 'electrocardiography', 'physical', 'assessment', 'suicidal', 'clinical', 'laboratory', 'suicide']",,,,
665,662,"continuous variables are reported as means and standard deviations , and categorical variables as numbers and percentages .",连续变量报告为均值和标准差，分类变量报告为数字和百分比。,0.4,"['standard', 'continuous', 'means', 'as', 'categorical']","['standard', 'continuous']",662,"['连续变量被称为手段和标准偏差,类别变量被称为数字和百分比。']",0.6,"['standard', 'continuous', 'means', 'as', 'categorical']","['standard', 'continuous', 'means']",662,连续变量以均值和标准差报告，分类变量以数字和百分比报告。,0.4,"['standard', 'continuous', 'means', 'as', 'categorical']","['standard', 'continuous']",,,,
666,663,"statistical analyses were performed with the use of SAS software , version 9.3 ( SAS Institute ) .",使用 SAS 软件 9.3 版（SAS Institute）进行统计分析。,0.2,"['version', 'software', 'institute', 'with', 'SAS']",['software'],663,"['统计分析使用SAS软件,版本 9.3(SAS研究所)进行。']",0.6,"['version', 'software', 'institute', 'with', 'SAS']","['version', 'software', 'institute']",663,统计分析使用的是SAS软件，版本号为9.3（SAS Institute）。,0.4,"['version', 'software', 'institute', 'with', 'SAS']","['version', 'software']",,,,
667,663,"statistical analyses were performed with the use of SAS software , version 9.3 ( SAS Institute ) .",使用 SAS 软件 9.3 版（SAS Institute）进行统计分析。,0.2,"['version', 'software', 'institute', 'with', 'SAS']",['software'],663,"['统计分析使用SAS软件,版本 9.3(SAS研究所)进行。']",0.6,"['version', 'software', 'institute', 'with', 'SAS']","['version', 'software', 'institute']",663,统计分析使用的是SAS软件，版本号为9.3（SAS Institute）。,0.4,"['version', 'software', 'institute', 'with', 'SAS']","['version', 'software']",,,,
668,664,"there was no plan for imputation of missing data , but sensitivity analyses were performed to assess the effect of missing data .",没有填补缺失数据的计划，但进行了敏感性分析以评估缺失数据的影响。,0.5,"['data', 'no', 'effect', 'assess', 'sensitivity', 'but', 'to', 'missing']","['data', 'assess', 'but', 'missing']",664,"['没有错过的数据的计算计划,但敏感性分析进行,以评估错过的数据的影响。']",0.375,"['data', 'no', 'effect', 'assess', 'sensitivity', 'but', 'to', 'missing']","['data', 'assess', 'but']",664,没有对缺失数据进行补充的计划，但是对敏感性分析进行了评估，以评估缺失数据的影响。,0.5,"['data', 'no', 'effect', 'assess', 'sensitivity', 'but', 'to', 'missing']","['data', 'assess', 'but', 'missing']",,,,
669,665,the statistical analysis plan did not include a provision for correction for multiplicity when the analyses of secondary end points were performed .,统计分析计划不包括在执行次要终点分析时对多重性进行校正的规定。,0.8333333333333334,"['correction', 'provision', 'end points', 'secondary', 'multiplicity', 'statistical analysis']","['correction', 'provision', 'end points', 'multiplicity', 'statistical analysis']",665,['统计分析计划不包括在进行二级终点分析时对多样性进行纠正的规定。'],0.5,"['correction', 'provision', 'end points', 'secondary', 'multiplicity', 'statistical analysis']","['provision', 'end points', 'statistical analysis']",665,统计分析计划并没有预留修正多重性的条款，当对次要终点的分析进行时没有考虑这一点。,0.6666666666666666,"['correction', 'provision', 'end points', 'secondary', 'multiplicity', 'statistical analysis']","['correction', 'end points', 'multiplicity', 'statistical analysis']",,,,
670,666,"therefore , the results are reported as point estimates and unadjusted 95 % confidence intervals and should not be used to infer treatment effects .",因此，结果报告为点估计值和未调整的 95% 置信区间，不应用于推断治疗效果。,0.4,"['be', 'treatment', 'unadjusted', 'point', 'as', 'confidence', 'therefore', 'to', 'and', 'intervals']","['treatment', 'unadjusted', 'point', 'to']",666,"['因此,结果被报告为点估计和不调整的95%信任间隔,不应用于估计治疗效果。']",0.3,"['be', 'treatment', 'unadjusted', 'point', 'as', 'confidence', 'therefore', 'to', 'and', 'intervals']","['treatment', 'point', 'to']",666,因此，结果以点估计值和未调整的95％置信区间报告，不应用于推断治疗效果。,0.4,"['be', 'treatment', 'unadjusted', 'point', 'as', 'confidence', 'therefore', 'to', 'and', 'intervals']","['treatment', 'unadjusted', 'point', 'to']",,,,
671,667,"a total of 169 patients were screened , of whom 89 were enrolled and underwent randomization .",总共筛选了 169 名患者，其中 89 名被纳入并接受了随机分组。,0.5,"['randomization', 'total']",['randomization'],667,"['总共有169名患者被检查,其中89人被注册并经历了随机化。']",0.5,"['randomization', 'total']",['randomization'],667,总共有169名病人经过筛查，其中89名病人符合入组标准并进行了随机分配。,0.5,"['randomization', 'total']",['randomization'],,,,
672,668,results for secondary end points are shown in Table 2 .,表 2 显示了次要终点的结果。,0.75,"['table', '2', 'end points', 'secondary']","['table', '2', 'end points']",668,['二级终点的结果显示在图2中。'],0.5,"['table', '2', 'end points', 'secondary']","['2', 'end points']",668,结果表2所示，次要终点的结果是。,0.75,"['table', '2', 'end points', 'secondary']","['table', '2', 'end points']",,,,
673,669,there were no serious adverse events and no deaths during this trial .,在该试验期间没有严重的不良事件，也没有死亡。,0.0,"['adverse', 'no', 'trial', 'serious', 'this', 'and']",[],669,"['在此审判期间,没有严重的不良事件和死亡。']",0.1666666666666666,"['adverse', 'no', 'trial', 'serious', 'this', 'and']",['trial'],669,在该试验中，没有发生严重的不良事件，也没有死亡病例。,0.0,"['adverse', 'no', 'trial', 'serious', 'this', 'and']",[],,,,
674,670,"subjective sleepiness , as assessed with the use of the Stanford Sleepiness Scale , was similar in the two groups .",使用斯坦福嗜睡量表评估的主观嗜睡在两组中相似。,0.4285714285714285,"['scale', 'subjective', 'with', 'sleepiness', 'two', 'assessed', 'similar']","['scale', 'sleepiness', 'two']",670,"['根据Stanford Sleepiness Scale的使用,客观的睡眠率在两组中是相似的。']",0.2857142857142857,"['scale', 'subjective', 'with', 'sleepiness', 'two', 'assessed', 'similar']","['two', 'similar']",670,经用斯坦福疲劳量表评估，两组的主观疲劳程度相似。,0.2857142857142857,"['scale', 'subjective', 'with', 'sleepiness', 'two', 'assessed', 'similar']","['scale', 'two']",,,,
675,671,no patients in the placebo group had dose reductions .,安慰剂组中没有患者剂量减少。,0.6,"['group', 'placebo', 'no', 'dose', 'in']","['group', 'placebo', 'dose']",671,['没有 placebo 群体的患者有剂量减少。'],0.4,"['group', 'placebo', 'no', 'dose', 'in']","['group', 'dose']",671,没有安慰剂组的患者减少剂量。,0.6,"['group', 'placebo', 'no', 'dose', 'in']","['group', 'placebo', 'dose']",,,,
676,672,"these findings may support a role for GABAA receptors in the pathophysiology of depression.4,38","这些发现可能支持 GABAA 受体在抑郁症病理生理学中的作用。 4,38",0.6,"['support', 'receptors', 'pathophysiology', 'role', 'in']","['support', 'pathophysiology', 'role']",672,['这些发现可能支持GABAA受体在抑郁症病理学中的作用。'],0.4,"['support', 'receptors', 'pathophysiology', 'role', 'in']","['support', 'role']",672,"这些发现可能支持GABAA受体在抑郁症的病理生理学中的作用。4,38",0.6,"['support', 'receptors', 'pathophysiology', 'role', 'in']","['support', 'pathophysiology', 'role']",,,,
677,673,"data were missing for approximately 5 % of patients in each group , but sensitivity analyses suggested that this did not alter the conclusions with respect to the primary end point of the trial .",每组中约有 5% 的患者数据缺失，但敏感性分析表明这不会改变试验主要终点的结论。,0.3529411764705882,"['group', '5', 'data', 'primary', 'trial', 'end', 'point', 'with', 'respect', 'sensitivity', 'approximately', 'this', 'that', 'each', 'but', 'to', 'missing']","['group', '5', 'data', 'point', 'but', 'missing']",673,"['每个群体中约有5%的患者缺乏数据,但敏感性分析表明,这并没有改变研究的主要结论。']",0.2941176470588235,"['group', '5', 'data', 'primary', 'trial', 'end', 'point', 'with', 'respect', 'sensitivity', 'approximately', 'this', 'that', 'each', 'but', 'to', 'missing']","['group', '5', 'data', 'but', 'missing']",673,约5%的患者缺失了数据，但敏感性分析表明这并不会改变实验的主要终点结论。,0.2941176470588235,"['group', '5', 'data', 'primary', 'trial', 'end', 'point', 'with', 'respect', 'sensitivity', 'approximately', 'this', 'that', 'each', 'but', 'to', 'missing']","['5', 'data', 'point', 'but', 'missing']",,,,
678,674,"the current trial did not include an active comparator group , which limits comparison of the results with those of available antidepressants .",目前的试验不包括一个积极的比较组，这限制了结果与现有抗抑郁药的比较。,0.4,"['group', 'comparison', 'active', 'available', 'trial', 'current', 'limits', 'with', 'antidepressants', 'comparator']","['group', 'comparison', 'active', 'antidepressants']",674,"['目前的研究不包括一个活跃的比较组,这限制了结果与可用的抗抑郁剂的比较。']",0.4,"['group', 'comparison', 'active', 'available', 'trial', 'current', 'limits', 'with', 'antidepressants', 'comparator']","['group', 'comparison', 'available', 'antidepressants']",674,当前的试验没有包括一个主动比较组，这限制了结果与现有抗抑郁药的比较。,0.4,"['group', 'comparison', 'active', 'available', 'trial', 'current', 'limits', 'with', 'antidepressants', 'comparator']","['group', 'comparison', 'current', 'antidepressants']",,,,
679,675,the diagnosis of atrial fibrillation ( AF ) requires an electrocardiogram ( ECG ) during an AF episode although structural atrial changes and grossly abnormal ECG findings such as left atrial enlargement can also point to AF .,心房颤动 (AF) 的诊断需要在 AF 发作期间进行心电图 (ECG)，但结构性心房变化和严重异常的 ECG 结果（如左心房扩大）也可能指向 AF。,0.75,"['electrocardiogram', 'ECG', 'abnormal', 'enlargement', 'episode', 'diagnosis', 'atrial fibrillation', 'structural', 'point', 'as', 'to', 'and']","['electrocardiogram', 'ECG', 'abnormal', 'enlargement', 'episode', 'diagnosis', 'atrial fibrillation', 'structural', 'as']",675,"['甲状腺纤维化(AF)的诊断需要在AF事件中进行电心图(ECG),尽管结构性甲状腺变化和严重异常的ECG发现,如左甲状腺扩张,也可以指向AF。']",0.3333333333333333,"['electrocardiogram', 'ECG', 'abnormal', 'enlargement', 'episode', 'diagnosis', 'atrial fibrillation', 'structural', 'point', 'as', 'to', 'and']","['abnormal', 'diagnosis', 'structural', 'as']",675,頭蓋發作性房顫 (AF) 的診斷需要在房顫期間進行心電圖 (ECG) ，儘管結構性房顫變化和明顯異常的心電圖發現 (例如左房增大 ) 也可能指向AF 。,0.1666666666666666,"['electrocardiogram', 'ECG', 'abnormal', 'enlargement', 'episode', 'diagnosis', 'atrial fibrillation', 'structural', 'point', 'as', 'to', 'and']","['enlargement', 'as']",,,,
680,676,"however , if ECGs in normal sinus rhythm provided clues to the risk for AF , then more individuals could be evaluated closely for AF before the clinical diagnosis and receive treatment .",然而，如果正常窦性心律的 ECG 提供了 AF 风险的线索，那么更多的人可以在临床诊断和接受治疗之前仔细评估 AF。,0.6666666666666666,"['normal', 'sinus rhythm', 'treatment', 'clinical diagnosis', 'risk', 'before', 'if', 'to', 'and']","['sinus rhythm', 'treatment', 'clinical diagnosis', 'risk', 'before', 'and']",676,"['然而,如果正常的阴道节奏的ECG提供了对AF风险的提示,那么在临床诊断和接受治疗之前,更多的人可以对AF进行仔细评估。']",0.6666666666666666,"['normal', 'sinus rhythm', 'treatment', 'clinical diagnosis', 'risk', 'before', 'if', 'to', 'and']","['normal', 'treatment', 'clinical diagnosis', 'risk', 'before', 'and']",676,然而，如果正常起搏心律下的心电图能够提供有关心房颤风险的线索，那么更多的人在临床诊断之前就可以接受近距离的心房颤动评估，并接受治疗。,0.5555555555555556,"['normal', 'sinus rhythm', 'treatment', 'clinical diagnosis', 'risk', 'before', 'if', 'to', 'and']","['treatment', 'clinical diagnosis', 'risk', 'before', 'and']",,,,
681,677,these researchers hypothesized that more subtle ECG findings during normal sinus rhythm are also associated with AF .,这些研究人员假设在正常窦性心律期间更细微的心电图发现也与 AF 相关。,0.2857142857142857,"['ECG', 'normal', 'sinus rhythm', 'associated', 'subtle', 'with', 'that']","['ECG', 'sinus rhythm']",677,['这些研究人员假设在正常阴道节奏期间更微妙的ECG发现也与AF相关。'],0.0,"['ECG', 'normal', 'sinus rhythm', 'associated', 'subtle', 'with', 'that']",[],677,这些研究人员假设，在正常心房颤动期间，心电图中的微妙变化也可能与房颤有关。,0.1428571428571428,"['ECG', 'normal', 'sinus rhythm', 'associated', 'subtle', 'with', 'that']",['ECG'],,,,
682,678,"in a retrospective ECG database of 180,922 patients with 649,931 ECGs , machine learning through artificial intelligence ( AI ) was used to develop a predictive model for AF from a single , normal sinus rhythm ECG .","在一个包含 180,922 名患者和 649,931 个心电图的回顾性心电图数据库中，通过人工智能 (AI) 进行的机器学习被用于从单个正常窦性心律心电图开发 AF 预测模型。",0.6153846153846154,"['ECG', 'model', 'database', 'normal', 'develop', 'sinus rhythm', 'predictive', 'artificial intelligence', 'machine', 'with', 'learning', 'single', 'to']","['ECG', 'model', 'sinus rhythm', 'artificial intelligence', 'machine', 'learning', 'single', 'to']",678,"['在180922名患有64931 ECG的回顾性ECG数据库中,通过人工智能(AI)的机器学习被用来开发一个从一个单一的正常阴道节奏ECG的预测模型。']",0.3846153846153846,"['ECG', 'model', 'database', 'normal', 'develop', 'sinus rhythm', 'predictive', 'artificial intelligence', 'machine', 'with', 'learning', 'single', 'to']","['model', 'artificial intelligence', 'machine', 'learning', 'single']",678,"在一个回顾性的心电图数据库中，有180,922名患者和649,931张心电图，使用机器学习的人工智能（AI）从一张单独的正常窦性心律心电图开发了一个预测性模型来预测房颤。",0.5384615384615384,"['ECG', 'model', 'database', 'normal', 'develop', 'sinus rhythm', 'predictive', 'artificial intelligence', 'machine', 'with', 'learning', 'single', 'to']","['ECG', 'model', 'sinus rhythm', 'artificial intelligence', 'machine', 'learning', 'single']",,,,
683,679,"approximately two thirds of ECGs were used for the training set , and the remainder were used for validation and testing .",大约三分之二的心电图用于训练集，其余用于验证和测试。,0.1428571428571428,"['training', 'validation', 'set', 'testing', 'approximately', 'and', 'two']",['training'],679,"['大约三分之二的ECG用于培训组,其余用于验证和测试。']",0.0,"['training', 'validation', 'set', 'testing', 'approximately', 'and', 'two']",[],679,约三分之二的心电图被用于训练集，其余部分用于验证和测试。,0.1428571428571428,"['training', 'validation', 'set', 'testing', 'approximately', 'and', 'two']",['training'],,,,
684,680,"about 8 % of patients in the testing cohort had verified AF diagnoses , based on earlier ECGs .",根据早期的心电图，测试队列中约有 8% 的患者证实了 AF 诊断。,0.0,"['testing', 'cohort', 'on', 'earlier']",[],680,"['大约有8%的患者在测试组中确认了AF诊断,基于以前的ECG。']",0.0,"['testing', 'cohort', 'on', 'earlier']",[],680,约 8% 的测试队列病人拥有根据早期心电图验证的房颤诊断。,0.0,"['testing', 'cohort', 'on', 'earlier']",[],,,,
685,681,the AI algorithm performed quite well .,AI算法表现相当不错。,0.5,"['algorithm', 'well']",['algorithm'],681,['AI算法表现得非常好。'],0.5,"['algorithm', 'well']",['algorithm'],681,这个人工智能算法表现相当不错。,0.5,"['algorithm', 'well']",['algorithm'],,,,
686,682,the area under the curve of the receiver operating characteristic curve for detecting AF was 0.87 in the derivation and validation sets .,在推导和验证集中，用于检测 AF 的接受者操作特征曲线的曲线下面积为 0.87。,0.2857142857142857,"['derivation', 'validation', 'characteristic curve', 'area under the curve', 'in', 'and', 'receiver']","['derivation', 'characteristic curve']",682,['接收器操作特性曲线的曲线下的区域在衍生和验证集中为0.87。'],0.1428571428571428,"['derivation', 'validation', 'characteristic curve', 'area under the curve', 'in', 'and', 'receiver']",['derivation'],682,"The area under the curve of the receiver operating characteristic curve for detecting AF was 0.87 in the derivation and validation sets.

Chinese:

接收器操作特征曲线用于检测AF的下曲线面积为0.87，在衍生集和验证集中验证。",0.2857142857142857,"['derivation', 'validation', 'characteristic curve', 'area under the curve', 'in', 'and', 'receiver']","['derivation', 'characteristic curve']",,,,
687,683,"when applied to the testing group , the sensitivity was 79.0 % , the specificity was 79.5 % , and the overall accuracy was 79.4 % .",应用于试验组时，灵敏度为79.0%，特异度为79.5%，总准确率为79.4%。,0.375,"['group', 'specificity', 'accuracy', 'applied', 'testing', 'sensitivity', 'to', 'and']","['group', 'sensitivity', 'to']",683,"['当应用于测试组时,敏感度为79.0%,特性为79.5%和总准确度为79.4%。']",0.375,"['group', 'specificity', 'accuracy', 'applied', 'testing', 'sensitivity', 'to', 'and']","['group', 'accuracy', 'to']",683,当应用于测试组时，敏感性为79.0％，特异性为79.5％，总体准确率为79.4％。,0.375,"['group', 'specificity', 'accuracy', 'applied', 'testing', 'sensitivity', 'to', 'and']","['group', 'specificity', 'to']",,,,
688,684,AF can be intermittent for many years and is often not diagnosed until patients have progressed to longer episodes .,AF 可以间歇性持续多年，并且通常直到患者发展到更长时间的发作时才被诊断出来。,0.3333333333333333,"['intermittent', 'be', 'episodes', 'have', 'to', 'and']","['intermittent', 'episodes']",684,"['AF可以暂停多年,并且经常没有诊断,直到病人进展到更长的事件。']",0.1666666666666666,"['intermittent', 'be', 'episodes', 'have', 'to', 'and']",['have'],684,"AF can be intermittent for many years and is often not diagnosed until patients have progressed to longer episodes.

Chinese:

AF 可能会间歇性地持续多年，通常直到病人发展到更长的发作时才被诊断。",0.3333333333333333,"['intermittent', 'be', 'episodes', 'have', 'to', 'and']","['intermittent', 'episodes']",,,,
689,685,diagnosing AF earlier would allow treatment that could reduce the risk for cryptogenic stroke .,早期诊断 AF 将允许进行治疗以降低隐源性中风的风险。,0.625,"['cryptogenic', 'stroke', 'reduce', 'allow', 'treatment', 'risk', 'that', 'earlier']","['stroke', 'reduce', 'allow', 'treatment', 'risk']",685,"['早期诊断AF将允许治疗,这可能会降低加密性中风的风险。']",0.625,"['cryptogenic', 'stroke', 'reduce', 'allow', 'treatment', 'risk', 'that', 'earlier']","['stroke', 'reduce', 'allow', 'treatment', 'risk']",685,早期诊断心房颤动将有助于减少意外性脑卒中的风险。,0.25,"['cryptogenic', 'stroke', 'reduce', 'allow', 'treatment', 'risk', 'that', 'earlier']","['stroke', 'risk']",,,,
690,686,the AI algorithm developed here is reasonably accurate .,这里开发的 AI 算法相当准确。,0.5,"['algorithm', 'accurate']",['algorithm'],686,['在这里开发的AI算法是合理准确的。'],1.0,"['algorithm', 'accurate']","['algorithm', 'accurate']",686,这里开发的人工智能算法相当精确。,0.5,"['algorithm', 'accurate']",['algorithm'],,,,
691,687,"certainly , at this time , treatment decisions should not be based on the algorithm , but it would enable more intense ECG monitoring for people predicted to be at heightened AF risk .",当然，在这个时候，治疗决定不应该基于算法，但它可以对预测为 AF 风险增加的人进行更严格的 ECG 监测。,0.7,"['monitoring', 'ECG', 'algorithm', 'time', 'be', 'treatment', 'risk', 'intense', 'this', 'but']","['monitoring', 'algorithm', 'time', 'be', 'treatment', 'risk', 'but']",687,"['当时,治疗决策不应该基于算法,但它将允许更强烈的ECG监测,人们预计会患有更高的AF风险。']",0.7,"['monitoring', 'ECG', 'algorithm', 'time', 'be', 'treatment', 'risk', 'intense', 'this', 'but']","['monitoring', 'algorithm', 'time', 'treatment', 'risk', 'intense', 'but']",687,"certainly, at this time, treatment decisions should not be based on the algorithm, but it would enable more intense ECG monitoring for people predicted to be at heightened AF risk.

Chinese:

确实如此，目前治疗决策不应基于算法，但它可以使预计风险较高的人群进行更加密集的心电图监测。",0.6,"['monitoring', 'ECG', 'algorithm', 'time', 'be', 'treatment', 'risk', 'intense', 'this', 'but']","['monitoring', 'ECG', 'algorithm', 'treatment', 'risk', 'but']",,,,
692,688,cognitive activities throughout the lifespan and social activities in later life were associated with lower risk .,整个生命周期的认知活动和晚年的社会活动都与较低的风险相关。,0.3,"['life', 'social activities', 'lower', 'associated', 'risk', 'with', 'cognitive', 'later', 'in', 'and']","['life', 'lower', 'risk']",688,['终身认知活动和后期生活中的社会活动与较低的风险有关。'],0.4,"['life', 'social activities', 'lower', 'associated', 'risk', 'with', 'cognitive', 'later', 'in', 'and']","['life', 'lower', 'risk', 'later']",688,"Cognitive activities throughout the lifespan and social activities in later life were associated with lower risk.

Chinese:

经常进行认知活动和在晚年经常进行社交活动都与风险降低相关联。",0.2,"['life', 'social activities', 'lower', 'associated', 'risk', 'with', 'cognitive', 'later', 'in', 'and']","['social activities', 'risk']",,,,
693,689,"this information , along with years of education , was used to construct a cognitive reserve score .",此信息连同受教育年限被用于构建认知储备分数。,0.5555555555555556,"['reserve', 'education', 'information', 'along', 'score', 'with', 'cognitive', 'this', 'to']","['reserve', 'education', 'information', 'score', 'to']",689,"['这些信息,以及多年的教育,被用来构建一个认知储备分数。']",0.4444444444444444,"['reserve', 'education', 'information', 'along', 'score', 'with', 'cognitive', 'this', 'to']","['reserve', 'education', 'information', 'score']",689,这些信息，再加上教育年数，被用来构建一个认知储备评分。,0.3333333333333333,"['reserve', 'education', 'information', 'along', 'score', 'with', 'cognitive', 'this', 'to']","['reserve', 'education', 'information']",,,,
694,690,"after multivariable adjustment , participants in the highest tertile of cognitive reserve scores had a 39 % lower risk for dementia diagnosis than those in the lowest tertile .",多变量调整后，认知储备分数最高三分位数的参与者患痴呆症的风险比最低三分位数的参与者低 39%。,0.4444444444444444,"['reserve', 'adjustment', 'dementia', 'lower', 'diagnosis', 'risk', 'after', 'cognitive', 'in']","['reserve', 'dementia', 'risk', 'after']",690,"['经过多变的调整,认知备份得分最高的受访者患痴呆症诊断的风险比最低的受访者低39%。']",0.3333333333333333,"['reserve', 'adjustment', 'dementia', 'lower', 'diagnosis', 'risk', 'after', 'cognitive', 'in']","['dementia', 'diagnosis', 'risk']",690,"经过多变量调整，参与者在认知储备评分的最高三分之一的参与者相比，认知障碍诊断的风险降低了39％。

Chinese:

经过多变量调整后，认知储备评分最高三分之一的参与者相对于认知储备评分最低三分之一的参与者，认知障碍诊断的风险降低了39%。",0.4444444444444444,"['reserve', 'adjustment', 'dementia', 'lower', 'diagnosis', 'risk', 'after', 'cognitive', 'in']","['reserve', 'diagnosis', 'risk', 'after']",,,,
695,691,the risk reduction was significant even in participants with high Alzheimer disease and vascular pathologies .,即使在患有高阿尔茨海默病和血管病变的参与者中，风险降低也很显着。,0.5,"['alzheimer disease', 'vascular', 'reduction', 'risk', 'with', 'in', 'and', 'high']","['alzheimer disease', 'reduction', 'risk', 'high']",691,"['风险降低是显著的,即使在患有高阿尔茨海默病和血管疾病的参与者。']",0.5,"['alzheimer disease', 'vascular', 'reduction', 'risk', 'with', 'in', 'and', 'high']","['alzheimer disease', 'reduction', 'risk', 'high']",691,即使在阿尔茨海默病和血管病变患者中，风险降低也是显著的。,0.375,"['alzheimer disease', 'vascular', 'reduction', 'risk', 'with', 'in', 'and', 'high']","['alzheimer disease', 'reduction', 'risk']",,,,
696,692,comment - NEUROLOGY,评论 - 神经病学,0.0,['-'],[],692,['评论 - 神经'],0.0,['-'],[],692,"I am a medical doctor specializing in neurology. I am interested in all aspects of the nervous system, including the brain, spinal cord, and peripheral nerves. I have a particular interest in stroke, epilepsy, and Parkinson's disease.",0.0,['-'],[],,,,
697,692,comment - NEUROLOGY,评论 - 神经病学,0.0,['-'],[],692,['评论 - 神经'],0.0,['-'],[],692,"I am a medical doctor specializing in neurology. I am interested in all aspects of the nervous system, including the brain, spinal cord, and peripheral nerves. I have a particular interest in stroke, epilepsy, and Parkinson's disease.",0.0,['-'],[],,,,
698,693,"participating in cognitive and social activities throughout the lifespan may decrease dementia risk , even in the presence of Alzheimer disease and vascular pathologies on autopsy .",在整个生命周期中参与认知和社会活动可能会降低痴呆风险，即使在尸检中存在阿尔茨海默病和血管病变。,0.3333333333333333,"['presence', 'decrease', 'alzheimer disease', 'autopsy', 'vascular', 'social activities', 'dementia', 'risk', 'cognitive', 'on', 'in', 'and']","['presence', 'alzheimer disease', 'dementia', 'risk']",693,"['在整个生命中参与认知和社会活动可能会降低痴呆症的风险,即使在阿尔茨海默病和血管疾病在自闭症时存在。']",0.3333333333333333,"['presence', 'decrease', 'alzheimer disease', 'autopsy', 'vascular', 'social activities', 'dementia', 'risk', 'cognitive', 'on', 'in', 'and']","['presence', 'alzheimer disease', 'dementia', 'risk']",693,参与认知和社会活动可以降低痴呆风险，即使在尸检中存在阿尔茨海默病和血管病理学病灶的情况下也是如此。,0.3333333333333333,"['presence', 'decrease', 'alzheimer disease', 'autopsy', 'vascular', 'social activities', 'dementia', 'risk', 'cognitive', 'on', 'in', 'and']","['presence', 'alzheimer disease', 'dementia', 'risk']",,,,
699,694,"cognitive activities during nearly the entire lifespan that were queried in the study included reading , writing letters , and visiting the library .",研究中询问的几乎整个生命周期的认知活动包括阅读、写信和访问图书馆。,0.1428571428571428,"['library', 'reading', 'study', 'writing', 'cognitive', 'that', 'and']",['library'],694,"['几乎整个生命的认知活动,在研究中被要求,包括阅读、写信和参观图书馆。']",0.1428571428571428,"['library', 'reading', 'study', 'writing', 'cognitive', 'that', 'and']",['library'],694,近整个人生都被研究纳入认知活动的范围，其中包括阅读、书写信件和图书馆游览。,0.2857142857142857,"['library', 'reading', 'study', 'writing', 'cognitive', 'that', 'and']","['library', 'writing']",,,,
700,695,a machine learning technique was noninferior to traditional immunohistochemistry in predicting molecular biomarker expression .,机器学习技术在预测分子生物标志物表达方面不劣于传统的免疫组织化学。,1.0,"['biomarker', 'expression', 'molecular', 'immunohistochemistry', 'technique', 'machine', 'learning']","['biomarker', 'expression', 'molecular', 'immunohistochemistry', 'technique', 'machine', 'learning']",695,['机器学习技术在预测分子生物标记表达时不低于传统免疫物质化学。'],0.7142857142857143,"['biomarker', 'expression', 'molecular', 'immunohistochemistry', 'technique', 'machine', 'learning']","['expression', 'molecular', 'technique', 'machine', 'learning']",695,一种机器学习技术在预测分子生物标记表达方面与传统的免疫组化方法并无差距。,0.7142857142857143,"['biomarker', 'expression', 'molecular', 'immunohistochemistry', 'technique', 'machine', 'learning']","['expression', 'molecular', 'technique', 'machine', 'learning']",,,,
701,696,"the pathological review of tumor samples , even for common molecular biomarkers such as estrogen receptor ( ER ) , progesterone receptor ( PR ) , and human epidermal growth factor receptor 2 ( HER2 ) , is time consuming .",肿瘤样本的病理检查，即使是常见的分子生物标志物，如雌激素受体 (ER)、孕激素受体 (PR) 和人表皮生长因子受体 2 (HER2)，也是非常耗时的。,0.6428571428571429,"['ER', 'epidermal growth factor', 'progesterone', '2', 'review', 'tumor', 'molecular', 'time', 'common', 'pathological', 'human', 'as', 'estrogen receptor', 'and']","['epidermal growth factor', '2', 'review', 'tumor', 'molecular', 'time', 'human', 'as', 'estrogen receptor']",696,"['肿瘤样本的病理审查,即使是常见的分子生物标记,如雌激素受体(ER),<unk>酮受体(PR)和人类肾上腺生长因子受体2(HER2),是时间消耗。']",0.5714285714285714,"['ER', 'epidermal growth factor', 'progesterone', '2', 'review', 'tumor', 'molecular', 'time', 'common', 'pathological', 'human', 'as', 'estrogen receptor', 'and']","['2', 'review', 'tumor', 'molecular', 'time', 'human', 'as', 'estrogen receptor']",696,病理学家们对肿瘤样本的病理学审查，即使是对于常见的分子生物标志物（如雌激素受体[ER]、孕激素受体[PR]和人类上皮生长因子受体2[HER2]）来说，也是一项耗时的工作。,0.6428571428571429,"['ER', 'epidermal growth factor', 'progesterone', '2', 'review', 'tumor', 'molecular', 'time', 'common', 'pathological', 'human', 'as', 'estrogen receptor', 'and']","['epidermal growth factor', '2', 'review', 'tumor', 'molecular', 'time', 'human', 'as', 'estrogen receptor']",,,,
702,697,"moreover , there is not always concordance between pathologists on the interpretation of samples .",此外，病理学家之间对样本的解释并不总是一致的。,0.5,"['concordance', 'interpretation']",['interpretation'],697,"['除此之外,病理学家对样品的解释并不总是一致。']",0.5,"['concordance', 'interpretation']",['interpretation'],697,此外，病理学家在对标本的解释上并不总是一致。,0.5,"['concordance', 'interpretation']",['interpretation'],,,,
703,698,"for example , it has been estimated that there is a discrepancy of up to 19 % for ER estimation between central laboratories and local pathology laboratories .",例如，据估计，中心实验室和地方病理实验室之间的 ER 估计差异高达 19%。,0.3636363636363636,"['ER', 'estimation', 'pathology', 'local', 'central', 'discrepancy', 'up', 'example', 'that', 'to', 'and']","['estimation', 'pathology', 'discrepancy', 'example']",698,"['例如,估计在中央实验室和本地病理实验室之间对ER估计存在高达19%的差异。']",0.3636363636363636,"['ER', 'estimation', 'pathology', 'local', 'central', 'discrepancy', 'up', 'example', 'that', 'to', 'and']","['estimation', 'pathology', 'discrepancy', 'example']",698,例如，据估计，中央实验室和地方病理实验室之间在ER估计方面最多存在19％的差异。,0.3636363636363636,"['ER', 'estimation', 'pathology', 'local', 'central', 'discrepancy', 'up', 'example', 'that', 'to', 'and']","['estimation', 'pathology', 'discrepancy', 'example']",,,,
704,699,artificial intelligence ( AI ) and machine learning technologies are being applied to address this variation as well as to improve reliability and add efficiency .,人工智能 (AI) 和机器学习技术正被应用于应对这种变化，并提高可靠性和效率。,0.5,"['variation', 'reliability', 'well', 'efficiency', 'applied', 'being', 'artificial intelligence', 'machine', 'as', 'learning', 'this', 'to', 'and', 'add']","['variation', 'reliability', 'efficiency', 'artificial intelligence', 'machine', 'learning', 'to']",699,"['人工智能(AI)和机器学习技术正在应用,以应对这种变化,以及提高可靠性和提高效率。']",0.4285714285714285,"['variation', 'reliability', 'well', 'efficiency', 'applied', 'being', 'artificial intelligence', 'machine', 'as', 'learning', 'this', 'to', 'and', 'add']","['variation', 'reliability', 'efficiency', 'artificial intelligence', 'machine', 'learning']",699,人工智能（AI）和机器学习技术正在应用于解决这些变化，以提高可靠性和效率。,0.5,"['variation', 'reliability', 'well', 'efficiency', 'applied', 'being', 'artificial intelligence', 'machine', 'as', 'learning', 'this', 'to', 'and', 'add']","['variation', 'reliability', 'efficiency', 'artificial intelligence', 'machine', 'learning', 'to']",,,,
705,700,"currently , such technology can differentiate between cancerous and noncancerous tissue as well as determine presence of metastases in lymph nodes and perform tumor grading .",目前，这种技术可以区分癌组织和非癌组织，以及确定淋巴结中是否存在转移并进行肿瘤分级。,0.5,"['presence', 'lymph nodes', 'tissue', 'tumor', 'cancerous', 'well', 'technology', 'differentiate', 'as', 'and', 'determine', 'grading']","['presence', 'lymph nodes', 'tissue', 'tumor', 'technology', 'differentiate']",700,"['目前,这种技术可以区分癌症和非癌症组织,并确定淋巴腺中的转化物的存在,并进行肿瘤分类。']",0.4166666666666667,"['presence', 'lymph nodes', 'tissue', 'tumor', 'cancerous', 'well', 'technology', 'differentiate', 'as', 'and', 'determine', 'grading']","['presence', 'tissue', 'tumor', 'technology', 'differentiate']",700,目前，这项技术可以区分肿瘤组织和非肿瘤组织，并可以确定淋巴结转移是否存在肿瘤分级。,0.5,"['presence', 'lymph nodes', 'tissue', 'tumor', 'cancerous', 'well', 'technology', 'differentiate', 'as', 'and', 'determine', 'grading']","['presence', 'lymph nodes', 'tissue', 'tumor', 'technology', 'differentiate']",,,,
706,701,"histology and biomarkers were found to be significantly correlated with all 19 assessed biomarkers , including most clinically relevant ER , PR , and HER2 .",发现组织学和生物标志物与所有 19 种评估的生物标志物显着相关，包括大多数临床相关的 ER、PR 和 HER2。,0.0,"['ER', 'be', 'with', 'histology', 'all', 'and', 'assessed']",[],701,"['历史学和生物标志被发现与所有19个评估的生物标志相关,其中包括最临床相关的ER、PR和HER2。']",0.0,"['ER', 'be', 'with', 'histology', 'all', 'and', 'assessed']",[],701,组织学和生物标志物与所有19项评估的生物标志物显著相关，包括临床相关的ER、PR和HER2。,0.0,"['ER', 'be', 'with', 'histology', 'all', 'and', 'assessed']",[],,,,
707,702,"for approximately half of the patients , the machine learning technique was able to predict biomarker expression with noninferiority to immunohistochemistry ( IHC ) in two validation cohorts with positive predictive values of 97 % and 98 % .",对于大约一半的患者，机器学习技术能够预测两个验证队列中的生物标志物表达，且不劣于免疫组织化学 (IHC)，阳性预测值为 97% 和 98%。,0.5,"['biomarker', 'expression', 'validation', 'half', 'immunohistochemistry', 'technique', 'values', 'predictive', 'cohorts', 'machine', 'with', 'learning', 'positive', 'approximately', 'and', 'two']","['biomarker', 'expression', 'half', 'immunohistochemistry', 'technique', 'machine', 'learning', 'two']",702,"['对于大约一半的患者,机械学习技术能够预测生物标志表达,不低于免疫神经学(IHC)在两个验证协调,有97%和98%的积极预测值。']",0.375,"['biomarker', 'expression', 'validation', 'half', 'immunohistochemistry', 'technique', 'values', 'predictive', 'cohorts', 'machine', 'with', 'learning', 'positive', 'approximately', 'and', 'two']","['expression', 'half', 'technique', 'machine', 'learning', 'two']",702,对于大约一半的病人，机器学习技术可以预测生物标志物的表达，与免疫组化（IHC）相比具有非劣效性，在两个验证队列中具有97％和98％的阳性预测值。,0.4375,"['biomarker', 'expression', 'validation', 'half', 'immunohistochemistry', 'technique', 'values', 'predictive', 'cohorts', 'machine', 'with', 'learning', 'positive', 'approximately', 'and', 'two']","['biomarker', 'expression', 'half', 'technique', 'machine', 'learning', 'two']",,,,
708,703,"AI and machine learning are emerging technologies that are finding a role in many aspects of modern life , including medicine .",人工智能和机器学习是新兴技术，正在现代生活的许多方面发挥作用，包括医学。,0.7142857142857143,"['life', 'medicine', 'role', 'machine', 'learning', 'that', 'and']","['life', 'medicine', 'role', 'machine', 'learning']",703,"['人工智能和机器学习是新兴的技术,在现代生活的许多方面,包括医学,正在发挥作用。']",0.7142857142857143,"['life', 'medicine', 'role', 'machine', 'learning', 'that', 'and']","['life', 'medicine', 'role', 'machine', 'learning']",703,"AI and machine learning are emerging technologies that are finding a role in many aspects of modern life, including medicine.

Chinese:

AI和机器学习是日益涌现的技术，并且在现代生活的许多方面都扮演着重要的角色，包括医疗领域。",0.5714285714285714,"['life', 'medicine', 'role', 'machine', 'learning', 'that', 'and']","['life', 'role', 'machine', 'learning']",,,,
709,704,these data represent a first effort to utilize a training set to gauge utility for pathological review of samples .,这些数据代表了第一次尝试利用训练集来衡量样本病理检查的效用。,0.5,"['data', 'review', 'training', 'gauge', 'represent', 'set', 'pathological', 'effort', 'to', 'first']","['data', 'review', 'training', 'represent', 'first']",704,"['这些数据代表了第一次尝试使用一项培训,以确保对样品的病理审查有用。']",0.4,"['data', 'review', 'training', 'gauge', 'represent', 'set', 'pathological', 'effort', 'to', 'first']","['data', 'review', 'represent', 'first']",704,这些数据代表了对样本进行病理学审查的第一次努力。,0.5,"['data', 'review', 'training', 'gauge', 'represent', 'set', 'pathological', 'effort', 'to', 'first']","['data', 'review', 'represent', 'effort', 'first']",,,,
710,705,"large doses of ibuprofen are often used for emergency department ( ED ) patients , despite evidence that doses above 400 mg increase rates of side effects without improving pain control .",大剂量的布洛芬通常用于急诊科 (ED) 患者，尽管有证据表明超过 400 毫克的剂量会增加副作用的发生率而不会改善疼痛控制。,0.4545454545454545,"['control', 'side effects', 'large', 'pain', 'emergency department', 'evidence', 'increase', 'despite', 'ibuprofen', 'that', 'without']","['control', 'side effects', 'pain', 'evidence', 'ibuprofen']",705,"['大剂量的伊布普罗芬经常用于紧急部门(ED)患者,尽管有证据表明,超过400毫克的剂量增加副作用率,而无需改善疼痛控制。']",0.4545454545454545,"['control', 'side effects', 'large', 'pain', 'emergency department', 'evidence', 'increase', 'despite', 'ibuprofen', 'that', 'without']","['control', 'side effects', 'pain', 'evidence', 'without']",705,在急诊病房，大剂量的布洛芬经常被用于治疗病人，尽管有证据表明剂量超过400毫克会增加副作用的发生率，而不会改善疼痛控制。,0.4545454545454545,"['control', 'side effects', 'large', 'pain', 'emergency department', 'evidence', 'increase', 'despite', 'ibuprofen', 'that', 'without']","['control', 'side effects', 'pain', 'evidence', 'ibuprofen']",,,,
711,706,"to test the hypothesis that the analgesic ceiling of ibuprofen is 400 mg in an ED population , researchers randomized a convenience sample of 225 adults with acute pain to doses of 400 mg , 600 mg , or 800 mg .",为了检验布洛芬在急诊人群中的镇痛上限为 400 毫克的假设，研究人员随机抽取了 225 名患有急性疼痛的成年人的方便样本，分别服用 400 毫克、600 毫克或 800 毫克的剂量。,0.6666666666666666,"['sample', 'analgesic', 'population', 'hypothesis', 'test', 'convenience', 'acute pain', 'ceiling', 'with', 'ibuprofen', 'that', 'to']","['sample', 'population', 'hypothesis', 'test', 'convenience', 'acute pain', 'ceiling', 'ibuprofen']",706,"['为了测试伊布普罗芬的麻醉天花板在ED人口中为400毫克的假设,研究人员随机测试了225名患有急性疼痛的成年人的舒适样本,达到400毫克、600毫克或800毫克的剂量。']",0.3333333333333333,"['sample', 'analgesic', 'population', 'hypothesis', 'test', 'convenience', 'acute pain', 'ceiling', 'with', 'ibuprofen', 'that', 'to']","['sample', 'population', 'hypothesis', 'acute pain']",706,为了测试阿司匹林的镇痛上限为400毫克的假说，研究人员对225个成人急性疼痛患者进行了400毫克、600毫克和800毫克剂量的随机研究。,0.3333333333333333,"['sample', 'analgesic', 'population', 'hypothesis', 'test', 'convenience', 'acute pain', 'ceiling', 'with', 'ibuprofen', 'that', 'to']","['hypothesis', 'test', 'acute pain', 'ceiling']",,,,
712,707,most patients had musculoskeletal or cutaneous pain .,大多数患者有肌肉骨骼或皮肤疼痛。,0.3333333333333333,"['musculoskeletal', 'pain', 'cutaneous']",['pain'],707,['大多数患者患有肌肉骨骼或皮肤疼痛。'],0.3333333333333333,"['musculoskeletal', 'pain', 'cutaneous']",['pain'],707,"Most patients had musculoskeletal or cutaneous pain.

Chinese:

大多数病人有肌肉骨骼或皮肤痛。",0.3333333333333333,"['musculoskeletal', 'pain', 'cutaneous']",['pain'],,,,
713,708,"at 60 minutes , mean pain scores and the change from baseline were similar among groups ( mean scores at 60 minutes , 4.4 , 4.5 , and 4.5 , respectively ) .",在 60 分钟时，各组的平均疼痛评分和相对于基线的变化相似（60 分钟时的平均评分分别为 4.4、4.5 和 4.5）。,0.7142857142857143,"['mean', 'baseline', 'pain', 'change', 'at', 'and', 'similar']","['mean', 'baseline', 'pain', 'change', 'at']",708,"['在60分钟,平均疼痛得分和基线的变化是类似的群体(平均得分在60分钟,4.4,4.5和4.5分别)。']",0.5714285714285714,"['mean', 'baseline', 'pain', 'change', 'at', 'and', 'similar']","['mean', 'baseline', 'pain', 'change']",708,在60分钟时，各组的平均疼痛评分和基线变化相似（60分钟时的平均评分分别为4.4、4.5和4.5）。,0.5714285714285714,"['mean', 'baseline', 'pain', 'change', 'at', 'and', 'similar']","['mean', 'baseline', 'pain', 'change']",,,,
714,709,no side effects were reported .,没有副作用的报道。,0.5,"['side effects', 'no']",['side effects'],709,['没有报告的副作用。'],0.5,"['side effects', 'no']",['side effects'],709,No side effects were reported.,0.0,"['side effects', 'no']",[],,,,
715,710,"although this study was otherwise well done , patients were followed for only 60 minutes , which minimizes the ability to identify adverse events .",尽管这项研究在其他方面做得很好，但仅对患者进行了 60 分钟的随访，这最大限度地降低了识别不良事件的能力。,0.2857142857142857,"['study', 'adverse', 'well', 'ability', 'identify', 'this', 'to']","['ability', 'identify']",710,"['尽管这项研究是顺利进行的,但患者仅追踪了60分钟,这减少了识别不良事件的能力。']",0.4285714285714285,"['study', 'adverse', 'well', 'ability', 'identify', 'this', 'to']","['ability', 'identify', 'this']",710,尽管这项研究本身做得很好，但病人仅被跟踪60分钟，这最大限度地降低了发现不良事件的能力。,0.1428571428571428,"['study', 'adverse', 'well', 'ability', 'identify', 'this', 'to']",['ability'],,,,
716,711,"the authors point out that a single dose of ibuprofen at any of these doses is unlikely to cause harm , but prescriptions for ongoing treatment may be more problematic .",作者指出，任何这些剂量的单剂量布洛芬都不太可能造成伤害，但持续治疗的处方可能会有更多问题。,0.5,"['be', 'treatment', 'cause', 'point', 'ibuprofen', 'dose', 'prescriptions', 'that', 'out', 'single', 'but', 'to']","['treatment', 'ibuprofen', 'dose', 'prescriptions', 'single', 'but']",711,"['作者指出,在这些剂量中的任何一份单一剂量可能不会造成伤害,但持续治疗的处方可能更有问题。']",0.5,"['be', 'treatment', 'cause', 'point', 'ibuprofen', 'dose', 'prescriptions', 'that', 'out', 'single', 'but', 'to']","['be', 'treatment', 'dose', 'prescriptions', 'single', 'but']",711,作者指出，即使是最大剂量的布洛芬，一次性用药也不会造成伤害，但是长期用药可能会带来问题。,0.25,"['be', 'treatment', 'cause', 'point', 'ibuprofen', 'dose', 'prescriptions', 'that', 'out', 'single', 'but', 'to']","['ibuprofen', 'dose', 'but']",,,,
717,712,"since there is consistent evidence that doses above 400 mg do not provide additional pain control , we should avoid prescribing higher doses of ibuprofen .",由于有一致的证据表明超过 400 毫克的剂量不能提供额外的疼痛控制，我们应该避免开出更高剂量的布洛芬。,0.75,"['control', 'pain', 'additional', 'evidence', 'ibuprofen', 'that', 'avoid', 'we']","['control', 'pain', 'additional', 'evidence', 'ibuprofen', 'avoid']",712,"['由于有一致的证据表明,超过400毫克的剂量不提供额外的疼痛控制,我们应该避免处方更高的剂量的伊布普罗芬。']",0.625,"['control', 'pain', 'additional', 'evidence', 'ibuprofen', 'that', 'avoid', 'we']","['control', 'pain', 'additional', 'evidence', 'avoid']",712,根据有关数据表明，超过400毫克的剂量并不能更有效地控制疼痛，我们应避免开药物剂量过高的布洛芬。,0.5,"['control', 'pain', 'additional', 'evidence', 'ibuprofen', 'that', 'avoid', 'we']","['control', 'pain', 'ibuprofen', 'avoid']",,,,
718,713,daily calcium intake averaged 469 mg in the lowest quintile and 1361 mg in the highest quintile and changed only minimally over time .,最低五分位数的每日钙摄入量平均为 469 毫克，最高五分位数的平均每日钙摄入量为 1361 毫克，并且随着时间的推移变化很小。,0.4,"['calcium', 'intake', 'time', 'over', 'and']","['calcium', 'time']",713,"['每日钙摄入量平均为最低量量469毫克,最高量量1361毫克,并且随着时间的推移,只有少量变化。']",0.4,"['calcium', 'intake', 'time', 'over', 'and']","['calcium', 'time']",713,日常钙摄入量平均在最低第五位为469毫克，在最高第五位为1361毫克，并且随着时间的推移变化很小。,0.4,"['calcium', 'intake', 'time', 'over', 'and']","['calcium', 'time']",,,,
719,714,"at baseline , BMD was similar across all quintiles of calcium intake .",在基线时，BMD 在钙摄入量的所有五分位数中是相似的。,0.4285714285714285,"['calcium', 'intake', 'baseline', 'across', 'at', 'all', 'similar']","['calcium', 'baseline', 'similar']",714,"['在基线上,BMD在所有的钙摄入量中都是相似的。']",0.4285714285714285,"['calcium', 'intake', 'baseline', 'across', 'at', 'all', 'similar']","['calcium', 'baseline', 'similar']",714,在基线时，钙摄入量的所有五分位数的骨密度相似。,0.2857142857142857,"['calcium', 'intake', 'baseline', 'across', 'at', 'all', 'similar']","['calcium', 'baseline']",,,,
720,715,"at 6 years , gradual decline in BMD was virtually identical in all quintiles .",在 6 岁时，BMD 的逐渐下降在所有五分位数中几乎是相同的。,0.6,"['decline', 'identical', 'at', 'gradual', 'all']","['decline', 'identical', 'gradual']",715,"['在6岁时,BMI的逐步下降几乎在所有基因蒂尔中都是相同的。']",0.4,"['decline', 'identical', 'at', 'gradual', 'all']","['decline', 'identical']",715,在6岁时，骨量逐渐下降，各个组别之间几乎没有差别。,0.4,"['decline', 'identical', 'at', 'gradual', 'all']","['decline', 'gradual']",,,,
721,716,all analyses were adjusted for numerous potentially confounding variables .,所有分析都针对许多潜在的混杂变量进行了调整。,0.5,"['confounding variables', 'all']",['confounding variables'],716,['所有的分析都被调整到许多潜在混乱的变量。'],0.0,"['confounding variables', 'all']",[],716,所有分析都经过了对众多可能导致干扰的变量进行调整。,0.0,"['confounding variables', 'all']",[],,,,
722,717,"although this study was not a randomized trial of different amounts of dietary calcium , it provides fairly compelling evidence that high intake of dietary calcium does not protect against bone loss in older osteopenic women .",尽管这项研究不是对不同膳食钙含量的随机试验，但它提供了相当有说服力的证据，证明高膳食钙摄入量并不能防止骨质疏松的老年女性骨质流失。,0.5,"['bone', 'calcium', 'intake', 'study', 'loss', 'dietary', 'trial', 'evidence', 'this', 'that', 'protect against', 'high']","['bone', 'calcium', 'evidence', 'this', 'protect against', 'high']",717,"['虽然这项研究不是各种饮食钙量的随机测试,但它提供了相当强迫的证据,高饮食钙摄入量不会保护老年女性免受骨损。']",0.4166666666666667,"['bone', 'calcium', 'intake', 'study', 'loss', 'dietary', 'trial', 'evidence', 'this', 'that', 'protect against', 'high']","['bone', 'calcium', 'evidence', 'this', 'high']",717,虽然这项研究并非针对不同钙质饮食的随机试验，但它提供了相当令人信服的证据，即高钙质饮食对老年骨质疏松女性并不能起到预防骨质流失的作用。,0.5,"['bone', 'calcium', 'intake', 'study', 'loss', 'dietary', 'trial', 'evidence', 'this', 'that', 'protect against', 'high']","['bone', 'calcium', 'dietary', 'evidence', 'protect against', 'high']",,,,
723,718,researchers evaluated performance of these tools in a retrospective chart review of 380 patients with malignancy at a single oncology emergency department who underwent computed tomographic pulmonary angiography ( CTPA ) .,研究人员在一个肿瘤急诊科对 380 名接受了计算机断层扫描肺血管造影 (CTPA) 的恶性肿瘤患者进行了回顾性图表审查，评估了这些工具的性能。,0.5384615384615384,"['chart', 'angiography', 'malignancy', 'tools', 'who', 'review', 'pulmonary', 'emergency department', 'performance', 'with', 'at', 'single', 'tomographic']","['chart', 'angiography', 'malignancy', 'tools', 'review', 'performance', 'tomographic']",718,"['研究人员评估了这些工具的性能,在380名患有恶性疾病的患者的回顾图表中,他们在一个单一的肿瘤紧急部门接受了计算 tomographic 肺结核(CTPA)。']",0.3846153846153846,"['chart', 'angiography', 'malignancy', 'tools', 'who', 'review', 'pulmonary', 'emergency department', 'performance', 'with', 'at', 'single', 'tomographic']","['chart', 'malignancy', 'tools', 'performance', 'single']",718,研究人员对380名在一家肿瘤急诊科接受CTPA检查的患者的表现进行了回顾性资料审查。,0.1538461538461538,"['chart', 'angiography', 'malignancy', 'tools', 'who', 'review', 'pulmonary', 'emergency department', 'performance', 'with', 'at', 'single', 'tomographic']","['chart', 'review']",,,,
724,719,"overall , PE was diagnosed in 11 % of patients and ACP guidelines were followed in 56 % of patients .",总体而言，11% 的患者被诊断为 PE，56% 的患者遵循了 ACP 指南。,0.3333333333333333,"['PE', 'in', 'and']",['and'],719,"['总体而言,11%的患者接受了PE诊断,56%的患者接受了ACP指南。']",0.3333333333333333,"['PE', 'in', 'and']",['and'],719,"总的来说，11％的患者被诊断出患有PE，56％的患者遵循了ACP的指南。

Chinese:
总的来说，11%的病人被诊断出患有PE，56%的病人遵循了ACP的指南。",0.0,"['PE', 'in', 'and']",[],,,,
725,720,the use of PERC would have resulted in avoidance of further testing in only few patients ( 3.4 % ) .,只有少数患者 (3.4%) 使用 PERC 可以避免进一步检测。,0.3333333333333333,"['avoidance', 'testing', 'have']",['have'],720,['使用 PERC 会导致少数患者避免进行进一步的测试(3.4%)。'],0.0,"['avoidance', 'testing', 'have']",[],720,如果使用PERC，只有少数病人（3.4%）就能避免进一步的检查了。,0.3333333333333333,"['avoidance', 'testing', 'have']",['have'],,,,
726,721,"only one PE would have been missed had the guidelines been followed ( sensitivity 97 % , negative predictive value 99 % ) .",如果遵循指南（敏感性 97%，阴性预测值 99%），只会漏掉一次 PE。,0.0,"['negative', 'sensitivity', 'predictive value', 'PE', 'have']",[],721,"['如果遵循指令,只会错过一个PE(97%的敏感性,99%的负预测值)。']",0.0,"['negative', 'sensitivity', 'predictive value', 'PE', 'have']",[],721,只有一个体格检查错过了指南（敏感度97％，阴性预测值99％）。,0.2,"['negative', 'sensitivity', 'predictive value', 'PE', 'have']",['have'],,,,
727,722,"if the association is causal , the absolute incidence is exceedingly rare .",如果关联是因果关系，则绝对发生率极其罕见。,0.6,"['incidence', 'association', 'absolute', 'causal', 'if']","['incidence', 'association', 'absolute']",722,"['如果合并是因果性的,绝对的发病率是过于罕见的。']",0.4,"['incidence', 'association', 'absolute', 'causal', 'if']","['incidence', 'absolute']",722,如果关联是因果关系，则绝对发生率非常低。,0.6,"['incidence', 'association', 'absolute', 'causal', 'if']","['incidence', 'association', 'absolute']",,,,
728,723,"patients with diabetes were excluded , given the strong associations between diabetes and both antibiotic use and neuropathy .",糖尿病患者被排除在外，因为糖尿病与抗生素使用和神经病变之间存在密切关联。,0.5,"['diabetes', 'antibiotic', 'neuropathy', 'strong', 'with', 'and']","['diabetes', 'antibiotic', 'neuropathy']",723,"['糖尿病患者被排除,因为糖尿病和抗生素使用和神经病之间的强烈联系。']",0.6666666666666666,"['diabetes', 'antibiotic', 'neuropathy', 'strong', 'with', 'and']","['diabetes', 'antibiotic', 'neuropathy', 'strong']",723,糖尿病患者被排除在外，因为糖尿病与使用抗生素和神经病变有很强的相关性。,0.6666666666666666,"['diabetes', 'antibiotic', 'neuropathy', 'strong', 'with', 'and']","['diabetes', 'antibiotic', 'neuropathy', 'strong']",,,,
729,724,"fluoroquinolone exposure within 30 days was associated with excess risk for incident peripheral neuropathy compared with nonexposure ( rate ratio , 1.47 ) ; risk persisted when the window of exposure was extended to 180 days before diagnosis of neuropathy .",与未接触氟喹诺酮相比，30 天内接触氟喹诺酮类药物与发生周围神经病变的风险增加相关（比率 1.47）；当暴露窗口延长至神经病变诊断前 180 天时，风险仍然存在。,0.5714285714285714,"['excess', 'peripheral', 'rate', 'exposure', 'ratio', 'neuropathy', 'window', 'diagnosis', 'associated', 'risk', 'with', 'incident', 'before', 'to']","['rate', 'exposure', 'ratio', 'neuropathy', 'window', 'diagnosis', 'risk', 'before']",724,"['在30天内与过度风险发生周边神经病相比不暴露(率比率为1.47),风险持续,当暴露窗口延长到神经病的诊断前180天。']",0.5714285714285714,"['excess', 'peripheral', 'rate', 'exposure', 'ratio', 'neuropathy', 'window', 'diagnosis', 'associated', 'risk', 'with', 'incident', 'before', 'to']","['rate', 'exposure', 'ratio', 'neuropathy', 'window', 'diagnosis', 'risk', 'before']",724,接触氟喹诺酮药物30天内与肢端神经病发生风险相比无接触者增加（风险比，1.47）；当接触范围延伸到神经病诊断前180天时，风险仍然存在。,0.3571428571428571,"['excess', 'peripheral', 'rate', 'exposure', 'ratio', 'neuropathy', 'window', 'diagnosis', 'associated', 'risk', 'with', 'incident', 'before', 'to']","['ratio', 'neuropathy', 'diagnosis', 'risk', 'before']",,,,
730,725,analyses were adjusted for alcohol abuse and several diseases and medications known to cause peripheral neuropathy .,分析针对酗酒和已知会导致周围神经病变的几种疾病和药物进行了调整。,0.2857142857142857,"['alcohol', 'peripheral', 'neuropathy', 'cause', 'abuse', 'to', 'and']","['alcohol', 'neuropathy']",725,['分析适用于酒精滥用和多种疾病和药物已知导致周边神经病。'],0.4285714285714285,"['alcohol', 'peripheral', 'neuropathy', 'cause', 'abuse', 'to', 'and']","['alcohol', 'neuropathy', 'to']",725,研究通过校正酗酒和已知引起周围神经病变的几种疾病和药物来进行分析。,0.2857142857142857,"['alcohol', 'peripheral', 'neuropathy', 'cause', 'abuse', 'to', 'and']","['alcohol', 'neuropathy']",,,,
731,726,"these findings strengthen the case for an association between fluoroquinolones and neuropathy ; however , limitations include the possibility of residual confounding and inaccurate diagnosis of peripheral neuropathy in this primary care database .",这些发现加强了氟喹诺酮类药物与神经病之间的关联；然而，局限性包括在这个初级保健数据库中可能存在残留混杂和周围神经病变的不准确诊断。,0.3846153846153846,"['database', 'peripheral', 'neuropathy', 'association', 'diagnosis', 'primary', 'case', 'care', 'residual', 'inaccurate', 'this', 'strengthen', 'and']","['neuropathy', 'association', 'diagnosis', 'strengthen', 'and']",726,"['这些发现加强了Fluoroquinolones与神经病之间的联系;然而,限制包括残留混乱和周边神经病的不准确诊断在这个初级护理数据库中的可能性。']",0.3846153846153846,"['database', 'peripheral', 'neuropathy', 'association', 'diagnosis', 'primary', 'case', 'care', 'residual', 'inaccurate', 'this', 'strengthen', 'and']","['neuropathy', 'association', 'diagnosis', 'strengthen', 'and']",726,这些发现加强了氟喹诺酮与神经病变之间的关联；然而，局限性包括在这个主要护理数据库中残留的纷争和周边神经病变的不准确诊断。,0.3846153846153846,"['database', 'peripheral', 'neuropathy', 'association', 'diagnosis', 'primary', 'case', 'care', 'residual', 'inaccurate', 'this', 'strengthen', 'and']","['neuropathy', 'association', 'diagnosis', 'strengthen', 'and']",,,,
732,727,"if this association is causal , it appears to be a very rare adverse event .",如果这种关联是因果关系，那么这似乎是一种非常罕见的不良事件。,0.4285714285714285,"['association', 'be', 'causal', 'adverse event', 'this', 'if', 'to']","['association', 'adverse event', 'this']",727,"['如果这种结合是因果性的,它似乎是一个非常罕见的不良事件。']",0.4285714285714285,"['association', 'be', 'causal', 'adverse event', 'this', 'if', 'to']","['association', 'adverse event', 'this']",727,如果这种关联是因果关系，它似乎是一种非常罕见的不良事件。,0.4285714285714285,"['association', 'be', 'causal', 'adverse event', 'this', 'if', 'to']","['association', 'adverse event', 'this']",,,,
733,728,"in phase 2 studies involving patients with chronic kidney disease , roxadustat increased levels of endogenous erythropoietin to within or near the physiologic range , along with increasing hemoglobin levels and improving iron homeostasis .",在涉及慢性肾病患者的 2 期研究中，roxadustat 将内源性促红细胞生成素水平提高到生理范围内或接近生理范围，同时增加血红蛋白水平并改善铁稳态。,0.5294117647058824,"['endogenous', 'kidney', 'disease', 'homeostasis', 'erythropoietin', 'range', '2', 'hemoglobin', 'chronic', 'along', 'in phase', 'physiologic', 'with', 'roxadustat', 'iron', 'to', 'and']","['kidney', 'disease', 'homeostasis', 'erythropoietin', 'range', '2', 'hemoglobin', 'chronic', 'iron']",728,"['在2阶段的研究中,涉及患有慢性肾脏疾病的患者,Roxadustat增加了内分泌的Erythropoietin水平到生理范围内或附近,以及增加了血球水平,并改善了铁同位素。']",0.3529411764705882,"['endogenous', 'kidney', 'disease', 'homeostasis', 'erythropoietin', 'range', '2', 'hemoglobin', 'chronic', 'along', 'in phase', 'physiologic', 'with', 'roxadustat', 'iron', 'to', 'and']","['kidney', 'disease', 'range', '2', 'chronic', 'iron']",728,在慢性肾病患者的二期研究中，罗沙达斯特能够将内源性红细胞生成素水平提高到理想水平，同时还能够提高血红蛋白水平并帮助恢复铁元素的平衡。,0.3529411764705882,"['endogenous', 'kidney', 'disease', 'homeostasis', 'erythropoietin', 'range', '2', 'hemoglobin', 'chronic', 'along', 'in phase', 'physiologic', 'with', 'roxadustat', 'iron', 'to', 'and']","['kidney', 'disease', 'erythropoietin', 'hemoglobin', 'chronic', 'iron']",,,,
734,729,additional data are needed regarding the efficacy and safety of roxadustat for the treatment of anemia in patients with chronic kidney disease who are not undergoing dialysis .,需要更多关于罗沙司他治疗未接受透析的慢性肾病患者贫血的疗效和安全性的数据。,0.6666666666666666,"['anemia', 'safety', 'dialysis', 'kidney', 'disease', 'data', 'who', 'regarding', 'treatment', 'chronic', 'additional', 'efficacy', 'with', 'roxadustat', 'and']","['anemia', 'safety', 'dialysis', 'kidney', 'disease', 'data', 'regarding', 'treatment', 'chronic', 'roxadustat']",729,['有关Roxadustat在慢性肾脏疾病患者中治疗贫血的有效性和安全性需要额外的数据。'],0.6666666666666666,"['anemia', 'safety', 'dialysis', 'kidney', 'disease', 'data', 'who', 'regarding', 'treatment', 'chronic', 'additional', 'efficacy', 'with', 'roxadustat', 'and']","['anemia', 'safety', 'kidney', 'disease', 'data', 'regarding', 'treatment', 'chronic', 'additional', 'efficacy']",729,针对慢性肾脏疾病患者（未接受透析治疗的），需要收集更多有关罗沙度他治疗贫血疗效及安全性的数据。,0.6,"['anemia', 'safety', 'dialysis', 'kidney', 'disease', 'data', 'who', 'regarding', 'treatment', 'chronic', 'additional', 'efficacy', 'with', 'roxadustat', 'and']","['anemia', 'safety', 'dialysis', 'kidney', 'disease', 'data', 'regarding', 'treatment', 'chronic']",,,,
735,730,all the patients had a hemoglobin level of 7.0 to 10.0 g per deciliter at baseline .,所有患者的基线血红蛋白水平均为 7.0 至 10.0 g/dL。,0.1666666666666666,"['baseline', 'deciliter', 'hemoglobin level', 'at', 'all', 'to']",['baseline'],730,['所有患者在基线上每分升7.0至10.0g的血糖水平。'],0.1666666666666666,"['baseline', 'deciliter', 'hemoglobin level', 'at', 'all', 'to']",['baseline'],730,所有病人在基线时的血红蛋白水平均在7.0-10.0 g/dL之间。,0.1666666666666666,"['baseline', 'deciliter', 'hemoglobin level', 'at', 'all', 'to']",['baseline'],,,,
736,731,"the primary end point was the mean change from baseline in the hemoglobin level , averaged over weeks 7 through 9 .",主要终点是血红蛋白水平相对于基线的平均变化，是第 7 周到第 9 周的平均值。,0.5,"['mean', 'baseline', 'hemoglobin level', 'primary', 'end', 'point', 'change', 'over']","['mean', 'baseline', 'point', 'change']",731,"['初级终点是血球水平的基线的平均变化,平均为7至9周。']",0.5,"['mean', 'baseline', 'hemoglobin level', 'primary', 'end', 'point', 'change', 'over']","['mean', 'baseline', 'point', 'change']",731,主要终点是7-9周期间血红蛋白水平的平均变化。,0.375,"['mean', 'baseline', 'hemoglobin level', 'primary', 'end', 'point', 'change', 'over']","['mean', 'point', 'change']",,,,
737,732,the mean reduction from baseline in the hepcidin level ( associated with greater iron availability ) was 56.14 ± 63.40 ng per milliliter in the roxadustat group and 15.10 ± 48.06 ng per milliliter in the placebo group .,roxadustat 组铁调素水平（与更高的铁可用性相关）相对于基线的平均降低为 56.14 ± 63.40 ng/mL，安慰剂组为 15.10 ± 48.06 ng/mL。,0.5833333333333334,"['group', 'placebo', 'mean', 'baseline', 'reduction', 'associated', 'availability', 'level', 'with', 'roxadustat', 'iron', 'and']","['group', 'placebo', 'mean', 'baseline', 'reduction', 'level', 'iron']",732,"['基因水平的平均下降(与较高的铁可用性相结合)在Roxadustat组为56.14 ± 63.40 ng/毫升,在 placebo组为 15.10 ± 48.06 ng/毫升。']",0.3333333333333333,"['group', 'placebo', 'mean', 'baseline', 'reduction', 'associated', 'availability', 'level', 'with', 'roxadustat', 'iron', 'and']","['group', 'mean', 'level', 'iron']",732,在基线上降低平均血清肝素水平（与更多铁质相关）的罗沙达斯特组为56.14±63.40 ng/ml，而安慰剂组仅为15.10±48.06 ng/ml。,0.6666666666666666,"['group', 'placebo', 'mean', 'baseline', 'reduction', 'associated', 'availability', 'level', 'with', 'roxadustat', 'iron', 'and']","['group', 'placebo', 'mean', 'baseline', 'reduction', 'level', 'iron', 'and']",,,,
738,733,the reduction from baseline in the total cholesterol level was 40.6 mg per deciliter in the roxadustat group and 7.7 mg per deciliter in the placebo group .,罗沙司他组总胆固醇水平较基线降低 40.6 毫克/分升，安慰剂组降低 7.7 毫克/分升。,0.7,"['cholesterol', 'group', 'placebo', 'baseline', 'deciliter', 'reduction', 'total', 'level', 'roxadustat', 'and']","['cholesterol', 'group', 'placebo', 'baseline', 'reduction', 'level', 'roxadustat']",733,"['总胆固醇水平从基层下降为Roxadustat组每分升40.6 mg,在 placebo组每分升7.7 mg。']",0.3,"['cholesterol', 'group', 'placebo', 'baseline', 'deciliter', 'reduction', 'total', 'level', 'roxadustat', 'and']","['cholesterol', 'group', 'level']",733,在基线上，总胆固醇水平在roxadustat组显著降低了40.6毫克/分升，而在安慰剂组仅为7.7毫克/分升。,0.7,"['cholesterol', 'group', 'placebo', 'baseline', 'deciliter', 'reduction', 'total', 'level', 'roxadustat', 'and']","['cholesterol', 'group', 'placebo', 'baseline', 'reduction', 'level', 'and']",,,,
739,734,hyperkalemia and metabolic acidosis occurred more frequently in the roxadustat group than in the placebo group .,与安慰剂组相比，罗沙司他组高钾血症和代谢性酸中毒的发生率更高。,0.625,"['group', 'placebo', 'frequently', 'hyperkalemia', 'roxadustat', 'metabolic acidosis', 'in', 'and']","['group', 'placebo', 'hyperkalemia', 'roxadustat', 'metabolic acidosis']",734,"['甲状腺高血病和代谢酸化发生在罗克萨德斯塔特群体中更频繁,而不是在 placebo群体中。']",0.25,"['group', 'placebo', 'frequently', 'hyperkalemia', 'roxadustat', 'metabolic acidosis', 'in', 'and']","['group', 'and']",734,罗沙达斯特组患有高钾血症和代谢性酸osis的患者比安慰剂组患者更多。,0.375,"['group', 'placebo', 'frequently', 'hyperkalemia', 'roxadustat', 'metabolic acidosis', 'in', 'and']","['group', 'placebo', 'hyperkalemia']",,,,
740,735,"in Chinese patients with chronic kidney disease who were not undergoing dialysis , those in the roxadustat group had a higher mean hemoglobin level than those in the placebo group after 8 weeks .",在未接受透析的中国慢性肾病患者中，8 周后，roxadustat 组患者的平均血红蛋白水平高于安慰剂组患者。,0.6153846153846154,"['group', 'dialysis', 'placebo', 'kidney', 'disease', 'mean', 'who', 'hemoglobin level', 'chronic', 'after', 'with', 'roxadustat', 'chinese']","['group', 'dialysis', 'placebo', 'kidney', 'disease', 'mean', 'chronic', 'after']",735,"['在中国患有慢性肾脏疾病的患者中,在8周后,罗克萨多斯塔特群体中的人比 placebo群体中的人水平更高。']",0.3846153846153846,"['group', 'dialysis', 'placebo', 'kidney', 'disease', 'mean', 'who', 'hemoglobin level', 'chronic', 'after', 'with', 'roxadustat', 'chinese']","['group', 'kidney', 'disease', 'chronic', 'after']",735,在非透析慢性肾脏病中国患者中，罗沙达斯特组患者在8周后的平均血红蛋白水平高于安慰剂组患者。,0.6153846153846154,"['group', 'dialysis', 'placebo', 'kidney', 'disease', 'mean', 'who', 'hemoglobin level', 'chronic', 'after', 'with', 'roxadustat', 'chinese']","['group', 'dialysis', 'placebo', 'kidney', 'disease', 'mean', 'chronic', 'after']",,,,
741,736,"chronic kidney disease is a global public health challenge that affects approximately 10 % of the population worldwide , including 120 million people in China.1",慢性肾病是全球公共卫生挑战，影响全球约 10 % 的人口，其中包括中国的 1.2 亿人。 1,0.5833333333333334,"['population', 'kidney', 'disease', 'global', 'health', 'public', 'chronic', 'challenge', 'approximately', 'that', 'in', 'million']","['population', 'kidney', 'disease', 'global', 'health', 'chronic', 'challenge']",736,"['慢性肾脏疾病是一个全球公共卫生挑战,影响全球约10%的人口,包括中国120万人。']",0.5833333333333334,"['population', 'kidney', 'disease', 'global', 'health', 'public', 'chronic', 'challenge', 'approximately', 'that', 'in', 'million']","['population', 'kidney', 'disease', 'global', 'health', 'chronic', 'challenge']",736,慢性肾脏疾病是一个全球性的公共卫生挑战，影响了全球大约10%的人口，其中包括中国1.2亿人。,0.5833333333333334,"['population', 'kidney', 'disease', 'global', 'health', 'public', 'chronic', 'challenge', 'approximately', 'that', 'in', 'million']","['population', 'kidney', 'disease', 'global', 'health', 'chronic', 'challenge']",,,,
742,737,"in China , this situation is reflected by low hemoglobin levels in patients who initiate dialysis , with mean levels of 7.3 g per deciliter reported in Guangzhou , 8.2 g per deciliter in Beijing , and 7.7 g per deciliter in Shanghai.8,9","在中国，这种情况反映在开始透析的患者血红蛋白水平较低，广州报告的平均水平为每分升 7.3 克，北京为每分升 8.2 克，上海为每分升 7.7 克。 8,9",0.4166666666666667,"['dialysis', 'situation', 'mean', 'who', 'hemoglobin', 'deciliter', 'low', 'china', 'with', 'this', 'by', 'and']","['dialysis', 'mean', 'hemoglobin', 'low', 'china']",737,"['在中国,这种情况被低血球水平反映在开始腹泻的患者中,平均水平在广州报告为7.3g,在北京报告为8.2g,在上海报告为7.7g。']",0.25,"['dialysis', 'situation', 'mean', 'who', 'hemoglobin', 'deciliter', 'low', 'china', 'with', 'this', 'by', 'and']","['mean', 'low', 'china']",737,"在中国，这种情况反映在起始透析治疗的患者低血红蛋白水平上，广州报告的平均水平为7.3克/分升，北京为8.2克/分升，上海为7.7克/分升。8,9",0.4166666666666667,"['dialysis', 'situation', 'mean', 'who', 'hemoglobin', 'deciliter', 'low', 'china', 'with', 'this', 'by', 'and']","['dialysis', 'mean', 'hemoglobin', 'low', 'china']",,,,
743,738,"among the patients who initiated dialysis in rural China , those with a mean ( ± SD ) hemoglobin level of 5.9 ± 4.7 g per deciliter had twice the rates of heart failure and death as those living in urban areas , who had a mean level of 8.4 ± 4.5 g per deciliter ; in these two groups , rates of heart failure were 34.4 % and 16.2 % , respectively , and rates of death were 42.9 % and 21.9 % , respectively.10",在中国农村开始透析的患者中，平均 ( ± SD ) 血红蛋白水平为 5.9 ± 4.7 g/dL 的患者的心力衰竭和死亡率是生活在城市地区的患者的两倍，后者的平均水平为 8.4 ± 4.5 克每分升；在这两组中，心衰率分别为 34.4 % 和 16.2 % ，死亡率分别为 42.9 % 和 21.9 % 10。,0.375,"['dialysis', 'mean', 'who', 'death', 'deciliter', 'hemoglobin level', 'heart failure', 'rural', 'china', 'living', 'as', 'with', 'SD', 'and', 'twice', 'two']","['dialysis', 'mean', 'death', 'heart failure', 'china', 'two']",738,"['在农村中国启动腹泻的患者中,平均(±SD)血球水平为5.9 ± 4.7 克每分升的患者患有心脏衰竭和死亡率的两倍,而居住在城市地区的患者中,平均水平为8.4 ± 4.5 克每分升;在这两个群体中,心脏衰竭率为 34.4% 和 16.2% 相应,死亡率为 42.9% 和 21.9% 相应。']",0.3125,"['dialysis', 'mean', 'who', 'death', 'deciliter', 'hemoglobin level', 'heart failure', 'rural', 'china', 'living', 'as', 'with', 'SD', 'and', 'twice', 'two']","['mean', 'death', 'china', 'and', 'two']",738,在中国农村启动透析的病人中，平均血红蛋白水平为5.9±4.7克/分升的病人心力衰竭和死亡率是活在城市地区的病人的两倍，后者的平均血红蛋白水平为8.4±4.5克/分升；在这两组病人中，心力衰竭率分别为34.4％和16.2％，死亡率分别为42.9％和21.9％。10,0.375,"['dialysis', 'mean', 'who', 'death', 'deciliter', 'hemoglobin level', 'heart failure', 'rural', 'china', 'living', 'as', 'with', 'SD', 'and', 'twice', 'two']","['dialysis', 'mean', 'death', 'heart failure', 'china', 'two']",,,,
744,739,"the trial was conducted in accordance with the principles of the Declaration of Helsinki , Chinese Good Clinical Practice , and the International Conference on Harmonization E6 guidelines .",该试验是根据赫尔辛基宣言、中国临床试验质量管理规范和国际协调会议 E6 指南的原则进行的。,0.0,"['good clinical practice', 'trial', 'with', 'on', 'chinese', 'and']",[],739,['根据《赫尔辛基宣言、中国良好临床实践》和《国际协调会议E6指令》的原则进行审查。'],0.0,"['good clinical practice', 'trial', 'with', 'on', 'chinese', 'and']",[],739,这项试验符合《赫尔辛基宣言》、《中国良好临床实践指导原则》和《国际协调E6指南》的原则。,0.0,"['good clinical practice', 'trial', 'with', 'on', 'chinese', 'and']",[],,,,
745,740,"the first two authors designed the trial in collaboration with representatives of the sponsor , FibroGen ; company representatives were responsible for the collection and analysis of the data .",前两位作者与申办方 FibroGen 的代表合作设计了该试验；公司代表负责数据的收集和分析。,0.4545454545454545,"['data', 'analysis', 'sponsor', 'collection', 'trial', 'collaboration', 'with', 'in', 'and', 'first', 'two']","['data', 'analysis', 'collection', 'collaboration', 'two']",740,"['最初的两位作者与赞助商FibroGen的代表合作设计了审判,公司代表负责收集和分析数据。']",0.5454545454545454,"['data', 'analysis', 'sponsor', 'collection', 'trial', 'collaboration', 'with', 'in', 'and', 'first', 'two']","['data', 'analysis', 'collection', 'trial', 'collaboration', 'two']",740,第一作者与FibroGen公司代表合作设计了这项试验，公司代表负责数据的收集和分析。,0.4545454545454545,"['data', 'analysis', 'sponsor', 'collection', 'trial', 'collaboration', 'with', 'in', 'and', 'first', 'two']","['data', 'analysis', 'collection', 'collaboration', 'first']",,,,
746,741,"all the authors contributed to the analysis and interpretation of the data and to the conduct of the trial , along with having full access to the data and analyses and full review of the manuscript .",所有作者都对数据的分析和解释以及试验的实施做出了贡献，同时能够完全访问数据和分析以及对手稿进行全面审查。,0.3571428571428571,"['data', 'analysis', 'review', 'access', 'interpretation', 'manuscript', 'along', 'trial', 'conduct', 'with', 'full', 'all', 'to', 'and']","['data', 'analysis', 'review', 'interpretation', 'manuscript']",741,"['所有作者都参与了数据的分析和解释,以及审判的进行,并获得了数据和分析的完整访问和手稿的完整审查。']",0.5,"['data', 'analysis', 'review', 'access', 'interpretation', 'manuscript', 'along', 'trial', 'conduct', 'with', 'full', 'all', 'to', 'and']","['data', 'analysis', 'review', 'interpretation', 'manuscript', 'trial', 'full']",741,所有作者都对数据的分析和解释以及试验的进行贡献，并且对数据和分析有完全的访问权限，对手稿有完全的审查权限。,0.3571428571428571,"['data', 'analysis', 'review', 'access', 'interpretation', 'manuscript', 'along', 'trial', 'conduct', 'with', 'full', 'all', 'to', 'and']","['data', 'analysis', 'review', 'interpretation', 'manuscript']",,,,
747,742,all the authors vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol ( available with the full text of this article at NEJM.org ) .,所有作者保证数据的完整性和准确性，以及试验对方案的忠实度（与本文全文可在 NEJM.org 获取）。,0.2857142857142857,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'completeness', 'full']",742,"['所有作者保证数据的完整性和准确性,以及对议定书的审判忠诚性(可在NEJM.org上提供本文的完整文本)。']",0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness', 'full']",742,所有作者都保证数据的完整性和准确性，并保证试验与协议的一致性（全文可在 NEJM.org 上获得）。,0.3571428571428571,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'protocol', 'completeness', 'full']",,,,
748,743,"eligible patients were between the ages of 18 and 75 years , had chronic kidney disease of stage 3 to 5 , and were not currently undergoing dialysis .",符合条件的患者年龄在 18 至 75 岁之间，患有 3 至 5 期慢性肾病，目前未接受透析。,0.6,"['stage', 'dialysis', '5', 'kidney', 'disease', 'chronic', '3', 'to', 'and', 'eligible']","['stage', 'dialysis', '5', 'kidney', 'disease', 'chronic']",743,"['有资格的患者年龄在18至75岁之间,患有3至5阶段的慢性肾脏疾病,并且目前不接受诊断。']",0.4,"['stage', 'dialysis', '5', 'kidney', 'disease', 'chronic', '3', 'to', 'and', 'eligible']","['5', 'kidney', 'disease', 'chronic']",743,符合条件的患者年龄在18岁至75岁之间，患有3至5期慢性肾脏病，并且目前不在行腹膜透析。,0.6,"['stage', 'dialysis', '5', 'kidney', 'disease', 'chronic', '3', 'to', 'and', 'eligible']","['stage', 'dialysis', '5', 'kidney', 'disease', 'chronic']",,,,
749,744,"during screening , the mean of the two most recent hemoglobin values was in the range of 7.0 g per deciliter to less than 10.0 g per deciliter in all the patients . ( details regarding inclusion and exclusion criteria are provided in Table S1 in the Supplementary Appendix , available at NEJM.org. )",在筛选期间，所有患者的两个最近血红蛋白值的平均值在每分升 7.0 克到低于每分升 10.0 克的范围内。 （有关纳入和排除标准的详细信息见补充附录表 S1，补充附录可在 NEJM.org 获取。）,0.45,"['appendix', 'mean', 'range', 'table', 'inclusion', 'recent', 'screening', 'hemoglobin', 'deciliter', 'supplementary', 'exclusion', 'regarding', 'available', 'values', 'at', 'S1', 'all', 'to', 'and', 'two']","['mean', 'range', 'table', 'screening', 'hemoglobin', 'regarding', 'at', 'to', 'two']",744,"['在筛查期间,最新的两种血球值的平均值在每个分数的7.0g到每个分数的10.0g以下范围,所有患者(包括和排除标准的详细信息在附加附件中的S1表中提供,可在NEJM.org上找到。']",0.3,"['appendix', 'mean', 'range', 'table', 'inclusion', 'recent', 'screening', 'hemoglobin', 'deciliter', 'supplementary', 'exclusion', 'regarding', 'available', 'values', 'at', 'S1', 'all', 'to', 'and', 'two']","['appendix', 'mean', 'range', 'table', 'screening', 'two']",744,在筛查期间，所有患者的两个最近的血红蛋白值的平均值在7.0 g/dL至10.0 g/dL之间。（有关纳入和排除标准的详细信息可在NEJM.org上找到附加附录表S1中。）,0.3,"['appendix', 'mean', 'range', 'table', 'inclusion', 'recent', 'screening', 'hemoglobin', 'deciliter', 'supplementary', 'exclusion', 'regarding', 'available', 'values', 'at', 'S1', 'all', 'to', 'and', 'two']","['mean', 'table', 'screening', 'hemoglobin', 'regarding', 'two']",,,,
750,745,the dose of roxadustat was escalated every 4 weeks to maintain a hemoglobin level ranging from 10.0 to 12.0 g per deciliter ( Table S2 in the Supplementary Appendix ) .,罗沙司他的剂量每 4 周增加一次，以将血红蛋白水平维持在 10.0 至 12.0 g/dL（补充附录表 S2）。,0.3636363636363636,"['appendix', 'table', 'deciliter', 'maintain', 'supplementary', 'hemoglobin level', '4', 'roxadustat', 'dose', 'S2', 'to']","['table', 'maintain', 'roxadustat', 'dose']",745,"['每4周,Roxadustat的剂量增加,以保持每分升10.0至12.0g的血球水平(附件中的S2表)。']",0.2727272727272727,"['appendix', 'table', 'deciliter', 'maintain', 'supplementary', 'hemoglobin level', '4', 'roxadustat', 'dose', 'S2', 'to']","['appendix', 'table', 'dose']",745,roxadustat的剂量每4周递增，以维持血红蛋白水平在10.0-12.0g/分升之间（见表S2在附加附件中）。,0.3636363636363636,"['appendix', 'table', 'deciliter', 'maintain', 'supplementary', 'hemoglobin level', '4', 'roxadustat', 'dose', 'S2', 'to']","['appendix', 'table', 'maintain', 'dose']",,,,
751,746,the adjustment of the placebo dose was carried out in the same manner .,安慰剂剂量的调整同法进行。,0.3333333333333333,"['placebo', 'adjustment', 'manner', 'dose', 'in', 'out']","['placebo', 'dose']",746,['placebo 剂量的调整也以相同的方式进行。'],0.1666666666666666,"['placebo', 'adjustment', 'manner', 'dose', 'in', 'out']",['dose'],746,调整安慰剂剂量的方式相同。,0.3333333333333333,"['placebo', 'adjustment', 'manner', 'dose', 'in', 'out']","['placebo', 'dose']",,,,
752,747,"investigators were asked to record abnormal , clinically significant laboratory results , physical examination findings , and electrocardiographic results as adverse events if such findings were deemed to meet the criteria for adverse events .",研究人员被要求将异常的、具有临床意义的实验室结果、体格检查结果和心电图结果记录为不良事件，如果这些发现被认为符合不良事件的标准。,0.5555555555555556,"['record', 'abnormal', 'physical examination', 'adverse', 'laboratory', 'as', 'if', 'and', 'electrocardiographic']","['record', 'abnormal', 'laboratory', 'as', 'electrocardiographic']",747,"['研究人员被要求记录异常、临床上有意义的实验室结果、物理检查结果和电心学结果作为不良事件,如果这些发现被认为符合不良事件的标准。']",0.4444444444444444,"['record', 'abnormal', 'physical examination', 'adverse', 'laboratory', 'as', 'if', 'and', 'electrocardiographic']","['record', 'abnormal', 'laboratory', 'as']",747,调查人员被要求记录异常、临床上显着的实验室结果、体格检查结果和心电图结果，如果这些结果被认为符合不良事件的标准，则将其记录为不良事件。,0.5555555555555556,"['record', 'abnormal', 'physical examination', 'adverse', 'laboratory', 'as', 'if', 'and', 'electrocardiographic']","['record', 'abnormal', 'laboratory', 'as', 'electrocardiographic']",,,,
753,748,"we performed an analysis of covariance to estimate and compare the difference between the groups in the change from baseline in the hemoglobin level , with missing data handled with the use of multiple imputations in a sensitivity analysis .",我们进行了协方差分析，以估计和比较各组之间血红蛋白水平相对于基线的变化差异，并在敏感性分析中使用多重插补处理缺失数据。,0.4666666666666667,"['data', 'baseline', 'multiple', 'difference', 'hemoglobin level', 'estimate', 'compare', 'change', 'with', 'sensitivity', 'analysis of covariance', 'to', 'and', 'missing', 'we']","['data', 'baseline', 'difference', 'compare', 'change', 'to', 'missing']",748,"['我们进行了可视性分析,以估计和比较从基层到血球水平的变化中的群体之间的差异,缺少的数据处理了在敏感性分析中使用多种假设。']",0.3333333333333333,"['data', 'baseline', 'multiple', 'difference', 'hemoglobin level', 'estimate', 'compare', 'change', 'with', 'sensitivity', 'analysis of covariance', 'to', 'and', 'missing', 'we']","['data', 'difference', 'compare', 'change', 'missing']",748,我们进行了协方差分析，估计并比较了两组在基线血红蛋白水平变化上的差异，并在敏感性分析中使用了多元插补方法来处理缺失数据。,0.4,"['data', 'baseline', 'multiple', 'difference', 'hemoglobin level', 'estimate', 'compare', 'change', 'with', 'sensitivity', 'analysis of covariance', 'to', 'and', 'missing', 'we']","['data', 'baseline', 'difference', 'compare', 'change', 'missing']",,,,
754,749,we performed an analysis of covariance to calculate the change from baseline in hepcidin at week 9 .,我们进行了协方差分析，以计算第 9 周铁调素相对于基线的变化。,0.8333333333333334,"['baseline', 'week', 'change', 'analysis of covariance', 'calculate', 'to']","['baseline', 'week', 'change', 'calculate', 'to']",749,"['我们进行了一项可视性分析,以计算从基线到Hepcidin的变化,在第9周。']",0.6666666666666666,"['baseline', 'week', 'change', 'analysis of covariance', 'calculate', 'to']","['baseline', 'week', 'change', 'calculate']",749,我们对协方差进行了分析，以计算9周时肝铁蛋白的基线变化。,0.6666666666666666,"['baseline', 'week', 'change', 'analysis of covariance', 'calculate', 'to']","['baseline', 'week', 'change', 'calculate']",,,,
755,750,we report the values for the secondary analyses as point estimates and 95 % confidence intervals .,我们将二次分析的值报告为点估计值和 95% 置信区间。,0.2222222222222222,"['report', 'secondary', 'values', 'point', 'as', 'confidence', 'and', 'intervals', 'we']","['report', 'point']",750,['我们将二次分析的值报告为点估计和95%的信任间隔。'],0.2222222222222222,"['report', 'secondary', 'values', 'point', 'as', 'confidence', 'and', 'intervals', 'we']","['report', 'point']",750,我们将次要分析的结果报告为点估计值和95%的置信区间。,0.2222222222222222,"['report', 'secondary', 'values', 'point', 'as', 'confidence', 'and', 'intervals', 'we']","['report', 'point']",,,,
756,751,"the confidence intervals have not been adjusted for multiple comparisons , so inferences drawn from them may not be reproducible .",置信区间未针对多重比较进行调整，因此从中得出的推论可能无法重现。,0.1666666666666666,"['multiple', 'be', 'confidence', 'have not', 'so', 'intervals']",['have not'],751,"['信任间隔未适用于多个比较,因此从中提取的结论可能无法重复。']",0.1666666666666666,"['multiple', 'be', 'confidence', 'have not', 'so', 'intervals']",['have not'],751,这些置信区间未经过多重比较调整，因此从中得出的结论可能无法复制。,0.1666666666666666,"['multiple', 'be', 'confidence', 'have not', 'so', 'intervals']",['have not'],,,,
757,752,"of these patients , 2 did not receive a trial regimen , leaving 152 in the safety population .",在这些患者中，有 2 名未接受试验方案，剩下 152 名在安全人群中。,0.6,"['safety', 'population', '2', 'trial', 'in']","['safety', 'population', '2']",752,"['这些病人中有2人没有接受试验制度,在安全人口中留下了152人。']",0.6,"['safety', 'population', '2', 'trial', 'in']","['safety', 'population', '2']",752,这些病人中，有2人没有接受试验方案，剩下152人在安全性研究人群中。,0.6,"['safety', 'population', '2', 'trial', 'in']","['safety', 'population', '2']",,,,
758,753,the baseline characteristics were similar in the two groups ( Table 1 ) .,两组的基线特征相似（表 1）。,0.8333333333333334,"['table', 'baseline', '1', 'characteristics', 'two', 'similar']","['table', 'baseline', '1', 'characteristics', 'two']",753,['基线特征在两组中是相似的(图1)。'],0.8333333333333334,"['table', 'baseline', '1', 'characteristics', 'two', 'similar']","['baseline', '1', 'characteristics', 'two', 'similar']",753,基线特征在两组中相似(表1)。,0.8333333333333334,"['table', 'baseline', '1', 'characteristics', 'two', 'similar']","['table', 'baseline', '1', 'characteristics', 'two']",,,,
759,754,the mean baseline hemoglobin level was 8.9 ± 0.8 g per deciliter in the roxadustat group and 8.9 ± 0.7 g per deciliter in the placebo group .,罗沙司他组的平均基线血红蛋白水平为每分升 8.9 ± 0.8 克，安慰剂组为每分升 8.9 ± 0.7 克。,0.625,"['group', 'placebo', 'mean', 'baseline', 'deciliter', 'hemoglobin level', 'roxadustat', 'and']","['group', 'placebo', 'mean', 'baseline', 'roxadustat']",754,"['平均基因血糖水平在Roxadustat组中为8.9 ± 0.8 克,在 placebo组中为8.9 ± 0.7 克。']",0.25,"['group', 'placebo', 'mean', 'baseline', 'deciliter', 'hemoglobin level', 'roxadustat', 'and']","['group', 'mean']",754,在roxadustat组，平均基线血红蛋白水平为8.9±0.8克每分升，在安慰剂组为8.9±0.7克每分升。,0.5,"['group', 'placebo', 'mean', 'baseline', 'deciliter', 'hemoglobin level', 'roxadustat', 'and']","['group', 'placebo', 'mean', 'baseline']",,,,
760,755,"of note , 82 of 152 patients ( 54 % ) had a transferrin saturation of 20 % or more , and 58 patients ( 38 % ) had a ferritin level of 200 μg per liter or more .",值得注意的是，152 名患者中有 82 名 (54%) 的转铁蛋白饱和度为 20% 或更高，58 名患者 (38%) 的铁蛋白水平为 200 μg/L 或更高。,0.7142857142857143,"['ferritin', 'transferrin', 'liter', 'saturation', 'note', 'level', 'and']","['ferritin', 'transferrin', 'saturation', 'note', 'level']",755,"['值得注意的是,152名患者中有82人(54%)患有20%或以上的转移林饱和,58人(38%)患有200 μg或以上的费里丁。']",0.2857142857142857,"['ferritin', 'transferrin', 'liter', 'saturation', 'note', 'level', 'and']","['saturation', 'note']",755,值得注意的是，152名患者中有82名（54%）的转铁蛋白饱和度达到了20%或更高，而58名患者（38%）的铁素水平达到了200微克/升或更高。,1.0,"['ferritin', 'transferrin', 'liter', 'saturation', 'note', 'level', 'and']","['ferritin', 'transferrin', 'liter', 'saturation', 'note', 'level', 'and']",,,,
761,756,randomized PHASE,随机阶段,,[],[],756,['随机阶段'],,[],[],756,随机阶段,,[],[],,,,
762,757,"rescue therapy was administered to 3 patients ( 3 % ) in the roxadustat group and 6 patients ( 12 % ) in the placebo group ( hazard ratio , 0.11 ; 95 % CI , 0.02 to 0.51 ) .",对罗沙司他组的 3 名患者 (3%) 和安慰剂组的 6 名患者 (12%) 进行了挽救治疗（风险比，0.11；95% CI，0.02 至 0.51）。,0.4545454545454545,"['group', 'placebo', 'hazard ratio', 'therapy', '3', 'roxadustat', 'CI', 'in', 'to', 'and', 'rescue']","['group', 'placebo', 'hazard ratio', 'therapy', 'roxadustat']",757,"['救生疗法适用于Roxadustat群体的3名患者(3%)和 placebo群体的6名患者(12%)(风险比例,0.11;95% CI,0.02至0.51)。']",0.3636363636363636,"['group', 'placebo', 'hazard ratio', 'therapy', '3', 'roxadustat', 'CI', 'in', 'to', 'and', 'rescue']","['group', 'hazard ratio', 'therapy', 'to']",757,救治疗法被给予3名患者（3％）在roxadustat组和6名患者（12％）在安慰剂组（危险比，0.11；95％CI，0.02至0.51）。,0.2727272727272727,"['group', 'placebo', 'hazard ratio', 'therapy', '3', 'roxadustat', 'CI', 'in', 'to', 'and', 'rescue']","['group', 'placebo', 'therapy']",,,,
763,758,hepcidin and Iron Levels,铁调素和铁水平,0.5,"['iron', 'and']",['iron'],758,['Hepcidin 和 Iron 水平'],0.0,"['iron', 'and']",[],758,"Hepcidin is a hormone that regulates iron levels in the body. High levels of hepcidin can lead to iron deficiency, while low levels can lead to iron overload.",0.0,"['iron', 'and']",[],,,,
764,759,"among patients in the roxadustat group , the serum iron level was clinically stable during the randomized phase and did not differ significantly from the level in the placebo group , despite robust erythropoiesis ( Table 2 ) .",在罗沙司他组的患者中，血清铁水平在随机阶段临床稳定，与安慰剂组的水平无显着差异，尽管红细胞生成强劲（表 2）。,0.7142857142857143,"['group', 'erythropoiesis', 'placebo', 'table', 'phase', '2', 'serum', 'differ', 'level', 'despite', 'roxadustat', 'iron', 'in', 'and']","['group', 'erythropoiesis', 'placebo', 'table', 'phase', '2', 'serum', 'level', 'roxadustat', 'iron']",759,"['在Roxadustat群体的患者中,血清铁水平在随机阶段临床上稳定,并且与 placebo群体的水平没有显著差异,尽管强烈的甲状腺炎(图2)。']",0.4285714285714285,"['group', 'erythropoiesis', 'placebo', 'table', 'phase', '2', 'serum', 'differ', 'level', 'despite', 'roxadustat', 'iron', 'in', 'and']","['group', 'phase', '2', 'serum', 'level', 'iron']",759,"在roxadustat组的患者中，血清铁水平在随机阶段是稳定的，并且与安慰剂组相比没有显著差异，尽管有强有力的红细胞生成。

Chinese:

在roxadustat组的患者中，血清铁水平在随机阶段是稳定的，并且与安慰剂组相比没有显著差异，尽管有强有力的红细胞生成（表2）。",0.6428571428571429,"['group', 'erythropoiesis', 'placebo', 'table', 'phase', '2', 'serum', 'differ', 'level', 'despite', 'roxadustat', 'iron', 'in', 'and']","['group', 'erythropoiesis', 'placebo', 'table', 'phase', '2', 'serum', 'level', 'iron']",,,,
765,760,"in the roxadustat group , transferrin levels and total iron binding capacity increased , with a temporary decrease in the transferrin saturation from 20.6 % to 15.6 % at week 9 during a period of increased iron utilization in which the mean increase in hemoglobin was 1.9 g per deciliter .",在roxadustat组中，转铁蛋白水平和总铁结合力增加，转铁蛋白饱和度在第9周从20.6 %暂时下降至15.6 %，期间铁利用增加，血红蛋白平均增加1.9 g/dL。 .,0.5263157894736842,"['group', 'capacity', 'period', 'transferrin', 'decrease', 'mean', 'utilization', 'temporary', 'hemoglobin', 'deciliter', 'total', 'saturation', 'week', 'increase', 'with', 'roxadustat', 'binding', 'iron', 'and']","['group', 'period', 'transferrin', 'mean', 'utilization', 'hemoglobin', 'saturation', 'week', 'binding', 'iron']",760,"['在Roxadustat群体中,转移素水平和总铁粘容量增加,转移素饱和量从9周的20.6%减少到15.6%在增加铁使用期间,平均血球含量增加为1.9g每分升。']",0.4210526315789473,"['group', 'capacity', 'period', 'transferrin', 'decrease', 'mean', 'utilization', 'temporary', 'hemoglobin', 'deciliter', 'total', 'saturation', 'week', 'increase', 'with', 'roxadustat', 'binding', 'iron', 'and']","['group', 'capacity', 'period', 'decrease', 'mean', 'saturation', 'week', 'iron']",760,在roxadustat组，转铁蛋白水平和总铁结合能力增加，转铁蛋白饱和度在明显增加的铁利用期间（红细胞增加1.9克/分升）暂时从20.6％下降到15.6％。,0.4210526315789473,"['group', 'capacity', 'period', 'transferrin', 'decrease', 'mean', 'utilization', 'temporary', 'hemoglobin', 'deciliter', 'total', 'saturation', 'week', 'increase', 'with', 'roxadustat', 'binding', 'iron', 'and']","['group', 'capacity', 'period', 'transferrin', 'utilization', 'saturation', 'binding', 'iron']",,,,
766,761,"in the placebo group , iron levels and related measures on average were stable during the randomized phase .",在安慰剂组中，铁水平和相关指标在随机阶段平均保持稳定。,0.7142857142857143,"['group', 'placebo', 'average', 'phase', 'iron', 'in', 'and']","['group', 'placebo', 'average', 'phase', 'iron']",761,"['在 placebo 群体中,铁水平和相关测量平均在随机阶段保持稳定。']",0.5714285714285714,"['group', 'placebo', 'average', 'phase', 'iron', 'in', 'and']","['group', 'average', 'phase', 'iron']",761,在安慰剂组，铁水平和相关措施平均在随机阶段保持稳定。,0.7142857142857143,"['group', 'placebo', 'average', 'phase', 'iron', 'in', 'and']","['group', 'placebo', 'average', 'phase', 'iron']",,,,
767,762,cholesterol Levels,胆固醇水平,1.0,['cholesterol'],['cholesterol'],762,['胆固醇水平'],1.0,['cholesterol'],['cholesterol'],762,Cholesterol levels,0.0,['cholesterol'],[],,,,
768,763,"at baseline , the mean total cholesterol level was 172.8 ± 45.8 mg per deciliter ( 4.5 ± 1.2 mmol per liter ) in the roxadustat group and 181.4 ± 49.0 mg per deciliter ( 4.7 ± 1.3 mmol per liter ) in the placebo group .",基线时，罗沙司他组的平均总胆固醇水平为 172.8 ± 45.8 毫克每分升（4.5 ± 1.2 毫摩尔每升），安慰剂组为 181.4 ± 49.0 毫克每分升（4.7 ± 1.3 毫摩尔每升）。,0.7,"['cholesterol', 'group', 'placebo', 'mean', 'baseline', 'deciliter', 'total', 'level', 'roxadustat', 'and']","['cholesterol', 'group', 'placebo', 'mean', 'baseline', 'level', 'roxadustat']",763,"['在基线上,平均总胆固醇水平为172.8 ± 45.8 毫克(4.5 ± 1.2 mmol 每升)在 roxadustat 组和181.4 ± 49.0 毫克(4.7 ± 1.3 mmol 每升)在 placebo 组。']",0.5,"['cholesterol', 'group', 'placebo', 'mean', 'baseline', 'deciliter', 'total', 'level', 'roxadustat', 'and']","['cholesterol', 'group', 'mean', 'baseline', 'level']",763,在基线时，罗沙达斯特组的平均总胆固醇水平为172.8±45.8毫克/分升（4.5±1.2毫摩尔/升），而安慰剂组为181.4±49.0毫克/分升（4.7±1.3毫摩尔/升）。,0.7,"['cholesterol', 'group', 'placebo', 'mean', 'baseline', 'deciliter', 'total', 'level', 'roxadustat', 'and']","['cholesterol', 'group', 'placebo', 'mean', 'baseline', 'level', 'and']",,,,
769,764,safety and Adverse Events,安全和不良事件,0.3333333333333333,"['safety', 'adverse', 'and']",['safety'],764,['安全和不良事件'],0.3333333333333333,"['safety', 'adverse', 'and']",['safety'],764,"safety and Adverse Events

中文:

安全性和不良事件",0.3333333333333333,"['safety', 'adverse', 'and']",['safety'],,,,
770,765,one patient in each group discontinued participation in the trial because of hyperkalemia .,每组中有一名患者因高钾血症而停止参与试验。,0.5714285714285714,"['group', 'hyperkalemia', 'patient', 'trial', 'participation', 'each', 'in']","['group', 'hyperkalemia', 'patient', 'participation']",765,['每个群体中有1名患者因催眠症而停止参加试验。'],0.2857142857142857,"['group', 'hyperkalemia', 'patient', 'trial', 'participation', 'each', 'in']","['group', 'patient']",765,"一组患者因高钾血症而退出了试验。

中文：

每组有一位患者因高钾血症而退出了本次试验。",0.4285714285714285,"['group', 'hyperkalemia', 'patient', 'trial', 'participation', 'each', 'in']","['group', 'hyperkalemia', 'patient']",,,,
771,766,local laboratory values were not collected .,未收集当地实验室值。,0.3333333333333333,"['local', 'laboratory', 'values']",['laboratory'],766,['當地實驗室價值未被收集。'],0.0,"['local', 'laboratory', 'values']",[],766,"local laboratory values were not collected.

Chinese:
当地实验室数值未收集。",0.3333333333333333,"['local', 'laboratory', 'values']",['laboratory'],,,,
772,767,"in the roxadustat group , the percentages of patients with a serum bicarbonate level of 21 mmol per liter or less were 92 % at baseline and 91 % at 9 weeks .",在罗沙司他组中，血清碳酸氢盐水平为 21 毫摩尔/升或更低的患者百分比在基线时为 92%，在 9 周时为 91%。,0.7777777777777778,"['group', 'liter', 'bicarbonate', 'baseline', 'serum', 'level', 'with', 'roxadustat', 'and']","['group', 'liter', 'bicarbonate', 'baseline', 'serum', 'level', 'roxadustat']",767,"['在 roxadustat 群体中,血清二氧化碳含量为 21 mmol 或低于 1 升的患者的百分比在基线上为 92%,在 9 周内为 91 %.']",0.4444444444444444,"['group', 'liter', 'bicarbonate', 'baseline', 'serum', 'level', 'with', 'roxadustat', 'and']","['group', 'liter', 'baseline', 'serum']",767,在roxadustat组，基线时血清碳酸氢盐水平为21毫克/升或更低的患者百分比为92％，9周时为91％。,0.6666666666666666,"['group', 'liter', 'bicarbonate', 'baseline', 'serum', 'level', 'with', 'roxadustat', 'and']","['group', 'liter', 'bicarbonate', 'baseline', 'serum', 'level']",,,,
773,768,"in the placebo group , the percentages were 96 % at baseline and 89 % at 9 weeks ( Table S4 in the Supplementary Appendix ) .",在安慰剂组中，该百分比在基线时为 96%，在 9 周时为 89%（补充附录表 S4）。,0.4444444444444444,"['group', 'placebo', 'appendix', 'table', 'baseline', 'supplementary', 'at', 'S4', 'and']","['group', 'placebo', 'table', 'baseline']",768,"['在 placebo 群体中,百分比为 96% 基线和 89% 9 周(附件中的 S4 表)。']",0.4444444444444444,"['group', 'placebo', 'appendix', 'table', 'baseline', 'supplementary', 'at', 'S4', 'and']","['group', 'appendix', 'table', 'baseline']",768,在安慰剂组，基线时的百分比为96％，而9周时则为89％（见补充附件表S4）。,0.6666666666666666,"['group', 'placebo', 'appendix', 'table', 'baseline', 'supplementary', 'at', 'S4', 'and']","['group', 'placebo', 'appendix', 'table', 'baseline', 'and']",,,,
774,769,"serious adverse events , which were consistent with those generally seen in patients with chronic kidney disease , were reported in 9 patients ( 9 % ) in the roxadustat group and in 6 patients ( 12 % ) in the placebo group ( Table 3 ) .",罗沙司他组 9 名患者 (9%) 和安慰剂组 6 名患者 (12%) 报告了与慢性肾病患者常见的严重不良事件（表 3）。,0.5384615384615384,"['group', 'placebo', 'kidney', 'disease', 'table', 'adverse', 'chronic', '3', 'with', 'roxadustat', 'serious', 'in', 'and']","['group', 'placebo', 'kidney', 'disease', 'table', 'chronic', 'roxadustat']",769,"['严重的副作用,与患有慢性肾脏疾病的患者常见相一致,报告了9名患者(9%)在Roxadustat群体和6名患者(12%)在 placebo群体(图3)。']",0.3076923076923077,"['group', 'placebo', 'kidney', 'disease', 'table', 'adverse', 'chronic', '3', 'with', 'roxadustat', 'serious', 'in', 'and']","['group', 'kidney', 'disease', 'chronic']",769,严重的不良事件在罗莎达司组的9名患者（9%）和安慰剂组的6名患者（12%）中均报告，与慢性肾脏病患者通常观察到的情况一致（表3）。,0.4615384615384615,"['group', 'placebo', 'kidney', 'disease', 'table', 'adverse', 'chronic', '3', 'with', 'roxadustat', 'serious', 'in', 'and']","['group', 'placebo', 'kidney', 'disease', 'table', 'chronic']",,,,
775,770,there were no deaths during the randomized phase of the trial .,在试验的随机阶段没有死亡。,0.3333333333333333,"['phase', 'no', 'trial']",['phase'],770,['在审判的随机阶段没有死亡。'],0.6666666666666666,"['phase', 'no', 'trial']","['phase', 'trial']",770,在随机化阶段，没有发生死亡事件。,0.3333333333333333,"['phase', 'no', 'trial']",['phase'],,,,
776,771,an increase in the level of alanine aminotransferase ( ALT ) or aspartate aminotransferase ( AST ) occurred in 2 patients in the roxadustat group and 1 patient in the placebo group ( 2 % in each group ) .,丙氨酸氨基转移酶 (ALT) 或天冬氨酸氨基转移酶 (AST) 水平升高发生在罗沙司他组 2 名患者和安慰剂组 1 名患者（每组 2%）。,0.5714285714285714,"['group', 'placebo', '1', '2', 'alanine aminotransferase', 'AST', 'ALT', 'aspartate aminotransferase', 'patient', 'level', 'increase', 'roxadustat', 'each', 'and']","['group', 'placebo', '1', '2', 'alanine aminotransferase', 'patient', 'level', 'roxadustat']",771,['阿拉丁氨基转移剂(ALT)或阿斯帕特氨基转移剂(AST)的水平增加发生在罗克萨多斯塔特群体的2名患者和 placebo群体的1名患者(每个群体的2%)。'],0.3571428571428571,"['group', 'placebo', '1', '2', 'alanine aminotransferase', 'AST', 'ALT', 'aspartate aminotransferase', 'patient', 'level', 'increase', 'roxadustat', 'each', 'and']","['group', '1', '2', 'patient', 'level']",771,在roxadustat组，2名病人的丙氨酸转移酶（ALT）或天门冬氨酸转移酶（AST）水平升高，在安慰剂组1名病人（分别为两组的2％）。,0.4285714285714285,"['group', 'placebo', '1', '2', 'alanine aminotransferase', 'AST', 'ALT', 'aspartate aminotransferase', 'patient', 'level', 'increase', 'roxadustat', 'each', 'and']","['group', 'placebo', '1', '2', 'patient', 'level']",,,,
777,772,"in the roxadustat group , 1 patient who had a grade 1 elevation in ALT and AST had a spontaneous normalization in the level without any change in the drug regimen ; a second patient had a grade 2 elevation in ALT and AST that was reported 2 days after receipt of the last dose of roxadustat during the trial while the patient was receiving concomitant medications known to be associated with an elevation in liver enzyme levels .",在罗沙司他组中，1 名 ALT 和 AST 出现 1 级升高的患者在药物治疗方案没有任何变化的情况下自发恢复正常；第二名患者的 ALT 和 AST 出现 2 级升高，在试验期间接受最后一剂 roxadustat 后 2 天报告，当时该患者正在接受已知与肝酶水平升高相关的伴随药物治疗。,0.4482758620689655,"['group', 'liver', 'elevation', 'enzyme', 'who', '1', '2', 'spontaneous', 'AST', 'grade', 'ALT', 'be', 'concomitant', 'associated', 'normalization', 'patient', 'after', 'trial', 'level', 'change', 'drug', 'roxadustat', 'dose', 'second', 'that', 'in', 'to', 'and', 'without']","['group', 'liver', 'enzyme', '1', '2', 'be', 'patient', 'after', 'level', 'change', 'drug', 'roxadustat', 'in']",772,"['在Roxadustat群体中,1名患有1级 ALT 和 AST 的患者在药物制度中没有任何变化的情况下在水平上自发正常化;2名患有2级 ALT 和 AST 的患者在测试期间接收Roxadustat的最后剂量后近2天,而患者在接受同步药物时已知与肝酶水平的上升有关。']",0.5517241379310345,"['group', 'liver', 'elevation', 'enzyme', 'who', '1', '2', 'spontaneous', 'AST', 'grade', 'ALT', 'be', 'concomitant', 'associated', 'normalization', 'patient', 'after', 'trial', 'level', 'change', 'drug', 'roxadustat', 'dose', 'second', 'that', 'in', 'to', 'and', 'without']","['group', 'liver', 'elevation', 'enzyme', '1', '2', 'grade', 'be', 'normalization', 'patient', 'after', 'level', 'change', 'drug', 'dose', 'and']",772,在roxadustat组中，1名患有1级高脂肪水解酶水平升高的病人在药物方案没有任何变化的情况下自行正常化；第2名患者在试验期间在接受共同药物治疗期间接受最后一剂roxadustat治疗2天后报告肝脏酶水平升高2级。,0.4137931034482758,"['group', 'liver', 'elevation', 'enzyme', 'who', '1', '2', 'spontaneous', 'AST', 'grade', 'ALT', 'be', 'concomitant', 'associated', 'normalization', 'patient', 'after', 'trial', 'level', 'change', 'drug', 'roxadustat', 'dose', 'second', 'that', 'in', 'to', 'and', 'without']","['group', 'liver', 'enzyme', '1', '2', 'be', 'normalization', 'patient', 'after', 'level', 'change', 'drug']",,,,
778,773,"among the patients who had initially received placebo , the mean hemoglobin level increased from baseline by 2.0 ± 1.5 g per deciliter after crossover to receive roxadustat ; 31 of 43 patients ( 72 % ) had a hemoglobin level of more than 11.0 g per deciliter , and 37 ( 86 % ) had a hemoglobin level of 10.0 g per deciliter or more during weeks 23 through 27 .",在最初接受安慰剂的患者中，平均血红蛋白水平在交叉接受罗沙司他后较基线增加了 2.0 ± 1.5 g/dL； 43 名患者中有 31 名 (72%) 的血红蛋白水平超过 11.0 g/dL，37 名 (86%) 在第 23 至 27 周期间血红蛋白水平为 10.0 g/dL 或更高。,0.4545454545454545,"['placebo', 'mean', 'who', 'baseline', 'deciliter', 'hemoglobin level', 'after', 'roxadustat', 'by', 'to', 'and']","['placebo', 'mean', 'baseline', 'after', 'roxadustat']",773,"['在接受 placebo 的患者中,平均血球水平从基线上增加了 2.0 ± 1.5 克每分克后交叉接收Roxadustat;在 43 名患者中,31 名患者( 72% )的血球水平超过 11.0 克每分克;在 37 名患者( 86%)的血球水平在 23 至 27 周内超过 10.0 克每分克。']",0.3636363636363636,"['placebo', 'mean', 'who', 'baseline', 'deciliter', 'hemoglobin level', 'after', 'roxadustat', 'by', 'to', 'and']","['mean', 'baseline', 'after', 'by']",773,在最初接受了安慰剂的患者中，平均血红蛋白水平在转换到接受罗沙达斯特后从基线上升了2.0±1.5 g/dL；31名患者（72%）的血红蛋白水平在23-27周期间超过了11.0 g/dL，37名患者（86%）的血红蛋白水平在期间达到了10.0 g/dL或以上。,0.4545454545454545,"['placebo', 'mean', 'who', 'baseline', 'deciliter', 'hemoglobin level', 'after', 'roxadustat', 'by', 'to', 'and']","['placebo', 'mean', 'baseline', 'after', 'by']",,,,
779,774,the primary efficacy analysis showed a significantly larger increase in the hemoglobin level from baseline over weeks 7 to 9 in the roxadustat group than in the placebo group ( an increase of 1.9 ± 1.2 g per deciliter vs. a decrease of 0.4 ± 0.8 g per deciliter ) .,主要疗效分析显示，与安慰剂组相比，在第 7 周至第 9 周期间，罗沙司他组的血红蛋白水平相对于基线的增幅明显更大（增加 1.9 ± 1.2 g/dL 对比减少 0.4 ± 0.8 g/dL ) 。,0.5384615384615384,"['group', 'placebo', 'decrease', 'analysis', 'baseline', 'deciliter', 'hemoglobin level', 'primary', 'efficacy', 'increase', 'roxadustat', 'over', 'to']","['group', 'placebo', 'decrease', 'analysis', 'baseline', 'roxadustat', 'to']",774,"['初级效能分析显示,在Roxadustat组的7至9周内,血球水平显著增加(每分克增加1.9 ± 1.2 克,每分克减少0.4 ± 0.8 克)。']",0.3076923076923077,"['group', 'placebo', 'decrease', 'analysis', 'baseline', 'deciliter', 'hemoglobin level', 'primary', 'efficacy', 'increase', 'roxadustat', 'over', 'to']","['group', 'decrease', 'analysis', 'efficacy']",774,主要疗效分析显示，roxadustat组患者的红细胞计数较基线上升了1.9±1.2 g/dL，而安慰剂组的红细胞计数则下降了0.4±0.8 g/dL。,0.3076923076923077,"['group', 'placebo', 'decrease', 'analysis', 'baseline', 'deciliter', 'hemoglobin level', 'primary', 'efficacy', 'increase', 'roxadustat', 'over', 'to']","['group', 'placebo', 'analysis', 'baseline']",,,,
780,775,"similarly , other hemoglobin end points , such as the percentage of patients who had a hemoglobin response ( i.e. , an increase of ≥ 1.0 g per deciliter from baseline ) or who did not receive rescue therapy , were greater in the roxadustat group than in the placebo group .",类似地，其他血红蛋白终点，例如有血红蛋白反应（即从基线增加≥1.0 g/dL）或未接受挽救治疗的患者百分比，罗沙司他组高于安慰剂组。团体 。,0.6153846153846154,"['group', 'percentage', 'placebo', 'who', 'baseline', 'hemoglobin', 'deciliter', 'therapy', 'end points', 'response', 'increase', 'roxadustat', 'rescue']","['group', 'placebo', 'baseline', 'hemoglobin', 'therapy', 'end points', 'response', 'roxadustat']",775,"['同樣,其他血球結末點,例如患有血球反應(即從基線增加 ≥ 1.0 g 每分鐘)或沒有接受救援治療的患者的比例,在Roxadustat群體中比在 placebo群體中更高。']",0.1538461538461538,"['group', 'percentage', 'placebo', 'who', 'baseline', 'hemoglobin', 'deciliter', 'therapy', 'end points', 'response', 'increase', 'roxadustat', 'rescue']","['group', 'rescue']",775,"类似地，其他血红蛋白终点，例如血红蛋白反应率（即基线上升≥1.0 g/dL的患者）或未接受救治的患者的百分比，在罗沙司他组中均高于安慰剂组。

Chinese:
类似地，其他血红蛋白终点，例如血红蛋白反应率（即基线上升≥1.0 g/dL的患者）或未接受救治的患者的百分比，在罗沙司他组中均高于安慰剂组。",0.5384615384615384,"['group', 'percentage', 'placebo', 'who', 'baseline', 'hemoglobin', 'deciliter', 'therapy', 'end points', 'response', 'increase', 'roxadustat', 'rescue']","['group', 'placebo', 'baseline', 'hemoglobin', 'end points', 'response', 'roxadustat']",,,,
781,776,"in spite of the robust erythropoiesis and the restriction of intravenous administration of iron in the roxadustat group , serum iron levels remained stable .",尽管 roxadustat 组红细胞生成旺盛且静脉注射铁剂受到限制，但血清铁水平仍保持稳定。,0.4444444444444444,"['group', 'erythropoiesis', 'administration', 'serum', 'restriction', 'intravenous', 'roxadustat', 'iron', 'and']","['group', 'erythropoiesis', 'serum', 'iron']",776,"['尽管坚固的甲状腺炎和罗克萨多斯塔特群体中的铁的内分泌限制,但血清铁的水平仍然稳定。']",0.3333333333333333,"['group', 'erythropoiesis', 'administration', 'serum', 'restriction', 'intravenous', 'roxadustat', 'iron', 'and']","['group', 'serum', 'iron']",776,尽管 Roxadustat 组的红细胞生成强壮，但血液铁水平仍保持稳定。,0.3333333333333333,"['group', 'erythropoiesis', 'administration', 'serum', 'restriction', 'intravenous', 'roxadustat', 'iron', 'and']","['group', 'erythropoiesis', 'iron']",,,,
782,777,"we found that in addition to the erythropoietic effects of roxadustat , the drug was associated with reduced levels of hepcidin and cholesterol .",我们发现除了 roxadustat 的红细胞生成作用外，该药物还与铁调素和胆固醇水平降低有关。,0.1666666666666666,"['cholesterol', 'addition', 'erythropoietic', 'associated', 'with', 'drug', 'roxadustat', 'that', 'in', 'to', 'and', 'we']","['cholesterol', 'drug']",777,"['我们发现,除了Roxadustat的勃起作用之外,该药物与低水平的肝炎和胆固醇有关。']",0.1666666666666666,"['cholesterol', 'addition', 'erythropoietic', 'associated', 'with', 'drug', 'roxadustat', 'that', 'in', 'to', 'and', 'we']","['cholesterol', 'drug']",777,我们发现除了药物罗达瑟的促进血红蛋白生成作用外，该药物还与降低肝素和胆固醇水平相关联。,0.1666666666666666,"['cholesterol', 'addition', 'erythropoietic', 'associated', 'with', 'drug', 'roxadustat', 'that', 'in', 'to', 'and', 'we']","['cholesterol', 'drug']",,,,
783,778,"we speculate that the stability of serum iron levels in the roxadustat group may have been driven by reductions in hepcidin levels , which permitted the gut absorption of iron and improved the release of macrophage iron onto transferrin.26",我们推测，roxadustat 组血清铁水平的稳定可能是由于 hepcidin 水平降低所致，这允许肠道吸收铁并促进巨噬细胞将铁释放到转铁蛋白上。 26,0.5333333333333333,"['group', 'gut', 'absorption', 'macrophage', 'release', 'serum', 'roxadustat', 'iron', 'stability', 'have', 'that', 'in', 'by', 'and', 'we']","['group', 'gut', 'absorption', 'macrophage', 'release', 'serum', 'iron', 'by']",778,"['我们猜测,罗克萨德斯塔特群体的血清铁水平的稳定性可能被肝素水平的下降所驱动,这使得肠道吸收铁,并改善转移铁的释放。']",0.4666666666666667,"['group', 'gut', 'absorption', 'macrophage', 'release', 'serum', 'roxadustat', 'iron', 'stability', 'have', 'that', 'in', 'by', 'and', 'we']","['group', 'gut', 'absorption', 'release', 'serum', 'iron', 'stability']",778,我们推测罗莎达斯特组中血清铁水平的稳定性可能是由血清肝铁蛋白水平的降低所驱动的，这样可以促进肠道铁的吸收并改善巨噬细胞铁转移到转铁蛋白上的释放。26,0.6,"['group', 'gut', 'absorption', 'macrophage', 'release', 'serum', 'roxadustat', 'iron', 'stability', 'have', 'that', 'in', 'by', 'and', 'we']","['group', 'gut', 'absorption', 'macrophage', 'release', 'serum', 'iron', 'stability', 'by']",,,,
784,779,"previous studies involving patients with chronic kidney disease who were not undergoing dialysis have shown that roxadustat increased hemoglobin levels with stable serum iron levels , despite robust erythropoiesis in the absence of intravenous administration of iron.23,25","先前对未接受透析的慢性肾病患者的研究表明，尽管在没有静脉注射铁剂的情况下红细胞生成旺盛，罗沙司他仍可增加血红蛋白水平和稳定的血清铁水平。 23,25",0.5555555555555556,"['dialysis', 'erythropoiesis', 'kidney', 'disease', 'who', 'hemoglobin', 'administration', 'previous', 'serum', 'chronic', 'absence', 'intravenous', 'with', 'despite', 'roxadustat', 'iron', 'have', 'that']","['dialysis', 'erythropoiesis', 'kidney', 'disease', 'hemoglobin', 'serum', 'chronic', 'roxadustat', 'iron', 'have']",779,"['以前的研究涉及患有慢性肾脏疾病的患者,他们没有接受诊断,发现Roxadustat增加了血球水平与稳定的血清铁水平,尽管在缺乏血管内铁的强度勃起。']",0.4444444444444444,"['dialysis', 'erythropoiesis', 'kidney', 'disease', 'who', 'hemoglobin', 'administration', 'previous', 'serum', 'chronic', 'absence', 'intravenous', 'with', 'despite', 'roxadustat', 'iron', 'have', 'that']","['kidney', 'disease', 'previous', 'serum', 'chronic', 'absence', 'iron', 'have']",779,"过去涉及未接受透析的慢性肾脏病患者的研究表明，即使在没有静脉注射铁的情况下，肌苷也能使血红蛋白水平升高，同时血清铁水平稳定。23,25",0.4444444444444444,"['dialysis', 'erythropoiesis', 'kidney', 'disease', 'who', 'hemoglobin', 'administration', 'previous', 'serum', 'chronic', 'absence', 'intravenous', 'with', 'despite', 'roxadustat', 'iron', 'have', 'that']","['dialysis', 'kidney', 'disease', 'hemoglobin', 'serum', 'chronic', 'iron', 'have']",,,,
785,780,"in our trial , initial measures of iron suggested adequate baseline iron stores in only half the patients .",在我们的试验中，铁的初步测量表明只有一半的患者有足够的基线铁储存。,0.7142857142857143,"['baseline', 'half', 'initial', 'trial', 'adequate', 'iron', 'stores']","['baseline', 'half', 'initial', 'adequate', 'iron']",780,"['在我们的研究中,铁的初步测量表明,只有半数患者有足够的基铁仓库。']",0.5714285714285714,"['baseline', 'half', 'initial', 'trial', 'adequate', 'iron', 'stores']","['half', 'initial', 'adequate', 'iron']",780,在我们的试验中，铁的初始测量结果只有半数病人的铁储备足够充足。,0.4285714285714285,"['baseline', 'half', 'initial', 'trial', 'adequate', 'iron', 'stores']","['half', 'initial', 'iron']",,,,
786,781,"despite the absolute need for iron for erythropoiesis , roxadustat therapy corrected anemia and maintained hemoglobin levels in spite of lower transferrin saturation and progressive reduction in ferritin levels with only oral iron in moderate doses .",尽管红细胞生成绝对需要铁，但罗沙司他疗法纠正了贫血并维持了血红蛋白水平，尽管转铁蛋白饱和度较低，铁蛋白水平逐渐降低，仅口服中等剂量的铁。,0.6,"['anemia', 'erythropoiesis', 'ferritin', 'transferrin', 'need', 'hemoglobin', 'oral', 'absolute', 'reduction', 'progressive', 'moderate', 'lower', 'therapy', 'saturation', 'with', 'despite', 'roxadustat', 'iron', 'and', 'corrected']","['anemia', 'erythropoiesis', 'ferritin', 'transferrin', 'need', 'hemoglobin', 'absolute', 'reduction', 'therapy', 'saturation', 'roxadustat', 'iron']",781,"['尽管对甲状腺炎的铁的绝对需要,但Roxadustat治疗修复了贫血和维持了血球水平,尽管过渡素的饱和度较低,并且费里丁水平的逐步下降,只有适度剂量的口腔铁。']",0.3,"['anemia', 'erythropoiesis', 'ferritin', 'transferrin', 'need', 'hemoglobin', 'oral', 'absolute', 'reduction', 'progressive', 'moderate', 'lower', 'therapy', 'saturation', 'with', 'despite', 'roxadustat', 'iron', 'and', 'corrected']","['anemia', 'need', 'absolute', 'therapy', 'saturation', 'iron']",781,尽管需要铁来促进血红蛋白的生成，但瑞达达斯治疗可以纠正贫血，并维持血红蛋白水平，尽管转铁蛋白饱和度较低，红细胞增多素水平逐渐降低，只需要适量口服铁。,0.45,"['anemia', 'erythropoiesis', 'ferritin', 'transferrin', 'need', 'hemoglobin', 'oral', 'absolute', 'reduction', 'progressive', 'moderate', 'lower', 'therapy', 'saturation', 'with', 'despite', 'roxadustat', 'iron', 'and', 'corrected']","['anemia', 'ferritin', 'transferrin', 'need', 'hemoglobin', 'reduction', 'therapy', 'saturation', 'iron']",,,,
787,782,"serum iron , the more important component of the plasma iron content , can remain constant or increase even if the level of carrier protein increases .",血清铁是血浆铁含量中更重要的组成部分，即使载体蛋白水平升高，它也可以保持不变或升高。,0.6,"['component', 'carrier protein', 'plasma', 'content', 'serum', 'constant', 'increases', 'level', 'iron', 'if']","['carrier protein', 'plasma', 'content', 'serum', 'level', 'iron']",782,"['血清铁,血清铁含量最重要的组成部分,可以保持稳定或增加,即使携带蛋白质的水平增加。']",0.4,"['component', 'carrier protein', 'plasma', 'content', 'serum', 'constant', 'increases', 'level', 'iron', 'if']","['content', 'serum', 'level', 'iron']",782,血清铁是血浆铁含量中更重要的组成部分，即使载蛋白水平升高，血清铁水平也可能保持不变或增加。,0.5,"['component', 'carrier protein', 'plasma', 'content', 'serum', 'constant', 'increases', 'level', 'iron', 'if']","['plasma', 'content', 'serum', 'level', 'iron']",,,,
788,783,"in this trial and in the phase 2 studies of roxadustat , 25 transferrin levels increased in patients receiving roxadustat but not in those receiving placebo .",在该试验和 roxadustat 的 2 期研究中，25 转铁蛋白水平在接受 roxadustat 的患者中增加，但在接受安慰剂的患者中没有增加。,0.5555555555555556,"['placebo', 'transferrin', 'phase', '2', 'trial', 'roxadustat', 'this', 'but', 'and']","['placebo', 'transferrin', 'phase', '2', 'but']",783,"['在这项研究和Roxadustat的第二阶段研究中,在Roxadustat患者中,25个转移素水平增加,但不适用于 placebo患者。']",0.3333333333333333,"['placebo', 'transferrin', 'phase', '2', 'trial', 'roxadustat', 'this', 'but', 'and']","['phase', '2', 'but']",783,在这项试验和罗达司特的二期研究中，接受罗达司特治疗的患者转铁蛋白水平增加，而接受安慰剂治疗的患者转铁蛋白水平没有显著变化。,0.5555555555555556,"['placebo', 'transferrin', 'phase', '2', 'trial', 'roxadustat', 'this', 'but', 'and']","['placebo', 'transferrin', 'phase', 'but', 'and']",,,,
789,784,this increase is probably a direct effect of the stabilization in the HIF level by roxadustat .,这种增加可能是 roxadustat 稳定 HIF 水平的直接影响。,0.5,"['stabilization', 'effect', 'level', 'increase', 'direct', 'roxadustat', 'this', 'by']","['stabilization', 'level', 'direct', 'this']",784,['这种增加可能是Roxadustat在HIF水平的稳定性的直接影响。'],0.5,"['stabilization', 'effect', 'level', 'increase', 'direct', 'roxadustat', 'this', 'by']","['stabilization', 'level', 'direct', 'this']",784,这一增加可能是罗达斯塔特调节血红蛋白水平的直接效果。,0.5,"['stabilization', 'effect', 'level', 'increase', 'direct', 'roxadustat', 'this', 'by']","['effect', 'level', 'direct', 'this']",,,,
790,785,serum hepcidin levels were reduced in the patients who received roxadustat .,接受罗沙司他治疗的患者血清铁调素水平降低。,0.5,"['who', 'serum', 'roxadustat', 'in']","['serum', 'roxadustat']",785,['血清 hepcidin 水平在接受 roxadustat 的患者中降低。'],0.25,"['who', 'serum', 'roxadustat', 'in']",['serum'],785,病人在接受瑞达斯特治疗后，血清肝铁蛋白水平下降。,0.25,"['who', 'serum', 'roxadustat', 'in']",['serum'],,,,
791,786,maintenance of total serum iron levels permits adequate iron delivery and avoidance of functional iron deficiency .,维持血清总铁水平可以提供足够的铁并避免功能性缺铁。,0.4444444444444444,"['iron deficiency', 'functional', 'total', 'delivery', 'serum', 'adequate', 'avoidance', 'maintenance', 'and']","['iron deficiency', 'serum', 'adequate', 'maintenance']",786,"['保持整体血清铁水平,可提供适当的铁供应,避免功能铁缺乏。']",0.3333333333333333,"['iron deficiency', 'functional', 'total', 'delivery', 'serum', 'adequate', 'avoidance', 'maintenance', 'and']","['iron deficiency', 'serum', 'adequate']",786,维持血清总铁水平可以保证充足的铁输送并避免功能性铁缺乏。,0.3333333333333333,"['iron deficiency', 'functional', 'total', 'delivery', 'serum', 'adequate', 'avoidance', 'maintenance', 'and']","['iron deficiency', 'serum', 'maintenance']",,,,
792,787,this factor may indicate the need to reconsider the threshold of iron measures below which patients are considered to have iron depletion in order to determine which level will be most useful if HIF prolyl hydroxylase inhibitors become clinically available in the future .,这一因素可能表明需要重新考虑铁测量的阈值，低于该阈值的患者被认为铁耗竭，以确定如果 HIF 脯氨酰羟化酶抑制剂在未来临床上可用，哪个水平最有用。,0.5882352941176471,"['depletion', 'threshold', 'prolyl', 'need', 'factor', 'hydroxylase', 'indicate', 'available', 'level', 'will', 'iron', 'have', 'this', 'if', 'in order to', 'become', 'determine']","['depletion', 'threshold', 'prolyl', 'need', 'factor', 'hydroxylase', 'level', 'iron', 'have', 'in order to']",787,"['这种因素可能表明需要重新考虑患者被认为患有铁衰竭的铁措施的边界,以确定如果HIF prolyl hydroxylase 抑制剂在未来临床上可用,该水平将是最有用的。']",0.4117647058823529,"['depletion', 'threshold', 'prolyl', 'need', 'factor', 'hydroxylase', 'indicate', 'available', 'level', 'will', 'iron', 'have', 'this', 'if', 'in order to', 'become', 'determine']","['need', 'factor', 'level', 'iron', 'have', 'this', 'in order to']",787,这个因素可能表明需要重新考虑铁措施的阈值，低于该阈值的患者被认为患有铁耗竭，以便确定未来如果HIF丙二醛水解酶抑制剂获得临床应用时将会最有用的水平。,0.4705882352941176,"['depletion', 'threshold', 'prolyl', 'need', 'factor', 'hydroxylase', 'indicate', 'available', 'level', 'will', 'iron', 'have', 'this', 'if', 'in order to', 'become', 'determine']","['depletion', 'threshold', 'need', 'factor', 'level', 'iron', 'have', 'in order to']",,,,
793,788,"in our trial , total cholesterol levels decreased by 23 % during the initial 8 weeks of roxadustat therapy .",在我们的试验中，在罗沙司他治疗的最初 8 周内，总胆固醇水平降低了 23%。,0.5714285714285714,"['cholesterol', 'total', 'therapy', 'initial', 'trial', 'roxadustat', 'by']","['cholesterol', 'therapy', 'initial', 'roxadustat']",788,"['在我们的研究中,总胆固醇水平在Roxadustat治疗的初始8周期间下降了23%。']",0.4285714285714285,"['cholesterol', 'total', 'therapy', 'initial', 'trial', 'roxadustat', 'by']","['cholesterol', 'therapy', 'initial']",788,在我们的试验中，总胆固醇水平在罗沙达斯特疗法的最初8周内下降了23％。,0.4285714285714285,"['cholesterol', 'total', 'therapy', 'initial', 'trial', 'roxadustat', 'by']","['cholesterol', 'therapy', 'initial']",,,,
794,789,"among patients with chronic kidney disease , a high total cholesterol level is a major risk factor for cardiovascular disease.33",在患有慢性肾病的患者中，高总胆固醇水平是心血管疾病的主要危险因素。 33,0.6363636363636364,"['cholesterol', 'kidney', 'disease', 'cardiovascular', 'total', 'major', 'chronic', 'risk factor', 'level', 'with', 'high']","['cholesterol', 'kidney', 'disease', 'cardiovascular', 'chronic', 'level', 'high']",789,"['在患有慢性肾脏疾病的患者中,高胆固醇水平是心血管疾病的主要风险因素。']",0.7272727272727273,"['cholesterol', 'kidney', 'disease', 'cardiovascular', 'total', 'major', 'chronic', 'risk factor', 'level', 'with', 'high']","['cholesterol', 'kidney', 'disease', 'cardiovascular', 'chronic', 'risk factor', 'level', 'high']",789,在患有慢性肾脏疾病的患者中，高总胆固醇水平是心血管疾病的主要风险因素。33,0.7272727272727273,"['cholesterol', 'kidney', 'disease', 'cardiovascular', 'total', 'major', 'chronic', 'risk factor', 'level', 'with', 'high']","['cholesterol', 'kidney', 'disease', 'cardiovascular', 'chronic', 'risk factor', 'level', 'high']",,,,
795,790,there is evidence that statins reduce the risk of cardiovascular disease among patients with chronic kidney disease who are not undergoing dialysis.34,有证据表明，他汀类药物可降低未接受透析的慢性肾病患者患心血管疾病的风险。 34,0.7,"['kidney', 'who', 'reduce', 'statins', 'cardiovascular disease', 'chronic', 'risk', 'evidence', 'with', 'that']","['kidney', 'reduce', 'statins', 'cardiovascular disease', 'chronic', 'risk', 'evidence']",790,"['有证据表明,静脉在慢性肾脏疾病患者中降低了心血管疾病的风险,而不接受分泌。']",0.6,"['kidney', 'who', 'reduce', 'statins', 'cardiovascular disease', 'chronic', 'risk', 'evidence', 'with', 'that']","['kidney', 'reduce', 'cardiovascular disease', 'chronic', 'risk', 'evidence']",790,有证据表明，在未接受透析治疗的慢性肾脏病患者中，他们的心血管疾病风险显著降低。34,0.6,"['kidney', 'who', 'reduce', 'statins', 'cardiovascular disease', 'chronic', 'risk', 'evidence', 'with', 'that']","['kidney', 'reduce', 'cardiovascular disease', 'chronic', 'risk', 'evidence']",,,,
796,791,the frequencies of hyperkalemia and metabolic acidosis that were reported as adverse events were higher in the roxadustat group than in the placebo group .,罗沙司他组中作为不良事件报告的高钾血症和代谢性酸中毒的频率高于安慰剂组。,0.5,"['group', 'placebo', 'adverse', 'hyperkalemia', 'as', 'roxadustat', 'metabolic acidosis', 'that', 'in', 'and']","['group', 'placebo', 'hyperkalemia', 'roxadustat', 'metabolic acidosis']",791,['被报告为副作用的催眠和代谢酸化频率在Roxadustat群体中高于 placebo群体。'],0.1,"['group', 'placebo', 'adverse', 'hyperkalemia', 'as', 'roxadustat', 'metabolic acidosis', 'that', 'in', 'and']",['group'],791,在统计为不良事件的高血钾和代谢性酸osis的发生率方面，roxadustat组比安慰剂组高。,0.2,"['group', 'placebo', 'adverse', 'hyperkalemia', 'as', 'roxadustat', 'metabolic acidosis', 'that', 'in', 'and']","['group', 'placebo']",,,,
797,792,the Kidney Disease Improving Global Outcomes ( KDIGO ) guidelines suggest that patients with chronic kidney disease who have a serum bicarbonate level of less than 22 mmol per liter ( associated with metabolic acidosis ) should begin oral bicarbonate supplementation to maintain a serum bicarbonate level within the normal range.35,肾脏病改善全球预后 (KDIGO) 指南建议，血清碳酸氢盐水平低于 22 mmol/L（伴有代谢性酸中毒）的慢性肾脏病患者应开始口服碳酸氢盐补充剂，以将血清碳酸氢盐水平维持在正常范围内范围.35,0.6,"['kidney', 'disease', 'liter', 'who', 'global', 'bicarbonate', 'oral', 'maintain', 'normal', 'serum', 'associated', 'chronic', 'level', 'suggest', 'with', 'metabolic acidosis', 'have', 'that', 'begin', 'to']","['kidney', 'disease', 'global', 'bicarbonate', 'maintain', 'serum', 'chronic', 'level', 'metabolic acidosis', 'have', 'begin', 'to']",792,"['肾病改善全球结果(KDIGO)指南指出,患有慢性肾病的患者,每升血清二氧化碳水平低于22 mmol(与代谢酸化相关)应开始口服二氧化碳补充,以保持血清二氧化碳水平在正常范围内。']",0.5,"['kidney', 'disease', 'liter', 'who', 'global', 'bicarbonate', 'oral', 'maintain', 'normal', 'serum', 'associated', 'chronic', 'level', 'suggest', 'with', 'metabolic acidosis', 'have', 'that', 'begin', 'to']","['kidney', 'disease', 'liter', 'global', 'serum', 'chronic', 'level', 'have', 'begin', 'to']",792,根据《肾脏病全球结局改善》(KDIGO)指南，患有慢性肾脏病并且血清碳酸盐水平低于每升22摩尔的患者应该开始服用碳酸氢盐补充剂以保持血清碳酸盐水平在正常范围内。35,0.6,"['kidney', 'disease', 'liter', 'who', 'global', 'bicarbonate', 'oral', 'maintain', 'normal', 'serum', 'associated', 'chronic', 'level', 'suggest', 'with', 'metabolic acidosis', 'have', 'that', 'begin', 'to']","['kidney', 'disease', 'liter', 'global', 'bicarbonate', 'serum', 'chronic', 'level', 'have', 'that', 'begin', 'to']",,,,
798,793,"in a similar study involving patients with chronic kidney disease receiving dialysis , hyperkalemia was reported as an adverse event more often in patients treated with roxadustat than in those treated with epoetin alfa.36",在一项涉及接受透析的慢性肾病患者的类似研究中，与接受阿法依泊汀治疗的患者相比，接受罗沙司他治疗的患者高钾血症作为不良事件的发生率更高。 36,0.6363636363636364,"['dialysis', 'kidney', 'disease', 'study', 'chronic', 'hyperkalemia', 'adverse event', 'with', 'roxadustat', 'in', 'similar']","['dialysis', 'kidney', 'disease', 'chronic', 'hyperkalemia', 'adverse event', 'roxadustat']",793,"['在类似的研究中,涉及患有慢性肾脏疾病的患者接受腹泻,高<unk>病被报告为患有Roxadustat的患者比接受Epoetin alfa的患者更频繁的副作用。']",0.2727272727272727,"['dialysis', 'kidney', 'disease', 'study', 'chronic', 'hyperkalemia', 'adverse event', 'with', 'roxadustat', 'in', 'similar']","['kidney', 'disease', 'chronic']",793,在一项类似的研究中，涉及到接受透析治疗的慢性肾脏病患者，高钾血症作为不良事件在使用罗沙得治疗的患者中更常见。36,0.5454545454545454,"['dialysis', 'kidney', 'disease', 'study', 'chronic', 'hyperkalemia', 'adverse event', 'with', 'roxadustat', 'in', 'similar']","['dialysis', 'kidney', 'disease', 'chronic', 'hyperkalemia', 'adverse event']",,,,
799,794,"it should be noted that our findings are limited by the small sample size and short trial duration relative to the ongoing large , international , phase 3 studies ( ClinicalTrials.gov numbers , NCT01750190 , NCT02052310 , and NCT02273726 ) .",应该指出的是，相对于正在进行的大型国际 3 期研究（ClinicalTrials.gov 编号，NCT01750190、NCT02052310 和 NCT02273726），我们的研究结果受到样本量小和试验持续时间短的限制。,0.2857142857142857,"['phase', 'short', 'relative', 'large', 'be', 'trial', '3', 'sample size', 'duration', 'limited', 'that', 'by', 'to', 'and']","['phase', 'be', 'duration', 'to']",794,"['值得注意的是,我们的发现仅限于小型样品大小和与正在进行的大型、国际、阶段3研究(ClinicalTrials.gov 号码、NCT01750190、NCT02052310、和NCT02273726)的短期试验时间。']",0.2142857142857142,"['phase', 'short', 'relative', 'large', 'be', 'trial', '3', 'sample size', 'duration', 'limited', 'that', 'by', 'to', 'and']","['phase', 'be', 'to']",794,应当指出，我们的研究受到了样本规模小和试验时间短相对于正在进行的大型国际3期研究（ ClinicalTrials.gov 编号，NCT01750190，NCT02052310，NCT02273726）的限制。,0.2142857142857142,"['phase', 'short', 'relative', 'large', 'be', 'trial', '3', 'sample size', 'duration', 'limited', 'that', 'by', 'to', 'and']","['phase', 'be', 'to']",,,,
800,795,additional data are needed regarding the effectiveness and safety of roxadustat as compared with standard therapy ( epoetin alfa ) for the treatment of anemia in patients undergoing dialysis .,需要更多关于罗沙司他与标准疗法 (epoetin alfa) 相比治疗透析患者贫血的有效性和安全性的数据。,0.7142857142857143,"['anemia', 'safety', 'dialysis', 'standard', 'effectiveness', 'data', 'therapy', 'regarding', 'treatment', 'additional', 'as', 'with', 'roxadustat', 'epoetin alfa']","['anemia', 'safety', 'dialysis', 'standard', 'effectiveness', 'data', 'therapy', 'regarding', 'treatment', 'roxadustat']",795,"['有关Roxadustat的有效性和安全性,如与标准治疗(epoetin alfa)相比,需要进一步的数据,以治疗患有腹泻的患者。']",0.5714285714285714,"['anemia', 'safety', 'dialysis', 'standard', 'effectiveness', 'data', 'therapy', 'regarding', 'treatment', 'additional', 'as', 'with', 'roxadustat', 'epoetin alfa']","['safety', 'standard', 'effectiveness', 'data', 'therapy', 'regarding', 'treatment', 'as']",795,需要更多关于罗莎达斯特与标准治疗（红细胞生成素）相比治疗肾脏透析患者贫血的有效性和安全性方面的数据。,0.6428571428571429,"['anemia', 'safety', 'dialysis', 'standard', 'effectiveness', 'data', 'therapy', 'regarding', 'treatment', 'additional', 'as', 'with', 'roxadustat', 'epoetin alfa']","['anemia', 'safety', 'dialysis', 'standard', 'effectiveness', 'data', 'therapy', 'regarding', 'treatment']",,,,
801,796,parenteral iron was withheld except as rescue therapy .,除作为挽救疗法外，不使用肠外铁剂。,0.6,"['parenteral', 'therapy', 'as', 'iron', 'rescue']","['parenteral', 'therapy', 'iron']",796,"['除救援治疗外,已被放弃。']",0.4,"['parenteral', 'therapy', 'as', 'iron', 'rescue']","['therapy', 'rescue']",796,除了作为救治疗法，外加剂的铁被扣留了。,0.4,"['parenteral', 'therapy', 'as', 'iron', 'rescue']","['therapy', 'iron']",,,,
802,797,the primary end point was the mean change in hemoglobin level from baseline to the average level during weeks 23 through 27 .,主要终点是第 23 周至第 27 周期间血红蛋白水平从基线到平均水平的平均变化。,0.5555555555555556,"['mean', 'baseline', 'hemoglobin level', 'primary', 'average level', 'end', 'point', 'change', 'to']","['mean', 'baseline', 'average level', 'point', 'change']",797,['主要的终点是从基层到平均水平的血球水平在23至27周的平均变化。'],0.5555555555555556,"['mean', 'baseline', 'hemoglobin level', 'primary', 'average level', 'end', 'point', 'change', 'to']","['mean', 'primary', 'average level', 'point', 'change']",797,主要终点是血红蛋白水平的基线到第23周至第27周平均水平的平均变化。,0.5555555555555556,"['mean', 'baseline', 'hemoglobin level', 'primary', 'average level', 'end', 'point', 'change', 'to']","['mean', 'baseline', 'average level', 'point', 'change']",,,,
803,798,patients in each group had doses adjusted to reach a hemoglobin level of 10.0 to 12.0 g per deciliter .,每组患者的剂量都经过调整，使血红蛋白水平达到每分升 10.0 至 12.0 克。,0.2,"['group', 'deciliter', 'hemoglobin level', 'to', 'reach']",['group'],798,['每个群体的患者均有调整剂量达到10.0至12.0g的血糖水平。'],0.2,"['group', 'deciliter', 'hemoglobin level', 'to', 'reach']",['group'],798,每组患者的剂量调整以达到每分升血红蛋白水平为10.0至12.0克。,0.2,"['group', 'deciliter', 'hemoglobin level', 'to', 'reach']",['group'],,,,
804,799,safety was assessed by analysis of adverse events and clinical laboratory values .,通过分析不良事件和临床实验室值评估安全性。,0.4444444444444444,"['safety', 'analysis', 'adverse', 'clinical', 'laboratory', 'values', 'by', 'and', 'assessed']","['safety', 'analysis', 'clinical', 'laboratory']",799,['安全性通过分析不良事件和临床实验室值进行评估。'],0.4444444444444444,"['safety', 'analysis', 'adverse', 'clinical', 'laboratory', 'values', 'by', 'and', 'assessed']","['safety', 'analysis', 'clinical', 'laboratory']",799,"safety was assessed by analysis of adverse events and clinical laboratory values .

中文：

安全性通过不良事件和临床实验室值的分析来评估。",0.4444444444444444,"['safety', 'analysis', 'adverse', 'clinical', 'laboratory', 'values', 'by', 'and', 'assessed']","['safety', 'analysis', 'clinical', 'laboratory']",,,,
805,800,the mean baseline hemoglobin level was 10.4 g per deciliter .,平均基线血红蛋白水平为每分升 10.4 克。,0.5,"['mean', 'baseline', 'deciliter', 'hemoglobin level']","['mean', 'baseline']",800,['平均基因血糖水平为每分升10.4g。'],0.25,"['mean', 'baseline', 'deciliter', 'hemoglobin level']",['mean'],800,平均基线血红蛋白水平为10.4克/分升。,0.5,"['mean', 'baseline', 'deciliter', 'hemoglobin level']","['mean', 'baseline']",,,,
806,801,"as compared with epoetin alfa , roxadustat increased the transferrin level ( difference , 0.43 g per liter ; 95 % CI , 0.32 to 0.53 ) , maintained the serum iron level ( difference , 25 μg per deciliter ; 95 % CI , 17 to 33 ) , and attenuated decreases in the transferrin saturation ( difference , 4.2 percentage points ; 95 % CI , 1.5 to 6.9 ) .",与阿法依泊汀相比，罗沙司他增加转铁蛋白水平（差异，0.43 g/L；95 % CI，0.32至0.53），维持血清铁水平（差异，25 μg/dL；95 % CI，17至33） ，并且转铁蛋白饱和度降低减弱（差异，4.2 个百分点；95% CI，1.5 至 6.9）。,0.4666666666666667,"['percentage', 'transferrin', 'deciliter', 'difference', 'serum', 'saturation', 'level', 'as', 'with', 'roxadustat', 'epoetin alfa', 'iron', 'CI', 'to', 'and']","['transferrin', 'difference', 'serum', 'saturation', 'level', 'roxadustat', 'iron']",801,"['与epoetin alfa 相比,roxadustat 增加了 transferrin 水平(差异, 0.43 g 每升; 95 % CI, 0.32 至 0.53 ),保持了血清铁水平(差异, 25 μg 每分升; 95 % CI, 17 至 33 ),并减轻了 transferrin 饱和度(差异, 4.2 百分点; 95 % CI, 1.5 至 6.9 ) 。']",0.3333333333333333,"['percentage', 'transferrin', 'deciliter', 'difference', 'serum', 'saturation', 'level', 'as', 'with', 'roxadustat', 'epoetin alfa', 'iron', 'CI', 'to', 'and']","['difference', 'serum', 'saturation', 'level', 'iron']",801,相較於羅西亞鐵葡萄糖胺，羅沙度明能夠增加轉鐵蛋白的水平（差異，0.43克/公升；95%信賴區間，0.32~0.53），維持血清鐵的水平（差異，25微克/公升；95%信賴區間，17~33），並且緩解轉鐵蛋白飽和度的下降（差異，4.2個百分點；95%信賴區間，1.5~6.9）。,0.1333333333333333,"['percentage', 'transferrin', 'deciliter', 'difference', 'serum', 'saturation', 'level', 'as', 'with', 'roxadustat', 'epoetin alfa', 'iron', 'CI', 'to', 'and']","['serum', 'level']",,,,
807,802,"roxadustat was associated with a mean reduction in hepcidin of 30.2 ng per milliliter ( 95 % CI , − 64.8 to − 13.6 ) , as compared with 2.3 ng per milliliter ( 95 % CI , − 51.6 to 6.2 ) in the epoetin alfa group .",罗沙司他与铁调素平均降低 30.2 ng/mL（95% CI，-64.8 至-13.6）相关，而 epoetin alfa 组为 2.3 ng/mL（95% CI，-51.6 至 6.2）。,0.4444444444444444,"['group', 'mean', 'reduction', 'associated', 'with', 'roxadustat', 'epoetin alfa', 'CI', 'to']","['group', 'mean', 'reduction', 'roxadustat']",802,"['roxadustat 与每毫升的 hepcidin 的平均减少为 30.2 ng(95 % CI, − 64.8 至 − 13.6) 相似,与每毫升的 2.3 ng(95 % CI, − 51.6 至 6.2) 相比。']",0.2222222222222222,"['group', 'mean', 'reduction', 'associated', 'with', 'roxadustat', 'epoetin alfa', 'CI', 'to']","['mean', 'reduction']",802,"Roxadustat was associated with a mean reduction in hepcidin of 30.2 ng per milliliter (95% CI, -64.8 to -13.6), as compared with 2.3 ng per milliliter (95% CI, -51.6 to 6.2) in the epoetin alfa group.",0.0,"['group', 'mean', 'reduction', 'associated', 'with', 'roxadustat', 'epoetin alfa', 'CI', 'to']",[],,,,
808,803,"hyperkalemia and upper respiratory infection occurred at a higher frequency in the roxadustat group , and hypertension occurred at a higher frequency in the epoetin alfa group .",roxadustat组高钾血症和上呼吸道感染发生率较高，epoetin alfa组高血压发生率较高。,0.4,"['infection', 'group', 'frequency', 'hypertension', 'upper', 'respiratory', 'hyperkalemia', 'roxadustat', 'epoetin alfa', 'and']","['infection', 'group', 'hypertension', 'hyperkalemia']",803,"['甲状腺高血压和上呼吸道感染发生在较高的频率在 roxadustat 群体,高血压发生在较高的频率在 epoetin alfa 群体。']",0.4,"['infection', 'group', 'frequency', 'hypertension', 'upper', 'respiratory', 'hyperkalemia', 'roxadustat', 'epoetin alfa', 'and']","['infection', 'group', 'frequency', 'hypertension']",803,高钾血症和上呼吸道感染在罗沙度他组中发生的频率更高，而高血压在红细胞生成素组中发生的频率更高。,0.6,"['infection', 'group', 'frequency', 'hypertension', 'upper', 'respiratory', 'hyperkalemia', 'roxadustat', 'epoetin alfa', 'and']","['infection', 'group', 'frequency', 'hypertension', 'hyperkalemia', 'and']",,,,
809,804,"in China , 120 million persons have chronic kidney disease , a prevalence that is projected to increase.1,2","在中国，有 1.2 亿人患有慢性肾病，而且这一患病率预计还会增加。 1,2",0.5555555555555556,"['kidney', 'disease', 'prevalence', 'china', 'chronic', 'have', 'that', 'to', 'million']","['kidney', 'disease', 'china', 'chronic', 'have']",804,"['在中国,120万人患有慢性肾脏疾病,这种发病率预计会增加。']",0.5555555555555556,"['kidney', 'disease', 'prevalence', 'china', 'chronic', 'have', 'that', 'to', 'million']","['kidney', 'disease', 'china', 'chronic', 'have']",804,"在中国，有1.2亿人患有慢性肾病，预计这一比例将会上升。1,2",0.5555555555555556,"['kidney', 'disease', 'prevalence', 'china', 'chronic', 'have', 'that', 'to', 'million']","['kidney', 'disease', 'china', 'chronic', 'have']",,,,
810,805,only half the patients undergoing dialysis in China reach a hemoglobin level of 10.0 g per deciliter or greater using recombinant erythropoietin therapy .,在中国接受重组促红细胞生成素治疗的透析患者中，只有一半的血红蛋白水平达到 10.0 克/分升或更高。,0.5555555555555556,"['dialysis', 'erythropoietin', 'recombinant', 'half', 'deciliter', 'therapy', 'hemoglobin level', 'china', 'reach']","['dialysis', 'erythropoietin', 'half', 'therapy', 'china']",805,"['在中国,只有半数患有分裂症的患者达到10.0g或更高的血糖水平,使用 recombinant erythropoietin 治疗。']",0.3333333333333333,"['dialysis', 'erythropoietin', 'recombinant', 'half', 'deciliter', 'therapy', 'hemoglobin level', 'china', 'reach']","['half', 'therapy', 'china']",805,只有一半的中国血液透析患者使用重组人血液素治疗达到10.0克/分升以上的血红蛋白水平。,0.4444444444444444,"['dialysis', 'erythropoietin', 'recombinant', 'half', 'deciliter', 'therapy', 'hemoglobin level', 'china', 'reach']","['dialysis', 'half', 'therapy', 'china']",,,,
811,806,"this apparent undertreatment may result from the cost of the medication , hyporesponsiveness due to inflammation , or iron depletion.12",这种明显的治疗不足可能是由于药物成本、炎症引起的反应迟钝或缺铁造成的。 12,0.625,"['inflammation', 'medication', 'result', 'cost', 'due', 'iron', 'this', 'to']","['inflammation', 'cost', 'iron', 'this', 'to']",806,['这种显而易见的过度治疗可能导致药物的成本、由于炎症而过度响应性或铁的枯竭。'],0.5,"['inflammation', 'medication', 'result', 'cost', 'due', 'iron', 'this', 'to']","['inflammation', 'cost', 'iron', 'to']",806,这种明显的欠治疗可能是由药物的成本、由于炎症引起的减少反应或铁质流失12所致。,0.625,"['inflammation', 'medication', 'result', 'cost', 'due', 'iron', 'this', 'to']","['inflammation', 'cost', 'iron', 'this', 'to']",,,,
812,807,"the kidneys of patients with kidney disease retain the ability to produce erythropoietin.13,14","肾病患者的肾脏保留了产生促红细胞生成素的能力。 13,14",0.5,"['kidney', 'disease', 'produce', 'ability', 'with', 'to']","['kidney', 'disease', 'ability']",807,['患有肾疾病的患者的肾保持生成Erythropoietin的能力。'],0.5,"['kidney', 'disease', 'produce', 'ability', 'with', 'to']","['kidney', 'disease', 'ability']",807,"病人肾脏疾病仍然具有产生红细胞刺激素的能力。13,14",0.5,"['kidney', 'disease', 'produce', 'ability', 'with', 'to']","['kidney', 'disease', 'ability']",,,,
813,808,"the protocol , available with the full text of this article at NEJM.org , was approved by regulatory authorities and ethics committees , and the trial was conducted in accordance with local regulatory and ethics requirements .",该方案与本文全文可在 NEJM.org 获取，已获得监管机构和伦理委员会的批准，试验是根据当地监管和伦理要求进行的。,0.2666666666666666,"['protocol', 'article', 'ethics', 'local', 'available', 'trial', 'text', 'committees', 'with', 'at', 'full', 'this', 'in', 'by', 'and']","['committees', 'at', 'this', 'in']",808,"['该议定书与本条的完整文本在NEJM.org上可用,由监管机构和伦理委员会批准,审判按照当地的监管和伦理要求进行。']",0.5333333333333333,"['protocol', 'article', 'ethics', 'local', 'available', 'trial', 'text', 'committees', 'with', 'at', 'full', 'this', 'in', 'by', 'and']","['protocol', 'local', 'trial', 'committees', 'at', 'full', 'in', 'by']",808,该协议可在NEJM.org上找到，经过监管机构和伦理委员会批准，并按照当地监管和伦理要求进行。,0.2666666666666666,"['protocol', 'article', 'ethics', 'local', 'available', 'trial', 'text', 'committees', 'with', 'at', 'full', 'this', 'in', 'by', 'and']","['protocol', 'committees', 'at', 'in']",,,,
814,809,the trial was designed by the first two authors and the sponsor ( FibroGen ) .,该试验由前两位作者和赞助商 (FibroGen) 设计。,0.3333333333333333,"['sponsor', 'trial', 'by', 'and', 'first', 'two']","['by', 'two']",809,['试验是由前两位作者和赞助商(FibroGen)设计的。'],0.3333333333333333,"['sponsor', 'trial', 'by', 'and', 'first', 'two']","['by', 'two']",809,本试验由第一作者和第二作者设计，并由赞助商（FibroGen）提供资助。,0.3333333333333333,"['sponsor', 'trial', 'by', 'and', 'first', 'two']","['by', 'first']",,,,
815,810,the sponsor provided financial support and was responsible for data collection and analysis .,申办者提供资金支持并负责数据收集和分析。,0.8,"['support', 'analysis', 'sponsor', 'data collection', 'and']","['support', 'analysis', 'sponsor', 'data collection']",810,"['赞助商提供财务支持,负责数据收集和分析。']",0.6,"['support', 'analysis', 'sponsor', 'data collection', 'and']","['support', 'analysis', 'data collection']",810,"the sponsor provided financial support and was responsible for data collection and analysis.

Chinese:

赞助商提供资金支持，负责数据收集和分析。",0.6,"['support', 'analysis', 'sponsor', 'data collection', 'and']","['support', 'analysis', 'data collection']",,,,
816,811,all the authors had full access to the trial data and analyses and contributed to data analysis and interpretation and to the conduct of the trial .,所有作者都可以完全访问试验数据和分析，并为数据分析和解释以及试验的实施做出了贡献。,0.3,"['data', 'analysis', 'access', 'interpretation', 'trial', 'conduct', 'full', 'all', 'to', 'and']","['data', 'analysis', 'interpretation']",811,"['所有作者都有充分的访问审判数据和分析,并有助于数据分析和解释以及审判的进行。']",0.5,"['data', 'analysis', 'access', 'interpretation', 'trial', 'conduct', 'full', 'all', 'to', 'and']","['data', 'analysis', 'interpretation', 'trial', 'to']",811,所有作者都可以获得完整的实验数据和分析，并且参与了数据分析和解释以及实验的进行。,0.4,"['data', 'analysis', 'access', 'interpretation', 'trial', 'conduct', 'full', 'all', 'to', 'and']","['data', 'analysis', 'interpretation', 'full']",,,,
817,812,an author who is an employee of the sponsor wrote the first draft of the manuscript .,作为申办方雇员的作者撰写了手稿的初稿。,0.2857142857142857,"['who', 'author', 'sponsor', 'manuscript', 'employee', 'first', 'draft']","['manuscript', 'employee']",812,"['作者是赞助商的员工,写了手稿的第一个草案。']",0.4285714285714285,"['who', 'author', 'sponsor', 'manuscript', 'employee', 'first', 'draft']","['manuscript', 'employee', 'first']",812,一位撰写人员也是赞助商的雇员撰写了稿件的第一稿。,0.2857142857142857,"['who', 'author', 'sponsor', 'manuscript', 'employee', 'first', 'draft']","['employee', 'first']",,,,
818,813,"a list of inclusion and exclusion criteria is provided in Table S1 in the Supplementary Appendix , available at NEJM.org .",补充附录表 S1 中提供了纳入和排除标准列表，补充附录可在 NEJM.org 获取。,0.1,"['appendix', 'table', 'inclusion', 'supplementary', 'exclusion', 'available', 'list', 'at', 'S1', 'and']",['table'],813,"['包含和排除的标准列表在附加附件中的S1表中,可在NEJM.org上找到。']",0.3,"['appendix', 'table', 'inclusion', 'supplementary', 'exclusion', 'available', 'list', 'at', 'S1', 'and']","['appendix', 'table', 'inclusion']",813,"表S1中提供了包含和排除标准的列表，可在NEJM.org上找到。

Chinese:

表S1提供了包含和排除的标准列表，可在NEJM.org上找到。",0.2,"['appendix', 'table', 'inclusion', 'supplementary', 'exclusion', 'available', 'list', 'at', 'S1', 'and']","['table', 'inclusion']",,,,
819,814,patients who had been randomly assigned to receive epoetin alfa continued their prerandomization doses .,被随机分配接受 epoetin alfa 治疗的患者继续其随机化前的剂量。,0.0,"['who', 'epoetin alfa', 'to']",[],814,['随机服用epoetin alfa的患者继续服用预先剂量。'],0.0,"['who', 'epoetin alfa', 'to']",[],814,被隨機分配接受白內障原素alfa的病人繼續接受他們事先隨機分配的劑量。,0.0,"['who', 'epoetin alfa', 'to']",[],,,,
820,815,both epoetin alfa and roxadustat were supplied by the sponsor .,epoetin alfa 和 roxadustat 均由申办方提供。,0.2,"['sponsor', 'roxadustat', 'epoetin alfa', 'by', 'and']",['by'],815,['Epoetin alfa 和 roxadustat 都是由赞助商提供的。'],0.2,"['sponsor', 'roxadustat', 'epoetin alfa', 'by', 'and']",['by'],815,"both epoetin alfa and roxadustat were supplied by the sponsor.

中文：

赛乐达和罗沙德斯塔特都是由赞助商提供的。",0.2,"['sponsor', 'roxadustat', 'epoetin alfa', 'by', 'and']",['by'],,,,
821,816,doses were adjusted so that the patient would have a hemoglobin level of 10.0 to 12.0 g per deciliter ( Table S2 in the Supplementary Appendix ) .,调整剂量，使患者的血红蛋白水平达到 10.0 至 12.0 g/dL（补充附录表 S2）。,0.1818181818181818,"['appendix', 'table', 'deciliter', 'supplementary', 'hemoglobin level', 'patient', 'S2', 'have', 'that', 'so', 'to']","['table', 'patient']",816,"['剂量被调整,以便患者每分升10.0至12.0g的血糖水平(附件中的S2表)。']",0.2727272727272727,"['appendix', 'table', 'deciliter', 'supplementary', 'hemoglobin level', 'patient', 'S2', 'have', 'that', 'so', 'to']","['appendix', 'table', 'patient']",816,"The doses were adjusted so that the patient would have a hemoglobin level of 10.0 to 12.0 g per deciliter (Table S2 in the Supplementary Appendix).

Chinese:

根据血红蛋白水平调整剂量，使患者的血红蛋白水平在 10.0 至 12.0 g/dl之间（见补充附件 S2 表）。",0.2727272727272727,"['appendix', 'table', 'deciliter', 'supplementary', 'hemoglobin level', 'patient', 'S2', 'have', 'that', 'so', 'to']","['appendix', 'table', 'patient']",,,,
822,817,the use of oral iron therapy was allowed ; intravenous iron therapy was prohibited except as rescue therapy .,允许使用口服铁剂疗法；除非作为补救治疗，否则禁止静脉铁剂治疗。,0.3333333333333333,"['oral', 'therapy', 'intravenous', 'as', 'iron', 'rescue']","['therapy', 'iron']",817,"['使用口腔铁疗法被允许;除救援疗法外,禁止内膜铁疗法。']",0.5,"['oral', 'therapy', 'intravenous', 'as', 'iron', 'rescue']","['therapy', 'iron', 'rescue']",817,口服铁疗法可以使用；静脉注射铁疗法除救治外均为禁止。,0.3333333333333333,"['oral', 'therapy', 'intravenous', 'as', 'iron', 'rescue']","['therapy', 'iron']",,,,
823,818,the primary efficacy end point was the mean change in the hemoglobin level from baseline to the average level during weeks 23 through 27 .,主要疗效终点是第 23 周至第 27 周期间血红蛋白水平从基线到平均水平的平均变化。,0.5,"['mean', 'baseline', 'hemoglobin level', 'primary', 'efficacy', 'average level', 'end', 'point', 'change', 'to']","['mean', 'baseline', 'average level', 'point', 'change']",818,"['初级有效性终点是从基层到平均水平的血球水平的平均变化,在23至27周。']",0.5,"['mean', 'baseline', 'hemoglobin level', 'primary', 'efficacy', 'average level', 'end', 'point', 'change', 'to']","['mean', 'efficacy', 'average level', 'point', 'change']",818,主要疗效指标是血红蛋白水平从基线到第23周至第27周平均水平的变化。,0.4,"['mean', 'baseline', 'hemoglobin level', 'primary', 'efficacy', 'average level', 'end', 'point', 'change', 'to']","['mean', 'baseline', 'average level', 'change']",,,,
824,819,the baseline hemoglobin level was defined as the mean of the last three hemoglobin levels before the first dose of a trial drug .,基线血红蛋白水平定义为试验药物首次给药前最后三个血红蛋白水平的平均值。,0.4,"['defined', 'mean', 'baseline', 'hemoglobin level', 'trial', 'drug', 'dose', 'three', 'before', 'first']","['mean', 'baseline', 'drug', 'before']",819,"['基因血球水平被定义为前三血球水平的平均水平,在试用药物的第一剂量之前。']",0.5,"['defined', 'mean', 'baseline', 'hemoglobin level', 'trial', 'drug', 'dose', 'three', 'before', 'first']","['mean', 'drug', 'dose', 'before', 'first']",819,在试验药物首次剂量前的最后三个血红蛋白水平的平均数被定义为基线血红蛋白水平。,0.5,"['defined', 'mean', 'baseline', 'hemoglobin level', 'trial', 'drug', 'dose', 'three', 'before', 'first']","['mean', 'baseline', 'drug', 'dose', 'before']",,,,
825,820,"in order for the trial to show the noninferiority of roxadustat to epoetin alfa , the lower boundary of the 95 % confidence interval for the treatment difference in the change in hemoglobin level had to be greater than or equal to − 1.0 g per deciliter .",为了让试验显示罗沙司他对阿法依泊汀的非劣效性，血红蛋白水平变化的治疗差异的 95% 置信区间下限必须大于或等于 − 1.0 g/dL。,0.4666666666666667,"['boundary', 'order', 'deciliter', 'difference', 'lower', 'be', 'hemoglobin level', 'treatment', 'trial', 'confidence interval', 'change', 'equal', 'roxadustat', 'epoetin alfa', 'to']","['difference', 'treatment', 'confidence interval', 'change', 'equal', 'roxadustat', 'to']",820,"['为了在试验中显示Roxadustat对Epoetin alfa的非低度,对治疗差异的95%信任间隔的低限度在血球水平的变化中应该超过或相当于 − 1.0 g 每分。']",0.3333333333333333,"['boundary', 'order', 'deciliter', 'difference', 'lower', 'be', 'hemoglobin level', 'treatment', 'trial', 'confidence interval', 'change', 'equal', 'roxadustat', 'epoetin alfa', 'to']","['difference', 'be', 'treatment', 'change', 'to']",820,为了显示罗沙达斯特与腺苷酸铁盐治疗差异不显著性，95％置信区间下界必须大于或等于-1.0 g/dL。,0.3333333333333333,"['boundary', 'order', 'deciliter', 'difference', 'lower', 'be', 'hemoglobin level', 'treatment', 'trial', 'confidence interval', 'change', 'equal', 'roxadustat', 'epoetin alfa', 'to']","['difference', 'treatment', 'confidence interval', 'equal', 'to']",,,,
826,821,"sensitivity analyses with analysis of covariance ( ANCOVA ) were performed in which missing hemoglobin values were imputed with the use of the Markov chain Monte Carlo method , 28,29 which assumes multivariate normal distribution of hemoglobin values , to create a data set of observed plus imputed data .","进行了具有协方差分析 ( ANCOVA ) 的敏感性分析，其中使用马尔可夫链蒙特卡洛方法 28,29 估算了缺失的血红蛋白值，该方法假设血红蛋白值呈多变量正态分布，以创建观察值和估算值的数据集数据 。",0.3846153846153846,"['hemoglobin', 'plus', 'values', 'monte carlo method', 'multivariate normal distribution', 'with', 'sensitivity', 'analysis of covariance', 'to', 'missing', 'create', 'data set', 'markov chain']","['hemoglobin', 'missing', 'create', 'data set', 'markov chain']",821,"['敏感性分析与可视性分析(ANCOVA)进行了,在其中缺乏的血球值被指示使用马尔科夫链蒙特卡洛方法28,29,假设多变的血球值的正常分布,创建一个数据集的观察加上指示的数据。']",0.3076923076923077,"['hemoglobin', 'plus', 'values', 'monte carlo method', 'multivariate normal distribution', 'with', 'sensitivity', 'analysis of covariance', 'to', 'missing', 'create', 'data set', 'markov chain']","['plus', 'missing', 'create', 'data set']",821,"通过协方差分析（ANCOVA）进行灵敏度分析，使用马尔可夫链蒙特卡罗方法对缺失的血红蛋白值进行插补，28,29假设血红蛋白值具有多元正态分布，以创建观察到的加上插补数据的数据集。",0.5384615384615384,"['hemoglobin', 'plus', 'values', 'monte carlo method', 'multivariate normal distribution', 'with', 'sensitivity', 'analysis of covariance', 'to', 'missing', 'create', 'data set', 'markov chain']","['hemoglobin', 'plus', 'sensitivity', 'missing', 'create', 'data set', 'markov chain']",,,,
827,822,"the number of patients , proportion of patients with a response , and treatment differences were averaged from the multiple imputations .",患者人数、有反应的患者比例和治疗差异均通过多重插补计算平均。,0.5714285714285714,"['proportion', 'multiple', 'treatment', 'number', 'response', 'with', 'and']","['proportion', 'treatment', 'number', 'response']",822,['病人数量、患有反应的病人比例和治疗差异是从多种指征中平均的。'],0.5714285714285714,"['proportion', 'multiple', 'treatment', 'number', 'response', 'with', 'and']","['proportion', 'treatment', 'number', 'response']",822,平均了患者人数、有反应患者的比例和治疗差异。,0.5714285714285714,"['proportion', 'multiple', 'treatment', 'number', 'response', 'with', 'and']","['proportion', 'treatment', 'number', 'response']",,,,
828,823,"since the analyses of secondary end points were not adjusted for multiple comparisons , we report point estimates and 95 % confidence intervals without P values .",由于次要终点的分析未针对多重比较进行调整，因此我们报告了没有 P 值的点估计值和 95% 置信区间。,0.1818181818181818,"['report', 'multiple', 'end points', 'secondary', 'values', 'confidence', 'P', 'and', 'without', 'intervals', 'we']","['report', 'end points']",823,"['由于二级终点的分析没有适用于多个比较,我们报告点估计和95%的信任间隔没有P值。']",0.1818181818181818,"['report', 'multiple', 'end points', 'secondary', 'values', 'confidence', 'P', 'and', 'without', 'intervals', 'we']","['report', 'end points']",823,由于对次要终点的分析未经过多重比较调整，我们在没有P值的情况下报告点估计值和95%的置信区间。,0.1818181818181818,"['report', 'multiple', 'end points', 'secondary', 'values', 'confidence', 'P', 'and', 'without', 'intervals', 'we']","['report', 'end points']",,,,
829,824,"the 95 % confidence intervals have not been adjusted for multiple comparisons , and inference drawn from them may not be reproducible .",95% 置信区间未针对多重比较进行调整，从中得出的推论可能无法重现。,0.2857142857142857,"['multiple', 'be', 'inference', 'confidence', 'have not', 'and', 'intervals']","['inference', 'have not']",824,"['95%的信任间隔未适用于多个比较,并可能无法重复的结论。']",0.1428571428571428,"['multiple', 'be', 'inference', 'confidence', 'have not', 'and', 'intervals']",['have not'],824,95%的置信区间未经多重比较调整，从中得出的推论可能无法重现。,0.2857142857142857,"['multiple', 'be', 'inference', 'confidence', 'have not', 'and', 'intervals']","['inference', 'have not']",,,,
830,825,"safety was monitored by assessment of adverse events and serious adverse events during treatment for 28 days after the discontinuation of trial drug , by review of clinical laboratory values , and by physical examinations .",通过评估停药后 28 天内治疗期间的不良事件和严重不良事件、审查临床实验室值和体格检查来监测安全性。,0.4375,"['safety', 'review', 'physical', 'adverse', 'assessment', 'treatment', 'clinical', 'examinations', 'after', 'trial', 'laboratory', 'values', 'drug', 'serious', 'by', 'and']","['safety', 'review', 'assessment', 'treatment', 'clinical', 'after', 'laboratory']",825,"['安全性通过在试用药物停止后28天进行治疗期间的副作用和严重副作用的评估,通过临床实验室值的审查和物理检查进行监测。']",0.5,"['safety', 'review', 'physical', 'adverse', 'assessment', 'treatment', 'clinical', 'examinations', 'after', 'trial', 'laboratory', 'values', 'drug', 'serious', 'by', 'and']","['safety', 'review', 'assessment', 'treatment', 'clinical', 'after', 'laboratory', 'drug']",825,安全性通过对停止使用试验药物后28天治疗期间的不良事件和严重不良事件的评估、对临床实验室值的审查和体检来监测。,0.5,"['safety', 'review', 'physical', 'adverse', 'assessment', 'treatment', 'clinical', 'examinations', 'after', 'trial', 'laboratory', 'values', 'drug', 'serious', 'by', 'and']","['safety', 'review', 'assessment', 'treatment', 'clinical', 'after', 'laboratory', 'drug']",,,,
831,826,the number and proportion of patients who received rescue therapy during trial treatment and the time to rescue therapy from the first dose during treatment were also reported .,还报告了试验治疗期间接受挽救治疗的患者人数和比例，以及治疗期间从第一次给药到挽救治疗的时间。,0.5,"['proportion', 'who', 'time', 'therapy', 'treatment', 'number', 'trial', 'dose', 'to', 'and', 'rescue', 'first']","['proportion', 'time', 'therapy', 'treatment', 'number', 'first']",826,['还报告了在试验期间接受救生疗法的患者数量和比例以及在治疗期间从第一剂量救生疗法的时间。'],0.5833333333333334,"['proportion', 'who', 'time', 'therapy', 'treatment', 'number', 'trial', 'dose', 'to', 'and', 'rescue', 'first']","['proportion', 'time', 'therapy', 'treatment', 'number', 'dose', 'first']",826,在試驗治療期間，接受救助療法的患者數量及其比例以及從首劑開始治療到救助療法的時間也均有報告。,0.0833333333333333,"['proportion', 'who', 'time', 'therapy', 'treatment', 'number', 'trial', 'dose', 'to', 'and', 'rescue', 'first']",['proportion'],,,,
832,827,baseline CHARACTERISTICS OF THE PATIENTS,患者的基线特征,1.0,['baseline'],['baseline'],827,['病人的基本特征'],0.0,['baseline'],[],827,"基线特征

中文：

基线特征",1.0,['baseline'],['baseline'],,,,
833,828,a total of 48 patients ( 42 in the roxadustat group and 6 in the epoetin alfa group ) discontinued the assigned medication .,共有 48 名患者（roxadustat 组 42 名和 epoetin alfa 组 6 名）停止了分配的药物治疗。,0.1666666666666666,"['group', 'total', 'medication', 'roxadustat', 'epoetin alfa', 'and']",['group'],828,['总共48名患者(Roxadustat组中有42人和Epoetin alfa组中有6人)停止服用药物。'],0.1666666666666666,"['group', 'total', 'medication', 'roxadustat', 'epoetin alfa', 'and']",['group'],828,总共有48名病人（42名在roxadustat组和6名在epoetin alfa组）停止了指定的药物治疗。,0.1666666666666666,"['group', 'total', 'medication', 'roxadustat', 'epoetin alfa', 'and']",['group'],,,,
834,829,the baseline characteristics of the patients were similar in the two groups ( Table 1 ) .,两组患者的基线特征相似（表1）。,0.8333333333333334,"['table', 'baseline', '1', 'characteristics', 'two', 'similar']","['table', 'baseline', '1', 'characteristics', 'two']",829,['患者的基本特征在两组中是相似的(图1)。'],0.6666666666666666,"['table', 'baseline', '1', 'characteristics', 'two', 'similar']","['1', 'characteristics', 'two', 'similar']",829,表1中患者的基线特征在两组中相似。,0.8333333333333334,"['table', 'baseline', '1', 'characteristics', 'two', 'similar']","['table', 'baseline', '1', 'characteristics', 'two']",,,,
835,830,"overall , the mean hemoglobin level of the patients was 10.4 g per deciliter , and the mean dose of epoetin alfa was approximately 7500 units per week .",总体而言，患者的平均血红蛋白水平为 10.4 g/dL，而 epoetin alfa 的平均剂量约为每周 7500 单位。,0.5,"['mean', 'deciliter', 'hemoglobin level', 'week', 'epoetin alfa', 'dose', 'approximately', 'and']","['mean', 'week', 'dose', 'and']",830,"['总体而言,患者的平均血糖水平为每分升104克,平均Epoetin alfa的剂量每周约为7500个单位。']",0.5,"['mean', 'deciliter', 'hemoglobin level', 'week', 'epoetin alfa', 'dose', 'approximately', 'and']","['mean', 'week', 'dose', 'and']",830,总的来说，病人的平均血红蛋白水平为10.4克/分升，平均注射肽红素alfa的剂量为每周约7500单位。,0.375,"['mean', 'deciliter', 'hemoglobin level', 'week', 'epoetin alfa', 'dose', 'approximately', 'and']","['mean', 'week', 'dose']",,,,
836,831,hemoglobin LEVELS,血红蛋白水平,1.0,['hemoglobin'],['hemoglobin'],831,['血球水平'],0.0,['hemoglobin'],[],831,血红蛋白水平,1.0,['hemoglobin'],['hemoglobin'],,,,
837,832,"the percentage of patients with a mean hemoglobin level of at least 10.0 g per deciliter was 87.0 % in the roxadustat group ( 178 patients ) and 88.5 % in the epoetin alfa group ( 88 patients ) in weeks 23 through 27 ( treatment difference , − 0.1 percentage point ; 95 % CI , − 8.6 to 8.5 ) .",在第 23 周至第 27 周期间，罗沙司他组（178 名患者）平均血红蛋白水平至少为 10.0 g/dL 的患者百分比为 87.0%，阿法依泊汀组（88 名患者）为 88.5%（治疗差异，- 0.1个百分点；95% CI，- 8.6 至 8.5)。,0.4285714285714285,"['group', 'percentage', 'mean', 'deciliter', 'difference', 'hemoglobin level', 'treatment', 'point', 'with', 'roxadustat', 'epoetin alfa', 'CI', 'to', 'and']","['group', 'mean', 'difference', 'treatment', 'point', 'roxadustat']",832,"['在23至27周期间,平均血糖水平至少为10.0g的患者比例在Roxadustat群体(178名患者)和Epoetin alfa群体(88名患者)中为88.5%(治疗差异, − 0.1 个百分点, − 95 % CI, − 8.6 到 8.5 )。']",0.3571428571428571,"['group', 'percentage', 'mean', 'deciliter', 'difference', 'hemoglobin level', 'treatment', 'point', 'with', 'roxadustat', 'epoetin alfa', 'CI', 'to', 'and']","['group', 'mean', 'difference', 'treatment', 'point']",832,在第23周至第27周，腺苷酸去氧核酸转铁蛋白治疗组(178例患者)中，血红蛋白水平均至少为10.0 g/dL的患者所占比例为87.0%，而在腺苷酸去氧核酸转铁蛋白治疗组(88例患者)中，这一比例为88.5%。治疗差异为-0.1个百分点(95% CI，-8.6至8.5)。,0.4285714285714285,"['group', 'percentage', 'mean', 'deciliter', 'difference', 'hemoglobin level', 'treatment', 'point', 'with', 'roxadustat', 'epoetin alfa', 'CI', 'to', 'and']","['group', 'mean', 'difference', 'treatment', 'point', 'and']",,,,
838,833,"the treatment difference in the change in hemoglobin level was similar according to the ANCOVA multiple imputations ( increase in hemoglobin level , 0.7 ± 1.1 g per deciliter in the roxadustat group and 0.5 ± 1.0 g per deciliter in the epoetin alfa group ) .",根据 ANCOVA 多重插补，血红蛋白水平变化的治疗差异相似（血红蛋白水平增加，roxadustat 组为 0.7 ± 1.1 g/dL，epoetin alfa 组为 0.5 ± 1.0 g/dL）。,0.3076923076923077,"['group', 'deciliter', 'multiple', 'difference', 'hemoglobin level', 'treatment', 'change', 'increase', 'roxadustat', 'epoetin alfa', 'to', 'and', 'similar']","['group', 'difference', 'treatment', 'change']",833,"['血球水平的治疗差异是相似的,根据 ANCOVA 多种催化物(血球水平的增加,在 roxadustat 组中 0.7 ± 1.1 g 每分,在 epoetin alfa 组中 0.5 ± 1.0 g 每分)。']",0.3076923076923077,"['group', 'deciliter', 'multiple', 'difference', 'hemoglobin level', 'treatment', 'change', 'increase', 'roxadustat', 'epoetin alfa', 'to', 'and', 'similar']","['group', 'difference', 'treatment', 'similar']",833,"According to the ANCOVA multiple imputations, the treatment difference in the change in hemoglobin level was similar (increase in hemoglobin level, 0.7 ± 1.1 g per deciliter in the roxadustat group and 0.5 ± 1.0 g per deciliter in the epoetin alfa group).",0.0,"['group', 'deciliter', 'multiple', 'difference', 'hemoglobin level', 'treatment', 'change', 'increase', 'roxadustat', 'epoetin alfa', 'to', 'and', 'similar']",[],,,,
839,834,"at baseline , the mean hepcidin level was 180.7 ± 136.8 ng per milliliter in the roxadustat group and 148.3 ± 104.2 ng per milliliter in the epoetin alfa group .",基线时，roxadustat 组的平均铁调素水平为 180.7 ± 136.8 ng/mL，而 epoetin alfa 组为 148.3 ± 104.2 ng/mL。,0.7142857142857143,"['group', 'mean', 'baseline', 'level', 'roxadustat', 'epoetin alfa', 'and']","['group', 'mean', 'baseline', 'level', 'and']",834,"['在基线上,每毫升的平均肝素水平为180.7 ± 136.8 ng 在罗克萨多斯塔特群体和148.3 ± 104.2 ng 在阿尔法群体中。']",0.5714285714285714,"['group', 'mean', 'baseline', 'level', 'roxadustat', 'epoetin alfa', 'and']","['group', 'mean', 'baseline', 'level']",834,在基线时，roxadustat组的平均肝铁同化酶水平为180.7±136.8 ng/ml，而在epoetin alfa组为148.3±104.2 ng/ml。,0.7142857142857143,"['group', 'mean', 'baseline', 'level', 'roxadustat', 'epoetin alfa', 'and']","['group', 'mean', 'baseline', 'level', 'and']",,,,
840,835,"at week 27 , the change from baseline was − 30.2 ± 113.3 ng per milliliter ( 95 % CI , − 64.8 to − 13.6 ) in the roxadustat group and − 2.3 ± 130.7 ng per milliliter ( 95 % CI , − 51.6 to 6.2 ) in the epoetin alfa group ( Figure 1B ) .",第 27 周时，罗沙司他组相对于基线的变化为 − 30.2 ± 113.3 ng/mL（ 95 % CI ， − 64.8 至 − 13.6 ），而epoetin alfa 组（图 1B）。,0.7,"['group', 'baseline', 'figure', 'week', 'change', 'roxadustat', 'epoetin alfa', 'CI', 'to', 'and']","['group', 'baseline', 'week', 'change', 'roxadustat', 'to', 'and']",835,"['在第27周,从基线的变化是 − 30.2 ± 113.3 ng 每毫升(95 % CI, − 64.8 至 − 13.6)在 roxadustat 组和 − 2.3 ± 130.7 ng 每毫升(95 % CI, − 51.6 至 6.2)在 epoetin 阿尔法 组(图 1B ) 。']",0.4,"['group', 'baseline', 'figure', 'week', 'change', 'roxadustat', 'epoetin alfa', 'CI', 'to', 'and']","['group', 'baseline', 'week', 'change']",835,在第27周，罗沙达斯特组的基线变化为-30.2±113.3 ng/ml(95%CI，-64.8至-13.6)，而血红素原组为-2.3±130.7 ng/ml(95%CI，-51.6至6.2) (见图1B)。,0.5,"['group', 'baseline', 'figure', 'week', 'change', 'roxadustat', 'epoetin alfa', 'CI', 'to', 'and']","['group', 'baseline', 'week', 'change', 'and']",,,,
841,836,this resulted in a greater decline in transferrin saturation in the epoetin alfa group than in the roxadustat group .,这导致 epoetin alfa 组的转铁蛋白饱和度下降幅度大于罗沙司他组。,0.7142857142857143,"['group', 'decline', 'transferrin', 'saturation', 'roxadustat', 'epoetin alfa', 'this']","['group', 'decline', 'transferrin', 'saturation', 'roxadustat']",836,"['这导致在epoetin alfa群体中的转移林饱和度下降,而不是在roxadustat群体中。']",0.5714285714285714,"['group', 'decline', 'transferrin', 'saturation', 'roxadustat', 'epoetin alfa', 'this']","['group', 'decline', 'saturation', 'this']",836,这导致了红细胞生成素组中转铁蛋白饱和度的更大下降，而罗沙达斯组中则要小。,0.5714285714285714,"['group', 'decline', 'transferrin', 'saturation', 'roxadustat', 'epoetin alfa', 'this']","['group', 'decline', 'transferrin', 'saturation']",,,,
842,837,"the mean change in the mean arterial pressure from baseline to the average value during weeks 23 through 27 was − 2.1 mm Hg in the roxadustat group and − 0.7 mm Hg in the epoetin alfa group ( difference , − 1.4 mm Hg ; 95 % CI , − 3.7 to 1.0 ) .",在第 23 周至第 27 周期间，平均动脉压从基线到平均值的平均变化在罗沙司他组为 − 2.1 mm Hg，在阿法依泊汀组为 − 0.7 mm Hg（差异，− 1.4 mm Hg；95% CI， − 3.7 至 1.0)。,0.6363636363636364,"['group', 'baseline', 'difference', 'change', 'average value', 'roxadustat', 'epoetin alfa', 'mean arterial pressure', 'CI', 'to', 'and']","['group', 'baseline', 'difference', 'change', 'average value', 'roxadustat', 'mean arterial pressure']",837,"['从基线到平均值的平均血压在23至27周的平均变化是 − 2.1 mm Hg 在 roxadustat 组和 − 0.7 mm Hg 在 epoetin alfa 组(差异, − 1.4 mm Hg ; 95 % CI, − 3.7 至 1.0 ) 。']",0.4545454545454545,"['group', 'baseline', 'difference', 'change', 'average value', 'roxadustat', 'epoetin alfa', 'mean arterial pressure', 'CI', 'to', 'and']","['group', 'baseline', 'difference', 'change', 'average value']",837,在第23周到第27周期间，roxadustat组平均动脉压的平均变化为-2.1毫米汞，而epoetin alfa组为-0.7毫米汞（差异为-1.4毫米汞；95％CI，-3.7至1.0）。,0.4545454545454545,"['group', 'baseline', 'difference', 'change', 'average value', 'roxadustat', 'epoetin alfa', 'mean arterial pressure', 'CI', 'to', 'and']","['group', 'difference', 'change', 'mean arterial pressure', 'and']",,,,
843,838,"during treatment , 67 patients ( 32.8 % ) in the roxadustat group received oral iron therapy , as compared with 43 ( 43.0 % ) in the epoetin alfa group .",在治疗期间，roxadustat 组中有 67 名患者 (32.8%) 接受了口服铁剂治疗，而 epoetin alfa 组中有 43 名患者 (43.0%) 接受了口服铁剂治疗。,0.4444444444444444,"['group', 'oral', 'therapy', 'treatment', 'as', 'with', 'roxadustat', 'epoetin alfa', 'iron']","['group', 'therapy', 'treatment', 'iron']",838,"['在治疗期间,Roxadustat组的67名患者(32.8%)接受了口服铁治疗,与Epoetin alfa组的43名患者(43.0%)相比。']",0.4444444444444444,"['group', 'oral', 'therapy', 'treatment', 'as', 'with', 'roxadustat', 'epoetin alfa', 'iron']","['group', 'therapy', 'treatment', 'iron']",838,在治疗期间，67名（32.8%）罗沙达斯特患者接受口服铁疗法，而在埃波艾发组中则有43名（43.0%）患者接受了同种疗法。,0.4444444444444444,"['group', 'oral', 'therapy', 'treatment', 'as', 'with', 'roxadustat', 'epoetin alfa', 'iron']","['group', 'therapy', 'treatment', 'iron']",,,,
844,839,"there was a 14 % improvement from baseline in the LDL : HDL cholesterol ratio with roxadustat as compared with epoetin alfa ( − 0.32 ± 0.89 ; 95 % CI for treatment difference , − 0.50 to − 0.17 ) .",与 epoetin alfa 相比，罗沙司他的低密度脂蛋白：高密度脂蛋白胆固醇比基线有 14% 的改善（- 0.32 ± 0.89；治疗差异的 95% CI，- 0.50 至 - 0.17）。,0.6923076923076923,"['cholesterol', 'improvement', 'baseline', 'ratio', 'HDL', 'difference', 'LDL', 'treatment', 'with', 'roxadustat', 'epoetin alfa', 'CI', 'to']","['cholesterol', 'improvement', 'baseline', 'ratio', 'HDL', 'difference', 'LDL', 'treatment', 'roxadustat']",839,"['在 LDL 的基线上有 14% 的改善: HDL 与 roxadustat 的胆固醇比例与 epoetin alfa 相比( − 0.32 ± 0.89 ; 治疗差异的 95% CI, − 0.50 至 − 0.17 ) 。']",0.4615384615384615,"['cholesterol', 'improvement', 'baseline', 'ratio', 'HDL', 'difference', 'LDL', 'treatment', 'with', 'roxadustat', 'epoetin alfa', 'CI', 'to']","['cholesterol', 'improvement', 'baseline', 'ratio', 'difference', 'treatment']",839,罗沙达斯特与红细胞增多素相比，在基线LDL：HDL胆固醇比上有14％的改善（-0.32±0.89；治疗差异的95％CI，-0.50到-0.17）。,0.4615384615384615,"['cholesterol', 'improvement', 'baseline', 'ratio', 'HDL', 'difference', 'LDL', 'treatment', 'with', 'roxadustat', 'epoetin alfa', 'CI', 'to']","['cholesterol', 'improvement', 'baseline', 'ratio', 'difference', 'treatment']",,,,
845,840,"in addition , there was a mean treatment difference between the roxadustat group and the epoetin alfa group of − 12.4 ± 9.7 mg per deciliter ( − 0.14 ± 0.11 mmol per liter ) in the decrease in triglyceride level .",此外，roxadustat 组和 epoetin alfa 组之间在甘油三酯水平降低方面的平均治疗差异为 − 12.4 ± 9.7 mg/dL（− 0.14 ± 0.11 mmol/L）。,0.5,"['triglyceride', 'group', 'decrease', 'mean', 'deciliter', 'addition', 'difference', 'treatment', 'level', 'roxadustat', 'epoetin alfa', 'and']","['triglyceride', 'group', 'mean', 'difference', 'treatment', 'level']",840,"['除此之外,Roxadustat 组和 Epoetin 阿尔法 组之间的治疗差异为 − 12.4 ± 9.7 mg 每分升( − 0.14 ± 0.11 mmol 每升)的三酯水平下降。']",0.3333333333333333,"['triglyceride', 'group', 'decrease', 'mean', 'deciliter', 'addition', 'difference', 'treatment', 'level', 'roxadustat', 'epoetin alfa', 'and']","['group', 'difference', 'treatment', 'level']",840,除此之外，羅薩膽固醇組與賀爾蒙組之間還存在一個平均治療差異，即羅薩膽固醇組每公克體重每天減少0.14±0.11毫克膽固醇的量，而賀爾蒙組每公克體重每天減少0.12±0.1毫克膽固醇的量。,0.1666666666666666,"['triglyceride', 'group', 'decrease', 'mean', 'deciliter', 'addition', 'difference', 'treatment', 'level', 'roxadustat', 'epoetin alfa', 'and']","['mean', 'and']",,,,
846,841,markers OF INFLAMMATION,炎症标志物,,[],[],841,['炎症标志'],,[],[],841,"标记物，炎症

Chinese:

标记物，炎症",,[],[],,,,
847,842,a total of 159 of 204 patients ( 77.9 % ) treated with roxadustat and 63 of 100 patients ( 63.0 % ) treated with epoetin alfa reported having at least one adverse event during treatment .,接受 roxadustat 治疗的 204 名患者中的 159 名 (77.9%) 和接受 epoetin alfa 治疗的 100 名患者中的 63 名 (63.0%) 报告在治疗期间至少有一次不良事件。,0.2857142857142857,"['total', 'treatment', 'adverse event', 'with', 'roxadustat', 'epoetin alfa', 'and']","['treatment', 'adverse event']",842,['共有159名204名(77.9%)用Roxadustat治疗的患者和100名(63.0%)用Epoetin alfa治疗的患者中有63名报告在治疗期间至少有1个副作用。'],0.1428571428571428,"['total', 'treatment', 'adverse event', 'with', 'roxadustat', 'epoetin alfa', 'and']",['treatment'],842,总共有159名（77.9%）使用罗莎达斯唑治疗的病人和63名（63.0%）使用腺苷氨酸治疗的病人报告了在治疗期间至少有一个不良事件。,0.2857142857142857,"['total', 'treatment', 'adverse event', 'with', 'roxadustat', 'epoetin alfa', 'and']","['treatment', 'adverse event']",,,,
848,843,"the most frequently reported event was upper respiratory infection , which occurred in 37 patients ( 18.1 % ) in the roxadustat group and in 11 ( 11.0 % ) in the epoetin alfa group .",最常报告的事件是上呼吸道感染，罗沙司他组有 37 名患者 (18.1%)，阿法依泊汀组有 11 名患者 (11.0%)。,0.3333333333333333,"['infection', 'group', 'frequently', 'upper', 'respiratory', 'roxadustat', 'epoetin alfa', 'event', 'and']","['infection', 'group', 'roxadustat']",843,"['最常报告的事件是上呼吸道感染,发生在37名患者(18.1%)在罗克萨多斯特群体和11名患者(11.0%)在阿尔法群体中。']",0.2222222222222222,"['infection', 'group', 'frequently', 'upper', 'respiratory', 'roxadustat', 'epoetin alfa', 'event', 'and']","['infection', 'group']",843,最常见的事件是上呼吸道感染，在罗沙达斯特组中有37名患者（18.1%），在埃波艾发组中有11名患者（11.0%）。,0.2222222222222222,"['infection', 'group', 'frequently', 'upper', 'respiratory', 'roxadustat', 'epoetin alfa', 'event', 'and']","['infection', 'group']",,,,
849,844,a total of 29 patients ( 14.2 % ) treated with roxadustat and 10 ( 10.0 % ) treated with epoetin alfa reported having at least one serious adverse event during treatment .,共有 29 名接受 roxadustat 治疗的患者 (14.2%) 和 10 名 (10.0%) 接受 epoetin alfa 治疗的患者报告在治疗期间至少发生一次严重不良事件。,0.2857142857142857,"['serious adverse event', 'total', 'treatment', 'with', 'roxadustat', 'epoetin alfa', 'and']","['serious adverse event', 'treatment']",844,['共 29 名( 14.2 % )用 roxadustat 和 10 (10.0 % )用 epoetin alfa 治疗的患者报告在治疗期间至少有 1 个严重的副作用。'],0.1428571428571428,"['serious adverse event', 'total', 'treatment', 'with', 'roxadustat', 'epoetin alfa', 'and']",['treatment'],844,总共有29名病人（14.2%）在使用罗泽达斯特治疗期间报告至少一个严重的不良事件，而在使用红细胞生成素治疗的10名病人（10.0%）中也有同样比例的人报告至少一个严重的不良事件。,0.2857142857142857,"['serious adverse event', 'total', 'treatment', 'with', 'roxadustat', 'epoetin alfa', 'and']","['treatment', 'and']",,,,
850,845,adverse events that occurred in at least 5 % of the patients in either group are listed in Table 3 .,表 3 列出了两组中至少 5% 的患者发生的不良事件。,0.4285714285714285,"['group', '5', 'table', 'adverse', '3', 'that', 'in']","['group', '5', 'table']",845,"['在任何群体中至少有5%的患者中发生的副作用,列入表3。']",0.4285714285714285,"['group', '5', 'table', 'adverse', '3', 'that', 'in']","['group', '5', 'table']",845,在表3中列出了至少5%的患者发生的不良事件。,0.2857142857142857,"['group', '5', 'table', 'adverse', '3', 'that', 'in']","['5', 'table']",,,,
851,846,"on the basis of central laboratory assessments of blood samples obtained at baseline ( week 1 ) and every 4 weeks , the mean changes in potassium level were as follows : at week 5 , a change of 0.12 mmol per liter in the roxadustat group and 0.01 mmol per liter in the epoetin alfa group ; at week 13 , a change of − 0.04 mmol per liter and − 0.01 mmol per liter , respectively ; and at week 21 , a change of − 0.07 mmol per liter and − 0.02 mmol per liter , respectively .",根据中央实验室对基线（第 1 周）和每 4 周采集的血样进行的评估，血钾水平的平均变化如下：第 5 周时，roxadustat 组每升变化 0.12 毫摩尔，每升变化 0.01 毫摩尔每升在 epoetin alfa 组中；在第 13 周，变化分别为 − 0.04 mmol/L 和 − 0.01 mmol/L ；在第 21 周，变化分别为 − 0.07 mmol/L 和 − 0.02 mmol/L。,0.5789473684210527,"['group', '5', 'mean', 'liter', 'baseline', '1', 'potassium', 'blood', 'basis', 'central', 'week', 'laboratory', '4', 'level', 'change', 'roxadustat', 'epoetin alfa', 'on', 'and']","['group', '5', 'mean', 'liter', 'baseline', '1', 'potassium', 'week', 'laboratory', 'level', 'change']",846,"['基于基线(第1周)和每4周获得的血液样本的中央实验室评估,<unk>水平的平均变化如下:第5周,<unk>分组每升 0.12 mmol 和<unk>分组每升 0.01 mmol;第13周,每升 - 0.04 mmol 和每升 - 0.01 mmol 分别;第21周,每升 - 0.07 mmol 和每升 - 0.02 mmol 分别。']",0.5789473684210527,"['group', '5', 'mean', 'liter', 'baseline', '1', 'potassium', 'blood', 'basis', 'central', 'week', 'laboratory', '4', 'level', 'change', 'roxadustat', 'epoetin alfa', 'on', 'and']","['group', '5', 'mean', 'liter', 'baseline', '1', 'blood', 'week', 'laboratory', 'level', 'change']",846,根据在基线（第1周）和每隔4周采集的血液样本的中心实验室评估，钾水平的平均变化如下：在第5周，roxadustat组为0.12 mmol/L，而epoetin alfa组为0.01 mmol/L；在第13周，分别为-0.04 mmol/L和-0.01 mmol/L；在第21周，分别为-0.07 mmol/L和-0.02 mmol/L。,0.631578947368421,"['group', '5', 'mean', 'liter', 'baseline', '1', 'potassium', 'blood', 'basis', 'central', 'week', 'laboratory', '4', 'level', 'change', 'roxadustat', 'epoetin alfa', 'on', 'and']","['group', '5', 'mean', 'baseline', '1', 'potassium', 'blood', 'week', 'laboratory', 'level', 'change', 'and']",,,,
852,847,"the proportion of patients with potassium values within categories from 5.5 mmol per liter or less , more than 5.5 to 6.0 mmol per liter , more than 6.0 to 6.5 mmol per liter , and more than 6.5 mmol per liter at baseline and at weeks 13 and 27 were generally similar in the treatment groups ( Table S4 in the Supplementary Appendix ) .",在基线以及第 13 周和第 27 周时钾值在 5.5 毫摩尔/升或以下、超过 5.5 至 6.0 毫摩尔/升、超过 6.0 至 6.5 毫摩尔/升以及超过 6.5 毫摩尔/升的类别中的患者比例治疗组的总体相似性（补充附录表 S4）。,0.4,"['proportion', 'appendix', 'liter', 'table', 'baseline', 'potassium', 'categories', 'supplementary', 'treatment', 'values', 'with', 'S4', 'to', 'and', 'similar']","['proportion', 'liter', 'table', 'baseline', 'potassium', 'treatment']",847,"['在每升5,5 mmol或更少的类别内,<unk>值患者的比例,每升5,5 mmol以上至6.0 mmol以上,每升6.0 mmol以上至6,5 mmol以上,在基线上每升6,5 mmol以上,在13周和27周,一般类似于治疗小组(附件中的S4表)。']",0.4666666666666667,"['proportion', 'appendix', 'liter', 'table', 'baseline', 'potassium', 'categories', 'supplementary', 'treatment', 'values', 'with', 'S4', 'to', 'and', 'similar']","['proportion', 'appendix', 'liter', 'table', 'baseline', 'treatment', 'to']",847,在基线和第13周和第27周，治疗组患者钾值在5.5毫克每升以下、5.5至6.0毫克每升、6.0至6.5毫克每升和6.5毫克每升以上的分类中的比例总体相似（表S4补充附件）。,0.4666666666666667,"['proportion', 'appendix', 'liter', 'table', 'baseline', 'potassium', 'categories', 'supplementary', 'treatment', 'values', 'with', 'S4', 'to', 'and', 'similar']","['proportion', 'appendix', 'liter', 'table', 'baseline', 'potassium', 'treatment']",,,,
853,848,the percentage of patients who received rescue therapy or who did not reach the lower end of the hemoglobin target range ( 10 g per deciliter ) did not differ substantially between groups .,接受挽救治疗或未达到血红蛋白目标范围下限（10 克/分升）的患者百分比在各组之间没有显着差异。,0.3333333333333333,"['percentage', 'range', 'who', 'hemoglobin', 'deciliter', 'lower', 'therapy', 'differ', 'target', 'end', 'rescue', 'reach']","['range', 'hemoglobin', 'therapy', 'target']",848,['接受救生疗法或未达到血球目标范围(每分克10g)的低端患者的比例在群体之间没有显著差异。'],0.25,"['percentage', 'range', 'who', 'hemoglobin', 'deciliter', 'lower', 'therapy', 'differ', 'target', 'end', 'rescue', 'reach']","['range', 'therapy', 'target']",848,经救治的患者或未达到目标血红蛋白水平下限（10克/分升）的患者百分比在两组之间没有显著差异。,0.1666666666666666,"['percentage', 'range', 'who', 'hemoglobin', 'deciliter', 'lower', 'therapy', 'differ', 'target', 'end', 'rescue', 'reach']","['hemoglobin', 'target']",,,,
854,849,"inflammation is known to increase the hepcidin level , resulting in functional iron deficiency .",众所周知，炎症会增加铁调素水平，导致功能性缺铁。,0.5,"['iron deficiency', 'inflammation', 'functional', 'level', 'increase', 'to']","['iron deficiency', 'inflammation', 'level']",849,"['炎症已知增加肝炎水平,导致功能铁缺乏。']",0.5,"['iron deficiency', 'inflammation', 'functional', 'level', 'increase', 'to']","['iron deficiency', 'inflammation', 'level']",849,炎症已知会增加肝铁蛋白水平，导致功能性铁缺乏。,0.5,"['iron deficiency', 'inflammation', 'functional', 'level', 'increase', 'to']","['iron deficiency', 'inflammation', 'level']",,,,
855,850,the use of intravenous iron therapy was restricted in both groups - a design that was based on the previous observation that oral iron therapy provided results equivalent to those of intravenous iron therapy with roxadustat.34,两组均限制静脉铁剂治疗的使用——这一设计基于之前的观察结果，即口服铁剂治疗提供的结果与罗沙司他静脉铁剂治疗的结果相同。 34,0.4166666666666667,"['equivalent', 'oral', 'previous', 'therapy', 'intravenous', 'design', 'observation', 'with', 'iron', '-', 'that', 'to']","['therapy', 'design', 'observation', 'iron', 'to']",850,"['在两组中使用 intravenous iron therapy 是有限的 - 一个设计是基于以前的观察,口腔铁疗法提供了与 roxadustat 的 intravenous iron therapy 相同的结果。']",0.5,"['equivalent', 'oral', 'previous', 'therapy', 'intravenous', 'design', 'observation', 'with', 'iron', '-', 'that', 'to']","['previous', 'therapy', 'design', 'observation', 'iron', 'to']",850,在两组中都限制了静脉输液铁疗法的使用 - 这是基于先前观察到口服铁疗法与罗沙度竭相当的结果而设计的。34,0.5,"['equivalent', 'oral', 'previous', 'therapy', 'intravenous', 'design', 'observation', 'with', 'iron', '-', 'that', 'to']","['equivalent', 'therapy', 'design', 'observation', 'iron', 'to']",,,,
856,851,the mechanism of action of epoetin alfa is limited to stimulation of the erythropoietin receptor ; oral iron is expected to be ineffective relative to intravenous iron with epoetin alfa in the treatment of anemia in patients undergoing dialysis.35,epoetin alfa 的作用机制仅限于刺激促红细胞生成素受体；在治疗透析患者的贫血方面，口服铁剂预计与静脉注射铁剂和阿法依泊汀相比无效。 35,0.5714285714285714,"['anemia', 'receptor', 'stimulation', 'erythropoietin', 'oral', 'relative', 'be', 'mechanism of action', 'treatment', 'intravenous', 'with', 'epoetin alfa', 'iron', 'limited']","['anemia', 'receptor', 'stimulation', 'erythropoietin', 'be', 'mechanism of action', 'treatment', 'iron']",851,['epoetin alfa的作用机制仅限于激发 erythropoietin 受体;预计口腔铁与 intravenous 铁与 epoetin alfa 无血病患者的治疗中将不有效。'],0.2857142857142857,"['anemia', 'receptor', 'stimulation', 'erythropoietin', 'oral', 'relative', 'be', 'mechanism of action', 'treatment', 'intravenous', 'with', 'epoetin alfa', 'iron', 'limited']","['receptor', 'mechanism of action', 'treatment', 'iron']",851,Epoetin alfa's mechanism of action is limited to stimulating the erythropoietin receptor; oral iron is expected to be ineffective compared to intravenous iron with epoetin alfa in treating anemia in patients undergoing dialysis.35,0.0,"['anemia', 'receptor', 'stimulation', 'erythropoietin', 'oral', 'relative', 'be', 'mechanism of action', 'treatment', 'intravenous', 'with', 'epoetin alfa', 'iron', 'limited']",[],,,,
857,852,"overall , changes in iron biomarker levels showed improvement with roxadustat as compared with epoetin alfa .",总体而言，与阿法依泊汀相比，罗沙司他铁生物标志物水平的变化有所改善。,0.5714285714285714,"['improvement', 'biomarker', 'as', 'with', 'roxadustat', 'epoetin alfa', 'iron']","['improvement', 'biomarker', 'roxadustat', 'iron']",852,"['总体而言,铁生物标记水平的变化表明,与epoetin alfa相比,roxadustat有所改善。']",0.2857142857142857,"['improvement', 'biomarker', 'as', 'with', 'roxadustat', 'epoetin alfa', 'iron']","['improvement', 'iron']",852,总的来说，铁的生物标志物水平的变化表明，与红细胞生成素相比，罗莎达斯特的疗效更好。,0.2857142857142857,"['improvement', 'biomarker', 'as', 'with', 'roxadustat', 'epoetin alfa', 'iron']","['biomarker', 'iron']",,,,
858,853,"the serum iron level is strongly affected by the serum transferrin level , which is increased with roxadustat .",血清铁水平受血清转铁蛋白水平的强烈影响，而罗沙司他会增加血清铁水平。,0.7142857142857143,"['transferrin', 'serum', 'level', 'with', 'roxadustat', 'iron', 'by']","['transferrin', 'serum', 'level', 'roxadustat', 'iron']",853,"['血清铁的水平受到血清转移素的水平的强烈影响,这与罗克萨德斯塔特增加。']",0.4285714285714285,"['transferrin', 'serum', 'level', 'with', 'roxadustat', 'iron', 'by']","['serum', 'level', 'iron']",853,血清铁水平受血清转铁蛋白水平影响很大，而转铁蛋白水平会在使用瑞达达斯特治疗时得到提升。,0.5714285714285714,"['transferrin', 'serum', 'level', 'with', 'roxadustat', 'iron', 'by']","['transferrin', 'serum', 'level', 'iron']",,,,
859,854,"the attenuation of the decrease in transferrin saturation with roxadustat as compared with epoetin alfa , despite the increase in transferrin level , supports an effect on enteric iron absorption with roxadustat .",尽管转铁蛋白水平增加，但与阿法依泊汀相比，罗沙司他转铁蛋白饱和度降低的减弱支持罗沙司他对肠内铁吸收的影响。,0.4285714285714285,"['attenuation', 'transferrin', 'decrease', 'absorption', 'enteric', 'saturation', 'effect', 'level', 'increase', 'with', 'despite', 'roxadustat', 'epoetin alfa', 'iron']","['transferrin', 'absorption', 'saturation', 'level', 'roxadustat', 'iron']",854,"['与epoetin alfa相比,转移林饱和量下降的减轻,尽管转移林水平上升,但支持与 roxadustat的内在铁吸收的影响。']",0.2857142857142857,"['attenuation', 'transferrin', 'decrease', 'absorption', 'enteric', 'saturation', 'effect', 'level', 'increase', 'with', 'despite', 'roxadustat', 'epoetin alfa', 'iron']","['absorption', 'saturation', 'level', 'iron']",854,roxadustat相較於epoetin alfa的輸送鐵飽和度下降減弱，儘管輸送鐵水平上升，這表明roxadustat對內臟鐵吸收的影響。,0.1428571428571428,"['attenuation', 'transferrin', 'decrease', 'absorption', 'enteric', 'saturation', 'effect', 'level', 'increase', 'with', 'despite', 'roxadustat', 'epoetin alfa', 'iron']","['absorption', 'level']",,,,
860,855,improvements in iron delivery to the bone marrow could result in a reduced use of intravenous iron therapy and an increased efficacy of oral iron therapy .,铁输送到骨髓的改善可能会减少静脉铁剂治疗的使用，并提高口服铁剂治疗的疗效。,0.3,"['bone marrow', 'oral', 'delivery', 'therapy', 'efficacy', 'intravenous', 'result', 'iron', 'to', 'and']","['bone marrow', 'therapy', 'iron']",855,"['向骨头发送铁的改进可能导致 intravenous iron therapy 的使用减少,以及口服 iron therapy 的有效性增加。']",0.2,"['bone marrow', 'oral', 'delivery', 'therapy', 'efficacy', 'intravenous', 'result', 'iron', 'to', 'and']","['efficacy', 'iron']",855,改善骨髓铁获取可以减少对静脉铁治疗的依赖，提高口服铁治疗的疗效。,0.3,"['bone marrow', 'oral', 'delivery', 'therapy', 'efficacy', 'intravenous', 'result', 'iron', 'to', 'and']","['bone marrow', 'therapy', 'iron']",,,,
861,856,the adverse events during treatment that we observed are consistent with those expected in patients undergoing dialysis .,我们在治疗期间观察到的不良事件与透析患者的预期一致。,0.2857142857142857,"['dialysis', 'adverse', 'treatment', 'with', 'that', 'in', 'we']","['dialysis', 'treatment']",856,['我们所观察到的治疗期间的副作用与患有分裂症患者的预期相一致。'],0.1428571428571428,"['dialysis', 'adverse', 'treatment', 'with', 'that', 'in', 'we']",['treatment'],856,我们观察到的治疗过程中的不良事件与那些在接受透析治疗的患者中预期的不良事件一致。,0.2857142857142857,"['dialysis', 'adverse', 'treatment', 'with', 'that', 'in', 'we']","['dialysis', 'treatment']",,,,
862,857,hyperkalemia was reported more often in patients who received roxadustat than in those who received epoetin alfa .,接受罗沙司他治疗的患者比接受阿法依泊汀治疗的患者更常报告高钾血症。,0.5,"['who', 'hyperkalemia', 'roxadustat', 'epoetin alfa']","['hyperkalemia', 'roxadustat']",857,"['甲状腺高血病在Roxadustat患者中更为常见,而在Epoetin alfa患者中更为常见。']",0.0,"['who', 'hyperkalemia', 'roxadustat', 'epoetin alfa']",[],857,在使用罗莎都斯特治疗的患者中，比使用艾泼替尼治疗的患者更常报告高钾血症。,0.25,"['who', 'hyperkalemia', 'roxadustat', 'epoetin alfa']",['hyperkalemia'],,,,
863,858,analyses of central laboratory data did not show any clinically significant changes in the mean potassium levels over time or between groups .,对中心实验室数据的分析未显示平均钾水平随时间或组间发生任何临床显着变化。,0.625,"['mean', 'data', 'potassium', 'time', 'central', 'laboratory', 'in', 'over']","['mean', 'data', 'potassium', 'time', 'laboratory']",858,['中央实验室数据的分析没有显示中间<unk>水平的临床上有意义的变化。'],0.25,"['mean', 'data', 'potassium', 'time', 'central', 'laboratory', 'in', 'over']","['data', 'laboratory']",858,经过对中央实验室数据的分析，并没有发现任何临床上显著的钾水平变化或者在不同组之间存在差异。,0.5,"['mean', 'data', 'potassium', 'time', 'central', 'laboratory', 'in', 'over']","['data', 'potassium', 'laboratory', 'over']",,,,
864,859,"the intermittent central laboratory monitoring may not have detected potassium elevations , and therefore continued evaluation will be important in presently ongoing trials ( ClinicalTrials.gov numbers , NCT02052310and NCT02273726 ) and as wider experience with roxadustat occurs .",间歇性中央实验室监测可能未检测到钾升高，因此在目前正在进行的试验（ClinicalTrials.gov 编号，NCT02052310 和 NCT02273726）中以及随着罗沙司他的更广泛经验的出现，持续评估将很重要。,0.5,"['monitoring', 'potassium', 'evaluation', 'intermittent', 'be', 'central', 'laboratory', 'experience', 'will', 'with', 'roxadustat', 'have', 'therefore', 'and']","['monitoring', 'potassium', 'intermittent', 'be', 'laboratory', 'experience', 'roxadustat']",859,"['中央实验室间隔监测可能没有发现<unk>升高,因此在目前正在进行的试验(ClinicalTrials.gov 号码、NCT02052310和NCT02273726 )中,继续进行评估,并且由于与 roxadustat 更广泛的经验发生。']",0.3571428571428571,"['monitoring', 'potassium', 'evaluation', 'intermittent', 'be', 'central', 'laboratory', 'experience', 'will', 'with', 'roxadustat', 'have', 'therefore', 'and']","['monitoring', 'be', 'laboratory', 'experience', 'have']",859,缺乏连续的中央实验室监测可能导致钾肌肉含量升高的情况被忽略，因此在目前正在进行的试验（ClinicalTrials.gov的编号，NCT02052310和NCT02273726）中以及随着更广泛使用罗沙达斯特发生的情况下，对其进行持续评估将是重要的。,0.2857142857142857,"['monitoring', 'potassium', 'evaluation', 'intermittent', 'be', 'central', 'laboratory', 'experience', 'will', 'with', 'roxadustat', 'have', 'therefore', 'and']","['monitoring', 'potassium', 'be', 'laboratory']",,,,
865,860,more patients receiving roxadustat discontinued treatment owing to adverse events than did patients receiving epoetin alfa .,接受 roxadustat 的患者因不良事件而停止治疗的患者多于接受 epoetin alfa 的患者。,0.4,"['adverse', 'treatment', 'roxadustat', 'epoetin alfa', 'to']","['treatment', 'to']",860,['因不良事件而接受Roxadustat的患者比接受Epoetin alfa的患者中断了治疗。'],0.2,"['adverse', 'treatment', 'roxadustat', 'epoetin alfa', 'to']",['treatment'],860,接受罗莎达斯塔治疗的患者由于不良事件而停止治疗的比例要高于接受多潘立酮治疗的患者。,0.4,"['adverse', 'treatment', 'roxadustat', 'epoetin alfa', 'to']","['treatment', 'to']",,,,
866,861,no clustering of severe adverse events during treatment was observed in either group .,两组在治疗期间均未观察到聚集性严重不良事件。,0.3333333333333333,"['group', 'clustering', 'adverse', 'treatment', 'no', 'severe']","['group', 'treatment']",861,"['在任何群体中,在治疗期间没有出现严重的副作用。']",0.3333333333333333,"['group', 'clustering', 'adverse', 'treatment', 'no', 'severe']","['group', 'treatment']",861,No clustering of severe adverse events was observed during treatment in either group.,0.0,"['group', 'clustering', 'adverse', 'treatment', 'no', 'severe']",[],,,,
867,862,"in conclusion , this phase 3 trial comparing 26 weeks of roxadustat therapy with epoetin alfa therapy in patients undergoing dialysis showed the noninferiority of roxadustat in the treatment of anemia .",总之，这项在接受透析的患者中比较 26 周罗沙司他疗法与阿法依泊汀疗法的 3 期试验表明，罗沙司他在治疗贫血方面具有非劣效性。,0.5,"['anemia', 'dialysis', 'phase', 'therapy', 'treatment', 'trial', '3', 'conclusion', 'with', 'roxadustat', 'epoetin alfa', 'this']","['anemia', 'dialysis', 'phase', 'therapy', 'treatment', 'roxadustat']",862,"['在结论中,这段阶段3试验与26周的罗克萨多斯特治疗与阿尔法治疗的病人进行对话,表明罗克萨多斯特在治疗贫血时不低。']",0.4166666666666667,"['anemia', 'dialysis', 'phase', 'therapy', 'treatment', 'trial', '3', 'conclusion', 'with', 'roxadustat', 'epoetin alfa', 'this']","['anemia', 'phase', 'therapy', 'treatment', 'conclusion']",862,结论：本阶段3的试验，对比了26周罗沙度他治疗与血液透析患者用赖丙哌酸治疗，表明罗沙度并不逊色于治疗贫血。,0.5,"['anemia', 'dialysis', 'phase', 'therapy', 'treatment', 'trial', '3', 'conclusion', 'with', 'roxadustat', 'epoetin alfa', 'this']","['anemia', 'dialysis', 'phase', 'therapy', 'treatment', 'conclusion']",,,,
868,863,"antibiotics are associated with CRC risk , but the effect depends on anatomical location and type of antibiotic .",抗生素与 CRC 风险相关，但效果取决于解剖位置和抗生素类型。,0.6,"['anatomical', 'type', 'location', 'associated', 'risk', 'effect', 'antibiotics', 'with', 'but', 'and']","['type', 'location', 'risk', 'effect', 'antibiotics', 'but']",863,"['抗生素与CRC风险有关,但效果取决于抗生素的解剖位置和类型。']",0.6,"['anatomical', 'type', 'location', 'associated', 'risk', 'effect', 'antibiotics', 'with', 'but', 'and']","['type', 'location', 'risk', 'effect', 'antibiotics', 'but']",863,抗生素与大肠癌风险有关，但影响取决于解剖部位和抗生素类型。,0.4,"['anatomical', 'type', 'location', 'associated', 'risk', 'effect', 'antibiotics', 'with', 'but', 'and']","['type', 'risk', 'antibiotics', 'but']",,,,
869,864,alterations of the gut microbiome can increase colorectal cancer ( CRC ) risk via bacteria that cause local inflammation and promote carcinogenesis .,肠道微生物组的改变可以通过引起局部炎症和促进癌变的细菌增加结直肠癌 (CRC) 的风险。,0.4166666666666667,"['carcinogenesis', 'bacteria', 'gut microbiome', 'inflammation', 'via', 'colorectal cancer', 'local', 'cause', 'risk', 'increase', 'that', 'and']","['bacteria', 'gut microbiome', 'inflammation', 'local', 'risk']",864,['肠道微生物的变化可以通过导致本地炎症并促进癌症的细菌来增加染色性癌症(CRC)的风险。'],0.25,"['carcinogenesis', 'bacteria', 'gut microbiome', 'inflammation', 'via', 'colorectal cancer', 'local', 'cause', 'risk', 'increase', 'that', 'and']","['bacteria', 'inflammation', 'risk']",864,肠道微生物群的改变可以通过引起局部炎症和促进肿瘤形成的细菌增加结直肠癌（CRC）风险。,0.3333333333333333,"['carcinogenesis', 'bacteria', 'gut microbiome', 'inflammation', 'via', 'colorectal cancer', 'local', 'cause', 'risk', 'increase', 'that', 'and']","['bacteria', 'inflammation', 'local', 'risk']",,,,
870,865,"previous studies suggest an association between CRC and exposure to antibiotics , but this remains insufficiently characterized .",先前的研究表明 CRC 与接触抗生素之间存在关联，但这仍未得到充分表征。,0.3333333333333333,"['exposure', 'association', 'previous', 'antibiotics', 'suggest', 'this', 'but', 'to', 'and']","['association', 'antibiotics', 'but']",865,"['以前的研究表明CRC与抗生素暴露之间的联系,但这一点仍然不够特征。']",0.5555555555555556,"['exposure', 'association', 'previous', 'antibiotics', 'suggest', 'this', 'but', 'to', 'and']","['exposure', 'association', 'previous', 'antibiotics', 'but']",865,以往的研究表明，暴露在抗生素中会与大肠癌存在关联，但是这种关联仍然不够充分地被描述。,0.5555555555555556,"['exposure', 'association', 'previous', 'antibiotics', 'suggest', 'this', 'but', 'to', 'and']","['exposure', 'association', 'antibiotics', 'this', 'but']",,,,
871,866,"using a large clinical research database in the U.K. , researchers compared antibiotic exposure in 28,980 sporadic CRC cases and 137,077 matched controls .","使用英国的大型临床研究数据库，研究人员比较了 28,980 例散发性 CRC 病例和 137,077 例匹配对照的抗生素暴露情况。",0.4444444444444444,"['antibiotic', 'research', 'database', 'exposure', 'large', 'clinical', 'sporadic', 'controls', 'and']","['antibiotic', 'research', 'exposure', 'clinical']",866,"['使用在英国的大型临床研究数据库,研究人员比较了抗生素暴露在28980例随机的CRC病例和13777匹配的检查。']",0.4444444444444444,"['antibiotic', 'research', 'database', 'exposure', 'large', 'clinical', 'sporadic', 'controls', 'and']","['antibiotic', 'research', 'exposure', 'clinical']",866,"使用英国一个大型临床研究数据库，研究人员对28,980例偶发性结直肠癌病例和137,077例配对对照组进行了抗生素暴露的对比研究。",0.4444444444444444,"['antibiotic', 'research', 'database', 'exposure', 'large', 'clinical', 'sporadic', 'controls', 'and']","['antibiotic', 'research', 'exposure', 'clinical']",,,,
872,867,the analysis was adjusted for demographic and clinical factors associated with CRC risk .,该分析针对与 CRC 风险相关的人口统计和临床因素进行了调整。,0.5,"['analysis', 'associated', 'clinical', 'risk', 'with', 'and']","['analysis', 'clinical', 'risk']",867,['分析对与CRC风险相关的人口和临床因素进行了调整。'],0.5,"['analysis', 'associated', 'clinical', 'risk', 'with', 'and']","['analysis', 'clinical', 'risk']",867,这项分析考虑了与CRC风险相关的人口和临床因素。,0.5,"['analysis', 'associated', 'clinical', 'risk', 'with', 'and']","['analysis', 'clinical', 'risk']",,,,
873,868,antibiotic exposure was comparable between those with rectal cancer and controls ( 67.1 % and 67.2 % ) .,直肠癌患者和对照组的抗生素暴露情况相当（67.1% 和 67.2%）。,0.5,"['antibiotic', 'exposure', 'rectal cancer', 'controls', 'with', 'and']","['antibiotic', 'exposure', 'rectal cancer']",868,['抗生素暴露在直肠癌和控制症(67.1%和67.2%)的人之间是相似的。'],0.5,"['antibiotic', 'exposure', 'rectal cancer', 'controls', 'with', 'and']","['antibiotic', 'exposure', 'rectal cancer']",868,抗生素暴露率在直肠癌患者和对照组之间相当（67.1%和67.2%）。,0.5,"['antibiotic', 'exposure', 'rectal cancer', 'controls', 'with', 'and']","['antibiotic', 'exposure', 'rectal cancer']",,,,
874,869,tetracyclines were associated with decreased rectal cancer risk .,四环素与直肠癌风险降低有关。,0.5,"['rectal cancer', 'associated', 'risk', 'with']","['rectal cancer', 'risk']",869,['泰特拉西克林与直肠癌风险降低有关。'],0.5,"['rectal cancer', 'associated', 'risk', 'with']","['rectal cancer', 'risk']",869,"Tetracyclines were associated with decreased rectal cancer risk.

Chinese:

四环素与降低直肠癌风险相关联。",0.5,"['rectal cancer', 'associated', 'risk', 'with']","['rectal cancer', 'risk']",,,,
875,870,these results provide useful information for patients who are contemplating quitting .,这些结果为正在考虑戒烟的患者提供了有用的信息。,0.5,"['who', 'information']",['information'],870,['这些结果为正在考虑退休的患者提供有用的信息。'],0.5,"['who', 'information']",['information'],870,这些结果为考虑戒烟的患者提供了有用的信息。,0.5,"['who', 'information']",['information'],,,,
876,871,"moreover , recent retrospective studies have suggested that lipophilic statins ( atorvastatin , lovastatin , simvastatin ) prevent HCC more effectively than hydrophilic statins ( pravastatin , rosuvastatin ) .",此外，最近的回顾性研究表明，亲脂性他汀类药物（阿托伐他汀、洛伐他汀、辛伐他汀）比亲水性他汀类药物（普伐他汀、瑞舒伐他汀）更能有效地预防 HCC。,0.5384615384615384,"['lipophilic', 'recent', 'statins', 'pravastatin', 'retrospective studies', 'prevent', 'rosuvastatin', 'simvastatin', 'lovastatin', 'atorvastatin', 'hydrophilic', 'have', 'that']","['statins', 'prevent', 'rosuvastatin', 'simvastatin', 'lovastatin', 'atorvastatin', 'have']",871,"['此外,最近的回顾研究表明,脂肪静脉(Atorvastatin、Lovastatin、Symvastatin)比水素静脉(Pravastatin、Rosuvastatin)更有效地预防HCC。']",0.1538461538461538,"['lipophilic', 'recent', 'statins', 'pravastatin', 'retrospective studies', 'prevent', 'rosuvastatin', 'simvastatin', 'lovastatin', 'atorvastatin', 'hydrophilic', 'have', 'that']","['prevent', 'have']",871,此外，最近的回顾研究表明，与水溶脂型他汀类药物（波伏他汀、罗伏他汀、辛伏他汀）相比，脂溶性他汀类药物（阿托伐他汀、洛伐他汀、西伏他汀）更有效地预防肝癌。,0.3846153846153846,"['lipophilic', 'recent', 'statins', 'pravastatin', 'retrospective studies', 'prevent', 'rosuvastatin', 'simvastatin', 'lovastatin', 'atorvastatin', 'hydrophilic', 'have', 'that']","['statins', 'prevent', 'lovastatin', 'atorvastatin', 'have']",,,,
877,872,statin use data were obtained from the Swedish Prescribed Drug Register .,他汀类药物使用数据来自瑞典处方药登记处。,0.5,"['statin', 'data', 'drug', 'register']","['data', 'drug']",872,['斯塔丁使用数据从瑞典处方药登记簿中获取。'],0.25,"['statin', 'data', 'drug', 'register']",['data'],872,统计数据来源于瑞典处方药品登记处。,0.5,"['statin', 'data', 'drug', 'register']","['data', 'drug']",,,,
878,873,"this nationwide Swedish registry study showed that among patients with viral hepatitis , lipophilic statin use reduced HCC risk but hydrophilic statin use did not .",这项全国范围的瑞典登记研究表明，在病毒性肝炎患者中，使用亲脂性他汀类药物可降低 HCC 风险，但使用亲水性他汀类药物则不能。,0.2727272727272727,"['statin', 'lipophilic', 'study', 'registry', 'risk', 'with', 'viral hepatitis', 'hydrophilic', 'this', 'that', 'but']","['risk', 'viral hepatitis', 'but']",873,"['这项全国性瑞典注册表研究表明,患有病毒性肝炎的患者中,<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性']",0.0909090909090909,"['statin', 'lipophilic', 'study', 'registry', 'risk', 'with', 'viral hepatitis', 'hydrophilic', 'this', 'that', 'but']",['viral hepatitis'],873,这项全国性的瑞典登记研究表明，在患有病毒性肝炎的患者中，使用脂溶性他汀类药物可以降低肝癌风险，但使用水溶性他汀类药物则不能。,0.2727272727272727,"['statin', 'lipophilic', 'study', 'registry', 'risk', 'with', 'viral hepatitis', 'hydrophilic', 'this', 'that', 'but']","['risk', 'viral hepatitis', 'but']",,,,
879,874,future studies should focus on the feasibility of lipophilic statins as an HCC prevention tool in patients with chronic liver disease .,未来的研究应侧重于亲脂性他汀类药物作为慢性肝病患者 HCC 预防工具的可行性。,0.5555555555555556,"['focus', 'lipophilic', 'statins', 'prevention', 'liver disease', 'chronic', 'tool', 'with', 'feasibility']","['statins', 'prevention', 'liver disease', 'chronic', 'tool']",874,['未来的研究应专注于患有慢性肝脏疾病的患者的HCC预防工具的脂肪静脉的可行性。'],0.3333333333333333,"['focus', 'lipophilic', 'statins', 'prevention', 'liver disease', 'chronic', 'tool', 'with', 'feasibility']","['prevention', 'chronic', 'tool']",874,未来的研究应该集中在检验油性他汀类药物作为慢性肝病患者预防肝癌的可行性上。,0.5555555555555556,"['focus', 'lipophilic', 'statins', 'prevention', 'liver disease', 'chronic', 'tool', 'with', 'feasibility']","['focus', 'statins', 'prevention', 'liver disease', 'chronic']",,,,
880,875,past and present studies now not only confirm the safety of statin use in liver disease but also its potential benefit in reducing HCC risk .,过去和现在的研究现在不仅证实了他汀类药物在肝病中使用的安全性，而且证实了它在降低 HCC 风险方面的潜在益处。,0.6,"['safety', 'statin', 'potential', 'liver disease', 'risk', 'present', 'benefit', 'but', 'and', 'past']","['safety', 'liver disease', 'risk', 'present', 'but', 'and']",875,"['过去和目前的研究现在不仅证实了在肝脏疾病中使用静素的安全性,而且降低HCC风险的潜在好处。']",0.5,"['safety', 'statin', 'potential', 'liver disease', 'risk', 'present', 'benefit', 'but', 'and', 'past']","['safety', 'risk', 'present', 'but', 'and']",875,过去和现在的研究不仅证实了在肝病中使用他汀类药物的安全性，而且还证明了它在降低肝癌风险方面的潜在益处。,0.6,"['safety', 'statin', 'potential', 'liver disease', 'risk', 'present', 'benefit', 'but', 'and', 'past']","['safety', 'liver disease', 'risk', 'present', 'but', 'and']",,,,
881,876,dietary factors have been implicated for many years as potential pathophysiologic triggers in the development of type 1 diabetes ( T1D ) .,多年来，饮食因素一直被认为是 1 型糖尿病 (T1D) 发展的潜在病理生理诱因。,0.4444444444444444,"['diabetes', 'type', '1', 'potential', 'dietary', 'development', 'as', 'have', 'in']","['diabetes', 'type', '1', 'development']",876,"['多年来,营养因素参与了1型糖尿病(T1D)的发展潜在的病理发育因素。']",0.5555555555555556,"['diabetes', 'type', '1', 'potential', 'dietary', 'development', 'as', 'have', 'in']","['diabetes', 'type', '1', 'potential', 'development']",876,饮食因素多年来一直被认为是type 1 diabetes (T1D)发展的潜在病理触发因素。,0.2222222222222222,"['diabetes', 'type', '1', 'potential', 'dietary', 'development', 'as', 'have', 'in']","['1', 'development']",,,,
882,877,this is the first study to report associations between intake of specific cereals and IA in children genetically predisposed to T1D .,这是第一项报告遗传易患 T1D 的儿童摄入特定谷物与 IA 之间关联的研究。,0.3333333333333333,"['intake', 'report', 'study', 'IA', 'specific', 'this', 'to', 'and', 'first']","['report', 'this', 'first']",877,['这是第一项研究报告特定的谷物摄入与基因偏向T1D儿童的AI之间的联系。'],0.3333333333333333,"['intake', 'report', 'study', 'IA', 'specific', 'this', 'to', 'and', 'first']","['report', 'this', 'first']",877,这是第一个研究，报告了儿童摄入特定谷物和先天性糖尿病之间的关联。,0.3333333333333333,"['intake', 'report', 'study', 'IA', 'specific', 'this', 'to', 'and', 'first']","['report', 'this', 'first']",,,,
883,878,"of concern is that some of the dietary components implicated , such as fiber , are promoted for their health benefits .",令人担忧的是，一些相关的膳食成分，如纤维，因其健康益处而得到推广。,0.5,"['health', 'fiber', 'dietary', 'concern', 'as', 'that']","['health', 'fiber', 'as']",878,"['令人担忧的是,其中的一些营养成分,如纤维,为其健康益处而受益。']",0.5,"['health', 'fiber', 'dietary', 'concern', 'as', 'that']","['health', 'fiber', 'as']",878,"People are concerned that some of the dietary components that have been linked to health benefits, such as fiber, are being promoted.

Chinese:
人们担心某些被认为有益健康的饮食成分，如纤维，正在受到宣传。",0.5,"['health', 'fiber', 'dietary', 'concern', 'as', 'that']","['health', 'fiber', 'as']",,,,
884,879,"until more is understood , encouraging moderate intake , not exceeding standard recommended amounts , of gluten , fiber , and selected grains might be reasonable , especially in the child who has a known strong family history of autoimmune disease .",在了解更多之前，鼓励适度摄入面筋、纤维和精选谷物，但不要超过标准推荐量，这可能是合理的，尤其是对于已知有明显自身免疫性疾病家族史的儿童。,0.4,"['intake', 'standard', 'grains', 'who', 'child', 'family history', 'fiber', 'moderate', 'strong', 'autoimmune disease']","['standard', 'child', 'family history', 'fiber']",879,"['更明白,鼓励适度的摄入量,不超过标准推荐量,葡萄糖,纤维和选择的谷物可能是合理的,特别是在儿童谁有已知的强烈的家庭历史的免疫疾病。']",0.5,"['intake', 'standard', 'grains', 'who', 'child', 'family history', 'fiber', 'moderate', 'strong', 'autoimmune disease']","['standard', 'child', 'family history', 'fiber', 'strong']",879,直到我們了解更多，勸導適中飲用，不超過標準建議的量，麩質，纖維和選定的穀物可能是合理的，特別是在已知有強烈自體免疫疾病家族史的兒童。,0.2,"['intake', 'standard', 'grains', 'who', 'child', 'family history', 'fiber', 'moderate', 'strong', 'autoimmune disease']","['family history', 'strong']",,,,
885,880,"we cardiologists have long lived with the idea that the assessment of myocardial viability should inform decisions about revascularization , particularly in patients with ischemic cardiomyopathy , but some studies have questioned this reasonable assumption .",我们心脏病专家长期以来一直认为，心肌活力评估应为血运重建决策提供信息，尤其是在缺血性心肌病患者中，但一些研究质疑这一合理假设。,0.3571428571428571,"['viability', 'revascularization', 'inform', 'assessment', 'idea', 'cardiomyopathy', 'myocardial', 'with', 'have', 'this', 'that', 'but', 'ischemic', 'we']","['revascularization', 'assessment', 'cardiomyopathy', 'this', 'but']",880,"['我们心脏病学家长期以来一直生活在这个想法中,评估心脏病的可行性应该告知关于复发的决策,特别是在患有心脏病的患者,但一些研究质疑了这个合理的假设。']",0.3571428571428571,"['viability', 'revascularization', 'inform', 'assessment', 'idea', 'cardiomyopathy', 'myocardial', 'with', 'have', 'this', 'that', 'but', 'ischemic', 'we']","['inform', 'assessment', 'have', 'this', 'but']",880,我们心脏病医生长期以来一直认为，心肌活性的评估应该能够指导再血管化治疗的决策，尤其是对于心肌缺血性心脏病患者来说，但是一些研究质疑了这一合理的假设。,0.2142857142857142,"['viability', 'revascularization', 'inform', 'assessment', 'idea', 'cardiomyopathy', 'myocardial', 'with', 'have', 'this', 'that', 'but', 'ischemic', 'we']","['assessment', 'this', 'but']",,,,
886,881,"of the 1212 patients enrolled in STICH , 601 had myocardial viability testing , of whom 19 % were classified as having no viability .",在参加 STICH 的 1212 名患者中，有 601 名进行了心肌活力测试，其中 19% 被归类为无活力。,0.0,"['viability', 'no', 'myocardial', 'testing', 'classified']",[],881,"['在1212名入学的患者中,601人接受了心血管可行性测试,其中19%被认为没有可行性。']",0.0,"['viability', 'no', 'myocardial', 'testing', 'classified']",[],881,在1212名参与STICH的患者中，有601名接受过心肌可活性测试，其中19%被分为无可活性。,0.0,"['viability', 'no', 'myocardial', 'testing', 'classified']",[],,,,
887,882,the incidence of death at 10 years did not differ significantly between patients with or without myocardial viability .,10 年的死亡率在有或没有心肌存活的患者之间没有显着差异。,0.1666666666666666,"['incidence', 'death', 'viability', 'differ', 'myocardial', 'without']",['death'],882,['10岁时死亡的发病率在患有或没有心脏病的患者之间没有显著的差异。'],0.3333333333333333,"['incidence', 'death', 'viability', 'differ', 'myocardial', 'without']","['incidence', 'death']",882,10年死亡率在有或没有心肌活性的患者中没有显著差异。,0.1666666666666666,"['incidence', 'death', 'viability', 'differ', 'myocardial', 'without']",['death'],,,,
888,883,CABG was not more effective for patients with viability than those without viability .,CABG 对于有生存力的患者并不比没有生存力的患者更有效。,0.0,"['viability', 'CABG', 'without']",[],883,['CABG在可行性患者中并不比不可行性患者更有效。'],0.0,"['viability', 'CABG', 'without']",[],883,"CABG was not more effective for patients with viability than those without viability.

Chinese:

CABG对于具有生存能力的患者并不比没有生存能力的患者更有效。",0.0,"['viability', 'CABG', 'without']",[],,,,
889,884,LVEF was measured in 318 participants at baseline and 4 months .,在基线和 4 个月时测量了 318 名参与者的 LVEF。,0.25,"['baseline', '4', 'at', 'and']",['baseline'],884,['LVEF在基线上的318名参与者和4个月进行了测量。'],0.25,"['baseline', '4', 'at', 'and']",['baseline'],884,"LVEF was measured in 318 participants at baseline and 4 months.

Chinese:

LVEF 在 318 名参与者的基线和 4 个月的测量。",0.25,"['baseline', '4', 'at', 'and']",['baseline'],,,,
890,885,"patients with myocardial viability had a significant increase in LVEF at 4 months , whereas those without viability did not .",有心肌活力的患者在 4 个月时 LVEF 显着增加，而没有心肌活力的患者则没有。,0.0,"['viability', 'myocardial', '4', 'increase', 'at', 'without']",[],885,"['患有心血管生存率的患者在4个月内在LVEF中显著增加,而没有生存率的患者则没有。']",0.0,"['viability', 'myocardial', '4', 'increase', 'at', 'without']",[],885,研究发现，心肌有活力的病人在4个月后心肺功能显著提高，而没有活力的病人则没有显著改善。,0.0,"['viability', 'myocardial', '4', 'increase', 'at', 'without']",[],,,,
891,886,mortality did not correlate with LVEF change .,死亡率与 LVEF 变化无关。,0.6666666666666666,"['mortality', 'change', 'with']","['mortality', 'change']",886,['死亡率与LVEF的变化无关。'],0.6666666666666666,"['mortality', 'change', 'with']","['mortality', 'change']",886,死亡率与心肺功能改变没有相关性。,0.3333333333333333,"['mortality', 'change', 'with']",['mortality'],,,,
892,887,"in this population , myocardial viability did not dictate the likelihood of benefit from surgical revascularization .",在这个人群中，心肌活力并不决定从手术血运重建中获益的可能性。,0.25,"['population', 'viability', 'surgical', 'revascularization', 'myocardial', 'benefit', 'this', 'in']","['population', 'revascularization']",887,"['在这个人口中,心脏病的可行性并没有定义从手术复发中受益的可能性。']",0.125,"['population', 'viability', 'surgical', 'revascularization', 'myocardial', 'benefit', 'this', 'in']",['population'],887,在这个人群中，心肌有效性并不决定手术再血管化的有益性。,0.125,"['population', 'viability', 'surgical', 'revascularization', 'myocardial', 'benefit', 'this', 'in']",['population'],,,,
893,888,"also , change in LVEF , a surrogate outcome , failed to correspond with benefit .",此外，作为替代结果的 LVEF 的变化与获益不符。,0.375,"['surrogate', 'outcome', 'change', 'benefit', 'with', 'correspond', 'in', 'to']","['surrogate', 'outcome', 'change']",888,"['此外,LVEF的变化,一个超越的结果,未能与利润相匹配。']",0.375,"['surrogate', 'outcome', 'change', 'benefit', 'with', 'correspond', 'in', 'to']","['outcome', 'change', 'benefit']",888,"Although there was also a change in LVEF, a surrogate outcome, this failed to correspond with any benefit.",0.0,"['surrogate', 'outcome', 'change', 'benefit', 'with', 'correspond', 'in', 'to']",[],,,,
894,889,I have some concerns about testing for interactions in relatively small groups .,我对在相对较小的群体中测试交互有一些担忧。,0.3333333333333333,"['testing', 'I', 'have']",['have'],889,['我对对相对较小群体的互动进行测试的一些担忧。'],0.0,"['testing', 'I', 'have']",[],889,我在相对较小的群体中测试交互方面有些担忧。,0.3333333333333333,"['testing', 'I', 'have']",['have'],,,,
895,890,we need larger studies to be certain about these findings .,我们需要更大规模的研究来确定这些发现。,0.2,"['need', 'be', 'certain', 'to', 'we']",['need'],890,['我们需要更大的研究来确定这些发现。'],0.2,"['need', 'be', 'certain', 'to', 'we']",['need'],890,我们需要更大规模的研究来确定这些发现。,0.2,"['need', 'be', 'certain', 'to', 'we']",['need'],,,,
896,891,"nevertheless , until people can demonstrate the value of testing for myocardial viability in patients with ischemic cardiomyopathy , we should hold off using these tests for similar patients to inform decisions .",尽管如此，在人们能够证明检测缺血性心肌病患者心肌活力的价值之前，我们应该推迟对类似患者使用这些检测来做出决定。,0.1666666666666666,"['value', 'viability', 'inform', 'cardiomyopathy', 'myocardial', 'testing', 'with', 'to', 'hold', 'ischemic', 'similar', 'we']","['value', 'cardiomyopathy']",891,"['然而,直到人们能够在患有催化性心脏病的患者中证明心脏病可行性测试的价值,我们应该停止使用这些类似患者的测试来告知决策。']",0.1666666666666666,"['value', 'viability', 'inform', 'cardiomyopathy', 'myocardial', 'testing', 'with', 'to', 'hold', 'ischemic', 'similar', 'we']","['value', 'inform']",891,尽管如此，直到人们可以证明在心肌缺血性心肌病患者中测试心肌生存的价值，我们应该推迟使用这些测试来为类似患者做出决策。,0.1666666666666666,"['value', 'viability', 'inform', 'cardiomyopathy', 'myocardial', 'testing', 'with', 'to', 'hold', 'ischemic', 'similar', 'we']","['value', 'cardiomyopathy']",,,,
897,892,more patients receiving the standard dose versus dose escalation had KRAS mutation ( 55 % vs. 39 % ) .,更多接受标准剂量与剂量递增的患者有 KRAS 突变（55% 对 39%）。,1.0,"['standard', 'mutation', 'dose']","['standard', 'mutation', 'dose']",892,"['接收标准剂量对剂量升级的患者多,患有KRAS突变(55%对39%)。']",1.0,"['standard', 'mutation', 'dose']","['standard', 'mutation', 'dose']",892,更多患者接受标准剂量而非加量治疗后出现KRAS突变（55% vs. 39%）。,1.0,"['standard', 'mutation', 'dose']","['standard', 'mutation', 'dose']",,,,
898,893,these results show that dose escalation of regorafenib does not appear to compromise the modest efficacy of this agent and support the use of this strategy in clinical practice .,这些结果表明，瑞戈非尼的剂量增加似乎不会损害该药物的适度疗效，并支持在临床实践中使用该策略。,0.4615384615384615,"['support', 'strategy', 'clinical', 'practice', 'efficacy', 'compromise', 'agent', 'dose', 'regorafenib', 'this', 'that', 'to', 'and']","['support', 'strategy', 'clinical', 'practice', 'dose', 'regorafenib']",893,"['这些结果表明,regorafenib的剂量升级似乎不会损害这种药物的微妙有效性,并支持在临床实践中使用这种策略。']",0.4615384615384615,"['support', 'strategy', 'clinical', 'practice', 'efficacy', 'compromise', 'agent', 'dose', 'regorafenib', 'this', 'that', 'to', 'and']","['support', 'strategy', 'clinical', 'practice', 'efficacy', 'dose']",893,这些结果表明，在临床实践中，不会出现药物剂量增加导致效力降低的情况，支持使用药物剂量增加策略。,0.3846153846153846,"['support', 'strategy', 'clinical', 'practice', 'efficacy', 'compromise', 'agent', 'dose', 'regorafenib', 'this', 'that', 'to', 'and']","['support', 'strategy', 'clinical', 'practice', 'dose']",,,,
899,894,a small multicenter study shows durable improvement in T2D indicators at 1 year after endoscopic duodenal mucosal resurfacing .,一项小型多中心研究表明，在内窥镜十二指肠粘膜表面重修术后 1 年，T2D 指标得到持久改善。,0.4444444444444444,"['improvement', 'year', '1', 'mucosal', 'duodenal', 'study', 'after', 'at', 'in']","['improvement', 'year', '1', 'after']",894,"['一项小多中心研究显示,在内分泌双膜粘膜复发后1年,T2D指标的持续改善。']",0.4444444444444444,"['improvement', 'year', '1', 'mucosal', 'duodenal', 'study', 'after', 'at', 'in']","['improvement', 'year', '1', 'after']",894,一项小型多中心研究表明，经内窥镜下的胰十二指肠表面再生治疗后，糖尿病患者的症状持续改善。,0.2222222222222222,"['improvement', 'year', '1', 'mucosal', 'duodenal', 'study', 'after', 'at', 'in']","['improvement', 'after']",,,,
900,895,"exclusion of the duodenum through bariatric surgery has shown immediate benefit of improved glycemic control , independent of weight loss , in obese patients with type 2 diabetes mellitus ( T2D ) .",通过减肥手术切除十二指肠已显示，在患有 2 型糖尿病 (T2D) 的肥胖患者中，独立于体重减轻，可以直接改善血糖控制。,0.4615384615384615,"['type', 'control', '2', 'surgery', 'exclusion', 'diabetes mellitus', 'obese', 'duodenum', 'independent', 'immediate', 'benefit', 'with', 'weight loss']","['type', 'control', '2', 'surgery', 'diabetes mellitus', 'duodenum']",895,"['通过 bariatric 手术排除双胞胎表明,在肥胖患者患有2型糖尿病(T2D)的体重损失独立的改善血糖控制的即时好处。']",0.4615384615384615,"['type', 'control', '2', 'surgery', 'exclusion', 'diabetes mellitus', 'obese', 'duodenum', 'independent', 'immediate', 'benefit', 'with', 'weight loss']","['type', 'control', '2', 'surgery', 'diabetes mellitus', 'independent']",895,通过胃肠道减重手术排除了十二指肠，立即在肥胖的2型糖尿病患者中显示出了显著的血糖控制改善，这与体重减轻无关。,0.5384615384615384,"['type', 'control', '2', 'surgery', 'exclusion', 'diabetes mellitus', 'obese', 'duodenum', 'independent', 'immediate', 'benefit', 'with', 'weight loss']","['type', 'control', '2', 'surgery', 'diabetes mellitus', 'obese', 'duodenum']",,,,
901,896,endoscopic duodenal mucosal resurfacing ( DMR ) - a new minimally invasive technique that involves circumferential hydrothermal ablation of the postampullary duodenal mucosa - might present a novel approach to improving glycemic control in T2D .,内窥镜十二指肠粘膜表面重修术 (DMR) - 一种新的微创技术，涉及壶腹后十二指肠粘膜的环状水热消融 - 可能会提供一种改善 T2D 血糖控制的新方法。,0.3571428571428571,"['approach', 'control', 'mucosal', 'duodenal', 'hydrothermal', 'ablation', 'novel', 'technique', 'present', '-', 'that', 'in', 'to', 'new']","['control', 'mucosal', 'ablation', 'technique', 'new']",896,"['内分泌双胞胎粘膜复发(DMR) - 一个新的最小侵入性技术,涉及周围的水热消化后双胞胎粘膜 - 可能提出一个新的方法,以改善血糖控制在T2D。']",0.2142857142857142,"['approach', 'control', 'mucosal', 'duodenal', 'hydrothermal', 'ablation', 'novel', 'technique', 'present', '-', 'that', 'in', 'to', 'new']","['control', 'technique', 'new']",896,endoscopic duodenal mucosal resurfacing (DMR)是一种新的微创技术，它涉及环形水热消融后十二指肠黏膜。这种技术可能提供了一种改善2型糖尿病血糖控制的新方法。,0.2857142857142857,"['approach', 'control', 'mucosal', 'duodenal', 'hydrothermal', 'ablation', 'novel', 'technique', 'present', '-', 'that', 'in', 'to', 'new']","['control', 'ablation', 'technique', 'new']",,,,
902,897,"at 24 weeks postprocedure , there were improvements in parameters of T2D , including glycated hemoglobin ( HbA1c ) level ( − 10 mmol / mol ) , fasting plasma glucose ( − 1.7 mmol / L ) , and homeostatic model assessment for insulin resistance ( − 2.9 ) , which were each sustained at 12 months .",术后 24 周，T2D 参数有所改善，包括糖化血红蛋白 ( HbA1c ) 水平 ( − 10 mmol / mol ) 、空腹血糖 ( − 1.7 mmol / L ) 和胰岛素抵抗的稳态模型评估 ( − 2.9 ) ，每一个持续 12 个月。,0.3076923076923077,"['glucose', 'plasma', 'model', 'hemoglobin', '/', 'assessment', 'fasting', 'insulin resistance', 'level', 'at', 'mol', 'each', 'and']","['model', 'hemoglobin', 'assessment', 'level']",897,"['在24周后程序中,T2D的参数有所改善,包括血糖血糖(HbA1c)水平( − 10 mmol / mol ),禁食血糖( − 1.7 mmol / L ),以及对胰岛素抵抗性( − 2.9 )的同位素模型评估,每分为12个月。']",0.2307692307692307,"['glucose', 'plasma', 'model', 'hemoglobin', '/', 'assessment', 'fasting', 'insulin resistance', 'level', 'at', 'mol', 'each', 'and']","['model', 'assessment', 'level']",897,在手术后的24周，糖尿病的指标有所改善，包括糖化血红蛋白（HbA1c）水平（-10毫克/克）、空腹血糖（-1.7毫克/升）和胰岛素抵抗家庭模型评估（-2.9），均在12个月内维持稳定。,0.3076923076923077,"['glucose', 'plasma', 'model', 'hemoglobin', '/', 'assessment', 'fasting', 'insulin resistance', 'level', 'at', 'mol', 'each', 'and']","['model', 'hemoglobin', 'assessment', 'level']",,,,
903,898,change in HbA1c did not correlate with weight loss .,HbA1c 的变化与体重减轻无关。,0.25,"['change', 'with', 'weight loss', 'in']",['change'],898,['HbA1c的变化与减肥无关。'],0.25,"['change', 'with', 'weight loss', 'in']",['change'],898,HbA1c变化与体重损失无关。,0.25,"['change', 'with', 'weight loss', 'in']",['change'],,,,
904,899,it is fascinating that the duodenum has such an important role in T2D and potential role in insulin regulation .,令人着迷的是，十二指肠在 T2D 中具有如此重要的作用，并且在胰岛素调节中具有潜在作用。,0.5714285714285714,"['insulin', 'regulation', 'potential', 'role', 'duodenum', 'that', 'and']","['insulin', 'regulation', 'role', 'duodenum']",899,"['令人兴奋的是,双胞胎在T2D中扮演着如此重要的角色,以及在胰岛素调节中的潜在角色。']",0.4285714285714285,"['insulin', 'regulation', 'potential', 'role', 'duodenum', 'that', 'and']","['insulin', 'regulation', 'role']",899,这很有趣，十二指肠在2型糖尿病中扮演着如此重要的角色，并且有可能在胰岛素调节中起到作用。,0.5714285714285714,"['insulin', 'regulation', 'potential', 'role', 'duodenum', 'that', 'and']","['insulin', 'regulation', 'role', 'duodenum']",,,,
905,900,further research is needed to define which patients with T2D would most benefit from this approach and to standardize endoscopic DMR technique .,需要进一步的研究来确定哪些 T2D 患者最能从这种方法中受益，并使内窥镜 DMR 技术标准化。,0.25,"['approach', 'research', 'technique', 'benefit', 'with', 'this', 'to', 'and']","['research', 'technique']",900,"['需要进一步的研究来确定哪些患有T2D的患者会从这种方法中受益,并标准化内分泌DMR技术。']",0.25,"['approach', 'research', 'technique', 'benefit', 'with', 'this', 'to', 'and']","['research', 'technique']",900,"further research is needed to define which patients with T2D would most benefit from this approach and to standardize endoscopic DMR technique .

Chinese:

需要進一步的研究來確定哪些糖尿病患者將最大程度受益於此方法，以及將内視鏡DMR技術規範化。",0.25,"['approach', 'research', 'technique', 'benefit', 'with', 'this', 'to', 'and']","['research', 'technique']",,,,
906,901,"moreover , carefully controlled studies are needed before DMR is used clinically in T2D .",此外，在将 DMR 临床用于 T2D 之前，需要进行仔细的对照研究。,0.3333333333333333,"['controlled', 'before', 'in']",['before'],901,"['此外,在 DMR 在 T2D 中临床使用之前需要仔细控制的研究。']",0.6666666666666666,"['controlled', 'before', 'in']","['controlled', 'before']",901,此外，在将DMR用于T2D的临床治疗之前，需要进行精心的控制研究。,0.6666666666666666,"['controlled', 'before', 'in']","['controlled', 'before']",,,,
907,902,"however , these results support the concept of an effective endoscopic intervention to favorably alter metabolism .",然而，这些结果支持有效的内窥镜干预以有利地改变新陈代谢的概念。,0.6,"['metabolism', 'support', 'intervention', 'concept', 'to']","['metabolism', 'support', 'concept']",902,"['然而,这些结果支持有效的内分泌干预的概念,有利于改变代谢。']",0.8,"['metabolism', 'support', 'intervention', 'concept', 'to']","['metabolism', 'support', 'concept', 'to']",902,然而，这些结果支持通过有效的内镜干预来有利地改变新陈代谢的概念。,0.6,"['metabolism', 'support', 'intervention', 'concept', 'to']","['metabolism', 'support', 'concept']",,,,
908,903,"compared with placebo , ursodeoxycholic acid modestly improved pruritis but did not reduce adverse perinatal outcomes .",与安慰剂相比，熊去氧胆酸适度改善了瘙痒症，但并未减少不良的围产期结局。,0.4285714285714285,"['placebo', 'perinatal', 'reduce', 'ursodeoxycholic acid', 'adverse', 'with', 'but']","['placebo', 'ursodeoxycholic acid', 'but']",903,"['与 placebo 相比, ursodeoxycholic 酸温和地改善了 pruritis 但并没有减少不良的阴道结果。']",0.1428571428571428,"['placebo', 'perinatal', 'reduce', 'ursodeoxycholic acid', 'adverse', 'with', 'but']",['but'],903,与安慰剂相比，乳酸黄油能够轻微改善皮疹症状，但并未减少不良产褥期后果。,0.2857142857142857,"['placebo', 'perinatal', 'reduce', 'ursodeoxycholic acid', 'adverse', 'with', 'but']","['placebo', 'but']",,,,
909,904,"ursodeoxycholic acid and placebo resulted in similar rates of preterm birth ( 17 % and 20 % ; risk ratio , 0.79 ) and admission to the neonatal intensive care unit ( 14 % and 17 % ; RR , 0.81 ) .",熊去氧胆酸和安慰剂导致相似的早产率（17% 和 20%；风险比，0.79）和进入新生儿重症监护病房的比率（14% 和 17%；RR，0.81）。,0.6363636363636364,"['placebo', 'neonatal', 'ratio', 'admission', 'birth', 'ursodeoxycholic acid', 'intensive care unit', 'risk', 'to', 'and', 'similar']","['placebo', 'ratio', 'admission', 'ursodeoxycholic acid', 'intensive care unit', 'risk', 'similar']",904,"['ursodeoxycholic acid and placebo resulted in similar rates of premature birth ( 17 % and 20 % ; risk ratio, 0.79 ) and admission to the neonatal intensive care unit ( 14 % and 17 % ; RR, 0.81 ) 。']",0.0,"['placebo', 'neonatal', 'ratio', 'admission', 'birth', 'ursodeoxycholic acid', 'intensive care unit', 'risk', 'to', 'and', 'similar']",[],904,在胎儿早产和新生儿入住新生儿重症监护室的风险上， ursodeoxycholic acid 和安慰剂的结果相似（17％和20％；风险比为0.79），并且住院时间也相似（14％和17％；风险比为0.81）。,0.2727272727272727,"['placebo', 'neonatal', 'ratio', 'admission', 'birth', 'ursodeoxycholic acid', 'intensive care unit', 'risk', 'to', 'and', 'similar']","['placebo', 'ratio', 'risk']",,,,
910,905,there are limited data from randomized trials evaluating the use of antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease .,评估房颤和稳定性冠状动脉疾病患者使用抗血栓治疗的随机试验数据有限。,0.4,"['disease', 'data', 'antithrombotic', 'therapy', 'atrial fibrillation', 'with', 'coronary artery', 'limited', 'in', 'and']","['disease', 'data', 'therapy', 'coronary artery']",905,['有有限的数据从随机测试评估使用抗血管治疗的患者和稳定的冠状动脉疾病。'],0.5,"['disease', 'data', 'antithrombotic', 'therapy', 'atrial fibrillation', 'with', 'coronary artery', 'limited', 'in', 'and']","['disease', 'data', 'therapy', 'coronary artery', 'limited']",905,There is limited data from randomized trials evaluating the use of antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease.,0.0,"['disease', 'data', 'antithrombotic', 'therapy', 'atrial fibrillation', 'with', 'coronary artery', 'limited', 'in', 'and']",[],,,,
911,906,"the primary efficacy end point was a composite of stroke , systemic embolism , myocardial infarction , unstable angina requiring revascularization , or death from any cause ; this end point was analyzed for noninferiority with a noninferiority margin of 1.46 .",主要疗效终点是卒中、全身性栓塞、心肌梗死、需要血运重建的不稳定型心绞痛或全因死亡的复合终点。对这一终点进行了非劣效性分析，非劣效性界值为 1.46。,0.5294117647058824,"['myocardial infarction', 'composite', 'stroke', 'margin', 'death', 'angina', 'revascularization', 'primary', 'cause', 'unstable', 'systemic', 'efficacy', 'end', 'point', 'embolism', 'with', 'this']","['myocardial infarction', 'stroke', 'death', 'angina', 'revascularization', 'unstable', 'point', 'embolism', 'this']",906,"['初级有效性终点是中风、系统性胚胎、心脏病发作、不稳定的腹泻,需要复发或因任何原因而死亡的组成部分;这一终点被分析为不低于不低于不低于不低于不低于不低于不低于不低于不低于不低于不低。']",0.4117647058823529,"['myocardial infarction', 'composite', 'stroke', 'margin', 'death', 'angina', 'revascularization', 'primary', 'cause', 'unstable', 'systemic', 'efficacy', 'end', 'point', 'embolism', 'with', 'this']","['stroke', 'death', 'cause', 'unstable', 'efficacy', 'point', 'this']",906,主要疗效指标是中风、系统性血栓栓塞、心肌梗死、不稳定性心绞痛需要血管再造的复合指标，该指标通过非劣效性间隔为1.46进行了分析。,0.4117647058823529,"['myocardial infarction', 'composite', 'stroke', 'margin', 'death', 'angina', 'revascularization', 'primary', 'cause', 'unstable', 'systemic', 'efficacy', 'end', 'point', 'embolism', 'with', 'this']","['myocardial infarction', 'stroke', 'death', 'angina', 'unstable', 'embolism', 'this']",,,,
912,907,"the primary safety end point was major bleeding , according to the criteria of the International Society on Thrombosis and Hemostasis ; this end point was analyzed for superiority .",根据国际血栓形成和止血学会的标准，主要安全终点是大出血；对该终点进行优效性分析。,0.5,"['bleeding', 'safety', 'thrombosis', 'hemostasis', 'major', 'society', 'primary', 'superiority', 'end', 'point', 'on', 'this', 'to', 'and']","['bleeding', 'safety', 'thrombosis', 'hemostasis', 'society', 'point', 'this']",907,"['主要安全终点是主要出血,根据国际血管和血管疾病协会的标准;这一终点被分析为优越性。']",0.4285714285714285,"['bleeding', 'safety', 'thrombosis', 'hemostasis', 'major', 'society', 'primary', 'superiority', 'end', 'point', 'on', 'this', 'to', 'and']","['bleeding', 'safety', 'society', 'superiority', 'point', 'this']",907,根据国际血栓与血液学会的标准，主要安全性终点是重度出血；对于优越性的分析，这一终点被分析。,0.5714285714285714,"['bleeding', 'safety', 'thrombosis', 'hemostasis', 'major', 'society', 'primary', 'superiority', 'end', 'point', 'on', 'this', 'to', 'and']","['bleeding', 'safety', 'thrombosis', 'society', 'superiority', 'point', 'this', 'to']",,,,
913,908,"as antithrombotic therapy , rivaroxaban monotherapy was noninferior to combination therapy for efficacy and superior for safety in patients with atrial fibrillation and stable coronary artery disease . ( Funded by the Japan Cardiovascular Research Foundation ; AFIRE UMIN Clinical Trials Registry number , UMIN000016612 ; and ClinicalTrials.gov number , NCT02642419 . )",作为抗血栓治疗，利伐沙班单药治疗在心房颤动和稳定性冠状动脉疾病患者中的疗效不劣于联合疗法，安全性优于联合疗法。 （由日本心血管研究基金会资助；AFIRE UMIN 临床试验注册号 UMIN000016612；ClinicalTrials.gov 号 NCT02642419。）,0.55,"['safety', 'combination therapy', 'disease', 'cardiovascular', 'research', 'antithrombotic', 'superior', 'atrial fibrillation', 'registry', 'number', 'clinical', 'japan', 'efficacy', 'with', 'coronary artery', 'rivaroxaban', 'foundation', 'by', 'to', 'and']","['safety', 'disease', 'cardiovascular', 'research', 'atrial fibrillation', 'number', 'clinical', 'coronary artery', 'rivaroxaban', 'by', 'to']",908,"['作为抗血管疗法,Rivaroxaban单疗法不低于结合疗法的有效性和安全性高于患有甲状腺纤维和稳定的冠状动脉疾病的患者(由日本心血管研究基金会资助;AFIRE UMIN临床试验登记号,UMIN000016612;和ClinicalTrials.gov号,NCT02642419。']",0.5,"['safety', 'combination therapy', 'disease', 'cardiovascular', 'research', 'antithrombotic', 'superior', 'atrial fibrillation', 'registry', 'number', 'clinical', 'japan', 'efficacy', 'with', 'coronary artery', 'rivaroxaban', 'foundation', 'by', 'to', 'and']","['safety', 'disease', 'cardiovascular', 'research', 'number', 'clinical', 'efficacy', 'coronary artery', 'by', 'to']",908,作为抗血栓疗法，利瓦膦单药疗法在心房颤动和稳定的冠状动脉疾病患者中的疗效与联合疗法相当，而在安全性方面优于联合疗法。（本研究得到日本心脏病研究基金会的资助；AFIRE UMIN临床试验注册编号，UMIN000016612；和ClinicalTrials.gov编号，NCT02642419。）,0.45,"['safety', 'combination therapy', 'disease', 'cardiovascular', 'research', 'antithrombotic', 'superior', 'atrial fibrillation', 'registry', 'number', 'clinical', 'japan', 'efficacy', 'with', 'coronary artery', 'rivaroxaban', 'foundation', 'by', 'to', 'and']","['safety', 'disease', 'research', 'atrial fibrillation', 'number', 'clinical', 'coronary artery', 'to', 'and']",,,,
914,909,"the use of dual antiplatelet therapy ( a P2Y12 inhibitor plus aspirin ) after percutaneous coronary intervention ( PCI ) reduces the risk of ischemic or atherothrombotic events , including stent thrombosis , recurrent myocardial infarction , and cardiovascular death.1",经皮冠状动脉介入治疗 (PCI) 后使用双重抗血小板治疗（P2Y12 抑制剂加阿司匹林）可降低缺血或动脉粥样硬化血栓形成事件的风险，包括支架内血栓形成、复发性心肌梗死和心血管死亡。 1,0.5555555555555556,"['inhibitor', 'myocardial infarction', 'aspirin', 'cardiovascular', 'plus', 'antiplatelet', 'coronary', 'thrombosis', 'therapy', 'recurrent', 'stent', 'intervention', 'risk', 'after', 'dual', 'percutaneous', 'and', 'ischemic']","['inhibitor', 'myocardial infarction', 'aspirin', 'cardiovascular', 'plus', 'coronary', 'thrombosis', 'therapy', 'risk', 'after']",909,"['二重抗板膜治疗(P2Y12抑制剂加上阿司匹林)的使用后,皮层干预(PCI)减少了伊斯基米或甲状腺炎事件的风险,包括<unk>血病,重复的心脏病发作和心血管死亡。']",0.3888888888888889,"['inhibitor', 'myocardial infarction', 'aspirin', 'cardiovascular', 'plus', 'antiplatelet', 'coronary', 'thrombosis', 'therapy', 'recurrent', 'stent', 'intervention', 'risk', 'after', 'dual', 'percutaneous', 'and', 'ischemic']","['inhibitor', 'aspirin', 'cardiovascular', 'plus', 'therapy', 'risk', 'after']",909,使用抗血小板治疗（P2Y12抑制剂加上阿司匹林）在心脏经皮冠状动脉介入术（PCI）后可以减少缺血性或动脉粥样硬化相关事件的风险，包括血管内支架血栓形成、再发心肌梗死和心血管死亡。1,0.6111111111111112,"['inhibitor', 'myocardial infarction', 'aspirin', 'cardiovascular', 'plus', 'antiplatelet', 'coronary', 'thrombosis', 'therapy', 'recurrent', 'stent', 'intervention', 'risk', 'after', 'dual', 'percutaneous', 'and', 'ischemic']","['inhibitor', 'myocardial infarction', 'aspirin', 'cardiovascular', 'plus', 'coronary', 'thrombosis', 'therapy', 'stent', 'risk', 'after']",,,,
915,910,"the use of antiplatelet agents in combination with anticoagulation results in an increased risk of bleeding events , as shown recently in a nationwide Danish cohort study.3",最近一项全国性的丹麦队列研究显示，抗血小板药物与抗凝药物联合使用会增加出血事件的风险。 3,0.5,"['bleeding', 'combination', 'anticoagulation', 'antiplatelet', 'risk', 'cohort', 'as', 'with']","['bleeding', 'combination', 'anticoagulation', 'risk']",910,"['与抗凝固剂相结合的抗阴膜药物的使用导致出血事件的风险增加,如最近在全国范围内的丹麦凝固研究中所示。']",0.625,"['bleeding', 'combination', 'anticoagulation', 'antiplatelet', 'risk', 'cohort', 'as', 'with']","['bleeding', 'combination', 'anticoagulation', 'risk', 'as']",910,使用抗血小板剂和抗凝剂一起会导致出血事件的风险增加，近期一项丹麦全国队列研究表明了这一点。3,0.375,"['bleeding', 'combination', 'anticoagulation', 'antiplatelet', 'risk', 'cohort', 'as', 'with']","['bleeding', 'anticoagulation', 'risk']",,,,
916,911,"as a consequence , the selection of the most effective antithrombotic treatment for patients with atrial fibrillation and stable coronary artery disease is a clinical challenge requiring careful assessment of the risks of ischemia and bleeding in each patient.2",因此，为心房颤动和稳定性冠状动脉疾病患者选择最有效的抗血栓治疗是一项临床挑战，需要仔细评估每位患者的缺血和出血风险。 2,0.6,"['bleeding', 'disease', 'ischemia', 'antithrombotic', 'atrial fibrillation', 'assessment', 'treatment', 'clinical', 'challenge', 'consequence', 'with', 'careful', 'coronary artery', 'each', 'and']","['bleeding', 'disease', 'ischemia', 'atrial fibrillation', 'assessment', 'treatment', 'clinical', 'challenge', 'coronary artery']",911,"['因此,在患有甲状腺纤维和稳定的冠状动脉疾病的患者中选择最有效的抗血管治疗是一种临床挑战,需要仔细评估每个患者的腹泻和出血风险。']",0.4666666666666667,"['bleeding', 'disease', 'ischemia', 'antithrombotic', 'atrial fibrillation', 'assessment', 'treatment', 'clinical', 'challenge', 'consequence', 'with', 'careful', 'coronary artery', 'each', 'and']","['bleeding', 'disease', 'assessment', 'treatment', 'clinical', 'challenge', 'coronary artery']",911,因此，对于心房颤动和稳定的冠状动脉疾病患者来说，选择最有效的抗血栓治疗方案是一个需要仔细评估缺血和出血风险的临床挑战。,0.6,"['bleeding', 'disease', 'ischemia', 'antithrombotic', 'atrial fibrillation', 'assessment', 'treatment', 'clinical', 'challenge', 'consequence', 'with', 'careful', 'coronary artery', 'each', 'and']","['bleeding', 'disease', 'ischemia', 'atrial fibrillation', 'assessment', 'treatment', 'clinical', 'challenge', 'coronary artery']",,,,
917,912,"such treatment is followed by combination therapy with an oral anticoagulant plus a P2Y12 inhibitor for 4 to 6 weeks8 or up to 12 months in selected patients.9,10","这种治疗之后是口服抗凝剂和 P2Y12 抑制剂联合治疗 4 至 6 周8，或在选定患者中长达 12 个月。 9,10",0.4,"['inhibitor', 'combination therapy', 'anticoagulant', 'plus', 'oral', 'treatment', '4', 'up', 'with', 'by']","['inhibitor', 'combination therapy', 'anticoagulant', 'treatment']",912,['这种治疗由口服抗凝固剂和P2Y12抑制剂进行4至6周8或最多12个月的组合治疗。'],0.3,"['inhibitor', 'combination therapy', 'anticoagulant', 'plus', 'oral', 'treatment', '4', 'up', 'with', 'by']","['inhibitor', 'treatment', 'by']",912,"这种治疗方法会被结合使用口服抗凝剂和P2Y12抑制剂4至6周8或在选择的患者达12个月9,10。",0.3,"['inhibitor', 'combination therapy', 'anticoagulant', 'plus', 'oral', 'treatment', '4', 'up', 'with', 'by']","['inhibitor', 'anticoagulant', 'treatment']",,,,
918,913,"after 12 months of combination therapy , or in patients with atrial fibrillation and stable coronary artery disease not requiring intervention , current guidelines recommend monotherapy with an oral anticoagulant.9,10","经过 12 个月的联合治疗后，或对于不需要干预的心房颤动和稳定型冠状动脉疾病患者，目前的指南建议使用口服抗凝剂进行单药治疗。 9,10",0.5454545454545454,"['combination therapy', 'disease', 'oral', 'recommend', 'atrial fibrillation', 'intervention', 'after', 'current', 'with', 'coronary artery', 'and']","['combination therapy', 'disease', 'recommend', 'atrial fibrillation', 'after', 'coronary artery']",913,"['经过12个月的组合治疗,或在不需要干预的静脉动脉和静脉动脉疾病的患者中,现行指导方针建议用口服抗凝固剂单治疗。']",0.1818181818181818,"['combination therapy', 'disease', 'oral', 'recommend', 'atrial fibrillation', 'intervention', 'after', 'current', 'with', 'coronary artery', 'and']","['disease', 'recommend']",913,"在经过12个月的组合治疗之后，或者是在心房颤动患者的稳定冠状动脉疾病中没有需要干预的情况下，目前的指导方针建议使用口服抗凝剂进行单药治疗。9,10",0.4545454545454545,"['combination therapy', 'disease', 'oral', 'recommend', 'atrial fibrillation', 'intervention', 'after', 'current', 'with', 'coronary artery', 'and']","['disease', 'recommend', 'atrial fibrillation', 'after', 'coronary artery']",,,,
919,914,"however , this approach has yet to be supported by evidence from randomized , controlled trials .",然而，这种方法尚未得到随机对照试验证据的支持。,0.1428571428571428,"['approach', 'controlled', 'be', 'evidence', 'this', 'by', 'to']",['evidence'],914,"['然而,这种方法尚未得到随机、控制的试验的证据的支持。']",0.2857142857142857,"['approach', 'controlled', 'be', 'evidence', 'this', 'by', 'to']","['controlled', 'evidence']",914,然而，这种方法尚未得到随机对照试验的支持。,0.0,"['approach', 'controlled', 'be', 'evidence', 'this', 'by', 'to']",[],,,,
920,915,"furthermore , substantial numbers of patients in this situation continue to be treated with combination therapy , which indicates a gap between guidelines and clinical practice.11",此外，大量处于这种情况的患者继续接受联合治疗，这表明指南与临床实践之间存在差距。 11,0.4545454545454545,"['combination therapy', 'situation', 'gap', 'be', 'clinical', 'with', 'continue', 'this', 'to', 'and', 'substantial']","['combination therapy', 'be', 'clinical', 'continue', 'to']",915,"['此外,在这种情况下,大量的患者仍在用结合疗法进行治疗,这表明指导方针与临床实践之间的差距。']",0.1818181818181818,"['combination therapy', 'situation', 'gap', 'be', 'clinical', 'with', 'continue', 'this', 'to', 'and', 'substantial']","['be', 'clinical']",915,此外，目前有大量患者仍在使用联合疗法，这表明指南和临床实践之间存在差距。11,0.1818181818181818,"['combination therapy', 'situation', 'gap', 'be', 'clinical', 'with', 'continue', 'this', 'to', 'and', 'substantial']","['be', 'clinical']",,,,
921,916,"one previous randomized , controlled trial has evaluated the efficacy and safety of monotherapy with an oral anticoagulant as compared with combination therapy with an oral anticoagulant plus a single antiplatelet agent in patients with atrial fibrillation and stable coronary artery disease more than 1 year after stenting , but this trial was underpowered and inconclusive because of the premature termination of enrollment.12",先前的一项随机对照试验评估了在支架置入术后 1 年以上的心房颤动和稳定型冠状动脉疾病患者中，口服抗凝剂单一疗法与口服抗凝剂加单一抗血小板药物联合疗法的疗效和安全性，但是由于提前终止入组，该试验的功效不足且不确定。 12,0.6956521739130435,"['safety', 'combination therapy', 'anticoagulant', 'disease', 'year', '1', 'plus', 'oral', 'antiplatelet', 'previous', 'atrial fibrillation', 'termination', 'after', 'efficacy', 'premature', 'with', 'coronary artery', 'agent', 'controlled trial', 'this', 'single', 'but', 'and']","['safety', 'anticoagulant', 'disease', 'year', '1', 'plus', 'atrial fibrillation', 'termination', 'after', 'efficacy', 'premature', 'coronary artery', 'controlled trial', 'this', 'single', 'but']",916,"['此前一项随机控制的研究评估了口服抗凝固剂单疗法的有效性和安全性,与口服抗凝固剂的结合疗法相比,并在关节炎和稳定的冠状动脉疾病1年以上的患者中进行单一抗凝固剂的单一抗凝固剂,但这项研究由于提前终止登记而被支持和无关紧要。']",0.4782608695652174,"['safety', 'combination therapy', 'anticoagulant', 'disease', 'year', '1', 'plus', 'oral', 'antiplatelet', 'previous', 'atrial fibrillation', 'termination', 'after', 'efficacy', 'premature', 'with', 'coronary artery', 'agent', 'controlled trial', 'this', 'single', 'but', 'and']","['safety', 'disease', 'year', '1', 'termination', 'efficacy', 'premature', 'coronary artery', 'single', 'but', 'and']",916,"一项先前的随机对照试验评估了口服抗凝剂单独治疗与口服抗凝剂加单一抗血小板剂联合治疗心房颤动且冠状动脉疾病患者的有效性和安全性，但这项试验未能获得成功，因为患者人数过少而导致提前终止了试验。

翻译：

一项先前随机对照试验评估了口服抗凝剂单独治疗和口服抗凝剂加单一抗血小板剂联合治疗心房颤动且冠状动脉疾病患者的有效性和安全性，但该试验由于患者人数过少而意外终止，结果不具备统计学意义。",0.6086956521739131,"['safety', 'combination therapy', 'anticoagulant', 'disease', 'year', '1', 'plus', 'oral', 'antiplatelet', 'previous', 'atrial fibrillation', 'termination', 'after', 'efficacy', 'premature', 'with', 'coronary artery', 'agent', 'controlled trial', 'this', 'single', 'but', 'and']","['safety', 'combination therapy', 'anticoagulant', 'disease', 'plus', 'atrial fibrillation', 'termination', 'efficacy', 'premature', 'coronary artery', 'controlled trial', 'single', 'but', 'and']",,,,
922,917,details regarding the trial design have been described previously.13,有关试验设计的详细信息已在前面描述过。 13,0.75,"['regarding', 'trial', 'design', 'have']","['regarding', 'design', 'have']",917,['关于试验设计的细节已被描述。13'],0.5,"['regarding', 'trial', 'design', 'have']","['regarding', 'design']",917,之前已经描述了有关试验设计的细节。13,0.75,"['regarding', 'trial', 'design', 'have']","['regarding', 'design', 'have']",,,,
923,918,funding was provided by the Japan Cardiovascular Research Foundation under a contract with Bayer Yakuhin .,日本心血管研究基金会根据与 Bayer Yakuhin 的合同提供资金。,0.4285714285714285,"['cardiovascular', 'research', 'contract', 'japan', 'with', 'foundation', 'by']","['cardiovascular', 'research', 'foundation']",918,['该资金由日本心血管研究基金会根据与Bayer Yakuhin的合同提供。'],0.5714285714285714,"['cardiovascular', 'research', 'contract', 'japan', 'with', 'foundation', 'by']","['cardiovascular', 'research', 'foundation', 'by']",918,日本心脏研究基金会为拜耳药品公司提供了资金支持。,0.1428571428571428,"['cardiovascular', 'research', 'contract', 'japan', 'with', 'foundation', 'by']",['research'],,,,
924,919,"the company had no role in the design of the trial , in the collection or analysis of the data , in the interpretation of the trial results , or in the writing of the manuscript .",该公司未参与试验设计、数据收集或分析、试验结果解释或文稿撰写。,0.6,"['data', 'analysis', 'collection', 'interpretation', 'role', 'no', 'manuscript', 'writing', 'trial', 'design']","['data', 'analysis', 'collection', 'interpretation', 'writing', 'design']",919,['公司在审查的设计、数据收集或分析、审查结果的解释或手稿的写作中没有任何作用。'],0.8,"['data', 'analysis', 'collection', 'interpretation', 'role', 'no', 'manuscript', 'writing', 'trial', 'design']","['data', 'analysis', 'collection', 'interpretation', 'role', 'manuscript', 'writing', 'design']",919,公司在试验的设计、数据收集和分析、结果解释或者手稿撰写中没有任何作用。,0.7,"['data', 'analysis', 'collection', 'interpretation', 'role', 'no', 'manuscript', 'writing', 'trial', 'design']","['data', 'analysis', 'collection', 'interpretation', 'role', 'manuscript', 'design']",,,,
925,920,"under the guidance of the authors , Mebix , a contract research organization , provided assistance in the selection of the participating centers , supervision or monitoring of the centers , collection and storage of trial data , data analysis , interpretation of the trial results , and preparation of the manuscript .",在作者的指导下，合同研究机构Mebix在参与中心的选择、中心的监督或监测、试验数据的收集和存储、数据分析、试验结果的解释以及准备手稿。,0.5625,"['monitoring', 'organization', 'research', 'data', 'analysis', 'preparation', 'collection', 'interpretation', 'supervision', 'contract', 'manuscript', 'storage', 'trial', 'assistance', 'and', 'guidance']","['monitoring', 'research', 'data', 'analysis', 'preparation', 'collection', 'interpretation', 'manuscript', 'storage']",920,"['在作者的指导下,Mebix是一家合同研究组织,在参与中心的选择、监督或监测中心、审查数据的收集和存储、数据分析、审查结果的解释和手稿的编制方面提供了协助。']",0.5625,"['monitoring', 'organization', 'research', 'data', 'analysis', 'preparation', 'collection', 'interpretation', 'supervision', 'contract', 'manuscript', 'storage', 'trial', 'assistance', 'and', 'guidance']","['monitoring', 'organization', 'research', 'data', 'analysis', 'collection', 'interpretation', 'manuscript', 'storage']",920,在作者的指导下，Mebix负责选择参与试验的中心、监督中心的进展，收集并存储试验数据、数据分析、试验结果解释和论文撰写。,0.3125,"['monitoring', 'organization', 'research', 'data', 'analysis', 'preparation', 'collection', 'interpretation', 'supervision', 'contract', 'manuscript', 'storage', 'trial', 'assistance', 'and', 'guidance']","['data', 'analysis', 'collection', 'interpretation', 'storage']",,,,
926,921,the trial was designed and led by an executive steering committee .,该试验由执行指导委员会设计和领导。,0.3333333333333333,"['steering', 'committee', 'trial', 'by', 'and', 'led']","['committee', 'by']",921,['审判是由执行管理委员会设计和领导的。'],0.5,"['steering', 'committee', 'trial', 'by', 'and', 'led']","['committee', 'trial', 'by']",921,试验由一个执行董事会设计和领导。,0.1666666666666666,"['steering', 'committee', 'trial', 'by', 'and', 'led']",['by'],,,,
927,922,"the trial was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the institutional review board of the National Cerebral and Cardiovascular Center , Japan , along with the institutional review boards of all participating institutions .",该试验是根据赫尔辛基宣言的原则进行的，并获得了日本国家脑心血管中心的机构审查委员会以及所有参与机构的机构审查委员会的批准。,0.3076923076923077,"['center', 'cardiovascular', 'review', 'cerebral', 'board', 'along', 'japan', 'trial', 'with', 'all', 'in', 'by', 'and']","['center', 'cardiovascular', 'review', 'by']",922,"['审查按照赫尔辛基宣言的原则进行,由日本国家大脑和心血管中心的机构审查委员会和所有参与机构的机构审查委员会批准。']",0.3846153846153846,"['center', 'cardiovascular', 'review', 'cerebral', 'board', 'along', 'japan', 'trial', 'with', 'all', 'in', 'by', 'and']","['center', 'cardiovascular', 'review', 'cerebral', 'by']",922,该试验符合《赫尔辛基宣言》的原则，经日本国家脑心血管中心的机构审查委员会批准，并经所有参与机构的机构审查委员会批准。,0.2307692307692307,"['center', 'cardiovascular', 'review', 'cerebral', 'board', 'along', 'japan', 'trial', 'with', 'all', 'in', 'by', 'and']","['center', 'cardiovascular', 'review']",,,,
928,923,data were reviewed by an independent data and safety monitoring committee .,数据由一个独立的数据和安全监测委员会审查。,0.8571428571428571,"['safety', 'monitoring', 'data', 'committee', 'independent', 'by', 'and']","['safety', 'monitoring', 'data', 'committee', 'independent', 'by']",923,['数据由独立的数据和安全监测委员会审查。'],0.8571428571428571,"['safety', 'monitoring', 'data', 'committee', 'independent', 'by', 'and']","['safety', 'monitoring', 'data', 'committee', 'independent', 'by']",923,数据经过独立的数据和安全监督委员会审核。,0.5714285714285714,"['safety', 'monitoring', 'data', 'committee', 'independent', 'by', 'and']","['safety', 'data', 'committee', 'independent']",,,,
929,924,"the authors vouch for the completeness and accuracy of the data and all analyses , and for the fidelity of the trial to the protocol , available with the full text of this article at NEJM.org .",作者保证数据和所有分析的完整性和准确性，以及试验对方案的忠实度，方案与本文全文可在 NEJM.org 获取。,0.2857142857142857,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'completeness', 'full']",924,"['作者保证数据和所有分析的完整性和准确性,以及审判对议定书的忠诚性,可在NEJM.org上提供本文的完整文本。']",0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness', 'full']",924,作者保证数据的完整性和准确性，以及所有分析的准确性，并保证本研究与可在NEJM.org上找到的协议完全一致。,0.3571428571428571,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'protocol', 'completeness', 'full']",,,,
930,925,trial POPULATION AND ELIGIBILITY CRITERIA,试验人群和资格标准,0.0,['trial'],[],925,['审判人口和可行性标准'],1.0,['trial'],['trial'],925,"The trial population will consist of patients who are admitted to the hospital with a diagnosis of heart failure. Inclusion criteria for the trial are patients who are 18 years of age or older, who have a left ventricular ejection fraction of 40% or less, and who are in New York Heart Association functional class III or IV. Patients will be excluded from the trial if they have had a myocardial infarction within the past 6 months, if they have unstable angina, if they have had a stroke within the past 6 months, or if they have a known history of malignancy.",0.0,['trial'],[],,,,
931,926,men and women who were 20 years of age or older and had received a diagnosis of atrial fibrillation and stable coronary artery disease were enrolled in Japan .,在日本，年龄在 20 岁或以上并被诊断为心房颤动和稳定型冠状动脉疾病的男性和女性被纳入研究。,0.5555555555555556,"['disease', 'who', 'diagnosis', 'atrial fibrillation', 'age', 'japan', 'coronary artery', 'in', 'and']","['disease', 'diagnosis', 'atrial fibrillation', 'age', 'coronary artery']",926,"['20岁及以上的男性和女性,并接受了甲状腺纤维化和稳定的冠状动脉疾病的诊断,被注册在日本。']",0.3333333333333333,"['disease', 'who', 'diagnosis', 'atrial fibrillation', 'age', 'japan', 'coronary artery', 'in', 'and']","['disease', 'diagnosis', 'coronary artery']",926,在日本，我们招募了年龄在20岁或以上，且已被诊断出心房颤动且冠状动脉疾病稳定的男性和女性。,0.5555555555555556,"['disease', 'who', 'diagnosis', 'atrial fibrillation', 'age', 'japan', 'coronary artery', 'in', 'and']","['disease', 'diagnosis', 'atrial fibrillation', 'age', 'coronary artery']",,,,
932,927,"during screening , we evaluated the patients on a CHADS2 scale , which ranges from 0 to 6 , with a higher score indicating a greater risk of stroke ; congestive heart failure , hypertension , diabetes , and an age of 75 years or older are each assigned 1 point , and prior stroke or transient ischemic attack is assigned 2 points .",在筛查期间，我们根据 CHADS2 量表对患者进行了评估，该量表的范围为 0 至 6，分数越高表明中风的风险越大；充血性心力衰竭、高血压、糖尿病和 75 岁或以上的患者各得 1 分，既往中风或短暂性脑缺血发作史得 2 分。,0.631578947368421,"['diabetes', 'stroke', 'hypertension', '1', '2', 'screening', 'scale', 'age', 'risk', 'prior', 'score', 'point', 'with', 'congestive heart failure', 'transient ischemic attack', 'each', 'to', 'and', 'we']","['diabetes', 'stroke', 'hypertension', '1', '2', 'screening', 'scale', 'risk', 'score', 'congestive heart failure', 'transient ischemic attack', 'each']",927,"['在筛查期间,我们评估了一个CHADS2规模的患者,从0到6的,一个更高的分数表明一个更大的心脏病发作风险;凝固性心脏衰竭,高血压,糖尿病,和75岁或以上的年龄,每人分为1分,并分为前进或过渡性心脏病发作2分。']",0.5263157894736842,"['diabetes', 'stroke', 'hypertension', '1', '2', 'screening', 'scale', 'age', 'risk', 'prior', 'score', 'point', 'with', 'congestive heart failure', 'transient ischemic attack', 'each', 'to', 'and', 'we']","['diabetes', 'stroke', 'hypertension', '1', '2', 'screening', 'scale', 'age', 'risk', 'score']",927,在筛查期间，我们根据CHADS2评分来评估患者风险，评分范围为0-6分，分数越高表示中风风险越大；心力衰竭、高血压、糖尿病、75岁以上年龄各被分配1分，先前中风或短暂脑缺血发作则被分配2分。,0.631578947368421,"['diabetes', 'stroke', 'hypertension', '1', '2', 'screening', 'scale', 'age', 'risk', 'prior', 'score', 'point', 'with', 'congestive heart failure', 'transient ischemic attack', 'each', 'to', 'and', 'we']","['diabetes', 'stroke', 'hypertension', '1', '2', 'screening', 'scale', 'age', 'risk', 'prior', 'score', 'each']",,,,
933,928,the patients were required to have a score of at least 1 on the scale .,要求患者的评分至少为 1 分。,0.2857142857142857,"['1', 'scale', 'score', 'at', 'on', 'have', 'to']","['1', 'scale']",928,['患者必须在规模上获得至少1分的成绩。'],0.1428571428571428,"['1', 'scale', 'score', 'at', 'on', 'have', 'to']",['1'],928,患者必須在量表上至少得到1分的評分。,0.2857142857142857,"['1', 'scale', 'score', 'at', 'on', 'have', 'to']","['1', 'scale']",,,,
934,929,"key exclusion criteria were a history of stent thrombosis , coexisting active tumor , and poorly controlled hypertension .",关键的排除标准是支架内血栓病史、共存的活动性肿瘤和控制不佳的高血压。,0.6,"['key', 'hypertension', 'tumor', 'active', 'thrombosis', 'history', 'exclusion', 'controlled', 'stent', 'and']","['key', 'hypertension', 'tumor', 'active', 'thrombosis', 'controlled']",929,['关键排除标准是<unk>血管病史、共同存在的活性肿瘤和不受控制的高血压。'],0.4,"['key', 'hypertension', 'tumor', 'active', 'thrombosis', 'history', 'exclusion', 'controlled', 'stent', 'and']","['key', 'hypertension', 'tumor', 'controlled']",929,"key exclusion criteria were a history of stent thrombosis , coexisting active tumor , and poorly controlled hypertension .

Chinese:

主要的排除标准包括：以往支架血栓形成史、合并活肿瘤以及高血压难以控制。",0.4,"['key', 'hypertension', 'tumor', 'active', 'thrombosis', 'history', 'exclusion', 'controlled', 'stent', 'and']","['hypertension', 'tumor', 'thrombosis', 'controlled']",,,,
935,930,other RISK EVALUATIONS,其他风险评估,,[],[],930,['其他风险评估'],,[],[],930,Other risk evaluations may be used to supplement the information provided by this assessment tool.,,[],[],,,,
936,931,"patients are evaluated on the basis of the five criteria of the CHADS2 scale plus three additional criteria : the presence of vascular disease , an age of 64 to 74 years , and sex .",患者根据 CHADS2 量表的五个标准加上三个附加标准进行评估：存在血管疾病、年龄在 64 至 74 岁之间以及性别。,0.5,"['presence', 'sex', 'scale', 'plus', 'vascular disease', 'basis', 'age', 'additional', 'three', 'five', 'to', 'and']","['presence', 'sex', 'scale', 'plus', 'vascular disease', 'age']",931,"['基于 CHADS2 尺寸的五个标准以及三个额外的标准进行评估:血管疾病的存在,年龄为 64 至 74 岁,性别。']",0.5,"['presence', 'sex', 'scale', 'plus', 'vascular disease', 'basis', 'age', 'additional', 'three', 'five', 'to', 'and']","['presence', 'sex', 'vascular disease', 'age', 'additional', 'to']",931,病人的评估基于CHADS2分数的5个标准，再加上3个额外标准：血管疾病的存在、年龄为64-74岁、性别。,0.5,"['presence', 'sex', 'scale', 'plus', 'vascular disease', 'basis', 'age', 'additional', 'three', 'five', 'to', 'and']","['presence', 'sex', 'plus', 'vascular disease', 'age', 'to']",,,,
937,932,"this score ranges from 0 to 9 , with 2 points for an age of 75 years or older ; higher scores indicate a greater risk .",该分数范围为 0 至 9，75 岁或以上为 2 分；分数越高表示风险越大。,0.375,"['2', 'indicate', 'age', 'risk', 'score', 'with', 'this', 'to']","['2', 'risk', 'score']",932,"['这个分数从 0 到 9,为 75 岁及以上的 2 个分数;更高的分数表明更大的风险。']",0.375,"['2', 'indicate', 'age', 'risk', 'score', 'with', 'this', 'to']","['2', 'risk', 'score']",932,这个分数从0到9分不等，对75岁及以上老人有2分；分数越高表明风险越大。,0.375,"['2', 'indicate', 'age', 'risk', 'score', 'with', 'this', 'to']","['2', 'risk', 'score']",,,,
938,933,"we randomly assigned the patients in a 1 : 1 ratio to receive either monotherapy with rivaroxaban ( 10 mg once daily for patients with a creatinine clearance of 15 to 49 ml per minute or 15 mg once daily for patients with a creatinine clearance of ≥ 50 ml per minute ) or combination therapy with rivaroxaban at the previously stated doses plus an antiplatelet agent ( either aspirin or a P2Y12 inhibitor , according to the discretion of the treating physician ) .",我们以 1 : 1 的比例随机分配患者接受利伐沙班单药治疗（肌酐清除率为每分钟 15 至 49 毫升的患者每天一次 10 毫克，肌酐清除率≥ 50 毫升的患者每天一次 15 毫克每分钟）或与先前规定剂量的利伐沙班联合抗血小板药物（阿司匹林或 P2Y12 抑制剂，由主治医师决定）联合治疗。,0.5625,"['inhibitor', 'combination therapy', 'creatinine', 'aspirin', '1', 'ratio', 'plus', 'antiplatelet', 'physician', 'minute', 'clearance', 'ml', 'with', 'rivaroxaban', 'agent', 'we']","['inhibitor', 'combination therapy', 'aspirin', '1', 'ratio', 'physician', 'minute', 'clearance', 'rivaroxaban']",933,"['我们随机分配给患者1:1的比例,以接受无论是单疗法与Rivaroxaban(每分钟15至49毫升或每分钟15毫升的克里亚丁清洁剂的患者每日10毫克或每分钟50毫克的克里亚丁清洁剂的患者每日15毫克)或与Rivaroxaban的结合疗法在前面提到的剂量加上抗平板剂(无论是阿司匹林或P2Y12抑制剂,根据治疗医生的判断)。']",0.4375,"['inhibitor', 'combination therapy', 'creatinine', 'aspirin', '1', 'ratio', 'plus', 'antiplatelet', 'physician', 'minute', 'clearance', 'ml', 'with', 'rivaroxaban', 'agent', 'we']","['inhibitor', 'aspirin', '1', 'ratio', 'plus', 'physician', 'minute']",933,我们以1:1的比例随机分配病人接受顺式瑞芬南单治疗（15-49ml/分钟肌酐清除率为10mg/天，≥50ml/分钟肌酐清除率为15mg/天）或顺式瑞芬南联合治疗（前述剂量加抗血小板药物，如阿司匹林或P2Y12抑制剂，由医师自行决定）。,0.5625,"['inhibitor', 'combination therapy', 'creatinine', 'aspirin', '1', 'ratio', 'plus', 'antiplatelet', 'physician', 'minute', 'clearance', 'ml', 'with', 'rivaroxaban', 'agent', 'we']","['inhibitor', 'combination therapy', 'aspirin', '1', 'ratio', 'plus', 'physician', 'minute', 'clearance']",,,,
939,934,"details regarding the randomization procedure and the administration of the trial drugs are provided in the Supplementary Appendix , available at NEJM.org .",有关随机化程序和试验药物给药的详细信息，请参见补充附录，补充附录可在 NEJM.org 获取。,0.4444444444444444,"['procedure', 'appendix', 'randomization', 'administration', 'drugs', 'supplementary', 'regarding', 'available', 'trial']","['procedure', 'randomization', 'drugs', 'regarding']",934,"['关于随机化程序和试用药物的处方的详细信息在附件中提供,可在NEJM.org上找到。']",0.5555555555555556,"['procedure', 'appendix', 'randomization', 'administration', 'drugs', 'supplementary', 'regarding', 'available', 'trial']","['procedure', 'appendix', 'randomization', 'drugs', 'regarding']",934,关于随机化程序和试用药物的细节可以在 NEJM.org 上的补充附录中找到。,0.4444444444444444,"['procedure', 'appendix', 'randomization', 'administration', 'drugs', 'supplementary', 'regarding', 'available', 'trial']","['procedure', 'randomization', 'drugs', 'regarding']",,,,
940,935,"the primary efficacy end point was the composite of stroke , systemic embolism , myocardial infarction , unstable angina requiring revascularization , or death from any cause .",主要疗效终点是中风、全身性栓塞、心肌梗塞、需要血运重建的不稳定型心绞痛或任何原因死亡的复合终点。,0.6428571428571429,"['myocardial infarction', 'composite', 'stroke', 'death', 'angina', 'revascularization', 'primary', 'cause', 'unstable', 'systemic', 'efficacy', 'end', 'point', 'embolism']","['myocardial infarction', 'stroke', 'death', 'angina', 'revascularization', 'cause', 'unstable', 'point', 'embolism']",935,"['初级有效性终点是中风、系统性胚胎、心脏病发作、不稳定的腹泻,需要复发或因任何原因而死亡的组成。']",0.4285714285714285,"['myocardial infarction', 'composite', 'stroke', 'death', 'angina', 'revascularization', 'primary', 'cause', 'unstable', 'systemic', 'efficacy', 'end', 'point', 'embolism']","['stroke', 'death', 'cause', 'unstable', 'efficacy', 'point']",935,主要疗效指标是中风、系统性血栓栓塞、心肌梗死、不稳定型冠状动脉疾病需要血管再造的或任何原因导致的死亡。,0.4285714285714285,"['myocardial infarction', 'composite', 'stroke', 'death', 'angina', 'revascularization', 'primary', 'cause', 'unstable', 'systemic', 'efficacy', 'end', 'point', 'embolism']","['myocardial infarction', 'stroke', 'death', 'cause', 'unstable', 'embolism']",,,,
941,936,"originally , the end point included only death from cardiovascular causes , but this composite was changed to include death from any cause in August 2015 .",最初，终点仅包括心血管原因死亡，但该复合终点在 2015 年 8 月更改为包括全因死亡。,0.5,"['composite', 'cardiovascular', 'death', 'cause', 'end', 'point', 'this', 'originally', 'but', 'to']","['cardiovascular', 'death', 'cause', 'point', 'but']",936,"['起初,终点仅包括心血管原因死亡,但该组成部分于2015年8月更改,包括任何原因死亡。']",0.6,"['composite', 'cardiovascular', 'death', 'cause', 'end', 'point', 'this', 'originally', 'but', 'to']","['cardiovascular', 'death', 'cause', 'point', 'but', 'to']",936,原本，终点只包括心血管原因的死亡，但是这个复合物在2015年8月改为包括任何原因的死亡。,0.8,"['composite', 'cardiovascular', 'death', 'cause', 'end', 'point', 'this', 'originally', 'but', 'to']","['composite', 'cardiovascular', 'death', 'cause', 'point', 'this', 'originally', 'but']",,,,
942,937,"the primary safety end point was major bleeding , as defined according to the criteria of the International Society on Thrombosis and Hemostasis .",主要安全性终点是根据国际血栓形成和止血学会的标准定义的大出血。,0.4615384615384615,"['bleeding', 'safety', 'defined', 'thrombosis', 'hemostasis', 'major', 'society', 'primary', 'end', 'point', 'on', 'to', 'and']","['bleeding', 'safety', 'thrombosis', 'hemostasis', 'society', 'point']",937,"['主要安全终点是主要出血,根据国际血管和血管疾病协会的标准定义。']",0.3076923076923077,"['bleeding', 'safety', 'defined', 'thrombosis', 'hemostasis', 'major', 'society', 'primary', 'end', 'point', 'on', 'to', 'and']","['bleeding', 'safety', 'society', 'point']",937,主要安全性终点是根据国际血栓与血液学会的标准定义的重度出血。,0.3846153846153846,"['bleeding', 'safety', 'defined', 'thrombosis', 'hemostasis', 'major', 'society', 'primary', 'end', 'point', 'on', 'to', 'and']","['bleeding', 'safety', 'thrombosis', 'society', 'point']",,,,
943,938,"secondary end points were the individual components of the primary end point ; death from any cause ; a composite of ischemic cardiovascular events or death ( death from any cause , myocardial infarction , unstable angina requiring revascularization , stroke , transient ischemic attack , systemic arterial embolism , venous thromboembolism , revascularization , or stent thrombosis ) ; net adverse clinical events ( death from any cause , myocardial infarction , stroke , and major bleeding ) ; and any bleeding events .",次要终点是主要终点的各个组成部分；因任何原因死亡；缺血性心血管事件或死亡（全因死亡、心肌梗死、需要血运重建的不稳定型心绞痛、中风、短暂性脑缺血发作、全身性动脉栓塞、静脉血栓栓塞、血运重建或支架内血栓形成）的复合事件；净不良临床事件（全因死亡、心肌梗死、中风和大出血）；以及任何出血事件。,0.56,"['bleeding', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'net', 'individual', 'death', 'venous', 'angina', 'thrombosis', 'thromboembolism', 'major', 'end points', 'revascularization', 'adverse', 'primary', 'stent', 'cause', 'clinical', 'unstable', 'systemic', 'secondary', 'transient ischemic attack', 'and']","['bleeding', 'myocardial infarction', 'cardiovascular', 'stroke', 'death', 'angina', 'thrombosis', 'thromboembolism', 'end points', 'revascularization', 'cause', 'clinical', 'unstable', 'transient ischemic attack']",938,"['二级终点是初级终点的个体组成部分;因任何原因而死亡;因任何原因而死亡或死亡的组成部分(因任何原因而死亡,心脏病发作,不稳定的腹泻,需要复发,中风,过渡性腹泻攻击,系统性血管胚胎,阴道血管,复发,或静脉血管);因任何原因而死亡(因任何原因而死亡,心脏病发作,中风和主要出血);以及任何出血事件。']",0.32,"['bleeding', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'net', 'individual', 'death', 'venous', 'angina', 'thrombosis', 'thromboembolism', 'major', 'end points', 'revascularization', 'adverse', 'primary', 'stent', 'cause', 'clinical', 'unstable', 'systemic', 'secondary', 'transient ischemic attack', 'and']","['bleeding', 'stroke', 'individual', 'death', 'end points', 'cause', 'unstable', 'and']",938,副要目标是主要目标的各个组成部分；任何原因导致的死亡；心血管疾病或死亡（任何原因导致的死亡，心肌梗死，需要血管重建的不稳定心绞痛，中风，短暂脑缺血发作，全身动脉栓塞，静脉血栓形成，血管重建或支架血栓）；不良临床事件（任何原因导致的死亡，心肌梗死，中风和重度出血）；任何出血事件。,0.4,"['bleeding', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'net', 'individual', 'death', 'venous', 'angina', 'thrombosis', 'thromboembolism', 'major', 'end points', 'revascularization', 'adverse', 'primary', 'stent', 'cause', 'clinical', 'unstable', 'systemic', 'secondary', 'transient ischemic attack', 'and']","['bleeding', 'myocardial infarction', 'cardiovascular', 'stroke', 'death', 'angina', 'thrombosis', 'cause', 'clinical', 'unstable']",,,,
944,939,the definitions of cardiovascular and bleeding events are provided in Table S1 in the Supplementary Appendix .,补充附录表 S1 中提供了心血管事件和出血事件的定义。,0.4285714285714285,"['bleeding', 'cardiovascular', 'appendix', 'table', 'supplementary', 'S1', 'and']","['bleeding', 'cardiovascular', 'table']",939,['心血管和出血事件的定义在附加附件中的表 S1 中提供。'],0.5714285714285714,"['bleeding', 'cardiovascular', 'appendix', 'table', 'supplementary', 'S1', 'and']","['bleeding', 'cardiovascular', 'appendix', 'table']",939,血管和出血事件的定义在补充附录中的表S1中提供。,0.2857142857142857,"['bleeding', 'cardiovascular', 'appendix', 'table', 'supplementary', 'S1', 'and']","['bleeding', 'table']",,,,
945,940,blinded adjudication of the end points was conducted by an independent clinical events committee .,终点的盲裁定由一个独立的临床事件委员会进行。,1.0,"['end points', 'clinical', 'committee', 'independent', 'by']","['end points', 'clinical', 'committee', 'independent', 'by']",940,['最终点的盲目交付由独立的临床活动委员会进行。'],1.0,"['end points', 'clinical', 'committee', 'independent', 'by']","['end points', 'clinical', 'committee', 'independent', 'by']",940,盲目的裁决是由独立的临床事件委员会进行的。,0.8,"['end points', 'clinical', 'committee', 'independent', 'by']","['clinical', 'committee', 'independent', 'by']",,,,
946,941,"the trial was powered to assess the noninferiority of rivaroxaban monotherapy , as compared with combination therapy , for the primary efficacy end point .",该试验旨在评估利伐沙班单药治疗与联合治疗相比在主要疗效终点方面的非劣效性。,0.4,"['combination therapy', 'primary', 'trial', 'efficacy', 'assess', 'end', 'point', 'with', 'rivaroxaban', 'to']","['combination therapy', 'assess', 'point', 'rivaroxaban']",941,"['试验被授权评估Rivaroxaban单疗法的非低效性,与组合疗法相比,为初级有效性终点。']",0.3,"['combination therapy', 'primary', 'trial', 'efficacy', 'assess', 'end', 'point', 'with', 'rivaroxaban', 'to']","['efficacy', 'assess', 'point']",941,试验目的在于评估rivaroxaban单药治疗与联合治疗相比，在主要疗效指标上的非劣效性。,0.3,"['combination therapy', 'primary', 'trial', 'efficacy', 'assess', 'end', 'point', 'with', 'rivaroxaban', 'to']","['combination therapy', 'assess', 'to']",,,,
947,942,the calculation of the trial sample size is provided in the Supplementary Appendix .,补充附录中提供了试验样本量的计算。,0.0,"['appendix', 'supplementary', 'trial', 'sample size', 'in']",[],942,['测试样品尺寸的计算在附件中提供。'],0.2,"['appendix', 'supplementary', 'trial', 'sample size', 'in']",['appendix'],942,試驗樣本大小的計算方法在附錄中提供。,0.0,"['appendix', 'supplementary', 'trial', 'sample size', 'in']",[],,,,
948,943,we estimated that the enrollment of 2200 patients and the occurrence of at least 219 primary efficacy end points were required .,我们估计需要纳入 2200 名患者并出现至少 219 个主要疗效终点。,0.2857142857142857,"['occurrence', 'end points', 'primary', 'efficacy', 'that', 'and', 'we']","['occurrence', 'end points']",943,"['我们估计,需要2200名患者的注册和至少219个初级有效性终点的出现。']",0.4285714285714285,"['occurrence', 'end points', 'primary', 'efficacy', 'that', 'and', 'we']","['occurrence', 'end points', 'efficacy']",943,我们估计需要2200名患者的入学和至少219个主要疗效指标的发生。,0.1428571428571428,"['occurrence', 'end points', 'primary', 'efficacy', 'that', 'and', 'we']",['occurrence'],,,,
949,944,this population included all the patients who had undergone randomization after the exclusion of patients who had a technical reason for not participating in the trial .,该人群包括排除因技术原因未参加试验的患者后接受随机分组的所有患者。,0.3636363636363636,"['population', 'randomization', 'who', 'reason', 'exclusion', 'technical', 'after', 'trial', 'all', 'this', 'in']","['population', 'randomization', 'reason', 'after']",944,"['该人口包括所有经过随机化后排除患者的患者,他们有技术理由不参加试验。']",0.3636363636363636,"['population', 'randomization', 'who', 'reason', 'exclusion', 'technical', 'after', 'trial', 'all', 'this', 'in']","['population', 'randomization', 'reason', 'after']",944,这个人群包括在排除因技术原因而不能参加试验的病人后随机选择的所有病人。,0.3636363636363636,"['population', 'randomization', 'who', 'reason', 'exclusion', 'technical', 'after', 'trial', 'all', 'this', 'in']","['population', 'randomization', 'reason', 'after']",,,,
950,945,"if noninferiority was shown for the primary efficacy end point , a closed testing procedure was to be conducted to determine superiority for the primary safety end point .",如果主要疗效终点显示非劣效性，则将进行封闭测试程序以确定主要安全终点的优效性。,0.1666666666666666,"['safety', 'be', 'primary', 'efficacy', 'superiority', 'end', 'testing procedure', 'point', 'closed', 'if', 'to', 'determine']","['safety', 'point']",945,"['如果对初级效能终点显示不低,则应进行关闭测试程序,以确定初级安全终点的优越性。']",0.3333333333333333,"['safety', 'be', 'primary', 'efficacy', 'superiority', 'end', 'testing procedure', 'point', 'closed', 'if', 'to', 'determine']","['safety', 'efficacy', 'superiority', 'point']",945,如果主要疗效指标显示出了非劣效性，则需要进行封闭测试程序以确定主要安全性指标的优越性。,0.1666666666666666,"['safety', 'be', 'primary', 'efficacy', 'superiority', 'end', 'testing procedure', 'point', 'closed', 'if', 'to', 'determine']","['safety', 'superiority']",,,,
951,946,"an assessment of superiority for the primary efficacy end point , which was not prespecified before the database lock , was performed after the demonstration of noninferiority for efficacy and superiority for the primary safety end point .",主要疗效终点的优效性评估在数据库锁定前未预先指定，是在证明疗效的非劣效性和主要安全性终点的优效性后进行的。,0.4615384615384615,"['safety', 'database', 'demonstration', 'assessment', 'primary', 'after', 'efficacy', 'superiority', 'lock', 'end', 'point', 'before', 'and']","['safety', 'assessment', 'after', 'lock', 'point', 'before']",946,"['对初级效率终点的优越性评估,在数据库锁之前没有预定,在对初级安全终点的效率和优越性表现后进行。']",0.5384615384615384,"['safety', 'database', 'demonstration', 'assessment', 'primary', 'after', 'efficacy', 'superiority', 'lock', 'end', 'point', 'before', 'and']","['safety', 'assessment', 'after', 'superiority', 'lock', 'point', 'before']",946,一项关于主要疗效指标优势的评估，在数据库锁定之前并没有事先指定，是在疗效非劣和安全性主要指标优势得到证明之后进行的。,0.3846153846153846,"['safety', 'database', 'demonstration', 'assessment', 'primary', 'after', 'efficacy', 'superiority', 'lock', 'end', 'point', 'before', 'and']","['safety', 'assessment', 'after', 'lock', 'before']",,,,
952,947,secondary end points are reported with hazard ratios and 95 % confidence intervals .,次要终点报告有风险比和 95% 置信区间。,0.1428571428571428,"['end points', 'hazard', 'secondary', 'with', 'confidence', 'and', 'intervals']",['end points'],947,['二级终点与危险率和95%的信任间隔报告。'],0.2857142857142857,"['end points', 'hazard', 'secondary', 'with', 'confidence', 'and', 'intervals']","['end points', 'hazard']",947,二次终点报告的危险比和95%的置信度区间。,0.4285714285714285,"['end points', 'hazard', 'secondary', 'with', 'confidence', 'and', 'intervals']","['end points', 'hazard', 'confidence']",,,,
953,948,"the confidence intervals have not been adjusted for multiple comparisons , so inferences drawn from these intervals may not be reproducible .",置信区间未针对多重比较进行调整，因此从这些区间得出的推论可能无法重现。,0.1666666666666666,"['multiple', 'be', 'confidence', 'have not', 'so', 'intervals']",['have not'],948,"['信任间隔未适用于多个比较,因此从这些间隔中提取的结论可能无法重复。']",0.1666666666666666,"['multiple', 'be', 'confidence', 'have not', 'so', 'intervals']",['have not'],948,这些置信区间未经多重比较调整，因此从这些区间得出的结论可能无法复制。,0.1666666666666666,"['multiple', 'be', 'confidence', 'have not', 'so', 'intervals']",['have not'],,,,
954,949,"all the statistical analyses were performed with the use of SAS software , version 9.4 for Windows ( SAS Institute ) .",所有统计分析均使用适用于 Windows 的 SAS 软件 9.4 版（SAS Institute）进行。,0.1666666666666666,"['version', 'software', 'institute', 'with', 'SAS', 'all']",['software'],949,"['所有统计分析都使用SAS软件,版本 9.4 for Windows(SAS Institute)进行。']",0.3333333333333333,"['version', 'software', 'institute', 'with', 'SAS', 'all']","['version', 'software']",949,所有统计分析都是在Windows上使用SAS软件（SAS Institute）的9.4版本进行的。,0.3333333333333333,"['version', 'software', 'institute', 'with', 'SAS', 'all']","['version', 'software']",,,,
955,950,"at baseline , the characteristics of the patients were similar in the two treatment groups ( Table 1 , and Table S2 in the Supplementary Appendix ) .",基线时，两个治疗组的患者特征相似（表1和补充附录表S2）。,0.5454545454545454,"['appendix', 'table', 'baseline', '1', 'supplementary', 'treatment', 'characteristics', 'S2', 'and', 'two', 'similar']","['table', 'baseline', '1', 'treatment', 'characteristics', 'two']",950,"['在基线上,患者的特征在两组治疗中是相似的(表1和附件S2的表)。']",0.7272727272727273,"['appendix', 'table', 'baseline', '1', 'supplementary', 'treatment', 'characteristics', 'S2', 'and', 'two', 'similar']","['appendix', 'table', 'baseline', '1', 'treatment', 'characteristics', 'two', 'similar']",950,在基线时，两组患者的特征相似（表1和表S2）。,0.4545454545454545,"['appendix', 'table', 'baseline', '1', 'supplementary', 'treatment', 'characteristics', 'S2', 'and', 'two', 'similar']","['table', 'baseline', '1', 'characteristics', 'two']",,,,
956,951,"the mean age was 74 years , and 79 % of the patients were men .",平均年龄为 74 岁，79% 的患者为男性。,0.6666666666666666,"['mean', 'age', 'and']","['mean', 'age']",951,"['平均年龄为74岁,79%的患者是男性。']",0.6666666666666666,"['mean', 'age', 'and']","['mean', 'age']",951,平均年龄为74岁，79%的病人为男性。,0.6666666666666666,"['mean', 'age', 'and']","['mean', 'age']",,,,
957,952,"a total of 1564 patients ( 70.6 % ) had undergone previous PCI , and 252 ( 11.4 % ) had undergone previous CABG .",共有1564名患者(70.6%)曾接受过PCI，252名(11.4%)患者曾接受过CABG。,0.0,"['previous', 'total', 'CABG', 'and']",[],952,"['总共有1564名患者(70.6%)经历过以前的PCI,252名患者(11.4%)经历过以前的CABG。']",0.25,"['previous', 'total', 'CABG', 'and']",['previous'],952,总共有1564名病人（70.6%）接受过既往的PCI手术，252名病人（11.4%）接受过既往的CABG手术。,0.0,"['previous', 'total', 'CABG', 'and']",[],,,,
958,953,early TERMINATION OF THE TRIAL,提前终止试验,0.0,['early'],[],953,['特里亚尔的早期终结'],1.0,['early'],['early'],953,如果你想提前终止试用期，你可以随时联系我们的客服人员。,0.0,['early'],[],,,,
959,954,the evaluation of the patients was planned to continue until September 2018 .,对患者的评估计划持续到 2018 年 9 月。,0.3333333333333333,"['evaluation', 'continue', 'to']",['continue'],954,['预计患者的评估将持续到2018年9月。'],0.3333333333333333,"['evaluation', 'continue', 'to']",['continue'],954,評估患者的計劃將持續到2018年9月。,0.0,"['evaluation', 'continue', 'to']",[],,,,
960,955,the trial database was locked in January 2019 .,试验数据库已于 2019 年 1 月锁定。,0.0,"['database', 'trial', 'in']",[],955,['测试数据库于2019年1月关闭。'],0.0,"['database', 'trial', 'in']",[],955,January 2019年，试用数据库被锁定。,0.0,"['database', 'trial', 'in']",[],,,,
961,956,primary EFFICACY AND SAFETY END POINTS,主要疗效和安全性终点,0.0,['primary'],[],956,['首要效率和安全终点'],0.0,['primary'],[],956,主要疗效和安全性终点,0.0,['primary'],[],,,,
962,957,"in the assessment of superiority for the primary efficacy end point ( which was not a prespecified analysis ) , the P value was 0.02 .",在主要疗效终点（不是预设分析）的优效性评估中，P 值为 0.02。,0.3333333333333333,"['analysis', 'value', 'assessment', 'primary', 'efficacy', 'superiority', 'end', 'point', 'P']","['analysis', 'assessment', 'point']",957,"['在对初级效率终点的优越性评估(这不是预定分析),P值为0.02。']",0.4444444444444444,"['analysis', 'value', 'assessment', 'primary', 'efficacy', 'superiority', 'end', 'point', 'P']","['analysis', 'assessment', 'superiority', 'point']",957,在对主要疗效指标的优势进行评估（这不是预先规定的分析）时，P值为0.02。,0.2222222222222222,"['analysis', 'value', 'assessment', 'primary', 'efficacy', 'superiority', 'end', 'point', 'P']","['analysis', 'assessment']",,,,
963,958,a sensitivity analysis using the original efficacy end point also showed consistent results ( Table S6 in the Supplementary Appendix ) .,使用原始疗效终点的敏感性分析也显示出一致的结果（补充附录表 S6）。,0.375,"['appendix', 'table', 'analysis', 'supplementary', 'efficacy', 'original', 'point', 'sensitivity']","['table', 'analysis', 'point']",958,['使用原始效率终点的敏感性分析也显示了一致的结果(附件中的S6表)。'],0.5,"['appendix', 'table', 'analysis', 'supplementary', 'efficacy', 'original', 'point', 'sensitivity']","['appendix', 'table', 'analysis', 'point']",958,一项使用原始疗效指标进行的敏感性分析也显示出了一致的结果（见表S6，附件）。,0.375,"['appendix', 'table', 'analysis', 'supplementary', 'efficacy', 'original', 'point', 'sensitivity']","['appendix', 'table', 'analysis']",,,,
964,959,the incidence of individual components of the primary end point in the two groups are provided in Table 2 .,表 2 提供了两组中主要终点的各个组成部分的发生率。,0.625,"['incidence', 'table', '2', 'individual', 'primary', 'end', 'point', 'two']","['incidence', 'table', '2', 'point', 'two']",959,['主要终点的各个组成部分在两组中的影响表2中表明。'],0.5,"['incidence', 'table', '2', 'individual', 'primary', 'end', 'point', 'two']","['table', '2', 'point', 'two']",959,表2中提供了两组主要终点各个组件的发生率。,0.625,"['incidence', 'table', '2', 'individual', 'primary', 'end', 'point', 'two']","['incidence', 'table', '2', 'point', 'two']",,,,
965,960,detailed information regarding bleeding sites is provided in Table S8 in the Supplementary Appendix .,补充附录表 S8 中提供了有关出血部位的详细信息。,0.6666666666666666,"['bleeding', 'appendix', 'table', 'supplementary', 'regarding', 'information']","['bleeding', 'table', 'regarding', 'information']",960,['有关出血场所的详细信息在附加附件中的表 S8 中提供。'],0.8333333333333334,"['bleeding', 'appendix', 'table', 'supplementary', 'regarding', 'information']","['bleeding', 'appendix', 'table', 'regarding', 'information']",960,"detailed information regarding bleeding sites is provided in Table S8 in the Supplementary Appendix.

Chinese:

详细有关出血点的信息可在补充附录中的表S8中找到。",0.6666666666666666,"['bleeding', 'appendix', 'table', 'supplementary', 'regarding', 'information']","['bleeding', 'table', 'regarding', 'information']",,,,
966,961,there were two fatal bleeding events in each group ( Table S9 in the Supplementary Appendix ) .,每组均有两起致命性出血事件（补充附录表 S9）。,0.5,"['bleeding', 'group', 'appendix', 'table', 'supplementary', 'fatal', 'each', 'two']","['bleeding', 'group', 'table', 'two']",961,['每个群体中有两起致命的出血事件(附件中的S9表)。'],0.75,"['bleeding', 'group', 'appendix', 'table', 'supplementary', 'fatal', 'each', 'two']","['bleeding', 'group', 'appendix', 'table', 'fatal', 'two']",961,在每组中都有两起致死的出血事件（表S9在附加附件中）。,0.75,"['bleeding', 'group', 'appendix', 'table', 'supplementary', 'fatal', 'each', 'two']","['bleeding', 'group', 'appendix', 'table', 'fatal', 'two']",,,,
967,962,selected SUBGROUP ANALYSES,选定的子组分析,,[],[],962,['选择的子组分析'],,[],[],962,selected SUBGROUP ANALYSES,,[],[],,,,
968,963,"with respect to the primary efficacy end point , the effect of monotherapy , as compared with combination therapy , was generally consistent across all prespecified subgroups , including those defined according to sex , age , stroke and bleeding risk scores , and renal function ( Figure 3 ) .",关于主要疗效终点，与联合治疗相比，单一疗法的效果在所有预先指定的亚组中基本一致，包括根据性别、年龄、中风和出血风险评分以及肾功能定义的亚组（图 3 ） .,0.4545454545454545,"['bleeding', 'combination therapy', 'stroke', 'defined', 'sex', 'figure', 'primary', 'across', 'age', 'risk', 'effect', 'efficacy', '3', 'end', 'point', 'as', 'with', 'respect', 'all', 'to', 'and', 'renal function']","['bleeding', 'combination therapy', 'stroke', 'sex', 'age', 'risk', 'effect', 'point', 'to', 'renal function']",963,"['至于初级有效性终点,与结合疗法相比,单疗法的效果在所有预定子群中都是一致的,包括根据性别、年龄、中风和出血风险分数和肾功能定义的子群。']",0.4545454545454545,"['bleeding', 'combination therapy', 'stroke', 'defined', 'sex', 'figure', 'primary', 'across', 'age', 'risk', 'effect', 'efficacy', '3', 'end', 'point', 'as', 'with', 'respect', 'all', 'to', 'and', 'renal function']","['bleeding', 'stroke', 'sex', 'age', 'risk', 'effect', 'efficacy', 'point', 'to', 'renal function']",963,就主要疗效指标而言，单药疗法与联合疗法相比，在所有预先规定的亚组中效果基本一致，包括按性别、年龄、脑卒中和出血风险评分以及肾功能定义的亚组（图3）。,0.3636363636363636,"['bleeding', 'combination therapy', 'stroke', 'defined', 'sex', 'figure', 'primary', 'across', 'age', 'risk', 'effect', 'efficacy', '3', 'end', 'point', 'as', 'with', 'respect', 'all', 'to', 'and', 'renal function']","['bleeding', 'stroke', 'sex', 'age', 'risk', 'effect', 'and', 'renal function']",,,,
969,964,"the trial met its primary objective of showing the noninferiority of rivaroxaban monotherapy , as compared with combination therapy with rivaroxaban plus antiplatelet therapy , for the composite of cardiovascular events or death from any cause .",该试验达到了其主要目标，即显示利伐沙班单一疗法与利伐沙班加抗血小板疗法的联合疗法相比，对于心血管事件或全因死亡的复合疗法具有非劣效性。,0.3846153846153846,"['combination therapy', 'composite', 'objective', 'cardiovascular', 'death', 'plus', 'antiplatelet', 'primary', 'cause', 'trial', 'with', 'rivaroxaban', 'met']","['cardiovascular', 'death', 'plus', 'cause', 'rivaroxaban']",964,"['该研究满足了其主要目标,表明Rivaroxaban单疗法与Rivaroxaban加上抗斑疗法的结合疗法相比,对心血管事件的组成或因任何原因而导致的死亡不低。']",0.3076923076923077,"['combination therapy', 'composite', 'objective', 'cardiovascular', 'death', 'plus', 'antiplatelet', 'primary', 'cause', 'trial', 'with', 'rivaroxaban', 'met']","['cardiovascular', 'death', 'plus', 'cause']",964,该试验达到了其主要目标，即显示利伐他汀单独使用与利伐他汀加抗血小板治疗相比，在心血管事件或任何原因死亡的复合事件方面并不逊色。,0.3076923076923077,"['combination therapy', 'composite', 'objective', 'cardiovascular', 'death', 'plus', 'antiplatelet', 'primary', 'cause', 'trial', 'with', 'rivaroxaban', 'met']","['cardiovascular', 'death', 'plus', 'cause']",,,,
970,965,"in an analysis that was not prespecified , monotherapy was superior to combination therapy for this same end point .",在一项未预先指定的分析中，就同一终点而言，单一疗法优于联合疗法。,0.375,"['combination therapy', 'analysis', 'superior', 'end', 'point', 'this', 'that', 'to']","['analysis', 'point', 'to']",965,"['在没有预定的分析中,单疗法比同一终点的结合疗法优越。']",0.25,"['combination therapy', 'analysis', 'superior', 'end', 'point', 'this', 'that', 'to']","['analysis', 'point']",965,在一项并未事先确定的分析中，单药物治疗在同一个终点上优于联合疗法。,0.375,"['combination therapy', 'analysis', 'superior', 'end', 'point', 'this', 'that', 'to']","['analysis', 'point', 'to']",,,,
971,966,"the trial also met its primary safety end point , with use of monotherapy associated with a significantly lower rate of major bleeding events .",该试验还达到了主要安全终点，使用单一疗法可显着降低大出血事件的发生率。,0.3333333333333333,"['bleeding', 'safety', 'rate', 'lower', 'major', 'associated', 'primary', 'trial', 'end', 'point', 'with', 'met']","['bleeding', 'safety', 'rate', 'point']",966,"['试验也满足了其主要安全终点,使用单治疗与重大出血事件的显著较低率有关。']",0.3333333333333333,"['bleeding', 'safety', 'rate', 'lower', 'major', 'associated', 'primary', 'trial', 'end', 'point', 'with', 'met']","['bleeding', 'safety', 'rate', 'point']",966,"the trial also met its primary safety end point, with use of monotherapy associated with a significantly lower rate of major bleeding events.",0.0,"['bleeding', 'safety', 'rate', 'lower', 'major', 'associated', 'primary', 'trial', 'end', 'point', 'with', 'met']",[],,,,
972,967,the trial was based on the concept that an antithrombotic regimen for patients with both atrial fibrillation and coronary artery disease should be less intensive than would be required if the regimens for both conditions were combined .,该试验基于这样的概念，即对于同时患有心房颤动和冠状动脉疾病的患者，抗血栓形成方案的强度应低于两种情况联合方案所需的强度。,0.4545454545454545,"['disease', 'antithrombotic', 'be', 'atrial fibrillation', 'intensive', 'concept', 'with', 'coronary artery', 'that', 'if', 'and']","['disease', 'antithrombotic', 'atrial fibrillation', 'concept', 'coronary artery']",967,"['该研究基于对患有甲状腺纤维和冠状动脉疾病的患者的抗血管制应比如果两种疾病的制应相结合,则所需的要少强度。']",0.1818181818181818,"['disease', 'antithrombotic', 'be', 'atrial fibrillation', 'intensive', 'concept', 'with', 'coronary artery', 'that', 'if', 'and']","['disease', 'coronary artery']",967,"the trial was based on the concept that an antithrombotic regimen for patients with both atrial fibrillation and coronary artery disease should be less intensive than would be required if the regimens for both conditions were combined .

Chinese:
该试验基于这样一个概念，针对同时患有心房颤动和冠状动脉疾病的患者，应当采用较为轻度的抗栓治疗方案，而不是如果将两种疾病的治疗方案结合起来所需要的那样强度较大的治疗方案。",0.4545454545454545,"['disease', 'antithrombotic', 'be', 'atrial fibrillation', 'intensive', 'concept', 'with', 'coronary artery', 'that', 'if', 'and']","['disease', 'atrial fibrillation', 'concept', 'coronary artery', 'and']",,,,
973,968,"these trials have shaped current guidelines and consensus documents , which recommend combination therapy with an anticoagulant plus a P2Y12 inhibitor for up to 1 year after PCI in patients with atrial fibrillation.8,10,14","这些试验形成了目前的指南和共识文件，建议在房颤患者 PCI 后使用抗凝剂和 P2Y12 抑制剂联合治疗长达 1 年。 8,10,14",0.5333333333333333,"['atrial', 'inhibitor', 'combination therapy', 'anticoagulant', 'consensus', 'year', '1', 'plus', 'recommend', 'after', 'current', 'up', 'with', 'have', 'and']","['inhibitor', 'combination therapy', 'anticoagulant', 'consensus', 'year', '1', 'recommend', 'after']",968,"['这些试验已经形成了当前的指导方针和共识文件,建议与抗凝固剂以及P2Y12抑制剂的结合治疗,在患有甲状腺纤维炎的患者中,PCI后1年。']",0.5333333333333333,"['atrial', 'inhibitor', 'combination therapy', 'anticoagulant', 'consensus', 'year', '1', 'plus', 'recommend', 'after', 'current', 'up', 'with', 'have', 'and']","['inhibitor', 'consensus', 'year', '1', 'recommend', 'after', 'current', 'have']",968,"这些试验已经形成了目前的指南和共识文件，其中推荐在心房颤动患者的PCI后继续使用抗凝剂加P2Y12抑制剂联合治疗1年。8,10,14",0.6,"['atrial', 'inhibitor', 'combination therapy', 'anticoagulant', 'consensus', 'year', '1', 'plus', 'recommend', 'after', 'current', 'up', 'with', 'have', 'and']","['inhibitor', 'combination therapy', 'anticoagulant', 'consensus', 'year', '1', 'plus', 'recommend', 'after']",,,,
974,969,"after 1 year following PCI , guidelines in western countries recommend oral anticoagulant monotherapy.9,10","PCI 术后 1 年后，西方国家的指南推荐口服抗凝剂单一疗法。 9,10",0.7142857142857143,"['anticoagulant', 'year', '1', 'oral', 'recommend', 'after', 'following']","['anticoagulant', 'year', '1', 'recommend', 'after']",969,"['PCI之后1年后,西方国家的指南建议口服抗凝固剂单治疗。']",0.5714285714285714,"['anticoagulant', 'year', '1', 'oral', 'recommend', 'after', 'following']","['year', '1', 'recommend', 'after']",969,"在PCI后的1年内，西方国家的指南建议口服抗凝剂单药治疗。9,10",0.7142857142857143,"['anticoagulant', 'year', '1', 'oral', 'recommend', 'after', 'following']","['anticoagulant', 'year', '1', 'recommend', 'after']",,,,
975,970,"this recommendation was based on the findings of a national Danish cohort study.3,15","该建议基于丹麦全国队列研究的结果。 3,15",0.0,"['a', 'cohort', 'on', 'this']",[],970,['该建议是基于国家丹麦联盟研究的结果。'],0.25,"['a', 'cohort', 'on', 'this']",['this'],970,"这一推荐是基于丹麦全国队列研究的发现。3,15",0.25,"['a', 'cohort', 'on', 'this']",['this'],,,,
976,971,"however , this recommendation has yet to be supported by evidence from randomized clinical trials .",然而，这一建议尚未得到随机临床试验证据的支持。,0.3333333333333333,"['be', 'clinical', 'evidence', 'this', 'by', 'to']","['clinical', 'evidence']",971,"['然而,这一建议尚未得到随机临床试验的证据支持。']",0.3333333333333333,"['be', 'clinical', 'evidence', 'this', 'by', 'to']","['clinical', 'evidence']",971,然而，这一建议尚未得到随机临床试验的支持。,0.1666666666666666,"['be', 'clinical', 'evidence', 'this', 'by', 'to']",['clinical'],,,,
977,972,"these anticoagulants have several advantages over warfarin , including an improved efficacy and safety profile , a predictable anticoagulant effect without the need for routine coagulation monitoring , and lower risks of food and drug interactions , intracranial hemorrhage , and death.16,17","与华法林相比，这些抗凝剂有几个优点，包括提高疗效和安全性、无需常规凝血监测即可预测抗凝效果，以及食物和药物相互作用、颅内出血和死亡的风险较低。 16,17",0.6666666666666666,"['safety', 'monitoring', 'coagulation', 'food', 'need', 'routine', 'intracranial hemorrhage', 'lower', 'warfarin', 'effect', 'efficacy', 'profile', 'drug', 'have', 'over', 'and', 'without', 'anticoagulants']","['safety', 'monitoring', 'coagulation', 'food', 'routine', 'intracranial hemorrhage', 'warfarin', 'effect', 'drug', 'have', 'without', 'anticoagulants']",972,"['这些抗凝固剂对瓦法林有几个好处,包括提高效率和安全性,预测性抗凝固剂效应,无需日常凝固监测,降低食物和药物相互作用的风险,内分泌出血和死亡。']",0.4444444444444444,"['safety', 'monitoring', 'coagulation', 'food', 'need', 'routine', 'intracranial hemorrhage', 'lower', 'warfarin', 'effect', 'efficacy', 'profile', 'drug', 'have', 'over', 'and', 'without', 'anticoagulants']","['safety', 'monitoring', 'coagulation', 'food', 'effect', 'drug', 'have', 'without']",972,"这些抗凝剂相对于华法林具有几个优势，包括更有效和安全的配置文件，不需要常规凝血监测就可以产生预测性的抗凝剂作用，以及食物和药物相互作用、颅内出血和死亡风险较低。16,17",0.6666666666666666,"['safety', 'monitoring', 'coagulation', 'food', 'need', 'routine', 'intracranial hemorrhage', 'lower', 'warfarin', 'effect', 'efficacy', 'profile', 'drug', 'have', 'over', 'and', 'without', 'anticoagulants']","['safety', 'monitoring', 'coagulation', 'food', 'need', 'routine', 'intracranial hemorrhage', 'warfarin', 'effect', 'drug', 'have', 'anticoagulants']",,,,
978,973,our results support the general concept that rivaroxaban monotherapy without antiplatelet therapy is the better approach in this population on the basis of both efficacy and safety .,我们的结果支持这样的一般概念，即在有效性和安全性的基础上，利伐沙班单药治疗而不进行抗血小板治疗是该人群的更好方法。,0.6,"['approach', 'safety', 'population', 'support', 'antiplatelet', 'basis', 'therapy', 'efficacy', 'general concept', 'rivaroxaban', 'this', 'that', 'in', 'and', 'without']","['safety', 'population', 'support', 'therapy', 'efficacy', 'general concept', 'rivaroxaban', 'this', 'and']",973,"['我们的结果支持普遍的概念,Rivaroxaban单治疗没有抗细胞治疗是这个人口的最佳方法,基于有效性和安全性。']",0.4,"['approach', 'safety', 'population', 'support', 'antiplatelet', 'basis', 'therapy', 'efficacy', 'general concept', 'rivaroxaban', 'this', 'that', 'in', 'and', 'without']","['safety', 'population', 'support', 'therapy', 'efficacy', 'this']",973,我们的研究结果支持在这个人群中以抗血小板疗法为主，而不是用抗凝血剂药物的总体概念是更好的方法，这是基于疗效和安全性。,0.4,"['approach', 'safety', 'population', 'support', 'antiplatelet', 'basis', 'therapy', 'efficacy', 'general concept', 'rivaroxaban', 'this', 'that', 'in', 'and', 'without']","['safety', 'population', 'support', 'therapy', 'this', 'and']",,,,
979,974,some limitations of our trial should be noted .,应注意我们试验的一些局限性。,0.0,"['be', 'trial']",[],974,['请注意我们审判的某些限制。'],0.5,"['be', 'trial']",['trial'],974,"Some limitations of our trial should be noted.

Chinese:

我们的试用有一些局限性应当被指出。",0.0,"['be', 'trial']",[],,,,
980,975,"however , these values were within the 5 % rate of discontinuation that was anticipated ( Table S12 in the Supplementary Appendix ) and were consistent between the two groups .",然而，这些值在预期的 5% 停药率范围内（补充附录中的表 S12），并且在两组之间是一致的。,0.5,"['5', 'appendix', 'table', 'rate', 'supplementary', 'values', 'that', 'in', 'and', 'two']","['5', 'table', 'rate', 'and', 'two']",975,"['然而,这些值在预期的5%中断率(附件中的S12表)之内,并在两组之间一致。']",0.6,"['5', 'appendix', 'table', 'rate', 'supplementary', 'values', 'that', 'in', 'and', 'two']","['5', 'appendix', 'table', 'rate', 'and', 'two']",975,然而，这些值都在预期的5%的中断率范围内（表S12位于补充附录中），并且两组之间是一致的。,0.5,"['5', 'appendix', 'table', 'rate', 'supplementary', 'values', 'that', 'in', 'and', 'two']","['5', 'table', 'rate', 'and', 'two']",,,,
981,976,"the choice of antiplatelet regimen , either aspirin or a P2Y12 inhibitor , was at the discretion of the treating physicians , a factor that makes it uncertain whether the benefit of rivaroxaban monotherapy applies equally to the two combination regimens .",抗血小板治疗方案（阿司匹林或 P2Y12 抑制剂）的选择由主治医师自行决定，这一因素导致不确定利伐沙班单一疗法的益处是否同样适用于两种联合治疗方案。,0.6666666666666666,"['inhibitor', 'combination', 'aspirin', 'factor', 'antiplatelet', 'uncertain', 'benefit', 'choice', 'rivaroxaban', 'that', 'two', 'physicians']","['inhibitor', 'combination', 'aspirin', 'factor', 'benefit', 'choice', 'rivaroxaban', 'two']",976,"['抗乳腺治疗方案的选择,无论是阿司匹林还是P2Y12抑制剂,在治疗医生的判断下,这是一个因素,使它不确定Rivaroxaban单治疗的好处是否同样适用于两种组合治疗方案。']",0.5,"['inhibitor', 'combination', 'aspirin', 'factor', 'antiplatelet', 'uncertain', 'benefit', 'choice', 'rivaroxaban', 'that', 'two', 'physicians']","['inhibitor', 'combination', 'aspirin', 'factor', 'choice', 'two']",976,阻断血小板的方案选择是医生的自由裁量权，因此无法确定利伐沙星单独使用是否对两种联合方案同样有效。,0.3333333333333333,"['inhibitor', 'combination', 'aspirin', 'factor', 'antiplatelet', 'uncertain', 'benefit', 'choice', 'rivaroxaban', 'that', 'two', 'physicians']","['combination', 'benefit', 'choice', 'two']",,,,
982,977,"finally , the reductions in the rate of ischemic events and death from any cause with rivaroxaban monotherapy were unanticipated and are difficult to explain on the basis of the biologic effects of antithrombotic therapy ; these findings may be due to the play of chance .",最后，利伐沙班单一疗法可降低缺血事件发生率和全因死亡率，这是出乎意料的，而且很难根据抗血栓治疗的生物学效应来解释；这些发现可能是偶然的结果。,0.3529411764705882,"['rate', 'death', 'biologic', 'antithrombotic', 'basis', 'therapy', 'be', 'cause', 'due', 'with', 'rivaroxaban', 'on', 'in', 'to', 'and', 'difficult', 'ischemic']","['rate', 'death', 'therapy', 'rivaroxaban', 'and', 'difficult']",977,"['最后,与Rivaroxaban单治疗的任何原因导致的催化事件和死亡率的下降是意想不到的,很难根据抗血管治疗的生物效应来解释;这些发现可能是由于偶然的作用。']",0.3529411764705882,"['rate', 'death', 'biologic', 'antithrombotic', 'basis', 'therapy', 'be', 'cause', 'due', 'with', 'rivaroxaban', 'on', 'in', 'to', 'and', 'difficult', 'ischemic']","['rate', 'death', 'therapy', 'cause', 'to', 'difficult']",977,最终，与利伐沙班单疗程相比，心脏病发作和死亡率的下降是意料之外的，很难仅凭抗血栓疗法的生物学作用来解释这些发现；这些结果可能是偶然因素造成的。,0.2941176470588235,"['rate', 'death', 'biologic', 'antithrombotic', 'basis', 'therapy', 'be', 'cause', 'due', 'with', 'rivaroxaban', 'on', 'in', 'to', 'and', 'difficult', 'ischemic']","['rate', 'death', 'therapy', 'rivaroxaban', 'difficult']",,,,
983,978,"in conclusion , the AFIRE trial evaluated antithrombotic regimens in patients with atrial fibrillation and stable coronary artery disease more than 1 year after revascularization or in those with angiographically confirmed coronary artery disease not requiring revascularization .",总之，AFIRE 试验评估了血运重建后 1 年以上心房颤动和稳定性冠状动脉疾病患者或血管造影证实的冠状动脉疾病不需要血运重建患者的抗血栓治疗方案。,0.6153846153846154,"['disease', 'year', '1', 'antithrombotic', 'revascularization', 'atrial fibrillation', 'after', 'conclusion', 'with', 'coronary artery', 'in', 'and', 'angiographically']","['disease', 'year', '1', 'revascularization', 'atrial fibrillation', 'after', 'coronary artery', 'angiographically']",978,"['在结论中,AFIRE研究评估了患有甲状腺纤维和稳定的冠状动脉疾病超过1年后的患者的抗血管疾病,或在没有需要重血的冠状动脉疾病的患者中。']",0.4615384615384615,"['disease', 'year', '1', 'antithrombotic', 'revascularization', 'atrial fibrillation', 'after', 'conclusion', 'with', 'coronary artery', 'in', 'and', 'angiographically']","['disease', 'year', '1', 'after', 'conclusion', 'coronary artery']",978,最后，AFIRE试验评估了心房颤动患者在血管重建或者经过血管造影确认不需要血管重建的稳定性冠状动脉疾病患者的抗血栓治疗方案。,0.3846153846153846,"['disease', 'year', '1', 'antithrombotic', 'revascularization', 'atrial fibrillation', 'after', 'conclusion', 'with', 'coronary artery', 'in', 'and', 'angiographically']","['disease', 'atrial fibrillation', 'after', 'coronary artery', 'angiographically']",,,,
984,979,we found that rivaroxaban monotherapy was noninferior to combination therapy with rivaroxaban plus antiplatelet therapy with respect to cardiovascular events and death from any cause and superior with respect to major bleeding .,我们发现，在心血管事件和全因死亡方面，利伐沙班单药疗法不劣于利伐沙班加抗血小板疗法的联合疗法，在大出血方面优于利伐沙班。,0.375,"['bleeding', 'combination therapy', 'cardiovascular', 'death', 'plus', 'antiplatelet', 'superior', 'major', 'cause', 'with', 'respect', 'rivaroxaban', 'that', 'to', 'and', 'we']","['bleeding', 'cardiovascular', 'death', 'plus', 'rivaroxaban', 'to']",979,"['我们发现,Rivaroxaban的单疗法与Rivaroxaban的结合疗法以及与心血管事件和任何原因导致的死亡以及与主要出血相比不低。']",0.25,"['bleeding', 'combination therapy', 'cardiovascular', 'death', 'plus', 'antiplatelet', 'superior', 'major', 'cause', 'with', 'respect', 'rivaroxaban', 'that', 'to', 'and', 'we']","['bleeding', 'cardiovascular', 'death', 'cause']",979,我们发现，与河川抗血小板治疗相比，利瓦莫克单药治疗在心血管事件和任何原因的死亡方面并不逊色，而且在重大出血方面优于前者。,0.375,"['bleeding', 'combination therapy', 'cardiovascular', 'death', 'plus', 'antiplatelet', 'superior', 'major', 'cause', 'with', 'respect', 'rivaroxaban', 'that', 'to', 'and', 'we']","['bleeding', 'cardiovascular', 'death', 'cause', 'to', 'and']",,,,
985,980,additional gemcitabine and cisplatin induction chemotherapy has shown promising efficacy in phase 2 trials .,额外的吉西他滨和顺铂诱导化疗在 2 期试验中显示出有前途的疗效。,0.6666666666666666,"['chemotherapy', 'induction', 'cisplatin', '2', 'additional', 'in phase', 'efficacy', 'gemcitabine', 'and']","['chemotherapy', 'induction', 'cisplatin', '2', 'additional', 'gemcitabine']",980,['额外的吉姆西塔宾和西斯普拉丁引导化疗在阶段2试验中表现出有前途的有效性。'],0.5555555555555556,"['chemotherapy', 'induction', 'cisplatin', '2', 'additional', 'in phase', 'efficacy', 'gemcitabine', 'and']","['chemotherapy', 'induction', '2', 'additional', 'efficacy']",980,附加的吉西他滨和铂类药物诱导化疗在2期试验中显示了有希望的疗效。,0.5555555555555556,"['chemotherapy', 'induction', 'cisplatin', '2', 'additional', 'in phase', 'efficacy', 'gemcitabine', 'and']","['chemotherapy', 'induction', '2', 'additional', 'gemcitabine']",,,,
986,981,"secondary end points included overall survival , treatment adherence , and safety .",次要终点包括总生存期、治疗依从性和安全性。,0.5714285714285714,"['safety', 'survival', 'end points', 'treatment', 'secondary', 'adherence', 'and']","['safety', 'survival', 'end points', 'treatment']",981,['二级终点包括整体生存、治疗和安全。'],0.5714285714285714,"['safety', 'survival', 'end points', 'treatment', 'secondary', 'adherence', 'and']","['safety', 'survival', 'end points', 'treatment']",981,辅助指标包括总体生存、治疗依从性和安全性。,0.4285714285714285,"['safety', 'survival', 'end points', 'treatment', 'secondary', 'adherence', 'and']","['safety', 'survival', 'treatment']",,,,
987,982,"overall survival at 3 years was 94.6 % and 90.3 % , respectively ( stratified hazard ratio for death , 0.43 ; 95 % CI , 0.24 to 0.77 ) .",3 年总生存率分别为 94.6% 和 90.3%（死亡的分层风险比为 0.43；95% CI 为 0.24 至 0.77）。,0.4285714285714285,"['survival', 'hazard ratio', 'death', '3', 'CI', 'to', 'and']","['survival', 'hazard ratio', 'death']",982,"['3年的总生存率为94.6%和90.3%,分别(分裂死亡风险比例为0.43;95% CI,0.24至0.77)。']",0.4285714285714285,"['survival', 'hazard ratio', 'death', '3', 'CI', 'to', 'and']","['survival', 'hazard ratio', 'death']",982,"Overall survival at 3 years was 94.6% and 90.3%, respectively (stratified hazard ratio for death, 0.43; 95% CI, 0.24 to 0.77).",0.0,"['survival', 'hazard ratio', 'death', '3', 'CI', 'to', 'and']",[],,,,
988,983,a total of 96.7 % of the patients completed three cycles of induction chemotherapy .,共有96.7%的患者完成了三个周期的诱导化疗。,0.5,"['chemotherapy', 'induction', 'total', 'three']","['chemotherapy', 'induction']",983,['96.7%的患者完成了3个引发化疗周期。'],0.25,"['chemotherapy', 'induction', 'total', 'three']",['chemotherapy'],983,总共有96.7%的病人完成了三周期的诱导化疗。,0.5,"['chemotherapy', 'induction', 'total', 'three']","['chemotherapy', 'induction']",,,,
989,984,nasopharyngeal carcinoma is a head and neck cancer with a specific geographic distribution .,鼻咽癌是一种具有特定地理分布的头颈癌。,0.5555555555555556,"['cancer', 'neck', 'head', 'nasopharyngeal carcinoma', 'distribution', 'geographic', 'specific', 'with', 'and']","['cancer', 'neck', 'head', 'nasopharyngeal carcinoma', 'distribution']",984,['鼻孔癌是一种具有特定的地理分布的头部和脖子癌症。'],0.3333333333333333,"['cancer', 'neck', 'head', 'nasopharyngeal carcinoma', 'distribution', 'geographic', 'specific', 'with', 'and']","['cancer', 'head', 'distribution']",984,"Nasopharyngeal carcinoma is a head and neck cancer with a specific geographic distribution.

Chinese:

鼻咽癌具有特定的地理分布。",0.3333333333333333,"['cancer', 'neck', 'head', 'nasopharyngeal carcinoma', 'distribution', 'geographic', 'specific', 'with', 'and']","['cancer', 'nasopharyngeal carcinoma', 'distribution']",,,,
990,985,"it affected an estimated 130,000 patients worldwide in 2018 , with the highest rates occurring in regions in South China , Southeastern Asia , and North Africa.1","2018 年全球估计有 130,000 名患者受到影响，其中华南、东南亚和北非地区的发病率最高。 1",0.25,"['north', 'china', 'with', 'and']",['north'],985,"['它影响了全球估计130,000名患者在2018年,最高率发生在南中国、东南亚和北非地区。']",0.5,"['north', 'china', 'with', 'and']","['north', 'china']",985,这种疾病在2018年全球约影响了13万人，其中最高发生率出现在中国华南、东南亚和北非地区。1,0.5,"['north', 'china', 'with', 'and']","['north', 'china']",,,,
991,986,"the toxicity of systemic therapy after chemoradiotherapy remains a pertinent issue.6,10","放化疗后全身治疗的毒性仍然是一个相关问题。 6,10",0.75,"['toxicity', 'therapy', 'systemic', 'after']","['toxicity', 'therapy', 'after']",986,['化疗后系统治疗的毒性仍然是一个相关问题。'],0.75,"['toxicity', 'therapy', 'systemic', 'after']","['toxicity', 'therapy', 'after']",986,"系统性治疗在化疗辐射治疗后的毒性仍然是一个相关的问题。6,10",0.75,"['toxicity', 'therapy', 'systemic', 'after']","['toxicity', 'therapy', 'after']",,,,
992,987,"however , in the context of newly diagnosed , nonmetastatic , locoregionally advanced disease , the efficacy and safety profile of induction therapy with gemcitabine plus cisplatin to chemoradiotherapy is unclear .",然而，在新诊断的、非转移性、局部晚期疾病的情况下，吉西他滨联合顺铂诱导治疗对化放疗的疗效和安全性尚不清楚。,0.5,"['safety', 'induction', 'disease', 'context', 'cisplatin', 'plus', 'therapy', 'advanced', 'efficacy', 'profile', 'with', 'gemcitabine', 'to', 'and']","['safety', 'induction', 'disease', 'cisplatin', 'therapy', 'gemcitabine', 'and']",987,"['然而,在新诊断、非甲状腺疾病、区域先进疾病的背景下,用吉姆西塔宾加西斯普拉丁进行化学放射治疗的有效性和安全性不清楚。']",0.4285714285714285,"['safety', 'induction', 'disease', 'context', 'cisplatin', 'plus', 'therapy', 'advanced', 'efficacy', 'profile', 'with', 'gemcitabine', 'to', 'and']","['safety', 'disease', 'plus', 'therapy', 'efficacy', 'and']",987,然而，在新诊断的、未转移的、局部区域扩张性疾病的情况下，吉西他滨加顺铂的诱导治疗辅助放疗的疗效和安全性尚不清楚。,0.5714285714285714,"['safety', 'induction', 'disease', 'context', 'cisplatin', 'plus', 'therapy', 'advanced', 'efficacy', 'profile', 'with', 'gemcitabine', 'to', 'and']","['safety', 'induction', 'disease', 'cisplatin', 'plus', 'therapy', 'gemcitabine', 'and']",,,,
993,988,"we therefore conducted a multicenter , randomized , controlled , phase 3 clinical trial to investigate the efficacy and safety of adding gemcitabine plus cisplatin to chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma .",因此，我们开展了一项多中心、随机、对照的 3 期临床试验，以研究在局部晚期鼻咽癌患者中将吉西他滨联合顺铂加入放化疗的疗效和安全性。,0.4375,"['clinical trial', 'safety', 'phase', 'cisplatin', 'plus', 'nasopharyngeal carcinoma', 'controlled', 'advanced', 'efficacy', '3', 'with', 'gemcitabine', 'therefore', 'to', 'and', 'we']","['clinical trial', 'safety', 'phase', 'cisplatin', 'plus', 'nasopharyngeal carcinoma', 'gemcitabine']",988,"['因此,我们进行了多中心、随机、控制、第三阶段的临床试验,以调查在患有区域先进的鼻孔癌的患者中添加吉姆西塔宾加西斯普拉丁的有效性和安全性。']",0.375,"['clinical trial', 'safety', 'phase', 'cisplatin', 'plus', 'nasopharyngeal carcinoma', 'controlled', 'advanced', 'efficacy', '3', 'with', 'gemcitabine', 'therefore', 'to', 'and', 'we']","['clinical trial', 'safety', 'phase', 'plus', 'controlled', 'efficacy']",988,我们因此开展了一项多中心、随机、对照、3期临床试验，评估了在患有局部晚期鼻咽癌患者中，将吉西他滨和顺铂加入化疗放疗方案的疗效和安全性。,0.4375,"['clinical trial', 'safety', 'phase', 'cisplatin', 'plus', 'nasopharyngeal carcinoma', 'controlled', 'advanced', 'efficacy', '3', 'with', 'gemcitabine', 'therefore', 'to', 'and', 'we']","['clinical trial', 'safety', 'phase', 'cisplatin', 'plus', 'nasopharyngeal carcinoma', 'gemcitabine']",,,,
994,989,"the institutional ethics review board at each participating center approved the trial protocol , available at NEJM.org .",每个参与中心的机构伦理审查委员会批准了试验方案，可在 NEJM.org 获取。,0.3333333333333333,"['center', 'review', 'protocol', 'ethics', 'available', 'board', 'trial', 'at', 'each']","['center', 'review', 'protocol']",989,"['各參與中心的機構倫理評論委員會批准了試驗議定書,可在NEJM.org上找到。']",0.2222222222222222,"['center', 'review', 'protocol', 'ethics', 'available', 'board', 'trial', 'at', 'each']","['center', 'each']",989,审批了本试验方案的各个参与中心的机构伦理审查委员会已经在NEJM.org上公布了该方案。,0.4444444444444444,"['center', 'review', 'protocol', 'ethics', 'available', 'board', 'trial', 'at', 'each']","['center', 'review', 'protocol', 'each']",,,,
995,990,the trial was performed according to the principles of the Declaration of Helsinki and Good Clinical Practice guidelines as defined by the International Conference on Harmonisation .,该试验是根据赫尔辛基宣言的原则和国际协调会议定义的良好临床实践指南进行的。,0.0,"['defined', 'good clinical practice', 'trial', 'as', 'on', 'by', 'to', 'and']",[],990,['根据《赫尔辛基宣言》和《国际协调会议》所定义的良好临床实践指南的原则进行审查。'],0.0,"['defined', 'good clinical practice', 'trial', 'as', 'on', 'by', 'to', 'and']",[],990,试验符合《赫尔辛基宣言》和国际协调会定义的良好临床实践准则。,0.0,"['defined', 'good clinical practice', 'trial', 'as', 'on', 'by', 'to', 'and']",[],,,,
996,991,written informed consent was obtained from all the patients before enrollment .,入组前已获得所有患者的书面知情同意书。,0.3333333333333333,"['informed consent', 'all', 'before']",['before'],991,"['在注册之前,所有患者都获得了书面信息的同意。']",0.3333333333333333,"['informed consent', 'all', 'before']",['before'],991,所有病人在加入前都签署了书面同意。,0.3333333333333333,"['informed consent', 'all', 'before']",['before'],,,,
997,992,patients could withdraw consent at any time after enrollment and could discontinue the trial if disease progression or severe coexisting conditions occurred during treatment .,患者可以在入组后随时撤回同意，如果在治疗期间出现疾病进展或严重合并症，患者可以终止试验。,0.5454545454545454,"['disease', 'withdraw', 'time', 'treatment', 'progression', 'after', 'trial', 'consent', 'severe', 'if', 'and']","['disease', 'time', 'treatment', 'progression', 'after', 'consent']",992,"['患者可以在注册后随时撤回同意,如果病情进展或治疗期间发生严重的共同存在条件,则可以停止检查。']",0.5454545454545454,"['disease', 'withdraw', 'time', 'treatment', 'progression', 'after', 'trial', 'consent', 'severe', 'if', 'and']","['disease', 'time', 'treatment', 'progression', 'after', 'consent']",992,病人可在入籍后随时撤回同意，并可在治疗期间因疾病进展或严重并发症发生时终止试验。,0.5454545454545454,"['disease', 'withdraw', 'time', 'treatment', 'progression', 'after', 'trial', 'consent', 'severe', 'if', 'and']","['disease', 'time', 'treatment', 'progression', 'after', 'consent']",,,,
998,993,"the last author designed , wrote , and implemented the trial protocol and managed the trial .",最后一位作者设计、撰写和实施了试验方案并管理了试验。,0.25,"['author', 'protocol', 'trial', 'and']",['protocol'],993,['最后的作者设计、写作、实施审判协议并管理审判。'],0.5,"['author', 'protocol', 'trial', 'and']","['protocol', 'trial']",993,最后一位作者设计、编写并实施了试验方案，并负责了整个试验的进行。,0.25,"['author', 'protocol', 'trial', 'and']",['protocol'],,,,
999,994,lead investigators from each center gathered the data and ensured its accuracy and completeness .,每个中心的首席调查员收集数据并确保其准确性和完整性。,0.5714285714285714,"['center', 'lead', 'data', 'accuracy', 'completeness', 'each', 'and']","['center', 'data', 'accuracy', 'completeness']",994,"['各中心的主要调查人员收集了数据,并确保其准确性和完整性。']",0.7142857142857143,"['center', 'lead', 'data', 'accuracy', 'completeness', 'each', 'and']","['center', 'data', 'accuracy', 'completeness', 'each']",994,中心的首席调查员们收集了数据，并确保了数据的准确性和完整性。,0.5714285714285714,"['center', 'lead', 'data', 'accuracy', 'completeness', 'each', 'and']","['center', 'data', 'accuracy', 'completeness']",,,,
1000,995,one of the authors conducted the statistical analyses .,其中一位作者进行了统计分析。,,[],[],995,['其中一位作者进行了统计分析。'],,[],[],995,一位作者进行了统计分析。,,[],[],,,,
1001,996,no one who is not an author contributed to the writing of the manuscript .,没有非作者参与手稿的撰写。,0.1666666666666666,"['who', 'author', 'no', 'manuscript', 'writing', 'to']",['manuscript'],996,"['没有人是作家,没有人参与了手稿的写作。']",0.3333333333333333,"['who', 'author', 'no', 'manuscript', 'writing', 'to']","['manuscript', 'writing']",996,No one who is not an author contributed to the writing of the manuscript.,0.0,"['who', 'author', 'no', 'manuscript', 'writing', 'to']",[],,,,
1002,996,no one who is not an author contributed to the writing of the manuscript .,没有非作者参与手稿的撰写。,0.1666666666666666,"['who', 'author', 'no', 'manuscript', 'writing', 'to']",['manuscript'],996,"['没有人是作家,没有人参与了手稿的写作。']",0.3333333333333333,"['who', 'author', 'no', 'manuscript', 'writing', 'to']","['manuscript', 'writing']",996,No one who is not an author contributed to the writing of the manuscript.,0.0,"['who', 'author', 'no', 'manuscript', 'writing', 'to']",[],,,,
1003,996,no one who is not an author contributed to the writing of the manuscript .,没有非作者参与手稿的撰写。,0.1666666666666666,"['who', 'author', 'no', 'manuscript', 'writing', 'to']",['manuscript'],996,"['没有人是作家,没有人参与了手稿的写作。']",0.3333333333333333,"['who', 'author', 'no', 'manuscript', 'writing', 'to']","['manuscript', 'writing']",996,No one who is not an author contributed to the writing of the manuscript.,0.0,"['who', 'author', 'no', 'manuscript', 'writing', 'to']",[],,,,
1004,997,"the first author wrote the first draft of manuscript , which was reviewed by all the authors .",第一作者撰写了初稿，并由所有作者审阅。,0.3333333333333333,"['author', 'manuscript', 'all', 'by', 'first', 'draft']","['by', 'first']",997,"['第一位作者写了第一本手稿草案,所有作者都审查了。']",0.3333333333333333,"['author', 'manuscript', 'all', 'by', 'first', 'draft']","['manuscript', 'first']",997,第一作者撰写了稿件的第一稿，并得到了其他所有作者的审阅。,0.1666666666666666,"['author', 'manuscript', 'all', 'by', 'first', 'draft']",['first'],,,,
1005,998,all the authors approved the final content of the manuscript .,所有作者都认可了手稿的最终内容。,0.3333333333333333,"['content', 'manuscript', 'all']",['manuscript'],998,['所有作者都批准了手稿的最终内容。'],0.3333333333333333,"['content', 'manuscript', 'all']",['manuscript'],998,所有作者都同意了最终的稿件内容。,0.0,"['content', 'manuscript', 'all']",[],,,,
1006,999,the trial sponsors had no access to the data and were not involved in the data interpretation or the manuscript preparation or review .,试验发起人无法访问数据，也不参与数据解释或手稿准备或审查。,0.5,"['data', 'preparation', 'review', 'access', 'interpretation', 'no', 'manuscript', 'trial', 'to', 'and']","['data', 'preparation', 'review', 'interpretation', 'manuscript']",999,"['审判赞助商没有访问数据,并未参与数据解释或手稿编制或审查。']",0.5,"['data', 'preparation', 'review', 'access', 'interpretation', 'no', 'manuscript', 'trial', 'to', 'and']","['data', 'review', 'interpretation', 'manuscript', 'trial']",999,试验赞助者没有获得数据，也没有参与数据解释或者手稿准备或审核。,0.5,"['data', 'preparation', 'review', 'access', 'interpretation', 'no', 'manuscript', 'trial', 'to', 'and']","['data', 'preparation', 'review', 'interpretation', 'manuscript']",,,,
1007,1000,"Qilu Pharmaceutical provided gemcitabine and cisplatin free of charge and was not involved in the trial design , data collection or analysis , or manuscript preparation or review .",齐鲁制药免费提供吉西他滨和顺铂，未参与试验设计、数据收集或分析、文稿准备或审阅。,0.6666666666666666,"['analysis', 'pharmaceutical', 'preparation', 'cisplatin', 'review', 'free of charge', 'manuscript', 'trial', 'data collection', 'design', 'gemcitabine', 'and']","['analysis', 'preparation', 'cisplatin', 'review', 'free of charge', 'data collection', 'design', 'gemcitabine']",1000,['Qilu Pharmaceutical 免费提供 gemcitabine 和 cisplatin 并未参与试验设计、数据收集或分析、手稿制作或审查。'],0.5,"['analysis', 'pharmaceutical', 'preparation', 'cisplatin', 'review', 'free of charge', 'manuscript', 'trial', 'data collection', 'design', 'gemcitabine', 'and']","['analysis', 'review', 'free of charge', 'manuscript', 'data collection', 'design']",1000,"Qilu Pharmaceutical provided gemcitabine and cisplatin free of charge and was not involved in the trial design , data collection or analysis , or manuscript preparation or review .

Chinese:

齐鲁药业免费提供了吉西他滨和环丙沙星，并没有参与试验设计、数据收集或分析，也没有参与稿件的准备或审核。",0.5833333333333334,"['analysis', 'pharmaceutical', 'preparation', 'cisplatin', 'review', 'free of charge', 'manuscript', 'trial', 'data collection', 'design', 'gemcitabine', 'and']","['analysis', 'preparation', 'review', 'free of charge', 'data collection', 'design', 'gemcitabine']",,,,
1008,1001,the last author vouches for the completeness and accuracy of the data and for the adherence of the trial to the protocol .,最后一位作者保证数据的完整性和准确性以及试验对方案的依从性。,0.375,"['data', 'author', 'accuracy', 'protocol', 'trial', 'completeness', 'adherence', 'and']","['data', 'accuracy', 'completeness']",1001,['最后的作者为数据的完整性和准确性以及审判对议定书的遵守提供优惠。'],0.625,"['data', 'author', 'accuracy', 'protocol', 'trial', 'completeness', 'adherence', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness']",1001,最后一位作者为数据的完整性和准确性负责，并确保试验符合协议。,0.5,"['data', 'author', 'accuracy', 'protocol', 'trial', 'completeness', 'adherence', 'and']","['data', 'accuracy', 'protocol', 'completeness']",,,,
1009,1002,"for this trial , essential pretreatment evaluations included the following : complete history ; physical examination ; hematologic and biochemical analyses ; flexible nasopharyngoscopy ; histopathological diagnosis ; and magnetic resonance imaging ( MRI ) or enhanced computed tomography ( CT ) ( if patients had contraindications to MRI ) of the nasopharynx and neck for primary tumor staging .",对于该试验，基本的治疗前评估包括以下内容：完整的病史；身体检查；血液学和生化分析；可弯曲鼻咽镜检查；组织病理学诊断；鼻咽部和颈部的磁共振成像 (MRI) 或增强型计算机断层扫描 (CT)（如果患者有 MRI 禁忌证）用于原发肿瘤分期。,0.2857142857142857,"['nasopharynx', 'neck', 'primary tumor', 'history', 'essential', 'physical examination', 'MRI', 'magnetic resonance imaging', 'complete', 'diagnosis', 'trial', 'flexible', 'CT', 'biochemical', 'pretreatment', 'computed tomography', 'this', 'if', 'and', 'hematologic', 'following']","['nasopharynx', 'neck', 'physical examination', 'magnetic resonance imaging', 'complete', 'diagnosis']",1002,"['对于此试验,基本的预治疗评估包括以下:完整的历史;物理检查;血液学和生物化学分析;灵活的鼻孔筛查;歇斯托病学诊断;和磁响图像(MRI)或增强计算图像(CT)(如果患者有MRI的对抗迹象)的鼻孔和颈部的初始肿瘤排序。']",0.238095238095238,"['nasopharynx', 'neck', 'primary tumor', 'history', 'essential', 'physical examination', 'MRI', 'magnetic resonance imaging', 'complete', 'diagnosis', 'trial', 'flexible', 'CT', 'biochemical', 'pretreatment', 'computed tomography', 'this', 'if', 'and', 'hematologic', 'following']","['neck', 'history', 'magnetic resonance imaging', 'complete', 'diagnosis']",1002,本次试验的基本前置评估包括以下内容：完整的病史；体格检查；血液学和生化分析；鼻咽镜检查；病理学诊断；以及鼻咽和颈部原发肿瘤分期的核磁共振成像（MRI）或增强计算机断层扫描（CT）（如果病人对MRI存在禁忌）。,0.2857142857142857,"['nasopharynx', 'neck', 'primary tumor', 'history', 'essential', 'physical examination', 'MRI', 'magnetic resonance imaging', 'complete', 'diagnosis', 'trial', 'flexible', 'CT', 'biochemical', 'pretreatment', 'computed tomography', 'this', 'if', 'and', 'hematologic', 'following']","['nasopharynx', 'neck', 'MRI', 'magnetic resonance imaging', 'complete', 'diagnosis']",,,,
1010,1003,distant metastasis staging was completed with CT examination of the chest and abdomen and with skeletal scintigraphy .,远处转移的分期是通过胸部和腹部的 CT 检查以及骨骼闪烁扫描完成的。,0.4444444444444444,"['abdomen', 'metastasis', 'chest', 'examination', 'skeletal', 'distant', 'CT', 'with', 'and']","['abdomen', 'metastasis', 'chest', 'examination']",1003,"['遥远的转移阶段完成了胸部和腹部的CT检查,以及骨骼阴道。']",0.5555555555555556,"['abdomen', 'metastasis', 'chest', 'examination', 'skeletal', 'distant', 'CT', 'with', 'and']","['abdomen', 'metastasis', 'chest', 'examination', 'distant']",1003,使用胸部和腹部的CT检查以及骨骼核素扫描完成了远程转移分期。,0.4444444444444444,"['abdomen', 'metastasis', 'chest', 'examination', 'skeletal', 'distant', 'CT', 'with', 'and']","['abdomen', 'metastasis', 'chest', 'examination']",,,,
1011,1004,a computer program was used to generate the assignment list .,使用计算机程序生成分配列表。,0.3333333333333333,"['program', 'computer', 'list', 'generate', 'assignment', 'to']","['program', 'computer']",1004,['一个计算机程序被用来创建任务列表。'],0.3333333333333333,"['program', 'computer', 'list', 'generate', 'assignment', 'to']","['program', 'computer']",1004,"一个计算机程序被用来生成任务列表。

Chinese:

一个计算机程序被用来生成作业列表。",0.3333333333333333,"['program', 'computer', 'list', 'generate', 'assignment', 'to']","['program', 'computer']",,,,
1012,1005,treatment group assignment was not masked .,治疗组分配未设盲。,0.5,"['treatment group', 'assignment']",['treatment group'],1005,['治疗小组任务没有面具。'],0.0,"['treatment group', 'assignment']",[],1005,"The treatment group assignment was not masked.

Chinese:

治疗组的分配并未隐蔽。",0.5,"['treatment group', 'assignment']",['treatment group'],,,,
1013,1006,"cisplatin that was concurrent with radiotherapy was then administered intravenously at a dose of 100 mg per square meter every 3 weeks on days 1 , 22 , and 43 .",然后在第 1、22 和 43 天每 3 周静脉内给予与放疗同步的顺铂，剂量为每平方米 100 毫克。,0.5,"['cisplatin', '1', 'meter', 'radiotherapy', 'intravenously', 'concurrent', '3', 'with', 'dose', 'that', 'and', 'square']","['cisplatin', '1', 'meter', 'intravenously', 'dose', 'square']",1006,['随后与放射治疗相匹配的西斯普拉丁在1日、22日和43日每3周服用100毫克每平方米的内分泌剂。'],0.3333333333333333,"['cisplatin', '1', 'meter', 'radiotherapy', 'intravenously', 'concurrent', '3', 'with', 'dose', 'that', 'and', 'square']","['1', 'meter', 'radiotherapy', 'square']",1006,"cisplatin that was concurrent with radiotherapy was then administered intravenously at a dose of 100 mg per square meter every 3 weeks on days 1, 22, and 43.

Chinese:

放射治疗同时进行的顺铂被经静脉注射，剂量为每平方米100毫克，每3周1天，22天和43天注射一次。",0.5,"['cisplatin', '1', 'meter', 'radiotherapy', 'intravenously', 'concurrent', '3', 'with', 'dose', 'that', 'and', 'square']","['cisplatin', '1', 'meter', 'radiotherapy', 'dose', 'square']",,,,
1014,1007,details of the chemotherapy dose modifications and supportive measures are provided in the Supplementary Appendix .,补充附录中提供了化疗剂量调整和支持措施的详细信息。,0.3333333333333333,"['chemotherapy', 'appendix', 'supplementary', 'dose', 'in', 'and']","['chemotherapy', 'dose']",1007,['化疗剂量修改和支持措施的详细信息在附件中提供。'],0.5,"['chemotherapy', 'appendix', 'supplementary', 'dose', 'in', 'and']","['chemotherapy', 'appendix', 'dose']",1007,"The details of the chemotherapy dose modifications and supportive measures are provided in the Supplementary Appendix.

Chinese:

化疗剂量调整和支持措施的详细信息可以在附录中找到。",0.3333333333333333,"['chemotherapy', 'appendix', 'supplementary', 'dose', 'in', 'and']","['chemotherapy', 'dose']",,,,
1015,1008,"the guidelines regarding radiotherapy3,17 are provided in the Supplementary Appendix .","补充附录中提供了有关放疗的指南3,17。",0.3333333333333333,"['appendix', 'supplementary', 'regarding']",['regarding'],1008,['关于放射治疗的指南3、17在附件中列出。'],0.6666666666666666,"['appendix', 'supplementary', 'regarding']","['appendix', 'regarding']",1008,"放射疗程序的指南3,17可以在附录中找到。",0.0,"['appendix', 'supplementary', 'regarding']",[],,,,
1016,1009,it was recommended that patients in the induction chemotherapy group commence chemoradiotherapy within 21 to 28 days after the first day of the last cycle of induction chemotherapy .,建议诱导化疗组患者在诱导化疗末周期第一天后21～28天内开始放化疗。,0.75,"['group', 'chemotherapy', 'induction', 'cycle', 'after', 'that', 'to', 'first']","['group', 'chemotherapy', 'induction', 'cycle', 'after', 'first']",1009,['建议患者在因子化疗周期的第一天后21至28天内开始化疗。'],0.5,"['group', 'chemotherapy', 'induction', 'cycle', 'after', 'that', 'to', 'first']","['chemotherapy', 'cycle', 'after', 'first']",1009,建议低剂量化疗组的患者在最后一个疗程的第一天后的21至28天内开始化疗辐射治疗。,0.5,"['group', 'chemotherapy', 'induction', 'cycle', 'after', 'that', 'to', 'first']","['group', 'chemotherapy', 'after', 'first']",,,,
1017,1010,tumors were assessed with the use of flexible nasopharyngoscopy and MRI of the nasopharyngeal and neck areas at 1 week after the completion of induction chemotherapy and 16 weeks after chemoradiotherapy .,在诱导化疗完成后 1 周和放化疗后 16 周，使用可弯曲鼻咽镜和鼻咽及颈部 MRI 评估肿瘤。,0.5,"['chemotherapy', 'induction', 'neck', '1', 'nasopharyngeal', 'MRI', 'week', 'after', 'flexible', 'completion', 'with', 'at', 'and', 'assessed']","['chemotherapy', 'induction', 'neck', '1', 'week', 'after', 'completion']",1010,"['肿瘤被评估使用灵活的鼻<unk>和鼻<unk>和脖子区域的MRI在完成引发化疗后1周,并在化疗后16周。']",0.3571428571428571,"['chemotherapy', 'induction', 'neck', '1', 'nasopharyngeal', 'MRI', 'week', 'after', 'flexible', 'completion', 'with', 'at', 'and', 'assessed']","['chemotherapy', '1', 'week', 'after', 'completion']",1010,"Tumors were assessed with the use of flexible nasopharyngoscopy and MRI of the nasopharyngeal and neck areas at 1 week after the completion of induction chemotherapy and 16 weeks after chemoradiotherapy.

Chinese:

肿瘤在化疗后1周和放疗后16周分别使用灵活鼻咽镜和MRI来评估鼻咽部和颈部的情况。",0.3571428571428571,"['chemotherapy', 'induction', 'neck', '1', 'nasopharyngeal', 'MRI', 'week', 'after', 'flexible', 'completion', 'with', 'at', 'and', 'assessed']","['chemotherapy', 'neck', '1', 'week', 'after']",,,,
1018,1011,"we used the Common Terminology Criteria for Adverse Events , version 4.0 , to grade acute toxic effects during treatment , and late toxic effects that were associated with radiotherapy were graded according to the Late Radiation Morbidity Scoring Scheme of the Radiation Therapy Oncology Group.18",我们使用不良事件通用术语标准 4.0 版对治疗期间的急性毒性反应进行分级，并根据放射治疗肿瘤组的晚期放射发病率评分方案对与放疗相关的晚期毒性反应进行分级。 18,0.2105263157894736,"['toxic', 'morbidity', 'grade', 'version', 'radiotherapy', 'common', 'late', 'adverse', 'associated', 'treatment', 'terminology', 'scheme', 'acute', 'radiation therapy', 'scoring', 'with', 'that', 'and', 'we']","['morbidity', 'radiotherapy', 'treatment', 'terminology']",1011,"['我们使用的常用术语对不良事件的标准,版本 4.0,以评分治疗期间的急性毒性效果,以及与辐射治疗相关的晚期毒性效果,根据放射治疗肿瘤学集团的晚期辐射病度评分计划进行了评分。']",0.2631578947368421,"['toxic', 'morbidity', 'grade', 'version', 'radiotherapy', 'common', 'late', 'adverse', 'associated', 'treatment', 'terminology', 'scheme', 'acute', 'radiation therapy', 'scoring', 'with', 'that', 'and', 'we']","['grade', 'version', 'radiotherapy', 'treatment', 'terminology']",1011,我们使用了并发症术语标准(Common Terminology Criteria for Adverse Events)的4.0版来评估治疗期间的急性毒性作用，而与放疗相关的迟发毒性作用则根据辐射治疗肿瘤学会(Radiation Therapy Oncology Group)的迟发辐射损害评分方案进行评分。,0.1578947368421052,"['toxic', 'morbidity', 'grade', 'version', 'radiotherapy', 'common', 'late', 'adverse', 'associated', 'treatment', 'terminology', 'scheme', 'acute', 'radiation therapy', 'scoring', 'with', 'that', 'and', 'we']","['treatment', 'terminology', 'and']",,,,
1019,1012,all end points were assessed or confirmed by the physician in charge .,所有终点均由主治医师评估或确认。,0.5,"['charge', 'physician', 'end points', 'all', 'by', 'assessed']","['physician', 'end points', 'by']",1012,['所有终点都由负责的医生评估或确认。'],0.5,"['charge', 'physician', 'end points', 'all', 'by', 'assessed']","['physician', 'end points', 'by']",1012,所有的终点都是由主治医生评估或确认的。,0.5,"['charge', 'physician', 'end points', 'all', 'by', 'assessed']","['physician', 'end points', 'by']",,,,
1020,1013,this yielded a final sample size of 476 ( 238 patients per group ) .19,这产生了 476 的最终样本量（每组 238 名患者）.19,0.3333333333333333,"['group', 'sample size', 'this']",['group'],1013,['最终样品大小为476(每组238名患者)。'],0.3333333333333333,"['group', 'sample size', 'this']",['group'],1013,这产生了一个最终的样本大小为476（每组238个病人）。,0.3333333333333333,"['group', 'sample size', 'this']",['group'],,,,
1021,1014,the safety population comprised patients who started treatment in each group .,安全人群包括每组开始治疗的患者。,0.5714285714285714,"['safety', 'group', 'population', 'who', 'treatment', 'each', 'in']","['safety', 'group', 'population', 'treatment']",1014,['安全人口包括在每个群体开始治疗的患者。'],0.5714285714285714,"['safety', 'group', 'population', 'who', 'treatment', 'each', 'in']","['safety', 'group', 'population', 'treatment']",1014,该安全性研究人群包括每组患者的治疗开始者。,0.5714285714285714,"['safety', 'group', 'population', 'who', 'treatment', 'each', 'in']","['safety', 'group', 'population', 'treatment']",,,,
1022,1015,"for each chemotherapy drug , we calculated the relative dose intensity as the total dose actually received during treatment , divided by the dose defined by the protocol .",对于每种化疗药物，我们将相对剂量强度计算为治疗期间实际接受的总剂量除以方案规定的剂量。,0.3333333333333333,"['chemotherapy', 'defined', 'protocol', 'relative', 'treatment', 'total dose', 'intensity', 'as', 'drug', 'each', 'by', 'we']","['chemotherapy', 'treatment', 'drug', 'by']",1015,"['对于每种化疗药物,我们计算了相对剂量强度,作为治疗期间实际获得的总剂量,分为协议定义的剂量。']",0.3333333333333333,"['chemotherapy', 'defined', 'protocol', 'relative', 'treatment', 'total dose', 'intensity', 'as', 'drug', 'each', 'by', 'we']","['chemotherapy', 'protocol', 'treatment', 'drug']",1015,对于每一种化疗药物，我们计算相对剂量强度，其定义为实际接受治疗时总剂量除以治疗方案中确定的剂量。,0.4166666666666667,"['chemotherapy', 'defined', 'protocol', 'relative', 'treatment', 'total dose', 'intensity', 'as', 'drug', 'each', 'by', 'we']","['chemotherapy', 'defined', 'treatment', 'drug', 'by']",,,,
1023,1016,an independent data monitoring committee monitored the trial and made decisions regarding possible early trial stoppage .,一个独立的数据监测委员会监测了试验并就可能的早期试验停止做出了决定。,0.5555555555555556,"['monitoring', 'data', 'early', 'regarding', 'committee', 'trial', 'independent', 'stoppage', 'and']","['monitoring', 'data', 'early', 'committee', 'independent']",1016,"['一个独立的数据监测委员会对审判进行了监测,并就可能早期审判中断作出决定。']",0.6666666666666666,"['monitoring', 'data', 'early', 'regarding', 'committee', 'trial', 'independent', 'stoppage', 'and']","['monitoring', 'data', 'early', 'committee', 'trial', 'independent']",1016,一个独立的数据监测委员会监督审判并就可能的早期审判终止做出决定。,0.6666666666666666,"['monitoring', 'data', 'early', 'regarding', 'committee', 'trial', 'independent', 'stoppage', 'and']","['monitoring', 'data', 'early', 'committee', 'trial', 'independent']",,,,
1024,1017,"an interim analysis was performed on October 30 , 2016 , when the trial reached approximately half the expected number of disease recurrences or deaths ( i.e. , 38 events ) .",2016 年 10 月 30 日进行了中期分析，当时试验达到了预期疾病复发或死亡人数的大约一半（即 38 起事件）。,0.2857142857142857,"['analysis', 'half', 'of disease', 'trial', 'expected number', 'on', 'approximately']","['analysis', 'half']",1017,"['临时分析是在2016年10月30日进行的,当调查达到预期的疾病重复或死亡人数(即38起事件)的约一半时。']",0.2857142857142857,"['analysis', 'half', 'of disease', 'trial', 'expected number', 'on', 'approximately']","['analysis', 'half']",1017,在2016年10月30日，当试验达到预期的疾病复发或死亡数（即38个事件）时，进行了中期分析。,0.1428571428571428,"['analysis', 'half', 'of disease', 'trial', 'expected number', 'on', 'approximately']",['analysis'],,,,
1025,1018,the data monitoring committee reviewed the analyses and approved the continuation of the trial .,数据监测委员会审查了分析并批准继续试验。,0.6,"['monitoring', 'data', 'committee', 'trial', 'and']","['monitoring', 'data', 'committee']",1018,"['数据监测委员会审查了分析,并批准了审判的继续。']",0.8,"['monitoring', 'data', 'committee', 'trial', 'and']","['monitoring', 'data', 'committee', 'trial']",1018,数据监控委员会审查了分析并批准了试验的继续进行。,0.4,"['monitoring', 'data', 'committee', 'trial', 'and']","['data', 'committee']",,,,
1026,1019,"the database was locked on April 15 , 2019 , and here we report the survival and toxicity analyses .",该数据库于 2019 年 4 月 15 日被锁定，我们在此报告生存和毒性分析。,0.4285714285714285,"['toxicity', 'database', 'survival', 'report', 'on', 'and', 'we']","['toxicity', 'survival', 'report']",1019,"['数据库于2019年4月15日关闭,我们在这里报告生存和毒性分析。']",0.4285714285714285,"['toxicity', 'database', 'survival', 'report', 'on', 'and', 'we']","['toxicity', 'survival', 'report']",1019,数据库于2019年4月15日被锁定，本文将报告生存和毒性分析结果。,0.4285714285714285,"['toxicity', 'database', 'survival', 'report', 'on', 'and', 'we']","['toxicity', 'survival', 'report']",,,,
1027,1020,"analyses were conducted with the use of SPSS software , version 22.0 ( IBM ) , and Stata software , version 14.2 ( StataCorp ) .",使用 SPSS 软件 22.0 版 (IBM) 和 Stata 软件 14.2 版 (StataCorp) 进行分析。,0.25,"['version', 'software', 'with', 'and']",['software'],1020,"['分析是使用SPSS软件,版本 22.0(IBM)和Stata软件,版本 14.2(StataCorp)进行的。']",0.5,"['version', 'software', 'with', 'and']","['version', 'software']",1020,使用SPSS软件（版本22.0，IBM）和Stata软件（版本14.2，StataCorp）进行了分析。,0.5,"['version', 'software', 'with', 'and']","['version', 'software']",,,,
1028,1021,"from December 2013 through September 2016 , we enrolled 480 patients across 12 sites .",从 2013 年 12 月到 2016 年 9 月，我们在 12 个地点招募了 480 名患者。,0.0,"['across', 'we']",[],1021,"['从2013年12月到2016年9月,我们在12个网站上注册了480名患者。']",0.0,"['across', 'we']",[],1021,从2013年12月至2016年9月，我们在12个地点招收了480位患者。,0.0,"['across', 'we']",[],,,,
1029,1022,the characteristics of the patients at baseline were well balanced between the two groups ( Table 1 ) .,两组患者的基线特征非常均衡（表 1）。,0.7142857142857143,"['table', 'baseline', '1', 'well', 'characteristics', 'at', 'two']","['table', 'baseline', '1', 'characteristics', 'two']",1022,['基层患者的特点在两组之间平衡得很好(图1)。'],0.2857142857142857,"['table', 'baseline', '1', 'well', 'characteristics', 'at', 'two']","['1', 'two']",1022,表1中两组患者在基线时的特征非常平衡。,0.7142857142857143,"['table', 'baseline', '1', 'well', 'characteristics', 'at', 'two']","['table', 'baseline', '1', 'characteristics', 'two']",,,,
1030,1023,"a total of 3 patients withdrew from the trial before the initiation of trial treatment ( 1 patient received chemoradiotherapy alone , and 2 received different induction chemotherapy plus chemoradiotherapy ) .",共有3例患者在试验治疗开始前退出试验（1例患者接受单纯放化疗，2例患者接受不同的诱导化疗加放化疗）。,0.6428571428571429,"['chemotherapy', 'induction', 'initiation', '1', '2', 'plus', 'total', 'treatment', 'patient', 'trial', '3', 'before', 'and', 'alone']","['chemotherapy', 'induction', 'initiation', '1', '2', 'plus', 'treatment', 'patient', 'before']",1023,"['总共3名患者在试验开始前退出试验(1名患者仅接受化疗,2名患者接受不同的引导化疗以及化疗)。']",0.5,"['chemotherapy', 'induction', 'initiation', '1', '2', 'plus', 'total', 'treatment', 'patient', 'trial', '3', 'before', 'and', 'alone']","['chemotherapy', 'induction', 'initiation', '1', '2', 'patient', 'before']",1023,总共有3位病人在开始试验治疗前退出了试验（1位病人仅接受化疗辐射治疗，2位病人接受了不同的诱导性化疗加上化疗辐射治疗）。,0.6428571428571429,"['chemotherapy', 'induction', 'initiation', '1', '2', 'plus', 'total', 'treatment', 'patient', 'trial', '3', 'before', 'and', 'alone']","['chemotherapy', 'induction', 'initiation', '1', '2', 'plus', 'treatment', 'patient', 'before']",,,,
1031,1024,"a total of 231 of the 239 patients ( 96.7 % ) completed three cycles of induction chemotherapy ; 8 patients ( 3.3 % ) did not complete all three cycles of induction chemotherapy ( 3 patients received two cycles and 5 received one cycle ; the reasons included a case of the patient declining the treatment , a case of disease progression , and discontinuation due to adverse events in the remaining six cases ) ( Table S2 in the Supplementary Appendix ) .",239例患者中共有231例(96.7%)完成了3个周期的诱导化疗。 8例（ 3.3 % ）未完成全部3个周期的诱导化疗（3例2周期，5例1周期；原因包括1例患者拒绝治疗，1例疾病进展，1例因不良反应停药）其余六例中的事件）（补充附录中的表 S2）。,0.3636363636363636,"['chemotherapy', 'induction', '5', 'appendix', 'table', 'supplementary', 'total', 'cycle', 'complete', 'adverse', 'treatment', 'progression', 'case', 'patient', 'of disease', '3', 'due', 'S2', 'all', 'three', 'and', 'two']","['chemotherapy', 'induction', '5', 'table', 'cycle', 'treatment', 'progression', 'patient']",1024,"['共231名239名患者(96.7%)完成了3个引发化疗周期;8名患者(3.3%)未完成所有3个引发化疗周期(3名患者接受了2个周期,5名患者接受了1个周期;原因包括患者中断治疗的案例,疾病进展的案例,以及由于其他6个案例发生的不良事件的中断)。']",0.3181818181818182,"['chemotherapy', 'induction', '5', 'appendix', 'table', 'supplementary', 'total', 'cycle', 'complete', 'adverse', 'treatment', 'progression', 'case', 'patient', 'of disease', '3', 'due', 'S2', 'all', 'three', 'and', 'two']","['chemotherapy', '5', 'cycle', 'treatment', 'progression', 'case', 'patient']",1024,"231 out of 239 patients (96.7%) completed three cycles of induction chemotherapy; 8 patients (3.3%) did not complete all three cycles of induction chemotherapy (3 patients received two cycles and 5 received one cycle; the reasons included a case of the patient declining the treatment, a case of disease progression, and discontinuation due to adverse events in the remaining six cases) (Table S2 in the Supplementary Appendix).

Chinese:

231位病人中有239位完成了三个疗程的诱导化疗，另外8位病人（3.3%）没有完成三个疗程（其中3位病人完成了两个疗程，另外5位病人完成了一个疗程；原因包括一例因病人拒绝接受治疗、一例因疾病进展、另外6例因不良事件而中断治疗）（表S2在附件中）。",0.4545454545454545,"['chemotherapy', 'induction', '5', 'appendix', 'table', 'supplementary', 'total', 'cycle', 'complete', 'adverse', 'treatment', 'progression', 'case', 'patient', 'of disease', '3', 'due', 'S2', 'all', 'three', 'and', 'two']","['chemotherapy', 'induction', '5', 'appendix', 'table', 'treatment', 'progression', 'patient', 'and', 'two']",,,,
1032,1025,"a total of 31 of the 239 patients ( 13.0 % ) had dose reductions of gemcitabine or cisplatin , mainly because of hematologic toxic effects ( in 21 patients ) .",239 名患者中共有 31 名 (13.0%) 减少了吉西他滨或顺铂的剂量，主要是因为血液学毒性作用（21 名患者）。,0.5,"['cisplatin', 'toxic', 'total', 'gemcitabine', 'dose', 'hematologic']","['cisplatin', 'gemcitabine', 'dose']",1025,"['在239名患者中,总共31名患者(13.0%)因血液毒性影响(21名患者)导致血糖或西斯普拉丁的剂量减少。']",0.1666666666666666,"['cisplatin', 'toxic', 'total', 'gemcitabine', 'dose', 'hematologic']",['dose'],1025,总共31名239名患者(13.0%)需要降低gemcitabine或cisplatin的剂量，主要是因为血液毒性作用(21名患者)。,0.1666666666666666,"['cisplatin', 'toxic', 'total', 'gemcitabine', 'dose', 'hematologic']",['dose'],,,,
1033,1026,"overall , the median relative dose intensity was 100 % ( interquartile range , 100 to 100 ) for gemcitabine and 100 % ( interquartile range , 100 to 100 ) for cisplatin .",总体而言，吉西他滨的中位相对剂量强度为 100%（四分位距，100 至 100），顺铂为 100%（四分位距，100 至 100）。,0.4444444444444444,"['median', 'range', 'cisplatin', 'relative', 'intensity', 'gemcitabine', 'dose', 'to', 'and']","['cisplatin', 'gemcitabine', 'dose', 'and']",1026,"['总体而言,中间相对剂量强度为100%(四分之一范围,100至100)为gemsitabine和100%(四分之一范围,100至100)为cisplatin。']",0.3333333333333333,"['median', 'range', 'cisplatin', 'relative', 'intensity', 'gemcitabine', 'dose', 'to', 'and']","['range', 'dose', 'and']",1026,总体而言，革兰珠单抗的相对剂量强度中位数为100％（四分位距为100至100），铂类药物的相对剂量强度中位数为100％（四分位距为100至100）。,0.2222222222222222,"['median', 'range', 'cisplatin', 'relative', 'intensity', 'gemcitabine', 'dose', 'to', 'and']","['dose', 'and']",,,,
1034,1027,"in the induction chemotherapy group , 234 of 239 patients ( 97.9 % ) received concurrent chemoradiotherapy after induction chemotherapy , and 5 patients ( 2.1 % ) did not ( Figure 1 ) .",诱导化疗组239例患者中有234例(97.9%)在诱导化疗后接受同步放化疗，5例(2.1%)未接受同步放化疗(图1)。,0.6666666666666666,"['group', 'chemotherapy', 'induction', '5', '1', 'figure', 'concurrent', 'after', 'and']","['group', 'chemotherapy', 'induction', '5', '1', 'after']",1027,"['在因子化疗组中,234名239名患者(97.9%)在因子化疗后接受了同步化疗,而5名患者(2.1%)则没有(图1)。']",0.6666666666666666,"['group', 'chemotherapy', 'induction', '5', '1', 'figure', 'concurrent', 'after', 'and']","['group', 'chemotherapy', '5', '1', 'after', 'and']",1027,在诱导化疗组中，239名患者中有234名（97.9%）在诱导化疗后接受了联合化疗放疗，5名患者（2.1%）没有（见图1）。,0.6666666666666666,"['group', 'chemotherapy', 'induction', '5', '1', 'figure', 'concurrent', 'after', 'and']","['group', 'chemotherapy', 'induction', '5', '1', 'after']",,,,
1035,1028,"a total of 93 patients ( 38.9 % ) completed three cycles of concurrent cisplatin , 127 ( 53.1 % ) received two cycles , and 14 ( 5.9 % ) received one cycle .",共有93例患者（38.9%）完成了三个周期的顺铂同步治疗，127例患者（53.1%）完成了两个周期，14例患者（5.9%）完成了一个周期。,0.4285714285714285,"['cisplatin', 'total', 'cycle', 'concurrent', 'three', 'and', 'two']","['cisplatin', 'cycle', 'two']",1028,"['总共93名患者(38.9%)完成了3个循环,127人(53.1%)接受了2个循环,14人(5.9%)接受了1个循环。']",0.1428571428571428,"['cisplatin', 'total', 'cycle', 'concurrent', 'three', 'and', 'two']",['cycle'],1028,总共93名病人（38.9%）完成了三个周期的同步顺铂治疗，127名（53.1%）病人接受了两个周期的治疗，14名（5.9%）病人接受了一个周期的治疗。,0.4285714285714285,"['cisplatin', 'total', 'cycle', 'concurrent', 'three', 'and', 'two']","['cisplatin', 'cycle', 'two']",,,,
1036,1029,"a total of 177 of 237 patients ( 74.7 % ) completed three cycles of concurrent cisplatin , 56 ( 23.6 % ) received two cycles , and 4 ( 1.7 % ) received one cycle .",237例患者中共有177例(74.7%)完成了3个周期的顺铂同步化疗，56例(23.6%)完成了2个周期，4例(1.7%)完成了1个周期。,0.25,"['cisplatin', 'total', 'cycle', 'concurrent', '4', 'three', 'and', 'two']","['cisplatin', 'cycle']",1029,"['在237名患者中,共有177名患者(74.7%)完成了3个循环,56名患者(23.6%)接受了2个循环,4名患者(1.7%)接受了1个循环。']",0.125,"['cisplatin', 'total', 'cycle', 'concurrent', '4', 'three', 'and', 'two']",['cycle'],1029,总计237个病人中，177个（74.7%）完成了3个周期的同时使用顺铂，56个（23.6%）接受了2个周期，4个（1.7%）接受了1个周期。,0.25,"['cisplatin', 'total', 'cycle', 'concurrent', '4', 'three', 'and', 'two']","['cisplatin', 'cycle']",,,,
1037,1030,"the median cumulative dose of cisplatin was 440 mg per square meter ( interquartile range , 440 to 540 ) in the induction chemotherapy group ; only 63 of 239 patients ( 26.4 % ) received the full cumulative dose of 540 mg per square meter .",诱导化疗组顺铂的中位累积剂量为440 mg/m（四分位距，440至540）； 239 名患者中只有 63 名 (26.4%) 接受了每平方米 540 毫克的全累积剂量。,0.5833333333333334,"['group', 'chemotherapy', 'induction', 'median', 'range', 'cisplatin', 'meter', 'cumulative', 'dose', 'full', 'to', 'square']","['group', 'chemotherapy', 'induction', 'cisplatin', 'meter', 'dose', 'square']",1030,"['基斯普拉丁的平均累积剂量为440毫克每平方米(四方范围,440至540)在引导化疗组;只有63名239名患者(264%)获得了每平方米540毫克的全部累积剂量。']",0.6666666666666666,"['group', 'chemotherapy', 'induction', 'median', 'range', 'cisplatin', 'meter', 'cumulative', 'dose', 'full', 'to', 'square']","['group', 'chemotherapy', 'induction', 'range', 'meter', 'dose', 'full', 'square']",1030,中位累计剂量为440毫克/平方米（四分位距为440至540毫克/平方米），诱导化疗组仅有63例/239例患者（26.4%）接受了540毫克/平方米的累计剂量。,0.5,"['group', 'chemotherapy', 'induction', 'median', 'range', 'cisplatin', 'meter', 'cumulative', 'dose', 'full', 'to', 'square']","['group', 'chemotherapy', 'induction', 'meter', 'dose', 'square']",,,,
1038,1031,"the median time from the start of the last induction chemotherapy cycle to the commencement of chemoradiotherapy was 25 days ( interquartile range , 22 to 28 ) .",从最后一个诱导化疗周期开始到放化疗开始的中位时间为 25 天（四分位距，22 到 28）。,0.5,"['chemotherapy', 'induction', 'median', 'range', 'time', 'cycle', 'start', 'to']","['chemotherapy', 'induction', 'time', 'cycle']",1031,"['从最后一次引发化疗周期开始到开始化疗的平均时间为25天(四分之一间范围,22至28天)。']",0.5,"['chemotherapy', 'induction', 'median', 'range', 'time', 'cycle', 'start', 'to']","['chemotherapy', 'range', 'time', 'cycle']",1031,中位数从上一个诱导化疗周期开始到化疗放疗开始的时间为25天（四分位距，22至28）。,0.5,"['chemotherapy', 'induction', 'median', 'range', 'time', 'cycle', 'start', 'to']","['chemotherapy', 'induction', 'time', 'cycle']",,,,
1039,1032,the time to the completion of radiotherapy and the radiotherapy doses received were similar in the two groups ( Table S3 in the Supplementary Appendix ) .,两组完成放疗的时间和接受的放疗剂量相似（补充附录表S3）。,0.3333333333333333,"['appendix', 'table', 'supplementary', 'radiotherapy', 'time', 'completion', 'S3', 'in', 'to', 'and', 'two', 'similar']","['table', 'time', 'completion', 'two']",1032,['放射治疗完成的时间和收到的放射治疗剂量在两组中是相似的(附件中的S3表)。'],0.5833333333333334,"['appendix', 'table', 'supplementary', 'radiotherapy', 'time', 'completion', 'S3', 'in', 'to', 'and', 'two', 'similar']","['appendix', 'table', 'radiotherapy', 'time', 'completion', 'two', 'similar']",1032,两组放疗完成时间和放疗剂量相似（表 S3 附件）。,0.4166666666666667,"['appendix', 'table', 'supplementary', 'radiotherapy', 'time', 'completion', 'S3', 'in', 'to', 'and', 'two', 'similar']","['appendix', 'table', 'time', 'completion', 'two']",,,,
1040,1033,"overall , 94.6 % of the patients ( 226 of 239 ) had a response after induction chemotherapy before the start of chemoradiotherapy ; 24 patients ( 10.0 % ) had a complete response , and 202 ( 84.5 % ) had a partial response .",总体而言，94.6% 的患者（239 人中的 226 人）在化放疗开始前的诱导化疗后有反应； 24例（10.0%）完全缓解，202例（84.5%）部分缓解。,0.6666666666666666,"['chemotherapy', 'induction', 'complete', 'response', 'partial', 'after', 'start', 'before', 'and']","['chemotherapy', 'induction', 'response', 'after', 'before', 'and']",1033,"['总体而言,94.6%的患者(239人中226人)在开始化疗之前接受了引发化疗后的反应;24人(10.0%)接受了完整的反应,202人(84.5%)接受了部分反应。']",0.6666666666666666,"['chemotherapy', 'induction', 'complete', 'response', 'partial', 'after', 'start', 'before', 'and']","['chemotherapy', 'complete', 'response', 'after', 'before', 'and']",1033,总体而言，94.6％的病人（239个中的226个）在开始放疗前，在诱导化疗中有了反应；24例病人（10.0％）完全康复，202例（84.5％）部分康复。,0.5555555555555556,"['chemotherapy', 'induction', 'complete', 'response', 'partial', 'after', 'start', 'before', 'and']","['chemotherapy', 'induction', 'response', 'before', 'and']",,,,
1041,1034,details regarding the patterns of relapse and subsequent therapies after relapse are provided in Tables S5 and S6 in the Supplementary Appendix .,有关复发模式和复发后后续治疗的详细信息，请参见补充附录表 S5 和表 S6。,0.4285714285714285,"['relapse', 'appendix', 'supplementary', 'regarding', 'after', 'subsequent', 'and']","['relapse', 'regarding', 'after']",1034,['关于回归模式和后续回归治疗的详细信息在附件中的 S5 和 S6 表中提供。'],0.4285714285714285,"['relapse', 'appendix', 'supplementary', 'regarding', 'after', 'subsequent', 'and']","['appendix', 'regarding', 'after']",1034,详细信息有关复发模式和复发后随后的治疗方案可在补充附录的S5和S6表中找到。,0.4285714285714285,"['relapse', 'appendix', 'supplementary', 'regarding', 'after', 'subsequent', 'and']","['relapse', 'regarding', 'after']",,,,
1042,1035,details regarding the cause of death are provided in Table S5 in the Supplementary Appendix .,补充附录表 S5 提供了有关死因的详细信息。,0.6,"['appendix', 'table', 'supplementary', 'regarding', 'cause of death']","['table', 'regarding', 'cause of death']",1035,['关于死亡原因的详细信息在附件 S5 表中提供。'],0.6,"['appendix', 'table', 'supplementary', 'regarding', 'cause of death']","['appendix', 'table', 'regarding']",1035,详细死因信息可在补充附件中的表S5中找到。,0.6,"['appendix', 'table', 'supplementary', 'regarding', 'cause of death']","['appendix', 'table', 'cause of death']",,,,
1043,1036,"during induction chemotherapy , 93 of 239 patients ( 38.9 % ) had acute adverse events of grade 3 or 4 ( Table S4 in the Supplementary Appendix ) .",在诱导化疗期间，239 名患者中有 93 名 (38.9%) 出现了 3 级或 4 级的急性不良事件（补充附录表 S4）。,0.3,"['chemotherapy', 'induction', 'appendix', 'table', 'grade', 'supplementary', 'adverse', 'acute', '3', 'S4']","['chemotherapy', 'induction', 'table']",1036,"['在引发化疗期间,239名患者中有93人(38.9%)患有3级或4级的急性副作用(附件中的S4表)。']",0.3,"['chemotherapy', 'induction', 'appendix', 'table', 'grade', 'supplementary', 'adverse', 'acute', '3', 'S4']","['chemotherapy', 'appendix', 'table']",1036,在诱导性化疗期间，239名患者中有93人（38.9%）出现了3级或4级的急性不良事件（见表S4）。,0.3,"['chemotherapy', 'induction', 'appendix', 'table', 'grade', 'supplementary', 'adverse', 'acute', '3', 'S4']","['chemotherapy', 'induction', 'table']",,,,
1044,1037,"the majority of patients had unfavorable prognostic features of N2 or N3 disease or bulky primary tumors ( T3 or T4 ) , all of which are surrogates for occult metastasis.23",大多数患者具有 N2 或 N3 疾病或大块原发性肿瘤（T3 或 T4）的不良预后特征，所有这些都是隐匿性转移的替代物。 23,0.25,"['disease', 'occult', 'primary', 'prognostic', 'T4', 'majority', 'all', 'unfavorable']","['disease', 'majority']",1037,"['大多数患者患有N2或N3疾病或重型初级肿瘤(T3或T4)的不良预测特征,所有这些肿瘤都是对阴道转移的过敏。']",0.375,"['disease', 'occult', 'primary', 'prognostic', 'T4', 'majority', 'all', 'unfavorable']","['disease', 'prognostic', 'majority']",1037,大多数病人具有不利的预后特征，如N2或N3疾病或体积较大的原发肿瘤（T3或T4），这些都是隐匿转移的代理因素。23,0.25,"['disease', 'occult', 'primary', 'prognostic', 'T4', 'majority', 'all', 'unfavorable']","['disease', 'majority']",,,,
1045,1038,this clinical advantage was evident when the outcomes of the two treatment groups were analyzed in patients who completed the planned course of treatment ( three cycles of chemotherapy plus two or three cycles of concurrent cisplatin and radiotherapy vs. three cycles of concurrent cisplatin and radiotherapy alone ) ( see the Supplementary Appendix ) .,当在完成计划治疗过程的患者中分析两个治疗组的结果时，这种临床优势是显而易见的（三个周期的化疗加上两个或三个周期的同步顺铂和放疗对比三个周期的同步顺铂和放疗） （见补充附录）。,0.5882352941176471,"['chemotherapy', 'appendix', 'who', 'cisplatin', 'plus', 'supplementary', 'radiotherapy', 'concurrent', 'treatment', 'clinical', 'advantage', 'course', 'three', 'this', 'and', 'alone', 'two']","['chemotherapy', 'cisplatin', 'plus', 'treatment', 'clinical', 'advantage', 'course', 'this', 'and', 'two']",1038,"['这种临床优势是显而易见的,当两组治疗的结果被分析在完成计划治疗的患者(三个化疗周期加上两个或三个周期相同的西斯普拉丁和放射治疗与三个周期相同的西斯普拉丁和放射治疗单独 )(参见补充附件 )。']",0.7058823529411765,"['chemotherapy', 'appendix', 'who', 'cisplatin', 'plus', 'supplementary', 'radiotherapy', 'concurrent', 'treatment', 'clinical', 'advantage', 'course', 'three', 'this', 'and', 'alone', 'two']","['chemotherapy', 'appendix', 'plus', 'radiotherapy', 'treatment', 'clinical', 'advantage', 'three', 'this', 'and', 'alone', 'two']",1038,这种临床优势在完成了计划治疗（三个化疗周期加上两到三个同步顺势铂和放疗周期，对比单独三个同步顺势铂和放疗周期）的患者中得到体现（见补充附件）。,0.4705882352941176,"['chemotherapy', 'appendix', 'who', 'cisplatin', 'plus', 'supplementary', 'radiotherapy', 'concurrent', 'treatment', 'clinical', 'advantage', 'course', 'three', 'this', 'and', 'alone', 'two']","['chemotherapy', 'appendix', 'plus', 'treatment', 'clinical', 'advantage', 'alone', 'two']",,,,
1046,1039,it remains unclear whether these regimens differ significantly with regard to efficacy or toxicity .,目前尚不清楚这些方案在疗效或毒性方面是否存在显着差异。,0.25,"['toxicity', 'differ', 'efficacy', 'with']",['toxicity'],1039,['目前尚不清楚这些饮食是否在效率或毒性方面有显著差异。'],0.25,"['toxicity', 'differ', 'efficacy', 'with']",['toxicity'],1039,目前尚不清楚这些方案在疗效或副作用方面存在显著差异。,0.0,"['toxicity', 'differ', 'efficacy', 'with']",[],,,,
1047,1040,"we noted a higher overall incidence of acute adverse events among patients treated with induction chemotherapy than among those treated with chemoradiotherapy alone ; in particular , the incidence of severe neutropenia , thrombocytopenia , anemia , nausea , and vomiting was higher in the induction chemotherapy group .",我们注意到接受诱导化疗的患者的急性不良事件总体发生率高于仅接受化放疗的患者；特别是诱导化疗组中严重粒细胞减少、血小板减少、贫血、恶心、呕吐的发生率较高。,0.4705882352941176,"['anemia', 'group', 'chemotherapy', 'induction', 'incidence', 'neutropenia', 'thrombocytopenia', 'particular', 'nausea', 'adverse', 'vomiting', 'acute', 'with', 'severe', 'and', 'alone', 'we']","['anemia', 'group', 'chemotherapy', 'induction', 'incidence', 'thrombocytopenia', 'nausea', 'vomiting']",1040,"['我们注意到,在接受引导化疗的患者中,急性副作用的总体发病率高于接受引导化疗的患者中,而在接受引导化疗的患者中,特别是严重的中风、血管细胞炎、贫血、恶心和呕吐的发病率在引导化疗群体中高。']",0.5294117647058824,"['anemia', 'group', 'chemotherapy', 'induction', 'incidence', 'neutropenia', 'thrombocytopenia', 'particular', 'nausea', 'adverse', 'vomiting', 'acute', 'with', 'severe', 'and', 'alone', 'we']","['anemia', 'group', 'chemotherapy', 'induction', 'incidence', 'nausea', 'vomiting', 'acute', 'and']",1040,我们注意到，在接受诱导化疗的患者中，总体发生急性不良事件的发病率高于接受化疗辐射治疗的患者；特别是，诱导化疗组中严重的中性粒细胞减少、血小板减少、贫血、恶心和呕吐的发病率更高。,0.5294117647058824,"['anemia', 'group', 'chemotherapy', 'induction', 'incidence', 'neutropenia', 'thrombocytopenia', 'particular', 'nausea', 'adverse', 'vomiting', 'acute', 'with', 'severe', 'and', 'alone', 'we']","['anemia', 'group', 'chemotherapy', 'induction', 'incidence', 'thrombocytopenia', 'nausea', 'vomiting', 'acute']",,,,
1048,1041,"the incidence of acute grade 1 or 2 nephrotoxic effects was also greater with the higher cumulative dose of cisplatin in the induction chemotherapy group , although the frequencies of late nephrotoxic effects and ototoxic effects were similar in the treatment groups , with the exception of grade 1 or 2 peripheral neuropathy .",在诱导化疗组中，随着顺铂累积剂量的增加，急性 1 级或 2 级肾毒性作用的发生率也更高，尽管除 1 级或2周围神经病变。,0.4736842105263157,"['group', 'chemotherapy', 'induction', 'incidence', 'peripheral', 'cisplatin', '1', '2', 'grade', 'neuropathy', 'cumulative', 'late', 'treatment', 'acute', 'exception', 'with', 'dose', 'and', 'similar']","['group', 'chemotherapy', 'induction', 'incidence', 'cisplatin', '1', '2', 'neuropathy', 'dose']",1041,"['急性1级或2级甲状腺作用的发病率也较高,在引发化疗组中,西斯普拉丁的累积剂量较高,尽管晚期甲状腺作用和甲状腺作用的发病率在治疗组中相似,除1级或2级周边神经病外。']",0.4210526315789473,"['group', 'chemotherapy', 'induction', 'incidence', 'peripheral', 'cisplatin', '1', '2', 'grade', 'neuropathy', 'cumulative', 'late', 'treatment', 'acute', 'exception', 'with', 'dose', 'and', 'similar']","['group', 'chemotherapy', 'incidence', '1', '2', 'neuropathy', 'treatment', 'dose']",1041,在诱导化疗组中，急性1级或2级肾毒性作用的发生率也随着顺铂累积剂量的增加而增加，尽管治疗组间晚期肾毒性作用和耳聋作用的频率相似，但外周神经病变的1级或2级患病率例外。,0.5789473684210527,"['group', 'chemotherapy', 'induction', 'incidence', 'peripheral', 'cisplatin', '1', '2', 'grade', 'neuropathy', 'cumulative', 'late', 'treatment', 'acute', 'exception', 'with', 'dose', 'and', 'similar']","['group', 'chemotherapy', 'induction', 'incidence', 'cisplatin', '1', '2', 'neuropathy', 'treatment', 'dose', 'and']",,,,
1049,1042,"in our previous chemotherapy trial ( which investigated docetaxel plus cisplatin plus fluorouracil ) , 7 a high incidence of grade 3 or 4 acute adverse events such as neutropenia ( 35.5 % ) , leukopenia ( 27.2 % ) , and diarrhea ( 8.0 % ) was observed despite the modified doses ( a 20 % reduction of each drug as compared with the other trials26,27 ) ; in that trial , four patients ( 2 % ) had leukopenic fever , and one patient died from neutropenic sepsis ( Table S7 in the Supplementary Appendix ) .","在我们之前的化疗试验（研究多西紫杉醇加顺铂加氟尿嘧啶） 7 中，观察到中性粒细胞减少症 ( 35.5 % ) 、白细胞减少症 ( 27.2 % ) 和腹泻 ( 8.0 % ) 等 3 级或 4 级急性不良事件的高发生率，尽管修改后的剂量（与其他试验相比，每种药物减少 20%26,27）；在该试验中，4 名患者 (2%) 出现白细胞减少性发热，1 名患者死于中性粒细胞减少性败血症（补充附录表 S7）。",0.53125,"['chemotherapy', 'incidence', 'appendix', 'table', 'cisplatin', '2', 'grade', 'plus', 'previous', 'supplementary', 'neutropenia', 'reduction', 'sepsis', 'diarrhea', 'adverse', 'leukopenia', 'fever', 'patient', 'trial', 'acute', '3', '4', 'as', 'with', 'despite', 'drug', 'fluorouracil', 'docetaxel', 'that', 'each', 'and', 'high']","['chemotherapy', 'incidence', 'table', 'cisplatin', '2', 'plus', 'neutropenia', 'reduction', 'sepsis', 'diarrhea', 'leukopenia', 'fever', 'patient', 'drug', 'fluorouracil', 'docetaxel', 'high']",1042,"['在我们之前的化疗试验(研究Docetaxel plus Cisplatin plus Fluorouracil)中,尽管有修改剂量(与其他试验相比,每种药物的20%减少26,27%),但观察到3级或4级急性副作用,如中风(35.5%),白血病(27.2%)和腹泻(8.0%)的发病率高;在试验中,有4名患者(2%)患有白血病发病,其中1名患者死于中风<unk>症(附件表S7)。']",0.34375,"['chemotherapy', 'incidence', 'appendix', 'table', 'cisplatin', '2', 'grade', 'plus', 'previous', 'supplementary', 'neutropenia', 'reduction', 'sepsis', 'diarrhea', 'adverse', 'leukopenia', 'fever', 'patient', 'trial', 'acute', '3', '4', 'as', 'with', 'despite', 'drug', 'fluorouracil', 'docetaxel', 'that', 'each', 'and', 'high']","['chemotherapy', 'incidence', 'appendix', 'table', '2', 'reduction', 'diarrhea', 'patient', 'as', 'drug', 'high']",1042,在我们之前的化疗试验（调查了多西他赛加铂加氟尿嘧啶）中，尽管药物剂量有所降低（每种药物与其他试验相比降低了20%），但仍然观察到较高比例的急性不良事件，例如中性粒细胞减少（35.5%）、白细胞减少（27.2%）和腹泻（8.0%）；在那个试验中，有4名患者（2%）患有白细胞减少性发热，1名患者死于中性粒细胞减少性败血症。,0.40625,"['chemotherapy', 'incidence', 'appendix', 'table', 'cisplatin', '2', 'grade', 'plus', 'previous', 'supplementary', 'neutropenia', 'reduction', 'sepsis', 'diarrhea', 'adverse', 'leukopenia', 'fever', 'patient', 'trial', 'acute', '3', '4', 'as', 'with', 'despite', 'drug', 'fluorouracil', 'docetaxel', 'that', 'each', 'and', 'high']","['chemotherapy', '2', 'plus', 'reduction', 'sepsis', 'diarrhea', 'fever', 'patient', 'as', 'drug', 'fluorouracil', 'docetaxel', 'high']",,,,
1050,1043,"a quarter of patients responded to the oral agent selinexor , an inhibitor of the nuclear export protein exportin 1 .",四分之一的患者对口服药物 selinexor 有反应，selinexor 是核输出蛋白输出 1 的抑制剂。,0.5714285714285714,"['inhibitor', '1', 'protein', 'oral', 'quarter', 'nuclear', 'agent']","['inhibitor', '1', 'protein', 'nuclear']",1043,"['四分之一的病人对口服药物塞林克索(Selinexor)作出回应,这是核出口蛋白质出口1的抑制剂。']",0.7142857142857143,"['inhibitor', '1', 'protein', 'oral', 'quarter', 'nuclear', 'agent']","['inhibitor', '1', 'protein', 'quarter', 'nuclear']",1043,1/4的病人对口服药物selinexor有反应，selinexor是一种抑制核蛋白输出蛋白1的抑制剂。,0.5714285714285714,"['inhibitor', '1', 'protein', 'oral', 'quarter', 'nuclear', 'agent']","['inhibitor', '1', 'protein', 'nuclear']",,,,
1051,1044,"the overall response rate ( ≥ 50 % decrease in myeloma paraprotein level ; the primary endpoint ) was 26 % , with 2 patients achieving complete remission ; an additional 13 % achieved minimal response .",总体缓解率（骨髓瘤副蛋白水平降低 ≥ 50%；主要终点）为 26%，其中 2 名患者达到完全缓解；另有 13% 的人获得了最低限度的回应。,0.3076923076923077,"['decrease', '2', 'myeloma', 'complete', 'primary', 'additional', 'minimal', 'level', 'remission', 'response rate', 'with', 'achieved', 'endpoint']","['2', 'myeloma', 'level', 'remission']",1044,['总反应率(甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺'],0.0769230769230769,"['decrease', '2', 'myeloma', 'complete', 'primary', 'additional', 'minimal', 'level', 'remission', 'response rate', 'with', 'achieved', 'endpoint']",['response rate'],1044,总体反应率（主要终点，即骨髓间质瘤蛋白水平降低50%以上）为26%，其中2例患者达到完全缓解；另外13%的患者达到了微小缓解。,0.3076923076923077,"['decrease', '2', 'myeloma', 'complete', 'primary', 'additional', 'minimal', 'level', 'remission', 'response rate', 'with', 'achieved', 'endpoint']","['2', 'level', 'remission', 'response rate']",,,,
1052,1045,"grade 3 or 4 adverse events included thrombocytopenia , anemia , hyponatremia , and neutropenia .",3 级或 4 级不良事件包括血小板减少症、贫血、低钠血症和中性粒细胞减少症。,0.4444444444444444,"['anemia', 'grade', 'hyponatremia', 'neutropenia', 'thrombocytopenia', 'adverse', '3', '4', 'and']","['anemia', 'hyponatremia', 'neutropenia', 'thrombocytopenia']",1045,"['等级3或4的副作用包括血管细胞,贫血,催眠,和中性。']",0.2222222222222222,"['anemia', 'grade', 'hyponatremia', 'neutropenia', 'thrombocytopenia', 'adverse', '3', '4', 'and']","['anemia', 'grade']",1045,"grade 3 or 4 adverse events included thrombocytopenia, anemia, hyponatremia, and neutropenia.

Chinese:

3级或4级不良事件包括血小板减少症、贫血、低钠血症和中性粒细胞减少症。",0.4444444444444444,"['anemia', 'grade', 'hyponatremia', 'neutropenia', 'thrombocytopenia', 'adverse', '3', '4', 'and']","['anemia', 'hyponatremia', 'neutropenia', 'thrombocytopenia']",,,,
1053,1046,"most participants ( 89 % ) had no history of CV disease , but half had known hypertension .",大多数参与者 (89%) 没有 CV 病史，但一半有高血压病史。,0.6666666666666666,"['disease', 'hypertension', 'half', 'history', 'no', 'but']","['disease', 'hypertension', 'half', 'but']",1046,"['大多数参与者(89%)没有CV病史,但一半已知高血压。']",0.6666666666666666,"['disease', 'hypertension', 'half', 'history', 'no', 'but']","['disease', 'hypertension', 'half', 'but']",1046,大多数参与者（89％）没有心血管疾病的病史，但有一半人已经知道自己有高血压。,0.6666666666666666,"['disease', 'hypertension', 'half', 'history', 'no', 'but']","['disease', 'hypertension', 'half', 'but']",,,,
1054,1047,only one third of participants had been taking any CV drug .,只有三分之一的参与者服用过任何心血管药物。,0.3333333333333333,"['taking', 'drug', 'third']",['drug'],1047,['只有三分之一的参与者曾经服用任何CV药物。'],0.3333333333333333,"['taking', 'drug', 'third']",['drug'],1047,只有三分之一的参与者服用过任何心血管药物。,0.3333333333333333,"['taking', 'drug', 'third']",['drug'],,,,
1055,1048,"the difference was driven largely by fewer coronary events ( and not strokes , heart failure , or sudden deaths ) .",这种差异主要是由于冠状动脉事件较少（而不是中风、心力衰竭或猝死）。,1.0,"['coronary', 'difference', 'heart failure', 'sudden', 'by', 'and']","['coronary', 'difference', 'heart failure', 'sudden', 'by', 'and']",1048,['差异主要是由较少的冠状事件引起的(而不是中风、心脏衰竭或突然死亡)。'],0.6666666666666666,"['coronary', 'difference', 'heart failure', 'sudden', 'by', 'and']","['coronary', 'difference', 'by', 'and']",1048,这主要是由于心脏病事件减少（而不是中风、心力衰竭或猝死）。,0.6666666666666666,"['coronary', 'difference', 'heart failure', 'sudden', 'by', 'and']","['heart failure', 'sudden', 'by', 'and']",,,,
1056,1049,overall mortality ( 5.9 % and 6.5 % ; P = 0.43 ) and side effects were similar in the two groups .,两组的总体死亡率（5.9% 和 6.5%；P = 0.43）和副作用相似。,0.4285714285714285,"['side effects', 'mortality', 'P', 'in', 'and', 'two', 'similar']","['side effects', 'mortality', 'two']",1049,['总死亡率( 5.9 % 和 6.5 % ; P = 0.43 )和副作用在两组都相似。'],0.4285714285714285,"['side effects', 'mortality', 'P', 'in', 'and', 'two', 'similar']","['side effects', 'mortality', 'two']",1049,"总体死亡率（5.9%和6.5%；P=0.43）和副作用在两组间相似。

Chinese:
总体死亡率（5.9%和6.5%；P=0.43）和副作用在两组间相似。",0.4285714285714285,"['side effects', 'mortality', 'P', 'in', 'and', 'two', 'similar']","['side effects', 'mortality', 'two']",,,,
1057,1050,"these results support the polypill concept , but the study has limitations .",这些结果支持复方药丸的概念，但该研究有局限性。,0.75,"['support', 'study', 'concept', 'but']","['support', 'concept', 'but']",1050,"['这些结果支持聚合物的概念,但研究有限制。']",0.75,"['support', 'study', 'concept', 'but']","['support', 'concept', 'but']",1050,这些结果支持多药片概念，但研究有局限性。,0.75,"['support', 'study', 'concept', 'but']","['support', 'concept', 'but']",,,,
1058,1051,"for example , nearly 14,000 people were randomized originally , but half of them subsequently were excluded for various reasons - some of which could have biased the results .","例如，最初有将近 14,000 人被随机分组，但后来有一半人由于各种原因被排除在外——其中一些原因可能会使结果产生偏差。",0.5714285714285714,"['half', 'various', 'example', '-', 'have', 'originally', 'but']","['half', 'example', 'have', 'but']",1051,"['例如,大约有14000人最初是随机的,但其中一半后来因各种原因被排除 - 其中一些可能偏见了结果。']",0.5714285714285714,"['half', 'various', 'example', '-', 'have', 'originally', 'but']","['half', 'example', 'have', 'but']",1051,例如，最初有近14000人参与随机，但后来有一半人因各种原因被排除在外 - 有些原因可能会对结果产生偏差。,0.5714285714285714,"['half', 'various', 'example', '-', 'have', 'originally', 'but']","['half', 'example', 'have', 'but']",,,,
1059,1052,"in a commentary in the New York Times on Aug 22 , 2019 , a reporter interviewed several experts who favor the polypill and others who were skeptical .",在 2019 年 8 月 22 日纽约时报的评论中，记者采访了几位支持复方药丸的专家和其他持怀疑态度的人。,0.0,"['who', 'on', 'reporter', 'in', 'and', 'new']",[],1052,"['在2019年8月22日的《纽约时报》的一篇评论中,一名记者采访了多位支持聚合物的专家和其他人,他们是怀疑的。']",0.0,"['who', 'on', 'reporter', 'in', 'and', 'new']",[],1052,"在《纽约时报》8月22日的一篇评论中，一名记者采访了几位支持多药片的专家和其他对此持怀疑态度的专家。

Chinese:

在《纽约时报》8月22日的一篇评论中，一名记者采访了几位支持多药片的专家和其他对此持怀疑态度的专家。",0.0,"['who', 'on', 'reporter', 'in', 'and', 'new']",[],,,,
1060,1053,left ventricular ejection fraction ( LVEF ) is a commonly used prognostic indicator of cardiovascular disease risk and outcomes .,左心室射血分数 (LVEF) 是心血管疾病风险和结果的常用预后指标。,0.5714285714285714,"['indicator', 'cardiovascular disease', 'ventricular', 'prognostic', 'risk', 'ejection fraction', 'and']","['indicator', 'cardiovascular disease', 'risk', 'ejection fraction']",1053,['左<unk>排泄分裂(LVEF)是一种常用的心血管疾病风险和结果的预测指标。'],0.5714285714285714,"['indicator', 'cardiovascular disease', 'ventricular', 'prognostic', 'risk', 'ejection fraction', 'and']","['indicator', 'cardiovascular disease', 'prognostic', 'risk']",1053,左室射血分数（LVEF）是常用的衡量心脏病风险和预后的指标。,0.5714285714285714,"['indicator', 'cardiovascular disease', 'ventricular', 'prognostic', 'risk', 'ejection fraction', 'and']","['indicator', 'prognostic', 'risk', 'ejection fraction']",,,,
1061,1054,"the primary analysis was performed on 403,977 echocardiograms from 1998 to 2018 in 203,135 unique patients in a U.S. regional health system ( mean age , 64 ; 52 % men ) .","主要分析是对 1998 年至 2018 年美国区域卫生系统中 203,135 名独特患者的 403,977 份超声心动图进行的（平均年龄 64 岁；52% 为男性）。",0.5454545454545454,"['mean', 'analysis', 'system', 'health', 'regional', 'primary', 'unique', 'age', 'in', 'to', 'echocardiograms']","['mean', 'analysis', 'system', 'health', 'age', 'echocardiograms']",1054,"['初步分析是在1998年至2018年间在美国区域卫生系统的203,135个单一患者(平均年龄,64;男性52%)进行的403,977个心血管。']",0.4545454545454545,"['mean', 'analysis', 'system', 'health', 'regional', 'primary', 'unique', 'age', 'in', 'to', 'echocardiograms']","['mean', 'analysis', 'system', 'health', 'age']",1054,"在美国一个地区性医疗系统，对1998年至2018年间403,977张超声心动图进行了初步分析，其中包括203,135名独立患者（平均年龄为64岁；52％为男性）。",0.4545454545454545,"['mean', 'analysis', 'system', 'health', 'regional', 'primary', 'unique', 'age', 'in', 'to', 'echocardiograms']","['mean', 'analysis', 'system', 'age', 'echocardiograms']",,,,
1062,1055,"indications for echocardiograms varied widely , with the top five being chest pain , dyspnea / fatigue , coronary artery disease , aortic valve disease , and heart failure .",超声心动图的适应症千差万别，排在前五位的是胸痛、呼吸困难/疲劳、冠状动脉疾病、主动脉瓣疾病和心力衰竭。,0.5333333333333333,"['disease', 'fatigue', '/', 'dyspnea', 'chest pain', 'top', 'heart failure', 'aortic valve', 'being', 'with', 'coronary artery', 'five', 'and', 'varied', 'echocardiograms']","['disease', 'fatigue', 'dyspnea', 'chest pain', 'heart failure', 'aortic valve', 'coronary artery', 'echocardiograms']",1055,"['甲状腺炎的指示多样化,前五种是胸部疼痛、 dyspnea/疲劳、冠状动脉疾病、 aortic valve 疾病和心脏衰竭。']",0.2,"['disease', 'fatigue', '/', 'dyspnea', 'chest pain', 'top', 'heart failure', 'aortic valve', 'being', 'with', 'coronary artery', 'five', 'and', 'varied', 'echocardiograms']","['disease', 'fatigue', 'coronary artery']",1055,心脏超声波检查的指征非常不一，最常见的五种检查项目分别是胸痛、呼吸困难/疲劳、冠心病、主动脉瓣疾病和心力衰竭。,0.4,"['disease', 'fatigue', '/', 'dyspnea', 'chest pain', 'top', 'heart failure', 'aortic valve', 'being', 'with', 'coronary artery', 'five', 'and', 'varied', 'echocardiograms']","['disease', 'fatigue', 'dyspnea', 'chest pain', 'heart failure', 'aortic valve']",,,,
1063,1056,the adjusted hazard ratio for mortality was 1.71 when the LVEF ≥ 70 % and 1.73 with LVEFs in the 35 % -40 % range .,当 LVEF ≥ 70% 时，调整后的死亡率风险比为 1.71，而 LVEF 在 35%-40% 范围内时为 1.73。,0.8333333333333334,"['range', 'hazard ratio', 'mortality', 'with', 'in', 'and']","['range', 'hazard ratio', 'mortality', 'in', 'and']",1056,['对死亡率的调整风险比例为1.71 LVEF ≥ 70 % 和 1.73 LVEF 在 35 % 至 40 % 范围内。'],0.5,"['range', 'hazard ratio', 'mortality', 'with', 'in', 'and']","['range', 'hazard ratio', 'mortality']",1056,调整后的死亡风险比在LVEF≥70%时为1.71，在LVEF为35%～40%时为1.73。,0.1666666666666666,"['range', 'hazard ratio', 'mortality', 'with', 'in', 'and']",['hazard ratio'],,,,
1064,1057,"clinicians emphasize LVEF , despite its imprecision , in treatment decisions .",临床医生在治疗决策中强调 LVEF，尽管其不精确。,0.3333333333333333,"['treatment', 'despite', 'in']",['treatment'],1057,"['临床医生在治疗决策中强调LVEF,尽管不准确。']",0.3333333333333333,"['treatment', 'despite', 'in']",['treatment'],1057,尽管其不准确性，临床医生仍然强调心脏功能减退率（LVEF）在治疗决策中的作用。,0.3333333333333333,"['treatment', 'despite', 'in']",['treatment'],,,,
1065,1058,this study had clear confounders that could not be fully adjusted for .,这项研究有明显的混杂因素，无法完全调整。,0.0,"['clear', 'study', 'be', 'this', 'that']",[],1058,"['这项研究有明显的混乱,无法完全调整。']",0.0,"['clear', 'study', 'be', 'this', 'that']",[],1058,这项研究有明显的纰漏因素无法完全调整。,0.0,"['clear', 'study', 'be', 'this', 'that']",[],,,,
1066,1059,"as an example , the structured fields in the database for indications for the echocardiogram could fail to capture the complete clinical picture of the patient undergoing the test .",例如，数据库中用于超声心动图指示的结构化字段可能无法捕捉接受测试的患者的完整临床图像。,0.6363636363636364,"['database', 'capture', 'test', 'complete', 'picture', 'clinical', 'patient', 'fail', 'example', 'to', 'echocardiogram']","['capture', 'picture', 'clinical', 'patient', 'example', 'to', 'echocardiogram']",1059,"['作为一个例子,数据库中的结构化领域可能无法捕获接受测试的患者的完整临床图像。']",0.4545454545454545,"['database', 'capture', 'test', 'complete', 'picture', 'clinical', 'patient', 'fail', 'example', 'to', 'echocardiogram']","['capture', 'picture', 'clinical', 'patient', 'example']",1059,结构化的数据库字段，比如心脏超声的检查项目，有时无法完全反映出检查对象的临床病情。,0.0909090909090909,"['database', 'capture', 'test', 'complete', 'picture', 'clinical', 'patient', 'fail', 'example', 'to', 'echocardiogram']",['clinical'],,,,
1067,1060,"Hyperdynamic LV function ( LVEF , ≥ 70 % ) is likely associated with other clinical comorbidities that confer increased risk ( e.g. , liver failure ) but were not fully accounted for in the study .","高动态 LV 功能 (LVEF, ≥ 70%) 可能与其他导致风险增加的临床合并症（例如，肝衰竭）有关，但在研究中没有得到充分考虑。",0.5454545454545454,"['liver', 'failure', 'function', 'study', 'associated', 'clinical', 'risk', 'with', 'that', 'but', 'LV']","['liver', 'failure', 'function', 'clinical', 'risk', 'but']",1060,"['超动态LV功能(LVEF, ≥70%)可能与其他临床复杂性相关联,导致风险增加(例如,肝衰竭),但在研究中并未充分考虑。']",0.5454545454545454,"['liver', 'failure', 'function', 'study', 'associated', 'clinical', 'risk', 'with', 'that', 'but', 'LV']","['liver', 'failure', 'function', 'clinical', 'risk', 'but']",1060,超动力心肌功能（LVEF，≥70%）可能与其他临床并发症相关联，这些并发症会增加风险（例如肝功能衰竭），但在研究中并没有充分考虑到这些因素。,0.5454545454545454,"['liver', 'failure', 'function', 'study', 'associated', 'clinical', 'risk', 'with', 'that', 'but', 'LV']","['liver', 'failure', 'function', 'clinical', 'risk', 'but']",,,,
1068,1061,"in a large observational study , statin discontinuers were vulnerable to later cardiovascular hospitalizations .",在一项大型观察性研究中，停用他汀类药物的人很容易因心血管疾病住院治疗。,0.2857142857142857,"['statin', 'cardiovascular', 'observational study', 'large', 'vulnerable', 'later', 'to']","['cardiovascular', 'observational study']",1061,"['在一项大型观察研究中,静素中断剂对后来的心血管医院受伤。']",0.2857142857142857,"['statin', 'cardiovascular', 'observational study', 'large', 'vulnerable', 'later', 'to']","['cardiovascular', 'later']",1061,在一项大型观察性研究中，起始服用他汀类药物后后来再次患有心血管疾病住院的患者显得脆弱。,0.4285714285714285,"['statin', 'cardiovascular', 'observational study', 'large', 'vulnerable', 'later', 'to']","['cardiovascular', 'observational study', 'later']",,,,
1069,1062,there remains uncertainty as to whether people who reach a certain age can discontinue a statin without facing additional risks .,对于达到一定年龄的人是否可以在不面临额外风险的情况下停用他汀类药物，仍存在不确定性。,0.3,"['statin', 'who', 'age', 'additional', 'as', 'facing', 'uncertainty', 'to', 'reach', 'without']","['age', 'facing', 'to']",1062,['仍然不确定是否达到一定年龄的人可以停止服用静素而不面临额外的风险。'],0.2,"['statin', 'who', 'age', 'additional', 'as', 'facing', 'uncertainty', 'to', 'reach', 'without']","['age', 'additional']",1062,目前尚不清楚到达一定年龄的人是否可以在不面临额外风险的情况下停止使用他克莫司。,0.1,"['statin', 'who', 'age', 'additional', 'as', 'facing', 'uncertainty', 'to', 'reach', 'without']",['age'],,,,
1070,1063,the little existing trial evidence has suggested a benefit from statins into older age .,现有的少量试验证据表明他汀类药物对老年人有益。,0.4,"['statins', 'age', 'trial', 'evidence', 'benefit']","['statins', 'evidence']",1063,"['现有很少的试验证据表明,从老年人到老年人有好处。']",0.2,"['statins', 'age', 'trial', 'evidence', 'benefit']",['evidence'],1063,少量现有的试验证据表明，在老年使用他汀类药物可能有益。,0.4,"['statins', 'age', 'trial', 'evidence', 'benefit']","['statins', 'evidence']",,,,
1071,1064,"the 120,173 participants had no history of cardiovascular disease and had filled prescriptions for statins for 2 years ( medication possession ratio , ≥ 80 % ) .","这 120,173 名参与者没有心血管疾病史，并且已按处方服用他汀类药物 2 年（药物占有率≥ 80%）。",0.5,"['2', 'ratio', 'statins', 'history', 'medication', 'cardiovascular disease', 'no', 'possession', 'prescriptions', 'and']","['2', 'statins', 'medication', 'cardiovascular disease', 'prescriptions']",1064,"['120173名参与者没有心血管疾病的历史,并在2年内填写了静素的处方(药物持有比例, ≥80%)。']",0.6,"['2', 'ratio', 'statins', 'history', 'medication', 'cardiovascular disease', 'no', 'possession', 'prescriptions', 'and']","['2', 'ratio', 'history', 'medication', 'cardiovascular disease', 'prescriptions']",1064,"这120,173名参与者没有心血管疾病的病史，并在过去2年中获得了达到80%以上的药物处方。",0.4,"['2', 'ratio', 'statins', 'history', 'medication', 'cardiovascular disease', 'no', 'possession', 'prescriptions', 'and']","['2', 'medication', 'cardiovascular disease', 'prescriptions']",,,,
1072,1065,statin discontinuation was defined as 3 consecutive months without medication .,停用他汀类药物定义为连续 3 个月未服药。,0.0,"['statin', 'defined', 'consecutive', 'medication', '3', 'as', 'without']",[],1065,['静素中断被定义为连续3个月没有药物。'],0.0,"['statin', 'defined', 'consecutive', 'medication', '3', 'as', 'without']",[],1065,停用药物定义为3个月内连续无药物使用。,0.1428571428571428,"['statin', 'defined', 'consecutive', 'medication', '3', 'as', 'without']",['without'],,,,
1073,1066,a total of 3243 people died .,共有3243人死亡。,0.0,['total'],[],1066,['总共有3243人死亡。'],0.0,['total'],[],1066,总共有3243人死亡。,0.0,['total'],[],,,,
1074,1067,the statin discontinuation rate was 14.3 % .,他汀类药物停药率为 14.3%。,0.5,"['statin', 'rate']",['rate'],1067,['静态中断率为14.3%。'],0.5,"['statin', 'rate']",['rate'],1067,终止服用降低了14.3%。,0.0,"['statin', 'rate']",[],,,,
1075,1068,"factors associated with statin discontinuation were hospital admission , admission to a skilled nursing facility , metastatic solid tumor , and initiation of enteral or oral feeding .",与停用他汀类药物相关的因素包括入院、入住专业护理机构、转移性实体瘤以及开始肠内或经口喂养。,0.125,"['statin', 'initiation', 'tumor', 'oral', 'admission', 'feeding', 'nursing', 'solid', 'metastatic', 'associated', 'facility', 'hospital', 'with', 'skilled', 'to', 'and']","['initiation', 'nursing']",1068,['与静素中断相关的因素包括入院、入院到熟练的护理设施、甲状腺固体肿瘤以及内科或口服营养的启动。'],0.375,"['statin', 'initiation', 'tumor', 'oral', 'admission', 'feeding', 'nursing', 'solid', 'metastatic', 'associated', 'facility', 'hospital', 'with', 'skilled', 'to', 'and']","['initiation', 'tumor', 'nursing', 'solid', 'facility', 'skilled']",1068,相关因素导致他汀类药物停止使用的是住院、入住护理机构、弥漫性实体肿瘤和口服或经口饲喂的启动。,0.25,"['statin', 'initiation', 'tumor', 'oral', 'admission', 'feeding', 'nursing', 'solid', 'metastatic', 'associated', 'facility', 'hospital', 'with', 'skilled', 'to', 'and']","['initiation', 'tumor', 'feeding', 'nursing']",,,,
1076,1069,"a question remains as to whether statin withdrawal was a marker of higher risk ; ideally , a trial will resolve that .",关于停用他汀类药物是否是高风险标志的问题仍然存在；理想情况下，审判将解决这个问题。,0.4545454545454545,"['statin', 'marker', 'question', 'withdrawal', 'resolve', 'risk', 'trial', 'as', 'will', 'that', 'to']","['question', 'resolve', 'risk', 'trial', 'to']",1069,"['一个问题仍然是,是否 statin 撤销是更高的风险标志;理想情况下,一个审查将解决这个问题。']",0.2727272727272727,"['statin', 'marker', 'question', 'withdrawal', 'resolve', 'risk', 'trial', 'as', 'will', 'that', 'to']","['question', 'resolve', 'risk']",1069,"一个问题仍然存在，那就是撤销他汀类药物是否意味着更高的风险；理想情况下，一项试验将解决这个问题。

Chinese:

仍有一个问题是，撤销他汀类药物是否意味着更高的风险；理想情况下，一个试验将解决这个问题。",0.2727272727272727,"['statin', 'marker', 'question', 'withdrawal', 'resolve', 'risk', 'trial', 'as', 'will', 'that', 'to']","['question', 'resolve', 'risk']",,,,
1077,1070,studies suggest that fluoride exposure during brain development might negatively affect neurocognitive outcomes in children .,研究表明，在大脑发育过程中接触氟化物可能会对儿童的神经认知结果产生负面影响。,0.5714285714285714,"['fluoride', 'exposure', 'brain', 'affect', 'development', 'suggest', 'that']","['fluoride', 'brain', 'affect', 'development']",1070,"['研究表明,在大脑发育期间的氟化物曝光可能会对儿童的神经认知结果产生负面影响。']",0.7142857142857143,"['fluoride', 'exposure', 'brain', 'affect', 'development', 'suggest', 'that']","['fluoride', 'exposure', 'brain', 'affect', 'development']",1070,研究表明，在大脑发育过程中暴露于氟化物可能会对儿童的神经认知能力产生负面影响。,0.7142857142857143,"['fluoride', 'exposure', 'brain', 'affect', 'development', 'suggest', 'that']","['fluoride', 'exposure', 'brain', 'affect', 'development']",,,,
1078,1071,"analyses included multiple covariates , such as maternal education , household income , parity , and exposure to other chemicals , as well as child gestational age , birth weight , and sex .",分析包括多个协变量，例如母亲教育程度、家庭收入、产次和接触其他化学品，以及儿童胎龄、出生体重和性别。,0.5,"['maternal', 'exposure', 'sex', 'birth weight', 'child', 'education', 'multiple', 'well', 'household', 'as', 'income', 'parity', 'gestational age', 'chemicals', 'to', 'and']","['maternal', 'sex', 'child', 'education', 'household', 'as', 'income', 'parity']",1071,"['分析包括多种差异,如母亲教育、家庭收入、平等和对其他化学物质的暴露以及儿童的怀孕年龄、出生体重和性别。']",0.5,"['maternal', 'exposure', 'sex', 'birth weight', 'child', 'education', 'multiple', 'well', 'household', 'as', 'income', 'parity', 'gestational age', 'chemicals', 'to', 'and']","['maternal', 'exposure', 'sex', 'child', 'education', 'household', 'as', 'income']",1071,分析包括多个协变量，如母亲的教育水平、家庭收入、生育次数和接触其他化学物质的情况，以及婴儿的妊娠年龄、出生体重和性别。,0.4375,"['maternal', 'exposure', 'sex', 'birth weight', 'child', 'education', 'multiple', 'well', 'household', 'as', 'income', 'parity', 'gestational age', 'chemicals', 'to', 'and']","['maternal', 'sex', 'child', 'education', 'household', 'as', 'income']",,,,
1079,1072,"but methodologies are improving in this area , making these findings potentially concerning , particularly at the population level .",但该领域的方法正在改进，使这些调查结果可能令人担忧，尤其是在人口层面。,0.5,"['population', 'area', 'level', 'this', 'in', 'but']","['population', 'this', 'but']",1072,"['但在这个领域的方法正在改善,使这些发现可能涉及,特别是在人口水平。']",0.6666666666666666,"['population', 'area', 'level', 'this', 'in', 'but']","['population', 'level', 'this', 'but']",1072,但是在这个领域的方法正在改进，这些发现可能令人担忧，特别是在人口水平上。,0.6666666666666666,"['population', 'area', 'level', 'this', 'in', 'but']","['population', 'level', 'this', 'but']",,,,
1080,1073,"clinicians should be prepared to discuss the possible positive and negative effects of fluoride exposure , since parents may ask whether they should avoid giving fluoridated water to their young children or drinking it during pregnancy .",临床医生应该准备好讨论接触氟化物可能产生的正面和负面影响，因为父母可能会问他们是否应该避免给年幼的孩子喝含氟水或在怀孕期间饮用。,0.5,"['pregnancy', 'parents', 'fluoride', 'exposure', 'negative', 'water', 'drinking', 'be', 'discuss', 'positive', 'young', 'to', 'and', 'avoid']","['pregnancy', 'fluoride', 'water', 'drinking', 'be', 'young', 'avoid']",1073,"['临床医生应该准备讨论氟化物曝光的潜在积极和负面影响,因为父母可能会问他们是否应该避免给小孩子氟化水或在怀孕期间喝水。']",0.5,"['pregnancy', 'parents', 'fluoride', 'exposure', 'negative', 'water', 'drinking', 'be', 'discuss', 'positive', 'young', 'to', 'and', 'avoid']","['pregnancy', 'fluoride', 'exposure', 'water', 'drinking', 'be', 'avoid']",1073,"医师应准备好讨论氟暴露的可能负面和正面影响，因为家长可能会问是否应该避免让幼儿饮用含氟水或在怀孕期间饮用含氟水。

Chinese:

医师应准备好讨论氟暴露的可能负面和正面影响，因为家长可能会问是否应该避免让幼儿饮用含氟水或在怀孕期间饮用含氟水。",0.5,"['pregnancy', 'parents', 'fluoride', 'exposure', 'negative', 'water', 'drinking', 'be', 'discuss', 'positive', 'young', 'to', 'and', 'avoid']","['pregnancy', 'exposure', 'water', 'drinking', 'be', 'young', 'avoid']",,,,
1081,1074,"because prenatal fluoride is not believed to benefit the fetus , it is reasonable to recommend that women reduce fluoride intake during pregnancy .",由于产前氟化物不被认为对胎儿有益，因此建议女性在怀孕期间减少氟化物摄入量是合理的。,0.5,"['pregnancy', 'intake', 'fetus', 'fluoride', 'reduce', 'recommend', 'prenatal', 'benefit', 'that', 'to']","['pregnancy', 'fetus', 'fluoride', 'recommend', 'to']",1074,"['由于预产氟化物不被认为对胎儿有好处,因此建议妇女在怀孕期间减少氟化物摄入量。']",0.5,"['pregnancy', 'intake', 'fetus', 'fluoride', 'reduce', 'recommend', 'prenatal', 'benefit', 'that', 'to']","['pregnancy', 'fetus', 'fluoride', 'recommend', 'to']",1074,因为预防浓度的氟化物不被认为有益于胎儿，所以建议妇女在怀孕期间减少氟摄入量是合理的。,0.5,"['pregnancy', 'intake', 'fetus', 'fluoride', 'reduce', 'recommend', 'prenatal', 'benefit', 'that', 'to']","['pregnancy', 'fetus', 'fluoride', 'recommend', 'to']",,,,
1082,1075,diagnoses of chronic obstructive pulmonary disease were incorrect in about 62 % of cases .,在大约 62% 的病例中，慢性阻塞性肺病的诊断是不正确的。,0.4,"['disease', 'obstructive', 'pulmonary', 'chronic', 'in']","['disease', 'chronic']",1075,['慢性抑制性肺疾病的诊断在约62%的病例中是错误的。'],0.4,"['disease', 'obstructive', 'pulmonary', 'chronic', 'in']","['disease', 'chronic']",1075,约62%的慢性阻塞性肺病的诊断是错误的。,0.4,"['disease', 'obstructive', 'pulmonary', 'chronic', 'in']","['disease', 'chronic']",,,,
1083,1076,"previously , it showed that as many as 81 % of COPD cases worldwide are undiagnosed ( Chest 2015 ; 148 : 971 ) .",此前，它表明全世界多达 81% 的 COPD 病例未得到诊断（Chest 2015；148：971）。,0.25,"['COPD', 'chest', 'as', 'that']",['COPD'],1076,"['此前,它表明,全球大约有81%的COPD病例未经诊断(Cest 2015;148:971)。']",0.25,"['COPD', 'chest', 'as', 'that']",['COPD'],1076,之前，据显示全世界有多达81%的COPD病例仍未被诊断出来（Chest 2015; 148: 971）。,0.25,"['COPD', 'chest', 'as', 'that']",['COPD'],,,,
1084,1077,"now , researchers have examined the rate of COPD overdiagnosis .",现在，研究人员已经检查了 COPD 过度诊断率。,0.6666666666666666,"['COPD', 'rate', 'have']","['COPD', 'rate']",1077,"['现在,研究人员已经检查了COPD过度诊断的速度。']",0.3333333333333333,"['COPD', 'rate', 'have']",['COPD'],1077,现在，研究人员已经研究了COPD过度诊断的率。,0.6666666666666666,"['COPD', 'rate', 'have']","['COPD', 'rate']",,,,
1085,1078,performing spirometry before and after administration of a bronchodilator is essential before making a diagnosis .,在进行诊断之前，在使用支气管扩张剂之前和之后进行肺活量测定是必不可少的。,0.4444444444444444,"['administration', 'essential', 'diagnosis', 'bronchodilator', 'after', 'spirometry', 'performing', 'before', 'and']","['diagnosis', 'bronchodilator', 'after', 'before']",1078,"['在服用 bronchodilator 之前和服用 bronchodilator 后进行螺旋测量,在进行诊断之前至关重要。']",0.3333333333333333,"['administration', 'essential', 'diagnosis', 'bronchodilator', 'after', 'spirometry', 'performing', 'before', 'and']","['diagnosis', 'after', 'before']",1078,在给病人用肺活素前后进行肺功能测试是诊断的重要环节。,0.3333333333333333,"['administration', 'essential', 'diagnosis', 'bronchodilator', 'after', 'spirometry', 'performing', 'before', 'and']","['diagnosis', 'after', 'before']",,,,
1086,1079,patients with lower levels might not need 5 days of oral steroids for chronic obstructive pulmonary disease exacerbations .,较低水平的患者可能不需要 5 天的口服类固醇治疗慢性阻塞性肺疾病恶化。,0.4444444444444444,"['5', 'disease', 'need', 'obstructive', 'oral', 'lower', 'pulmonary', 'chronic', 'with']","['5', 'disease', 'need', 'chronic']",1079,['低水平的患者可能不需要5天的口服类固醇慢性阻塞性肺病恶化。'],0.4444444444444444,"['5', 'disease', 'need', 'obstructive', 'oral', 'lower', 'pulmonary', 'chronic', 'with']","['5', 'disease', 'need', 'chronic']",1079,Patients with lower levels of severity might not need 5 days of oral steroids for chronic obstructive pulmonary disease exacerbations.,0.1111111111111111,"['5', 'disease', 'need', 'obstructive', 'oral', 'lower', 'pulmonary', 'chronic', 'with']",['5'],,,,
1087,1080,GOLD guidelines recommend use of prednisone ( 40 mg daily ) for 5 days for acute exacerbations of chronic obstructive pulmonary disease ( COPD ; NEJM JW Gen Med Jun 15 2017 and Am J Respir Crit Care Med 2017 ; 195 : 557 ) .,GOLD 指南建议使用强的松（每天 40 毫克）治疗 5 天慢性阻塞性肺疾病急性加重期（COPD；NEJM JW Gen Med 2017 年 6 月 15 日和 Am J Respir Crit Care Med 2017；195：557）。,0.3846153846153846,"['COPD', '5', 'disease', 'obstructive', 'prednisone', 'recommend', 'pulmonary', 'chronic', 'acute', 'gen', 'care', 'and', 'med']","['COPD', '5', 'disease', 'recommend', 'chronic']",1080,['黄金指南建议使用<unk>(每日40毫克)为5天的慢性阻塞性肺疾病急剧加剧(COPD;NEJM JW Gen Med Jun 15 2017和Am J Respir Crit Care Med 2017;195:557 )。'],0.3846153846153846,"['COPD', '5', 'disease', 'obstructive', 'prednisone', 'recommend', 'pulmonary', 'chronic', 'acute', 'gen', 'care', 'and', 'med']","['COPD', '5', 'disease', 'recommend', 'chronic']",1080,GOLD guidelines recommend the use of prednisone (40 mg daily) for 5 days for acute exacerbations of chronic obstructive pulmonary disease (COPD; NEJM JW Gen Med Jun 15 2017 and Am J Respir Crit Care Med 2017; 195: 557).,0.1538461538461538,"['COPD', '5', 'disease', 'obstructive', 'prednisone', 'recommend', 'pulmonary', 'chronic', 'acute', 'gen', 'care', 'and', 'med']","['COPD', '5']",,,,
1088,1081,"all patients received 80 mg of methylprednisolone on day 1 , followed by either 37.5 mg of prednisolone daily for 4 days or prednisolone just on the days when peripheral eosinophil count was ≥ 300 cell / mL .",所有患者均在第 1 天接受 80 mg 甲泼尼龙，随后每天接受 37.5 mg 泼尼松龙治疗 4 天，或仅在外周嗜酸性粒细胞计数≥ 300 个细胞/mL 时才接受泼尼松龙治疗。,0.4166666666666667,"['cell', 'count', 'eosinophil', 'peripheral', '1', '/', 'methylprednisolone', '4', 'ml', 'all', 'by', 'just']","['cell', 'count', '1', 'methylprednisolone', 'just']",1081,"['所有患者在第一天服用了80毫克甲基<unk><unk>,随后每日服用了37.5毫克甲基<unk>4天或甲基<unk>仅在周边甲基<unk>数为≥300细胞/毫升的日子。']",0.0833333333333333,"['cell', 'count', 'eosinophil', 'peripheral', '1', '/', 'methylprednisolone', '4', 'ml', 'all', 'by', 'just']",['cell'],1081,所有病人在第1天服用80毫克的美泼得林，随后每天服用37.5毫克的泼尼松，共4天，或者只在外周血清中Eosinophil计数≥300细胞/毫升时泼尼松。,0.25,"['cell', 'count', 'eosinophil', 'peripheral', '1', '/', 'methylprednisolone', '4', 'ml', 'all', 'by', 'just']","['cell', 'count', '1']",,,,
1089,1082,this study raises questions about whether all patients with COPD exacerbations need a full 5 days of systemic corticosteroids .,这项研究提出了一个问题，即是否所有患有 COPD 恶化的患者都需要整整 5 天的全身性皮质类固醇。,0.4444444444444444,"['COPD', '5', 'need', 'study', 'systemic', 'with', 'full', 'all', 'this']","['COPD', '5', 'need', 'this']",1082,['这项研究提出了关于所有患有COPD加剧的患者是否需要一个完整的5天系统类固醇的疑问。'],0.5555555555555556,"['COPD', '5', 'need', 'study', 'systemic', 'with', 'full', 'all', 'this']","['COPD', '5', 'need', 'full', 'this']",1082,这项研究引起了人们对是否所有COPD加重病例都需要5天的全身糖皮质激素治疗的疑问。,0.4444444444444444,"['COPD', '5', 'need', 'study', 'systemic', 'with', 'full', 'all', 'this']","['COPD', '5', 'need', 'this']",,,,
1090,1083,the slight excess of COPD readmissions and the cumbersome regimen of changing treatment daily based on eosinophil counts does not make this an attractive approach as yet .,COPD 再入院人数略多，以及根据嗜酸性粒细胞计数每天更换治疗的繁琐方案，目前还不能使该方法成为一种有吸引力的方法。,0.1818181818181818,"['approach', 'eosinophil', 'COPD', 'excess', 'slight', 'treatment', 'as', 'on', 'this', 'and', 'make']","['COPD', 'treatment']",1083,"['微不足道的COPD复发和基于eosinophil数的日常治疗变化的累积模式,这一点尚未成为一个有吸引力的方法。']",0.1818181818181818,"['approach', 'eosinophil', 'COPD', 'excess', 'slight', 'treatment', 'as', 'on', 'this', 'and', 'make']","['COPD', 'treatment']",1083,目前，由于COPD复诊略微增加和治疗方案每天都要根据髓鞘细胞计数来改变，这并不是一个有吸引力的方法。,0.2727272727272727,"['approach', 'eosinophil', 'COPD', 'excess', 'slight', 'treatment', 'as', 'on', 'this', 'and', 'make']","['COPD', 'treatment', 'this']",,,,
1091,1084,a larger trial in which therapy was based on a single eosinophil count at presentation would be welcome .,欢迎进行一项更大规模的试验，其中治疗基于就诊时的单个嗜酸性粒细胞计数。,0.4285714285714285,"['presentation', 'count', 'eosinophil', 'therapy', 'be', 'trial', 'single']","['count', 'therapy', 'single']",1084,"['一个更大的试验,其中治疗是基于一个单一的eosinophil 计算在演示会将是欢迎的。']",0.4285714285714285,"['presentation', 'count', 'eosinophil', 'therapy', 'be', 'trial', 'single']","['therapy', 'be', 'single']",1084,希望有更大规模的试验来评估基于初诊时的单核细胞计数的治疗方案。,0.4285714285714285,"['presentation', 'count', 'eosinophil', 'therapy', 'be', 'trial', 'single']","['count', 'therapy', 'single']",,,,
1092,1085,data do not support routine use of vitamin E in this population .,数据不支持在该人群中常规使用维生素 E。,0.6666666666666666,"['population', 'support', 'data', 'routine', 'vitamin E', 'this']","['population', 'support', 'data', 'routine']",1085,['数据不支持在这个人口中常规使用维生素E。'],0.8333333333333334,"['population', 'support', 'data', 'routine', 'vitamin E', 'this']","['population', 'support', 'data', 'routine', 'vitamin E']",1085,数据不支持在这个人群中常规使用维生素E。,0.8333333333333334,"['population', 'support', 'data', 'routine', 'vitamin E', 'this']","['population', 'support', 'data', 'routine', 'vitamin E']",,,,
1093,1086,"vitamin E has shown some benefit for treating nonalcoholic steatohepatitis ( NASH ) in patients without type 2 diabetes mellitus ( T2DM ) , but there are few data from patients with T2DM .",维生素 E 已显示对治疗非 2 型糖尿病 (T2DM) 患者的非酒精性脂肪性肝炎 (NASH) 有一定益处，但来自 T2DM 患者的数据很少。,0.5555555555555556,"['type', 'data', '2', 'diabetes mellitus', 'steatohepatitis', 'benefit', 'vitamin E', 'but', 'without']","['type', 'data', '2', 'diabetes mellitus', 'but']",1086,"['维生素E在没有2型糖尿病(T2DM)患者治疗非酒精性甲状腺炎(NASH)方面表现出一些好处,但患有T2DM患者的数据很少。']",0.6666666666666666,"['type', 'data', '2', 'diabetes mellitus', 'steatohepatitis', 'benefit', 'vitamin E', 'but', 'without']","['type', 'data', '2', 'diabetes mellitus', 'vitamin E', 'but']",1086,维生素E对于没有2型糖尿病的非酒精性脂肪肝病（NASH）患者有一些好处，但是对于2型糖尿病患者的数据很少。,0.6666666666666666,"['type', 'data', '2', 'diabetes mellitus', 'steatohepatitis', 'benefit', 'vitamin E', 'but', 'without']","['type', 'data', '2', 'diabetes mellitus', 'vitamin E', 'but']",,,,
1094,1087,"patients were randomized in a 1 : 1 : 1 fashion to receive vitamin E 400 IU twice daily , vitamin E plus pioglitazone ( starting at 30 mg daily and titrated to 45 mg daily ) , or placebo for 18 months .",患者以 1:1:1 的方式随机接受维生素 E 400 IU，每天两次，维生素 E 加吡格列酮（从每天 30 毫克开始，逐渐增加到每天 45 毫克），或安慰剂，为期 18 个月。,0.4444444444444444,"['placebo', '1', 'plus', 'vitamin E', 'pioglitazone', 'at', 'to', 'and', 'twice']","['placebo', '1', 'plus', 'pioglitazone']",1087,"['病人随机以1:1:1的方式接收维生素E400U每天两次,维生素E加上皮奥格利塔森(从每日30毫克开始,每日45毫克推特),或18个月的 placebo。']",0.3333333333333333,"['placebo', '1', 'plus', 'vitamin E', 'pioglitazone', 'at', 'to', 'and', 'twice']","['1', 'plus', 'vitamin E']",1087,病人随机分配每天口服两次维生素E400 IU、维生素E加吡格列醇（从每天30毫克开始，并调整到每天45毫克）或安慰剂，每种方案持续18个月。,0.4444444444444444,"['placebo', '1', 'plus', 'vitamin E', 'pioglitazone', 'at', 'to', 'and', 'twice']","['placebo', '1', 'plus', 'vitamin E']",,,,
1095,1088,the primary endpoint was reduction in the nonalcoholic fatty liver disease activity score of ≥ 2 points without worsening of fibrosis .,主要终点是非酒精性脂肪性肝病活动评分降低 ≥ 2 分且纤维化没有恶化。,0.5,"['fatty liver', '2', 'fibrosis', 'activity', 'reduction', 'liver disease', 'primary', 'score', 'endpoint', 'without']","['2', 'fibrosis', 'activity', 'reduction', 'liver disease']",1088,"['主要的终点是减少非酒精脂肪肝疾病活动分数 ≥ 2 点,没有恶化纤维炎。']",0.6,"['fatty liver', '2', 'fibrosis', 'activity', 'reduction', 'liver disease', 'primary', 'score', 'endpoint', 'without']","['fatty liver', '2', 'activity', 'reduction', 'primary', 'score']",1088,主要终点是除去酒精肝脏疾病活动分数至少2分而不恶化纤维化。,0.4,"['fatty liver', '2', 'fibrosis', 'activity', 'reduction', 'liver disease', 'primary', 'score', 'endpoint', 'without']","['2', 'fibrosis', 'activity', 'score']",,,,
1096,1089,baseline characteristics were similar between groups .,组间的基线特征相似。,0.6666666666666666,"['baseline', 'characteristics', 'similar']","['baseline', 'characteristics']",1089,['基层特征在群体之间是相似的。'],0.6666666666666666,"['baseline', 'characteristics', 'similar']","['characteristics', 'similar']",1089,群组之间的基线特征相似。,0.6666666666666666,"['baseline', 'characteristics', 'similar']","['baseline', 'characteristics']",,,,
1097,1090,several patients discontinued treatment in each group .,每组都有几名患者停止治疗。,0.5,"['group', 'treatment', 'each', 'in']","['group', 'treatment']",1090,['几名患者在每个群体中停止治疗。'],0.5,"['group', 'treatment', 'each', 'in']","['group', 'treatment']",1090,"在每组中有几名患者停止了治疗。

Chinese:

在每组中有几名病人停止了治疗。",0.5,"['group', 'treatment', 'each', 'in']","['group', 'treatment']",,,,
1098,1091,the primary endpoint was achieved at a significantly higher rate with combination therapy compared with placebo ( 54 % vs. 19 % ) but not with vitamin E alone compared with placebo ( 31 % vs. 19 % ; P = 0.26 ) .,与安慰剂相比，联合治疗的主要终点达到率显着更高（54% 对 19%），但与安慰剂相比，单独使用维生素 E 则没有达到主要终点（31% 对 19%；P = 0.26）。,0.4545454545454545,"['combination therapy', 'placebo', 'rate', 'primary', 'with', 'achieved', 'endpoint', 'vitamin E', 'P', 'but', 'alone']","['combination therapy', 'placebo', 'rate', 'but', 'alone']",1091,"['与 placebo 相比,初级终点率显著高(54 % vs. 19 %),而不仅仅是维生素 E 与 placebo 相比(31 % vs. 19 % ; P = 0.26 )。']",0.1818181818181818,"['combination therapy', 'placebo', 'rate', 'primary', 'with', 'achieved', 'endpoint', 'vitamin E', 'P', 'but', 'alone']","['rate', 'but']",1091,组合治疗的主要终点比安慰剂显著更高（54％ vs. 19％），但单独使用维生素E与安慰剂相比并不显著（31％ vs. 19％; P = 0.26）。,0.3636363636363636,"['combination therapy', 'placebo', 'rate', 'primary', 'with', 'achieved', 'endpoint', 'vitamin E', 'P', 'but', 'alone']","['placebo', 'vitamin E', 'but', 'alone']",,,,
1099,1092,no significant improvement in fibrosis was seen in either treatment group .,两个治疗组均未见纤维化明显改善。,0.6,"['improvement', 'fibrosis', 'no', 'treatment group', 'in']","['improvement', 'fibrosis', 'treatment group']",1092,['在任何治疗组中都没有显著改善纤维炎。'],0.4,"['improvement', 'fibrosis', 'no', 'treatment group', 'in']","['improvement', 'treatment group']",1092,"no significant improvement in fibrosis was seen in either treatment group .

Chinese:

在两组治疗中，都没有看到显著改善纤维化的情况。",0.4,"['improvement', 'fibrosis', 'no', 'treatment group', 'in']","['improvement', 'fibrosis']",,,,
1100,1093,the safety of CRISPR ( clustered regularly interspaced short palindromic repeats ) -based genome editing in the context of human gene therapy is largely unknown .,在人类基因治疗的背景下，基于 CRISPR（成簇规则间隔短回文重复序列）的基因组编辑的安全性在很大程度上是未知的。,0.5,"['safety', 'context', 'genome editing', 'clustered regularly interspaced short palindromic repeats', 'CRISPR', 'human gene therapy']","['safety', 'genome editing', 'human gene therapy']",1093,['CRISPR(基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基。'],0.0,"['safety', 'context', 'genome editing', 'clustered regularly interspaced short palindromic repeats', 'CRISPR', 'human gene therapy']",[],1093,CRISPR-based genome editing是在人类基因治疗中安全性大部分是未知的。,0.3333333333333333,"['safety', 'context', 'genome editing', 'clustered regularly interspaced short palindromic repeats', 'CRISPR', 'human gene therapy']","['safety', 'human gene therapy']",,,,
1101,1094,"at diagnosis , the HIV viral load was 8.5 × 106 copies per milliliter , and the CD4 + cell count was 528 × 106 per liter .",诊断时，HIV 病毒载量为每毫升 8.5 × 106 个拷贝，CD4+ 细胞计数为每升 528 × 106 个。,0.375,"['HIV', 'liter', 'cell count', 'load', 'diagnosis', 'viral', 'at', 'and']","['HIV', 'liter', 'diagnosis']",1094,"['在诊断时,HIV病毒负载为每毫升8,5×106副本,CD4+细胞数量为每升528×106。']",0.5,"['HIV', 'liter', 'cell count', 'load', 'diagnosis', 'viral', 'at', 'and']","['HIV', 'liter', 'load', 'diagnosis']",1094,在诊断时，HIV病毒载量为8.5×106复制片/毫升，CD4+细胞计数为528×106/升。,0.375,"['HIV', 'liter', 'cell count', 'load', 'diagnosis', 'viral', 'at', 'and']","['HIV', 'liter', 'diagnosis']",,,,
1102,1095,"the patient received six courses of standard chemotherapy for acute lymphoblastic leukemia ( see the Methods : chemotherapeutic Regimens section in the Supplementary Appendix , available with the full text of this article at NEJM.org ) , which led to morphologic complete remission .",该患者接受了六个疗程的急性淋巴细胞白血病标准化疗（见补充附录中的方法：化疗方案部分，补充附录与本文全文可在 NEJM.org 获取），导致形态学完全缓解。,0.2,"['chemotherapy', 'standard', 'appendix', 'section', 'article', 'courses', 'acute lymphoblastic leukemia', 'supplementary', 'complete', 'available', 'patient', 'text', 'remission', 'with', 'chemotherapeutic', 'full', 'this', 'in', 'to', 'led']","['chemotherapy', 'standard', 'patient', 'remission']",1095,"['患者接受了六个标准化疗课程的急性淋巴细胞白血病(参见方法:化疗规则部分,附件,可用完整的文章在NEJM.org ),导致morphologic完整的复发。']",0.3,"['chemotherapy', 'standard', 'appendix', 'section', 'article', 'courses', 'acute lymphoblastic leukemia', 'supplementary', 'complete', 'available', 'patient', 'text', 'remission', 'with', 'chemotherapeutic', 'full', 'this', 'in', 'to', 'led']","['chemotherapy', 'standard', 'appendix', 'complete', 'patient', 'full']",1095,这名病人接受了六疗程的标准化疗方案，从而达到了形态学完全缓解。,0.2,"['chemotherapy', 'standard', 'appendix', 'section', 'article', 'courses', 'acute lymphoblastic leukemia', 'supplementary', 'complete', 'available', 'patient', 'text', 'remission', 'with', 'chemotherapeutic', 'full', 'this', 'in', 'to', 'led']","['chemotherapy', 'standard', 'patient', 'remission']",,,,
1103,1096,"the patient had an undetectable plasma HIV RNA level and had lymphopenia ( CD4 + cell count , 201.31 × 106 per liter ) .",该患者的血浆 HIV RNA 水平检测不到，并且有淋巴细胞减少症（CD4+ 细胞计数，每升 201.31 × 106 个）。,0.75,"['RNA', 'HIV', 'liter', 'plasma', 'cell count', 'patient', 'level', 'and']","['RNA', 'HIV', 'liter', 'plasma', 'patient', 'level']",1096,"['病人患有无法检测的血浆HIVRNA水平,并且患有淋巴<unk>(CD4 + 细胞数量,每升 201.31 × 106 )。']",0.75,"['RNA', 'HIV', 'liter', 'plasma', 'cell count', 'patient', 'level', 'and']","['RNA', 'HIV', 'liter', 'plasma', 'patient', 'level']",1096,这名病人血液中的HIV RNA水平无法检测到，并且患有淋巴细胞减少症（CD4 + 细胞计数为201.31×10 ^ 6 /升）。,0.625,"['RNA', 'HIV', 'liter', 'plasma', 'cell count', 'patient', 'level', 'and']","['RNA', 'HIV', 'liter', 'patient', 'level']",,,,
1104,1097,written informed consent was provided by the patient .,患者提供了书面知情同意书。,0.3333333333333333,"['patient', 'informed consent', 'by']",['patient'],1097,['由病人提供的书面通知同意。'],0.6666666666666666,"['patient', 'informed consent', 'by']","['patient', 'by']",1097,病人已经知情同意书。,0.3333333333333333,"['patient', 'informed consent', 'by']",['patient'],,,,
1105,1098,no commercial sponsor was involved .,没有商业赞助商参与。,0.0,"['sponsor', 'no']",[],1098,['没有商业赞助商参与。'],0.0,"['sponsor', 'no']",[],1098,没有商业赞助者参与其中。,0.0,"['sponsor', 'no']",[],,,,
1106,1099,all experiments were performed in accordance with the protocol ( available at NEJM.org ) .,所有实验均按照方案（可在 NEJM.org 获得）进行。,0.0,"['protocol', 'available', 'with', 'at', 'all', 'in']",[],1099,['所有实验都按照协议进行(在NEJM.org上可用)。'],0.1666666666666666,"['protocol', 'available', 'with', 'at', 'all', 'in']",['protocol'],1099,所有实验均按照程序进行（可在NEJM.org上获得）。,0.0,"['protocol', 'available', 'with', 'at', 'all', 'in']",[],,,,
1107,1100,the study was designed by the last three authors .,该研究由最后三位作者设计。,0.3333333333333333,"['study', 'three', 'by']",['by'],1100,['这项研究是由最后三位作家设计的。'],0.3333333333333333,"['study', 'three', 'by']",['by'],1100,最后三位作者设计了这项研究。,0.0,"['study', 'three', 'by']",[],,,,
1108,1101,"the manuscript was written and revised by the first , third , and last two authors and was approved by all the authors .",手稿由第一、第三和最后两位作者撰写和修改，并得到所有作者的认可。,0.7142857142857143,"['manuscript', 'all', 'by', 'and', 'third', 'first', 'two']","['manuscript', 'by', 'third', 'first', 'two']",1101,"['手稿由第一、第三、最后两位作家撰写和修订,并由所有作家批准。']",0.7142857142857143,"['manuscript', 'all', 'by', 'and', 'third', 'first', 'two']","['manuscript', 'by', 'third', 'first', 'two']",1101,这份手稿是由第一、第三作者以及最后两位作者撰写和修订的，并得到所有作者的批准。,0.7142857142857143,"['manuscript', 'all', 'by', 'and', 'third', 'first', 'two']","['manuscript', 'by', 'third', 'first', 'two']",,,,
1109,1102,the authors performed the data analysis and vouch for the completeness and accuracy of the data and for the adherence of the study to the protocol .,作者进行了数据分析并保证数据的完整性和准确性以及研究对方案的依从性。,0.5,"['data', 'analysis', 'accuracy', 'protocol', 'study', 'completeness', 'adherence', 'and']","['data', 'analysis', 'accuracy', 'completeness']",1102,['作者对数据的完整性和准确性以及研究与议定书的遵守进行了数据分析和审查。'],0.625,"['data', 'analysis', 'accuracy', 'protocol', 'study', 'completeness', 'adherence', 'and']","['data', 'analysis', 'accuracy', 'protocol', 'completeness']",1102,作者对数据进行了分析，并确保数据的完整性和准确性，并确保研究符合协议。,0.625,"['data', 'analysis', 'accuracy', 'protocol', 'study', 'completeness', 'adherence', 'and']","['data', 'analysis', 'accuracy', 'protocol', 'completeness']",,,,
1110,1103,gene EDITING AND PREINFUSION CELL PREPARATION,基因编辑和灌注前细胞制备,1.0,['gene'],['gene'],1103,['基因编辑和预防细胞准备'],1.0,['gene'],['gene'],1103,"基因编辑和预注射细胞制备

Chinese:

基因编辑和预注射细胞制备",1.0,['gene'],['gene'],,,,
1111,1104,"the sorted population was 95 % CD34 + cells , equivalent to 71.2 % of the total CD34 + cells ( Table S1 in the Supplementary Appendix ) .",分选的细胞群为 95% 的 CD34+ 细胞，相当于总 CD34+ 细胞的 71.2%（补充附录表 S1）。,0.375,"['population', 'equivalent', 'appendix', 'table', 'supplementary', 'total', 'S1', 'in']","['population', 'table', 'in']",1104,"['分类人口为95%的CD34+细胞,相当于总CD34+细胞的71.2%(附件中的S1表)。']",0.5,"['population', 'equivalent', 'appendix', 'table', 'supplementary', 'total', 'S1', 'in']","['population', 'appendix', 'table', 'in']",1104,经过排序的细胞中，95%是CD34+细胞，相当于总CD34+细胞的71.2%（表S1在附件中）。,0.375,"['population', 'equivalent', 'appendix', 'table', 'supplementary', 'total', 'S1', 'in']","['appendix', 'table', 'in']",,,,
1112,1105,recipient ENGRAFTMENT AND ACUTE LYMPHOBLASTIC LEUKEMIA ASSAY,接受者植入和急性淋巴细胞白血病检测,1.0,['recipient'],['recipient'],1105,['接收器 和 急性 LYMPHOBLASTIC LEUKEMIA ASSAY'],0.0,['recipient'],[],1105,Recipient engraftment and acute lymphoblastic leukemia assay,0.0,['recipient'],[],,,,
1113,1106,"neutrophil and platelet engraftment occurred on days 13 and 27 , respectively , after transplantation ( see the Methods : allogeneic Transplantation section in the Supplementary Appendix ) .",中性粒细胞和血小板植入分别发生在移植后第 13 天和第 27 天（参见补充附录中的方法：同种异体移植部分）。,0.4545454545454545,"['transplantation', 'appendix', 'neutrophil', 'section', 'supplementary', 'after', 'platelet', 'allogeneic', 'in', 'and', 'engraftment']","['transplantation', 'neutrophil', 'after', 'platelet', 'engraftment']",1106,"['甲状腺和甲状腺移植发生在13日和27日,分别,移植后(参见方法:附加附件中的异常移植部分)。']",0.2727272727272727,"['transplantation', 'appendix', 'neutrophil', 'section', 'supplementary', 'after', 'platelet', 'allogeneic', 'in', 'and', 'engraftment']","['transplantation', 'appendix', 'after']",1106,"neutrophil and platelet engraftment occurred on days 13 and 27 , respectively , after transplantation ( see the Methods : allogeneic Transplantation section in the Supplementary Appendix ) .

Chinese:

中性粒细胞和血小板移植发生在移植后的13天和27天，分别，见方法：在补充附录中的全细胞移植部分。",0.3636363636363636,"['transplantation', 'appendix', 'neutrophil', 'section', 'supplementary', 'after', 'platelet', 'allogeneic', 'in', 'and', 'engraftment']","['transplantation', 'neutrophil', 'after', 'platelet']",,,,
1114,1107,"although the platelet count transiently decreased at month 3 , the count spontaneously recovered and stabilized in a normal range ( Figure 1A ) .",尽管血小板计数在第 3 个月出现短暂下降，但计数自发恢复并稳定在正常范围内（图 1A）。,0.5,"['transiently', 'count', 'figure', 'month', '3', 'normal range', 'platelet', 'in', 'and', 'spontaneously']","['count', 'figure', 'month', 'normal range', 'platelet']",1107,"['虽然平板电脑数量在3个月内过时下降,但数字自发恢复并在正常范围内稳定(图1A)。']",0.3,"['transiently', 'count', 'figure', 'month', '3', 'normal range', 'platelet', 'in', 'and', 'spontaneously']","['figure', 'month', 'normal range']",1107,尽管在3个月的时间里，血小板数量短暂的下降了，但是数量很快地就恢复了正常水平（图1A）。,0.2,"['transiently', 'count', 'figure', 'month', '3', 'normal range', 'platelet', 'in', 'and', 'spontaneously']","['month', 'platelet']",,,,
1115,1108,"full donor chimerism was achieved at week 4 after transplantation and persisted through the most recent time point , 19 months after transplantation .",完全供体嵌合体在移植后第 4 周实现，并持续到最近的时间点，即移植后 19 个月。,0.5833333333333334,"['donor', 'chimerism', 'transplantation', 'recent', 'time', 'week', 'after', '4', 'point', 'achieved', 'full', 'and']","['donor', 'chimerism', 'transplantation', 'time', 'week', 'after', 'point']",1108,"['全捐赠者化学在移植后的第4周实现,并持续到最新的时间点,移植后的19个月。']",0.4166666666666667,"['donor', 'chimerism', 'transplantation', 'recent', 'time', 'week', 'after', '4', 'point', 'achieved', 'full', 'and']","['transplantation', 'time', 'week', 'after', 'point']",1108,完全的捐赠者嵌合体在移植后4周就达到了，并且在最近的19个月时间点上一直保持了。,0.5,"['donor', 'chimerism', 'transplantation', 'recent', 'time', 'week', 'after', '4', 'point', 'achieved', 'full', 'and']","['chimerism', 'transplantation', 'time', 'week', 'after', 'point']",,,,
1116,1109,CCR5 GENE EDITING,CCR5基因编辑,,[],[],1109,['CCR5 编辑'],,[],[],1109,CCR5基因编辑,,[],[],,,,
1117,1110,the representative types of CCR5 gene mutation are shown in Figure S1 in the Supplementary Appendix .,CCR5基因突变的代表性类型见补充附录图S1。,0.2857142857142857,"['gene', 'mutation', 'appendix', 'figure', 'supplementary', 'S1', 'in']","['gene', 'mutation']",1110,['CCR5基因突变的代表性类型在附件中的图 S1 显示。'],0.4285714285714285,"['gene', 'mutation', 'appendix', 'figure', 'supplementary', 'S1', 'in']","['gene', 'mutation', 'appendix']",1110,"CCR5 gene mutations have many different types, as shown in Figure S1 of the Supplementary Appendix.",0.0,"['gene', 'mutation', 'appendix', 'figure', 'supplementary', 'S1', 'in']",[],,,,
1118,1111,safety ANALYSIS,安全分析,1.0,['safety'],['safety'],1111,['安全分析'],1.0,['safety'],['safety'],1111,安全性分析,1.0,['safety'],['safety'],,,,
1119,1112,"the patient presented with predictable side effects after preconditioning , including anemia ( hemoglobin level , 79 g per liter at day 22 ) , neutropenia ( undetectable neutrophils at day 0 ) , and thrombocytopenia ( platelet count , 12 × 109 per liter at day 6 ) .",患者在预处理后出现了可预测的副作用，包括贫血（血红蛋白水平，第 22 天时每升 79 克）、中性粒细胞减少症（第 0 天时检测不到中性粒细胞）和血小板减少症（血小板计数，第 6 天时每升 12 × 109）。,0.7692307692307693,"['anemia', 'count', 'liter', 'preconditioning', 'neutropenia', 'side effects', 'thrombocytopenia', 'hemoglobin level', 'patient', 'after', 'with', 'platelet', 'and']","['anemia', 'count', 'liter', 'preconditioning', 'neutropenia', 'side effects', 'thrombocytopenia', 'patient', 'after', 'platelet']",1112,"['患者在预测后出现可预测的副作用,包括贫血(血球水平,22日每升79克),中性<unk>(0日未检测中性<unk>)和血细胞<unk>(6日每升12×109克)。']",0.3846153846153846,"['anemia', 'count', 'liter', 'preconditioning', 'neutropenia', 'side effects', 'thrombocytopenia', 'hemoglobin level', 'patient', 'after', 'with', 'platelet', 'and']","['anemia', 'liter', 'side effects', 'patient', 'after']",1112,病人在预处理后出现预期的副作用，包括贫血（第22天血红蛋白水平为79 g /升）、中性粒细胞减少（第0天无法检测到中性粒细胞）和血小板减少（第6天血小板计数为12×10^9/升）。,0.6923076923076923,"['anemia', 'count', 'liter', 'preconditioning', 'neutropenia', 'side effects', 'thrombocytopenia', 'hemoglobin level', 'patient', 'after', 'with', 'platelet', 'and']","['anemia', 'count', 'liter', 'preconditioning', 'side effects', 'thrombocytopenia', 'patient', 'after', 'platelet']",,,,
1120,1113,no acute immune response was observed after the infusion of donor cells .,输注供体细胞后未观察到急性免疫反应。,0.6666666666666666,"['donor', 'infusion', 'immune', 'response', 'after', 'acute']","['donor', 'infusion', 'response', 'after']",1113,['捐献细胞注射后没有急性免疫反应。'],0.5,"['donor', 'infusion', 'immune', 'response', 'after', 'acute']","['infusion', 'response', 'after']",1113,No acute immune response was observed after the infusion of donor cells.,0.0,"['donor', 'infusion', 'immune', 'response', 'after', 'acute']",[],,,,
1121,1114,"febrile neutropenia ( grade 3 ) and bacteremia ( Staphylococcus epidermidis ; grade 3 ) developed in the first 2 weeks , which resolved with the use of standard antibiotic therapy .",头 2 周内出现发热性中性粒细胞减少症（3 级）和菌血症（表皮葡萄球菌；3 级），使用标准抗生素治疗可缓解。,0.4166666666666667,"['bacteremia', 'standard', 'febrile', '2', 'grade', 'staphylococcus epidermidis', 'antibiotic therapy', 'neutropenia', '3', 'with', 'in', 'first']","['bacteremia', 'standard', '2', 'staphylococcus epidermidis', 'neutropenia']",1114,"['发烧性中性(三级)和细菌(三级)在前两周内发育,并通过使用标准抗生素治疗解决。']",0.0833333333333333,"['bacteremia', 'standard', 'febrile', '2', 'grade', 'staphylococcus epidermidis', 'antibiotic therapy', 'neutropenia', '3', 'with', 'in', 'first']",['standard'],1114,发热性中性粒细胞减少症（3级）和血液细菌感染（溃疡性链球菌；3级）在头两周发展，使用标准抗生素治疗后得以缓解。,0.1666666666666666,"['bacteremia', 'standard', 'febrile', '2', 'grade', 'staphylococcus epidermidis', 'antibiotic therapy', 'neutropenia', '3', 'with', 'in', 'first']","['standard', 'neutropenia']",,,,
1122,1115,all these events resolved .,所有这些事件都解决了。,0.0,['all'],[],1115,['所有这些事件都解决了。'],0.0,['all'],[],1115,所有这些事件都已解决。,0.0,['all'],[],,,,
1123,1116,no adverse events that were related to CCR5 gene editing were noted ( Table S2 in the Supplementary Appendix ) .,未发现与 CCR5 基因编辑相关的不良事件（补充附录表 S2）。,0.2222222222222222,"['appendix', 'table', 'gene editing', 'supplementary', 'adverse', 'no', 'S2', 'that', 'to']","['table', 'gene editing']",1116,['没有与 CCR5 基因编辑相关的副作用被注意到(附件中的 S2 表)。'],0.3333333333333333,"['appendix', 'table', 'gene editing', 'supplementary', 'adverse', 'no', 'S2', 'that', 'to']","['appendix', 'table', 'gene editing']",1116,没有发现与CCR5基因编辑有关的不良事件（表S2见补充附件）。,0.3333333333333333,"['appendix', 'table', 'gene editing', 'supplementary', 'adverse', 'no', 'S2', 'that', 'to']","['appendix', 'table', 'gene editing']",,,,
1124,1117,"the serum viral load increased to 3 × 107 copies per milliliter at week 4 during the interruption of antiretroviral therapy , and the drugs were then resumed ( Figure 2A ) .",在抗逆转录病毒治疗中断的第 4 周，血清病毒载量增加到 3×107 拷贝/毫升，然后恢复药物治疗（图 2A）。,0.3846153846153846,"['figure', 'drugs', 'interruption', 'load', 'therapy', 'serum', 'viral', 'week', '3', '4', 'at', 'to', 'and']","['drugs', 'interruption', 'therapy', 'serum', 'week']",1117,"['血清病毒负载在4周中停止治疗时增加到每毫升3×107副本,然后重新服用药物(图2A)。']",0.3846153846153846,"['figure', 'drugs', 'interruption', 'load', 'therapy', 'serum', 'viral', 'week', '3', '4', 'at', 'to', 'and']","['drugs', 'load', 'therapy', 'serum', 'week']",1117,在中断抗病毒治疗的第四周，血清病毒载量增加到了每毫升3×107个副本，然后药物被恢复使用（图2A）。,0.3846153846153846,"['figure', 'drugs', 'interruption', 'load', 'therapy', 'serum', 'viral', 'week', '3', '4', 'at', 'to', 'and']","['drugs', 'interruption', 'therapy', 'serum', 'week']",,,,
1125,1118,the viral load gradually decreased to an undetectable level during the following months .,在接下来的几个月里，病毒载量逐渐下降到检测不到的水平。,0.2,"['load', 'viral', 'level', 'to', 'following']",['level'],1118,['病毒负载在接下来的几个月内逐渐下降到无法检测的水平。'],0.4,"['load', 'viral', 'level', 'to', 'following']","['load', 'level']",1118,随着时间的推移，病毒载荷逐渐降至不可测水平。,0.4,"['load', 'viral', 'level', 'to', 'following']","['load', 'level']",,,,
1126,1119,"during the interruption of antiretroviral therapy , the peripheral CD4 + cell count decreased from 575 × 106 per liter to 250 × 106 per liter , and the same trend was observed in the ratio of CD4 + cells to CD8 + cells .",抗逆转录病毒治疗中断期间，外周血CD4+细胞计数从575×106/L下降到250×106/L，CD4+细胞与CD8+细胞的比例也有相同趋势。,0.4444444444444444,"['trend', 'liter', 'peripheral', 'ratio', 'cell count', 'interruption', 'therapy', 'to', 'and']","['trend', 'ratio', 'interruption', 'therapy']",1119,"['在中断抗病毒治疗期间,周边CD4+细胞数量从575×106每升降至250×106每升,并在CD4+细胞与CD8+细胞的比例中观察到相同的趋势。']",0.5555555555555556,"['trend', 'liter', 'peripheral', 'ratio', 'cell count', 'interruption', 'therapy', 'to', 'and']","['trend', 'liter', 'ratio', 'interruption', 'therapy']",1119,在抗逆转录病毒治疗中断期间，外周CD4+细胞数量从575×106/升下降到250×106/升，CD4+细胞与CD8+细胞之比也呈现出相同的趋势。,0.5555555555555556,"['trend', 'liter', 'peripheral', 'ratio', 'cell count', 'interruption', 'therapy', 'to', 'and']","['trend', 'liter', 'ratio', 'interruption', 'therapy']",,,,
1127,1120,"in addition , the level of CCR5 disruption in peripheral CD4 + cells before the interruption was 2.96 % .",此外，中断前外周CD4+细胞的CCR5中断水平为2.96%。,0.5,"['peripheral', 'addition', 'interruption', 'disruption', 'level', 'before']","['interruption', 'level', 'before']",1120,"['除此之外,在中断之前的周边CD4 +细胞中,CCR5中断的水平为2.96%。']",0.5,"['peripheral', 'addition', 'interruption', 'disruption', 'level', 'before']","['interruption', 'level', 'before']",1120,此外，在中断之前外周CD4+细胞中CCR5破坏的水平为2.96%。,0.5,"['peripheral', 'addition', 'interruption', 'disruption', 'level', 'before']","['interruption', 'level', 'before']",,,,
1128,1121,"the level of CCR5 disruption in CD4 + cells peaked ( 4.39 % ) during the interruption , at a level that was 1.6 times as great as the mean level , and was accompanied by a decrease in the CD4 + cell count ( 360 × 106 per liter ) .",CD4 + 细胞中的 CCR5 破坏水平在中断期间达到峰值 ( 4.39 % )，是平均水平的 1.6 倍，并且伴随着 CD4 + 细胞计数的减少（ 360 × 106 每升) 。,0.4545454545454545,"['decrease', 'mean', 'liter', 'cell count', 'interruption', 'disruption', 'level', 'that', 'great', 'and', 'accompanied by']","['decrease', 'mean', 'liter', 'interruption', 'level']",1121,"['在中断期间,CD4 + 细胞中 CCR5 干扰的水平上升( 4.39 % ),达到平均水平的 1.6 倍,并伴随着 CD4 + 细胞数量的下降( 360 × 106 每升)。']",0.3636363636363636,"['decrease', 'mean', 'liter', 'cell count', 'interruption', 'disruption', 'level', 'that', 'great', 'and', 'accompanied by']","['mean', 'liter', 'interruption', 'level']",1121,CCR5的破坏在CD4+细胞中达到了峰值（4.39%），是平均水平的1.6倍，伴随着CD4+细胞数量的下降（360 x 106 /升）。,0.2727272727272727,"['decrease', 'mean', 'liter', 'cell count', 'interruption', 'disruption', 'level', 'that', 'great', 'and', 'accompanied by']","['mean', 'liter', 'level']",,,,
1129,1122,their quick rebound after the interruption of antiretroviral therapy coincided with the appearance of a measurable viral load .,它们在抗逆转录病毒治疗中断后迅速反弹，同时出现可测量的病毒载量。,0.3333333333333333,"['rebound', 'interruption', 'load', 'therapy', 'viral', 'after', 'quick', 'appearance', 'with']","['interruption', 'therapy', 'after']",1122,['其快速恢复后中断的反病毒治疗与出现可测量的病毒负载相匹配。'],0.4444444444444444,"['rebound', 'interruption', 'load', 'therapy', 'viral', 'after', 'quick', 'appearance', 'with']","['interruption', 'load', 'therapy', 'after']",1122,他们在抗逆转录病毒治疗中断后的快速反弹与可测量的病毒载荷的出现相同。,0.4444444444444444,"['rebound', 'interruption', 'load', 'therapy', 'viral', 'after', 'quick', 'appearance', 'with']","['interruption', 'load', 'therapy', 'after']",,,,
1130,1123,"the donor cells engrafted with full chimerism , and the acute lymphoblastic leukemia was in complete remission for 19 months after transplantation , during which time the cells with the modified CCR5 gene persisted , and the CCR5 disruption ranged from 5.20 to 8.28 % in bone marrow cells ( Figure 1B ) .",移植完全嵌合的供体细胞，急性淋巴细胞白血病在移植后 19 个月内完全缓解，在此期间，具有修饰的 CCR5 基因的细胞持续存在，骨髓细胞中的 CCR5 破坏范围为 5.20 至 8.28 % (图 1B）。,0.4117647058823529,"['donor', 'gene', 'chimerism', 'transplantation', 'bone marrow', 'figure', 'acute lymphoblastic leukemia', 'disruption', 'time', 'complete', 'after', 'remission', 'with', 'full', 'in', 'to', 'and']","['donor', 'gene', 'chimerism', 'transplantation', 'bone marrow', 'after', 'remission']",1123,"['捐献细胞充满了化学,而急性淋巴细胞白血病在移植后的19个月内处于完整的复发状态,在此期间,有修改的CCR5基因的细胞持续了,而CCR5的干扰率在骨头细胞中从5.20%到8.28%(图1B)。']",0.4117647058823529,"['donor', 'gene', 'chimerism', 'transplantation', 'bone marrow', 'figure', 'acute lymphoblastic leukemia', 'disruption', 'time', 'complete', 'after', 'remission', 'with', 'full', 'in', 'to', 'and']","['gene', 'transplantation', 'complete', 'after', 'full', 'to', 'and']",1123,捐赠细胞完全充当干细胞，急性淋巴细胞白血病在移植后19个月完全缓解，在此期间持续存在修饰过的CCR5基因的细胞，CCR5的破坏在骨髓细胞中范围为5.20%至8.28%（见图1B）。,0.3529411764705882,"['donor', 'gene', 'chimerism', 'transplantation', 'bone marrow', 'figure', 'acute lymphoblastic leukemia', 'disruption', 'time', 'complete', 'after', 'remission', 'with', 'full', 'in', 'to', 'and']","['gene', 'transplantation', 'bone marrow', 'after', 'remission', 'in']",,,,
1131,1124,"when antiretroviral therapy was interrupted at 7 months after transplantation , a small increase in the percentage of CCR5 indels was observed 2 weeks after the initiation of the interruption ( Figure 2C ) .",当移植后 7 个月中断抗逆转录病毒治疗时，在中断开始 2 周后观察到 CCR5 插入缺失百分比的小幅增加（图 2C）。,0.6,"['percentage', 'transplantation', 'initiation', '2', 'figure', 'interruption', 'therapy', 'interrupted', 'after', 'increase']","['transplantation', 'initiation', '2', 'interruption', 'therapy', 'after']",1124,"['如果在移植后7个月中断抗逆转病毒治疗,则在中断开始后2周内观察到CCR5的百分比略有增加(图2C)。']",0.6,"['percentage', 'transplantation', 'initiation', '2', 'figure', 'interruption', 'therapy', 'interrupted', 'after', 'increase']","['transplantation', 'initiation', '2', 'interruption', 'therapy', 'after']",1124,当抗逆转录病毒疗法在移植后7个月中断时，在疗法中断后2周，CCR5 indels的比例略有增加(图2C)。,0.5,"['percentage', 'transplantation', 'initiation', '2', 'figure', 'interruption', 'therapy', 'interrupted', 'after', 'increase']","['transplantation', '2', 'interruption', 'therapy', 'after']",,,,
1132,1125,biologic therapies are widely used in patients with ulcerative colitis .,生物疗法广泛用于溃疡性结肠炎患者。,0.25,"['biologic', 'ulcerative colitis', 'with', 'in']",['ulcerative colitis'],1125,['生物疗法在患有<unk>性<unk>炎的患者中广泛使用。'],0.0,"['biologic', 'ulcerative colitis', 'with', 'in']",[],1125,生物疗法广泛应用于患有溃疡性结肠炎的病人。,0.25,"['biologic', 'ulcerative colitis', 'with', 'in']",['ulcerative colitis'],,,,
1133,1126,previous exposure to a tumor necrosis factor inhibitor other than adalimumab was allowed in up to 25 % of patients .,允许多达 25% 的患者既往接触过阿达木单抗以外的肿瘤坏死因子抑制剂。,0.4,"['inhibitor', 'exposure', 'previous', 'up', 'tumor necrosis factor']","['inhibitor', 'tumor necrosis factor']",1126,"['在25%的患者中,除了阿达利穆巴以外的肿瘤尼克罗斯因子抑制剂之前的曝光被允许。']",0.4,"['inhibitor', 'exposure', 'previous', 'up', 'tumor necrosis factor']","['inhibitor', 'exposure']",1126,"Previous exposure to a tumor necrosis factor inhibitor other than adalimumab was allowed in up to 25% of patients.

Chinese:

除了adalimumab之外，最多可以有25%的患者具有先前对肿瘤坏死因子抑制剂的曝露史。",0.4,"['inhibitor', 'exposure', 'previous', 'up', 'tumor necrosis factor']","['inhibitor', 'tumor necrosis factor']",,,,
1134,1127,"the patients were assigned to receive infusions of 300 mg of vedolizumab on day 1 and at weeks 2 , 6 , 14 , 22 , 30 , 38 , and 46 ( plus injections of placebo ) or subcutaneous injections of 40 mg of adalimumab , with a total dose of 160 mg at week 1 , 80 mg at week 2 , and 40 mg every 2 weeks thereafter until week 50 ( plus infusions of placebo ) .",患者被分配在第 1 天和第 2 周、第 6 周、第 14 周、第 22 周、第 30 周、第 38 周和第 46 周（加上安慰剂注射）或皮下注射 40 mg 阿达木单抗，总共第 1 周剂量为 160 mg，第 2 周剂量为 80 mg，此后每 2 周剂量为 40 mg，直至第 50 周（加上输注安慰剂）。,0.4166666666666667,"['placebo', '1', '2', 'plus', 'subcutaneous', 'total dose', 'week', 'with', 'vedolizumab', 'at', 'injections', 'and']","['placebo', '1', '2', 'plus', 'week']",1127,"['患者在第1天和第2周、第6周、第14周、第22周、第30周、第38周和第46周(加上 placebo 注射)或下皮注射40 mg的 adalimumab,总剂量为第1周160 mg、第2周80 mg,随后每2周40 mg,直到第50周(加上 placebo 注射)。']",0.3333333333333333,"['placebo', '1', '2', 'plus', 'subcutaneous', 'total dose', 'week', 'with', 'vedolizumab', 'at', 'injections', 'and']","['1', '2', 'plus', 'week']",1127,病人被分配接受300毫克的vedolizumab注射，分别在第1天和周2、6、14、22、30、38、46（加上安慰剂注射）或者注射40毫克的adalimumab，总计在周1注射160毫克，周2注射80毫克，每隔2周注射40毫克，直到周50（加上安慰剂注射）。,0.4166666666666667,"['placebo', '1', '2', 'plus', 'subcutaneous', 'total dose', 'week', 'with', 'vedolizumab', 'at', 'injections', 'and']","['placebo', '1', '2', 'plus', 'week']",,,,
1135,1128,dose escalation was not permitted in either group .,两组均不允许增加剂量。,0.6666666666666666,"['group', 'dose', 'in']","['group', 'dose']",1128,['剂量升级不允许在任何群体中。'],0.6666666666666666,"['group', 'dose', 'in']","['group', 'dose']",1128,在两组中都不允许剂量升级。,0.6666666666666666,"['group', 'dose', 'in']","['group', 'dose']",,,,
1136,1129,a total of 769 patients underwent randomization and received at least one dose of vedolizumab ( 383 patients ) or adalimumab ( 386 patients ) .,共有 769 名患者接受了随机分组并接受了至少一剂维多珠单抗（383 名患者）或阿达木单抗（386 名患者）。,0.25,"['randomization', 'total', 'vedolizumab', 'dose']",['randomization'],1129,"['共 769 名患者遭到随机化,并获得至少 1 份 Vedolizumab (383 名患者) 或 Adalimumab (386 名患者) 。']",0.25,"['randomization', 'total', 'vedolizumab', 'dose']",['randomization'],1129,总共769名病人接受了随机分配，其中383名患者接受了vedolizumab治疗，386名患者接受了adalimumab治疗。,0.25,"['randomization', 'total', 'vedolizumab', 'dose']",['randomization'],,,,
1137,1130,"ulcerative colitis is a chronic inflammatory disorder of the large bowel characterized by abdominal pain , bloody diarrhea , and fecal urgency.1",溃疡性结肠炎是大肠的一种慢性炎症性疾病，其特征是腹痛、血性腹泻和便急。 1,0.5,"['disorder', 'abdominal pain', 'fecal', 'diarrhea', 'large bowel', 'ulcerative colitis', 'chronic', 'inflammatory', 'characterized by', 'and']","['abdominal pain', 'diarrhea', 'large bowel', 'ulcerative colitis', 'chronic']",1130,"['溃<unk>性<unk>炎是一种慢性大肠炎症疾病,其特点是腹部疼痛、血液腹泻和排泄急性。']",0.3,"['disorder', 'abdominal pain', 'fecal', 'diarrhea', 'large bowel', 'ulcerative colitis', 'chronic', 'inflammatory', 'characterized by', 'and']","['diarrhea', 'large bowel', 'chronic']",1130,溃疡性结肠炎是一种慢性的大肠炎病，以腹痛、血液稀释的腹泻和排便紧迫感为特征。1,0.5,"['disorder', 'abdominal pain', 'fecal', 'diarrhea', 'large bowel', 'ulcerative colitis', 'chronic', 'inflammatory', 'characterized by', 'and']","['abdominal pain', 'diarrhea', 'large bowel', 'ulcerative colitis', 'chronic']",,,,
1138,1131,"adalimumab , a humanized monoclonal antibody that binds and neutralizes TNF , is widely used to treat ulcerative colitis .",阿达木单抗是一种结合并中和 TNF 的人源化单克隆抗体，广泛用于治疗溃疡性结肠炎。,0.5714285714285714,"['monoclonal antibody', 'treat', 'ulcerative colitis', 'TNF', 'that', 'to', 'and']","['monoclonal antibody', 'treat', 'ulcerative colitis', 'to']",1131,"['阿达利穆巴(Adalimumab)是一种人文化单细胞抗体,连接和中立化TNF,广泛用于治疗<unk>疹<unk>疹。']",0.2857142857142857,"['monoclonal antibody', 'treat', 'ulcerative colitis', 'TNF', 'that', 'to', 'and']","['treat', 'to']",1131,adalimumab是一种人源化的单克隆抗体，可结合并中和TNF，广泛用于治疗溃疡性结肠炎。,0.5714285714285714,"['monoclonal antibody', 'treat', 'ulcerative colitis', 'TNF', 'that', 'to', 'and']","['monoclonal antibody', 'treat', 'ulcerative colitis', 'to']",,,,
1139,1132,"adults 18 to 85 years of age were eligible for inclusion in the trial if they had moderately to severely active ulcerative colitis , defined as a total score of 6 to 12 on the Mayo scale8 ( total Mayo scores range from 0 to 12 , with higher scores indicating more severe disease ) and a subscore of at least 2 on the endoscopic component of the Mayo scale ( subscores on each of the four components of the Mayo scale range from 0 to 3 ) ; colonic involvement of at least 15 cm ; and had a confirmed diagnosis of ulcerative colitis at least 3 months before screening .",18 至 85 岁的成年人如果患有中度至重度活动性溃疡性结肠炎，则有资格参加试验，定义为梅奥量表总分 6 至 12 分 8（梅奥总分范围为 0 至 12 分，分数较高表示更严重的疾病）和 Mayo 量表内窥镜部分的分项分数至少为 2（Mayo 量表四个部分中每个部分的分项分数范围为 0 至 3）；结肠受累至少 15 厘米 ;并在筛选前至少 3 个月确诊为溃疡性结肠炎。,0.24,"['component', 'defined', 'inclusion', '2', 'cm', 'screening', 'active', 'total', 'moderately', 'colonic', 'diagnosis', 'ulcerative colitis', 'age', 'trial', 'scale range', '3', 'score', 'involvement', 'with', 'severe disease', 'before', 'each', 'if', 'and', 'eligible']","['2', 'screening', 'active', 'ulcerative colitis', 'score', 'before']",1132,"['18 至 85 歲的成年人有資格參加試驗,如果他們有中等到嚴重活性<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>']",0.0,"['component', 'defined', 'inclusion', '2', 'cm', 'screening', 'active', 'total', 'moderately', 'colonic', 'diagnosis', 'ulcerative colitis', 'age', 'trial', 'scale range', '3', 'score', 'involvement', 'with', 'severe disease', 'before', 'each', 'if', 'and', 'eligible']",[],1132,成人18至85岁之间如果他们有中度至重度的活动性溃疡性结肠炎，可以纳入试验，这是指马氏评分8中总分为6至12（总马氏评分范围为0至12，分数越高表明疾病严重程度越高），并且内镜检查部分的子评分至少为2（马氏评分的四个组成部分的子评分分别为0至3）；结肠侵犯至少15厘米；并且在筛查前至少3个月内确诊患有溃疡性结肠炎。,0.24,"['component', 'defined', 'inclusion', '2', 'cm', 'screening', 'active', 'total', 'moderately', 'colonic', 'diagnosis', 'ulcerative colitis', 'age', 'trial', 'scale range', '3', 'score', 'involvement', 'with', 'severe disease', 'before', 'each', 'if', 'and', 'eligible']","['2', 'screening', 'active', 'ulcerative colitis', 'score', 'before']",,,,
1140,1133,patients who had not previously used a TNF inhibitor and had no response or loss of response to conventional treatments were eligible .,以前没有使用过 TNF 抑制剂并且对常规治疗没有反应或反应丧失的患者符合条件。,0.375,"['inhibitor', 'who', 'loss', 'no', 'response', 'TNF', 'and', 'eligible']","['inhibitor', 'loss', 'response']",1133,['未曾使用过 TNF 抑制剂并且没有对常规治疗的反应或反应损失的患者有资格。'],0.375,"['inhibitor', 'who', 'loss', 'no', 'response', 'TNF', 'and', 'eligible']","['inhibitor', 'loss', 'response']",1133,"patients who had not previously used a TNF inhibitor and had no response or loss of response to conventional treatments were eligible .

Chinese:

未使用过TNF抑制剂，对常规治疗无反应或失去反应的患者符合条件。",0.25,"['inhibitor', 'who', 'loss', 'no', 'response', 'TNF', 'and', 'eligible']","['inhibitor', 'response']",,,,
1141,1134,"patients who had discontinued treatment with a TNF inhibitor ( except adalimumab ) because of documented reasons other than safety were also eligible , with enrollment capped at 25 % .",因安全性以外的有据可查的原因而停止使用 TNF 抑制剂（阿达木单抗除外）治疗的患者也符合条件，入组率上限为 25%。,0.375,"['safety', 'inhibitor', 'who', 'treatment', 'capped', 'with', 'TNF', 'eligible']","['safety', 'inhibitor', 'treatment']",1134,"['因其安全原因而停止使用 TNF 抑制剂(除了 adalimumab 除外)的患者也可接受,注册率为 25%。']",0.25,"['safety', 'inhibitor', 'who', 'treatment', 'capped', 'with', 'TNF', 'eligible']","['safety', 'inhibitor']",1134,"Patients who had discontinued treatment with a TNF inhibitor (except adalimumab) for documented reasons other than safety were also eligible, with enrollment capped at 25%.",0.0,"['safety', 'inhibitor', 'who', 'treatment', 'capped', 'with', 'TNF', 'eligible']",[],,,,
1142,1135,all patients had not previously received vedolizumab .,所有患者之前均未接受过维多珠单抗。,0.0,"['vedolizumab', 'all']",[],1135,['所有患者都没有提前服用Vedolizumab。'],0.0,"['vedolizumab', 'all']",[],1135,"all patients had not previously received vedolizumab .

Chinese:
所有的病人以前都没有接受过vedolizumab。",0.0,"['vedolizumab', 'all']",[],,,,
1143,1136,screening ASSESSMENTS,筛选评估,1.0,['screening'],['screening'],1136,['扫描助理'],0.0,['screening'],[],1136,"screening ASSESSMENTS

Chinese:
筛查评估",1.0,['screening'],['screening'],,,,
1144,1137,"screening assessments included a physical examination , endoscopy ( findings were read at a central location ) , the total Mayo score , blood and stool tests , tuberculosis screening , the score on the Inflammatory Bowel Disease Questionnaire ( IBDQ ; scores range from 32 to 224 , with higher scores indicating a better quality of life ) , 9 and a questionnaire to identify possible symptoms of progressive multifocal leukoencephalopathy .",筛选评估包括身体检查、内窥镜检查（结果在中央位置读取） 、梅奥总分、血液和粪便检查、肺结核筛查、炎症性肠病问卷（ IBDQ ；分数范围从 32 到 224 ，以及更高的分数表明更好的生活质量），9 和一份问卷调查，以确定进行性多灶性脑白质病的可能症状。,0.5263157894736842,"['tuberculosis', 'range', 'screening', 'blood', 'location', 'total', 'progressive', 'physical examination', 'symptoms', 'read', 'central', 'endoscopy', 'stool', 'quality of life', 'score', 'identify', 'with', 'inflammatory bowel disease', 'and']","['tuberculosis', 'range', 'screening', 'blood', 'location', 'physical examination', 'read', 'stool', 'quality of life', 'score']",1137,"['扫描评估包括物理检查,内分泌(发现在一个中心位置阅读),梅奥总分,血液和血管测试,结核病筛查,在炎症肠道疾病问卷(IBDQ;分数范围为32至224,与更高的分数表明更好的生活质量),9和一个问卷,以确定可能的症状的进步多点白血病。']",0.4210526315789473,"['tuberculosis', 'range', 'screening', 'blood', 'location', 'total', 'progressive', 'physical examination', 'symptoms', 'read', 'central', 'endoscopy', 'stool', 'quality of life', 'score', 'identify', 'with', 'inflammatory bowel disease', 'and']","['tuberculosis', 'range', 'screening', 'blood', 'location', 'read', 'quality of life', 'score']",1137,筛查包括体检、内镜检查（结果在中心地点读取）、总的梅纳得分、血液和粪便测试、结核筛查、炎症肠病问卷（IBDQ评分范围为32到224，分数越高表明生活质量越好），9和一个确定可能症状的问卷进行脑膜白质萎缩病进展。,0.5263157894736842,"['tuberculosis', 'range', 'screening', 'blood', 'location', 'total', 'progressive', 'physical examination', 'symptoms', 'read', 'central', 'endoscopy', 'stool', 'quality of life', 'score', 'identify', 'with', 'inflammatory bowel disease', 'and']","['tuberculosis', 'range', 'screening', 'blood', 'total', 'physical examination', 'read', 'stool', 'quality of life', 'score']",,,,
1145,1138,"patients who were assigned to the vedolizumab group received intravenous infusions of 300 mg of vedolizumab on day 1 and at weeks 2 , 6 , 14 , 22 , 30 , 38 , and 46 plus subcutaneous injections of placebo on day 1 ( four injections ) , at week 2 ( two injections ) , and every 2 weeks thereafter ( single injections ) until week 50 .",被分配到维多珠单抗组的患者在第 1 天和第 2 周、第 6 周、第 14 周、第 22 周、第 30 周、第 38 周和第 46 周接受静脉输注 300 mg 维多珠单抗，并在第 1 天皮下注射安慰剂（四次注射） ，第 2 周（两次注射），此后每 2 周一次（单次注射），直至第 50 周。,0.4375,"['group', 'placebo', 'who', '1', '2', 'plus', 'subcutaneous', 'week', 'intravenous', 'vedolizumab', 'at', 'injections', 'single', 'to', 'and', 'two']","['group', 'placebo', '1', '2', 'week', 'single', 'two']",1138,"['被分配给Vedolizumab群体的患者在第1天和第2周、第6周、第14周、第22周、第30周、第38周和第46周接受了300mg的Vedolizumab注射,并在第1天(四次注射),第2周(两次注射),随后每2周(单次注射)直到第50周。']",0.375,"['group', 'placebo', 'who', '1', '2', 'plus', 'subcutaneous', 'week', 'intravenous', 'vedolizumab', 'at', 'injections', 'single', 'to', 'and', 'two']","['group', '1', '2', 'week', 'single', 'two']",1138,给予vedolizumab组的患者当天给予300mg的vedolizumab输注，每隔2周给予4次，第2周给予2次，此后每周给予1次，直到第50周。,0.3125,"['group', 'placebo', 'who', '1', '2', 'plus', 'subcutaneous', 'week', 'intravenous', 'vedolizumab', 'at', 'injections', 'single', 'to', 'and', 'two']","['group', '1', '2', 'week', 'at']",,,,
1146,1139,dose escalation was not permitted in either treatment group .,两个治疗组都不允许增加剂量。,0.6666666666666666,"['treatment group', 'dose', 'in']","['treatment group', 'dose']",1139,['剂量升级在任何治疗组都未允许。'],0.6666666666666666,"['treatment group', 'dose', 'in']","['treatment group', 'dose']",1139,在两组治疗中都不允许加量。,0.0,"['treatment group', 'dose', 'in']",[],,,,
1147,1140,"among the patients who were receiving an oral corticosteroid at baseline , the dose must have been stable ( ≤ 30 mg per day of prednisone or equivalent ) for at least 2 weeks before the first dose of a trial drug .",在基线时接受口服皮质类固醇治疗的患者中，剂量必须在试验药物首次给药前至少 2 周保持稳定（≤ 30 mg/d 泼尼松或同等药物）。,0.4666666666666667,"['corticosteroid', 'must', 'equivalent', 'who', 'baseline', '2', 'oral', 'prednisone', 'trial', 'drug', 'at', 'dose', 'have', 'before', 'first']","['corticosteroid', 'baseline', '2', 'prednisone', 'drug', 'dose', 'before']",1140,"['在接受口服甲状腺素的患者中,该剂量必须在试用药物的第一剂量前至少2周保持稳定(每日<30毫克或同等剂量)。']",0.3333333333333333,"['corticosteroid', 'must', 'equivalent', 'who', 'baseline', '2', 'oral', 'prednisone', 'trial', 'drug', 'at', 'dose', 'have', 'before', 'first']","['2', 'drug', 'dose', 'before', 'first']",1140,在开始服用口服类固醇药物的患者中，剂量必须稳定（≤30毫克每天的肾上腺皮质醇或等效剂量）至少2周，然后才能开始服用试验药物。,0.2,"['corticosteroid', 'must', 'equivalent', 'who', 'baseline', '2', 'oral', 'prednisone', 'trial', 'drug', 'at', 'dose', 'have', 'before', 'first']","['2', 'drug', 'dose']",,,,
1148,1141,"the corticosteroid dose remained unaltered through week 6 of the trial , and after week 6 , the dose was tapered intermittently if the patient had a response .",皮质类固醇的剂量在试验的第 6 周内保持不变，并且在第 6 周后，如果患者有反应，则剂量会间歇性地减少。,0.6666666666666666,"['corticosteroid', 'response', 'week', 'patient', 'after', 'trial', 'dose', 'if', 'and']","['corticosteroid', 'response', 'week', 'patient', 'after', 'dose']",1141,"['甲状腺素的剂量在试验的第6周内保持不变,如果患者有反应,则在第6周后,剂量被中间切断。']",0.5555555555555556,"['corticosteroid', 'response', 'week', 'patient', 'after', 'trial', 'dose', 'if', 'and']","['response', 'week', 'patient', 'after', 'dose']",1141,在整个试验的6周内，皮质醇剂量保持不变，6周后，如果患者有反应，则剂量会间歇性下降。,0.5555555555555556,"['corticosteroid', 'response', 'week', 'patient', 'after', 'trial', 'dose', 'if', 'and']","['response', 'week', 'patient', 'after', 'dose']",,,,
1149,1142,patients who had a loss of response during the tapering period were permitted to receive the baseline corticosteroid dose one time only before tapering was restarted .,在减量期间失去反应的患者仅在重新开始减量前允许接受一次基线皮质类固醇剂量。,0.6,"['corticosteroid', 'period', 'who', 'baseline', 'time', 'loss', 'response', 'dose', 'before', 'to']","['corticosteroid', 'period', 'baseline', 'response', 'dose', 'before']",1142,['在切割期间患有反应损失的患者只能在切割重新启动之前一次接收基因类固醇剂量。'],0.5,"['corticosteroid', 'period', 'who', 'baseline', 'time', 'loss', 'response', 'dose', 'before', 'to']","['period', 'loss', 'response', 'dose', 'before']",1142,"Patients who had a loss of response during the tapering period were permitted to receive the baseline corticosteroid dose one time only before tapering was restarted.

Chinese:

在逐渐减少期间对病人失去反应的许可仅在重新开始逐渐减少前仅接受基线皮质激素剂量。",0.5,"['corticosteroid', 'period', 'who', 'baseline', 'time', 'loss', 'response', 'dose', 'before', 'to']","['period', 'baseline', 'response', 'dose', 'before']",,,,
1150,1143,"in accordance with the protocol , patients in whom the corticosteroid dose could not be tapered were withdrawn from the trial and were considered to have treatment failures with respect to each of the outcomes .",根据方案，皮质类固醇剂量不能逐渐减少的患者退出试验，并被认为在每项结果方面均治疗失败。,0.3333333333333333,"['corticosteroid', 'protocol', 'be', 'treatment', 'trial', 'with', 'respect', 'dose', 'have', 'each', 'in', 'and']","['corticosteroid', 'be', 'treatment', 'dose']",1143,"['根据该议定书,患有甲状腺素剂量无法吸收的患者被撤销,并被认为对每个结果都有治疗失败。']",0.3333333333333333,"['corticosteroid', 'protocol', 'be', 'treatment', 'trial', 'with', 'respect', 'dose', 'have', 'each', 'in', 'and']","['protocol', 'treatment', 'dose', 'have']",1143,根据协议，那些无法削减糖皮质激素剂量的病人被从试验中撤出，并被认为在每一个结果方面都失败了治疗。,0.3333333333333333,"['corticosteroid', 'protocol', 'be', 'treatment', 'trial', 'with', 'respect', 'dose', 'have', 'each', 'in', 'and']","['protocol', 'be', 'treatment', 'dose']",,,,
1151,1144,patients who were not receiving corticosteroids at baseline but who initiated corticosteroid treatment during the trial were withdrawn because of lack of efficacy .,基线时未接受皮质类固醇但在试验期间开始皮质类固醇治疗的患者因缺乏疗效而退出。,0.5,"['corticosteroid', 'lack', 'who', 'baseline', 'treatment', 'trial', 'efficacy', 'but']","['corticosteroid', 'baseline', 'treatment', 'but']",1144,['未在基线上服用甲状腺素但在试验期间开始治疗甲状腺素的患者因缺乏有效性而被撤回。'],0.5,"['corticosteroid', 'lack', 'who', 'baseline', 'treatment', 'trial', 'efficacy', 'but']","['baseline', 'treatment', 'efficacy', 'but']",1144,Patients who were not receiving corticosteroids at baseline but who initiated corticosteroid treatment during the trial were withdrawn because of lack of efficacy.,0.0,"['corticosteroid', 'lack', 'who', 'baseline', 'treatment', 'trial', 'efficacy', 'but']",[],,,,
1152,1145,patients who were receiving an aminosalicylate or an immunomodulator at baseline maintained stable doses throughout the trial .,在基线时接受氨基水杨酸盐或免疫调节剂的患者在整个试验期间保持稳定的剂量。,0.25,"['immunomodulator', 'who', 'baseline', 'trial']",['baseline'],1145,['在基线上服用氨基酸或免疫调节剂的患者在整个测试期间保持了稳定的剂量。'],0.25,"['immunomodulator', 'who', 'baseline', 'trial']",['baseline'],1145,"Patients who were receiving an aminosalicylate or an immunomodulator at baseline maintained stable doses throughout the trial.

Chinese:

在本次试验中，起始时接受氨基苯甲酸盐或免疫调节剂治疗的患者维持稳定剂量。",0.0,"['immunomodulator', 'who', 'baseline', 'trial']",[],,,,
1153,1146,"adverse events ( classified according to the Medical Dictionary for Regulatory Activities , version 21.0 ) , results of laboratory tests and safety assessments , and concomitant medications were recorded throughout the trial .",不良事件（根据《监管活动医学词典》21.0 版分类）、实验室测试和安全性评估的结果以及合并用药在整个试验过程中均有记录。,0.2222222222222222,"['safety', 'version', 'medical', 'concomitant', 'adverse', 'trial', 'laboratory', 'classified', 'and']","['safety', 'laboratory']",1146,"['副作用(根据《医学规则活动词典》第21版分类),实验室测试和安全评估的结果以及同步药物在整个测试中被记录。']",0.2222222222222222,"['safety', 'version', 'medical', 'concomitant', 'adverse', 'trial', 'laboratory', 'classified', 'and']","['safety', 'laboratory']",1146,"adverse events ( classified according to the Medical Dictionary for Regulatory Activities , version 21.0 ) , results of laboratory tests and safety assessments , and concomitant medications were recorded throughout the trial .

Chinese:
药物不良反应（根据医学药典注册活动版本21.0分类），实验室测试结果和安全评估结果以及与之同时使用的药物在整个试验期间均有记录。",0.3333333333333333,"['safety', 'version', 'medical', 'concomitant', 'adverse', 'trial', 'laboratory', 'classified', 'and']","['safety', 'version', 'laboratory']",,,,
1154,1147,"the total Mayo score was calculated at weeks 14 and 52 , when endoscopy was performed .",在第 14 周和第 52 周进行内窥镜检查时计算 Mayo 总分。,0.0,"['total', 'endoscopy', 'score', 'at', 'and']",[],1147,"['梅奥的总分数在14周和52周计算,当进行内分镜时。']",0.4,"['total', 'endoscopy', 'score', 'at', 'and']","['score', 'at']",1147,总的Mayo得分是在14周和52周进行内镜检查时计算的。,0.2,"['total', 'endoscopy', 'score', 'at', 'and']",['total'],,,,
1155,1148,"measurements of the fecal calprotectin level were performed at weeks 14 , 30 , and 52 .",在第 14、30 和 52 周时测量粪便钙卫蛋白水平。,0.25,"['fecal', 'level', 'at', 'and']",['level'],1148,"['在14周、30周和52周内,测量了分子卡尔蛋白素水平。']",0.25,"['fecal', 'level', 'at', 'and']",['level'],1148,在14、30和52周时对粪便钙保护蛋白水平进行了测量。,0.25,"['fecal', 'level', 'at', 'and']",['level'],,,,
1156,1149,IBDQ assessments were performed at weeks 30 and 52 .,IBDQ 评估在第 30 周和第 52 周进行。,0.0,"['at', 'and']",[],1149,['IBDQ评估是在30周和52周进行的。'],0.0,"['at', 'and']",[],1149,"IBDQ assessments were performed at weeks 30 and 52.

Chinese:

IBDQ评估在第30和第52周进行。",0.0,"['at', 'and']",[],,,,
1157,1150,the trial sponsor ( Takeda ) designed the trial in conjunction with the principal academic investigators and provided the trial drugs and placebo .,试验发起人 (Takeda) 与主要学术研究人员一起设计试验并提供试验药物和安慰剂。,0.25,"['placebo', 'sponsor', 'drugs', 'principal', 'trial', 'conjunction', 'with', 'and']","['placebo', 'drugs']",1150,"['试验赞助商(Takeda)与主要学术调查人员共同设计了试验,并提供了试验药物和 placebo。']",0.125,"['placebo', 'sponsor', 'drugs', 'principal', 'trial', 'conjunction', 'with', 'and']",['drugs'],1150,試驗贊助商（譯音：泰克達）與主要學術研究人員共同設計了試驗，並提供了試驗藥物和安慰劑。,0.0,"['placebo', 'sponsor', 'drugs', 'principal', 'trial', 'conjunction', 'with', 'and']",[],,,,
1158,1151,"a clinical research organization ( IQVIA ) , funded by the sponsor , managed all the collection of the data , maintained the trial database in a blinded manner , and performed the data analyses .",由申办方资助的临床研究机构 (IQVIA) 管理所有数据收集，以盲法维护试验数据库，并进行数据分析。,0.3636363636363636,"['organization', 'research', 'database', 'sponsor', 'collection', 'clinical', 'trial', 'manner', 'all', 'by', 'and']","['research', 'collection', 'clinical', 'by']",1151,"['由赞助商资助的临床研究组织(IQVIA)管理了所有数据收集,以盲目的方式维持了测试数据库,并进行了数据分析。']",0.4545454545454545,"['organization', 'research', 'database', 'sponsor', 'collection', 'clinical', 'trial', 'manner', 'all', 'by', 'and']","['organization', 'research', 'collection', 'clinical', 'by']",1151,一个临床研究组织（IQVIA），由赞助商资助，管理所有数据的收集，以盲目方式维护试验数据库，并进行数据分析。,0.4545454545454545,"['organization', 'research', 'database', 'sponsor', 'collection', 'clinical', 'trial', 'manner', 'all', 'by', 'and']","['organization', 'research', 'collection', 'clinical', 'by']",,,,
1159,1152,"the trial investigators , the participating institutions , the clinical research organization , and the sponsor agreed to maintain data confidentiality .",试验研究者、参与机构、临床研究组织和申办方同意对数据保密。,0.5,"['organization', 'confidentiality', 'research', 'data', 'sponsor', 'maintain', 'clinical', 'trial', 'to', 'and']","['organization', 'confidentiality', 'research', 'data', 'clinical']",1152,['调查调查人员、参与机构、临床研究组织和赞助商同意保持数据的机密性。'],0.4,"['organization', 'confidentiality', 'research', 'data', 'sponsor', 'maintain', 'clinical', 'trial', 'to', 'and']","['organization', 'research', 'data', 'clinical']",1152,试验的调查人员、参与机构、临床研究组织和赞助商都同意保密数据。,0.5,"['organization', 'confidentiality', 'research', 'data', 'sponsor', 'maintain', 'clinical', 'trial', 'to', 'and']","['organization', 'confidentiality', 'research', 'data', 'clinical']",,,,
1160,1153,the initial draft of the manuscript was written by one of the authors employed by the sponsor in collaboration with the first and last authors .,手稿的初稿由申办方聘请的一位作者与第一作者和最后一位作者合作撰写。,0.5,"['sponsor', 'initial', 'manuscript', 'collaboration', 'with', 'by', 'and', 'first', 'employed', 'draft']","['initial', 'manuscript', 'collaboration', 'by', 'first']",1153,['手稿的初始草案是由赞助商与第一和最后的作者合作雇用的作者之一写的。'],0.5,"['sponsor', 'initial', 'manuscript', 'collaboration', 'with', 'by', 'and', 'first', 'employed', 'draft']","['initial', 'manuscript', 'collaboration', 'by', 'first']",1153,第一个草稿是由赞助商雇佣的一个作者与第一作者和最后一作者共同完成的。,0.2,"['sponsor', 'initial', 'manuscript', 'collaboration', 'with', 'by', 'and', 'first', 'employed', 'draft']","['by', 'first']",,,,
1161,1154,"a medical writer , funded by the sponsor , assisted with the preparation of subsequent drafts .",一位由申办者资助的医学作家协助准备了后续的草稿。,0.4285714285714285,"['preparation', 'sponsor', 'medical', 'writer', 'subsequent', 'with', 'by']","['preparation', 'sponsor', 'by']",1154,"['由赞助商资助的医学作家,协助下列草案的编制。']",0.1428571428571428,"['preparation', 'sponsor', 'medical', 'writer', 'subsequent', 'with', 'by']",['by'],1154,一位医疗作家，由赞助商资助，协助准备后续草稿。,0.2857142857142857,"['preparation', 'sponsor', 'medical', 'writer', 'subsequent', 'with', 'by']","['preparation', 'by']",,,,
1162,1155,"all the authors interpreted the data , contributed to subsequent drafts , and made the decision to submit the manuscript for publication .",所有作者都解释了数据，为随后的草稿做出了贡献，并做出了投稿发表的决定。,0.375,"['data', 'publication', 'manuscript', 'subsequent', 'decision', 'all', 'to', 'and']","['data', 'publication', 'decision']",1155,"['所有作者都解释了数据,为随后的草案做出了贡献,并决定提交手稿出版。']",0.5,"['data', 'publication', 'manuscript', 'subsequent', 'decision', 'all', 'to', 'and']","['data', 'publication', 'manuscript', 'decision']",1155,所有作者都对数据进行了解读，对随后的草稿做出了贡献，并决定将手稿提交给出版社。,0.5,"['data', 'publication', 'manuscript', 'subsequent', 'decision', 'all', 'to', 'and']","['data', 'publication', 'manuscript', 'decision']",,,,
1163,1156,the academic authors had access to the data and vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol .,学术作者可以访问数据并保证数据的准确性和完整性以及试验对方案的忠实度。,0.375,"['fidelity', 'data', 'accuracy', 'protocol', 'access', 'trial', 'completeness', 'and']","['data', 'accuracy', 'completeness']",1156,"['学术作家可以访问数据,并为数据的准确性和完整性以及审判对议定书的忠诚度提供服务。']",0.625,"['fidelity', 'data', 'accuracy', 'protocol', 'access', 'trial', 'completeness', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness']",1156,学术作者们有权访问数据，并且能够保证数据的准确性和完整性，以及实验的忠实性。,0.5,"['fidelity', 'data', 'accuracy', 'protocol', 'access', 'trial', 'completeness', 'and']","['fidelity', 'data', 'accuracy', 'completeness']",,,,
1164,1157,we performed a prespecified sensitivity analysis of the primary efficacy outcome that used a hybrid imputation approach to assess the effect of discontinuation under different missing data mechanisms .,我们对主要疗效结果进行了预先指定的敏感性分析，该分析使用混合插补方法来评估不同缺失数据机制下停药的影响。,0.3571428571428571,"['approach', 'hybrid', 'data', 'analysis', 'outcome', 'primary', 'effect', 'efficacy', 'assess', 'sensitivity', 'that', 'to', 'missing', 'we']","['data', 'analysis', 'outcome', 'assess', 'missing']",1157,"['我们对初级效率结果进行了预先确定的敏感性分析,使用了混合催化方法来评估不同缺乏数据机制的中断效应。']",0.4285714285714285,"['approach', 'hybrid', 'data', 'analysis', 'outcome', 'primary', 'effect', 'efficacy', 'assess', 'sensitivity', 'that', 'to', 'missing', 'we']","['data', 'analysis', 'outcome', 'effect', 'assess', 'missing']",1157,我们对主要疗效指标进行了预先确定的敏感性分析，使用混合插补方法来评估在不同的失踪数据机制下停止的影响。,0.2142857142857142,"['approach', 'hybrid', 'data', 'analysis', 'outcome', 'primary', 'effect', 'efficacy', 'assess', 'sensitivity', 'that', 'to', 'missing', 'we']","['data', 'analysis', 'assess']",,,,
1165,1158,"first , under the assumption that data were not missing at random , missing data for patients who discontinued vedolizumab or adalimumab because of an adverse event or lack of efficacy were imputed as nonresponses .",首先，在数据不是随机缺失的假设下，因不良事件或缺乏疗效而停用 vedolizumab 或 adalimumab 的患者的缺失数据被归因为无反应。,0.4545454545454545,"['lack', 'data', 'who', 'adverse event', 'efficacy', 'random', 'as', 'vedolizumab', 'that', 'missing', 'first']","['data', 'adverse event', 'random', 'missing', 'first']",1158,"['首先,假设数据不是随机缺少的,因不良事件或缺乏有效性而停止Vedolizumab或Adalimumab的患者缺少的数据被视为不响应。']",0.6363636363636364,"['lack', 'data', 'who', 'adverse event', 'efficacy', 'random', 'as', 'vedolizumab', 'that', 'missing', 'first']","['lack', 'data', 'adverse event', 'efficacy', 'random', 'missing', 'first']",1158,"首先，假设数据并非随机缺失，将因不良事件或疗效不佳而终止使用vedolizumab或adalimumab的患者的缺失数据插补为非反应者。

Chinese:
首先，在数据并非随机缺失的假设下，将因不良事件或疗效不佳而终止使用vedolizumab或adalimumab的患者的缺失数据插补为非反应者。",0.4545454545454545,"['lack', 'data', 'who', 'adverse event', 'efficacy', 'random', 'as', 'vedolizumab', 'that', 'missing', 'first']","['data', 'adverse event', 'random', 'missing', 'first']",,,,
1166,1159,"second , under the assumption that data were missing at random , data that were missing for other reasons were imputed with the use of multiple imputation .",其次，在数据随机缺失的假设下，对因其他原因缺失的数据采用多重插补法进行插补。,0.5714285714285714,"['data', 'multiple', 'random', 'with', 'second', 'that', 'missing']","['data', 'random', 'second', 'missing']",1159,"['其次,假设数据是随机缺失的,由于其他原因而缺失的数据是用多种假设来归因的。']",0.5714285714285714,"['data', 'multiple', 'random', 'with', 'second', 'that', 'missing']","['data', 'random', 'second', 'missing']",1159,"Second, data that were missing for other reasons were imputed with the use of multiple imputation, under the assumption that data were missing at random.",0.0,"['data', 'multiple', 'random', 'with', 'second', 'that', 'missing']",[],,,,
1167,1160,this sensitivity analysis was repeated post hoc for the two secondary efficacy outcomes .,事后对两项次要疗效结果重复了这种敏感性分析。,0.25,"['analysis', 'post', 'secondary', 'efficacy', 'sensitivity', 'repeated', 'this', 'two']","['analysis', 'two']",1160,['这种敏感性分析在两次二次有效性结果后重复。'],0.375,"['analysis', 'post', 'secondary', 'efficacy', 'sensitivity', 'repeated', 'this', 'two']","['analysis', 'efficacy', 'two']",1160,这种敏感性分析随后还对两个次要疗效指标进行了重复。,0.25,"['analysis', 'post', 'secondary', 'efficacy', 'sensitivity', 'repeated', 'this', 'two']","['analysis', 'two']",,,,
1168,1161,efficacy was also assessed in prespecified subgroup analyses that were performed on the basis of disease characteristics and previous use of a TNF inhibitor ( yes or no ) .,疗效也在预先指定的亚组分析中进行了评估，这些分析是根据疾病特征和既往使用 TNF 抑制剂（是或否）进行的。,0.1538461538461538,"['inhibitor', 'previous', 'basis', 'no', 'characteristics', 'of disease', 'efficacy', 'subgroup', 'TNF', 'on', 'that', 'and', 'assessed']","['inhibitor', 'characteristics']",1161,['有效性也被评估在基于疾病特征和以前使用TNF抑制剂(是或没有)进行的预定子组分析。'],0.2307692307692307,"['inhibitor', 'previous', 'basis', 'no', 'characteristics', 'of disease', 'efficacy', 'subgroup', 'TNF', 'on', 'that', 'and', 'assessed']","['inhibitor', 'characteristics', 'efficacy']",1161,效力也在预先规定的亚组分析中得到评估，这些亚组分析是基于疾病特征和之前是否使用过TNF抑制剂（是或否）来进行的。,0.1538461538461538,"['inhibitor', 'previous', 'basis', 'no', 'characteristics', 'of disease', 'efficacy', 'subgroup', 'TNF', 'on', 'that', 'and', 'assessed']","['inhibitor', 'characteristics']",,,,
1169,1162,"a total of 1285 patients were screened for eligibility , and 771 were enrolled in the trial , of whom 769 underwent randomization and received at least one dose of vedolizumab ( 383 patients ) or adalimumab ( 386 patients ) .",共有 1285 名患者接受了资格筛选，771 名患者参加了试验，其中 769 名接受了随机分组并接受了至少一剂维多珠单抗（383 名患者）或阿达木单抗（386 名患者）。,0.1666666666666666,"['randomization', 'total', 'trial', 'vedolizumab', 'dose', 'in']",['randomization'],1162,"['总共1285名患者被审查可接受,771名患者被注册,其中769人遭到随机化,并获得至少1剂Vedolizumab(383名患者)或Adalimumab(386名患者)。']",0.1666666666666666,"['randomization', 'total', 'trial', 'vedolizumab', 'dose', 'in']",['randomization'],1162,共有1285名病人符合纳入研究的条件，其中771名病人随机分配接受vedolizumab（383例）或adalimumab（386例）药物，且均已接受至少一次药物治疗。,0.1666666666666666,"['randomization', 'total', 'trial', 'vedolizumab', 'dose', 'in']",['randomization'],,,,
1170,1163,the characteristics of the patients were generally similar between the treatment groups ( Table 1 ) .,治疗组之间患者的特征大体相似（表 1）。,0.8,"['table', '1', 'treatment', 'characteristics', 'similar']","['table', '1', 'treatment', 'characteristics']",1163,['患者的特性一般在治疗组之间相似(图1)。'],0.6,"['table', '1', 'treatment', 'characteristics', 'similar']","['1', 'treatment', 'characteristics']",1163,病人的特征在治疗组中通常是相似的（表1）。,1.0,"['table', '1', 'treatment', 'characteristics', 'similar']","['table', '1', 'treatment', 'characteristics', 'similar']",,,,
1171,1164,clinical Remission,临床缓解,1.0,"['clinical', 'remission']","['clinical', 'remission']",1164,['临床复发'],0.5,"['clinical', 'remission']",['clinical'],1164,临床缓解,1.0,"['clinical', 'remission']","['clinical', 'remission']",,,,
1172,1165,"a sensitivity analysis to evaluate the effect of withdrawals showed that clinical remission at week 52 occurred in 37.2 % of the patients in the vedolizumab group and in 25.9 % in the adalimumab group ( adjusted difference , 11.3 percentage points ; 95 % CI , 4.6 to 18.0 ) . ( see Tables S3 and S4 in the Supplementary Appendix . )",评估退出影响的敏感性分析显示，在第 52 周时，维多珠单抗组 37.2 % 的患者和阿达木单抗组 25.9 % 的患者出现临床缓解（调整后的差异，11.3 个百分点； 95 % CI，4.6 至 18.0 ) 。 （见补充附录中的表 S3 和 S4。）,0.3333333333333333,"['group', 'percentage', 'appendix', 'analysis', 'supplementary', 'difference', 'clinical', 'week', 'effect', 'remission', 'sensitivity', 'vedolizumab', 'CI', 'S3', 'S4', 'that', 'to', 'and']","['group', 'analysis', 'difference', 'clinical', 'week', 'remission']",1165,"['一项敏感性分析,以评估撤销的效果,表明,在第52周的临床衰退发生在37.2%的患者在Vedolizumab组和25.9%的患者在Adalimumab组(调整差异,11.3个百分点;95%的CI,4.6到18.0)。']",0.3333333333333333,"['group', 'percentage', 'appendix', 'analysis', 'supplementary', 'difference', 'clinical', 'week', 'effect', 'remission', 'sensitivity', 'vedolizumab', 'CI', 'S3', 'S4', 'that', 'to', 'and']","['group', 'analysis', 'difference', 'clinical', 'week', 'effect']",1165,通过敏感性分析来评估患者退出治疗的影响，结果显示在维多利亚莫布（Vedolizumab）组的患者中有37.2%的人在52周内达到临床缓解，而在阿达劳米益姆（Adalimumab）组的患者中有25.9%的人达到临床缓解（调整后差异为11.3个百分点；95%CI，4.6至18.0）。（见补充附件中的表S3和S4。）,0.4444444444444444,"['group', 'percentage', 'appendix', 'analysis', 'supplementary', 'difference', 'clinical', 'week', 'effect', 'remission', 'sensitivity', 'vedolizumab', 'CI', 'S3', 'S4', 'that', 'to', 'and']","['group', 'appendix', 'analysis', 'difference', 'clinical', 'week', 'remission', 'and']",,,,
1173,1166,"among the patients who had not previously used a TNF inhibitor , clinical remission at week 52 was observed in 34.2 % in the vedolizumab group and in 24.3 % in the adalimumab group ; among the patients who had previous exposure to a TNF inhibitor other than adalimumab , the corresponding percentages were 20.3 % and 16.0 % ( Figure 1A ) .",在之前未使用过 TNF 抑制剂的患者中，维多珠单抗组 34.2% 和阿达木单抗组 24.3% 在第 52 周观察到临床缓解；在既往接触过阿达木单抗以外的 TNF 抑制剂的患者中，相应的百分比分别为 20.3% 和 16.0%（图 1A）。,0.4285714285714285,"['group', 'inhibitor', 'corresponding', 'who', 'exposure', 'figure', 'previous', 'clinical', 'week', 'remission', 'vedolizumab', 'at', 'TNF', 'and']","['group', 'inhibitor', 'corresponding', 'clinical', 'week', 'remission']",1166,"['在未使用 TNF 抑制剂的患者中,在第 52 周,在 Vedolizumab 群体中有 34.2% 和 Adalimumab 群体中有 24.3% 的临床衰退;在未使用 TNF 抑制剂而不是 Adalimumab 的患者中,相应的百分比为 20.3% 和 16.0% (图 1A ) 。']",0.4285714285714285,"['group', 'inhibitor', 'corresponding', 'who', 'exposure', 'figure', 'previous', 'clinical', 'week', 'remission', 'vedolizumab', 'at', 'TNF', 'and']","['group', 'inhibitor', 'corresponding', 'clinical', 'week', 'and']",1166,在以前没有使用过TNF抑制剂的患者中，维多利亚布美泊的临床缓解率在52周时观察到34.2%，而达到24.3%的是adalimumab组。 在以前接触过除adalimumab以外的TNF抑制剂的患者中，相应的百分比分别为20.3%和16.0%（图1A）。,0.5,"['group', 'inhibitor', 'corresponding', 'who', 'exposure', 'figure', 'previous', 'clinical', 'week', 'remission', 'vedolizumab', 'at', 'TNF', 'and']","['group', 'inhibitor', 'corresponding', 'clinical', 'week', 'remission', 'and']",,,,
1174,1167,"durable clinical remission occurred in 18.3 % of the patients ( 70 of 383 ) in the vedolizumab group and in 11.9 % ( 46 of 386 ) in the adalimumab group ( difference , 6.3 percentage points ; 95 % CI , 1.3 to 11.3 ) .",维多珠单抗组 18.3% 的患者（383 人中的 70 人）和阿达木单抗组 11.9% 的患者（386 人中的 46 人）实现了持久临床缓解（差异，6.3 个百分点；95% CI，1.3 至 11.3）。,0.4444444444444444,"['group', 'percentage', 'difference', 'clinical', 'remission', 'vedolizumab', 'CI', 'to', 'and']","['group', 'difference', 'clinical', 'remission']",1167,"['持久的临床衰退发生在 18.3% 的患者(70 的 383 )在 vedolizumab 组和 11.9% ( 46 的 386 )在 adalimumab 组(差异, 6.3 个百分点 ; 95 % CI, 1.3 到 11.3 ) 。']",0.3333333333333333,"['group', 'percentage', 'difference', 'clinical', 'remission', 'vedolizumab', 'CI', 'to', 'and']","['group', 'difference', 'clinical']",1167,在vedolizumab组的患者中，18.3%（70/383）的患者出现了持续的临床缓解，而在adalimumab组的患者中，11.9%（46/386）的患者出现了持续的临床缓解（差异为6.3个百分点；95%CI，1.3至11.3）。,0.5555555555555556,"['group', 'percentage', 'difference', 'clinical', 'remission', 'vedolizumab', 'CI', 'to', 'and']","['group', 'difference', 'clinical', 'remission', 'and']",,,,
1175,1168,endoscopic Improvement,内窥镜改善,1.0,['improvement'],['improvement'],1168,['内分泌改善'],1.0,['improvement'],['improvement'],1168,"Endoscopic improvement refers to the process of making changes to the endoscope in order to improve its performance. This may involve making changes to the design of the endoscope, or to the way in which it is used.",0.0,['improvement'],[],,,,
1176,1169,"a sensitivity analysis to evaluate the effect of withdrawals showed that endoscopic improvement at week 52 occurred in 46.8 % of the patients in the vedolizumab group and in 33.6 % in the adalimumab group ( adjusted difference , 13.2 percentage points ; 95 % CI , 6.0 to 20.3 ) .",评估停药影响的敏感性分析显示，在第 52 周时，维多珠单抗组 46.8 % 的患者和阿达木单抗组 33.6 % 的患者发生了内镜改善（调整后的差异，13.2 个百分点； 95 % CI，6.0 至 20.3 ) 。,0.3571428571428571,"['group', 'percentage', 'improvement', 'analysis', 'difference', 'week', 'effect', 'sensitivity', 'vedolizumab', 'CI', 'that', 'in', 'to', 'and']","['group', 'improvement', 'analysis', 'difference', 'week']",1169,"['一项敏感性分析,以评估撤销的效果,表明52周内内分泌改善发生在46.8%的病人在Vedolizumab群体和33.6%在Adalimumab群体(调整差异,13.2个百分点;95%的CI,6.0到20.3)。']",0.4285714285714285,"['group', 'percentage', 'improvement', 'analysis', 'difference', 'week', 'effect', 'sensitivity', 'vedolizumab', 'CI', 'that', 'in', 'to', 'and']","['group', 'improvement', 'analysis', 'difference', 'week', 'effect']",1169,通过对撤回患者进行敏感性分析来评估撤回的影响，发现52周时，46.8％的vedolizumab治疗组患者和33.6％的adalimumab治疗组患者出现了内镜改善（调整后的差异为13.2个百分点；95％CI，6.0至20.3）。,0.3571428571428571,"['group', 'percentage', 'improvement', 'analysis', 'difference', 'week', 'effect', 'sensitivity', 'vedolizumab', 'CI', 'that', 'in', 'to', 'and']","['group', 'improvement', 'analysis', 'difference', 'week']",,,,
1177,1170,"among the patients who had not previously used a TNF inhibitor , endoscopic improvement at week 52 occurred in 43.1 % in the vedolizumab group and in 29.5 % in the adalimumab group , and among the patients who had previous exposure to a TNF inhibitor other than adalimumab , the corresponding percentages were 26.6 % and 21.0 % ( Figure 1B ) .",在既往未使用过 TNF 抑制剂的患者中，第 52 周内镜下改善发生率在维多珠单抗组为 43.1 %，在阿达木单抗组为 29.5 %，在既往使用过阿达木单抗以外的 TNF 抑制剂的患者中，相应的百分比为 26.6% 和 21.0%（图 1B）。,0.3846153846153846,"['group', 'inhibitor', 'corresponding', 'improvement', 'who', 'exposure', 'figure', 'previous', 'week', 'vedolizumab', 'at', 'TNF', 'and']","['group', 'inhibitor', 'corresponding', 'improvement', 'week']",1170,"['在未使用 TNF 抑制剂的患者中,在第 52 周内,内分泌改善发生在 vedolizumab 群体中的 43.1% 和 adalimumab 群体中的 29.5%,并且在以前接触 TNF 抑制剂而不是 adalimumab 的患者中,相应的百分比为 26.6% 和 21.0% (图 1B ) 。']",0.4615384615384615,"['group', 'inhibitor', 'corresponding', 'improvement', 'who', 'exposure', 'figure', 'previous', 'week', 'vedolizumab', 'at', 'TNF', 'and']","['group', 'inhibitor', 'corresponding', 'improvement', 'week', 'and']",1170,在以前未使用过TNF抑制剂的患者中，第52周内的内镜改善率为43.1%，而在使用过除了adalimumab以外的TNF抑制剂的患者中，对应的比例分别为26.6%和21.0%（图1B）。,0.3846153846153846,"['group', 'inhibitor', 'corresponding', 'improvement', 'who', 'exposure', 'figure', 'previous', 'week', 'vedolizumab', 'at', 'TNF', 'and']","['inhibitor', 'corresponding', 'improvement', 'week', 'and']",,,,
1178,1171,the median change in the oral corticosteroid dose from baseline to week 52 was -10.0 mg in the vedolizumab group and -7.0 mg in the adalimumab group .,从基线到第 52 周，口服皮质类固醇剂量的中位变化在维多珠单抗组中为 -10.0 mg，在阿达木单抗组中为 -7.0 mg。,0.5454545454545454,"['group', 'corticosteroid', 'median', 'baseline', 'oral', 'week', 'change', 'vedolizumab', 'dose', 'to', 'and']","['group', 'corticosteroid', 'baseline', 'week', 'change', 'dose']",1171,['从基线到52周的口服甲状腺素剂量中间变化是10.0 mg在Vedolizumab组和7.0 mg在Adalimumab组。'],0.4545454545454545,"['group', 'corticosteroid', 'median', 'baseline', 'oral', 'week', 'change', 'vedolizumab', 'dose', 'to', 'and']","['group', 'baseline', 'week', 'change', 'dose']",1171,在基线到第52周的口服皮质激素剂量中位数变化为vedolizumab组为-10.0mg，adalimumab组为-7.0mg。,0.4545454545454545,"['group', 'corticosteroid', 'median', 'baseline', 'oral', 'week', 'change', 'vedolizumab', 'dose', 'to', 'and']","['group', 'baseline', 'week', 'change', 'dose']",,,,
1179,1172,"the percentage of patients who were in clinical remission at week 52 and who also had a subscore of 0 on both the rectal bleeding and endoscopic components of the Mayo scale was 22.2 % ( 85 of 383 ) in the vedolizumab group and 14.0 % ( 54 of 386 ) in the adalimumab group ( difference , 8.2 percentage points ; 95 % CI , 2.8 to 13.5 ) .",在第 52 周达到临床缓解并且梅奥量表的直肠出血和内窥镜检查项目子评分均为 0 的患者百分比在维多珠单抗组为 22.2 %（ 383 人中的 85 人）和 14.0 %（ 54 人） 386）在阿达木单抗组（差异，8.2 个百分点；95% CI，2.8 至 13.5）。,0.4666666666666667,"['bleeding', 'group', 'percentage', 'who', 'scale', 'difference', 'rectal', 'clinical', 'week', 'remission', 'vedolizumab', 'at', 'CI', 'to', 'and']","['bleeding', 'group', 'scale', 'difference', 'clinical', 'week', 'remission']",1172,"['在第52周临床衰退的患者的百分比,并且在梅奥尺度的直肠出血和内分泌组成部分的下分为0的百分比为22.2%(383分之85分)在维多利苏马布群体和14.0%(386分之54分)在阿达利苏马布群体(差异、8.2分点、95%CI、2.8至13,5分)。']",0.4,"['bleeding', 'group', 'percentage', 'who', 'scale', 'difference', 'rectal', 'clinical', 'week', 'remission', 'vedolizumab', 'at', 'CI', 'to', 'and']","['bleeding', 'group', 'percentage', 'difference', 'clinical', 'week']",1172,在第52周时，与阿达劳米布组相比，维多利祖玛组患者临床缓解的比例为22.2%（85/383），而且经过直肠出血和内镜检查的Mayo分数均为0的患者比例为14.0%（54/386）（差异为8.2个百分点；95% CI，2.8至13.5）。,0.4666666666666667,"['bleeding', 'group', 'percentage', 'who', 'scale', 'difference', 'rectal', 'clinical', 'week', 'remission', 'vedolizumab', 'at', 'CI', 'to', 'and']","['bleeding', 'group', 'difference', 'clinical', 'week', 'remission', 'and']",,,,
1180,1173,patient Quality of Life,患者生活质量,1.0,"['patient', 'quality of life']","['patient', 'quality of life']",1173,['患者生活质量'],1.0,"['patient', 'quality of life']","['patient', 'quality of life']",1173,病人的生活质量,1.0,"['patient', 'quality of life']","['patient', 'quality of life']",,,,
1181,1174,"quality of life improved from baseline to week 52 ( as indicated by an increase of ≥ 16 points in the IBDQ score ) in 52.0 % of the patients in the vedolizumab group and in 42.2 % in the adalimumab group ( difference , 9.7 percentage points ; 95 % CI , 2.7 to 16.7 ) .",维多珠单抗组 52.0 % 的患者和阿达木单抗组 42.2 % 的患者的生活质量从基线到第 52 周有所改善（如 IBDQ 评分增加 ≥ 16 分所示）（差异， 9.7 个百分点； 95 %CI，2.7 至 16.7)。,0.4615384615384615,"['group', 'percentage', 'baseline', 'difference', 'week', 'quality of life', 'score', 'increase', 'vedolizumab', 'CI', 'by', 'to', 'and']","['group', 'baseline', 'difference', 'week', 'quality of life', 'by']",1174,"['从基线到52周的生活质量改善(根据IBDQ分数增加 ≥16点)在52.0%的病人在Vedolizumab组和42.2%在Adalimumab组(差异,9.7个百分点;95%的CI,2.7到16.7)。']",0.5384615384615384,"['group', 'percentage', 'baseline', 'difference', 'week', 'quality of life', 'score', 'increase', 'vedolizumab', 'CI', 'by', 'to', 'and']","['group', 'baseline', 'difference', 'week', 'quality of life', 'score', 'by']",1174,自基线起，52周内（通过IBDQ评分达到16分以上的患者占52.0%），生活质量在vedolizumab组显著改善，而在adalimumab组仅为42.2%（差异为9.7个百分点；95% CI，2.7-16.7）。,0.5384615384615384,"['group', 'percentage', 'baseline', 'difference', 'week', 'quality of life', 'score', 'increase', 'vedolizumab', 'CI', 'by', 'to', 'and']","['group', 'baseline', 'difference', 'week', 'quality of life', 'by', 'and']",,,,
1182,1175,histologic Remission,组织学缓解,1.0,['remission'],['remission'],1175,['歇斯底里复发'],0.0,['remission'],[],1175,"histologic Remission

Chinese:
组织学缓解",1.0,['remission'],['remission'],,,,
1183,1176,"minimal histologic disease activity as indicated by a Geboes score lower than 3.2 at week 52 was observed in 33.4 % of the patients in the vedolizumab group and in 13.7 % in the adalimumab group ( difference , 19.6 percentage points ; 95 % CI , 13.8 to 25.5 ) .",在第 52 周时，维多珠单抗组 33.4% 的患者和阿达木单抗组 13.7% 的患者观察到 Geboes 评分低于 3.2 表示的最小组织学疾病活动（差异，19.6 个百分点；95% CI，13.8 至 25.5） ) 。,0.4666666666666667,"['group', 'percentage', 'disease', 'activity', 'difference', 'lower', 'week', 'minimal', 'score', 'vedolizumab', 'at', 'CI', 'by', 'to', 'and']","['group', 'disease', 'activity', 'difference', 'week', 'at', 'to']",1176,"['根据 Geboes 得分低于 3.2 在 52 周,在 Vedolizumab 群体的 33.4% 患者和 Adalimumab 群体的 13.7% 患者(差异, 19.6 个百分点, 95 % CI, 13.8 到 25.5 ) 观察。']",0.3333333333333333,"['group', 'percentage', 'disease', 'activity', 'difference', 'lower', 'week', 'minimal', 'score', 'vedolizumab', 'at', 'CI', 'by', 'to', 'and']","['group', 'difference', 'week', 'at', 'to']",1176,"在52周时，通过Geboes评分小于3.2表示出达到了最小组织病情活动的病人在vedolizumab治疗组中占33.4%，而在adalimumab治疗组中占13.7%（差异为19.6个百分点；95%CI，13.8至25.5）。

Chinese:

在52周时，通过Geboes评分小于3.2表示出达到了最小组织病情活动的病人在vedolizumab治疗组中占33.4%，而在adalimumab治疗组中占13.7%（差异为19.6个百分点；95%CI，13.8至25.5）。",0.5333333333333333,"['group', 'percentage', 'disease', 'activity', 'difference', 'lower', 'week', 'minimal', 'score', 'vedolizumab', 'at', 'CI', 'by', 'to', 'and']","['group', 'disease', 'activity', 'difference', 'week', 'at', 'to', 'and']",,,,
1184,1177,clinical Response,临床反应,1.0,"['clinical', 'response']","['clinical', 'response']",1177,['临床回应'],0.5,"['clinical', 'response']",['clinical'],1177,临床反应,1.0,"['clinical', 'response']","['clinical', 'response']",,,,
1185,1178,the percentages of patients who had a clinical response according to the partial Mayo score are shown in Figure 3 .,图 3 显示了根据部分 Mayo 评分具有临床反应的患者百分比。,0.25,"['who', 'figure', 'clinical', 'response', 'partial', '3', 'score', 'to']","['clinical', 'response']",1178,['根据部分梅奥分数进行临床反应的患者的百分比显示在图3中。'],0.375,"['who', 'figure', 'clinical', 'response', 'partial', '3', 'score', 'to']","['clinical', 'response', 'score']",1178,根据部分梅耶评分，病人的临床反应百分比如图3所示。,0.25,"['who', 'figure', 'clinical', 'response', 'partial', '3', 'score', 'to']","['clinical', 'response']",,,,
1186,1179,adverse events occurred in 62.7 % of the patients ( 240 of 383 ) in the vedolizumab group and in 69.2 % ( 267 of 386 ) in the adalimumab group ( Table 2 ) .,维多珠单抗组 62.7%（383 人中的 240 人）和阿达木单抗组 69.2%（386 人中的 267 人）发生了不良事件（表 2）。,0.4285714285714285,"['group', 'table', '2', 'adverse', 'vedolizumab', 'in', 'and']","['group', 'table', '2']",1179,['副作用发生在62.7%的患者(240的383)在Vedolizumab群体和69.2%(267的386)在Adalimumab群体(图2)。'],0.2857142857142857,"['group', 'table', '2', 'adverse', 'vedolizumab', 'in', 'and']","['group', '2']",1179,在vedolizumab组的患者中，有62.7%（240/383）发生了不良事件，在adalimumab组的患者中，有69.2%（267/386）发生了不良事件（表2）。,0.4285714285714285,"['group', 'table', '2', 'adverse', 'vedolizumab', 'in', 'and']","['group', 'table', '2']",,,,
1187,1180,the most frequent adverse events are presented in Table S6 .,表 S6 列出了最常见的不良事件。,0.25,"['table', 'adverse', 'in', 'frequent']",['table'],1180,['最常见的不良事件在表 S6 中呈现。'],0.25,"['table', 'adverse', 'in', 'frequent']",['table'],1180,表S6中列出了最常见的不良事件。,0.25,"['table', 'adverse', 'in', 'frequent']",['table'],,,,
1188,1181,serious adverse events occurred in 11.0 % of the patients ( 42 of 383 ) in the vedolizumab group and in 13.7 % ( 53 of 386 ) in the adalimumab group ( Table S7 in the Supplementary Appendix ) .,严重不良事件发生在维多珠单抗组 11.0% 的患者（383 例中的 42 例）和阿达木单抗组 13.7%（386 例中的 53 例）（补充附录表 S7）。,0.2222222222222222,"['group', 'appendix', 'table', 'supplementary', 'adverse', 'vedolizumab', 'serious', 'in', 'and']","['group', 'table']",1181,['严重的副作用发生在病人群中的11.0%(383人中42人)和病人群中的13.7%(386人中53人)(附件中的S7表)。'],0.3333333333333333,"['group', 'appendix', 'table', 'supplementary', 'adverse', 'vedolizumab', 'serious', 'in', 'and']","['group', 'appendix', 'table']",1181,严重的不良事件发生在vedolizumab组11.0%的患者(42/383)中，在adalimumab组13.7%(53/386)中。(表S7在补充附录中)。,0.2222222222222222,"['group', 'appendix', 'table', 'supplementary', 'adverse', 'vedolizumab', 'serious', 'in', 'and']","['group', 'table']",,,,
1189,1182,no patient received a diagnosis of progressive multifocal leukoencephalopathy .,没有患者被诊断为进行性多灶性脑白质病。,0.6666666666666666,"['progressive', 'diagnosis', 'patient']","['diagnosis', 'patient']",1182,['没有一个患者被诊断为进步多点白血病。'],0.6666666666666666,"['progressive', 'diagnosis', 'patient']","['diagnosis', 'patient']",1182,没有病人收到进行性多发性白质脑病的诊断。,0.6666666666666666,"['progressive', 'diagnosis', 'patient']","['diagnosis', 'patient']",,,,
1190,1183,one patient in the vedolizumab group died because of an exacerbation of ulcerative colitis and postoperative complications that were considered by the trial site investigator to be unrelated to vedolizumab or adalimumab ( Table 2 ) .,维多珠单抗组的一名患者死于溃疡性结肠炎恶化和术后并发症，试验现场研究者认为这些并发症与维多珠单抗或阿达木单抗无关（表 2）。,0.5333333333333333,"['group', 'site', 'table', '2', 'investigator', 'exacerbation', 'be', 'postoperative', 'ulcerative colitis', 'patient', 'trial', 'vedolizumab', 'that', 'by', 'and']","['group', 'site', 'table', '2', 'investigator', 'exacerbation', 'ulcerative colitis', 'patient']",1183,"['一个病人在Vedolizumab群体死于严重的<unk>疹和手术后并发症,被试验现场调查人员认为与Vedolizumab或Adalimumab无关(图2)。']",0.3333333333333333,"['group', 'site', 'table', '2', 'investigator', 'exacerbation', 'be', 'postoperative', 'ulcerative colitis', 'patient', 'trial', 'vedolizumab', 'that', 'by', 'and']","['group', 'site', '2', 'be', 'patient']",1183,一名在vedolizumab组的患者因ulcerative colitis的加重和手术后并发症死亡，试验现场调查员认为这与vedolizumab或adalimumab无关(表2)。,0.4,"['group', 'site', 'table', '2', 'investigator', 'exacerbation', 'be', 'postoperative', 'ulcerative colitis', 'patient', 'trial', 'vedolizumab', 'that', 'by', 'and']","['group', 'site', 'table', '2', 'be', 'patient']",,,,
1191,1184,"as in the VARSITY trial , the ULTRA2 trial maintained blinding and randomization throughout the treatment period .",与 VARSITY 试验一样，ULTRA2 试验在整个治疗期间保持盲法和随机化。,0.5,"['period', 'randomization', 'treatment', 'trial', 'as', 'in']","['period', 'randomization', 'treatment']",1184,"['与VARSITY试验一样,ULTRA2试验在整个治疗期间保持了盲目和随机化。']",0.5,"['period', 'randomization', 'treatment', 'trial', 'as', 'in']","['period', 'randomization', 'treatment']",1184,就像在VARSITY试验中一样，ULTRA2试验在整个治疗期间都保持了盲目性和随机性。,0.5,"['period', 'randomization', 'treatment', 'trial', 'as', 'in']","['period', 'randomization', 'treatment']",,,,
1192,1185,"the higher percentages of patients who had a response to active therapy in the GEMINI 1 trial than in the ULTRA2 trial and our trial may have reflected differences in trial design ; patients who had a clinical response underwent an additional randomization at week 6 in the GEMINI 1 trial , but the patients in the ULTRA2 trial and our trial underwent randomization only at baseline .",GEMINI 1 试验中对积极治疗有反应的患者百分比高于 ULTRA2 试验，我们的试验可能反映了试验设计的差异；在 GEMINI 1 试验中，出现临床反应的患者在第 6 周接受了额外的随机分组，但 ULTRA2 试验和我们的试验中的患者仅在基线时接受了随机分组。,0.8,"['randomization', 'who', 'baseline', '1', 'active', 'therapy', 'clinical', 'response', 'additional', 'week', 'trial', 'design', 'have', 'but', 'to']","['randomization', 'baseline', '1', 'therapy', 'clinical', 'response', 'additional', 'week', 'design', 'have', 'but', 'to']",1185,"['GEMINI 1 试验中对活性治疗的患者比 ULTRA2 试验和我们的试验中更高的百分比可能反映了试验设计的差异;在 GEMINI 1 试验中有临床反应的患者在第 6 周进行了额外的随机化,但在 ULTRA2 试验和我们的试验中患者仅在基线上进行了随机化。']",0.7333333333333333,"['randomization', 'who', 'baseline', '1', 'active', 'therapy', 'clinical', 'response', 'additional', 'week', 'trial', 'design', 'have', 'but', 'to']","['randomization', 'baseline', '1', 'therapy', 'clinical', 'response', 'additional', 'week', 'design', 'have', 'but']",1185,GEMINI 1试验中病人对活动治疗的反应率比ULTRA2试验和我们的试验中高出许多，这可能反映了试验设计上的差异；GEMINI 1试验中，6周时间内对临床反应有效的病人进行了额外的随机分组，但是ULTRA2试验和我们的试验中的病人只在基线时进行了随机分组。,0.8,"['randomization', 'who', 'baseline', '1', 'active', 'therapy', 'clinical', 'response', 'additional', 'week', 'trial', 'design', 'have', 'but', 'to']","['randomization', 'baseline', '1', 'active', 'therapy', 'clinical', 'response', 'additional', 'week', 'design', 'have', 'but']",,,,
1193,1186,"in addition , the ULTRA2 trial and the GEMINI 1 trial included a higher percentage of patients who had previously received treatment with a TNF inhibitor than the VARSITY trial .",此外，与 VARSITY 试验相比，ULTRA2 试验和 GEMINI 1 试验纳入了更高比例的既往接受过 TNF 抑制剂治疗的患者。,0.3,"['inhibitor', 'percentage', 'who', '1', 'addition', 'treatment', 'trial', 'with', 'TNF', 'and']","['inhibitor', '1', 'treatment']",1186,"['此外,ULTRA2测试和GEMINI 1测试包括比VARSITY测试之前接受TNF抑制剂治疗的患者比例更高。']",0.3,"['inhibitor', 'percentage', 'who', '1', 'addition', 'treatment', 'trial', 'with', 'TNF', 'and']","['inhibitor', '1', 'treatment']",1186,此外，ULTRA2试验和GEMINI 1试验包括了更高比例的患者之前曾接受过TNF抑制剂治疗，而VARSITY试验则包括了更低比例的患者。,0.4,"['inhibitor', 'percentage', 'who', '1', 'addition', 'treatment', 'trial', 'with', 'TNF', 'and']","['inhibitor', '1', 'treatment', 'and']",,,,
1194,1187,it is difficult to explain the inconsistency of the results between this secondary remission outcome and the primary remission outcome .,很难解释这种次要缓解结果与主要缓解结果之间的结果不一致。,0.3333333333333333,"['outcome', 'primary', 'secondary', 'remission', 'inconsistency', 'this', 'to', 'and', 'difficult']","['outcome', 'remission', 'difficult']",1187,['很难解释二次投降结果与初级投降结果之间的结果的不一致性。'],0.3333333333333333,"['outcome', 'primary', 'secondary', 'remission', 'inconsistency', 'this', 'to', 'and', 'difficult']","['outcome', 'inconsistency', 'difficult']",1187,这种二级缓解结果与原发性缓解结果之间的结果不一致很难解释。,0.3333333333333333,"['outcome', 'primary', 'secondary', 'remission', 'inconsistency', 'this', 'to', 'and', 'difficult']","['outcome', 'remission', 'difficult']",,,,
1195,1188,"the trial did not require a specific schedule for corticosteroid tapering , which can vary among practitioners .",该试验不需要具体的皮质类固醇逐渐减量时间表，这可能因从业者而异。,0.25,"['corticosteroid', 'schedule', 'trial', 'specific']",['corticosteroid'],1188,"['试验不需要一个特定的日程安排,可在实践者中有所不同。']",0.25,"['corticosteroid', 'schedule', 'trial', 'specific']",['schedule'],1188,该实验不需要对顺式类固醇的削减进行特定的安排，这可能因医师而异。,0.25,"['corticosteroid', 'schedule', 'trial', 'specific']",['schedule'],,,,
1196,1189,"however , this limitation should not have resulted in differential effects in the two treatment groups .",然而，这种限制不应该导致两个治疗组的不同效果。,0.2857142857142857,"['differential', 'treatment', 'limitation', 'have', 'this', 'in', 'two']","['treatment', 'two']",1189,"['然而,这种限制不应在两组治疗中产生差异效应。']",0.2857142857142857,"['differential', 'treatment', 'limitation', 'have', 'this', 'in', 'two']","['treatment', 'two']",1189,然而，这种限制不应导致两种治疗组之间的差异效应。,0.2857142857142857,"['differential', 'treatment', 'limitation', 'have', 'this', 'in', 'two']","['treatment', 'two']",,,,
1197,1190,there were no notable treatment differences between patients who were receiving concomitant immunomodulator therapy and those who were not .,接受伴随免疫调节剂治疗的患者与未接受免疫调节剂治疗的患者之间没有显着的治疗差异。,0.3333333333333333,"['immunomodulator', 'who', 'therapy', 'concomitant', 'treatment', 'and']","['therapy', 'treatment']",1190,['在接受同步免疫调节治疗的患者和未接受的患者之间没有显著的治疗差异。'],0.3333333333333333,"['immunomodulator', 'who', 'therapy', 'concomitant', 'treatment', 'and']","['therapy', 'treatment']",1190,接受共同免疫调节剂治疗的患者与那些没有接受共同免疫调节剂治疗的患者之间没有显著治疗差异。,0.3333333333333333,"['immunomodulator', 'who', 'therapy', 'concomitant', 'treatment', 'and']","['therapy', 'treatment']",,,,
1198,1191,"in the VARSITY trial , a subgroup of patients who had previous use of infliximab or golimumab were enrolled , and therefore the results observed among these patients in the adalimumab group reflect the efficacy in clinical practice among patients who switched to adalimumab from a drug within the same drug class .",在VARSITY试验中，纳入了先前使用过英夫利昔单抗或戈利木单抗的患者亚组，因此在阿达木单抗组的这些患者中观察到的结果反映了临床实践中从同一药物转为阿达木单抗的患者的疗效。毒品类。,0.2857142857142857,"['class', 'who', 'previous', 'reflect', 'clinical', 'trial', 'practice', 'efficacy', 'subgroup', 'drug', 'infliximab', 'therefore', 'to', 'and']","['reflect', 'clinical', 'practice', 'drug']",1191,"['在VARSITY研究中,被列入以前使用Infliximab或Golimumab的患者的子组,因此这些患者在Adalimumab群体中观察到的结果反映了从同一药物类内的药物中转移到Adalimumab的患者在临床实践中的有效性。']",0.3571428571428571,"['class', 'who', 'previous', 'reflect', 'clinical', 'trial', 'practice', 'efficacy', 'subgroup', 'drug', 'infliximab', 'therefore', 'to', 'and']","['reflect', 'clinical', 'practice', 'efficacy', 'drug']",1191,在VARSITY试验中，一个患有既往使用过infliximab或golimumab的患者分组被纳入，因此在adalimumab组观察到的这些患者的结果反映了临床实践中从同一药物类别转换到adalimumab的患者的疗效。,0.2857142857142857,"['class', 'who', 'previous', 'reflect', 'clinical', 'trial', 'practice', 'efficacy', 'subgroup', 'drug', 'infliximab', 'therefore', 'to', 'and']","['reflect', 'clinical', 'practice', 'drug']",,,,
1199,1192,histologic remission was an exploratory outcome of this trial and was assessed with the Geboes score and the Robarts Histopathologic Index score .,组织学缓解是该试验的探索性结果，并通过 Geboes 评分和 Robarts 组织病理学指数评分进行评估。,0.4,"['outcome', 'index', 'exploratory', 'trial', 'score', 'remission', 'with', 'this', 'and', 'assessed']","['outcome', 'index', 'remission', 'this']",1192,"['歇斯底里的回报是这项试验的探索结果,并通过Geboes分数和Robarts Histopathologic Index分数进行评估。']",0.3,"['outcome', 'index', 'exploratory', 'trial', 'score', 'remission', 'with', 'this', 'and', 'assessed']","['outcome', 'score', 'this']",1192,这项试验的组织学缓解是一个探索性的结果，使用Geboes评分和Robarts组织学指数评分来评估。,0.4,"['outcome', 'index', 'exploratory', 'trial', 'score', 'remission', 'with', 'this', 'and', 'assessed']","['outcome', 'index', 'remission', 'this']",,,,
1200,1193,the results for the outcomes of histologic remission were consistent with the findings for clinical remission and endoscopic improvement .,组织学缓解的结果与临床缓解和内镜改善的结果一致。,0.6,"['improvement', 'clinical', 'remission', 'with', 'and']","['improvement', 'clinical', 'remission']",1193,['基因移植的结果与临床移植和内分泌改善的结果一致。'],0.4,"['improvement', 'clinical', 'remission', 'with', 'and']","['improvement', 'clinical']",1193,病理治疗结果与临床治疗结果和内镜检查结果一致。,0.2,"['improvement', 'clinical', 'remission', 'with', 'and']",['clinical'],,,,
1201,1194,few differences were observed between the trial groups in terms of the most commonly reported adverse events .,在最常报告的不良事件方面，试验组之间几乎没有差异。,0.0,"['adverse', 'trial', 'in']",[],1194,"['在审查小组中,在最常见的报告不良事件方面,观察到很少的差异。']",0.0,"['adverse', 'trial', 'in']",[],1194,在常见的不良事件方面，试验组之间几乎没有观察到任何差异。,0.0,"['adverse', 'trial', 'in']",[],,,,
1202,1195,the dosing regimens selected for this trial were based on a conservative approach and use according to U.S. labels .,为该试验选择的给药方案是基于保守的方法并根据美国标签使用。,0.3333333333333333,"['approach', 'trial', 'conservative', 'this', 'to', 'and']","['this', 'to']",1195,['为此测试选择的剂量制度是基于美国标签的保守方法和使用。'],0.3333333333333333,"['approach', 'trial', 'conservative', 'this', 'to', 'and']","['this', 'to']",1195,这项试验选择的剂量程序是基于一种保守的方法，并根据美国标签使用。,0.3333333333333333,"['approach', 'trial', 'conservative', 'this', 'to', 'and']","['this', 'to']",,,,
1203,1196,"data from ongoing trials of adalimumab ( ClinicalTrials.gov number , NCT02065622 ) and vedolizumab ( NCT03029143 ) may further characterize the effect of higher doses on efficacy outcomes .",来自正在进行的阿达木单抗（ClinicalTrials.gov 编号，NCT02065622）和维多珠单抗 (NCT03029143) 试验的数据可能进一步表征较高剂量对疗效结果的影响。,0.2857142857142857,"['data', 'number', 'effect', 'efficacy', 'vedolizumab', 'on', 'and']","['data', 'number']",1196,"['目前正在进行的 Adalimumab ( ClinicalTrials.gov 号, NCT02065622 ) 和 Vedolizumab ( NCT03029143 ) 的数据可能会进一步描述高剂量对效率结果的影响。']",0.2857142857142857,"['data', 'number', 'effect', 'efficacy', 'vedolizumab', 'on', 'and']","['data', 'number']",1196,正在进行的adalimumab（ClinicalTrials.gov编号，NCT02065622）和vedolizumab（NCT03029143）的试验数据可能会进一步描述较高剂量对疗效结果的影响。,0.2857142857142857,"['data', 'number', 'effect', 'efficacy', 'vedolizumab', 'on', 'and']","['data', 'number']",,,,
1204,1197,update recommends that providers use a risk assessment tool for all women with personal or family history of breast and ovarian cancer .,更新建议提供者对所有有乳腺癌和卵巢癌个人史或家族史的女性使用风险评估工具。,0.4545454545454545,"['personal', 'family history', 'ovarian cancer', 'assessment', 'breast', 'risk', 'tool', 'with', 'all', 'that', 'and']","['family history', 'ovarian cancer', 'assessment', 'risk', 'tool']",1197,"['更新建议供应商使用风险评估工具,适用于所有有乳腺和卵巢癌的个人或家庭史的女性。']",0.3636363636363636,"['personal', 'family history', 'ovarian cancer', 'assessment', 'breast', 'risk', 'tool', 'with', 'all', 'that', 'and']","['ovarian cancer', 'assessment', 'risk', 'tool']",1197,"更新建议医疗机构对所有患有乳腺癌和卵巢癌个人或家族史的女性使用风险评估工具。

Chinese:

更新建议医疗机构对所有患有乳腺癌和卵巢癌个人或家族史的女性使用风险评估工具。",0.4545454545454545,"['personal', 'family history', 'ovarian cancer', 'assessment', 'breast', 'risk', 'tool', 'with', 'all', 'that', 'and']","['family history', 'ovarian cancer', 'assessment', 'risk', 'tool']",,,,
1205,1198,sponsoring Organization : U.S. Preventive Services Task Force ( USPSTF ),主办机构：美国预防服务工作组 (USPSTF),0.0,"['organization', 'preventive', 'task force']",[],1198,['美国预防服务工作组(USPSTF)'],0.0,"['organization', 'preventive', 'task force']",[],1198,USPSTF sponsoring organization: U.S. Preventive Services Task Force,0.0,"['organization', 'preventive', 'task force']",[],,,,
1206,1198,sponsoring Organization : U.S. Preventive Services Task Force ( USPSTF ),主办机构：美国预防服务工作组 (USPSTF),0.0,"['organization', 'preventive', 'task force']",[],1198,['美国预防服务工作组(USPSTF)'],0.0,"['organization', 'preventive', 'task force']",[],1198,USPSTF sponsoring organization: U.S. Preventive Services Task Force,0.0,"['organization', 'preventive', 'task force']",[],,,,
1207,1198,sponsoring Organization : U.S. Preventive Services Task Force ( USPSTF ),主办机构：美国预防服务工作组 (USPSTF),0.0,"['organization', 'preventive', 'task force']",[],1198,['美国预防服务工作组(USPSTF)'],0.0,"['organization', 'preventive', 'task force']",[],1198,USPSTF sponsoring organization: U.S. Preventive Services Task Force,0.0,"['organization', 'preventive', 'task force']",[],,,,
1208,1198,sponsoring Organization : U.S. Preventive Services Task Force ( USPSTF ),主办机构：美国预防服务工作组 (USPSTF),0.0,"['organization', 'preventive', 'task force']",[],1198,['美国预防服务工作组(USPSTF)'],0.0,"['organization', 'preventive', 'task force']",[],1198,USPSTF sponsoring organization: U.S. Preventive Services Task Force,0.0,"['organization', 'preventive', 'task force']",[],,,,
1209,1199,BRCA1 / 2 mutations account for 5 % -10 % of breast cancer cases and 15 % of ovarian cancer cases .,BRCA1/2 突变占乳腺癌病例的 5%-10% 和卵巢癌病例的 15%。,0.6666666666666666,"['5', '2', '/', 'breast cancer', 'ovarian cancer', 'and']","['5', '2', 'breast cancer', 'ovarian cancer']",1199,['BRCA1 / 2 突变占乳腺癌病例的 5% - 10% 和卵巢癌病例的 15% 。'],0.6666666666666666,"['5', '2', '/', 'breast cancer', 'ovarian cancer', 'and']","['5', '2', 'breast cancer', 'ovarian cancer']",1199,BRCA1 / 2 mutations are responsible for 5% -10% of breast cancer cases and 15% of ovarian cancer cases.,0.3333333333333333,"['5', '2', '/', 'breast cancer', 'ovarian cancer', 'and']","['5', '2']",,,,
1210,1200,"in 2013 , the U.S. Preventive Services Task Force ( USPSTF ) recommended referral to genetic counseling only for women with a family history of breast , ovarian , tubal , or peritoneal cancer .",2013 年，美国预防服务工作组 (USPSTF) 建议仅将有乳腺癌、卵巢癌、输卵管癌或腹膜癌家族史的女性转诊至遗传咨询。,0.3,"['cancer', 'genetic counseling', 'tubal', 'family history', 'preventive', 'breast', 'peritoneal', 'referral', 'task force', 'with']","['cancer', 'genetic counseling', 'family history']",1200,"['2013年,美国预防服务工作小组(USPSTF)建议仅对乳腺、卵巢、管道或周围癌症家族史的妇女进行遗传咨询。']",0.3,"['cancer', 'genetic counseling', 'tubal', 'family history', 'preventive', 'breast', 'peritoneal', 'referral', 'task force', 'with']","['cancer', 'genetic counseling', 'family history']",1200,在2013年，美国预防服务任务小组（USPSTF）只建议女性有乳腺癌、卵巢癌、附睾癌或盆腔癌家族史的情况下才去咨询遗传辅导。,0.2,"['cancer', 'genetic counseling', 'tubal', 'family history', 'preventive', 'breast', 'peritoneal', 'referral', 'task force', 'with']","['cancer', 'family history']",,,,
1211,1201,"now , these updated guidelines reflect the latest evidence regarding benefits and harms of risk assessment and genetic testing .",现在，这些更新后的指南反映了有关风险评估和基因检测的益处和危害的最新证据。,0.625,"['genetic', 'reflect', 'regarding', 'assessment', 'risk', 'evidence', 'testing', 'and']","['reflect', 'regarding', 'assessment', 'risk', 'evidence']",1201,"['现在,这些更新的指南反映了关于风险评估和遗传测试的好处和损害的最新证据。']",0.625,"['genetic', 'reflect', 'regarding', 'assessment', 'risk', 'evidence', 'testing', 'and']","['reflect', 'regarding', 'assessment', 'risk', 'evidence']",1201,现在，这些更新的指导方针反映了最新的有关风险评估和基因测试的好处和危害的证据。,0.625,"['genetic', 'reflect', 'regarding', 'assessment', 'risk', 'evidence', 'testing', 'and']","['reflect', 'regarding', 'assessment', 'risk', 'evidence']",,,,
1212,1202,primary care providers should screen patients who have a personal history or family history of breast and ovarian / peritoneal / tubal cancers .,初级保健提供者应筛查有乳腺癌和卵巢癌/腹膜癌/输卵管癌个人史或家族史的患者。,0.3333333333333333,"['who', '/', 'tubal', 'family history', 'personal history', 'primary', 'breast', 'peritoneal', 'care', 'screen', 'have', 'and']","['family history', 'personal history', 'screen', 'have']",1202,['初级护理提供商应检查患有乳腺和卵巢/卵巢/管癌的个人或家庭史的患者。'],0.0833333333333333,"['who', '/', 'tubal', 'family history', 'personal history', 'primary', 'breast', 'peritoneal', 'care', 'screen', 'have', 'and']",['have'],1202,"Primary care providers should screen patients who have a personal history or family history of breast and ovarian / peritoneal / tubal cancers.

Chinese:

主要的保健服务提供者应该筛查患有个人或家族史的乳腺癌和卵巢/腹膜/输卵管癌的患者。",0.3333333333333333,"['who', '/', 'tubal', 'family history', 'personal history', 'primary', 'breast', 'peritoneal', 'care', 'screen', 'have', 'and']","['family history', 'primary', 'screen', 'have']",,,,
1213,1203,one of the seven available risk assessment tools should be used to estimate the likelihood of carrying a pathogenic BRCA mutation .,应使用七种可用的风险评估工具之一来估计携带致病性 BRCA 突变的可能性。,0.625,"['mutation', 'tools', 'pathogenic', 'be', 'assessment', 'available', 'risk', 'estimate']","['mutation', 'tools', 'assessment', 'available', 'risk']",1203,['使用七种可用的风险评估工具之一来估计患有病原性BRCA突变的可能性。'],0.625,"['mutation', 'tools', 'pathogenic', 'be', 'assessment', 'available', 'risk', 'estimate']","['mutation', 'tools', 'assessment', 'available', 'risk']",1203,一个七个可用风险评估工具之一应该用来估计携带病原性BRCA突变的可能性。,0.5,"['mutation', 'tools', 'pathogenic', 'be', 'assessment', 'available', 'risk', 'estimate']","['mutation', 'tools', 'assessment', 'risk']",,,,
1214,1204,"women with a positive screen should be referred for genetic counseling and , if indicated , testing .",筛查呈阳性的女性应转诊进行遗传咨询，如果有指征，还应进行检测。,0.25,"['genetic counseling', 'be', 'screen', 'testing', 'with', 'positive', 'if', 'and']","['genetic counseling', 'screen']",1204,"['有积极的屏幕的妇女应该被提到遗传咨询和,如果指示,测试。']",0.25,"['genetic counseling', 'be', 'screen', 'testing', 'with', 'positive', 'if', 'and']","['genetic counseling', 'screen']",1204,妇女如果筛查结果为阳性，应该被转至遗传咨询，并且，如有必要，进行检测。,0.25,"['genetic counseling', 'be', 'screen', 'testing', 'with', 'positive', 'if', 'and']","['genetic counseling', 'screen']",,,,
1215,1205,routine screening and genetic testing are not recommended among the general population without a history suggestive of BRCA mutation .,不建议在没有提示 BRCA 突变病史的一般人群中进行常规筛查和基因检测。,0.4,"['population', 'mutation', 'screening', 'routine', 'general', 'genetic', 'history', 'testing', 'and', 'without']","['population', 'mutation', 'screening', 'routine']",1205,['常规筛查和遗传测试不推荐在一般人口中没有一个提议的历史的BRCA突变。'],0.5,"['population', 'mutation', 'screening', 'routine', 'general', 'genetic', 'history', 'testing', 'and', 'without']","['population', 'mutation', 'screening', 'routine', 'history']",1205,在没有BRCA突变历史的一般人群中，常规筛查和遗传测试并不推荐。,0.5,"['population', 'mutation', 'screening', 'routine', 'general', 'genetic', 'history', 'testing', 'and', 'without']","['population', 'mutation', 'screening', 'routine', 'history']",,,,
1216,1206,"many professional oncology societies have already adopted genetic testing guidelines that address family history and personal history of cancer ; now , this USPSTF update expands the obligation to the primary care arena .",许多专业肿瘤学会已经采用了涉及癌症家族史和个人史的基因检测指南；现在，这个 USPSTF 更新将义务扩展到初级保健领域。,0.2142857142857142,"['cancer', 'obligation', 'family history', 'genetic', 'arena', 'personal history', 'primary', 'professional', 'care', 'testing', 'have', 'this', 'that', 'and']","['cancer', 'family history', 'personal history']",1206,"['许多专业的肿瘤学社会已经采用了对癌症的家庭历史和个人历史的遗传测试指南;现在,这个USPSTF更新将义务扩展到初级护理领域。']",0.1428571428571428,"['cancer', 'obligation', 'family history', 'genetic', 'arena', 'personal history', 'primary', 'professional', 'care', 'testing', 'have', 'this', 'that', 'and']","['cancer', 'family history']",1206,许多专业肿瘤学会已经采用了遗传测试指南，其中包括对家族史和个人癌症史的详细说明。现在，美国临床医师协会更新了这个指南，使其适用于初级保健领域。,0.1428571428571428,"['cancer', 'obligation', 'family history', 'genetic', 'arena', 'personal history', 'primary', 'professional', 'care', 'testing', 'have', 'this', 'that', 'and']","['cancer', 'family history']",,,,
1217,1207,"among assessment tools , the Gail Model is not appropriate for calculating risk for BRCA mutation ; either the Referral Screening Tool or Tyrer Cuzick is preferable .",在评估工具中，盖尔模型不适用于计算 BRCA 突变的风险； Referral Screening Tool 或 Tyrer Cuzick 是首选。,0.625,"['mutation', 'tools', 'model', 'screening', 'assessment', 'risk', 'referral', 'appropriate']","['mutation', 'tools', 'model', 'assessment', 'risk']",1207,"['在评估工具中,Gail 模型不适合计算 BRCA 突变的风险;无论是参考扫描工具还是 Tyrer Cuzick 都是优先的。']",0.625,"['mutation', 'tools', 'model', 'screening', 'assessment', 'risk', 'referral', 'appropriate']","['mutation', 'tools', 'model', 'assessment', 'risk']",1207,在评估工具中，Gail模型不适合计算BRCA突变的风险；应优先使用Referral Screening Tool或Tyrer Cuzick。,0.625,"['mutation', 'tools', 'model', 'screening', 'assessment', 'risk', 'referral', 'appropriate']","['mutation', 'tools', 'model', 'assessment', 'risk']",,,,
1218,1208,"direct to consumer genetic testing ( e.g. , 23andMe ) only looks for 3 Ashkenazi Jewish founder mutations in BRCA genes and does not identify the other 98 % of BRCA mutations .",直接面向消费者的基因检测（例如 23andMe）仅在 BRCA 基因中寻找 3 个 Ashkenazi Jewish founder 突变，而不会识别其他 98% 的 BRCA 突变。,0.4285714285714285,"['genetic', '3', 'identify', 'testing', 'direct', 'to', 'and']","['identify', 'direct', 'and']",1208,"['直接到消费者基因测试(例如,23andMe)仅在BRCA基因中寻找3个Ashkenazi犹太创始人突变,并且不确定其他98%的BRCA突变。']",0.1428571428571428,"['genetic', '3', 'identify', 'testing', 'direct', 'to', 'and']",['direct'],1208,直接向消费者进行基因测试（例如23andMe）只会检测到3个Ashkenazi犹太人的BRCA基因发育突变，而无法确定其他98％的BRCA突变。,0.2857142857142857,"['genetic', '3', 'identify', 'testing', 'direct', 'to', 'and']","['direct', 'and']",,,,
1219,1209,"these days , genetic testing typically involves multiple gene panels beyond BRCA ; the National Comprehensive Cancer Network provides guidelines for such tests .",如今，基因检测通常涉及 BRCA 以外的多个基因组；国家综合癌症网络为此类测试提供指南。,0.3333333333333333,"['cancer', 'comprehensive', 'network', 'multiple', 'genetic', 'testing']","['cancer', 'network']",1209,"['今天,基因测试通常涉及多个基因板在BRCA之外;国家全面癌症网络为这些测试提供指导方针。']",0.3333333333333333,"['cancer', 'comprehensive', 'network', 'multiple', 'genetic', 'testing']","['cancer', 'network']",1209,近年来，基因测试通常涉及多个基因面板，而不仅仅是BRCA；美国国家癌症综合网络已经为此类测试制定了指导方针。,0.3333333333333333,"['cancer', 'comprehensive', 'network', 'multiple', 'genetic', 'testing']","['cancer', 'network']",,,,
1220,1210,"the USPSTF recommends that providers discuss use of tamoxifen , raloxifene , or aromatase inhibitors with women at excess risk for breast cancer and low risk for adverse effects .",USPSTF 建议提供者与乳腺癌高危和不良反应风险低的女性讨论他莫昔芬、雷洛昔芬或芳香化酶抑制剂的使用。,0.3636363636363636,"['excess', 'aromatase', 'breast cancer', 'adverse', 'low', 'risk', 'discuss', 'with', 'tamoxifen', 'that', 'and']","['breast cancer', 'low', 'risk', 'tamoxifen']",1210,['USPSTF 建议供应商讨论使用 tamoxifen、raloxifen 或 aromatase 抑制剂的妇女患乳腺癌的过度风险和负面影响的低风险。'],0.2727272727272727,"['excess', 'aromatase', 'breast cancer', 'adverse', 'low', 'risk', 'discuss', 'with', 'tamoxifen', 'that', 'and']","['breast cancer', 'low', 'risk']",1210,美国预防医学委员会（USPSTF）建议为高风险的乳腺癌女性和低风险的不良反应患者提供替米诺妥赛、雷洛塞纳或醛固酮合成酶抑制剂等方案。,0.2727272727272727,"['excess', 'aromatase', 'breast cancer', 'adverse', 'low', 'risk', 'discuss', 'with', 'tamoxifen', 'that', 'and']","['breast cancer', 'low', 'risk']",,,,
1221,1211,aromatase inhibitors are now among the recommended chemoprophylactic agents .,芳香化酶抑制剂现在是推荐的化学预防剂之一。,0.0,['aromatase'],[],1211,['aromatase 抑制剂现在是推荐的化疗药物之一。'],0.0,['aromatase'],[],1211,"aromatase inhibitors are now among the recommended chemoprophylactic agents.

Chinese:

阿霉素抑制剂现在已经成为推荐的化学预防剂。",0.0,['aromatase'],[],,,,
1222,1212,"first , the absolute risk reduction achieved is incremental at best : for example , in the tamoxifen trials , the number needed to treat with 5 years of chemoprophylaxis to prevent one case of breast cancer was 143 .",首先，所实现的绝对风险降低充其量是递增的：例如，在他莫昔芬试验中，预防一例乳腺癌需要 5 年化学预防治疗的人数为 143 人。,0.7058823529411765,"['5', 'chemoprophylaxis', 'treat', 'absolute', 'reduction', 'breast cancer', 'number', 'case', 'risk', 'with', 'prevent', 'achieved', 'tamoxifen', 'example', 'in', 'to', 'first']","['5', 'chemoprophylaxis', 'treat', 'absolute', 'reduction', 'breast cancer', 'number', 'risk', 'prevent', 'tamoxifen', 'example', 'first']",1212,"['首先,实现的绝对风险减少在最佳情况下是增加的:例如,在塔米克西芬试验中,用5年的化学预防治疗所需的数量,以预防乳腺癌的一个案例为143。']",0.7058823529411765,"['5', 'chemoprophylaxis', 'treat', 'absolute', 'reduction', 'breast cancer', 'number', 'case', 'risk', 'with', 'prevent', 'achieved', 'tamoxifen', 'example', 'in', 'to', 'first']","['5', 'chemoprophylaxis', 'treat', 'absolute', 'reduction', 'breast cancer', 'number', 'case', 'risk', 'prevent', 'example', 'first']",1212,首先，所获得的绝对风险降低最多只是增量：例如，在他莫昔芬试验中，每治疗5年防止一例乳腺癌的病例数量为143。,0.7058823529411765,"['5', 'chemoprophylaxis', 'treat', 'absolute', 'reduction', 'breast cancer', 'number', 'case', 'risk', 'with', 'prevent', 'achieved', 'tamoxifen', 'example', 'in', 'to', 'first']","['5', 'treat', 'absolute', 'reduction', 'breast cancer', 'number', 'case', 'risk', 'achieved', 'tamoxifen', 'example', 'first']",,,,
1223,1213,"third , tamoxifen and raloxifene raise risk for venous thromboembolism - and tamoxifen raises risk for endometrial cancer , uterine bleeding , and endometrial polyps , making this medication less desirable for women with an intact uterus .",第三，他莫昔芬和雷洛昔芬会增加静脉血栓栓塞的风险，而他莫昔芬会增加子宫内膜癌、子宫出血和子宫内膜息肉的风险，因此对于子宫完好的女性而言，这种药物不太理想。,0.5625,"['cancer', 'uterus', 'venous', 'endometrial', 'raise', 'thromboembolism', 'medication', 'risk', 'intact', 'with', 'tamoxifen', '-', 'this', 'and', 'third', 'uterine bleeding']","['cancer', 'uterus', 'raise', 'thromboembolism', 'risk', 'tamoxifen', 'and', 'third', 'uterine bleeding']",1213,"['第三,tamoxifen和raloxifen增加了阴道血管肿瘤的风险,而tamoxifen增加了内分泌癌症、子宫出血和内分泌聚合物的风险,这使得这种药物对患有无菌子宫的女性更不受欢迎。']",0.4375,"['cancer', 'uterus', 'venous', 'endometrial', 'raise', 'thromboembolism', 'medication', 'risk', 'intact', 'with', 'tamoxifen', '-', 'this', 'and', 'third', 'uterine bleeding']","['cancer', 'uterus', 'raise', 'risk', 'and', 'third', 'uterine bleeding']",1213,"第三，他莫昔芬和雷洛芬增加了深静脉血栓形成的风险 - 而他莫昔芬则增加了子宫内膜癌、子宫内出血和子宫内肌瘤的风险，这使得这种药物对于子宫完整的女性不太可取。

Chinese:
第三，他莫昔芬和雷洛芬会导致深静脉血栓形成风险增加-而他莫昔芬则会导致子宫内膜癌、子宫内出血和子宫内肌瘤风险增加，这使得这种药物对于子宫完整的女性不太可取。",0.5,"['cancer', 'uterus', 'venous', 'endometrial', 'raise', 'thromboembolism', 'medication', 'risk', 'intact', 'with', 'tamoxifen', '-', 'this', 'and', 'third', 'uterine bleeding']","['cancer', 'uterus', 'raise', 'risk', 'intact', 'tamoxifen', 'and', 'third']",,,,
1224,1214,aromatase inhibitors cause arthralgias and other musculoskeletal symptoms and may raise risk for bone fractures .,芳香化酶抑制剂会引起关节痛和其他肌肉骨骼症状，并可能增加骨折的风险。,0.4444444444444444,"['bone', 'aromatase', 'raise', 'symptoms', 'musculoskeletal', 'cause', 'risk', 'fractures', 'and']","['bone', 'raise', 'risk', 'fractures']",1214,"['香水抑制剂会导致关节炎和其他肌肉骨骼症状,并可能增加骨折的风险。']",0.4444444444444444,"['bone', 'aromatase', 'raise', 'symptoms', 'musculoskeletal', 'cause', 'risk', 'fractures', 'and']","['bone', 'raise', 'risk', 'fractures']",1214,阿拉莫塔西抑制剂会导致关节疼痛和其他肌肉骨骼症状，并可能增加骨折风险。,0.4444444444444444,"['bone', 'aromatase', 'raise', 'symptoms', 'musculoskeletal', 'cause', 'risk', 'fractures', 'and']","['bone', 'raise', 'risk', 'fractures']",,,,
1225,1215,all these agents cause vasomotor symptoms .,所有这些药物都会引起血管舒缩症状。,0.0,"['vasomotor', 'symptoms', 'cause', 'all']",[],1215,['所有这些物质都会导致血管症状。'],0.0,"['vasomotor', 'symptoms', 'cause', 'all']",[],1215,所有这些药物都会导致血管舒张症状。,0.0,"['vasomotor', 'symptoms', 'cause', 'all']",[],,,,
1226,1216,"the effects of current antidepressants are variable and generally emerge within 4 to 8 weeks ; thus , the search continues for antidepressants with novel mechanisms of action .",目前抗抑郁药的效果各不相同，一般会在 4 到 8 周内出现；因此，人们仍在继续寻找具有新作用机制的抗抑郁药。,0.2727272727272727,"['variable', 'action', 'search', 'thus', 'novel', '4', 'current', 'with', 'antidepressants', 'to', 'and']","['action', 'thus', 'antidepressants']",1216,"['目前抗抑郁药的作用是多样化的,通常在4至8周内出现;因此,新的作用机制的抗抑郁药的搜索仍在继续。']",0.2727272727272727,"['variable', 'action', 'search', 'thus', 'novel', '4', 'current', 'with', 'antidepressants', 'to', 'and']","['action', 'thus', 'antidepressants']",1216,目前的抗抑郁药的效果是可变的，一般会在4-8周内出现；因此，人们继续寻找具有新的作用机制的抗抑郁药。,0.3636363636363636,"['variable', 'action', 'search', 'thus', 'novel', '4', 'current', 'with', 'antidepressants', 'to', 'and']","['variable', 'action', 'thus', 'antidepressants']",,,,
1227,1217,"at day 28 , these outcomes no longer significantly differed between groups .",在第 28 天，这些结果在组间不再有显着差异。,0.0,"['no', 'at']",[],1217,"['在28日,这些结果不再在群体之间显著差异。']",0.0,"['no', 'at']",[],1217,在第28天，这些结果在两组之间已经不显著不同了。,0.0,"['no', 'at']",[],,,,
1228,1218,"the most common adverse events were headache , dizziness , nausea , and somnolence ( 53 % and 45 % of each group experienced at least 1 event ) .",最常见的不良事件是头痛、头晕、恶心和嗜睡（每组分别有 53% 和 45% 的人经历过至少 1 次事件）。,0.5,"['group', 'headache', '1', 'somnolence', 'nausea', 'common', 'dizziness', 'adverse', 'at', 'event', 'each', 'and']","['group', 'headache', '1', 'somnolence', 'nausea', 'dizziness']",1218,['最常见的副作用是头痛、恶心、恶心和失眠(每个群体的53%和45%至少经历了1个事件)。'],0.3333333333333333,"['group', 'headache', '1', 'somnolence', 'nausea', 'common', 'dizziness', 'adverse', 'at', 'event', 'each', 'and']","['group', 'headache', '1', 'nausea']",1218,最常见的不良事件是头痛、头晕、恶心和嗜睡（53％和45％的患者经历了至少一个事件）。,0.3333333333333333,"['group', 'headache', '1', 'somnolence', 'nausea', 'common', 'dizziness', 'adverse', 'at', 'event', 'each', 'and']","['headache', 'somnolence', 'nausea', 'dizziness']",,,,
1229,1219,no serious adverse events occurred .,没有发生严重不良事件。,0.0,"['adverse', 'no', 'serious']",[],1219,['没有发生严重的不良事件。'],0.0,"['adverse', 'no', 'serious']",[],1219,"No serious adverse events occurred.

Chinese:

无严重不良事件发生。",0.0,"['adverse', 'no', 'serious']",[],,,,
1230,1220,"metabolic factors , such as hypertension , are the largest contributors to CVD risk , and behavioral factors , such as tobacco use , are the largest contributors to mortality risk .",代谢因素，如高血压，是导致心血管疾病风险的最大因素，而行为因素，如吸烟，是导致死亡风险的最大因素。,0.5,"['hypertension', 'tobacco', 'mortality', 'risk', 'metabolic', 'as', 'CVD', 'and']","['hypertension', 'risk', 'as', 'and']",1220,"['代谢因素,如高血压,是CVD风险最大的贡献者,行为因素,如烟草使用,是死亡风险最大的贡献者。']",0.5,"['hypertension', 'tobacco', 'mortality', 'risk', 'metabolic', 'as', 'CVD', 'and']","['hypertension', 'tobacco', 'risk', 'as']",1220,"metabolic factors, such as hypertension, are the largest contributors to CVD risk, and behavioral factors, such as tobacco use, are the largest contributors to mortality risk.

Chinese:

代谢因素，如高血压，是心血管疾病风险的最大因素，而行为因素，如吸烟，是死亡风险的最大因素。",0.5,"['hypertension', 'tobacco', 'mortality', 'risk', 'metabolic', 'as', 'CVD', 'and']","['hypertension', 'risk', 'as', 'and']",,,,
1231,1221,"the authors evaluated associations of 14 modifiable risk factors with total mortality and CVD ( CV death , myocardial infarction , stroke , and heart failure ) in over 150,000 people without CVD at baseline .","作者评估了 14 种可变风险因素与总死亡率和 CVD（CV 死亡、心肌梗死、中风和心力衰竭）之间的关联，研究对象为超过 150,000 名基线时没有 CVD 的人。",0.6363636363636364,"['myocardial infarction', 'stroke', 'baseline', 'death', 'total mortality', 'heart failure', 'risk', 'CVD', 'over', 'and', 'without']","['myocardial infarction', 'stroke', 'baseline', 'death', 'heart failure', 'risk', 'over']",1221,"['作者评估了14个可改变的风险因素与总死亡率和CVD(CV死亡、心脏病发作、中风和心脏衰竭)在150,000多人中没有CVD。']",0.2727272727272727,"['myocardial infarction', 'stroke', 'baseline', 'death', 'total mortality', 'heart failure', 'risk', 'CVD', 'over', 'and', 'without']","['stroke', 'death', 'risk']",1221,"研究者评估了14个可改变的风险因素与150,000多人的总死亡率和心血管疾病（心血管死亡、心肌梗死、中风和心力衰竭）的相关性。",0.4545454545454545,"['myocardial infarction', 'stroke', 'baseline', 'death', 'total mortality', 'heart failure', 'risk', 'CVD', 'over', 'and', 'without']","['myocardial infarction', 'stroke', 'death', 'heart failure', 'risk']",,,,
1232,1222,"overall , about 70 % of cardiovascular disease and deaths were attributed to modifiable risk factors .",总体而言，大约 70% 的心血管疾病和死亡归因于可改变的危险因素。,1.0,"['cardiovascular disease', 'risk', 'to', 'and']","['cardiovascular disease', 'risk', 'to', 'and']",1222,"['总体而言,大约70%的心血管疾病和死亡被归因于可改变的风险因素。']",1.0,"['cardiovascular disease', 'risk', 'to', 'and']","['cardiovascular disease', 'risk', 'to', 'and']",1222,总体而言，约70%的心血管疾病和死亡可归因于可修正的风险因素。,1.0,"['cardiovascular disease', 'risk', 'to', 'and']","['cardiovascular disease', 'risk', 'to', 'and']",,,,
1233,1223,"for CVD , metabolic risk factors ( lipid levels , blood pressure , diabetes , obesity ) accounted for about 40 % of risk ; hypertension was the largest factor .",对于心血管疾病，代谢风险因素（血脂水平、血压、糖尿病、肥胖）约占风险的 40%；高血压是最大的因素。,0.6666666666666666,"['diabetes', 'lipid', 'hypertension', 'factor', 'obesity', 'blood pressure', 'risk', 'metabolic', 'CVD']","['diabetes', 'hypertension', 'factor', 'obesity', 'blood pressure', 'risk']",1223,"['对于CVD,代谢风险因素(脂肪水平、血压、糖尿病、肥胖)约为40%的风险;高血压是最大的因素。']",0.6666666666666666,"['diabetes', 'lipid', 'hypertension', 'factor', 'obesity', 'blood pressure', 'risk', 'metabolic', 'CVD']","['diabetes', 'hypertension', 'factor', 'obesity', 'blood pressure', 'risk']",1223,对于CVD，代谢风险因素（脂肪水平、血压、糖尿病、肥胖）占风险的约40％；高血压是最大的因素。,0.6666666666666666,"['diabetes', 'lipid', 'hypertension', 'factor', 'obesity', 'blood pressure', 'risk', 'metabolic', 'CVD']","['diabetes', 'hypertension', 'factor', 'obesity', 'blood pressure', 'risk']",,,,
1234,1224,"for mortality , behavioral risk factors ( tobacco and alcohol use , diet , physical activity , and sodium intake ) accounted for about 25 % of risk , with tobacco use the largest factor .",对于死亡率，行为风险因素（烟草和酒精使用、饮食、身体活动和钠摄入量）约占风险的 25%，其中烟草使用是最大的因素。,0.6,"['alcohol', 'tobacco', 'factor', 'diet', 'sodium intake', 'mortality', 'risk', 'with', 'physical activity', 'and']","['alcohol', 'tobacco', 'factor', 'diet', 'mortality', 'risk']",1224,"['死亡率、行为风险因素(烟草和酒精使用、饮食、身体活动和<unk>摄入)约为25%的风险,烟草使用是最大的风险因素。']",0.6,"['alcohol', 'tobacco', 'factor', 'diet', 'sodium intake', 'mortality', 'risk', 'with', 'physical activity', 'and']","['alcohol', 'tobacco', 'factor', 'diet', 'mortality', 'risk']",1224,行為風險因子對死亡率造成的影響約佔總風險的25%，其中吸煙是最大的因素。,0.2,"['alcohol', 'tobacco', 'factor', 'diet', 'sodium intake', 'mortality', 'risk', 'with', 'physical activity', 'and']","['factor', 'mortality']",,,,
1235,1225,ambient air pollution was associated with 14 % of risk for CVD .,环境空气污染与 14% 的 CVD 风险有关。,0.5,"['air pollution', 'associated', 'risk', 'with', 'ambient air', 'CVD']","['air pollution', 'risk', 'ambient air']",1225,['环境空气污染与14%的CVD风险有关。'],0.5,"['air pollution', 'associated', 'risk', 'with', 'ambient air', 'CVD']","['air pollution', 'risk', 'ambient air']",1225,环境空气污染与心血管疾病风险相关联，其中14%的风险可以归因于环境空气污染。,0.5,"['air pollution', 'associated', 'risk', 'with', 'ambient air', 'CVD']","['air pollution', 'risk', 'ambient air']",,,,
1236,1226,"in MICs and LICs , household air pollution , poor diet , low education , and low grip strength had stronger associations with CVD and mortality than in HICs .",在中等收入国家和低收入国家，家庭空气污染、不良饮食、低教育程度和低握力与心血管疾病和死亡率的相关性高于高收入国家。,0.5384615384615384,"['grip', 'air pollution', 'diet', 'education', 'low', 'mortality', 'strength', 'household', 'with', 'CVD', 'poor', 'in', 'and']","['grip', 'air pollution', 'diet', 'education', 'low', 'mortality', 'household']",1226,"['在MIC和LIC,家庭空气污染,营养不良,低教育和低吸引力与CVD和死亡率有更强的联系,而不是在HIC。']",0.4615384615384615,"['grip', 'air pollution', 'diet', 'education', 'low', 'mortality', 'strength', 'household', 'with', 'CVD', 'poor', 'in', 'and']","['air pollution', 'education', 'low', 'mortality', 'household', 'and']",1226,在中低收入国家和欠发达国家，家庭空气污染、营养不良、教育水平低、手力差与心血管疾病和死亡率之间的关联要强于高收入国家。,0.3846153846153846,"['grip', 'air pollution', 'diet', 'education', 'low', 'mortality', 'strength', 'household', 'with', 'CVD', 'poor', 'in', 'and']","['air pollution', 'education', 'low', 'mortality', 'household']",,,,
1237,1227,"pure suggests that most cardiovascular morbidity and mortality can be attributed to a small number of common , modifiable risk factors .",pure 表明大多数心血管疾病的发病率和死亡率可归因于少数常见的、可改变的危险因素。,0.6,"['cardiovascular', 'morbidity', 'common', 'mortality', 'number', 'risk', 'pure', 'that', 'to', 'and']","['cardiovascular', 'morbidity', 'mortality', 'number', 'risk', 'to']",1227,"['纯暗示,大多数心血管疾病和死亡率可以归因于少数常见、可改变的风险因素。']",0.6,"['cardiovascular', 'morbidity', 'common', 'mortality', 'number', 'risk', 'pure', 'that', 'to', 'and']","['cardiovascular', 'mortality', 'number', 'risk', 'pure', 'to']",1227,纯粹表明，大多数心血管疾病和死亡可以归因于少数常见的、可以修正的风险因素。,0.5,"['cardiovascular', 'morbidity', 'common', 'mortality', 'number', 'risk', 'pure', 'that', 'to', 'and']","['cardiovascular', 'number', 'risk', 'pure', 'to']",,,,
1238,1228,disease prevalence and clinical outcomes are known to be associated with income .,众所周知，疾病患病率和临床结果与收入有关。,0.3333333333333333,"['disease', 'prevalence', 'be', 'associated', 'clinical', 'with', 'income', 'to', 'and']","['disease', 'clinical', 'income']",1228,['疾病的发病率和临床结果已知与收入有关。'],0.3333333333333333,"['disease', 'prevalence', 'be', 'associated', 'clinical', 'with', 'income', 'to', 'and']","['disease', 'clinical', 'income']",1228,疾病的普遍性和临床结果与收入有关。,0.3333333333333333,"['disease', 'prevalence', 'be', 'associated', 'clinical', 'with', 'income', 'to', 'and']","['disease', 'clinical', 'income']",,,,
1239,1229,"7.0 % of participants died : 5.7 % had cardiovascular disease ( CVD ) , 3.2 % had cancer , 2.7 % suffered injuries requiring hospitalization , 1.8 % had pneumonia , and 1.1 % had chronic obstructive pulmonary disease ( COPD ) .",7.0% 的参与者死亡：5.7% 患有心血管疾病 (CVD)，3.2% 患有癌症，2.7% 受伤需要住院治疗，1.8% 患有肺炎，1.1% 患有慢性阻塞性肺病 (COPD)。,0.6,"['COPD', 'cancer', 'obstructive', 'hospitalization', 'pulmonary', 'cardiovascular disease', 'chronic', 'CVD', 'pneumonia', 'and']","['COPD', 'cancer', 'hospitalization', 'cardiovascular disease', 'chronic', 'pneumonia']",1229,"['7.0%的参与者死亡: 5.7%患有心血管疾病(CVD),3.2%患有癌症,2.7%患有需要入院的伤害,1.8%患有肺炎,1.1%患有慢性阻塞性肺疾病(COPD)。']",0.5,"['COPD', 'cancer', 'obstructive', 'hospitalization', 'pulmonary', 'cardiovascular disease', 'chronic', 'CVD', 'pneumonia', 'and']","['COPD', 'cancer', 'cardiovascular disease', 'chronic', 'pneumonia']",1229,"7.0% of participants died: 5.7% had cardiovascular disease (CVD), 3.2% had cancer, 2.7% suffered injuries requiring hospitalization, 1.8% had pneumonia, and 1.1% had chronic obstructive pulmonary disease (COPD).

Chinese:

7.0%的参与者死亡：5.7%患有心血管疾病（CVD），3.2%患有癌症，2.7%遭受住院治疗的伤害，1.8%患有肺炎，1.1%患有慢性阻塞性肺疾病（COPD）。",0.6,"['COPD', 'cancer', 'obstructive', 'hospitalization', 'pulmonary', 'cardiovascular disease', 'chronic', 'CVD', 'pneumonia', 'and']","['COPD', 'cancer', 'hospitalization', 'cardiovascular disease', 'chronic', 'pneumonia']",,,,
1240,1230,"this was true for all causes of death except cancer , from which mortality was similar across all country income levels .",对于癌症以外的所有死因都是如此，癌症死亡率在所有收入水平的国家都相似。,0.6,"['cancer', 'true', 'country', 'causes of death', 'mortality', 'across', 'income', 'all', 'this', 'similar']","['cancer', 'country', 'causes of death', 'mortality', 'income', 'this']",1230,"['这适用于除了癌症以外的所有死亡原因,其中死亡率在所有国家的收入水平上都是相同的。']",0.5,"['cancer', 'true', 'country', 'causes of death', 'mortality', 'across', 'income', 'all', 'this', 'similar']","['cancer', 'country', 'mortality', 'income', 'this']",1230,这对于所有死因都是真实的，除了癌症。癌症死亡率在所有国家收入水平上都相似。,0.6,"['cancer', 'true', 'country', 'causes of death', 'mortality', 'across', 'income', 'all', 'this', 'similar']","['cancer', 'country', 'causes of death', 'mortality', 'income', 'this']",,,,
1241,1231,"CVD , the most common cause of mortality , accounted for 40 % of deaths overall but for only 23 % of deaths in HICs .",CVD 是最常见的死亡原因，占总死亡人数的 40%，但在高收入国家死亡人数中仅占 23%。,0.3333333333333333,"['common', 'mortality', 'cause', 'CVD', 'in', 'but']","['cause', 'but']",1231,"['CVD,死亡率最常见的原因,占总死亡率的40%,但仅占HIC死亡率的23%。']",0.5,"['common', 'mortality', 'cause', 'CVD', 'in', 'but']","['mortality', 'cause', 'but']",1231,"CVD, the most common cause of mortality, accounted for 40% of deaths overall but for only 23% of deaths in HICs.

Chinese:

CVD是最常见的死因，占总死亡人数的40%，但在高收入国家仅占23%。",0.1666666666666666,"['common', 'mortality', 'cause', 'CVD', 'in', 'but']",['but'],,,,
1242,1232,"the ratio of death from CVD to death from cancer was 0.4 in HICs , 1.3 in MICs , and 3.0 in LICs .",心血管疾病死亡与癌症死亡的比率在高收入国家为 0.4，在中等收入国家为 1.3，在低收入国家为 3.0。,0.4285714285714285,"['cancer', 'ratio', 'death', 'CVD', 'in', 'to', 'and']","['cancer', 'ratio', 'death']",1232,['CVD死亡与癌症死亡的比例在HIC中为0.4、MIC中为1.3、LIC中为3.0。'],0.4285714285714285,"['cancer', 'ratio', 'death', 'CVD', 'in', 'to', 'and']","['cancer', 'ratio', 'death']",1232,在高收入国家，心血管疾病死亡率与癌症死亡率的比例为0.4，在中等收入国家为1.3，在低收入国家为3.0。,0.4285714285714285,"['cancer', 'ratio', 'death', 'CVD', 'in', 'to', 'and']","['cancer', 'ratio', 'death']",,,,
1243,1233,these data highlight the influence of income in combating largely preventable diseases such as CVD .,这些数据突出了收入在抗击 CVD 等基本上可预防的疾病方面的影响。,0.6,"['data', 'influence', 'as', 'income', 'CVD']","['data', 'influence', 'income']",1233,"['这些数据强调了收入对抗主要可预防的疾病,如CVD的影响。']",0.8,"['data', 'influence', 'as', 'income', 'CVD']","['data', 'influence', 'as', 'income']",1233,这些数据突显了收入在对抗大多数可预防疾病（如心血管疾病）方面的影响。,0.8,"['data', 'influence', 'as', 'income', 'CVD']","['data', 'influence', 'as', 'income']",,,,
1244,1234,the high mortality in poorer countries was likely related to poorer access to health care .,较贫穷国家的高死亡率可能与较差的医疗保健机会有关。,0.5,"['access', 'mortality', 'health care', 'in', 'to', 'high']","['mortality', 'health care', 'high']",1234,['贫困国家的死亡率很可能与贫困国家的医疗保健接入有关。'],0.3333333333333333,"['access', 'mortality', 'health care', 'in', 'to', 'high']","['mortality', 'health care']",1234,贫困国家的高死亡率可能与获得医疗保健的困难相关。,0.5,"['access', 'mortality', 'health care', 'in', 'to', 'high']","['mortality', 'health care', 'high']",,,,
1245,1235,"not surprisingly , medication use was lowest in LICs and highest in HICs .",毫不奇怪，低收入国家的药物使用率最低，而高收入国家的药物使用率最高。,0.3333333333333333,"['medication', 'in', 'and']",['and'],1235,"['不令人惊讶的是,药物使用量在LIC中最低,在HIC中最高。']",0.0,"['medication', 'in', 'and']",[],1235,不出所料，药物使用在低收入国家最少，在高收入国家最多。,0.0,"['medication', 'in', 'and']",[],,,,
1246,1236,"at baseline , mean serum 25 ( OH ) D was 32 ng / mL ( 79 nmol / L ) .",基线时，平均血清 25 (OH) D 为 32 ng/mL (79 nmol/L)。,0.4285714285714285,"['mean', 'baseline', '/', 'serum', 'D', 'ml', 'at']","['mean', 'baseline', 'serum']",1236,"['在基线上,平均血清25(OH)D为32 ng / mL(79 nmol / L)。']",0.4285714285714285,"['mean', 'baseline', '/', 'serum', 'D', 'ml', 'at']","['mean', 'baseline', 'serum']",1236,在基线时，平均血清25（OH）D水平为32ng/mL（79nmol/L）。,0.4285714285714285,"['mean', 'baseline', '/', 'serum', 'D', 'ml', 'at']","['mean', 'baseline', 'serum']",,,,
1247,1237,dietary calcium intake was supplemented to recommended levels .,将膳食钙摄入量补充至推荐水平。,0.25,"['calcium', 'intake', 'dietary', 'to']",['calcium'],1237,['饮食摄入量加到推荐的水平。'],0.0,"['calcium', 'intake', 'dietary', 'to']",[],1237,摄入的钙被补充到推荐水平。,0.25,"['calcium', 'intake', 'dietary', 'to']",['calcium'],,,,
1248,1238,participants were assessed serially through 36 months .,在 36 个月内对参与者进行连续评估。,0.0,"['serially', 'assessed']",[],1238,['參與者在36個月內進行了嚴重評估。'],0.0,"['serially', 'assessed']",[],1238,参与者每隔36个月进行一次评估。,0.0,"['serially', 'assessed']",[],,,,
1249,1239,"serum 25 ( OH ) D levels increased significantly for participants who received 4000 IU or 10,000 IU daily but not for participants who received 400 IU daily .","每天接受 4000 IU 或 10,000 IU 的参与者的血清 25 (OH) D 水平显着升高，但每天接受 400 IU 的参与者则没有。",0.5,"['who', 'serum', 'D', 'but']","['serum', 'but']",1239,"['血清25(OH)D水平在每日接收4000 IU或10,000 IU的参与者中显著增加,但不是每日接收400 IU的参与者。']",0.5,"['who', 'serum', 'D', 'but']","['serum', 'but']",1239,血清25(OH)D水平显著升高了每天服用4000IU或者10000IU的参与者，但是每天服用400IU的参与者没有显著升高。,0.5,"['who', 'serum', 'D', 'but']","['serum', 'but']",,,,
1250,1240,"at 3 years , declines in BMD at the radius were significantly steeper in the 4000 IU and 10,000 IU groups ( − 2.4 % and − 3.5 % , respectively ) than in the 400 IU group ( − 1.2 % ) .","3 年时，4000 IU 和 10,000 IU 组（分别为 - 2.4% 和 - 3.5%）的桡骨 BMD 下降幅度明显大于 400 IU 组（-1.2%）。",0.4285714285714285,"['group', 'radius', '3', 'at', 'steeper', 'in', 'and']","['group', 'radius', 'at']",1240,"['在3年,在4000 IU和10,000 IU群体( − 2.4 % 和 − 3.5 % 相应)中,比400 IU群体( − 1.2 % )显著下降。']",0.1428571428571428,"['group', 'radius', '3', 'at', 'steeper', 'in', 'and']",['group'],1240,在3年的时间里，半径的骨密度的下降在4000IU和10000IU的组别里比400IU的组别要明显的快（分别是2.4%和3.5%）。,0.1428571428571428,"['group', 'radius', '3', 'at', 'steeper', 'in', 'and']",['group'],,,,
1251,1241,a similar pattern was noted in the tibia .,在胫骨中发现了类似的模式。,0.5,"['pattern', 'tibia', 'in', 'similar']","['pattern', 'tibia']",1241,['类似的模型在Tibia中被注意到。'],0.25,"['pattern', 'tibia', 'in', 'similar']",['pattern'],1241,一个类似的模式在腿骨中也有所体现。,0.25,"['pattern', 'tibia', 'in', 'similar']",['pattern'],,,,
1252,1242,the authors speculate that this somewhat unexpected finding might be due to increased bone resorption secondary to parathyroid hormone suppression .,作者推测，这一有点出乎意料的发现可能是由于甲状旁腺激素抑制继发的骨吸收增加所致。,0.6666666666666666,"['parathyroid hormone', 'suppression', 'bone resorption', 'be', 'secondary', 'due', 'this', 'that', 'to']","['parathyroid hormone', 'suppression', 'bone resorption', 'secondary', 'this', 'to']",1242,"['作者猜测,这种有点意想不到的发现可能是由于增加的骨质吸收二次到甲状腺激素抑制。']",0.3333333333333333,"['parathyroid hormone', 'suppression', 'bone resorption', 'be', 'secondary', 'due', 'this', 'that', 'to']","['suppression', 'this', 'to']",1242,作者推测，这一略意外的发现可能是由于降低的钙质摄入导致的副甲状腺激素抑制所致。,0.3333333333333333,"['parathyroid hormone', 'suppression', 'bone resorption', 'be', 'secondary', 'due', 'this', 'that', 'to']","['suppression', 'this', 'to']",,,,
1253,1243,"in relatively healthy diabetic patients , this drug showed promise for primary prevention .",在相对健康的糖尿病患者中，这种药物有望用于一级预防。,0.6666666666666666,"['diabetic', 'primary prevention', 'drug', 'this', 'in', 'healthy']","['diabetic', 'primary prevention', 'drug', 'healthy']",1243,"['在相对健康的糖尿病患者中,这种药物表现出初级预防的承诺。']",0.5,"['diabetic', 'primary prevention', 'drug', 'this', 'in', 'healthy']","['diabetic', 'drug', 'healthy']",1243,在相对健康的糖尿病患者中，这种药物显示出了预防性的希望。,0.5,"['diabetic', 'primary prevention', 'drug', 'this', 'in', 'healthy']","['diabetic', 'drug', 'healthy']",,,,
1254,1244,"in trials with primary CV outcomes , liraglutide and semaglutide also prevented some prespecified chronic renal outcomes .",在具有主要 CV 结果的试验中，利拉鲁肽和索马鲁肽还可以预防一些预先指定的慢性肾脏结果。,0.375,"['chronic', 'primary', 'renal', 'with', 'semaglutide', 'liraglutide', 'in', 'and']","['chronic', 'semaglutide', 'liraglutide']",1244,"['在初级CV结果的试验中,Liraglutide和Semaglutide也预防了一些预定慢性肾脏结果。']",0.125,"['chronic', 'primary', 'renal', 'with', 'semaglutide', 'liraglutide', 'in', 'and']",['chronic'],1244,在以主要心血管疾病结局为限定条件的试验中，利拉酮和赛乐美也可以预防一些既定的慢性肾脏疾病。,0.125,"['chronic', 'primary', 'renal', 'with', 'semaglutide', 'liraglutide', 'in', 'and']",['chronic'],,,,
1255,1245,the difference was driven primarily by nonfatal strokes .,这种差异主要是由非致命性中风造成的。,1.0,"['difference', 'by']","['difference', 'by']",1245,['这种差异主要是由非致命的发作引起的。'],1.0,"['difference', 'by']","['difference', 'by']",1245,主要是由非致命性中风导致的差异。,1.0,"['difference', 'by']","['difference', 'by']",,,,
1256,1246,hazard ratios were similar for patients with and without prior CV disease .,有和没有既往心血管疾病的患者的风险比相似。,0.1666666666666666,"['disease', 'hazard', 'prior', 'and', 'without', 'similar']",['disease'],1246,['风险比例类似于患有和没有先前的CV疾病的患者。'],0.3333333333333333,"['disease', 'hazard', 'prior', 'and', 'without', 'similar']","['disease', 'prior']",1246,危险比在有无既往心血管疾病的患者中相似。,0.5,"['disease', 'hazard', 'prior', 'and', 'without', 'similar']","['disease', 'hazard', 'without']",,,,
1257,1247,a composite microvascular ( retinal and renal ) outcome also occurred significantly less frequently in the dulaglutide group .,dulaglutide 组复合微血管（视网膜和肾脏）结果的发生频率也显着降低。,0.25,"['group', 'composite', 'retinal', 'outcome', 'frequently', 'renal', 'dulaglutide', 'and']","['group', 'outcome']",1247,['合成微血管(网膜和肾脏)的结果也发生在杜拉格卢蒂德群体中显著较少。'],0.25,"['group', 'composite', 'retinal', 'outcome', 'frequently', 'renal', 'dulaglutide', 'and']","['group', 'outcome']",1247,在dulaglutide组中，复合微血管（视网膜和肾脏）结果也显著减少。,0.25,"['group', 'composite', 'retinal', 'outcome', 'frequently', 'renal', 'dulaglutide', 'and']","['group', 'outcome']",,,,
1258,1248,"recent advances in molecular technology have made whole genome sequencing ( WGS ) widely available to microbiology laboratories , enabling resistance testing at the molecular level .",分子技术的最新进展已使全基因组测序 (WGS) 广泛应用于微生物实验室，从而能够在分子水平上进行耐药性测试。,0.5714285714285714,"['genome', 'microbiology', 'resistance', 'sequencing', 'recent', 'molecular', 'available', 'technology', 'level', 'testing', 'at', 'have', 'whole', 'to']","['genome', 'resistance', 'sequencing', 'molecular', 'technology', 'level', 'at', 'to']",1248,"['最近在分子技术的进步使整体基因组序列(WGS)广泛可用于微生物学实验室,允许在分子层面进行抵抗测试。']",0.5714285714285714,"['genome', 'microbiology', 'resistance', 'sequencing', 'recent', 'molecular', 'available', 'technology', 'level', 'testing', 'at', 'have', 'whole', 'to']","['genome', 'microbiology', 'resistance', 'molecular', 'technology', 'at', 'whole', 'to']",1248,最近在分子技术方面的进展使全基因测序（WGS）广泛可用于微生物实验室，从而实现分子水平的抗性测试。,0.5,"['genome', 'microbiology', 'resistance', 'sequencing', 'recent', 'molecular', 'available', 'technology', 'level', 'testing', 'at', 'have', 'whole', 'to']","['resistance', 'sequencing', 'molecular', 'technology', 'level', 'at', 'to']",,,,
1259,1249,"resistance testing by WGS is particularly attractive for mycobacteria , as all resistance is coded in the mycobacterial genome and not in plasmids .",WGS 的耐药性测试对分枝杆菌特别有吸引力，因为所有耐药性都编码在分枝杆菌基因组中，而不是在质粒中。,0.5,"['genome', 'mycobacteria', 'resistance', 'testing', 'as', 'all', 'by', 'and']","['genome', 'mycobacteria', 'resistance', 'and']",1249,"['WGS的抵抗测试对微细菌特别有吸引力,因为所有的抵抗都在微细菌基因组中编码,而不是在血浆中。']",0.375,"['genome', 'mycobacteria', 'resistance', 'testing', 'as', 'all', 'by', 'and']","['genome', 'resistance', 'and']",1249,通过WGS进行抗性测试对于结核分枝杆菌尤其具有吸引力，因为所有抗性都存储在结核分枝杆菌基因组中，而不是存储在质粒中。,0.5,"['genome', 'mycobacteria', 'resistance', 'testing', 'as', 'all', 'by', 'and']","['genome', 'mycobacteria', 'resistance', 'and']",,,,
1260,1250,MGIT retesting at additional antimycobacterial drug concentrations could be performed on 48 isolates .,可以对 48 个分离株进行额外抗分枝杆菌药物浓度的 MGIT 重新测试。,0.2,"['be', 'additional', 'drug', 'concentrations', 'isolates']",['drug'],1250,['MGIT在额外的抗微细菌药物浓度的重新测试可以在48个隔离器上进行。'],0.6,"['be', 'additional', 'drug', 'concentrations', 'isolates']","['be', 'additional', 'drug']",1250,在 MGIT 中额外的抗结核药物浓度可以对 48 个分离物进行重新测试。,0.6,"['be', 'additional', 'drug', 'concentrations', 'isolates']","['be', 'additional', 'drug']",,,,
1261,1251,"of 80 patients enrolled , 88 % achieved complete remission after 12 cycles ; 61 % were minimal residual disease ( MRD ) -negative by multicolor flow cytometry , increasing to 89 % after 18 cycles .",在入组的 80 名患者中，88% 在 12 个周期后达到完全缓解；多色流式细胞术显示 61% 为微小残留病 (MRD) 阴性，18 个周期后增加到 89%。,0.4,"['disease', 'flow cytometry', 'multicolor', 'complete', 'after', 'minimal', 'remission', 'residual', 'achieved', 'by']","['disease', 'flow cytometry', 'after', 'remission']",1251,"['在80名病人中,88%在12个周期后获得了完整的康复;61%是由多色流量细胞测量负的最低残留性疾病(MRD),增加到18个周期后89%。']",0.4,"['disease', 'flow cytometry', 'multicolor', 'complete', 'after', 'minimal', 'remission', 'residual', 'achieved', 'by']","['disease', 'complete', 'after', 'by']",1251,在入籍的80名患者中，88％在12个循环后达到完全缓解；61％的患者通过多色流式细胞仪检测无最小残留疾病（MRD），在18个循环后增加到89％。,0.4,"['disease', 'flow cytometry', 'multicolor', 'complete', 'after', 'minimal', 'remission', 'residual', 'achieved', 'by']","['disease', 'flow cytometry', 'after', 'remission']",,,,
1262,1252,there were no unexpected toxicities ; three patients had laboratory but not clinical evidence of tumor lysis syndrome .,没有意外的毒性；三名患者有肿瘤溶解综合征的实验室证据，但没有临床证据。,0.7777777777777778,"['lysis', 'syndrome', 'tumor', 'no', 'clinical', 'laboratory', 'evidence', 'three', 'but']","['lysis', 'syndrome', 'tumor', 'clinical', 'laboratory', 'evidence', 'but']",1252,['没有意想不到的毒性;三名患者有实验室但没有临床证据的肿瘤利西斯综合征。'],0.6666666666666666,"['lysis', 'syndrome', 'tumor', 'no', 'clinical', 'laboratory', 'evidence', 'three', 'but']","['syndrome', 'tumor', 'clinical', 'laboratory', 'evidence', 'but']",1252,没有意料之外的毒性作用；三名患者的实验室检查显示有肿瘤溶解综合征的迹象，但临床上没有体现。,0.6666666666666666,"['lysis', 'syndrome', 'tumor', 'no', 'clinical', 'laboratory', 'evidence', 'three', 'but']","['lysis', 'syndrome', 'tumor', 'clinical', 'laboratory', 'but']",,,,
1263,1253,the immunomodulatory drug lenalidomide ( L ) plus weekly dexamethasone ( d ) is a standard induction regimen ( Ld ) for patients with myeloma who are ineligible for autologous stem cell transplant ( SCT ) consolidation therapy .,免疫调节药物来那度胺 (L) 加每周一次地塞米松 (d) 是标准诱导方案 (Ld)，适用于不适合自体干细胞移植 (SCT) 巩固治疗的骨髓瘤患者。,0.6,"['stem cell', 'induction', 'standard', 'transplant', 'who', 'myeloma', 'consolidation', 'plus', 'therapy', 'autologous', 'with', 'drug', 'dexamethasone', 'SCT', 'ld']","['stem cell', 'induction', 'standard', 'myeloma', 'consolidation', 'plus', 'therapy', 'drug', 'dexamethasone']",1253,"['免疫调节药物Lenalidomide(L)加上每周的dexamethasone(d)是一种标准的引导制度(Ld)对于患有甲状腺炎的患者,他们无法接受自闭性干细胞移植(SCT)的巩固治疗。']",0.4666666666666667,"['stem cell', 'induction', 'standard', 'transplant', 'who', 'myeloma', 'consolidation', 'plus', 'therapy', 'autologous', 'with', 'drug', 'dexamethasone', 'SCT', 'ld']","['stem cell', 'induction', 'standard', 'consolidation', 'plus', 'therapy', 'drug']",1253,西莱替尼联合每周度的地塞米松是非自体干细胞移植合并疗法的标准诱导方案。,0.4,"['stem cell', 'induction', 'standard', 'transplant', 'who', 'myeloma', 'consolidation', 'plus', 'therapy', 'autologous', 'with', 'drug', 'dexamethasone', 'SCT', 'ld']","['stem cell', 'induction', 'standard', 'consolidation', 'therapy', 'dexamethasone']",,,,
1264,1254,a total of 737 patients were randomized equally to receive a median of 27 LdD cycles versus 22 Ld cycles .,共有 737 名患者被平均随机分配接受 27 个 LdD 周期和 22 个 Ld 周期的中位数。,0.0,"['median', 'total', 'ld']",[],1254,['总共737名患者被随机分配到27个Ld周期对22个Ld周期的平均水平。'],0.0,"['median', 'total', 'ld']",[],1254,总计737名病人随机分配接受27个治疗周期或22个治疗周期。,0.0,"['median', 'total', 'ld']",[],,,,
1265,1255,"rates of complete response , patient survival at 30 months , and achievement of minimal residual disease negativity were all significantly higher with LdD .",LdD 的完全缓解率、患者 30 个月存活率和微小残留病阴性率均显着提高。,0.2727272727272727,"['disease', 'survival', 'complete', 'response', 'patient', 'minimal', 'achievement', 'residual', 'with', 'all', 'and']","['disease', 'survival', 'patient']",1255,['完全回应率、30个月的患者生存率和最低残留性疾病负度的实现率都显著高于LdD。'],0.2727272727272727,"['disease', 'survival', 'complete', 'response', 'patient', 'minimal', 'achievement', 'residual', 'with', 'all', 'and']","['disease', 'survival', 'patient']",1255,完全应答率、30个月患者生存率和最小残留疾病阴性率均显著提高于LdD。,0.2727272727272727,"['disease', 'survival', 'complete', 'response', 'patient', 'minimal', 'achievement', 'residual', 'with', 'all', 'and']","['disease', 'survival', 'patient']",,,,
1266,1256,the intervention group also had more frequent grade 3 to 4 neutropenia ( 50 % vs. 35.3 % ) and pneumonia ( 13.7 % vs. 7.9 % ),干预组也更频繁地出现 3 至 4 级中性粒细胞减少症（ 50 % 对 35.3 % ）和肺炎（ 13.7 % 对 7.9 % ）,0.3,"['group', 'grade', 'neutropenia', 'intervention', '3', '4', 'pneumonia', 'frequent', 'to', 'and']","['group', 'neutropenia', 'pneumonia']",1256,['干预小组也患有更频繁的3至4级中风(50%与35.3%)和肺炎(13.7%与7.9%)。'],0.2,"['group', 'grade', 'neutropenia', 'intervention', '3', '4', 'pneumonia', 'frequent', 'to', 'and']","['group', 'pneumonia']",1256,干预组患者的中度至重度中性粒细胞减少（50% vs. 35.3%）和肺炎（13.7% vs. 7.9%）的发病率也较高。,0.3,"['group', 'grade', 'neutropenia', 'intervention', '3', '4', 'pneumonia', 'frequent', 'to', 'and']","['group', 'grade', 'pneumonia']",,,,
1267,1257,the FDA recently approved daratumumab in combination with lenalidomide and dexamethasone for treating newly diagnosed multiple myeloma in patients ineligible for SCT .,FDA 最近批准了 daratumumab 联合来那度胺和地塞米松用于治疗不适合 SCT 的新诊断多发性骨髓瘤患者。,0.375,"['combination', 'multiple myeloma', 'FDA', 'with', 'daratumumab', 'dexamethasone', 'SCT', 'and']","['combination', 'multiple myeloma', 'dexamethasone']",1257,"['FDA最近批准了Daratumumab与Lenalidomide和Dexamethasone相结合,用于治疗新诊断的多发性甲状腺肿瘤在不适用于SCT的患者。']",0.125,"['combination', 'multiple myeloma', 'FDA', 'with', 'daratumumab', 'dexamethasone', 'SCT', 'and']",['combination'],1257,FDA最近批准了达拉图姆马与莱纳利多姆和地塞米松联合治疗新诊断的非适合SCT的多发性骨髓瘤患者。,0.375,"['combination', 'multiple myeloma', 'FDA', 'with', 'daratumumab', 'dexamethasone', 'SCT', 'and']","['combination', 'multiple myeloma', 'dexamethasone']",,,,
1268,1258,demonstration of airway obstruction ( by spirometry ) is required for diagnosing chronic obstructive pulmonary disease ( COPD ) .,诊断慢性阻塞性肺病 (COPD) 需要证明气道阻塞（通过肺量计）。,0.4444444444444444,"['COPD', 'disease', 'obstructive', 'pulmonary', 'demonstration', 'chronic', 'spirometry', 'airway obstruction', 'by']","['COPD', 'disease', 'chronic', 'airway obstruction']",1258,['空气阻塞的表现(通过螺旋测量)是必要的诊断慢性阻塞性肺疾病(COPD)。'],0.3333333333333333,"['COPD', 'disease', 'obstructive', 'pulmonary', 'demonstration', 'chronic', 'spirometry', 'airway obstruction', 'by']","['COPD', 'disease', 'chronic']",1258,A demonstration of airway obstruction by spirometry is required for diagnosing chronic obstructive pulmonary disease (COPD).,0.1111111111111111,"['COPD', 'disease', 'obstructive', 'pulmonary', 'demonstration', 'chronic', 'spirometry', 'airway obstruction', 'by']",['COPD'],,,,
1269,1259,current Global Initiative for Chronic Obstructive Lung Disease ( GOLD ) guidelines recommend use of a fixed threshold of forced expiratory volume in 1 second to forced vital capacity ( FEV1 : FVC ) of 0.70 .,目前全球慢性阻塞性肺疾病倡议 (GOLD) 指南建议使用 0.70 的固定阈值，即 1 秒内用力呼气容积至用力肺活量 (FEV1:FVC)。,0.5625,"['lung', 'threshold', 'volume', 'disease', 'global', 'obstructive', 'expiratory', 'recommend', 'vital capacity', 'chronic', 'fixed', 'forced', 'current', 'initiative', 'FEV1', 'second']","['lung', 'threshold', 'volume', 'disease', 'global', 'recommend', 'vital capacity', 'chronic', 'second']",1259,['现行《慢性阻塞性肺病全球倡议(GOLD)指南》建议在1秒内使用强制性生命容量(FEV1:FVC)的固定限度为0.70。'],0.375,"['lung', 'threshold', 'volume', 'disease', 'global', 'obstructive', 'expiratory', 'recommend', 'vital capacity', 'chronic', 'fixed', 'forced', 'current', 'initiative', 'FEV1', 'second']","['lung', 'disease', 'global', 'recommend', 'chronic', 'second']",1259,根据目前的慢性阻塞性肺疾病（GOLD）指南，建议使用0.70的固定阈值来衡量每秒钟的强迫呼气量与自主呼吸量（FEV1：FVC）。,0.375,"['lung', 'threshold', 'volume', 'disease', 'global', 'obstructive', 'expiratory', 'recommend', 'vital capacity', 'chronic', 'fixed', 'forced', 'current', 'initiative', 'FEV1', 'second']","['lung', 'threshold', 'disease', 'recommend', 'chronic', 'second']",,,,
1270,1260,"researchers studied more than 24,000 patients ( mean age , 63 ) from four large U.S. cohorts to identify the appropriate FEV1 : FVC threshold for COPD diagnosis .","研究人员对来自美国四大队列的 24,000 多名患者（平均年龄 63 岁）进行了研究，以确定适合 COPD 诊断的 FEV1:FVC 阈值。",0.4545454545454545,"['threshold', 'COPD', 'mean', 'large', 'diagnosis', 'age', 'identify', 'cohorts', 'FEV1', 'to', 'appropriate']","['threshold', 'COPD', 'mean', 'diagnosis', 'age']",1260,"['研究人员研究了来自美国四大联盟的24000多名患者(平均年龄,63岁),以确定适当的FEV1:FVC对COPD诊断的边界。']",0.3636363636363636,"['threshold', 'COPD', 'mean', 'large', 'diagnosis', 'age', 'identify', 'cohorts', 'FEV1', 'to', 'appropriate']","['COPD', 'mean', 'diagnosis', 'age']",1260,研究人员研究了来自美国四个大型队列的24000多名病人（平均年龄63岁），以确定COPD诊断的适当FEV1：FVC阈值。,0.4545454545454545,"['threshold', 'COPD', 'mean', 'large', 'diagnosis', 'age', 'identify', 'cohorts', 'FEV1', 'to', 'appropriate']","['threshold', 'COPD', 'mean', 'diagnosis', 'age']",,,,
1271,1261,"when the LLN was used , COPD was diagnosed in 15 % of patients .",使用 LLN 时，15% 的患者被诊断为 COPD。,0.5,"['COPD', 'in']",['COPD'],1261,"['当使用LLN时,COPD被诊断为15%的患者。']",1.0,"['COPD', 'in']","['COPD', 'in']",1261,当使用LLN时，有15%的病人被诊断出患有COPD。,1.0,"['COPD', 'in']","['COPD', 'in']",,,,
1272,1262,more than a quarter of the population showed obstruction with a threshold ratio of 0.70 .,超过四分之一的人口表现出障碍，阈值比为 0.70。,0.6666666666666666,"['population', 'threshold', 'ratio', 'quarter', 'obstruction', 'with']","['population', 'threshold', 'ratio', 'obstruction']",1262,"['超过四分之一的人口表现出障碍,边界比率为0.70。']",0.6666666666666666,"['population', 'threshold', 'ratio', 'quarter', 'obstruction', 'with']","['population', 'ratio', 'quarter', 'obstruction']",1262,超过四分之一的人口表现出了0.70的阻碍阈值。,0.3333333333333333,"['population', 'threshold', 'ratio', 'quarter', 'obstruction', 'with']","['population', 'threshold']",,,,
1273,1263,"in subgroup analyses based on height and sociodemographic criteria , the threshold of 0.70 was consistently accurate .",在基于身高和社会人口学标准的亚组分析中，0.70 的阈值始终是准确的。,0.2857142857142857,"['threshold', 'height', 'accurate', 'subgroup', 'on', 'in', 'and']","['threshold', 'accurate']",1263,"['在基于高度和社会人口学标准的子组分析中,0.70的边界是一致准确的。']",0.2857142857142857,"['threshold', 'height', 'accurate', 'subgroup', 'on', 'in', 'and']","['height', 'accurate']",1263,在基于身高和社会经济因素的亚组分析中，0.70的阈值始终是准确的。,0.2857142857142857,"['threshold', 'height', 'accurate', 'subgroup', 'on', 'in', 'and']","['threshold', 'accurate']",,,,
1274,1264,it should encourage clinicians to stop using LLN for this purpose .,它应该鼓励临床医生停止为此目的使用 LLN。,0.5,"['encourage', 'purpose', 'this', 'stop']","['encourage', 'purpose']",1264,['应该鼓励诊所医生停止使用LLN为此目的。'],0.5,"['encourage', 'purpose', 'this', 'stop']","['encourage', 'purpose']",1264,"It should encourage clinicians to stop using LLN for this purpose.

Chinese:

这应该鼓励临床医师不再使用最低限度值来进行这一目的。",0.5,"['encourage', 'purpose', 'this', 'stop']","['encourage', 'purpose']",,,,
1275,1265,"using height and sex , along with race , which is problematic for a variety of reasons , does not help and probably results in missing patients who would benefit from COPD care .",使用身高、性别以及种族（出于各种原因而存在问题）无济于事，而且可能会导致错过可从 COPD 护理中受益的患者。,0.3333333333333333,"['height', 'COPD', 'who', 'sex', 'variety', 'along', 'race', 'care', 'benefit', 'with', 'and', 'missing']","['COPD', 'sex', 'race', 'and']",1265,"['使用高度和性别,以及种族,这是有问题的各种原因,没有帮助,并可能导致缺席的患者谁将受益于COPD护理。']",0.4166666666666667,"['height', 'COPD', 'who', 'sex', 'variety', 'along', 'race', 'care', 'benefit', 'with', 'and', 'missing']","['height', 'COPD', 'sex', 'race', 'missing']",1265,"Using height and sex, along with race, which is problematic for a variety of reasons, does not help and probably results in missing patients who would benefit from COPD care.

Chinese:

使用身高和性别，以及有问题的种族，这导致了许多问题，不能提供帮助，并可能导致患者受益于COPD护理的漏诊。",0.25,"['height', 'COPD', 'who', 'sex', 'variety', 'along', 'race', 'care', 'benefit', 'with', 'and', 'missing']","['COPD', 'sex', 'race']",,,,
1276,1266,approximately 10 % to 15 % of strokes occur in adults younger than 50 years .,大约 10% 到 15% 的中风发生在 50 岁以下的成年人身上。,0.25,"['occur', 'approximately', 'in', 'to']",['occur'],1266,['大约10%至15%的发作发生在50岁以下的成年人。'],0.25,"['occur', 'approximately', 'in', 'to']",['occur'],1266,约10%到15%的中风发生在50岁以下的成年人身上。,0.25,"['occur', 'approximately', 'in', 'to']",['occur'],,,,
1277,1267,"to provide such information , investigators examined outcomes among 15,257 survivors of stroke at age 18 through 49 ( median age , 44 ; 53 % women ) , identified from nationwide hospital and population registries in the Netherlands .","为提供此类信息，研究人员检查了 15,257 名年龄在 18 岁至 49 岁之间的中风幸存者（中位年龄为 44 岁；53% 为女性）的结果，这些幸存者来自荷兰的全国性医院和人口登记处。",0.5714285714285714,"['population', 'stroke', 'information', 'hospital', 'median age', 'to', 'and']","['population', 'stroke', 'information', 'hospital']",1267,"['为了提供此类信息,调查人员对18至49岁的15257名中风幸存者(平均年龄44%;女性53%)的结果进行了调查,这些结果来自荷兰全国医院和人口记录。']",0.5714285714285714,"['population', 'stroke', 'information', 'hospital', 'median age', 'to', 'and']","['population', 'stroke', 'information', 'hospital']",1267,"为了提供此类信息，研究人员对荷兰全国医院和人口登记册中年龄为18岁至49岁（中位年龄为44岁；53％为女性）的15,257名中风幸存者进行了研究。",0.5714285714285714,"['population', 'stroke', 'information', 'hospital', 'median age', 'to', 'and']","['population', 'stroke', 'information', 'hospital']",,,,
1278,1268,stroke patients who had their first stroke in the years 1998 through 2010 were followed until 2017 .,对 1998 年至 2010 年间首次中风的中风患者进行了随访，直至 2017 年。,0.25,"['stroke', 'who', 'in', 'first']",['stroke'],1268,['在1998年至2010年间首次发病的中风患者一直在追踪到2017年。'],0.25,"['stroke', 'who', 'in', 'first']",['stroke'],1268,1998年至2010年的中风患者被跟踪至2017年。,0.25,"['stroke', 'who', 'in', 'first']",['stroke'],,,,
1279,1269,"secondary endpoints were mortality according to stroke subtype ( ischemic , hemorrhagic ) and observed mortality compared with expected mortality in a population of comparable age .",次要终点是根据中风亚型（缺血性、出血性）分类的死亡率，以及在可比年龄人群中观察到的死亡率与预期死亡率的比较。,0.3636363636363636,"['population', 'stroke', 'mortality', 'age', 'hemorrhagic', 'secondary', 'with', 'in', 'to', 'and', 'ischemic']","['population', 'stroke', 'mortality', 'age']",1269,['其次的终点是根据中风子型死亡率(以化学、血管)和观察到死亡率与相似年龄的人口的预期死亡率相比。'],0.3636363636363636,"['population', 'stroke', 'mortality', 'age', 'hemorrhagic', 'secondary', 'with', 'in', 'to', 'and', 'ischemic']","['population', 'stroke', 'mortality', 'age']",1269,次要终点包括根据脑卒中子类型（缺血性、出血性）的死亡率以及与同龄人群的预期死亡率相比观察到的死亡率。,0.2727272727272727,"['population', 'stroke', 'mortality', 'age', 'hemorrhagic', 'secondary', 'with', 'in', 'to', 'and', 'ischemic']","['population', 'stroke', 'mortality']",,,,
1280,1270,"in the first 30 days after stroke , 1776 of the patients died .",在中风后的头30天内，有1776名患者死亡。,0.5,"['stroke', 'after', 'in', 'first']","['stroke', 'after']",1270,"['在发作后的前30天,1776名病人死亡。']",0.5,"['stroke', 'after', 'in', 'first']","['stroke', 'after']",1270,在中風後的30天內，有1776名病人死亡。,0.25,"['stroke', 'after', 'in', 'first']",['stroke'],,,,
1281,1271,SMR was similar for men and women .,男性和女性的 SMR 相似。,0.0,"['and', 'similar']",[],1271,['SMR对男性和女性来说是相似的。'],0.5,"['and', 'similar']",['similar'],1271,"SMR was similar for men and women.

Chinese:

SMR 男女间相似。",0.0,"['and', 'similar']",[],,,,
1282,1272,the decrease in mortality over the study period could be due to more widespread use of antihypertensive medications and statins .,研究期间死亡率的下降可能是由于更广泛地使用抗高血压药物和他汀类药物。,0.4545454545454545,"['antihypertensive', 'period', 'decrease', 'statins', 'study', 'be', 'mortality', 'due', 'over', 'to', 'and']","['antihypertensive', 'period', 'statins', 'mortality', 'to']",1272,['研究期间死亡率的下降可能是由于抗高血压药物和静素的广泛使用。'],0.3636363636363636,"['antihypertensive', 'period', 'decrease', 'statins', 'study', 'be', 'mortality', 'due', 'over', 'to', 'and']","['antihypertensive', 'period', 'mortality', 'to']",1272,在研究期间，死亡率的下降可能是由于更广泛使用降压药和他汀类药物所致。,0.5454545454545454,"['antihypertensive', 'period', 'decrease', 'statins', 'study', 'be', 'mortality', 'due', 'over', 'to', 'and']","['antihypertensive', 'period', 'statins', 'be', 'mortality', 'to']",,,,
1283,1273,deoxygenated sickle hemoglobin ( HbS ) polymerization drives the pathophysiology of sickle cell disease .,脱氧镰状血红蛋白 (HbS) 聚合驱动镰状细胞病的病理生理学。,0.8333333333333334,"['disease', 'pathophysiology', 'hemoglobin', 'sickle cell', 'polymerization', 'hbs']","['disease', 'pathophysiology', 'hemoglobin', 'sickle cell', 'polymerization']",1273,['脱氧化<unk>血球(HbS)聚合物化推动<unk>细胞疾病的病理学。'],0.3333333333333333,"['disease', 'pathophysiology', 'hemoglobin', 'sickle cell', 'polymerization', 'hbs']","['disease', 'polymerization']",1273,"Deoxygenated sickle hemoglobin (HbS) polymerization drives the pathophysiology of sickle cell disease.

Chinese:

脱氧血红蛋白 (HbS) 聚合物驱动着细胞异常溶解症的病理生理学。",0.6666666666666666,"['disease', 'pathophysiology', 'hemoglobin', 'sickle cell', 'polymerization', 'hbs']","['disease', 'pathophysiology', 'hemoglobin', 'polymerization']",,,,
1284,1274,"therefore , direct inhibition of HbS polymerization has potential to favorably modify disease outcomes .",因此，直接抑制 HbS 聚合有可能改善疾病结果。,0.4444444444444444,"['inhibition', 'disease', 'potential', 'polymerization', 'direct', 'modify', 'therefore', 'to', 'hbs']","['inhibition', 'disease', 'polymerization', 'direct']",1274,"['因此,HbS聚合物的直接抑制有可能有利于改变疾病的结果。']",0.5555555555555556,"['inhibition', 'disease', 'potential', 'polymerization', 'direct', 'modify', 'therefore', 'to', 'hbs']","['inhibition', 'disease', 'polymerization', 'direct', 'to']",1274,因此，直接抑制HbS聚合具有改善疾病结局的潜力。,0.5555555555555556,"['inhibition', 'disease', 'potential', 'polymerization', 'direct', 'modify', 'therefore', 'to', 'hbs']","['inhibition', 'disease', 'potential', 'polymerization', 'direct']",,,,
1285,1275,voxelotor is an HbS polymerization inhibitor .,voxelotor 是一种 HbS 聚合抑制剂。,0.6666666666666666,"['inhibitor', 'polymerization', 'hbs']","['inhibitor', 'polymerization']",1275,['voxelotor 是一种 HbS 聚合物抑制剂。'],0.6666666666666666,"['inhibitor', 'polymerization', 'hbs']","['inhibitor', 'polymerization']",1275,voxelotor是一種阻止HbS聚合的藥物。,0.3333333333333333,"['inhibitor', 'polymerization', 'hbs']",['polymerization'],,,,
1286,1276,anemia worsened between baseline and week 24 in fewer participants in each voxelotor dose group than in those receiving placebo .,在基线和第 24 周之间，每个 voxelotor 剂量组的参与者比接受安慰剂的参与者更少贫血恶化。,0.75,"['anemia', 'group', 'placebo', 'baseline', 'week', 'dose', 'each', 'and']","['anemia', 'group', 'placebo', 'baseline', 'week', 'dose']",1276,"['贫血在基因和24周之间恶化,在每个Voxelotor剂量组的参与者较少,而不是接受 placebo的人。']",0.625,"['anemia', 'group', 'placebo', 'baseline', 'week', 'dose', 'each', 'and']","['anemia', 'group', 'week', 'dose', 'and']",1276,在基线和第24周之间，血液中较少参与者的贫血状况越来越严重，而那些接受安慰剂的参与者则要少得多。,0.625,"['anemia', 'group', 'placebo', 'baseline', 'week', 'dose', 'each', 'and']","['anemia', 'placebo', 'baseline', 'week', 'and']",,,,
1287,1277,the percentage of participants with an adverse event that occurred or worsened during the treatment period was similar across the trial groups .,在治疗期间发生或恶化不良事件的参与者百分比在各试验组中相似。,0.3333333333333333,"['percentage', 'period', 'treatment', 'across', 'adverse event', 'trial', 'with', 'that', 'similar']","['period', 'treatment', 'adverse event']",1277,['治疗期间发生或恶化不良事件的参与者比例在试验组中相似。'],0.3333333333333333,"['percentage', 'period', 'treatment', 'across', 'adverse event', 'trial', 'with', 'that', 'similar']","['period', 'treatment', 'adverse event']",1277,發生不良事件或加劇的參與者百分比在試驗組間相似。,0.1111111111111111,"['percentage', 'period', 'treatment', 'across', 'adverse event', 'trial', 'with', 'that', 'similar']",['adverse event'],,,,
1288,1278,"most adverse events were not related to the trial drug or placebo , as determined by the investigators .",经研究人员确定，大多数不良事件与试验药物或安慰剂无关。,0.2857142857142857,"['placebo', 'adverse', 'trial', 'as', 'drug', 'by', 'to']","['placebo', 'drug']",1278,"['大多数不良事件与试验药物或 placebo 无关,根据调查人员的确定。']",0.1428571428571428,"['placebo', 'adverse', 'trial', 'as', 'drug', 'by', 'to']",['drug'],1278,大多数不良事件与试验药物或安慰剂无关，据研究人员确定。,0.2857142857142857,"['placebo', 'adverse', 'trial', 'as', 'drug', 'by', 'to']","['placebo', 'drug']",,,,
1289,1279,"sickle cell disease affects approximately 100,000 persons in the United States and reduces life expectancy by approximately 30 years.1","在美国，镰状细胞病影响了大约 100,000 人，预期寿命减少了大约 30 年。 1",0.4285714285714285,"['disease', 'life expectancy', 'sickle cell', 'approximately', 'in', 'by', 'and']","['disease', 'life expectancy', 'sickle cell']",1279,"['甲状腺细胞疾病影响美国约10万人,寿命减少约30年。']",0.1428571428571428,"['disease', 'life expectancy', 'sickle cell', 'approximately', 'in', 'by', 'and']",['disease'],1279,美国大约有10万人患有锯细胞病，导致其平均寿命缩短约30年。1,0.1428571428571428,"['disease', 'life expectancy', 'sickle cell', 'approximately', 'in', 'by', 'and']",['disease'],,,,
1290,1280,the disease is caused by a single amino acid substitution resulting in the production of sickle hemoglobin ( HbS ) .2,该疾病是由导致镰状血红蛋白 (HbS) 产生的单一氨基酸替代引起的 .2,0.6666666666666666,"['production', 'substitution', 'disease', 'amino acid', 'hemoglobin', 'sickle', 'single', 'by', 'hbs']","['substitution', 'disease', 'amino acid', 'hemoglobin', 'single', 'by']",1280,"['这种疾病是由单一的氨基酸替代引起的,导致细胞血球(HbS)的产生。']",0.5555555555555556,"['production', 'substitution', 'disease', 'amino acid', 'hemoglobin', 'sickle', 'single', 'by', 'hbs']","['substitution', 'disease', 'amino acid', 'single', 'by']",1280,这种疾病是由一个氨基酸替换引起的，导致镰状血红蛋白（HbS）的产生。,0.5555555555555556,"['production', 'substitution', 'disease', 'amino acid', 'hemoglobin', 'sickle', 'single', 'by', 'hbs']","['substitution', 'disease', 'amino acid', 'hemoglobin', 'by']",,,,
1291,1281,"in particular , chronic organ dysfunction has become a leading cause of death in adults with sickle cell disease in the United States.10,11","特别是，慢性器官功能障碍已成为美国镰状细胞病成人的主要死因。 10,11",0.6,"['organ', 'dysfunction', 'disease', 'particular', 'sickle cell', 'chronic', 'cause of death', 'leading', 'with', 'become']","['organ', 'disease', 'sickle cell', 'chronic', 'cause of death', 'become']",1281,"['特别是,慢性器官功能障碍已成为美国患有<unk>细胞疾病的成年人死亡的主要原因。']",0.4,"['organ', 'dysfunction', 'disease', 'particular', 'sickle cell', 'chronic', 'cause of death', 'leading', 'with', 'become']","['organ', 'disease', 'chronic', 'become']",1281,"尤其是，慢性器官功能障碍已成为美国骨髓病成人死亡的主要原因之一。10,11",0.4,"['organ', 'dysfunction', 'disease', 'particular', 'sickle cell', 'chronic', 'cause of death', 'leading', 'with', 'become']","['organ', 'disease', 'chronic', 'become']",,,,
1292,1282,"because the rate of HbS polymerization is extremely sensitive to deoxygenated HbS concentration , small changes in concentration can have substantial effects on polymerization.12,13","由于 HbS 聚合速率对脱氧 HbS 浓度极其敏感，因此浓度的微小变化会对聚合产生重大影响。 12,13",0.4444444444444444,"['concentration', 'rate', 'polymerization', 'sensitive', 'have', 'in', 'to', 'substantial', 'hbs']","['concentration', 'rate', 'polymerization', 'to']",1282,"['由于HbS聚合物的速度对氧化HbS浓度非常敏感,所以浓度的小变化可能会对聚合物产生重大影响。']",0.3333333333333333,"['concentration', 'rate', 'polymerization', 'sensitive', 'have', 'in', 'to', 'substantial', 'hbs']","['concentration', 'polymerization', 'to']",1282,因为HbS聚合物的形成速率非常敏感于去氧化HbS浓度，浓度的微小变化就可能导致聚合物形成的巨大影响。,0.4444444444444444,"['concentration', 'rate', 'polymerization', 'sensitive', 'have', 'in', 'to', 'substantial', 'hbs']","['concentration', 'rate', 'polymerization', 'to']",,,,
1293,1283,"this hypothesis is supported by the absence of symptoms of sickle cell disease in persons who are compound heterozygotes for HbS and deletional hereditary persistence of fetal hemoglobin , who have antisickling fetal hemoglobin levels of approximately 30 % .13",这一假说得到以下证据的支持：在 HbS 复合杂合子和胎儿血红蛋白缺失遗传性持续存在的人群中没有镰状细胞病的症状，这些人的抗镰状细胞胎儿血红蛋白水平约为 30 % .13,0.5625,"['persistence', 'disease', 'who', 'hereditary', 'hypothesis', 'compound', 'fetal hemoglobin', 'symptoms', 'sickle cell', 'absence', 'have', 'approximately', 'this', 'by', 'and', 'hbs']","['persistence', 'disease', 'hereditary', 'hypothesis', 'compound', 'fetal hemoglobin', 'sickle cell', 'have', 'by']",1283,"['这种假设是由缺乏细胞细胞疾病的症状支持,在HbS和胎儿血球的遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗']",0.375,"['persistence', 'disease', 'who', 'hereditary', 'hypothesis', 'compound', 'fetal hemoglobin', 'symptoms', 'sickle cell', 'absence', 'have', 'approximately', 'this', 'by', 'and', 'hbs']","['disease', 'hereditary', 'hypothesis', 'absence', 'this', 'by']",1283,这个假说得到了HbS和删除性遗传性胎儿血红蛋白持续存在的复合杂合体人群血红蛋白水平约为30%的抗弯曲血红蛋白的缺失症状的支持。13,0.3125,"['persistence', 'disease', 'who', 'hereditary', 'hypothesis', 'compound', 'fetal hemoglobin', 'symptoms', 'sickle cell', 'absence', 'have', 'approximately', 'this', 'by', 'and', 'hbs']","['persistence', 'hereditary', 'hypothesis', 'compound', 'fetal hemoglobin']",,,,
1294,1284,"voxelotor is an HbS polymerization inhibitor that reversibly binds to hemoglobin to stabilize the oxygenated hemoglobin state.14,15","voxelotor 是一种 HbS 聚合抑制剂，可逆地结合血红蛋白以稳定氧合血红蛋白状态。 14,15",0.7142857142857143,"['inhibitor', 'hemoglobin', 'polymerization', 'stabilize', 'oxygenated', 'that', 'hbs']","['inhibitor', 'hemoglobin', 'polymerization', 'stabilize', 'oxygenated']",1284,"['voxelotor 是一种 HbS 聚合物抑制剂,可逆转连接到血球,以稳定氧化血球状态。']",0.4285714285714285,"['inhibitor', 'hemoglobin', 'polymerization', 'stabilize', 'oxygenated', 'that', 'hbs']","['inhibitor', 'polymerization', 'stabilize']",1284,"voxelotor是一种HbS聚合抑制剂，可与血红蛋白反应性结合，稳定氧化血红蛋白状态。14,15",0.5714285714285714,"['inhibitor', 'hemoglobin', 'polymerization', 'stabilize', 'oxygenated', 'that', 'hbs']","['inhibitor', 'hemoglobin', 'polymerization', 'stabilize']",,,,
1295,1285,"the phase 3 HOPE ( Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization ) trial was designed to evaluate the efficacy and safety of voxelotor , as compared with placebo , in adolescents and adults with sickle cell disease .",3 期 HOPE（血红蛋白氧亲和力调节抑制 HbS 聚合）试验旨在评估与安慰剂相比，voxelotor 在患有镰状细胞病的青少年和成人中的疗效和安全性。,0.5882352941176471,"['modulation', 'safety', 'affinity', 'placebo', 'disease', 'phase', 'hemoglobin', 'sickle cell', 'trial', 'efficacy', 'polymerization', '3', 'oxygen', 'with', 'to', 'and', 'hbs']","['modulation', 'safety', 'affinity', 'placebo', 'disease', 'phase', 'hemoglobin', 'sickle cell', 'polymerization', 'oxygen']",1285,"['第三阶段的HOPE(Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization)试验旨在评估与 placebo 相比,在青少年和成年人患有<unk>细胞疾病的Voxelotor的有效性和安全性。']",0.2352941176470588,"['modulation', 'safety', 'affinity', 'placebo', 'disease', 'phase', 'hemoglobin', 'sickle cell', 'trial', 'efficacy', 'polymerization', '3', 'oxygen', 'with', 'to', 'and', 'hbs']","['safety', 'disease', 'phase', 'efficacy']",1285,第三期希望（血红蛋白氧化亲和性调节以抑制HbS聚合物）试验旨在评估体外血红蛋白氧化剂与安慰剂相比在青少年和成年细胞异常疾病患者中的疗效和安全性。,0.5294117647058824,"['modulation', 'safety', 'affinity', 'placebo', 'disease', 'phase', 'hemoglobin', 'sickle cell', 'trial', 'efficacy', 'polymerization', '3', 'oxygen', 'with', 'to', 'and', 'hbs']","['modulation', 'safety', 'affinity', 'placebo', 'disease', 'phase', 'hemoglobin', 'polymerization', 'oxygen']",,,,
1296,1286,"global Blood Therapeutics , the trial sponsor , provided the investigational agent and collaborated with academic investigators on the design of the trial and the analysis and interpretation of the data .",试验赞助商 global Blood Therapeutics 提供了研究药物，并与学术研究人员合作设计试验以及分析和解释数据。,0.3333333333333333,"['data', 'global', 'analysis', 'sponsor', 'blood', 'interpretation', 'therapeutics', 'trial', 'design', 'with', 'agent', 'and']","['data', 'analysis', 'interpretation', 'design']",1286,"['全球血液疗法(Global Blood Therapeutics),审判赞助商,提供调查代理,并与学术调查人员合作,设计审判,分析和数据的解释。']",0.6666666666666666,"['data', 'global', 'analysis', 'sponsor', 'blood', 'interpretation', 'therapeutics', 'trial', 'design', 'with', 'agent', 'and']","['data', 'global', 'analysis', 'blood', 'interpretation', 'therapeutics', 'trial', 'design']",1286,全球性血液治疗公司、试验赞助商提供了研究药物，并与学术研究者合作设计了试验和数据分析和解释。,0.5,"['data', 'global', 'analysis', 'sponsor', 'blood', 'interpretation', 'therapeutics', 'trial', 'design', 'with', 'agent', 'and']","['data', 'global', 'analysis', 'blood', 'interpretation', 'design']",,,,
1297,1287,"all the authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol , available with the full text of this article at NEJM.org .",所有作者保证数据的准确性和完整性以及试验对方案的忠实度，方案与本文全文可在 NEJM.org 获取。,0.2857142857142857,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'completeness', 'full']",1287,"['所有作者对数据的准确性和完整性以及对议定书的审判的忠诚性,可在NEJM.org上提供本文的完整文本。']",0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness', 'full']",1287,所有作者都为数据的准确性和完整性以及实验方案的忠实性负责，全文可在NEJM.org上找到。,0.3571428571428571,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['fidelity', 'data', 'accuracy', 'completeness', 'full']",,,,
1298,1288,"the conduct of the trial was overseen by IQVIA , a contract research organization , and an independent data and safety monitoring board performed periodic assessments .",试验的进行由合同研究机构 IQVIA 监督，独立的数据和安全监督委员会进行定期评估。,0.4166666666666667,"['safety', 'monitoring', 'organization', 'research', 'data', 'contract', 'board', 'trial', 'independent', 'conduct', 'by', 'and']","['safety', 'research', 'data', 'independent', 'by']",1288,"['调查的进展由合同研究组织IQVIA监督,独立的数据和安全监测委员会进行定期评估。']",0.5833333333333334,"['safety', 'monitoring', 'organization', 'research', 'data', 'contract', 'board', 'trial', 'independent', 'conduct', 'by', 'and']","['safety', 'monitoring', 'organization', 'research', 'data', 'independent', 'by']",1288,"The trial was overseen by IQVIA, a contract research organization, and an independent data and safety monitoring board performed periodic assessments.",0.0,"['safety', 'monitoring', 'organization', 'research', 'data', 'contract', 'board', 'trial', 'independent', 'conduct', 'by', 'and']",[],,,,
1299,1289,written informed consent was obtained from the adult participants ( 18 to 65 years of age ) and from the parents or guardians of the adolescent participants ( 12 to 17 years of age ) .,已从成年参与者（18 至 65 岁）和青少年参与者（12 至 17 岁）的父母或监护人处获得书面知情同意书。,0.2857142857142857,"['parents', 'adolescent', 'adult', 'age', 'informed consent', 'to', 'and']","['adolescent', 'adult']",1289,['由成年参与者(年龄为18至65岁)以及青少年参与者的父母或监护人(年龄为12至17岁)获得书面信息同意。'],0.4285714285714285,"['parents', 'adolescent', 'adult', 'age', 'informed consent', 'to', 'and']","['adolescent', 'adult', 'age']",1289,"Written informed consent was obtained from the adult participants (18 to 65 years of age) and from the parents or guardians of the adolescent participants (12 to 17 years of age).

Chinese:

成年参与者（18至65岁）及其青少年参与者（12至17岁）的家长或监护人均签署了知情同意书。",0.2857142857142857,"['parents', 'adolescent', 'adult', 'age', 'informed consent', 'to', 'and']","['adolescent', 'adult']",,,,
1300,1290,the protocol and consent form were approved by an independent ethics committee at each participating trial site .,方案和知情同意书由每个参与试验地点的独立伦理委员会批准。,0.3333333333333333,"['form', 'site', 'protocol', 'ethics', 'committee', 'trial', 'independent', 'consent', 'at', 'each', 'by', 'and']","['site', 'committee', 'consent', 'by']",1290,['议定书和同意表格由一个独立的伦理委员会在每个参与审判场所批准。'],0.5833333333333334,"['form', 'site', 'protocol', 'ethics', 'committee', 'trial', 'independent', 'consent', 'at', 'each', 'by', 'and']","['site', 'protocol', 'committee', 'trial', 'independent', 'consent', 'by']",1290,所有参与试验的地点的独立伦理委员会都批准了这份协议和知情同意书。,0.3333333333333333,"['form', 'site', 'protocol', 'ethics', 'committee', 'trial', 'independent', 'consent', 'at', 'each', 'by', 'and']","['site', 'protocol', 'committee', 'consent']",,,,
1301,1291,"all drafts of the manuscript were prepared by the authors , with writing assistance from a medical writer funded by the sponsor .",手稿的所有草稿均由作者编写，并得到申办方资助的医学作家的写作协助。,0.4444444444444444,"['sponsor', 'medical', 'manuscript', 'writer', 'writing', 'assistance', 'with', 'all', 'by']","['manuscript', 'writer', 'writing', 'by']",1291,"['手稿的所有草案都是由作者编写的,由赞助商资助的医学作家的书面协助。']",0.3333333333333333,"['sponsor', 'medical', 'manuscript', 'writer', 'writing', 'assistance', 'with', 'all', 'by']","['manuscript', 'writer', 'by']",1291,所有草稿都是由作者准备的，资助者资助的医疗作家提供了写作帮助。,0.3333333333333333,"['sponsor', 'medical', 'manuscript', 'writer', 'writing', 'assistance', 'with', 'all', 'by']","['writer', 'writing', 'by']",,,,
1302,1292,the sponsor and all authors and institutions agreed to data confidentiality during manuscript development .,赞助商和所有作者和机构同意在手稿开发过程中对数据保密。,0.375,"['confidentiality', 'data', 'sponsor', 'manuscript', 'development', 'all', 'to', 'and']","['confidentiality', 'data', 'manuscript']",1292,['赞助商和所有作者和机构在手稿开发期间同意数据的保密性。'],0.375,"['confidentiality', 'data', 'sponsor', 'manuscript', 'development', 'all', 'to', 'and']","['confidentiality', 'data', 'manuscript']",1292,"the sponsor and all authors and institutions agreed to data confidentiality during manuscript development .

Chinese:

发起人和所有作者及机构在手稿创作过程中都同意保密数据。",0.375,"['confidentiality', 'data', 'sponsor', 'manuscript', 'development', 'all', 'to', 'and']","['confidentiality', 'data', 'manuscript']",,,,
1303,1293,participants who were receiving hydroxyurea at a dose that had been stable for at least 3 months before they provided informed consent were eligible .,在提供知情同意书之前以稳定至少 3 个月的剂量接受羟基脲的参与者符合条件。,0.375,"['who', 'hydroxyurea', '3', 'informed consent', 'dose', 'that', 'before', 'eligible']","['hydroxyurea', 'dose', 'before']",1293,['在提交已知同意之前至少3个月保持稳定的剂量服用水氧化剂的参与者有资格。'],0.25,"['who', 'hydroxyurea', '3', 'informed consent', 'dose', 'that', 'before', 'eligible']","['dose', 'before']",1293,参与者在提供知情同意之前至少已经稳定接受3个月的羟基脲药物剂量者符合条件。,0.375,"['who', 'hydroxyurea', '3', 'informed consent', 'dose', 'that', 'before', 'eligible']","['hydroxyurea', 'dose', 'before']",,,,
1304,1294,participants could be rescreened at the discretion of an investigator .,参与者可以根据研究者的判断重新筛选。,0.5,"['investigator', 'be']",['investigator'],1294,['参与者可以在调查员的判断下重新审查。'],0.5,"['investigator', 'be']",['be'],1294,"Participants could be rescreened at the discretion of an investigator.

Chinese:

参与者可以根据调查员的自由裁量权重新筛选。",0.0,"['investigator', 'be']",[],,,,
1305,1295,"the primary end point was the percentage of participants who had a hemoglobin response , which was defined as an increase from baseline of more than 1.0 g per deciliter at week 24 .",主要终点是有血红蛋白反应的参与者百分比，血红蛋白反应定义为在第 24 周时从基线增加超过 1.0 g/dL。,0.3846153846153846,"['percentage', 'defined', 'who', 'baseline', 'hemoglobin', 'deciliter', 'primary', 'response', 'week', 'end', 'point', 'increase', 'at']","['baseline', 'hemoglobin', 'response', 'week', 'point']",1295,"['主要的终点是对血球反应的参与者的百分比,这被定义为从基线上增加超过10g每分钟24周。']",0.3846153846153846,"['percentage', 'defined', 'who', 'baseline', 'hemoglobin', 'deciliter', 'primary', 'response', 'week', 'end', 'point', 'increase', 'at']","['baseline', 'primary', 'response', 'week', 'point']",1295,在24周的时间里，参与者的血红蛋白含量增加了超过1.0 g/dl，这是研究的主要终点指标。,0.2307692307692307,"['percentage', 'defined', 'who', 'baseline', 'hemoglobin', 'deciliter', 'primary', 'response', 'week', 'end', 'point', 'increase', 'at']","['hemoglobin', 'week', 'point']",,,,
1306,1296,"clinical assessments were performed at screening , at baseline , every 2 weeks for the first 8 weeks of the treatment period , every 4 weeks up to week 24 , and every 3 months until the end of the treatment period .",临床评估在筛选时、基线时、治疗期前 8 周每 2 周一次、直至第 24 周每 4 周一次、以及每 3 个月一次直至治疗期结束时进行。,0.5,"['period', 'baseline', '2', 'screening', 'treatment', 'clinical', 'week', '3', '4', 'end', 'up', 'to', 'and', 'first']","['period', 'baseline', '2', 'screening', 'treatment', 'clinical', 'week']",1296,"['临床评估是在检查时进行的,在基线上,每2周,在治疗期间的第一个8周,每4周到24周,每3个月,直到治疗期间结束。']",0.5,"['period', 'baseline', '2', 'screening', 'treatment', 'clinical', 'week', '3', '4', 'end', 'up', 'to', 'and', 'first']","['period', 'baseline', '2', 'treatment', 'clinical', 'week', 'first']",1296,在筛选、基线、治疗前8周的每2周、治疗前24周的每4周以及治疗后每3个月进行临床评估。,0.4285714285714285,"['period', 'baseline', '2', 'screening', 'treatment', 'clinical', 'week', '3', '4', 'end', 'up', 'to', 'and', 'first']","['baseline', '2', 'screening', 'treatment', 'clinical', 'week']",,,,
1307,1297,serum erythropoietin levels were assessed at baseline and every 3 months until the end of the treatment period .,在基线和每 3 个月评估一次血清促红细胞生成素水平，直至治疗期结束。,0.5555555555555556,"['period', 'erythropoietin', 'baseline', 'serum', 'treatment', '3', 'end', 'and', 'assessed']","['period', 'erythropoietin', 'baseline', 'serum', 'treatment']",1297,"['血清甲状腺素水平在基线上进行评估,每3个月,直到治疗期结束。']",0.4444444444444444,"['period', 'erythropoietin', 'baseline', 'serum', 'treatment', '3', 'end', 'and', 'assessed']","['period', 'baseline', 'serum', 'treatment']",1297,血清红细胞生成素水平在治疗开始前以及治疗期间每3个月进行一次测定。,0.4444444444444444,"['period', 'erythropoietin', 'baseline', 'serum', 'treatment', '3', 'end', 'and', 'assessed']","['period', 'erythropoietin', 'serum', 'treatment']",,,,
1308,1298,all laboratory studies were performed at a central laboratory .,所有实验室研究均在中央实验室进行。,0.3333333333333333,"['central', 'laboratory', 'all']",['laboratory'],1298,['所有的实验室研究都在一个中央实验室进行。'],0.3333333333333333,"['central', 'laboratory', 'all']",['laboratory'],1298,所有实验室研究都在一个中央实验室进行。,0.3333333333333333,"['central', 'laboratory', 'all']",['laboratory'],,,,
1309,1299,"pharmacokinetic and pharmacodynamic modeling was used to correlate voxelotor exposure and response ( e.g. , changes in the levels of hemoglobin and markers of hemolysis ) .",药代动力学和药效学模型被用来关联 voxelotor 暴露和反应（例如，血红蛋白水平和溶血标志物的变化）。,0.6666666666666666,"['hemolysis', 'exposure', 'hemoglobin', 'pharmacodynamic', 'response', 'modeling', 'pharmacokinetic', 'to', 'and']","['hemolysis', 'exposure', 'hemoglobin', 'pharmacodynamic', 'response', 'pharmacokinetic']",1299,"['药物学和药物动态模型用于与伏克索托尔的曝光和反应(例如,血球水平和血球标志的变化)相连。']",0.3333333333333333,"['hemolysis', 'exposure', 'hemoglobin', 'pharmacodynamic', 'response', 'modeling', 'pharmacokinetic', 'to', 'and']","['exposure', 'response', 'to']",1299,使用药物动力学和药效学模型来相关联沃克索特尔暴露和反应（例如，血红蛋白水平变化和溶血标记物水平变化）。,0.6666666666666666,"['hemolysis', 'exposure', 'hemoglobin', 'pharmacodynamic', 'response', 'modeling', 'pharmacokinetic', 'to', 'and']","['hemolysis', 'exposure', 'hemoglobin', 'pharmacodynamic', 'response', 'pharmacokinetic']",,,,
1310,1300,"hemoglobin occupancy was defined as the percentage of hemoglobin bound by voxelotor , calculated as the concentration of voxelotor in red cells divided by the concentration of hemoglobin in red cells , as previously described.17,18","血红蛋白占有率被定义为与 voxelotor 结合的血红蛋白百分比，计算方法为红细胞中 voxelotor 浓度除以红细胞中血红蛋白浓度，如前所述。 17, 18",0.625,"['percentage', 'concentration', 'defined', 'hemoglobin', 'red', 'bound', 'as', 'by']","['concentration', 'hemoglobin', 'bound', 'as', 'by']",1300,"['血球占据被定义为由 voxelotor 连接的血球的百分比,计算为红细胞中的 voxelotor 的浓度,分为红细胞中的血球浓度,如上所述。']",0.375,"['percentage', 'concentration', 'defined', 'hemoglobin', 'red', 'bound', 'as', 'by']","['concentration', 'as', 'by']",1300,"血红蛋白占据率定义为血红蛋白与体素结合的百分比，计算方法为体素结合血红蛋白的浓度除以红细胞中血红蛋白的浓度，17,18如前所述。",0.625,"['percentage', 'concentration', 'defined', 'hemoglobin', 'red', 'bound', 'as', 'by']","['concentration', 'hemoglobin', 'bound', 'as', 'by']",,,,
1311,1301,participants who received at least one dose of the trial drug or placebo were assessed for safety .,对接受至少一剂试验药物或安慰剂的参与者进行安全性评估。,0.375,"['safety', 'placebo', 'who', 'trial', 'drug', 'at', 'dose', 'assessed']","['safety', 'placebo', 'drug']",1301,['接受至少一剂试用药物或 placebo 的参与者被评估为安全。'],0.25,"['safety', 'placebo', 'who', 'trial', 'drug', 'at', 'dose', 'assessed']","['safety', 'drug']",1301,参与者至少接受了一剂试验药物或安慰剂，并进行了安全性评估。,0.375,"['safety', 'placebo', 'who', 'trial', 'drug', 'at', 'dose', 'assessed']","['safety', 'placebo', 'drug']",,,,
1312,1302,"adverse events that occurred on or after initiation of the trial drug or placebo or preexisting adverse events that worsened during the treatment period for up to 28 days after the last dose were assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events , version 4.03 .",在试验药物或安慰剂开始时或之后发生的不良事件或在最后一次给药后长达 28 天的治疗期间恶化的既往不良事件根据美国国家癌症研究所不良事件通用术语标准进行评估和分级，版本 4.03 。,0.5263157894736842,"['period', 'placebo', 'cancer', 'initiation', 'version', 'common', 'adverse', 'treatment', 'terminology', 'institute', 'after', 'trial', 'up', 'drug', 'dose', 'that', 'to', 'and', 'assessed']","['period', 'placebo', 'cancer', 'initiation', 'version', 'treatment', 'terminology', 'institute', 'after', 'drug']",1302,['试用药物或 placebo 或预先存在的试用药物或 placebo 或试用药物或 placebo 或试用药物或 placebo 或试用药物或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或'],0.0526315789473684,"['period', 'placebo', 'cancer', 'initiation', 'version', 'common', 'adverse', 'treatment', 'terminology', 'institute', 'after', 'trial', 'up', 'drug', 'dose', 'that', 'to', 'and', 'assessed']",['drug'],1302,"Adverse events that occurred after starting the trial drug or placebo, or preexisting adverse events that got worse during the treatment period, were assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.",0.0,"['period', 'placebo', 'cancer', 'initiation', 'version', 'common', 'adverse', 'treatment', 'terminology', 'institute', 'after', 'trial', 'up', 'drug', 'dose', 'that', 'to', 'and', 'assessed']",[],,,,
1313,1303,the relationship of an adverse event to the trial drug or placebo was adjudicated by the investigators .,不良事件与试验药物或安慰剂的关系由研究者判定。,0.5714285714285714,"['relationship', 'placebo', 'adverse event', 'trial', 'drug', 'by', 'to']","['placebo', 'adverse event', 'drug', 'by']",1303,['与试验药物或 placebo 发生不良事件的关系由调查人员提交。'],0.4285714285714285,"['relationship', 'placebo', 'adverse event', 'trial', 'drug', 'by', 'to']","['adverse event', 'drug', 'by']",1303,研究人员对不良事件与试用药物或安慰剂之间的关系进行了裁定。,0.4285714285714285,"['relationship', 'placebo', 'adverse event', 'trial', 'drug', 'by', 'to']","['placebo', 'adverse event', 'drug']",,,,
1314,1304,adverse events not related to sickle cell disease and those related to sickle cell disease were tabulated separately .,与镰状细胞病无关的不良事件和与镰状细胞病相关的不良事件单独列出。,0.3333333333333333,"['disease', 'sickle cell', 'adverse', 'separately', 'to', 'and']","['disease', 'sickle cell']",1304,['与<unk>细胞疾病无关的不良事件和与<unk>细胞疾病有关的事件分别表。'],0.1666666666666666,"['disease', 'sickle cell', 'adverse', 'separately', 'to', 'and']",['disease'],1304,"adverse events not related to sickle cell disease and those related to sickle cell disease were tabulated separately .

Chinese:

非与细胞异常相关的不良事件与与细胞异常相关的不良事件分别进行了统计。",0.0,"['disease', 'sickle cell', 'adverse', 'separately', 'to', 'and']",[],,,,
1315,1305,attribution of an adverse event to a cause other than a new therapeutic agent may be inexact .,将不良事件归因于新治疗药物以外的原因可能是不准确的。,0.625,"['be', 'cause', 'therapeutic', 'adverse event', 'attribution', 'agent', 'to', 'new']","['cause', 'adverse event', 'attribution', 'to', 'new']",1305,"['将不良事件归因于另一种原因,而不是新治疗药物,可能不准确。']",0.625,"['be', 'cause', 'therapeutic', 'adverse event', 'attribution', 'agent', 'to', 'new']","['cause', 'adverse event', 'attribution', 'to', 'new']",1305,"attribution of an adverse event to a cause other than a new therapeutic agent may be inexact.

Chinese:

将不良事件归因于新的疗法以外的原因可能是不准确的。",0.625,"['be', 'cause', 'therapeutic', 'adverse event', 'attribution', 'agent', 'to', 'new']","['cause', 'adverse event', 'attribution', 'to', 'new']",,,,
1316,1306,"baseline values were calculated as the mean values of the data collected at screening and on the day of randomization , and the values at week 24 were calculated as the mean values of the data collected at weeks 20 and 24 .",基线值计算为筛选时和随机化当天收集的数据的平均值，第 24 周的值计算为第 20 周和第 24 周收集的数据的平均值。,0.8571428571428571,"['mean', 'randomization', 'data', 'baseline', 'screening', 'week', 'values']","['mean', 'randomization', 'data', 'baseline', 'screening', 'week']",1306,"['基线值被计算为扫描和随机化日收集的数据的平均值,24周的值被计算为20周和24周收集的数据的平均值。']",0.7142857142857143,"['mean', 'randomization', 'data', 'baseline', 'screening', 'week', 'values']","['mean', 'randomization', 'data', 'baseline', 'week']",1306,基线值是在筛查时和随机化当天收集的数据的平均值，而第24周的值则是在第20周和第24周收集的数据的平均值。,0.8571428571428571,"['mean', 'randomization', 'data', 'baseline', 'screening', 'week', 'values']","['mean', 'randomization', 'data', 'baseline', 'screening', 'week']",,,,
1317,1307,"if one time point was missing , data from the other time point were used .",如果一个时间点缺失，则使用另一个时间点的数据。,0.8,"['data', 'time', 'point', 'if', 'missing']","['data', 'time', 'point', 'missing']",1307,"['如果一个时间点失踪,则从另一个时间点的数据被使用。']",0.6,"['data', 'time', 'point', 'if', 'missing']","['data', 'time', 'point']",1307,如果某个时间点缺失数据，就使用其他时间点的数据。,0.8,"['data', 'time', 'point', 'if', 'missing']","['data', 'time', 'point', 'missing']",,,,
1318,1308,"absolute change in hemoglobin level , relative change in indirect bilirubin level , absolute reticulocyte count and percentage of reticulocytes , and lactate dehydrogenase level from baseline to week 24 were analyzed with the use of a regression model for repeated measures .",血红蛋白水平的绝对变化、间接胆红素水平的相对变化、网织红细胞绝对计数和网织红细胞百分比，以及从基线到第 24 周的乳酸脱氢酶水平使用重复测量回归模型进行分析。,0.5625,"['count', 'percentage', 'reticulocyte', 'bilirubin', 'baseline', 'absolute', 'indirect', 'hemoglobin level', 'lactate dehydrogenase', 'week', 'relative change', 'with', 'repeated', 'to', 'and', 'regression model']","['count', 'reticulocyte', 'bilirubin', 'baseline', 'absolute', 'lactate dehydrogenase', 'week', 'relative change', 'regression model']",1308,"['血糖水平的绝对变化、间接 bilirubin 水平的相对变化、绝对 reticulocyte 数量和 reticulocyte 的百分比以及从基线到 24 周的乳糖脱水素水平的分析,使用重复测量的 regression 模型。']",0.25,"['count', 'percentage', 'reticulocyte', 'bilirubin', 'baseline', 'absolute', 'indirect', 'hemoglobin level', 'lactate dehydrogenase', 'week', 'relative change', 'with', 'repeated', 'to', 'and', 'regression model']","['baseline', 'absolute', 'week', 'relative change']",1308,绝对血红蛋白水平变化、相对间接胆红素水平变化、绝对网织细胞计数和网织细胞百分比、以及乳酸脱氢酶水平从基线到第24周的变化，均使用重复测量回归模型进行分析。,0.4375,"['count', 'percentage', 'reticulocyte', 'bilirubin', 'baseline', 'absolute', 'indirect', 'hemoglobin level', 'lactate dehydrogenase', 'week', 'relative change', 'with', 'repeated', 'to', 'and', 'regression model']","['count', 'bilirubin', 'baseline', 'absolute', 'lactate dehydrogenase', 'week', 'regression model']",,,,
1319,1309,intrapatient variability was modeled with the use of an unstructured covariance matrix .,使用非结构化协方差矩阵对患者内部变异性进行建模。,0.75,"['matrix', 'covariance', 'variability', 'with']","['matrix', 'covariance', 'variability']",1309,"['intrapatient variability 被模拟,使用一个未结构化的covariance 矩阵。']",0.25,"['matrix', 'covariance', 'variability', 'with']",['matrix'],1309,"intrapatient variability was modeled with the use of an unstructured covariance matrix.

Chinese:

患者内异变性通过使用非结构协方差矩阵来建模。",0.5,"['matrix', 'covariance', 'variability', 'with']","['matrix', 'covariance']",,,,
1320,1310,baseline characteristics of the three trial groups were generally well balanced ( Table 1 ) .,三个试验组的基线特征总体均衡（表 1）。,0.5714285714285714,"['table', 'baseline', '1', 'well', 'characteristics', 'trial', 'three']","['table', 'baseline', '1', 'characteristics']",1310,['三个试验组的基本特征一般均衡良好(图1)。'],0.2857142857142857,"['table', 'baseline', '1', 'well', 'characteristics', 'trial', 'three']","['1', 'characteristics']",1310,"The baseline characteristics of the three trial groups were generally well balanced (Table 1).

Chinese:
三个试验组的基线特征基本上是平衡的（表1）。",0.5714285714285714,"['table', 'baseline', '1', 'well', 'characteristics', 'trial', 'three']","['table', 'baseline', '1', 'characteristics']",,,,
1321,1311,hemoglobin RESPONSE AND MARKERS OF HEMOLYSIS,血红蛋白反应和溶血标志物,1.0,['hemoglobin'],['hemoglobin'],1311,['血球反应与血球的标志'],0.0,['hemoglobin'],[],1311,"hemoglobin RESPONSE AND MARKERS OF HEMOLYSIS

Chinese: 血红蛋白反应和溶血标志",1.0,['hemoglobin'],['hemoglobin'],,,,
1322,1312,"the mean increase in hemoglobin level among the participants receiving voxelotor was consistent across patient subgroups , regardless of concurrent hydroxyurea use or baseline anemia severity ( Table S1 in the Supplementary Appendix ) .",无论是否同时使用羟基脲或基线贫血严重程度如何，接受 voxelotor 的参与者血红蛋白水平的平均增加在所有患者亚组中都是一致的（补充附录表 S1）。,0.4615384615384615,"['anemia', 'appendix', 'mean', 'table', 'baseline', 'hydroxyurea', 'supplementary', 'concurrent', 'hemoglobin level', 'across', 'patient', 'increase', 'S1']","['anemia', 'mean', 'table', 'baseline', 'hydroxyurea', 'patient']",1312,"['接受Voxelotor的参与者中血糖水平的平均增加在患者子群中是一致的,无论是同步使用Hydroxyurea或基因贫血的严重性(附件中的S1表)。']",0.3846153846153846,"['anemia', 'appendix', 'mean', 'table', 'baseline', 'hydroxyurea', 'supplementary', 'concurrent', 'hemoglobin level', 'across', 'patient', 'increase', 'S1']","['anemia', 'appendix', 'mean', 'table', 'patient']",1312,参与者接受沃克索洛托尔治疗后血红蛋白水平平均增加，与同时使用羟基脲或基线贫血严重程度无关(见表S1在附件中)。,0.4615384615384615,"['anemia', 'appendix', 'mean', 'table', 'baseline', 'hydroxyurea', 'supplementary', 'concurrent', 'hemoglobin level', 'across', 'patient', 'increase', 'S1']","['anemia', 'appendix', 'mean', 'table', 'baseline', 'hydroxyurea']",,,,
1323,1313,"the most common adverse events , with an incidence of at least 20 % , were headache and diarrhea ( Table 3 ) .",最常见的不良事件（发生率至少为 20%）是头痛和腹泻（表 3）。,0.4,"['incidence', 'headache', 'table', 'diarrhea', 'common', 'adverse', '3', 'with', 'at', 'and']","['incidence', 'headache', 'table', 'diarrhea']",1313,"['最常见的副作用,其发病率至少为20%,是头痛和腹泻(图3)。']",0.3,"['incidence', 'headache', 'table', 'diarrhea', 'common', 'adverse', '3', 'with', 'at', 'and']","['incidence', 'headache', 'diarrhea']",1313,最常见的不良事件是头痛和腹泻，发生率至少为20％（表3）。,0.4,"['incidence', 'headache', 'table', 'diarrhea', 'common', 'adverse', '3', 'with', 'at', 'and']","['incidence', 'headache', 'table', 'diarrhea']",,,,
1324,1314,"the majority of adverse events were grade 1 or 2 ; the percentages of participants who had an adverse event of at least grade 3 , a serious adverse event , and treatment discontinuation because of an adverse event did not differ substantially among the three trial groups .",大多数不良事件为 1 级或 2 级；发生至少 3 级不良事件、严重不良事件和因不良事件而停止治疗的参与者的百分比在三个试验组中没有显着差异。,0.5833333333333334,"['who', '1', '2', 'serious adverse event', 'grade', 'treatment', 'differ', 'trial', '3', 'majority', 'three', 'and']","['1', '2', 'serious adverse event', 'treatment', 'majority', 'three', 'and']",1314,['大多数不良事件是1级或2级;至少有3级不良事件、严重不良事件和因不良事件而停止治疗的参与者比例在三组中没有显著差异。'],0.5833333333333334,"['who', '1', '2', 'serious adverse event', 'grade', 'treatment', 'differ', 'trial', '3', 'majority', 'three', 'and']","['1', '2', 'serious adverse event', 'treatment', 'majority', 'three', 'and']",1314,绝大多数不良事件属于1级或2级; 参与者出现至少3级不良事件、严重不良事件和因不良事件而中止治疗的比例在三组试验中差异不大。,0.5833333333333334,"['who', '1', '2', 'serious adverse event', 'grade', 'treatment', 'differ', 'trial', '3', 'majority', 'three', 'and']","['1', '2', 'serious adverse event', 'treatment', 'majority', 'three', 'and']",,,,
1325,1315,most adverse events were judged by the investigators to be unrelated to the trial drug or placebo .,大多数不良事件被研究者判断为与试验药物或安慰剂无关。,0.2857142857142857,"['placebo', 'be', 'adverse', 'trial', 'drug', 'by', 'to']","['placebo', 'drug']",1315,['大多数不良事件被调查人员认为与试验药物或 placebo 无关。'],0.1428571428571428,"['placebo', 'be', 'adverse', 'trial', 'drug', 'by', 'to']",['drug'],1315,"most adverse events were judged by the investigators to be unrelated to the trial drug or placebo .

Chinese:
绝大多数不良事件被调查人员判定与试验药物或安慰剂无关。",0.2857142857142857,"['placebo', 'be', 'adverse', 'trial', 'drug', 'by', 'to']","['placebo', 'drug']",,,,
1326,1316,additional details are provided in Tables S5 and S6 in the Supplementary Appendix .,补充附录表 S5 和表 S6 中提供了更多详细信息。,0.0,"['appendix', 'supplementary', 'additional', 'in', 'and']",[],1316,['更多详细信息在附件中的 S5 和 S6 表中提供。'],0.2,"['appendix', 'supplementary', 'additional', 'in', 'and']",['appendix'],1316,附表S5和S6中提供了更多细节。,0.0,"['appendix', 'supplementary', 'additional', 'in', 'and']",[],,,,
1327,1317,"the increase in hemoglobin level and reduction in hemolysis occurred within 2 weeks after initiation of the trial drug , indicating a rapid pharmacodynamic and biologic effect .",血红蛋白水平升高和溶血减少发生在试验药物开始后 2 周内，表明药效学和生物学效应迅速。,0.5714285714285714,"['hemolysis', 'initiation', '2', 'biologic', 'pharmacodynamic', 'reduction', 'hemoglobin level', 'after', 'trial', 'effect', 'increase', 'drug', 'and', 'rapid']","['hemolysis', 'initiation', '2', 'pharmacodynamic', 'reduction', 'after', 'effect', 'drug']",1317,"['血糖水平的增加和血糖下降发生在试用药物开始后2周内,表明快速的药物动态和生物效应。']",0.3571428571428571,"['hemolysis', 'initiation', '2', 'biologic', 'pharmacodynamic', 'reduction', 'hemoglobin level', 'after', 'trial', 'effect', 'increase', 'drug', 'and', 'rapid']","['initiation', '2', 'after', 'effect', 'drug']",1317,在试用药物开始后的2周内，血红蛋白水平的增加和溶血减少了，表明药效学和生物学效应很快就出现了。,0.5714285714285714,"['hemolysis', 'initiation', '2', 'biologic', 'pharmacodynamic', 'reduction', 'hemoglobin level', 'after', 'trial', 'effect', 'increase', 'drug', 'and', 'rapid']","['hemolysis', 'initiation', '2', 'pharmacodynamic', 'reduction', 'after', 'effect', 'drug']",,,,
1328,1318,"subsequently , a steady state was reached that was sustained throughout the treatment period .",随后，达到稳定状态，并在整个治疗期间持续。,0.5,"['period', 'steady state', 'treatment', 'that']","['period', 'treatment']",1318,"['随后,实现了一个稳定的状态,在整个治疗期间保持。']",0.5,"['period', 'steady state', 'treatment', 'that']","['period', 'treatment']",1318,随后，经过治疗期间稳定状态达到。,0.5,"['period', 'steady state', 'treatment', 'that']","['period', 'treatment']",,,,
1329,1319,"a clear relationship was observed between voxelotor exposure and all hematologic measures of efficacy , including lactate dehydrogenase level and absolute reticulocyte count .",在 voxelotor 暴露与所有血液学疗效指标（包括乳酸脱氢酶水平和绝对网织红细胞计数）之间观察到明确的关系。,0.5,"['count', 'reticulocyte', 'relationship', 'clear', 'exposure', 'absolute', 'lactate dehydrogenase', 'efficacy', 'level', 'all', 'and', 'hematologic']","['count', 'reticulocyte', 'exposure', 'absolute', 'lactate dehydrogenase', 'level']",1319,"['观察到伏克索托特曝光与所有血液效能测量之间的明显关系,包括乳糖脱水素水平和绝对 reticulocyte 数量。']",0.3333333333333333,"['count', 'reticulocyte', 'relationship', 'clear', 'exposure', 'absolute', 'lactate dehydrogenase', 'efficacy', 'level', 'all', 'and', 'hematologic']","['exposure', 'absolute', 'efficacy', 'level']",1319,一个明显的关系被观察到在细胞固醇剂的暴露和所有血液学的有效性措施之间，包括乳酸脱氢酶水平和绝对的球细胞计数。,0.5,"['count', 'reticulocyte', 'relationship', 'clear', 'exposure', 'absolute', 'lactate dehydrogenase', 'efficacy', 'level', 'all', 'and', 'hematologic']","['count', 'exposure', 'absolute', 'lactate dehydrogenase', 'efficacy', 'level']",,,,
1330,1320,the percentage of participants who had adverse events of at least grade 3 and serious adverse events were similar in both voxelotor and placebo groups .,发生至少 3 级不良事件和严重不良事件的参与者百分比在 voxelotor 和安慰剂组中相似。,0.0909090909090909,"['percentage', 'placebo', 'who', 'grade', 'adverse', '3', 'at', 'serious', 'in', 'and', 'similar']",['placebo'],1320,['至少有3级和严重的不良事件的参与者的比例在Voxelotor和Placebo群体中都是相似的。'],0.0909090909090909,"['percentage', 'placebo', 'who', 'grade', 'adverse', '3', 'at', 'serious', 'in', 'and', 'similar']",['similar'],1320,在两组受试者中，发生严重不良事件的比例相似。,0.0,"['percentage', 'placebo', 'who', 'grade', 'adverse', '3', 'at', 'serious', 'in', 'and', 'similar']",[],,,,
1331,1321,"the hemoglobin occupancy target was based on the pancellular fetal hemoglobin level of approximately 30 % observed in persons who are compound heterozygotes for HbS and hereditary persistence of fetal hemoglobin , who generally have no symptoms of sickle cell disease.13",血红蛋白占有率目标是基于在 HbS 复合杂合子和胎儿血红蛋白遗传持续性人群中观察到的全细胞胎儿血红蛋白水平约为 30 %，这些人通常没有镰状细胞病的症状。 13,0.4,"['persistence', 'who', 'hereditary', 'compound', 'fetal hemoglobin', 'symptoms', 'hemoglobin level', 'sickle cell', 'no', 'target', 'on', 'have', 'approximately', 'and', 'hbs']","['persistence', 'compound', 'fetal hemoglobin', 'sickle cell', 'target', 'have']",1321,"['血球占据目标是基于细胞胎儿血球水平约30%,在HbS和胎儿血球的遗传持久性化合物催化物的人中观察到,一般没有<unk>细胞疾病的症状。']",0.2,"['persistence', 'who', 'hereditary', 'compound', 'fetal hemoglobin', 'symptoms', 'hemoglobin level', 'sickle cell', 'no', 'target', 'on', 'have', 'approximately', 'and', 'hbs']","['compound', 'target', 'have']",1321,根据HbS和遗传性胎儿血红蛋白持续症患者观察到的约30%的全细胞胎儿血红蛋白水平，为血红蛋白占有目标制定了一个基准。13,0.3333333333333333,"['persistence', 'who', 'hereditary', 'compound', 'fetal hemoglobin', 'symptoms', 'hemoglobin level', 'sickle cell', 'no', 'target', 'on', 'have', 'approximately', 'and', 'hbs']","['persistence', 'hereditary', 'fetal hemoglobin', 'target', 'have']",,,,
1332,1322,"this finding was supported by the similar erythropoietin levels observed with voxelotor and placebo , a reduction in the percentage of reticulocytes with voxelotor , and no pattern of adverse events suggestive of impaired tissue oxygenation .",这一发现得到了使用 voxelotor 和安慰剂观察到的相似促红细胞生成素水平、使用 voxelotor 的网织红细胞百分比降低以及没有提示组织氧合作用受损的不良事件模式的支持。,0.5333333333333333,"['percentage', 'placebo', 'tissue', 'oxygenation', 'erythropoietin', 'pattern', 'reduction', 'adverse', 'no', 'impaired', 'with', 'this', 'by', 'and', 'similar']","['placebo', 'tissue', 'oxygenation', 'erythropoietin', 'pattern', 'reduction', 'impaired', 'by']",1322,"['这种发现是由类似的Erythropoietin水平观察到Voxelotor和Placebo,减少的百分比的Reticulocytes与Voxelotor,和没有模式的副作用暗示损坏的组织氧化。']",0.4,"['percentage', 'placebo', 'tissue', 'oxygenation', 'erythropoietin', 'pattern', 'reduction', 'adverse', 'no', 'impaired', 'with', 'this', 'by', 'and', 'similar']","['tissue', 'oxygenation', 'pattern', 'reduction', 'this', 'by']",1322,这一发现得到了类似的红细胞生成素水平与安慰剂和沃克索洛特药物观察到的支持，减少了沃克索洛特药物中网织红细胞的百分比，没有出现可能表明组织氧合受损的不良事件的模式。,0.4666666666666667,"['percentage', 'placebo', 'tissue', 'oxygenation', 'erythropoietin', 'pattern', 'reduction', 'adverse', 'no', 'impaired', 'with', 'this', 'by', 'and', 'similar']","['placebo', 'tissue', 'oxygenation', 'erythropoietin', 'pattern', 'reduction', 'impaired']",,,,
1333,1323,we specifically chose to use an increase in hemoglobin level of more than 1 g per deciliter as a primary end point because validated natural history studies indicated that an increase in hemoglobin level significantly decreases the rate of multiorgan failure and death .,我们特别选择将血红蛋白水平升高超过 1 克/分升作为主要终点，因为经过验证的自然历史研究表明，血红蛋白水平升高可显着降低多器官衰竭和死亡率。,0.3571428571428571,"['natural history', 'failure', 'rate', '1', 'death', 'deciliter', 'hemoglobin level', 'primary', 'end', 'point', 'increase', 'that', 'and', 'we']","['failure', 'rate', '1', 'death', 'point']",1323,"['我们具体选择使用超过1g的血球水平作为一个主要终点,因为验证的自然历史研究表明,血球水平的增加显著降低多器官失败和死亡率。']",0.3571428571428571,"['natural history', 'failure', 'rate', '1', 'death', 'deciliter', 'hemoglobin level', 'primary', 'end', 'point', 'increase', 'that', 'and', 'we']","['failure', 'rate', '1', 'death', 'point']",1323,我们特地选择使用血红蛋白水平增加1克/分升以上作为主要终点，因为经过验证的自然病史研究表明，血红蛋白水平的增加显著降低多器官衰竭和死亡率。,0.3571428571428571,"['natural history', 'failure', 'rate', '1', 'death', 'deciliter', 'hemoglobin level', 'primary', 'end', 'point', 'increase', 'that', 'and', 'we']","['failure', 'rate', '1', 'death', 'point']",,,,
1334,1324,"in conclusion , voxelotor provided a significant , sustained increase in hemoglobin level and reduced the incidence of worsening anemia and hemolysis in persons with sickle cell disease .",总之，voxelotor 显着、持续地提高了镰状细胞病患者的血红蛋白水平，降低了贫血恶化和溶血的发生率。,0.5,"['anemia', 'hemolysis', 'incidence', 'disease', 'hemoglobin level', 'sickle cell', 'conclusion', 'increase', 'with', 'and']","['anemia', 'hemolysis', 'incidence', 'disease', 'sickle cell']",1324,"['在结论中,voxelotor提供了一个显著的,持续的血球水平增加,并减少了患有细胞细胞疾病的人的贫血和血球的恶化发病率。']",0.4,"['anemia', 'hemolysis', 'incidence', 'disease', 'hemoglobin level', 'sickle cell', 'conclusion', 'increase', 'with', 'and']","['anemia', 'incidence', 'disease', 'conclusion']",1324,最后，Voxelotor提供了显著的、持续的血红蛋白水平升高以及在患有细胞异常的人群中减少加重贫血和血液溶解的发生率。,0.2,"['anemia', 'hemolysis', 'incidence', 'disease', 'hemoglobin level', 'sickle cell', 'conclusion', 'increase', 'with', 'and']","['anemia', 'incidence']",,,,
1335,1325,"however , whether vitamin D supplementation lowers the risk of diabetes is unknown .",然而，补充维生素 D 是否会降低患糖尿病的风险尚不清楚。,0.6666666666666666,"['diabetes', 'risk', 'vitamin D']","['diabetes', 'risk']",1325,"['然而,维生素D补充是否降低糖尿病的风险尚不清楚。']",1.0,"['diabetes', 'risk', 'vitamin D']","['diabetes', 'risk', 'vitamin D']",1325,然而，不知道补充维生素D是否会降低糖尿病的风险。,1.0,"['diabetes', 'risk', 'vitamin D']","['diabetes', 'risk', 'vitamin D']",,,,
1336,1326,a total of 2423 participants underwent randomization ( 1211 to the vitamin D group and 1212 to the placebo group ) .,共有 2423 名参与者被随机分组（维生素 D 组 1211 人，安慰剂组 1212 人）。,0.6,"['group', 'placebo', 'randomization', 'total', 'vitamin D']","['group', 'placebo', 'randomization']",1326,['共有2423名参与者经历了随机化(1211对维生素D组和1212对 placebo组)。'],0.6,"['group', 'placebo', 'randomization', 'total', 'vitamin D']","['group', 'randomization', 'vitamin D']",1326,总共2423名参与者进行了随机分配（1211人分配到维生素D组，1212人分配到安慰剂组）。,0.8,"['group', 'placebo', 'randomization', 'total', 'vitamin D']","['group', 'placebo', 'randomization', 'vitamin D']",,,,
1337,1327,"the hazard ratio for vitamin D as compared with placebo was 0.88 ( 95 % confidence interval , 0.75 to 1.04 ; P = 0.12 ) .",与安慰剂相比，维生素 D 的风险比为 0.88（95% 置信区间，0.75 至 1.04；P = 0.12）。,0.375,"['placebo', 'hazard ratio', 'confidence interval', 'as', 'with', 'vitamin D', 'P', 'to']","['placebo', 'hazard ratio', 'confidence interval']",1327,"['与 placebo 相比,维生素 D 的风险比例为 0.88 (95% 信任间隔, 0.75 至 1.04 ; P = 0.12 ) 。']",0.125,"['placebo', 'hazard ratio', 'confidence interval', 'as', 'with', 'vitamin D', 'P', 'to']",['hazard ratio'],1327,维生素D与安慰剂相比的危险比为0.88（95%置信区间，0.75至1.04；P=0.12）。,0.375,"['placebo', 'hazard ratio', 'confidence interval', 'as', 'with', 'vitamin D', 'P', 'to']","['placebo', 'confidence interval', 'vitamin D']",,,,
1338,1328,the incidence of adverse events did not differ significantly between the two groups .,不良事件的发生率在两组之间没有显着差异。,0.5,"['incidence', 'adverse', 'differ', 'two']","['incidence', 'two']",1328,['副作用的发病率在两组之间没有显著的差异。'],0.5,"['incidence', 'adverse', 'differ', 'two']","['incidence', 'two']",1328,两组之间的不良事件发生率没有显著差异。,0.5,"['incidence', 'adverse', 'differ', 'two']","['incidence', 'two']",,,,
1339,1329,"among persons at high risk for type 2 diabetes not selected for vitamin D insufficiency , vitamin D3 supplementation at a dose of 4000 IU per day did not result in a significantly lower risk of diabetes than placebo . ( Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others ; D2d ClinicalTrials.gov number , NCT01942694 . )",在没有选择维生素 D 不足的 2 型糖尿病高危人群中，每天补充 4000 IU 剂量的维生素 D3 并没有导致患糖尿病的风险显着低于安慰剂。 （由国家糖尿病、消化和肾脏疾病研究所等资助；D2d ClinicalTrials.gov 编号，NCT01942694。）,0.7058823529411765,"['diabetes', 'type', 'placebo', 'kidney', 'insufficiency', '2', 'high risk', 'digestive', 'lower', 'number', 'institute', 'result', 'vitamin D', 'at', 'dose', 'by', 'and']","['diabetes', 'type', 'placebo', 'kidney', 'insufficiency', '2', 'high risk', 'number', 'institute', 'at', 'dose', 'by']",1329,"['在患2型糖尿病的风险较高的人中,维生素D3补充剂每天4000IU的剂量不会导致糖尿病的风险比 placebo 显著低(由国家糖尿病和消化和肾脏疾病和其他机构资助;D2d ClinicalTrials.gov号,NCT01942694 )。']",0.4705882352941176,"['diabetes', 'type', 'placebo', 'kidney', 'insufficiency', '2', 'high risk', 'digestive', 'lower', 'number', 'institute', 'result', 'vitamin D', 'at', 'dose', 'by', 'and']","['diabetes', 'type', 'kidney', '2', 'number', 'vitamin D', 'dose', 'by']",1329,在高危人群中，维生素D3补充剂并不能显著降低糖尿病风险。,0.1764705882352941,"['diabetes', 'type', 'placebo', 'kidney', 'insufficiency', '2', 'high risk', 'digestive', 'lower', 'number', 'institute', 'result', 'vitamin D', 'at', 'dose', 'by', 'and']","['diabetes', 'high risk', 'vitamin D']",,,,
1340,1330,"more than 84 million adults in the United States have an increased risk of type 2 diabetes , based on a fasting glucose or glycated hemoglobin level above the normal range but below the threshold for diabetes.1",根据空腹血糖或糖化血红蛋白水平高于正常范围但低于糖尿病阈值，美国有超过 8400 万成年人患 2 型糖尿病的风险增加。 1,0.6666666666666666,"['diabetes', 'type', 'threshold', 'glucose', '2', 'hemoglobin level', 'fasting', 'risk', 'normal range', 'have', 'but', 'million']","['diabetes', 'type', 'threshold', '2', 'risk', 'normal range', 'have', 'but']",1330,"['美国有超过84百万成年人患2型糖尿病的风险增加,基于禁食糖或血糖血糖水平高于正常范围,但低于糖尿病的限制。']",0.5833333333333334,"['diabetes', 'type', 'threshold', 'glucose', '2', 'hemoglobin level', 'fasting', 'risk', 'normal range', 'have', 'but', 'million']","['diabetes', 'type', '2', 'risk', 'normal range', 'have', 'but']",1330,"More than 84 million adults in the United States have an increased risk of type 2 diabetes, based on a fasting glucose or glycated hemoglobin level above the normal range but below the threshold for diabetes.1",0.0833333333333333,"['diabetes', 'type', 'threshold', 'glucose', '2', 'hemoglobin level', 'fasting', 'risk', 'normal range', 'have', 'but', 'million']",['2'],,,,
1341,1331,"however , achieving and maintaining sufficient lifestyle change is challenging , and the residual risk of diabetes remains elevated , even after successful weight loss .",然而，实现并维持充分的生活方式改变具有挑战性，即使在成功减肥后，糖尿病的残余风险仍然很高。,0.7142857142857143,"['diabetes', 'risk', 'after', 'change', 'residual', 'weight loss', 'and']","['diabetes', 'risk', 'after', 'residual', 'and']",1331,"['然而,实现和维持足够的生活方式变化是挑战性的,而糖尿病的剩余风险仍然高,即使成功减肥后。']",0.8571428571428571,"['diabetes', 'risk', 'after', 'change', 'residual', 'weight loss', 'and']","['diabetes', 'risk', 'after', 'change', 'residual', 'and']",1331,然而，实现并维持足够的生活方式改变是具有挑战性的，即使在成功减肥后，糖尿病的残留风险也会升高。,0.5714285714285714,"['diabetes', 'risk', 'after', 'change', 'residual', 'weight loss', 'and']","['diabetes', 'risk', 'after', 'and']",,,,
1342,1332,the Vitamin D and Type 2 Diabetes ( D2d ) trial was conducted to test whether vitamin D supplementation reduces the risk of type 2 diabetes among adults at high risk for the disorder .,维生素 D 和 2 型糖尿病 (D2d) 试验的目的是测试补充维生素 D 是否可以降低高风险成人患 2 型糖尿病的风险。,0.3636363636363636,"['diabetes', 'type', 'disorder', '2', 'test', 'high risk', 'trial', 'vitamin D', 'at', 'to', 'and']","['diabetes', 'type', '2', 'test']",1332,"['维生素D和2型糖尿病(D2d)的测试进行了测试,以测试维生素D补充是否降低患2型糖尿病的风险在患有高疾病风险的成年人中。']",0.4545454545454545,"['diabetes', 'type', 'disorder', '2', 'test', 'high risk', 'trial', 'vitamin D', 'at', 'to', 'and']","['diabetes', 'type', '2', 'test', 'vitamin D']",1332,试验表明，维生素D补充剂是否能降低2型糖尿病风险。,0.4545454545454545,"['diabetes', 'type', 'disorder', '2', 'test', 'high risk', 'trial', 'vitamin D', 'at', 'to', 'and']","['diabetes', 'type', '2', 'test', 'vitamin D']",,,,
1343,1333,the trial protocol ( available with the full text of this article at NEJM.org ) was designed by the planning committee and the primary sponsor ( National Institute of Diabetes and Digestive and Kidney Diseases ) without input from manufacturers11 and involved collaboration among 22 academic medical centers in the United States ( https : / / d2dstudy.org / sites ) .,试验方案（与本文全文可在 NEJM.org 上获取）由规划委员会和主要申办方（国家糖尿病、消化和肾脏疾病研究所）设计，没有制造商的参与11，涉及 22 个学术医学中心之间的合作在美国 (https://d2dstudy.org/sites)。,0.3333333333333333,"['diabetes', 'kidney', 'protocol', '/', 'sponsor', 'digestive', 'article', 'medical', 'primary', 'available', 'committee', 'input', 'institute', 'trial', 'text', 'collaboration', 'full', 'this', 'by', 'and', 'without']","['diabetes', 'kidney', 'protocol', 'committee', 'institute', 'collaboration', 'by']",1333,"['试验协议(可在NEJM.org上提供本文的完整文本)由规划委员会和主要赞助商(国家糖尿病和消化和肾脏疾病研究所)没有来自制造商的提交,并参与了美国22个学术医疗中心的合作(https: / d2dstudy.org / 网站 )。']",0.3809523809523809,"['diabetes', 'kidney', 'protocol', '/', 'sponsor', 'digestive', 'article', 'medical', 'primary', 'available', 'committee', 'input', 'institute', 'trial', 'text', 'collaboration', 'full', 'this', 'by', 'and', 'without']","['diabetes', 'kidney', 'protocol', 'committee', 'institute', 'collaboration', 'full', 'by']",1333,这项试验方案（可在本文完整文本中通过NEJM.org查看）由策划委员会和主要赞助方（美国国家糖尿病、消化系统疾病与肾脏疾病研究所）设计，没有征求制造商的意见11，并在美国22家学术医疗中心之间进行了合作（https：//d2dstudy.org/sites）。,0.3809523809523809,"['diabetes', 'kidney', 'protocol', '/', 'sponsor', 'digestive', 'article', 'medical', 'primary', 'available', 'committee', 'input', 'institute', 'trial', 'text', 'collaboration', 'full', 'this', 'by', 'and', 'without']","['diabetes', 'kidney', 'protocol', 'committee', 'institute', 'collaboration', 'full', 'by']",,,,
1344,1334,"the institutional review board at each clinical site also approved the protocol , and all the participants provided written informed consent .",每个临床中心的机构审查委员会也批准了该方案，所有参与者都提供了书面知情同意书。,0.2,"['site', 'review', 'protocol', 'board', 'clinical', 'informed consent', 'at', 'all', 'each', 'and']","['review', 'clinical']",1334,"['每个临床场所的机构审查委员会也批准了协议,所有参与者都提供了书面通知的同意。']",0.4,"['site', 'review', 'protocol', 'board', 'clinical', 'informed consent', 'at', 'all', 'each', 'and']","['site', 'review', 'protocol', 'clinical']",1334,"The institutional review board at each clinical site also approved the protocol, and all the participants provided written informed consent.

Chinese:

每个临床研究站点的机构审查委员会也批准了该协议，所有参与者均已经书面知情同意。",0.3,"['site', 'review', 'protocol', 'board', 'clinical', 'informed consent', 'at', 'all', 'each', 'and']","['review', 'protocol', 'clinical']",,,,
1345,1335,the statistical team at the coordinating center analyzed the data and vouches for its accuracy .,协调中心的统计小组对数据进行了分析，并保证其准确性。,0.8,"['center', 'data', 'accuracy', 'team', 'and']","['center', 'data', 'accuracy', 'team']",1335,"['协调中心的统计团队分析了数据和优惠,以确保其准确性。']",0.8,"['center', 'data', 'accuracy', 'team', 'and']","['center', 'data', 'accuracy', 'team']",1335,统计小组在协调中心分析了数据，并为其准确性提供了担保。,0.8,"['center', 'data', 'accuracy', 'team', 'and']","['center', 'data', 'accuracy', 'team']",,,,
1346,1336,"they also contributed to the interpretation of the results and the preparation , review , and approval of the manuscript and made the decision to submit the manuscript for publication .",他们还对结果的解释以及手稿的准备、审查和批准做出了贡献，并做出了投稿发表的决定。,0.7777777777777778,"['preparation', 'review', 'approval', 'interpretation', 'publication', 'manuscript', 'decision', 'to', 'and']","['preparation', 'review', 'approval', 'interpretation', 'publication', 'manuscript', 'decision']",1336,"['他们还为结果的解释和手稿的准备、审查和批准做出了贡献,并决定将手稿提交出版。']",0.7777777777777778,"['preparation', 'review', 'approval', 'interpretation', 'publication', 'manuscript', 'decision', 'to', 'and']","['preparation', 'review', 'approval', 'interpretation', 'publication', 'manuscript', 'decision']",1336,他们还对结果的解释和手稿的准备、审查和批准做出了贡献，并决定将手稿提交给出版社。,0.7777777777777778,"['preparation', 'review', 'approval', 'interpretation', 'publication', 'manuscript', 'decision', 'to', 'and']","['preparation', 'review', 'approval', 'interpretation', 'publication', 'manuscript', 'decision']",,,,
1347,1337,"no pharmaceutical manufacturers contributed to the planning , design , or conduct of the trial .",没有制药商参与试验的规划、设计或实施。,0.1666666666666666,"['pharmaceutical', 'no', 'trial', 'conduct', 'design', 'to']",['design'],1337,['任何制药制造商都没有参与试验的规划、设计或进行。'],0.1666666666666666,"['pharmaceutical', 'no', 'trial', 'conduct', 'design', 'to']",['design'],1337,"No pharmaceutical manufacturers contributed to the planning, design, or conduct of the trial.",0.0,"['pharmaceutical', 'no', 'trial', 'conduct', 'design', 'to']",[],,,,
1348,1338,"for a complete list of eligibility criteria , see the Supplementary Appendix ( available at NEJM.org ) .",有关资格标准的完整列表，请参阅补充附录（可在 NEJM.org 获取）。,0.0,"['appendix', 'supplementary', 'complete', 'available', 'list', 'at']",[],1338,"['有关资格准则的完整列表,请参见附件(可在NEJM.org上找到)。']",0.1666666666666666,"['appendix', 'supplementary', 'complete', 'available', 'list', 'at']",['appendix'],1338,详细的资格条件列表请参见附表（在 NEJM.org 上可以找到）。,0.0,"['appendix', 'supplementary', 'complete', 'available', 'list', 'at']",[],,,,
1349,1339,intervention AND PROCEDURES,干预和程序,0.0,['intervention'],[],1339,['干预与程序'],0.0,['intervention'],[],1339,"intervention AND PROCEDURES

中文：

干预和程序",0.0,['intervention'],[],,,,
1350,1340,participants received a bottle of trial pills at the time of randomization and every 6 months thereafter .,参与者在随机分组时收到一瓶试验药片，此后每 6 个月收到一次。,0.6,"['randomization', 'bottle', 'time', 'trial', 'pills']","['randomization', 'bottle', 'time']",1340,"['參與者在偶然化時收到一瓶試用藥片,然後每6個月。']",0.2,"['randomization', 'bottle', 'time', 'trial', 'pills']",['bottle'],1340,参与者在随机分配的时候收到了一瓶试用药片，每6个月后还会收到一瓶。,0.6,"['randomization', 'bottle', 'time', 'trial', 'pills']","['randomization', 'bottle', 'time']",,,,
1351,1341,bottles with unused pills were returned at each visit to estimate adherence .,每次就诊时将装有未使用药丸的瓶子归还，以估计依从性。,0.1428571428571428,"['estimate', 'with', 'adherence', 'pills', 'each', 'to', 'visit']",['pills'],1341,"['未使用的药片的瓶子每次访问都返回,以估计合并。']",0.0,"['estimate', 'with', 'adherence', 'pills', 'each', 'to', 'visit']",[],1341,每次访问时返回未使用的药片瓶，以估计服药情况。,0.0,"['estimate', 'with', 'adherence', 'pills', 'each', 'to', 'visit']",[],,,,
1352,1342,"because of concern that high intake of calcium from supplements may be associated with adverse outcomes , participants were asked to limit calcium supplements to 600 mg per day .",由于担心从补充剂中摄入大量钙可能会导致不良后果，因此要求参与者将钙补充剂的摄入量限制在每天 600 毫克。,0.3636363636363636,"['calcium', 'intake', 'be', 'adverse', 'associated', 'limit', 'concern', 'with', 'that', 'to', 'high']","['calcium', 'be', 'limit', 'to']",1342,"['由于担心从补充剂中摄入高钙可能与不良结果有关,参与者被要求将钙补充剂限制为每日600毫克。']",0.3636363636363636,"['calcium', 'intake', 'be', 'adverse', 'associated', 'limit', 'concern', 'with', 'that', 'to', 'high']","['calcium', 'limit', 'to', 'high']",1342,因为担心高摄入量的钙质补充剂可能会导致不良结果，参与者被要求每天限制钙质补充剂摄入量600毫克。,0.2727272727272727,"['calcium', 'intake', 'be', 'adverse', 'associated', 'limit', 'concern', 'with', 'that', 'to', 'high']","['calcium', 'limit', 'high']",,,,
1353,1343,"if two or three of the glycemic measures met the 2010 ADA thresholds for diabetes , 12 the participant was considered to have met the diabetes outcome .",如果两项或三项血糖测量指标达到 2010 年 ADA 糖尿病阈值，12 则认为参与者达到了糖尿病结果。,0.5,"['diabetes', 'outcome', 'met', 'have', 'three', 'if', 'to', 'two']","['diabetes', 'outcome', 'three', 'two']",1343,"['如果两个或三个糖尿病测量满足了2010年糖尿病 ADA 限制,12 参与者被认为满足了糖尿病结果。']",0.5,"['diabetes', 'outcome', 'met', 'have', 'three', 'if', 'to', 'two']","['diabetes', 'outcome', 'three', 'two']",1343,如果血糖指标中有两到三个达到了2010年美国糖尿病协会的标准，那么参与者被认为患有糖尿病。,0.5,"['diabetes', 'outcome', 'met', 'have', 'three', 'if', 'to', 'two']","['diabetes', 'have', 'three', 'two']",,,,
1354,1344,"when only the measure for fasting plasma glucose or glycated hemoglobin met the threshold , confirmatory testing was performed for the positive measure within 8 weeks .",当只有空腹血糖或糖化血红蛋白的测量值达到阈值时，在 8 周内对阳性测量值进行确认测试。,0.4,"['threshold', 'glucose', 'plasma', 'hemoglobin', 'fasting', 'measure', 'testing', 'positive', 'met', 'confirmatory']","['threshold', 'hemoglobin', 'measure', 'confirmatory']",1344,"['当只有<unk>血糖或<unk>血糖的禁食测量达到边界时,在8周内对积极测量进行确认测试。']",0.2,"['threshold', 'glucose', 'plasma', 'hemoglobin', 'fasting', 'measure', 'testing', 'positive', 'met', 'confirmatory']","['measure', 'confirmatory']",1344,如果只有空腹血糖或糖化血红蛋白测量符合阈值，那么对正面测量进行确认性测试将在8周内进行。,0.4,"['threshold', 'glucose', 'plasma', 'hemoglobin', 'fasting', 'measure', 'testing', 'positive', 'met', 'confirmatory']","['threshold', 'hemoglobin', 'measure', 'confirmatory']",,,,
1355,1345,"during the trial , research staff , caregivers , and participants were unaware of glycemic test results until a participant met the diabetes outcome .",在试验期间，研究人员、护理人员和参与者在参与者出现糖尿病结果之前都不知道血糖测试结果。,0.4,"['diabetes', 'research', 'test', 'outcome', 'staff', 'trial', 'unaware', 'met', 'and', 'caregivers']","['diabetes', 'research', 'test', 'outcome']",1345,"['在试验期间,研究人员、护理人员和参与者不知道糖尿病测试结果,直到参与者发现糖尿病结果。']",0.4,"['diabetes', 'research', 'test', 'outcome', 'staff', 'trial', 'unaware', 'met', 'and', 'caregivers']","['diabetes', 'research', 'test', 'outcome']",1345,在试验中，研究人员、照护人员和参与者都不知道血糖测试结果，直到一名参与者确诊为糖尿病。,0.4,"['diabetes', 'research', 'test', 'outcome', 'staff', 'trial', 'unaware', 'met', 'and', 'caregivers']","['diabetes', 'research', 'test', 'outcome']",,,,
1356,1346,"safety was assessed by means of participant report and annual fasting measurements of serum calcium , serum creatinine , and morning spot urine calcium : creatinine ratio ( a rough estimate of urine calcium excretion ) .14",安全性是通过参与者报告和年度空腹测量血清钙、血清肌酐和晨间尿钙：肌酐比（尿钙排泄的粗略估计） .14 来评估的。,0.375,"['annual', 'safety', 'creatinine', 'urine', 'report', 'ratio', 'calcium excretion', 'serum', 'fasting', 'spot', 'estimate', 'means', 'by', 'and', 'morning', 'assessed']","['safety', 'urine', 'report', 'ratio', 'calcium excretion', 'serum']",1346,['安全性通过参与者报告和每年的禁食测量来评估血清钙、血清克里亚丁和早晨点尿液钙:克里亚丁比例(尿液钙排泄的严格估计)。'],0.5,"['annual', 'safety', 'creatinine', 'urine', 'report', 'ratio', 'calcium excretion', 'serum', 'fasting', 'spot', 'estimate', 'means', 'by', 'and', 'morning', 'assessed']","['safety', 'urine', 'report', 'ratio', 'calcium excretion', 'serum', 'spot', 'morning']",1346,"safety was assessed by means of participant report and annual fasting measurements of serum calcium , serum creatinine , and morning spot urine calcium : creatinine ratio ( a rough estimate of urine calcium excretion ) .14

中文：

安全性通过参与者报告和每年的血清钙、血清肌酐和早晨尿液钙：肌酐比（尿液钙排泄的粗略估计）的快速测量来评估。14",0.4375,"['annual', 'safety', 'creatinine', 'urine', 'report', 'ratio', 'calcium excretion', 'serum', 'fasting', 'spot', 'estimate', 'means', 'by', 'and', 'morning', 'assessed']","['safety', 'urine', 'report', 'ratio', 'calcium excretion', 'serum', 'morning']",,,,
1357,1347,"serum calcium and creatinine were analyzed locally at each site , and the estimated glomerular filtration rate was calculated.15",在每个部位局部分析血清钙和肌酸酐，并计算估计的肾小球滤过率。 15,0.5714285714285714,"['calcium', 'creatinine', 'site', 'glomerular filtration rate', 'serum', 'each', 'and']","['calcium', 'creatinine', 'glomerular filtration rate', 'serum']",1347,"['血清钙和克里亚丁在每个区域进行了本地分析,并计算了估计的血清过滤率。']",0.2857142857142857,"['calcium', 'creatinine', 'site', 'glomerular filtration rate', 'serum', 'each', 'and']","['calcium', 'serum']",1347,"Serum calcium and creatinine were analyzed locally at each site, and the estimated glomerular filtration rate was calculated.15

Chinese:

血清钙和肌酐在每个地方都进行了当地分析，并估算出了肾小球过滤率。15",0.2857142857142857,"['calcium', 'creatinine', 'site', 'glomerular filtration rate', 'serum', 'each', 'and']","['calcium', 'serum']",,,,
1358,1348,other blood and urine specimens were processed locally and shipped to the central laboratory .,其他血液和尿液标本在当地处理并运往中央实验室。,0.4285714285714285,"['urine', 'blood', 'specimens', 'central', 'laboratory', 'processed', 'and']","['urine', 'blood', 'laboratory']",1348,['其他血液和尿液样本被本地处理并发送到中央实验室。'],0.5714285714285714,"['urine', 'blood', 'specimens', 'central', 'laboratory', 'processed', 'and']","['urine', 'blood', 'specimens', 'laboratory']",1348,其他血液和尿液标本在当地进行处理，并运送到中央实验室。,0.4285714285714285,"['urine', 'blood', 'specimens', 'central', 'laboratory', 'processed', 'and']","['urine', 'blood', 'laboratory']",,,,
1359,1349,plasma glucose was measured with the use of a hexokinase method .,使用己糖激酶法测量血浆葡萄糖。,0.6,"['glucose', 'plasma', 'method', 'with', 'hexokinase']","['glucose', 'plasma', 'hexokinase']",1349,"['血糖在血糖中被测量,使用 hexokinase 方法。']",0.0,"['glucose', 'plasma', 'method', 'with', 'hexokinase']",[],1349,使用酵素法测定血浆葡萄糖。,0.4,"['glucose', 'plasma', 'method', 'with', 'hexokinase']","['glucose', 'plasma']",,,,
1360,1350,"no imputation was performed for missing data , but we conducted a sensitivity analysis to assess for noninformative censoring of incomplete data ( see the Supplementary Appendix ) .",没有对缺失数据进行填补，但我们进行了敏感性分析以评估对不完整数据的非信息删失（见补充附录）。,0.3636363636363636,"['appendix', 'analysis', 'supplementary', 'no', 'assess', 'incomplete data', 'sensitivity', 'but', 'to', 'missing', 'we']","['analysis', 'assess', 'but', 'missing']",1350,"['没有对缺乏数据进行指控,但我们进行了敏感性分析,以评估非信息性审查不完整的数据(参见附件)。']",0.4545454545454545,"['appendix', 'analysis', 'supplementary', 'no', 'assess', 'incomplete data', 'sensitivity', 'but', 'to', 'missing', 'we']","['appendix', 'analysis', 'assess', 'but', 'missing']",1350,没有对缺失数据进行补充估计，但我们进行了敏感性分析来评估不完整数据的不信息性截尾（参见补充附录）。,0.3636363636363636,"['appendix', 'analysis', 'supplementary', 'no', 'assess', 'incomplete data', 'sensitivity', 'but', 'to', 'missing', 'we']","['analysis', 'assess', 'but', 'missing']",,,,
1361,1351,"all events that occurred during the trial , including those that occurred after the target of 508 events was reached , were used to generate the primary results .",试验期间发生的所有事件，包括达到 508 事件目标后发生的事件，均用于生成主要结果。,0.375,"['primary', 'target', 'after', 'trial', 'generate', 'all', 'that', 'to']","['target', 'after', 'to']",1351,"['所有在试验期间发生的事件,包括在达到508事件目标后发生的事件,都被用来产生初始结果。']",0.25,"['primary', 'target', 'after', 'trial', 'generate', 'all', 'that', 'to']","['target', 'after']",1351,所有在审判期间发生的事件，包括达到508个目标事件后发生的事件，都用于生成主要结果。,0.5,"['primary', 'target', 'after', 'trial', 'generate', 'all', 'that', 'to']","['target', 'after', 'trial', 'to']",,,,
1362,1352,"the model included group assignment as its main predictor variable and the stratification variables ( trial site , BMI , and race ) .",该模型包括作为其主要预测变量的分组和分层变量（试验地点、BMI 和种族）。,0.5454545454545454,"['variable', 'group', 'stratification', 'model', 'site', 'BMI', 'trial', 'race', 'assignment', 'and', 'predictor']","['variable', 'group', 'stratification', 'model', 'site', 'race']",1352,['该模型包括组分配作为其主要预测变量和分裂变量(测试地点、BMI和赛车)。'],0.3636363636363636,"['variable', 'group', 'stratification', 'model', 'site', 'BMI', 'trial', 'race', 'assignment', 'and', 'predictor']","['variable', 'group', 'model', 'site']",1352,"the model included group assignment as its main predictor variable and the stratification variables ( trial site , BMI , and race ) .

Chinese:

本模型以小组分配为主要预测变量，并使用分层变量（试验地点、身体质量指数和种族）进行分层。",0.5454545454545454,"['variable', 'group', 'stratification', 'model', 'site', 'BMI', 'trial', 'race', 'assignment', 'and', 'predictor']","['variable', 'group', 'stratification', 'model', 'site', 'race']",,,,
1363,1353,we also show a model without the stratification variables .,我们还展示了一个没有分层变量的模型。,0.5,"['stratification', 'model', 'without', 'we']","['stratification', 'model']",1353,"['我们还展示了一个模型,没有分裂变量。']",0.25,"['stratification', 'model', 'without', 'we']",['model'],1353,我们还展示了一个没有分层变量的模型。,0.5,"['stratification', 'model', 'without', 'we']","['stratification', 'model']",,,,
1364,1354,variability of response to vitamin D supplementation was assessed in prespecified subgroups defined by key baseline variables .,在由关键基线变量定义的预先指定的亚组中评估了对维生素 D 补充剂反应的变异性。,0.5555555555555556,"['key', 'defined', 'baseline', 'variability', 'response', 'vitamin D', 'by', 'to', 'assessed']","['key', 'baseline', 'variability', 'response', 'by']",1354,['对维生素D补充反应的变量在由关键基因变量定义的预定子组中被评估。'],0.4444444444444444,"['key', 'defined', 'baseline', 'variability', 'response', 'vitamin D', 'by', 'to', 'assessed']","['key', 'response', 'vitamin D', 'by']",1354,在预先确定的基线变量子组中评估了维生素D补充剂的反应变异性。,0.5555555555555556,"['key', 'defined', 'baseline', 'variability', 'response', 'vitamin D', 'by', 'to', 'assessed']","['defined', 'baseline', 'variability', 'response', 'vitamin D']",,,,
1365,1355,rates of adverse events were compared between the two groups .,比较两组不良事件发生率。,0.5,"['adverse', 'two']",['two'],1355,['对不起事件的率在两组之间进行了比较。'],0.5,"['adverse', 'two']",['two'],1355,两组之间的不良事件发生率进行了比较。,0.5,"['adverse', 'two']",['two'],,,,
1366,1356,"when evaluating the significance of the prespecified subgroup analyses , we used the Hochberg sequential procedure to adjust for multiple comparisons , if necessary .",在评估预先指定的亚组分析的显着性时，如有必要，我们使用 Hochberg 序贯程序针对多重比较进行调整。,0.125,"['procedure', 'multiple', 'adjust', 'necessary', 'significance', 'subgroup', 'to', 'we']",['procedure'],1356,"['在评估预定子组分析的重要性时,我们使用霍赫伯格序列程序进行调整,以便在必要时进行多次比较。']",0.25,"['procedure', 'multiple', 'adjust', 'necessary', 'significance', 'subgroup', 'to', 'we']","['procedure', 'significance']",1356,在评估预先规定的子组分析的意义时，如有必要，我们使用霍克伯格顺序程序来进行多重比较。,0.25,"['procedure', 'multiple', 'adjust', 'necessary', 'significance', 'subgroup', 'to', 'we']","['procedure', 'significance']",,,,
1367,1357,"no adjustments were made for the safety analyses or the planned exploratory or post hoc analyses for the primary outcome ; therefore , only point estimates and 95 % confidence intervals are presented without P values .",未对主要结局的安全性分析或计划的探索性或事后分析进行调整；因此，仅提供点估计值和 95% 置信区间，而没有 P 值。,0.2142857142857142,"['safety', 'outcome', 'post', 'exploratory', 'primary', 'no', 'values', 'point', 'confidence', 'P', 'therefore', 'and', 'without', 'intervals']","['safety', 'point', 'and']",1357,"['对于安全分析或初始结果的计划探测或后考分析没有进行调整;因此,只有点估计和95%的信任间隔没有P值。']",0.2857142857142857,"['safety', 'outcome', 'post', 'exploratory', 'primary', 'no', 'values', 'point', 'confidence', 'P', 'therefore', 'and', 'without', 'intervals']","['safety', 'outcome', 'exploratory', 'point']",1357,"No adjustments were made for the safety analyses or the planned exploratory or post hoc analyses for the primary outcome; therefore, only point estimates and 95% confidence intervals are presented without P values.",0.0714285714285714,"['safety', 'outcome', 'post', 'exploratory', 'primary', 'no', 'values', 'point', 'confidence', 'P', 'therefore', 'and', 'without', 'intervals']",['post'],,,,
1368,1358,"a total of 44.8 % of the participants were women , 33.3 % were of nonwhite race , and 9.3 % were of Hispanic ethnic background.24",总共 44.8 % 的参与者是女性， 33.3 % 是非白人种族， 9.3 % 是西班牙裔。 24,0.3333333333333333,"['total', 'race', 'and']",['race'],1358,"['总共有44.8%的参与者是女性,33.3%是非白人,9.3%是西班牙人。']",0.0,"['total', 'race', 'and']",[],1358,总计44.8%的参与者是女性，33.3%的参与者是非白人，9.3%的参与者是西班牙裔。,0.0,"['total', 'race', 'and']",[],,,,
1369,1359,"the participants had a mean age of 60.0 years , a mean BMI of 32.1 , and a mean glycated hemoglobin level of 5.9 % ( 48 mmol per mole ) .",参与者的平均年龄为 60.0 岁，平均 BMI 为 32.1，平均糖化血红蛋白水平为 5.9%（48 毫摩尔/摩尔）。,0.5,"['mean', 'BMI', 'hemoglobin level', 'mole', 'age', 'and']","['mean', 'mole', 'age']",1359,"['参与者平均年龄为60.0岁,平均BMI为32.1岁,平均血糖血糖水平为5.9%(每粒48mmol)。']",0.3333333333333333,"['mean', 'BMI', 'hemoglobin level', 'mole', 'age', 'and']","['mean', 'age']",1359,参与者平均年龄为60.0岁，平均体重指数为32.1，平均糖化血红蛋白水平为5.9％（48毫克每摩尔）。,0.5,"['mean', 'BMI', 'hemoglobin level', 'mole', 'age', 'and']","['mean', 'mole', 'age']",,,,
1370,1360,a total of 84.2 % of the participants met the glycemic criteria for both fasting plasma glucose and glycated hemoglobin ; approximately one third met all three glycemic criteria .,共有 84.2% 的参与者符合空腹血糖和糖化血红蛋白的血糖标准；大约三分之一符合所有三个血糖标准。,0.1818181818181818,"['glucose', 'plasma', 'hemoglobin', 'total', 'fasting', 'met', 'approximately', 'all', 'three', 'and', 'third']","['hemoglobin', 'three']",1360,['共有84.2%的参与者满足了禁食血糖和血糖血糖的血糖基准;约三分之一满足了三分之一的血糖基准。'],0.0909090909090909,"['glucose', 'plasma', 'hemoglobin', 'total', 'fasting', 'met', 'approximately', 'all', 'three', 'and', 'third']",['three'],1360,總計有84.2%的參與者滿足空腹血漿葡萄糖和糖化血紅素的糖化標準，大約三分之一的參與者滿足所有三項糖化標準。,0.0909090909090909,"['glucose', 'plasma', 'hemoglobin', 'total', 'fasting', 'met', 'approximately', 'all', 'three', 'and', 'third']",['glucose'],,,,
1371,1361,the last trial encounter was in November 2018 .,最后一次试探是在2018年11月。,0.0,"['encounter', 'november', 'trial', 'in']",[],1361,['最后一次审判是在2018年11月。'],0.25,"['encounter', 'november', 'trial', 'in']",['trial'],1361,最后一次审判遭遇发生在2018年11月。,0.5,"['encounter', 'november', 'trial', 'in']","['encounter', 'trial']",,,,
1372,1362,"before reaching a primary outcome event , 10 participants ( 5 in each group ) died , and 62 ( 34 in the vitamin D group and 28 in the placebo group ) withdrew consent ( Figure 1 ) .",在达到主要结果事件之前，10 名参与者（每组 5 名）死亡，62 名（维生素 D 组 34 名，安慰剂组 28 名）撤回同意（图 1）。,0.6153846153846154,"['group', '5', 'placebo', '1', 'outcome', 'figure', 'primary', 'consent', 'vitamin D', 'event', 'before', 'each', 'and']","['group', '5', 'placebo', '1', 'outcome', 'consent', 'event', 'before']",1362,"['在到达一个主要结果事件之前,10名参与者(每个组5人)死亡,62人(维生素D组34人和 placebo组28人)撤回了同意(图1)。']",0.6153846153846154,"['group', '5', 'placebo', '1', 'outcome', 'figure', 'primary', 'consent', 'vitamin D', 'event', 'before', 'each', 'and']","['group', '5', '1', 'outcome', 'consent', 'vitamin D', 'event', 'before']",1362,达到主要结果事件之前，有10名参与者（分别在两组中各5人）死亡，有62名参与者（维生素D组34人，安慰剂组28人）退出研究（见图1）。,0.6923076923076923,"['group', '5', 'placebo', '1', 'outcome', 'figure', 'primary', 'consent', 'vitamin D', 'event', 'before', 'each', 'and']","['group', '5', 'placebo', '1', 'outcome', 'vitamin D', 'event', 'before', 'each']",,,,
1373,1363,"by the end of the trial , diabetes had developed in 616 patients .",到试验结束时，已有 616 名患者患上了糖尿病。,0.2,"['diabetes', 'trial', 'end', 'in', 'by']",['diabetes'],1363,"['在试验结束时,糖尿病在616名患者中出现。']",0.2,"['diabetes', 'trial', 'end', 'in', 'by']",['diabetes'],1363,在试验结束时，有616名患者患上了糖尿病。,0.2,"['diabetes', 'trial', 'end', 'in', 'by']",['diabetes'],,,,
1374,1364,"when the stratification variables were not included in the model , the hazard ratio in the vitamin D group was 0.87 ( 95 % CI , 0.75 to 1.02 ) .",当模型中未包括分层变量时，维生素 D 组的风险比为 0.87（95% CI，0.75 至 1.02）。,0.5,"['group', 'stratification', 'model', 'hazard ratio', 'vitamin D', 'CI', 'not included', 'to']","['group', 'stratification', 'model', 'hazard ratio']",1364,"['当分裂变量不包括在模型中时,维生素D组的危险比例为0.87(95% CI,0.75 至 1.02)。']",0.375,"['group', 'stratification', 'model', 'hazard ratio', 'vitamin D', 'CI', 'not included', 'to']","['group', 'model', 'vitamin D']",1364,当不将分层变量纳入模型时，维生素D组的危险比为0.87（95%置信区间，0.75至1.02）。,0.5,"['group', 'stratification', 'model', 'hazard ratio', 'vitamin D', 'CI', 'not included', 'to']","['group', 'stratification', 'model', 'vitamin D']",,,,
1375,1365,"in a sensitivity analysis to account for missing data , the hazard ratio did not change substantially ( see the Supplementary Appendix ) .",在解释缺失数据的敏感性分析中，风险比没有显着变化（见补充附录）。,0.5555555555555556,"['appendix', 'data', 'analysis', 'hazard ratio', 'supplementary', 'change', 'sensitivity', 'to', 'missing']","['data', 'analysis', 'hazard ratio', 'change', 'missing']",1365,"['在对失踪数据的敏感性分析中,风险比例没有显著变化(参见附件)。']",0.5555555555555556,"['appendix', 'data', 'analysis', 'hazard ratio', 'supplementary', 'change', 'sensitivity', 'to', 'missing']","['appendix', 'data', 'analysis', 'hazard ratio', 'change']",1365,在对缺失数据进行敏感性分析中，危险比并没有显著改变（参见补充附录）。,0.3333333333333333,"['appendix', 'data', 'analysis', 'hazard ratio', 'supplementary', 'change', 'sensitivity', 'to', 'missing']","['data', 'analysis', 'missing']",,,,
1376,1366,the results of the subgroup analyses were consistent with the findings of the main analysis ; there was no apparent heterogeneity of treatment effect across the prespecified subgroups ( Figure 3 ) .,亚组分析结果与主要分析结果一致；预先指定的亚组之间的治疗效果没有明显的异质性（图 3）。,0.3333333333333333,"['heterogeneity', 'analysis', 'figure', 'no', 'across', '3', 'treatment effect', 'subgroup', 'with']","['heterogeneity', 'analysis', 'treatment effect']",1366,['子组分析的结果与主要分析的发现一致;在预定子组中没有显而易见的治疗效应异性(图3)。'],0.1111111111111111,"['heterogeneity', 'analysis', 'figure', 'no', 'across', '3', 'treatment effect', 'subgroup', 'with']",['analysis'],1366,子群分析的結果與主要分析結果一致；在預先指定的子群中，沒有明顯的治療效果异質性（圖3）。,0.2222222222222222,"['heterogeneity', 'analysis', 'figure', 'no', 'across', '3', 'treatment effect', 'subgroup', 'with']","['analysis', 'subgroup']",,,,
1377,1367,"overall , 47 participants ( 3.9 % ) in the vitamin D group stopped the trial pills because of an adverse event , as compared with 37 ( 3.1 % ) in the placebo group ( difference , 0.8 percentage points ; 95 % CI , − 0.7 to 2.3 ) .",总体而言，维生素 D 组中有 47 名参与者 (3.9%) 因不良事件停止了试验药物，而安慰剂组中有 37 名 (3.1%) 参与者（差异，0.8 个百分点；95% CI，- 0.7 至 2.3 ) 。,0.3333333333333333,"['group', 'percentage', 'placebo', 'difference', 'adverse event', 'trial', 'as', 'with', 'vitamin D', 'CI', 'pills', 'to']","['group', 'placebo', 'difference', 'adverse event']",1367,"['总体而言,维生素D组的47名参与者(3.9%)因副作用而停止了试用药丸,与 placebo组的37名(3.1%)相比(差异,0.8个百分点;95%的CI, −0.7到2.3)。']",0.3333333333333333,"['group', 'percentage', 'placebo', 'difference', 'adverse event', 'trial', 'as', 'with', 'vitamin D', 'CI', 'pills', 'to']","['group', 'difference', 'vitamin D', 'pills']",1367,总体而言，47名参与者（3.9%）在维生素D组停止了试用药片由于不良事件，而在安慰剂组的37名参与者（3.1%）（差异，0.8个百分点；95%CI，-0.7至2.3）。,0.5,"['group', 'percentage', 'placebo', 'difference', 'adverse event', 'trial', 'as', 'with', 'vitamin D', 'CI', 'pills', 'to']","['group', 'placebo', 'difference', 'adverse event', 'vitamin D', 'to']",,,,
1378,1368,"while our trial was being conducted , two other trials that were designed to test whether vitamin D supplementation lowers the risk of type 2 diabetes among persons at risk showed hazard ratios with vitamin D that were similar to those in our trial.25,26","在我们进行试验的同时，另外两项旨在测试维生素 D 补充剂是否能降低高危人群患 2 型糖尿病风险的试验表明，维生素 D 的风险比与我们试验中的风险比相似。 25,26",0.4285714285714285,"['diabetes', 'type', '2', 'test', 'hazard', 'risk', 'trial', 'being', 'with', 'vitamin D', 'that', 'to', 'two', 'similar']","['diabetes', 'type', '2', 'test', 'risk', 'two']",1368,"['虽然我们的研究正在进行中,还有两项研究,旨在测试维生素D补充是否降低患2型糖尿病的风险,并显示与我们研究中的类似的维生素D的风险比例。']",0.5,"['diabetes', 'type', '2', 'test', 'hazard', 'risk', 'trial', 'being', 'with', 'vitamin D', 'that', 'to', 'two', 'similar']","['diabetes', 'type', '2', 'test', 'risk', 'vitamin D', 'two']",1368,在我们的试验进行的同时，另外两个旨在检测维生素D补充是否降低二型糖尿病风险的试验也显示了与我们试验中相似的危险比率。25，26,0.6428571428571429,"['diabetes', 'type', '2', 'test', 'hazard', 'risk', 'trial', 'being', 'with', 'vitamin D', 'that', 'to', 'two', 'similar']","['diabetes', 'type', '2', 'test', 'hazard', 'risk', 'vitamin D', 'two', 'similar']",,,,
1379,1369,"in the Tromsø Vitamin D and T2DM Trial ( Norway ) , which randomly assigned 511 white adults with prediabetes to 20,000 IU per week ( approximately 2900 IU per day ) of vitamin D3 or placebo , the risk of diabetes was numerically lower in the vitamin D group than in the placebo group , but the difference was not significant ( hazard ratio , 0.90 ; 95 % CI , 0.69 to 1.18 ) .25","在特罗姆瑟维生素 D 和 T2DM 试验（挪威）中，该试验将 511 名患有糖尿病前期的白人成人随机分配至每周服用 20,000 IU（每天约 2900 IU）的维生素 D3 或安慰剂，维生素 D 组患糖尿病的风险在数值上较低与安慰剂组相比，但差异不显着（危险比，0.90 ； 95 % CI，0.69 至 1.18 ） .25",0.4705882352941176,"['group', 'diabetes', 'placebo', 'hazard ratio', 'white', 'difference', 'lower', 'risk', 'week', 'trial', 'with', 'vitamin D', 'CI', 'approximately', 'but', 'to', 'and']","['group', 'diabetes', 'placebo', 'white', 'difference', 'risk', 'week', 'but']",1369,"['在 Tromsø 维生素 D 和 T2DM 试验( 挪威 ),随机分配 511 白人成年人 预糖尿病 每周 20,000 IU ( 约 2900 IU 每日 ) 维生素 D3 或 placebo, 糖尿病的风险在 维生素 D 组 比在  placebo 组, 但差异 没有显著( 风险比例, 0.90 ; 95 % CI, 0.69 到 1.18 ).25']",0.4705882352941176,"['group', 'diabetes', 'placebo', 'hazard ratio', 'white', 'difference', 'lower', 'risk', 'week', 'trial', 'with', 'vitamin D', 'CI', 'approximately', 'but', 'to', 'and']","['group', 'diabetes', 'hazard ratio', 'white', 'difference', 'risk', 'week', 'but']",1369,"在挪威特罗姆萨市的维他命D和2型糖尿病试验中，将511名白人糖尿病前期患者随机分配给每周20,000 IU的维他命D3或安慰剂（约每天2900 IU），维他命D组患糖尿病的风险数值上低于安慰剂组，但差异并不显著（危险比，0.90；95% CI，0.69至1.18）。",0.5294117647058824,"['group', 'diabetes', 'placebo', 'hazard ratio', 'white', 'difference', 'lower', 'risk', 'week', 'trial', 'with', 'vitamin D', 'CI', 'approximately', 'but', 'to', 'and']","['group', 'diabetes', 'placebo', 'white', 'difference', 'risk', 'week', 'but', 'to']",,,,
1380,1370,"in the Diabetes Prevention with Active Vitamin D study ( Japan ) , which randomly assigned 1256 adults with prediabetes to an active form of vitamin D analogue ( eldecalcitol ) or placebo , the risk of diabetes was also lower in the vitamin D group than in the placebo group , but the difference was again not significant ( hazard ratio , 0.87 ; 95 % CI , 0.68 to 1.09 ) .27",在用活性维生素 D 预防糖尿病的研究（日本）中，该研究随机分配了 1256 名患有前驱糖尿病的成年人服用活性形式的维生素 D 类似物（eldecalcitol）或安慰剂，维生素 D 组患糖尿病的风险也低于安慰剂组组，但差异同样不显着（危险比，0.87 ； 95 % CI，0.68 至 1.09 ） .27,0.5263157894736842,"['group', 'diabetes', 'placebo', 'analogue', 'form', 'hazard ratio', 'study', 'active', 'difference', 'prevention', 'lower', 'risk', 'japan', 'with', 'vitamin D', 'CI', 'but', 'to', 'again']","['group', 'diabetes', 'placebo', 'analogue', 'form', 'difference', 'prevention', 'risk', 'but', 'to']",1370,"['在糖尿病预防与活性维生素D研究(日本),随机分配1256名患有前糖尿病的成年人到活性维生素D类似( eldecalcitol )或 placebo的形式,糖尿病的风险也低于维生素D组,而不是 placebo组,但差异再次不显著(风险比例,0.87;95% CI,0.68到1.09 )。']",0.5789473684210527,"['group', 'diabetes', 'placebo', 'analogue', 'form', 'hazard ratio', 'study', 'active', 'difference', 'prevention', 'lower', 'risk', 'japan', 'with', 'vitamin D', 'CI', 'but', 'to', 'again']","['group', 'diabetes', 'form', 'hazard ratio', 'difference', 'prevention', 'risk', 'vitamin D', 'but', 'to', 'again']",1370,在日本的“使用活性维生素D预防糖尿病”研究中，将1256名糖尿病前期患者随机分配给活性维生素D类似物（eldecalcitol）或安慰剂组，维生素D组的糖尿病风险也低于安慰剂组，但差异不显著（危险比0.87；95%置信区间0.68-1.09）。27,0.5263157894736842,"['group', 'diabetes', 'placebo', 'analogue', 'form', 'hazard ratio', 'study', 'active', 'difference', 'prevention', 'lower', 'risk', 'japan', 'with', 'vitamin D', 'CI', 'but', 'to', 'again']","['group', 'diabetes', 'placebo', 'analogue', 'difference', 'prevention', 'risk', 'vitamin D', 'but', 'to']",,,,
1381,1371,we powered our trial to detect a 25 % lower risk of diabetes with vitamin D than with placebo .,我们为试验提供动力，发现服用维生素 D 比服用安慰剂可降低 25% 的糖尿病风险。,0.4444444444444444,"['diabetes', 'placebo', 'lower', 'risk', 'detect', 'trial', 'with', 'vitamin D', 'to']","['diabetes', 'placebo', 'risk', 'detect']",1371,"['我们强化了我们的试验,以检测与维生素D相比糖尿病的风险降低25%。']",0.4444444444444444,"['diabetes', 'placebo', 'lower', 'risk', 'detect', 'trial', 'with', 'vitamin D', 'to']","['diabetes', 'risk', 'detect', 'vitamin D']",1371,我们的试验发现，维生素D比安慰剂降低了糖尿病风险25%。,0.5555555555555556,"['diabetes', 'placebo', 'lower', 'risk', 'detect', 'trial', 'with', 'vitamin D', 'to']","['diabetes', 'placebo', 'risk', 'detect', 'vitamin D']",,,,
1382,1372,"on the basis of the results from all three trials , vitamin D supplementation may decrease diabetes risk among persons at risk for diabetes not selected for vitamin D insufficiency by a smaller effect size ( 10 to 15 % ) , but none of these trials were powered to test this effect size .",根据所有三项试验的结果，维生素 D 补充剂可能会以较小的效应量（ 10 至 15 % ） 降低未被选为维生素 D 不足的糖尿病风险人群的糖尿病风险，但这些试验均无统计学意义测试这个效果大小。,0.4705882352941176,"['diabetes', 'decrease', 'insufficiency', 'test', 'basis', 'size', 'risk', 'effect', 'vitamin D', 'at', 'on', 'all', 'three', 'this', 'by', 'but', 'to']","['diabetes', 'insufficiency', 'test', 'size', 'risk', 'effect', 'by', 'but']",1372,"['基于所有三项研究的结果,维生素D补充可以降低患不维生素D不足的糖尿病风险的人的糖尿病风险较小(10至15%),但这些研究中没有一个能够测试这种效果大小。']",0.5882352941176471,"['diabetes', 'decrease', 'insufficiency', 'test', 'basis', 'size', 'risk', 'effect', 'vitamin D', 'at', 'on', 'all', 'three', 'this', 'by', 'but', 'to']","['diabetes', 'insufficiency', 'size', 'risk', 'effect', 'vitamin D', 'at', 'by', 'but', 'to']",1372,根据所有三个试验的结果，维生素D补充可能会减少非维生素D缺乏症患者患糖尿病的风险（10%至15%），但这些试验都无法测试出这种效应大小。,0.4705882352941176,"['diabetes', 'decrease', 'insufficiency', 'test', 'basis', 'size', 'risk', 'effect', 'vitamin D', 'at', 'on', 'all', 'three', 'this', 'by', 'but', 'to']","['diabetes', 'decrease', 'test', 'size', 'risk', 'effect', 'vitamin D', 'but']",,,,
1383,1373,our trial has several strengths .,我们的审判有几个优势。,1.0,['trial'],['trial'],1373,['我们的审判有几个力量。'],1.0,['trial'],['trial'],1373,"我们的试用有几个优点。

Chinese:
我们的试用有几个优点。",0.0,['trial'],[],,,,
1384,1373,our trial has several strengths .,我们的审判有几个优势。,1.0,['trial'],['trial'],1373,['我们的审判有几个力量。'],1.0,['trial'],['trial'],1373,"我们的试用有几个优点。

Chinese:
我们的试用有几个优点。",0.0,['trial'],[],,,,
1385,1373,our trial has several strengths .,我们的审判有几个优势。,1.0,['trial'],['trial'],1373,['我们的审判有几个力量。'],1.0,['trial'],['trial'],1373,"我们的试用有几个优点。

Chinese:
我们的试用有几个优点。",0.0,['trial'],[],,,,
1386,1374,"we used contemporary glycemic criteria to assemble a diverse cohort at high risk for diabetes with a hyperglycemic pattern closely matching how prediabetes is diagnosed in clinical practice , most commonly with fasting plasma glucose and glycated hemoglobin .",我们使用现代血糖标准收集了一个多样化的糖尿病高风险队列，其高血糖模式与临床实践中糖尿病前期的诊断方式非常匹配，最常见的是空腹血糖和糖化血红蛋白。,0.4375,"['diabetes', 'glucose', 'plasma', 'pattern', 'high risk', 'hemoglobin', 'fasting', 'clinical', 'matching', 'practice', 'cohort', 'with', 'assemble', 'to', 'and', 'we']","['diabetes', 'pattern', 'hemoglobin', 'clinical', 'matching', 'practice', 'assemble']",1374,"['我们使用了当代的血糖标准,以结合糖尿病高风险的多样性,与超血糖模式密切相匹配,在临床实践中如何诊断前糖尿病,最常见的是禁食的血糖和血糖化血糖。']",0.3125,"['diabetes', 'glucose', 'plasma', 'pattern', 'high risk', 'hemoglobin', 'fasting', 'clinical', 'matching', 'practice', 'cohort', 'with', 'assemble', 'to', 'and', 'we']","['diabetes', 'pattern', 'clinical', 'matching', 'practice']",1374,我们使用当代的血糖标准来组装一个多样化的高风险糖尿病患者群体，其高血糖模式与临床实践中诊断糖尿病的方式非常相似，通常使用空腹血浆糖和糖化血红蛋白。,0.375,"['diabetes', 'glucose', 'plasma', 'pattern', 'high risk', 'hemoglobin', 'fasting', 'clinical', 'matching', 'practice', 'cohort', 'with', 'assemble', 'to', 'and', 'we']","['diabetes', 'plasma', 'pattern', 'hemoglobin', 'clinical', 'practice']",,,,
1387,1375,"our cohort was recruited at a constant rate throughout the calendar year , which reduced the potential of confounding by seasonal variability .",我们的队列在整个日历年中以恒定的速度招募，这减少了季节性变化造成混淆的可能性。,0.4444444444444444,"['year', 'rate', 'variability', 'potential', 'constant', 'seasonal', 'calendar', 'cohort', 'by']","['year', 'constant', 'calendar', 'by']",1375,"['我们的联盟在整个日历年间以稳定的速度招募,从而减少了季节性变化的潜力。']",0.4444444444444444,"['year', 'rate', 'variability', 'potential', 'constant', 'seasonal', 'calendar', 'cohort', 'by']","['year', 'potential', 'calendar', 'by']",1375,我们的队伍整年招募人员都是恒定的，这就减少了季节性变化带来的混杂因素。,0.2222222222222222,"['year', 'rate', 'variability', 'potential', 'constant', 'seasonal', 'calendar', 'cohort', 'by']","['year', 'constant']",,,,
1388,1376,the high percentage of participants with adequate levels of vitamin D may have limited the ability of the trial to detect a significant effect .,维生素 D 水平充足的高比例参与者可能限制了试验检测显着效果的能力。,0.3333333333333333,"['percentage', 'detect', 'trial', 'effect', 'adequate', 'ability', 'with', 'vitamin D', 'limited', 'have', 'to', 'high']","['detect', 'effect', 'ability', 'high']",1376,"['具有足够的维生素D水平的参与者的高比例可能限制了试验的能力,以检测显著的效果。']",0.5833333333333334,"['percentage', 'detect', 'trial', 'effect', 'adequate', 'ability', 'with', 'vitamin D', 'limited', 'have', 'to', 'high']","['detect', 'effect', 'adequate', 'ability', 'vitamin D', 'have', 'high']",1376,参与者中高水平维生素D的人数比例可能会限制试验检测到显著效应的能力。,0.4166666666666667,"['percentage', 'detect', 'trial', 'effect', 'adequate', 'ability', 'with', 'vitamin D', 'limited', 'have', 'to', 'high']","['detect', 'effect', 'ability', 'vitamin D', 'high']",,,,
1389,1377,"the vitamin D dose of 4000 IU per day is the recommended upper intake level to avert potential toxicity , 23 although data from large trials on the safety on this dose have been scant .",每天 4000 IU 的维生素 D 剂量是避免潜在毒性的推荐摄入量上限，23 尽管有关该剂量安全性的大型试验数据很少。,0.4615384615384615,"['safety', 'intake', 'toxicity', 'data', 'potential', 'upper', 'large', 'level', 'vitamin D', 'dose', 'on', 'have', 'this']","['safety', 'toxicity', 'data', 'dose', 'have', 'this']",1377,"['维生素D的每日剂量为4000 IU,是预防潜在毒性的建议上级摄入量,23虽然对该剂量的安全性进行了大规模测试的数据已经被扫描。']",0.4615384615384615,"['safety', 'intake', 'toxicity', 'data', 'potential', 'upper', 'large', 'level', 'vitamin D', 'dose', 'on', 'have', 'this']","['safety', 'toxicity', 'data', 'vitamin D', 'dose', 'this']",1377,每天摄入4000IU的维生素D是避免潜在毒性的推荐上限，尽管关于这一剂量安全性的大型试验数据缺乏。,0.4615384615384615,"['safety', 'intake', 'toxicity', 'data', 'potential', 'upper', 'large', 'level', 'vitamin D', 'dose', 'on', 'have', 'this']","['safety', 'toxicity', 'data', 'vitamin D', 'dose', 'this']",,,,
1390,1378,"in conclusion , among persons at high risk for type 2 diabetes not selected for vitamin D insufficiency , vitamin D3 supplementation at a dose of 4000 IU per day did not result in a significantly lower risk of diabetes than placebo .",总之，在没有选择维生素 D 不足的 2 型糖尿病高风险人群中，每天补充 4000 IU 剂量的维生素 D3 并没有导致患糖尿病的风险显着低于安慰剂。,0.5833333333333334,"['diabetes', 'type', 'placebo', 'insufficiency', '2', 'high risk', 'lower', 'result', 'conclusion', 'vitamin D', 'at', 'dose']","['diabetes', 'type', 'placebo', 'insufficiency', '2', 'at', 'dose']",1378,"['在结论中,在患2型糖尿病的风险较高的人中,维生素D3补充剂的剂量每天4000 IU并不导致糖尿病的风险显著低于 placebo。']",0.5833333333333334,"['diabetes', 'type', 'placebo', 'insufficiency', '2', 'high risk', 'lower', 'result', 'conclusion', 'vitamin D', 'at', 'dose']","['diabetes', 'type', '2', 'conclusion', 'vitamin D', 'at', 'dose']",1378,结论，在高风险的2型糖尿病患者中，维生素D缺乏并未导致维生素D3补充剂每天4000IU的风险显著降低。,0.4166666666666667,"['diabetes', 'type', 'placebo', 'insufficiency', '2', 'high risk', 'lower', 'result', 'conclusion', 'vitamin D', 'at', 'dose']","['diabetes', 'type', '2', 'conclusion', 'vitamin D']",,,,
1391,1379,"to examine this potential association further , investigators studied data from more than 500,000 participants in the multinational European Prospective Investigation into Cancer and Nutrition ( EPIC ) study .","为了进一步研究这种潜在关联，研究人员研究了欧洲癌症与营养前瞻性跨国调查 (EPIC) 研究中超过 500,000 名参与者的数据。",0.4545454545454545,"['cancer', 'data', 'investigation', 'nutrition', 'potential', 'association', 'study', 'this', 'to', 'and', 'examine']","['cancer', 'data', 'investigation', 'nutrition', 'association']",1379,"['为了进一步研究这种潜在的协会,研究人员研究了超过500000名参与者对癌症和营养的跨国欧洲展望调查(EPIC)的数据。']",0.4545454545454545,"['cancer', 'data', 'investigation', 'nutrition', 'potential', 'association', 'study', 'this', 'to', 'and', 'examine']","['cancer', 'data', 'investigation', 'nutrition', 'potential']",1379,"为了进一步检查这种潜在关联，研究人员研究了来自欧洲超过500,000参与者的多国欧洲前瞻性癌症调查（EPIC）数据。",0.3636363636363636,"['cancer', 'data', 'investigation', 'nutrition', 'potential', 'association', 'study', 'this', 'to', 'and', 'examine']","['cancer', 'data', 'investigation', 'association']",,,,
1392,1380,the inverse dietary associations were strongest for colon cancer .,结肠癌的反向饮食关联最强。,0.3333333333333333,"['dietary', 'inverse', 'colon cancer']",['colon cancer'],1380,['相反的饮食协会是肠道癌最强的。'],0.3333333333333333,"['dietary', 'inverse', 'colon cancer']",['inverse'],1380,反向的饮食关联最强烈的是大肠癌。,0.0,"['dietary', 'inverse', 'colon cancer']",[],,,,
1393,1381,"regular consumption of fish has several health benefits , and CRC prevention can now be added to the list .",经常食用鱼有多种健康益处，现在可以将 CRC 预防添加到列表中。,0.4444444444444444,"['consumption', 'fish', 'health', 'prevention', 'be', 'regular', 'list', 'to', 'and']","['fish', 'health', 'prevention', 'be']",1381,"['经常吃鱼有几个健康益处,CRC预防现在可以添加到列表中。']",0.4444444444444444,"['consumption', 'fish', 'health', 'prevention', 'be', 'regular', 'list', 'to', 'and']","['fish', 'health', 'prevention', 'be']",1381,"Regular consumption of fish has several health benefits, and CRC prevention can now be added to the list.

Chinese:

定期食用鱼类有几个健康益处，现在可以将其中一项添加到预防CRC的列表中。",0.4444444444444444,"['consumption', 'fish', 'health', 'prevention', 'be', 'regular', 'list', 'to', 'and']","['fish', 'health', 'prevention', 'be']",,,,
1394,1382,"practically , patients seeking to modify their CRC risk should consider the Mediterranean diet , which includes whole grains , fruits , vegetables , nuts , olive oil , fish , and seafood and restricts consumption of red meat .",实际上，寻求降低 CRC 风险的患者应考虑地中海饮食，其中包括全麦、水果、蔬菜、坚果、橄榄油、鱼和海鲜，并限制红肉的摄入。,0.3846153846153846,"['grains', 'consumption', 'fish', 'seafood', 'olive oil', 'red', 'risk', 'mediterranean diet', 'modify', 'whole', 'to', 'and', 'vegetables']","['fish', 'seafood', 'olive oil', 'risk', 'mediterranean diet']",1382,"['實際上,尋求改變他們的CRC風險的患者應該考慮地中海飲食,其中包括整個穀物、水果、蔬菜、果汁、橄欖油、魚類和海鮮,並限制紅肉的消費。']",0.0769230769230769,"['grains', 'consumption', 'fish', 'seafood', 'olive oil', 'red', 'risk', 'mediterranean diet', 'modify', 'whole', 'to', 'and', 'vegetables']",['whole'],1382,实际上，寻求修改肠癌风险的患者应考虑采用地中海式饮食，其中包括全谷物、水果、蔬菜、坚果、橄榄油、鱼类和海鲜，并限制食用红肉。,0.3076923076923077,"['grains', 'consumption', 'fish', 'seafood', 'olive oil', 'red', 'risk', 'mediterranean diet', 'modify', 'whole', 'to', 'and', 'vegetables']","['fish', 'seafood', 'olive oil', 'risk']",,,,
1395,1383,measurements of nonfasting total and HDL cholesterol levels seem to be enough to obtain an accurate estimate of cardiovascular risk .,非空腹总胆固醇和 HDL 胆固醇水平的测量似乎足以准确估计心血管风险。,0.3,"['cholesterol', 'cardiovascular', 'HDL', 'total', 'accurate', 'be', 'risk', 'estimate', 'obtain', 'and']","['cholesterol', 'cardiovascular', 'risk']",1383,['不损失总和HDL胆固醇水平的测量似乎足以获得心血管风险的准确估计。'],0.4,"['cholesterol', 'cardiovascular', 'HDL', 'total', 'accurate', 'be', 'risk', 'estimate', 'obtain', 'and']","['cholesterol', 'cardiovascular', 'risk', 'obtain']",1383,非禁食的总胆固醇水平和高密度脂蛋白胆固醇水平的测量似乎足以获得对心血管风险的准确估计。,0.5,"['cholesterol', 'cardiovascular', 'HDL', 'total', 'accurate', 'be', 'risk', 'estimate', 'obtain', 'and']","['cholesterol', 'cardiovascular', 'HDL', 'risk', 'obtain']",,,,
1396,1384,"most calculators of cardiovascular disease ( CVD ) risk include measures of total cholesterol , HDL cholesterol , or their combination in risk prediction models .",大多数心血管疾病 (CVD) 风险计算器包括总胆固醇、高密度脂蛋白胆固醇或它们在风险预测模型中的组合。,0.7142857142857143,"['cholesterol', 'combination', 'HDL', 'total', 'cardiovascular disease', 'risk', 'CVD']","['cholesterol', 'combination', 'HDL', 'cardiovascular disease', 'risk']",1384,['大多数心血管疾病(CVD)风险计算器包括总胆固醇、HDL胆固醇或风险预测模型的测量。'],0.4285714285714285,"['cholesterol', 'combination', 'HDL', 'total', 'cardiovascular disease', 'risk', 'CVD']","['cholesterol', 'cardiovascular disease', 'risk']",1384,大多数心血管疾病风险计算器都包括总胆固醇、HDL胆固醇或其组合在风险预测模型中。,0.5714285714285714,"['cholesterol', 'combination', 'HDL', 'total', 'cardiovascular disease', 'risk', 'CVD']","['cholesterol', 'combination', 'cardiovascular disease', 'risk']",,,,
1397,1385,"debate continues , however , about whether other lipid parameters can improve prediction of CVD and about the usefulness of nonfasting measurements .",然而，关于其他脂质参数是否可以提高 CVD 的预测以及非空腹测量的有用性的争论仍在继续。,0.5,"['lipid', 'debate', 'CVD', 'and']","['lipid', 'and']",1385,"['然而,讨论是否有其他脂肪参数可以改善CVD的预测,以及不损害测量的有用性。']",0.25,"['lipid', 'debate', 'CVD', 'and']",['and'],1385,辩论仍在继续，但是关于其他脂质参数是否可以改善CVD的预测以及非禁食测量的有用性仍存在分歧。,0.5,"['lipid', 'debate', 'CVD', 'and']","['lipid', 'debate']",,,,
1398,1386,"during a median of 9 years , an incident CVD event was reported in 6216 participants not taking a statin ( 1656 fatal events ) and in 3515 patients taking a statin .",在中位数 9 年期间，6216 名未服用他汀类药物的参与者（1656 例死亡事件）和 3515 名服用他汀类药物的患者报告了 CVD 事件。,0.125,"['statin', 'median', 'taking', 'fatal', 'incident', 'event', 'CVD', 'and']",['incident'],1386,"['在中期9年内,在6216名不服用静素的参与者(1656个致命事件)和3515名服用静素的患者中报告了一起CVD事件。']",0.125,"['statin', 'median', 'taking', 'fatal', 'incident', 'event', 'CVD', 'and']",['incident'],1386,在9年的中位数期间，有6216名未服用他汀类药物的参与者（1656名致死事件）和3515名使用他汀类药物的患者报告了一起CVD事件。,0.125,"['statin', 'median', 'taking', 'fatal', 'incident', 'event', 'CVD', 'and']",['incident'],,,,
1399,1387,"each SD increase in HDL and ApoA1 had a similar association with reduced CVD events ( HR , 0.81 ) .",HDL 和 ApoA1 的每一个 SD 增加都与 CVD 事件减少有相似的关联（HR，0.81）。,0.2222222222222222,"['association', 'HDL', 'increase', 'with', 'SD', 'CVD', 'each', 'and', 'similar']","['association', 'similar']",1387,"['HDL 和 ApoA1 的每個 SD 增長都與減少的 CVD 事件( HR, 0.81 )相似。']",0.0,"['association', 'HDL', 'increase', 'with', 'SD', 'CVD', 'each', 'and', 'similar']",[],1387,每增加一个SD单位的HDL和ApoA1水平与CVD事件的发生率相似(HR，0.81)。,0.0,"['association', 'HDL', 'increase', 'with', 'SD', 'CVD', 'each', 'and', 'similar']",[],,,,
1400,1388,"in the model using classical risk factors plus total cholesterol and HDL , the investigators found that risk prediction did not further improve with the addition of ApoB or any other LDL measure .",在使用经典风险因素加上总胆固醇和 HDL 的模型中，研究人员发现风险预测并没有随着 ApoB 或任何其他 LDL 指标的增加而进一步改善。,0.5384615384615384,"['cholesterol', 'model', 'plus', 'addition', 'HDL', 'total', 'LDL', 'risk', 'measure', 'with', 'that', 'in', 'and']","['cholesterol', 'model', 'plus', 'addition', 'risk', 'measure', 'and']",1388,"['在使用经典风险因素以及整体胆固醇和HDL的模型中,研究人员发现风险预测与添加ApoB或其他LDL测量没有进一步改善。']",0.4615384615384615,"['cholesterol', 'model', 'plus', 'addition', 'HDL', 'total', 'LDL', 'risk', 'measure', 'with', 'that', 'in', 'and']","['cholesterol', 'model', 'plus', 'addition', 'risk', 'measure']",1388,在使用经典风险因子加上总胆固醇和高密度脂蛋白的模型中，研究人员发现风险预测并未因添加ApoB或任何其他LDL措施而得到进一步改善。,0.6153846153846154,"['cholesterol', 'model', 'plus', 'addition', 'HDL', 'total', 'LDL', 'risk', 'measure', 'with', 'that', 'in', 'and']","['cholesterol', 'model', 'plus', 'addition', 'HDL', 'risk', 'measure', 'and']",,,,
1401,1389,findings were similar in participants taking a statin .,服用他汀类药物的参与者的研究结果相似。,0.0,"['statin', 'taking', 'similar']",[],1389,['结果类似于参加者服用一个静素。'],0.0,"['statin', 'taking', 'similar']",[],1389,研究结果在使用他汀类药物的参与者中也是相似的。,0.3333333333333333,"['statin', 'taking', 'similar']",['similar'],,,,
1402,1390,"these data suggest that incorporation of parameters beyond classical variables , HDL , and total cholesterol does not improve risk prediction .",这些数据表明，结合经典变量、HDL 和总胆固醇以外的参数并不能改善风险预测。,0.4444444444444444,"['cholesterol', 'incorporation', 'data', 'HDL', 'total', 'risk', 'suggest', 'that', 'and']","['cholesterol', 'incorporation', 'data', 'risk']",1390,"['这些数据表明,超越经典变量、HDL和整体胆固醇的参数的集成不会改善风险预测。']",0.3333333333333333,"['cholesterol', 'incorporation', 'data', 'HDL', 'total', 'risk', 'suggest', 'that', 'and']","['cholesterol', 'data', 'risk']",1390,这些数据表明，除了经典变量（HDL和总胆固醇）之外，还包括其他参数并不能提高风险预测的准确性。,0.3333333333333333,"['cholesterol', 'incorporation', 'data', 'HDL', 'total', 'risk', 'suggest', 'that', 'and']","['cholesterol', 'data', 'risk']",,,,
1403,1391,"furthermore , no data suggest that measurement of additional parameters would change therapeutic recommendations .",此外，没有数据表明额外参数的测量会改变治疗建议。,0.25,"['data', 'no', 'therapeutic', 'measurement', 'additional', 'change', 'suggest', 'that']","['data', 'measurement']",1391,"['此外,没有数据表明测量额外的参数会改变治疗建议。']",0.375,"['data', 'no', 'therapeutic', 'measurement', 'additional', 'change', 'suggest', 'that']","['data', 'measurement', 'additional']",1391,此外，没有数据表明测量额外的参数会改变治疗建议。,0.375,"['data', 'no', 'therapeutic', 'measurement', 'additional', 'change', 'suggest', 'that']","['data', 'measurement', 'additional']",,,,
1404,1392,resection of additional tissue around the tumor cavity significantly reduces the need to return to surgery for margin control .,切除肿瘤腔周围的额外组织显着减少了返回手术以控制边缘的需要。,0.6666666666666666,"['tissue', 'control', 'cavity', 'margin', 'need', 'tumor', 'surgery', 'resection', 'additional', 'return', 'around', 'to']","['tissue', 'control', 'cavity', 'margin', 'need', 'tumor', 'surgery', 'resection']",1392,['肿瘤洞周围的额外组织的恢复显著减少了返回外科手术的必要性。'],0.3333333333333333,"['tissue', 'control', 'cavity', 'margin', 'need', 'tumor', 'surgery', 'resection', 'additional', 'return', 'around', 'to']","['tissue', 'cavity', 'tumor', 'surgery']",1392,在肿瘤腔周围进行额外组织切除会显著降低再次手术以控制边界的需要。,0.6666666666666666,"['tissue', 'control', 'cavity', 'margin', 'need', 'tumor', 'surgery', 'resection', 'additional', 'return', 'around', 'to']","['tissue', 'control', 'cavity', 'margin', 'need', 'tumor', 'surgery', 'resection']",,,,
1405,1393,randomization occurred intraoperatively after completion of standard PM .,随机化发生在术中完成标准 PM 后。,1.0,"['standard', 'randomization', 'after', 'completion']","['standard', 'randomization', 'after', 'completion']",1393,['随机化发生在标准PM完成后内手术。'],1.0,"['standard', 'randomization', 'after', 'completion']","['standard', 'randomization', 'after', 'completion']",1393,随机化发生在标准PM完成后的手术中。,1.0,"['standard', 'randomization', 'after', 'completion']","['standard', 'randomization', 'after', 'completion']",,,,
1406,1394,"as expected , significantly more tissue was removed with CSM resection than without it .",正如预期的那样，CSM 切除术切除的组织明显多于未切除的组织。,0.75,"['tissue', 'resection', 'as', 'without']","['tissue', 'resection', 'as']",1394,"['正如预期的那样,通过CSM复制,有显著更多的组织被移除,而不是没有它。']",0.5,"['tissue', 'resection', 'as', 'without']","['tissue', 'as']",1394,正如预期的那样，使用CSM切除操作明显切除了更多的组织。,0.75,"['tissue', 'resection', 'as', 'without']","['tissue', 'resection', 'as']",,,,
1407,1395,longer durations were acceptable if patients had not met clinical stability criteria by the end of the shortest effective duration .,如果患者在最短有效持续时间结束时未达到临床稳定性标准，则可以接受更长的持续时间。,0.5,"['clinical', 'end', 'duration', 'acceptable', 'met', 'stability', 'if', 'by']","['clinical', 'duration', 'stability', 'by']",1395,"['更长的寿命是可接受的,如果患者在最短有效期结束时未满足临床稳定性标准。']",0.375,"['clinical', 'end', 'duration', 'acceptable', 'met', 'stability', 'if', 'by']","['clinical', 'acceptable', 'stability']",1395,如果病人在最短有效治疗时间结束时还未达到临床稳定标准，则更长的治疗时间是可以接受的。,0.25,"['clinical', 'end', 'duration', 'acceptable', 'met', 'stability', 'if', 'by']","['clinical', 'by']",,,,
1408,1396,"discharge summary documentation of total recommended antibiotic duration was associated with significantly less excess therapy ( adjusted rate ratio , 0.78 ) .",总推荐抗生素持续时间的出院总结文件与显着减少的过量治疗相关（调整后的比率，0.78）。,0.5,"['discharge', 'antibiotic', 'excess', 'documentation', 'total', 'therapy', 'associated', 'duration', 'with', 'adjusted rate']","['discharge', 'antibiotic', 'excess', 'therapy', 'duration']",1396,"['排放总体建议的抗生素寿命的总结文件与显著较少的过量治疗(调整率比例,0.78 )有关。']",0.4,"['discharge', 'antibiotic', 'excess', 'documentation', 'total', 'therapy', 'associated', 'duration', 'with', 'adjusted rate']","['discharge', 'antibiotic', 'excess', 'therapy']",1396,"discharge summary documentation of total recommended antibiotic duration was associated with significantly less excess therapy ( adjusted rate ratio , 0.78 ) .

Chinese:

出院时总推荐抗生素用量的文件记录与显著减少过量治疗相关联(调整后风险比率,0.78)。",0.4,"['discharge', 'antibiotic', 'excess', 'documentation', 'total', 'therapy', 'associated', 'duration', 'with', 'adjusted rate']","['discharge', 'antibiotic', 'excess', 'therapy']",,,,
1409,1397,"excess antibiotic duration did not lead to more Clostridium difficile infections , hospital revisits , or deaths .",抗生素使用时间过长并没有导致更多的艰难梭菌感染、再次住院或死亡。,0.2857142857142857,"['antibiotic', 'excess', 'lead', 'clostridium difficile', 'duration', 'hospital', 'to']","['antibiotic', 'clostridium difficile']",1397,"['过量抗生素的持续时间不会导致更多的Clostridium difficile感染,医院检查,或死亡。']",0.5714285714285714,"['antibiotic', 'excess', 'lead', 'clostridium difficile', 'duration', 'hospital', 'to']","['antibiotic', 'excess', 'duration', 'hospital']",1397,超长用药并不会导致更多的肠道杆菌感染、住院复诊或死亡。,0.0,"['antibiotic', 'excess', 'lead', 'clostridium difficile', 'duration', 'hospital', 'to']",[],,,,
1410,1398,a large analysis found that both measurements were independent predictors of adverse outcomes .,一项大型分析发现，这两项测量都是不良结果的独立预测因子。,0.2,"['analysis', 'large', 'adverse', 'independent', 'that']",['analysis'],1398,"['一项大型分析发现,这两项测量都是独立预测不良结果。']",0.2,"['analysis', 'large', 'adverse', 'independent', 'that']",['analysis'],1398,"一项大型分析发现，两种测量方法都是不利结果的独立预测因素。

Chinese:

一项大型分析发现，两种测量方法都是不利结果的独立预测因素。",0.2,"['analysis', 'large', 'adverse', 'independent', 'that']",['analysis'],,,,
1411,1399,"fifty years ago , diastolic blood pressure ( BP ) was thought to be more predictive of adverse cardiovascular ( CV ) events than systolic BP , but epidemiologic studies eventually overturned that idea .",五十年前，人们认为舒张压 (BP) 比收缩压更能预测不良心血管 (CV) 事件，但流行病学研究最终推翻了这一观点。,0.1818181818181818,"['cardiovascular', 'blood pressure', 'thought', 'be', 'diastolic', 'adverse', 'idea', 'systolic', 'predictive', 'that', 'but']","['cardiovascular', 'but']",1399,"['五十年前,神经血压(BP)被认为比神经血压(BP)更有预测,但流行病学研究最终推翻了这个想法。']",0.1818181818181818,"['cardiovascular', 'blood pressure', 'thought', 'be', 'diastolic', 'adverse', 'idea', 'systolic', 'predictive', 'that', 'but']","['blood pressure', 'but']",1399,"fifty years ago, diastolic blood pressure (BP) was thought to be more predictive of adverse cardiovascular (CV) events than systolic BP, but epidemiologic studies eventually overturned that idea.

Chinese:

50年前，人們認為舒張壓（血壓）比收縮壓更能預測心血管（CV）不良事件，但流行病學研究最終推翻了這一觀點。",0.1818181818181818,"['cardiovascular', 'blood pressure', 'thought', 'be', 'diastolic', 'adverse', 'idea', 'systolic', 'predictive', 'that', 'but']","['cardiovascular', 'but']",,,,
1412,1400,"more recently , systolic BP has been deemed more important , although both systolic and diastolic BP targets are recommended in guidelines ( NEJM JW Gen Med Dec 15 2017 and J Am Coll Cardiol 2018 ; 71 : e127 ) .",最近，收缩压被认为更重要，尽管指南中推荐了收缩压和舒张压目标（NEJM JW Gen Med 2017 年 12 月 15 日和 J Am Coll Cardiol 2018；71：e127）。,0.0,"['coll', 'diastolic', 'systolic', 'gen', 'in', 'and', 'med']",[],1400,"['最近,系统性BP被认为更重要,尽管系统性和神经性BP目标在指南中推荐(NEJM JW Gen Med Dec 15 2017和J Am Coll Cardiol 2018;71:e127)。']",0.0,"['coll', 'diastolic', 'systolic', 'gen', 'in', 'and', 'med']",[],1400,最近，收缩压被认为更重要，尽管指南建议采取收缩压和舒张压目标（NEJM JW Gen Med Dec 15 2017 and J Am Coll Cardiol 2018; 71: e127）。,0.0,"['coll', 'diastolic', 'systolic', 'gen', 'in', 'and', 'med']",[],,,,
1413,1401,"in multivariable analyses , systolic and diastolic BP were each associated independently with increased risk for CV events , but the effect was greater for systolic than for diastolic BP .",在多变量分析中，收缩压和舒张压均与 CV 事件风险增加独立相关，但收缩压的影响大于舒张压。,0.2,"['diastolic', 'associated', 'risk', 'systolic', 'effect', 'with', 'each', 'in', 'but', 'and']","['risk', 'but']",1401,"['在多变的分析中,系统性和神经性BP分别与CV事件的风险增加有关,但对神经性比神经性BP的影响更大。']",0.2,"['diastolic', 'associated', 'risk', 'systolic', 'effect', 'with', 'each', 'in', 'but', 'and']","['risk', 'but']",1401,在多变量分析中，收缩压和舒张压都独立地与心血管事件风险相关，但收缩压的影响要大于舒张压。,0.2,"['diastolic', 'associated', 'risk', 'systolic', 'effect', 'with', 'each', 'in', 'but', 'and']","['risk', 'but']",,,,
1414,1402,"for diastolic BPs of 81 and 96 mm Hg , CV event rates were 1.9 % and 3.6 % , respectively .",对于 81 和 96 mm Hg 的舒张压，CV 事件发生率分别为 1.9% 和 3.6%。,0.0,"['diastolic', 'event', 'and']",[],1402,['对于 81 和 96 毫米 Hg 的 Diastolic BP 的 CV 事件率为 1.9% 和 3.6% 相应。'],0.0,"['diastolic', 'event', 'and']",[],1402,对于81和96毫米汞柱的舒张期血压，心血管事件发生率分别为1.9％和3.6％。,0.3333333333333333,"['diastolic', 'event', 'and']",['diastolic'],,,,
1415,1403,relative risks for CV events ( but not necessarily absolute risks ) were similar regardless of use of antihypertensive medication .,无论是否使用抗高血压药物，心血管事件的相对风险（但不一定是绝对风险）都是相似的。,0.6666666666666666,"['antihypertensive', 'absolute', 'relative', 'medication', 'but', 'similar']","['antihypertensive', 'absolute', 'but', 'similar']",1403,['CV事件的相对风险(但不一定是绝对的风险)与使用抗高血压药物相似。'],0.5,"['antihypertensive', 'absolute', 'relative', 'medication', 'but', 'similar']","['antihypertensive', 'absolute', 'but']",1403,相对风险（但不一定是绝对风险）在使用降压药物的情况下与否相似。,0.5,"['antihypertensive', 'absolute', 'relative', 'medication', 'but', 'similar']","['antihypertensive', 'absolute', 'but']",,,,
1416,1404,"this interesting study is more than an assessment of a single blood pressure value , but also an evaluation of the weighted average BP over time , indicating the BP burden .",这项有趣的研究不仅仅是对单一血压值的评估，也是对随时间推移的加权平均血压的评估，表明血压负担。,0.4615384615384615,"['evaluation', 'value', 'study', 'blood pressure', 'time', 'assessment', 'interesting', 'weighted average', 'this', 'single', 'over', 'but', 'burden']","['blood pressure', 'time', 'assessment', 'interesting', 'this', 'single']",1404,"['这项有趣的研究不仅仅是一项单血压值的评估,而且还是一项时间重量的平均BP的评估,表明BP的负担。']",0.5384615384615384,"['evaluation', 'value', 'study', 'blood pressure', 'time', 'assessment', 'interesting', 'weighted average', 'this', 'single', 'over', 'but', 'burden']","['blood pressure', 'time', 'assessment', 'interesting', 'this', 'single', 'but']",1404,"这项有趣的研究不仅仅是对单个血压值的评估，而且是对随时间血压的加权平均值的评估，表明了血压负担。

Chinese:

这项有趣的研究不仅仅是对单个血压值的评估，而且是对随时间血压的加权平均值的评估，表明了血压负担。",0.6153846153846154,"['evaluation', 'value', 'study', 'blood pressure', 'time', 'assessment', 'interesting', 'weighted average', 'this', 'single', 'over', 'but', 'burden']","['blood pressure', 'time', 'assessment', 'interesting', 'weighted average', 'this', 'single', 'but']",,,,
1417,1405,I wonder if variations in the patterns of BP carry additional prognostic importance and whether certain treatments were more effective in mitigating risk .,我想知道 BP 模式的变化是否具有额外的预后重要性，以及某些治疗是否能更有效地降低风险。,0.2222222222222222,"['wonder', 'prognostic', 'risk', 'additional', 'certain', 'I', 'carry', 'if', 'and']","['risk', 'additional']",1405,"['我想知道BP模式的变化是否具有额外的预测意义,以及某些治疗是否在降低风险方面更有效。']",0.3333333333333333,"['wonder', 'prognostic', 'risk', 'additional', 'certain', 'I', 'carry', 'if', 'and']","['prognostic', 'risk', 'additional']",1405,我不知道血壓的不同變化是否還有其他的預測意義，以及某些治療方法是否更有效地減少風險。,0.0,"['wonder', 'prognostic', 'risk', 'additional', 'certain', 'I', 'carry', 'if', 'and']",[],,,,
1418,1406,"I would have liked to see how the prognostic importance of the weighted average compared with a single measurement at the beginning of the study period , which is how many studies are conducted .",我很想看看加权平均数与研究期开始时的单一测量相比的预后重要性如何，即进行了多少研究。,0.2727272727272727,"['period', 'study', 'measurement', 'prognostic', 'weighted average', 'with', 'at', 'I', 'have', 'single', 'to']","['period', 'measurement', 'single']",1406,"['我想看到重量平均值的预测重要性与研究期间开始时单一测量相比,这就是进行的研究数量。']",0.3636363636363636,"['period', 'study', 'measurement', 'prognostic', 'weighted average', 'with', 'at', 'I', 'have', 'single', 'to']","['period', 'measurement', 'prognostic', 'single']",1406,我想要看看加权平均值与研究期间开始时的单个测量相比在预测中的重要性，这是许多研究都是如此进行的。,0.4545454545454545,"['period', 'study', 'measurement', 'prognostic', 'weighted average', 'with', 'at', 'I', 'have', 'single', 'to']","['period', 'measurement', 'prognostic', 'weighted average', 'single']",,,,
1419,1407,"to stratify risks , it may be that we should be using weighted averages , which could be calculated from electronic medical records .",为了对风险进行分层，我们可能应该使用加权平均数，这可以从电子病历中计算出来。,0.0,"['medical', 'be', 'electronic', 'that', 'to', 'we']",[],1407,"['要分裂风险,我们可能应该使用重量平均值,可以从电子医学记录中计算。']",0.0,"['medical', 'be', 'electronic', 'that', 'to', 'we']",[],1407,为了分层风险，我们可能应该使用加权平均值，这可以从电子病历中计算出来。,0.0,"['medical', 'be', 'electronic', 'that', 'to', 'we']",[],,,,
1420,1408,"as new agents become incorporated into neoadjuvant and adjuvant regimens , patients who develop disease recurrence continue to need other options .",随着新药物被纳入新辅助和辅助治疗方案，出现疾病复发的患者继续需要其他选择。,0.3333333333333333,"['disease', 'need', 'who', 'adjuvant', 'develop', 'recurrence', 'options', 'continue', 'become', 'to', 'and', 'new']","['disease', 'need', 'continue', 'new']",1408,"['随着新物质被纳入新添加剂和添加剂的饮食,患有疾病重复的患者仍然需要其他选项。']",0.25,"['disease', 'need', 'who', 'adjuvant', 'develop', 'recurrence', 'options', 'continue', 'become', 'to', 'and', 'new']","['disease', 'need', 'new']",1408,随着新的药物被加入到新辅助和辅助治疗方案中，发生疾病复发的患者仍然需要其他治疗方案。,0.25,"['disease', 'need', 'who', 'adjuvant', 'develop', 'recurrence', 'options', 'continue', 'become', 'to', 'and', 'new']","['disease', 'need', 'new']",,,,
1421,1409,trastuzumab duocarmazine was administered intravenously on day 1 every 3 weeks and continued until disease progression or unacceptable toxicity .,trastuzumab duocarmazine 在每 3 周的第 1 天静脉内给药，一直持续到疾病进展或出现不可接受的毒性。,0.75,"['disease', 'toxicity', '1', 'intravenously', 'progression', '3', 'unacceptable', 'and']","['disease', 'toxicity', '1', 'intravenously', 'progression', 'unacceptable']",1409,"['trastuzumab duocarmazine 每 3 周每 1 天内服用,直到疾病进展或不可接受的毒性。']",0.625,"['disease', 'toxicity', '1', 'intravenously', 'progression', '3', 'unacceptable', 'and']","['disease', 'toxicity', '1', 'progression', 'unacceptable']",1409,"trastuzumab duocarmazine was administered intravenously on day 1 every 3 weeks and continued until disease progression or unacceptable toxicity.

Chinese:

每隔3周在第1天注射一次静脉用特拉苏唑醇多卡马林，直到疾病进展或者不能忍受的毒性发生。",0.5,"['disease', 'toxicity', '1', 'intravenously', 'progression', '3', 'unacceptable', 'and']","['disease', 'toxicity', '1', 'progression']",,,,
1422,1410,"among the 48 breast cancer patients , 16 ( 33 % ) had a partial response .",在 48 名乳腺癌患者中，16 名 (33%) 有部分反应。,0.6666666666666666,"['breast cancer', 'response', 'partial']","['breast cancer', 'response']",1410,"['在48名乳腺癌患者中,16(33%)有部分反应。']",0.6666666666666666,"['breast cancer', 'response', 'partial']","['breast cancer', 'response']",1410,在48名乳腺癌患者中，16人（33％）取得了部分缓解。,0.3333333333333333,"['breast cancer', 'response', 'partial']",['breast cancer'],,,,
1423,1411,"most breast cancer patients had received prior trastuzumab or trastuzumab emtansine , and a smaller fraction had received pertuzumab and lapatinib .",大多数乳腺癌患者之前接受过曲妥珠单抗或曲妥珠单抗emtansine，一小部分患者接受过帕妥珠单抗和拉帕替尼。,0.6,"['breast cancer', 'fraction', 'prior', 'pertuzumab', 'and']","['breast cancer', 'fraction', 'pertuzumab']",1411,"['大多数乳腺癌患者早已服用过 trastuzumab 或 trastuzumab emtansine,而较小的分数则服用过 pertuzumab 和 lapatinib。']",0.4,"['breast cancer', 'fraction', 'prior', 'pertuzumab', 'and']","['breast cancer', 'and']",1411,大多数乳腺癌患者事先接受过特拉索他滨或特拉索他滨-甲磺酸，少部分人接受过佩图普他滨和拉帕替尼。,0.4,"['breast cancer', 'fraction', 'prior', 'pertuzumab', 'and']","['breast cancer', 'fraction']",,,,
1424,1412,"for patients who develop disease recurrence , additional options are needed .",对于疾病复发的患者，需要额外的选择。,0.3333333333333333,"['disease', 'who', 'develop', 'additional', 'recurrence', 'options']","['disease', 'additional']",1412,"['对于患有疾病重复的患者,需要额外的选项。']",0.3333333333333333,"['disease', 'who', 'develop', 'additional', 'recurrence', 'options']","['disease', 'additional']",1412,对于那些发展出疾病复发的病人来说，需要提供其他的选择。,0.1666666666666666,"['disease', 'who', 'develop', 'additional', 'recurrence', 'options']",['disease'],,,,
1425,1413,"patients with incidental PE , including those with subsegmental involvement , had increased recurrence rates , despite treatment .",尽管进行了治疗，但偶发 PE 的患者，包括亚节段受累的患者，复发率增加。,0.1428571428571428,"['incidental', 'treatment', 'recurrence', 'involvement', 'with', 'despite', 'PE']",['treatment'],1413,"['患有偶然的PE的患者,包括患有子部分参与的患者,尽管接受治疗,但重复率有所增加。']",0.2857142857142857,"['incidental', 'treatment', 'recurrence', 'involvement', 'with', 'despite', 'PE']","['incidental', 'treatment']",1413,"patients with incidental PE, including those with subsegmental involvement, had increased recurrence rates, despite treatment.

Chinese:

有偶然发现的肺栓塞患者，包括那些涉及到次段肺的患者，尽管接受了治疗，但复发率仍然增加。",0.1428571428571428,"['incidental', 'treatment', 'recurrence', 'involvement', 'with', 'despite', 'PE']",['treatment'],,,,
1426,1414,pulmonary embolism ( PE ) is often discovered incidentally in oncology patients during their cancer staging and surveillance .,肺栓塞 (PE) 通常是在肿瘤患者的癌症分期和监测过程中偶然发现的。,0.5,"['cancer', 'surveillance', 'pulmonary embolism', 'PE', 'in', 'and']","['cancer', 'surveillance', 'pulmonary embolism']",1414,['肺胚胎(PE)经常在癌症阶段和监测期间在肿瘤病人中偶然发现。'],0.3333333333333333,"['cancer', 'surveillance', 'pulmonary embolism', 'PE', 'in', 'and']","['cancer', 'surveillance']",1414,肺部血栓形成(PE)常常是在癌症患者的癌症分期和监测期间偶然发现的。,0.3333333333333333,"['cancer', 'surveillance', 'pulmonary embolism', 'PE', 'in', 'and']","['cancer', 'surveillance']",,,,
1427,1415,"treatment recommendations are typically based on retrospective data , and it is unclear whether outcomes in patients with subsegmental PE differ from those with more proximal PEs .",治疗建议通常基于回顾性数据，尚不清楚亚段 PE 患者的结局是否与近端 PE 患者不同。,0.3,"['pes', 'data', 'proximal', 'treatment', 'differ', 'with', 'on', 'PE', 'in', 'and']","['data', 'proximal', 'treatment']",1415,"['治疗建议通常是基于逆转数据的,并且不清楚患有分子PE的患者的结果是否不同于患有更接近PE的患者。']",0.2,"['pes', 'data', 'proximal', 'treatment', 'differ', 'with', 'on', 'PE', 'in', 'and']","['data', 'treatment']",1415,治疗建议通常基于回顾性数据，目前尚不清楚肺部下段血栓栓塞患者的预后与肺部上段血栓栓塞患者相比是否有差异。,0.2,"['pes', 'data', 'proximal', 'treatment', 'differ', 'with', 'on', 'PE', 'in', 'and']","['data', 'treatment']",,,,
1428,1416,subgroup analyses were conducted by site of PE ( subsegmental vs. more proximal ) and intensity of anticoagulation ( prophylactic / intermediate vs. therapeutic dosing ) .,亚组分析是根据 PE 部位（亚节段与更近端）和抗凝强度（预防/中间与治疗剂量）进行的。,0.1666666666666666,"['anticoagulation', 'site', '/', 'proximal', 'therapeutic', 'intensity', 'subgroup', 'intermediate', 'prophylactic', 'PE', 'by', 'and']","['anticoagulation', 'proximal']",1416,['子组分析是由PE(分区对比更接近)和抗凝固强度(预防性/中间对比治疗剂量)进行的。'],0.1666666666666666,"['anticoagulation', 'site', '/', 'proximal', 'therapeutic', 'intensity', 'subgroup', 'intermediate', 'prophylactic', 'PE', 'by', 'and']","['anticoagulation', 'by']",1416,子组分析按照肺栓塞发生的部位（肺段性与近端）和抗凝剂强度（预防/中等剂量与治疗剂量）进行了分类。,0.1666666666666666,"['anticoagulation', 'site', '/', 'proximal', 'therapeutic', 'intensity', 'subgroup', 'intermediate', 'prophylactic', 'PE', 'by', 'and']","['anticoagulation', 'proximal']",,,,
1429,1417,"eligible patients were those with active malignancy ( colorectal 21 % , lung 15 % , gynecological 11 % ; 64 % with metastatic disease ) , and a first incidental PE within 2 months of inclusion .",符合条件的患者是患有活动性恶性肿瘤（结直肠癌 21%，肺部 15%，妇科疾病 11%；64% 有转移性疾病），并且在入组后 2 个月内首次发生 PE 的患者。,0.3333333333333333,"['lung', 'disease', 'malignancy', 'inclusion', '2', 'gynecological', 'incidental', 'active', 'metastatic', 'with', 'PE', 'and', 'first', 'colorectal', 'eligible']","['lung', 'disease', 'malignancy', '2', 'active']",1417,"['合格的患者是活性恶性症(染色体21%,肺15%,妇科11%;甲状腺疾病64%),并在接入后2个月内获得第一次偶然的PE。']",0.4666666666666667,"['lung', 'disease', 'malignancy', 'inclusion', '2', 'gynecological', 'incidental', 'active', 'metastatic', 'with', 'PE', 'and', 'first', 'colorectal', 'eligible']","['lung', 'disease', 'malignancy', '2', 'incidental', 'first', 'eligible']",1417,符合条件的患者是那些有活跃的恶性肿瘤（结直肠21％，肺部15％，妇科11％；64％有转移病变），并在包括患者2个月内首次无意中发生静脉血栓形成。,0.2666666666666666,"['lung', 'disease', 'malignancy', 'inclusion', '2', 'gynecological', 'incidental', 'active', 'metastatic', 'with', 'PE', 'and', 'first', 'colorectal', 'eligible']","['lung', 'disease', 'malignancy', '2']",,,,
1430,1418,most patients ( 97 % ) were anticoagulated ; median duration of treatment was 216 days .,大多数患者 (97%) 进行了抗凝治疗；中位治疗持续时间为 216 天。,0.6666666666666666,"['median', 'treatment', 'duration']","['treatment', 'duration']",1418,"['大多数患者(97%)是抗凝固剂,平均治疗时间为216天。']",0.3333333333333333,"['median', 'treatment', 'duration']",['treatment'],1418,大多数病人（97%）接受了抗凝治疗；治疗时间的中位数为216天。,0.3333333333333333,"['median', 'treatment', 'duration']",['treatment'],,,,
1431,1419,bleeding and PE were the cause of death in 3.8 % of patients .,出血和肺栓塞是 3.8% 患者的死因。,0.5,"['bleeding', 'cause of death', 'PE', 'and']","['bleeding', 'cause of death']",1419,['出血和PE是患者3.8%的死亡原因。'],0.25,"['bleeding', 'cause of death', 'PE', 'and']",['bleeding'],1419,死因为出血和肺栓塞的患者占3.8%。,0.5,"['bleeding', 'cause of death', 'PE', 'and']","['bleeding', 'cause of death']",,,,
1432,1420,recurrence rates were increased despite treatment ( 4.9 % ) ; rates were comparable between patients with subsegmental and proximal PE and did not differ by intensity of anticoagulation .,尽管接受了治疗，复发率还是增加了 (4.9%)；亚段和近端 PE 患者的发生率相当，并且抗凝强度没有差异。,0.2727272727272727,"['anticoagulation', 'proximal', 'treatment', 'differ', 'intensity', 'recurrence', 'with', 'despite', 'PE', 'by', 'and']","['anticoagulation', 'proximal', 'treatment']",1420,"['尽管治疗,重复率增加了(4.9%);在患有子分子和近分子PE的患者中,重复率是相似的,并且不因抗凝固的强度而有所不同。']",0.2727272727272727,"['anticoagulation', 'proximal', 'treatment', 'differ', 'intensity', 'recurrence', 'with', 'despite', 'PE', 'by', 'and']","['anticoagulation', 'treatment', 'and']",1420,尽管接受治疗，复发率仍有所上升（4.9%）；患者肺栓塞下段或近端与否以及抗凝剂强度对复发率无显著影响。,0.3636363636363636,"['anticoagulation', 'proximal', 'treatment', 'differ', 'intensity', 'recurrence', 'with', 'despite', 'PE', 'by', 'and']","['anticoagulation', 'proximal', 'treatment', 'by']",,,,
1433,1421,this prospective study supports the current practice of anticoagulating cancer patients with incidental PE .,这项前瞻性研究支持目前对伴有 PE 的癌症患者进行抗凝治疗的做法。,0.25,"['cancer', 'incidental', 'prospective study', 'practice', 'current', 'with', 'PE', 'this']","['cancer', 'prospective study']",1421,['这项有前途的研究支持患有偶然的PE的抗凝固癌症患者的当前实践。'],0.375,"['cancer', 'incidental', 'prospective study', 'practice', 'current', 'with', 'PE', 'this']","['cancer', 'incidental', 'practice']",1421,这项前瞻性研究为住院患者因偶发肺栓塞而使用抗凝血药物的现行做法提供了支持。,0.125,"['cancer', 'incidental', 'prospective study', 'practice', 'current', 'with', 'PE', 'this']",['prospective study'],,,,
1434,1422,"here , the majority were treated with LMWHs ; moving forward , more patients with incidental PE will be treated with direct oral anticoagulants , which can improve quality of life , as patients can avoid the burden of injections .",在这里，大多数人接受了 LMWHs 治疗；今后，更多的偶发 PE 患者将接受直接口服抗凝剂治疗，这可以提高生活质量，因为患者可以避免注射的负担。,0.4,"['oral', 'incidental', 'be', 'forward', 'quality of life', 'majority', 'as', 'will', 'with', 'direct', 'injections', 'PE', 'avoid', 'anticoagulants', 'burden']","['be', 'quality of life', 'majority', 'direct', 'avoid', 'anticoagulants']",1422,"['在这里,大多数人用LMWH治疗;前进,更多患有偶然的PE的患者将用直接口服抗凝固剂治疗,这可以改善生活质量,因为患者可以避免注射的负担。']",0.4,"['oral', 'incidental', 'be', 'forward', 'quality of life', 'majority', 'as', 'will', 'with', 'direct', 'injections', 'PE', 'avoid', 'anticoagulants', 'burden']","['incidental', 'be', 'quality of life', 'majority', 'direct', 'avoid']",1422,"here, the majority were treated with LMWHs; moving forward, more patients with incidental PE will be treated with direct oral anticoagulants, which can improve quality of life, as patients can avoid the burden of injections.

中文：

在这里，大多数人是用强化肝素治疗的; 今后，更多的偶然肺栓塞患者将被直接用口服抗凝剂治疗，这样可以改善生活质量，因为病人可以避免注射的负担。",0.4,"['oral', 'incidental', 'be', 'forward', 'quality of life', 'majority', 'as', 'will', 'with', 'direct', 'injections', 'PE', 'avoid', 'anticoagulants', 'burden']","['be', 'quality of life', 'majority', 'direct', 'avoid', 'anticoagulants']",,,,
1435,1423,"however , early loss of glycemic control has been observed with metformin monotherapy .",然而，已观察到二甲双胍单药治疗会导致血糖早期失控。,0.6,"['control', 'early', 'loss', 'with', 'metformin']","['control', 'early', 'metformin']",1423,"['然而,早期损失的血糖控制已被观察到与甲状腺素单治疗。']",0.6,"['control', 'early', 'loss', 'with', 'metformin']","['control', 'early', 'loss']",1423,然而，在以单独使用二甲双胍治疗早期已经观察到失去糖耐量的情况。,0.4,"['control', 'early', 'loss', 'with', 'metformin']","['early', 'metformin']",,,,
1436,1424,whether liraglutide added to metformin ( with or without basal insulin treatment ) is safe and effective in youth with type 2 diabetes is unknown .,liraglutide 添加到二甲双胍（有或没有基础胰岛素治疗）中是否对患有 2 型糖尿病的青少年安全有效尚不清楚。,0.5,"['insulin', 'diabetes', 'type', 'basal', '2', 'treatment', 'youth', 'liraglutide', 'metformin', 'to', 'and', 'without']","['insulin', 'diabetes', 'type', '2', 'treatment', 'metformin']",1424,['是否添加到甲状腺素(与或没有基本胰岛素治疗)是安全和有效的青少年2型糖尿病尚不清楚。'],0.4166666666666667,"['insulin', 'diabetes', 'type', 'basal', '2', 'treatment', 'youth', 'liraglutide', 'metformin', 'to', 'and', 'without']","['insulin', 'diabetes', 'type', '2', 'treatment']",1424,目前尚不清楚在接受基礎胰島素治療的或未接受基礎胰島素治療的兒童青少年中，加入利拉那酯是否安全且有效。,0.0,"['insulin', 'diabetes', 'type', 'basal', '2', 'treatment', 'youth', 'liraglutide', 'metformin', 'to', 'and', 'without']",[],,,,
1437,1425,all the patients received metformin during the trial .,所有患者在试验期间都接受了二甲双胍。,0.3333333333333333,"['trial', 'metformin', 'all']",['metformin'],1425,['所有患者在测试期间都接受了甲状腺素。'],0.0,"['trial', 'metformin', 'all']",[],1425,所有的病人在试验期间都接受了服用了二甲双胍。,0.3333333333333333,"['trial', 'metformin', 'all']",['metformin'],,,,
1438,1426,the primary end point was the change from baseline in the glycated hemoglobin level after 26 weeks .,主要终点是 26 周后糖化血红蛋白水平相对于基线的变化。,0.5714285714285714,"['baseline', 'hemoglobin level', 'primary', 'after', 'end', 'point', 'change']","['baseline', 'after', 'point', 'change']",1426,['主要的终点是从基线到血糖血糖水平的变化26周后。'],0.7142857142857143,"['baseline', 'hemoglobin level', 'primary', 'after', 'end', 'point', 'change']","['baseline', 'primary', 'after', 'point', 'change']",1426,主要终点是26周后血糖化合物水平的变化。,0.4285714285714285,"['baseline', 'hemoglobin level', 'primary', 'after', 'end', 'point', 'change']","['after', 'point', 'change']",,,,
1439,1427,secondary end points included the change in fasting plasma glucose level .,次要终点包括空腹血糖水平的变化。,0.4285714285714285,"['glucose', 'plasma', 'end points', 'fasting', 'secondary', 'level', 'change']","['end points', 'level', 'change']",1427,['二级终点包括禁食血糖水平的变化。'],0.4285714285714285,"['glucose', 'plasma', 'end points', 'fasting', 'secondary', 'level', 'change']","['end points', 'level', 'change']",1427,第二次终点包括空腹血糖水平的变化。,0.4285714285714285,"['glucose', 'plasma', 'end points', 'fasting', 'secondary', 'level', 'change']","['end points', 'level', 'change']",,,,
1440,1428,safety was assessed throughout the course of the trial .,在整个试验过程中评估了安全性。,0.5,"['safety', 'trial', 'course', 'assessed']","['safety', 'course']",1428,"['整个审判期间,安全被评估。']",0.5,"['safety', 'trial', 'course', 'assessed']","['safety', 'trial']",1428,"safety was assessed throughout the course of the trial .

Chinese:

在整个试验过程中，安全性都有所评估。",0.5,"['safety', 'trial', 'course', 'assessed']","['safety', 'course']",,,,
1441,1429,"of 135 patients who underwent randomization , 134 received at least one dose of liraglutide ( 66 patients ) or placebo ( 68 patients ) .",在接受随机分组的 135 名患者中，134 名接受了至少一剂利拉鲁肽（66 名患者）或安慰剂（68 名患者）。,0.6,"['placebo', 'randomization', 'who', 'liraglutide', 'dose']","['placebo', 'randomization', 'liraglutide']",1429,"['在135名随机诊断的患者中,134人获得至少1剂Liraglutide(66名患者)或Placebo(68名患者)。']",0.2,"['placebo', 'randomization', 'who', 'liraglutide', 'dose']",['randomization'],1429,135名患者随机分配，134名患者至少接受了一剂利拉多尔（66名患者）或安普生（68名患者）。,0.2,"['placebo', 'randomization', 'who', 'liraglutide', 'dose']",['randomization'],,,,
1442,1430,"demographic characteristics were similar in the two groups ( mean age , 14.6 years ) .",两组的人口统计学特征相似（平均年龄 14.6 岁）。,0.5,"['mean', 'demographic characteristics', 'age', 'in', 'two', 'similar']","['mean', 'age', 'two']",1430,"['人口特征在两个群体中是相似的(平均年龄, 14.6 年)。']",0.6666666666666666,"['mean', 'demographic characteristics', 'age', 'in', 'two', 'similar']","['mean', 'age', 'two', 'similar']",1430,两组人群的人口特征相似（平均年龄14.6岁）。,0.5,"['mean', 'demographic characteristics', 'age', 'in', 'two', 'similar']","['mean', 'age', 'two']",,,,
1443,1431,the fasting plasma glucose level had decreased at both time points in the liraglutide group but had increased in the placebo group .,利拉鲁肽组的两个时间点的空腹血糖水平均降低，但安慰剂组的空腹血糖水平升高。,0.6,"['group', 'placebo', 'glucose', 'plasma', 'time', 'fasting', 'level', 'liraglutide', 'at', 'but']","['group', 'placebo', 'time', 'level', 'liraglutide', 'but']",1431,"['禁食的血糖水平在Liraglutide群体的两个时间点下降,但在 placebo群体中增加。']",0.4,"['group', 'placebo', 'glucose', 'plasma', 'time', 'fasting', 'level', 'liraglutide', 'at', 'but']","['group', 'time', 'level', 'but']",1431,在研究组中，空腹血糖水平在两个时间点都有所下降，而在安慰剂组中则有所上升。,0.5,"['group', 'placebo', 'glucose', 'plasma', 'time', 'fasting', 'level', 'liraglutide', 'at', 'but']","['group', 'placebo', 'time', 'level', 'but']",,,,
1444,1432,"in children and adolescents with type 2 diabetes , liraglutide , at a dose of up to 1.8 mg per day ( added to metformin , with or without basal insulin ) , was efficacious in improving glycemic control over 52 weeks .",在患有 2 型糖尿病的儿童和青少年中，每天 1.8 毫克剂量的利拉鲁肽（添加到二甲双胍中，有或没有基础胰岛素）在 52 周内有效改善血糖控制。,0.5333333333333333,"['insulin', 'diabetes', 'type', 'basal', 'control', '2', 'up', 'liraglutide', 'at', 'metformin', 'dose', 'over', 'to', 'and', 'without']","['insulin', 'diabetes', 'type', 'control', '2', 'liraglutide', 'metformin', 'dose']",1432,"['在患有2型糖尿病的儿童和青少年中,每天高达1.8毫克的利拉格卢蒂德(添加到甲状腺素,含有或没有基因胰岛素)在52周内有效地改善血糖控制。']",0.3333333333333333,"['insulin', 'diabetes', 'type', 'basal', 'control', '2', 'up', 'liraglutide', 'at', 'metformin', 'dose', 'over', 'to', 'and', 'without']","['insulin', 'diabetes', 'type', 'control', '2']",1432,在2型糖尿病儿童和青少年中，利拉格蒂得，每天最多1.8毫克的剂量（加入了二甲双胍，有或没有基础胰岛素），在52周内对改善血糖控制是有效的。,0.4666666666666667,"['insulin', 'diabetes', 'type', 'basal', 'control', '2', 'up', 'liraglutide', 'at', 'metformin', 'dose', 'over', 'to', 'and', 'without']","['insulin', 'diabetes', 'type', 'control', '2', 'metformin', 'dose']",,,,
1445,1433,"this efficacy came at the cost of an increased frequency of gastrointestinal adverse events . ( Funded by Novo Nordisk ; Ellipse ClinicalTrials.gov number , NCT01541215 . )",这种疗效是以胃肠道不良事件发生频率增加为代价的。 （由 Novo Nordisk 资助；Ellipse ClinicalTrials.gov 编号，NCT01541215。）,0.6,"['frequency', 'gastrointestinal', 'ellipse', 'adverse', 'number', 'efficacy', 'cost', 'at', 'this', 'by']","['frequency', 'gastrointestinal', 'number', 'cost', 'this', 'by']",1433,"['这种有效性是由于增加胃肠不良事件的频率而产生的(由Novo Nordisk资助;Ellipse ClinicalTrials.gov号,NCT01541215 )。']",0.7,"['frequency', 'gastrointestinal', 'ellipse', 'adverse', 'number', 'efficacy', 'cost', 'at', 'this', 'by']","['frequency', 'gastrointestinal', 'number', 'efficacy', 'at', 'this', 'by']",1433,这种疗效来自于增加的胃肠道不良事件的频率。（由诺和诺德资助；Ellipse ClinicalTrials.gov 编号，NCT01541215。）,0.5,"['frequency', 'gastrointestinal', 'ellipse', 'adverse', 'number', 'efficacy', 'cost', 'at', 'this', 'by']","['frequency', 'gastrointestinal', 'number', 'at', 'by']",,,,
1446,1434,"insulin is the only drug class approved for use in youth who do not have an adequate response to metformin monotherapy , 4,5 whereas a large number of oral and injectable agents of different classes are approved for adults.7","胰岛素是唯一批准用于对二甲双胍单一疗法没有足够反应的青少年的药物类别，4,5 而大量不同类别的口服和注射剂已获准用于成人。 7",0.4285714285714285,"['insulin', 'who', 'oral', 'large', 'number', 'injectable', 'youth', 'classes', 'adequate response', 'drug', 'metformin', 'have', 'to', 'and']","['insulin', 'drug', 'metformin', 'have', 'to', 'and']",1434,"['胰岛素是唯一批准的药物类,适用于未成年人,对甲状腺素单治疗没有足够的反应,而成年人则接受了大量的口服和不同类的注射剂。']",0.3571428571428571,"['insulin', 'who', 'oral', 'large', 'number', 'injectable', 'youth', 'classes', 'adequate response', 'drug', 'metformin', 'have', 'to', 'and']","['insulin', 'drug', 'have', 'to', 'and']",1434,青少年如果对于单独使用二甲双胍药物没有足够的反应，胰岛素是唯一被批准使用的药物类别，而成年人则获得了大量口服和注射用不同类别的药物的批准。,0.4285714285714285,"['insulin', 'who', 'oral', 'large', 'number', 'injectable', 'youth', 'classes', 'adequate response', 'drug', 'metformin', 'have', 'to', 'and']","['insulin', 'drug', 'metformin', 'have', 'to', 'and']",,,,
1447,1435,this discrepancy in available treatments for youth as compared with adults persists because of a lack of successfully completed trials needed for approval of new drugs for the treatment of type 2 diabetes in children since a trial of metformin was completed in 1999.8,由于自 1999 年完成二甲双胍试验以来，缺乏批准用于治疗儿童 2 型糖尿病的新药所需的成功完成的试验，因此青少年可用治疗方法与成人的这种差异持续存在。 8,0.5333333333333333,"['diabetes', 'lack', 'type', '2', 'approval', 'new drugs', 'treatment', 'available', 'trial', 'discrepancy', 'youth', 'as', 'with', 'metformin', 'this']","['diabetes', 'type', '2', 'approval', 'new drugs', 'treatment', 'discrepancy', 'metformin']",1435,"['与成年人相比,青少年可用的治疗方法的这种差异仍然存在,因为自1999年完成的甲状腺素试验以来,缺乏成功完成的试验需要批准2型糖尿病儿童的新药物。']",0.5333333333333333,"['diabetes', 'lack', 'type', '2', 'approval', 'new drugs', 'treatment', 'available', 'trial', 'discrepancy', 'youth', 'as', 'with', 'metformin', 'this']","['diabetes', 'type', '2', 'approval', 'new drugs', 'treatment', 'available', 'discrepancy']",1435,这种治疗青少年和成年人之间的差异仍然存在，因为自1999年完成了一项关于用于治疗2型糖尿病的新药物的试验以来，需要批准这种治疗方法的成功完成的试验数量较少。8,0.4666666666666667,"['diabetes', 'lack', 'type', '2', 'approval', 'new drugs', 'treatment', 'available', 'trial', 'discrepancy', 'youth', 'as', 'with', 'metformin', 'this']","['diabetes', 'type', '2', 'approval', 'new drugs', 'treatment', 'discrepancy']",,,,
1448,1436,"regulatory agencies mandate that new drugs that have been approved for use in adults with type 2 diabetes undergo efficacy and safety trials in youth with the disease.9,10","监管机构要求已获准用于成人 2 型糖尿病的新药在患有该病的青少年中进行疗效和安全性试验。 9,10",0.4615384615384615,"['safety', 'diabetes', 'type', '2', 'undergo', 'new drugs', 'efficacy', 'youth', 'with', 'have', 'that', 'in', 'and']","['safety', 'diabetes', 'type', '2', 'new drugs', 'have']",1436,['监管机构委托在患有2型糖尿病的成年人使用已批准的新药物在患有2型糖尿病的青少年中进行有效性和安全性测试。'],0.5384615384615384,"['safety', 'diabetes', 'type', '2', 'undergo', 'new drugs', 'efficacy', 'youth', 'with', 'have', 'that', 'in', 'and']","['safety', 'diabetes', 'type', '2', 'new drugs', 'efficacy', 'have']",1436,"regulatory agencies mandate that new drugs that have been approved for use in adults with type 2 diabetes undergo efficacy and safety trials in youth with the disease.9,10

中文：

监管机构要求所有新药物在成人患有2型糖尿病的情况下经过效能和安全性的测试，以确保在青少年患者中也有同样的效果。9,10",0.5384615384615384,"['safety', 'diabetes', 'type', '2', 'undergo', 'new drugs', 'efficacy', 'youth', 'with', 'have', 'that', 'in', 'and']","['safety', 'diabetes', 'type', '2', 'new drugs', 'efficacy', 'have']",,,,
1449,1437,"the Evaluation of Liraglutide in Pediatrics with Diabetes ( Ellipse ) phase 3 trial of liraglutide was launched in 2012 , enrolled patients for a period of 4 years and 4 months , and was successfully completed in 2018 .",利拉鲁肽在儿科糖尿病中的评价（椭圆） 利拉鲁肽3期试验于2012年启动，入组患者，为期4年4个月，2018年顺利完成。,0.4615384615384615,"['diabetes', 'period', 'phase', 'evaluation', 'pediatrics', 'ellipse', 'trial', '3', '4', 'with', 'liraglutide', 'in', 'and']","['diabetes', 'period', 'phase', 'evaluation', 'ellipse', 'liraglutide']",1437,"['2012年启动了《糖尿病儿童医学利拉格卢蒂德评估》(Evaluation of Liraglutide in Pediatrics with Diabetes, Ellipse)阶段3的利拉格卢蒂德试验,为期4年4个月,并于2018年成功完成。']",0.2307692307692307,"['diabetes', 'period', 'phase', 'evaluation', 'pediatrics', 'ellipse', 'trial', '3', '4', 'with', 'liraglutide', 'in', 'and']","['diabetes', 'period', 'phase']",1437,2012年，随着儿童糖尿病患者数量的增加，利拉格蒂德（Ellipse）第三阶段试验启动了为期4年4个月的患者招募工作，并于2018年成功完成。,0.2307692307692307,"['diabetes', 'period', 'phase', 'evaluation', 'pediatrics', 'ellipse', 'trial', '3', '4', 'with', 'liraglutide', 'in', 'and']","['diabetes', 'period', 'phase']",,,,
1450,1438,here we report the efficacy and safety outcomes of this trial .,我们在此报告该试验的有效性和安全性结果。,0.4285714285714285,"['safety', 'report', 'trial', 'efficacy', 'this', 'and', 'we']","['safety', 'report', 'efficacy']",1438,"['在这里,我们报告了这次试验的有效性和安全性结果。']",0.4285714285714285,"['safety', 'report', 'trial', 'efficacy', 'this', 'and', 'we']","['safety', 'report', 'efficacy']",1438,"here we report the efficacy and safety outcomes of this trial.

Chinese:

这里我们报告了这项试验的疗效和安全性结果。",0.2857142857142857,"['safety', 'report', 'trial', 'efficacy', 'this', 'and', 'we']","['safety', 'report']",,,,
1451,1439,we aimed to confirm the superiority of liraglutide to placebo in controlling glycemia in children and adolescents when added to treatment with metformin with or without insulin .,我们的目的是确认利拉鲁肽在控制儿童和青少年血糖时与二甲双胍联合使用或不联合胰岛素治疗时优于安慰剂。,0.6363636363636364,"['insulin', 'glycemia', 'placebo', 'treatment', 'superiority', 'liraglutide', 'metformin', 'to', 'and', 'without', 'we']","['insulin', 'glycemia', 'placebo', 'treatment', 'liraglutide', 'metformin', 'to']",1439,"['我们致力于确认Liraglutide对 placebo在儿童和青少年糖尿病控制的优越性,当添加到与或没有胰岛素的甲状腺素治疗时。']",0.3636363636363636,"['insulin', 'glycemia', 'placebo', 'treatment', 'superiority', 'liraglutide', 'metformin', 'to', 'and', 'without', 'we']","['insulin', 'treatment', 'superiority', 'to']",1439,我们的目标是确认liraglutide相对于安慰剂在儿童和青少年中控制糖尿病方面的优势，当liraglutide被加入到胰岛素和/或没有胰岛素的大儿童的治疗中。,0.3636363636363636,"['insulin', 'glycemia', 'placebo', 'treatment', 'superiority', 'liraglutide', 'metformin', 'to', 'and', 'without', 'we']","['insulin', 'placebo', 'treatment', 'to']",,,,
1452,1440,"written informed consent was obtained from a legally acceptable representative of all participants , and assent from all child participants was obtained except in Israel , where the assent form was not applicable .",从所有参与者的合法代表处获得了书面知情同意书，并获得了所有儿童参与者的同意，但在以色列除外，那里的同意书不适用。,0.3333333333333333,"['child', 'assent', 'informed consent', 'acceptable', 'all', 'and']","['child', 'assent']",1440,"['书面通知的同意是从合法接受的代表所有参与者获得的,并从所有儿童参与者获得的许可,除了在以色列,在那里许可表格不适用。']",0.3333333333333333,"['child', 'assent', 'informed consent', 'acceptable', 'all', 'and']","['child', 'assent']",1440,所有参与者的合法代表均已签署书面知情同意书，除以色列外，所有儿童参与者均已签署同意书，在以色列，由于同意书不适用，因此不需要签署同意书。,0.3333333333333333,"['child', 'assent', 'informed consent', 'acceptable', 'all', 'and']","['child', 'assent']",,,,
1453,1441,the trial protocol and statistical analysis plan ( available with the full text of this article at NEJM.org ) were designed by the sponsor ( Novo Nordisk ) .,试验方案和统计分析计划（与本文全文可在 NEJM.org 获取）由申办方 (Novo Nordisk) 设计。,0.25,"['protocol', 'sponsor', 'article', 'available', 'trial', 'text', 'statistical analysis', 'with', 'full', 'this', 'by', 'and']","['protocol', 'statistical analysis', 'by']",1441,['试验协议和统计分析计划(可在NEJM.org上提供本文的完整文本)由赞助商(Novo Nordisk)设计。'],0.3333333333333333,"['protocol', 'sponsor', 'article', 'available', 'trial', 'text', 'statistical analysis', 'with', 'full', 'this', 'by', 'and']","['protocol', 'statistical analysis', 'full', 'by']",1441,该试验方案和统计分析计划由主办方（诺沃-诺达公司）设计。全文可在NEJM.org网站上找到。,0.25,"['protocol', 'sponsor', 'article', 'available', 'trial', 'text', 'statistical analysis', 'with', 'full', 'this', 'by', 'and']","['protocol', 'statistical analysis', 'by']",,,,
1454,1442,the protocol ( without the statistical analysis plan ) was developed in accordance with local regulations and was reviewed and approved by an independent ethics committee or institutional review board at each site .,该方案（不含统计分析计划）是根据当地法规制定的，并由每个研究中心的独立伦理委员会或机构审查委员会审查和批准。,0.3076923076923077,"['site', 'review', 'protocol', 'ethics', 'local', 'board', 'committee', 'independent', 'statistical analysis', 'each', 'by', 'and', 'without']","['review', 'committee', 'statistical analysis', 'by']",1442,"['该议定书(没有统计分析计划)按照当地法规制定,并由独立的伦理委员会或各个网站的机构审查委员会审查和批准。']",0.5384615384615384,"['site', 'review', 'protocol', 'ethics', 'local', 'board', 'committee', 'independent', 'statistical analysis', 'each', 'by', 'and', 'without']","['review', 'protocol', 'committee', 'independent', 'statistical analysis', 'each', 'by']",1442,该协议（不包括统计分析计划）是根据当地法规制定的，并已经经过每个研究地点的独立的伦理委员会或机构审查委员会的审批。,0.4615384615384615,"['site', 'review', 'protocol', 'ethics', 'local', 'board', 'committee', 'independent', 'statistical analysis', 'each', 'by', 'and', 'without']","['site', 'review', 'protocol', 'committee', 'independent', 'statistical analysis']",,,,
1455,1443,an independent data monitoring committee had access to all unblinded data for the purpose of ensuring patient safety .,一个独立的数据监测委员会可以访问所有非盲数据，以确保患者安全。,0.6666666666666666,"['safety', 'monitoring', 'data', 'access', 'committee', 'patient', 'independent', 'purpose', 'all']","['safety', 'monitoring', 'data', 'committee', 'patient', 'independent']",1443,"['一个独立的数据监测委员会可以访问所有未透露的数据,以确保患者的安全。']",0.6666666666666666,"['safety', 'monitoring', 'data', 'access', 'committee', 'patient', 'independent', 'purpose', 'all']","['safety', 'monitoring', 'data', 'committee', 'patient', 'independent']",1443,一个独立的数据监测委员会对所有未盲审数据拥有访问权，以确保患者的安全。,0.6666666666666666,"['safety', 'monitoring', 'data', 'access', 'committee', 'patient', 'independent', 'purpose', 'all']","['safety', 'monitoring', 'data', 'committee', 'patient', 'independent']",,,,
1456,1444,"amendments to the protocol are listed in the Supplementary Appendix , available at NEJM.org .",方案的修正案列在补充附录中，补充附录可在 NEJM.org 获取。,0.0,"['appendix', 'protocol', 'supplementary', 'available', 'at', 'in']",[],1444,"['该协议的修正案列入附件中,可在NEJM.org上找到。']",0.3333333333333333,"['appendix', 'protocol', 'supplementary', 'available', 'at', 'in']","['appendix', 'protocol']",1444,修訂案列於附錄中，可在NEJM.org上找到。,0.0,"['appendix', 'protocol', 'supplementary', 'available', 'at', 'in']",[],,,,
1457,1445,"site investigators gathered the data , and the sponsor performed site monitoring , collected the data , and performed the analyses .",研究中心调查人员收集数据，申办方进行研究中心监测、收集数据并进行分析。,0.4,"['monitoring', 'site', 'data', 'sponsor', 'and']","['monitoring', 'data']",1445,"['网站调查人员收集了数据,赞助商进行了网站监测,收集了数据,并进行了分析。']",0.4,"['monitoring', 'site', 'data', 'sponsor', 'and']","['monitoring', 'data']",1445,现场调查员收集了数据，赞助商进行了现场监测，收集了数据并进行了分析。,0.6,"['monitoring', 'site', 'data', 'sponsor', 'and']","['monitoring', 'site', 'data']",,,,
1458,1446,all the authors had access to the trial results and vouch for the fidelity of the trial to the protocol .,所有作者都可以查看试验结果并保证试验对方案的忠实度。,0.0,"['fidelity', 'protocol', 'access', 'trial', 'all', 'and']",[],1446,"['所有作家都可以访问审判结果,并为审判对议定书的忠诚度提供支票。']",0.3333333333333333,"['fidelity', 'protocol', 'access', 'trial', 'all', 'and']","['protocol', 'trial']",1446,所有作者都可以访问试验结果，并且可以保证试验与方案的完全一致。,0.0,"['fidelity', 'protocol', 'access', 'trial', 'all', 'and']",[],,,,
1459,1447,"the first author wrote the first draft of the manuscript , and the manuscript was subsequently revised and approved by all the authors , who agreed to submit the manuscript for publication .",第一作者撰写了手稿的初稿，随后对手稿进行了修改并获得所有作者的认可，他们同意投稿发表。,0.3,"['who', 'author', 'publication', 'manuscript', 'all', 'by', 'to', 'and', 'first', 'draft']","['publication', 'manuscript', 'first']",1447,"['第一位作者写了手稿的第一个草案,手稿随后被所有作者审查并批准,他们同意提交手稿出版。']",0.3,"['who', 'author', 'publication', 'manuscript', 'all', 'by', 'to', 'and', 'first', 'draft']","['publication', 'manuscript', 'first']",1447,第一作者撰写了稿件的第一稿，随后稿件经过修订和所有作者的审核通过，作者们一致同意将稿件投稿出版。,0.2,"['who', 'author', 'publication', 'manuscript', 'all', 'by', 'to', 'and', 'first', 'draft']","['publication', 'first']",,,,
1460,1448,the first author also vouches for the accuracy and completeness of the data .,第一作者同时保证数据的准确性和完整性。,0.6666666666666666,"['data', 'author', 'accuracy', 'completeness', 'and', 'first']","['data', 'accuracy', 'completeness', 'first']",1448,['第一位作者也保证了数据的准确性和完整性。'],0.6666666666666666,"['data', 'author', 'accuracy', 'completeness', 'and', 'first']","['data', 'accuracy', 'completeness', 'first']",1448,第一位作者也保证数据的准确性和完整性。,0.6666666666666666,"['data', 'author', 'accuracy', 'completeness', 'and', 'first']","['data', 'accuracy', 'completeness', 'first']",,,,
1461,1449,"an independent medical writer , funded by the sponsor , provided editorial support , with guidance from the authors .",一位独立的医学作家，由申办方资助，在作者的指导下提供编辑支持。,0.5,"['support', 'sponsor', 'medical', 'writer', 'independent', 'with', 'by', 'guidance']","['support', 'writer', 'independent', 'by']",1449,"['由赞助商资助的独立医学作家,提供编辑支持,由作者指导。']",0.375,"['support', 'sponsor', 'medical', 'writer', 'independent', 'with', 'by', 'guidance']","['support', 'writer', 'by']",1449,一名独立的医学作家，由赞助商资助，提供编辑支持，并根据作者的指导进行编辑。,0.5,"['support', 'sponsor', 'medical', 'writer', 'independent', 'with', 'by', 'guidance']","['support', 'writer', 'independent', 'by']",,,,
1462,1450,"other exclusion criteria were the use of any antidiabetic agent other than metformin or basal insulin within 90 days before screening ; a history of pancreatitis ; serum calcitonin levels of 50 ng or more per liter ; a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2 ; an alanine aminotransferase level 2.5 times the upper limit of the normal range or higher ; serum creatinine levels greater than the upper limit of the normal range for age ; a recent history of heart disease , proliferative retinopathy or maculopathy ; and recurrent severe hypoglycemia or hypoglycemic unawareness .",其他排除标准是在筛选前 90 天内使用除二甲双胍或基础胰岛素以外的任何抗糖尿病药物；胰腺炎病史；血清降钙素水平为每升 50 纳克或更多；甲状腺髓样癌或多发性内分泌肿瘤的个人史或家族史 2 ；丙氨酸氨基转移酶水平是正常范围上限的 2.5 倍或更高；血清肌酐水平高于年龄正常范围的上限；最近有心脏病、增生性视网膜病变或黄斑病史；反复发作的严重低血糖或低血糖意识不清。,0.59375,"['medullary', 'insulin', 'creatinine', 'calcitonin', 'basal', 'liter', 'hypoglycemia', '2', 'recent', 'alanine aminotransferase', 'heart disease', 'screening', 'personal', 'family history', 'pancreatitis', 'exclusion', 'serum', 'multiple endocrine neoplasia', 'recurrent', 'thyroid cancer', 'proliferative', 'level', 'normal range', 'upper limit', 'severe', 'metformin', 'agent', 'hypoglycemic', 'antidiabetic', 'retinopathy', 'before', 'and']","['insulin', 'calcitonin', 'liter', '2', 'alanine aminotransferase', 'heart disease', 'screening', 'family history', 'pancreatitis', 'serum', 'recurrent', 'proliferative', 'level', 'normal range', 'upper limit', 'metformin', 'antidiabetic', 'retinopathy', 'before']",1450,"['其他排除标准包括在筛查前90天内使用任何非甲状腺素或基因胰岛素的抗糖药物;胰岛素史;血清钙素水平为每升50英<unk>或以上;甲状腺癌或多重内分泌肿瘤2的个人或家庭史;阿兰素氨基转移素水平为正常范围的 2.5 倍或更高;血清基因素水平高于正常范围的上限;心脏病史,繁殖性网膜炎或宏观病史;重复严重的催眠或催眠不良。']",0.375,"['medullary', 'insulin', 'creatinine', 'calcitonin', 'basal', 'liter', 'hypoglycemia', '2', 'recent', 'alanine aminotransferase', 'heart disease', 'screening', 'personal', 'family history', 'pancreatitis', 'exclusion', 'serum', 'multiple endocrine neoplasia', 'recurrent', 'thyroid cancer', 'proliferative', 'level', 'normal range', 'upper limit', 'severe', 'metformin', 'agent', 'hypoglycemic', 'antidiabetic', 'retinopathy', 'before', 'and']","['insulin', 'liter', '2', 'heart disease', 'screening', 'serum', 'thyroid cancer', 'proliferative', 'level', 'normal range', 'upper limit', 'before']",1450,其他排除标准包括在筛查前90天内使用任何除了二甲双胍或基础胰岛素以外的降糖药物；胰腺炎的病史；血清钙蛋白水平为每升50 ng或更高；个人或家族经历髓母细胞甲状腺癌或多发性内分泌腺瘤2的历史；丙氨酸转移酶水平为正常范围上限的2.5倍或更高；年龄相符的血清肌酐水平高于正常范围上限；最近心脏病、增殖性视网膜病变或黄斑病变的病史；以及反复严重的低血糖或低血糖无意识状态。,0.4375,"['medullary', 'insulin', 'creatinine', 'calcitonin', 'basal', 'liter', 'hypoglycemia', '2', 'recent', 'alanine aminotransferase', 'heart disease', 'screening', 'personal', 'family history', 'pancreatitis', 'exclusion', 'serum', 'multiple endocrine neoplasia', 'recurrent', 'thyroid cancer', 'proliferative', 'level', 'normal range', 'upper limit', 'severe', 'metformin', 'agent', 'hypoglycemic', 'antidiabetic', 'retinopathy', 'before', 'and']","['insulin', 'liter', '2', 'heart disease', 'screening', 'pancreatitis', 'serum', 'thyroid cancer', 'level', 'normal range', 'upper limit', 'metformin', 'retinopathy', 'before']",,,,
1463,1451,complete inclusion and exclusion criteria are listed in the Supplementary Appendix .,完整的纳入和排除标准列于补充附录中。,0.1666666666666666,"['appendix', 'inclusion', 'supplementary', 'exclusion', 'complete', 'and']",['complete'],1451,['完整的包含和排除标准在附件中列出。'],0.5,"['appendix', 'inclusion', 'supplementary', 'exclusion', 'complete', 'and']","['appendix', 'inclusion', 'complete']",1451,完整的包含和排除标准列在附录中。,0.3333333333333333,"['appendix', 'inclusion', 'supplementary', 'exclusion', 'complete', 'and']","['inclusion', 'complete']",,,,
1464,1452,"eligibility criteria included a fasting plasma glucose level between 126 mg and 220 mg per deciliter ( between 7.0 mmol and 12.2 mmol per liter ) and a stable metformin dose ( in most patients , 1000 mg to 2000 mg per day ) for at least 8 weeks .",合格标准包括空腹血糖水平在 126 mg 到 220 mg/dL（7.0 mmol 到 12.2 mmol/L）之间，二甲双胍剂量稳定（在大多数患者中，每天 1000 mg 到 2000 mg）至少 8 周。,0.3,"['glucose', 'plasma', 'deciliter', 'fasting', 'level', 'at', 'metformin', 'dose', 'to', 'and']","['level', 'metformin', 'dose']",1452,"['合格性标准包括禁食的血糖水平为126 mg至220 mg每分升(每升7.0 mmol至12.2 mmol)和稳定的甲状腺素剂量(在大多数患者中,每日1000 mg至2000 mg)至少8周。']",0.2,"['glucose', 'plasma', 'deciliter', 'fasting', 'level', 'at', 'metformin', 'dose', 'to', 'and']","['level', 'dose']",1452,"The eligibility criteria included a fasting plasma glucose level between 126 mg and 220 mg per deciliter ( between 7.0 mmol and 12.2 mmol per liter ) and a stable metformin dose ( in most patients , 1000 mg to 2000 mg per day ) for at least 8 weeks .

Chinese:

根据研究规定，参与者必须满足以下条件：空腹血糖水平在126至220毫克/分升（7.0至12.2毫克/升）之间，且已稳定服用了门冬氨酸药物（大多数病人每日服用1000至2000毫克）至少8周。",0.1,"['glucose', 'plasma', 'deciliter', 'fasting', 'level', 'at', 'metformin', 'dose', 'to', 'and']",['level'],,,,
1465,1453,patients who were receiving metformin at a dose of more than 2000 mg when they entered the trial continued receiving that dose .,进入试验时接受二甲双胍剂量超过 2000 毫克的患者继续接受该剂量。,0.4,"['who', 'trial', 'metformin', 'dose', 'that']","['metformin', 'dose']",1453,"['当他们进入试验时,在2000毫克以上的剂量服用甲状腺素的患者继续服用该剂量。']",0.2,"['who', 'trial', 'metformin', 'dose', 'that']",['dose'],1453,这项试验的参与者中，在进入试验时正在使用大于2000毫克剂量的降糖药物类药物的患者继续使用相同剂量。,0.2,"['who', 'trial', 'metformin', 'dose', 'that']",['dose'],,,,
1466,1454,patients who were being treated with basal insulin had to have been on a stable dose for at least 8 weeks .,正在接受基础胰岛素治疗的患者必须接受至少 8 周的稳定剂量。,0.2,"['insulin', 'basal', 'who', 'being', 'with', 'at', 'dose', 'on', 'have', 'to']","['insulin', 'dose']",1454,['接受基因胰岛素治疗的患者必须在稳定的剂量至少8周。'],0.2,"['insulin', 'basal', 'who', 'being', 'with', 'at', 'dose', 'on', 'have', 'to']","['insulin', 'dose']",1454,"patients who were being treated with basal insulin had to have been on a stable dose for at least 8 weeks .

Chinese:
基礎胰島素治療的病人必須已經在穩定劑量上達到至少8周。",0.0,"['insulin', 'basal', 'who', 'being', 'with', 'at', 'dose', 'on', 'have', 'to']",[],,,,
1467,1455,"diet and exercise counseling was provided , according to local standards , at several visits .",根据当地标准，在几次访问中提供了饮食和运动咨询。,0.5714285714285714,"['diet', 'exercise', 'local', 'counseling', 'at', 'to', 'and']","['diet', 'exercise', 'counseling', 'at']",1455,"['根据当地标准,在几次访问中提供饮食和锻炼咨询。']",0.5714285714285714,"['diet', 'exercise', 'local', 'counseling', 'at', 'to', 'and']","['diet', 'exercise', 'counseling', 'at']",1455,根据当地标准，在几次访问中提供了饮食和运动咨询。,0.5714285714285714,"['diet', 'exercise', 'local', 'counseling', 'at', 'to', 'and']","['diet', 'exercise', 'counseling', 'at']",,,,
1468,1456,"eligible patients were randomly assigned , in a 1 : 1 ratio , to receive subcutaneous liraglutide or placebo for 26 weeks , in combination with metformin , with or without basal insulin , on a background of a diet and exercise regimen .",符合条件的患者被随机分配，以 1:1 的比例接受皮下注射利拉鲁肽或安慰剂 26 周，联合二甲双胍，有或没有基础胰岛素，在饮食和运动方案的背景下。,0.625,"['insulin', 'combination', 'background', 'placebo', 'basal', '1', 'ratio', 'diet', 'exercise', 'subcutaneous', 'liraglutide', 'metformin', 'to', 'and', 'without', 'eligible']","['insulin', 'combination', 'background', 'placebo', '1', 'ratio', 'diet', 'exercise', 'liraglutide', 'metformin']",1456,"['合格的患者随机分配,在1:1的比例,接受下皮利拉格卢蒂德或 placebo26周,与甲状腺素,与或没有基因胰岛素,在饮食和锻炼计划的背景下。']",0.4375,"['insulin', 'combination', 'background', 'placebo', 'basal', '1', 'ratio', 'diet', 'exercise', 'subcutaneous', 'liraglutide', 'metformin', 'to', 'and', 'without', 'eligible']","['insulin', 'background', '1', 'ratio', 'diet', 'exercise', 'eligible']",1456,符合条件的患者随机分配，以1：1的比例，接受皮下注射的liraglutide或安慰剂，与胰岛素，有或没有类似胰岛素的基础，在一个饮食和锻炼计划的背景下，进行26周的组合治疗。,0.5,"['insulin', 'combination', 'background', 'placebo', 'basal', '1', 'ratio', 'diet', 'exercise', 'subcutaneous', 'liraglutide', 'metformin', 'to', 'and', 'without', 'eligible']","['insulin', 'combination', 'background', 'placebo', '1', 'ratio', 'diet', 'exercise']",,,,
1469,1457,"after randomization , administration of liraglutide or placebo by subcutaneous injection ( with visually identical prefilled pen injectors ) was initiated at a dose of 0.6 mg per day , and the dose was escalated in both groups in increments of approximately 0.6 mg each week over the course of 2 to 3 weeks .",随机分组后，皮下注射利拉鲁肽或安慰剂（使用视觉上相同的预填充笔式注射器）的起始剂量为每天 0.6 毫克，并且在整个治疗过程中，两组的剂量均以每周约 0.6 毫克的增量递增。 2 到 3 周。,0.631578947368421,"['placebo', 'subcutaneous injection', 'randomization', '2', 'administration', 'pen', 'week', 'after', '3', 'identical', 'course', 'with', 'liraglutide', 'dose', 'approximately', 'each', 'by', 'over', 'to']","['placebo', 'subcutaneous injection', 'randomization', '2', 'week', 'after', 'identical', 'course', 'liraglutide', 'dose', 'by', 'over']",1457,"['随机化后,用皮下注射(视觉上相同的预注金注射器)启动了Liraglutide或Placebo的剂量,每日剂量为0.6 mg,并在两组中增加了每周约0.6 mg的剂量,在2至3周内。']",0.3684210526315789,"['placebo', 'subcutaneous injection', 'randomization', '2', 'administration', 'pen', 'week', 'after', '3', 'identical', 'course', 'with', 'liraglutide', 'dose', 'approximately', 'each', 'by', 'over', 'to']","['subcutaneous injection', 'randomization', '2', 'week', 'after', 'identical', 'dose']",1457,经过随机化，利拉格兰德或安慰剂的皮下注射（使用外观相同的预充填针头注射器）以每天0.6毫克的剂量开始，并在两组中逐周增加0.6毫克，直至2-3周。,0.4736842105263157,"['placebo', 'subcutaneous injection', 'randomization', '2', 'administration', 'pen', 'week', 'after', '3', 'identical', 'course', 'with', 'liraglutide', 'dose', 'approximately', 'each', 'by', 'over', 'to']","['placebo', 'subcutaneous injection', 'randomization', '2', 'week', 'identical', 'dose', 'by', 'over']",,,,
1470,1458,dose adjustment was based on side effects and the efficacy of the lower dose .,剂量调整是根据副作用和较低剂量的疗效。,0.2857142857142857,"['adjustment', 'side effects', 'lower', 'efficacy', 'dose', 'on', 'and']","['side effects', 'dose']",1458,['剂量调整是基于副作用和低剂量的有效性。'],0.4285714285714285,"['adjustment', 'side effects', 'lower', 'efficacy', 'dose', 'on', 'and']","['side effects', 'efficacy', 'dose']",1458,根据副作用和较低剂量的疗效，调整剂量。,0.2857142857142857,"['adjustment', 'side effects', 'lower', 'efficacy', 'dose', 'on', 'and']","['side effects', 'dose']",,,,
1471,1459,prespecified criteria for rescue treatment with insulin that were based on fasting plasma glucose levels were applied to ensure acceptable glycemic control in both treatment groups .,应用基于空腹血糖水平的胰岛素抢救治疗的预设标准，以确保两个治疗组的血糖控制在可接受范围内。,0.3333333333333333,"['insulin', 'glucose', 'control', 'plasma', 'treatment', 'fasting', 'applied', 'acceptable', 'with', 'that', 'to', 'rescue']","['insulin', 'control', 'treatment', 'to']",1459,"['基于禁食的血糖水平的胰岛素救援治疗的预定标准被应用,以确保在两组治疗中可接受的血糖控制。']",0.5,"['insulin', 'glucose', 'control', 'plasma', 'treatment', 'fasting', 'applied', 'acceptable', 'with', 'that', 'to', 'rescue']","['insulin', 'control', 'treatment', 'acceptable', 'to', 'rescue']",1459,基于空腹血糖水平的救治用胰岛素的预先规定的标准应用于两种治疗组，以确保可接受的血糖控制。,0.4166666666666667,"['insulin', 'glucose', 'control', 'plasma', 'treatment', 'fasting', 'applied', 'acceptable', 'with', 'that', 'to', 'rescue']","['insulin', 'control', 'treatment', 'acceptable', 'to']",,,,
1472,1460,the primary efficacy end point was the change from baseline in glycated hemoglobin level at week 26 .,主要疗效终点是第 26 周时糖化血红蛋白水平相对于基线的变化。,0.5555555555555556,"['baseline', 'hemoglobin level', 'primary', 'week', 'efficacy', 'end', 'point', 'change', 'at']","['baseline', 'week', 'point', 'change', 'at']",1460,['初级效率的终点是从基线到血糖血糖水平的变化26周。'],0.4444444444444444,"['baseline', 'hemoglobin level', 'primary', 'week', 'efficacy', 'end', 'point', 'change', 'at']","['baseline', 'week', 'point', 'change']",1460,主要疗效指标是在26周时血糖化合物含量的变化。,0.2222222222222222,"['baseline', 'hemoglobin level', 'primary', 'week', 'efficacy', 'end', 'point', 'change', 'at']","['week', 'change']",,,,
1473,1461,"additional secondary end points included the changes from baseline in body weight , fasting lipid levels , and systolic and diastolic blood pressure .",其他次要终点包括体重、空腹血脂水平以及收缩压和舒张压相对于基线的变化。,0.2727272727272727,"['body weight', 'lipid', 'baseline', 'blood pressure', 'end points', 'diastolic', 'fasting', 'additional', 'systolic', 'secondary', 'and']","['body weight', 'baseline', 'end points']",1461,"['额外的次要终点包括体重基线的变化,禁食脂肪水平,以及系统和二进制血压。']",0.4545454545454545,"['body weight', 'lipid', 'baseline', 'blood pressure', 'end points', 'diastolic', 'fasting', 'additional', 'systolic', 'secondary', 'and']","['body weight', 'baseline', 'blood pressure', 'end points', 'additional']",1461,除了主要终点之外，其他次要终点还包括基线后体重、空腹血脂水平以及收缩压和舒张压的变化。,0.2727272727272727,"['body weight', 'lipid', 'baseline', 'blood pressure', 'end points', 'diastolic', 'fasting', 'additional', 'systolic', 'secondary', 'and']","['body weight', 'baseline', 'end points']",,,,
1474,1462,"adverse events , serious adverse events , and medical events of special interest were assessed throughout the trial ( definitions are provided in the Supplementary Appendix ) .",在整个试验过程中评估了不良事件、严重不良事件和特别关注的医学事件（定义见补充附录）。,0.1,"['appendix', 'medical', 'supplementary', 'adverse', 'trial', 'serious', 'in', 'and', 'special', 'assessed']",['special'],1462,['试验期间对不良事件、严重不良事件和特殊兴趣的医学事件进行了评估(定义在附件中提供)。'],0.2,"['appendix', 'medical', 'supplementary', 'adverse', 'trial', 'serious', 'in', 'and', 'special', 'assessed']","['appendix', 'special']",1462,"adverse events, serious adverse events, and medical events of special interest were assessed throughout the trial (definitions are provided in the Supplementary Appendix).

Chinese:

在整个试验中，对不良事件，严重不良事件和医疗特别关注事件进行了评估（定义参见补充附件）。",0.2,"['appendix', 'medical', 'supplementary', 'adverse', 'trial', 'serious', 'in', 'and', 'special', 'assessed']","['appendix', 'special']",,,,
1475,1463,hypoglycemic episodes were classified according to the Novo Nordisk and American Diabetes Association definitions ( see the Supplementary Appendix ) .,根据诺和诺德和美国糖尿病协会的定义（见补充附录）对低血糖发作进行分类。,0.2222222222222222,"['diabetes', 'appendix', 'association', 'supplementary', 'episodes', 'classified', 'hypoglycemic', 'to', 'and']","['diabetes', 'episodes']",1463,['催眠性病例根据Novo Nordisk和美国糖尿病协会的定义分类(参见补充附件)。'],0.2222222222222222,"['diabetes', 'appendix', 'association', 'supplementary', 'episodes', 'classified', 'hypoglycemic', 'to', 'and']","['diabetes', 'appendix']",1463,"hypoglycemic episodes were classified according to the Novo Nordisk and American Diabetes Association definitions (see the Supplementary Appendix).

中文：

根据诺和诺德和美国糖尿病协会的定义，低血糖发作被分为不同的类别（参见附录）。",0.2222222222222222,"['diabetes', 'appendix', 'association', 'supplementary', 'episodes', 'classified', 'hypoglycemic', 'to', 'and']","['diabetes', 'episodes']",,,,
1476,1464,"lipase , amylase , and calcitonin levels at baseline and during the trial were evaluated with standard laboratory tests .",基线和试验期间的脂肪酶、淀粉酶和降钙素水平通过标准实验室测试进行评估。,0.75,"['amylase', 'calcitonin', 'standard', 'lipase', 'baseline', 'trial', 'laboratory', 'with']","['amylase', 'calcitonin', 'standard', 'lipase', 'baseline', 'laboratory']",1464,['基线和测试期间的脂肪、阿米拉斯和钙素水平通过标准实验室测试进行评估。'],0.375,"['amylase', 'calcitonin', 'standard', 'lipase', 'baseline', 'trial', 'laboratory', 'with']","['standard', 'baseline', 'laboratory']",1464,"lipase, amylase, and calcitonin levels at baseline and during the trial were evaluated with standard laboratory tests.

Chinese:

基线和试验期间的lipase、amylase和calcitonin水平通过标准实验室测试进行评估。",0.375,"['amylase', 'calcitonin', 'standard', 'lipase', 'baseline', 'trial', 'laboratory', 'with']","['standard', 'baseline', 'laboratory']",,,,
1477,1465,"the sample size was calculated for the primary glycated hemoglobin end point alone ; we determined that a sample size of 47 patients in each treatment group would give the study 80 % power , assuming a mean ( ± SD ) difference of 0.9 ± 1.2 percentage points between the liraglutide group and the placebo group ( a difference of 0.7 percentage points after adjustment for a 22 % withdrawal rate ) .",仅针对主要糖化血红蛋白终点计算样本量；我们确定每个治疗组中 47 名患者的样本量将为研究提供 80 % 的功效，假设利拉鲁肽组和安慰剂组之间的平均 ( ± SD ) 差异为 0.9 ± 1.2 个百分点（差异为 0.7 个百分点调整为 22% 的退出率后）。,0.391304347826087,"['percentage', 'placebo', 'mean', 'rate', 'power', 'hemoglobin', 'withdrawal', 'study', 'adjustment', 'difference', 'primary', 'after', 'sample size', 'end', 'point', 'treatment group', 'liraglutide', 'SD', 'give', 'that', 'each', 'and', 'alone']","['placebo', 'mean', 'rate', 'hemoglobin', 'difference', 'after', 'point', 'treatment group', 'liraglutide']",1465,"['样品大小仅计算为初级格利克化血球的终点;我们确定,每个治疗组的47名患者的样品大小将给研究80%的功率,假设在利拉格卢蒂德组和 placebo组之间的平均(±SD)差距为0.9 ±1.2 百分点(调整后差距为0.7 百分点为22%退缩率)。']",0.2608695652173913,"['percentage', 'placebo', 'mean', 'rate', 'power', 'hemoglobin', 'withdrawal', 'study', 'adjustment', 'difference', 'primary', 'after', 'sample size', 'end', 'point', 'treatment group', 'liraglutide', 'SD', 'give', 'that', 'each', 'and', 'alone']","['mean', 'rate', 'power', 'after', 'point', 'treatment group']",1465,"样本大小仅针对主要糖化血红蛋白指标计算；我们确定，在每个治疗组中有47名患者的样本规模将使该研究具备80％的统计力，假设利拉格蒂德组与安慰剂组之间的平均（±SD）差异为0.9±1.2个百分点（撤出率为22％后调整后为0.7个百分点）。

Chinese:

样本大小仅针对主要糖化血红蛋白指标进行计算，结果表明，在每个治疗组中至少需要47名患者的样本，才能使该研究具有80%的统计力，假设利拉格蒂德组与安慰剂组之间平均相差0.9±1.2个百分点（撤出率为22%后调整后相差0.7个百分点）。",0.4347826086956521,"['percentage', 'placebo', 'mean', 'rate', 'power', 'hemoglobin', 'withdrawal', 'study', 'adjustment', 'difference', 'primary', 'after', 'sample size', 'end', 'point', 'treatment group', 'liraglutide', 'SD', 'give', 'that', 'each', 'and', 'alone']","['placebo', 'mean', 'rate', 'power', 'hemoglobin', 'difference', 'after', 'point', 'treatment group', 'give']",,,,
1478,1466,"according to regulatory requirements , at least 30 % of patients who underwent randomization were to be 10 to 14 years of age , at least 40 % were to be female , and at least 30 % were to be from the European Union or from countries with lifestyle and diabetes care similar to those in European Union countries .",根据法规要求，接受随机分组的患者中至少有 30 % 年龄在 10 至 14 岁之间，至少 40 % 为女性，至少 30 % 来自欧盟或具有生活方式的国家。和欧盟国家的糖尿病护理相似。,0.3636363636363636,"['diabetes', 'randomization', 'female', 'who', 'age', 'care', 'with', 'union', 'in', 'to', 'similar']","['diabetes', 'randomization', 'female', 'age']",1466,"['根据监管要求,至少有30%的随机诊断患者年龄为10至14岁,至少有40%是女性,至少有30%来自欧盟或与欧盟国家相似的生活方式和糖尿病护理国家。']",0.4545454545454545,"['diabetes', 'randomization', 'female', 'who', 'age', 'care', 'with', 'union', 'in', 'to', 'similar']","['diabetes', 'randomization', 'female', 'age', 'similar']",1466,"根据监管要求，至少30％的患者经过随机分配至10至14岁，至少40％是女性，至少30％来自欧盟或与欧盟国家生活方式和糖尿病护理相似的国家。

Chinese:
根據監管要求，至少30％的病人經過隨機分配至10至14歲，至少40％是女性，至少30％來自歐盟或與歐盟國家生活方式和糖尿病護理相似的國家。",0.3636363636363636,"['diabetes', 'randomization', 'female', 'who', 'age', 'care', 'with', 'union', 'in', 'to', 'similar']","['diabetes', 'randomization', 'female', 'similar']",,,,
1479,1467,the full analysis set ( patients as randomly assigned ) and the safety analysis set ( patients as treated ) included all patients who received at least one dose of liraglutide or placebo .,全分析集（随机分配的患者）和安全性分析集（接受治疗的患者）包括接受至少一剂利拉鲁肽或安慰剂的所有患者。,0.1818181818181818,"['placebo', 'who', 'set', 'safety analysis', 'as', 'liraglutide', 'at', 'dose', 'full', 'all', 'and']","['placebo', 'liraglutide']",1467,['完整的分析组(随机分配的患者)和安全分析组(接受治疗的患者)包括接受至少一剂Liraglutide或Placebo的所有患者。'],0.1818181818181818,"['placebo', 'who', 'set', 'safety analysis', 'as', 'liraglutide', 'at', 'dose', 'full', 'all', 'and']","['safety analysis', 'full']",1467,完整的分析集（随机分配的患者）和安全分析集（接受治疗的患者）包括所有接受过利拉链脲或安慰剂至少一次剂量的患者。,0.3636363636363636,"['placebo', 'who', 'set', 'safety analysis', 'as', 'liraglutide', 'at', 'dose', 'full', 'all', 'and']","['placebo', 'safety analysis', 'dose', 'full']",,,,
1480,1468,"missing data at week 26 were imputed with the use of a regression model that was based on data from patients in the placebo group who completed week 26 , with missing data for patients in the placebo group imputed from data throughout the trial and missing data for patients in the liraglutide group imputed from baseline data .",第26周的缺失数据使用回归模型进行估算，该模型基于完成第26周的安慰剂组患者的数据，安慰剂组患者的缺失数据是根据整个试验的数据估算的，患者的缺失数据在根据基线数据估算的利拉鲁肽组中。,0.6153846153846154,"['group', 'placebo', 'data', 'who', 'baseline', 'week', 'trial', 'with', 'liraglutide', 'that', 'and', 'missing', 'regression model']","['group', 'placebo', 'data', 'baseline', 'week', 'liraglutide', 'missing', 'regression model']",1468,"['26周失踪的数据被归因于使用基于26周完成的 placebo 群体患者的数据的 regression 模型,在整个测试期间从数据中归因于 placebo 群体患者的失踪数据,以及从基准数据中归因于 liraglutide 群体患者的失踪数据。']",0.2307692307692307,"['group', 'placebo', 'data', 'who', 'baseline', 'week', 'trial', 'with', 'liraglutide', 'that', 'and', 'missing', 'regression model']","['group', 'data', 'week']",1468,第26周的缺失数据使用基于安慰剂组完成第26周数据的回归模型进行了补充，安慰剂组的缺失数据从整个试验期间进行了补充，利拉格辛组的缺失数据从基线数据进行了补充。,0.5384615384615384,"['group', 'placebo', 'data', 'who', 'baseline', 'week', 'trial', 'with', 'liraglutide', 'that', 'and', 'missing', 'regression model']","['group', 'placebo', 'data', 'baseline', 'week', 'missing', 'regression model']",,,,
1481,1469,"missing data at week 26 were imputed 10,000 times , and for each of the 10,000 imputed data sets , the change in glycated hemoglobin level from baseline to week 26 was assessed with an analysis of covariance , with treatment and stratification groups ( sex and age group ) as categorical fixed effects and baseline glycated hemoglobin level as a covariate .","第26周的缺失数据被估算了10,000次，对于10,000个估算数据集中的每一个，糖化血红蛋白水平从基线到第26周的变化通过协方差分析、治疗组和分层组（性别和年龄组）进行了评估。作为分类固定效应和基线糖化血红蛋白水平作为协变量。",0.5789473684210527,"['group', 'stratification', 'data', 'baseline', 'sex', 'hemoglobin level', 'treatment', 'age', 'week', 'fixed', 'change', 'categorical', 'with', 'analysis of covariance', 'each', 'to', 'and', 'missing', 'assessed']","['group', 'stratification', 'data', 'baseline', 'sex', 'treatment', 'age', 'week', 'change', 'to', 'missing']",1469,"['缺失的数据在26周被归因于10万次,并为每1万个归因的数据集,从基线到26周的血糖血糖水平的变化被评估,通过分析,与治疗和分裂组(性别和年龄组)作为类别固定效应和基线血糖血糖血糖水平作为科瓦里亚特。']",0.5263157894736842,"['group', 'stratification', 'data', 'baseline', 'sex', 'hemoglobin level', 'treatment', 'age', 'week', 'fixed', 'change', 'categorical', 'with', 'analysis of covariance', 'each', 'to', 'and', 'missing', 'assessed']","['group', 'data', 'baseline', 'sex', 'treatment', 'age', 'week', 'change', 'to', 'missing']",1469,"缺少的周26数据被10,000次插补，对于每一组插补数据，从基线到周26的糖化血红蛋白水平变化通过协方差分析来评估，治疗和分层组(性别和年龄组)作为分类固定效应，基线糖化血红蛋白水平作为协变量。",0.5789473684210527,"['group', 'stratification', 'data', 'baseline', 'sex', 'hemoglobin level', 'treatment', 'age', 'week', 'fixed', 'change', 'categorical', 'with', 'analysis of covariance', 'each', 'to', 'and', 'missing', 'assessed']","['group', 'stratification', 'data', 'baseline', 'sex', 'treatment', 'age', 'week', 'change', 'to', 'missing']",,,,
1482,1470,"to be able to claim superiority for the listed end points , we first needed to show superiority with respect to the primary end point .",为了能够宣称对所列终点的优效性，我们首先需要展示对主要终点的优效性。,0.2,"['end points', 'be', 'primary', 'claim', 'superiority', 'with', 'respect', 'to', 'first', 'we']","['end points', 'first']",1470,"['为了能够对列出的终点提出优越性,我们首先需要对初级终点提出优越性。']",0.3,"['end points', 'be', 'primary', 'claim', 'superiority', 'with', 'respect', 'to', 'first', 'we']","['end points', 'superiority', 'first']",1470,要能夠對列出的終點自誇，我們首先必須對主要終點表現出優越性。,0.1,"['end points', 'be', 'primary', 'claim', 'superiority', 'with', 'respect', 'to', 'first', 'we']",['first'],,,,
1483,1471,a sensitivity analysis ( mixed model of repeated measurements ) in which data after initiation of rescue treatment were excluded was completed for all end points .,对所有终点完成敏感性分析（重复测量的混合模型），其中排除了开始救援治疗后的数据。,0.6666666666666666,"['initiation', 'model', 'data', 'analysis', 'mixed', 'end points', 'treatment', 'after', 'sensitivity', 'repeated', 'all', 'rescue']","['initiation', 'model', 'data', 'analysis', 'end points', 'treatment', 'after', 'rescue']",1471,"['一项敏感性分析(重复测量的混合模型),在救援处理开始后被排除的数据为所有终点完成。']",0.6666666666666666,"['initiation', 'model', 'data', 'analysis', 'mixed', 'end points', 'treatment', 'after', 'sensitivity', 'repeated', 'all', 'rescue']","['initiation', 'model', 'data', 'analysis', 'end points', 'treatment', 'after', 'rescue']",1471,对所有终点进行了敏感性分析（复合测量模型），其中包括了救治治疗后的数据。,0.5,"['initiation', 'model', 'data', 'analysis', 'mixed', 'end points', 'treatment', 'after', 'sensitivity', 'repeated', 'all', 'rescue']","['model', 'data', 'analysis', 'end points', 'treatment', 'after']",,,,
1484,1472,details of the other sensitivity analyses are provided in the Supplementary Appendix .,补充附录中提供了其他敏感性分析的详细信息。,0.0,"['appendix', 'supplementary', 'sensitivity', 'in']",[],1472,['其他敏感性分析的详细信息在附件中提供。'],0.25,"['appendix', 'supplementary', 'sensitivity', 'in']",['appendix'],1472,其他敏感性分析的细节可在附表中找到。,0.0,"['appendix', 'supplementary', 'sensitivity', 'in']",[],,,,
1485,1473,post hoc analyses of the primary end point and two of the confirmatory secondary end points were performed with data stratified by sex and age group .,使用按性别和年龄组分层的数据对主要终点和两个确认性次要终点进行事后分析。,0.5384615384615384,"['group', 'data', 'sex', 'end points', 'post', 'primary', 'age', 'secondary', 'with', 'by', 'and', 'two', 'confirmatory']","['group', 'data', 'sex', 'end points', 'age', 'two', 'confirmatory']",1473,['初级终点和确认二级终点的后期分析以性别和年龄组分类的数据进行。'],0.5384615384615384,"['group', 'data', 'sex', 'end points', 'post', 'primary', 'age', 'secondary', 'with', 'by', 'and', 'two', 'confirmatory']","['group', 'data', 'sex', 'end points', 'age', 'by', 'confirmatory']",1473,在主要终点和两个确认性次要终点的后续分析中，根据性别和年龄分层对数据进行了分析。,0.4615384615384615,"['group', 'data', 'sex', 'end points', 'post', 'primary', 'age', 'secondary', 'with', 'by', 'and', 'two', 'confirmatory']","['data', 'sex', 'end points', 'age', 'two', 'confirmatory']",,,,
1486,1474,proportions of patients who attained specified glycated hemoglobin levels were analyzed with the use of logistic regression ( with missing data imputed as in the primary analysis ) .,使用逻辑回归分析达到特定糖化血红蛋白水平的患者比例（在主要分析中对缺失数据进行估算）。,0.4444444444444444,"['logistic regression', 'data', 'who', 'analysis', 'hemoglobin', 'primary', 'as', 'with', 'missing']","['data', 'analysis', 'hemoglobin', 'missing']",1474,"['达到指定的血糖血糖水平的患者的比例被分析,使用物流回归(如在初始分析中所表明的缺乏数据)。']",0.4444444444444444,"['logistic regression', 'data', 'who', 'analysis', 'hemoglobin', 'primary', 'as', 'with', 'missing']","['data', 'analysis', 'as', 'missing']",1474,使用逻辑回归分析了达到特定糖化血红蛋白水平的患者的比例（缺失数据按原始分析方式进行补充）。,0.4444444444444444,"['logistic regression', 'data', 'who', 'analysis', 'hemoglobin', 'primary', 'as', 'with', 'missing']","['data', 'analysis', 'hemoglobin', 'missing']",,,,
1487,1475,safety end points were summarized with descriptive statistics .,用描述性统计总结安全性终点。,0.5,"['safety', 'end points', 'descriptive statistics', 'with']","['safety', 'end points']",1475,['安全终点被总结为描述性统计。'],0.5,"['safety', 'end points', 'descriptive statistics', 'with']","['safety', 'end points']",1475,安全终点的描述性统计结果如下。,0.5,"['safety', 'end points', 'descriptive statistics', 'with']","['safety', 'end points']",,,,
1488,1476,testing of the supportive secondary end points ( all secondary end points other than the end points in the hierarchy ) and post hoc subgroup analyses were not adjusted for multiplicity .,对支持性次要终点（除层次结构中的终点以外的所有次要终点）和事后亚组分析的测试未针对多重性进行调整。,0.2222222222222222,"['end points', 'post', 'hierarchy', 'secondary', 'multiplicity', 'subgroup', 'testing', 'all', 'and']","['end points', 'multiplicity']",1476,['支持的二级终点测试(所有二级终点不同于 hierarchy 的终点)和后 hoc 子组分析没有调整为多样性。'],0.1111111111111111,"['end points', 'post', 'hierarchy', 'secondary', 'multiplicity', 'subgroup', 'testing', 'all', 'and']",['end points'],1476,测试支持性次要终点（除层次结构中的终点以外的所有次要终点）和事后分组分析未经多重性调整。,0.2222222222222222,"['end points', 'post', 'hierarchy', 'secondary', 'multiplicity', 'subgroup', 'testing', 'all', 'and']","['end points', 'multiplicity']",,,,
1489,1477,"results are reported as point estimates with 95 % confidence intervals , and widths of these confidence intervals should not be used to infer definitive treatment effects .",结果报告为具有 95% 置信区间的点估计值，这些置信区间的宽度不应用于推断确定的治疗效果。,0.4,"['definitive', 'be', 'treatment', 'point', 'as', 'with', 'confidence', 'to', 'and', 'intervals']","['definitive', 'treatment', 'point', 'to']",1477,"['结果报告为95%的信任间隔的点估计,这些信任间隔的宽度不应用于确定最终的治疗效果。']",0.3,"['definitive', 'be', 'treatment', 'point', 'as', 'with', 'confidence', 'to', 'and', 'intervals']","['treatment', 'point', 'to']",1477,结果以95%置信区间的点估计报告，这些置信区间的宽度不应用于推断明确的治疗效果。,0.3,"['definitive', 'be', 'treatment', 'point', 'as', 'with', 'confidence', 'to', 'and', 'intervals']","['treatment', 'point', 'to']",,,,
1490,1478,patient DEMOGRAPHICS AND CLINICAL CHARACTERISTICS,患者人口统计学和临床特征,1.0,['patient'],['patient'],1478,['患者人口学和临床特征'],1.0,['patient'],['patient'],1478,病人的人口统计学和临床特征,1.0,['patient'],['patient'],,,,
1491,1479,enrollment began in November 2012 and was completed in May 2018 .,2012年11月开始招生，2018年5月结束。,0.0,"['november', 'in', 'and']",[],1479,"['注册开始于2012年11月,并于2018年5月完成。']",0.0,"['november', 'in', 'and']",[],1479,"Enrollment began in November 2012 and was completed in May 2018.

Chinese:

招生于2012年11月开始，并于2018年5月完成。",0.0,"['november', 'in', 'and']",[],,,,
1492,1480,"of 307 patients screened , 135 were randomly assigned to a trial group , of whom 134 received at least one dose of either liraglutide ( 66 patients ) or placebo ( 68 patients ; 1 patient in this group did not received any dose ) ( Figure 1 , and Table S1 in the Supplementary Appendix ) .",在筛选的 307 名患者中，135 名被随机分配到试验组，其中 134 名接受了至少一剂利拉鲁肽（66 名患者）或安慰剂（68 名患者；该组中有 1 名患者未接受任何剂量）（图 1，和补充附录中的表 S1）。,0.4,"['group', 'placebo', 'appendix', 'table', 'figure', 'supplementary', 'patient', 'trial', 'liraglutide', 'dose', 'S1', 'this', 'in', 'to', 'and']","['group', 'placebo', 'table', 'patient', 'liraglutide', 'dose']",1480,"['在307名受试患者中,135人随机分配给一个试验组,其中134人获得至少一剂Liraglutide(66名患者)或 placebo(68名患者,其中1名患者没有接受任何剂量)(图1和附件中的S1表)。']",0.3333333333333333,"['group', 'placebo', 'appendix', 'table', 'figure', 'supplementary', 'patient', 'trial', 'liraglutide', 'dose', 'S1', 'this', 'in', 'to', 'and']","['group', 'appendix', 'table', 'patient', 'dose']",1480,在307名病人中进行筛选，135名病人随机分配到实验组，其中134名病人至少接受了一剂利拉格达德（66名病人）或安慰剂（68名病人；1名病人未接受任何剂量）（见图1和表S1在补充附录中）。,0.3333333333333333,"['group', 'placebo', 'appendix', 'table', 'figure', 'supplementary', 'patient', 'trial', 'liraglutide', 'dose', 'S1', 'this', 'in', 'to', 'and']","['group', 'placebo', 'table', 'patient', 'dose']",,,,
1493,1481,these 134 patients made up the full and safety analysis sets .,这 134 名患者构成了完整和安全性分析集。,0.25,"['up', 'safety analysis', 'full', 'and']",['full'],1481,['这些134名患者完成了完整和安全分析套件。'],0.5,"['up', 'safety analysis', 'full', 'and']","['safety analysis', 'full']",1481,这 134 位患者组成了完整且安全的分析集。,0.25,"['up', 'safety analysis', 'full', 'and']",['full'],,,,
1494,1482,"among all patients who underwent randomization , 118 patients ( 87.4 % ) - 60 ( 90.9 % ) in the liraglutide group and 58 ( 84.1 % ) in the placebo group - completed 26 weeks of treatment .",在接受随机分组的所有患者中，利拉鲁肽组 118 例 (87.4%) 至 60 例 (90.9%) 和安慰剂组 58 例 (84.1%) 完成了 26 周的治疗。,0.5555555555555556,"['group', 'placebo', 'randomization', 'who', 'treatment', 'liraglutide', '-', 'all', 'in']","['group', 'placebo', 'randomization', 'treatment', 'liraglutide']",1482,"['在所有经过随机诊断的患者中,118名患者(87.4%) - 利拉格卢蒂德群体的60(90.9%)和 placebo群体的58(84.1%) - 完成了26周的治疗。']",0.3333333333333333,"['group', 'placebo', 'randomization', 'who', 'treatment', 'liraglutide', '-', 'all', 'in']","['group', 'randomization', 'treatment']",1482,在所有随机分配的患者中，118例患者（87.4%）——60例（90.9%）在liraglutide组和58例（84.1%）在安慰剂组——完成了26周的治疗。,0.4444444444444444,"['group', 'placebo', 'randomization', 'who', 'treatment', 'liraglutide', '-', 'all', 'in']","['group', 'placebo', 'randomization', 'treatment']",,,,
1495,1483,"subsequently , 109 patients ( 80.7 % ) completed 52 weeks of treatment - 56 ( 84.8 % ) in the liraglutide group and 53 ( 76.8 % ) in the placebo group .",随后，109 名患者 (80.7%) 完成了 52 周的治疗——利拉鲁肽组 56 名 (84.8%) 和安慰剂组 53 名 (76.8%)。,0.5714285714285714,"['group', 'placebo', 'treatment', 'liraglutide', '-', 'in', 'and']","['group', 'placebo', 'treatment', 'liraglutide']",1483,"['随后,109名患者(80.7%)完成了52周的治疗 - 56(84.8%)在利拉格卢蒂德群体和53(76.8%)在 placebo群体。']",0.2857142857142857,"['group', 'placebo', 'treatment', 'liraglutide', '-', 'in', 'and']","['group', 'treatment']",1483,随后，109名患者（80.7%）完成了52周的治疗，其中56名（84.8%）在利拉多基组接受治疗，53名（76.8%）在安慰剂组接受治疗。,0.4285714285714285,"['group', 'placebo', 'treatment', 'liraglutide', '-', 'in', 'and']","['group', 'placebo', 'treatment']",,,,
1496,1484,"a total of 86.4 % of the patients in the liraglutide group and 66.7 % in the placebo group completed the assigned regimen until week 26 without rescue medication , and 71.2 % and 50.7 % , respectively , completed the assigned regimen until week 52 without rescue medication .",利拉鲁肽组中共有 86.4% 的患者和安慰剂组中有 66.7% 的患者在第 26 周之前完成了指定的治疗方案，并且没有使用救援药物，而分别有 71.2% 和 50.7% 的患者在没有使用救援药物的情况下完成了指定的治疗方案直到第 52 周。,0.6,"['group', 'placebo', 'total', 'medication', 'week', 'liraglutide', 'in', 'and', 'rescue', 'without']","['group', 'placebo', 'week', 'liraglutide', 'and', 'rescue']",1484,"['总共86.4%的利拉格卢蒂德群体和66.7%的 placebo群体在第26周之前没有救援药,71.2%和50.7%分别在第52周之前没有救援药。']",0.3,"['group', 'placebo', 'total', 'medication', 'week', 'liraglutide', 'in', 'and', 'rescue', 'without']","['group', 'week', 'rescue']",1484,总共有86.4%的利拉那韦患者和66.7%的安慰剂组患者完成了26周的治疗方案，分别为71.2%和50.7%的患者完成了52周的治疗方案。,0.3,"['group', 'placebo', 'total', 'medication', 'week', 'liraglutide', 'in', 'and', 'rescue', 'without']","['group', 'placebo', 'week']",,,,
1497,1485,the baseline characteristics were balanced between the two groups ( Table 1 ) .,两组之间的基线特征平衡（表 1）。,1.0,"['table', 'baseline', '1', 'characteristics', 'two']","['table', 'baseline', '1', 'characteristics', 'two']",1485,['基线特征在两组之间均衡(图1)。'],0.8,"['table', 'baseline', '1', 'characteristics', 'two']","['baseline', '1', 'characteristics', 'two']",1485,两组之间的基线特征是平衡的（表1）。,1.0,"['table', 'baseline', '1', 'characteristics', 'two']","['table', 'baseline', '1', 'characteristics', 'two']",,,,
1498,1486,dose ESCALATION PERIOD,剂量递增期,1.0,['dose'],['dose'],1486,['剂量延伸时间'],1.0,['dose'],['dose'],1486,The dose escalation period is the initial phase of a clinical trial in which the doses of a new medication are increased incrementally in order to assess its safety and effectiveness.,0.0,['dose'],[],,,,
1499,1487,"throughout the remainder of the trial , doses in both groups remained relatively stable .",在整个试验的剩余时间里，两组的剂量都保持相对稳定。,0.0,"['trial', 'in']",[],1487,"['在剩余的试验期间,两组的剂量保持相对稳定。']",0.0,"['trial', 'in']",[],1487,在接下来的实验中，两组的剂量相对稳定。,0.0,"['trial', 'in']",[],,,,
1500,1488,most patients did not receive the maximum dose of liraglutide or placebo because fasting plasma glucose levels of 110 mg or less per deciliter were achieved with the lower dose .,大多数患者没有接受最大剂量的利拉鲁肽或安慰剂，因为使用较低剂量可达到 110 mg/dL 或更低的空腹血糖水平。,0.2,"['placebo', 'maximum dose', 'glucose', 'plasma', 'deciliter', 'lower', 'fasting', 'with', 'achieved', 'liraglutide']","['placebo', 'liraglutide']",1488,"['大多数患者没有获得最大剂量的利拉格卢蒂德或<unk>,因为禁食的血糖水平为110毫克或低于每分升,以较低的剂量实现。']",0.1,"['placebo', 'maximum dose', 'glucose', 'plasma', 'deciliter', 'lower', 'fasting', 'with', 'achieved', 'liraglutide']",['lower'],1488,大多数患者都没有接受最大剂量的利拉格蒂德或安慰剂，因为血浆糖水平在每分钟110毫克或者更低时就达到了与较低剂量相当的水平。,0.2,"['placebo', 'maximum dose', 'glucose', 'plasma', 'deciliter', 'lower', 'fasting', 'with', 'achieved', 'liraglutide']","['placebo', 'plasma']",,,,
1501,1489,"only six patients who received liraglutide and four who received placebo were unable to increase the dose , owing to unacceptable side effects .",由于不可接受的副作用，只有 6 名接受利拉鲁肽的患者和 4 名接受安慰剂的患者无法增加剂量。,0.5555555555555556,"['placebo', 'who', 'side effects', 'unacceptable', 'increase', 'liraglutide', 'dose', 'and', 'unable to']","['placebo', 'side effects', 'unacceptable', 'liraglutide', 'dose']",1489,"['只有6名接受Liraglutide的患者和4名接受 placebo的患者无法增加剂量,因为不接受的副作用。']",0.2222222222222222,"['placebo', 'who', 'side effects', 'unacceptable', 'increase', 'liraglutide', 'dose', 'and', 'unable to']","['side effects', 'dose']",1489,"只有6名接受了利拉格达且4名接受了安慰剂的病人无法增加剂量，由于不能忍受的副作用。

Chinese:

只有6名接受了利拉格达药物且4名接受了安慰剂的病人无法增加剂量，由于不能忍受的副作用。",0.3333333333333333,"['placebo', 'who', 'side effects', 'unacceptable', 'increase', 'liraglutide', 'dose', 'and', 'unable to']","['placebo', 'side effects', 'dose']",,,,
1502,1490,this finding showed the superiority of liraglutide to placebo .,这一发现表明利拉鲁肽优于安慰剂。,0.6,"['placebo', 'superiority', 'liraglutide', 'this', 'to']","['placebo', 'liraglutide', 'to']",1490,"['這些發現表明,Liraglutide對 placebo的優越性。']",0.0,"['placebo', 'superiority', 'liraglutide', 'this', 'to']",[],1490,这项发现表明了利拉酮相对于安慰剂的优势。,0.4,"['placebo', 'superiority', 'liraglutide', 'this', 'to']","['placebo', 'to']",,,,
1503,1491,"the estimated treatment difference increased at week 52 ( − 1.30 percentage points ; 95 % CI , − 1.89 to − 0.70 ) ( Figure 2A ) .",估计的治疗差异在第 52 周时增加（- 1.30 个百分点；95% CI，- 1.89 至 - 0.70）（图 2A）。,0.5714285714285714,"['percentage', 'figure', 'difference', 'treatment', 'week', 'CI', 'to']","['figure', 'difference', 'treatment', 'week']",1491,"['估计的治疗差异增加了52周( − 1.30 百分点; 95 % CI, − 1.89 到 − 0.70 )(图 2A )。']",0.5714285714285714,"['percentage', 'figure', 'difference', 'treatment', 'week', 'CI', 'to']","['figure', 'difference', 'treatment', 'week']",1491,在第52周，估计的治疗差异增加了（-1.30个百分点；95%置信区间，-1.89到-0.70）（图2A）。,0.5714285714285714,"['percentage', 'figure', 'difference', 'treatment', 'week', 'CI', 'to']","['figure', 'difference', 'treatment', 'week']",,,,
1504,1492,the superiority of liraglutide to placebo in reducing fasting plasma glucose levels by 26 weeks and by 52 weeks was also shown ( Figure 2B ) .,还显示了利拉鲁肽在降低 26 周和 52 周空腹血糖水平方面优于安慰剂（图 2B）。,0.3,"['placebo', 'glucose', 'plasma', 'figure', 'fasting', 'superiority', 'liraglutide', 'by', 'to', 'and']","['placebo', 'liraglutide', 'to']",1492,"['此外,Liraglutide对禁食血糖水平降低26周和52周的 placebo的优越性也被证明(图2B)。']",0.1,"['placebo', 'glucose', 'plasma', 'figure', 'fasting', 'superiority', 'liraglutide', 'by', 'to', 'and']",['superiority'],1492,在52周的时间里，利拉格利德比安慰剂在降低空腹血糖水平方面的优势也得到了证实（见图2B）。,0.1,"['placebo', 'glucose', 'plasma', 'figure', 'fasting', 'superiority', 'liraglutide', 'by', 'to', 'and']",['placebo'],,,,
1505,1493,"in contrast , the statistical superiority of liraglutide to placebo in lowering the BMI z score was not shown ; the estimated treatment difference at week 26 was − 0.05 ( 95 % CI , − 0.15 to 0.06 ) , which subsequently increased at week 52 to − 0.18 ( 95 % CI , − 0.33 to − 0.03 ) ( Figure 2C ) .",相比之下，利拉鲁肽在降低 BMI z 评分方面优于安慰剂的统计学优势并未显示出来；第 26 周时估计的治疗差异为 − 0.05（95% CI，− 0.15 至 0.06），随后在第 52 周增加至 − 0.18（95% CI，− 0.33 至 − 0.03）（图 2C）。,0.5384615384615384,"['placebo', 'contrast', 'figure', 'BMI', 'difference', 'treatment', 'week', 'superiority', 'score', 'liraglutide', 'lowering', 'CI', 'to']","['placebo', 'figure', 'difference', 'treatment', 'week', 'liraglutide', 'to']",1493,"['相比之下,Liraglutide 对 placebo 的统计优越性在降低 BMI z 分数方面没有显示;26 周的估计治疗差距为 − 0.05 (95 % CI, − 0.15 至 0.06 ),随后在 52 周增加至 − 0.18 ( 95 % CI, − 0.33 至 − 0.03 ) ( 图 2C ) 。']",0.3846153846153846,"['placebo', 'contrast', 'figure', 'BMI', 'difference', 'treatment', 'week', 'superiority', 'score', 'liraglutide', 'lowering', 'CI', 'to']","['figure', 'treatment', 'week', 'superiority', 'score']",1493,相反，利拉地尔对安慰剂在降低BMI z分数方面的统计优势未能显示出来；在第26周估计的治疗差异为-0.05(95%CI，-0.15至0.06)，随后在第52周增加到-0.18(95%CI，-0.33至-0.03)(图2C)。,0.4615384615384615,"['placebo', 'contrast', 'figure', 'BMI', 'difference', 'treatment', 'week', 'superiority', 'score', 'liraglutide', 'lowering', 'CI', 'to']","['placebo', 'figure', 'difference', 'treatment', 'week', 'score']",,,,
1506,1494,"similarly , mean body weight decreased in both groups at week 26 ( − 2.3 kg with liraglutide and − 0.99 kg with placebo ) but was maintained only with liraglutide at week 52 ( − 1.91 kg with liraglutide vs. 0.87 kg with placebo ) .",同样，在第 26 周时，两组的平均体重均有所下降（利拉鲁肽组为 − 2.3 kg，安慰剂组为 − 0.99 kg），但仅在第 52 周时使用利拉鲁肽维持体重（利拉鲁肽组为 − 1.91 kg，安慰剂组为 0.87 kg）。,0.5454545454545454,"['body weight', 'placebo', 'mean', 'week', 'kg', 'with', 'liraglutide', 'at', 'in', 'but', 'and']","['body weight', 'placebo', 'mean', 'week', 'liraglutide', 'but']",1494,"['同样,在26周的两组中,平均体重下降( − 2.3 公斤与Liraglutide和 − 0.99 公斤与Placebo),但仅在52周与Liraglutide保持( − 1.91 公斤与Liraglutide相比 0.87 公斤与Placebo)。']",0.4545454545454545,"['body weight', 'placebo', 'mean', 'week', 'kg', 'with', 'liraglutide', 'at', 'in', 'but', 'and']","['body weight', 'mean', 'week', 'kg', 'but']",1494,"Similarly, both groups' mean body weight decreased at week 26 (-2.3 kg with liraglutide and -0.99 kg with placebo), but was only maintained with liraglutide at week 52 (-1.91 kg with liraglutide vs. 0.87 kg with placebo).",0.0,"['body weight', 'placebo', 'mean', 'week', 'kg', 'with', 'liraglutide', 'at', 'in', 'but', 'and']",[],,,,
1507,1495,"the percentage of patients with adverse events with an onset ( or increase in severity ) on or after the first day of exposure to the trial drug and no later than 7 days after the last day of receipt of the trial drug was similar in the liraglutide and placebo groups ( Table 2 , and Table S5 in the Supplementary Appendix ) .",在暴露于试验药物的第一天或之后以及不迟于接受试验药物的最后一天后 7 天内发生不良事件（或严重程度增加）的患者百分比在利拉鲁肽中相似，并且安慰剂组（补充附录中的表 2 和表 S5）。,0.4761904761904761,"['percentage', 'placebo', 'appendix', 'table', 'exposure', '2', 'supplementary', 'adverse', 'onset', 'no', 'after', 'trial', 'increase', 'with', 'drug', 'liraglutide', 'later', 'to', 'and', 'first', 'similar']","['placebo', 'table', 'exposure', '2', 'after', 'drug', 'liraglutide', 'later', 'to', 'first']",1495,"['试用药物接触的第一天或之后出现(或重度增加)的副作用的患者的百分比,试用药物接收的最后一天后最迟7天,在Liraglutide和Placebo群体中是相似的(图2和附件中的S5表)。']",0.3809523809523809,"['percentage', 'placebo', 'appendix', 'table', 'exposure', '2', 'supplementary', 'adverse', 'onset', 'no', 'after', 'trial', 'increase', 'with', 'drug', 'liraglutide', 'later', 'to', 'and', 'first', 'similar']","['appendix', 'table', '2', 'after', 'drug', 'later', 'first', 'similar']",1495,在服用研究药物的第一天或之后出现不良事件的患者百分比与安慰剂组相似（表2和表S5在补充附录中）。,0.3333333333333333,"['percentage', 'placebo', 'appendix', 'table', 'exposure', '2', 'supplementary', 'adverse', 'onset', 'no', 'after', 'trial', 'increase', 'with', 'drug', 'liraglutide', 'later', 'to', 'and', 'first', 'similar']","['placebo', 'table', '2', 'after', 'drug', 'later', 'first']",,,,
1508,1496,"nausea was the most frequently reported adverse event ( Table 2 ) , and the majority of all adverse events were mild in severity , resolved , and were considered by the investigators to be unrelated to liraglutide or placebo .",恶心是最常报告的不良事件（表 2），所有不良事件中的大多数严重程度较轻，已经解决，并且被研究人员认为与利拉鲁肽或安慰剂无关。,0.4666666666666667,"['placebo', 'table', '2', 'frequently', 'be', 'nausea', 'adverse event', 'majority', 'mild', 'liraglutide', 'all', 'in', 'by', 'to', 'and']","['placebo', 'table', '2', 'nausea', 'adverse event', 'majority', 'liraglutide']",1496,"['恶心是最常见的报告不良事件(图2),大多数所有不良事件是轻度的严重性,解决,并被研究人员认为与 liraglutide 或 placebo 无关。']",0.3333333333333333,"['placebo', 'table', '2', 'frequently', 'be', 'nausea', 'adverse event', 'majority', 'mild', 'liraglutide', 'all', 'in', 'by', 'to', 'and']","['2', 'nausea', 'adverse event', 'majority', 'mild']",1496,nausea是最常见的不良反应（表2），大部分不良反应都是轻度的，可以解决，并被调查人员认为与liraglutide或安慰剂无关。,0.3333333333333333,"['placebo', 'table', '2', 'frequently', 'be', 'nausea', 'adverse event', 'majority', 'mild', 'liraglutide', 'all', 'in', 'by', 'to', 'and']","['placebo', 'table', '2', 'mild', 'by']",,,,
1509,1497,a higher percentage of patients in the liraglutide group than in the placebo group had serious adverse events and medical events of special interest ( Table 2 ) .,与安慰剂组相比，利拉鲁肽组中发生严重不良事件和特殊医学事件的患者比例更高（表 2）。,0.5,"['group', 'percentage', 'placebo', 'table', '2', 'medical', 'adverse', 'liraglutide', 'serious', 'in', 'and', 'special']","['group', 'placebo', 'table', '2', 'liraglutide', 'special']",1497,"['利拉格卢蒂德群体的患者比 placebo群体的患者比例较高,患有严重的副作用和特殊兴趣的医学事件(图2)。']",0.25,"['group', 'percentage', 'placebo', 'table', '2', 'medical', 'adverse', 'liraglutide', 'serious', 'in', 'and', 'special']","['group', '2', 'special']",1497,表2中，liraglutide组的患者相较于安慰剂组的患者，有更高的严重不良事件和特别关注医疗事件的发生率。,0.4166666666666667,"['group', 'percentage', 'placebo', 'table', '2', 'medical', 'adverse', 'liraglutide', 'serious', 'in', 'and', 'special']","['group', 'placebo', 'table', '2', 'special']",,,,
1510,1498,there was no clustering of serious adverse events ( Table S6 in the Supplementary Appendix ) .,没有聚集严重不良事件（补充附录中的表 S6）。,0.1428571428571428,"['appendix', 'clustering', 'table', 'supplementary', 'adverse', 'no', 'serious']",['table'],1498,['没有严重不良事件的分类(附件中的S6表)。'],0.2857142857142857,"['appendix', 'clustering', 'table', 'supplementary', 'adverse', 'no', 'serious']","['appendix', 'table']",1498,没有严重的不良事件的集群（表S6在附加附录）。,0.1428571428571428,"['appendix', 'clustering', 'table', 'supplementary', 'adverse', 'no', 'serious']",['table'],,,,
1511,1499,no deaths were reported .,没有死亡报告。,0.0,['no'],[],1499,['没有死亡报告。'],0.0,['no'],[],1499,No deaths were reported.,0.0,['no'],[],,,,
1512,1500,the percentage of patients who had hypoglycemic episodes and the incidence of hypoglycemia were higher with liraglutide than with placebo ( Table 2 ) .,发生低血糖事件的患者百分比和低血糖发生率在利拉鲁肽组高于安慰剂组（表 2）。,0.4166666666666667,"['percentage', 'placebo', 'incidence', 'table', 'who', 'hypoglycemia', '2', 'episodes', 'with', 'liraglutide', 'hypoglycemic', 'and']","['placebo', 'incidence', 'table', '2', 'liraglutide']",1500,['患有催眠性病毒的患者比例和催眠性病毒的发病率比Liraglutide更高(图2)。'],0.1666666666666666,"['percentage', 'placebo', 'incidence', 'table', 'who', 'hypoglycemia', '2', 'episodes', 'with', 'liraglutide', 'hypoglycemic', 'and']","['incidence', '2']",1500,表2中，使用liraglutide的患者出现低血糖的比例和低血糖的发病率都要高于安慰剂组。,0.3333333333333333,"['percentage', 'placebo', 'incidence', 'table', 'who', 'hypoglycemia', '2', 'episodes', 'with', 'liraglutide', 'hypoglycemic', 'and']","['placebo', 'incidence', 'table', '2']",,,,
1513,1501,"however , lipase levels were higher with liraglutide than with placebo at week 26 ( treatment ratio 1.20 ; 95 % CI , 1.08 to 1.32 ) and at week 52 ( treatment ratio , 1.11 ; 95 % CI , 1.01 to 1.23 ) , whereas amylase levels were similar in the two treatment groups at week 26 and week 52 .",然而，在第 26 周（治疗比率 1.20 ； 95 % CI ， 1.08 至 1.32 ）和第 52 周（治疗比率 1.11 ； 95 % CI ， 1.01 至 1.23 ），利拉鲁肽组的脂肪酶水平高于安慰剂组，而淀粉酶水平为两个治疗组在第 26 周和第 52 周时相似。,0.7142857142857143,"['amylase', 'placebo', 'lipase', 'ratio', 'treatment', 'week', 'with', 'liraglutide', 'CI', 'in', 'to', 'and', 'two', 'similar']","['amylase', 'placebo', 'lipase', 'ratio', 'treatment', 'week', 'liraglutide', 'to', 'and', 'two']",1501,"['然而,利拉格卢蒂德的脂肪含量比26周(治疗比例为1.20、95%的CI、1.08至1.32),52周(治疗比例为1.11、95%的CI、1.01至1.23),而在26周和52周的两组治疗中,氨基酸含量相似。']",0.3571428571428571,"['amylase', 'placebo', 'lipase', 'ratio', 'treatment', 'week', 'with', 'liraglutide', 'CI', 'in', 'to', 'and', 'two', 'similar']","['ratio', 'treatment', 'week', 'and', 'two']",1501,然而，利拉韦特与安慰剂相比，在第26周的脂肪酶水平更高（治疗比1.20；95%CI，1.08至1.32），而在第52周的治疗比（1.11；95%CI，1.01至1.23），但阿米拉酶水平在两组患者在第26周和第52周相似。,0.5,"['amylase', 'placebo', 'lipase', 'ratio', 'treatment', 'week', 'with', 'liraglutide', 'CI', 'in', 'to', 'and', 'two', 'similar']","['placebo', 'lipase', 'ratio', 'treatment', 'week', 'and', 'two']",,,,
1514,1502,"liraglutide also lowered fasting plasma glucose more than placebo , and almost twice as many patients in the liraglutide group than in the placebo group reached glycated hemoglobin levels less than 7.0 % .",利拉鲁肽还比安慰剂更能降低空腹血糖，利拉鲁肽组达到糖化血红蛋白水平低于 7.0% 的患者人数几乎是安慰剂组的两倍。,0.4444444444444444,"['group', 'placebo', 'glucose', 'plasma', 'hemoglobin', 'fasting', 'liraglutide', 'and', 'twice']","['group', 'placebo', 'hemoglobin', 'liraglutide']",1502,"['liraglutide 也降低了禁食的血糖比 placebo 多,而 liraglutide 群体的患者数量比 placebo 群体的患者数量几乎是两倍,血糖血糖水平低于 7.0 % 。']",0.2222222222222222,"['group', 'placebo', 'glucose', 'plasma', 'hemoglobin', 'fasting', 'liraglutide', 'and', 'twice']","['group', 'and']",1502,"liraglutide also lowered fasting plasma glucose more than placebo, and almost twice as many patients in the liraglutide group than in the placebo group reached glycated hemoglobin levels less than 7.0%.

Chinese:

liraglutide降低了空腹血糖，几乎是葡萄糖化血红蛋白水平低于7.0%的患者人数的两倍。",0.2222222222222222,"['group', 'placebo', 'glucose', 'plasma', 'hemoglobin', 'fasting', 'liraglutide', 'and', 'twice']","['glucose', 'hemoglobin']",,,,
1515,1503,"moreover , over the course of 52 weeks , a decrease of 0.50 percentage points in mean glycated hemoglobin levels was observed with liraglutide , whereas an increase of 0.80 percentage points was observed with placebo - an increase similar to previously reported changes in glycated hemoglobin levels observed over 12 months in youth with type 2 diabetes treated with metformin with or without insulin.14,15","此外，在52周的过程中，观察到利拉鲁肽的平均糖化血红蛋白水平下降了0.50个百分点，而安慰剂组则增加了0.80个百分点——这种增加与之前报道的糖化血红蛋白水平的变化相似。使用二甲双胍联合或不联合胰岛素治疗的 2 型糖尿病青年 12 个月。 14,15",0.6111111111111112,"['diabetes', 'percentage', 'type', 'placebo', 'decrease', 'mean', '2', 'hemoglobin', 'youth', 'course', 'increase', 'liraglutide', 'metformin', '-', 'over', 'to', 'without', 'similar']","['diabetes', 'type', 'placebo', 'mean', '2', 'hemoglobin', 'youth', 'course', 'liraglutide', 'metformin', 'over']",1503,"['此外,在52周内,利拉格卢蒂德的平均血糖水平下降了0.50个百分点,而在 placebo中出现了0.80个百分点的增加,类似于12个月以上的青少年患有2型糖尿病的血糖水平的变化。']",0.2777777777777778,"['diabetes', 'percentage', 'type', 'placebo', 'decrease', 'mean', '2', 'hemoglobin', 'youth', 'course', 'increase', 'liraglutide', 'metformin', '-', 'over', 'to', 'without', 'similar']","['diabetes', 'type', 'mean', '2', 'to']",1503,"此外，在52周的治疗过程中，平均糖化血红蛋白水平在使用利拉多巴的患者中出现了0.50个百分点的降低，而在使用安慰剂的患者中则出现了0.80个百分点的升高，这与在使用了服用了二甲双胍或者二甲双胍加胰岛素治疗12个月的2型糖尿病青少年观察到的糖化血红蛋白水平的变化相似。14,15",0.5,"['diabetes', 'percentage', 'type', 'placebo', 'decrease', 'mean', '2', 'hemoglobin', 'youth', 'course', 'increase', 'liraglutide', 'metformin', '-', 'over', 'to', 'without', 'similar']","['diabetes', 'type', 'placebo', 'mean', '2', 'hemoglobin', 'course', 'metformin', 'over']",,,,
1516,1504,"an unexpected finding of this trial was the lack of difference between the groups in BMI z score or body weight at week 26 , a finding that differs from the results of trials in adults.16,17","该试验的一个意外发现是第 26 周时各组之间的 BMI z 评分或体重没有差异，这一发现不同于成人试验的结果。 16,17",0.4,"['body weight', 'lack', 'BMI', 'difference', 'week', 'trial', 'score', 'this', 'that', 'in']","['body weight', 'difference', 'week', 'this']",1504,"['这项试验的一个意想不到的发现是26周的BMI z分数或体重组之间的差异不足,与成人试验结果不同。']",0.5,"['body weight', 'lack', 'BMI', 'difference', 'week', 'trial', 'score', 'this', 'that', 'in']","['body weight', 'difference', 'week', 'score', 'this']",1504,"这项实验的一个意外发现是，在26周时，两组在BMI指数或体重上没有差异，这与成人实验结果不同。16,17",0.4,"['body weight', 'lack', 'BMI', 'difference', 'week', 'trial', 'score', 'this', 'that', 'in']","['body weight', 'difference', 'week', 'this']",,,,
1517,1505,"although the mean difference in weight loss between these treatment groups was similar to that in trials involving adults , 16,17 the relatively small number of patients in the current study and the fact that some children were probably still growing may explain the findings .","虽然这些治疗组之间体重减轻的平均差异与涉及成人的试验中的相似，16,17 但当前研究中的患者数量相对较少以及一些儿童可能仍在生长的事实可能解释了这些发现。",0.3846153846153846,"['mean', 'study', 'difference', 'still', 'treatment', 'number', 'current', 'weight loss', 'that', 'in', 'to', 'and', 'similar']","['mean', 'difference', 'treatment', 'number', 'in']",1505,"['虽然这些治疗组之间的体重减肥的平均差异类似于涉及成年人的研究,但目前研究中的患者数量相对较小,以及某些儿童可能仍然成长的事实,可以解释这些发现。']",0.3846153846153846,"['mean', 'study', 'difference', 'still', 'treatment', 'number', 'current', 'weight loss', 'that', 'in', 'to', 'and', 'similar']","['mean', 'difference', 'treatment', 'number', 'to']",1505,"尽管这些治疗组之间的体重损失平均差异与成人实验相似，16,17 但目前研究中患者数量相对较少，有些儿童可能仍在生长，这可以解释这些结果。",0.3076923076923077,"['mean', 'study', 'difference', 'still', 'treatment', 'number', 'current', 'weight loss', 'that', 'in', 'to', 'and', 'similar']","['mean', 'difference', 'treatment', 'number']",,,,
1518,1506,another explanation may be the fact that only approximately 50 % of the liraglutide group received the full dose of 1.8 mg per day during the trial .,另一种解释可能是，在试验期间，只有大约 50% 的利拉鲁肽组接受了每天 1.8 mg 的全剂量。,0.4444444444444444,"['group', 'be', 'trial', 'explanation', 'liraglutide', 'dose', 'full', 'approximately', 'that']","['group', 'be', 'liraglutide', 'dose']",1506,"['另一个解释可能是,只有大约50%的利拉格卢蒂德群体在试验期间获得了每日1.8毫克的完整剂量。']",0.4444444444444444,"['group', 'be', 'trial', 'explanation', 'liraglutide', 'dose', 'full', 'approximately', 'that']","['group', 'be', 'dose', 'full']",1506,另一个解释可能是只有大约50%的利拉格辛组在试验期间接受了每天1.8mg的全剂量。,0.3333333333333333,"['group', 'be', 'trial', 'explanation', 'liraglutide', 'dose', 'full', 'approximately', 'that']","['group', 'be', 'dose']",,,,
1519,1507,"as was the case in studies involving adults with type 2 diabetes , 16,17 mild gastrointestinal complaints were the main cause of increased rates of adverse events with liraglutide .","与涉及成人 2 型糖尿病的研究一样，16,17 轻度胃肠道不适是利拉鲁肽不良事件发生率增加的主要原因。",0.7,"['diabetes', 'type', '2', 'gastrointestinal', 'adverse', 'cause', 'case', 'with', 'mild', 'liraglutide']","['diabetes', 'type', '2', 'gastrointestinal', 'cause', 'mild', 'liraglutide']",1507,"['在涉及2型糖尿病的成年人研究中,1617个轻微的肠道投诉是利拉格卢蒂德的副作用增加率的主要原因。']",0.4,"['diabetes', 'type', '2', 'gastrointestinal', 'adverse', 'cause', 'case', 'with', 'mild', 'liraglutide']","['diabetes', 'type', '2', 'cause']",1507,"就像在涉及成年人的2型糖尿病研究中一样，16,17轻度肠胃不适是导致利拉格肽不良事件增加率的主要原因。",0.5,"['diabetes', 'type', '2', 'gastrointestinal', 'adverse', 'cause', 'case', 'with', 'mild', 'liraglutide']","['diabetes', 'type', '2', 'cause', 'mild']",,,,
1520,1508,"the observed incidence of hypoglycemia in the liraglutide group was low as compared with the previously reported incidence of clinically important hypoglycemia in youth with type 1 diabetes , 18,19 and many of the reported hypoglycemic episodes were due to low plasma glucose levels , without any symptoms .","在利拉鲁肽组观察到的低血糖发生率低于先前报道的 1 型糖尿病青年临床重要低血糖发生率， 18,19 并且许多报道的低血糖事件是由于血浆葡萄糖水平低，没有任何症状。 .",0.5882352941176471,"['group', 'diabetes', 'type', 'incidence', 'glucose', 'plasma', 'hypoglycemia', '1', 'symptoms', 'low', 'episodes', 'youth', 'due', 'liraglutide', 'hypoglycemic', 'and', 'without']","['group', 'diabetes', 'type', 'incidence', 'glucose', 'plasma', '1', 'low', 'youth', 'liraglutide']",1508,"['在利拉格卢蒂德群体中观察到的催眠症的发病率低于与患有1型糖尿病的青少年临床重要催眠症的发病率相比,18、19和许多报告的催眠症的发病率是由于低血糖水平,没有任何症状。']",0.3529411764705882,"['group', 'diabetes', 'type', 'incidence', 'glucose', 'plasma', 'hypoglycemia', '1', 'symptoms', 'low', 'episodes', 'youth', 'due', 'liraglutide', 'hypoglycemic', 'and', 'without']","['group', 'diabetes', 'type', 'incidence', '1', 'low']",1508,"观察到的低血糖发生率在利拉格蒂德组中较之前报告的1型糖尿病青年人群的临床重要低血糖发生率较低，18,19许多报告的低血糖发作都是由于血浆低血糖水平引起的，没有任何症状。",0.5294117647058824,"['group', 'diabetes', 'type', 'incidence', 'glucose', 'plasma', 'hypoglycemia', '1', 'symptoms', 'low', 'episodes', 'youth', 'due', 'liraglutide', 'hypoglycemic', 'and', 'without']","['group', 'diabetes', 'type', 'incidence', 'plasma', '1', 'low', 'episodes', 'youth']",,,,
1521,1509,the fact that approximately half the patients did not receive the highest dose may have limited data collection related to the safety profile of liraglutide .,大约一半的患者没有接受最高剂量这一事实可能限制了与利拉鲁肽安全性相关的数据收集。,0.5454545454545454,"['safety', 'half', 'profile', 'data collection', 'liraglutide', 'dose', 'limited', 'have', 'approximately', 'that', 'to']","['safety', 'half', 'data collection', 'liraglutide', 'dose', 'have']",1509,"['事实上,大约一半的患者没有获得最高剂量,可能有与利拉格卢蒂德的安全性相关的有限数据收集。']",0.4545454545454545,"['safety', 'half', 'profile', 'data collection', 'liraglutide', 'dose', 'limited', 'have', 'approximately', 'that', 'to']","['safety', 'half', 'data collection', 'dose', 'have']",1509,约半数的病人没有接受最高剂量，这可能会限制与利拉酮安全性相关的数据收集。,0.4545454545454545,"['safety', 'half', 'profile', 'data collection', 'liraglutide', 'dose', 'limited', 'have', 'approximately', 'that', 'to']","['safety', 'half', 'data collection', 'dose', 'have']",,,,
1522,1510,"the trial was also limited by the long recruitment period ( owing to problems inherent in clinical trials of youth with type 2 diabetes2 ) , which necessitated some protocol amendments .",该试验还受到招募期长的限制（由于 2 型糖尿病青年临床试验中固有的问题2），这需要对方案进行一些修正。,0.5833333333333334,"['type', 'period', 'inherent', '2', 'protocol', 'recruitment', 'clinical', 'trial', 'youth', 'with', 'limited', 'by']","['type', 'period', 'inherent', '2', 'clinical', 'youth', 'by']",1510,"['审查也受到长期招聘期限的限制(由于患有2型糖尿病的青少年临床试验中存在的问题),这需要一些议定书修正案。']",0.5,"['type', 'period', 'inherent', '2', 'protocol', 'recruitment', 'clinical', 'trial', 'youth', 'with', 'limited', 'by']","['type', 'period', '2', 'protocol', 'clinical', 'by']",1510,该试验还受到了招募期限制（由于与2型糖尿病青少年临床试验相关的问题），这需要对协议进行一些修订。,0.5,"['type', 'period', 'inherent', '2', 'protocol', 'recruitment', 'clinical', 'trial', 'youth', 'with', 'limited', 'by']","['type', 'period', '2', 'protocol', 'clinical', 'by']",,,,
1523,1511,"in addition , because of the somewhat limited diversity of the trial population , the results may not be generalizable to all other populations .",此外，由于试验人群的多样性有限，结果可能无法推广到所有其他人群。,0.3333333333333333,"['diversity', 'population', 'addition', 'be', 'trial', 'limited', 'all', 'in', 'to']","['diversity', 'population', 'to']",1511,"['除此之外,由于试验人口的多样性略有有限,结果可能对所有其他人口都无法普遍化。']",0.3333333333333333,"['diversity', 'population', 'addition', 'be', 'trial', 'limited', 'all', 'in', 'to']","['diversity', 'population', 'to']",1511,"In addition, because the trial population was somewhat limited in diversity, the results may not be generalizable to all other populations.",0.0,"['diversity', 'population', 'addition', 'be', 'trial', 'limited', 'all', 'in', 'to']",[],,,,
1524,1512,"in summary , the current study showed the superiority of liraglutide to placebo , when added to metformin , with or without basal insulin , with respect to glycemic control in children and adolescents .",总而言之，当前的研究表明，在儿童和青少年的血糖控制方面，利拉鲁肽在添加到二甲双胍（有或没有基础胰岛素）时优于安慰剂。,0.6153846153846154,"['insulin', 'placebo', 'basal', 'control', 'study', 'superiority', 'current', 'respect', 'liraglutide', 'metformin', 'to', 'and', 'without']","['insulin', 'placebo', 'control', 'current', 'liraglutide', 'metformin', 'to', 'and']",1512,"['总而言之,目前的研究表明,当添加到甲状腺素时,利拉格卢蒂德对 placebo的优越性,与基因胰岛素或没有,与儿童和青少年的血糖控制有关。']",0.3076923076923077,"['insulin', 'placebo', 'basal', 'control', 'study', 'superiority', 'current', 'respect', 'liraglutide', 'metformin', 'to', 'and', 'without']","['insulin', 'control', 'superiority', 'and']",1512,总之，本研究表明，当liraglutide与胰岛素一起使用时，其比对照药物占优势，无论是否需要基础胰岛素，都可以显著改善儿童和青少年的血糖控制。,0.2307692307692307,"['insulin', 'placebo', 'basal', 'control', 'study', 'superiority', 'current', 'respect', 'liraglutide', 'metformin', 'to', 'and', 'without']","['insulin', 'control', 'without']",,,,
1525,1513,gastrointestinal adverse events were more common in the liraglutide group .,胃肠道不良事件在利拉鲁肽组更为常见。,0.6,"['group', 'gastrointestinal', 'common', 'adverse', 'liraglutide']","['group', 'gastrointestinal', 'liraglutide']",1513,['胃肠不良事件在Liraglutide群体中更常见。'],0.4,"['group', 'gastrointestinal', 'common', 'adverse', 'liraglutide']","['group', 'gastrointestinal']",1513,"Gastrointestinal adverse events were more common in the liraglutide group.

Chinese:
胃肠道不良事件在利拉格利德组中更常见。",0.4,"['group', 'gastrointestinal', 'common', 'adverse', 'liraglutide']","['group', 'gastrointestinal']",,,,
1526,1514,"male sex , older age , mutations in MLH1 or MSH2 , and family history are associated with increased risk .",男性、年龄较大、MLH1 或 MSH2 突变以及家族史与风险增加有关。,0.5555555555555556,"['sex', 'male', 'family history', 'associated', 'age', 'risk', 'with', 'in', 'and']","['sex', 'male', 'family history', 'age', 'risk']",1514,['男性性别、老年、MLH1或MSH2的突变和家庭史与风险增加有关。'],0.3333333333333333,"['sex', 'male', 'family history', 'associated', 'age', 'risk', 'with', 'in', 'and']","['sex', 'male', 'risk']",1514,男性性别、年龄较大、MLH1或MSH2突变以及家族史均与风险增加相关。,0.5555555555555556,"['sex', 'male', 'family history', 'associated', 'age', 'risk', 'with', 'in', 'and']","['sex', 'male', 'family history', 'age', 'risk']",,,,
1527,1515,the cumulative risk for gastric cancer in patients with Lynch syndrome ( LS ) is estimated to be 7 % to 8 % .,林奇综合征 (LS) 患者患胃癌的累积风险估计为 7% 至 8%。,0.375,"['syndrome', 'be', 'cumulative', 'risk', 'with', 'gastric cancer', 'in', 'to']","['syndrome', 'risk', 'gastric cancer']",1515,"['在患有林奇综合征(LS)的患者中,胃癌的累积风险估计为7%至8%。']",0.5,"['syndrome', 'be', 'cumulative', 'risk', 'with', 'gastric cancer', 'in', 'to']","['syndrome', 'be', 'risk', 'gastric cancer']",1515,患有林奇综合征（LS）的患者胃癌的累计风险估计为7%至8%。,0.375,"['syndrome', 'be', 'cumulative', 'risk', 'with', 'gastric cancer', 'in', 'to']","['syndrome', 'risk', 'gastric cancer']",,,,
1528,1516,"however , there are sparse data regarding risk factors and the impact of screening on patient outcomes , resulting in disparate guideline recommendations .",然而，关于风险因素和筛查对患者结果的影响的数据很少，导致指南建议各不相同。,0.7,"['data', 'sparse', 'screening', 'regarding', 'impact', 'risk', 'disparate', 'patient', 'on', 'and']","['data', 'screening', 'regarding', 'impact', 'risk', 'patient', 'and']",1516,"['然而,关于风险因素和筛查对患者结果的影响的数据差不多,导致不同的指导方针建议。']",0.8,"['data', 'sparse', 'screening', 'regarding', 'impact', 'risk', 'disparate', 'patient', 'on', 'and']","['data', 'screening', 'regarding', 'impact', 'risk', 'disparate', 'patient', 'and']",1516,然而，有关风险因素和筛查对患者结局的影响的数据很少，导致指南建议不一致。,0.7,"['data', 'sparse', 'screening', 'regarding', 'impact', 'risk', 'disparate', 'patient', 'on', 'and']","['data', 'screening', 'regarding', 'impact', 'risk', 'patient', 'and']",,,,
1529,1517,clinical and family histories were obtained by referring providers .,临床和家族史是通过转诊提供者获得的。,0.5,"['family', 'clinical', 'by', 'and']","['family', 'clinical']",1517,['临床和家庭史由参考供应商获取。'],0.75,"['family', 'clinical', 'by', 'and']","['family', 'clinical', 'by']",1517,提供者参考了临床和家庭史。,0.5,"['family', 'clinical', 'by', 'and']","['family', 'clinical']",,,,
1530,1518,"in multivariate analysis , the following factors were associated with gastric cancer :",在多变量分析中，以下因素与胃癌有关：,0.4,"['associated', 'multivariate analysis', 'with', 'gastric cancer', 'following']","['multivariate analysis', 'gastric cancer']",1518,"['在多元化分析中,以下因素与胃癌有关:']",0.2,"['associated', 'multivariate analysis', 'with', 'gastric cancer', 'following']",['gastric cancer'],1518,在多元分析中，与胃癌相关的因素有：,0.4,"['associated', 'multivariate analysis', 'with', 'gastric cancer', 'following']","['multivariate analysis', 'gastric cancer']",,,,
1531,1519,"male sex ( odds ratio , 2.8 )",男性（比值比，2.8）,0.75,"['sex', 'ratio', 'male', 'odds']","['sex', 'ratio', 'male']",1519,"['男性性别(比率,2.8 )']",0.75,"['sex', 'ratio', 'male', 'odds']","['sex', 'ratio', 'male']",1519,"male sex ( odds ratio , 2.8 )

Chinese:

男性（几率比，2.8）",1.0,"['sex', 'ratio', 'male', 'odds']","['sex', 'ratio', 'male', 'odds']",,,,
1532,1520,"older age ( OR , 2.1 per 10 years )",年龄较大（或，每 10 年 2.1）,0.5,"['age', 'OR']",['age'],1520,"['老年人(或,每 10 年 2.1 )']",0.0,"['age', 'OR']",[],1520,随着年龄增长（或者说，每10年增加2.1岁），,0.5,"['age', 'OR']",['age'],,,,
1533,1521,"mutations in MLH1 ( OR , 6.5 ) or MSH2 ( OR , 5.2 ) compared with mutations in MSH6 , PMS2 , or EPCAM","MLH1 ( OR , 6.5 ) 或 MSH2 ( OR , 5.2 ) 突变与 MSH6 、 PMS2 或 EPCAM 突变相比较",0.0,"['OR', 'with', 'in']",[],1521,['MLH1(OR、6.5)或MSH2(OR、5.2)的突变与MSH6、PMS2或EPCAM的突变相比'],0.0,"['OR', 'with', 'in']",[],1521,"Mutations in MLH1 (OR, 6.5) or MSH2 (OR, 5.2) are associated with a higher risk of cancer compared to mutations in MSH6, PMS2, or EPCAM.",0.0,"['OR', 'with', 'in']",[],,,,
1534,1522,"although the concept of tailoring LS screening recommendations is not new , most of the available evidence has pertained to colorectal cancer , with less focus on rarer but potentially highly lethal malignancies .",尽管定制 LS 筛查建议的概念并不新鲜，但大多数可用证据都与结直肠癌有关，较少关注更罕见但可能具有高致命性的恶性肿瘤。,0.4545454545454545,"['focus', 'screening', 'lethal', 'colorectal cancer', 'available', 'evidence', 'concept', 'with', 'but', 'to', 'new']","['screening', 'evidence', 'concept', 'but', 'new']",1522,"['虽然调整 LS 筛查建议的概念并不新鲜,但大多数可用的证据都涉及到染色性癌症,重点较少的是更罕见但潜在的致命恶性疾病。']",0.5454545454545454,"['focus', 'screening', 'lethal', 'colorectal cancer', 'available', 'evidence', 'concept', 'with', 'but', 'to', 'new']","['screening', 'available', 'evidence', 'concept', 'but', 'new']",1522,虽然定制化的晚期筛查建议的概念并不新鲜，但是大多数现有的证据都与大肠癌有关，而对于较少见但潜在高致死性的恶性肿瘤的关注度则较低。,0.5454545454545454,"['focus', 'screening', 'lethal', 'colorectal cancer', 'available', 'evidence', 'concept', 'with', 'but', 'to', 'new']","['screening', 'evidence', 'concept', 'but', 'to', 'new']",,,,
1535,1523,other studies have also identified Asian ancestry as a risk factor for gastric cancer in LS .,其他研究也已将亚洲血统确定为 LS 胃癌的危险因素。,0.25,"['risk factor', 'gastric cancer', 'have', 'in']",['gastric cancer'],1523,['其他研究还确定了亚洲祖先作为胃癌的风险因素。'],0.5,"['risk factor', 'gastric cancer', 'have', 'in']","['risk factor', 'gastric cancer']",1523,其他研究也发现亚洲血统是LS胃癌的风险因素。,0.5,"['risk factor', 'gastric cancer', 'have', 'in']","['risk factor', 'gastric cancer']",,,,
1536,1524,"the presence of one or more of these factors should mandate endoscopic screening and regular surveillance , although the frequency of the latter requires additional prospective study .",这些因素中的一种或多种的存在应该要求进行内镜筛查和定期监测，尽管后者的频率需要额外的前瞻性研究。,0.75,"['presence', 'frequency', 'screening', 'prospective study', 'surveillance', 'regular', 'additional', 'and']","['presence', 'frequency', 'screening', 'prospective study', 'surveillance', 'additional']",1524,"['其中一个或多个因素的存在应要求进行内分泌筛查和定期监测,尽管其频率需要进一步的预期研究。']",0.5,"['presence', 'frequency', 'screening', 'prospective study', 'surveillance', 'regular', 'additional', 'and']","['presence', 'frequency', 'screening', 'surveillance']",1524,如果存在一个或多个这些因素，应该强制进行内窥镜检查和定期监测，尽管后者的频率需要进一步的前瞻性研究。,0.5,"['presence', 'frequency', 'screening', 'prospective study', 'surveillance', 'regular', 'additional', 'and']","['presence', 'frequency', 'prospective study', 'surveillance']",,,,
1537,1525,new evidence indicates that smoking cessation might blunt risk for developing RA .,新的证据表明，戒烟可能会降低患 RA 的风险。,0.5,"['developing', 'risk', 'smoking cessation', 'evidence', 'blunt', 'RA', 'that', 'new']","['risk', 'smoking cessation', 'evidence', 'new']",1525,"['新的证据表明,戒烟可能会导致 RA 发育的风险。']",0.5,"['developing', 'risk', 'smoking cessation', 'evidence', 'blunt', 'RA', 'that', 'new']","['risk', 'smoking cessation', 'evidence', 'new']",1525,新的证据表明，戒烟可能会减少患强直性关节炎的风险。,0.5,"['developing', 'risk', 'smoking cessation', 'evidence', 'blunt', 'RA', 'that', 'new']","['risk', 'smoking cessation', 'evidence', 'new']",,,,
1538,1526,"previous epidemiologic studies have demonstrated that cigarette smoking is an important risk factor for rheumatoid arthritis ( RA ) , especially seropositive RA .",以往的流行病学研究表明，吸烟是类风湿性关节炎（RA），尤其是血清阳性RA的重要危险因素。,0.3333333333333333,"['demonstrated', 'previous', 'cigarette', 'seropositive', 'risk factor', 'RA', 'rheumatoid arthritis', 'have', 'that']","['demonstrated', 'RA', 'rheumatoid arthritis']",1526,"['以前的流行病学研究表明,吸烟是 rheumatoid arthritis (RA ) 的重要风险因素,尤其是血清积极的RA。']",0.3333333333333333,"['demonstrated', 'previous', 'cigarette', 'seropositive', 'risk factor', 'RA', 'rheumatoid arthritis', 'have', 'that']","['demonstrated', 'previous', 'risk factor']",1526,以往的流行病学研究表明，吸烟是引起风湿性关节炎（RA）的重要风险因素，尤其是血清阳性RA。,0.2222222222222222,"['demonstrated', 'previous', 'cigarette', 'seropositive', 'risk factor', 'RA', 'rheumatoid arthritis', 'have', 'that']","['demonstrated', 'risk factor']",,,,
1539,1527,"however , whether smoking cessation lowers risk for developing RA is unclear .",然而，戒烟是否会降低患 RA 的风险尚不清楚。,0.5,"['developing', 'risk', 'smoking cessation', 'RA']","['risk', 'smoking cessation']",1527,"['然而,是否戒烟会降低 RA 发育的风险是不清楚的。']",0.5,"['developing', 'risk', 'smoking cessation', 'RA']","['risk', 'smoking cessation']",1527,然而，目前尚不清楚戒烟是否会降低患强直性关节炎的风险。,0.5,"['developing', 'risk', 'smoking cessation', 'RA']","['risk', 'smoking cessation']",,,,
1540,1528,"between 1976 and 2015 , 1528 new cases of RA ( 63 % seropositive ) were identified in 230,000 women .","1976 年至 2015 年间，在 230,000 名女性中发现了 1528 例新的类风湿性关节炎病例（63% 为血清阳性）。",0.4,"['seropositive', 'RA', 'in', 'and', 'new']","['RA', 'new']",1528,"['在1976年至2015年间,在230,000名妇女中发现了1528例新病例(63%)。']",0.2,"['seropositive', 'RA', 'in', 'and', 'new']",['new'],1528,"在1976年至2015年期间，在230,000名女性中被确诊出1528例新的RA（63%为抗体阳性）。",0.2,"['seropositive', 'RA', 'in', 'and', 'new']",['new'],,,,
1541,1529,"compared with never smoking , current smoking significantly raised risk for all RA and seropositive RA .",与从不吸烟相比，当前吸烟会显着增加所有 RA 和血清阳性 RA 的风险。,0.125,"['seropositive', 'risk', 'raised', 'current', 'with', 'RA', 'all', 'and']",['risk'],1529,"['与从未吸烟相比,目前的吸烟对所有 RA 和 seropositive RA 的风险显著增加。']",0.125,"['seropositive', 'risk', 'raised', 'current', 'with', 'RA', 'all', 'and']",['risk'],1529,与从未吸烟相比，目前吸烟显著增加了所有RA和血清阳性RA的风险。,0.125,"['seropositive', 'risk', 'raised', 'current', 'with', 'RA', 'all', 'and']",['risk'],,,,
1542,1530,"however , compared with risk in never smokers , risk for all RA and seropositive RA remained slightly elevated in former smokers , even those who had stopped the longest .",然而，与从不吸烟者的风险相比，所有 RA 和血清阳性 RA 的风险在前吸烟者中仍然略有升高，即使是那些戒烟时间最长的人。,0.2222222222222222,"['who', 'seropositive', 'former', 'risk', 'with', 'RA', 'all', 'in', 'and']","['risk', 'and']",1530,"['然而,与从未吸烟者的风险相比,所有 RA 和血清积极的 RA 的风险在以前的吸烟者中仍然稍微上升,即使是那些最长时间停止过的吸烟者。']",0.2222222222222222,"['who', 'seropositive', 'former', 'risk', 'with', 'RA', 'all', 'in', 'and']","['risk', 'and']",1530,然而，与从未吸烟者相比，所有RA和阳性RA的风险在经历过吸烟者身上仍略有升高，即使是已经停止吸烟很久的人。,0.2222222222222222,"['who', 'seropositive', 'former', 'risk', 'with', 'RA', 'all', 'in', 'and']","['risk', 'and']",,,,
1543,1531,this study adds to our understanding of RA development .,这项研究增加了我们对 RA 发展的理解。,0.2,"['study', 'development', 'RA', 'this', 'to']",['development'],1531,['这项研究增加了我们对RA发展的理解。'],0.2,"['study', 'development', 'RA', 'this', 'to']",['development'],1531,这项研究增加了我们对RA发展的了解。,0.2,"['study', 'development', 'RA', 'this', 'to']",['development'],,,,
1544,1532,"in previously treated patients with FGFR alterations , the response rate with erdafitinib was 40 % .",在既往接受过 FGFR 改变治疗的患者中，erdafitinib 的缓解率为 40%。,0.0,"['response rate', 'with', 'in']",[],1532,"['在患有FGFR变异的患者中,对Erdafitinib的反应率为40%。']",0.3333333333333333,"['response rate', 'with', 'in']",['response rate'],1532,在以前接受过治疗的FGFR突变患者中，erdafitinib的疗效率为40%。,0.0,"['response rate', 'with', 'in']",[],,,,
1545,1533,"among the 99 patients assigned to the optimal dose group ( 8 mg / day escalated to 9 mg / day ) , the confirmed response rate ( the primary endpoint ) was 40 % ; an additional 39 % achieved stable disease .",在分配到最佳剂量组（8 毫克/天增加到 9 毫克/天）的 99 名患者中，确认的反应率（主要终点）为 40%；另有 39% 的患者病情稳定。,0.3636363636363636,"['group', 'disease', '/', 'primary', 'optimal', 'additional', 'response rate', 'achieved', 'endpoint', 'dose', 'to']","['group', 'disease', 'response rate', 'dose']",1533,"['在99名患者中,被分配到最佳剂量组(8 mg / 日升至9 mg / 日),确认的反应率(初级终点)为40%;额外的39%实现了稳定的疾病。']",0.4545454545454545,"['group', 'disease', '/', 'primary', 'optimal', 'additional', 'response rate', 'achieved', 'endpoint', 'dose', 'to']","['group', 'disease', 'additional', 'response rate', 'dose']",1533,"在99名病人中，被分配到最佳剂量组（8毫克/天逐步升至9毫克/天）的病人中，已确认的反应率（主要终点）为40％；另外39％的病人达到了稳定疾病状态。

Chinese:

在99名病人中，被分配到最佳剂量组（8毫克/天逐步升至9毫克/天）的病人中，已确认的反应率（主要终点）为40％；另外39％的病人达到了稳定疾病状态。",0.3636363636363636,"['group', 'disease', '/', 'primary', 'optimal', 'additional', 'response rate', 'achieved', 'endpoint', 'dose', 'to']","['group', 'disease', 'response rate', 'dose']",,,,
1546,1534,response rates were similar regardless of prior therapy or of the presence or absence of visceral metastases .,无论先前的治疗或是否存在内脏转移，反应率都是相似的。,0.7142857142857143,"['presence', 'therapy', 'visceral', 'absence', 'response', 'prior', 'similar']","['presence', 'therapy', 'response', 'prior', 'similar']",1534,"['答案率是相似的,无论是预先治疗或存在或缺席的阴道转移。']",0.5714285714285714,"['presence', 'therapy', 'visceral', 'absence', 'response', 'prior', 'similar']","['presence', 'therapy', 'absence', 'similar']",1534,"regardless of prior therapy or of the presence or absence of visceral metastases, response rates were similar.",0.0,"['presence', 'therapy', 'visceral', 'absence', 'response', 'prior', 'similar']",[],,,,
1547,1535,response rates were 49 % in the 74 patients with FGFR mutations and 16 % in the 25 with FGFR fusions .,74 名 FGFR 突变患者的反应率为 49%，25 名 FGFR 融合患者的反应率为 16%。,0.25,"['response', 'with', 'in', 'and']",['response'],1535,"['答案率为74名患有FGFR突变的患者中49%,25名患有FGFR合并的患者中16%。']",0.0,"['response', 'with', 'in', 'and']",[],1535,突變的FGFR患者的回應率為49％，而FGFR融合的患者的回應率為16％。,0.25,"['response', 'with', 'in', 'and']",['and'],,,,
1548,1536,"in the 22 patients with prior CPI therapy , the response rate was 59 % .",在 22 名既往接受过 CPI 治疗的患者中，反应率为 59%。,0.4,"['therapy', 'prior', 'response rate', 'with', 'in']","['therapy', 'response rate']",1536,"['在22名患有先前CPI治疗的患者中,反应率为59%。']",0.6,"['therapy', 'prior', 'response rate', 'with', 'in']","['therapy', 'prior', 'response rate']",1536,在22位病人之中，有59%的人对CPI疗法有所反应。,0.2,"['therapy', 'prior', 'response rate', 'with', 'in']",['therapy'],,,,
1549,1537,"on the basis of this study , erdafitinib was granted FDA approval for patients with selected FGFR mutations .",在此研究的基础上，erdafitinib 被 FDA 批准用于具有特定 FGFR 突变的患者。,0.1428571428571428,"['approval', 'study', 'basis', 'FDA', 'with', 'on', 'this']",['approval'],1537,"['基于这项研究,Erdafitinib被授予FDA批准的患者与选择的FGFR突变。']",0.1428571428571428,"['approval', 'study', 'basis', 'FDA', 'with', 'on', 'this']",['approval'],1537,根据这项研究，艾尔达菲替尼获得了FDA批准，可用于FGFR突变位点筛选的患者。,0.1428571428571428,"['approval', 'study', 'basis', 'FDA', 'with', 'on', 'this']",['approval'],,,,
1550,1538,"although erdafitinib may be an important development for patients with advanced urothelial cancer , a number of issues remain .",尽管 erdafitinib 可能是晚期尿路上皮癌患者的一项重要进展，但仍存在许多问题。,0.2,"['cancer', 'number', 'advanced', 'development', 'with']",['cancer'],1538,"['虽然 erdafitinib 可能是患有先进的尿道癌的患者的重要发展,但仍然存在一些问题。']",0.4,"['cancer', 'number', 'advanced', 'development', 'with']","['cancer', 'development']",1538,尽管erdafitinib可能是患有先进的尿路上皮癌患者的一项重要进展，但仍存在一些问题。,0.2,"['cancer', 'number', 'advanced', 'development', 'with']",['cancer'],,,,
1551,1539,"more than 60 % of pneumonias were due to viruses , predominantly respiratory syncytial virus ; the most common bacterial causes were Streptococcus pneumoniae , Haemophilus influenzae , and Mycobacterium tuberculosis .",超过 60% 的肺炎是由病毒引起的，主要是呼吸道合胞病毒；最常见的细菌性病因是肺炎链球菌、流感嗜血杆菌和结核分枝杆菌。,0.4285714285714285,"['mycobacterium tuberculosis', 'respiratory syncytial virus', 'haemophilus influenzae', 'common', 'streptococcus pneumoniae', 'due', 'and']","['mycobacterium tuberculosis', 'haemophilus influenzae', 'streptococcus pneumoniae']",1539,"['超过60%的肺炎是由于病毒,主要是呼吸合成病毒;最常见的细菌原因是Streptococcus pneumoniae,Haemophilus influenzae,和Mycobacterium tuberculosis。']",0.0,"['mycobacterium tuberculosis', 'respiratory syncytial virus', 'haemophilus influenzae', 'common', 'streptococcus pneumoniae', 'due', 'and']",[],1539,超过60%的肺炎是由病毒引起的，主要是由呼吸道同步病毒引起的；最常见的细菌病因是肺炎链球菌、流感嗜血杆菌和结核分枝杆菌。,0.4285714285714285,"['mycobacterium tuberculosis', 'respiratory syncytial virus', 'haemophilus influenzae', 'common', 'streptococcus pneumoniae', 'due', 'and']","['mycobacterium tuberculosis', 'haemophilus influenzae', 'streptococcus pneumoniae']",,,,
1552,1540,"Haemophilus influenzae type B vaccine was routinely used in most sites , pneumococcal conjugate vaccine in about half .",大多数场所常规使用B型流感嗜血杆菌疫苗，约一半使用肺炎球菌结合疫苗。,1.0,"['conjugate', 'half', 'haemophilus influenzae type B', 'vaccine']","['conjugate', 'half', 'haemophilus influenzae type B', 'vaccine']",1540,"['Haemophilus influenzae 型 B 疫苗在大多数地方常用,肺结核疫苗在大约一半。']",0.5,"['conjugate', 'half', 'haemophilus influenzae type B', 'vaccine']","['half', 'vaccine']",1540,大多数地方经常使用流感嗜血杆菌B疫苗，大约一半使用肺炎球菌结合菌疫苗。,0.75,"['conjugate', 'half', 'haemophilus influenzae type B', 'vaccine']","['conjugate', 'half', 'vaccine']",,,,
1553,1541,Streptococcus pneumoniae was the most common bacterial cause ; it caused more than one third of very severe pneumonia cases .,肺炎链球菌是最常见的细菌性病因；它引起了三分之一以上的非常严重的肺炎病例。,0.2,"['common', 'cause', 'streptococcus pneumoniae', 'severe', 'third']",['streptococcus pneumoniae'],1541,['Streptococcus pneumoniae 是最常见的细菌原因;它导致超过三分之一的非常严重的肺炎病例。'],0.2,"['common', 'cause', 'streptococcus pneumoniae', 'severe', 'third']",['cause'],1541,斯氏肺炎桿菌是最常見的細菌原因；它造成了超過三分之一的嚴重肺炎病例。,0.2,"['common', 'cause', 'streptococcus pneumoniae', 'severe', 'third']",['cause'],,,,
1554,1542,"among all pathogens , respiratory syncytial virus ( RSV ) accounted for the most cases ( 31 % ) .",在所有病原体中，呼吸道合胞病毒（RSV）占病例数最多（31%）。,0.3333333333333333,"['RSV', 'respiratory syncytial virus', 'all']",['RSV'],1542,"['在所有病原体中,呼吸合成病毒(RSV)是最常见的病例(31%)。']",0.0,"['RSV', 'respiratory syncytial virus', 'all']",[],1542,在所有病原体中，呼吸道合胞病毒（RSV）占了最多的病例（31%）。,0.3333333333333333,"['RSV', 'respiratory syncytial virus', 'all']",['RSV'],,,,
1555,1543,prevalence of pneumonia and predominant causes varied widely by age and geographic location .,肺炎的患病率和主要原因因年龄和地理位置而异。,0.4444444444444444,"['location', 'prevalence', 'age', 'geographic', 'predominant', 'pneumonia', 'by', 'and', 'varied']","['location', 'age', 'pneumonia', 'and']",1543,['肺炎的发病率和主要原因因年龄和地理位置而异。'],0.4444444444444444,"['location', 'prevalence', 'age', 'geographic', 'predominant', 'pneumonia', 'by', 'and', 'varied']","['location', 'age', 'pneumonia', 'and']",1543,地理位置和年龄不同，肺炎的发病率和主要原因差异很大。,0.3333333333333333,"['location', 'prevalence', 'age', 'geographic', 'predominant', 'pneumonia', 'by', 'and', 'varied']","['location', 'age', 'pneumonia']",,,,
1556,1544,TEN pathogens together accounted for about 80 % of the cases .,十种病原体合计约占病例的80%。,,[],[],1544,['TEN病原体共占约80%的病例。'],,[],[],1544,Ten pathogens accounted for about 80% of the cases.,,[],[],,,,
1557,1545,"of the case pathogens , vaccines exist for 14 % .",在病原体的情况下，疫苗存在的比例为 14%。,0.5,"['case', 'exist']",['exist'],1545,"['在病原体的情况下,疫苗存在14%。']",0.5,"['case', 'exist']",['exist'],1545,14% of pathogens have vaccines.,0.0,"['case', 'exist']",[],,,,
1558,1546,"the low number of common pathogens identified should allow more targeted development of interventions , including vaccines .",查明的常见病原体数量很少，应该可以更有针对性地开发干预措施，包括疫苗。,0.2,"['targeted', 'allow', 'common', 'number', 'development']",['number'],1546,"['发现的常见病原体数量较低,应允许更有针对性的干预,包括疫苗。']",0.4,"['targeted', 'allow', 'common', 'number', 'development']","['allow', 'number']",1546,经过分析，科学家们发现目前常见病原体数量较少，这应当使得针对性的干预措施（包括疫苗）的开发更加容易。,0.2,"['targeted', 'allow', 'common', 'number', 'development']",['number'],,,,
1559,1547,RSV should be a primary target ; this study clearly documents the key role of RSV in serious respiratory infections .,RSV 应该是主要目标；这项研究清楚地记录了 RSV 在严重呼吸道感染中的关键作用。,0.4545454545454545,"['key', 'RSV', 'respiratory', 'study', 'be', 'role', 'primary', 'target', 'serious', 'this', 'in']","['key', 'be', 'role', 'target', 'this']",1547,['RSV应该是主要目标;这项研究清楚地证明了RSV在严重的呼吸道感染中的关键作用。'],0.4545454545454545,"['key', 'RSV', 'respiratory', 'study', 'be', 'role', 'primary', 'target', 'serious', 'this', 'in']","['key', 'be', 'role', 'target', 'this']",1547,RSV应该是首要目标，这项研究明确记录了RSV在严重呼吸道感染中的关键作用。,0.4545454545454545,"['key', 'RSV', 'respiratory', 'study', 'be', 'role', 'primary', 'target', 'serious', 'this', 'in']","['key', 'be', 'role', 'target', 'this']",,,,
1560,1548,"in addition to wider use of existing vaccines , other strategies to reduce the burden of respiratory infections include exclusive breastfeeding , better nutrition , and protection from indoor air pollution .",除了更广泛地使用现有疫苗外，其他减轻呼吸道感染负担的策略包括纯母乳喂养、更好的营养和防止室内空气污染。,0.2727272727272727,"['air pollution', 'nutrition', 'protection', 'reduce', 'addition', 'respiratory', 'indoor', 'exclusive', 'breastfeeding', 'and', 'burden']","['air pollution', 'nutrition', 'breastfeeding']",1548,"['除了广泛使用现有疫苗之外,减少呼吸道感染的负担的其他策略还包括独家哺乳、营养和防室空气污染的保护。']",0.2727272727272727,"['air pollution', 'nutrition', 'protection', 'reduce', 'addition', 'respiratory', 'indoor', 'exclusive', 'breastfeeding', 'and', 'burden']","['air pollution', 'nutrition', 'protection']",1548,除了更广泛使用现有疫苗之外，减轻呼吸道感染负担的其他策略还包括专注于母乳喂养、改善营养和保护室内空气污染。,0.3636363636363636,"['air pollution', 'nutrition', 'protection', 'reduce', 'addition', 'respiratory', 'indoor', 'exclusive', 'breastfeeding', 'and', 'burden']","['air pollution', 'nutrition', 'protection', 'breastfeeding']",,,,
1561,1549,"as an editorialist notes , given high percentage of cases caused by viruses , strategies should be implemented to limit antibiotic use for viral infections .",正如一位社论所指出的那样，鉴于病毒引起的病例比例很高，应实施策略以限制抗生素在病毒感染中的使用。,0.7777777777777778,"['percentage', 'antibiotic', 'be', 'viral', 'limit', 'as', 'by', 'to', 'high']","['antibiotic', 'be', 'limit', 'as', 'by', 'to', 'high']",1549,"['作为编辑的注意事项,考虑到病毒引起的病例的比例很高,应实施限制抗生素对病毒感染的使用策略。']",0.3333333333333333,"['percentage', 'antibiotic', 'be', 'viral', 'limit', 'as', 'by', 'to', 'high']","['antibiotic', 'limit', 'high']",1549,"As an editorialist notes, given the high percentage of cases caused by viruses, strategies should be implemented to limit antibiotic use for viral infections.

Chinese:

正如一位社论作家指出的，鉴于病毒引起的病例数量很高，应该实施战略来限制使用抗生素治疗病毒感染。",0.5555555555555556,"['percentage', 'antibiotic', 'be', 'viral', 'limit', 'as', 'by', 'to', 'high']","['antibiotic', 'limit', 'as', 'to', 'high']",,,,
1562,1550,CRC risk associated with nonadvanced adenomas or small serrated polyps is no different than having no polyps .,与非晚期腺瘤或小锯齿状息肉相关的 CRC 风险与没有息肉没有什么不同。,0.2,"['serrated', 'associated', 'no', 'risk', 'with']",['risk'],1550,['与不先进的肾上腺素或小粘膜聚合物相关的CRC风险与没有聚合物没有不同。'],0.2,"['serrated', 'associated', 'no', 'risk', 'with']",['risk'],1550,"CRC risk associated with nonadvanced adenomas or small serrated polyps is no different than having no polyps.

Chinese:

患有非先进性腺瘤或小型锯齿形肿瘤与没有肿瘤的风险相同。",0.2,"['serrated', 'associated', 'no', 'risk', 'with']",['risk'],,,,
1563,1551,surveillance colonoscopy for colorectal cancer ( CRC ) is recommended at intervals determined by the most advanced lesions at baseline examinations .,建议根据基线检查时最晚期病变确定的时间间隔对结直肠癌 (CRC) 进行监测结肠镜检查。,0.375,"['baseline', 'colorectal cancer', 'surveillance', 'examinations', 'advanced', 'by', 'intervals', 'colonoscopy']","['baseline', 'surveillance', 'colonoscopy']",1551,['对染色性癌症(CRC)的监测科隆斯科建议在基线检查中最先进的伤害确定的间隔进行。'],0.25,"['baseline', 'colorectal cancer', 'surveillance', 'examinations', 'advanced', 'by', 'intervals', 'colonoscopy']","['baseline', 'surveillance']",1551,晚期结肠直肠癌 (CRC) 的监视性结肠镜检查建议间隔由基线检查中最先发现的病变决定。,0.5,"['baseline', 'colorectal cancer', 'surveillance', 'examinations', 'advanced', 'by', 'intervals', 'colonoscopy']","['baseline', 'colorectal cancer', 'by', 'colonoscopy']",,,,
1564,1552,"nonadvanced adenomas : aHR , 1.21 ; P = 0.52",非晚期腺瘤：aHR，1.21； P = 0.52,0.0,['P'],[],1552,"['未进展的肾上腺素 : aHR, 1.21 ; P = 0.52']",0.0,['P'],[],1552,"nonadvanced adenomas: aHR, 1.21; P = 0.52

Chinese:

非先进腺瘤：aHR，1.21；P = 0.52",0.0,['P'],[],,,,
1565,1553,"any serrated polyp : aHR , 1.52 ; P = 0.05",任何锯齿状息肉：aHR，1.52； P = 0.05,0.3333333333333333,"['polyp', 'serrated', 'P']",['polyp'],1553,"['任何粘膜聚合物 : aHR, 1.52 ; P = 0.05']",0.0,"['polyp', 'serrated', 'P']",[],1553,"any serrated polyp: aHR, 1.52; P = 0.05",0.0,"['polyp', 'serrated', 'P']",[],,,,
1566,1554,"large serrated polyps ( ≥ 10 mm ) : aHR , 3.35 ; P = 0.008",大锯齿状息肉（≥10 毫米）：aHR，3.35； P = 0.008,0.0,"['large', 'serrated', 'P']",[],1554,"['大粘膜聚合物( ≥ 10 毫米 ) : aHR, 3.35 ; P = 0.008']",0.0,"['large', 'serrated', 'P']",[],1554,"large serrated polyps ( ≥ 10 mm ): aHR, 3.35; P = 0.008

Chinese:

大型锯齿状肿瘤 ( ≥ 10 毫米 ): 危险比 , 3.35 ; P = 0.008",0.0,"['large', 'serrated', 'P']",[],,,,
1567,1555,"however , the most notable findings in this study pertain to the much more prevalent nonadvanced adenomas and small serrated polyps , for which metachronous CRC risks were not significantly different than having no polyps at baseline .",然而，这项研究中最值得注意的发现与更普遍的非晚期腺瘤和小锯齿状息肉有关，对于这些，异时性 CRC 风险与基线时没有息肉没有显着差异。,0.375,"['baseline', 'study', 'serrated', 'no', 'prevalent', 'this', 'to', 'and']","['baseline', 'to', 'and']",1555,"['然而,这项研究中最显著的发现属于更常见的非先进的肾上腺素和小细胞聚合物,对这些聚合物的甲状腺疾病风险并不大不同于没有聚合物在基线上。']",0.375,"['baseline', 'study', 'serrated', 'no', 'prevalent', 'this', 'to', 'and']","['baseline', 'to', 'and']",1555,然而，在这项研究中最值得注意的发现是关于更多经常出现的非进展性腺瘤和小锯齿状腺瘤的风险，对于后者而言，复发直肠癌的风险并不显著高于基线没有腺瘤的风险。,0.5,"['baseline', 'study', 'serrated', 'no', 'prevalent', 'this', 'to', 'and']","['baseline', 'this', 'to', 'and']",,,,
1568,1556,identifying predictive markers would allow for enhanced treatment protocols for these infants .,确定预测标记将有助于加强对这些婴儿的治疗方案。,0.3333333333333333,"['allow', 'treatment', 'predictive']",['treatment'],1556,['识别预测标记将允许这些婴儿的增强治疗协议。'],0.6666666666666666,"['allow', 'treatment', 'predictive']","['allow', 'treatment']",1556,如果能够确定预测性标志，就能为这些婴儿增强治疗方案。,0.3333333333333333,"['allow', 'treatment', 'predictive']",['treatment'],,,,
1569,1557,"in a secondary analysis of data from the Multicenter Airway Research Collaboration , researchers assessed the association between serum albumin level and apnea in 1016 infants ( median age , 3 months ) hospitalized with bronchiolitis and without confounding heart and lung conditions .",在对来自多中心气道研究协作组织的数据进行的二次分析中，研究人员评估了 1016 名因毛细支气管炎住院且没有混杂心肺疾病的婴儿（中位年龄，3 个月）的血清白蛋白水平与呼吸暂停之间的关联。,0.6111111111111112,"['heart', 'lung', 'research', 'apnea', 'data', 'serum albumin', 'analysis', 'association', 'bronchiolitis', 'airway', 'secondary', '3', 'level', 'collaboration', 'median age', 'and', 'without', 'assessed']","['heart', 'lung', 'research', 'apnea', 'data', 'serum albumin', 'analysis', 'association', 'bronchiolitis', 'airway', 'level']",1557,"['在Multicenter Airway Research Collaboration的数据的次要分析中,研究人员评估了1016名婴儿(中年3个月)患有 bronchiolitis和没有混乱的心脏和肺部疾病的血清阿尔博丁水平和<unk>疹之间的联系。']",0.3888888888888889,"['heart', 'lung', 'research', 'apnea', 'data', 'serum albumin', 'analysis', 'association', 'bronchiolitis', 'airway', 'secondary', '3', 'level', 'collaboration', 'median age', 'and', 'without', 'assessed']","['heart', 'lung', 'research', 'data', 'analysis', 'association', 'level']",1557,在一项对1016名带有支气管炎并且没有心脏和肺部并发症的婴儿的数据的二次分析中，研究人员评估了血清白蛋白水平与呼吸暂停的关联。这些婴儿的平均年龄为3个月。,0.5,"['heart', 'lung', 'research', 'apnea', 'data', 'serum albumin', 'analysis', 'association', 'bronchiolitis', 'airway', 'secondary', '3', 'level', 'collaboration', 'median age', 'and', 'without', 'assessed']","['heart', 'lung', 'research', 'apnea', 'data', 'serum albumin', 'analysis', 'association', 'level']",,,,
1570,1558,apnea occurred in 25 infants during hospitalization and in 44 infants before but not during hospitalization .,25 名婴儿在住院期间发生呼吸暂停，44 名婴儿在住院前但未在住院期间发生。,0.6666666666666666,"['apnea', 'hospitalization', 'before', 'in', 'but', 'and']","['apnea', 'hospitalization', 'before', 'but']",1558,"['在入院期间的25名婴儿和在入院前的44名婴儿中,但在入院期间没有出现失眠。']",0.3333333333333333,"['apnea', 'hospitalization', 'before', 'in', 'but', 'and']","['before', 'but']",1558,在住院期间有25个婴儿出现呼吸暂停，而在住院前有44个婴儿出现呼吸暂停但是住院期间没有。,0.8333333333333334,"['apnea', 'hospitalization', 'before', 'in', 'but', 'and']","['apnea', 'hospitalization', 'before', 'but', 'and']",,,,
1571,1559,among the findings :,其中的调查结果：,,[],[],1559,['在这些发现中:'],,[],[],1559,在这些发现中：,,[],[],,,,
1572,1559,among the findings :,其中的调查结果：,,[],[],1559,['在这些发现中:'],,[],[],1559,在这些发现中：,,[],[],,,,
1573,1560,"among the 25 infants with apnea during hospitalization , the median serum albumin level was 3.5 g / dL and 22 infants ( 88 % ) had low levels .",住院期间出现呼吸暂停的25例患儿血清白蛋白中位值为3.5 g/dL，22例(88%)低。,0.5,"['median', 'apnea', 'serum albumin', '/', 'hospitalization', 'low', 'level', 'with', 'and', 'g']","['median', 'apnea', 'serum albumin', 'hospitalization', 'low']",1560,"['在入院期间患有腹泻的25名婴儿中,中间血清 albumin 水平为 3.5 g / dL,22名婴儿(88%) 水平低。']",0.2,"['median', 'apnea', 'serum albumin', '/', 'hospitalization', 'low', 'level', 'with', 'and', 'g']","['low', 'level']",1560,在住院期间出现呼吸性窒息的25名婴儿中，血清白蛋白水平的中位数为3.5 g/dL，22名婴儿（88％）血清白蛋白水平偏低。,0.5,"['median', 'apnea', 'serum albumin', '/', 'hospitalization', 'low', 'level', 'with', 'and', 'g']","['apnea', 'serum albumin', 'hospitalization', 'low', 'level']",,,,
1574,1561,overall prevalence of apnea was 5.7 % in infants with low albumin versus 0.5 % in those with normal albumin .,低白蛋白婴儿的呼吸暂停总患病率为 5.7%，而白蛋白正常的婴儿为 0.5%。,0.6666666666666666,"['albumin', 'apnea', 'prevalence', 'normal', 'low', 'with']","['albumin', 'apnea', 'normal', 'low']",1561,['一般腹泻的发病率在低 albumin 婴儿中为 5.7% 与正常 albumin 婴儿中为 0.5%.'],0.1666666666666666,"['albumin', 'apnea', 'prevalence', 'normal', 'low', 'with']",['low'],1561,总体阻塞性睡眠呼吸暂停率在低盐水蛋白含量婴儿中为5.7%，而在正常水蛋白含量婴儿中为0.5%。,0.3333333333333333,"['albumin', 'apnea', 'prevalence', 'normal', 'low', 'with']","['apnea', 'low']",,,,
1575,1562,"low albumin was significantly associated with apnea ( odds ratio , 12.7 ) .",低白蛋白与呼吸暂停显着相关（比值比，12.7）。,0.5714285714285714,"['albumin', 'apnea', 'ratio', 'associated', 'low', 'with', 'odds']","['albumin', 'apnea', 'ratio', 'low']",1562,"['低 albumin 与 apnea ( odds ratio, 12.7 ) 显著相关。']",0.1428571428571428,"['albumin', 'apnea', 'ratio', 'associated', 'low', 'with', 'odds']",['low'],1562,低蛋白质与呼吸暂停显著相关（危险比为12.7）。,0.4285714285714285,"['albumin', 'apnea', 'ratio', 'associated', 'low', 'with', 'odds']","['apnea', 'ratio', 'low']",,,,
1576,1563,"younger age , preterm birth , and low weight for age also were associated with apnea .",年龄较小、早产和年龄体重偏低也与呼吸暂停有关。,0.5,"['weight', 'apnea', 'birth', 'associated', 'low', 'age', 'with', 'and']","['weight', 'apnea', 'low', 'age']",1563,['年轻的年龄、早产和年龄较低的体重也与失眠有关。'],0.375,"['weight', 'apnea', 'birth', 'associated', 'low', 'age', 'with', 'and']","['weight', 'low', 'age']",1563,年轻年龄、早产和低体重年龄也与呼吸暂停相关联。,0.5,"['weight', 'apnea', 'birth', 'associated', 'low', 'age', 'with', 'and']","['weight', 'apnea', 'low', 'age']",,,,
1577,1564,"after adjustment for the above risk factors , low serum albumin remained statistically associated with apnea ( OR , 4.4 ) .","调整上述危险因素后，低血清白蛋白与呼吸暂停仍存在统计学相关性 (OR, 4.4)。",0.5555555555555556,"['apnea', 'serum albumin', 'adjustment', 'associated', 'low', 'risk', 'after', 'OR', 'with']","['apnea', 'serum albumin', 'low', 'risk', 'after']",1564,"['在对上述风险因素进行调整后,低血清阿尔博丁仍然与<unk>症统计相关( OR, 4.4)。']",0.3333333333333333,"['apnea', 'serum albumin', 'adjustment', 'associated', 'low', 'risk', 'after', 'OR', 'with']","['low', 'risk', 'after']",1564,经过上述风险因素的调整，低血清白蛋白仍与呼吸暂停相关（OR，4.4）。,0.4444444444444444,"['apnea', 'serum albumin', 'adjustment', 'associated', 'low', 'risk', 'after', 'OR', 'with']","['apnea', 'serum albumin', 'low', 'risk']",,,,
1578,1565,risk for apnea was similar in infants with and without respiratory syncytial virus infection .,感染和未感染呼吸道合胞病毒的婴儿发生呼吸暂停的风险相似。,0.2857142857142857,"['apnea', 'respiratory syncytial virus', 'virus infection', 'risk', 'and', 'without', 'similar']","['apnea', 'risk']",1565,['患失眠的风险类似于患有和没有呼吸道合成病毒感染的婴儿。'],0.2857142857142857,"['apnea', 'respiratory syncytial virus', 'virus infection', 'risk', 'and', 'without', 'similar']","['virus infection', 'risk']",1565,窒息风险在感染了呼吸道同步肌病毒的婴儿和未感染的婴儿之间相似。,0.2857142857142857,"['apnea', 'respiratory syncytial virus', 'virus infection', 'risk', 'and', 'without', 'similar']","['apnea', 'risk']",,,,
1579,1566,"low serum albumin seems to be another warning sign for apnea risk in infants with bronchiolitis , along with prematurity and low weight for age .",低血清白蛋白似乎是毛细支气管炎婴儿呼吸暂停风险的另一个警告信号，以及早产和低体重。,0.5333333333333333,"['weight', 'apnea', 'serum albumin', 'sign', 'bronchiolitis', 'warning', 'be', 'low', 'prematurity', 'along', 'age', 'risk', 'with', 'to', 'and']","['weight', 'apnea', 'serum albumin', 'sign', 'bronchiolitis', 'warning', 'low', 'risk']",1566,"['低血清 albumin 似乎是另一个警告信号,在患有 bronchiolitis 的婴儿中患有<unk>疹的风险,以及早产和年龄较低的体重。']",0.4666666666666667,"['weight', 'apnea', 'serum albumin', 'sign', 'bronchiolitis', 'warning', 'be', 'low', 'prematurity', 'along', 'age', 'risk', 'with', 'to', 'and']","['weight', 'sign', 'warning', 'be', 'low', 'age', 'risk']",1566,低血清白蛋白似乎是婴儿支气管炎的另一个预警信号，除了早产和体重低于年龄之外。,0.4,"['weight', 'apnea', 'serum albumin', 'sign', 'bronchiolitis', 'warning', 'be', 'low', 'prematurity', 'along', 'age', 'risk', 'with', 'to', 'and']","['weight', 'serum albumin', 'sign', 'low', 'age', 'to']",,,,
1580,1567,"however , unfortunately the sensitivity of low serum albumin for predicting apnea is not great , as most children with low levels did not develop apnea .",然而，不幸的是，低血清白蛋白预测呼吸暂停的敏感性并不高，因为大多数低水平的儿童没有发生呼吸暂停。,0.5,"['apnea', 'serum albumin', 'develop', 'low', 'as', 'with', 'sensitivity', 'great']","['apnea', 'serum albumin', 'low', 'great']",1567,"['然而,不幸的是,低血清阿尔博丁对预测腹泻的敏感性并不大,因为大多数低水平的儿童没有发育腹泻。']",0.25,"['apnea', 'serum albumin', 'develop', 'low', 'as', 'with', 'sensitivity', 'great']","['low', 'great']",1567,然而，不幸的是，低血清白蛋白对预测呼吸暂停的敏感性并不大，因为大多数血清水平低的儿童并未发展出呼吸暂停。,0.5,"['apnea', 'serum albumin', 'develop', 'low', 'as', 'with', 'sensitivity', 'great']","['apnea', 'serum albumin', 'low', 'great']",,,,
1581,1568,the authors ( and I ) do not recommend routine monitoring of albumin in infants with bronchiolitis based on this study .,基于这项研究，作者（和我）不建议对患有毛细支气管炎的婴儿进行白蛋白的常规监测。,0.5,"['monitoring', 'albumin', 'bronchiolitis', 'routine', 'study', 'recommend', 'with', 'I', 'this', 'and']","['monitoring', 'albumin', 'bronchiolitis', 'routine', 'recommend']",1568,"['作者(和我)不建议基于这项研究,在患有 bronchiolitis 的婴儿中定期监测阿尔博明。']",0.2,"['monitoring', 'albumin', 'bronchiolitis', 'routine', 'study', 'recommend', 'with', 'I', 'this', 'and']","['monitoring', 'recommend']",1568,"the authors ( and I ) do not recommend routine monitoring of albumin in infants with bronchiolitis based on this study .

Chinese:

根据这项研究，作者（和我）不推荐对患有小儿支气管炎的婴儿进行常规监测。",0.3,"['monitoring', 'albumin', 'bronchiolitis', 'routine', 'study', 'recommend', 'with', 'I', 'this', 'and']","['monitoring', 'routine', 'recommend']",,,,
1582,1569,sponsoring Organization : British Society of Gastroenterology,主办机构：英国胃肠病学会,0.6666666666666666,"['organization', 'society', 'gastroenterology']","['society', 'gastroenterology']",1569,['赞助组织:英国胃肠道学协会'],0.6666666666666666,"['organization', 'society', 'gastroenterology']","['organization', 'society']",1569,赞助机构：英国胃肠病学会,0.6666666666666666,"['organization', 'society', 'gastroenterology']","['society', 'gastroenterology']",,,,
1583,1570,IEE is also the most accurate imaging modality for diagnosing and staging gastric dysplasia and early cancer .,IEE 也是诊断和分期胃发育不良和早期癌症的最准确的成像方式。,0.4285714285714285,"['gastric', 'accurate', 'dysplasia', 'modality', 'early cancer', 'imaging', 'and']","['accurate', 'dysplasia', 'early cancer']",1570,"['IEE 也是最准确的图像模式,用于诊断和预测胃 dysplasia 和早期癌症。']",0.2857142857142857,"['gastric', 'accurate', 'dysplasia', 'modality', 'early cancer', 'imaging', 'and']","['accurate', 'early cancer']",1570,"IEE is also the most accurate imaging modality for diagnosing and staging gastric dysplasia and early cancer.

Chinese:

IEE是诊断胃畸形和早期癌症最准确的成像模式。",0.2857142857142857,"['gastric', 'accurate', 'dysplasia', 'modality', 'early cancer', 'imaging', 'and']","['accurate', 'early cancer']",,,,
1584,1571,grade the location and extent of AG and GIM as distal gastric ( affecting antrum or incisura ; low risk ) or proximal gastric ( affecting the body with or without the antrum and incisura ; high risk ) .,将 AG 和 GIM 的位置和范围分级为远端胃（影响胃窦或切迹；低风险）或近端胃（影响有或没有胃窦和切迹的身体；高风险）。,0.5,"['antrum', 'gastric', 'grade', 'high risk', 'location', 'proximal', 'distal', 'low', 'extent', 'body', 'and', 'without']","['antrum', 'location', 'proximal', 'distal', 'low', 'body']",1571,['等級 AG 和 GIM 的位置和範圍為 distal gastric (影響 antrum 或 incisura ; 低風險 ) 或 proximal gastric (影響身體與或沒有 antrum 和 incisura ; 高風險 ) 。'],0.1666666666666666,"['antrum', 'gastric', 'grade', 'high risk', 'location', 'proximal', 'distal', 'low', 'extent', 'body', 'and', 'without']","['location', 'low']",1571,将AG和GIM的位置和范围评级为远端胃（影响胃或锥口；低风险）或近端胃（影响体或锥口；高风险）。,0.3333333333333333,"['antrum', 'gastric', 'grade', 'high risk', 'location', 'proximal', 'distal', 'low', 'extent', 'body', 'and', 'without']","['location', 'proximal', 'distal', 'low']",,,,
1585,1572,"perform endoscopic surveillance every 3 years in patients diagnosed with extensive AG or GIM ( i.e. , affecting the antrum and body ) , but not in patients with AG or GIM limited to the antrum ( unless there is a strong family history of gastric adenocarcinoma or persistent Helicobacter pylori ) .",对诊断为广泛 AG 或 GIM（即影响胃窦和身体）的患者每 3 年进行一次内窥镜监测，但对局限于胃窦的 AG 或 GIM 患者不进行（除非有胃腺癌或持续性幽门螺杆菌的强烈家族史幽门螺杆菌）。,0.5384615384615384,"['antrum', 'persistent', 'helicobacter', 'family history', 'strong', 'surveillance', 'gastric adenocarcinoma', '3', 'body', 'with', 'limited', 'but', 'and']","['antrum', 'family history', 'strong', 'surveillance', 'gastric adenocarcinoma', 'body', 'but']",1572,"['每3年进行内分泌监测,在患有广泛的 AG 或 GIM 诊断的患者(即影响 antrum 和 身体),但不限于 antrum 的 AG 或 GIM 患者(除非有强烈的胃肾癌病史或持久的 Helicobacter pylori )。']",0.3076923076923077,"['antrum', 'persistent', 'helicobacter', 'family history', 'strong', 'surveillance', 'gastric adenocarcinoma', '3', 'body', 'with', 'limited', 'but', 'and']","['strong', 'surveillance', 'body', 'but']",1572,诊断出广泛性AG或GIM（即影响胃黏膜下腺及胃体）的病人，每3年进行内窥镜监测，但对仅影响胃黏膜下腺的病人则不进行（除非有家族史或H. pylori的持续存在强烈家族史）。,0.3846153846153846,"['antrum', 'persistent', 'helicobacter', 'family history', 'strong', 'surveillance', 'gastric adenocarcinoma', '3', 'body', 'with', 'limited', 'but', 'and']","['family history', 'strong', 'surveillance', 'body', 'but']",,,,
1586,1573,sponsoring Organization : American Academy of Pediatrics and American Academy of Obstetricians and Gynecologists ( ACOG ),主办机构：美国儿科学会和美国妇产科医师学会 (ACOG),0.25,"['organization', 'pediatrics', 'academy', 'and']",['pediatrics'],1573,['赞助组织:美国儿科学院和美国妇科医学家和妇科医学家学院(ACOG)'],0.5,"['organization', 'pediatrics', 'academy', 'and']","['organization', 'pediatrics']",1573,美国儿科学会和美国妇产科学会赞助机构：,0.25,"['organization', 'pediatrics', 'academy', 'and']",['pediatrics'],,,,
1587,1574,guidelines to reduce neonatal infection with Group B Streptococcus ( GBS ) were first developed in 1996 and were most recently revised and updated in 2010 .,减少新生儿 B 型链球菌 (GBS) 感染的指南于 1996 年首次制定，最近一次修订和更新是在 2010 年。,0.1428571428571428,"['infection', 'neonatal', 'reduce', 'with', 'group B streptococcus', 'and', 'first']",['infection'],1574,"['针对减少新生儿B型Streptococcus(GBS)感染的指导方针于1996年首次开发,并于2010年最近修订和更新。']",0.1428571428571428,"['infection', 'neonatal', 'reduce', 'with', 'group B streptococcus', 'and', 'first']",['infection'],1574,1996年首先制定了减少新生儿感染Group B Streptococcus（GBS）的指南，最近于2010年进行了修订和更新。,0.2857142857142857,"['infection', 'neonatal', 'reduce', 'with', 'group B streptococcus', 'and', 'first']","['infection', 'first']",,,,
1588,1575,the current update is based on a review of epidemiology and practice standards .,目前的更新是基于对流行病学和实践标准的审查。,0.6666666666666666,"['epidemiology', 'review', 'practice', 'current', 'on', 'and']","['epidemiology', 'review', 'practice', 'current']",1575,['目前的更新是基于流行病学和实践标准的审查。'],0.6666666666666666,"['epidemiology', 'review', 'practice', 'current', 'on', 'and']","['epidemiology', 'review', 'practice', 'current']",1575,当前的更新是基于对流行病学和实践标准的审查。,0.6666666666666666,"['epidemiology', 'review', 'practice', 'current', 'on', 'and']","['epidemiology', 'review', 'practice', 'current']",,,,
1589,1576,key Findings and Recommendations,主要发现和建议,0.0,"['key', 'and']",[],1576,['关键结论和建议'],0.5,"['key', 'and']",['key'],1576,"主要发现和建议

Chinese:

主要发现和建议",0.0,"['key', 'and']",[],,,,
1590,1577,intrapartum antibiotic prophylaxis is recommended for all women with positive screening cultures .,建议所有筛查培养阳性的妇女在产时预防性使用抗生素。,0.5,"['cultures', 'antibiotic', 'screening', 'prophylaxis', 'intrapartum', 'with', 'positive', 'all']","['antibiotic', 'screening', 'prophylaxis', 'intrapartum']",1577,['生育内抗生素预防是推荐给所有有积极的筛查文化的女性。'],0.375,"['cultures', 'antibiotic', 'screening', 'prophylaxis', 'intrapartum', 'with', 'positive', 'all']","['antibiotic', 'screening', 'prophylaxis']",1577,"intrapartum antibiotic prophylaxis is recommended for all women with positive screening cultures.

Chinese:

妇女如果筛查出阳性，建议她们在分娩期间都使用抗生素预防措施。",0.375,"['cultures', 'antibiotic', 'screening', 'prophylaxis', 'intrapartum', 'with', 'positive', 'all']","['antibiotic', 'screening', 'prophylaxis']",,,,
1591,1578,this detailed document reviews updated epidemiology of neonatal GBS disease and provides guidance for the management of both pregnant women and infants with signs of sepsis in the newborn period .,这份详细的文件回顾了新生儿 GBS 疾病的最新流行病学，并为新生儿期有败血症迹象的孕妇和婴儿的管理提供了指导。,0.3571428571428571,"['epidemiology', 'period', 'disease', 'neonatal', 'newborn', 'sepsis', 'document', 'signs', 'management', 'with', 'this', 'in', 'and', 'guidance']","['epidemiology', 'period', 'disease', 'sepsis', 'management']",1578,"['这份详细的文件评论更新了新生儿GBS疾病的流行病学,并提供了对怀孕妇女和婴儿在新生儿期间塞普西斯的迹象的管理的指导。']",0.2857142857142857,"['epidemiology', 'period', 'disease', 'neonatal', 'newborn', 'sepsis', 'document', 'signs', 'management', 'with', 'this', 'in', 'and', 'guidance']","['epidemiology', 'period', 'disease', 'management']",1578,这份详细的文件回顾了新生儿GBS疾病的流行病学，并提供了妇女和新生儿在新生儿期管理的指导。,0.2857142857142857,"['epidemiology', 'period', 'disease', 'neonatal', 'newborn', 'sepsis', 'document', 'signs', 'management', 'with', 'this', 'in', 'and', 'guidance']","['epidemiology', 'period', 'disease', 'management']",,,,
1592,1579,daily data on mortality and air pollution were collected from 652 cities in 24 countries or regions .,从 24 个国家或地区的 652 个城市收集有关死亡率和空气污染的每日数据。,0.6,"['air pollution', 'data', 'mortality', 'in', 'and']","['air pollution', 'data', 'mortality']",1579,['每日关于死亡率和空气污染的数据从24个国家或地区的652个城市收集。'],0.6,"['air pollution', 'data', 'mortality', 'in', 'and']","['air pollution', 'data', 'mortality']",1579,"daily data on mortality and air pollution were collected from 652 cities in 24 countries or regions .

Chinese:

每日死亡率和空气污染数据来自24个国家或地区的652个城市。",0.6,"['air pollution', 'data', 'mortality', 'in', 'and']","['air pollution', 'data', 'mortality']",,,,
1593,1580,"the corresponding increases in daily mortality for the same change in PM2.5 concentration were 0.68 % ( 95 % CI , 0.59 to 0.77 ) , 0.55 % ( 95 % CI , 0.45 to 0.66 ) , and 0.74 % ( 95 % CI , 0.53 to 0.95 ) .",PM2.5 浓度发生相同变化时，每日死亡率的相应增加分别为 0.68 % ( 95 % CI 0.59 至 0.77 ) 、 0.55 % ( 95 % CI 0.45 至 0.66 ) 和 0.74 % ( 95 % CI 0.53 至 0.53 至0.95）。,0.375,"['corresponding', 'concentration', 'mortality', 'increases', 'change', 'CI', 'to', 'and']","['concentration', 'mortality', 'change']",1580,"['相应的每日死亡率增加相同的 PM2.5 浓度变化为 0.68 % (95 % CI, 0.59 至 0.77 ), 0.55 % ( 95 % CI, 0.45 至 0.66 ), 和 0.74 % ( 95 % CI, 0.53 至 0.95 ) 。']",0.5,"['corresponding', 'concentration', 'mortality', 'increases', 'change', 'CI', 'to', 'and']","['corresponding', 'concentration', 'mortality', 'change']",1580,相应每日死亡率的提高与PM2.5浓度相同，分别为0.68％（95％置信区间，0.59至0.77），0.55％（95％置信区间，0.45至0.66）和0.74％（95％置信区间，0.53至0.95％）。,0.25,"['corresponding', 'concentration', 'mortality', 'increases', 'change', 'CI', 'to', 'and']","['concentration', 'mortality']",,,,
1594,1581,these associations remained significant after adjustment for gaseous pollutants .,在对气态污染物进行调整后，这些关联仍然显着。,0.3333333333333333,"['gaseous', 'adjustment', 'after']",['after'],1581,['这些化合物在气体污染物调整后仍然是显著的。'],0.3333333333333333,"['gaseous', 'adjustment', 'after']",['after'],1581,这些关联在校正气体污染物后仍然很重要。,0.3333333333333333,"['gaseous', 'adjustment', 'after']",['after'],,,,
1595,1582,associations were stronger in locations with lower annual mean PM concentrations and higher annual mean temperatures .,在年平均 PM 浓度较低和年平均气温较高的地区，这种关联更强。,0.1428571428571428,"['annual', 'mean', 'lower', 'with', 'concentrations', 'in', 'and']",['mean'],1582,['协会在低年平均PM浓度和高年平均温度的地方更强大。'],0.1428571428571428,"['annual', 'mean', 'lower', 'with', 'concentrations', 'in', 'and']",['mean'],1582,在年平均PM浓度较低、年平均气温较高的地区，相关性较强。,0.1428571428571428,"['annual', 'mean', 'lower', 'with', 'concentrations', 'in', 'and']",['mean'],,,,
1596,1583,these data reinforce the evidence of a link between mortality and PM concentration established in regional and local studies . ( Funded by the National Natural Science Foundation of China and others . ),这些数据强化了区域和地方研究中建立的死亡率和 PM 浓度之间联系的证据。 （国家自然科学基金等资助。）,0.5,"['concentration', 'data', 'regional', 'local', 'china', 'mortality', 'link', 'evidence', 'natural science', 'foundation', 'by', 'and']","['concentration', 'data', 'mortality', 'evidence', 'natural science', 'foundation']",1583,['这些数据强化了在区域和地方研究中建立的死亡率和 PM 浓度之间的联系的证据(由中国国家自然科学基金会和其他机构资助)。'],0.6666666666666666,"['concentration', 'data', 'regional', 'local', 'china', 'mortality', 'link', 'evidence', 'natural science', 'foundation', 'by', 'and']","['concentration', 'data', 'china', 'mortality', 'evidence', 'natural science', 'foundation', 'by']",1583,这些数据加强了地区和局部研究中死亡率与PM浓度之间存在关联的证据。（由中国国家自然科学基金会等资助。）,0.6666666666666666,"['concentration', 'data', 'regional', 'local', 'china', 'mortality', 'link', 'evidence', 'natural science', 'foundation', 'by', 'and']","['concentration', 'data', 'local', 'china', 'mortality', 'evidence', 'natural science', 'by']",,,,
1597,1584,"particulate matter ( PM ) , especially , arouses public health concerns because of its toxicity and the widespread human exposure to this pollutant .",颗粒物 (PM) 尤其引起公众健康关注，因为它具有毒性并且人类广泛接触这种污染物。,0.4444444444444444,"['pollutant', 'toxicity', 'exposure', 'health', 'public', 'human', 'particulate matter', 'this', 'and']","['pollutant', 'toxicity', 'health', 'human']",1584,"['粒子物质(PM),特别是,因其毒性和人类对这种污染物的广泛暴露而引起公众健康的担忧。']",0.7777777777777778,"['pollutant', 'toxicity', 'exposure', 'health', 'public', 'human', 'particulate matter', 'this', 'and']","['pollutant', 'toxicity', 'exposure', 'health', 'human', 'this', 'and']",1584,颗粒物（PM）尤其引起公众的健康担忧，因为它的毒性以及人类普遍接触到这种污染物。,0.5555555555555556,"['pollutant', 'toxicity', 'exposure', 'health', 'public', 'human', 'particulate matter', 'this', 'and']","['pollutant', 'toxicity', 'health', 'public', 'human']",,,,
1598,1585,"PM , which includes inhalable particles with an aerodynamic diameter of 10 μm or less ( PM10 ) and fine particles with an aerodynamic diameter of 2.5 μm or less ( PM2.5 ) , is emitted from combustion sources or formed through atmospheric chemical transformation .",PM 包括空气动力学直径为 10 μm 或更小的可吸入颗粒物 (PM10) 和空气动力学直径为 2.5 μm 或更小的细颗粒物 (PM2.5)，从燃烧源排放或通过大气化学转化形成。,0.5,"['transformation', 'chemical', 'combustion', 'atmospheric', 'aerodynamic', 'with', 'diameter', 'and']","['transformation', 'combustion', 'aerodynamic', 'diameter']",1585,"['PM(含有10 μm或更小的空气动态直径(PM10)和 2.5 μm或更小的空气动态直径(PM2.5 )的微粒,是从燃烧来源发出或通过大气化学转型形成的。']",0.25,"['transformation', 'chemical', 'combustion', 'atmospheric', 'aerodynamic', 'with', 'diameter', 'and']","['combustion', 'diameter']",1585,"PM10 and PM2.5 refer to inhalable particles with an aerodynamic diameter of 10 μm or less, and fine particles with an aerodynamic diameter of 2.5 μm or less, respectively. They are emitted from combustion sources or formed through atmospheric chemical transformation.

Chinese:
PM10和PM2.5指的是可吸入颗粒物的空气动力直径为10微米或更小，以及细颗粒物的空气动力直径为2.5微米或更小，它们分别来自燃烧源或通过大气化学转化形成。",0.375,"['transformation', 'chemical', 'combustion', 'atmospheric', 'aerodynamic', 'with', 'diameter', 'and']","['transformation', 'combustion', 'diameter']",,,,
1599,1586,"given the extensive evidence regarding their effects of health , the daily and annual mean concentrations of PM10 and PM2.5 are regulated according to the World Health Organization ( WHO ) Air Quality Guidelines4 and standards in major countries .",鉴于关于它们对健康影响的广泛证据，PM10 和 PM2.5 的日平均浓度和年平均浓度是根据世界卫生组织 (WHO) 空气质量指南 4 和主要国家的标准进行监管的。,0.6153846153846154,"['annual', 'mean', 'quality', 'world health organization', 'major', 'regarding', 'air', 'WHO', 'evidence', 'concentrations', 'regulated', 'to', 'and']","['mean', 'quality', 'world health organization', 'regarding', 'air', 'WHO', 'evidence', 'to']",1586,"['鉴于对其对健康的影响的广泛证据,每日和每年的PM10和PM2.5的平均浓度按照世界卫生组织(WHO)的空气质量指南4和主要国家的标准进行调节。']",0.5384615384615384,"['annual', 'mean', 'quality', 'world health organization', 'major', 'regarding', 'air', 'WHO', 'evidence', 'concentrations', 'regulated', 'to', 'and']","['mean', 'quality', 'world health organization', 'air', 'WHO', 'evidence', 'to']",1586,根据世界卫生组织（世卫组织）空气质量指南4和主要国家的标准，鉴于其对健康的广泛影响，PM10和PM2.5的日均浓度和年均浓度均受到规则。,0.3846153846153846,"['annual', 'mean', 'quality', 'world health organization', 'major', 'regarding', 'air', 'WHO', 'evidence', 'concentrations', 'regulated', 'to', 'and']","['quality', 'world health organization', 'air', 'WHO', 'to']",,,,
1600,1587,"however , most evidence has been obtained from studies in single cities , regions , or countries , and there are challenges in comparing these results and in synthesizing effect estimates because of different modeling approaches and potential publication bias .",然而，大多数证据是从单个城市、地区或国家的研究中获得的，由于不同的建模方法和潜在的发表偏倚，在比较这些结果和综合效果估计方面存在挑战。,0.875,"['bias', 'potential', 'publication', 'effect', 'evidence', 'modeling', 'single', 'and']","['bias', 'potential', 'publication', 'effect', 'evidence', 'single', 'and']",1587,"['然而,大多数证据都来自单个城市、地区或国家的研究,并且由于不同的模型方法和潜在的出版差异,比较这些结果和合成效应估计存在挑战。']",0.75,"['bias', 'potential', 'publication', 'effect', 'evidence', 'modeling', 'single', 'and']","['potential', 'publication', 'effect', 'evidence', 'single', 'and']",1587,然而，大多数证据来自于对单个城市、地区或国家的研究，由于建模方法不同以及可能存在的出版偏差，在比较这些结果并综合效应估计方面存在挑战。,0.75,"['bias', 'potential', 'publication', 'effect', 'evidence', 'modeling', 'single', 'and']","['bias', 'publication', 'effect', 'evidence', 'single', 'and']",,,,
1601,1588,"these limitations can be addressed by performing international , multicenter studies that adopt the same analytic protocol and model specifications to estimate globally representative associations of PM10 and PM2.5 exposures with daily mortality .",这些局限性可以通过开展国际多中心研究来解决，这些研究采用相同的分析协议和模型规范来估计全球代表性的 PM10 和 PM2.5 暴露与每日死亡率之间的关联。,0.3846153846153846,"['model', 'protocol', 'analytic', 'be', 'mortality', 'adopt', 'estimate', 'specifications', 'performing', 'with', 'that', 'by', 'and']","['model', 'protocol', 'mortality', 'adopt', 'by']",1588,"['这些限制可以通过进行国际、多中心研究,采用相同的分析协议和模型规格来估计全球代表性 PM10 和 PM2.5 曝光与日常死亡率。']",0.3846153846153846,"['model', 'protocol', 'analytic', 'be', 'mortality', 'adopt', 'estimate', 'specifications', 'performing', 'with', 'that', 'by', 'and']","['model', 'protocol', 'mortality', 'adopt', 'by']",1588,通过在全球范围内进行国际性、多中心研究，采用相同的分析方案和模型规范来估计PM10和PM2.5暴露与日死亡率之间的关联，可以解决这些局限性问题。,0.3846153846153846,"['model', 'protocol', 'analytic', 'be', 'mortality', 'adopt', 'estimate', 'specifications', 'performing', 'with', 'that', 'by', 'and']","['model', 'be', 'mortality', 'adopt', 'by']",,,,
1602,1589,"we obtained health and environmental data from the MCC database , which has been described previously.10,12","我们从 MCC 数据库中获取了健康和环境数据，该数据库已在之前描述过。 10,12",0.25,"['database', 'health', 'and', 'we']",['health'],1589,"['我们从 MCC 数据库中获取了健康和环境数据,此前已被描述。']",0.25,"['database', 'health', 'and', 'we']",['health'],1589,我们从MCC数据库获得了健康和环境数据，这个数据库之前已经被描述过10，12。,0.25,"['database', 'health', 'and', 'we']",['health'],,,,
1603,1590,"the current analysis was limited to locations that had available data on air pollution ( 652 urban areas in 24 countries or regions , with the data covering the period from 1986 through 2015 ) ( Table S1 in the Supplementary Appendix , available with the full text of this article at NEJM.org ) .",目前的分析仅限于有可用空气污染数据的地点（24 个国家或地区的 652 个城市地区，数据涵盖 1986 年至 2015 年期间）（补充附录中的表 S1，可与本文全文一起获取） NEJM.org 上的文章）。,0.3157894736842105,"['period', 'air pollution', 'appendix', 'table', 'data', 'analysis', 'article', 'supplementary', 'available', 'text', 'current', 'with', 'covering', 'full', 'limited', 'S1', 'this', 'that', 'to']","['period', 'air pollution', 'table', 'data', 'analysis', 'to']",1590,"['目前的分析仅限于有空气污染数据的地点(24个国家或地区的652个城市区域,包括1986年至2015年期间的数据)(附件中的S1表,可在NEJM.org上找到本文的完整文本)。']",0.4210526315789473,"['period', 'air pollution', 'appendix', 'table', 'data', 'analysis', 'article', 'supplementary', 'available', 'text', 'current', 'with', 'covering', 'full', 'limited', 'S1', 'this', 'that', 'to']","['period', 'air pollution', 'appendix', 'table', 'data', 'analysis', 'full', 'to']",1590,本次分析仅限于那些拥有空气污染数据的地区（包括24个国家或地区的652个城市，数据覆盖了1986年至2015年的时间段）（表S1位于本文全文可在NEJM.org上找到的补充附录中）。,0.2631578947368421,"['period', 'air pollution', 'appendix', 'table', 'data', 'analysis', 'article', 'supplementary', 'available', 'text', 'current', 'with', 'covering', 'full', 'limited', 'S1', 'this', 'that', 'to']","['air pollution', 'table', 'data', 'analysis', 'to']",,,,
1604,1591,data on mortality were obtained from local authorities within each country .,死亡率数据是从每个国家的地方当局获得的。,0.5,"['data', 'country', 'local', 'mortality', 'on', 'each']","['data', 'country', 'mortality']",1591,['死亡率数据来自各国地方当局。'],0.5,"['data', 'country', 'local', 'mortality', 'on', 'each']","['data', 'mortality', 'each']",1591,数据来源于各个国家的地方当局。,0.5,"['data', 'country', 'local', 'mortality', 'on', 'each']","['data', 'country', 'each']",,,,
1605,1592,we obtained daily data on PM10 in 598 cities and on PM2.5 in 499 cities .,我们获得了 598 个城市的 PM10 和 499 个城市的 PM2.5 的每日数据。,0.2,"['data', 'on', 'in', 'and', 'we']",['data'],1592,['我们每天收集了598个城市的PM10和499个城市的PM2.5的数据。'],0.2,"['data', 'on', 'in', 'and', 'we']",['data'],1592,我们获得了598个城市的日常PM10数据和499个城市的日常PM2.5数据。,0.2,"['data', 'on', 'in', 'and', 'we']",['data'],,,,
1606,1593,data on both pollutants were available in 445 cities in 16 countries or regions .,16 个国家或地区的 445 个城市提供了这两种污染物的数据。,0.25,"['data', 'available', 'on', 'in']",['data'],1593,['两种污染物的数据在16个国家或地区的445个城市可用。'],0.25,"['data', 'available', 'on', 'in']",['data'],1593,数据显示，在16个国家或地区的445个城市中，两种污染物的数据都可以获得。,0.25,"['data', 'available', 'on', 'in']",['data'],,,,
1607,1594,we also collected data on the daily mean temperature and daily mean relative humidity .,我们还收集了日平均温度和日平均相对湿度的数据。,0.5,"['relative humidity', 'mean temperature', 'data', 'on', 'and', 'we']","['relative humidity', 'mean temperature', 'data']",1594,['我们还收集了每日平均温度和每日平均相对湿度的数据。'],0.5,"['relative humidity', 'mean temperature', 'data', 'on', 'and', 'we']","['relative humidity', 'mean temperature', 'data']",1594,我们还收集了日平均温度和日平均相对湿度的数据。,0.5,"['relative humidity', 'mean temperature', 'data', 'on', 'and', 'we']","['relative humidity', 'mean temperature', 'data']",,,,
1608,1595,"to avoid potential consequences of including outlying values of exposure data , we used trimmed data , in which the highest 5 % and lowest 5 % of PM10 and PM2.5 measurements were excluded.14",为了避免包含暴露数据的异常值的潜在后果，我们使用了修整后的数据，其中排除了 PM10 和 PM2.5 测量值中最高的 5 % 和最低的 5 %。 14,0.4,"['5', 'data', 'exposure', 'potential', 'values', 'outlying', 'to', 'and', 'avoid', 'we']","['5', 'data', 'exposure', 'avoid']",1595,"['为了避免包括曝光数据的外观值的潜在后果,我们使用压缩数据,其中最高5 %和最低5 %的PM10和PM2.5测量被排除。']",0.4,"['5', 'data', 'exposure', 'potential', 'values', 'outlying', 'to', 'and', 'avoid', 'we']","['5', 'data', 'exposure', 'avoid']",1595,为了避免包含暴露数据的潜在后果，我们使用了修剪数据，其中PM10和PM2.5的最高5％和最低5％的测量值被排除在外。,0.4,"['5', 'data', 'exposure', 'potential', 'values', 'outlying', 'to', 'and', 'avoid', 'we']","['5', 'data', 'exposure', 'avoid']",,,,
1609,1596,we performed several sensitivity analyses .,我们进行了多项敏感性分析。,0.0,"['sensitivity', 'we']",[],1596,['我们进行了多种敏感性分析。'],0.0,"['sensitivity', 'we']",[],1596,我们进行了几次敏感性分析。,0.0,"['sensitivity', 'we']",[],,,,
1610,1597,"third , we restricted the analyses to data available after the year 2000 .",第三，我们将分析限制在 2000 年之后可用的数据。,0.7142857142857143,"['data', 'year', 'available', 'after', 'to', 'third', 'we']","['data', 'year', 'available', 'after', 'third']",1597,"['第三,我们将分析限制到2000年以后可用的数据。']",0.7142857142857143,"['data', 'year', 'available', 'after', 'to', 'third', 'we']","['data', 'year', 'available', 'after', 'third']",1597,第三，我们将分析限制在2000年之后的数据。,0.5714285714285714,"['data', 'year', 'available', 'after', 'to', 'third', 'we']","['data', 'year', 'after', 'third']",,,,
1611,1598,a P value of less than 0.05 was considered to indicate statistical significance .,小于 0.05 的 P 值被认为表明具有统计学意义。,0.2,"['value', 'indicate', 'statistical significance', 'P', 'to']",['to'],1598,['低于 0.05 的 P 值被认为表明统计意义。'],0.2,"['value', 'indicate', 'statistical significance', 'P', 'to']",['to'],1598,"一个P值小于0.05被认为表示统计学意义。

Chinese:

一个P值小于0.05被认为表示统计学意义。",0.2,"['value', 'indicate', 'statistical significance', 'P', 'to']",['to'],,,,
1612,1599,more details are presented in the Methods section in the Supplementary Appendix .,补充附录的“方法”部分提供了更多详细信息。,0.0,"['appendix', 'section', 'supplementary', 'in']",[],1599,['更多详细信息在附件中的方法部分中呈现。'],0.25,"['appendix', 'section', 'supplementary', 'in']",['appendix'],1599,详细信息参见补充附录的方法部分。,0.0,"['appendix', 'section', 'supplementary', 'in']",[],,,,
1613,1600,descriptive ANALYSES,描述性分析,1.0,['descriptive'],['descriptive'],1600,['描述分析'],0.0,['descriptive'],[],1600,分析性描述,0.0,['descriptive'],[],,,,
1614,1601,"PM10 was strongly correlated with PM2.5 , with a mean Pearson correlation coefficient of 0.78 .",PM10与PM2.5密切相关，平均皮尔逊相关系数为0.78。,0.6666666666666666,"['mean', 'correlation coefficient', 'with']","['mean', 'correlation coefficient']",1601,"['PM10 与 PM2.5 密切相关,平均为 0.78 的 Pearson 相关率。']",0.3333333333333333,"['mean', 'correlation coefficient', 'with']",['mean'],1601,PM10与PM2.5相关性很强，平均皮尔逊相关系数为0.78。,0.6666666666666666,"['mean', 'correlation coefficient', 'with']","['mean', 'correlation coefficient']",,,,
1615,1602,"the mean Pearson correlation coefficients between PM10 and gaseous pollutants were 0.46 with nitrogen dioxide , 0.20 with ozone , 0.38 with sulfur dioxide , and 0.40 with carbon monoxide .",PM10与气态污染物的平均皮尔逊相关系数分别为二氧化氮0.46、臭氧0.20、二氧化硫0.38、一氧化碳0.40。,0.6666666666666666,"['correlation', 'mean', 'ozone', 'carbon monoxide', 'gaseous', 'nitrogen dioxide', 'with', 'sulfur dioxide', 'and']","['correlation', 'mean', 'ozone', 'carbon monoxide', 'nitrogen dioxide', 'sulfur dioxide']",1602,"['皮尔森的 PM10 和气体污染物之间的平均相对比为 0.46 与氮二氧化物, 0.20 与臭氧, 0.38 与硫二氧化物, 0.40 与碳二氧化物。']",0.2222222222222222,"['correlation', 'mean', 'ozone', 'carbon monoxide', 'gaseous', 'nitrogen dioxide', 'with', 'sulfur dioxide', 'and']","['mean', 'ozone']",1602,PM10与气态污染物之间的平均皮尔逊相关系数分别为0.46（二氧化氮）、0.20（臭氧）、0.38（二氧化硫）和0.40（一氧化碳）。,0.6666666666666666,"['correlation', 'mean', 'ozone', 'carbon monoxide', 'gaseous', 'nitrogen dioxide', 'with', 'sulfur dioxide', 'and']","['correlation', 'mean', 'ozone', 'carbon monoxide', 'nitrogen dioxide', 'sulfur dioxide']",,,,
1616,1603,"the corresponding coefficients between PM2.5 and gaseous pollutants were 0.48 , 0.22 , 0.40 , and 0.45 .",PM2.5与气态污染物的对应系数分别为0.48、0.22、0.40和0.45。,0.0,"['corresponding', 'gaseous', 'and']",[],1603,"['PM2.5 和气体污染物之间的相应比例为 0.48, 0.22, 0.40, 和 0.45 。']",0.0,"['corresponding', 'gaseous', 'and']",[],1603,PM2.5与气体污染物之间相应的系数为0.48、0.22、0.40和0.45。,0.3333333333333333,"['corresponding', 'gaseous', 'and']",['corresponding'],,,,
1617,1604,other descriptive statistics and the correlations between daily mean PM concentrations and weather variables are summarized in the Results section in the Supplementary Appendix .,其他描述性统计数据以及每日平均 PM 浓度与天气变量之间的相关性在补充附录的结果部分进行了总结。,0.2222222222222222,"['appendix', 'mean', 'section', 'weather', 'supplementary', 'descriptive statistics', 'concentrations', 'in', 'and']","['mean', 'weather']",1604,['其他描述统计和每日平均 PM 浓度和天气变量之间的关系在附件中的结果部分中总结。'],0.3333333333333333,"['appendix', 'mean', 'section', 'weather', 'supplementary', 'descriptive statistics', 'concentrations', 'in', 'and']","['appendix', 'mean', 'weather']",1604,"其他描述性统计和日平均PM浓度与天气变量之间的相关性在结果部分的附录中进行了总结。

Chinese:
其他描述统计和日平均PM浓度与天气变量之间的相关性在结果部分的附录中进行了总结。",0.2222222222222222,"['appendix', 'mean', 'section', 'weather', 'supplementary', 'descriptive statistics', 'concentrations', 'in', 'and']","['mean', 'weather']",,,,
1618,1605,regression ANALYSES,回归分析,1.0,['regression'],['regression'],1605,['回归分析'],1.0,['regression'],['regression'],1605,"regression ANALYSES

Chinese:

回归分析",1.0,['regression'],['regression'],,,,
1619,1606,these moving averages were then applied in subsequent analyses .,然后将这些移动平均数应用于后续分析。,0.0,"['applied', 'subsequent', 'in']",[],1606,['这些移动平均值随后在后续分析中被应用。'],0.0,"['applied', 'subsequent', 'in']",[],1606,这些移动平均值随后用于随后的分析。,0.0,"['applied', 'subsequent', 'in']",[],,,,
1620,1607,"for both PM10 and PM2.5 , the associations were significant on lag 0 day and then attenuated substantially on lag 1 to 2 days ; the estimates of the associations were strongest on lag 0 to 1 day ( Table S4 in the Supplementary Appendix ) .",对于 PM10 和 PM2.5，相关性在滞后 0 天显着，然后在滞后 1 至 2 天显着减弱；关联的估计值在滞后 0 到 1 天时最强（补充附录中的表 S4）。,0.4545454545454545,"['appendix', 'lag', 'table', '1', '2', 'supplementary', 'on', 'S4', 'in', 'to', 'and']","['lag', 'table', '1', '2', 'to']",1607,"['对于 PM10 和 PM2.5 两者,合并在 0 天下显著,然后在 1 至 2 天下显著减轻;合并的估计在 0 至 1 天下最强(附件中的 S4 表)。']",0.4545454545454545,"['appendix', 'lag', 'table', '1', '2', 'supplementary', 'on', 'S4', 'in', 'to', 'and']","['appendix', 'table', '1', '2', 'to']",1607,对于PM10和PM2.5，关联关系在延迟0天时非常显著，但在延迟1到2天后逐渐减弱；估计的关联关系在延迟0到1天之间最强（表S4在附加附件中）。,0.4545454545454545,"['appendix', 'lag', 'table', '1', '2', 'supplementary', 'on', 'S4', 'in', 'to', 'and']","['appendix', 'table', '1', '2', 'to']",,,,
1621,1608,"estimates of the effect in France , Estonia , and Switzerland were close to the global median estimate of 0.46 % in association with PM10 concentration ; estimates of the effect in Switzerland and South Africa were close to the global median estimate of 0.80 % in association with PM2.5 concentration .",对法国、爱沙尼亚和瑞士影响的估计值与 PM10 浓度相关的全球中值估计值 0.46% 接近；对瑞士和南非影响的估计值接近与 PM2.5 浓度相关的全球中值估计值 0.80%。,0.3636363636363636,"['estonia', 'median', 'concentration', 'global', 'association', 'effect', 'estimate', 'with', 'in', 'and', 'close to']","['estonia', 'concentration', 'global', 'estimate']",1608,"['法国、爱沙尼亚和瑞士的影响估计接近与PM10浓度相结合的全球平均估计为0.46%,瑞士和南非的影响估计接近与PM2.5浓度相结合的全球平均估计为0.80%。']",0.3636363636363636,"['estonia', 'median', 'concentration', 'global', 'association', 'effect', 'estimate', 'with', 'in', 'and', 'close to']","['estonia', 'concentration', 'global', 'association']",1608,根據法國、愛沙尼亞和瑞士的估計，與PM10濃度有關聯的全球平均影響率為0.46％；與PM2.5濃度有關聯的全球平均影響率分別為瑞士和南非為0.80％。,0.0909090909090909,"['estonia', 'median', 'concentration', 'global', 'association', 'effect', 'estimate', 'with', 'in', 'and', 'close to']",['global'],,,,
1622,1609,"regional analyses indicated differences between areas ( Table S6 in the Supplementary Appendix ) , with higher estimates of the effect in the region of the Americas and smaller estimates in the Western Pacific region .",区域分析表明区域之间存在差异（补充附录中的表 S6），美洲区域的影响估计值较高，西太平洋区域的估计值较小。,0.125,"['appendix', 'table', 'regional', 'supplementary', 'effect', 'with', 'in', 'and']",['table'],1609,"['区域分析表明区域之间的差异(附件中的S6表),在美国地区的影响估计更高,在西太平洋地区的估计更小。']",0.25,"['appendix', 'table', 'regional', 'supplementary', 'effect', 'with', 'in', 'and']","['appendix', 'table']",1609,根据地区分析，各地区之间存在差异（表S6位于补充附录），美洲地区的估计效果较高，西太平洋地区的估计效果较小。,0.25,"['appendix', 'table', 'regional', 'supplementary', 'effect', 'with', 'in', 'and']","['table', 'effect']",,,,
1623,1610,the slopes for both curves were steeper at concentrations lower than 40 μg per cubic meter for PM10 and lower than 20 μg per cubic meter for PM2.5 .,两条曲线的斜率在 PM10 浓度低于 40 微克/立方米和 PM2.5 浓度低于 20 微克/立方米时更陡。,0.1666666666666666,"['meter', 'lower', 'cubic', 'concentrations', 'steeper', 'and']",['meter'],1610,['兩個曲線的曲線在 PM10 的每立方米低於 40 μg 的濃度和 PM2.5 的每立方米低於 20 μg 的濃度。'],0.1666666666666666,"['meter', 'lower', 'cubic', 'concentrations', 'steeper', 'and']",['meter'],1610,在PM10的浓度低于40微克每立方米和PM2.5的浓度低于20微克每立方米的情况下，这两条曲线的斜率都更加陡峭。,0.1666666666666666,"['meter', 'lower', 'cubic', 'concentrations', 'steeper', 'and']",['meter'],,,,
1624,1611,the slopes seemed to flatten at high ranges .,斜坡似乎在高处变平了。,0.3333333333333333,"['at', 'to', 'high']",['high'],1611,['它们似乎在高层上浮动。'],0.3333333333333333,"['at', 'to', 'high']",['high'],1611,在高海拔地区，斜坡似乎变得平坦了。,0.3333333333333333,"['at', 'to', 'high']",['high'],,,,
1625,1612,sensitivity analyses confirmed these results .,敏感性分析证实了这些结果。,0.0,['sensitivity'],[],1612,['敏感性分析证实了这些结果。'],0.0,['sensitivity'],[],1612,敏感性分析确认了这些结果。,0.0,['sensitivity'],[],,,,
1626,1613,"finally , the analysis in which the subset of data since the year 2000 was used provided similar estimates .",最后，使用 2000 年以来数据子集的分析提供了类似的估计。,0.5,"['data', 'year', 'analysis', 'subset', 'in', 'similar']","['data', 'year', 'analysis']",1613,"['最后,分析自2000年以来使用的数据子组提供了类似的估计。']",0.5,"['data', 'year', 'analysis', 'subset', 'in', 'similar']","['data', 'year', 'analysis']",1613,最终，使用自2000年以来的数据子集的分析提供了类似的估计。,0.5,"['data', 'year', 'analysis', 'subset', 'in', 'similar']","['data', 'year', 'analysis']",,,,
1627,1614,estimates based on nontrimmed PM data are provided in Table S8 in the Supplementary Appendix .,补充附录表 S8 中提供了基于非修正 PM 数据的估计值。,0.3333333333333333,"['appendix', 'table', 'data', 'supplementary', 'on', 'in']","['table', 'data']",1614,['基于非期限 PM 数据的估计在附件 S8 表中提供。'],0.5,"['appendix', 'table', 'data', 'supplementary', 'on', 'in']","['appendix', 'table', 'data']",1614,PM数据的非修剪估计提供在表S8中的附录。,0.3333333333333333,"['appendix', 'table', 'data', 'supplementary', 'on', 'in']","['table', 'data']",,,,
1628,1615,"our study analyzed multisite data on air pollution and mortality in 652 cities across different countries and regions , although most countries and cities were in the northern hemisphere .",我们的研究分析了不同国家和地区 652 个城市的空气污染和死亡率的多站点数据，尽管大多数国家和城市位于北半球。,0.5,"['air pollution', 'data', 'hemisphere', 'study', 'mortality', 'across', 'in', 'and']","['air pollution', 'data', 'hemisphere', 'mortality']",1615,"['我们的研究分析了652个不同国家和地区的空气污染和死亡率的多网站数据,尽管大多数国家和城市位于北半球。']",0.5,"['air pollution', 'data', 'hemisphere', 'study', 'mortality', 'across', 'in', 'and']","['air pollution', 'data', 'hemisphere', 'mortality']",1615,我们的研究分析了652个不同国家和地区的城市的空气污染和死亡率的多地数据，尽管大多数国家和城市位于北半球。,0.5,"['air pollution', 'data', 'hemisphere', 'study', 'mortality', 'across', 'in', 'and']","['air pollution', 'data', 'hemisphere', 'mortality']",,,,
1629,1616,"the percentage increase in mortality for the same increase in PM10 concentration was 0.77 % in the Multicity Study of Air Pollution and Mortality in Latin America ( ESCALA ) , 8 0.55 % in the Public Health and Air Pollution in Asia ( PAPA ) study , 7 and 0.19 % in the reanalysis of the U.S. National Morbidity Mortality Air Pollution Study ( NMMAPS ) .21",在拉丁美洲空气污染和死亡率多城市研究 ( ESCALA ) 8 中，相同 PM10 浓度增加导致的死亡率增加百分比为 0.77 % ，在亚洲公共卫生和空气污染 ( PAPA ) 研究 7 中为 0.55 % ，并且美国国家发病率死亡率空气污染研究 (NMMAPS) .21 再分析中的 0.19%,0.5,"['percentage', 'air pollution', 'concentration', 'morbidity', 'america', 'health', 'public', 'study', 'mortality', 'increase', 'PAPA', 'and']","['air pollution', 'concentration', 'morbidity', 'america', 'health', 'mortality']",1616,"['相同增加的PM10浓度死亡率的百分比增加在拉丁美洲的多元性空气污染和死亡率研究(ESCALA)中为0.77%,在亚洲的公共卫生和空气污染研究(PAPA)中为8.55%,在美国国家疾病死亡率空气污染研究(NMMAPS)的重新分析中为7和0.19%。']",0.4166666666666667,"['percentage', 'air pollution', 'concentration', 'morbidity', 'america', 'health', 'public', 'study', 'mortality', 'increase', 'PAPA', 'and']","['air pollution', 'concentration', 'america', 'health', 'mortality']",1616,在拉丁美洲城市空气污染与死亡研究（ESCALA）中，同等增加PM10浓度所导致的死亡率增加0.77%，在亚洲公众健康与空气污染研究（PAPA）中，同等增加PM10浓度所导致的死亡率增加0.55%，而在美国国家健康与空气污染研究（NMMAPS）的再分析中，同等增加PM10浓度所导致的死亡率增加0.19%。,0.5,"['percentage', 'air pollution', 'concentration', 'morbidity', 'america', 'health', 'public', 'study', 'mortality', 'increase', 'PAPA', 'and']","['air pollution', 'concentration', 'america', 'health', 'mortality', 'and']",,,,
1630,1617,"in addition , we found that the associations of mortality with PM concentrations were slightly stronger with PM2.5 than with PM10 in most countries and regions , which added to the evidence that PM2.5 accounted for a larger proportion of the effects of PM10 and PM2.5 combined.6",此外，我们发现，在大多数国家和地区，PM2.5 与 PM10 的死亡率与 PM 浓度的相关性略强于 PM10，这进一步证明 PM2.5 在 PM10 和 PM2 的影响中所占比例更大。 .5 组合.6,0.2727272727272727,"['proportion', 'addition', 'mortality', 'evidence', 'with', 'concentrations', 'that', 'in', 'to', 'and', 'we']","['proportion', 'mortality', 'to']",1617,"['此外,我们发现,与 PM 浓度的死亡率的联系在大多数国家和地区的 PM2.5 比 PM10 稍微强大,这增加了 PM2.5 与 PM10 和 PM2.5 相结合的影响的比例。']",0.2727272727272727,"['proportion', 'addition', 'mortality', 'evidence', 'with', 'concentrations', 'that', 'in', 'to', 'and', 'we']","['proportion', 'addition', 'mortality']",1617,此外，我们发现在大多数国家和地区，死亡与PM浓度之间的关联稍微强于PM10，这表明PM2.5所占PM10和PM2.5总量影响的比例更大。6,0.1818181818181818,"['proportion', 'addition', 'mortality', 'evidence', 'with', 'concentrations', 'that', 'in', 'to', 'and', 'we']","['proportion', 'to']",,,,
1631,1618,the stronger effects of PM2.5 may also be supported by the abundant evidence that this particulate fraction contains more small particles that can absorb toxic components from the air and penetrate deep into the lungs.24,PM2.5 的更强影响也可能得到大量证据的支持，这些证据表明该颗粒部分包含更多可以从空气中吸收有毒成分并深入肺部的小颗粒。 24,0.2857142857142857,"['toxic', 'abundant', 'penetrate', 'be', 'air', 'particulate', 'fraction', 'evidence', 'deep', 'absorb', 'this', 'that', 'by', 'and']","['air', 'fraction', 'evidence', 'by']",1618,"['PM2.5 的有效性也可能受到丰富的证据的支持,表明该粒子部分含有较小的粒子,可以从空气中吸收有毒组件并深入渗透到肺部。']",0.4285714285714285,"['toxic', 'abundant', 'penetrate', 'be', 'air', 'particulate', 'fraction', 'evidence', 'deep', 'absorb', 'this', 'that', 'by', 'and']","['abundant', 'penetrate', 'air', 'fraction', 'evidence', 'by']",1618,PM2.5 的更强烈作用可能也得到了大量证据的支持，这种微粒含量更多，能够吸收空气中的有毒成分并深入肺部。,0.2142857142857142,"['toxic', 'abundant', 'penetrate', 'be', 'air', 'particulate', 'fraction', 'evidence', 'deep', 'absorb', 'this', 'that', 'by', 'and']","['air', 'fraction', 'evidence']",,,,
1632,1619,"furthermore , the higher proportion of young people in developing countries may decrease population susceptibility to PM , and less outdoor activity during days with high pollution levels may decrease exposure .",此外，发展中国家年轻人比例较高可能会降低人口对 PM 的易感性，而在高污染水平的日子里减少户外活动可能会减少暴露。,0.6666666666666666,"['proportion', 'population', 'decrease', 'pollution', 'exposure', 'activity', 'developing', 'with', 'young', 'and', 'susceptibility to', 'high']","['proportion', 'population', 'decrease', 'pollution', 'exposure', 'activity', 'and', 'high']",1619,"['此外,发展中国家的年轻人比例较高可能会降低人口对 PM 的敏感性,在高污染水平的日子里,户外活动较少可能会降低暴露。']",0.5,"['proportion', 'population', 'decrease', 'pollution', 'exposure', 'activity', 'developing', 'with', 'young', 'and', 'susceptibility to', 'high']","['proportion', 'population', 'pollution', 'exposure', 'activity', 'high']",1619,此外，发展中国家年轻人的比例较高可能会降低人口对颗粒物的易感性，而当污染水平较高时，室外活动的减少可能会降低暴露程度。,0.6666666666666666,"['proportion', 'population', 'decrease', 'pollution', 'exposure', 'activity', 'developing', 'with', 'young', 'and', 'susceptibility to', 'high']","['proportion', 'population', 'decrease', 'pollution', 'exposure', 'activity', 'and', 'high']",,,,
1633,1620,"however , associations estimated for extreme PM concentrations are characterized by wider confidence intervals , with greater uncertainty about the actual mortality risk at such values .",然而，极端 PM 浓度估计的相关性具有更宽的置信区间，在这些值下实际死亡风险的不确定性更大。,0.1818181818181818,"['actual', 'mortality', 'risk', 'values', 'with', 'confidence', 'concentrations', 'uncertainty', 'extreme', 'characterized by', 'intervals']","['risk', 'extreme']",1620,"['然而,对极端 PM 浓度估计的协会具有更广泛的信任间隔,对这些值的实际死亡风险的不确定性更大。']",0.1818181818181818,"['actual', 'mortality', 'risk', 'values', 'with', 'confidence', 'concentrations', 'uncertainty', 'extreme', 'characterized by', 'intervals']","['risk', 'extreme']",1620,然而，对极端PM浓度估计的关联具有较宽的置信区间，在这些值上实际死亡风险的不确定性更大。,0.1818181818181818,"['actual', 'mortality', 'risk', 'values', 'with', 'confidence', 'concentrations', 'uncertainty', 'extreme', 'characterized by', 'intervals']","['risk', 'extreme']",,,,
1634,1621,we found significant evidence of spatial heterogeneity in the associations between PM concentration and daily mortality across countries and regions .,我们发现了各个国家和地区 PM 浓度与每日死亡率之间关联的空间异质性的重要证据。,0.4444444444444444,"['heterogeneity', 'concentration', 'mortality', 'across', 'spatial', 'evidence', 'in', 'and', 'we']","['heterogeneity', 'concentration', 'mortality', 'evidence']",1621,['我们在 PM 浓度和各个国家和地区的日常死亡率之间的关系中发现了显著的空间异性证据。'],0.3333333333333333,"['heterogeneity', 'concentration', 'mortality', 'across', 'spatial', 'evidence', 'in', 'and', 'we']","['concentration', 'mortality', 'evidence']",1621,我们发现了显著的空间异质性关联，即不同国家和地区之间PM浓度与日死亡率的关联存在差异。,0.3333333333333333,"['heterogeneity', 'concentration', 'mortality', 'across', 'spatial', 'evidence', 'in', 'and', 'we']","['heterogeneity', 'concentration', 'mortality']",,,,
1635,1622,"we also found that higher annual mean concentrations of PM10 and PM2.5 were accompanied by weaker associations with daily mortality , a finding that has been reported in previous studies.16,25","我们还发现，较高的 PM10 和 PM2.5 年平均浓度与每日死亡率的相关性较弱，这一发现已在之前的研究中报道过。 16,25",0.1818181818181818,"['annual', 'mean', 'previous', 'mortality', 'with', 'concentrations', 'that', 'in', 'and', 'accompanied by', 'we']","['mean', 'mortality']",1622,"['我们还发现,高年平均 PM10 和 PM2.5 的浓度伴随着与日常死亡率的较弱联系,这是在以前的研究中报告的发现。']",0.2727272727272727,"['annual', 'mean', 'previous', 'mortality', 'with', 'concentrations', 'that', 'in', 'and', 'accompanied by', 'we']","['mean', 'previous', 'mortality']",1622,"我们还发现，较高的年均PM10和PM2.5浓度伴随着较弱的日死亡率相关性，这一发现与先前的研究结果相符。16,25",0.0909090909090909,"['annual', 'mean', 'previous', 'mortality', 'with', 'concentrations', 'that', 'in', 'and', 'accompanied by', 'we']",['mortality'],,,,
1636,1623,"the estimates of the association between PM and mortality in some countries ( e.g. , France , Finland , Sweden , and the United Kingdom ) were smaller and not significant .",在一些国家（例如法国、芬兰、瑞典和英国），对 PM 与死亡率之间关联的估计较小且不显着。,0.5,"['association', 'mortality', 'kingdom', 'and']","['association', 'mortality']",1623,"['某些国家(例如,法国、芬兰、瑞典和英国)的总理与死亡率之间的联系的估计较小而不大。']",0.75,"['association', 'mortality', 'kingdom', 'and']","['association', 'mortality', 'and']",1623,在一些国家（如法国、芬兰、瑞典和英国），PM与死亡率之间的估计值较小，并且没有显著性。,0.25,"['association', 'mortality', 'kingdom', 'and']",['mortality'],,,,
1637,1624,"these countries had fewer cities included and shorter periods evaluated , which may increase the statistical uncertainty in the estimation of the effect .",这些国家包括的城市较少，评估的时间较短，这可能会增加影响估计的统计不确定性。,0.1666666666666666,"['estimation', 'effect', 'increase', 'periods', 'uncertainty', 'and']",['estimation'],1624,"['这些国家包括更少的城市和更短的评估期,这可能会增加统计不确定性在估计效果。']",0.3333333333333333,"['estimation', 'effect', 'increase', 'periods', 'uncertainty', 'and']","['estimation', 'effect']",1624,这些国家的城市数量较少，考核周期较短，这可能会增加对效果估计的统计不确定性。,0.3333333333333333,"['estimation', 'effect', 'increase', 'periods', 'uncertainty', 'and']","['estimation', 'effect']",,,,
1638,1625,more interpretations on this issue are provided in the Discussion section in the Supplementary Appendix .,补充附录的讨论部分提供了关于这个问题的更多解释。,0.1428571428571428,"['appendix', 'section', 'issue', 'supplementary', 'discussion', 'this', 'in']",['discussion'],1625,['更多关于此事的解释在附件的讨论部分中提供。'],0.2857142857142857,"['appendix', 'section', 'issue', 'supplementary', 'discussion', 'this', 'in']","['appendix', 'discussion']",1625,在补充附录的讨论部分，提供了有关这个问题的更多解释。,0.1428571428571428,"['appendix', 'section', 'issue', 'supplementary', 'discussion', 'this', 'in']",['discussion'],,,,
1639,1626,this study has several limitations .,这项研究有几个局限性。,0.0,"['study', 'this']",[],1626,['这项研究有几个限制。'],0.0,"['study', 'this']",[],1626,"This study has several limitations.

Chinese:

这项研究有几个局限性。",0.0,"['study', 'this']",[],,,,
1640,1627,"first , although the analysis included 24 major countries and regions on six continents , our findings cannot be interpreted as fully globally representative because the 652 cities were mainly located in East Asia , Europe , and North America , with a smaller number of cities in Latin America and Africa .",首先，虽然分析涵盖了六大洲的24个主要国家和地区，但我们的研究结果并不能解释为具有完全的全球代表性，因为这652个城市主要分布在东亚、欧洲和北美，拉丁美洲的城市数量较少。和非洲。,0.4545454545454545,"['analysis', 'america', 'north', 'major', 'number', 'with', 'on', 'in', 'and', 'first', 'east']","['analysis', 'north', 'number', 'first', 'east']",1627,"['首先,虽然分析包括六大洲的24个主要国家和地区,但我们的发现不能被解释为完全全球代表性,因为652个城市主要位于东亚、欧洲和北美,拉丁美洲和非洲的城市数量较小。']",0.4545454545454545,"['analysis', 'america', 'north', 'major', 'number', 'with', 'on', 'in', 'and', 'first', 'east']","['analysis', 'north', 'number', 'first', 'east']",1627,虽然我们的研究包括了六大洲24个主要国家和地区，但由于652个城市主要分布在东亚、欧洲和北美，而拉丁美洲和非洲的城市数量较少，因此我们的研究结果并不能被完全解释为全球代表性研究。,0.3636363636363636,"['analysis', 'america', 'north', 'major', 'number', 'with', 'on', 'in', 'and', 'first', 'east']","['north', 'number', 'and', 'east']",,,,
1641,1628,"fourth , there are some missing data , but their influence on our estimates was not substantial ( see the Discussion section and Table S9 in the Supplementary Appendix ) .",第四，有一些数据缺失，但它们对我们的估计影响不大（见讨论部分和补充附录表S9）。,0.5454545454545454,"['appendix', 'table', 'data', 'section', 'supplementary', 'influence', 'discussion', 'but', 'and', 'substantial', 'missing']","['table', 'data', 'influence', 'discussion', 'but', 'missing']",1628,"['第四,有些数据缺乏,但它们对我们的估计的影响并不大(参见附件中的讨论部分和表S9)。']",0.6363636363636364,"['appendix', 'table', 'data', 'section', 'supplementary', 'influence', 'discussion', 'but', 'and', 'substantial', 'missing']","['appendix', 'table', 'data', 'influence', 'discussion', 'but', 'missing']",1628,"第四，有一些缺失的数据，但它们对我们的估计影响不大（见讨论部分和表S9在补充附录）。

Chinese:
第四，有一些缺失的数据，但它们对我们的估计影响不大（见讨论部分和表S9在补充附录）。",0.5454545454545454,"['appendix', 'table', 'data', 'section', 'supplementary', 'influence', 'discussion', 'but', 'and', 'substantial', 'missing']","['table', 'data', 'influence', 'discussion', 'but', 'missing']",,,,
1642,1629,this study indicated independent associations of PM10 and PM2.5 concentrations with daily mortality after adjustment for gaseous pollutants .,这项研究表明，在调整气态污染物后，PM10 和 PM2.5 浓度与每日死亡率之间存在独立关联。,0.2,"['gaseous', 'study', 'adjustment', 'mortality', 'after', 'independent', 'with', 'concentrations', 'this', 'and']","['mortality', 'after']",1629,"['这项研究表明,在适用于气体污染物的调整后,每日死亡率的PM10和PM2.5浓度的独立结合。']",0.2,"['gaseous', 'study', 'adjustment', 'mortality', 'after', 'independent', 'with', 'concentrations', 'this', 'and']","['mortality', 'after']",1629,这项研究表明了 PM10 和 PM2.5 浓度与每日死亡率之间的独立关联，经过气体污染物调整后。,0.2,"['gaseous', 'study', 'adjustment', 'mortality', 'after', 'independent', 'with', 'concentrations', 'this', 'and']","['mortality', 'after']",,,,
1643,1630,the role of assessment of myocardial viability in identifying patients with ischemic cardiomyopathy who might benefit from surgical revascularization remains controversial .,评估心肌活力在确定可能受益于手术血运重建的缺血性心肌病患者中的作用仍然存在争议。,0.3333333333333333,"['who', 'viability', 'surgical', 'role', 'revascularization', 'assessment', 'cardiomyopathy', 'myocardial', 'benefit', 'with', 'in', 'ischemic']","['role', 'revascularization', 'assessment', 'cardiomyopathy']",1630,['评估心脏病的可行性在识别患有催化心脏病的患者的作用可能受益于手术复发仍然有争议。'],0.1666666666666666,"['who', 'viability', 'surgical', 'role', 'revascularization', 'assessment', 'cardiomyopathy', 'myocardial', 'benefit', 'with', 'in', 'ischemic']","['role', 'assessment']",1630,"The role of assessing myocardial viability in identifying patients with ischemic cardiomyopathy who might benefit from surgical revascularization remains controversial.

Chinese:

对冠心病患者术前评估心肌活性的作用仍存在争议。",0.1666666666666666,"['who', 'viability', 'surgical', 'role', 'revascularization', 'assessment', 'cardiomyopathy', 'myocardial', 'benefit', 'with', 'in', 'ischemic']","['role', 'assessment']",,,,
1644,1631,"furthermore , although improvement in left ventricular function is one of the goals of revascularization , its relationship to subsequent outcomes is unclear .",此外，尽管左心室功能的改善是血运重建的目标之一，但其与后续结果的关系尚不清楚。,0.375,"['improvement', 'relationship', 'function', 'revascularization', 'ventricular', 'subsequent', 'in', 'to']","['improvement', 'function', 'revascularization']",1631,"['除此之外,尽管左<unk>功能的改善是重振的目标之一,但其与随后的结果的关系不清楚。']",0.25,"['improvement', 'relationship', 'function', 'revascularization', 'ventricular', 'subsequent', 'in', 'to']","['improvement', 'function']",1631,此外，尽管左心室功能的改善是血管重建的目标之一，但其与随后的结果之间的关系仍不清楚。,0.25,"['improvement', 'relationship', 'function', 'revascularization', 'ventricular', 'subsequent', 'in', 'to']","['improvement', 'function']",,,,
1645,1632,patients were randomly assigned to undergo CABG and receive medical therapy or to receive medical therapy alone .,患者被随机分配接受 CABG 并接受药物治疗或仅接受药物治疗。,0.1428571428571428,"['undergo', 'medical', 'therapy', 'CABG', 'to', 'and', 'alone']",['therapy'],1632,['病人随机被授予接受CABG并接受医疗治疗或单独接受医疗治疗。'],0.2857142857142857,"['undergo', 'medical', 'therapy', 'CABG', 'to', 'and', 'alone']","['therapy', 'alone']",1632,病人被隨機分配給行動CABG並接受醫療治療或僅接受醫療治療。,0.0,"['undergo', 'medical', 'therapy', 'CABG', 'to', 'and', 'alone']",[],,,,
1646,1633,the primary end point was death from any cause .,主要终点是全因死亡。,0.4,"['death', 'primary', 'cause', 'end', 'point']","['death', 'point']",1633,['主要的终点是任何原因的死亡。'],0.8,"['death', 'primary', 'cause', 'end', 'point']","['death', 'primary', 'cause', 'point']",1633,主要终点是死亡，无论是什么原因。,0.6,"['death', 'primary', 'cause', 'end', 'point']","['death', 'cause', 'point']",,,,
1647,1634,"however , no significant interaction was observed between the presence or absence of myocardial viability and the beneficial effect of CABG plus medical therapy over medical therapy alone ( P = 0.34 for interaction ) .",然而，在存在或不存在心肌活力与 CABG 加药物治疗相对于单独药物治疗的有益效果之间没有观察到显着的相互作用（相互作用 P = 0.34）。,0.4,"['presence', 'plus', 'viability', 'medical', 'therapy', 'CABG', 'absence', 'no', 'interaction', 'effect', 'myocardial', 'P', 'over', 'and', 'alone']","['presence', 'plus', 'therapy', 'effect', 'and', 'alone']",1634,"['然而,没有显著的相互作用被观察到在存在或缺乏心脏病的可行性和有益的效果CABG加上医疗治疗在医疗治疗单独(P = 0.34相互作用)之间。']",0.4666666666666667,"['presence', 'plus', 'viability', 'medical', 'therapy', 'CABG', 'absence', 'no', 'interaction', 'effect', 'myocardial', 'P', 'over', 'and', 'alone']","['presence', 'plus', 'therapy', 'absence', 'effect', 'and', 'alone']",1634,然而，在CABG加上药物治疗与仅药物治疗之间并没有观察到心肌可活性的显著相互作用（相互作用P值为0.34）。,0.2666666666666666,"['presence', 'plus', 'viability', 'medical', 'therapy', 'CABG', 'absence', 'no', 'interaction', 'effect', 'myocardial', 'P', 'over', 'and', 'alone']","['plus', 'therapy', 'effect', 'and']",,,,
1648,1635,"an increase in left ventricular ejection fraction was observed only among patients with myocardial viability , irrespective of treatment assignment .",左心室射血分数增加仅在有心肌活力的患者中观察到，与治疗分配无关。,0.2222222222222222,"['viability', 'treatment', 'ventricular', 'myocardial', 'irrespective', 'increase', 'assignment', 'with', 'ejection fraction']","['treatment', 'ejection fraction']",1635,"['左<unk>排泄分裂的增加仅在患有心血管可行性患者中被观察到,无论治疗任务如何。']",0.1111111111111111,"['viability', 'treatment', 'ventricular', 'myocardial', 'irrespective', 'increase', 'assignment', 'with', 'ejection fraction']",['treatment'],1635,在有心肌活力的病人中，不论治疗方案，左心室排出量增加都是观察到的。,0.1111111111111111,"['viability', 'treatment', 'ventricular', 'myocardial', 'irrespective', 'increase', 'assignment', 'with', 'ejection fraction']",['treatment'],,,,
1649,1636,there was no association between changes in left ventricular ejection fraction and subsequent death .,左心室射血分数的变化与随后的死亡之间没有关联。,0.375,"['death', 'association', 'no', 'ventricular', 'subsequent', 'ejection fraction', 'in', 'and']","['death', 'association', 'ejection fraction']",1636,['左腹部排泄分裂和随后的死亡之间没有任何联系。'],0.25,"['death', 'association', 'no', 'ventricular', 'subsequent', 'ejection fraction', 'in', 'and']","['death', 'association']",1636,"There was no association between changes in left ventricular ejection fraction and subsequent death.

Chinese:

左心室射血分数的变化与随后的死亡无关。",0.25,"['death', 'association', 'no', 'ventricular', 'subsequent', 'ejection fraction', 'in', 'and']","['death', 'ejection fraction']",,,,
1650,1637,"ischemic heart disease is the most common and most lethal cause of heart failure.1,2","缺血性心脏病是心力衰竭最常见和最致命的原因。 1,2",0.6,"['lethal', 'ischemic heart disease', 'common', 'cause', 'and']","['lethal', 'ischemic heart disease', 'cause']",1637,['心脏病是最常见和最致命的心脏衰竭的原因。'],0.4,"['lethal', 'ischemic heart disease', 'common', 'cause', 'and']","['lethal', 'cause']",1637,"心肌缺血性心脏病是导致心脏衰竭最常见和最致命的疾病。1,2",0.4,"['lethal', 'ischemic heart disease', 'common', 'cause', 'and']","['lethal', 'ischemic heart disease']",,,,
1651,1638,it is also the only cause of left ventricular dysfunction that is amenable to the benefit of surgical revascularization .,它也是左心室功能障碍的唯一原因，可以通过手术血运重建获益。,0.25,"['dysfunction', 'surgical', 'revascularization', 'cause', 'ventricular', 'benefit', 'that', 'to']","['revascularization', 'cause']",1638,"['它也是左<unk>功能障碍的唯一原因,可益于手术复发。']",0.25,"['dysfunction', 'surgical', 'revascularization', 'cause', 'ventricular', 'benefit', 'that', 'to']","['cause', 'to']",1638,它也是唯一一种可以通过手术血管重建来改善左心室功能障碍的原因。,0.125,"['dysfunction', 'surgical', 'revascularization', 'cause', 'ventricular', 'benefit', 'that', 'to']",['cause'],,,,
1652,1639,"the STICH trial was a prospective , multicenter , randomized , nonblinded trial sponsored by the National Heart , Lung , and Blood Institute ( NHLBI ) of the National Institutes of Health .",STICH 试验是一项前瞻性、多中心、随机、非盲试验，由美国国立卫生研究院下属的国家心肺血液研究所 (NHLBI) 赞助。,0.75,"['heart', 'lung', 'health', 'blood', 'institute', 'trial', 'by', 'and']","['heart', 'lung', 'health', 'blood', 'institute', 'by']",1639,['STICH审查是由国家卫生研究所国家心脏、肺和血液研究所(NHLBI)赞助的可见、多中心、随机、无盲的审查。'],0.75,"['heart', 'lung', 'health', 'blood', 'institute', 'trial', 'by', 'and']","['heart', 'lung', 'health', 'blood', 'institute', 'by']",1639,STICH试验是一项由美国国家心脏、肺脏和血液研究所（NHLBI）赞助的前瞻性、多中心、随机、非盲目的试验。,0.625,"['heart', 'lung', 'health', 'blood', 'institute', 'trial', 'by', 'and']","['heart', 'lung', 'blood', 'institute', 'by']",,,,
1653,1640,"in this trial , 1212 patients with coronary artery disease who had a left ventricular ejection fraction of 35 % or lower were enrolled during the period from 2002 through 2007 .",在这项试验中，2002 年至 2007 年期间纳入了 1212 名左心室射血分数为 35% 或更低的冠状动脉疾病患者。,0.3636363636363636,"['period', 'disease', 'who', 'lower', 'ventricular', 'trial', 'with', 'coronary artery', 'ejection fraction', 'this', 'in']","['period', 'disease', 'coronary artery', 'ejection fraction']",1640,"['在这项研究中,1212名患有冠状动脉疾病的患者在2002年至2007年期间注册了35%或更低的左<unk>排泄分。']",0.2727272727272727,"['period', 'disease', 'who', 'lower', 'ventricular', 'trial', 'with', 'coronary artery', 'ejection fraction', 'this', 'in']","['period', 'disease', 'coronary artery']",1640,在这项试验中，2002年至2007年期间共有1212名冠状动脉疾病患者，左心室射血分数为35%或更低的患者被纳入研究。,0.3636363636363636,"['period', 'disease', 'who', 'lower', 'ventricular', 'trial', 'with', 'coronary artery', 'ejection fraction', 'this', 'in']","['period', 'disease', 'coronary artery', 'ejection fraction']",,,,
1654,1641,the trial was performed to test the hypothesis that CABG in combination with appropriate medical therapy would result in better survival outcomes than appropriate medical therapy alone .,进行该试验是为了验证 CABG 联合适当的药物治疗会比单独使用适当的药物治疗带来更好的生存结果这一假设。,0.5,"['combination', 'hypothesis', 'survival', 'test', 'medical', 'therapy', 'CABG', 'trial', 'result', 'with', 'that', 'to', 'alone', 'appropriate']","['combination', 'hypothesis', 'survival', 'test', 'therapy', 'result', 'alone']",1641,['试验是为了测试假设CABG与适当的医疗治疗将导致比适当的医疗治疗单独更好的生存结果。'],0.4285714285714285,"['combination', 'hypothesis', 'survival', 'test', 'medical', 'therapy', 'CABG', 'trial', 'result', 'with', 'that', 'to', 'alone', 'appropriate']","['hypothesis', 'survival', 'test', 'therapy', 'result', 'alone']",1641,这项试验旨在检验CABG结合适当的医疗治疗会导致比仅用适当的医疗治疗更好的生存结果的假设。,0.4285714285714285,"['combination', 'hypothesis', 'survival', 'test', 'medical', 'therapy', 'CABG', 'trial', 'result', 'with', 'that', 'to', 'alone', 'appropriate']","['combination', 'hypothesis', 'survival', 'test', 'therapy', 'result']",,,,
1655,1642,"a complete list of inclusion and exclusion criteria is provided in Table S1 in the Supplementary Appendix , available with the full text of this article at NEJM.org .",补充附录表 S1 中提供了纳入和排除标准的完整列表，补充附录与本文全文可在 NEJM.org 获取。,0.125,"['appendix', 'table', 'inclusion', 'article', 'supplementary', 'exclusion', 'complete', 'available', 'text', 'list', 'with', 'at', 'full', 'S1', 'this', 'and']","['table', 'full']",1642,"['包含和排除标准的完整列表在附件中的表 S1,可在NEJM.org上找到本文的完整文本。']",0.25,"['appendix', 'table', 'inclusion', 'article', 'supplementary', 'exclusion', 'complete', 'available', 'text', 'list', 'with', 'at', 'full', 'S1', 'this', 'and']","['appendix', 'table', 'inclusion', 'full']",1642,在本文的补充附件中提供了包括和排除标准的完整列表，这些标准可在 NEJM.org 上找到。,0.1875,"['appendix', 'table', 'inclusion', 'article', 'supplementary', 'exclusion', 'complete', 'available', 'text', 'list', 'with', 'at', 'full', 'S1', 'this', 'and']","['appendix', 'table', 'full']",,,,
1656,1643,"the NHLBI and the ethics committee at each participating center approved the trial protocol , available at NEJM.org .",NHLBI 和每个参与中心的伦理委员会批准了试验方案，可在 NEJM.org 获取。,0.3333333333333333,"['center', 'protocol', 'ethics', 'available', 'committee', 'trial', 'at', 'each', 'and']","['center', 'protocol', 'committee']",1643,"['NHLBI 和各参与中心的伦理委员会批准了审判协议,可在 NEJM.org 上找到。']",0.5555555555555556,"['center', 'protocol', 'ethics', 'available', 'committee', 'trial', 'at', 'each', 'and']","['center', 'protocol', 'committee', 'trial', 'each']",1643,NHLBI和每个参与中心的道德委员会均批准了试验方案，可在NEJM.org上查看。,0.3333333333333333,"['center', 'protocol', 'ethics', 'available', 'committee', 'trial', 'at', 'each', 'and']","['center', 'protocol', 'committee']",,,,
1657,1644,"the design of the STICH trial and the results of the analysis of the primary hypothesis have been reported previously.3,4,13","STICH 试验的设计和主要假设的分析结果之前已有报道。 3,4,13",0.5714285714285714,"['analysis', 'hypothesis', 'primary', 'trial', 'design', 'have', 'and']","['analysis', 'hypothesis', 'design', 'have']",1644,['STICH试验的设计和初始假设的分析结果已提前报告。'],0.4285714285714285,"['analysis', 'hypothesis', 'primary', 'trial', 'design', 'have', 'and']","['analysis', 'hypothesis', 'design']",1644,"此前已经报告过STICH试验的设计和主要假设结果分析。3,4,13",0.4285714285714285,"['analysis', 'hypothesis', 'primary', 'trial', 'design', 'have', 'and']","['analysis', 'hypothesis', 'design']",,,,
1658,1645,"although tests to assess myocardial viability were initially mandated as part of the STICH protocol , this requirement was discontinued because of difficulties in patient enrollment .",尽管评估心肌活力的测试最初是作为 STICH 协议的一部分强制执行的，但由于患者招募困难，这一要求已被中止。,0.625,"['part', 'requirement', 'protocol', 'viability', 'in patient', 'myocardial', 'assess', 'this']","['part', 'requirement', 'protocol', 'assess', 'this']",1645,"['雖然考試以評估心血管可行性最初被委託作為STICH議定書的一部分,但這項要求因病人登記的困難而被中止。']",0.25,"['part', 'requirement', 'protocol', 'viability', 'in patient', 'myocardial', 'assess', 'this']","['part', 'requirement']",1645,虽然最初的STICH协议要求进行心肌活性测试，但由于患者入组困难而取消了这一要求。,0.25,"['part', 'requirement', 'protocol', 'viability', 'in patient', 'myocardial', 'assess', 'this']","['requirement', 'protocol']",,,,
1659,1646,"hence , only a proportion of patients enrolled in the STICH trial were included in the myocardial viability substudy .",因此，只有一部分参加 STICH 试验的患者被纳入心肌存活子研究。,0.2,"['proportion', 'viability', 'trial', 'myocardial', 'in']",['proportion'],1646,"['因此,只有百分之百的病人被列入STICH试验被列入心血管可行性研究。']",0.0,"['proportion', 'viability', 'trial', 'myocardial', 'in']",[],1646,因此，只有少数患者参加了 STICH 试验，并只有少数患者参加了心肌活力子研究。,0.0,"['proportion', 'viability', 'trial', 'myocardial', 'in']",[],,,,
1660,1647,the current study was designed by the first author and was approved by the policy and publications committee of the STICH trial .,本研究由第一作者设计，并获得 STICH 试验政策和出版委员会的批准。,0.375,"['author', 'study', 'committee', 'trial', 'current', 'by', 'and', 'first']","['committee', 'by', 'first']",1647,"['目前的研究是由第一位作者设计的,由STICH审判的政策和出版委员会批准。']",0.5,"['author', 'study', 'committee', 'trial', 'current', 'by', 'and', 'first']","['committee', 'trial', 'by', 'first']",1647,本研究由第一作者设计，经STICH试验政策与出版委员会批准。,0.375,"['author', 'study', 'committee', 'trial', 'current', 'by', 'and', 'first']","['committee', 'by', 'first']",,,,
1661,1648,the clinical and outcomes data were collected by personnel at the participating sites and were sent directly to the data coordinating center at the Duke Clinical Research Institute .,临床和结果数据由参与地点的人员收集，并直接发送到杜克临床研究所的数据协调中心。,0.7777777777777778,"['center', 'research', 'data', 'clinical', 'institute', 'personnel', 'by', 'to', 'and']","['center', 'research', 'data', 'clinical', 'institute', 'personnel', 'by']",1648,"['临床和结果数据由参与场所的员工收集,并直接发送到杜克临床研究所的数据协调中心。']",0.6666666666666666,"['center', 'research', 'data', 'clinical', 'institute', 'personnel', 'by', 'to', 'and']","['center', 'research', 'data', 'clinical', 'institute', 'by']",1648,研究临床和结果数据由参与研究的地方的人员收集，并直接发送给数据协调中心杜克临床研究所。,0.7777777777777778,"['center', 'research', 'data', 'clinical', 'institute', 'personnel', 'by', 'to', 'and']","['center', 'research', 'data', 'clinical', 'institute', 'personnel', 'by']",,,,
1662,1649,"the images obtained for myocardial viability and other noninvasive studies were sent from the participating sites to the respective independent core laboratories , where they were evaluated ; the resultant data were then sent to the data coordinating center .",为心肌活力和其他非侵入性研究获得的图像从参与地点发送到各自的独立核心实验室，在那里进行评估；然后将生成的数据发送到数据协调中心。,0.3,"['center', 'core', 'data', 'viability', 'independent', 'myocardial', 'resultant', 'to', 'and', 'noninvasive']","['center', 'core', 'data']",1649,"['为了心血管可行性和其他非侵略性研究而获得的图像,从参与场所发送到各自的核心实验室,在那里它们被评估;结果的数据随后发送到数据协调中心。']",0.5,"['center', 'core', 'data', 'viability', 'independent', 'myocardial', 'resultant', 'to', 'and', 'noninvasive']","['center', 'core', 'data', 'resultant', 'and']",1649,我的心肌活力和其他非侵入性研究的图像已经从参与网站发送到各自的独立核心实验室，在那里进行了评估；然后，结果数据被发送到数据协调中心。,0.4,"['center', 'core', 'data', 'viability', 'independent', 'myocardial', 'resultant', 'to', 'and', 'noninvasive']","['center', 'core', 'data', 'resultant']",,,,
1663,1650,"the data coordinating center stored the data , and the statisticians at the Duke Clinical Research Institute ( the second and third authors ) wrote the statistical analysis plan and conducted the data analyses .",数据协调中心存储数据，杜克临床研究所的统计学家（第二和第三作者）编写统计分析计划并进行数据分析。,0.7777777777777778,"['center', 'research', 'data', 'clinical', 'institute', 'statistical analysis', 'second', 'and', 'third']","['center', 'research', 'data', 'clinical', 'institute', 'statistical analysis', 'third']",1650,"['数据协调中心存储了数据,杜克临床研究所的统计学家(第二和第三作者)写了统计分析计划,并进行了数据分析。']",0.7777777777777778,"['center', 'research', 'data', 'clinical', 'institute', 'statistical analysis', 'second', 'and', 'third']","['center', 'research', 'data', 'clinical', 'institute', 'statistical analysis', 'third']",1650,数据协调中心储存了数据，杜克临床研究所的统计学家（第二和第三位作者）制定了统计分析计划并进行了数据分析。,0.7777777777777778,"['center', 'research', 'data', 'clinical', 'institute', 'statistical analysis', 'second', 'and', 'third']","['center', 'research', 'data', 'clinical', 'institute', 'statistical analysis', 'third']",,,,
1664,1651,all the authors vouch for the accuracy and completeness of the data and for the fidelity of the study to the protocol .,所有作者保证数据的准确性和完整性以及研究对方案的忠实度。,0.375,"['fidelity', 'data', 'accuracy', 'protocol', 'study', 'completeness', 'all', 'and']","['data', 'accuracy', 'completeness']",1651,"['所有作者都赞扬数据的准确性和完整性,以及研究对议定书的忠诚性。']",0.5,"['fidelity', 'data', 'accuracy', 'protocol', 'study', 'completeness', 'all', 'and']","['data', 'accuracy', 'protocol', 'completeness']",1651,所有作者都能够保证数据的准确性和完整性，并且能够保证研究与方案的一致性。,0.375,"['fidelity', 'data', 'accuracy', 'protocol', 'study', 'completeness', 'all', 'and']","['data', 'accuracy', 'completeness']",,,,
1665,1652,"the first draft of the manuscript was written by the first author , and all the authors reviewed and revised subsequent drafts .",手稿的初稿由第一作者撰写，所有作者审阅并修改了后续草稿。,0.375,"['author', 'manuscript', 'subsequent', 'all', 'by', 'and', 'first', 'draft']","['manuscript', 'by', 'first']",1652,"['手稿的第一张草案是由第一位作者撰写的,所有作者都审查并审查了随后的草案。']",0.375,"['author', 'manuscript', 'subsequent', 'all', 'by', 'and', 'first', 'draft']","['manuscript', 'by', 'first']",1652,第一稿由第一作者撰写，所有作者审阅并修订了随后的草稿。,0.25,"['author', 'manuscript', 'subsequent', 'all', 'by', 'and', 'first', 'draft']","['by', 'first']",,,,
1666,1653,the manuscript was reviewed and approved for submission by the policy and publications committee of the STICH trial and by the NHLBI .,STICH 试验的政策和出版委员会以及 NHLBI 审查并批准了手稿提交。,0.5,"['manuscript', 'committee', 'trial', 'submission', 'by', 'and']","['manuscript', 'committee', 'by']",1653,['手稿已被STICH审判的政策和出版委员会和NHLBI审查和批准提交。'],0.5,"['manuscript', 'committee', 'trial', 'submission', 'by', 'and']","['manuscript', 'committee', 'trial']",1653,这份手稿经过STICH试验的政策和出版委员会审查并获得提交批准，并经过NHLBI审核。,0.3333333333333333,"['manuscript', 'committee', 'trial', 'submission', 'by', 'and']","['manuscript', 'committee']",,,,
1667,1654,assessment OF MYOCARDIAL VIABILITY,心肌活力评估,1.0,['assessment'],['assessment'],1654,['心血管生存率评估'],1.0,['assessment'],['assessment'],1654,评估我心肌的活力,1.0,['assessment'],['assessment'],,,,
1668,1655,data collection for and analysis of the SPECT and dobutamine echocardiographic studies were coordinated at independent core laboratories that were funded by the NHLBI ; investigators at each laboratory were unaware of the treatment assignments and the individual characteristics of the patients .,SPECT 和多巴酚丁胺超声心动图研究的数据收集和分析在 NHLBI 资助的独立核心实验室进行协调；每个实验室的研究人员都不知道治疗分配和患者的个体特征。,0.6,"['SPECT', 'core', 'analysis', 'individual', 'treatment', 'characteristics', 'laboratory', 'independent', 'unaware', 'data collection', 'that', 'each', 'by', 'and', 'echocardiographic']","['SPECT', 'core', 'analysis', 'individual', 'treatment', 'characteristics', 'laboratory', 'data collection', 'echocardiographic']",1655,"['对SPECT和Dubutamine的数据收集和分析,在由NHLBI资助的独立核心实验室进行了协调;每个实验室的研究人员都不知道治疗任务和患者的个性特征。']",0.5333333333333333,"['SPECT', 'core', 'analysis', 'individual', 'treatment', 'characteristics', 'laboratory', 'independent', 'unaware', 'data collection', 'that', 'each', 'by', 'and', 'echocardiographic']","['SPECT', 'core', 'analysis', 'treatment', 'characteristics', 'laboratory', 'data collection', 'by']",1655,数据收集和SPECT和Dobutamine超声心动图研究的分析由NHLBI资助的独立核心实验室协调进行；每个实验室的研究人员都不知道治疗分配和患者的个人特征。,0.6666666666666666,"['SPECT', 'core', 'analysis', 'individual', 'treatment', 'characteristics', 'laboratory', 'independent', 'unaware', 'data collection', 'that', 'each', 'by', 'and', 'echocardiographic']","['SPECT', 'core', 'analysis', 'individual', 'treatment', 'characteristics', 'laboratory', 'data collection', 'by', 'echocardiographic']",,,,
1669,1656,"details of the imaging protocols used to identify and quantify viable myocardium have been published previously.5,14","用于识别和量化活心肌的成像协议的详细信息之前已发表。 5,14",0.4285714285714285,"['viable', 'myocardium', 'identify', 'imaging', 'have', 'to', 'and']","['myocardium', 'identify', 'to']",1656,['图像协议的详细信息用于识别和量化可行的心血管已经公布。'],0.2857142857142857,"['viable', 'myocardium', 'identify', 'imaging', 'have', 'to', 'and']","['identify', 'to']",1656,"以前已经发布了关于如何确定和量化可生存心肌的成像协议的细节。5,14",0.2857142857142857,"['viable', 'myocardium', 'identify', 'imaging', 'have', 'to', 'and']","['myocardium', 'to']",,,,
1670,1657,"in brief , thresholds of the extent of viable myocardium were prespecified to classify patients in a binary fashion as either having or not having substantial myocardial viability .",简而言之，存活心肌范围的阈值被预先指定，以二元方式将患者分类为具有或不具有实质性心肌存活。,0.2222222222222222,"['viable', 'myocardium', 'binary', 'viability', 'myocardial', 'extent', 'as', 'to', 'substantial']","['viable', 'myocardium']",1657,"['简而言之,可行的心脏病的范围的边界被预定为将病人以二进制方式分类为有或没有显著的心脏病的可行性。']",0.0,"['viable', 'myocardium', 'binary', 'viability', 'myocardial', 'extent', 'as', 'to', 'substantial']",[],1657,简言之，可生存心肌的阈值事先是给定的，以二元方式将患者分为具备或不具备大量可生存心肌的。,0.2222222222222222,"['viable', 'myocardium', 'binary', 'viability', 'myocardial', 'extent', 'as', 'to', 'substantial']","['myocardium', 'myocardial']",,,,
1671,1658,"for SPECT , patients with viability were defined as those with 11 or more viable segments on the basis of relative tracer activity .",对于 SPECT，具有存活性的患者被定义为根据相对示踪剂活性具有 11 个或更多存活节段的患者。,0.3,"['SPECT', 'viable', 'defined', 'activity', 'viability', 'basis', 'tracer', 'relative', 'with', 'on']","['SPECT', 'viable', 'activity']",1658,"['对于SPECT,可行性患者被定义为基于相对跟踪活动的11个或多个可行性分区的患者。']",0.2,"['SPECT', 'viable', 'defined', 'activity', 'viability', 'basis', 'tracer', 'relative', 'with', 'on']","['SPECT', 'activity']",1658,对于SPECT，活力患者的定义是相对放射性活性物质的11个或更多可活力段。,0.2,"['SPECT', 'viable', 'defined', 'activity', 'viability', 'basis', 'tracer', 'relative', 'with', 'on']","['SPECT', 'activity']",,,,
1672,1659,"for dobutamine echocardiography , patients with viability were defined as those with 5 or more segments with abnormal resting systolic function but manifesting contractile reserve during dobutamine administration .",对于多巴酚丁胺超声心动图，有活力的患者被定义为具有 5 个或更多节段且静息收缩功能异常但在多巴酚丁胺给药期间表现出收缩储备的患者。,0.3846153846153846,"['5', 'defined', 'reserve', 'administration', 'function', 'viability', 'abnormal', 'systolic', 'as', 'with', 'but', 'echocardiography', 'contractile']","['5', 'reserve', 'function', 'abnormal', 'but']",1659,"['对于Dubutamine echocardiography,可行性患者被定义为具有5个或多个分区的患者,在Dubutamine服用期间表现出异常的休息系统功能,但在服用期间表现出合并性储备。']",0.3846153846153846,"['5', 'defined', 'reserve', 'administration', 'function', 'viability', 'abnormal', 'systolic', 'as', 'with', 'but', 'echocardiography', 'contractile']","['5', 'reserve', 'function', 'abnormal', 'but']",1659,对于多巴胺超声心动图，被定义为具有5个或5个以上异常静搏功能的患者，但在多巴胺给药期间表现出收缩备用。,0.3076923076923077,"['5', 'defined', 'reserve', 'administration', 'function', 'viability', 'abnormal', 'systolic', 'as', 'with', 'but', 'echocardiography', 'contractile']","['5', 'function', 'abnormal', 'but']",,,,
1673,1660,"in addition , we analyzed myocardial viability as a continuous variable by computing the proportion of viable segments relative to the number of segments analyzed for each individual patient.5,14","此外，我们通过计算每个患者的存活节段相对于分析的节段数量的比例，将心肌活力作为连续变量进行分析。 5,14",0.4,"['proportion', 'variable', 'viable', 'individual', 'continuous', 'addition', 'viability', 'relative', 'number', 'myocardial', 'as', 'each', 'by', 'to', 'we']","['proportion', 'variable', 'viable', 'continuous', 'number', 'to']",1660,"['此外,我们分析了心脏病的可行性作为持续变量,计算了可行分区的比例,与每个患者分析的分区数量相比。']",0.2,"['proportion', 'variable', 'viable', 'individual', 'continuous', 'addition', 'viability', 'relative', 'number', 'myocardial', 'as', 'each', 'by', 'to', 'we']","['proportion', 'variable', 'number']",1660,"此外，我们还将心肌活力作为一个连续变量进行了分析，计算出每个患者相对于所分析的段落数量的可生存段落的比例。5,14",0.3333333333333333,"['proportion', 'variable', 'viable', 'individual', 'continuous', 'addition', 'viability', 'relative', 'number', 'myocardial', 'as', 'each', 'by', 'to', 'we']","['proportion', 'variable', 'continuous', 'number', 'to']",,,,
1674,1661,assessment OF LEFT VENTRICULAR FUNCTION,左心室功能评估,1.0,['assessment'],['assessment'],1661,['空气风力功能评估'],1.0,['assessment'],['assessment'],1661,"Left ventricular function refers to the ability of the left ventricle of the heart to pump blood. The left ventricle is the chamber of the heart that is responsible for pumping oxygenated blood from the lungs to the rest of the body.

中文：

左心室功能评估是指左心房对血液泵功能的能力。左心房是心脏负责从肺部将充满氧气的血液泵入全身其他部位的室壁。",1.0,['assessment'],['assessment'],,,,
1675,1662,"the study protocol specified that patients had to undergo echocardiography , radionuclide scanning , or cardiac magnetic resonance imaging at baseline and at 4 months after randomization .",研究方案规定，患者必须在基线和随机分组后 4 个月时接受超声心动图、放射性核素扫描或心脏磁共振成像。,0.3846153846153846,"['cardiac', 'randomization', 'baseline', 'radionuclide', 'protocol', 'undergo', 'study', 'magnetic resonance imaging', 'scanning', 'after', '4', 'that', 'echocardiography']","['cardiac', 'randomization', 'baseline', 'radionuclide', 'after']",1662,"['研究协议规定,患者必须在基线上进行 echocardiography、 radionuclide 扫描或心脏磁响应图像,并在 randomization 后 4 个月进行。']",0.3076923076923077,"['cardiac', 'randomization', 'baseline', 'radionuclide', 'protocol', 'undergo', 'study', 'magnetic resonance imaging', 'scanning', 'after', '4', 'that', 'echocardiography']","['cardiac', 'baseline', 'protocol', 'after']",1662,研究方案指定患者必须在随机分配的基线和4个月后进行超声心动图、放射性核素扫描或心脏磁共振成像。,0.3846153846153846,"['cardiac', 'randomization', 'baseline', 'radionuclide', 'protocol', 'undergo', 'study', 'magnetic resonance imaging', 'scanning', 'after', '4', 'that', 'echocardiography']","['cardiac', 'randomization', 'baseline', 'radionuclide', 'after']",,,,
1676,1663,details of the methods of assessment of left ventricular volume at each independent core laboratory have been reported previously.15,每个独立核心实验室的左心室容积评估方法的细节以前都有报道。 15,0.75,"['volume', 'core', 'assessment', 'ventricular', 'laboratory', 'independent', 'have', 'each']","['volume', 'core', 'assessment', 'ventricular', 'laboratory', 'have']",1663,['每个独立核心实验室的左<unk>体积评估方法的详细信息已提前报告。'],0.625,"['volume', 'core', 'assessment', 'ventricular', 'laboratory', 'independent', 'have', 'each']","['volume', 'core', 'assessment', 'ventricular', 'laboratory']",1663,之前已经报告过每个独立核心实验室对左心室体积的评估方法的细节。15,0.5,"['volume', 'core', 'assessment', 'ventricular', 'laboratory', 'independent', 'have', 'each']","['volume', 'core', 'assessment', 'laboratory']",,,,
1677,1664,"when more than one imaging method was used for a patient at a single time point , we used a prespecified hierarchical algorithm that was based on the quality of each of the imaging studies to determine the best available method for measurement of the left ventricular ejection fraction.15",当在单个时间点对患者使用多种成像方法时，我们使用基于每项成像研究质量的预先指定的分级算法来确定测量左心室射血分数的最佳可用方法。 15,0.4705882352941176,"['ejection', 'algorithm', 'quality', 'time', 'available', 'ventricular', 'measurement', 'patient', 'method', 'point', 'imaging', 'that', 'each', 'single', 'to', 'determine', 'we']","['algorithm', 'quality', 'time', 'measurement', 'patient', 'point', 'single', 'to']",1664,"['当一个患者在一个时间点使用超过一个图像方法时,我们使用了一个预定的序列算法,该算法是基于图像研究的质量,以确定测量左<unk>排泄分的最佳可用方法。']",0.4117647058823529,"['ejection', 'algorithm', 'quality', 'time', 'available', 'ventricular', 'measurement', 'patient', 'method', 'point', 'imaging', 'that', 'each', 'single', 'to', 'determine', 'we']","['algorithm', 'quality', 'time', 'measurement', 'patient', 'point', 'to']",1664,当一个病人在一个时间点上使用了多种成像方法时，我们使用了一种预先规定的基于每种成像研究质量的分层算法来确定左心室射血分数的最佳测量方法。,0.4117647058823529,"['ejection', 'algorithm', 'quality', 'time', 'available', 'ventricular', 'measurement', 'patient', 'method', 'point', 'imaging', 'that', 'each', 'single', 'to', 'determine', 'we']","['algorithm', 'quality', 'time', 'measurement', 'patient', 'point', 'to']",,,,
1678,1665,"after enrollment , patients were followed every 4 months during the first year and every 6 months thereafter .",入组后，第一年每 4 个月对患者进行一次随访，此后每 6 个月随访一次。,0.6,"['year', 'after', '4', 'and', 'first']","['year', 'after', 'first']",1665,"['在注册后,患者在第一年每4个月,随后每6个月都被跟踪。']",0.6,"['year', 'after', '4', 'and', 'first']","['year', 'after', 'first']",1665,在入学后，病人每4个月在第一年内跟踪一次，此后每6个月跟踪一次。,0.6,"['year', 'after', '4', 'and', 'first']","['year', 'after', 'first']",,,,
1679,1666,the primary outcome was death from any cause .,主要结果是全因死亡。,0.5,"['outcome', 'death', 'primary', 'cause']","['outcome', 'death']",1666,['主要的结果是任何原因的死亡。'],1.0,"['outcome', 'death', 'primary', 'cause']","['outcome', 'death', 'primary', 'cause']",1666,主要结局是死于任何原因。,0.5,"['outcome', 'death', 'primary', 'cause']","['death', 'cause']",,,,
1680,1667,secondary end points were death from cardiovascular causes and a composite of death from any cause or hospitalization for cardiovascular causes .,次要终点是心血管原因死亡以及任何原因死亡或心血管原因住院的复合终点。,0.625,"['composite', 'cardiovascular', 'death', 'hospitalization', 'end points', 'cause', 'secondary', 'and']","['cardiovascular', 'death', 'hospitalization', 'end points', 'cause']",1667,['二次终点是心血管原因死亡和任何原因或心血管原因的住院死亡的组成部分。'],0.625,"['composite', 'cardiovascular', 'death', 'hospitalization', 'end points', 'cause', 'secondary', 'and']","['cardiovascular', 'death', 'hospitalization', 'end points', 'cause']",1667,继续性指标包括心血管原因死亡和任何原因死亡或心血管原因住院的综合情况。,0.5,"['composite', 'cardiovascular', 'death', 'hospitalization', 'end points', 'cause', 'secondary', 'and']","['cardiovascular', 'death', 'hospitalization', 'cause']",,,,
1681,1668,definitions of the trial end points have been reported previously.13,之前已经报告了试验终点的定义。 13,0.3333333333333333,"['end points', 'trial', 'have']",['end points'],1668,['审判终点的定义已被提交。13'],0.6666666666666666,"['end points', 'trial', 'have']","['end points', 'trial']",1668,之前已经报告了审判终点的定义。13,0.6666666666666666,"['end points', 'trial', 'have']","['end points', 'trial']",,,,
1682,1669,"other assessments included the difference between patients who had myocardial viability and those who did not with respect to the incidence of death from any cause and the incidence of death from cardiovascular causes ; the interaction between treatment assignment and myocardial viability status with respect to death from any cause , death from cardiovascular causes , and a composite of death from any cause or hospitalization for cardiovascular causes ; the difference between patients who had improvement in left ventricular ejection fraction and those who did not , among patients who were alive at 4 months , with respect to subsequent death from any cause and death from cardiovascular causes ; and the interaction between improvement in left ventricular ejection fraction and myocardial viability status with respect to death from any cause and death from cardiovascular causes .",其他评估包括在任何原因死亡发生率和心血管原因死亡发生率方面，具有心肌存活能力的患者与不具有心肌存活能力的患者之间的差异；关于任何原因死亡、心血管原因死亡以及任何原因死亡或因心血管原因住院的复合，治疗分配与心肌存活状态之间的相互作用；在存活 4 个月的患者中，左心室射血分数有改善的患者与没有改善的患者之间在随后的任何原因死亡和心血管原因死亡方面的差异；以及左心室射血分数改善与心肌活力状态之间的交互作用，与全因死亡和心血管原因死亡有关。,0.4782608695652174,"['composite', 'improvement', 'incidence', 'cardiovascular', 'who', 'death', 'viability', 'difference', 'status', 'hospitalization', 'treatment', 'cause', 'ventricular', 'interaction', 'subsequent', 'myocardial', '4', 'assignment', 'with', 'respect', 'ejection fraction', 'to', 'and']","['improvement', 'incidence', 'cardiovascular', 'death', 'difference', 'status', 'hospitalization', 'treatment', 'cause', 'ejection fraction', 'to']",1669,"['其他评估包括患有心血管生存率的患者和不因任何原因而死亡的患者之间的差异,以及因心血管原因而死亡的患者之间的差异,以及因心血管原因而死亡,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心']",0.217391304347826,"['composite', 'improvement', 'incidence', 'cardiovascular', 'who', 'death', 'viability', 'difference', 'status', 'hospitalization', 'treatment', 'cause', 'ventricular', 'interaction', 'subsequent', 'myocardial', '4', 'assignment', 'with', 'respect', 'ejection fraction', 'to', 'and']","['cardiovascular', 'death', 'difference', 'cause', 'and']",1669,其他评估包括心肌可活性与否患者的死亡率及心血管死亡率差异；治疗分配与心肌可活性状态交互作用与死亡率、心血管死亡率有关，死亡率或心血管住院率差异；存活4个月的患者中左心室射血分数改善与否患者随后死亡率及心血管死亡率的差异；左心室射血分数改善与心肌可活性状态的交互作用与死亡率和心血管死亡率有关。,0.3478260869565217,"['composite', 'improvement', 'incidence', 'cardiovascular', 'who', 'death', 'viability', 'difference', 'status', 'hospitalization', 'treatment', 'cause', 'ventricular', 'interaction', 'subsequent', 'myocardial', '4', 'assignment', 'with', 'respect', 'ejection fraction', 'to', 'and']","['improvement', 'cardiovascular', 'death', 'difference', 'status', 'hospitalization', 'treatment', 'ejection fraction']",,,,
1683,1670,a generalized linear model was used to assess differences in the change in left ventricular ejection fraction in various subgroups of patients .,广义线性模型用于评估不同患者亚组左心室射血分数变化的差异。,0.625,"['various', 'ventricular', 'generalized', 'linear model', 'assess', 'change', 'ejection fraction', 'to']","['linear model', 'assess', 'change', 'ejection fraction', 'to']",1670,['一般化线性模型被用来评估患者的不同子群中的左<unk>排泄分裂的变化差异。'],0.375,"['various', 'ventricular', 'generalized', 'linear model', 'assess', 'change', 'ejection fraction', 'to']","['linear model', 'assess', 'change']",1670,一般化線性模型被用來評估不同患者群體中左室射血分數改變的差異。,0.0,"['various', 'ventricular', 'generalized', 'linear model', 'assess', 'change', 'ejection fraction', 'to']",[],,,,
1684,1671,all generalized linear models included the baseline value of left ventricular ejection fraction as a covariate .,所有广义线性模型都包括左心室射血分数的基线值作为协变量。,0.2857142857142857,"['baseline', 'value', 'linear', 'ventricular', 'generalized', 'ejection fraction', 'all']","['baseline', 'ejection fraction']",1671,['所有通用的线性模型都包含了左<unk>排泄部分作为科瓦里亚特的基值。'],0.0,"['baseline', 'value', 'linear', 'ventricular', 'generalized', 'ejection fraction', 'all']",[],1671,所有广义线性模型都包括了左心室射血分数的基线值作为协变量。,0.2857142857142857,"['baseline', 'value', 'linear', 'ventricular', 'generalized', 'ejection fraction', 'all']","['baseline', 'ejection fraction']",,,,
1685,1672,"because the study protocol did not include a method for adjusting for multiplicity in testing , summary statistics are limited to point estimates and 95 % confidence intervals .",因为研究方案不包括调整测试多重性的方法，所以汇总统计仅限于点估计和 95% 置信区间。,0.25,"['statistics', 'protocol', 'study', 'method', 'multiplicity', 'point', 'testing', 'confidence', 'limited', 'and', 'intervals', 'adjusting']","['statistics', 'multiplicity', 'point']",1672,"['由于研究协议不包含对测试中的多样性进行调整的方法,总结统计数据仅限于点估计和95%的信任间隔。']",0.25,"['statistics', 'protocol', 'study', 'method', 'multiplicity', 'point', 'testing', 'confidence', 'limited', 'and', 'intervals', 'adjusting']","['statistics', 'protocol', 'point']",1672,"This is because the study protocol did not include a method for adjusting for multiplicity in testing, so summary statistics are limited to point estimates and 95% confidence intervals.",0.0,"['statistics', 'protocol', 'study', 'method', 'multiplicity', 'point', 'testing', 'confidence', 'limited', 'and', 'intervals', 'adjusting']",[],,,,
1686,1673,"the widths of the intervals were not adjusted for multiplicity ; therefore , the intervals should not be viewed as evidence for significant associations or treatment effects .",间隔的宽度未针对多重性进行调整；因此，间隔不应被视为显着关联或治疗效果的证据。,0.4285714285714285,"['be', 'treatment', 'evidence', 'multiplicity', 'as', 'therefore', 'intervals']","['treatment', 'evidence', 'multiplicity']",1673,"['间隔的宽度不适用于多样性;因此,间隔不应视为显著的结合或治疗效果的证据。']",0.2857142857142857,"['be', 'treatment', 'evidence', 'multiplicity', 'as', 'therefore', 'intervals']","['treatment', 'evidence']",1673,"Interval widths were not adjusted for multiplicity, so the intervals should not be interpreted as evidence for significant associations or treatment effects.",0.0,"['be', 'treatment', 'evidence', 'multiplicity', 'as', 'therefore', 'intervals']",[],,,,
1687,1674,P values of less than 0.05 were considered to indicate statistical significance .,小于 0.05 的 P 值被认为表明具有统计学意义。,0.2,"['indicate', 'statistical significance', 'values', 'P', 'to']",['to'],1674,['低于 0.05 的 P 值被认为表明统计意义。'],0.2,"['indicate', 'statistical significance', 'values', 'P', 'to']",['to'],1674,"P values of less than 0.05 were considered to indicate statistical significance.

中文：

P值小于0.05被认为表明统计学意义。",0.2,"['indicate', 'statistical significance', 'values', 'P', 'to']",['to'],,,,
1688,1675,study POPULATION AND THE EFFECT OF CABG,研究人口和 CABG 的影响,0.0,"['study', 'CABG']",[],1675,['研究人口和CABG的影响'],0.0,"['study', 'CABG']",[],1675,研究人口和CABG的影响,0.0,"['study', 'CABG']",[],,,,
1689,1676,"of the 1212 patients enrolled in the STICH trial , 601 patients who underwent myocardial viability testing met the inclusion criteria for the substudy .",在参加 STICH 试验的 1212 名患者中，有 601 名接受过心肌活力测试的患者符合子研究的纳入标准。,0.0,"['who', 'inclusion', 'viability', 'trial', 'myocardial', 'testing', 'met']",[],1676,"['在 STICH 研究中注册的 1212 名患者中,601 名接受心血管可行性测试的患者满足了本科研究的包含标准。']",0.1428571428571428,"['who', 'inclusion', 'viability', 'trial', 'myocardial', 'testing', 'met']",['inclusion'],1676,在STICH实验中共有1212名患者，601名经过心肌活性测试符合副研究的入选标准。,0.0,"['who', 'inclusion', 'viability', 'trial', 'myocardial', 'testing', 'met']",[],,,,
1690,1677,the baseline characteristics of the 1212 patients overall and according to whether they underwent viability testing are shown in Table S2 in the Supplementary Appendix .,补充附录表 S2 显示了 1212 名患者的总体基线特征以及他们是否接受了生存力测试。,0.3,"['appendix', 'table', 'baseline', 'viability', 'supplementary', 'characteristics', 'testing', 'S2', 'to', 'and']","['table', 'baseline', 'characteristics']",1677,"['根据1212名患者的基本特征,以及他们是否经过可行性测试,在附件中的表 S2 显示。']",0.3,"['appendix', 'table', 'baseline', 'viability', 'supplementary', 'characteristics', 'testing', 'S2', 'to', 'and']","['appendix', 'table', 'characteristics']",1677,表S2中的1212位病人的基线特征，根据是否进行过可活性测试进行了分类。,0.3,"['appendix', 'table', 'baseline', 'viability', 'supplementary', 'characteristics', 'testing', 'S2', 'to', 'and']","['table', 'baseline', 'characteristics']",,,,
1691,1678,outcomes IN PATIENTS WITH AND THOSE WITHOUT MYOCARDIAL VIABILITY,具有和不具有心肌活力的患者的结果,,[],[],1678,['患有和没有心脏病的患者的结果'],,[],[],1678,结果表明，肌梗死患者与非肌梗死患者的病情转归情况并无明显差异。,,[],[],,,,
1692,1679,"among the 601 patients , 487 ( 81 % ) were considered to have myocardial viability , as defined in the protocol .",在 601 名患者中，487 名 (81%) 被认为具有方案中定义的心肌活力。,0.1666666666666666,"['defined', 'protocol', 'viability', 'myocardial', 'as', 'have']",['have'],1679,"['在601名患者中,487人(81%)被认为有心脏病的可行性,如议定书所定义。']",0.5,"['defined', 'protocol', 'viability', 'myocardial', 'as', 'have']","['protocol', 'as', 'have']",1679,在601名病人中，487名（81％）被认为具有心肌存活能力，根据协议的定义。,0.3333333333333333,"['defined', 'protocol', 'viability', 'myocardial', 'as', 'have']","['protocol', 'have']",,,,
1693,1680,the remaining 114 patients ( 19 % ) were classified as not having viability .,其余 114 名患者 (19%) 被归类为没有生存能力。,0.0,"['viability', 'classified']",[],1680,['其余的114名患者(19%)被列为无可行性。'],0.0,"['viability', 'classified']",[],1680,剩余的114名病人（19%）被归类为无生命力。,0.0,"['viability', 'classified']",[],,,,
1694,1681,Table 1 lists the demographic and clinical characteristics of the patients overall and according to the presence or absence of myocardial viability .,表 1 列出了患者的总体人口统计学和临床特征，以及是否存在心肌活力。,0.5,"['presence', 'table', '1', 'viability', 'absence', 'clinical', 'characteristics', 'myocardial', 'to', 'and']","['presence', 'table', '1', 'clinical', 'characteristics']",1681,"['图1列出患者的人口和临床特征,并根据心血管可行性的存在或缺席。']",0.5,"['presence', 'table', '1', 'viability', 'absence', 'clinical', 'characteristics', 'myocardial', 'to', 'and']","['presence', '1', 'absence', 'clinical', 'characteristics']",1681,表1列出了患者总体及根据心肌可活性存在或缺失情况的人口学和临床特征。,0.5,"['presence', 'table', '1', 'viability', 'absence', 'clinical', 'characteristics', 'myocardial', 'to', 'and']","['presence', 'table', '1', 'clinical', 'characteristics']",,,,
1695,1682,"although CABG plus medical therapy was associated with a lower incidence of death from any cause than medical therapy alone ( Figure 1A ) , the interaction between the presence or absence of myocardial viability and the beneficial effect of CABG plus medical therapy over medical therapy alone was not significant ( P = 0.34 ) ( Figure 1B and 1C ) .",尽管 CABG 联合药物治疗与全因死亡发生率低于单独药物治疗相关（图 1A ），但心肌活力的存在与否与 CABG 联合药物治疗相对于单独药物治疗的有益效果之间的交互作用并不明显。显着 (P = 0.34)（图 1B 和 1C）。,0.2857142857142857,"['presence', 'incidence', 'death', 'figure', 'plus', 'viability', 'medical', 'lower', 'therapy', 'CABG', 'associated', 'absence', 'cause', 'interaction', 'effect', 'myocardial', 'with', 'P', 'over', 'and', 'alone']","['presence', 'incidence', 'death', 'therapy', 'effect', 'alone']",1682,"['雖然CABG加上醫療治療與任何原因死亡率低於醫療治療(圖1A)相結合,但心血管生存能力的存在或缺乏與CABG加上醫療治療對醫療治療的有益效應之間的相互作用並不顯著(圖1B和1C)。']",0.2857142857142857,"['presence', 'incidence', 'death', 'figure', 'plus', 'viability', 'medical', 'lower', 'therapy', 'CABG', 'associated', 'absence', 'cause', 'interaction', 'effect', 'myocardial', 'with', 'P', 'over', 'and', 'alone']","['presence', 'death', 'plus', 'absence', 'cause', 'effect']",1682,尽管CABG加上医疗疗法与仅有医疗疗法相比，死于任何原因的发生率较低(图1A)，但心肌可活性相关因素对CABG加上医疗疗法超越仅有医疗疗法的有益影响并不显著(P=0.34)(图1B与1C)。,0.238095238095238,"['presence', 'incidence', 'death', 'figure', 'plus', 'viability', 'medical', 'lower', 'therapy', 'CABG', 'associated', 'absence', 'cause', 'interaction', 'effect', 'myocardial', 'with', 'P', 'over', 'and', 'alone']","['incidence', 'death', 'plus', 'therapy', 'cause']",,,,
1696,1683,left VENTRICULAR EJECTION FRACTION AND SUBSEQUENT OUTCOMES,左心室射血分数和后续结果,,[],[],1683,['左'],,[],[],1683,"Left ventricular ejection fraction (LVEF) is a measure of how much blood the left ventricle of the heart pumps out with each beat. LVEF is an important predictor of future cardiovascular events, such as heart failure, stroke, and death.",,[],[],,,,
1697,1684,"of the remaining 567 patients , 318 ( 56 % ) had paired imaging at baseline and at 4 months for measurement of left ventricular ejection fraction .",在其余 567 名患者中，318 名 (56%) 在基线和 4 个月时进行了配对成像测量左心室射血分数。,0.375,"['baseline', 'ventricular', 'measurement', '4', 'ejection fraction', 'at', 'imaging', 'and']","['baseline', 'measurement', 'ejection fraction']",1684,"['在剩余567名患者中,有318人(56%)在基线上和4个月内进行测量,以测量左<unk>排泄分。']",0.25,"['baseline', 'ventricular', 'measurement', '4', 'ejection fraction', 'at', 'imaging', 'and']","['baseline', 'measurement']",1684,在剩余的567名病人中，有318名（56%）在基线和4个月时进行了成对的影像检查，以测量左心室射血分数。,0.375,"['baseline', 'ventricular', 'measurement', '4', 'ejection fraction', 'at', 'imaging', 'and']","['baseline', 'measurement', 'ejection fraction']",,,,
1698,1685,"in contrast , among patients without myocardial viability , there was no improvement in left ventricular ejection fraction in either treatment group ( Figure 3 ) .",相反，在没有心肌活力的患者中，两个治疗组的左心室射血分数都没有改善（图 3）。,0.25,"['improvement', 'contrast', 'figure', 'viability', 'no', 'ventricular', 'myocardial', '3', 'treatment group', 'ejection fraction', 'in', 'without']","['improvement', 'treatment group', 'ejection fraction']",1685,"['相比之下,在没有心血管可行性患者中,在任何治疗组中,左<unk>排泄分子没有改善(图3)。']",0.1666666666666666,"['improvement', 'contrast', 'figure', 'viability', 'no', 'ventricular', 'myocardial', '3', 'treatment group', 'ejection fraction', 'in', 'without']","['improvement', 'treatment group']",1685,相比之下，在没有心肌可活力的病人中，两组治疗都没有改善左心室射血分数（图3）。,0.1666666666666666,"['improvement', 'contrast', 'figure', 'viability', 'no', 'ventricular', 'myocardial', '3', 'treatment group', 'ejection fraction', 'in', 'without']","['improvement', 'ejection fraction']",,,,
1699,1686,our study showed a lower incidence of death from any cause with CABG plus medical therapy than with medical therapy alone .,我们的研究表明，CABG 联合药物治疗的全因死亡发生率低于单独药物治疗。,0.3636363636363636,"['incidence', 'death', 'plus', 'study', 'medical', 'lower', 'therapy', 'CABG', 'cause', 'with', 'alone']","['incidence', 'death', 'therapy', 'alone']",1686,"['我们的研究表明,与CABG加医疗治疗的任何原因死亡的发病率低于单独医疗治疗的发病率。']",0.5454545454545454,"['incidence', 'death', 'plus', 'study', 'medical', 'lower', 'therapy', 'CABG', 'cause', 'with', 'alone']","['incidence', 'death', 'plus', 'therapy', 'cause', 'alone']",1686,我们的研究表明，CABG加上医疗治疗相比仅靠医疗治疗，死亡率较低。,0.2727272727272727,"['incidence', 'death', 'plus', 'study', 'medical', 'lower', 'therapy', 'CABG', 'cause', 'with', 'alone']","['death', 'plus', 'therapy']",,,,
1700,1687,"however , the tests of interaction between myocardial viability and treatment effect of CABG were not significant for any of the three end points .",然而，心肌活力与CABG治疗效果之间交互作用的检验对于三个终点中的任何一个都不显着。,0.375,"['viability', 'end points', 'CABG', 'interaction', 'myocardial', 'treatment effect', 'three', 'and']","['end points', 'treatment effect', 'and']",1687,"['然而,心血管可行性和CABG的治疗效应之间的相互作用测试在三个终点中都没有显著。']",0.25,"['viability', 'end points', 'CABG', 'interaction', 'myocardial', 'treatment effect', 'three', 'and']","['end points', 'and']",1687,然而，对于三个终点来说，心肌活力与CABG治疗效果之间的测试并不显著。,0.375,"['viability', 'end points', 'CABG', 'interaction', 'myocardial', 'treatment effect', 'three', 'and']","['end points', 'treatment effect', 'and']",,,,
1701,1688,"therefore , we must conclude that there is no statistical evidence of association between myocardial viability and benefit from CABG .",因此，我们必须得出结论，没有统计证据表明心肌活力与 CABG 获益之间存在关联。,0.1538461538461538,"['must', 'association', 'viability', 'CABG', 'no', 'myocardial', 'evidence', 'benefit', 'conclude', 'therefore', 'that', 'and', 'we']","['association', 'evidence']",1688,"['因此,我们必须得出结论,心血管可行性与CABG的好处之间没有统计证据的联系。']",0.1538461538461538,"['must', 'association', 'viability', 'CABG', 'no', 'myocardial', 'evidence', 'benefit', 'conclude', 'therefore', 'that', 'and', 'we']","['association', 'evidence']",1688,因此，我们必须得出结论，肌酐与CABG的益处之间没有统计学证据相关联。,0.1538461538461538,"['must', 'association', 'viability', 'CABG', 'no', 'myocardial', 'evidence', 'benefit', 'conclude', 'therefore', 'that', 'and', 'we']","['association', 'evidence']",,,,
1702,1689,"a number of various possibilities , alone or in combination , may account for the negative results of our study .",许多不同的可能性，单独或组合，可能会导致我们研究的负面结果。,0.5,"['combination', 'study', 'negative', 'various', 'number', 'alone']","['combination', 'various', 'alone']",1689,"['多种不同的可能性,单独或结合,可能会对我们的研究的负面结果负责。']",0.5,"['combination', 'study', 'negative', 'various', 'number', 'alone']","['combination', 'various', 'alone']",1689,"There are a number of possible explanations for the negative results of our study, either alone or in combination.",0.0,"['combination', 'study', 'negative', 'various', 'number', 'alone']",[],,,,
1703,1690,"it is certainly possible that a true biologic interaction exists between myocardial viability and the benefit of revascularization and that we were unable to unveil it because of the relatively small number of patients , especially patients without myocardial viability , included in our study .",心肌活力和血运重建的益处之间存在真正的生物学相互作用当然是可能的，但由于纳入我们研究的患者数量相对较少，尤其是没有心肌活力的患者，我们无法揭示这一点。,0.2142857142857142,"['true', 'biologic', 'viability', 'study', 'revascularization', 'number', 'interaction', 'myocardial', 'benefit', 'that', 'and', 'unable to', 'without', 'we']","['revascularization', 'number', 'without']",1690,"['毫无疑问,在心脏病的可行性和复发的好处之间存在真正的生物相互作用,并且由于我们研究中所涉及的患者,尤其是没有心脏病的可行性患者,相对较少的数量,我们无法揭示它。']",0.1428571428571428,"['true', 'biologic', 'viability', 'study', 'revascularization', 'number', 'interaction', 'myocardial', 'benefit', 'that', 'and', 'unable to', 'without', 'we']","['number', 'without']",1690,有可能存在一种真正的心肌活性与再血管化益处之间的生物学相互作用，我们之所以没能发现它，是因为我们的研究对象相对较少，特别是没有心肌活性的患者。,0.0,"['true', 'biologic', 'viability', 'study', 'revascularization', 'number', 'interaction', 'myocardial', 'benefit', 'that', 'and', 'unable to', 'without', 'we']",[],,,,
1704,1691,"a complementary explanation is that the physiological complexity underpinning the potential therapeutic benefit of surgical revascularization cannot be surmised from the results of a single test of myocardial viability , particularly when those results are expressed in a dichotomous fashion ( i.e. , patients having or not having viability ) .",一个补充的解释是，不能从单一的心肌活力测试结果中推测支持手术血运重建潜在治疗益处的生理学复杂性，特别是当这些结果以二分法方式表示时（即，患者有或没有活力） .,0.1333333333333333,"['complementary', 'test', 'potential', 'complexity', 'viability', 'surgical', 'revascularization', 'therapeutic', 'myocardial', 'physiological', 'benefit', 'underpinning', 'explanation', 'that', 'single']","['revascularization', 'single']",1691,"['一个补充的解释是,基于外科复发的潜在治疗好处的生理复杂性不能从单一心脏可行性测试的结果中超越,特别是当这些结果以二元性方式表达(即有或没有可行性患者)。']",0.0666666666666666,"['complementary', 'test', 'potential', 'complexity', 'viability', 'surgical', 'revascularization', 'therapeutic', 'myocardial', 'physiological', 'benefit', 'underpinning', 'explanation', 'that', 'single']",['single'],1691,一个补充解释是，手术再血管化的潜在治疗效益的生理复杂性无法从一项心肌可活性测试的结果中推断出来，特别是当这些结果以二元化的方式表示（即患者有或没有可活性）时。,0.0,"['complementary', 'test', 'potential', 'complexity', 'viability', 'surgical', 'revascularization', 'therapeutic', 'myocardial', 'physiological', 'benefit', 'underpinning', 'explanation', 'that', 'single']",[],,,,
1705,1692,"in fact , previous results from the STICH trial showed that the degree of left ventricular systolic dysfunction and remodeling and the number of stenotic coronary arteries appear to be stronger determinants of the benefit of revascularization than myocardial viability.19",事实上，之前 STICH 试验的结果表明，左心室收缩功能障碍和重塑的程度以及狭窄冠状动脉的数量似乎是血运重建获益的比心肌活力更强的决定因素。 19,0.2666666666666666,"['dysfunction', 'previous', 'coronary', 'degree', 'revascularization', 'stenotic', 'number', 'ventricular', 'systolic', 'trial', 'myocardial', 'benefit', 'that', 'in', 'and']","['coronary', 'degree', 'revascularization', 'number']",1692,"['事实上,STICH试验的先前结果表明,左腹部系统性功能障碍和修复的程度以及甲状腺甲状腺的数量似乎比心血管生存能力更为决定性。']",0.1333333333333333,"['dysfunction', 'previous', 'coronary', 'degree', 'revascularization', 'stenotic', 'number', 'ventricular', 'systolic', 'trial', 'myocardial', 'benefit', 'that', 'in', 'and']","['degree', 'number']",1692,实际上，STICH试验的先前结果表明，心肌功能障碍和心肌重构的程度以及狭窄的冠状动脉数量似乎是决定再血管化效益的更强因素。19,0.2,"['dysfunction', 'previous', 'coronary', 'degree', 'revascularization', 'stenotic', 'number', 'ventricular', 'systolic', 'trial', 'myocardial', 'benefit', 'that', 'in', 'and']","['coronary', 'degree', 'number']",,,,
1706,1693,patients with ischemic cardiomyopathy often present with complex and challenging clinical scenarios .,缺血性心肌病患者通常会出现复杂且具有挑战性的临床情况。,0.4285714285714285,"['complex', 'clinical', 'cardiomyopathy', 'present', 'with', 'and', 'ischemic']","['clinical', 'cardiomyopathy', 'present']",1693,['患有催化性心脏病的患者经常面临复杂和挑战性的临床场景。'],0.1428571428571428,"['complex', 'clinical', 'cardiomyopathy', 'present', 'with', 'and', 'ischemic']",['clinical'],1693,缺血性心肌病患者经常出现复杂而具挑战性的临床情况。,0.5714285714285714,"['complex', 'clinical', 'cardiomyopathy', 'present', 'with', 'and', 'ischemic']","['clinical', 'cardiomyopathy', 'present', 'and']",,,,
1707,1694,"therefore , the results of tests for detection of viable myocardium must be interpreted within the context of the multiplicity of factors necessary to reach the best treatment decision for each patient .",因此，必须在为每位患者做出最佳治疗决策所需的多种因素的背景下解释活心肌检测试验的结果。,0.4285714285714285,"['must', 'viable', 'detection', 'myocardium', 'context', 'be', 'treatment', 'necessary', 'patient', 'decision', 'multiplicity', 'therefore', 'to', 'reach']","['detection', 'myocardium', 'be', 'treatment', 'patient', 'decision']",1694,"['因此,可行的心脏病检测测试的结果必须在每个患者获得最佳治疗决策所需的因素多样性背景下进行解释。']",0.3571428571428571,"['must', 'viable', 'detection', 'myocardium', 'context', 'be', 'treatment', 'necessary', 'patient', 'decision', 'multiplicity', 'therefore', 'to', 'reach']","['detection', 'be', 'treatment', 'patient', 'decision']",1694,因此，必须在每个患者的最佳治疗决策的背景下解释存活的心肌的检测结果。,0.5,"['must', 'viable', 'detection', 'myocardium', 'context', 'be', 'treatment', 'necessary', 'patient', 'decision', 'multiplicity', 'therefore', 'to', 'reach']","['viable', 'detection', 'myocardium', 'be', 'treatment', 'patient', 'decision']",,,,
1708,1695,"these factors include not only the results of functional tests but also the anatomical extent of coronary and myocardial disease , as well as the regional correspondence between segmental left ventricular dysfunction and the likelihood of successful revascularization of the corresponding coronary arteries .",这些因素不仅包括功能测试的结果，还包括冠状动脉和心肌疾病的解剖范围，以及节段性左心室功能障碍与相应冠状动脉成功血运重建的可能性之间的区域对应关系。,0.25,"['correspondence', 'corresponding', 'dysfunction', 'anatomical', 'disease', 'regional', 'functional', 'coronary', 'revascularization', 'well', 'ventricular', 'segmental', 'myocardial', 'extent', 'but', 'and']","['correspondence', 'disease', 'coronary', 'revascularization']",1695,"['这些因素不仅包括功能测试的结果,而且还包括冠状和心血管疾病的解剖学范围,以及分区左<unk>功能障碍和相关冠状动脉的成功复发的可能性之间的区域匹配。']",0.25,"['correspondence', 'corresponding', 'dysfunction', 'anatomical', 'disease', 'regional', 'functional', 'coronary', 'revascularization', 'well', 'ventricular', 'segmental', 'myocardial', 'extent', 'but', 'and']","['disease', 'coronary', 'but', 'and']",1695,这些因素不仅包括功能测试的结果，还包括心冠和心肌病的解剖范围，以及段落左心室功能障碍与相应心冠血管成功再通的区域对应关系。,0.1875,"['correspondence', 'corresponding', 'dysfunction', 'anatomical', 'disease', 'regional', 'functional', 'coronary', 'revascularization', 'well', 'ventricular', 'segmental', 'myocardial', 'extent', 'but', 'and']","['correspondence', 'disease', 'coronary']",,,,
1709,1696,a putative mechanism that mediates the benefit of CABG among patients with myocardial viability is the improvement in left ventricular systolic function that results from revascularization .,在有心肌活力的患者中介导 CABG 获益的推定机制是血运重建导致左心室收缩功能的改善。,0.3076923076923077,"['improvement', 'mechanism', 'function', 'viability', 'revascularization', 'CABG', 'ventricular', 'systolic', 'myocardial', 'benefit', 'with', 'that', 'in']","['improvement', 'mechanism', 'function', 'revascularization']",1696,['在患有心血管可行性患者中介CABG的好处的突出机制是由于重复性而导致的左侧阴道系统功能的改善。'],0.2307692307692307,"['improvement', 'mechanism', 'function', 'viability', 'revascularization', 'CABG', 'ventricular', 'systolic', 'myocardial', 'benefit', 'with', 'that', 'in']","['improvement', 'mechanism', 'function']",1696,一种据称可以使心肌有生命力的人从CABG中受益的机制是，通过再血管化改善左心室收缩功能。,0.2307692307692307,"['improvement', 'mechanism', 'function', 'viability', 'revascularization', 'CABG', 'ventricular', 'systolic', 'myocardial', 'benefit', 'with', 'that', 'in']","['improvement', 'mechanism', 'function']",,,,
1710,1697,"in our study , a modest but significant increase in left ventricular ejection fraction at 4 months was indeed observed among patients with viable myocardium .",在我们的研究中，确实在有存活心肌的患者中观察到 4 个月时左心室射血分数适度但显着的增加。,0.3636363636363636,"['viable', 'myocardium', 'study', 'ventricular', '4', 'increase', 'with', 'ejection fraction', 'at', 'indeed', 'but']","['viable', 'myocardium', 'ejection fraction', 'but']",1697,"['在我們的研究中,在4個月的左<unk>排泄分子中,實際上在患有生存性心臟病的患者中發現了一種微不足道但有意義的增加。']",0.0909090909090909,"['viable', 'myocardium', 'study', 'ventricular', '4', 'increase', 'with', 'ejection fraction', 'at', 'indeed', 'but']",['but'],1697,在我们的研究中，4个月后可见心脏组织中离心率的轻微但显著增加。,0.0909090909090909,"['viable', 'myocardium', 'study', 'ventricular', '4', 'increase', 'with', 'ejection fraction', 'at', 'indeed', 'but']",['but'],,,,
1711,1698,"nevertheless , when the amount of viable myocardium was assessed as a continuous variable , no association was observed between the extent of viability and the magnitude of improvement in left ventricular function either with or without CABG , findings that indicate that the quantitative relationship between these variables is weak .",尽管如此，当存活心肌的数量被评估为一个连续变量时，无论有无 CABG，在存活程度和左心室功能改善程度之间均未观察到关联，这些发现表明这些变量之间的定量关系是虚弱的 。,0.4761904761904761,"['variable', 'improvement', 'relationship', 'viable', 'myocardium', 'association', 'continuous', 'function', 'viability', 'indicate', 'CABG', 'amount', 'no', 'ventricular', 'weak', 'magnitude', 'extent', 'that', 'and', 'without', 'assessed']","['variable', 'improvement', 'viable', 'myocardium', 'association', 'continuous', 'function', 'amount', 'magnitude', 'without']",1698,"['然而,当可行的心血管量被评为连续变量时,没有观察到可行的程度和左肢功能的改善程度之间的联系,无论是与或没有CABG,这些发现表明这些变量之间的定量关系很弱。']",0.4285714285714285,"['variable', 'improvement', 'relationship', 'viable', 'myocardium', 'association', 'continuous', 'function', 'viability', 'indicate', 'CABG', 'amount', 'no', 'ventricular', 'weak', 'magnitude', 'extent', 'that', 'and', 'without', 'assessed']","['variable', 'improvement', 'association', 'continuous', 'function', 'amount', 'magnitude', 'and', 'without']",1698,尽管如此，当可生存的心肌的数量被评估为一个连续变量时，无论是否有CABG，在左心室功能的改善程度上都没有观察到可生存程度与这些变量之间的量化关系是微弱的。,0.3809523809523809,"['variable', 'improvement', 'relationship', 'viable', 'myocardium', 'association', 'continuous', 'function', 'viability', 'indicate', 'CABG', 'amount', 'no', 'ventricular', 'weak', 'magnitude', 'extent', 'that', 'and', 'without', 'assessed']","['variable', 'improvement', 'myocardium', 'continuous', 'function', 'amount', 'magnitude', 'without']",,,,
1712,1699,"there was no association between improvement in left ventricular ejection fraction at 4 months and subsequent survival , nor was there a significant interaction between myocardial viability and changes in left ventricular ejection fraction with regard to death from any cause or death from cardiovascular causes .",4 个月时左心室射血分数的改善与随后的生存率之间没有关联，在任何原因死亡或心血管原因死亡方面，心肌活力和左心室射血分数变化之间也没有显着的相互作用。,0.4117647058823529,"['improvement', 'cardiovascular', 'survival', 'death', 'association', 'viability', 'cause', 'no', 'ventricular', 'interaction', 'subsequent', 'myocardial', '4', 'with', 'ejection fraction', 'to', 'and']","['improvement', 'cardiovascular', 'survival', 'death', 'association', 'cause', 'ejection fraction']",1699,"['4个月的左<unk>排泄部分的改善和随后的生存之间没有任何联系,心血管生存和左<unk>排泄部分的变化与任何原因死亡或心血管原因死亡之间没有任何显著的相互作用。']",0.3529411764705882,"['improvement', 'cardiovascular', 'survival', 'death', 'association', 'viability', 'cause', 'no', 'ventricular', 'interaction', 'subsequent', 'myocardial', '4', 'with', 'ejection fraction', 'to', 'and']","['improvement', 'cardiovascular', 'survival', 'death', 'association', 'cause']",1699,"There was no association between improvement in left ventricular ejection fraction at 4 months and subsequent survival, nor was there a significant interaction between myocardial viability and changes in left ventricular ejection fraction with regard to death from any cause or death from cardiovascular causes.",0.0,"['improvement', 'cardiovascular', 'survival', 'death', 'association', 'viability', 'cause', 'no', 'ventricular', 'interaction', 'subsequent', 'myocardial', '4', 'with', 'ejection fraction', 'to', 'and']",[],,,,
1713,1700,"thus , our results suggest that abatement or reversal of left ventricular systolic dysfunction is not a critical mechanism involved in mediating the beneficial effect of CABG in these patients .",因此，我们的研究结果表明，减轻或逆转左心室收缩功能障碍并不是介导这些患者接受 CABG 有益效果的关键机制。,0.25,"['dysfunction', 'mechanism', 'CABG', 'abatement', 'ventricular', 'thus', 'systolic', 'effect', 'critical', 'suggest', 'that', 'in']","['mechanism', 'thus', 'effect']",1700,"['因此,我們的結果表明,左<unk>系統功能障礙的下降或逆轉並不是對這些患者中介CABG的有益效果的關鍵機制。']",0.1666666666666666,"['dysfunction', 'mechanism', 'CABG', 'abatement', 'ventricular', 'thus', 'systolic', 'effect', 'critical', 'suggest', 'that', 'in']","['thus', 'effect']",1700,因此，我们的结果表明，在这些患者中，减轻或逆转左心室心脏功能不足并不是促使CABG有益影响的关键机制。,0.1666666666666666,"['dysfunction', 'mechanism', 'CABG', 'abatement', 'ventricular', 'thus', 'systolic', 'effect', 'critical', 'suggest', 'that', 'in']","['mechanism', 'thus']",,,,
1714,1701,certain limitations of this study must be acknowledged .,必须承认这项研究的某些局限性。,0.0,"['must', 'study', 'be', 'certain', 'this']",[],1701,['该研究的某些限制必须得到认可。'],0.0,"['must', 'study', 'be', 'certain', 'this']",[],1701,There are certain limitations to this study that must be acknowledged.,0.0,"['must', 'study', 'be', 'certain', 'this']",[],,,,
1715,1702,"first , only half the patients enrolled in the STICH trial had an assessment of myocardial viability .",首先，参加 STICH 试验的患者中只有一半对心肌活力进行了评估。,0.4285714285714285,"['half', 'viability', 'assessment', 'trial', 'myocardial', 'in', 'first']","['half', 'assessment', 'first']",1702,"['首先,只有半数参加STICH试验的患者对心血管可行性进行了评估。']",0.4285714285714285,"['half', 'viability', 'assessment', 'trial', 'myocardial', 'in', 'first']","['half', 'assessment', 'first']",1702,首先，只有一半的参与STICH实验的病人进行了心肌活力评估。,0.4285714285714285,"['half', 'viability', 'assessment', 'trial', 'myocardial', 'in', 'first']","['half', 'assessment', 'first']",,,,
1716,1703,"consequently , the development and potential prognostic effect of changes in left ventricular function that might have occurred at a later time could not be assessed as part of this study .",因此，作为本研究的一部分，无法评估可能在稍后时间发生的左心室功能变化的发展和潜在的预后影响。,0.4117647058823529,"['part', 'potential', 'function', 'study', 'time', 'be', 'ventricular', 'prognostic', 'effect', 'development', 'have', 'this', 'that', 'later', 'in', 'and', 'assessed']","['part', 'potential', 'function', 'time', 'be', 'development', 'later']",1703,"['因此,在后期可能发生的左<unk>功能的变化的发展和潜在的预测效果不能作为这项研究的一部分进行评估。']",0.4705882352941176,"['part', 'potential', 'function', 'study', 'time', 'be', 'ventricular', 'prognostic', 'effect', 'development', 'have', 'this', 'that', 'later', 'in', 'and', 'assessed']","['part', 'potential', 'function', 'be', 'prognostic', 'effect', 'development', 'later']",1703,因此，在这项研究中无法评估随后可能发生的左心室功能改变的发展和预后效应。,0.2941176470588235,"['part', 'potential', 'function', 'study', 'time', 'be', 'ventricular', 'prognostic', 'effect', 'development', 'have', 'this', 'that', 'later', 'in', 'and', 'assessed']","['function', 'be', 'effect', 'development', 'later']",,,,
1717,1704,"it must also be noted that the assessment of changes in left ventricular ejection fraction was performed only among patients with paired studies at baseline and 4 months , with the resultant reduction in the number of observations .",还必须指出的是，左心室射血分数变化的评估仅在基线和 4 个月时进行配对研究的患者中进行，结果导致观察次数减少。,0.5,"['must', 'baseline', 'reduction', 'assessment', 'number', 'ventricular', 'resultant', '4', 'with', 'ejection fraction', 'that', 'and']","['baseline', 'reduction', 'assessment', 'number', 'resultant', 'ejection fraction']",1704,"['值得注意的是,左腹部排泄部分的变化评估仅在基线和4个月的患者中进行,结果观测数量减少。']",0.4166666666666667,"['must', 'baseline', 'reduction', 'assessment', 'number', 'ventricular', 'resultant', '4', 'with', 'ejection fraction', 'that', 'and']","['baseline', 'reduction', 'assessment', 'number', 'resultant']",1704,需要指出的是，对左心室射血分数变化的评估仅在基线和4个月的配对研究中进行，这导致观察结果的减少。,0.5,"['must', 'baseline', 'reduction', 'assessment', 'number', 'ventricular', 'resultant', '4', 'with', 'ejection fraction', 'that', 'and']","['baseline', 'reduction', 'assessment', 'number', 'resultant', 'ejection fraction']",,,,
1718,1705,"finally , our findings are based on the assessment of myocardial viability with either SPECT or dobutamine echocardiography .",最后，我们的研究结果基于使用 SPECT 或多巴酚丁胺超声心动图评估心肌活力。,0.2857142857142857,"['SPECT', 'viability', 'assessment', 'myocardial', 'with', 'on', 'echocardiography']","['SPECT', 'assessment']",1705,"['最后,我们的发现是基于对心脏病的可行性评估,无论是SPECT还是Dubutamine echocardiography。']",0.2857142857142857,"['SPECT', 'viability', 'assessment', 'myocardial', 'with', 'on', 'echocardiography']","['SPECT', 'assessment']",1705,最终，我们的研究结果是基于对心肌活性的SPECT或Dobutamine超声心动图的评估。,0.2857142857142857,"['SPECT', 'viability', 'assessment', 'myocardial', 'with', 'on', 'echocardiography']","['SPECT', 'assessment']",,,,
1719,1706,"the study did not include the routine performance of cardiac magnetic resonance imaging , which has become an accepted technique for the assessment of myocardial scarring .",该研究不包括心脏磁共振成像的常规表现，这已成为评估心肌瘢痕形成的公认技术。,0.5454545454545454,"['cardiac', 'routine', 'study', 'magnetic resonance imaging', 'assessment', 'scarring', 'technique', 'myocardial', 'performance', 'accepted', 'become']","['cardiac', 'routine', 'assessment', 'scarring', 'technique', 'become']",1706,"['该研究不包括心脏磁响图像的日常性能,这已成为评估心脏刺激的接受技术。']",0.4545454545454545,"['cardiac', 'routine', 'study', 'magnetic resonance imaging', 'assessment', 'scarring', 'technique', 'myocardial', 'performance', 'accepted', 'become']","['cardiac', 'assessment', 'technique', 'performance', 'become']",1706,这项研究并没有包括所谓的常规性心脏磁共振成像，而这已经成为评估心肌瘢痕的一种普遍接受的技术。,0.4545454545454545,"['cardiac', 'routine', 'study', 'magnetic resonance imaging', 'assessment', 'scarring', 'technique', 'myocardial', 'performance', 'accepted', 'become']","['cardiac', 'routine', 'assessment', 'technique', 'become']",,,,
1720,1707,"for neonatal as well as maternal outcomes , the 39th week of gestation appears to be the sweet spot .",对于新生儿和产妇的结局，妊娠第 39 周似乎是最佳时期。,0.3,"['neonatal', 'maternal', 'gestation', 'be', 'well', 'week', 'spot', 'as', 'sweet', 'to']","['gestation', 'week', 'to']",1707,"['对于新生儿和母亲的结果,第39周的怀孕似乎是甜点。']",0.5,"['neonatal', 'maternal', 'gestation', 'be', 'well', 'week', 'spot', 'as', 'sweet', 'to']","['maternal', 'gestation', 'week', 'spot', 'to']",1707,根据新生儿和母亲的结局来看，孕39周似乎是最佳时期。,0.3,"['neonatal', 'maternal', 'gestation', 'be', 'well', 'week', 'spot', 'as', 'sweet', 'to']","['maternal', 'gestation', 'week']",,,,
1721,1708,"the composite adverse maternal outcome ( ICU admission , blood transfusion , uterine rupture , unplanned hysterectomy ) occurred in 0.21 % , 0.24 % , and 0.31 % of births ( aOR for 41 vs. 39 weeks , 1.50 ) .",复合不良母体结局（入住 ICU、输血、子宫破裂、计划外子宫切除术）分别发生在 0.21%、0.24% 和 0.31% 的分娩中（41 周对 39 周的 aOR 为 1.50）。,0.4,"['composite', 'maternal', 'hysterectomy', 'rupture', 'outcome', 'uterine', 'admission', 'adverse', 'blood transfusion', 'and']","['maternal', 'hysterectomy', 'rupture', 'blood transfusion']",1708,['合成不良母性结果(ICU接收、血液转移、子宫骨折、未计划的歇斯底里)发生在0.21%、0.24%和0.31%的出生(AOR为41对39周、1.50)。'],0.3,"['composite', 'maternal', 'hysterectomy', 'rupture', 'outcome', 'uterine', 'admission', 'adverse', 'blood transfusion', 'and']","['maternal', 'outcome', 'admission']",1708,0.21%、0.24%和0.31%的分娩母親會出現複合不良結局（住院、輸血、子宮破裂、未經計劃的子宮切除手術）（41週與39週相比的aOR為1.50）。,0.2,"['composite', 'maternal', 'hysterectomy', 'rupture', 'outcome', 'uterine', 'admission', 'adverse', 'blood transfusion', 'and']","['maternal', 'rupture']",,,,
1722,1709,both these studies are limited by their retrospective design .,这两项研究都受到回顾性设计的限制。,0.3333333333333333,"['design', 'limited', 'by']",['design'],1709,['这两项研究都受到其逆向设计的限制。'],0.3333333333333333,"['design', 'limited', 'by']",['design'],1709,这两项研究都受到其回顾性设计的限制。,0.3333333333333333,"['design', 'limited', 'by']",['design'],,,,
1723,1710,decisions about induction or expectant management are jointly made by clinicians and patients .,关于诱导或期待治疗的决定由临床医生和患者共同做出。,0.5,"['induction', 'management', 'by', 'and']","['induction', 'by']",1710,['关于引发或预期管理的决定由临床医生和患者共同做出。'],0.5,"['induction', 'management', 'by', 'and']","['management', 'by']",1710,决策有关感应或期望的管理是由临床医生和病人共同做出的。,0.75,"['induction', 'management', 'by', 'and']","['induction', 'management', 'by']",,,,
1724,1711,"in our practice , such decisions reflect national guidelines to avoid elective induction before 39 weeks and 0 days gestation ; also , we recommend against continuing pregnancy beyond 41 weeks and 0 days gestation .",在我们的实践中，此类决定反映了避免在妊娠 39 周和 0 天前进行选择性引产的国家指南；此外，我们建议不要继续怀孕超过 41 周和 0 天妊娠。,0.5833333333333334,"['pregnancy', 'induction', 'gestation', 'recommend', 'reflect', 'elective', 'practice', 'before', 'to', 'and', 'avoid', 'we']","['pregnancy', 'gestation', 'recommend', 'reflect', 'practice', 'before', 'avoid']",1711,"['在我们的实践中,这些决定反映了国家指南,以避免在39周和0天怀孕前选择性引发;此外,我们建议在41周和0天怀孕后继续怀孕。']",0.5833333333333334,"['pregnancy', 'induction', 'gestation', 'recommend', 'reflect', 'elective', 'practice', 'before', 'to', 'and', 'avoid', 'we']","['pregnancy', 'gestation', 'recommend', 'reflect', 'practice', 'before', 'avoid']",1711,在我們的做法中，這些決定反映了國家建議，以避免在39週0天的胎兒誘導選擇性誘導；此外，我們建議不要繼續懷孕超過41週0天。,0.25,"['pregnancy', 'induction', 'gestation', 'recommend', 'reflect', 'elective', 'practice', 'before', 'to', 'and', 'avoid', 'we']","['gestation', 'reflect', 'avoid']",,,,
1725,1712,"limited data document the benefits and safety of intensive lipid lowering in adults aged ≥ 75 , who are often underrepresented in clinical trials .",有限的数据记录了强化降脂对 75 岁以上成年人的益处和安全性，这些人在临床试验中的代表性往往不足。,0.4545454545454545,"['safety', 'lipid', 'data', 'who', 'document', 'intensive', 'clinical', 'aged', 'lowering', 'limited', 'and']","['safety', 'data', 'document', 'clinical', 'limited']",1712,"['有限的数据证明了75岁以上的成年人强烈脂肪降低的好处和安全性,他们在临床试验中经常被低估。']",0.3636363636363636,"['safety', 'lipid', 'data', 'who', 'document', 'intensive', 'clinical', 'aged', 'lowering', 'limited', 'and']","['safety', 'data', 'clinical', 'limited']",1712,There is limited data documenting the benefits and safety of intensive lipid lowering in adults aged 75 and older. These adults are often underrepresented in clinical trials.,0.0,"['safety', 'lipid', 'data', 'who', 'document', 'intensive', 'clinical', 'aged', 'lowering', 'limited', 'and']",[],,,,
1726,1713,no group had an increase in adverse events .,没有任何一组的不良事件增加。,0.25,"['group', 'adverse', 'no', 'increase']",['group'],1713,['没有一个群体出现了不良事件的增加。'],0.25,"['group', 'adverse', 'no', 'increase']",['group'],1713,没有一个组群的不良事件有所增加。,0.25,"['group', 'adverse', 'no', 'increase']",['group'],,,,
1727,1714,"every additional hour engaged in social media , computer use , or television viewing was associated with increased severity of depressive symptoms .",参与社交媒体、使用电脑或看电视的时间每增加一小时，抑郁症状的严重程度就会增加。,0.4,"['computer', 'symptoms', 'media', 'associated', 'additional', 'depressive', 'with', 'television', 'hour', 'in']","['computer', 'depressive', 'television', 'hour']",1714,['社交媒体、计算机使用或电视观看的每一个额外的小时都与抑郁症状的严重性增加有关。'],0.5,"['computer', 'symptoms', 'media', 'associated', 'additional', 'depressive', 'with', 'television', 'hour', 'in']","['computer', 'additional', 'depressive', 'television', 'hour']",1714,每增加一小時參與社交媒體、使用電腦或看電視的時間，就會導致憂鬱症症狀加劇。,0.0,"['computer', 'symptoms', 'media', 'associated', 'additional', 'depressive', 'with', 'television', 'hour', 'in']",[],,,,
1728,1715,whether increased screen time contributes to the rise in depression among adolescents is unclear .,屏幕时间的增加是否会导致青少年抑郁症的增加尚不清楚。,0.5,"['depression', 'time', 'rise', 'screen', 'in', 'to']","['depression', 'time', 'screen']",1715,['是否增加屏幕时间有助于青少年抑郁症的上升是不清楚的。'],0.8333333333333334,"['depression', 'time', 'rise', 'screen', 'in', 'to']","['depression', 'time', 'rise', 'screen', 'to']",1715,"Whether increased screen time contributes to the rise in depression among adolescents is unclear.

Chinese:

目前尚不清楚增加的屏幕时间是否会导致青少年的抑郁症患病率上升。",0.6666666666666666,"['depression', 'time', 'rise', 'screen', 'in', 'to']","['depression', 'time', 'rise', 'screen']",,,,
1729,1716,researchers conducted a secondary analysis of survey data for 3826 adolescents in Montreal followed over 4 years .,研究人员对蒙特利尔 3826 名青少年跟踪调查 4 年的调查数据进行了二次分析。,0.3333333333333333,"['analysis', 'secondary', '4', 'survey data', 'in', 'over']","['analysis', 'survey data']",1716,"['研究人员对蒙特利尔的3826名青少年进行了次要分析,其次是4年。']",0.1666666666666666,"['analysis', 'secondary', '4', 'survey data', 'in', 'over']",['analysis'],1716,研究人员对蒙特利尔3826名青少年进行了为期4年的调查数据的二次分析。,0.3333333333333333,"['analysis', 'secondary', '4', 'survey data', 'in', 'over']","['analysis', 'survey data']",,,,
1730,1717,increased time engaged in video games was not associated with increased depressive symptoms in either analysis .,在任何一项分析中，增加玩电子游戏的时间都与抑郁症状增加无关。,0.375,"['analysis', 'symptoms', 'time', 'associated', 'depressive', 'video', 'with', 'in']","['analysis', 'time', 'depressive']",1717,['在视频游戏中花费的时间增加与任何分析中增加的抑郁症状无关。'],0.375,"['analysis', 'symptoms', 'time', 'associated', 'depressive', 'video', 'with', 'in']","['analysis', 'time', 'depressive']",1717,增加的视频游戏时间与增加的抑郁症状无关。,0.25,"['analysis', 'symptoms', 'time', 'associated', 'depressive', 'video', 'with', 'in']","['time', 'depressive']",,,,
1731,1718,these findings confirm that increased screen time is associated with adverse mental health outcomes for teens .,这些发现证实，屏幕时间增加与青少年的不良心理健康结果有关。,0.5,"['mental health', 'time', 'adverse', 'associated', 'screen', 'with', 'teens', 'that']","['mental health', 'time', 'screen', 'teens']",1718,"['这些发现证实,增加屏幕时间与青少年精神健康的负面结果有关。']",0.5,"['mental health', 'time', 'adverse', 'associated', 'screen', 'with', 'teens', 'that']","['mental health', 'time', 'screen', 'teens']",1718,这些研究结果证实，青少年增加的屏幕时间与不利的心理健康结果有关。,0.5,"['mental health', 'time', 'adverse', 'associated', 'screen', 'with', 'teens', 'that']","['mental health', 'time', 'screen', 'teens']",,,,
1732,1719,ischemic stroke risk was associated with Lp ( a ) levels and LPA gene variants in a contemporary Danish population study .,在当代丹麦人口研究中，缺血性中风风险与 Lp (a) 水平和 LPA 基因变异有关。,0.6,"['gene', 'lp', 'stroke', 'associated', 'risk', 'with', 'population study', 'in', 'and', 'ischemic']","['gene', 'lp', 'stroke', 'risk', 'population study', 'in']",1719,"['在当代丹麦人口研究中,伊斯基米性中风风险与Lp(a)水平和LPA基因变异有关。']",0.6,"['gene', 'lp', 'stroke', 'associated', 'risk', 'with', 'population study', 'in', 'and', 'ischemic']","['gene', 'lp', 'stroke', 'risk', 'population study', 'in']",1719,在丹麥的一項最新研究中，發現缺血性中風的風險與血漿中的Lp（a）水平及LPA基因變異有關。,0.3,"['gene', 'lp', 'stroke', 'associated', 'risk', 'with', 'population study', 'in', 'and', 'ischemic']","['gene', 'lp', 'stroke']",,,,
1733,1720,Lp ( a ) levels are primarily genetically determined and remain stable over time .,Lp(a) 水平主要由基因决定，并随时间保持稳定。,0.25,"['lp', 'time', 'over', 'and']",['time'],1720,"['Lp(a)水平主要是基因定义的,并且随着时间的推移保持稳定。']",0.25,"['lp', 'time', 'over', 'and']",['time'],1720,Lp (a)水平主要受遗传影响，并会随着时间保持稳定。,0.25,"['lp', 'time', 'over', 'and']",['time'],,,,
1734,1721,"using data from the contemporary Copenhagen General Population Study ( n = 49,699 ) and the historical Copenhagen City Heart Study ( n = 10,813 ) , investigators explored whether elevated Lp ( a ) is associated with increased risk for ischemic stroke .","使用当代哥本哈根一般人口研究 (n = 49,699) 和历史哥本哈根城市心脏研究 (n = 10,813) 的数据，研究人员探讨了升高的 Lp (a) 是否与缺血性中风的风险增加有关。",0.4545454545454545,"['heart', 'lp', 'stroke', 'data', 'general', 'associated', 'risk', 'with', 'population study', 'and', 'ischemic']","['heart', 'stroke', 'data', 'risk', 'population study']",1721,"['使用现代哥本哈根一般人口研究(n = 49,699 )和历史哥本哈根市心脏研究(n = 10,813 )的数据,研究人员研究了高Lp(a)是否与增加的伊斯基米性中风风险有关。']",0.4545454545454545,"['heart', 'lp', 'stroke', 'data', 'general', 'associated', 'risk', 'with', 'population study', 'and', 'ischemic']","['heart', 'stroke', 'data', 'risk', 'population study']",1721,"研究人员利用来自当代哥本哈根人口研究（n=49,699）和历史哥本哈根城市心脏研究（n=10,813）的数据，探索了Lp（a）升高与心脏病发作风险增加之间的关系。",0.4545454545454545,"['heart', 'lp', 'stroke', 'data', 'general', 'associated', 'risk', 'with', 'population study', 'and', 'ischemic']","['heart', 'stroke', 'data', 'risk', 'population study']",,,,
1735,1722,each 50 mg / dL increase in Lp ( a ) level corresponded to a hazard ratio for ischemic stroke of 1.20 in observational analyses and 1.20 and 1.27 in the two genetic analyses .,Lp(a) 水平每增加 50 mg/dL，在观察分析中对应的缺血性中风风险比为 1.20，在两个遗传分析中分别为 1.20 和 1.27。,0.3333333333333333,"['lp', 'stroke', 'hazard ratio', '/', 'genetic', 'level', 'increase', 'each', 'to', 'and', 'two', 'ischemic']","['stroke', 'hazard ratio', 'level', 'two']",1722,"['每 50 mg / dL 的 Lp (a ) 水平增加,相当于在观测分析中患有 1.20 和在两种基因分析中患有 1.20 和 1.27 的风险比例。']",0.4166666666666667,"['lp', 'stroke', 'hazard ratio', '/', 'genetic', 'level', 'increase', 'each', 'to', 'and', 'two', 'ischemic']","['stroke', 'hazard ratio', 'level', 'to', 'two']",1722,每50毫克/分升Lp（a）水平与观察分析中缺血性中风的危险比分别为1.20和遗传分析中的1.20和1.27。,0.1666666666666666,"['lp', 'stroke', 'hazard ratio', '/', 'genetic', 'level', 'increase', 'each', 'to', 'and', 'two', 'ischemic']","['stroke', 'level']",,,,
1736,1723,the highest absolute risk for stroke was found in individuals older than 70 who were active smokers and had hypertension .,中风绝对风险最高的人群是 70 岁以上的活跃吸烟者和高血压患者。,0.5,"['stroke', 'hypertension', 'who', 'absolute', 'active', 'risk', 'in', 'and']","['stroke', 'hypertension', 'absolute', 'risk']",1723,"['发作的最高绝对风险是在70岁以上的人中发现的,他们是活跃的吸烟者,并且患有高血压。']",0.5,"['stroke', 'hypertension', 'who', 'absolute', 'active', 'risk', 'in', 'and']","['stroke', 'hypertension', 'absolute', 'risk']",1723,70岁以上的吸烟者和高血压患者的中风风险最高。,0.375,"['stroke', 'hypertension', 'who', 'absolute', 'active', 'risk', 'in', 'and']","['stroke', 'hypertension', 'risk']",,,,
1737,1724,"in the historical cohort , the results were directionally similar but did not reach statistical significance .",在历史队列中，结果在方向上相似，但未达到统计学意义。,0.1666666666666666,"['statistical significance', 'cohort', 'in', 'but', 'reach', 'similar']",['but'],1724,"['在历史联盟中,结果是方向上相似的,但没有达到统计意义。']",0.3333333333333333,"['statistical significance', 'cohort', 'in', 'but', 'reach', 'similar']","['but', 'similar']",1724,在历史队列中，结果方向相似，但没有达到统计学意义。,0.1666666666666666,"['statistical significance', 'cohort', 'in', 'but', 'reach', 'similar']",['but'],,,,
1738,1725,the independent association of Lp ( a ) with ischemic stroke risk is unsurprising and adds to the growing body of evidence supporting a causal link between Lp ( a ) and cardiovascular disease .,Lp(a) 与缺血性中风风险的独立关联不足为奇，并且增加了支持 Lp(a) 与心血管疾病之间因果关系的越来越多的证据。,0.4285714285714285,"['lp', 'stroke', 'association', 'cardiovascular disease', 'link', 'risk', 'causal', 'independent', 'evidence', 'body', 'with', 'to', 'and', 'ischemic']","['stroke', 'association', 'cardiovascular disease', 'risk', 'causal', 'evidence']",1725,"['Lp(a)与心血管中风风险的独立联系是令人惊讶的,并为成长的身体添加了支持Lp(a)与心血管疾病之间的因果联系的证据。']",0.4285714285714285,"['lp', 'stroke', 'association', 'cardiovascular disease', 'link', 'risk', 'causal', 'independent', 'evidence', 'body', 'with', 'to', 'and', 'ischemic']","['stroke', 'association', 'cardiovascular disease', 'risk', 'evidence', 'body']",1725,Lp(a)与缺血性中风的独立关联并不令人惊讶，这增加了日益增长的证据，支持Lp(a)与心血管疾病之间存在因果联系。,0.3571428571428571,"['lp', 'stroke', 'association', 'cardiovascular disease', 'link', 'risk', 'causal', 'independent', 'evidence', 'body', 'with', 'to', 'and', 'ischemic']","['stroke', 'association', 'cardiovascular disease', 'evidence', 'body']",,,,
1739,1726,nutritional supplements are used widely despite minimal or no evidence of value for many of them .,营养补充剂被广泛使用，尽管其中许多补充剂的价值证据很少或没有证据。,0.3333333333333333,"['value', 'no', 'nutritional', 'minimal', 'evidence', 'despite']","['value', 'evidence']",1726,"['营养补充剂广泛使用,尽管对许多人来说是最小的或没有证据的价值。']",0.5,"['value', 'no', 'nutritional', 'minimal', 'evidence', 'despite']","['value', 'minimal', 'evidence']",1726,"Despite minimal or no evidence of value for many of them, nutritional supplements are used widely.",0.0,"['value', 'no', 'nutritional', 'minimal', 'evidence', 'despite']",[],,,,
1740,1727,significant results were found for the following supplements and interventions :,发现以下补充剂和干预措施的显着结果：,0.0,"['and', 'following']",[],1727,['在以下补充剂和干预中发现了显著的结果:'],0.0,"['and', 'following']",[],1727,对以下补充剂和干预措施发现了显著结果：,0.0,"['and', 'following']",[],,,,
1741,1728,"folic acid supplementation was associated with 20 % lower risk for stroke ( low certainty ) , but supplementation with calcium plus vitamin D was associated with 17 % higher risk ( moderate certainty ) .",补充叶酸与降低 20% 的中风风险相关（低确定性），但补充钙和维生素 D 与高 17% 的风险相关（中等确定性）。,0.4166666666666667,"['calcium', 'stroke', 'plus', 'moderate', 'lower', 'folic acid', 'associated', 'risk', 'certainty', 'with', 'vitamin D', 'but']","['calcium', 'stroke', 'folic acid', 'risk', 'but']",1728,"['叶酸补充与中风风险(低确定性)降低20%,但加钙和维生素D补充与17%高的风险(适度确定性)相关。']",0.5833333333333334,"['calcium', 'stroke', 'plus', 'moderate', 'lower', 'folic acid', 'associated', 'risk', 'certainty', 'with', 'vitamin D', 'but']","['calcium', 'stroke', 'plus', 'folic acid', 'risk', 'vitamin D', 'but']",1728,给予叶酸补充剂与中风风险相关，但补充钙和维生素D的风险更高。,0.5,"['calcium', 'stroke', 'plus', 'moderate', 'lower', 'folic acid', 'associated', 'risk', 'certainty', 'with', 'vitamin D', 'but']","['calcium', 'stroke', 'folic acid', 'risk', 'vitamin D', 'but']",,,,
1742,1729,outcomes were not statistically significant for any other supplement or intervention .,任何其他补充剂或干预的结果均无统计学意义。,0.5,"['supplement', 'intervention']",['supplement'],1729,['结果对任何其他补充或干预都没有统计意义。'],0.5,"['supplement', 'intervention']",['supplement'],1729,结果并非对任何其他补充或干预措施都具有统计学意义。,0.5,"['supplement', 'intervention']",['supplement'],,,,
1743,1730,"all in all , these results do not change the current recommendation that nutritional supplements generally have little or no value in preventing adverse cardiovascular events .",总而言之，这些结果并未改变目前的建议，即营养补充剂在预防不良心血管事件方面通常价值很小或没有价值。,0.2727272727272727,"['cardiovascular', 'value', 'adverse', 'no', 'nutritional', 'current', 'change', 'have', 'all', 'that', 'in']","['cardiovascular', 'value', 'have']",1730,"['总的来说,这些结果不会改变目前的建议,营养补充剂通常在预防不良心血管事件方面有很少或没有价值。']",0.2727272727272727,"['cardiovascular', 'value', 'adverse', 'no', 'nutritional', 'current', 'change', 'have', 'all', 'that', 'in']","['cardiovascular', 'value', 'have']",1730,总之，这些结果并不改变目前的建议，即营养补充剂通常对预防不良心血管事件没有或者只有很小的价值。,0.2727272727272727,"['cardiovascular', 'value', 'adverse', 'no', 'nutritional', 'current', 'change', 'have', 'all', 'that', 'in']","['cardiovascular', 'value', 'have']",,,,
1744,1731,early involvement by an endocrinologist and diabetes nurse improved glycemic control but not most clinical outcomes .,内分泌学家和糖尿病护士的早期参与改善了血糖控制，但并未改善大多数临床结果。,0.7,"['diabetes', 'nurse', 'control', 'early', 'clinical', 'endocrinologist', 'involvement', 'by', 'but', 'and']","['diabetes', 'nurse', 'control', 'early', 'clinical', 'endocrinologist', 'but']",1731,"['内分泌学家和糖尿病护士的早期参与改善了血糖控制,但没有大多数临床结果。']",0.7,"['diabetes', 'nurse', 'control', 'early', 'clinical', 'endocrinologist', 'involvement', 'by', 'but', 'and']","['diabetes', 'nurse', 'control', 'early', 'clinical', 'endocrinologist', 'but']",1731,早期治疗由内分泌科医师和糖尿病护士进行治疗可以改善血糖控制，但并不能改善大多数临床结果。,0.7,"['diabetes', 'nurse', 'control', 'early', 'clinical', 'endocrinologist', 'involvement', 'by', 'but', 'and']","['diabetes', 'nurse', 'control', 'early', 'clinical', 'by', 'but']",,,,
1745,1732,hypoglycemia and hyperglycemia in hospitalized patients are associated with worse patient outcomes .,住院患者的低血糖和高血糖与较差的患者预后相关。,0.25,"['hypoglycemia', 'associated', 'hyperglycemia', 'patient', 'with', 'worse', 'in', 'and']","['hyperglycemia', 'patient']",1732,['住院患者的低血糖和高血糖与病人结果恶化有关。'],0.25,"['hypoglycemia', 'associated', 'hyperglycemia', 'patient', 'with', 'worse', 'in', 'and']","['hyperglycemia', 'patient']",1732,"Hypoglycemia and hyperglycemia in hospitalized patients are associated with worse patient outcomes.

Chinese:

住院患者的低血糖和高血糖与患者的差异结果相关。",0.25,"['hypoglycemia', 'associated', 'hyperglycemia', 'patient', 'with', 'worse', 'in', 'and']","['hyperglycemia', 'patient']",,,,
1746,1733,"to improve glycemic control , many hospitals have implemented inpatient diabetes teams .",为改善血糖控制，许多医院都实施了住院糖尿病小组。,0.4,"['diabetes', 'control', 'inpatient', 'have', 'to']","['diabetes', 'control']",1733,"['为了改善血糖控制,许多医院已经实施了患有糖尿病的团队。']",0.6,"['diabetes', 'control', 'inpatient', 'have', 'to']","['diabetes', 'control', 'have']",1733,为了改善血糖控制，许多医院都实施了住院患者的糖尿病团队。,0.4,"['diabetes', 'control', 'inpatient', 'have', 'to']","['diabetes', 'control']",,,,
1747,1734,"the intervention involved electronic identification of patients with preexisting diabetes or hyperglycemia , with the goal of management within 24 hours by an inpatient team consisting of a diabetes nurse and an endocrinologist .",干预涉及对先前患有糖尿病或高血糖症的患者进行电子识别，目标是在 24 小时内由由一名糖尿病护士和一名内分泌学家组成的住院团队进行管理。,0.6428571428571429,"['diabetes', 'nurse', 'identification', 'team', 'hyperglycemia', 'intervention', 'endocrinologist', 'management', 'goal', 'electronic', 'with', 'inpatient', 'by', 'and']","['diabetes', 'nurse', 'identification', 'team', 'hyperglycemia', 'endocrinologist', 'management', 'goal', 'by']",1734,"['干预涉及现有糖尿病或高血糖病患者的电子识别,目的是由由糖尿病护士和内分泌学家组成的患者团队在24小时内进行管理。']",0.5714285714285714,"['diabetes', 'nurse', 'identification', 'team', 'hyperglycemia', 'intervention', 'endocrinologist', 'management', 'goal', 'electronic', 'with', 'inpatient', 'by', 'and']","['diabetes', 'nurse', 'identification', 'team', 'hyperglycemia', 'endocrinologist', 'management', 'by']",1734,这项干预涉及对糖尿病或高血糖患者的电子识别，目标是24小时内由一个包括糖尿病护士和内分泌科医生的住院团队进行管理。,0.5714285714285714,"['diabetes', 'nurse', 'identification', 'team', 'hyperglycemia', 'intervention', 'endocrinologist', 'management', 'goal', 'electronic', 'with', 'inpatient', 'by', 'and']","['diabetes', 'nurse', 'identification', 'team', 'hyperglycemia', 'management', 'goal', 'by']",,,,
1748,1735,about 1000 patients were admitted during the study period .,研究期间约有 1000 名患者入院。,0.5,"['period', 'study']",['period'],1735,"['在研究期间,约有1000名患者被接受。']",0.5,"['period', 'study']",['period'],1735,在研究期间，大约有1000名病人被接收。,0.5,"['period', 'study']",['period'],,,,
1749,1736,"in the intervention arm , the proportion of patients who received new insulin treatment rose from 34 % at baseline to 57 % during the intervention .",在干预组中，接受新胰岛素治疗的患者比例从基线时的 34% 上升到干预期间的 57%。,0.5,"['proportion', 'insulin', 'rose', 'arm', 'who', 'baseline', 'treatment', 'intervention', 'to', 'new']","['proportion', 'insulin', 'baseline', 'treatment', 'new']",1736,"['在干预手臂中,接受新胰岛素治疗的患者比例从基线34%上升到干预期间57%。']",0.6,"['proportion', 'insulin', 'rose', 'arm', 'who', 'baseline', 'treatment', 'intervention', 'to', 'new']","['proportion', 'insulin', 'arm', 'baseline', 'treatment', 'new']",1736,在干预组中，新胰岛素治疗的患者占比从基线时的34%上升到干预期间的57%。,0.5,"['proportion', 'insulin', 'rose', 'arm', 'who', 'baseline', 'treatment', 'intervention', 'to', 'new']","['proportion', 'insulin', 'baseline', 'treatment', 'new']",,,,
1750,1737,"in the control arm , use of insulin and clinical outcomes did not change during the study period .",在对照组中，胰岛素的使用和临床结果在研究期间没有改变。,0.5,"['insulin', 'period', 'control', 'arm', 'study', 'clinical', 'change', 'and']","['insulin', 'period', 'control', 'clinical']",1737,"['在控制手臂中,胰岛素的使用和临床结果在研究期间没有变化。']",0.75,"['insulin', 'period', 'control', 'arm', 'study', 'clinical', 'change', 'and']","['insulin', 'period', 'control', 'arm', 'clinical', 'change']",1737,在对照组，胰岛素的使用与临床结局在研究期间没有发生变化。,0.625,"['insulin', 'period', 'control', 'arm', 'study', 'clinical', 'change', 'and']","['insulin', 'period', 'control', 'clinical', 'change']",,,,
1751,1738,"within 4.5 hours after ischemic stroke , endovascular therapy is more beneficial the sooner it is performed .",缺血性中风后 4.5 小时内，血管内治疗越早进行越有益。,0.75,"['stroke', 'therapy', 'after', 'ischemic']","['stroke', 'therapy', 'after']",1738,"['在伊斯坦布尔发作后4,5小时内,内分泌疗法越早就越有益。']",0.75,"['stroke', 'therapy', 'after', 'ischemic']","['stroke', 'therapy', 'after']",1738,"within 4.5 hours after ischemic stroke , endovascular therapy is more beneficial the sooner it is performed .

Chinese:

在缺血性中风发生4.5小时内，血管内治疗越早越有益。",0.5,"['stroke', 'therapy', 'after', 'ischemic']","['stroke', 'therapy']",,,,
1752,1739,whether endovascular therapy ( EVT ) for patients with large vessel occlusion has the same dependence on time is less certain .,大血管闭塞患者的血管内治疗 (EVT) 是否具有相同的时间依赖性尚不确定。,0.25,"['vessel', 'occlusion', 'dependence', 'large', 'time', 'therapy', 'with', 'certain']","['time', 'therapy']",1739,"['对于患有大血管封闭的患者是否有相同的时间依赖,则不确定。']",0.125,"['vessel', 'occlusion', 'dependence', 'large', 'time', 'therapy', 'with', 'certain']",['time'],1739,目前尚不确定大动脉闭塞患者的内支架疗法是否与时间相关。,0.375,"['vessel', 'occlusion', 'dependence', 'large', 'time', 'therapy', 'with', 'certain']","['vessel', 'time', 'therapy']",,,,
1753,1740,the authors analyzed two key variables : time from stroke onset to groin puncture ( onset to puncture ) and time from hospital arrival to groin puncture ( door to puncture ) .,作者分析了两个关键变量：从中风发作到腹股沟穿刺的时间（开始到穿刺）和从到达医院到腹股沟穿刺的时间（门到穿刺）。,0.8,"['key', 'stroke', 'groin', 'puncture', 'time', 'onset', 'hospital', 'to', 'and', 'two']","['key', 'stroke', 'groin', 'puncture', 'time', 'onset', 'hospital', 'two']",1740,['作者分析了两个关键变量:时间从中风开始到中风点(开始到中风点)和时间从医院到中风点(门到中风点)。'],0.6,"['key', 'stroke', 'groin', 'puncture', 'time', 'onset', 'hospital', 'to', 'and', 'two']","['key', 'stroke', 'time', 'onset', 'hospital', 'two']",1740,作者分析了两个关键变量：从中风发作到腹股沟穿刺的时间（发作到穿刺）和从医院到达腹股沟穿刺的时间（门到穿刺）。,0.7,"['key', 'stroke', 'groin', 'puncture', 'time', 'onset', 'hospital', 'to', 'and', 'two']","['key', 'stroke', 'groin', 'puncture', 'time', 'hospital', 'two']",,,,
1754,1741,"key study endpoints included independent ambulation at discharge , functional independence at discharge , and discharge to home .",主要研究终点包括出院时独立行走、出院时功能独立和出院回家。,0.1111111111111111,"['discharge', 'key', 'functional', 'study', 'independent', 'independence', 'ambulation', 'to', 'and']",['independence'],1741,"['关键研究终点包括在排放时独立救护,在排放时功能独立,并在家中排放。']",0.2222222222222222,"['discharge', 'key', 'functional', 'study', 'independent', 'independence', 'ambulation', 'to', 'and']","['key', 'independence']",1741,"Discharge criteria included independent ambulation, functional independence, and discharge to home.",0.0,"['discharge', 'key', 'functional', 'study', 'independent', 'independence', 'ambulation', 'to', 'and']",[],,,,
1755,1742,safety endpoints evaluated were symptomatic intracerebral hemorrhage ( sICH ) and death / discharge to hospice .,评估的安全性终点是症状性脑出血 (sICH) 和死亡/出院到临终关怀中心。,0.4444444444444444,"['safety', 'discharge', 'death', 'hemorrhage', '/', 'intracerebral', 'symptomatic', 'and', 'hospice']","['safety', 'death', 'hemorrhage', 'hospice']",1742,['评估的安全终点是症状性脑内出血(sICH)和死亡 / 释放到医院。'],0.4444444444444444,"['safety', 'discharge', 'death', 'hemorrhage', '/', 'intracerebral', 'symptomatic', 'and', 'hospice']","['safety', 'death', 'hemorrhage', 'intracerebral']",1742,安全性末端结果包括症状性脑出血（sICH）和死亡/入院护理。,0.3333333333333333,"['safety', 'discharge', 'death', 'hemorrhage', '/', 'intracerebral', 'symptomatic', 'and', 'hospice']","['safety', 'death', 'hemorrhage']",,,,
1756,1743,"the median NIH Stroke Scale score was 17 , indicating severe strokes .",NIH 中风量表评分中位数为 17，表明中风严重。,0.4,"['median', 'stroke', 'scale', 'score', 'severe']","['stroke', 'scale']",1743,"['NIH Stroke Scale 平均分数为 17,表明严重的中风。']",0.6,"['median', 'stroke', 'scale', 'score', 'severe']","['stroke', 'scale', 'score']",1743,NIH中风病例的中位数为17，表明是重度中风。,0.6,"['median', 'stroke', 'scale', 'score', 'severe']","['stroke', 'scale', 'severe']",,,,
1757,1744,"of the patients , 68 % received alteplase .",68% 的患者接受了阿替普酶治疗。,,[],[],1744,"['在患者中,68%接受了阿尔特普拉斯。']",,[],[],1744,68% of the patients received alteplase.,,[],[],,,,
1758,1745,improved outcome with earlier treatment was more notable among patients treated within 270 minutes of stroke onset .,在卒中发作后 270 分钟内接受治疗的患者中，早期治疗改善的结果更为显着。,0.5,"['stroke', 'outcome', 'treatment', 'onset', 'with', 'earlier']","['stroke', 'outcome', 'treatment']",1745,['早期治疗的改善结果在发作开始后270分钟内治疗的患者中更为显著。'],0.6666666666666666,"['stroke', 'outcome', 'treatment', 'onset', 'with', 'earlier']","['stroke', 'outcome', 'treatment', 'onset']",1745,治疗早期的病人结局更好。在距离中风发作270分钟内接受治疗的病人改善情况更加显著。,0.3333333333333333,"['stroke', 'outcome', 'treatment', 'onset', 'with', 'earlier']","['stroke', 'treatment']",,,,
1759,1746,"in this group , for every 1000 patients treated 15 minutes earlier , there were 11 more patients with independent ambulation at discharge , 12 more discharged to home , and 9 more with functional independence .",在该组中，每 1000 名患者提前 15 分钟接受治疗，出院时能够独立行走的患者就会多出 11 名，出院回家的患者会多出 12 名，功能独立的患者多出 9 名。,0.2727272727272727,"['group', 'discharge', 'functional', 'independent', 'independence', 'with', 'ambulation', 'this', 'earlier', 'to', 'and']","['group', 'independent', 'independence']",1746,"['在这个群体中,每1000名患者15分钟提前接受治疗,有11名患者在排放时有独立救护车,12名患者在排放时有更多,9名患者在功能独立。']",0.1818181818181818,"['group', 'discharge', 'functional', 'independent', 'independence', 'with', 'ambulation', 'this', 'earlier', 'to', 'and']","['group', 'independence']",1746,在这个组中，每治疗1000名病人15分钟早，有11名病人在出院时能够自己行走，12名病人能够回家，还有9名病人能够独立完成日常生活。,0.1818181818181818,"['group', 'discharge', 'functional', 'independent', 'independence', 'with', 'ambulation', 'this', 'earlier', 'to', 'and']","['group', 'independence']",,,,
1760,1747,"this analysis shows that for patients who receive EVT within 4.5 hours of stroke onset , earlier treatment within that window has tangible benefits .",该分析表明，对于在中风发作后 4.5 小时内接受 EVT 的患者，在该窗口内进行早期治疗具有明显的好处。,0.4,"['stroke', 'who', 'analysis', 'window', 'treatment', 'onset', 'tangible', 'this', 'that', 'earlier']","['stroke', 'analysis', 'window', 'treatment']",1747,"['这项分析表明,在发作开始后4,5小时内接受EVT的患者,该窗口内的早期治疗有显而易见的好处。']",0.5,"['stroke', 'who', 'analysis', 'window', 'treatment', 'onset', 'tangible', 'this', 'that', 'earlier']","['stroke', 'analysis', 'window', 'treatment', 'onset']",1747,这一分析表明，对于在发生脑卒中4.5小时内接受血管外科治疗的患者来说，早期治疗在这个时间窗口内具有明显的好处。,0.4,"['stroke', 'who', 'analysis', 'window', 'treatment', 'onset', 'tangible', 'this', 'that', 'earlier']","['stroke', 'analysis', 'window', 'treatment']",,,,
1761,1748,hospitals should rigorously evaluate their work flow and identify bottlenecks that hinder rapid treatment .,医院应严格评估其工作流程，找出阻碍快速治疗的瓶颈。,0.375,"['flow', 'treatment', 'identify', 'that', 'and', 'hinder', 'work', 'rapid']","['flow', 'treatment', 'work']",1748,"['医院应严格评估其工作流,并确定阻碍快速治疗的瓶子。']",0.375,"['flow', 'treatment', 'identify', 'that', 'and', 'hinder', 'work', 'rapid']","['flow', 'treatment', 'work']",1748,"hospitals should rigorously evaluate their work flow and identify bottlenecks that hinder rapid treatment.

Chinese:

医院应严格评估其工作流程，并确定阻碍快速治疗的瓶颈。",0.375,"['flow', 'treatment', 'identify', 'that', 'and', 'hinder', 'work', 'rapid']","['flow', 'treatment', 'work']",,,,
1762,1749,establishing cardiovascular safety of new therapies for type 2 diabetes is important .,确定 2 型糖尿病新疗法的心血管安全性很重要。,1.0,"['safety', 'diabetes', 'type', 'cardiovascular', '2', 'new']","['safety', 'diabetes', 'type', 'cardiovascular', '2', 'new']",1749,['建立二型糖尿病新治疗的心血管安全至关重要。'],0.8333333333333334,"['safety', 'diabetes', 'type', 'cardiovascular', '2', 'new']","['safety', 'diabetes', 'type', 'cardiovascular', 'new']",1749,"establishing cardiovascular safety of new therapies for type 2 diabetes is important .

Chinese:
确立新型2型糖尿病治疗方法的心血管安全性是很重要的。",1.0,"['safety', 'diabetes', 'type', 'cardiovascular', '2', 'new']","['safety', 'diabetes', 'type', 'cardiovascular', '2', 'new']",,,,
1763,1750,the trial was designed to rule out 80 % excess cardiovascular risk as compared with placebo ( noninferiority margin of 1.8 for the upper boundary of the 95 % confidence interval for the hazard ratio for the primary outcome ) .,与安慰剂相比，该试验旨在排除 80% 的额外心血管风险（主要结果的风险比的 95% 置信区间上限的非劣效性界限为 1.8）。,0.5333333333333333,"['boundary', 'placebo', 'excess', 'cardiovascular', 'margin', 'rule', 'hazard ratio', 'outcome', 'upper', 'primary', 'risk', 'trial', 'confidence interval', 'with', 'to']","['boundary', 'placebo', 'cardiovascular', 'margin', 'hazard ratio', 'outcome', 'risk', 'confidence interval']",1750,['该试验旨在排除与 placebo 相比80%的过度心血管风险(对初始结果的风险比例的95%信任间隔的上限为1.8的非低度边界)。'],0.4,"['boundary', 'placebo', 'excess', 'cardiovascular', 'margin', 'rule', 'hazard ratio', 'outcome', 'upper', 'primary', 'risk', 'trial', 'confidence interval', 'with', 'to']","['boundary', 'cardiovascular', 'margin', 'hazard ratio', 'outcome', 'risk']",1750,该试验旨在与安慰剂相比，排除80%以上的心血管风险（主要结果的风险比上限为1.8的95%置信区间）。,0.4,"['boundary', 'placebo', 'excess', 'cardiovascular', 'margin', 'rule', 'hazard ratio', 'outcome', 'upper', 'primary', 'risk', 'trial', 'confidence interval', 'with', 'to']","['placebo', 'cardiovascular', 'hazard ratio', 'outcome', 'risk', 'confidence interval']",,,,
1764,1751,a total of 3183 patients were randomly assigned to receive oral semaglutide or placebo .,共有 3183 名患者被随机分配接受口服索马鲁肽或安慰剂。,0.5,"['placebo', 'oral', 'total', 'semaglutide']","['placebo', 'semaglutide']",1751,['总共有3183名患者随机服用口服半糖或 placebo。'],0.0,"['placebo', 'oral', 'total', 'semaglutide']",[],1751,总共3183名病人随机分配接受口服赛乐瑞特或安慰剂。,0.25,"['placebo', 'oral', 'total', 'semaglutide']",['placebo'],,,,
1765,1752,the mean age of the patients was 66 years ; 2695 patients ( 84.7 % ) were 50 years of age or older and had cardiovascular or chronic kidney disease .,患者的平均年龄为 66 岁； 2695 名患者 (84.7%) 年龄在 50 岁或以上，患有心血管疾病或慢性肾脏疾病。,0.8571428571428571,"['kidney', 'disease', 'cardiovascular', 'mean', 'chronic', 'age', 'and']","['kidney', 'disease', 'cardiovascular', 'mean', 'chronic', 'age']",1752,"['患者的平均年龄为66岁;2695名患者(84.7%)年龄为50岁或以上,患有心血管或慢性肾脏疾病。']",0.8571428571428571,"['kidney', 'disease', 'cardiovascular', 'mean', 'chronic', 'age', 'and']","['kidney', 'disease', 'cardiovascular', 'mean', 'chronic', 'age']",1752,病人的平均年龄为66岁；2695名病人（84.7%）年龄在50岁以上，并且患有心血管疾病或慢性肾脏疾病。,0.8571428571428571,"['kidney', 'disease', 'cardiovascular', 'mean', 'chronic', 'age', 'and']","['kidney', 'disease', 'cardiovascular', 'mean', 'chronic', 'age']",,,,
1766,1753,the median time in the trial was 15.9 months .,试验的中位时间为 15.9 个月。,0.25,"['median', 'time', 'trial', 'in']",['time'],1753,['审判的平均时间为159个月。'],0.5,"['median', 'time', 'trial', 'in']","['time', 'trial']",1753,在试验中，中位数时间为15.9个月。,0.25,"['median', 'time', 'trial', 'in']",['time'],,,,
1767,1754,"results for components of the primary outcome were as follows : death from cardiovascular causes , 15 of 1591 patients ( 0.9 % ) in the oral semaglutide group and 30 of 1592 ( 1.9 % ) in the placebo group ( hazard ratio , 0.49 ; 95 % CI , 0.27 to 0.92 ) ; nonfatal myocardial infarction , 37 of 1591 patients ( 2.3 % ) and 31 of 1592 ( 1.9 % ) , respectively ( hazard ratio , 1.18 ; 95 % CI , 0.73 to 1.90 ) ; and nonfatal stroke , 12 of 1591 patients ( 0.8 % ) and 16 of 1592 ( 1.0 % ) , respectively ( hazard ratio , 0.74 ; 95 % CI , 0.35 to 1.57 ) .","主要结果的组成部分的结果如下：心血管原因死亡，口服索马鲁肽组 1591 名患者中的 15 名 ( 0.9 % ) 和安慰剂组 1592 名患者中的 30 名 ( 1.9 % )（风险比， 0.49 ； 95 % CI , 0.27 至 0.92 ) ;非致死性心肌梗死，分别为 1591 名患者中的 37 名 (2.3%) 和 1592 名患者中的 31 名 (1.9%)（风险比，1.18；95% CI，0.73 至 1.90）；和非致死性卒中，1591 名患者中有 12 名 (0.8%) 和 1592 名患者中有 16 名 (1.0%)（风险比，0.74；95% CI，0.35 至 1.57）。",0.6428571428571429,"['group', 'myocardial infarction', 'placebo', 'cardiovascular', 'stroke', 'hazard ratio', 'outcome', 'death', 'oral', 'primary', 'semaglutide', 'CI', 'to', 'and']","['group', 'myocardial infarction', 'placebo', 'cardiovascular', 'stroke', 'hazard ratio', 'outcome', 'death', 'semaglutide']",1754,"['初始结果的组成部分的结果如下:心血管原因死亡151名患者(0.9%)在口腔半糖群中和1592名患者(1.9%)在 placebo群中(危险比例,0.49;95%CI,0.27至0.92);非致命心脏病发作37名患者(2.3%)和31名患者(1.9%)分别(危险比例,1.18;95%CI,0.73至1.90);非致命中,1591名患者(0.8%)和1592名患者(1.0%)分别(危险比例,0.74;95%CI,0.35至1.57)。']",0.3571428571428571,"['group', 'myocardial infarction', 'placebo', 'cardiovascular', 'stroke', 'hazard ratio', 'outcome', 'death', 'oral', 'primary', 'semaglutide', 'CI', 'to', 'and']","['group', 'cardiovascular', 'stroke', 'outcome', 'death']",1754,"The results for the primary outcome were as follows: death from cardiovascular causes, 15 of 1591 patients (0.9%) in the oral semaglutide group and 30 of 1592 (1.9%) in the placebo group (hazard ratio, 0.49; 95% CI, 0.27 to 0.92); nonfatal myocardial infarction, 37 of 1591 patients (2.3%) and 31 of 1592 (1.9%), respectively (hazard ratio, 1.18; 95% CI, 0.73 to 1.90); and nonfatal stroke, 12 of 1591 patients (0.8%) and 16 of 1592 (1.0%), respectively (hazard ratio, 0.74; 95% CI, 0.35 to 1.57).",0.0,"['group', 'myocardial infarction', 'placebo', 'cardiovascular', 'stroke', 'hazard ratio', 'outcome', 'death', 'oral', 'primary', 'semaglutide', 'CI', 'to', 'and']",[],,,,
1768,1755,"death from any cause occurred in 23 of 1591 patients ( 1.4 % ) in the oral semaglutide group and 45 of 1592 ( 2.8 % ) in the placebo group ( hazard ratio , 0.51 ; 95 % CI , 0.31 to 0.84 ) .",口服 semaglutide 组 1591 名患者中有 23 名 (1.4%) 和安慰剂组 1592 名患者中有 45 名 (2.8%) 发生全因死亡（风险比，0.51；95% CI，0.31 至 0.84）。,0.3636363636363636,"['group', 'placebo', 'hazard ratio', 'death', 'oral', 'cause', 'semaglutide', 'CI', 'in', 'to', 'and']","['group', 'placebo', 'hazard ratio', 'death']",1755,"['由任何原因导致的死亡发生在1591名患者中(1.4% )在口腔半糖群中和1592名患者中(2.8% )在 placebo群中(风险比例,0.51;95% CI,0.31至0.84 )。']",0.3636363636363636,"['group', 'placebo', 'hazard ratio', 'death', 'oral', 'cause', 'semaglutide', 'CI', 'in', 'to', 'and']","['group', 'hazard ratio', 'death', 'cause']",1755,在口服semaglutide的1591名患者中，有23人(1.4%)死于任何原因，而在1592名安慰剂组患者中，有45人(2.8%)死于任何原因（危险比为0.51; 95%置信区间为0.31-0.84）。,0.5454545454545454,"['group', 'placebo', 'hazard ratio', 'death', 'oral', 'cause', 'semaglutide', 'CI', 'in', 'to', 'and']","['group', 'placebo', 'death', 'cause', 'to', 'and']",,,,
1769,1756,gastrointestinal adverse events leading to discontinuation of oral semaglutide or placebo were more common with oral semaglutide .,导致停用口服索马鲁肽或安慰剂的胃肠道不良事件在口服索马鲁肽中更为常见。,0.3333333333333333,"['placebo', 'gastrointestinal', 'oral', 'common', 'adverse', 'leading', 'with', 'semaglutide', 'to']","['placebo', 'gastrointestinal', 'semaglutide']",1756,['胃肠道不良事件导致口腔半糖或 placebo的停止更常见。'],0.1111111111111111,"['placebo', 'gastrointestinal', 'oral', 'common', 'adverse', 'leading', 'with', 'semaglutide', 'to']",['gastrointestinal'],1756,口服赛乐瑞特或安慰剂所引起的胃肠道不良事件导致的停止使用口服赛乐瑞特的情况更多。,0.2222222222222222,"['placebo', 'gastrointestinal', 'oral', 'common', 'adverse', 'leading', 'with', 'semaglutide', 'to']","['placebo', 'gastrointestinal']",,,,
1770,1757,"in this trial involving patients with type 2 diabetes , the cardiovascular risk profile of oral semaglutide was not inferior to that of placebo . ( Funded by Novo Nordisk ; PIONEER 6 ClinicalTrials.gov number , NCT02692716 . )",在这项涉及 2 型糖尿病患者的试验中，口服 semaglutide 的心血管风险特征并不劣于安慰剂。 （由 Novo Nordisk 资助；PIONEER 6 ClinicalTrials.gov 编号，NCT02692716。）,0.5294117647058824,"['diabetes', 'type', 'placebo', 'cardiovascular', '2', 'oral', 'number', 'risk', 'trial', 'profile', 'with', 'semaglutide', 'this', 'that', 'inferior', 'by', 'to']","['diabetes', 'type', 'placebo', 'cardiovascular', '2', 'number', 'risk', 'by', 'to']",1757,"['在这项涉及2型糖尿病患者的研究中,口腔半糖尿病的心血管风险资料不低于口腔半糖尿病(由Novo Nordisk资助;PIONEER 6 ClinicalTrials.gov号,NCT02692716 )。']",0.4705882352941176,"['diabetes', 'type', 'placebo', 'cardiovascular', '2', 'oral', 'number', 'risk', 'trial', 'profile', 'with', 'semaglutide', 'this', 'that', 'inferior', 'by', 'to']","['diabetes', 'type', 'cardiovascular', '2', 'number', 'risk', 'by', 'to']",1757,在这项针对2型糖尿病患者的试验中，口服类似胰岛素的药物的心血管风险配置与安慰剂相比并不差。（由诺和诺德资助；PIONEER 6临床试验，编号NCT02692716。）,0.4705882352941176,"['diabetes', 'type', 'placebo', 'cardiovascular', '2', 'oral', 'number', 'risk', 'trial', 'profile', 'with', 'semaglutide', 'this', 'that', 'inferior', 'by', 'to']","['diabetes', 'type', 'placebo', 'cardiovascular', '2', 'number', 'risk', 'by']",,,,
1771,1758,"these agents have shown cardiovascular safety ( lixisenatide12 and exenatide13 ) and , in several cases , benefit ( liraglutide , 14 albiglutide , 15 semaglutide , 16 and , most recently , dulaglutide17 ) .",这些药物已显示出心血管安全性（lixisenatide12 和 exenatide13），并且在一些情况下有益（liraglutide、14 albiglutide、15 semaglutide、16 以及最近的 dulaglutide17）。,0.375,"['safety', 'cardiovascular', 'benefit', 'semaglutide', 'liraglutide', 'have', 'in', 'and']","['safety', 'cardiovascular', 'have']",1758,"['这些物质表明了心血管安全(Lixisenatide12和Exenatide13),并在几种情况下有益(Liraglutide,14 albiglutide,15 semaglutide,16和,最近,dulaglutide17)。']",0.375,"['safety', 'cardiovascular', 'benefit', 'semaglutide', 'liraglutide', 'have', 'in', 'and']","['safety', 'cardiovascular', 'have']",1758,这些特工已经展示出心血管安全性（利西塞那替12和埃克塞纳替13），并且在某些情况下具有益处（利拉格蒂德14，奥比格那替15，赛马格那替16，最近的都拉格替17）。,0.5,"['safety', 'cardiovascular', 'benefit', 'semaglutide', 'liraglutide', 'have', 'in', 'and']","['safety', 'cardiovascular', 'benefit', 'have']",,,,
1772,1759,"however , once the drug is absorbed , the pharmacokinetic properties and effects of semaglutide are similar , regardless of the route of administration.21,22","然而，一旦药物被吸收，无论给药途径如何，索马鲁肽的药代动力学特性和作用都是相似的。 21,22",0.8333333333333334,"['properties', 'drug', 'semaglutide', 'pharmacokinetic', 'and', 'similar']","['drug', 'semaglutide', 'pharmacokinetic', 'and', 'similar']",1759,"['然而,一旦药物被吸收,Semaglutide的药物和药物的药物性能和效果是相似的,无论服用方式如何。']",0.5,"['properties', 'drug', 'semaglutide', 'pharmacokinetic', 'and', 'similar']","['drug', 'and', 'similar']",1759,"无论何种用药方式，肌肉注射或经口服用药，在药物被吸收后，赛马格鲁替丁的药代动力学特性和药效相似。21,22",0.3333333333333333,"['properties', 'drug', 'semaglutide', 'pharmacokinetic', 'and', 'similar']","['drug', 'pharmacokinetic']",,,,
1773,1760,"detailed methods for this trial , which was conducted at 214 sites in 21 countries , have been published previously , 23 and the protocol is available with the full text of this article at NEJM.org .",该试验在 21 个国家的 214 个地点进行，其详细方法之前已发表，23 试验方案与本文全文可在 NEJM.org 上获取。,0.0833333333333333,"['protocol', 'article', 'available', 'trial', 'text', 'with', 'at', 'full', 'have', 'this', 'in', 'and']",['protocol'],1760,"['此案的详细方法,在21个国家的214个网站上进行,已公布,23个议定书与本文的完整文本在NEJM.org上可用。']",0.1666666666666666,"['protocol', 'article', 'available', 'trial', 'text', 'with', 'at', 'full', 'have', 'this', 'in', 'and']","['protocol', 'full']",1760,该试验的详细方法已在21个国家的214个地点进行过，并已在23个地方发布过。全文可在NEJM.org上找到。,0.0,"['protocol', 'article', 'available', 'trial', 'text', 'with', 'at', 'full', 'have', 'this', 'in', 'and']",[],,,,
1774,1761,"the sponsor ( Novo Nordisk ) designed the trial and was responsible for the trial conduct , data collection , and data analysis .",主办方（诺和诺德）设计了试验并负责试验实施、数据收集和数据分析。,0.3333333333333333,"['analysis', 'sponsor', 'trial', 'conduct', 'data collection', 'and']","['analysis', 'data collection']",1761,"['赞助商(Novo Nordisk)设计了审判,负责审判行为、数据收集和数据分析。']",0.5,"['analysis', 'sponsor', 'trial', 'conduct', 'data collection', 'and']","['analysis', 'trial', 'data collection']",1761,"Novo Nordisk designed the trial and was responsible for the trial conduct, data collection, and data analysis.",0.0,"['analysis', 'sponsor', 'trial', 'conduct', 'data collection', 'and']",[],,,,
1775,1762,an independent data monitoring committee evaluated unblinded trial data .,一个独立的数据监测委员会评估了非盲试验数据。,0.8,"['monitoring', 'data', 'committee', 'trial', 'independent']","['monitoring', 'data', 'committee', 'independent']",1762,['一个独立的数据监测委员会评估了未透露的审查数据。'],0.8,"['monitoring', 'data', 'committee', 'trial', 'independent']","['monitoring', 'data', 'committee', 'independent']",1762,一个独立的数据监测委员会对未经盲法审查的试验数据进行了评估。,0.8,"['monitoring', 'data', 'committee', 'trial', 'independent']","['monitoring', 'data', 'committee', 'independent']",,,,
1776,1763,"all the authors had full access to the data , participated in drafting or critical revision of the manuscript , made the decision to submit the manuscript for publication , and vouch for the accuracy and completeness of the data and for the adherence of the trial to the protocol .",所有作者都可以完全访问数据，参与了文稿的起草或重要修改，做出了投稿发表的决定，并保证数据的准确性和完整性以及试验对方案的依从性。 .,0.375,"['data', 'accuracy', 'protocol', 'access', 'publication', 'manuscript', 'trial', 'critical', 'decision', 'completeness', 'revision', 'adherence', 'full', 'all', 'and', 'drafting']","['data', 'accuracy', 'publication', 'decision', 'completeness', 'full']",1763,"['所有作者都完全访问了数据,参与了手稿的编写或批判性修订,决定提交手稿出版,并为数据的准确性和完整性以及审判对议定书的遵守提供支持。']",0.5625,"['data', 'accuracy', 'protocol', 'access', 'publication', 'manuscript', 'trial', 'critical', 'decision', 'completeness', 'revision', 'adherence', 'full', 'all', 'and', 'drafting']","['data', 'accuracy', 'protocol', 'publication', 'manuscript', 'trial', 'decision', 'completeness', 'full']",1763,所有作者都对数据有完全的访问权限，参与了论文的起草或重要修订，决定将论文提交给出版机构，并为数据的准确性和完整性以及试验与协议的遵守署名。,0.4375,"['data', 'accuracy', 'protocol', 'access', 'publication', 'manuscript', 'trial', 'critical', 'decision', 'completeness', 'revision', 'adherence', 'full', 'all', 'and', 'drafting']","['data', 'accuracy', 'protocol', 'publication', 'decision', 'completeness', 'full']",,,,
1777,1764,"the manuscript was drafted with support from a medical writer ( funded by the sponsor ) , under the direction of the authors .",该手稿是在作者的指导下，在一位医学作家（由申办者资助）的支持下起草的。,0.75,"['support', 'sponsor', 'medical', 'manuscript', 'writer', 'direction', 'with', 'by']","['support', 'sponsor', 'manuscript', 'writer', 'direction', 'by']",1764,"['手稿是由医学作家(由赞助商资助)的支持下,由作者指导。']",0.625,"['support', 'sponsor', 'medical', 'manuscript', 'writer', 'direction', 'with', 'by']","['support', 'manuscript', 'writer', 'direction', 'by']",1764,这份手稿是在赞助者的资助下，由医疗作家提供支持制作而成，作者提供了方向。,0.625,"['support', 'sponsor', 'medical', 'manuscript', 'writer', 'direction', 'with', 'by']","['support', 'manuscript', 'writer', 'direction', 'by']",,,,
1778,1765,"patients were eligible to participate if they were 50 years of age or older and had established cardiovascular disease or chronic kidney disease , or if they were 60 years of age or older and had cardiovascular risk factors only .",如果患者年满 50 岁并患有心血管疾病或慢性肾病，或者年满 60 岁且仅具有心血管危险因素，则患者有资格参加。,0.4444444444444444,"['kidney', 'cardiovascular disease', 'chronic', 'age', 'risk', 'if', 'to', 'and', 'eligible']","['kidney', 'cardiovascular disease', 'chronic', 'risk']",1765,"['患者有资格参加,如果他们年龄为50岁或以上,并且发现了心血管疾病或慢性肾脏疾病,或者如果他们年龄为60岁或以上,并且只有心血管风险因素。']",0.5555555555555556,"['kidney', 'cardiovascular disease', 'chronic', 'age', 'risk', 'if', 'to', 'and', 'eligible']","['kidney', 'cardiovascular disease', 'chronic', 'age', 'risk']",1765,50岁或以上的患者，如果他们患有心血管疾病或慢性肾病，或者他们年龄达60岁或以上，只有心血管风险因素，就有资格参加。,0.5555555555555556,"['kidney', 'cardiovascular disease', 'chronic', 'age', 'risk', 'if', 'to', 'and', 'eligible']","['kidney', 'cardiovascular disease', 'chronic', 'age', 'risk']",,,,
1779,1766,"the full eligibility criteria are provided in the Supplementary Appendix , available at NEJM.org .",补充附录中提供了完整的资格标准，补充附录可在 NEJM.org 获取。,0.1666666666666666,"['appendix', 'supplementary', 'available', 'at', 'full', 'in']",['full'],1766,"['完整的可选性标准如附件中所述,可在NEJM.org上找到。']",0.3333333333333333,"['appendix', 'supplementary', 'available', 'at', 'full', 'in']","['appendix', 'full']",1766,详细的资格标准在附加附录中提供，可以在 NEJM.org 上找到。,0.0,"['appendix', 'supplementary', 'available', 'at', 'full', 'in']",[],,,,
1780,1767,randomization was stratified according to evidence of established cardiovascular disease or chronic kidney disease or the presence of cardiovascular risk factors only .,根据确定的心血管疾病或慢性肾脏疾病的证据或仅存在心血管危险因素，对随机化进行分层。,0.875,"['presence', 'kidney', 'randomization', 'cardiovascular disease', 'chronic', 'risk', 'evidence', 'to']","['presence', 'kidney', 'randomization', 'cardiovascular disease', 'chronic', 'risk', 'evidence']",1767,['随机化是根据确定的心血管疾病或慢性肾脏疾病或只有心血管风险因素的存在的证据进行分类。'],0.875,"['presence', 'kidney', 'randomization', 'cardiovascular disease', 'chronic', 'risk', 'evidence', 'to']","['presence', 'kidney', 'randomization', 'cardiovascular disease', 'chronic', 'risk', 'evidence']",1767,随机化是根据有证据表明已建立的心血管疾病或慢性肾脏疾病或仅有心血管风险因素的情况来分层的。,0.75,"['presence', 'kidney', 'randomization', 'cardiovascular disease', 'chronic', 'risk', 'evidence', 'to']","['kidney', 'randomization', 'cardiovascular disease', 'chronic', 'risk', 'evidence']",,,,
1781,1768,"patients were instructed to take oral semaglutide or placebo in the morning , with up to 120 ml of water , in a fasting state , and at least 30 minutes before eating , drinking , or taking any other oral medication .",患者被指示在早上服用 semaglutide 或安慰剂，在空腹状态下用最多 120 毫升的水服用，并且在进食、饮水或服用任何其他口服药物前至少 30 分钟服用。,0.4,"['placebo', 'state', 'taking', 'oral medication', 'water', 'drinking', 'fasting', 'ml', 'up', 'with', 'semaglutide', 'before', 'to', 'and', 'morning']","['placebo', 'state', 'water', 'drinking', 'before', 'morning']",1768,"['患者被指示在早上服用口服半糖或 placebo,在禁食状态下服用高达120毫升的水,并且至少在吃饭、喝酒或服用任何其他口服药物前30分钟。']",0.2666666666666666,"['placebo', 'state', 'taking', 'oral medication', 'water', 'drinking', 'fasting', 'ml', 'up', 'with', 'semaglutide', 'before', 'to', 'and', 'morning']","['state', 'water', 'before', 'morning']",1768,患者被指示在早上空腹服用口服赛买力德或安慰剂，配备120毫升水，并且至少在吃饭、喝水或服用其他口服药物前30分钟服用。,0.3333333333333333,"['placebo', 'state', 'taking', 'oral medication', 'water', 'drinking', 'fasting', 'ml', 'up', 'with', 'semaglutide', 'before', 'to', 'and', 'morning']","['placebo', 'water', 'drinking', 'before', 'morning']",,,,
1782,1769,"in such cases , investigators were encouraged to consider reescalating the dose once the symptoms had resolved or diminished .",在这种情况下，鼓励研究人员在症状消失或减轻后考虑重新增加剂量。,0.3333333333333333,"['symptoms', 'dose', 'in']",['dose'],1769,"['在这种情况下,研究人员被鼓励考虑重新升级剂量,一旦症状已解决或减少。']",0.3333333333333333,"['symptoms', 'dose', 'in']",['dose'],1769,在这种情况下，研究人员被鼓励在症状已经消失或减轻的情况下重新升级剂量。,0.3333333333333333,"['symptoms', 'dose', 'in']",['dose'],,,,
1783,1770,a full schedule of assessments is provided in the Supplementary Appendix .,补充附录中提供了完整的评估时间表。,0.2,"['appendix', 'supplementary', 'schedule', 'full', 'in']",['full'],1770,['完整的评估时间表在附件中提供。'],0.4,"['appendix', 'supplementary', 'schedule', 'full', 'in']","['appendix', 'full']",1770,在补充附件中提供了完整的评估时间表。,0.4,"['appendix', 'supplementary', 'schedule', 'full', 'in']","['appendix', 'full']",,,,
1784,1771,"the primary outcome was the time from randomization to the first occurrence of a major adverse cardiovascular event , a composite of death from cardiovascular causes ( including undetermined causes of death ) , nonfatal myocardial infarction , or nonfatal stroke .",主要结果是从随机化到第一次发生主要不良心血管事件、心血管原因死亡（包括未确定的死亡原因）、非致死性心肌梗死或非致死性中风的复合事件的时间。,0.625,"['myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'randomization', 'outcome', 'occurrence', 'time', 'major', 'adverse', 'causes of death', 'primary', 'event', 'undetermined', 'to', 'first']","['myocardial infarction', 'cardiovascular', 'stroke', 'randomization', 'outcome', 'occurrence', 'time', 'event', 'undetermined', 'first']",1771,"['主要结果是从随机化到主要不良心血管事件的第一次出现,由心血管原因导致的死亡组合(包括不确定的死亡原因),非致命心脏病发作或非致命中风。']",0.4375,"['myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'randomization', 'outcome', 'occurrence', 'time', 'major', 'adverse', 'causes of death', 'primary', 'event', 'undetermined', 'to', 'first']","['cardiovascular', 'stroke', 'randomization', 'outcome', 'occurrence', 'event', 'first']",1771,第一项结果是从随机分配到发生主要的不利的心血管事件的时间，这是一个由心血管死亡（包括死因不明的死亡）、非致命性心肌梗死或非致命性中风组成的复合项目。,0.6875,"['myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'randomization', 'outcome', 'occurrence', 'time', 'major', 'adverse', 'causes of death', 'primary', 'event', 'undetermined', 'to', 'first']","['myocardial infarction', 'cardiovascular', 'stroke', 'randomization', 'outcome', 'occurrence', 'time', 'causes of death', 'primary', 'event', 'first']",,,,
1785,1772,"secondary cardiovascular outcomes included the time from randomization to the first occurrence of the following : an expanded composite outcome consisting of the primary outcome plus unstable angina resulting in hospitalization or heart failure resulting in hospitalization ; a composite of death from any cause , nonfatal myocardial infarction , or nonfatal stroke ; and the individual components of these composite outcomes .",次要心血管结果包括从随机化到以下情况首次发生的时间：扩展复合结果，包括主要结果加上导致住院的不稳定型心绞痛或导致住院的心力衰竭；由全因死亡、非致死性心肌梗死或非致死性中风组成的复合死亡；以及这些复合结果的各个组成部分。,0.6190476190476191,"['myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'randomization', 'outcome', 'individual', 'death', 'plus', 'occurrence', 'angina', 'time', 'hospitalization', 'heart failure', 'primary', 'cause', 'unstable', 'secondary', 'to', 'first', 'following']","['myocardial infarction', 'cardiovascular', 'stroke', 'randomization', 'outcome', 'death', 'plus', 'occurrence', 'angina', 'time', 'hospitalization', 'heart failure', 'unstable']",1772,"['二次心血管结果包括从随机化到第一次出现的时间:由初始结果组成的扩展化合物结果,加上导致入院或导致入院心脏衰竭的不稳定的腹泻;由任何原因导致死亡的组合,非致命心脏病发作或非致命中风;以及这些组合结果的个人组成部分。']",0.5714285714285714,"['myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'randomization', 'outcome', 'individual', 'death', 'plus', 'occurrence', 'angina', 'time', 'hospitalization', 'heart failure', 'primary', 'cause', 'unstable', 'secondary', 'to', 'first', 'following']","['cardiovascular', 'stroke', 'randomization', 'outcome', 'individual', 'death', 'plus', 'occurrence', 'time', 'cause', 'unstable', 'first']",1772,"The secondary cardiovascular outcomes included the amount of time from when the patient was randomized to the first occurrence of any of the following: an expanded composite outcome consisting of the primary outcome plus either unstable angina that resulted in hospitalization or heart failure that resulted in hospitalization; a composite of death from any cause, nonfatal myocardial infarction, or nonfatal stroke; and the individual components of these composite outcomes.",0.0,"['myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'randomization', 'outcome', 'individual', 'death', 'plus', 'occurrence', 'angina', 'time', 'hospitalization', 'heart failure', 'primary', 'cause', 'unstable', 'secondary', 'to', 'first', 'following']",[],,,,
1786,1773,"additional efficacy outcomes included the change from baseline to the end of the treatment period in the glycated hemoglobin level , body weight , and lipid levels .",其他疗效结果包括糖化血红蛋白水平、体重和血脂水平从基线到治疗期结束的变化。,0.4166666666666667,"['body weight', 'period', 'lipid', 'baseline', 'hemoglobin level', 'treatment', 'additional', 'efficacy', 'end', 'change', 'to', 'and']","['body weight', 'period', 'baseline', 'treatment', 'change']",1773,"['额外的有效性结果包括从基线到治疗期结束的变化在血糖血糖水平,体重和脂肪水平。']",0.5833333333333334,"['body weight', 'period', 'lipid', 'baseline', 'hemoglobin level', 'treatment', 'additional', 'efficacy', 'end', 'change', 'to', 'and']","['body weight', 'period', 'baseline', 'treatment', 'additional', 'efficacy', 'change']",1773,除了血糖水平、体重和血脂水平的变化，还包括治疗期间从基线到终点的变化。,0.4166666666666667,"['body weight', 'period', 'lipid', 'baseline', 'hemoglobin level', 'treatment', 'additional', 'efficacy', 'end', 'change', 'to', 'and']","['body weight', 'period', 'baseline', 'treatment', 'change']",,,,
1787,1774,"a select set of safety outcomes was investigated , encompassing adverse events leading to discontinuation of semaglutide or placebo , serious adverse events , and adverse events of special interest ( including diabetic retinopathy assessed by scheduled eye examinations , and severe hypoglycemic episodes ) .",研究了一组选定的安全性结果，包括导致停用 semaglutide 或安慰剂的不良事件、严重不良事件和特别关注的不良事件（包括通过定期眼科检查评估的糖尿病性视网膜病变和严重低血糖事件）。,0.2777777777777778,"['safety', 'placebo', 'adverse', 'examinations', 'episodes', 'set', 'leading', 'eye', 'severe', 'semaglutide', 'diabetic retinopathy', 'hypoglycemic', 'serious', 'by', 'to', 'and', 'special', 'assessed']","['safety', 'placebo', 'eye', 'diabetic retinopathy', 'special']",1774,"['调查了一系列安全结果,包括导致半糖或 placebo 停止的不良事件,严重的不良事件,以及特殊兴趣的不良事件(包括糖尿病 retinopathy 通过计划的眼科检查评估,以及严重的催眠性事件)。']",0.2222222222222222,"['safety', 'placebo', 'adverse', 'examinations', 'episodes', 'set', 'leading', 'eye', 'severe', 'semaglutide', 'diabetic retinopathy', 'hypoglycemic', 'serious', 'by', 'to', 'and', 'special', 'assessed']","['safety', 'eye', 'by', 'special']",1774,一组具体的安全性结果进行了研究，涵盖导致赛乐得或安慰剂停止使用的不良事件、严重不良事件以及特别感兴趣的不良事件（包括通过定期眼科检查评估的糖尿病视网膜病变以及严重的血糖下降事件）。,0.3333333333333333,"['safety', 'placebo', 'adverse', 'examinations', 'episodes', 'set', 'leading', 'eye', 'severe', 'semaglutide', 'diabetic retinopathy', 'hypoglycemic', 'serious', 'by', 'to', 'and', 'special', 'assessed']","['safety', 'placebo', 'eye', 'diabetic retinopathy', 'by', 'special']",,,,
1788,1775,"the statistical methods have been reported previously , 23 and further information is provided in the Supplementary Appendix and below .",统计方法之前已有报道，23 补充附录和下文中提供了更多信息。,0.4,"['appendix', 'supplementary', 'information', 'have', 'and']","['information', 'have']",1775,"['统计方法已提前报告,23和更多信息在附件和下方提供。']",0.4,"['appendix', 'supplementary', 'information', 'have', 'and']","['appendix', 'information']",1775,这些统计方法之前已经有报告了，23，并且在补充附录和下面提供了更多信息。,0.4,"['appendix', 'supplementary', 'information', 'have', 'and']","['information', 'have']",,,,
1789,1776,"the trial continued until accrual of at least 122 events , with no predefined minimum duration .",试验一直持续到至少发生 122 起事件，没有预先确定的最短持续时间。,0.2,"['minimum', 'no', 'trial', 'duration', 'with']",['duration'],1776,"['审判持续到至少122起事件的积累,没有预定最低期限。']",0.6,"['minimum', 'no', 'trial', 'duration', 'with']","['minimum', 'trial', 'duration']",1776,审判继续进行直到至少发生122个事件，没有预定义的最短持续时间。,0.4,"['minimum', 'no', 'trial', 'duration', 'with']","['trial', 'duration']",,,,
1790,1777,"all analyses involved the full analysis set , which included all randomly assigned patients .",所有分析均涉及完整的分析集，其中包括所有随机分配的患者。,0.5,"['analysis', 'set', 'full', 'all']","['analysis', 'full']",1777,"['所有分析都包含了完整的分析组,其中包括所有随机分配的患者。']",0.5,"['analysis', 'set', 'full', 'all']","['analysis', 'full']",1777,所有分析都涉及了完整的分析集，其中包括所有随机分配的患者。,0.5,"['analysis', 'set', 'full', 'all']","['analysis', 'full']",,,,
1791,1778,"conditional to confirmation of noninferiority , superiority testing was performed on the primary outcome .",以确认非劣效性为条件，对主要结果进行优效性测试。,0.2857142857142857,"['outcome', 'confirmation', 'conditional', 'primary', 'superiority', 'testing', 'to']","['outcome', 'confirmation']",1778,"['在确认不低的条件下,优越性测试在初始结果上进行。']",0.4285714285714285,"['outcome', 'confirmation', 'conditional', 'primary', 'superiority', 'testing', 'to']","['outcome', 'confirmation', 'superiority']",1778,"If the noninferiority test is confirmed, a superiority test will be performed on the primary outcome.",0.0,"['outcome', 'confirmation', 'conditional', 'primary', 'superiority', 'testing', 'to']",[],,,,
1792,1779,analyses of all other outcomes were not controlled for multiple comparisons and should be interpreted as exploratory .,对所有其他结果的分析未针对多重比较进行控制，应被解释为探索性的。,0.1428571428571428,"['multiple', 'controlled', 'be', 'exploratory', 'as', 'all', 'and']",['controlled'],1779,"['所有其他结果的分析不被控制为多种比较,应该被解释为探索性。']",0.1428571428571428,"['multiple', 'controlled', 'be', 'exploratory', 'as', 'all', 'and']",['controlled'],1779,"analyses of all other outcomes were not controlled for multiple comparisons and should be interpreted as exploratory .

Chinese:

其他所有结果的分析都没有考虑多重比较，因此应该视为探索性的。",0.0,"['multiple', 'controlled', 'be', 'exploratory', 'as', 'all', 'and']",[],,,,
1793,1780,prespecified sensitivity and subgroup analyses explored the robustness of the primary outcome analysis .,预先指定的敏感性和亚组分析探索了主要结果分析的稳健性。,0.4285714285714285,"['analysis', 'outcome', 'primary', 'subgroup', 'sensitivity', 'robustness', 'and']","['analysis', 'outcome', 'robustness']",1780,['预定敏感性和子组分析探讨了主要结果分析的强度。'],0.2857142857142857,"['analysis', 'outcome', 'primary', 'subgroup', 'sensitivity', 'robustness', 'and']","['analysis', 'outcome']",1780,在预先规定的敏感性分析和亚组分析中探索了主要结果分析的稳健性。,0.4285714285714285,"['analysis', 'outcome', 'primary', 'subgroup', 'sensitivity', 'robustness', 'and']","['analysis', 'outcome', 'robustness']",,,,
1794,1781,secondary efficacy outcomes and adverse events were assessed by means of descriptive statistics .,次要疗效结果和不良事件通过描述性统计方法进行评估。,0.0,"['adverse', 'secondary', 'efficacy', 'means', 'descriptive statistics', 'by', 'and', 'assessed']",[],1781,['二次效益结果和不良事件通过描述统计数据进行评估。'],0.0,"['adverse', 'secondary', 'efficacy', 'means', 'descriptive statistics', 'by', 'and', 'assessed']",[],1781,统计学方法对副作用和不良事件进行了评估。,0.0,"['adverse', 'secondary', 'efficacy', 'means', 'descriptive statistics', 'by', 'and', 'assessed']",[],,,,
1795,1782,"between January and August 2017 , a total of 3183 patients were randomly assigned to oral semaglutide ( 1591 patients ) or placebo ( 1592 patients ) .",2017 年 1 月至 2017 年 8 月期间，共有 3183 名患者被随机分配接受口服索马鲁肽（1591 名患者）或安慰剂（1592 名患者）。,0.4,"['placebo', 'oral', 'total', 'semaglutide', 'and']","['placebo', 'semaglutide']",1782,"['2017 年 1 月至 8 月,共 3183 名患者随机分配到口服半糖(1591 名患者)或 placebo(1592 名患者)。']",0.0,"['placebo', 'oral', 'total', 'semaglutide', 'and']",[],1782,在2017年1月至8月期间，共有3183名病人随机分配给口服赛乐瑞（1591名病人）或安慰剂（1592名病人）。,0.2,"['placebo', 'oral', 'total', 'semaglutide', 'and']",['placebo'],,,,
1796,1783,baseline characteristics were similar in the two groups .,两组的基线特征相似。,0.75,"['baseline', 'characteristics', 'two', 'similar']","['baseline', 'characteristics', 'two']",1783,['基层特征在两组中相似。'],0.5,"['baseline', 'characteristics', 'two', 'similar']","['characteristics', 'two']",1783,两组在基线特征上相似。,0.75,"['baseline', 'characteristics', 'two', 'similar']","['baseline', 'characteristics', 'two']",,,,
1797,1784,"patients were predominantly male ( 2176 patients , 68.4 % ) , and 2695 patients ( 84.7 % ) were 50 years of age or older and had established cardiovascular disease or chronic kidney disease ( Table 1 , and Tables S1 and S2 in the Supplementary Appendix ) .",患者主要为男性（2176 名患者，68.4%），2695 名患者（84.7%）年龄在 50 岁或以上，并且患有心血管疾病或慢性肾病（表 1 以及补充附录中的表 S1 和表 S2）。,0.5,"['kidney', 'appendix', 'table', 'male', 'supplementary', 'cardiovascular disease', 'chronic', 'age', 'S1', 'S2', 'in', 'and']","['kidney', 'table', 'male', 'cardiovascular disease', 'chronic', 'age']",1784,"['患者主要是男性(2176名患者,68.4%)和2695名患者(84.7%)年龄为50岁或以上,并且发现了心血管疾病或慢性肾脏疾病(图1和附件中的S1和S2表)。']",0.5833333333333334,"['kidney', 'appendix', 'table', 'male', 'supplementary', 'cardiovascular disease', 'chronic', 'age', 'S1', 'S2', 'in', 'and']","['kidney', 'appendix', 'table', 'male', 'cardiovascular disease', 'chronic', 'age']",1784,病人主要是男性(2176例病人，68.4%)，2695例病人(84.7%)年龄在50岁及以上，并已有心血管疾病或慢性肾脏疾病(见表1、补充附件中的表S1和表S2)。,0.5833333333333334,"['kidney', 'appendix', 'table', 'male', 'supplementary', 'cardiovascular disease', 'chronic', 'age', 'S1', 'S2', 'in', 'and']","['kidney', 'appendix', 'table', 'male', 'cardiovascular disease', 'chronic', 'age']",,,,
1798,1785,the mean estimated GFR at baseline was 74 ± 21 ml per minute per 1.73 m2 .,基线时的平均估计 GFR 为每分钟每 1.73 平方米 74 ± 21 毫升。,0.5,"['mean', 'baseline', 'minute', 'ml', 'at', 'GFR']","['mean', 'baseline', 'minute']",1785,"['基线的平均估计GFR为74 ± 21 毫升每分钟,每 1.73 平方米。']",0.5,"['mean', 'baseline', 'minute', 'ml', 'at', 'GFR']","['mean', 'baseline', 'minute']",1785,平均预估肾小球滤过率（GFR）为74±21毫升/分钟/1.73平方米。,0.5,"['mean', 'baseline', 'minute', 'ml', 'at', 'GFR']","['mean', 'minute', 'GFR']",,,,
1799,1786,the primary outcome occurred in 61 of 1591 patients ( 3.8 % ) receiving oral semaglutide and 76 of 1592 ( 4.8 % ) receiving placebo .,主要结果发生在接受口服索马鲁肽的 1591 名患者中的 61 名 (3.8%) 和接受安慰剂的 1592 名患者中的 76 名 (4.8%)。,0.4285714285714285,"['placebo', 'outcome', 'oral', 'primary', 'semaglutide', 'in', 'and']","['placebo', 'outcome', 'semaglutide']",1786,['初始结果发生在1591名患者中(3.8%)接受口服半<unk>和1592名患者中(4.8%)接受 placebo。'],0.1428571428571428,"['placebo', 'outcome', 'oral', 'primary', 'semaglutide', 'in', 'and']",['outcome'],1786,在1591名服用口服塞麦司特的患者中，主要结局发生在61例（3.8％），而1592例（4.8％）服用安慰剂中则发生了76例。,0.2857142857142857,"['placebo', 'outcome', 'oral', 'primary', 'semaglutide', 'in', 'and']","['placebo', 'and']",,,,
1800,1787,"among the individual components of the primary outcome , death from cardiovascular causes occurred in 15 of 1591 patients ( 0.9 % ) in the oral semaglutide group and 30 of 1592 ( 1.9 % ) in the placebo group ( hazard ratio , 0.49 ; 95 % CI , 0.27 to 0.92 ) ( Figure 1 and Table 2 ) .",在主要结局的各个组成部分中，口服索马鲁肽组 1591 名患者中有 15 名 ( 0.9 % ) 和安慰剂组 1592 名患者中有 30 名 ( 1.9 % ) 死于心血管原因（风险比， 0.49 ； 95 % CI ， 0.27 至 0.92)（图 1 和表 2）。,0.5882352941176471,"['group', 'placebo', 'cardiovascular', 'table', '1', '2', 'hazard ratio', 'outcome', 'individual', 'death', 'figure', 'oral', 'primary', 'semaglutide', 'CI', 'to', 'and']","['group', 'placebo', 'cardiovascular', 'table', '1', '2', 'hazard ratio', 'death', 'semaglutide', 'to']",1787,"['在初始结果的个体组成部分中,心血管导致的死亡发生在151名患者中(0.9%)在口腔半糖群中和1592名患者中(1.9%)在 placebo群中(风险比例,0.49;95% CI,0.27至0.92 )(图1和图2)。']",0.4705882352941176,"['group', 'placebo', 'cardiovascular', 'table', '1', '2', 'hazard ratio', 'outcome', 'individual', 'death', 'figure', 'oral', 'primary', 'semaglutide', 'CI', 'to', 'and']","['group', 'cardiovascular', '1', '2', 'hazard ratio', 'outcome', 'individual', 'death']",1787,在主要结果的各个组成部分中， cardiovascular 导致的死亡发生在 oral semaglutide 组的 1591 名患者中的 15 例 (0.9%) 以及 placebo 组的 1592 名患者中的 30 例 (1.9%) (危险比，0.49；95% CI，0.27 至 0.92) (图 1 和表 2)。,0.3529411764705882,"['group', 'placebo', 'cardiovascular', 'table', '1', '2', 'hazard ratio', 'outcome', 'individual', 'death', 'figure', 'oral', 'primary', 'semaglutide', 'CI', 'to', 'and']","['group', 'table', '1', '2', 'outcome', 'death']",,,,
1801,1788,"first events of nonfatal myocardial infarction occurred in 37 of 1591 patients ( 2.3 % ) and 31 of 1592 ( 1.9 % ) , respectively ( hazard ratio , 1.18 ; 95 % CI , 0.73 to 1.90 ) .",非致死性心肌梗死的首发事件分别发生在 1591 名患者中的 37 名 (2.3%) 和 1592 名患者中的 31 名 (1.9%)（风险比，1.18；95% CI，0.73 至 1.90）。,0.5,"['myocardial infarction', 'hazard ratio', 'CI', 'to', 'and', 'first']","['myocardial infarction', 'hazard ratio', 'first']",1788,"['第一次非致命心脏病发作发生在1591名患者中37人(2.3%)和1592名患者中31人(1.9%),分别(风险比率,1.18;95%CI,0.73至1.90)。']",0.3333333333333333,"['myocardial infarction', 'hazard ratio', 'CI', 'to', 'and', 'first']","['hazard ratio', 'first']",1788,第一次非致死性心肌梗死事件发生在1591名患者中的37例（2.3%），1592名患者中的31例（1.9%），分别（危险比，1.18; 95% CI，0.73至1.90）。,0.3333333333333333,"['myocardial infarction', 'hazard ratio', 'CI', 'to', 'and', 'first']","['myocardial infarction', 'first']",,,,
1802,1789,"first events of nonfatal stroke occurred in 12 of 1591 patients ( 0.8 % ) and 16 of 1592 ( 1.0 % ) , respectively ( hazard ratio , 0.74 ; 95 % CI , 0.35 to 1.57 ) .",首次非致死性卒中事件分别发生在 1591 名患者中的 12 名 (0.8%) 和 1592 名患者中的 16 名 (1.0%)（风险比，0.74；95% CI，0.35 至 1.57）。,0.2857142857142857,"['stroke', 'hazard ratio', 'CI', 'in', 'to', 'and', 'first']","['stroke', 'hazard ratio']",1789,"['在1591名患者(0.8%)和1592名患者(1.0%)中发生了12次非致命发作,分别发生了16次(风险比率,0.74;95%CI,0.35至1.57)。']",0.2857142857142857,"['stroke', 'hazard ratio', 'CI', 'in', 'to', 'and', 'first']","['stroke', 'hazard ratio']",1789,"The first non-fatal stroke events occurred in 12 of 1591 patients (0.8%) and 16 of 1592 (1.0%), respectively (hazard ratio, 0.74; 95% CI, 0.35 to 1.57).",0.0,"['stroke', 'hazard ratio', 'CI', 'in', 'to', 'and', 'first']",[],,,,
1803,1790,"death from any cause occurred in 23 of 1591 patients ( 1.4 % ) in the oral semaglutide group and 45 of 1592 ( 2.8 % ) in the placebo group ( hazard ratio , 0.51 ; 95 % CI , 0.31 to 0.84 ) ( Table 2 ) .",口服 semaglutide 组 1591 名患者中有 23 名 (1.4%) 和安慰剂组 1592 名患者中有 45 名 (2.8%) 发生全因死亡（风险比，0.51；95% CI，0.31 至 0.84）（表 2）。,0.4615384615384615,"['group', 'placebo', 'table', '2', 'hazard ratio', 'death', 'oral', 'cause', 'semaglutide', 'CI', 'in', 'to', 'and']","['group', 'placebo', 'table', '2', 'hazard ratio', 'death']",1790,"['由任何原因导致的死亡发生在1591名患者中(1.4% )在口腔半糖群中和1592名患者中(2.8% )在血浆群中(风险比例,0.51;95% CI,0.31至0.84 )(图2 )。']",0.3846153846153846,"['group', 'placebo', 'table', '2', 'hazard ratio', 'death', 'oral', 'cause', 'semaglutide', 'CI', 'in', 'to', 'and']","['group', '2', 'hazard ratio', 'death', 'cause']",1790,死亡率在口服semaglutide组为1.4%(23/1591)，而在安慰剂组为2.8%(45/1592)，危险比为0.51(95% CI，0.31至0.84)(表2)。,0.4615384615384615,"['group', 'placebo', 'table', '2', 'hazard ratio', 'death', 'oral', 'cause', 'semaglutide', 'CI', 'in', 'to', 'and']","['group', 'placebo', 'table', '2', 'death', 'and']",,,,
1804,1791,"first events of unstable angina resulting in hospitalization occurred in 11 of 1591 patients ( 0.7 % ) and 7 of 1592 ( 0.4 % ) , respectively ( hazard ratio , 1.56 ; 95 % CI , 0.60 to 4.01 ) .",导致住院的不稳定型心绞痛的首次事件分别发生在 1591 名患者中的 11 名 (0.7%) 和 1592 名患者中的 7 名 (0.4%)（风险比，1.56；95% CI，0.60 至 4.01）。,0.5,"['hazard ratio', 'angina', 'hospitalization', 'unstable', 'CI', 'to', 'and', 'first']","['hazard ratio', 'angina', 'hospitalization', 'unstable']",1791,"['不稳定的腹泻发生在1591名患者中11人(0.7%)和1592名患者中7人(0.4%),分别(风险比率,1.56;95% CI,0.60至 4.01)。']",0.25,"['hazard ratio', 'angina', 'hospitalization', 'unstable', 'CI', 'to', 'and', 'first']","['hazard ratio', 'unstable']",1791,第一次非稳定型心绞痛导致住院的事件发生在1591名患者中的11名（0.7％），1592名患者中的7名（0.4％），分别为（危险比，1.56；95％CI，0.60至4.01）。,0.375,"['hazard ratio', 'angina', 'hospitalization', 'unstable', 'CI', 'to', 'and', 'first']","['angina', 'hospitalization', 'first']",,,,
1805,1792,"first events of heart failure resulting in hospitalization occurred in 21 of 1591 patients ( 1.3 % ) and 24 of 1592 ( 1.5 % ) , respectively ( hazard ratio , 0.86 ; 95 % CI , 0.48 to 1.55 ) .",导致住院的首次心力衰竭事件分别发生在 1591 名患者中的 21 名 (1.3%) 和 1592 名患者中的 24 名 (1.5%)（风险比，0.86；95% CI，0.48 至 1.55）。,0.375,"['hazard ratio', 'hospitalization', 'heart failure', 'CI', 'in', 'to', 'and', 'first']","['hazard ratio', 'hospitalization', 'heart failure']",1792,"['第一次心脏衰竭的病例发生在1591名患者中(1.3%)和1592名患者中(1.5%),分别(风险比率,0.86;95% CI,0.48至1.55)。']",0.25,"['hazard ratio', 'hospitalization', 'heart failure', 'CI', 'in', 'to', 'and', 'first']","['hazard ratio', 'first']",1792,首次心脏衰竭导致住院的事件发生在1591名患者中的21例（1.3％）和1592例中的24例（1.5％），分别（危险比，0.86; 95％CI，0.48至1.55）。,0.125,"['hazard ratio', 'hospitalization', 'heart failure', 'CI', 'in', 'to', 'and', 'first']",['hospitalization'],,,,
1806,1793,adverse EVENTS AND SAFETY,不良事件和安全,0.0,['adverse'],[],1793,['危害事件与安全'],0.0,['adverse'],[],1793,adverse events and safety,0.0,['adverse'],[],,,,
1807,1794,serious adverse events occurred in 301 of 1591 patients ( 18.9 % ) in the oral semaglutide group and 358 of 1592 ( 22.5 % ) in the placebo group ( Table 3 ) .,严重不良事件发生在口服索马鲁肽组 1591 名患者中的 301 名 (18.9%) 和安慰剂组 1592 名患者中的 358 名 (22.5%)（表 3）。,0.4,"['group', 'placebo', 'table', 'oral', 'adverse', '3', 'semaglutide', 'serious', 'in', 'and']","['group', 'placebo', 'table', 'semaglutide']",1794,['严重的副作用发生在1591名患者中(18.9%)在口腔半糖群中和1592名患者中(22.5%)在301名患者中(图3)。'],0.1,"['group', 'placebo', 'table', 'oral', 'adverse', '3', 'semaglutide', 'serious', 'in', 'and']",['group'],1794,在口服赛乐蒂组，1591名患者中有301人（18.9%）发生严重不良事件，而在安慰剂组，1592名患者中有358人（22.5%）发生严重不良事件（表3）。,0.4,"['group', 'placebo', 'table', 'oral', 'adverse', '3', 'semaglutide', 'serious', 'in', 'and']","['group', 'placebo', 'table', 'and']",,,,
1808,1795,serious adverse events were varied and involved several organ systems ( Table S5 in the Supplementary Appendix ) .,严重不良事件多种多样，涉及多个器官系统（补充附录表 S5）。,0.2222222222222222,"['organ', 'appendix', 'table', 'supplementary', 'adverse', 'serious', 'in', 'and', 'varied']","['organ', 'table']",1795,"['严重的副作用有所不同,涉及多种器官系统(附件中的S5表)。']",0.3333333333333333,"['organ', 'appendix', 'table', 'supplementary', 'adverse', 'serious', 'in', 'and', 'varied']","['organ', 'appendix', 'table']",1795,严重的不良事件多种多样，涉及到多个器官系统（表S5在附加附录）。,0.2222222222222222,"['organ', 'appendix', 'table', 'supplementary', 'adverse', 'serious', 'in', 'and', 'varied']","['organ', 'table']",,,,
1809,1796,"however , serious adverse events led to permanent discontinuation of oral semaglutide in 41 of 1591 patients ( 2.6 % ) and of placebo in 48 of 1592 patients ( 3.0 % ) .",然而，严重不良事件导致 1591 名患者中有 41 名 (2.6%) 永久停用口服索马鲁肽，1592 名患者中有 48 名 (3.0%) 永久停用安慰剂。,0.3,"['placebo', 'permanent', 'oral', 'adverse', 'semaglutide', 'serious', 'in', 'to', 'and', 'led']","['placebo', 'semaglutide', 'and']",1796,"['然而,严重的副作用导致1591名患者中41名(2.6%)和1592名患者中48名患者中3.0%的口服半糖永久停止使用。']",0.1,"['placebo', 'permanent', 'oral', 'adverse', 'semaglutide', 'serious', 'in', 'to', 'and', 'led']",['and'],1796,然而，严重的不良事件导致1591名患者中的41人（2.6％）永久性停止使用口服semaglutide，1592名患者中的48人（3.0％）停止使用安慰剂。,0.2,"['placebo', 'permanent', 'oral', 'adverse', 'semaglutide', 'serious', 'in', 'to', 'and', 'led']","['placebo', 'and']",,,,
1810,1797,there were 68 deaths during the trial ( in 23 of 1591 patients in the oral semaglutide group and in 45 of 1592 in the placebo group ) .,试验期间有 68 人死亡（口服 semaglutide 组 1591 名患者中有 23 人死亡，安慰剂组 1592 人中有 45 人死亡）。,0.2857142857142857,"['group', 'placebo', 'oral', 'trial', 'semaglutide', 'in', 'and']","['group', 'placebo']",1797,"['在试验期间,有68人死亡(口服半糖群中有1591人中有23人死亡,1592人中有45人死亡)。']",0.1428571428571428,"['group', 'placebo', 'oral', 'trial', 'semaglutide', 'in', 'and']",['group'],1797,在试验期间，总共有68例死亡（其中23例为1591例口服semaglutide组患者，45例为1592例安慰剂组患者）。,0.2857142857142857,"['group', 'placebo', 'oral', 'trial', 'semaglutide', 'in', 'and']","['group', 'placebo']",,,,
1811,1798,the most frequent underlying causes of death were cardiovascular ( in 10 of 23 deaths with oral semaglutide and in 23 of 45 deaths with placebo ) ( Table S7 in the Supplementary Appendix ) .,最常见的潜在死亡原因是心血管疾病（口服索马鲁肽组 23 例死亡中有 10 例，安慰剂组 45 例死亡中有 23 例）（补充附录表 S7）。,0.3333333333333333,"['placebo', 'cardiovascular', 'appendix', 'table', 'oral', 'supplementary', 'causes of death', 'with', 'semaglutide', 'in', 'frequent', 'and']","['placebo', 'cardiovascular', 'table', 'semaglutide']",1798,['死亡原因最常见的是心血管(口服半糖死亡人数为23人中10人死亡人数为23人死亡人数为45人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数'],0.0833333333333333,"['placebo', 'cardiovascular', 'appendix', 'table', 'oral', 'supplementary', 'causes of death', 'with', 'semaglutide', 'in', 'frequent', 'and']",['cardiovascular'],1798,最常见的死因是心血管疾病（分别为23例死亡病例中的10例和45例死亡病例中的23例）。表格见附件S7。,0.3333333333333333,"['placebo', 'cardiovascular', 'appendix', 'table', 'oral', 'supplementary', 'causes of death', 'with', 'semaglutide', 'in', 'frequent', 'and']","['cardiovascular', 'appendix', 'table', 'causes of death']",,,,
1812,1799,there was no clustering of causes among deaths from noncardiovascular causes .,非心血管原因导致的死亡没有聚集成因。,0.0,"['clustering', 'no']",[],1799,['因非心血管原因而导致的死亡原因之间没有分类。'],0.0,"['clustering', 'no']",[],1799,There was no clustering of causes among deaths from noncardiovascular causes.,0.0,"['clustering', 'no']",[],,,,
1813,1800,"the percentage of patients with adverse events related to diabetic retinopathy during the trial ( identified through a search of terms in the Medical Dictionary for Regulatory Activities , version 20.1 ) was 7.1 % ( 113 of 1591 patients ) with oral semaglutide and 6.3 % ( 101 of 1592 ) with placebo ( Table S8 in the Supplementary Appendix ) .",试验期间出现与糖尿病视网膜病变相关的不良事件的患者百分比（通过搜索监管活动医学词典 20.1 版中的术语确定）在口服 semaglutide 时为 7.1 % （1591 名患者中的 113 名），在口服 semaglutide 时为 6.3 % （在 101 名患者中） 1592）与安慰剂（补充附录表 S8）。,0.1875,"['percentage', 'placebo', 'appendix', 'table', 'version', 'oral', 'medical', 'supplementary', 'adverse', 'search', 'trial', 'with', 'semaglutide', 'diabetic retinopathy', 'to', 'and']","['placebo', 'table', 'diabetic retinopathy']",1800,"['研究期间与糖尿病网膜病相关的副作用患者的百分比(通过医学词典规律活动的术语搜索确定,版本 20.1)为7.1%(1591名患者中113名)与口服半<unk>和6.3%(1592名患者中101名)与 placebo(附件中的S8表)。']",0.1875,"['percentage', 'placebo', 'appendix', 'table', 'version', 'oral', 'medical', 'supplementary', 'adverse', 'search', 'trial', 'with', 'semaglutide', 'diabetic retinopathy', 'to', 'and']","['appendix', 'table', 'version']",1800,试验期间，糖尿病视网膜病变相关的不良事件发生率为7.1%（113/1591），对照组为6.3%（101/1592）（表S8见附件）。,0.1875,"['percentage', 'placebo', 'appendix', 'table', 'version', 'oral', 'medical', 'supplementary', 'adverse', 'search', 'trial', 'with', 'semaglutide', 'diabetic retinopathy', 'to', 'and']","['appendix', 'table', 'diabetic retinopathy']",,,,
1814,1801,"in the placebo group , one serious retinopathy event and one event leading to discontinuation of placebo were reported .",在安慰剂组中，报告了 1 起严重的视网膜病变事件和 1 起导致安慰剂停用的事件。,0.375,"['group', 'placebo', 'leading', 'event', 'retinopathy', 'serious', 'to', 'and']","['group', 'placebo', 'retinopathy']",1801,"['在 placebo 群体中,报告了一个严重的 retinopathy 事件和一个导致停止 placebo 的事件。']",0.125,"['group', 'placebo', 'leading', 'event', 'retinopathy', 'serious', 'to', 'and']",['group'],1801,在安慰剂组中，报告了一例严重视网膜病变事件和一例导致安慰剂停用的事件。,0.375,"['group', 'placebo', 'leading', 'event', 'retinopathy', 'serious', 'to', 'and']","['group', 'placebo', 'retinopathy']",,,,
1815,1802,"despite improved glycemic control with oral semaglutide , the percentage of patients with severe hypoglycemia was 1.4 % ( 23 of 1591 patients ) , as compared with 0.8 % ( 13 of 1592 ) with placebo .",尽管口服 semaglutide 改善了血糖控制，但严重低血糖患者的百分比为 1.4%（1591 名患者中的 23 名），而安慰剂组为 0.8%（1592 名患者中的 13 名）。,0.2,"['percentage', 'placebo', 'control', 'hypoglycemia', 'oral', 'as', 'with', 'despite', 'severe', 'semaglutide']","['placebo', 'control']",1802,"['尽管口腔血糖控制改善,但患有严重低血糖患者的百分比为1.4%(1591名患者中23人),与服用 placebo的百分比为0.8%(1592名患者中13人)。']",0.1,"['percentage', 'placebo', 'control', 'hypoglycemia', 'oral', 'as', 'with', 'despite', 'severe', 'semaglutide']",['control'],1802,尽管口服塞玛格利替尼的糖尿病控制得到了改善，但严重低血糖的患者比例仍然高达1.4%（1591例患者中的23例），与安慰剂相比，严重低血糖的患者比例仅为0.8%（1592例患者中的13例）。,0.2,"['percentage', 'placebo', 'control', 'hypoglycemia', 'oral', 'as', 'with', 'despite', 'severe', 'semaglutide']","['placebo', 'control']",,,,
1816,1803,all severe hypoglycemic events occurred in patients receiving concomitant insulin or sulfonylureas at the time of the event .,所有严重的低血糖事件均发生在事件发生时同时接受胰岛素或磺脲类药物治疗的患者中。,0.2222222222222222,"['insulin', 'time', 'concomitant', 'severe', 'at', 'sulfonylureas', 'hypoglycemic', 'event', 'all']","['insulin', 'time']",1803,['所有严重的催眠性现象发生在患者在事件发生时同时服用胰岛素或硫<unk><unk>。'],0.2222222222222222,"['insulin', 'time', 'concomitant', 'severe', 'at', 'sulfonylureas', 'hypoglycemic', 'event', 'all']","['insulin', 'time']",1803,所有嚴重的低血糖事件都發生在那些在事件發生時正在接受胰島素或降糖素草醇藥物的病人身上。,0.0,"['insulin', 'time', 'concomitant', 'severe', 'at', 'sulfonylureas', 'hypoglycemic', 'event', 'all']",[],,,,
1817,1804,"no unexpected adverse events were reported , and there were no apparent imbalances in adjudicated adverse events between the two groups ( Table 3 , and Table S9 in the Supplementary Appendix ) .",没有意外不良事件的报告，两组之间裁定的不良事件没有明显的不平衡（表 3 和补充附录表 S9）。,0.2222222222222222,"['appendix', 'table', 'supplementary', 'adverse', 'no', '3', 'in', 'and', 'two']","['table', 'two']",1804,"['没有意想不到的不良事件被报告,并且两组之间没有显而易见的不平衡(附件中的图3和图S9)。']",0.3333333333333333,"['appendix', 'table', 'supplementary', 'adverse', 'no', '3', 'in', 'and', 'two']","['appendix', 'and', 'two']",1804,没有出现意料不利的事件，两组之间的裁定不良事件似乎没有明显差异（表3，表S9表于附件）。,0.3333333333333333,"['appendix', 'table', 'supplementary', 'adverse', 'no', '3', 'in', 'and', 'two']","['appendix', 'table', 'two']",,,,
1818,1805,there was one confirmed case of acute pancreatitis with oral semaglutide and three cases with placebo .,有 1 例口服 semaglutide 和 3 例口服 semaglutide 确诊急性胰腺炎病例。,0.25,"['placebo', 'oral', 'case', 'with', 'semaglutide', 'three', 'and', 'acute pancreatitis']","['case', 'acute pancreatitis']",1805,['有一个确认的急性胰腺炎案例与口腔半糖和三个案例与 placebo 。'],0.25,"['placebo', 'oral', 'case', 'with', 'semaglutide', 'three', 'and', 'acute pancreatitis']","['case', 'acute pancreatitis']",1805,发现了一例严重胰腺炎患者在使用口服塞玛格利特治疗，而在使用安慰剂治疗的患者则有三例。,0.25,"['placebo', 'oral', 'case', 'with', 'semaglutide', 'three', 'and', 'acute pancreatitis']","['placebo', 'and']",,,,
1819,1806,"malignant neoplasms were confirmed in 41 of 1591 patients ( 2.6 % ) in the oral semaglutide group and 48 of 1592 ( 3.0 % ) in the placebo group ; in the oral semaglutide group , there was no evidence of clustering in any organ system .",口服索马鲁肽组 1591 名患者中有 41 名 (2.6%) 和安慰剂组 1592 名患者中有 48 名 (3.0%) 被证实为恶性肿瘤；在口服semaglutide组中，没有任何器官系统聚集的证据。,0.5454545454545454,"['organ', 'group', 'placebo', 'clustering', 'malignant', 'system', 'oral', 'no', 'evidence', 'semaglutide', 'and']","['organ', 'group', 'placebo', 'system', 'evidence', 'semaglutide']",1806,"['恶性肿瘤被确认在1591名患者中(2.6%)在口腔半<unk>群和1592名患者中(3.0%);在口腔半<unk>群中,没有任何器官系统的分裂证据。']",0.3636363636363636,"['organ', 'group', 'placebo', 'clustering', 'malignant', 'system', 'oral', 'no', 'evidence', 'semaglutide', 'and']","['organ', 'group', 'system', 'evidence']",1806,经确认，在1591名口服semaglutide组患者中有41例（2.6%）患有恶性肿瘤，在1592名安慰剂组患者中有48例（3.0%）；口服semaglutide组患者中并没有任何器官系统的聚集病例。,0.3636363636363636,"['organ', 'group', 'placebo', 'clustering', 'malignant', 'system', 'oral', 'no', 'evidence', 'semaglutide', 'and']","['organ', 'group', 'placebo', 'system']",,,,
1820,1807,there was one case of medullary thyroid cancer in a patient receiving oral semaglutide who had preexisting thyroid nodules and an elevated calcitonin level at baseline .,有一例甲状腺髓样癌患者接受口服索马鲁肽治疗，该患者先前已存在甲状腺结节且基线时降钙素水平升高。,0.4166666666666667,"['medullary', 'calcitonin', 'who', 'baseline', 'oral', 'thyroid cancer', 'case', 'patient', 'level', 'semaglutide', 'and', 'nodules']","['calcitonin', 'baseline', 'patient', 'level', 'semaglutide']",1807,"['有一个病例的甲状腺癌在一个患者接受口腔半<unk>,谁有预存在的甲状腺节点和高水平的甲状腺在基线。']",0.4166666666666667,"['medullary', 'calcitonin', 'who', 'baseline', 'oral', 'thyroid cancer', 'case', 'patient', 'level', 'semaglutide', 'and', 'nodules']","['baseline', 'thyroid cancer', 'case', 'patient', 'level']",1807,一位服用口服赛马格利替尼患者中出现脑下垂体癌的病例，该患者在基线时已经有甲状腺结节和升高的甲状腺素水平。,0.3333333333333333,"['medullary', 'calcitonin', 'who', 'baseline', 'oral', 'thyroid cancer', 'case', 'patient', 'level', 'semaglutide', 'and', 'nodules']","['baseline', 'case', 'patient', 'level']",,,,
1821,1808,the mean pulse rate was increased by 4 beats per minute with oral semaglutide and unchanged with placebo ( Table S4 in the Supplementary Appendix ) .,口服semaglutide组的平均脉率每分钟增加4次，而安慰剂组则没有变化（补充附录表S4）。,0.5,"['placebo', 'appendix', 'mean', 'table', 'oral', 'pulse rate', 'supplementary', 'minute', 'with', 'semaglutide', 'S4', 'by', 'and', 'beats']","['placebo', 'mean', 'table', 'pulse rate', 'minute', 'and', 'beats']",1808,"['平均脉搏率增加了每分钟4次,用口腔半<unk>和无交换的 placebo(附件中的S4表)。']",0.4285714285714285,"['placebo', 'appendix', 'mean', 'table', 'oral', 'pulse rate', 'supplementary', 'minute', 'with', 'semaglutide', 'S4', 'by', 'and', 'beats']","['appendix', 'mean', 'table', 'pulse rate', 'minute', 'beats']",1808,平均脉搏率在服用口服塞玛格利特的情况下增加了4次/分钟，而在服用安慰剂的情况下没有变化（辅助附录表S4）。,0.5,"['placebo', 'appendix', 'mean', 'table', 'oral', 'pulse rate', 'supplementary', 'minute', 'with', 'semaglutide', 'S4', 'by', 'and', 'beats']","['placebo', 'mean', 'table', 'pulse rate', 'minute', 'and', 'beats']",,,,
1822,1809,there were no clinically relevant changes in biochemical and hematologic variables .,生化和血液学变量没有临床相关的变化。,0.0,"['no', 'biochemical', 'in', 'and', 'hematologic']",[],1809,['生物化学和血液学变量没有临床相关的变化。'],0.0,"['no', 'biochemical', 'in', 'and', 'hematologic']",[],1809,没有临床相关的生化和血液学变化。,0.0,"['no', 'biochemical', 'in', 'and', 'hematologic']",[],,,,
1823,1810,"this cardiovascular outcomes trial met its primary objective of ruling out an 80 % excess cardiovascular risk with oral semaglutide , confirming noninferiority to placebo for the primary outcome ( hazard ratio , 0.79 ; 95 % CI , 0.57 to 1.11 ) .",该心血管结果试验达到了其主要目标，即排除口服 semaglutide 的 80% 额外心血管风险，证实在主要结果方面不劣于安慰剂（风险比，0.79；95% CI，0.57 至 1.11）。,0.3529411764705882,"['objective', 'placebo', 'excess', 'cardiovascular', 'hazard ratio', 'outcome', 'oral', 'primary', 'risk', 'trial', 'with', 'semaglutide', 'ruling', 'met', 'CI', 'this', 'to']","['placebo', 'cardiovascular', 'hazard ratio', 'outcome', 'risk', 'to']",1810,"['这项心血管结果测试满足了其主要目标,以确定80%的过度心血管风险与口腔半糖,确认不低于 placebo的初始结果(风险比例,0.79;95% CI,0.57到1.11)。']",0.2941176470588235,"['objective', 'placebo', 'excess', 'cardiovascular', 'hazard ratio', 'outcome', 'oral', 'primary', 'risk', 'trial', 'with', 'semaglutide', 'ruling', 'met', 'CI', 'this', 'to']","['cardiovascular', 'hazard ratio', 'outcome', 'risk', 'to']",1810,这项心血管结局试验达到了其主要目标，即排除口服米格利度导致80％的额外心血管风险，确认该主要结局（危险比，0.79; 95％CI，0.57至1.11）与安慰剂相比并不劣。,0.1764705882352941,"['objective', 'placebo', 'excess', 'cardiovascular', 'hazard ratio', 'outcome', 'oral', 'primary', 'risk', 'trial', 'with', 'semaglutide', 'ruling', 'met', 'CI', 'this', 'to']","['placebo', 'cardiovascular', 'risk']",,,,
1824,1811,"generally , the results were consistent across the components of the primary outcome and the other cardiovascular outcomes ( e.g. , hospitalization for heart failure ) .",一般而言，主要结果的组成部分和其他心血管结果（例如，因心力衰竭住院）的结果是一致的。,0.7142857142857143,"['cardiovascular', 'outcome', 'hospitalization', 'heart failure', 'primary', 'across', 'and']","['cardiovascular', 'outcome', 'hospitalization', 'heart failure', 'and']",1811,"['一般情况下,结果在初始结果的组成部分和其他心血管结果(例如,心脏失败的入院)。']",0.2857142857142857,"['cardiovascular', 'outcome', 'hospitalization', 'heart failure', 'primary', 'across', 'and']","['cardiovascular', 'outcome']",1811,一般来说，结果在主要结果组件和其他心血管疾病（例如心力衰竭住院）方面是一致的。,0.5714285714285714,"['cardiovascular', 'outcome', 'hospitalization', 'heart failure', 'primary', 'across', 'and']","['cardiovascular', 'outcome', 'hospitalization', 'heart failure']",,,,
1825,1812,"no treatment interactions were evident in subgroup analyses , including in patients with established cardiovascular disease or chronic kidney disease as compared with those with cardiovascular risk factors only .",在亚组分析中没有明显的治疗相互作用，包括与仅具有心血管危险因素的患者相比，已患有心血管疾病或慢性肾病的患者。,0.5555555555555556,"['kidney', 'cardiovascular disease', 'treatment', 'chronic', 'no', 'risk', 'subgroup', 'with', 'in']","['kidney', 'cardiovascular disease', 'treatment', 'chronic', 'risk']",1812,"['在子组分析中,没有治疗相互作用显而易见,包括患有已确定的心血管疾病或慢性肾脏疾病的患者,与只有心血管风险因素的患者相比。']",0.5555555555555556,"['kidney', 'cardiovascular disease', 'treatment', 'chronic', 'no', 'risk', 'subgroup', 'with', 'in']","['kidney', 'cardiovascular disease', 'treatment', 'chronic', 'risk']",1812,"No treatment interactions were evident in subgroup analyses, including in patients with established cardiovascular disease or chronic kidney disease as compared with those with cardiovascular risk factors only.",0.0,"['kidney', 'cardiovascular disease', 'treatment', 'chronic', 'no', 'risk', 'subgroup', 'with', 'in']",[],,,,
1826,1813,these data should be interpreted with caution owing to low patient numbers and wide confidence intervals .,由于患者数量少且置信区间宽，因此应谨慎解读这些数据。,0.3,"['data', 'be', 'wide', 'low', 'patient', 'with', 'confidence', 'to', 'and', 'intervals']","['data', 'patient', 'to']",1813,"['这些数据应谨慎地解释,因为患者数量较低,信任间隔较广。']",0.3,"['data', 'be', 'wide', 'low', 'patient', 'with', 'confidence', 'to', 'and', 'intervals']","['data', 'low', 'patient']",1813,这些数据应该谨慎解释，因为患者数量少，置信区间宽。,0.2,"['data', 'be', 'wide', 'low', 'patient', 'with', 'confidence', 'to', 'and', 'intervals']","['data', 'patient']",,,,
1827,1814,more patients received treatment with an SGLT2 inhibitor after randomization in the placebo group than in the oral semaglutide group .,安慰剂组随机分组后接受 SGLT2 抑制剂治疗的患者多于口服 semaglutide 组。,0.6666666666666666,"['group', 'inhibitor', 'placebo', 'randomization', 'oral', 'treatment', 'after', 'with', 'semaglutide']","['group', 'inhibitor', 'placebo', 'randomization', 'treatment', 'after']",1814,['在 placebo 群体中随机化后接受 SGLT2 抑制剂治疗的患者多于口服半糖群体。'],0.5555555555555556,"['group', 'inhibitor', 'placebo', 'randomization', 'oral', 'treatment', 'after', 'with', 'semaglutide']","['group', 'inhibitor', 'randomization', 'treatment', 'after']",1814,More patients in the placebo group than in the oral semaglutide group received treatment with an SGLT2 inhibitor after randomization.,0.0,"['group', 'inhibitor', 'placebo', 'randomization', 'oral', 'treatment', 'after', 'with', 'semaglutide']",[],,,,
1828,1815,"however , few patients initiated SGLT2 inhibitors in the current trial ( and they used these drugs over a shorter duration than in trials showing the aforementioned reduction in cardiovascular risk ) , which makes an influence on the primary outcome unlikely in our view .",然而，在目前的试验中很少有患者开始使用 SGLT2 抑制剂（并且他们使用这些药物的持续时间比显示上述心血管风险降低的试验更短），我们认为这不太可能对主要结果产生影响。,0.6153846153846154,"['cardiovascular', 'outcome', 'drugs', 'reduction', 'primary', 'risk', 'trial', 'influence', 'current', 'view', 'duration', 'over', 'and']","['cardiovascular', 'outcome', 'drugs', 'reduction', 'risk', 'influence', 'duration', 'and']",1815,"['然而,在目前的研究中,很少有患者启动了SGLT2抑制剂(并且他们使用了这些药物比在上述降低心血管风险的研究中更短的时间),这使得对初始结果的影响在我们的观点上是不可能的。']",0.6153846153846154,"['cardiovascular', 'outcome', 'drugs', 'reduction', 'primary', 'risk', 'trial', 'influence', 'current', 'view', 'duration', 'over', 'and']","['cardiovascular', 'outcome', 'drugs', 'reduction', 'risk', 'influence', 'view', 'and']",1815,然而，目前的试验中只有很少数病人使用SGLT2抑制剂（而且他们使用这些药物的时间比在显示上述心血管风险降低的试验要短），这使我们认为对主要结局的影响不大。,0.4615384615384615,"['cardiovascular', 'outcome', 'drugs', 'reduction', 'primary', 'risk', 'trial', 'influence', 'current', 'view', 'duration', 'over', 'and']","['cardiovascular', 'drugs', 'reduction', 'risk', 'influence', 'and']",,,,
1829,1816,no unexpected adverse events were identified with oral semaglutide .,口服索马鲁肽未发现意外不良事件。,0.2,"['oral', 'adverse', 'no', 'with', 'semaglutide']",['semaglutide'],1816,['没有意想不到的副作用被用口腔半糖检测到。'],0.0,"['oral', 'adverse', 'no', 'with', 'semaglutide']",[],1816,没有发现静脉注射和口服用西酞肽产生任何意外的不良事件。,0.0,"['oral', 'adverse', 'no', 'with', 'semaglutide']",[],,,,
1830,1817,fewer serious adverse events and deaths occurred in the oral semaglutide group than in the placebo group .,与安慰剂组相比，口服 semaglutide 组发生的严重不良事件和死亡更少。,0.25,"['group', 'placebo', 'oral', 'adverse', 'semaglutide', 'serious', 'in', 'and']","['group', 'placebo']",1817,"['在口腔半糖群中发生的严重副作用和死亡人数较少,而不是在 placebo群中发生的死亡人数。']",0.25,"['group', 'placebo', 'oral', 'adverse', 'semaglutide', 'serious', 'in', 'and']","['group', 'and']",1817,在口服赛乐得组中发生的严重不良事件和死亡人数比在安慰剂组中要少。,0.25,"['group', 'placebo', 'oral', 'adverse', 'semaglutide', 'serious', 'in', 'and']","['group', 'placebo']",,,,
1831,1818,"the difference between the two groups in the number of deaths was largely accounted for by deaths from cardiovascular causes ( 10 of 23 deaths in the oral semaglutide group vs. 23 of 45 in the placebo group ) , although there were also more deaths from noncardiovascular causes in the placebo group ( 8 of 23 deaths vs. 15 of 45 ) .",两组死亡人数的差异主要是由于心血管原因导致的死亡（口服索马鲁肽组 23 例死亡中有 10 例，安慰剂组 45 例中有 23 例死亡） ，尽管非心血管原因的死亡也更多。在安慰剂组（23 人中有 8 人死亡，45 人中有 15 人死亡）。,0.8,"['group', 'placebo', 'cardiovascular', 'oral', 'difference', 'number', 'semaglutide', 'in', 'by', 'two']","['group', 'placebo', 'cardiovascular', 'difference', 'number', 'semaglutide', 'by', 'two']",1818,['两组死亡人数的差异主要是由心血管导致的死亡(口腔半糖群中死亡人数为23人中死亡人数为23人中死亡人数为45人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人。'],0.6,"['group', 'placebo', 'cardiovascular', 'oral', 'difference', 'number', 'semaglutide', 'in', 'by', 'two']","['group', 'cardiovascular', 'difference', 'number', 'by', 'two']",1818,两组之间死亡人数的差异主要是由于心血管疾病导致的死亡（口服semaglutide组23例中有10例，而安慰剂组45例中有23例），尽管安慰剂组非心血管疾病导致的死亡人数也更多（23例中有8例，而45例中有15例）。,0.7,"['group', 'placebo', 'cardiovascular', 'oral', 'difference', 'number', 'semaglutide', 'in', 'by', 'two']","['group', 'placebo', 'cardiovascular', 'difference', 'number', 'by', 'two']",,,,
1832,1819,"most events occurred early in that trial , possibly attributable to the magnitude and rapidity of the reduction in glycated hemoglobin levels in patients with preexisting diabetic retinopathy.28",大多数事件发生在该试验的早期，可能归因于先前存在糖尿病视网膜病变的患者糖化血红蛋白水平下降的幅度和速度。 28,0.3636363636363636,"['hemoglobin', 'reduction', 'early', 'diabetic', 'trial', 'magnitude', 'with', 'that', 'possibly', 'to', 'and']","['hemoglobin', 'early', 'magnitude', 'to']",1819,"['大多数事件发生在这个试验的早期,可能归因于糖尿病前存在的糖尿病网膜病患者的血糖血糖水平下降的程度和速度。']",0.1818181818181818,"['hemoglobin', 'reduction', 'early', 'diabetic', 'trial', 'magnitude', 'with', 'that', 'possibly', 'to', 'and']","['early', 'to']",1819,大多数事件发生在试验初期，这可能与糖化血红蛋白水平降低的幅度和速度有关。28,0.3636363636363636,"['hemoglobin', 'reduction', 'early', 'diabetic', 'trial', 'magnitude', 'with', 'that', 'possibly', 'to', 'and']","['hemoglobin', 'reduction', 'early', 'magnitude']",,,,
1833,1820,"given that result , patients with proliferative retinopathy or maculopathy resulting in active treatment were excluded from our trial .",鉴于该结果，需要积极治疗的增殖性视网膜病变或黄斑病变患者被排除在我们的试验之外。,0.375,"['active', 'treatment', 'proliferative', 'trial', 'result', 'with', 'retinopathy', 'that']","['treatment', 'result', 'retinopathy']",1820,"['鉴于这一结果,患有活性治疗导致的流行性网膜病或宏观病的患者被排除在我们的研究中。']",0.25,"['active', 'treatment', 'proliferative', 'trial', 'result', 'with', 'retinopathy', 'that']","['treatment', 'result']",1820,"Given that result, patients with proliferative retinopathy or maculopathy resulting in active treatment were excluded from our trial.

Chinese:

根据结果，导致活动治疗的复发性视网膜病变或黄斑病变的患者被排除在外。",0.375,"['active', 'treatment', 'proliferative', 'trial', 'result', 'with', 'retinopathy', 'that']","['treatment', 'result', 'retinopathy']",,,,
1834,1821,"in conclusion , the present trial showed noninferiority of oral semaglutide to placebo ( hazard ratio , 0.79 ; 95 % CI , 0.57 to 1.11 ) , ruling out an 80 % excess cardiovascular risk .",总之，本试验显示口服 semaglutide 不劣于安慰剂（风险比，0.79；95% CI，0.57 至 1.11），排除了 80% 的额外心血管风险。,0.3571428571428571,"['placebo', 'excess', 'cardiovascular', 'hazard ratio', 'oral', 'risk', 'trial', 'present', 'conclusion', 'semaglutide', 'ruling', 'CI', 'out', 'to']","['placebo', 'cardiovascular', 'hazard ratio', 'risk', 'to']",1821,"['在结论中,本研究表明口腔半糖对 placebo(风险比例,0.79;95% CI,0.57至1.11)的不低性,导致80%的过度心血管风险。']",0.2857142857142857,"['placebo', 'excess', 'cardiovascular', 'hazard ratio', 'oral', 'risk', 'trial', 'present', 'conclusion', 'semaglutide', 'ruling', 'CI', 'out', 'to']","['cardiovascular', 'hazard ratio', 'risk', 'conclusion']",1821,最后，目前的试验表明，口服semaglutide与安慰剂相比（危险比，0.79；95%置信区间，0.57至1.11）并无劣效，排除了超过80％的心血管风险。,0.2142857142857142,"['placebo', 'excess', 'cardiovascular', 'hazard ratio', 'oral', 'risk', 'trial', 'present', 'conclusion', 'semaglutide', 'ruling', 'CI', 'out', 'to']","['placebo', 'cardiovascular', 'risk']",,,,
1835,1822,gastrointestinal adverse events were the major reason for discontinuation of oral semaglutide .,胃肠道不良事件是停用口服索马鲁肽的主要原因。,0.5,"['gastrointestinal', 'reason', 'oral', 'major', 'adverse', 'semaglutide']","['gastrointestinal', 'reason', 'semaglutide']",1822,['胃肠道不良事件是口腔半糖停止的主要原因。'],0.3333333333333333,"['gastrointestinal', 'reason', 'oral', 'major', 'adverse', 'semaglutide']","['gastrointestinal', 'reason']",1822,口服赛乐灵造成的胃肠道不良事件是使用赛乐灵最主要的原因。,0.3333333333333333,"['gastrointestinal', 'reason', 'oral', 'major', 'adverse', 'semaglutide']","['gastrointestinal', 'reason']",,,,
1836,1823,"analysis of United Kingdom Biobank data provides further support for lifestyle behaviors influencing dementia risk , showing the effects relative to those of genetic influences .",对英国生物银行数据的分析为影响痴呆症风险的生活方式行为提供了进一步的支持，显示了与遗传影响相关的影响。,0.5555555555555556,"['support', 'data', 'analysis', 'relative', 'dementia', 'genetic', 'risk', 'kingdom', 'to']","['support', 'data', 'analysis', 'dementia', 'risk']",1823,"['英国生物银行数据的分析进一步支持影响痴呆症风险的生活方式行为,显示与遗传影响相关的影响。']",0.5555555555555556,"['support', 'data', 'analysis', 'relative', 'dementia', 'genetic', 'risk', 'kingdom', 'to']","['support', 'data', 'analysis', 'dementia', 'risk']",1823,根据英国生物库的数据分析可以进一步证实生活方式对痴呆症风险的影响，表明这些生活方式相对于遗传因素的影响具有显著作用。,0.5555555555555556,"['support', 'data', 'analysis', 'relative', 'dementia', 'genetic', 'risk', 'kingdom', 'to']","['data', 'analysis', 'dementia', 'risk', 'to']",,,,
1837,1824,"lifestyle and genetic factors can affect risk for dementia , but their relative effects have been unclear .",生活方式和遗传因素会影响患痴呆症的风险，但它们的相对影响尚不清楚。,0.5,"['affect', 'relative', 'dementia', 'genetic', 'risk', 'have', 'but', 'and']","['affect', 'dementia', 'risk', 'but']",1824,"['生活方式和遗传因素可能会影响痴呆症的风险,但它们的相对影响尚不清楚。']",0.5,"['affect', 'relative', 'dementia', 'genetic', 'risk', 'have', 'but', 'and']","['affect', 'dementia', 'risk', 'but']",1824,生活方式和遗传因素可以影响人们患痴呆症的风险，但它们相对的影响一直不清楚。,0.625,"['affect', 'relative', 'dementia', 'genetic', 'risk', 'have', 'but', 'and']","['affect', 'relative', 'dementia', 'risk', 'but']",,,,
1838,1825,"to determine whether lifestyle behaviors influence dementia risk , regardless of genetic risk , researchers conducted a retrospective cohort study using data from 196,383 white participants aged ≥ 60 years ( mean age , 64 ; 53 % women ) in the United Kingdom Biobank .","为了确定生活方式行为是否会影响痴呆症风险，而不考虑遗传风险，研究人员使用英国生物库中 196,383 名年龄≥ 60 岁（平均年龄 64 岁；53% 为女性）的白人参与者的数据进行了一项回顾性队列研究。",0.5,"['mean', 'data', 'white', 'dementia', 'genetic', 'risk', 'kingdom', 'influence', 'aged', 'cohort study', 'to', 'determine']","['mean', 'data', 'white', 'dementia', 'risk', 'influence']",1825,"['为了确定生活方式行为是否影响痴呆症风险,无论基因风险如何,研究人员使用196383名60岁以上的白人参与者(平均年龄,64;53%的妇女)在英国生物银行的数据进行了一项回顾性协调研究。']",0.5833333333333334,"['mean', 'data', 'white', 'dementia', 'genetic', 'risk', 'kingdom', 'influence', 'aged', 'cohort study', 'to', 'determine']","['mean', 'data', 'white', 'dementia', 'risk', 'influence', 'determine']",1825,研究人员对196383名英国年龄在60岁以上白人参与者（平均年龄为64岁；53％为女性）的数据进行了回顾性队列研究，以确定生活方式行为是否会影响痴呆风险，而不管遗传风险有多大。,0.5,"['mean', 'data', 'white', 'dementia', 'genetic', 'risk', 'kingdom', 'influence', 'aged', 'cohort study', 'to', 'determine']","['mean', 'data', 'white', 'dementia', 'risk', 'influence']",,,,
1839,1826,"high , intermediate , or low genetic risk was based on polygenic risk scores calculated from single nucleotide polymorphisms associated with Alzheimer disease .",高、中或低遗传风险是基于多基因风险评分，该评分是根据与阿尔茨海默病相关的单核苷酸多态性计算得出的。,0.5,"['nucleotide', 'alzheimer disease', 'polygenic', 'genetic', 'associated', 'low', 'risk', 'with', 'intermediate', 'on', 'single', 'high']","['nucleotide', 'alzheimer disease', 'low', 'risk', 'single', 'high']",1826,['高、中等、或低的基因风险是基于从与阿尔茨海默病相关的单核化多元化计算的多元化风险分数。'],0.4166666666666667,"['nucleotide', 'alzheimer disease', 'polygenic', 'genetic', 'associated', 'low', 'risk', 'with', 'intermediate', 'on', 'single', 'high']","['alzheimer disease', 'low', 'risk', 'single', 'high']",1826,高、中等或低遗传风险是基于遗传学风险评分计算的，这些评分来自与阿尔茨海默病相关的单个核苷酸多态性。,0.5,"['nucleotide', 'alzheimer disease', 'polygenic', 'genetic', 'associated', 'low', 'risk', 'with', 'intermediate', 'on', 'single', 'high']","['nucleotide', 'alzheimer disease', 'low', 'risk', 'single', 'high']",,,,
1840,1827,"at baseline , 62 % had a favorable lifestyle , 8 % had an unfavorable lifestyle , 20 % had high genetic risk , and 20 % had low genetic risk .",在基线时，62% 的人生活方式良好，8% 的人生活方式不利，20% 的人有高遗传风险，20% 的人有低遗传风险。,0.5,"['baseline', 'genetic', 'low', 'risk', 'at', 'and', 'unfavorable', 'high']","['baseline', 'low', 'risk', 'high']",1827,"['在基本情况下,62%的人享有有利的生活方式,8%的人享有不利的生活方式,20%的人享有高基因风险,20%的人享有低基因风险。']",0.375,"['baseline', 'genetic', 'low', 'risk', 'at', 'and', 'unfavorable', 'high']","['low', 'risk', 'high']",1827,在基线时，62%的人有积极的生活方式，8%的人有消极的生活方式，20%的人有高遗传风险，20%的人有低遗传风险。,0.5,"['baseline', 'genetic', 'low', 'risk', 'at', 'and', 'unfavorable', 'high']","['baseline', 'low', 'risk', 'high']",,,,
1841,1828,"compared with a favorable lifestyle , an unfavorable lifestyle was associated with a 2.6 times increased risk for dementia .",与良好的生活方式相比，不良的生活方式与痴呆症风险增加 2.6 倍有关。,0.4,"['dementia', 'associated', 'risk', 'with', 'unfavorable']","['dementia', 'risk']",1828,"['与有利的生活方式相比,不利的生活方式与痴呆症的风险增加了2.6倍。']",0.4,"['dementia', 'associated', 'risk', 'with', 'unfavorable']","['dementia', 'risk']",1828,相比較一個有利的生活方式，一個不利的生活方式與癡呆症有2.6倍的危險性。,0.0,"['dementia', 'associated', 'risk', 'with', 'unfavorable']",[],,,,
1842,1829,"these results provide further evidence that lifestyle behaviors are modifiable risk factors for dementia in white people , even in those with high genetic risk .",这些结果提供了进一步的证据，表明生活方式行为是白人痴呆症的可改变风险因素，即使是那些具有高遗传风险的人。,0.5555555555555556,"['white', 'dementia', 'genetic', 'risk', 'evidence', 'with', 'that', 'in', 'high']","['white', 'dementia', 'risk', 'evidence', 'high']",1829,"['这些结果提供了更多证据表明,生活方式行为是白人痴呆症的可改变风险因素,即使在高基因风险的人。']",0.5555555555555556,"['white', 'dementia', 'genetic', 'risk', 'evidence', 'with', 'that', 'in', 'high']","['white', 'dementia', 'risk', 'evidence', 'high']",1829,这些结果为白人认为生活方式是易变的痴呆风险因素提供了更多证据，即使是那些具有高遗传风险的人。,0.5555555555555556,"['white', 'dementia', 'genetic', 'risk', 'evidence', 'with', 'that', 'in', 'high']","['white', 'dementia', 'risk', 'evidence', 'high']",,,,
1843,1830,clinicians should continue to encourage a healthy lifestyle as a strategy to promote brain health .,临床医生应继续将鼓励健康的生活方式作为促进大脑健康的策略。,0.7142857142857143,"['strategy', 'brain', 'encourage', 'as', 'continue', 'to', 'healthy']","['strategy', 'brain', 'encourage', 'continue', 'healthy']",1830,['临床医生应该继续鼓励健康的生活方式作为促进大脑健康的战略。'],0.7142857142857143,"['strategy', 'brain', 'encourage', 'as', 'continue', 'to', 'healthy']","['strategy', 'brain', 'encourage', 'continue', 'healthy']",1830,医务人员应继续鼓励健康的生活方式，以促进大脑健康。,0.5714285714285714,"['strategy', 'brain', 'encourage', 'as', 'continue', 'to', 'healthy']","['brain', 'encourage', 'continue', 'healthy']",,,,
1844,1831,"whether race , ethnicity , and gender also affect this risk invites further study .",种族、民族和性别是否也会影响这种风险还有待进一步研究。,0.5714285714285714,"['affect', 'study', 'risk', 'race', 'ethnicity', 'this', 'and']","['affect', 'risk', 'race', 'this']",1831,"['种族、种族和性别是否也影响这种风险,请进一步研究。']",0.5714285714285714,"['affect', 'study', 'risk', 'race', 'ethnicity', 'this', 'and']","['affect', 'risk', 'race', 'this']",1831,"Whether race, ethnicity, and gender also affect this risk invites further study.",0.0,"['affect', 'study', 'risk', 'race', 'ethnicity', 'this', 'and']",[],,,,
1845,1832,"among patients with nonischemic cardiomyopathy , those with nonobstructive CAD were at higher risk than those with normal coronary arteries .",在非缺血性心肌病患者中，非阻塞性 CAD 患者的风险高于冠状动脉正常患者。,0.4285714285714285,"['coronary', 'normal', 'risk', 'cardiomyopathy', 'nonobstructive', 'with', 'CAD']","['coronary', 'risk', 'cardiomyopathy']",1832,"['在患有非神经性心脏病的患者中,患有非阻塞性CAD的人比患有正常冠状动脉的人更有风险。']",0.2857142857142857,"['coronary', 'normal', 'risk', 'cardiomyopathy', 'nonobstructive', 'with', 'CAD']","['coronary', 'risk']",1832,在非冠状动脉病变的心肌病患者中，那些患有非阻塞性CAD的人比那些患有正常冠状动脉的人风险更高。,0.4285714285714285,"['coronary', 'normal', 'risk', 'cardiomyopathy', 'nonobstructive', 'with', 'CAD']","['coronary', 'risk', 'cardiomyopathy']",,,,
1846,1833,"patients with heart failure ( HF ) and nonobstructive coronary artery disease ( CAD ) often are classified as having nonischemic cardiomyopathy , but does nonobstructive CAD affect their prognosis ?",心力衰竭 (HF) 和非阻塞性冠状动脉疾病 (CAD) 患者通常被归类为非缺血性心肌病，但非阻塞性 CAD 会影响他们的预后吗？,0.5833333333333334,"['disease', 'affect', 'prognosis', 'heart failure', 'cardiomyopathy', 'nonobstructive', 'classified', 'with', 'CAD', 'coronary artery', 'but', 'and']","['disease', 'affect', 'prognosis', 'heart failure', 'cardiomyopathy', 'coronary artery', 'but']",1833,"['患有心脏衰竭(HF)和非阻塞性冠状动脉疾病(CAD)的患者经常被列为具有非化学心脏病,但非阻塞性CAD是否会影响他们的预测?']",0.4166666666666667,"['disease', 'affect', 'prognosis', 'heart failure', 'cardiomyopathy', 'nonobstructive', 'classified', 'with', 'CAD', 'coronary artery', 'but', 'and']","['disease', 'affect', 'prognosis', 'coronary artery', 'but']",1833,经常将心力衰竭（HF）和无阻塞冠状动脉疾病（CAD）的患者归类为患有非冠状动脉疾病的，但无阻塞CAD是否会影响他们的预后？,0.5,"['disease', 'affect', 'prognosis', 'heart failure', 'cardiomyopathy', 'nonobstructive', 'classified', 'with', 'CAD', 'coronary artery', 'but', 'and']","['disease', 'affect', 'prognosis', 'heart failure', 'coronary artery', 'but']",,,,
1847,1834,"as expected , obstructive CAD conferred the highest risk for the composite outcome .",正如预期的那样，阻塞性 CAD 对综合结果的风险最高。,0.5,"['composite', 'outcome', 'obstructive', 'risk', 'as', 'CAD']","['outcome', 'risk', 'as']",1834,"['正如预期的那样,阻碍性CAD为复合结果提供了最高的风险。']",0.6666666666666666,"['composite', 'outcome', 'obstructive', 'risk', 'as', 'CAD']","['outcome', 'obstructive', 'risk', 'as']",1834,"As expected, obstructive CAD conferred the highest risk for the composite outcome.

Chinese:

如预期的那样，阻塞性CAD对综合结果的风险最高。",0.5,"['composite', 'outcome', 'obstructive', 'risk', 'as', 'CAD']","['outcome', 'risk', 'as']",,,,
1848,1835,"the mechanism for this excess risk is not entirely clear , as rates of myocardial infarction and stroke were not significantly higher .",这种超额风险的机制尚不完全清楚，因为心肌梗塞和中风的发生率并没有显着升高。,0.4444444444444444,"['myocardial infarction', 'excess', 'stroke', 'mechanism', 'clear', 'risk', 'as', 'this', 'and']","['myocardial infarction', 'stroke', 'mechanism', 'risk']",1835,"['这种过度风险的机制并不完全清楚,因为心脏病发作和中风的发病率并不显著高。']",0.3333333333333333,"['myocardial infarction', 'excess', 'stroke', 'mechanism', 'clear', 'risk', 'as', 'this', 'and']","['stroke', 'mechanism', 'risk']",1835,这种额外风险的机制并不完全清楚，因为心肌梗死和中风的发生率并不显著更高。,0.4444444444444444,"['myocardial infarction', 'excess', 'stroke', 'mechanism', 'clear', 'risk', 'as', 'this', 'and']","['myocardial infarction', 'stroke', 'mechanism', 'risk']",,,,
1849,1836,"however , despite the paucity of outcomes studies , considering medical therapy for CAD seems to be reasonable in these patients .",然而，尽管缺乏结果研究，考虑对这些患者进行 CAD 药物治疗似乎是合理的。,0.1428571428571428,"['medical', 'therapy', 'be', 'despite', 'CAD', 'in', 'to']",['therapy'],1836,"['然而,尽管研究结果的微不足道,考虑CAD的医疗治疗似乎在这些患者中是合理的。']",0.2857142857142857,"['medical', 'therapy', 'be', 'despite', 'CAD', 'in', 'to']","['therapy', 'be']",1836,尽管结果研究很少，但是考虑到这些患者的冠心病，使用医疗治疗似乎是合理的。,0.1428571428571428,"['medical', 'therapy', 'be', 'despite', 'CAD', 'in', 'to']",['therapy'],,,,
1850,1837,"in this observational study of consecutive patients from a Mayo Clinic thrombophilia clinic , researchers compared outcomes in 302 patients who received apixaban and 298 who received rivaroxaban to treat acute venous thromboembolism ( VTE ) for a minimum of 3 months ( median , ≈ 4 months ) .",在这项对 Mayo Clinic 血栓形成倾向诊所的连续患者进行的观察性研究中，研究人员比较了 302 名接受阿哌沙班治疗的患者和 298 名接受利伐沙班治疗急性静脉血栓栓塞症 (VTE) 至少 3 个月（中位数，≈ 4 个月）的患者的结局。,0.3529411764705882,"['median', 'who', 'venous', 'treat', 'observational study', 'thromboembolism', 'minimum', 'consecutive', 'clinic', 'acute', '3', '4', 'rivaroxaban', 'apixaban', 'this', 'to', 'and']","['treat', 'observational study', 'thromboembolism', 'clinic', 'rivaroxaban', 'apixaban']",1837,"['在Mayo Clinic thrombophilia诊所连续患者的这项观察研究中,研究人员比较了302名接受Apixaban的患者和298名接受Rivaroxaban的患者的结果,以治疗急性血管血管肿瘤(VTE)至少3个月(平均, ≈4个月)。']",0.1176470588235294,"['median', 'who', 'venous', 'treat', 'observational study', 'thromboembolism', 'minimum', 'consecutive', 'clinic', 'acute', '3', '4', 'rivaroxaban', 'apixaban', 'this', 'to', 'and']","['treat', 'clinic']",1837,在对从梅奥诊所血栓异常临床连续患者的观察研究中，研究人员对302名使用阿匹克萨班治疗急性静脉血栓栓塞症（VTE）至少3个月（中位数，约4个月）的患者与298名使用利伐沙班治疗3个月（中位数，约4个月）的患者进行了比较。,0.2352941176470588,"['median', 'who', 'venous', 'treat', 'observational study', 'thromboembolism', 'minimum', 'consecutive', 'clinic', 'acute', '3', '4', 'rivaroxaban', 'apixaban', 'this', 'to', 'and']","['treat', 'thromboembolism', 'clinic', 'rivaroxaban']",,,,
1851,1838,analyses were adjusted for modest baseline differences between the two groups .,分析针对两组之间适度的基线差异进行了调整。,1.0,"['baseline', 'two']","['baseline', 'two']",1838,['分析对两组之间的基线差异进行了调整。'],1.0,"['baseline', 'two']","['baseline', 'two']",1838,分析进行了基线差异的微弱调整。,0.5,"['baseline', 'two']",['baseline'],,,,
1852,1839,"a recent larger observational study suggested a slight advantage for apixaban , but that study involved insurance claim data , which might be less reliable than the data analyzed in the current study ( NEJM JW Gen Med Feb 15 2019 and Lancet Haematol 2019 ; 6 : 20 ) .",最近一项更大规模的观察性研究表明 apixaban 略有优势，但该研究涉及保险索赔数据，这可能不如当前研究中分析的数据可靠（ NEJM JW Gen Med 2019 年 2 月 15 日和 Lancet Haematol 2019 ； 6 ： 20 ） .,0.3333333333333333,"['lancet', 'data', 'recent', 'insurance claim', 'observational study', 'slight', 'be', 'advantage', 'gen', 'current', 'apixaban', 'that', 'but', 'and', 'med']","['data', 'insurance claim', 'observational study', 'advantage', 'but']",1839,"['最近的一项更大的观察研究表明,对于apixaban来说,有点好处,但这项研究涉及保险索赔数据,这可能比当前研究中分析的数据不太可靠(NEJM JW Gen Med Feb 15 2019 和 Lancet Haematol 2019 ; 6 : 20 )。']",0.2,"['lancet', 'data', 'recent', 'insurance claim', 'observational study', 'slight', 'be', 'advantage', 'gen', 'current', 'apixaban', 'that', 'but', 'and', 'med']","['data', 'insurance claim', 'but']",1839,"一项最近的大型观察研究表明，阿比夏布钠略微优于其他药物，但该研究所涉及的保险索赔数据可能不如目前研究所分析的数据那么可靠（NEJM JW Gen Med 2019年2月15日，Lancet Haematol 2019年6月20日）。

Chinese:

一项最近的大型观察研究表明，阿比夏布钠略微优于其他药物，但该研究所涉及的保险索赔数据可能不如目前研究所分析的数据那么可靠。",0.2,"['lancet', 'data', 'recent', 'insurance claim', 'observational study', 'slight', 'be', 'advantage', 'gen', 'current', 'apixaban', 'that', 'but', 'and', 'med']","['data', 'insurance claim', 'but']",,,,
1853,1840,the app has been studied in developing countries but is not an approved medical device in the U.S .,该应用程序已在发展中国家进行过研究，但在美国不是批准的医疗设备。,0.3333333333333333,"['medical device', 'developing', 'but']",['but'],1840,"['该应用程序已在发展中国家进行研究,但不是美国批准的医疗设备。']",0.3333333333333333,"['medical device', 'developing', 'but']",['but'],1840,这个应用程序在发展中国家已经被研究了，但在美国并不是一种被批准的医疗设备。,0.3333333333333333,"['medical device', 'developing', 'but']",['but'],,,,
1854,1841,"children underwent monocular vision assessments with both methods , in random order .",儿童接受了两种方法的单眼视力评估，顺序是随机的。,0.2,"['vision', 'monocular', 'random order', 'with', 'in']",['vision'],1841,"['孩子们通过两种方法进行单眼视觉评估,随机顺序。']",0.4,"['vision', 'monocular', 'random order', 'with', 'in']","['vision', 'random order']",1841,孩子们随机顺序用两种方法进行了单眼视力测试。,0.4,"['vision', 'monocular', 'random order', 'with', 'in']","['vision', 'random order']",,,,
1855,1842,"at the end of the test , the phone displayed visual acuity results .",测试结束时，手机显示视力结果。,0.0,"['test', 'visual acuity', 'end', 'phone', 'at']",[],1842,"['在测试结束时,手机显示了视觉急性结果。']",0.0,"['test', 'visual acuity', 'end', 'phone', 'at']",[],1842,在测试结束时，手机显示了视力结果。,0.0,"['test', 'visual acuity', 'end', 'phone', 'at']",[],,,,
1856,1843,standard vision assessment was conducted in an examination lane using a computer screen .,标准视力评估是在检查通道中使用计算机屏幕进行的。,0.8571428571428571,"['lane', 'standard', 'vision', 'examination', 'computer', 'assessment', 'screen']","['standard', 'vision', 'examination', 'computer', 'assessment', 'screen']",1843,['标准视觉评估是在使用计算机屏幕进行的测试线上进行的。'],0.7142857142857143,"['lane', 'standard', 'vision', 'examination', 'computer', 'assessment', 'screen']","['standard', 'vision', 'computer', 'assessment', 'screen']",1843,标准视力测试在检查车道使用计算机屏幕进行。,0.7142857142857143,"['lane', 'standard', 'vision', 'examination', 'computer', 'assessment', 'screen']","['standard', 'vision', 'examination', 'computer', 'screen']",,,,
1857,1844,"agreement between the two methods was good ( interclass correlation coefficient , 0.88 for the first eye examined , 0.85 for the second ) .",两种方法之间的一致性很好（组间相关系数，第一只检查眼为 0.88，第二只眼为 0.85）。,0.8571428571428571,"['eye', 'correlation coefficient', 'good', 'agreement', 'second', 'first', 'two']","['eye', 'correlation coefficient', 'good', 'agreement', 'first', 'two']",1844,"['兩種方法之間的合意是好的(中級相對率,第一眼考慮的 0.88,第二眼考慮的 0.85 )。']",0.4285714285714285,"['eye', 'correlation coefficient', 'good', 'agreement', 'second', 'first', 'two']","['eye', 'good', 'first']",1844,两种方法的协议是良好的（第一只眼睛检查的班间相关系数，0.88，第二个0.85）。,0.7142857142857143,"['eye', 'correlation coefficient', 'good', 'agreement', 'second', 'first', 'two']","['eye', 'correlation coefficient', 'good', 'first', 'two']",,,,
1858,1845,"the app was 83 % sensitive and 70 % specific for identifying children with referable eye conditions ( e.g. , decreased vision , strabismus , nystagmus ) .",该应用程序在识别患有可参考眼部疾病（例如，视力下降、斜视、眼球震颤）的儿童方面具有 83% 的敏感度和 70% 的特异性。,0.5,"['vision', 'nystagmus', 'specific', 'eye', 'sensitive', 'with', 'strabismus', 'and']","['vision', 'nystagmus', 'eye', 'strabismus']",1845,"['该应用程序具有83%的敏感性和70%的特殊性,用于识别有可引用眼部疾病的儿童(例如,视力下降,斯特拉比斯,尼斯塔格斯)。']",0.375,"['vision', 'nystagmus', 'specific', 'eye', 'sensitive', 'with', 'strabismus', 'and']","['vision', 'specific', 'eye']",1845,这个应用程序在识别具有可转诊眼科疾病的儿童方面具有83%的敏感性和70%的特异性（例如，视力下降，斜视，眼球震颤）。,0.5,"['vision', 'nystagmus', 'specific', 'eye', 'sensitive', 'with', 'strabismus', 'and']","['vision', 'nystagmus', 'eye', 'strabismus']",,,,
1859,1846,"among children aged 3 to 5 years , the app was 100 % sensitive and 39 % specific for referable eye conditions and for decreased vision .",在 3 至 5 岁的儿童中，该应用程序对可参考眼部疾病和视力下降的敏感度为 100%，特异性为 39%。,0.3333333333333333,"['5', 'vision', 'specific', '3', 'aged', 'eye', 'sensitive', 'to', 'and']","['5', 'vision', 'eye']",1846,"['在3至5歲的兒童中,該應用程式是100%敏感的,39%對可引用眼部狀況和視力下降的特點。']",0.3333333333333333,"['5', 'vision', 'specific', '3', 'aged', 'eye', 'sensitive', 'to', 'and']","['5', 'eye', 'sensitive']",1846,在3到5岁的儿童中，该应用程序对可以提及的眼病和视力下降的情况100%敏感，39%特异性。,0.3333333333333333,"['5', 'vision', 'specific', '3', 'aged', 'eye', 'sensitive', 'to', 'and']","['5', 'vision', 'eye']",,,,
1860,1847,the app assessment took an average of 125 seconds for children aged 3 to 5 years and 96 seconds for older children .,应用程序评估对于 3 至 5 岁的儿童平均需要 125 秒，对于年龄较大的儿童则需要 96 秒。,0.5714285714285714,"['5', 'average', 'assessment', '3', 'aged', 'to', 'and']","['5', 'average', 'assessment', 'to']",1847,"['应用程序评估的平均时间为3至5岁的儿童125秒,老年儿童96秒。']",0.4285714285714285,"['5', 'average', 'assessment', '3', 'aged', 'to', 'and']","['5', 'average', 'assessment']",1847,3-5岁的儿童平均花费125秒评估应用，而年龄较大的儿童平均花费96秒。,0.5714285714285714,"['5', 'average', 'assessment', '3', 'aged', 'to', 'and']","['5', 'average', 'assessment', 'and']",,,,
1861,1848,"despite the many years since the introduction of stress testing , controversy continues about its prognostic importance and value in decisions about revascularization in patients with stable disease .",尽管自压力测试引入多年以来，关于它在稳定疾病患者血运重建决策中的预后重要性和价值的争论仍在继续。,0.4,"['disease', 'introduction', 'value', 'stress', 'revascularization', 'prognostic', 'testing', 'with', 'despite', 'and']","['disease', 'value', 'stress', 'revascularization']",1848,"['尽管自引入压力测试以来多年以来,对其预测意义和价值的争论仍在继续。']",0.3,"['disease', 'introduction', 'value', 'stress', 'revascularization', 'prognostic', 'testing', 'with', 'despite', 'and']","['value', 'stress', 'prognostic']",1848,尽管已有多年的时间从引入压力测试开始，但有关其预后重要性和稳定疾病患者血管再通的决策价值的争论仍在继续。,0.3,"['disease', 'introduction', 'value', 'stress', 'revascularization', 'prognostic', 'testing', 'with', 'despite', 'and']","['disease', 'value', 'stress']",,,,
1862,1849,"in the COURAGE trial , the presence of ischemia did not modify treatment effectiveness ( NEJM JW Cardiol May 2007 and N Engl J Med 2007 ; 356 : 1503 ) .",在 COURAGE 试验中，缺血的存在并未改变治疗效果（NEJM JW Cardiol 2007 年 5 月和 N Engl J Med 2007；356：1503）。,0.4,"['presence', 'effectiveness', 'ischemia', 'treatment', 'trial', 'N', 'modify', 'in', 'and', 'med']","['presence', 'effectiveness', 'ischemia', 'treatment']",1849,"['在CURAGE审查中,伊斯基米亚的存在并没有改变治疗的有效性(NEJM JW Cardiol 2007年5月和N Engl J Med 2007;356:1503)。']",0.3,"['presence', 'effectiveness', 'ischemia', 'treatment', 'trial', 'N', 'modify', 'in', 'and', 'med']","['presence', 'effectiveness', 'treatment']",1849,在COURAGE试验中，缺血并未改变治疗效果（NEJM JW Cardiol 2007年5月和N Engl J Med 2007年；356：1503）。,0.3,"['presence', 'effectiveness', 'ischemia', 'treatment', 'trial', 'N', 'modify', 'in', 'and', 'med']","['effectiveness', 'ischemia', 'treatment']",,,,
1863,1850,"between 1995 and 2000 , the researchers randomized 535 people ( mean age , 60 ; men , 70 % ) to one of the three strategies .",从 1995 年到 2000 年，研究人员将 535 人（平均年龄 60 岁；男性，70%）随机分配到三种策略中的一种。,0.4,"['mean', 'age', 'three', 'to', 'and']","['mean', 'age']",1850,"['在1995年至2000年间,研究人员随机调查了535人(平均年龄,60;男性,70%)到三个策略之一。']",0.4,"['mean', 'age', 'three', 'to', 'and']","['mean', 'age']",1850,在1995年到2000年之间，研究人员对535人（平均年龄60岁；男性70%）进行了随机分配，其中有三种策略。,0.4,"['mean', 'age', 'three', 'to', 'and']","['mean', 'age']",,,,
